<SEC-DOCUMENT>0000875045-18-000005.txt : 20180201
<SEC-HEADER>0000875045-18-000005.hdr.sgml : 20180201
<ACCEPTANCE-DATETIME>20180201163503
ACCESSION NUMBER:		0000875045-18-000005
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		193
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180201
DATE AS OF CHANGE:		20180201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		18567291

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>biib-20171231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA172A5C231E25D268BCADD67DDB40387"></a></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</font></div><div style="line-height:100%;text-align:center;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;10-K</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the fiscal year ended December 31, 2017</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">or</font></div><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission file number:&#160;0-19311</font></div><div style="line-height:100%;padding-top:4px;text-align:center;"><img src="biogenlogostandarda06.jpg" alt="biogenlogostandarda06.jpg" style="height:45px;width:138px;"></div><div style="line-height:100%;text-align:center;font-size:24pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">33-0112644</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">225 Binney Street, Cambridge, Massachusetts 02142</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(617)&#160;679-2000</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act:</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Title of Each Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Common Stock, $0.0005&#160;par value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">The Nasdaq Global Select Market</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(g) of the Act:</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">None</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files):&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K is not contained herein, and will not be contained, to the best of the registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:38%;"></td><td style="width:24%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Large&#160;accelerated&#160;filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated&#160;filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Do&#160;not&#160;check&#160;if&#160;a&#160;smaller&#160;reporting&#160;company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Emerging growth company&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) computed by reference to the price at which the common stock was last sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$57,220,188,450</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January&#160;26, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the registrant had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211,562,686</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock, $0.0005&#160;par value, outstanding.</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Portions of the definitive proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this report.</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="sF31F0ADD9BBA55B68768652DF7B6557E"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">ANNUAL REPORT ON FORM&#160;10-K</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Year Ended December 31, 2017</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">TABLE OF CONTENTS</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:76%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s9F911D27D1F15364BC48EBD1706A9DF3"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;I</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sAB90BD2EB9CD586880622A5A9AD270E1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sAB90BD2EB9CD586880622A5A9AD270E1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sAB90BD2EB9CD586880622A5A9AD270E1">1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB3B1FD6C33C6555B93E19512F76AFECF"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB3B1FD6C33C6555B93E19512F76AFECF"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB3B1FD6C33C6555B93E19512F76AFECF">33</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFF7334E1F34B5B8080A179224EF911B1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFF7334E1F34B5B8080A179224EF911B1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFF7334E1F34B5B8080A179224EF911B1">46</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6D04B8FB211C5D56BD8A5E0DEEF6AAC5"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6D04B8FB211C5D56BD8A5E0DEEF6AAC5"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6D04B8FB211C5D56BD8A5E0DEEF6AAC5">46</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s8A0FE0CB5D355270B047F6DA110AF04C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s8A0FE0CB5D355270B047F6DA110AF04C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s8A0FE0CB5D355270B047F6DA110AF04C">47</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s75FFB3F747E95885AA082AB9C892448B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s75FFB3F747E95885AA082AB9C892448B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s75FFB3F747E95885AA082AB9C892448B">47</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s4483A356E41454D3AE40081C0902080C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;II</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA04145B8299F5CE092D66F1A36BCCBC7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 5.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA04145B8299F5CE092D66F1A36BCCBC7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA04145B8299F5CE092D66F1A36BCCBC7">48</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB004255537615F4BBFF1022499F44597"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB004255537615F4BBFF1022499F44597"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB004255537615F4BBFF1022499F44597">50</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC68B8A1615A6576E8C481EF8DEF3459D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 7.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC68B8A1615A6576E8C481EF8DEF3459D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC68B8A1615A6576E8C481EF8DEF3459D">53</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sF310F791B3105688A21180474C505938"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 7A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sF310F791B3105688A21180474C505938"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sF310F791B3105688A21180474C505938">88</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDDB7F59BBB37530986AB5E935432B2E4"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 8.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDDB7F59BBB37530986AB5E935432B2E4"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDDB7F59BBB37530986AB5E935432B2E4">90</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s38FEA9B34CB35E179575016901C70070"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s38FEA9B34CB35E179575016901C70070"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s38FEA9B34CB35E179575016901C70070">90</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB65D807B24F95E9AAB98E9261792F819"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB65D807B24F95E9AAB98E9261792F819"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB65D807B24F95E9AAB98E9261792F819">91</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA63CF350D631590DA38F2E597E34D641"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA63CF350D631590DA38F2E597E34D641"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA63CF350D631590DA38F2E597E34D641">91</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s5CE162B9D8C057EEAEEBD62113F6C3A1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;III</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA72CFBF2FC805BCBA3B6010B4D3976D7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 10.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA72CFBF2FC805BCBA3B6010B4D3976D7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA72CFBF2FC805BCBA3B6010B4D3976D7">92</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s92DF18A3C5455DE2B4F2F788CEF4ECB5"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 11.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s92DF18A3C5455DE2B4F2F788CEF4ECB5"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s92DF18A3C5455DE2B4F2F788CEF4ECB5">92</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB89D3D280D99568BBC1E7D57D4BC3E56"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 12.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB89D3D280D99568BBC1E7D57D4BC3E56"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB89D3D280D99568BBC1E7D57D4BC3E56">92</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s21F70A3CD6845C1A921D5BA5D8831382"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 13.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s21F70A3CD6845C1A921D5BA5D8831382"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s21F70A3CD6845C1A921D5BA5D8831382">92</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5DBEB1666A7651A2843A5BB0AEEB0151"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 14.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5DBEB1666A7651A2843A5BB0AEEB0151"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5DBEB1666A7651A2843A5BB0AEEB0151">92</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#sF79BC10CF0435AB38B8E8A59444BE17B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;IV</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s27C5CD1727A1538ABA6830DDAA2F7437"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;15.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s27C5CD1727A1538ABA6830DDAA2F7437"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exhibits and Financial Statement Schedules</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s27C5CD1727A1538ABA6830DDAA2F7437">93</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5bf2d2c3a82448b2aa46626f2bb9a7f3"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 16.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5bf2d2c3a82448b2aa46626f2bb9a7f3"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form 10-K Summary</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5bf2d2c3a82448b2aa46626f2bb9a7f3">93</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFC6B26CBE6385556B9212C79CF160F60"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFC6B26CBE6385556B9212C79CF160F60">97</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sADF33712D6FF5FEFAFF550A406956AAE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sADF33712D6FF5FEFAFF550A406956AAE">F- 1</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="sE93FED20B25B5F1AA268BA7DAB01098C"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues, contingent payments, milestone, royalty and other payments under licensing, collaboration or acquisition agreements, tax positions and contingencies, collectability of receivables, pre-approval inventory, cost of sales, research and development costs, compensation and other selling, general and administrative expenses, amortization of intangible assets, foreign currency exchange risk, estimated fair value of assets and liabilities and impairment assessments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our plans to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filings and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intent to commit resources relating to business development opportunities and research and development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated benefits and the potential costs and expenses related to our current or future initiatives to streamline our operations and reallocate resources; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations and plans and timing relating to the expansion of our manufacturing capabilities, including anticipated investments and activities in new manufacturing facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.) intent to voluntarily depart from the European Union (E.U.);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs to constrain the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated benefits, costs and tax treatment of the spin-off of our hemophilia business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws, including the Tax Cuts and Jobs Act of 2017, and accounting standards.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</font></div><div><br></div><hr style="page-break-after:always"><div><a name="sD89B3511763E5F288DA87AD3DF986776"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in this report to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">"ELOCTATE" refers to both ELOCTATE (the trade name for Antihemophilic Factor (recombinant), Fc Fusion Protein in the U.S., Canada and Japan) and ELOCTA (the trade name for Antihemophilic Factor (recombinant), Fc Fusion Protein in the E.U.).</font></div></td></tr></table><div><a name="s34957EEEFFFF5728BCF08684EFD50CF8"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and ZINBRYTA&#174; are registered trademarks of Biogen. BENEPALI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FLIXABI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FUMADERM</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and IMRALDI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">are trademarks of Biogen. ALPROLIX&#174;, ELOCTATE&#174;, ENBREL&#174;, FAMPYRA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, GAZYVA&#174;, HUMIRA&#174;, OCREVUS&#174;, REMICADE&#174; and other trademarks referenced in this report are the property of their respective owners.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="s9F911D27D1F15364BC48EBD1706A9DF3"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I</font></div><div><a name="sAB90BD2EB9CD586880622A5A9AD270E1"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1. &#160;&#160;&#160;&#160;Business</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer&#8217;s disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;"><img src="corporatestrategy.jpg" alt="corporatestrategy.jpg" style="height:159px;width:682px;"></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS and relapsing MS and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), a rare condition that affects movement, speech, vision and cognitive function, Parkinson's disease and ALS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the E.U.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="sE8EF4FF82ADF598FA1312B39FA049196"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Key Developments</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2017 we had a number of key developments affecting our business.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Corporate Matters</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2017 Corporate Strategy</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we announced an updated strategic framework to optimize the value of our MS business while investing for the future across our core growth areas of MS and neuroimmunology, AD and dementia, movement disorders and neuromuscular diseases, including SMA and ALS. We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to deliver positive results in the near term while investing in the next stages of our growth, we will focus on the following strategic priorities:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">maximizing the resilience of our MS core business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">accelerating efforts in SMA as a significant new growth opportunity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">developing and expanding our neuroscience portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">focusing our capital allocation efforts to drive investment for future growth; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">creating a leaner and simpler operating model to streamline our operations and reallocate resources towards prioritized research and development and commercial value creation opportunities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We expect to make total non-recurring operating and capital expenditures of up to $170.0 million, primarily in 2018, and our goal is to redirect resources of up to $400.0 million annually by 2020 to prioritized research and development and other value creation opportunities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA Settlement and License Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement with Forward Pharma A/S (Forward Pharma). Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property, including Forward Pharma&#8217;s intellectual property related to TECFIDERA.  In exchange, we paid Forward Pharma $1.25 billion in cash. During the fourth quarter of 2016 we recognized a pre-tax charge of $454.8 million and in the first quarter of 2017 we recognized intangible assets of $795.2 million related to this agreement. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. In January 2018 the European Patent Office (EPO) announced its decision revoking Forward Pharma&#8217;s European Patent No. 2 801 355. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. Based upon our assessment of these rulings, we continue to amortize the remaining net book value of the U.S. and rest of world intangible assets in our consolidated statements of income utilizing an economic consumption model.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our settlement and license agreement with Forward Pharma and related intangible assets, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on these disputes, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Reform</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Tax Cuts and Jobs Act of 2017 (the 2017 Tax Act), which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as global intangible low-taxed income (GILTI). These changes are effective beginning in 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax).</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in tax rates and tax laws are accounted for in the period of enactment. Therefore, during the year ended December 31, 2017, we recorded a charge totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,173.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to our current estimate of the provisions of the 2017 Tax Act, including a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;expense under the Transition Toll Tax. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act will provide us with flexibility in deploying our cash resources to advance our business interests. We expect that it will have a modest positive effect on our income tax rate in 2018 and a potential incremental benefit thereafter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. (Sangamo).</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated results of operations and financial position included in this report reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB093 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 we completed an asset purchase of the Phase 3-ready candidate BIIB093 (intravenous glibencamide) (formerly known as CIRARA) from Remedy Pharmaceuticals Inc. (Remedy). The target indication for BIIB093 is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) recently granted BIIB093 Orphan Drug Designation for severe cerebral edema in patients with acute ischemic (AI) stroke. The FDA has also granted BIIB093 Fast Track designation.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we are responsible for the future development and commercialization of BIIB093. Remedy will share in the cost of development for the target indication for BIIB093 in LHI stroke.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our transaction with Remedy, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB092 License Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for BIIB092 (formerly known as BMS-986168), a Phase 2-ready experimental medicine with potential in AD and PSP. BIIB092 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received worldwide rights to BIIB092 and are responsible for the full development and global commercialization of BIIB092 in AD and PSP. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with BMS, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Eisai Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we entered into a new collaboration agreement with Eisai Co. Ltd. (Eisai) for the joint development and commercialization of aducanumab, our anti-amyloid beta antibody candidate for AD (Aducanumab Collaboration Agreement). Under the Aducanumab Collaboration Agreement, we will continue to lead the ongoing Phase 3 development of aducanumab and will remain responsible for 100% of development costs for aducanumab until April 2018. Eisai will then reimburse us for 15% of aducanumab development expenses for the period April 2018 through December 2018, and 45% thereafter. Upon commercialization, both companies will co-promote aducanumab with a region-based profit split.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai will continue to jointly develop two product candidates for AD, BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and E2609, a BACE inhibitor. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai will co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai will distribute AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Eisai, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of our collaboration and license agreement with Neurimmune Subone AG (Neurimmune). Under the amended agreement, we made a $150.0 million payment to Neurimmune, which is reflected as a charge to noncontrolling interests, in exchange for a 15% reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab. Our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, will now range from the high single digits to low-teens. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the amended agreement, we also have an option that will expire in April 2018 to further reduce our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, by an additional 5% in exchange for a $50.0 million payment to Neurimmune.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Neurimmune, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB098 License Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), for BIIB098 (formerly known as ALKS 8700), an oral monomethyl fumarate (MMF) prodrug in Phase 3 development for the treatment of relapsing forms of MS. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received an exclusive, worldwide license to develop and commercialize BIIB098 and will pay Alkermes a royalty on potential worldwide net sales of BIIB098. Beginning in 2018 we are responsible for all development expenses related to BIIB098. Alkermes will maintain responsibility for regulatory interactions with the FDA through the  potential approval of the New Drug Application (NDA) for BIIB098 for the treatment of MS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Alkermes, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Ionis Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2017 we entered into a new collaboration agreement with Ionis Pharmaceuticals Inc. (Ionis) to identify new antisense oligonucleotide (ASO) drug candidates for the treatment of SMA. Under this agreement, we have the option to license therapies arising out of this collaboration and will be responsible for the development and commercialization of these therapies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our new collaboration arrangement with Ionis, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Management Changes</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2017 we appointed several new executives, each of whom has significant experience in the biopharmaceutical industry and is a leader in his or her functional area. These appointments included:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos, Chief Executive Officer; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey Capello, Executive Vice President and Chief Financial Officer; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ginger Gregory, Executive Vice President and Chief Human Resources Officer; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chirfi Guindo, Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on these and our other executive officers, please read the subsection entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Our Executive Officers&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s9D412CEB18125B489A1776840E27DDF3"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product/Pipeline Developments</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Core Growth Areas</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Multiple Sclerosis and Neuroimmunology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">TECFIDERA (dimethyl fumarate)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2017 we presented new real-world data evidence supporting TECFIDERA at the 69</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of the American Academy of Neurology (AAN) in Boston, MA.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We presented a comparison of real-world data that supported TECFIDERA&#8217;s strong efficacy relative to other oral MS therapies, both in newly-treated MS patients and those previously treated with a prior disease modifying therapy (DMT). Subgroup analyses of the open-label studies PROTEC and RESPOND assessed TECFIDERA in early MS and early switch patients, respectively. Results showed that TECFIDERA significantly reduced the annualized relapse rate over one year in the early MS subgroups, including those who switched to TECFIDERA from a prior DMT. Additional data presented at the AAN meeting affirmed the well-characterized, long-term safety profile of TECFIDERA in patients treated for up to nine years.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">TYSABRI (natalizumab)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2017 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion to update the TYSABRI E.U. label with pediatric information to remove the contraindication in pediatrics and to describe the results of the post-marketing meta-analysis of pediatric data. The label update entitles us to apply for a six-month extension to the E.U. patent Supplementary Protection Certificate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2017 we presented new real-world data from the TYSABRI Observational Program that confirmed the efficacy of TYSABRI and demonstrated that early and continued treatment leads to better clinical outcomes. These data were presented at the 69</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of AAN in Boston, MA.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">FAMPYRA (prolonged-release fampridine tablets)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 the European Commission (EC) granted a standard marketing authorization for FAMPYRA for walking improvement in people with MS. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">ZINBRYTA (daclizumab)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 the EMA announced that it had provisionally restricted the use of ZINBRYTA to adult patients with highly active relapsing disease despite a full and adequate course of treatment with at least one DMT or with rapidly evolving severe relapsing MS who are unsuitable for treatment with other DMTs. These restrictions followed the initiation of an EMA review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, as part of the Article 20 Procedure of ZINBRYTA, the EMA Pharmacovigilance Risk Assessment Committee (PRAC) completed its assessment and recommended a further set of restrictions on the use of ZINBRYTA by MS patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 the CHMP adopted an opinion, confirming the PRAC's recommendations, for further restrictions to minimize the risk of serious liver injury with ZINBRYTA, including restriction of its use to adult patients with relapsing forms of MS who have had an inadequate response to at least two DMTs and for whom treatment with any other DMT is contraindicated or otherwise unsuitable. In January 2018 the EC adopted a final and legally-binding decision, which concluded the Article 20 Procedure, confirming the CHMP opinion. As a result of the CHMP's recommendation of these restrictions, we recorded net impairment charges related to intangible assets, inventory, property, plant and equipment and prepaid tax assets, totaling approximately </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$190.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Offsetting these amounts was an unrecorded tax benefit related to certain ZINBRYTA related assets totaling approximately </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$93.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Opicinumab (anti-LINGO-1)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we initiated the Phase 2b clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with relapsing MS. The trial follows the comprehensive review of SYNERGY, a Phase 2 trial, which identified a specific population that may be more likely to respond to treatment.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we presented data supporting opicinumab as a potential therapy to repair damage to the central nervous system caused by MS. These data were presented at the seventh Joint Meeting of the European Committee for Treatment and Research in MS and Americas Committee for Treatment and Research in MS (ECTRIMS-ACTRIMS).</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neuromuscular Disorders</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">SPINRAZA (nusinersen)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we presented new data from the Phase 3 ENDEAR study of SPINRAZA, which demonstrated a statistically significant reduction in the risk of death or permanent ventilation in SPINRAZA-treated infants with SMA compared to untreated infants. The data were presented at the British Pediatric Neurology Association annual conference in Cambridge, U.K.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2017 the CHMP of the EMA adopted a positive opinion recommending the granting of a marketing authorization in the E.U. for SPINRAZA to treat patients with SMA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2017 we presented Phase 3 end of study SPINRAZA data from CHERISH, which demonstrated a highly statistically significant and clinically meaningful improvement in motor function in children with later-onset (most likely to develop Type 2 or Type 3) SMA compared to untreated children. The overall findings continued to support the efficacy and favorable safety profile of SPINRAZA across a broad range of individuals with SMA.  </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also presented interim data from the Phase 2 NURTURE study evaluating SPINRAZA for the treatment of infants under six weeks old with genetically diagnosed SMA who were presymptomatic at treatment initiation. At the time of the interim analysis, infants (n=20) were enrolled for a median of 317.5 days, and all infants were alive and none required respiratory intervention (chronic non-invasive ventilation, invasive ventilation or tracheostomy). Further, most infants achieved motor milestone and growth parameter gains generally consistent with normal development, such as head control, independent sitting, standing and walking independently, as measured by validated scales.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These data were presented at the 69</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of AAN in Boston, MA.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 the EC granted a marketing authorization for SPINRAZA for the treatment of 5q SMA in pediatric and adult patients in the E.U. SPINRAZA is the first approved treatment in the E.U. for SMA. SPINRAZA was reviewed under the EMA&#8217;s accelerated assessment program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 we presented robust efficacy and safety data from Phase 2 and Phase 3 SPINRAZA studies at the Cure SMA 2017 Annual SMA Conference in Orlando, FL. Data demonstrated motor function improvements in infants on permanent ventilation and no increase in the risk of adverse events in children with scoliosis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 the Japanese Ministry of Health, Labor and Welfare approved the use of SPINRAZA for the treatment of infantile SMA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2017 the Japanese Ministry of Health, Labor and Welfare approved the use of SPINRAZA for the treatment of pediatric and adult patients with SMA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we presented new data at the 22</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;International Congress of the World Muscle Society demonstrating that earlier initiation of treatment with SPINRAZA may improve motor function outcomes in infants and children with SMA. Results demonstrated the favorable efficacy and safety profile of SPINRAZA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we and Ionis were awarded the 2017 Prix Galien USA Award for Best Biotechnology Product for SPINRAZA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 the end of study results from ENDEAR, the Phase 3 study of SPINRAZA, were published in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">The New England Journal of Medicine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Alzheimer's Disease and Dementia</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Aducanumab (BIIB037)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 we presented data from research of aducanumab at the 13</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases (AD/PD&#8482;) in Vienna, Austria.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2017 we presented data from a Phase 1b study of aducanumab at the 69</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of the AAN in Boston, MA. This data was previously presented at the Clinical Trials on Alzheimer&#8217;s Disease (CTAD) meeting </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">in December 2016 and included interim results from the titration cohort of the placebo-controlled period of the Phase 1b study as well as data from the first year of the long-term extension (LTE).</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 we announced that we had amended the protocol of the Phase 3 trials of aducanumab. ApoE4 carriers that previously would be on a high dose of 6 mg/kg may now be titrated up to 10 mg/kg. This amendment is being reviewed by regulatory bodies and clinical study ethic independent review boards globally and may be implemented on a country by country basis. The change has already been incorporated in the U.S.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we presented a new post-hoc analysis of the Phase 1b PRIME study of aducanumab at the Alzheimer&#8217;s Association International Conference in London, U.K. Data presented included changes in the cognitive and functional subscores of the clinical dementia rating score. Aducanumab slowed decline on both the cognitive and functional assessments compared to placebo, and the results of all subgroups studied were consistent with the overall study population.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 we announced results from a recently conducted analysis of the LTE of our ongoing Phase 1b study of aducanumab. The updated analyses include data from the placebo-controlled period and the LTE for patients treated with aducanumab up to 24 months in the titration cohort and up to 36 months in the fixed-dose cohorts. The results are consistent with previously reported analyses from this ongoing Phase 1b study and support the design of the ongoing Phase 3 studies of aducanumab for early AD.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we presented new data from the LTE of our ongoing Phase 1b study of aducanumab at the CTAD meeting in Boston, MA. The data included results from patients in the Phase 1b study who were treated with a gradually increased dose of aducanumab for up to 24 months and those who were treated with a fixed dose of 3, 6 or 10 mg/kg aducanumab for up to 36 months. The results are consistent with previously reported analyses from the Phase 1b study and support the design of the ongoing Phase 3 studies of aducanumab for early AD.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BAN2401 (A&#946; mAb)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2017 we announced that an Independent Data Monitoring Committee determined that BAN2401 did not meet the criteria for success based on a Bayesian analysis at 12 months as the primary endpoint in an 856-patient Phase 2 clinical study. Following the predefined study protocol, the blinded study will continue and a comprehensive final analysis will be conducted at 18 months seeking to demonstrate clinically significant results. The results of the final analysis are expected to be obtained during the second half of 2018.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB076</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we initiated a Phase 1 trial of BIIB076, an anti-tau monoclonal antibody, in healthy volunteers and participants with AD.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB092</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 we dosed our first patient in our Phase 2 study of BIIB092 for PSP.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB080 (also known as Ionis-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 our collaboration partner Ionis announced the initiation of a Phase 1/2a clinical study of IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in patients with mild AD. IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is an antisense drug designed to selectively reduce the production of microtubule-associated protein tau (MAPT), or tau protein, in the brain. We have an option to develop and commercialize IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Movement Disorders</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB054 (anti-alpha-synuclein antibody)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 we presented data from research of BIIB054, our investigational treatment for Parkinson&#8217;s disease, at the 13</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases (AD/PD&#8482;) in Vienna, Austria.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we completed enrollment in the Phase 1 study of BIIB054 in both healthy volunteers and patients with early onset Parkinson&#8217;s disease.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we dosed our first patient in our Phase 2 SPARK study of BIIB054 in Parkinson's disease.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Emerging Growth Areas</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acute Neurology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Natalizumab (&#945;4-integrin inhibitor) - Acute Ischemic Stroke</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 we completed enrollment in the Phase 2b ACTION2 study evaluating the effects of natalizumab versus placebo on clinical measures of functional independence and activities of daily living in acute ischemic stroke patients.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Natalizumab - Epilepsy</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we initiated the Phase 2 OPUS study evaluating the efficacy, safety and tolerability of natalizumab in drug-resistant focal epilepsy.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Samsung Bioepis - Biogen's Joint Venture with Samsung Biologics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BENEPALI (Etanercept)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 we presented real-world evidence from investigator-initiated studies supported by us demonstrating sustained efficacy and safety of, and high acceptance and adherence in patients initiating treatment with, BENEPALI. These data were presented at the Annual European Congress of Rheumatology (EULAR) in Madrid.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">IMRALDI (Adalimumab)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 the CHMP of the EMA issued a positive opinion for IMRALDI, an adalimumab biosimilar candidate referencing HUMIRA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the EC granted a marketing authorization for IMRALDI. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Genentech Relationship</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-CD20 Therapies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">OCREVUS (ocrelizumab)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FDA approved OCREVUS, a humanized anti-CD20 monoclonal antibody, for the treatment of relapsing MS (RMS) and primary progressive MS (PPMS).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 OCREVUS was approved in Australia for the treatment of RMS and PPMS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2017 OCREVUS was approved in Switzerland for the treatment of RMS and PPMS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 the EC granted a marketing authorization for OCREVUS for the treatment of RMS and PPMS.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">RITUXAN (rituximab)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 Roche announced that the FDA&#8217;s Oncologic Drugs Advisory Committee voted unanimously that the benefit-risk of rituximab/hyaluronidase for subcutaneous (under the skin) injection was favorable for the treatment of certain blood cancers. This new co-formulation includes the same monoclonal antibody as intravenous RITUXAN and hyaluronidase, a molecule that helps to deliver medicine under the skin.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 the FDA approved RITUXAN HYCELA (rituximab and hyaluronidase human) for subcutaneous injection for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma and CLL. This new treatment includes the same monoclonal antibody as intravenous RITUXAN in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">GAZYVA</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone in those who responded, for people with previously untreated advanced follicular lymphoma. The approval is based on results from the Phase 3 GALLIUM study, which showed superior progression-free survival for patients who received this GAZYVA-based regimen compared with those who received a RITUXAN-based regimen as an initial therapy.&#160;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Idiopathic Pulmonary Fibrosis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BG00011 (STX-100)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we reported that BG00011 (STX-100) achieved proof of biology in a Phase 2a study in patients with idiopathic pulmonary fibrosis (IPF), a chronic irreversible and ultimately fatal disease characterized by a progressive decline in lung function. We plan to initiate a Phase 2b study for BG00011 in 2018.</font></div></td></tr></table><div><a name="sD1D664C05F9E516299D5F0C70BF286C7"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Marketed Products</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following graphs show our revenues by product and revenues from anti-CD20 therapeutic programs and geography as a percentage of revenues for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:center;"><img src="principalproductschart.jpg" alt="principalproductschart.jpg" style="height:637px;width:317px;"></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(1) Interferon includes AVONEX and PLEGRIDY</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(2) Other includes ZINBRYTA, FAMPYRA, ELOCTATE, ALPROLIX, FUMADERM, BENEPALI and FLIXABI</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:center;"><img src="geographicsaleschart.jpg" alt="geographicsaleschart.jpg" style="height:508px;width:317px;"></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales for TECFIDERA, AVONEX and TYSABRI and anti-CD20 therapeutic programs for RITUXAN each accounted for more than 10% of our total revenues for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional financial information about our product and other revenues and geographic areas where we operate, please read Note&#160;25, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements, Item&#160;6. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Selected Financial Data </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Item 7. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management's Discussion and Analysis of Financial Condition and Results of Operations </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">included in this report. A discussion of the risks attendant to our operations is set forth in Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis and Neuroimmunology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, leading to a loss of muscle control, paralysis and, in some cases, death. Patients with active RMS experience an uneven pattern of disease progression characterized by periods of stability that are interrupted by flare-ups of the disease after which the patient returns to a new baseline of functioning. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our MS products and major markets include:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:28%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Collaborator</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="tecfidera.jpg" alt="tecfidera.jpg" style="height:37px;width:172px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS in the U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing-remitting MS (RRMS) in the E.U.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="avonex.jpg" alt="avonex.jpg" style="height:49px;width:134px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="plegridy.jpg" alt="plegridy.jpg" style="height:77px;width:128px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS in the U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RRMS in the E.U.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="tysabri.jpg" alt="tysabri.jpg" style="height:62px;width:114px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Crohn's disease in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="zinbryta.jpg" alt="zinbryta.jpg" style="height:53px;width:144px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AbbVie Inc. (AbbVie)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="fampyra.jpg" alt="fampyra.jpg" style="height:37px;width:133px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Walking ability for patients with MS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acorda Therapeutics, Inc. (Acorda)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Neuromuscular Diseases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SMA is characterized by loss of motor neurons in the spinal cord and lower brain stem, resulting in severe and progressive muscular atrophy and weakness. Ultimately, individuals with the most severe type of SMA can become paralyzed and have difficulty performing the basic functions of life, like breathing and swallowing. Due to a loss of, or defect in, the SMN1 gene, people with SMA do not produce enough survival motor neuron (SMN) protein, which is critical for the maintenance of motor neurons. The severity of SMA correlates with the amount of SMN protein. People with Type 1 SMA, the most severe life-threatening form, produce very little SMN protein and do not achieve the ability to sit without support or live beyond two years without respiratory support. People with Type 2 and Type 3 SMA produce greater amounts of SMN protein and have less severe, but still life-altering, forms of SMA.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 the FDA approved SPINRAZA for the treatment of SMA in pediatric and adult patients. In June 2017 the EC approved SPINRAZA for the treatment of SMA in pediatric and adult patients in the E.U. The Japanese Ministry of Health, Labor and Welfare approved SPINRAZA for the treatment of infantile SMA in July 2017 and for the treatment of pediatric and adult patients with SMA in September 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products for SMA and major markets include: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:28%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Collaborator</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><img src="spinrazalogonewa01.jpg" alt="spinrazalogonewa01.jpg" style="height:80px;width:160px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SMA</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Turkey</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars are a group of biologic medicines that are similar to currently available biologic therapies known as originators. Under our agreement with Samsung Bioepis, we manufacture and commercialize two anti-TNF biosimilars in certain countries in the E.U.: BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE. In August 2017 the EC granted a marketing authorization for IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the E.U. </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="benepalia02.jpg" alt="benepalia02.jpg" style="height:49px;width:141px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Moderate to severe rheumatoid arthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Progressive psoriatic arthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Axial spondyloarthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Moderate to severe plaque psoriasis</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Norway</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sweden</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="flixabi.jpg" alt="flixabi.jpg" style="height:49px;width:133px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rheumatoid arthritis<br>Moderate to severe Crohn's disease<br>Severe ulcerative colitis<br>Severe ankylosing spondylitis<br>Psoriatic arthritis<br>Moderate to severe plaque psoriasis</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Genentech that entitles us to certain business and financial rights with respect to RITUXAN, GAZYVA, OCREVUS and other anti-CD20 product candidates. Current products include:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="rituxan.jpg" alt="rituxan.jpg" style="height:46px;width:128px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-Hodgkin's lymphoma</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CLL</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rheumatoid arthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Two forms of ANCA-associated vasculitis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="gazyva.jpg" alt="gazyva.jpg" style="height:57px;width:76px;"></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In combination with chlorambucil for previously untreated CLL</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Follicular lymphoma</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="ocrevusmultiplesclerosislogo.jpg" alt="ocrevusmultiplesclerosislogo.jpg" style="height:48px;width:156px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RMS</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">PPMS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australia</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information about our anti-CD20 therapeutic programs and related agreements with Genentech, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:28%;"></td><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Collaborator</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="fumaderm.jpg" alt="fumaderm.jpg" style="height:45px;width:116px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Moderate to severe plaque psoriasis</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><a name="sD41F0C62AF1D53DA85C80DA7400CA460"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Patient Support and Access</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We interact with patients, advocacy organizations and healthcare societies in order to gain insights into unmet needs. The insights gained from these engagements help us support patients with services, programs and applications that are designed to help patients lead better lives. Among other things, we provide customer service and other related programs for our products, such as disease and product specific websites, insurance research services, financial assistance programs and the facilitation of the procurement of our marketed products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are dedicated to helping patients obtain access to our therapies. Our patient representatives have access to a comprehensive suite of financial assistance tools. With those tools, we help patients understand their insurance coverage and, if needed, help patients compare and select new insurance options and programs. In the U.S., we have established programs that provide co-pay assistance or free marketed product for qualified uninsured or underinsured patients, based on specific eligibility criteria. We also provide charitable contributions to independent charitable organizations that assist patients with out-of-pocket expenses associated with their therapy.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Marketing and Distribution</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales Force and Marketing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We promote our products worldwide, including in the U.S., most of the major countries of the E.U. and Japan, primarily through our own sales forces and marketing groups. In some countries, particularly in areas where we continue to expand into new geographic areas, we partner with third parties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We co-promote ZINBRYTA with AbbVie in the U.S., E.U. and Canadian territories and BENEPALI and FLIXABI with Samsung Bioepis in certain countries in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN, GAZYVA and OCREVUS are marketed by the Roche Group and its sublicensees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We focus our sales and marketing efforts on specialist physicians in private practice or at major medical centers. We use customary pharmaceutical company practices to market our products and to educate physicians, such as sales representatives calling on individual physicians, advertisements, professional symposia, direct mail, public relations and other methods. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Distribution Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We distribute our products in the U.S. principally through wholesale distributors of pharmaceutical products, mail order specialty distributors or shipping service providers. In other countries, the distribution of our products varies from country to country, including through wholesale distributors of pharmaceutical products and third-party distribution partners who are responsible for most marketing and distribution activities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AbbVie distributes ZINBRYTA in the U.S., and we distribute ZINBRYTA in ex-U.S. markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We distribute BENEPALI and FLIXABI in certain countries in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN, GAZYVA and OCREVUS are distributed by the Roche Group and its sublicensees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our product sales to two wholesale distributors, AmerisourceBergen and McKesson, each accounted for more than 10% of our total revenues for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and on a combined basis, accounted for approximately 56%, 57% and 60% of our gross product revenues for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information, please read Note 25, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div><a name="sF61B36DC7411547F96D4ADC288C9F082"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Patents and Other Proprietary Rights</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patents are important to obtaining and protecting exclusive rights in our products and product candidates. We regularly seek patent protection in the U.S.&#160;and in selected countries outside the U.S.&#160;for inventions originating from our research and development efforts. In addition, we license rights to various patents and patent applications. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.&#160;patents, as well as most foreign patents, are generally effective for 20&#160;years from the date the earliest application was filed; however, U.S.&#160;patents that issue on applications filed before June&#160;8, 1995&#160;may be effective until 17&#160;years from the issue date, if that is later than the 20-year date. In some cases, the patent term may be extended to recapture a portion of the term lost during regulatory review of the claimed therapeutic or, in the case of the U.S., because of U.S.&#160;Patent and Trademark Office (USPTO) delays in prosecuting the application. Specifically, in the U.S., under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, a patent that covers an FDA-approved drug may be eligible for patent term </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">extension (for up to 5 years, but not beyond a total of 14 years from the date of product approval) as compensation for patent term lost during the FDA regulatory review process. The duration and extension of the term of foreign patents varies, in accordance with local law. For example, supplementary protection certificates (SPCs) on some of our products have been granted in a number of European countries, compensating in part for delays in obtaining marketing approval.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory exclusivity, which may consist of regulatory data protection and market protection, also can provide meaningful protection for our products. Regulatory data protection provides to the holder of a drug or biologic marketing authorization, for a set period of time, the exclusive use of the proprietary pre-clinical and clinical data that it created at significant cost and submitted to the applicable regulatory authority to obtain approval of its product. After the applicable set period of time, third parties are then permitted to rely upon our data to file for approval of their abbreviated applications for, and to market (subject to any applicable market protection), their generic drugs and biosimilars referencing our data. Market protection provides to the holder of a drug or biologic marketing authorization the exclusive right to commercialize its product for a set period of time, thereby preventing the commercialization of another product containing the same active ingredient(s) during that period. Although the World Trade Organization's agreement on trade-related aspects of intellectual property rights (TRIPS) requires signatory countries to provide regulatory exclusivity to innovative pharmaceutical products, implementation and enforcement varies widely from country to country.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely upon other forms of unpatented confidential information to remain competitive. We protect such information principally through confidentiality agreements with our employees, consultants, outside scientific collaborators, scientists whose research we sponsor and other advisers. In the case of our employees, these agreements also provide, in compliance with relevant law, that inventions and other intellectual property conceived by such employees during their employment shall be our exclusive property.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our trademarks are important to us and are generally covered by trademark applications or registrations in the USPTO and the patent or trademark offices of other countries. We also use trademarks licensed from third parties, such as the trademark FAMPYRA which we license from Acorda. Trademark protection varies in accordance with local law, and continues in some countries as long as the trademark is used and in other countries as long as the trademark is registered. Trademark registrations generally are for fixed but renewable terms.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our Patent Portfolio </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes our patents in the U.S. and Europe that we currently consider of primary importance to our marketed products, including the territory, patent number, general subject matter and expected expiration dates. Except as otherwise noted, the expected expiration dates include any granted patent term extensions and issued SPCs. In some instances, there are later-expiring patents relating to our products directed to, among other things, particular forms or compositions, methods of manufacturing or use of the drug in the treatment of particular diseases or conditions. We also continue to pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our products that may, if issued, extend exclusivity beyond the expiration of the patents listed in the table.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Patent No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">General Subject Matter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Patent </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Expiration</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,619,001</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,803,840</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,399,514</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2028</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,524,773</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">6,509,376</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Formulations of dialkyl fumarates for use in the treatment of autoimmune diseases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,759,393</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Formulations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,320,999</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1131065</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Formulations of dialkyl fumarates and their use for treating autoimmune diseases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2137537</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of use</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2028</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">AVONEX and PLEGRIDY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,588,755</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Use of recombinant beta interferon for immunomodulation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">PLEGRIDY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,446,173</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon beta-1a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,524,660</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,017,733</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon beta-1a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1656952</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon-beta-1a and uses thereof</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1476181</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon-beta-1a and uses thereof</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TYSABRI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">6,602,503</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Humanized recombinant antibodies; nucleic acids and host cells; processes for production; therapeutic compositions; methods of use</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,807,167</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">9,493,567</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">0804237</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Humanized immunoglobulins; nucleic acids; pharmaceutical compositions; medical uses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2020</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(5)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1485127</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of use </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">FAMPYRA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1732548</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Sustained-release aminopyridine compositions for increasing walking speed in patients with MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(6)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">23775536</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Sustained-release aminopyridine compositions for treating MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(7)</sup></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">ZINBRYTA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,454,965</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,258,859</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">9,340,619</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Daclizumab HYP compositions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2032</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1539200</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Anti-IL-2-receptor antibody for use in a method of treating a subject with MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">SPINRAZA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">6,166,197</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Oligomeric Compounds Having Pyrimidine Nucleotide(s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">6,210,892</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Alteration of Cellular Behavior By Antisense Modulation of MRNA Processing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,101,993</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Oligonucleotides Containing 2&#8217;-O-Modified Purines</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,838,657</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">SMA Treatment Via Targeting of SMN2 Splice Site Inhibitory Sequences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,110,560</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">SMA Treatment Via Targeting of SMN2 Splice Site Inhibitory Sequences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,361,977</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions And Methods For Modulation of SMN2 Splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,980,853</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions And Methods For Modulation of SMN2 Splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">9,717,750</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and Methods For Modulation of SMN2 Splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1910395</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions And Methods For Modulation of SMN2 Splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2548560</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions And Methods For Modulation of SMN2 Splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Footnotes follow on next page.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">In addition to patent protection, certain of our products are entitled to regulatory exclusivity in the U.S. and the E.U. expected until the dates set forth below:</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:2%;"></td><td style="width:21%;"></td><td style="width:2%;"></td><td style="width:55%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Expected Expiration</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">PLEGRIDY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">FAMPYRA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2021</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">ZINBRYTA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2028</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">SPINRAZA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027**</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-6px;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*ZINBRYTA was not designated a new active substance at the time of its approval in the E.U. and is not automatically entitled to regulatory exclusivity. Regulatory exclusivity may, however, be available for independent development of known active substances. We intend to assert the protection of its data on this basis.</font></div><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-6px;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**SPINRAZA may be eligible for an additional two years exclusivity in Europe based on the orphan pediatric indication.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2024. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent was revoked in a European opposition. This decision is being appealed. The patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2029.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2028.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Reflects SPCs granted in most European countries and pediatric extension in some countries.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2026.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2026.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The existence of patents does not guarantee our right to practice the patented technology or commercialize the patented product. Patents relating to pharmaceutical, biopharmaceutical and biotechnology products, compounds and processes, such as those that cover our existing compounds, products and processes and those that we will likely file in the future, do not always provide complete or adequate protection. Litigation, interferences, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews or other proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our patents, regulatory exclusivities or other proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patents, regulatory exclusivities and other proprietary rights covering our products by manufacturers of generics and biosimilars. A discussion of certain risks and uncertainties that may affect our patent position, regulatory exclusivities and other proprietary rights is set forth in Item 1A.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report, and a discussion of legal proceedings related to certain patents described above is set forth in Note&#160;21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><a name="sC6E3E408D49D544E94DC0116ED86B7D8"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition in the biopharmaceutical industry is intense and comes from many sources, including specialized biotechnology firms and large pharmaceutical companies. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. Certain of these companies have substantially greater financial, marketing and research and development resources than we do.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that competition and leadership in the industry is based on managerial and technological excellence and innovation as well as establishing patent and other proprietary positions through research and development. The achievement of a leadership position also depends largely upon our ability to maximize the approval, acceptance and use of products resulting from research and the availability of adequate financial resources to fund facilities, equipment, personnel, clinical testing, manufacturing and marketing. Another key aspect of remaining competitive within the industry is recruiting and retaining leading scientists and technicians. We believe that we have been successful in attracting and retaining skilled and experienced scientific personnel.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition among products approved for sale may be based, among other things, on patent position, product efficacy, safety, convenience/delivery devices, reliability, availability and price. In addition, early entry of a new pharmaceutical product into the market may have important advantages in gaining product acceptance and market share. Accordingly, the relative speed with which we can develop products, complete the testing and approval process and supply commercial quantities of products will have a significant impact on our competitive position.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The introduction of new products or technologies, including the development of new processes or technologies by competitors or new information about existing products or technologies, may result in increased competition for our marketed products or pricing pressure on our marketed products. It is also possible that the development of new or improved treatment options or standards of care or cures for the diseases our products treat could reduce or eliminate the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates. We may also face increased competitive pressures as a result of generics and the emergence of biosimilars in the U.S. and E.U. If a generic or biosimilar version of one of our products were approved, it could reduce our sales of that product.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional information about the competition that our marketed products face is set forth below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and ZINBRYTA each compete with one or more of the following products: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:2%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Competing Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Competitor</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">AUBAGIO (teriflunomide)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sanofi</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">BETASERON/BETAFERON (interferon-beta-1b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Bayer Group</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">COPAXONE </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(glatiramer acetate)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Teva Pharmaceuticals Industries Ltd.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">EXTAVIA </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(interferon-beta-1b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Novartis AG</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">GILENYA (fingolimod)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Novartis AG</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">GLATOPA (glatiramer acetate)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sandoz, a division of Novartis AG</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">LEMTRADA (alemtuzumab)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sanofi</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">OCREVUS (ocrelizumab)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Genentech</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">REBIF </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(interferon-beta-1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Merck KGaA (and co-promoted with Pfizer Inc. in the U.S.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA is indicated as a treatment to improve walking in adult patients with MS who have walking disability and is the first treatment that addresses this unmet medical need with demonstrated efficacy in people with all types of MS. FAMPYRA is currently the only therapy approved to improve walking in patients with MS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition in the MS market is intense.&#160;Along with us, a number of companies are working to develop additional treatments for MS that may in the future compete with our MS products. One such product that was approved in the U.S. in 2017 and in the E.U. in 2018 is OCREVUS, a treatment for RMS and PPMS that was developed by Genentech. While we have a financial interest in OCREVUS, future sales of our MS products may be adversely affected if OCREVUS continues to gain market share, or if other MS products that we or our competitors are developing are commercialized</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Future sales may also be negatively impacted</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">by</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of generics, prodrugs of existing therapeutics or biosimilars of existing products and other technologies.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA is the only approved treatment for SMA. We are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Psoriasis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM competes with several different types of therapies in the psoriasis market within Germany, including oral systemics such as methotrexate and cyclosporine.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI and FLIXABI, the two biosimilars we currently manufacture and commercialize in the E.U. for Samsung Bioepis, compete with their applicable reference products, ENBREL and REMICADE, respectively, as well as other biosimilars of those reference products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech Relationships in Other Indications</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN and GAZYVA in Oncology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN and GAZYVA compete with a number of therapies in the oncology market, including TREANDA (bendamustine HCL), ARZERRA (ofatumumab), IMBRUVICA (ibrutinib) and ZYDELIG (idelalisib). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also expect that over time GAZYVA will increasingly compete with RITUXAN in the oncology market. In addition, we are aware of other anti-CD20 molecules, including biosimilars, in development that, if successfully developed and approved, may compete with RITUXAN and GAZYVA in the oncology market.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN in Rheumatoid Arthritis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN competes with several different types of therapies in the rheumatoid arthritis market, including, among others, traditional disease-modifying anti-rheumatic drugs such as steroids, methotrexate and cyclosporine, TNF inhibitors, ORENCIA (abatacept), ACTEMRA (tocilizumab) and XELJANZ (tofacitinib).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also aware of other products, including biosimilars, in development that, if successfully developed and approved, may compete with RITUXAN in the rheumatoid arthritis market. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="sCA4651F904DF5AEAB5C4F6A9BAADB67A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Research and Development Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A commitment to research is fundamental to our mission. Our research efforts are focused on better understanding the underlying biology of diseases so we can discover and deliver treatments that have the potential to make a real difference in the lives of patients with high unmet medical needs. By applying our expertise in biologics and our growing capabilities in small molecule, antisense, gene therapy, gene editing and other technologies, we target specific medical needs where we believe new or better treatments are needed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to research and development opportunities.  As part of our ongoing research and development efforts, we have devoted significant resources to conducting clinical studies to advance the development of new pharmaceutical products and technologies and to explore the utility of our existing products in treating disorders beyond those currently approved in their labels.</font></div><div style="line-height:120%;text-align:center;"><img src="part1researchanddevchart.jpg" alt="part1researchanddevchart.jpg" style="height:198px;width:317px;"></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The table below highlights our current research and development programs that are in clinical trials and the current phase of such programs. Drug development involves a high degree of risk and investment, and the status, timing and scope of our development programs are subject to change. Important factors that could adversely affect our drug development efforts are discussed in Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:8%;"></td><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:3%;"></td><td style="width:6%;"></td><td style="width:6%;"></td></tr><tr><td rowspan="21" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Core Growth Areas</font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">MS and Neuroimmunology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BIIB098 (monomethly fumarate prodrug)* - MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Opicinumab (anti-LINGO-1) - MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="11" style="vertical-align:middle;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Alzheimer's Disease and Dementia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Aducanumab (A&#946; mAb)* - Alzheimer's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Elenbecestat (E2609)* - Alzheimer's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BAN2401 (A&#946; mAb)* - Alzheimer's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BIIB092 (anti-tau mAb) - Alzheimer's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BIIB076 (anti-tau mAb)* - Alzheimer's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BIIB080 (IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)* - Alzheimer's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Parkinson's Disease and Movement Disorders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BIIB092 (anti-tau mAb) - PSP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BIIB054 (anti-</font><font style="font-family:Arial;font-size:8pt;color:#2573ba;">alpha</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">-synuclein mAb) - Parkinson's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Neuromuscular Disease Including SMA and ALS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BIIB067 (IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)* - ALS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="11" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Emerging Growth Areas</font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Pain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BIIB074 (Vixotrigine) - Trigeminal Neuralgia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BIIB074 (Nav1.7) - PLSR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Ophthalmology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BIIB087 (gene therapy)* - XLRS^</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1/2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Acute Neurology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BIIB093 (glibenclamide IV) - LHI Stroke</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Natalizumab - AI Stroke</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Natalizumab - Epilepsy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cecece;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cecece;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">Dapirolzumab pegol (anti-CD40L)* - SLE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">@</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cecece;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BG00011 (STX-100) - IPF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cecece;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">BIIB059 (anti-BDCA2) - SLE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">@</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Collaboration programs</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"># Painful Lumbosacral Radiculophath (PLSR)</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">^ X-linked Retinoschisis (XLRS)</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">@ Systemic Lupus Erythematosus (SLE)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information about certain of our agreements with collaborators and other third parties, please read the subsection entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Business Relationships&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;below and Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s93838FF5772354599E1DC8A1C0478B55"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Business Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of our business strategy, we establish business relationships, including joint ventures and collaborative arrangements with other companies, universities and medical research institutions, to assist in the clinical development and/or commercialization of certain of our products and product candidates and to provide support for our research programs. We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business from other companies, universities and medical research institutions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Below is a brief description of certain business relationships and collaborations that expand our </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pipeline and provide us with certain rights to existing and potential new products and technologies. For additional information on certain of these relationships, including their ongoing financial and accounting impact on our business, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie for the development and commercialization of ZINBRYTA in MS. Under this agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories, and we are responsible for all manufacturing and research and development activities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Acorda to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Alkermes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive license and collaboration agreement with Alkermes to develop and commercialize BIIB098, an oral MMF prodrug in Phase 3 development for the treatment of relapsing forms of MS.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Applied Genetic Technologies Corporation (AGTC) to develop gene-based therapies for multiple ophthalmic diseases. This collaboration is focused on the development of a clinical-stage candidate for X-linked Retinoschisis (XLRS) and a preclinical candidate for the treatment of X-linked Retinitis Pigmentosa (XLRP), for which we were granted worldwide commercialization rights. This agreement also provides us with options to early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive license agreement with BMS for the development and commercialization of BIIB092. Under this agreement, we received worldwide rights to BIIB092 and are responsible for the full development and global commercialization of BIIB092 in AD and PSP. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai to jointly develop and commercialize E2609 and BAN2401, two Eisai product candidates for the treatment of AD.&#160;Eisai serves as the global operational and regulatory lead for both E2609 and BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. Following marketing approval in major markets, we will co-promote E2609 and BAN2401 with Eisai and share profits equally. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have the Aducanumab Collaboration Agreement with Eisai for the joint development and commercialization of aducanumab. Under the Aducanumab Collaboration Agreement, the two companies will co-promote aducanumab with a region-based profit split and we will continue to lead the ongoing Phase 3 development of aducanumab. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai will co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai will distribute AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Genentech which entitles us to certain financial and other rights with respect to RITUXAN, GAZYVA, OCREVUS and other anti-CD20 product candidates. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive, worldwide option and collaboration agreement with Ionis relating to the development and commercialization of up to three gene targets, and an exclusive, worldwide option and collaboration agreement with Ionis under which both companies are responsible for the development and commercialization of SPINRAZA for the treatment of SMA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have research collaboration agreements with Ionis, under which both companies perform discovery level research and will develop and commercialize new ASO drug candidates for the treatment of SMA and additional antisense and other therapeutics for the treatment of neurological disorders.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Neurimmune</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the treatment of AD, including aducanumab. Under this agreement, we are responsible for the development, manufacturing and commercialization of all licensed products.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Samsung Biologics established a joint venture, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;We also have an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-TNF biosimilar product candidates in specified E.U. countries and, in the case of BENEPALI, Japan.&#160;Under this agreement, we are manufacturing and commercializing BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our joint venture and commercialization agreement with Samsung Bioepis, we license certain of our proprietary technology to Samsung Bioepis in connection with Samsung Bioepis' development, manufacture and commercialization of its biosimilar products. We also provide technical development and technology transfer services to Samsung Bioepis, and manufacture clinical and commercial quantities of bulk drug substance of Samsung Bioepis' biosimilar products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">University of Pennsylvania</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and alliance with the University of Pennsylvania (UPenn) to advance gene therapy and gene editing technologies. The collaboration is primarily focused on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. The alliance is also focused on the research and validation of next-generation gene transfer technology using adeno-associated virus gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s794503D533BA5639818ED287A7FD51D5"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Regulatory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current and contemplated activities and the products, technologies and processes that result from such activities are subject to substantial government regulation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation of Pharmaceuticals</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Approval and Post-Approval Regulation in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">APPROVAL PROCESS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Before new pharmaceutical products may be sold in the U.S., preclinical studies and clinical trials of the products must be conducted and the results submitted to the FDA for approval. With limited exceptions, the FDA requires companies to register both pre-approval and post-approval clinical trials and disclose clinical trial results in public databases. Failure to register a trial or disclose study results within the required time periods could result in penalties, including civil monetary penalties. Clinical trial programs must establish efficacy, determine an appropriate dose and dosing regimen, and define the conditions for safe use. This is a high-risk process that requires stepwise clinical studies in which the candidate product must successfully meet predetermined endpoints. The results of the preclinical and clinical testing of a product are then submitted to the FDA in the form of a Biologics License Application (BLA) or a New Drug Application (NDA). In response to a BLA or NDA, the FDA may grant marketing approval, request additional information or deny the application if it determines the application does not provide an adequate basis for approval.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development and receipt of regulatory approval takes a number of years, involves the expenditure of substantial resources and depends on a number of factors, including the severity of the disease in question, the availability of alternative treatments, potential safety signals observed in preclinical or clinical tests and the risks and benefits of the product as demonstrated in clinical trials. The FDA has substantial discretion in the product approval process, and it is impossible to predict with any certainty whether and when the FDA will grant marketing approval. The agency may require the sponsor of a BLA or NDA to conduct additional clinical studies or to provide other scientific or technical information about the product, and these additional requirements may lead to unanticipated delay or expense. Furthermore, even if a product is approved, the approval may be subject to limitations based on the FDA's interpretation of the existing pre-clinical or clinical data. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA has developed four distinct approaches intended to make therapeutically important drugs available as rapidly as possible, especially when the drugs are the first available treatment or have advantages over existing treatments: accelerated approval, fast track, breakthrough therapy and priority review.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Accelerated Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant &#8220;accelerated approval&#8221; status to products that treat serious or life-threatening illnesses and that provide meaningful therapeutic benefits to patients over existing treatments. Under this pathway, the FDA may approve a product based on surrogate endpoints, or clinical endpoints other than survival or irreversible morbidity. When approval is based on surrogate endpoints or clinical endpoints other than survival or morbidity, the sponsor will be required to conduct additional post-approval clinical studies to verify and describe clinical benefit. Under the FDA's accelerated approval regulations, if the FDA concludes that a drug that has been shown to be effective can be safely used only if distribution or use is restricted, it may require certain post-marketing restrictions as necessary to assure safe use. In addition, for products approved under accelerated approval, sponsors may be required to submit all copies of their promotional materials, including advertisements, to the FDA at least 30 days prior to initial dissemination. The FDA may withdraw approval under accelerated approval after a hearing if, for instance, post-marketing studies fail to verify any clinical benefit, it becomes clear that restrictions on the distribution of the product are inadequate to ensure its safe use, or if a sponsor fails to comply with the conditions of the accelerated approval.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fast Track Status</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant "fast track" status to products that treat a serious condition and have data demonstrating the potential to address an unmet medical need or a drug that has been designated as a qualified infectious disease product.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Breakthrough Therapy</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant &#8220;breakthrough therapy&#8221; status to drugs designed to treat, alone or in combination with another drug or drugs, a serious or life-threatening disease or condition and for which preliminary clinical evidence suggests a substantial improvement over existing therapies. Such drugs need not address an unmet need, but are nevertheless eligible for expedited review if they offer the potential for an improvement. Breakthrough therapy status entitles the sponsor to earlier and more frequent meetings with the </font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FDA regarding the development of nonclinical and clinical data and permits the FDA to offer product development or regulatory advice for the purpose of shortening the time to product approval. Breakthrough therapy status does not guarantee that a product will be developed or reviewed more quickly and does not ensure FDA approval.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Priority Review</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Priority Review only applies to applications (original or efficacy supplement) for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, diagnosis or prevention of serious conditions when compared to standard applications. Priority Review may also be granted for any supplement that proposes a labeling change due to studies completed in response to a written request from the FDA for pediatric studies, for an application for a drug that has been designated as a qualified infectious disease product, or any application or supplement for a drug submitted with a priority review voucher.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016, the FDA issued us a rare pediatric disease priority review voucher in connection with the approval of SPINRAZA. </font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">POST-MARKETING STUDIES</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of the approval pathway employed, the FDA may require a sponsor to conduct additional post-marketing studies as a condition of approval to provide data on safety and effectiveness. If a sponsor fails to conduct the required studies, the agency may withdraw its approval. In addition, if the FDA concludes that a drug that has been shown to be effective can be safely used only if distribution or use is restricted, it can mandate post-marketing restrictions as necessary to assure safe use. In such a case, the sponsor may be required to establish rigorous systems to assure use of the product under safe conditions. These systems are usually referred to as Risk Evaluation and Mitigation Strategies (REMS). The FDA can impose financial penalties for failing to comply with certain post-marketing commitments, including REMS. In addition, any changes to an approved REMS must be reviewed and approved by the FDA prior to implementation.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">ADVERSE EVENT REPORTING</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor information on side effects and adverse events reported during clinical studies and after marketing approval and report such information and events to regulatory agencies. Non-compliance with the FDA's safety reporting requirements may result in civil or criminal penalties. Side effects or adverse events that are reported during clinical trials </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">can delay, impede or prevent marketing approval. Based on new safety information that emerges after approval, the FDA can mandate product labeling changes, impose a new REMS or the addition of elements to an existing REMS, require new post-marketing studies (including additional clinical trials), or suspend or withdraw approval of the product. These requirements may affect our ability to maintain marketing approval of our products or require us to make significant expenditures to obtain or maintain such approvals.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">APPROVAL OF CHANGES TO AN APPROVED PRODUCT</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we seek to make certain types of changes to an approved product, such as adding a new indication, making certain manufacturing changes or changing manufacturers or suppliers of certain ingredients or components, the FDA will need to review and approve such changes in advance. In the case of a new indication, we are required to demonstrate with additional clinical data that the product is safe and effective for a use other than that initially approved. FDA regulatory review may result in denial or modification of the planned changes, or requirements to conduct additional tests or evaluations that can substantially delay or increase the cost of the planned changes.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">REGULATION OF PRODUCT ADVERTISING AND PROMOTION</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA regulates all advertising and promotion activities and communications for products under its jurisdiction both before and after approval. Pursuant to FDA guidance, a company can make safety and efficacy claims from data either in or consistent with the label. However, physicians may prescribe legally available drugs for uses that are not described in the drug's labeling. Such off-label uses are common across medical specialties, and often reflect a physician's belief that the off-label use is the best treatment for patients. The FDA does not regulate the behavior of physicians in their choice of treatments, but FDA regulations do impose stringent restrictions on manufacturers' communications regarding off-label uses. Failure to comply with applicable FDA requirements may subject a company to adverse publicity, enforcement action by the FDA, corrective advertising and the full range of civil and criminal penalties available to the government.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Regulation of Combination Products</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Combination products are defined by the FDA to include products comprising two or more regulated components (e.g., a biologic and a device). Biologics and devices each have their own regulatory requirements, and combination products may have additional requirements. Some of our marketed </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">products meet this definition and are regulated under this framework and similar regulations outside the U.S., and we expect that some of our pipeline product candidates may be evaluated for regulatory approval under this framework as well. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Approval and Post-Approval Regulation Outside the U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We market our products in numerous jurisdictions outside the U.S. Most of these jurisdictions have product approval and post-approval regulatory processes that are similar in principle to those in the U.S. In Europe, for example, where a substantial part of our ex-U.S. efforts are focused, there are several tracks for marketing approval, depending on the type of product for which approval is sought. Under the centralized procedure, a company submits a single application to the EMA. The marketing authorization application is similar to the NDA or BLA in the U.S. and is evaluated by the CHMP, the expert scientific committee of the EMA responsible for human medicines. If the CHMP determines that the marketing authorization application fulfills the requirements for quality, safety and efficacy and that the medicine has a positive benefit risk balance, it will adopt a positive opinion recommending grant of the marketing authorization by the EC. The CHMP opinion is not binding, but is typically adopted by the EC. A marketing application approved by the EC is valid in all member states of the E.U. The centralized procedure is required for all biological products, orphan medicinal products and new treatments for neurodegenerative disorders, and it is available for certain other products, including those which constitute a significant therapeutic, scientific or technical innovation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the centralized procedure, Europe also has: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a national procedure, which requires an application to the competent authority of an E.U. country (if an application is to be made in more than one E.U. country, following approval in the first country, the applicant must submit applications in the other countries using the mutual recognition procedure); </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a decentralized procedure, whereby applicants submit identical applications to several countries and receive simultaneous approval, if the medicine has not yet been authorized in any E.U. country; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a mutual recognition procedure, where applicants that have a medicine authorized in one E.U. country can apply for mutual recognition of this authorization in other E.U. countries. </font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U., there is detailed legislation on pharmacovigilance and extensive guidance on good pharmacovigilance practices.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of the approval process employed, various parties share responsibilities for the monitoring, detection and evaluation of adverse events post-approval, including national authorities, the EMA, the EC and the marketing authorization holder. The EMA&#8217;s PRAC is responsible for assessing and monitoring the safety of human medicines and makes recommendations on product safety issues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In some regions, it is possible to receive an &#8220;accelerated&#8221; review whereby the national regulatory authority will commit to truncated review timelines for products that meet specific medical needs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Good Manufacturing Practices</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory agencies regulate and inspect equipment, facilities and processes used in the manufacturing and testing of pharmaceutical and biologic products prior to approving a product. If, after receiving approval from regulatory agencies, a company makes a material change in manufacturing equipment, location or process, additional regulatory review and approval may be required. We also must adhere to current Good Manufacturing Practices (cGMP) and product-specific regulations enforced by regulatory agencies following product approval. The FDA, the EMA and other regulatory agencies also conduct periodic visits to re-inspect equipment, facilities and processes following the initial approval of a product. If, as a result of these inspections, it is determined that our equipment, facilities or processes do not comply with applicable regulations and conditions of product approval, regulatory agencies may seek civil, criminal or administrative sanctions or remedies against us, including significant financial penalties and the suspension of our manufacturing operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Good Clinical Practices</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA, the EMA and other regulatory agencies promulgate regulations and standards for designing, conducting, monitoring, auditing and reporting the results of clinical trials to ensure that the data and results are accurate and that the rights and welfare of trial participants are adequately protected (commonly referred to as current Good Clinical Practices (cGCP)). Regulatory agencies enforce cGCP through periodic inspections of trial sponsors, principal investigators and trial sites, contract research organizations (CROs) and institutional review boards. If our studies fail to comply with applicable cGCP guidelines, the clinical data generated in our clinical trials may be deemed unreliable and relevant regulatory agencies may require us to perform additional clinical trials before approving our marketing applications. Noncompliance </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">can also result in civil or criminal sanctions. We rely on third parties, including CROs, to carry out many of our clinical trial-related activities. Failure of such third parties to comply with cGCP can likewise result in rejection of our clinical trial data or other sanctions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2014, the EC adopted a new Clinical Trial Regulation, which was effective in June 2014 but is not expected to apply until the second half of 2019. The regulation harmonizes the procedures for assessment and governance of clinical trials throughout the E.U. and will require that information on the authorization, conduct and results of each clinical trial conducted in the E.U. be publicly available.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Approval of Biosimilars </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Patient Protection and Affordable Care Act (PPACA) amended the Public Health Service Act (PHSA) to authorize the FDA to approve biological products, referred to as biosimilars or follow-on biologics that are shown to be highly similar to previously approved biological products based upon potentially abbreviated data packages.&#160;The biosimilar must show it has no clinically meaningful differences in terms of safety and effectiveness from the reference product, and only minor differences in clinically inactive components are allowable in biosimilars products. The approval pathway for biosimilars does, however, grant a biologics manufacturer a 12-year period of exclusivity from the date of approval of its biological product before biosimilar competition can be introduced. There is uncertainty, however, as the approval framework for biosimilars originally was enacted as part of the PPACA. In 2017 there were, and there are likely to continue to be, federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. If the PPACA is repealed, substantially modified or invalidated, it is unclear what, if any, impact such action would have on biosimilar regulation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A biosimilars approval pathway has been in place in the E.U. since 2003. The EMA has issued a number of scientific and product specific biosimilar guidelines, including requirements for approving biosimilars containing monoclonal antibodies. In the E.U., biosimilars are generally approved under the centralized procedure. The approval pathway allows sponsors of a biosimilar to seek and obtain regulatory approval based in part on reliance on the clinical trial data of an innovator product to which the biosimilar has been demonstrated, through comprehensive comparability studies, to be &#8220;similar&#8221;. In many cases, this allows biosimilars to be brought to market without conducting the full complement of clinical trials typically required for novel biologic drugs.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Orphan Drug Act</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the U.S.&#160;Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a &#8220;rare disease or condition,&#8221; which generally is a disease or condition that affects fewer than 200,000 individuals in the U.S.&#160;If a product which has an orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, i.e., the FDA may not approve any other applications to market the same drug for the same indication for a period of seven years following marketing approval, except in certain very limited circumstances, such as if the later product is shown to be clinically superior to the orphan product. Legislation similar to the U.S.&#160;Orphan Drug Act has been enacted in other countries to encourage the research, development and marketing of medicines to treat, prevent or diagnose rare diseases. In the E.U., medicinal products that receive an orphan designation are entitled to 10 years of market exclusivity following approval, protocol assistance and access to the centralized procedure for marketing authorization. SPINRAZA has been granted orphan drug designation in the U.S., E.U. and Japan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation Pertaining to Pricing and Reimbursement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In both domestic and foreign markets, sales of our products depend, in part, on the availability and amount of reimbursement by third-party payors, including governments, private health plans and other organizations. Substantial uncertainty exists regarding the pricing and reimbursement of our products, and drug prices continue to receive significant scrutiny. Governments may regulate coverage, reimbursement and pricing of our products to control cost or affect utilization of our products. Challenges to our pricing strategies, by either government or private stakeholders, could harm our business. The U.S.&#160;and foreign governments have enacted and regularly consider additional reform measures that affect health care coverage and costs. Private health plans may also seek to manage cost and utilization by implementing coverage and reimbursement limitations. Other payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities and private health insurers, seek price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, may impose restrictions on access, coverage or pricing of particular drugs based on perceived value.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Within the U.S.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Medicaid</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Medicaid is a joint federal and state program that is administered by the states for low income and disabled beneficiaries. Under the Medicaid Drug Rebate Program, we are required to pay a rebate for each unit of product reimbursed by the state Medicaid programs. The amount of the rebate is established by law and is adjusted upward if average manufacture price (AMP) increases more than inflation (measured by the Consumer Price Index&#160;- Urban). The rebate amount is calculated each quarter based on our report of current AMP and best price for each of our products to the Centers for Medicare&#160;&amp; Medicaid Services (CMS). The requirements for calculating AMP and best price are complex. We are required to report any revisions to AMP or best price previously reported within a certain period, which revisions could affect our rebate liability for prior quarters. In addition, if we fail to provide information timely or we are found to have knowingly submitted false information to the government, the statute governing the Medicaid Drug Rebate Program provides for civil monetary penalties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Medicare</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Medicare is a federal program that is administered by the federal government. The program covers individuals age&#160;65 and over as well as those with certain disabilities. Medicare Part&#160;B generally covers drugs that must be administered by physicians or other health care practitioners; are provided in connection with certain durable medical equipment; or are certain oral anti-cancer drugs and certain oral immunosuppressive drugs. Medicare Part B pays for such drugs under a payment methodology based on the average sales price (ASP) of the drugs. Manufacturers, including us, are required to provide ASP information to the CMS on a quarterly basis. The manufacturer-submitted information is used to calculate Medicare payment rates. If a manufacturer is found to have made a misrepresentation in the reporting of ASP, the governing statute provides for civil monetary penalties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicare Part D provides coverage to enrolled Medicare patients for self-administered drugs (i.e., drugs that are not administered by a physician). Medicare Part D is administered by private prescription drug plans approved by the U.S. government. Each drug plan establishes its own Medicare Part D formulary for prescription drug coverage and pricing, which the drug plan may modify from time-to-time. The prescription drug plans negotiate pricing with manufacturers and pharmacies, and may condition formulary placement on the availability of manufacturer </font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">discounts. In addition, manufacturers, including us, are required to provide to the CMS a 50% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries reach the coverage gap in their drug benefits.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Federal Agency Discounted Pricing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Our products are subject to discounted pricing when purchased by federal agencies via the Federal Supply Schedule (FSS). FSS participation is required for our products to be covered and reimbursed by the Veterans Administration (VA), Department of Defense, Coast Guard and Public Health Service (PHS). Coverage under Medicaid, Medicare and the PHS pharmaceutical pricing program is also conditioned upon FSS participation. FSS pricing is intended not to exceed the price that we charge our most-favored non-federal customer for a product. In addition, prices for drugs purchased by the VA, Department of Defense (including drugs purchased by military personnel and dependents through the TriCare retail pharmacy program), Coast Guard and PHS are subject to a cap on pricing equal to 76% of the non-federal average manufacturer price (non-FAMP). An additional discount applies if non-FAMP increases more than inflation (measured by the Consumer Price Index&#160;- Urban). In addition, if we fail to provide information timely or we are found to have knowingly submitted false information to the government, the governing statute provides for civil monetary penalties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">340B Discounted Pricing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: To maintain coverage of our products under the Medicaid Drug Rebate Program and Medicare Part B, we are required to extend significant discounts to certain covered entities that purchase products under Section 340B of the PHS pharmaceutical pricing program. Purchasers eligible for discounts include hospitals that serve a disproportionate share of financially needy patients, community health clinics and other entities that receive certain types of grants under the PHSA. For all of our products, we must agree to charge a price that will not exceed the amount determined under statute (the &#8220;ceiling price&#8221;) when we sell outpatient drugs to these covered entities. In addition, we may, but are not required to, offer these covered entities a price lower than the 340B ceiling price. The 340B discount formula is based on AMP and is generally similar to the level of rebates calculated under the Medicaid Drug Rebate Program. </font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Outside the U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outside the U.S., our products are paid for by a variety of payors, with governments being the primary source of payment. Governments may determine or influence reimbursement of products and may also set prices or otherwise regulate pricing. Negotiating prices with governmental authorities can delay commercialization of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing and reference pricing (i.e., referencing prices in other countries and using those reference prices to set a price). Budgetary pressures in many countries are continuing to cause governments to consider or implement various cost-containment measures, such as price freezes, increased price cuts and rebates and expanded generic substitution and patient cost-sharing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation Pertaining to Sales and Marketing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claims laws. Anti-kickback laws generally prohibit a prescription drug manufacturer from soliciting, offering, receiving or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. There is therefore a possibility that our practices might be challenged under anti-kickback or similar laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third-party payors (including Medicare and Medicaid), claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Our activities relating to the sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and exclusion from federal health care programs (including Medicare and Medicaid). In the U.S., federal and state authorities are paying increased attention to enforcement of these laws within the pharmaceutical industry and private individuals have been active in alleging violations of the laws and bringing suits on behalf of the government under the federal civil False Claims Act. If we were subject to allegations concerning, or were convicted of violating, these laws, our business could be harmed.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Laws and regulations have been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers. The laws and regulations generally limit financial interactions between manufacturers and health care providers or require disclosure to the government and public of such interactions. The laws include federal &#8220;sunshine&#8221; provisions. The sunshine provisions apply to pharmaceutical manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government (for re-disclosure to the public) certain payments made to physicians and certain other healthcare practitioners or to teaching hospitals. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Many of these laws and regulations contain ambiguous requirements. Given the lack of clarity in laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations. Outside the U.S., other countries have implemented requirements for disclosure of financial interactions with healthcare providers and additional countries may consider or implement such laws.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Regulations</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Foreign Anti-Corruption</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to various federal and foreign laws that govern our international business practices with respect to payments to government officials. Those laws include the U.S.&#160;Foreign Corrupt Practices Act (FCPA), which prohibits U.S.&#160;companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect their transactions and to devise and maintain an adequate system of internal accounting controls.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The laws to which we are subject also include the U.K. Bribery Act 2010 (Bribery Act), which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official and failing to have adequate procedures to prevent employees and other agents from giving bribes. U.S. companies that conduct business in the U.K. generally will be subject to the Bribery Act. Penalties under the Bribery Act include significant fines for </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">companies and criminal sanctions for corporate officers under certain circumstances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">NIH Guidelines</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We seek to conduct research at our U.S. facilities in compliance with the current U.S.&#160;National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines). By local ordinance, we are required to, among other things, comply with the NIH Guidelines in relation to our facilities in Research Triangle Park (RTP), NC and are required to operate pursuant to certain permits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Laws</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our present and future business has been and will continue to be subject to various other laws and regulations. Various laws, regulations and recommendations relating to data privacy and protection, safe working conditions, laboratory practices, the experimental use of animals and the purchase, storage, movement, import, export and use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research work are or may be applicable to our activities. Certain agreements entered into by us involving exclusive license rights may be subject to national or international antitrust regulatory control, the effect of which cannot be predicted. The extent of government regulation, which might result from future legislation or administrative action, cannot accurately be predicted.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The European Parliament and the Council of the European Union adopted a comprehensive general data privacy regulation (GDPR) in 2016 to replace the current E.U. Data Protection Directive and related country-specific legislation. The GDPR will take effect in May 2018 and governs the collection and use of personal data in the E.U. The GDPR, which is wide-ranging in scope, will impose several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of the personal data. The GDPR will also impose strict rules on the transfer of personal data out of the E.U. to the U.S., will provide an enforcement authority and will impose large penalties for noncompliance, including the potential for fines of up to &#8364;20 million or 4% of the annual global revenues of the infringer, whichever is greater.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><a name="sEBBFB4D98F9F5E7BB55A3BE53158AC26"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Environmental Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We strive to comply in all material respects with applicable laws and regulations concerning the environment. While it is impossible to predict accurately the future costs associated with environmental compliance and potential remediation activities, compliance with environmental laws is not expected to require significant capital expenditures and has not had, and is not expected to have, a material adverse effect on our operations or competitive position.</font></div><div><a name="s6A7802062C0A53728FA171D839CAF0E8"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Manufacturing</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are committed to ensuring an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. We believe that our manufacturing facilities, together with the third-party contract manufacturing organizations we outsource to, currently provide sufficient capacity for our products and the contract manufacturing services we provide to Samsung Bioepis, our joint venture that develops, manufactures and markets biosimilars, and other strategic contract manufacturing partners. In light of the development of our pipeline, we are expanding our production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of the decade.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing Facilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our drug substance manufacturing facilities include:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Facility</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Drug Substance Manufactured</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">RTP, North Carolina</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ALPROLIX</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">AVONEX</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ELOCTATE</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">PLEGRIDY</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">TYSABRI</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ZINBRYTA</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Other*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Hiller&#248;d, Denmark</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">TYSABRI</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biosimilars</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-12px;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Other includes products manufactured for contract manufacturing partners</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our drug substance manufacturing facilities, we have a drug product manufacturing facility and supporting infrastructure in RTP, NC including a parenteral facility and an oral solid dose products manufacturing facility. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The parenteral facility adds capabilities and capacity for filling biologics into vials and is principally used for filling product candidates. The oral solid dose products facility supplements our outsourced small molecule manufacturing capabilities, including the manufacture of TECFIDERA.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have a new oligonucleotide synthesis manufacturing (OSM) facility in RTP, NC. This facility gives us the capability to manufacture ASO drugs like SPINRAZA as well as our other ASO candidates currently in our clinical pipeline.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2016 we purchased land in Solothurn, Switzerland and are building a large-scale biologics manufacturing facility at this site. We expect this facility to be operational by the end of the decade. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is responsible for all worldwide manufacturing activities for bulk RITUXAN and GAZYVA and has sourced the manufacture of certain bulk RITUXAN and GAZYVA requirements to a third party. Acorda supplies FAMPYRA to us pursuant to its supply agreement with Alkermes, Inc. and Ionis supplies the active pharmaceutical ingredient (API) for SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Third-Party Suppliers and Manufacturers</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We principally use third parties to manufacture the API and the final product for our small molecule products and product candidates, including TECFIDERA and FUMADERM, and the final drug product for our large molecule products and, to a lesser extent, product candidates. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We source all of our fill-finish and the majority of final product assembly and storage operations for our products, along with a substantial part of our packaging operations, to a concentrated group of third-party contract manufacturing organizations. We have internal label and packaging capability for clinical and commercial products at our Hiller&#248;d facility. Raw materials, delivery devices, such as syringes and auto-injectors, and other supplies required for the production of our products and product candidates are procured from various third-party suppliers and manufacturers in quantities adequate to meet our needs. Continuity of supply of such raw materials, devices and supplies is assured using a strategy of dual sourcing where possible or by a risk-based inventory strategy. Our third-party service providers, suppliers and manufacturers may be subject to routine cGMP inspections by the FDA or comparable agencies in other jurisdictions and undergo assessment and certification by our quality management group.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><a name="s0F34927491575EE5A8F42C26260707E2"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Our Employees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately 7,300 employees worldwide.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Our Executive Officers (as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">February&#160;1, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Officer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Current Position</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Age</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year Joined Biogen</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michel Vounatsos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Susan H. Alexander</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Chief Legal, Corporate Services and Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2006</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Jeffrey D. Capello</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Gregory F. Covino</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Finance and Chief Accounting Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michael D. Ehlers, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Research and Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Ginger Gregory, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and Chief Human Resources Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Chirfi Guindo</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Paul McKenzie, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Pharmaceutical Operations and Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Alfred W. Sandrock, Jr., M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and Chief Medical Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1998</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michel Vounatsos</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Vounatsos has served as our Chief Executive Officer since January 2017. Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President and Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck where he most recently served as President, Primary Care, Customer Business Line. In this role, he led Merck&#8217;s global primary care business unit, a role which encompassed Merck&#8217;s cardiology-metabolic, general medicine, women&#8217;s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company&#8217;s relationships with key constituents, including the most significant providers, payors and retailers and the world&#8217;s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Universite Victor Segalen, Bordeaux II, France, C.S.C.T. Certificate in Medicine</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">HEC School of Management - Paris, M.B.A.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Susan H. Alexander</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ms. Alexander has served as our Executive Vice President, Chief Legal, Corporate Services and Secretary since March 2017. Prior to that, from December 2011 to March 2017, Ms. Alexander served as our Executive Vice President, Chief Legal Officer and Secretary and from 2006 to December 2011, as our Executive Vice President, General Counsel and Corporate Secretary. From 2003 to January 2006, Ms.&#160;Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company. From 2001 to 2003, Ms.&#160;Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001, Ms.&#160;Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms.&#160;Alexander was a partner at the law firms of Hinckley, Allen&#160;&amp; Snyder and Fine&#160;&amp; Ambrogne. </font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Invacare Corporation, a medical and healthcare product company</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Wellesley College, B.A.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston University School of Law, J.D.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Jeffrey D. Capello</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Capello has served as our Executive Vice President and Chief Financial Officer since December 2017.  Prior to that, Mr. Capello served as the Chief Financial Officer of Beacon Health Options, Inc., a behavioral health company, with responsibility for finance, human resources, information technology, real estate and procurement, from October 2016 until November 2017. From July 2015 until September 2016, Mr. Capello was the founder and Chief Executive Officer of Monomoy Advisors which focuses on helping companies drive shareholder value. From July 2014 until June 2015, Mr. Capello served as the Executive Vice President and Chief Financial Officer of Ortho-Clinical Diagnostics, an in vitro diagnostics company that was acquired by the Carlyle Group from Johnson &amp; Johnson, with responsibility for global finance and business development. Prior to his role at Ortho-Clinical Diagnostics, Mr. Capello served as Chief Financial Officer and Executive Vice President of Boston Scientific Corporation, a medical device company, from March 2010 to December 2013. At Boston Scientific, Mr. Capello was responsible for the worldwide management of Boston Scientific&#8217;s finance, information systems, business development and corporate strategy functions. Mr. Capello joined Boston Scientific in June 2008 and served as Senior Vice President and Chief Accounting Officer until March 2010. Prior to joining Boston Scientific, he was the Senior Vice President and Chief Financial Officer with responsibilities for global finance and business development at PerkinElmer, Inc., a life sciences tool company, from 2006 to 2008. Previously, he served as PerkinElmer&#8217;s Vice President of Finance, Corporate Controller, Treasurer and Chief Accounting Officer from 2001 to 2006. Prior to his tenure at PerkinElmer, Mr. Capello was a Partner at PricewaterhouseCoopers LLP, both in the United States and in the Netherlands.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">OvaScience, Inc., a biotechnology company</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Flex Pharma, Inc., a biotechnology company</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Vermont, B.S. in Business Administration</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard Business School, M.B.A.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Gregory F. Covino</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Covino has served as our Vice President and Chief Accounting Officer since April 2012. From June 2017 to December 2017, Mr. Covino also served as our interim Principal Financial Officer. From March 2010 to April 2012, Mr. Covino served at Boston Scientific Corporation, a medical device company, as Vice President, Corporate Analysis and Control, having responsibility for the company's internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company's international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to January 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporate Accounting from 1999 to 2002. </font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bryant University, B.S. in Business Administration</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michael D. Ehlers, M.D., Ph.D.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Ehlers has served as our Executive Vice President, Head of Research and Development since May 2016. Prior to joining Biogen, from August 2010 to April 2016, Dr. Ehlers served in leadership positions at Pfizer, Inc., a biopharmaceutical company, including Senior Vice President &amp; Head BioTherapeutics R&amp;D and Chief Scientific Officer, Neuroscience &amp; Pain. Prior to that, Dr. Ehlers was the George Barth Geller Professor of Neurobiology and an Investigator of the Howard Hughes Medical Institute at Duke University Medical Center. He is the recipient of numerous awards including the Eppendorf &amp; Science Prize in Neurobiology, the John J. Abel Award in Pharmacology, the Society for Neuroscience Young Investigator Award, a National Institute of Mental Health MERIT Award, the National Alliance for Schizophrenia and Depression Distinguished Investigator Award and the Massachusetts Medical Society Honored Business Leader Award. In 2013, Dr. Ehlers became the 11</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;recipient of the Thudichum Medal of the Biochemical Society of the United Kingdom. Past recipients include two Nobel laureates. Dr. Ehlers has authored over 100 scientific papers, has served on the Editorial Boards of Annual Reviews in Medicine, Annual Reviews in Pharmacology and Toxicology, the Journal of Neuroscience, the Journal of Biological Chemistry, the Journal of Molecular and Cellular Neuroscience and has sat on advisory committees of the National Institutes of Health.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Outside Affiliations</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">PhRMA Foundation Basic Pharmacology Advisory Committee</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Janelia Research Institute Advisory Committee</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">McKnight Endowment Fund for Neuroscience Board</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">World Economic Forum Global Agenda Council on Brain Research</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">California Institute of Technology, B.S. Chemistry</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Johns Hopkins University School of Medicine, M.D.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Johns Hopkins University School of Medicine, Ph.D. Neuroscience</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Ginger Gregory, Ph.D.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Gregory has served as our Executive Vice President and Chief Human Resources Officer since July 2017.  Prior to joining Biogen, Dr. Gregory served as Executive Vice President and Chief Human Resources Officer at Shire PLC, a global specialty biopharmaceutical company, from February 2014 to April 2017. Prior to that, Dr. Gregory held executive-level human resources positions for several multinational companies across a variety of industries, including Dunkin&#8217; Brands, where she served as Chief Human Resource Officer; Novartis, AG, where she was the division head of Human Resources for Novartis Vaccines and Diagnostics, Novartis Consumer Health and Novartis Institutes of BioMedical Research from 2005 to 2012; and Novo Nordisk, where she served as Senior Vice President, Corporate People &amp; Organization at the company&#8217;s headquarters in Copenhagen, Denmark. Earlier in her career, she held a variety of human resources generalist and specialist positions at Bristol-Myers Squibb and served as a consultant with Booz Allen &amp; Hamilton in the area of organization change and effectiveness.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Massachusetts B.A., in Psychology</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The George Washington University, Ph.D. Psychology</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Chirfi Guindo</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Guindo has served as our Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation since November 2017. Prior to joining Biogen, Mr. Guindo spent 27 years in the global pharmaceutical industry and has held several leadership positions at Merck in Canada, the U.S., France, Africa and the Netherlands.  He worked in several disciplines including Finance, Sales &amp; Marketing, General Management and Global Strategy/Product Development in specialty, acute and hospital care. Most recently Mr. Guindo was Vice President and Managing Director and President and Managing Director of Merck Canada from October 2014 to November 2017. From January 2011 to October 2014, he was Vice President and General Manager, Global HIV Franchise at Merck &amp; Co.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ecole Central de Paris (France), Engineering</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stern School of Business, New York University, M.B.A. in Finance/Economics</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Paul McKenzie, Ph.D.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. McKenzie has served as our Executive Vice President, Pharmaceutical Operations and Technology since July 2016. Prior to that, from February 2016 to June 2016, he served as our Senior Vice President for Global Biologics Manufacturing &amp; Technical Operations. Prior to joining Biogen, since 2008, Dr. McKenzie held a number of positions of increasing responsibility at Johnson &amp; Johnson (J&amp;J), including Vice President of R&amp;D for J&amp;J&#8217;s Ethicon business where he led the manufacturing and technical operations team responsible for internal and external manufacturing of Janssen&#8217;s pharmaceutical portfolio. He also ran global Development for Janssen R&amp;D, helping to manage pipeline activities from discovery through clinical development and commercialization. Prior to J&amp;J, Dr. McKenzie also held various R&amp;D and manufacturing positions at Bristol-Myers Squibb and Merck &amp; Co.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Pennsylvania, B.S. Chemical Engineering</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Carnegie Mellon University, Ph.D. Chemical Engineering</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Alfred W. Sandrock, Jr., M.D., Ph.D.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Sandrock has served as our Executive Vice President and Chief Medical Officer since October 2017. Prior to that, Dr. Sandrock served as our Executive Vice President, Chief Medical Officer Neurology and Neurodegeneration from October 2015 to October 2017, as our Chief Medical Officer and Group Senior Vice President from April 2013 to October 2015 and as our Chief Medical Officer and Senior Vice President of Development Sciences from February 2012 to April 2013. Prior to that, Dr. Sandrock held several senior executive positions since joining us in 1998, including Senior Vice President of Neurology Research and Development and Vice President of Clinical Development, Neurology.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Neurocrine Biosciences, Inc., a life sciences company</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stanford University, B.A. in Human Biology</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard Medical School, M.D. </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard University, Ph.D. in Neurobiology</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts General Hospital, internship in Medicine, residency and chief residency in Neurology, and clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography)</font></div></td></tr></table></div></div><div><a name="s0C48D2C40CD351C4AFB289077B664F50"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Available Information</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our principal executive offices are located at 225 Binney Street, Cambridge, MA 02142 and our telephone number is (617)&#160;679-2000. Our website address is www.biogen.com. We make available free of charge through the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of our website our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (SEC). We include our website address in this report only as an inactive textual reference and do not intend it to be an active link to our website. The contents of our website are not incorporated into this report.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><a name="sB3B1FD6C33C6555B93E19512F76AFECF"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;1A. &#160;&#160;&#160;&#160;Risk Factors</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our principal products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products, and, unless we develop or acquire rights to new products and technologies, we will be substantially dependent on sales from our principal products for many years. Further, following the completion of the spin-off of our hemophilia business, our revenues are further reliant and concentrated on sales of our MS products in an increasingly competitive market, and revenues from sales of our product for SMA. Any of the following negative developments relating to any of our principal products may adversely affect our revenues and results of operations or could cause a decline in our stock price: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including lower-priced competing products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">constraints and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition or changes in, or implementation of, reimbursement policies and practices of payors and other third parties; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA has been approved by, among others, the FDA, the EC and the Japanese Ministry of Health, Labor and Welfare, and is in the early stages of commercial launch in these and other markets.&#160;In addition to risks associated with new product launches and the other factors described in these &#8220;Risk Factors,&#8221; our ability to successfully commercialize SPINRAZA may be adversely affected due to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within the SMA market, which may impact our ability to develop relationships with the associated medical and scientific community; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the lack of readiness of healthcare providers to treat patients with SMA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effectiveness of our commercial strategy for marketing SPINRAZA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to maintain a positive reputation among patients, healthcare providers and others in the SMA community, which may be impacted by pricing and reimbursement decisions relating to SPINRAZA. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, greater financial and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition from generics and biosimilars in many markets.&#160;Generic versions of drugs and biosimilars are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of generic or biosimilar versions of our marketed products, as well as lower-priced competing products, likely would significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, our business may be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of lower-cost biosimilars, follow-on products or generic versions of branded MS products sold by our competitors, and the possibility of future competition from generic versions or prodrugs of existing therapeutics or from off-label use by physicians of therapies indicated for other conditions to treat MS patients; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract new patients to our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, revenues and results of operations and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our value-based contracting pilot program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products varies significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure favorable prices in a particular country may not only limit the revenues from our products within that country, but may also adversely affect our ability to obtain acceptable prices in other markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to maintain adequate coverage, pricing or reimbursement for our products would have an adverse effect on our business, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. In addition, competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products or treatments brought to market by our competitors could cause revenues for our products to decrease due to potential price reductions and lower sales volumes. As a result, our business and reputation may be harmed, our stock price may be adversely impacted and experience periods of volatility, and our results of operations may be adversely impacted.&#160; </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in liabilities, loss of revenues, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges and other adverse impacts on our results of operations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy, a serious brain infection, or liver injury in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection that will be afforded to our products and processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts, administrative bodies and lawmakers in these countries. We can provide no assurance that we will successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or that the protection obtained will be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. If we cannot prevent others from exploiting our inventions, we will not derive the benefit from them that we currently expect. Furthermore, we can provide no assurance that our products will not infringe patents or other intellectual property rights held by third parties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenues for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon successful development of additional indications for our existing products as well as successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung Biologics or licenses or acquisitions from third parties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or the processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue development of a product or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends in large part on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with cGCP. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our clinical trial related activities and reporting. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the PPACA have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and the expansion of the number of hospitals eligible for discounts under Section 340B of the PHSA. These changes have had and are expected to continue to have a significant impact on our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that results in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures to reduce health care costs to limit their overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possibly retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenues, and may continue to adversely affect our revenues and results of operations in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with cGMP.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data. Our computer systems continue to increase in multitude and complexity due to the growth in our business, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. While we continue to build and improve our systems and infrastructure and believe we have taken appropriate security measures to reduce these risks to our data and information technology systems, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative and other third-party relationships for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships subjects us to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborators or third parties devote to our programs or products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise under the agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators or other third parties, and the underlying contract with our collaborators or other third parties may fail to provide significant protection or may fail to be effectively enforced if the collaborators or third parties fail to perform; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborators or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third-party relationships and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of products under joint control or could result in termination of the research, development or commercialization of product candidates or result in litigation or arbitration; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborators or other third parties to comply with applicable laws and regulatory requirements in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not successfully execute our growth initiatives.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate growth through internal development projects, commercial initiatives and external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. While we believe we have a number of promising programs in our pipeline, failure of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. The availability of high quality, cost-effective development opportunities is limited and competitive, and we are not certain that we will be able to identify candidates that we and our shareholders consider suitable or complete transactions on terms that are acceptable to us and our shareholders. We may fail to complete transactions for other reasons, including if we are unable to obtain desired financing on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions and other strategic alliances and collaborations, we may face unanticipated costs or liabilities in connection with the transaction or we may not be able to integrate them or take full advantage of them or otherwise realize the benefits that we expect.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supporting our growth initiatives and the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. If we do not successfully execute our growth initiatives, then our business and financial results may be adversely affected and we may incur asset impairment or restructuring charges.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have experienced changes in management and other key personnel in critical functions across our organization, including our chief executive officer and our chief financial officer. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition and results of operations. Further, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change emphasis on our existing business programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, such as management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. We cannot assure you that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are pursuing opportunities to expand our manufacturing capacity for future clinical and commercial requirements for product candidates, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we currently have sufficient large scale manufacturing capacity to meet our near-term manufacturing requirements, it is probable that we would need additional large scale manufacturing capacity to support future clinical and commercial manufacturing requirements for product candidates in our pipeline, if such candidates are successful and approved. We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Due to the long lead times necessary for the expansion of manufacturing capacity, we expect to make significant investments to build or obtain third-party contract manufacturers with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of the products and place significant restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third party charities that provide such assistance. If we, or our vendors or donation recipients, are deemed to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulations governing the health care industry are subject to change, with possibly retroactive effect, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the hiring freeze implemented by the federal government in 2017, including at the FDA, could impact the review and potential approval of new products, which may adversely affect our business and financial condition;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA&#8217;s clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action which could harm our business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure you that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and/or adversely affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions.  As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws, including the 2017 Tax Act. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as GILTI. These changes are effective beginning in 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our preliminary estimate of the Transition Toll Tax and the remeasurement of our deferred tax assets and liabilities is subject to the finalization of management's analysis related to certain matters, such as developing interpretations of the provisions of the 2017 Tax Act, changes to certain estimates and amounts related to the earnings and profits of certain subsidiaries and the filing of our tax returns. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial conditions. The final determination of the Transition Toll Tax and the remeasurement of our deferred tax assets and liabilities will be completed as additional information becomes available, but no later than one year from the enactment of the 2017 Tax Act.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues, such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">uncertainties regarding the collectability of accounts receivable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates that may adversely impact our revenues and net income; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the Bribery Act, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effects of the implementation of the U.K.&#8217;s decision to voluntarily depart from the E.U., known as Brexit;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws and tariffs.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the FCPA prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product; recalls, seizures or withdrawal of an approved product from the market; disruption in the supply or availability of our products or suspension of export or import privileges; the imposition of civil or criminal sanctions; the prosecution of executives overseeing our international operations; and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including in-process R&amp;D and other intangible assets; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions and other business development activities.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and the other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from hedge ineffectiveness or from the termination of a hedge relationship.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, is subject to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If Samsung Bioepis or such other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Ability to Provide Adequate Supply.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Manufacturing biosimilars is complex.&#160;If we encounter any manufacturing or supply chain difficulties, we may be unable to meet higher than anticipated demand; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective matter are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a leased property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase stock or that we will repurchase stock at favorable prices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time our Board of Directors authorizes stock repurchase programs, including most recently a program to repurchase up to $5.0 billion of our common stock, which was authorized by our Board of Directors in July 2016 (2016 Share Repurchase Program). The amount and timing of stock repurchases are subject to capital availability and our determination that stock repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our agreements applicable to the repurchase of stock. Our ability to repurchase stock will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in, or the completion or expiration of, our stock repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase stock at favorable prices, if at all.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption in the past, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit versions of our products or stolen products could have a negative impact on our reputation and business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Stolen inventory that is not properly stored or sold through unauthorized channels could adversely impact patient safety, our reputation and our business. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders.&#160;Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may incur operational difficulties or be exposed to claims and liabilities as a result of the spin-off of our hemophilia business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we distributed all of the then outstanding shares of Bioverativ common stock to Biogen shareholders in connection with the spin-off of our hemophilia business.  In connection with the distribution, we entered into a separation and distribution agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between us and Bioverativ going forward, including with respect to potential tax-related losses associated with the separation and distribution. They also provide for the performance of services by each company for the benefit of the other for a period of time (including under the manufacturing and supply agreement pursuant to which we will manufacture and supply certain products and materials to Bioverativ).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The spin-off of our hemophilia business as an independent public company is intended to qualify for tax-free treatment to Biogen and its shareholders under the Internal Revenue Code. Completion of the spin-off was conditioned upon, among other things, our receipt of a favorable opinion from our tax advisors with respect to the tax-free nature of the transaction. The opinion is not binding on the U.S. Internal Revenue Service (IRS) or the courts, and there can be no assurance that the IRS or the courts will not challenge the qualification of the spin-off as a tax-free transaction or that any such challenge would not prevail. If the spin-off is determined to be taxable, the full financial benefits expected to result from the separation may not be achieved and/or Biogen and its shareholders could incur significant tax liabilities, which could adversely affect our business, financial condition or results of operations and the value of our stock could be adversely impacted.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bioverativ has agreed to indemnify us for certain potential liabilities that may arise, but we cannot guarantee that Bioverativ will be able to satisfy its indemnification obligations. The separation and distribution agreement provides for indemnification obligations designed to make Bioverativ financially responsible for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation. It is possible that a court would disregard the allocation agreed to between us and Bioverativ and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to assume responsibility for obligations allocated to Bioverativ. Third parties could also seek to hold us responsible for any of these liabilities or obligations, and the indemnity rights we have under the separation and distribution agreement may not be sufficient to fully cover all of these liabilities and obligations. Even if we are successful in obtaining indemnification, we may have to bear costs temporarily. In addition, our indemnity obligations to Bioverativ may be significant. These risks could negatively affect our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The spin-off of Bioverativ continues to involve a number of risks, including, among other things, the indemnification risks described above. Certain of the agreements described above provide for the performance of services by each company for the benefit of the other for a period of time. If Bioverativ is unable to satisfy its obligations under these agreements, including its indemnification obligations, we could incur losses. These arrangements could also lead to disputes over rights to certain shared property and over the allocation of costs and revenues for products and operations. Our inability to effectively manage the separation activities and related events could adversely affect our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not achieve some or all of the anticipated benefits of the spin-off of our hemophilia business, which may adversely affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may not be able to achieve the full strategic and financial benefits expected to result from the spin-off of our hemophilia business, or such benefits may not occur at all. If we fail to achieve some or all of the expected benefits of the spin-off, our business, financial condition, results of operations and the value of our stock could be adversely impacted.</font></div><div><a name="sFF7334E1F34B5B8080A179224EF911B1"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;1B. &#160;&#160;&#160;&#160;Unresolved Staff Comments</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</font></div><div><a name="s6D04B8FB211C5D56BD8A5E0DEEF6AAC5"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;2. &#160;&#160;&#160;&#160;Properties</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Below is a summary of our owned and leased properties as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Massachusetts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In Cambridge, MA, we own approximately 508,000&#160;square feet of real estate space, consisting of a building that houses a research laboratory and a cogeneration plant totaling approximately 263,000&#160;square feet and a building that contains research, development and quality laboratories totaling approximately 245,000&#160;square feet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we lease a total of approximately 1,157,000&#160;square feet in Massachusetts, which is summarized as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">800,000&#160;square feet in Cambridge, MA, which is comprised of offices for our corporate headquarters, and other administrative and development functions and laboratories, of which 242,000 square feet is subleased by multiple companies for general office space, laboratories and manufacturing facilities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">357,000&#160;square feet of office space in Weston, MA, of which 174,000 square feet has been subleased through the remaining term of our lease agreement.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Massachusetts lease agreements expire at various dates through the year 2028.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">North Carolina</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In RTP, NC, we own approximately 1,022,000&#160;square feet of real estate space, which is summarized as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">357,000&#160;square feet of laboratory and office space;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">188,000 square feet related to an oral solid dose manufacturing facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">175,000&#160;square feet related to a large-scale biologics manufacturing facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">105,000&#160;square feet related to a small-scale biologics manufacturing facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84,000&#160;square feet of warehouse space and utilities;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70,000 square feet related to a parenteral fill-finish facility; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43,000&#160;square feet related to a large-scale purification facility.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we own approximately 40,000 square feet of warehouse space in Durham, NC. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Denmark</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own a large-scale biologics manufacturing facility totaling approximately 228,000&#160;square feet located in Hiller&#248;d, Denmark. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also own approximately 306,000&#160;square feet of additional space, which is summarized as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">139,000&#160;square feet of warehouse, utilities and support space;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70,000&#160;square feet related to a label and packaging facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50,000&#160;square feet related to a laboratory facility;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47,000&#160;square feet of administrative space.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Switzerland</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015 we purchased land in Solothurn, Switzerland and are building a large-scale biologics manufacturing facility at this site. We expect this facility to be operational by the end of the decade. Upon completion, the facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other International</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease office space in Zug, Switzerland, our international headquarters, the U.K., Germany, France, Denmark and numerous other countries. Our international lease agreements expire at various dates through the year 2028.</font></div><div><a name="s8A0FE0CB5D355270B047F6DA110AF04C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;3. &#160;&#160;&#160;&#160;Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal matters as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report, which is incorporated into this item by reference.</font></div><div><a name="s75FFB3F747E95885AA082AB9C892448B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;4. &#160;&#160;&#160;&#160;Mine Safety Disclosures</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><a name="s4483A356E41454D3AE40081C0902080C"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;II</font></div><div><a name="sA04145B8299F5CE092D66F1A36BCCBC7"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;5. &#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Market and Stockholder Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our common stock trades on The Nasdaq Global Select Market under the symbol &#8220;BIIB.&#8221; The following table shows the high and low sales price for our common stock as reported by The Nasdaq Global Select Market for each quarter in the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common Stock Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Low</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">298.00</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">254.15</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">301.02</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.07</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">291.90</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">244.28</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">292.69</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">223.02</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">330.00</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">269.50</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">333.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">240.07</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">348.84</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">301.81</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">329.83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">268.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The sales prices in the first quarter of 2017 in the tables above have been adjusted for the impact of the spin-off of our hemophilia business. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January&#160;26, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, there were approximately 665 shareholders of record of our common stock.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not paid cash dividends since our inception. While we historically have not paid cash dividends and do not have a current intention to pay cash dividends, we continually review our capital allocation strategies, including, among other things, payment of cash dividends, stock repurchases or acquisitions.</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized our 2016 Share Repurchase Program, which is a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock. This authorization does not have an expiration date. All share repurchases under this authorization will be retired.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2016 Share Repurchase Program. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains available for share repurchases under our 2016 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock (2011 Share Repurchase Program). Shares repurchased under this authorization were principally used to offset common stock issuances under our share-based compensation programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2011 Share Repurchase Program. Our 2011 Share Repurchase Program was completed as of March 31, 2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Stock Performance Graph</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The graph below compares the five-year cumulative total stockholder return on our common stock, the S&amp;P 500 Index, the Nasdaq Pharmaceutical Index and the Nasdaq Biotechnology Index assuming the investment of $100.00 on December&#160;31, 2012 with dividends being reinvested. The stock price performance in the graph below is not necessarily indicative of future price performance. The table below reflects the stock prices as adjusted for the spin-off of our hemophilia business, which was effected on February 1, 2017. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;text-align:center;"><img src="stockperformancechart.jpg" alt="stockperformancechart.jpg" style="height:480px;width:613px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:22%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2012</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">191.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">209.30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">193.74</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.96</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nasdaq Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">135.68</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">165.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">174.27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">172.37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">205.33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">S&amp;P 500 Index</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">132.39</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.51</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">152.59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">208.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nasdaq Biotechnology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.02</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">223.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.39</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.64</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><a name="sB004255537615F4BBFF1022499F44597"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6. &#160;&#160;&#160;&#160;Selected Financial Data</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SELECTED FINANCIAL DATA</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="20" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:18px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are summarized as follows:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">(a) (b) (c) (d) (e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(c) (e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(e) (f)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(g)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Results of Operations (1)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,542.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,559.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,126.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">360.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">263.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,273.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,448.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,763.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,703.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,932.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,929.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,298.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,872.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,747.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,441.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain on sale of rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,344.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,150.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,972.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,515.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(215.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(217.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,128.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,933.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,767.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,946.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,480.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,458.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,237.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,161.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">989.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">601.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,670.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,695.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,593.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">131.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Diluted Earnings Per Share</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="20" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Financial Condition (1)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,746.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,724.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,188.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,316.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,848.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">23,652.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22,876.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19,504.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,314.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,863.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements, less current portion </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,935.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,512.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,521.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">592.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,612.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,140.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,372.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,809.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,620.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the following notes, the financial data included within the tables above should be read in conjunction with our consolidated financial statements and related notes and Item 7. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report and our previously filed Annual Reports on Form&#160;10-K.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company. Our consolidated results of operations and financial position reflect the financial results of our hemophilia business for all periods through January 31, 2017. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net reflect the impact of the following product launches:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial sales of SPINRAZA in the U.S. began in the fourth quarter of 2016 and in rest of world markets in the first quarter of 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under our collaboration agreement with AbbVie, we began to recognize revenues on sales of ZINBRYTA to third parties in the E.U. in the third quarter of 2016. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under our commercial agreement with Samsung Bioepis, we began to recognize revenues on sales of BENEPALI and FLIXABI to third parties in the E.U. in the first quarter of 2016 and third quarter of 2016, respectively. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial sales of ALPROLIX commenced in the second quarter of 2014 and commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial sales of TECFIDERA began in April 2013.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements reflects:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our 2017 repayment of our 6.875% notes that were issued in 2008 with an aggregate principal amount of $550.0 million, and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The issuance of our senior unsecured notes for an aggregate principal amount of $6.0 billion in September 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders' equity reflects the repurchase of approximately 29.9 million shares of our common stock at a cost of approximately $8.7 billion between 2013 and 2017:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2017 we repurchased and retired approximately 3.7 million shares of our common stock at a cost of $1.0 billion under our 2016 Share Repurchase Program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2017 we repurchased approximately 1.2 million shares of our common stock at a cost of $365.4 million under our 2011 Share Repurchase Program. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2016 we repurchased and retired approximately 3.3 million shares of our common stock at a cost of $1.0 billion under our 2016 Share Repurchase Program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we repurchased and retired approximately 16.8 million shares of our common stock at a cost of $5.0 billion under a program authorized by our Board of Directors in May 2015 for the repurchase of up to $5.0 billion of our common stock (2015 Share Repurchase Program).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2014 and 2013 we repurchased approximately 2.9 million and 2.0 million shares, respectively, of our common stock at a cost of approximately $1.3 billion under our 2011 Share Repurchase Program.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses for the year ended December 31, 2017, includes a pre-tax charge to acquired in-process research and development of $120.0 million for an upfront payment made to Remedy upon closing of our asset purchase transaction for BIIB093.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to noncontrolling interests, net of tax for the year ended December 31, 2017, includes a pre-tax charge of $150.0 million for a payment to Neurimmune in exchange for a 15% reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses for the year ended December 31, 2016, includes a pre-tax charge of $454.8 million related to our January 2017 settlement and license agreement with Forward Pharma.</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses for the year ended December 31, 2017, includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$444.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of amortization and impairment charges related to our U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. For additional information on our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">settlement and license agreement with Forward Pharma and related intangible assets, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense for the year ended December 31, 2017, includes </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,173.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to our current estimate of the provisions of the 2017 Tax Act, including a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;expense under the Transition Toll Tax. For additional information on the 2017 Tax Act, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses for the years ended December 31, 2017, 2016 and 2015, include restructuring charges of $0.9 million, $33.1 million and $93.4 million, respectively. In addition, total cost and expenses for the year ended December 31, 2016, also include charges to cost of sales totaling $52.4 million of expenses incurred as a result of our determination to cease manufacturing and vacate our small-scale biologics facility in Cambridge, MA as well as close and vacate our warehouse in Somerville, MA. Total cost and expenses for the years ended December 31, 2017 and 2016, also includes $19.2 million and $18.1 million, respectively, of costs incurred directly related to the spin-off of our hemophilia business into an independent, publicly traded company. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. for the year ended December 31, 2015, includes a pre-tax charge to noncontrolling interest of $60.0 million for a milestone payment due to Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commencing in the second quarter of 2013 product and total revenues include 100% of net revenues related to sales of TYSABRI as a result of our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Upon closing of this transaction, our collaboration agreement was terminated. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><a name="sC68B8A1615A6576E8C481EF8DEF3459D"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;7. &#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our consolidated financial statements and related notes beginning on page&#160;F-1 of this report. Certain totals may not sum due to rounding.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of MS and neuroimmunology, AD and dementia, movement disorders and neuromuscular disorders, including SMA and ALS. We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of PPMS and RMS, and other potential anti-CD20 therapies under a collaboration agreement with Genentech.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products and, unless we develop, acquire rights to and/or commercialize new products and technologies, we may be substantially dependent on sales from our principal products for many years. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the longer term, our revenue growth will be dependent upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies, which expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung Biologics. Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2017 Corporate Strategy</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we announced an updated strategic framework to optimize the value of our MS business while investing for the future across our core growth areas of MS and neuroimmunology, AD and dementia, movement disorders, and neuromuscular diseases, including SMA and ALS. We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry, and acute neurology. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect the continued performance of our commercial assets and the expiration of the contingent payments related to TECFIDERA, discussed further in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Contractual Obligations and Off-Balance Sheet Arrangements&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report, to enable us to invest in and build an industry leading neuroscience pipeline. We view investment in growth as our top priority, but also recognize the value of opportunistically returning excess capital to shareholders through share repurchases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to deliver positive results in the near term while investing in the next stages of our growth, we will focus on the following strategic priorities:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">maximizing the resilience of our MS core business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">accelerating efforts in SMA as a significant new growth opportunity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">developing and expanding our neuroscience portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">focusing our capital allocation efforts to drive investment for future growth; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">creating a leaner and simpler operating model to streamline our operations and reallocate resources towards prioritized research and development and commercial value creation opportunities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We expect to make total non-recurring operating and </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">capital expenditures of up to $170.0 million, primarily in 2018, and our goal is to redirect resources of up to $400.0 million annually by 2020 to prioritized research and development and other value creation opportunities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Reform</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as GILTI. These changes are effective beginning in 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in tax rates and tax laws are accounted for in the period of enactment. Therefore, during the year ended December 31, 2017, we recorded a charge totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,173.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to our current estimate of the provisions of the 2017 Tax Act, including a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;expense under the Transition Toll Tax. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act will provide us with flexibility in deploying our cash resources to advance our business interests. We expect that it will have a modest positive effect on our income tax rate in 2018 and a potential incremental benefit thereafter.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Sobi and our collaboration and license agreement with Sangamo.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated results of operations and financial position included in this report reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;"><img src="financialhighlightschart.jpg" alt="financialhighlightschart.jpg" style="height:433px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.92</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of 29.6% versus the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#8221; our income from operations for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflects the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$12,273.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">7.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$10,354.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by revenues from SPINRAZA, TECFIDERA and BENEPALI, partially offset by the elimination of worldwide ALPROLIX and ELOCTATE revenues resulting from the spin-off of our hemophilia business on February 1, 2017 and a net decrease in total Interferon sales. </font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,559.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">18.6%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by royalty revenues on sales of OCREVUS and Biogen's share of pre-tax profits on RITUXAN.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$360.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">13.8%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by an increase in other royalty and corporate revenues.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$6,929.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">10.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$444.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of amortization and impairment charges related to our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">14.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in research and development primarily related to higher milestone and upfront expenses, a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">10.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in cost of goods sold, a $120.0 million pre-tax charge to acquired in-process research and development for an upfront payment made to Remedy upon the closing of the asset purchase transaction for BIIB093 and an increase in collaboration profit sharing. These increases were partially offset by a $454.8 million litigation settlement charge in the prior year.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Financial Condition, Liquidity and Capital Resources"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$4,551.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net cash flows from operations for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were primarily driven by earnings. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities totaled approximately </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$6,746.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We repurchased approximately 4.9 million shares of common stock at a cost of $1.4 billion during 2017 under our share repurchase programs. </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB093 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 we completed an asset purchase of the Phase 3-ready candidate BIIB093 (intravenous glibencamide) (formerly known as CIRARA) from Remedy. The target indication for BIIB093 is LHI, a severe form of ischemic stroke where cerebral edema often leads to a disproportionately large share of stroke-related morbidity and mortality. The FDA recently granted BIIB093 Orphan Drug Designation for </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 Fast Track designation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we are responsible for the future development and commercialization of BIIB093. Remedy will share in the cost of development for the target indication for BIIB093 in LHI stroke.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our transaction with Remedy, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB092 License Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 we completed an exclusive license agreement with BMS for BIIB092 (formerly known as BMS-986168), a Phase 2-ready experimental medicine with potential in AD and PSP. BIIB092 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received worldwide rights to BIIB092 and are responsible for the full development and global commercialization of BIIB092 in AD and PSP. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with BMS, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Eisai Collaboration Agreement</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we entered into a new collaboration agreement with Eisai for the joint development and commercialization of aducanumab (the Aducanumab Collaboration Agreement). Under the Aducanumab Collaboration Agreement, we will continue to lead the ongoing Phase 3 development of aducanumab and will remain responsible for 100% of development costs for aducanumab until April 2018. Eisai will then reimburse us for 15% of aducanumab development expenses for the period April 2018 through December 2018, and 45% thereafter. Upon commercialization, both companies will co-promote aducanumab with a region-based profit split.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai will continue to jointly develop BAN2401 and E2609.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai will co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai will distribute AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Eisai, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of our collaboration and license agreement with Neurimmune. Under the amended agreement, we made a $150.0 million payment to Neurimmune, which is reflected as a charge to noncontrolling interests, in exchange for a 15% reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab. Our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, will now range from the high single digits to low-teens. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the amended agreement, we also have an option that will expire in April 2018 to further reduce our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, by an additional 5% in exchange for a $50.0 million payment to Neurimmune.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Neurimmune, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB098 License Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes for BIIB098 (formerly known as ALKS 8700), an oral MMF prodrug in Phase 3 development for the treatment of relapsing forms of MS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received an exclusive, worldwide license to develop and commercialize BIIB098 and will pay Alkermes a royalty on potential worldwide net sales of BIIB098. Beginning in 2018 we are responsible for all development expenses related to BIIB098. Alkermes will maintain responsibility for regulatory interactions with the FDA through the potential approval of the NDA for BIIB098 for the treatment of MS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Alkermes, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Ionis Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2017 we entered into a new collaboration agreement with Ionis to identify new ASO drug candidates for the treatment of SMA. Under this agreement, we have the option to license therapies arising out of this collaboration and will be responsible for the development and commercialization of these therapies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our new collaboration arrangement with Ionis, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved MS products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing MS products. Our products may also face increased competitive pressures from the introduction of generic versions, prodrugs of existing therapies or biosimilars of existing products and other technologies. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;Drug pricing and other health care costs continue to be subject to intense political and societal pressures on a global basis.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition,&#160;our sales and operations are subject to the risks of doing business internationally. For example, the effects of the implementation of the U.K.&#8217;s decision to voluntarily depart from the E.U., known as Brexit, remain unclear; compliance with any resulting regulatory mandates may prove challenging and the macroeconomic impact on our sales and consolidated results of operations from these developments remains unknown.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our competition and pricing risks that could negatively impact our product sales, please read Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and Item 7A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><a name="s6B0941789508583A8C0BA76FAE8EE8F1"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017 compared to 2016</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016 compared to 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,017.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,050.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,545.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,337.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,767.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,642.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">20.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,559.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">360.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,273.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,448.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,763.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017 compared to 2016</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016 compared to 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,214.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,968.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,638.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,645.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,795.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,968.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,973.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,963.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,886.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">883.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">513.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">319.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(90.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">26.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">333.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">234.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(92.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">370.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Interferon includes AVONEX and PLEGRIDY.</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><a name="s0B37EF7BE4985D04B142EAE274FDA63E"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</font></div><div style="line-height:120%;text-align:left;"><img src="tecfiderachart.jpg" alt="tecfiderachart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TECFIDERA revenues was primarily due to price increases, partially offset by higher discounts and allowances and a decrease in unit sales volume of 3%. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TECFIDERA revenues was primarily due to price increases, partially offset by higher discounts and allowances and a decrease in unit sales volume of 1%.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TECFIDERA revenues was primarily due to increases in unit sales volume of 19% primarily in the E.U., partially offset by pricing reductions in certain European countries.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TECFIDERA revenues was primarily due to increases in unit sales volume of 32% in existing markets and new markets where we continue to launch the product and expand our presence around the world. These increases were partially offset by pricing reductions in certain European countries. Rest of world TECFIDERA revenues for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were also negatively impacted by a $50.2 million decrease in hedge gains recognized under our foreign currency hedging program in the comparative period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate a modest increase in TECFIDERA demand on a global basis in 2018, compared to 2017, with expected volume growth in our international markets partially offset by declines in the U.S., due to increased competition from additional treatments for MS, including OCREVUS.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX and PLEGRIDY</font></div><div style="line-height:120%;text-align:left;"><img src="interferonchart.jpg" alt="interferonchart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. Interferon revenues was primarily due to an overall decrease in Interferon unit sales volumes of 12%, which was primarily attributable to patients transitioning to other MS therapies, partially offset by price increases.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. Interferon revenues was primarily due to an overall decrease in Interferon unit sales volume of 10%, which was attributable to a decrease in AVONEX unit sales volume primarily due to patients transitioning to other oral MS therapies, as well as higher discounts and allowances. These decreases were partially offset by price increases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world Interferon revenues was primarily due to an overall decrease in AVONEX unit sales volume of 14% primarily due to patients transitioning to other MS therapies in the E.U. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world Interferon revenues was primarily due to pricing reductions in certain European countries and an overall decrease in AVONEX unit sales volume of 10% due primarily to patients transitioning to other oral MS therapies, including TECFIDERA. Rest of world Interferon revenues for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were also negatively impacted by a $66.1 million decrease in hedge gains recognized under our hedging program in the comparative period. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that overall Interferon revenues will continue to decline compared to prior year periods as a result of increasing competition from our other products as well as other treatments for MS, including biosimilars.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, U.S. AVONEX revenues totaled $1,593.6 million, $1,675.3 million and $1,790.2 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;rest of world AVONEX revenues totaled $557.9 million, $638.2 million and $840.0 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">PLEGRIDY</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, U.S. PLEGRIDY revenues totaled $295.5 million, $305.0 million and $227.1 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, rest of world PLEGRIDY revenues totaled $198.8 million, $176.7 million and $111.4 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;text-align:left;"><img src="tysabrichart.jpg" alt="tysabrichart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. TYSABRI revenues was primarily due to higher discounts and allowances and a decrease in unit sales volume of 4%, partially offset by price increases. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TYSABRI revenues was primarily due to an increase in unit sales volume of 4% and increases in price, partially offset by higher discounts and allowances.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TYSABRI revenues was primarily due to the recognition of approximately $45.0 million of previously deferred revenue in Italy relating to the pricing agreement with AIFA and a 12% increase in unit sales volume primarily in our international partner markets, partially offset by a prior year favorable adjustment of approximately $20.0 million to previous reserves estimates related to a government price reimbursement program included in our discounts and allowances. For information on our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world TYSABRI revenues was primarily due to the impact of a $46.1 million decrease in hedge gains recognized under our hedging program in the comparative period. This decrease was partially offset by an increase in unit sales volume of 8%, primarily in Europe.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate a decline in TYSABRI demand on a global basis in 2018, compared to 2017, with expected volume declines in the U.S., due to increased competition from additional treatments for MS, including OCREVUS, offsetting volume growth in our international markets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ZINBRYTA</font></div><div style="line-height:120%;text-align:left;"><img src="zinbrytachart.jpg" alt="zinbrytachart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under our collaboration agreement with AbbVie, we began to recognize revenues on sales of ZINBRYTA to third parties in the E.U. in the third quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in ZINBRYTA revenues was primarily due to an increase in unit sales volume.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that the future sales growth of ZINBRYTA will be negatively impacted as a result of the EC approved restrictions on the use of ZINBRYTA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with AbbVie, including information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy (SMA)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;text-align:left;text-indent:18px;"><img src="spinrazachart.jpg" alt="spinrazachart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of SPINRAZA in the U.S. in the fourth quarter of 2016 and the rest of world in the first quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that the rate at which SPINRAZA revenues will grow will moderate over time due to the loading dynamics as patients transition to dosing once every four months.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Ionis, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">BENEPALI and FLIXABI</font></div><div style="line-height:120%;"><img src="biosimilarschart.jpg" alt="biosimilarschart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under our commercial agreement with Samsung Bioepis, we began to recognize revenues on sales of BENEPALI and FLIXABI to third parties in the E.U. in the first and third quarters of 2016, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in biosimilar revenues was primarily due to an increase in BENEPALI unit sales volume in new and existing markets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Samsung Bioepis, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><a name="s2B2532A816C2508983F642DBC748FDDC"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN and GAZYVA collaboration operating profits in the U.S. and other revenues on anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;"><img src="anticd20revenueschart.jpg" alt="anticd20revenueschart.jpg" style="height:366px;width:317px;"></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of amounts comprising our share of pre-tax profits on RITUXAN and GAZYVA in the U.S.:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,206.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,941.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,847.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">755.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">744.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">673.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,451.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,197.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,174.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,316.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN annual pre-tax co-promotion profits in the U.S. in excess of $50.0 million decreased to 39% from 40% in February 2016 when GAZYVA was approved by the FDA as a new treatment for follicular lymphoma and further decreased to 37.5% in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12-month period exceeded $150.0 million.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 the FDA approved RITUXAN HYCELA for subcutaneous injection for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma and CLL. This new treatment includes the same monoclonal antibody as intravenous RITUXAN in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues was primarily due to selling price increases and an increase in RITUXAN and GAZYA unit sales volume of 2% and 6%, respectively, partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues was primarily due to an increase in GAZYVA unit sales volume of 41%, an increase in RITUXAN unit sales of 1% and selling price increases, partially offset by higher RITUXAN discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration costs and expenses for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as depicted in the table above, excludes certain expenses charged to the collaboration by Genentech that we believe remain the responsibility of Genentech and that we are not obligated to pay under the terms of the collaboration agreement. Accordingly, we did not recognize the effect of those expenses in the determination of our share of pre-tax collaboration profits and Genentech has withheld approximately $120 million from amounts due to us in relation to collaboration activity for 2017, representing Genentech&#8217;s estimate of our share of these expenses. We remain in discussions with Genentech about a resolution relating to these amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Excluding amounts under dispute, collaboration costs and expenses for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increased primarily due to higher branded pharmaceutical drug fees and an increase in RITUXAN selling and marketing costs, partially offset by a decrease in GAZYVA research and development costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration costs and expenses for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increased primarily due to an increase in RITUXAN product cost of sales.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs primarily consist of royalty revenues on sales of OCREVUS and our share of pre-tax co-promotion profits on RITUXAN in Canada. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, other revenues from anti-CD20 therapeutic programs increased primarily due to the launch of OCREVUS in the second quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, other revenues from anti-CD20 therapeutic programs decreased as a result of lower pre-tax co-promotion profits on RITUXAN in Canada.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">OCREVUS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FDA approved OCREVUS, a humanized anti-CD20 monoclonal antibody, for the treatment of RMS and PPMS. Under our agreement with Genentech, we will receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24% if annual net sales exceed $900.0 million. There will be a 50% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we will receive a 3% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS was approved for treatment of RMS and PPMS in Australia, Switzerland and the E.U. in July 2017, September 2017 and January 2018, respectively. Marketing applications for OCREVUS are currently under review in numerous markets worldwide, including in Latin America and the Middle East. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration with Genentech, including information regarding the pre-tax profit sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><div><a name="sD0BC839310045812B0B0D57617ADD3E5"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For The Years </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017 compared to 2016</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016 compared to 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">36.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(43.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">323.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">277.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">167.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">360.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from collaborative and other relationships include revenues earned under our 50% share of the co-promotion profits or losses of ZINBRYTA in the U.S. with AbbVie and revenues from our technical development and manufacturing services agreements with Samsung Bioepis. Prior to the spin-off of our hemophilia business, other revenues from collaborative and other relationships also included revenues earned under our manufacturing services agreement with Sobi on shipments of ELOCTA and ALPROLIX to Sobi and royalties from Sobi on sales of ELOCTA and ALPROLIX in their territory, which included substantially all of Europe, Russia and certain markets in Northern Africa and the Middle East. Bioverativ assumed all of our rights and obligations under our agreement with Sobi on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in other revenues from collaborative and other relationships was primarily due to the impact of the spin-off of our hemophilia business on February 1, 2017, partially offset by higher revenues earned under our manufacturing services agreement with Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in other revenues from collaborative and other relationships was primarily due to a net overall loss in the collaboration with AbbVie of $21.9 million within the U.S. and lower revenues earned under our manufacturing services agreement with Samsung Bioepis, partially offset by an increase in ELOCTA shipments made under our manufacturing services agreement with Sobi.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborative and other relationships, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Royalty and Corporate Revenues</font></div><div style="line-height:120%;text-align:left;"><img src="otherrevenueschart.jpg" alt="otherrevenueschart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenues primarily from amounts earned under contract manufacturing agreements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty and other corporate revenues was primarily due to an increase in sales of the underlying products from which we receive royalties and higher contract manufacturing revenues related to the volume of shipments of drug substance production provided to our strategic partners, including Bioverativ.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty and other corporate revenues was primarily due to higher contract manufacturing revenues related to drug substance manufacturing provided to a strategic partner.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><a name="s445B158330BF592D9090EC08662AF0A6"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which will have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:center;"><img src="reserveschart.jpg" alt="reserveschart.jpg" style="height:328px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reserves for discounts and allowances as a percentage of gross product revenues were 22.0%, 21.3% and 19.3%, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in discounts was primarily driven by the impact from the spin-off of our hemophilia business on February 1, 2017, partially offset by an increase in rest of world product revenues, due in part to an increase in biosimilar revenues, as well as an increase in gross selling prices.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in discounts was primarily driven by increases in gross selling price, contractual discount rates and volume related to our hemophilia products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment assistance (copay), VA and PHS discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to higher managed care rebates and Medicaid and other governmental rebates and allowances in the U.S., due in part to an increase in gross selling prices and the launch of SPINRAZA in the U.S. in the fourth quarter of 2016, partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to higher Medicaid and other governmental rebates and allowances in the U.S. and managed care rebates, due in part to an increase in gross selling prices.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return provisions were relatively consistent.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return reserves decreased primarily due to a reduction in return rates based on recent experiences of returned products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our reserves, please read Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reserves for Discounts and Allowances,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><a name="s49322DBF37225224A35B92D158B6949A"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017 compared to 2016</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016 compared to 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,630.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,478.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,240.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,253.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,973.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,012.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,935.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,947.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,113.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">814.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">385.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">382.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">111.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">112.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss (gain) on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">62.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">323.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(51.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(97.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(64.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA litigation settlement charge</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(100.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,929.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,298.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,872.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s92B7AC90303D5A7C9246F8F7BF1BF1A8"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization of Acquired Intangible Assets (Cost of Sales)</font></div><div style="line-height:120%;text-align:left;"><img src="costofsaleschart.jpg" alt="costofsaleschart.jpg" style="height:306px;width:317px;"></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily driven by higher unit sales volume related to our biosimilar product shipments, higher contract manufacturing shipments of drug substance production provided to our strategic partners, including Bioverativ, and an increase in inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons. These increases were partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017, and the accelerated depreciation recorded in the second, third and fourth quarters of 2016 as a result of our decision to cease manufacturing in Cambridge, MA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily driven by costs noted below as well as increased contract manufacturing shipments and higher unit sales volume related to our biosimilars and hemophilia products, partially offset by favorable production costs and mix of products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product cost of sales for 2016 reflects the recognition of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of accelerated depreciation as a result of the determination to cease manufacturing in Cambridge, MA and vacate our small-scale biologics manufacturing facility in Cambridge, MA and warehouse space in Somerville, MA.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$76.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Amounts written down during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes the impairment of $14.4 million related to the EC approved restrictions on the use of ZINBRYTA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily driven by the recognition of royalties payable to Ionis on sales of SPINRAZA and higher royalties on sales of AVONEX and PLEGRIDY in the U.S., as described below. These increases were partially offset by the elimination of royalties payable on sales of hemophilia product resulting from the spin-off of our hemophilia business on February 1, 2017 and lower royalties on sales of TYSABRI resulting from the expiration of certain third-party royalties.</font></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily driven by the increase in royalty rates payable to Sobi, increased sales of our hemophilia products and higher royalties on sales of AVONEX and PLEGRIDY in the U.S., partially offset by a decrease in TYSABRI royalties due to the expiration of certain third-party royalties.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 28, 2016, the U.S. Patent and Trademark Office issued to the Japanese Foundation for Cancer Research (JFCR) a patent related to recombinant interferon-beta protein. This patent, U.S. Patent No. 9,376,478, expires in June 2033. This patent was issued following an interference proceeding between JFCR and us. This patent is relevant to AVONEX and PLEGRIDY, and we will pay royalties in the mid-single digits in relation to this patent during the life of the patent. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s153DCE0D3848577DA47A7954E8E6BDC2"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;"><img src="researchanddevelopmentchart.jpg" alt="researchanddevelopmentchart.jpg" style="height:733px;width:317px;"></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:center;"><img src="rdpiechart2017.jpg" alt="rdpiechart2017.jpg" style="height:281px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="rdpiechart2016.jpg" alt="rdpiechart2016.jpg" style="height:281px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="rdpiechart2015.jpg" alt="rdpiechart2015.jpg" style="height:281px;width:317px;"></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in research and development expense was primarily related to milestone and upfront expenses and costs incurred in connection with our early stage and late stage programs, partially offset by decreased costs incurred in connection with our marketed products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in research and development expense was primarily related to a decrease in costs incurred in connection with our early stage programs, marketed products and other research and development costs. These decreases were partially offset by increased costs incurred in connection with our late stage and research and discovery programs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Milestone and Upfront Expenses included in Research and Development Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;includes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million upfront payment made to BMS upon entering into our agreement to exclusively license BIIB092;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million developmental milestone payment due to the former shareholders of iPierian, Inc. (iPierian), which became payable upon dosing of the first patient in the Phase 2 PSP study for BIIB092;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million upfront payment made to Alkermes upon entering into our agreement to exclusively license BIIB098, representing our share of BIIB098 development costs already incurred in 2017;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million accrual based upon the expected continuation of our agreement with Alkermes to develop and exclusively license BIIB098; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million upfront payment recognized upon entering into a new collaboration agreement with Ionis to identify new ASO drug candidates for the treatment of SMA. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;includes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA from Ionis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million milestone payment to Eisai related to the initiation of a Phase 3 trial for E2609; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million upfront payment recognized upon entering into a collaboration and alliance agreement with UPenn. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;includes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million recognized upon entering into our collaboration with Mitsubishi Tanabe Pharma Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.1 million recognized upon entering into our collaboration with AGTC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million in milestones recognized in relation to our collaboration agreements with Ionis; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 million paid to AbbVie related to milestones for the development of ZINBRYTA as a result of filing with the FDA and EMA during 2015. </font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These payments are classified as research and development expense as the programs they relate to had not achieved regulatory approval as of the payment date.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information about these collaborations, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Early Stage Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with our early stage programs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily related to spending associated with the development of BIIB092 in AD and PSP pursuant to our license agreement with BMS, BIIB074 in trigeminal neuralgia (TGN) and BIIB076 in AD. These increases were partially offset by a reduction in costs resulting from our discontinuance of development of amiselimod in the third quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our early stage programs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to the advancement of our aducanumab program in AD to a late stage program in the third quarter of 2015, decreased costs incurred in connection with opicinumab in MS and the discontinuance of development of anti-TWEAK in lupus nephritis. These decreases were partially offset by increased costs of BIIB074 in TGN and increased costs associated with our discontinuance of development of amiselimod in the third quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Late Stage Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with our late stage programs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily related the increased costs associated with the development of aducanumab in AD and costs incurred associated with the development of E2609, a BACE inhibitor that was advanced to a late stage program in the fourth quarter of 2016. These increases were partially offset by advancement of SPINRAZA to marketed products following its approval in the U.S. in the fourth quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with our late stage programs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily driven by costs incurred to advance our aducanumab program in AD, the increased costs incurred to advance our SPINRAZA program and the advancement of E2609 to a late stage program in the fourth quarter of 2016, partially offset by the approval of ZINBRYTA in the third quarter of 2016.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketed Products</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our marketed products for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to a reduction in spending resulting from the spin-off of our hemophilia business on February 1, 2017 and a reduction in spending related to TECFIDERA. These decreases were partially offset by increased spending related to SPINRAZA following its approval in the U.S. in the fourth quarter of 2016. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our marketed products for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to the discontinuance of development of TYSABRI and TECFIDERA in secondary primary MS in the third and fourth quarters of 2015, respectively, and decreased costs incurred in connection with our hemophilia products. These decreases were partially offset by the approvals of ZINBRYTA and SPINRAZA in the third and fourth quarters of 2016, respectively.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;"><img src="sellinggeneraladminchart.jpg" alt="sellinggeneraladminchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in selling, general and administrative expenses was primarily due to a reduction in operational spending resulting from the spin-off of our hemophilia business on February 1, 2017, the execution of targeted cost reduction initiatives and a reduction in costs resulting from the discontinuance of our TECFIDERA television advertising campaign in the second quarter of 2016. These decreases were offset by an increase in SPINRAZA commercialization costs and an increase in corporate giving.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in selling, general and administrative expenses reflect cost savings in connection with our corporate restructuring, which are described below under the heading "</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Restructuring, Business Transformation and Other Cost Savings Initiatives</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">," partially offset by an increase in costs associated with developing commercial capabilities for ZINBRYTA and SPINRAZA.  </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s1C970A69C15A552686D5EAF6439250A9"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="amortofacqintanassetschart.jpg" alt="amortofacqintanassetschart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TECFIDERA, AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of TECFIDERA, AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The results of our TECFIDERA, AVONEX and TYSABRI analyses were impacted by changes in the estimated timing of the impact of other alternative MS formulations, including OCREVUS, which may compete with TYSABRI, TECFIDERA and AVONEX. The outcome of this most recent analysis did not result in a significant net change in our expected rate of amortization for acquired intangible assets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">423.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">401.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">381.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">254.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">242.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense associated with our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in amortization of acquired intangible assets was primarily due to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$444.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of amortization and impairment charges associated with our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, acquired in the first quarter of 2017, as discussed further below. Amortization of acquired intangible assets for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;also reflects the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;impairment of our acquired and in-licensed rights and patents intangible asset related to the Article 20 Procedure of ZINBRYTA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization of acquired intangible assets was relatively consistent as our most recent analysis completed during the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;resulted in no significant net change in our expected rate of amortization for acquired intangible assets. Amortization of acquired intangible assets for 2016 also reflects impairment charges recognized upon the termination of our collaboration agreements with Rodin Therapeutics, Inc. and Ataxion Inc., which resulted in impairment losses of $8.7 million and $3.5 million, respectively, related to the IPR&amp;D assets recorded upon entering into the collaboration agreements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment charges related to intangible assets during 2015 were insignificant.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement with Forward Pharma. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;$1.25 billion&#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of&#160;$454.8 million&#160;and in the first quarter of 2017 we recognized an intangible asset of&#160;$795.2 million&#160;related to this agreement. The pre-tax charge recognized in the fourth quarter of 2016 represented the fair value of our licenses to Forward Pharma&#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016. The intangible asset represented the fair value of the U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property related to TECFIDERA revenues for the period January 2017, the month in which we entered into this agreement, through December 2020, the last month before royalty payments could first commence pursuant to this agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. In January 2018 the EPO announced its decision revoking Forward Pharma&#8217;s European Patent No. 2 801 355. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. Based upon our assessment of these rulings, we continue to amortize the remaining net book value of the U.S. and rest of world intangible assets in our consolidated statements of income utilizing an economic consumption model.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our settlement and license agreement with Forward Pharma and related intangible assets, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on these disputes, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">In Process Research &amp; Development (IPR&amp;D) related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon a number of variables, including estimates of future revenues and the effects of competition, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from a clinical trial phase to the next.&#160;We are continually reevaluating our estimates concerning these variables and evaluating industry data regarding the productivity of clinical research and the development process.&#160;Changes in our estimates of items may result in a significant change to our valuation of these assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We review amounts capitalized as acquired IPR&amp;D for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. Our most recent impairment assessment as of October 31, 2017, resulted in no impairments. Changes to clinical development plans, regulatory feedback received, life cycle management strategies and changes in program economics, including foreign currency exchange rates, are evaluated regularly. The field of developing treatments for forms of neuropathic pain, such as TGN, is highly competitive and can be affected by changes to expected market candidates and changes in timing and the clinical development of our product candidates. There can be no assurance that we will be able to successfully develop BIIB074 for the treatment of TGN or other indications, including our ability to confirm safety and efficacy based on data from clinical trials, or that a successfully developed therapy will be able to secure sufficient pricing in a competitive market. Changes in events and circumstances for these programs may have a material impact on the value of our related IPR&amp;D.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the impairment and amortization of acquired intangible assets, including our TECFIDERA settlement and license agreement, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s01063ea6816d41b2b9a7abfdacbff673"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</font></div><div style="line-height:120%;"><img src="acquiredinprocessrdchart.jpg" alt="acquiredinprocessrdchart.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 we completed an asset purchase of the Phase 3-ready candidate, BIIB093, from Remedy. In connection with the closing of this transaction, we made an upfront $120.0 million payment to Remedy, which was recorded as acquired in-process research and development in our consolidated statements of income as BIIB093 had not yet reached technological feasibility. For additional information on our transaction with Remedy, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div><a name="sCBC468A53F9353EAA58BD223E542393F"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit (Loss) Sharing</font></div><div style="line-height:120%;"><img src="collabprofitsharechart.jpg" alt="collabprofitsharechart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing includes our partner's 50% share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis and our partner's 50% share of the co-promotion profits or losses in the E.U. and Canada related to our collaboration agreement with AbbVie on the commercialization of ZINBRYTA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of biosimilars in the first quarter of 2016. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we shared collaboration profits and therefore recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as compared to net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period. The increase in profit sharing expense for the comparative period was primarily due to increased collaboration profits resulting from increased biosimilar product sales.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect AbbVie's 50% sharing of the net collaboration profits in the E.U. and Canada as compared to net income recognized of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period, to reflect AbbVie's 50% sharing of the net collaboration losses in the E.U. and Canada. The increase in profit sharing expense for the comparative period was primarily due to increased collaboration profits resulting from increased ZINBRYTA product sales. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that the future sales growth of ZINBRYTA will be negatively impacted as a result of the EC approved restrictions on the use of ZINBRYTA. For additional information on our relationship with AbbVie, including information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s2F8D51A1507155E1BF3BE94437345D92"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss (Gain) on Fair Value Remeasurement of Contingent Consideration</font></div><div style="line-height:120%;"><img src="glonfvcontconsideration.jpg" alt="glonfvcontconsideration.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The loss on fair value remeasurement of contingent consideration for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to the increase in the probability of achieving certain developmental milestones based upon the progression of the underlying clinical programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The loss on fair value remeasurement of contingent consideration for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to changes in the probability of achieving certain developmental milestones based upon the progression of the underlying clinical programs and changes in the discount rate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The loss on fair value remeasurement of contingent consideration for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones and in the discount rate.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><a name="s01B1E615B38151959BA473D47332D19C"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring, Business Transformation and Other Cost Saving Initiatives</font></div><div style="line-height:120%;"><img src="restructuringchargeschart.jpg" alt="restructuringchargeschart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2017 Corporate Strategy</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we announced an updated strategic framework to optimize the value of our MS business while investing for the future across our core growth areas of MS and neuroimmunology, AD and dementia, Parkinson&#8217;s disease and movement disorders and neuromuscular diseases including SMA and ALS. We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect the continued performance of our commercial assets and the expiration of the contingent payments related to TECFIDERA, discussed further in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Contractual Obligations and Off-Balance Sheet Arrangements&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report, to enable us to invest in and build an industry leading neuroscience pipeline. We view investment in growth as our top priority, but also recognize the value of opportunistically returning excess capital to shareholders through share repurchases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to deliver positive results in the near term while investing in the next stages of our growth, we will focus on the following strategic priorities:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">maximizing the resilience of our MS core business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">accelerating efforts in SMA as a significant new growth opportunity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">developing and expanding our neuroscience portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">focusing our capital allocation efforts to drive investment for future growth; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">creating a leaner and simpler operating model to streamline our operations and reallocate resources towards prioritized research and development and commercial value creation opportunities.</font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We expect to make total non-recurring operating and capital expenditures of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$170.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily in 2018, and our goal is to redirect resources of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$400.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annually by 2020 to prioritized research and development and other value creation opportunities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges in our consolidated statements of income totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this effort, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is included in selling, general and administrative expense and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is reflected as restructuring charges. These restructuring charges, which were substantially incurred and paid in 2017, were primarily related to severance.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2016 Organizational Changes and Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2016 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we initiated cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin-off our hemophilia business, and to achieve further targeted cost reductions. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this effort, which are in addition to, and separate from, the 2015 restructuring charges described below. These amounts, which were substantially incurred and paid by the end of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were primarily related to severance and are reflected in restructuring charges in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cambridge, MA Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 following an evaluation of our current and future manufacturing capabilities and capacity needs, we determined that we intended to cease manufacturing and vacate our 67,000 square foot small-scale biologics manufacturing facility in Cambridge, MA and close and vacate our 46,000 square foot warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December&#160;2016 we subleased our rights to the Cambridge, MA manufacturing facility to Brammer Bio MA,&#160;LLC (Brammer). Brammer also purchased from us certain manufacturing equipment, leasehold improvements and other assets in exchange for shares of Brammer common LLC interests and assumed manufacturing operations effective January 1, 2017. In December 2016 we closed and vacated our warehouse space in Somerville, MA.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our departure from these facilities shortened the expected useful lives of certain leasehold improvements and other assets at these facilities. As a result, we recorded additional depreciation expense to reflect the assets' new shorter useful lives. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of this additional depreciation, which was recorded as cost of sales in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2016 we also recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for severance costs related to certain employees separated from Biogen in connection with this transaction. These amounts were substantially incurred and paid by the end of first quarter of 2017 and are reflected in restructuring charges in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2015 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2015 we announced a corporate restructuring, which included the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in workforce. Under this restructuring, cash payments were estimated to total approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were related to previously accrued 2015 incentive compensation, resulting in net restructuring charges totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These amounts were substantially paid by the end of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of restructuring charges related to our 2015 restructuring program in our consolidated statements of income.&#160;Our restructuring reserve is included in accrued expenses and other in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our 2015 restructuring program:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(40.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s1157C24DB8D856338650204AB629D57B"></a></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TECFIDERA Litigation Settlement Charge</font></div><div style="line-height:120%;"><img src="teclitigationchart.jpg" alt="teclitigationchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described above under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Amortization of Acquired Intangible Assets - TECFIDERA License Rights,&#8221; </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">in January 2017 we entered into a settlement and license agreement with Forward Pharma pursuant to which we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;$1.25 billion&#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of&#160;$454.8 million&#160;and in the first quarter of 2017 we recognized an intangible asset of&#160;$795.2 million&#160;related to this agreement. The pre-tax charge recognized in the fourth quarter of 2016 represented the fair value of our licenses to Forward Pharma&#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our TECFIDERA settlement and license agreement, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><a name="s9C5CAD8FE90357959E19B8CD1F7F0D25"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;"><img src="oiechart.jpg" alt="oiechart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to an increase in foreign currency exchange gains, an increase in interest income and a decrease in interest expense, partially offset by other than temporary impairments recorded on strategic investments and marketable debt securities during the year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense for the year ended December 31, 2017, includes a net </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;debt extinguishment charge recognized in November 2017 upon redemption of our 6.875% Senior Notes due March 1, 2018. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on this redemption and our outstanding indebtedness, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to an increase in interest expense as a result of the issuance of our senior unsecured notes in the third quarter of 2015. This increase was partially offset by an increase in interest income on higher yields and cash, cash equivalents and marketable securities balances as well as a decrease in foreign exchange losses recognized during the year ended December 31, 2016, compared to the prior year comparative period. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="sB81472390F85575481A75275BE2CC8FE"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</font></div><div style="line-height:120%;"><img src="incometaxprovisionchart.jpg" alt="incometaxprovisionchart.jpg" style="height:338px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increased primarily due to the effect of the 2017 Tax Act and the impairment of prepaid tax assets related to our ZINBRYTA program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 22, 2017, the 2017 Tax Act was signed into law and has resulted in significant changes to the U.S. corporate income tax system. The 2017 Tax Act includes a federal statutory rate reduction from 35% to 21%, the elimination or reduction of certain domestic deductions and credits, the Transition Toll Tax and other changes to taxation of foreign subsidiaries.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in tax rates and tax laws are accounted for in the period of enactment. Therefore, during the year ended December 31, 2017, we recorded a charge totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,173.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to our current estimate of the provisions of the 2017 Tax Act, including a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;expense under the Transition Toll Tax. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act will provide us with flexibility in deploying our cash resources to advance our business interests. We expect that it will have a modest positive effect on our income tax rate in 2018 and a potential incremental benefit thereafter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Article 20 Procedure of ZINBRYTA</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the CHMP's recommendation of restrictions on the use of ZINBRYTA, we impaired prepaid tax balances totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$142.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Offsetting these amounts was an unrecorded tax benefit related to certain ZINBRYTA related assets totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Excluding the effect of the 2017 Tax Act and the ZINBRTYA impairments, our income tax rate would have decreased due to a lower percentage of our earnings being recognized in the U.S., a higher tax jurisdiction. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we earned a lower benefit from the orphan drug credit due to the FDA's approval of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increased primarily due to a net state tax benefit in 2015 of $27.0 million resulting from the remeasurement of one of our uncertain tax positions and a higher relative percentage of our earnings being attributed to the U.S., a higher tax jurisdiction.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our uncertain tax positions and income tax rate reconciliation for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s925E633B0AA5592D95B37D0E0F5730C7"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity in Loss of Investee, Net of Tax</font></div><div style="line-height:120%;"><img src="equityinlossofinvesteechart.jpg" alt="equityinlossofinvesteechart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into an agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals. We account for this investment under the equity method of accounting. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;our share of losses exceeded the carrying value of our investment. We therefore suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on this transaction, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><a name="s4A075A40021F59AC8FED2B260248E85B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Noncontrolling Interest</font></div><div style="line-height:120%;"><img src="noncontrollinginterestchart.jpg" alt="noncontrollinginterestchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in net income (loss) attributable to noncontrolling interests, net of tax, was primarily related to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;pre-tax upfront payment made to Neurimmune in exchange for a 15% reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the amended agreement, we also have an option that will expire in April 2018 to further reduce our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment to Neurimmune.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in net income (loss) attributable to noncontrolling interests, net of tax, was primarily related to a $60.0 million pre-tax milestone payment made to Neurimmune in 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Neurimmune, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><div><a name="s052E0DD8F5815CAB9DCABC35448D0A55"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017 compared to 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,573.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,326.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,115.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,057.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,829.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,746.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,724.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,935.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,512.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,938.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,517.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working Capital:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,873.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,732.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3,368.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,419.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,505.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,312.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><a name="s94B545B65CBA5B748E755C2720304D30"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$4.6 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities, net of: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#32;in total net payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$463.0 million in upfront and milestone payments to BMS, iPierian, Eisai, Alkermes and Ionis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$454.8 million payment made to Forward Pharma for the litigation settlement charge that was accrued as of December 31, 2016;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$867.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million payment made to Forward Pharma to license Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$557.7 million payment made for the redemption of our </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due March 1, 2018 prior to their maturity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million net cash contribution made in connection with the spin-off of our hemophilia business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$295.0 million in upfront and milestone payments made to Remedy, Ionis and Samsung Bioepis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$132.4 million payment, net of tax, made to Neurimmune in exchange for a 15% reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$4.6 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities, net of:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.6 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total net payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million license fee payment made to Ionis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million upfront payment to UPenn;</font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$616.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$82.0 million in milestone payments made to Samsung Bioepis and AbbVie.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. We expect to continue funding our current and planned operating requirements principally through our cash flows from operations, as well as our existing cash resources. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Reform</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 22, 2017, the 2017 Tax Act was signed into law and has resulted in significant changes to the U.S. corporate income tax system.  </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminates the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on undistributed foreign earnings. The Transition Toll Tax is assessed on the U.S. shareholder's share of the foreign corporation's accumulated foreign earnings that have not previously been taxed. Earnings in the form of cash and cash equivalents will be taxed at a rate of 15.5% and all other earnings will be taxed at a rate of 8.0%. As of December 31, 2017, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the Transition Toll Tax, of which $78.3 million is expected to be paid within one year. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Of the total cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately $4.0 billion was generated in foreign </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">jurisdictions and may now be deployed with greater flexibility to advance our business interests. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on certain risks that could negatively impact our consolidated financial position or future results of operations, please read Item 1A. R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">isk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and Item 7A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized our 2016 Share Repurchase Program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock. This authorization does not have an expiration date. All share repurchases under this authorization will be retired. Under this authorization, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for each year. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains available for share repurchases under this authorization.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015 our Board of Directors authorized our 2015 Share Repurchase Program to repurchase up to $5.0 billion of our common stock. All share repurchases under this authorization were retired. Our 2015 Share Repurchase Program was completed as of December 31, 2015. Under this authorization, we repurchased and retired 16.8 million shares of our common stock at a cost of $5.0 billion during the year ended December 31, 2015.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized our 2011 Share Repurchase Program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock. Shares repurchased under this authorization have been principally used to offset common stock issuances under our share-based compensation plans. Our 2011 Share Repurchase Program was completed as of March 31, 2017. Under this authorization, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We did not repurchase any shares of our common stock under this authorization during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and 2015. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments and other interest bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">portfolio that limits the amount of exposure as to institution, maturity and investment type. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net decrease in cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to the payment made to Forward Pharma in connection with our January 2017 settlement and license agreement, the payment made for the redemption of our 6.875% Senior Notes due March 1, 2018 prior to their maturity in November 2017, cash used for share repurchases, the net cash contribution made in connection with the spin-off of our hemophilia business in February 2017, net purchases of property, plant and equipment, upfront and milestone payments made to Remedy, Ionis and Samsung Bioepis and the payment to Neurimmune in exchange for a 15% reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These senior unsecured notes were issued at a discount and are amortized as additional interest expense over the period from issuance through maturity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we redeemed our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due March 1, 2018, with an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on this redemption please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015, we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs that are payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica, payable in June 2018, had a carrying value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair values of our outstanding borrowings as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We define working capital as current assets less current liabilities. The change in working capital at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects a decrease in total current assets of $858.9 million, partially offset by a decrease in current liabilities of $51.7 million. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in total current assets was driven by a decrease in net cash, cash equivalents and marketable securities, as described above, partially offset by an increase in accounts receivable due to an increase in revenues and the timing of customer payments, including amounts due in connection with anti-CD20 therapeutic programs.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in total current liabilities primarily resulted from a reduction in taxes payable and accrued expenses primarily due to the payment of the $454.8 million charge that was accrued as of December 31, 2016, in relation to our settlement and license agreement with Forward Pharma, offset by an increase in the accrual of contingent payments related to FUMADERM and TECFIDERA (together, the Fumapharm Products) upon reaching $15.0 billion and $16.0 billion in total cumulative sales of Fumapharm Products in the fourth quarter of 2017.</font></div></div></div><div><a name="s1C3719EED79E566998C8C99C98E119A2"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017 compared to 2016</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016 compared to 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,551.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,587.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,919.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in by investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,963.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,484.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,553.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(45.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows (used in) provided by financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,380.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,052.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">783.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">126.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(234.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sA2B1C6345CF15DFAB94651FA3E933CE3"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cash operating items such as depreciation and amortization, impairment charges, acquired in-process research and development and share-based compensation;</font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes associated with the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net cash flows provided by operations were relatively consistent. Higher sales and lower income tax payments were offset by the $454.8 million payment related to our settlement and license agreement with Forward Pharma, which had been accrued as of December 31, 2016, and the timing of customer payments, including </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">amounts due in connection with anti-CD20 therapeutic programs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income was lower in 2017, primarily due to the Transition Toll Tax under the 2017 Tax Act and higher depreciation and amortization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in cash provided by operating activities was primarily driven by higher net income, non-cash charges for depreciation and amortization, a comparative increase in accrued expenses and other liabilities, partially offset by a comparative increase in accounts receivable.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in investing activities was primarily due to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#32;$795.2 million payment made to Forward Pharma to license Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">an increase in purchases of property, plant and equipment primarily related to the construction of our Solothurn, Switzerland facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$175.0 million in milestone payments made to Ionis and Samsung Bioepis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">the $120.0 million payment made to Remedy for the purchase of BIIB093.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These increases were partially offset by an increase in net proceeds of marketable securities.  </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows used in investing activities was primarily due to a decrease in net purchases of marketable securities and cash paid for the acquisition of Convergence Pharmaceuticals (Convergence) in February 2015, partially offset by an increase in the contingent consideration related to the Fumapharm AG acquisition. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in financing activities was primarily due to an increase in cash used for share repurchases, the payment made for the redemption of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due March 1, 2018 prior to their maturity, the $302.7 million net cash contribution made in connection with the spin-off of our hemophilia business on February 1, 2017, and the net distributions to noncontrolling interest, including the payment made to Neurimmune in exchange for a 15% reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows provided by financing activities was primarily due to the issuance of our senior unsecured notes issued in the third quarter of 2015, partially offset by a decrease in the purchases of common stock.</font></div></div></div><div><a name="s7F84B629FA335B0DB619A922B1E1441D"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our contractual obligations as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, TYSABRI contingent payments and contingent consideration related to our business combinations, as described below.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Less&#160;than</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1 Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1 to 3</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">3 to 5</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">After</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">5&#160;Years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cancellable operating leases (1), (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">428.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">92.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">88.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">199.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term debt obligations (3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,430.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">244.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,983.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,396.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,805.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase and other obligations (4)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,657.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">637.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">344.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">234.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">440.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Defined benefit obligation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total contractual obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,607.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">930.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,420.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,719.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,537.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><a name="s4888C1A6960550C49366CA827DEF5E53"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease properties and equipment for use in our operations. Amounts reflected within the table above detail future minimum rental commitments under non-cancelable operating leases as of December&#160;31 for each of the periods presented. In addition to the minimum rental commitments, these leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Obligations are presented net of sublease income expected to be received for the vacated small-scale biologics manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term debt obligations are primarily related to our Senior Notes, including principal and interest payments. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase and other obligations primarily includes our obligations to purchase direct materials, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to our current estimate of the impact of the 2017 Tax Act, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$270.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contractual commitments for the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$111.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the fair value of net liabilities on derivative contracts. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013, and Perrigo subsequently sold its rights to these payments to a third party effective January 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix, Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN), we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN occurred after January&#160;1, 2009, we recorded the contingent consideration liabilities associated with these transactions at their fair value on the </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">acquisition date and revalue these obligations each reporting period. We may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestones related to these acquisitions. For additional information on our acquisition of Convergence please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We are required to make contingent payments to the former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2016 and the first, second and third quarters of 2017, respectively, and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products in the fourth quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. If the prior 12 months sales of Fumapharm Products are less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, contingent payments remain payable on a decreasing tiered basis. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment that is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.7 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in development milestones, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in regulatory milestones and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in commercial milestones </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$110.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of milestone payments in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$460.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$77.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net liabilities associated with uncertain tax positions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of December 31, 2017, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the Transition Toll Tax, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$78.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is expected to be paid within one year. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s20BA32AB3936539786D4384147DA3F13"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Legal Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal matters as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(U.S.&#160;GAAP), requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions. Other significant accounting policies are outlined in Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition and Related Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenues when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured. For additional information on the new accounting standard for revenues from contracts with customers please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. Product revenues are recorded net of applicable reserves for discounts and allowances. The timing of distributor orders and shipments can cause variability in earnings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts and rebates described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments within selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales in the U.S. and Europe and are primarily due from wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to longer collection periods for our accounts receivable and greater collection risk in certain countries. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Where our collections continue to be subject to significant payment delays due to government funding and reimbursement practices and a portion of these receivables are routinely being collected beyond our contractual payment terms and over periods in excess of one year, we have discounted our receivables and reduced related revenues based on the period of time that we estimate those amounts will be paid, to the extent such period exceeds one year, using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. If economic conditions worsen and/or the financial condition of our customers were to further </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">deteriorate, our risk of collectability may increase, which may result in additional allowances and/or significant bad debts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our concentration of credit risk associated with our accounts receivable balances, please read the subsection entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Credit Risk&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in Item 7A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies. All changes in judgment in relation to pre-approval inventory have historically been insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired Intangible Assets, including In-process Research and Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we purchase a business, the acquired IPR&amp;D is measured at fair value, capitalized as an intangible asset and tested for impairment at least annually, as of October 31, until commercialization, after which time the IPR&amp;D is amortized over its estimated useful life. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, the acquired IPR&amp;D is expensed upon its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have acquired, and expect to continue to acquire, intangible assets through the acquisition of biotechnology companies or through the consolidation of variable interest entities. These intangible assets primarily consist of technology associated with human therapeutic products and IPR&amp;D product candidates. When significant identifiable intangible assets are acquired, we generally engage an independent third-party valuation firm to assist in determining the fair values of these assets as of the acquisition date. Management will determine the fair value of less significant identifiable intangible assets acquired. Discounted cash flow models are typically used in these valuations, and these models require the use of significant estimates and assumptions including but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">estimating the timing of and expected costs to complete the in-process projects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">projecting regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">estimating future cash flows from product sales resulting from completed products and in process projects;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">developing appropriate discount rates and probability rates by project.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe the fair values assigned to the intangible assets acquired are based upon reasonable estimates and assumptions given available facts and circumstances as of the acquisition dates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If these projects are not successfully developed, the sales and profitability of the company may be adversely affected in future periods. Additionally, the value of the acquired intangible assets may become impaired. We believe that the foregoing assumptions used in the IPR&amp;D analysis were reasonable. No assurance can be given that the underlying assumptions used to estimate expected project sales, development costs or profitability, or the events associated with such projects, will transpire as estimated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of TGN. Such programs could become impaired if assumptions used in determining the fair value change.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment and Amortization of Long-lived Assets and Accounting for Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Long-lived Assets Other than Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used include property, plant and equipment as well as intangible assets, including IPR&amp;D and trademarks. Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Acquired Intangible Assets, including In-process Research and Development (IPR&amp;D)"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including treatments for forms of neuropathic pain, such as TGN. Such programs could become impaired if assumptions used in determining the fair value change.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most significant intangible assets are our acquired and in-licensed rights and patents and developed technology. Acquired and in-licensed rights and patents primarily relate to obtaining the fair value of the U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and our acquisition of all remaining rights to TYSABRI from Elan. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TECFIDERA, TYSABRI and AVONEX using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TECFIDERA, TYSABRI and AVONEX is performed annually during our long-range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TECFIDERA, TYSABRI or AVONEX.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the impairment charges related to our long-lived assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report. Impairment charges related to our long-lived assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were insignificant. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill relates largely to amounts that arose in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003 and amounts that are being paid in connection with the acquisition of Fumapharm AG. Our goodwill balances represent the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess our goodwill balance within our single reporting unit annually, as of October&#160;31, and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable to determine whether any impairment in this asset may exist and, if so, the extent of such impairment. We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We completed our required annual impairment test in the fourth quarters of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and determined in each of those periods that the carrying value of goodwill was not impaired. In each year, the fair value of our reporting unit, which includes goodwill, was significantly in excess of the carrying value of our reporting unit.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Investments, including Fair Value Measures and Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We invest in various types of securities, including short-term and long-term marketable securities, principally corporate notes, government securities including government sponsored enterprise mortgage-backed securities and credit card and auto loan asset-backed securities, in which our excess cash balances are invested.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In accordance with the accounting standard for fair value measurements, we have classified our financial assets as Level&#160;1, 2 or 3 within the fair value hierarchy. Fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that we have the ability to access. Fair values determined by Level&#160;2 inputs utilize data points that are observable such as quoted prices, interest rates, yield curves and foreign currency spot rates. Fair values determined by Level&#160;3 inputs utilize unobservable data points for the asset.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As noted in Note&#160;8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report, a majority of our financial assets have been classified as Level&#160;2. These assets have been initially valued at the transaction price and subsequently valued utilizing third-party pricing services. The pricing services use many observable market inputs to determine value, including reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Impairment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected within earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security and are reflected within earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make certain assumptions in order to value and record expense associated with awards made under our share-based compensation arrangements. Changes in these assumptions may lead to variability with respect to the amount of expense we recognize in connection with share-based payments.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determining the appropriate valuation model and related assumptions requires judgment, and includes estimating the expected market price of our stock on vesting date and stock price volatility as well as the term of the expected awards. Determining the appropriate amount to expense based on the anticipated achievement of performance targets requires judgment, including forecasting the achievement of future financial targets. The estimate of expense is revised periodically based on the probability of achieving the required performance targets and adjustments are made throughout the term as appropriate. The cumulative impact of any revision is reflected in the period of change.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also estimate forfeitures over the requisite service period when recognizing share-based compensation expense based on historical rates and forward-looking factors. These estimates are adjusted to the extent that actual forfeitures differ, or are expected to materially differ, from our estimates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions completed after January&#160;1, 2009, we record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value as an adjustment to contingent consideration expense in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs including adjustments to the discount rates and achievement and timing of any cumulative sales-based and development milestones, or changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions described above, could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made estimates and judgments regarding the amount and timing of our restructuring expense and liability, including current and future period termination benefits, pipeline program termination costs and other exit costs to be incurred when related actions take place. Severance and other related costs are reflected in our consolidated statements of income as a component of total restructuring charges incurred. Actual results may differ from these estimates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We prepare and file income tax returns based on our interpretation of each jurisdiction&#8217;s tax laws and regulations. In preparing our consolidated financial statements, we estimate our income tax liability in each of the jurisdictions in which we operate by estimating our actual current tax expense together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred tax assets and liabilities, which are included in our consolidated balance sheets. Significant management judgment is required in assessing the realizability of our deferred tax assets. In performing this assessment, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial accounting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and the effects of tax planning strategies. Our estimates of future taxable income include, among other items, our estimates of future income tax deductions related to the exercise of stock options. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All tax effects associated with intercompany transfers of assets within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the asset transferred is sold to a third-party or otherwise recovered through amortization of the asset's remaining economic life.&#160;If the asset transferred becomes impaired, for example through the obsolescence of inventory or the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total deferred charges and prepaid taxes were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$617.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on the new accounting standard related to tax effects associated with intercompany transfers of assets within our consolidated group, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Our liabilities for uncertain tax positions can be relieved only if the contingency becomes legally extinguished, through either payment to the taxing authority or the expiration of the statute of limitations, the recognition of the benefits associated with the position meet the &#8220;more-likely-than-not&#8221; threshold or the liability becomes effectively settled through the examination process. We consider matters to be effectively settled once the taxing authority has completed all of its required or expected examination procedures, including all appeals and administrative reviews, we have no plans to appeal or litigate any aspect of the tax position, and we believe that it is highly unlikely that the taxing authority would examine or re-examine the related tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We earn a significant amount of our operating income outside the U.S.&#160;As a result, a portion of our cash, cash equivalents and marketable securities are held by foreign subsidiaries.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 22, 2017, the 2017 Tax Act was signed into law and has resulted in significant changes to the U.S. corporate income tax system.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminates the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on undistributed foreign earnings. The Transition Toll Tax is assessed on the U.S. shareholder's share of the foreign corporation's accumulated foreign earnings that have not previously been taxed. Earnings in the form of cash and cash equivalents will be taxed at a rate of 15.5% and all other earnings will be taxed at a rate of 8.0%. As of December 31, 2017, we have accrued </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the Transition Toll Tax, of which $78.3 million is expected to be paid within one year. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest. </font></div><div><a name="sDAD1D3E1062F5C97AD4579E55972F771"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards and their expected impact on our consolidated financial statements or disclosures, please read Note&#160;1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><a name="sF310F791B3105688A21180474C505938"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Market Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks that may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. We have operations or maintain distribution relationships in the U.S., Europe, Canada, Asia, and Central and South America. In addition, we recognize our share of pre-tax co-promotion profits on RITUXAN in Canada. As a result, our consolidated financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Danish krone and Japanese yen.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenues will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expenses, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenues and expenses will increase when reported in U.S. dollars.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the U.K. voted in a referendum to voluntarily depart from the E.U., known as Brexit, and in March 2017, the U.K. formally started the process for the U.K. to leave the E.U. The macroeconomic impact on our results of operations from these developments remains unknown. To date, the foreign currency exchange impact has been insignificant since we hedged the balance sheet foreign currency exchange risk. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of exchange rate changes on revenues and net income diminishes as significant exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our consolidated statements of cash flows.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $286.0 million and $172.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $50.0 million to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">annual interest expense by approximately $6.8&#160;million. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in some international markets in which we operate have implemented measures aimed at reducing healthcare costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possibly retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure favorable prices in a particular country may impair our ability to obtain acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our consolidated financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition from generics and biosimilars in many markets.&#160;Generic versions of drugs and biosimilars are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of generic or biosimilar versions of our marketed products, as well as lower-priced competing products, likely would significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may have an adverse impact on our consolidated results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that results in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, to impose restrictions on the coverage of </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">particular drugs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to long collection periods for our accounts receivable and greater collection risk in certain countries. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</font></div><div><a name="sDDB7F59BBB37530986AB5E935432B2E4"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information required by this Item&#160;8 is contained on pages F-1 through F-78 of this report and is incorporated herein by reference.</font></div><div><a name="s38FEA9B34CB35E179575016901C70070"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90</font></div></div><hr style="page-break-after:always"><div><a name="sB65D807B24F95E9AAB98E9261792F819"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers and effected by a company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.&#160;GAAP. Our internal control over financial reporting includes those policies and procedures that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S.&#160;GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our management assessed the effectiveness of our internal control over financial reporting as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control&#160;&#8212; Integrated Framework.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our assessment, our management has concluded that, as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our internal control over financial reporting is effective based on those criteria.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The effectiveness of our internal control over financial reporting as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their attestation report, which is included herein.</font></div><div><a name="sA63CF350D631590DA38F2E597E34D641"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91</font></div></div><hr style="page-break-after:always"><div><a name="s5CE162B9D8C057EEAEEBD62113F6C3A1"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;III</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sA72CFBF2FC805BCBA3B6010B4D3976D7"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information concerning our executive officers is set forth under the heading </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Our Executive Officers&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in Item 1 of this report. The text of our code of business conduct, which includes the code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions, is posted on our website, www.biogen.com, under the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Governance</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; subsection of the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">About Us</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of the site. We intend to make all required disclosures regarding any amendments to, or waivers from, provisions of our code of business conduct at the same location of our website. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to the remainder of this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Proposal&#160;1&#160;- Election of Directors,&#8221; &#8220;Corporate Governance at Biogen,&#8221; &#8220;Stock Ownership&#160;- Section&#160;16(a) Beneficial Ownership Reporting Compliance</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Miscellaneous&#160;- Stockholder Proposals</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div><div><a name="s92DF18A3C5455DE2B4F2F788CEF4ECB5"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Executive Compensation Matters</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Corporate Governance at Biogen&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div><div><a name="sB89D3D280D99568BBC1E7D57D4BC3E56"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Stock Ownership&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Equity Compensation Plan Information&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s21F70A3CD6845C1A921D5BA5D8831382"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Certain Relationships and Related Person Transactions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Corporate Governance at Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div><div><a name="s5DBEB1666A7651A2843A5BB0AEEB0151"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accounting Fees and Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the section entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Proposal&#160;2&#160;&#8212; Ratification of the Selection of our Independent Registered Public Accounting Firm</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92</font></div></div><hr style="page-break-after:always"><div><a name="sF79BC10CF0435AB38B8E8A59444BE17B"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;IV</font></div><div><a name="s27C5CD1727A1538ABA6830DDAA2F7437"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;15. &#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">a. &#160;&#160;&#160;&#160;(1)&#160;Consolidated Financial Statements:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following financial statements are filed as part of this report:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:37%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page&#160;Number</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-2</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-3</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-4</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-5</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-6</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-9</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-77</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain totals may not sum due to rounding.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;(2) Exhibits</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed on the Exhibit&#160;Index beginning on page&#160;94, which is incorporated herein by reference, are filed or furnished as part of this report or are incorporated into this report by reference.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(3) Financial Statement Schedules</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Schedules are omitted because they are not applicable, or are not required, or because the information is included in the consolidated financial statements and notes thereto.</font></div><div><a name="s5bf2d2c3a82448b2aa46626f2bb9a7f3"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;16. &#160;&#160;&#160;&#160;Form 10-K Summary</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93</font></div></div><hr style="page-break-after:always"><div><a name="s59C41119CE1B54148B6DE58FA422F67C"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;-sec-extract:summary;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT INDEX</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:7%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504513000010/apa.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset Purchase Agreement among Biogen Idec International Holding Ltd., Elan Pharma International Limited and Elan Pharmaceuticals, Inc., dated as of February 5, 2013. Filed as Exhibit 2.1 to our Current Report on Form 8-K/A filed on February 12, 2013.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000007/ex21_separationxagreement.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Separation Agreement between Biogen Inc. and Bioverativ Inc. dated as of January 31, 2017. Filed as Exhibit 2.1 to our Current Report on Form 8-K filed on February 2, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312512312222/d362642dex31.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amended and Restated Certificate of Incorporation, as amended. Filed as Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504515000008/biib-2015x327xexhibit31.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certificate of Amendment to the Certificate of Incorporation. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on March 27, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312517200127/d406783dex31.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fourth Amended and Restated Bylaws. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on June 9, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312512312222/d362642dex31.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reference is made to Exhibit 3.1 for a description of the rights, preferences and privileges of our Series A Preferred Stock and Series X Junior Participating Preferred Stock.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312515320650/d78596dex41.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indenture between Biogen Inc. and U.S. Bank National Association, dated as of September 15, 2015. Filed as Exhibit 4.1 to our Current Report on Form 8-K filed on September 16, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312515320650/d78596dex42.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">First Supplemental Indenture between Biogen Inc. and U.S. Bank National Association, dated September 15, 2015. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on September 16, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504515000028/creditagreement2015biogen.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit Agreement between Biogen Inc., Bank of America, N.A., Goldman Sachs Bank USA and other lenders party thereto, dated August 28, 2015. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on September 1, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012311009300/b83162exv10w5.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Second Amended and Restated Collaboration Agreement between Biogen Idec Inc. and Genentech, Inc., dated as of October 18, 2010. Filed as Exhibit 10.5 to our Annual Report on Form 10-K for the year ended December 31, 2010.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012311009300/b83162exv10w6.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter Agreement regarding GA101 financial terms between Biogen Idec Inc. and Genentech, Inc., dated October 18, 2010. Filed as Exhibit 10.6 to our Annual Report on Form 10-K for the year ended December 31, 2010.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095015717000082/ex10-1.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement and License Agreement, dated January 17, 2017, between Biogen Swiss Manufacturing GmbH, Biogen International Holdings ltd., Forward Pharma A/S and other parties thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on February 1, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312517139450/d43428ddef14a.htm#toc43428_63"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2017 Omnibus Equity Plan. Filed as Appendix B to our Definitive Proxy Statement on Schedule 14A filed on April 26, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.6*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit102.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of restricted stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit103.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of market stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.8*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit104.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.4 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.9*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit105.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of cash-settled performance unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.5 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.10*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20171231xex1010.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement (cash-settled) under the Biogen Inc. 2017 Omnibus Equity Plan.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.11*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20171231xex1011.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.12*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000011/biib-2014331xex101.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. 2008 Amended and Restated Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.13*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000011/biib-2014331xex102.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</font></a></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">94</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:7%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.14*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000011/biib-2014331xex103.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of market stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.15*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508005246/b71469biexv10w1.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of restricted stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 1, 2008.</font></a></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.16*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508005246/b71469biexv10w2.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of nonqualified stock option award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Current Report on Form 8-K filed on August 1, 2008.</font></a></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.17*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012310036233/b79987exv10w1.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of cash-settled performance shares award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.18*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504515000014/biib-2015331xex101.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2006 Non-Employee Directors Equity Plan, as amended. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.19*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312515159387/d786327ddef14a.htm#toc786327_57"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2015 Employee Stock Purchase Plan. Filed as Appendix A to our Definitive Proxy Statement on Schedule 14A filed on April 30, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.20*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508003542/b67068dfdefc14a.htm#152"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. 2008 Performance-Based Management Incentive Plan. Filed as Appendix B to our Definitive Proxy Statement on Schedule 14A filed on May 8, 2008.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.21*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013504001180/b48790biexv10w13.txt"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Voluntary Executive Supplemental Savings Plan, as amended and restated effective January 1, 2004. Filed as Exhibit 10.13 to our Annual Report on Form 10-K for the year ended December 31, 2003.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.22*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000042/biib-20151231xex1023.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Supplemental Savings Plan, as amended. Filed as Exhibit 10.23 to our Annual Report on Form 10-K for the year ended December 31, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.23*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000042/biib-20151231xex1024.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Voluntary Board of Directors Savings Plan, as amended. Filed as Exhibit 10.24 to our Annual Report on Form 10-K for the year ended December 31, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.24*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000004/biib-20131231xex1039.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective January 1, 2014. Filed as Exhibit 10.39 to our Annual Report on Form 10-K for the year ended December 31, 2013.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.25*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000004/biib-20131231xex1040.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy - International Executive Vice President, as amended effective January 1, 2014. Filed as Exhibit 10.40 to our Annual Report on Form 10-K for the year ended December 31, 2013.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.26*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013509000730/b73435biexv10w53.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy - U.S.  Senior Vice President, as amended effective October 13, 2008. Filed as Exhibit 10.53 to our Annual Report on Form 10-K for the year ended December 31, 2008.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.27*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013509000730/b73435biexv10w54.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy - International Senior Vice President, as amended effective October 13, 2008. Filed as Exhibit 10.54 to our Annual Report on Form 10-K for the year ended December 31, 2008.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.28*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20171231xex1028.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Annual Retainer Summary for Board of Directors.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.29*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012311057276/b86869exv10w1.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of indemnification agreement for directors and executive officers. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on June 7, 2011.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.30*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000076/biogenemploymentagreementf.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employment Agreement between Biogen Inc. and Michel Vounatsos dated December 18, 2016. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on December 19, 2016.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.31*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20171231xex1031.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Jeffrey Capello dated November 14, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.32*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20171231xex1032.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Gregory Covino dated February 25, 2012.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.33*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20171231xex1033.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Michael Ehlers dated April 16, 2016.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.34*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012310010528/b77985exv10w58.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Susan Alexander dated December 31, 2005. Filed as Exhibit 10.58 to our Annual Report on Form 10-K for the year ended December 31, 2009.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.35*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504513000029/exhibit101amendedemploymen.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employment Agreement between Biogen Idec. Inc. and George A. Scangos amended as of August 23, 2013. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 26, 2013.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.36*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508001029/b68103biexv10w49.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Paul J. Clancy dated August 17, 2007. Filed as Exhibit 10.49 to our Annual Report on Form 10-K for the year ended December 31, 2007.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.37*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000065/biib-2016630xex101.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of John Cox dated May 19, 2016. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.</font></a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:6%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.38*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504513000006/biib-20121231xex1049.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Kenneth DiPietro dated December 12, 2011. Filed as Exhibit 10.49 to our Annual Report on Form 10-K for the year ended December 31, 2012.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20171231xex21.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subsidiaries. </font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20171231xex23.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20171231xex311.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20171231xex312.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20171231xex321.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017, formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flows, (v) the Consolidated Statements of Equity and (vi) Notes to Consolidated Financial Statements.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">^</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References to &#8220;our&#8221; filings mean filings made by Biogen Inc. and filings made by IDEC Pharmaceuticals Corporation prior to the merger with Biogen, Inc. Unless otherwise indicated exhibits were previously filed with the Securities and Exchange Commission under Commission File Number 0-19311 and are incorporated herein by reference.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management contract or compensatory plan or arrangement.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Confidential treatment has been granted or requested with respect to portions of this exhibit.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Filed herewith.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:2%;"></td><td style="width:4%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furnished herewith.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">96</font></div></div><hr style="page-break-after:always"><div><a name="sFC6B26CBE6385556B9212C79CF160F60"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:316px;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:50px;"></td><td style="width:265px;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">BIOGEN INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;M</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHEL</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;V</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OUNATSOS</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:42%;"></td><td style="width:3%;"></td><td style="width:34%;"></td><td style="width:3%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Capacity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;M</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHEL</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;V</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OUNATSOS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director&#160;and&#160;Chief&#160;Executive&#160;Officer (principal&#160;executive&#160;officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;Jeffrey D. Capello</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive&#160;Vice&#160;President and Chief Financial Officer (principal financial officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;G</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">REGORY</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;F. C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OVINO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Finance, Chief Accounting Officer (principal accounting officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gregory F. Covino</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TELIOS</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">APADOPOULOS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director&#160;and&#160;Chairman&#160;of&#160;the&#160;Board&#160;of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stelios Papadopoulos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">LEXANDER </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">J</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ENNER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Alexander J. Denner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AROLINE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;D. D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ORSA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Caroline D. Dorsa</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;N</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ANCY</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;L. L</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">EAMING</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nancy L. Leaming</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHARD </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">M</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ULLIGAN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Richard C. Mulligan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OBERT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;W. P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ANGIA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robert W. Pangia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">RIAN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;S. P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OSNER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Brian S. Posner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;E</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">RIC</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;K. R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OWINSKY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eric K. Rowinsky</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;L</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">YNN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">CHENK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Lynn Schenk</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TEPHEN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;A. S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">HERWIN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stephen A. Sherwin</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98</font></div></div><hr style="page-break-after:always"><div><a name="sADF33712D6FF5FEFAFF550A406956AAE"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:37%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page&#160;Number</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-5</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-6</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-9</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-77</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:300px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 1</font></div></div><hr style="page-break-after:always"><div><a name="sC712CED67F0A586CB61E0BD6BA66E132"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions, except per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,559.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">360.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,273.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,448.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,763.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,630.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,478.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,240.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,253.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,973.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,012.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,935.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,947.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,113.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">814.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">385.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">382.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">112.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss (gain) on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">62.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA litigation settlement charge</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,929.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,298.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,872.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,344.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,150.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(215.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(217.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,128.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,933.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,767.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,458.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,237.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,161.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,670.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,695.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,593.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">131.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.94</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.96</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:120px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 2</font></div></div><hr style="page-break-after:always"><div><a name="s9EF6448C34045ACAA22D27CEACE2E4B6"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: reclassification adjustment for (gains) losses included in net income, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(193.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: reclassification adjustment for (gains) losses included in net income, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(172.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(162.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(61.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">158.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,540.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,606.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,382.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">131.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,671.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,599.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,428.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 3</font></div></div><hr style="page-break-after:always"><div><a name="s2ECDAA6E25A852FDB7B7A446780F62A0"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions, except per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,573.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,326.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,115.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,787.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,441.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">532.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">300.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">902.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,001.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">962.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,093.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,873.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,732.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,057.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,829.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,182.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,501.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,879.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,808.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,632.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,669.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,027.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,335.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">23,652.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22,876.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">68.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">395.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">279.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,901.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,368.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,419.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,935.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,512.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">122.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,628.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">722.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,054.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,748.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">97.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(318.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15,810.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15,071.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost; 23.8 million and 22.6 million shares, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,612.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,140.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,598.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,128.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">23,652.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22,876.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 4</font></div></div><hr style="page-break-after:always"><div><a name="s41B72004B4025B709270F6FE439FA1D6"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2,670.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">3,695.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">3,593.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Adjustments to reconcile net income to net cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1,081.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">682.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">600.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">128.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">154.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">161.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">91.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(175.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(145.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">62.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">14.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">30.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">162.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">89.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">129.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Changes in operating assets and liabilities, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(435.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(241.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">29.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Due from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(232.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">13.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(31.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(94.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(165.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(174.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(76.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">59.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(127.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(227.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">622.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">199.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income tax assets and liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1,303.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(232.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(429.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(2.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">69.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">83.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net cash flows provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">4,551.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">4,587.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">3,919.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Proceeds from sales and maturities of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">5,565.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">7,378.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">4,063.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(5,355.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(7,913.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(6,864.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Contingent consideration related to Fumapharm AG acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(1,200.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1,200.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(850.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Acquisitions of businesses, net of cash acquired</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(198.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Purchases of property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(867.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(616.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(643.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Acquisitions of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(975.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(111.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(15.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(11.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(22.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(44.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net cash flows used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(2,963.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2,484.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(4,553.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Purchases of treasury stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(1,365.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(5,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Payments related to issuance of stock for share-based compensation arrangements, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(5.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(8.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(70.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net distribution to noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(134.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(56.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Proceeds from borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">5,930.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Repayments of borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(560.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net cash contribution to Bioverativ, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Contingent consideration payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(38.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(13.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(8.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(5.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net cash flows provided by (used in) financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(2,380.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1,052.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">783.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">(792.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">1,049.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">148.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">39.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(31.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(45.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cash and cash equivalents, beginning of the year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2,326.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">1,308.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">1,204.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cash and cash equivalents, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1,573.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">2,326.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">1,308.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 5</font></div></div><hr style="page-break-after:always"><div><a name="s92B8A967570D5C3D9219F858B9B2DE21"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">238.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(319.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15,071.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,611.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,140.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,128.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">131.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,670.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital contribution by noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(150.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(150.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(964.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2011 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(365.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(365.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(365.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(44.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(45.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(45.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">138.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">138.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">138.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(852.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(852.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(852.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">97.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(318.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15,810.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,612.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,598.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">241.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,208.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,372.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,374.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,695.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition of noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital contribution by noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deconsolidation of noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(835.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(47.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(52.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(52.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">169.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">169.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">169.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit from share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15,071.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,140.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,128.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">257.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,196.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,283.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,809.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,814.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,593.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition of noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2015 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,377.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(622.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,000.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(125.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(125.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(125.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit from share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">241.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,208.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,372.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,374.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 8</font></div></div><hr style="page-break-after:always"><div><a name="sBCB7D60AB72E5BB5847562CCCFD2D824"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="s3193B1C952C15AE2A215505471C33336"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1. &#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer&#8217;s disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS and relapsing MS and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), a rare condition that affects movement, speech, vision and cognitive function, Parkinson's disease and ALS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE in the European Union (E.U.). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these audited consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenues when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates, non-US pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the United States (U.S.) for RITUXAN and GAZYVA; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160; </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">reimbursement of our selling and development expenses in the U.S. for RITUXAN; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(iii)&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech, the Roche Group and us. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information on our collaboration with Genentech, please read Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Multiple-Element Revenue Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenues to the various elements based on their estimated selling price as a component of total revenues.&#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&#8217;s best estimate of a selling price. Revenues allocated to an individual element are recognized when all other revenue recognition criteria are met for that element.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangement with AbbVie Inc. (AbbVie) represents a collaborative arrangement as each party is an active participant and exposed to significant risks and rewards of the arrangement. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenue in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration with AbbVie, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms that generally require payment within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of accounts receivable, net, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Marketable Securities and Other Investments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions and are included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Investments for Other-than-Temporary Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Equity Method of Accounting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or market with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three to five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to obtaining the fair value of the U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd. (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TECFIDERA, TYSABRI and AVONEX using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TECFIDERA, TYSABRI and AVONEX is performed annually during our long-range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TECFIDERA, TYSABRI or AVONEX.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired In-process Research and Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including treatments for forms of neuropathic pain, such as trigeminal neuralgia (TGN). Such programs could become impaired if assumptions used in determining the fair value change. Impairments are recorded as amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&#160;25, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Translation of Foreign Currencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Share-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&#8217; vesting periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense, net of forfeitures, for RSUs is recognized straight-line over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price of common stock under our ESPP is equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the lesser of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;discount is recognized as compensation expense over the 90-day purchase period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$106.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$108.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All tax effects associated with intercompany transfers of assets within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&#160;If the asset transferred becomes impaired, for example through the obsolescence of inventory or discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Earnings per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry-specific guidance. This new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date. These new standards became effective for us on January 1, 2018, and will be adopted using the modified retrospective method through a cumulative-effect adjustment directly to retained earnings as of that date. We have performed a review of these new standards as compared to our current accounting policies for customer contracts and collaborative relationships. During the fourth quarter of 2017 we finalized our assessments over the impact that these new standards will have on our consolidated results of operations, financial position and disclosures. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have not identified any accounting changes that would materially impact the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues; however, the adoption of these new standards may result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we expect to recognize an immaterial adjustment to retained earnings reflecting the cumulative impact for the accounting changes related to certain contract manufacturing arrangements made upon adoption of these new standards.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. This new standard became effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this new standard is not expected to have a material impact on our consolidated financial position or results of operations; however, it will result in the reclassification of where we recognize changes in fair value related to certain investments prospectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard establishes a right-of-use (ROU) model that requires all lessees recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This new standard will become effective for us on January 1, 2019. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While we are currently evaluating the impact that this new standard may have on our consolidated results of operations, financial position and disclosures, we expect that the adoption of this new standard may materially affect the reported amount of total assets and total liabilities within our consolidated balance sheet with no material impact to our consolidated statement of income. We are unable to quantify the impact at this time as the ultimate impact of adopting this new standard will depend on the total amount of our lease commitments as of the adoption date. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences and classification of awards as either equity or liabilities in the statement of cash flows. This new standard became effective for us on January 1, 2017. The adoption of this new standard did not have a material impact on our consolidated financial position, results of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">operations or statement of cash flows; however, it has resulted in the reclassification of certain prior year amounts in our consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. This new standard became effective for us on January 1, 2018. We will adopt this new standard using the modified retrospective method, through a cumulative-effect adjustment directly to retained earnings as of the beginning of that date. Based on currently enacted tax rates, upon adoption, we will record additional deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and an increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-01,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. We elected to early adopt this new standard as of January 1, 2017, with prospective application to any business development transactions, including our recent asset acquisition of BIIB093 from Remedy Pharmaceuticals Inc. (Remedy) in May 2017. For additional information on this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-04, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates Step 2 from the goodwill impairment test. Under the amendments in ASU No. 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds that reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. We elected to early adopt this new standard as of October 31, 2017, during our annual review of goodwill. The adoption of this new standard resulted in a change to our accounting policy; however, did not have an impact on our consolidated financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. This new standard will become effective for us on January 1, 2019. We are currently evaluating the potential impact that this new standard may have on our consolidated financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard is intended to simplify hedge accounting by better aligning how an entity&#8217;s risk management activities and hedging relationships are presented in its financial statements and simplifies the application of hedge accounting guidance in certain situations. This new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This new standard will become effective for us on January 1, 2019; however, early adoption is permitted. For cash flow hedges existing at the adoption date, this new standard requires adoption on a modified retrospective basis with a cumulative-effect adjustment to retained earnings as of the effective date. The amendments to presentation guidance and disclosure requirements are required to be adopted prospectively. We are currently evaluating the date upon which we will adopt this new standard and the impact this new standard may have on our consolidated financial statements. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 22</font></div></div><hr style="page-break-after:always"><div><a name="s2D98F85DD87252F7916B9D83315AF4A9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Remedy Pharmaceuticals Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 we completed an asset purchase of the Phase 3-ready candidate, BIIB093 (intravenous glibencamide) (formerly known as CIRARA), from Remedy. The target indication for BIIB093 is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) recently granted BIIB093 Orphan Drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 Fast Track designation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we are responsible for the future development and commercialization of BIIB093 and Remedy will share in the cost of development for the target indication for BIIB093 in LHI stroke.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as we did not acquire any employees from Remedy nor did we acquire any significant processes required in the development of BIIB093. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Remedy, which was recorded as acquired in-process research and development in our consolidated statements of income as BIIB093 has not yet reached technological feasibility. We also have agreed to pay Remedy certain development and sales based milestone payments that are substantially payable upon or after regulatory approval, as well as royalties on future commercial sales. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Convergence Pharmaceuticals</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence&#8217;s lead candidate was a Phase 2 clinical candidate BIIB074 (formerly known as CNV1014802), which had demonstrated clinical activity in proof-of-concept studies for TGN. Additionally, BIIB074 had potential applicability in several other neuropathic pain states, including lumbosacral radiculopathy and erythromelalgia. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price consisted of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$350.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is associated with the development and approval of BIIB074 for the treatment of TGN. In connection with the closing of this transaction, we recorded a liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;representing the fair value of the contingent consideration resulting in an adjusted purchase price of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$474.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The separately identifiable assets and liabilities acquired were primarily comprised of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;attributed to in-process research and development and goodwill, respectively.&#160;These amounts were partially offset by the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets which had no tax basis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&amp;D intangible assets. The goodwill was not tax deductible.</font></div><div><a name="s1a4feb751cf946048415c9903f60a467"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. (Sangamo).</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution, Biogen and Bioverativ entered into a separation agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward. They also provide for the performance of services by each company for the benefit of the other for a period of time. In addition, under the separation agreement, Bioverativ is obligated to indemnify us for </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The services under these agreements generally commenced on February 1, 2017 (the distribution date), and terminate within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the distribution date, with the exception of the manufacturing and supply agreement, which has an initial term of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5 years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with a 5 year extension at Bioverativ's sole discretion and a further 5 year extension with Bioverativ's and our consent. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution we made a net cash contribution to Bioverativ, during the first quarter of 2017, totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">155.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the terms of our agreements with Bioverativ, upon completion of the spin-off, we distributed ALPROLIX and ELOCTATE on behalf of Bioverativ until Bioverativ obtained appropriate regulatory authorizations in certain countries, including a Biologics License Application transfer in the U.S., which was received in September 2017. Accordingly, commencing October 2017, we ceased distribution of ALPROLIX and ELOCTATE on behalf of Bioverativ under this arrangement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the manufacturing and supply agreement, we manufacture and supply certain products and materials to Bioverativ. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in revenues in relation to these contract manufacturing services, which is reflected as a component of other royalty and corporate revenues in our consolidated statements of income. We also recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as cost of sales in relation to these services during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts earned under the non-manufacturing and supply related transaction service agreements are recorded as a reduction of costs and expenses in their respective expense line items. These amounts, which were primarily reflected as a reduction to selling, general and administrative expenses in our consolidated statements of income, were not significant for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia related product revenues reflected in our consolidated statements of income for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$846.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$554.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Results for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;only reflect hemophilia-related product revenues through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to the spin-off of our hemophilia business, we were awarded various methods of treatment and composition of matter patents related to ELOCTATE and ALPROLIX. Upon completion of the spin-off, these patents were transferred to the patent portfolio of Bioverativ.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 24</font></div></div><hr style="page-break-after:always"><div><a name="s8E68116FCF8654FDA215F2FAD8F4532D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Restructuring, Business Transformation and Other Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2017 Corporate Strategy</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we announced an updated strategic framework to optimize the value of our MS business while investing for the future across our core growth areas of MS and neuroimmunology, AD and dementia, movement disorders and neuromuscular diseases including SMA and ALS. We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to deliver positive results in the near term while investing in the next stages of our growth, we will focus on the following strategic priorities:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">maximizing the resilience of our MS core business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">accelerating efforts in SMA as a significant new growth opportunity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">developing and expanding our neuroscience portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">focusing our capital allocation efforts to drive investment for future growth; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">creating a leaner and simpler operating model to streamline our operations and reallocate resources towards prioritized research and development and commercial value creation opportunities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We expect to make total non-recurring operating and capital expenditures of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$170.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily in 2018, and our goal is to redirect resources of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$400.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annually by 2020 to prioritized research and development and other value creation opportunities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges in our consolidated statements of income totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this effort, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is included in selling, general and administrative expense and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is reflected as restructuring charges. These restructuring charges, which were substantially incurred and paid in 2017, were primarily related to severance.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2016 Organizational Changes and Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2016 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we initiated cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin-off our hemophilia business, and to achieve further targeted cost reductions. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this effort, which are in addition to, and separate from, the 2015 restructuring charges described below. These amounts, which were substantially incurred and paid by the end of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were primarily related to severance and are reflected in restructuring charges in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cambridge, MA Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 following an evaluation of our current and future manufacturing capabilities and capacity needs, we determined that we intended to cease manufacturing and vacate our 67,000 square foot small-scale biologics manufacturing facility in Cambridge, MA and close and vacate our 46,000 square foot warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December&#160;2016 we subleased our rights to the Cambridge, MA manufacturing facility to Brammer Bio MA,&#160;LLC (Brammer). Brammer also purchased from us certain manufacturing equipment, leasehold improvements and other assets in exchange for shares of Brammer common LLC interests and assumed manufacturing operations effective January 1, 2017. In December 2016 we closed and vacated our warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our departure from these facilities shortened the expected useful lives of certain leasehold improvements and other assets at these facilities. As a result, we recorded additional depreciation expense to reflect the assets' new </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">shorter useful lives. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of this additional depreciation, which was recorded as cost of sales in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2016 we also recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for severance costs related to certain employees separated from Biogen in connection with our departure from these facilities. These amounts were substantially incurred and paid by the end of first quarter of 2017 and are reflected in restructuring charges in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2015 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2015, we announced a corporate restructuring, which included the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in workforce. Under this restructuring, cash payments were estimated to total approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were related to previously accrued 2015 incentive compensation, resulting in net restructuring charges totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These amounts were substantially paid by the end of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of restructuring charges related to our 2015 restructuring program in our consolidated statements of income.&#160;Our restructuring reserve is included in accrued expenses and other in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our 2015 restructuring program during 2017:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(40.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s8F1EDE33161C5420BB8C7DC7DC1C8B7E"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">482.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">605.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">583.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,307.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">26.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,917.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(475.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,756.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,232.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(69.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(442.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(534.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">109.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">606.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">548.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">592.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,044.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,668.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(522.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,576.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,099.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(536.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(609.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">482.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">387.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">459.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,732.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,229.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(405.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,258.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,666.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(44.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(296.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(351.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">548.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">189.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">572.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s237514CEE2C65F54B82F0BF2A7C39922"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">162.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">605.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">698.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">157.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">902.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,001.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances in the table above as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. Balances transferred to Bioverativ related to work in process and finished goods inventory totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$84.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$76.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div><a name="s7951ED54FCA15920AE75B7E971603705"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:21%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(535.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(523.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,689.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,634.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">680.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">680.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,971.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,160.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,811.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,481.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(776.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,705.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,264.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,385.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,879.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,742.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,934.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,808.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$814.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$385.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$382.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$444.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of amortization and impairment charges related to our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below. Amortization of acquired intangible assets for 2017 also reflects a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;impairment charge related to the Article 20 Procedure of ZINBRYTA in the E.U. For additional information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances in the table above as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;also reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. In-process research and development balances include adjustments related to foreign currency exchange rate fluctuations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Out-licensed Patents</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$309.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired and had not reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life and amortize these amounts based upon an economic consumption method. The carrying value associated with our IPR&amp;D assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of Convergence, Stromedix Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN) in 2015, 2012 and 2010, respectively. These amounts have and will be adjusted for foreign exchange rate fluctuations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long-range planning cycle, which was updated in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&#160;&#160; </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,236.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net change in acquired and in-licensed rights and patents during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflects </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total milestone payments paid to Ionis Pharmaceuticals, Inc. (Ionis) for the approvals of SPINRAZA in the E.U. and Japan in June 2017 and July 2017, respectively, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment paid to Samsung Bioepis, for the approval of IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the E.U. in August 2017, and the net carrying value recognized in relation to our acquisition of TECFIDERA license rights, as described below. These net increases were in part offset by amortization and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;impairment charge related to the Article 20 Procedure of ZINBRYTA.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationships with Ionis and Samsung Bioepis and the European Commission (EC) approved restrictions on the use of ZINBRYTA, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this agreement and in the first quarter of 2017 we recognized an intangible asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this agreement. The pre-tax charge recognized in the fourth quarter of 2016 represented the fair value of our license to Forward Pharma&#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016. The intangible asset represented the fair value of the U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property related to TECFIDERA revenues for the period January 2017, the month in which we entered into this agreement, through December 2020, the last month before royalty payments could first commence pursuant to this agreement. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. In January 2018 the European Patent Office (EPO) announced its decision revoking Forward Pharma&#8217;s European Patent No. 2 801 355. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. Based upon our assessment of these rulings, we continue to amortize the remaining net book value of the U.S. and rest of world intangible assets in our consolidated statements of income utilizing an economic consumption model.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on these disputes, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TECFIDERA, AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of TECFIDERA, AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon this analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">423.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">401.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">381.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">254.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">242.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,669.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to our hemophilia business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,267.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,026.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,632.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,669.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The elimination of goodwill represents an allocation based upon the relative enterprise fair value of the hemophilia business as of the distribution date. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$232.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$173.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in tax benefits), respectively, and payable to the former shareholders of Fumapharm AG or holders of their rights. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other includes changes related to foreign currency exchange rate fluctuations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;accumulated impairment losses related to goodwill.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;For additional information on future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 22, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 30</font></div></div><hr style="page-break-after:always"><div><a name="s3F12D886A6FF59409EB48522E47EF0B7"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,229.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,229.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,609.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,609.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,919.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,919.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">643.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">643.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,444.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,433.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">111.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">111.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">634.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">111.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,558.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,533.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">481.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,517.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,521.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,032.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,026.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,851.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,796.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,077.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,874.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,483.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,808.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we redeemed our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due March 1, 2018 with an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For information on this redemption please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair value of each series of our Senior Notes was determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix and BIN in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">62.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$279.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$246.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. Changes in the fair value of our contingent consideration obligations are primarily due to changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones and changes in the discount rate. Payments and other for 2016 includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of a Convergence milestone converted to a short-term obligation under the acquisition agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;changes in valuation techniques or transfers between fair value measurement levels during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Convergence</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was based on probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was the estimated cost of debt financing for market participants. This liability reflected the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For additional information on this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$259.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$258.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash flow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$400.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in the fair value of this obligation was primarily due to changes in the discount rate, partially offset by changes in the expected timing related to the achievement of certain remaining developmental milestones. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$147.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Stromedix Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Stromedix in March 2012 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$122.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$162.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$133.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$344.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in the fair value of this obligation was primarily due to an increase in the probability of success related to the achievement of certain remaining developmental milestones, partially offset by changes in the discount rate. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$76.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen Idec International Neuroscience GmbH</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$355.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in the fair value of this obligation was primarily due to an increase in the probability of success related to the achievement of certain remaining developmental milestones, partially offset by a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;developmental milestone payment. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is reflected as a component of accrued expenses and other in our consolidated balance sheets as we achieved the developmental milestone of dosing our first patient in our Phase 2 SPARK study of BIIB054 in Parkinson's disease in January 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we also allocated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the total purchase price to acquired IPR&amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. These assets will be tested for impairment annually until commercialization, after which time the IPR&amp;D will be amortized over its estimated useful life using the economic consumption method. For additional information on this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 33</font></div></div><hr style="page-break-after:always"><div><a name="sED8748D4521059F6A6907CAC3966F96F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">948.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">741.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">247.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,266.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,229.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available for sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,039.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,039.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,570.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,569.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,075.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,075.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">844.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">845.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">642.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">642.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,408.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,409.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,255.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,258.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,016.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,019.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">557.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,115.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,116.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,569.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,730.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,730.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,552.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,559.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">327.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">327.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">276.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">277.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;months and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,565.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,378.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,063.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;primarily relate to impairments recognized on certain of our available-for-sale marketable debt securities as we intend to sell these securities as a result of the Tax Cuts and Jobs Act of 2017 (the 2017 Tax Act), sales of agency mortgage-backed securities, corporate bonds and government securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies. </font></div><div><a name="s48C0FB559CE654ECBB7EC9E3F8693E47"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,875.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">150.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">88.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">83.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,198.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$98.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is expected to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion) (in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion) (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Lock Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we entered into treasury rate locks, with an aggregated notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes, as described in Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements, we settled the treasury rate locks and realized an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Swap Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes, as described in Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$564.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$902.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to these contracts were recognized as a component of other income (expense), net, for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:40%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br>As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">84.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">23.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:40%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br>As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 37</font></div></div><hr style="page-break-after:always"><div><a name="sCCD31880C6A55EFA8B51CBC6B7DDD8E9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;&#160;&#160;Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">141.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">137.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,213.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,107.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">80.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">123.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,207.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,105.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">767.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">746.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,276.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">658.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,741.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,941.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,439.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,182.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,501.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation expense totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$266.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$309.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$217.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we capitalized interest costs related to construction in progress totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The increase in capitalized interest costs is primarily due to the construction of our Solothurn, Switzerland facility, as discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2016 we purchased land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and are building a large-scale biologics manufacturing facility at this site. We expect this facility to be operational by the end of the decade. Upon completion, the facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$481.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research Triangle Park Facility Purchase</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we completed the purchase of a drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), NC from Eisai Inc. (Eisai). The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;purchase price was comprised of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for buildings, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for machinery and equipment and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for land.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we also amended our existing </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year lease related to Eisai's oral solid dose products manufacturing facility in RTP, NC. The amended lease provided for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year term and our agreement to purchase the facility upon expiration of the lease term or at Eisai's option, their completion of certain activities at the facility. Upon signing, we recognized assets along with a corresponding financing obligation in our consolidated balance sheet of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net present value of the future minimum lease payments. These assets were recorded as a component of buildings and machinery and equipment. In December 2017, upon the earlier than expected completion of Eisai's activities, we completed our purchase of this facility for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 38</font></div></div><hr style="page-break-after:always"><div><a name="s79A7DAAC97345CB3A57EF4471102C4C4"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;&#160;Indebtedness</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">558.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,482.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">994.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">993.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,736.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,734.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,722.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,935.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,512.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">6.875% Senior Notes due March 1, 2018</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March&#160;4, 2008, we issued $550.0&#160;million aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Senior Notes due March&#160;1, 2018 at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99.184%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par. These notes were senior unsecured obligations. We also entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these contracts, the carrying amount of these notes were increased by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;with this amount being amortized using the effective interest rate method over the remaining life of the Senior Notes and recognized as a reduction of interest expense.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we redeemed these notes prior to their maturity and recognized a net charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon the extinguishment of these notes. This charge, which was recognized in interest expense in other income (expense) net in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the payment of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;gain related to the remaining unamortized balance of the interest rate swap liability discussed above.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Senior Notes</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The costs associated with these offerings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These notes are senior unsecured obligations. These Senior Notes may be redeemed at our option at any time at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the principal amount plus accrued interest and a specified make-whole amount. These Senior Notes </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">contain a change of control provision that may require us to purchase the notes at a price equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes offering due in 2020, we entered into interest rate swap contracts. The carrying value of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to changes in the fair value of these contracts. For additional information on our interest rate contracts, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Notes Payable to Fumedica</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs that are payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica, payable in June 2018, had a carrying value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financing Arrangement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we recorded a financing obligation in relation to the amendment of our lease agreement for Eisai's oral solid dose products manufacturing facility in RTP, NC. In December 2017 we completed the purchase of this facility for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and derecognized the remaining unamortized portion of the financing obligation from our consolidated balance sheet as of that date. For additional information on this transaction, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Maturity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments, excluding our financing arrangement, due under our debt arrangements are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,500.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,003.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our debt is disclosed in Note&#160;8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><a name="sAF84D3430EC45927BBF351C7F8A84EA0"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13.&#160;&#160;&#160;&#160;&#160; Equity</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares of Preferred Stock authorized, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares are authorized as Series A, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares are authorized as Series X junior participating and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.25 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:24%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. All share repurchases under this authorization will be retired. Under this authorization, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for each year. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains available for share repurchases under this authorization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2015 Share Repurchase Program). All shares repurchased under this authorization were retired. Our 2015 Share Repurchase Program was completed as of December 31, 2015. Under this authorization, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock (2011 Share Repurchase Program). Shares repurchased under this authorization were principally used to offset common stock issuances under our share-based compensation programs. Our 2011 Share Repurchase Program was completed as of March 31, 2017. Under this authorization, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We did not repurchase any shares of common stock under this authorization during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div><a name="s33EF00ADAFE559DE9A3FBE9E9C20B997"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14.&#160;&#160;&#160;&#160;&#160;&#160;Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(334.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(319.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(193.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">158.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">44.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(162.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">158.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(104.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(318.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(92.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(334.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(172.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(171.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(61.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:28%;"></td><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(19.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(44.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">171.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 42</font></div></div><hr style="page-break-after:always"><div><a name="s9DE0A55A5DC059608DD05ED7C1B2F91A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;&#160;&#160;Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Earnings per share for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflects, on a weighted average basis, the repurchase of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares, respectively, of our common stock under our share repurchase authorizations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adjustments related to the spin-off of our hemophilia business did not have a material impact on the potentially dilutive securities to be considered in the calculation of diluted earnings per share of common stock.</font></div><div><a name="sDFF0ED2A6C2A5930A103B20BB105F3B7"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;&#160;&#160;&#160;Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">74.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">95.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">121.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">169.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">160.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(54.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">117.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">135.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">140.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">107.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">119.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">169.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">160.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, unrecognized compensation cost related to unvested share-based compensation was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$168.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spin-off Related Equity Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to an employee matters agreement entered into in connection with the spin-off of our hemophilia business and the provisions of our existing share-based compensation arrangements, we made certain adjustments to the number and terms of our outstanding stock options, RSUs, CSPUs and other share-based awards to preserve the intrinsic value of the awards immediately before and after the spin-off. For purposes of the vesting of these equity awards, continued employment or service with Biogen or with Bioverativ was treated as continued employment for purposes of both Biogen&#8217;s and Bioverativ&#8217;s equity awards with the outstanding awards continuing to vest over their respective original vesting periods. Outstanding unvested awards for employees transferring to Bioverativ were converted to unvested Bioverativ awards.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to the number of our share-based compensation awards were made using an adjustment ratio based upon the weighted-average closing price of our common stock for the 10 calendar days prior to the effective date of the spin-off and the volume-weighted average prices for the 10 calendar days of our common stock following the effective date of the spin-off. For stock options, the exercise prices of the awards were modified to maintain the pre-spin intrinsic value of the awards in relation to the post-spin stock price of Biogen. The difference between the fair value of the awards based upon the adjustment ratio and the opening price on the distribution date was not material.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Directors Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2006 our shareholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Omnibus Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2008 Omnibus Equity Plan as of June 7, 2017 or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017 are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;ratio.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a ten-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options&#8217; vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;grants of stock options made in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all outstanding options were exercisable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility or both, we have concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January&#160;1, 2006 were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.06</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.89</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.11</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">42,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total intrinsic values of options exercised in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic values of options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The weighted average remaining contractual term for options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;years. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Market Stock Units (MSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees prior to 2014 vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">four</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees in 2014 and thereafter vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">355.60</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">94,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">382.59</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(112,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">311.17</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(45,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">372.35</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">171,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">370.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted in 2017 include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">9,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;MSUs issued in 2017 based upon the attainment of performance criteria set for 2013, in relation to awards granted in that year. MSUs granted during 2017 also include awards granted in conjunction with our annual awards made in February 2017 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2017 reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2016, 2015 and 2014.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, including the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price on grant date for MSUs awarded prior to 2014, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price on the date of grant for MSUs awarded in 2014 and thereafter, expected volatility of our stock price, risk-free rates of return and expected dividend yield.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The assumptions used in our valuation are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:44%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.0% - 35.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.2% - 40.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0% - 33.2%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9% - 1.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6% - 0.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2% - 1.0%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$263.18 - $267.88</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$260.67 - $304.86</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$277.35 - $426.27</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$382.59</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$328.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$493.43</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of MSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Settled Performance Units (CSPUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CSPUs awarded to employees vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs awarded prior to 2014 are settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. CSPUs awarded in 2014 and thereafter will be settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">122,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">83,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(69,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(34,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">105,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">CSPUs granted in 2017 include awards granted in conjunction with our annual awards made in February 2017 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. CSPUs granted in 2017 also include CSPUs issued in 2017 based upon the attainment of performance criteria set for 2016 in relation to shares granted in 2016.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cash paid in settlement of CSPUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$79.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance-vested Restricted Stock Units (PUs)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">PUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">110,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(43,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(19,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PUs granted in 2017 include awards granted in conjunction with our annual awards made in February 2017 and PUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;PUs were converted to share settlements, of which approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares were vested and issued. All other PUs that vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were settled in cash totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All PUs that vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were settled in cash totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Time-Vested Restricted Stock Units (RSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs awarded to employees generally vest no sooner than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one-third per year over three years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">888,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">303.49</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">464,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">293.41</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(350,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">308.04</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(182,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">292.57</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">832,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">291.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2017 primarily represent RSUs granted in conjunction with our annual awards made in February 2017 and awards made in conjunction with the hiring of new employees. RSUs granted in 2017 also include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">11,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;RSUs granted to our Board of Directors.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs granted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;had weighted average grant date fair values of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$268.52</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$388.88</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of RSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$239.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015 our shareholders approved the 2015 ESPP. The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">167,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">190,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 1995 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 1995 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sED86C9206B9A50A8829CE9549601F510"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Tax Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,540.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,655.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,386.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,588.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,277.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,380.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,128.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,933.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,767.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,201.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,304.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,214.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">108.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,367.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,412.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,307.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">241.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(125.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(129.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(159.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(45.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(145.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,458.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,237.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,161.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Reform</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as global intangible low-taxed income (GILTI). These changes are effective beginning in 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in tax rates and tax laws are accounted for in the period of enactment. Therefore, during the year ended December 31, 2017, we recorded a charge totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,173.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to our current estimate of the provisions of the 2017 Tax Act.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Transition Toll Tax</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminates the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on undistributed foreign earnings. The Transition Toll Tax is assessed on the U.S. shareholder's share of the foreign corporation's accumulated foreign earnings that have not previously been taxed. Earnings in the form of cash and cash equivalents will be taxed at a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and all other earnings will be taxed at a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of December 31, 2017, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the Transition Toll Tax, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$78.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is expected to be paid within one year. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At December 31, 2017, we considered none of our earnings to be permanently reinvested outside the U.S. and have therefore recorded tax liabilities associated with an estimate of the total withholding taxes that may be a result of our repatriation of earnings.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Effect on Deferred Tax Assets and Liabilities and other Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our deferred tax assets and liabilities are measured at the enacted tax rate expected to apply when these temporary differences are expected to be realized or settled.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As our deferred tax assets exceed the balance of our deferred tax liabilities at the date of enactment, we have recorded a tax expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$184.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflecting the decrease in the U.S. corporate income tax rate and other changes to U.S. tax law. It is our current policy to not recognize deferred taxes for basis differences expected to reverse as GILTI is incurred and instead to account for any taxes assessed as period costs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Status of our Assessment</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our preliminary estimate of the Transition Toll Tax and the remeasurement of our deferred tax assets and liabilities is subject to the finalization of management&#8217;s analysis related to certain matters, such as developing interpretations of the provisions of the 2017 Tax Act, changes to certain estimates and amounts related to the earnings and profits of certain subsidiaries and the filing of our tax returns. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates.  </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The final determination of the Transition Toll Tax and the remeasurement of our deferred assets and liabilities will be completed as additional information becomes available, but no later than one year from the enactment of the 2017 Tax Act.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Article 20 Procedure of ZINBRYTA</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the Article 20 Procedure of ZINBRYTA, we have recognized a net impairment charge on certain tax assets reflected within income tax expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This charge reflects the write off of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$142.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to prepaid taxes, which was partially offset by the recognition of an unrecorded deferred tax benefit of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">201.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">147.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">250.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">378.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">459.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">209.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">26.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">831.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,071.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(250.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(376.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(107.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(113.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(358.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(490.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total deferred charges and prepaid taxes were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$617.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This new standard becomes effective for us on January 1, 2018.&#160;We will adopt this standard using the modified retrospective method, through a cumulative-effect adjustment directly to retained earnings as of that date.&#160;Based on currently enacted tax rates, upon adoption in 2018, we will record additional deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and an increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:55%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 Tax Act</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment of ZINBRYTA related tax assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Changes in Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The most significant factors contributing to the increase in our effective tax rate for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is the effect of the enactment of the 2017 Tax Act and the impairment of certain ZINBRYTA related tax assets, both of which are discussed above. Excluding the effect of these items, our income tax rate would have decreased due to a lower percentage of our earnings being recognized in the U.S., a higher tax jurisdiction. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we earned a lower benefit from the orphan drug credit due to the FDA's approval of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increased primarily due to a net state tax benefit in 2015 resulting from the remeasurement of one of our uncertain tax positions, described below, and a higher relative percentage of our earnings being attributed to the U.S., a higher tax jurisdiction.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Attributes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which begin to expire in 2020. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;that begin to expire in 2018. For state income tax purposes, we also had research and investment credit carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$129.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;that begin to expire in 2018. For foreign income tax purposes, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net operating loss carryforwards that begin to expire in 2021.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">32.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(21.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(49.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement refund (payment)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">44.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(64.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our 2017 activity above reflects a refund received from a state, related to the settlement of an uncertain tax position.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in the balance of unrecognized tax benefits as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recognized a net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recognized net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recognized a net interest expense of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have accrued approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the payment of interest and penalties as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">International Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to the Danish Tax Authority (SKAT) for assessments received for fiscal 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to Danish withholding taxes based on potential European court decisions expected in 2018 on similar matters.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Federal and State Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to our revenues from anti-CD20 therapeutic programs and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div><div><a name="s2631B47FAE1D5E50B6892BB54C5EE86B"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Supplemental Cash Flow Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:51%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">281.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,066.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,642.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,674.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-cash Operating, Investing and Financing Activity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2017 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 billion</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of FUMADERM and TECFIDERA (together, the Fumapharm Products). The amount, net of tax benefit, was accounted for as an increase to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm, and is expected to be paid in the first quarter of 2018. For additional information on this transaction, please read Note 22, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our consolidated balance sheets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information on this matter, please read Note 11,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Property, Plant and Equipment,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the settlement and license agreement with Forward Pharma. For additional information on this transaction, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2015 upon completion of our acquisition of Convergence, we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as part of the purchase price. For additional information on this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">78.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(250.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(260.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(215.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(217.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;charge recognized in November 2017 upon the redemption of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due March 1, 2018. For additional information on the redemption of these notes, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes other than temporary impairments recorded on strategic investments and marketable debt securities during the year.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets include prepaid taxes totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$657.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$817.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the Article 20 Procedure of ZINBRYTA, we impaired prepaid tax balances totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$142.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">844.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">572.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">297.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">282.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">206.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">195.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">183.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">130.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">159.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued TECFIDERA litigation settlement charge</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">636.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">685.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,901.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011 Biogen Italia SRL, our Italian subsidiary, received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 through mid-February 2011 exceeded by EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In January 2012 we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit in the Price Determination Resolution should apply as written to only &#8220;the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months&#8221; of TYSABRI sales, which ended in mid-February 2009. Since being notified in the fourth quarter of 2011 that AIFA believed a reimbursement limit was still in effect, we deferred revenue on sales of TYSABRI as if the reimbursement limit were in effect for each biannual period </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">beginning in mid-February 2009.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2013 we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee that would have resolved all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As a result of this agreement in principle, we recorded a liability and reduction to revenue of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;at June 30, 2013, which approximated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the claim related to the period from mid-February 2009 through mid-February 2011. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of TYSABRI revenues related to the periods February 2013 through June 2014 that were previously deferred.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2017 we reached an agreement with AIFA's Price and Reimbursement Committee resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods. As a result, in the first quarter of 2017, we recognized EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) in revenues for sales that were previously deferred. These amounts were previously accrued for and included in the table above in Other as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><a name="s5DBCEFD9B0C35C0F88AE911724FB59E4"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19.&#160;&#160;&#160;&#160;&#160;Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2007 we entered into a collaboration and license agreement with Neurimmune Subone AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product, or 12 years from the first commercial sale of any product using such a licensed compound. Our anti-amyloid beta antibody, aducanumab, for the treatment of AD resulted from this collaboration. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. Under this agreement, we are also required to pay royalties on sales of any resulting commercial products and make payments upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of our collaboration and license agreement with Neurimmune. Under the amended agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab.&#160;Our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, will now range from the high single digits to low teens.&#160;As we consolidate the results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the fourth quarter of 2017 and treated it as a distribution. Under the amended agreement, we also have an option that will expire in April 2018 to further reduce our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment to Neurimmune. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;amounts reimbursed were immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015 we recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payable to Neurimmune upon enrollment of the first patient in a Phase 3 trial for aducanumab. We recognized this payment as a charge to noncontrolling interest. Based upon our current development plans for aducanumab, we may pay Neurimmune up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$275.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestone payments. Future milestone payments and royalties, if any, will be reflected in our consolidated statements of income as a charge to noncontrolling interest, net of tax when such milestones are achieved.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our October 2017 collaboration agreement with Eisai for the joint development and commercialization of aducanumab, Eisai may elect to share in the benefit and cost associated with the royalty reductions discussed above. Eisai has elected to not share in the benefit and cost of the October 2017 royalty reduction. For additional information on our collaboration arrangement with Eisai, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div><a name="sBB3D007BD1F75D6AB2943679C0BDCCFF"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">20.&#160;&#160;&#160;&#160;&#160;&#160;Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depending on the collaborative arrangement, we may record funding receivable or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration agreement will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#8217;s offer or purchase Genentech&#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is responsible for the worldwide manufacturing of RITUXAN. Development and commercialization rights and responsibilities under this collaboration are divided as follows:</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share with Genentech co-exclusive rights to develop, commercialize and market RITUXAN in the U.S.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Canada</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Genentech have assigned our rights under our collaboration agreement with respect to Canada to the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">OCREVUS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FDA approved OCREVUS, a humanized anti-CD20 monoclonal antibody, for the treatment of RMS and PPMS. Under our agreement with Genentech, we will receive a tiered royalty on U.S. net sales from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and increasing up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;if annual net sales exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$900.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. There will be a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we will receive a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11 years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS was approved for the treatment of RMS and PPMS in Australia, Switzerland and the E.U. in July 2017, September 2017 and January 2018, respectively. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Profit-sharing Formulas</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">RITUXAN Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</font></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN pre-tax profits in the U.S. decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in February 2016 when GAZYVA was approved by the FDA as a new treatment for follicular lymphoma and was further decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12 month period exceeded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;based on certain events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 the FDA approved RITUXAN HYCELA for subcutaneous injection for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma and CLL. This new treatment includes the same monoclonal antibody as intravenous RITUXAN in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GAZYVA Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax profit-sharing formula for GAZYVA provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of operating profits earned each calendar year. Our share of annual profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;our share of operating profits on GAZYVA was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,316.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">242.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,559.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;profit-sharing threshold was met during the third quarter and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;profit-sharing threshold was met during the first quarter. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;profit-sharing threshold was met during the first quarter. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;profit-sharing threshold was met during the first quarter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as depicted in the table above, excludes certain expenses charged to the collaboration by Genentech that we believe remain the responsibility of Genentech and that we are not obligated to pay under the terms of the collaboration agreement. Accordingly, we did not recognize the effect of those expenses in the determination of our share of pre-tax collaboration profits and Genentech has withheld approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from amounts due to us in relation to collaboration activity for 2017, representing Genentech&#8217;s estimate of our share of these expenses. We remain in discussions with Genentech about a resolution relating to these amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie for the development and commercialization of ZINBRYTA, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. Under this agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory) where development and commercialization costs and profits are shared equally. Outside of the Collaboration Territory, we are solely responsible for development and commercialization of ZINBRYTA and will pay a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are responsible for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and record these activities within their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures received from AbbVie.&#160;For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the collaboration incurred </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for research and development activities, respectively, for which we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we also recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of pre-commercialization expenses within our selling, general and administrative expense, which represented </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the collaboration's pre-commercialization costs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. After ZINBRYTA was approved by the FDA and European Medicines Agency (EMA) in 2016, we began to recognize our share of the collaboration activities within the U.S., E.U. and Canadian territories as described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Co-promotion Profits and Losses."</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Article 20 Procedure of ZINBRYTA</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 the EMA announced that it had provisionally restricted the use of ZINBRYTA to adult patients with highly active relapsing disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) or with rapidly evolving severe relapsing MS who are unsuitable for treatment with other DMTs.&#160;These restrictions followed the initiation of an EMA review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, as part of this Article 20 Procedure of ZINBRYTA, the EMA Pharmacovigilance Risk Assessment Committee (PRAC) completed its assessment and recommended a further set of restrictions on the use of ZINBRYTA by MS patients. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 the Committee for Medicinal Products for Human Use (CHMP) adopted an opinion, confirming the PRAC's recommendations, for further restrictions to minimize the risk of serious liver injury with ZINBRYTA, including restriction of its use to adult patients with relapsing forms of MS who have had an inadequate response to at least two DMTs and for whom treatment with any other DMT is contraindicated or otherwise unsuitable. In January 2018 the EC adopted a final and legally-binding decision, which concluded the Article 20 Procedure, confirming the CHMP opinion.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The recommendation of these restrictions by the CHMP resulted in the impairment of substantially all of our assets related to ZINBRYTA as we have determined that these amounts may not be recoverable. As a result, we recorded net impairment charges related to intangible assets, inventory, property, plant and equipment and prepaid tax assets, totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$190.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Inventory related losses are subject to our profit share with AbbVie and are included above net of expected reimbursement. Offsetting these amounts was an unrecorded tax benefit related to certain ZINBRYTA related assets totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie recognizes revenues on sales to third parties and we recognize our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. The collaboration began selling ZINBRYTA in the U.S. in the third quarter of 2016. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenue of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect our share of an overall net loss within the collaboration.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">92.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, we recognize revenues on sales to third parties in product revenues, net in our consolidated statements of income. We also record the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income as these costs are incurred. We reimburse AbbVie for their </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the co-promotion profits or losses in the E.U. and Canada. This reimbursement is recognized in collaboration profit (loss) sharing in our consolidated statements of income. We began to recognize product revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration profits in the E.U. and Canada, as compared to net income recognized of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration losses in the E.U. and Canada in the prior year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. The next expected milestone would be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due if ex-U.S. net sales reach </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over a period of four consecutive quarters. Royalty payments are recognized in cost of sales within our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Collaborations </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis to develop and commercialize SPINRAZA for the treatment of SMA. During 2014 we amended this agreement to adjust the amount of potential additional payments and terms of the exercise of our opt-in right to license SPINRAZA, which included providing for additional opt-in scenarios, based on the filing or acceptance of a New Drug Application (NDA) with the FDA or marketing authorization application with the EMA. Consistent with the initial agreement, Ionis remained responsible for conducting the pivotal/Phase 3 trials and we provided input on the clinical trial design and regulatory strategy for the development of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA was approved for the treatment of SMA in the U.S., E.U. and Japan in December 2016, June 2017 and July 2017, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized product revenues totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$883.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, on our sales of SPINRAZA. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$112.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Ionis. In addition, during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we made milestone payments to Ionis totaling&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;related to the marketing approvals discussed above, which were capitalized in intangible assets, net in our consolidated balance sheets. During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, upon the exercise of our option to develop and commercialize SPINRAZA, we also paid a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;license fee to Ionis, which was recognized as research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;no clinical trial payments were made to Ionis due to the completion of study activities. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we made clinical trial payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of the program, which were recorded in investments and other assets in our consolidated balance sheets as they represented prepaid research and development expenditures. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, these prepaid research and development amounts were fully expensed as the services were provided.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$234.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$257.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reflected in total costs and expenses in our consolidated statements of income related to the advancement and commercialization of the program. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Antisense Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three therapeutic targets. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, Ionis is responsible for global development of any product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to another </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if we successfully develop the product candidate after option exercise. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Ionis and agreed to make potential additional payments, prior to licensing, of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 we recognized this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;developmental milestone upon the selection of BIIB080 (also known as IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), which is currently in Phase 1 development. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Research Collaborations</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">2013 Long-term Strategic Research Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2013 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the treatment of neurological disorders.&#160;Under the collaboration, Ionis will perform research on a set of neurological targets identified within this agreement. Once the research has reached a specific stage of development, we will make a determination whether antisense therapy is the preferred approach to developing a therapeutic candidate or whether another modality is preferred. If an antisense approach is selected, Ionis will continue development and identify a potential product candidate. If another modality is selected, we will assume responsibility for identifying a potential product candidate and assume development responsibility for development in that modality. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Ionis, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was recorded as research and development expense representing the value of intellectual property purchased that had not reached technological feasibility.&#160;We recognized the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as prepaid research and discovery services, representing the value of the Ionis full time equivalent employee resources required by the collaboration to provide research and discovery services over the term of the collaboration.&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis is also eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered milestones of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the treatment of ALS and other neurological targets identified.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. &#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For product candidates using a different modality, we will be responsible for global development through all stages and will pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon the achievement of certain regulatory milestones and royalties on future sales if we successfully develop the product candidate. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">2017 SMA Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2017 we entered into a new collaboration agreement with Ionis to identify new antisense oligonucleotide drug candidates for the treatment of SMA. Under this agreement, we will have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of these therapies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment to Ionis and we may pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$260.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional development and regulatory milestone payments if new drugs advance to marketing approval. Upon commercialization, we may also pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$800.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and E2609 Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2014 we entered into a collaboration agreement with Eisai (Eisai Collaboration Agreement) to jointly develop and commercialize two Eisai product candidates for the treatment of AD, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor. Under the Eisai Collaboration Agreement, Eisai serves as the global operational and regulatory lead for both compounds with all costs, including research, development, sales and marketing expenses shared equally by us and Eisai; and following marketing approval in major markets, such as the U.S., the E.U. and Japan, we and Eisai would co-promote BAN2401 and E2609 and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. In addition, the Eisai Collaboration Agreement provides both parties with certain rights and obligations in the event of a change in control of either party.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Eisai Collaboration Agreement also provided Eisai with an option to jointly develop and commercialize aducanumab (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, a separate collaboration agreement would be entered into with Eisai on terms and conditions that mirror the Eisai Collaboration Agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, both companies will continue to jointly develop BAN2401 and E2609 in accordance with the Eisai Collaboration Agreement; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of activity related to the Eisai Collaboration Agreement is as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration in development of BAN2401 and E2609</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">146.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and E2609 development expense reflected in our consolidated statements of income, excluding upfront and milestone payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">74.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2016 we recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment related to the initiation of a Phase 3 trial for E2609, which is included in research and development expense in our consolidated statements of income. We could pay Eisai up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$625.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the Eisai Collaboration Agreement based on the future achievement of certain development, regulatory and commercial milestones.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, we will continue to lead the ongoing Phase 3 development of aducanumab and will remain responsible for 100% of development costs for aducanumab incurred in support of this agreement until April 2018. Eisai will then reimburse us for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of aducanumab development expenses for the period April 2018 through December 2018, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;thereafter. Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. We will receive a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the potential profits (losses) in the U.S., a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the potential profits (losses) in the E.U. and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The companies will continue to share equally in the potential profits (losses) in rest of world markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai also agreed to co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai will distribute AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$263.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was reflected in research and development expense in our consolidated statements of income related to the advancement of our aducanumab program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-Tau Option</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for BIIB092 (formerly known as BMS-986168), a Phase 2-ready experimental medicine with potential in AD and PSP. BIIB092 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received worldwide rights to BIIB092 and are responsible for the full development and global commercialization of BIIB092 in AD and PSP. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to BMS and we may pay BMS up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$410.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestone payments, and potential royalties. We also assumed all remaining obligations to the former shareholders of iPierian, Inc. (iPierian) related to BMS&#8217;s acquisition of iPierian in 2014. In June 2017 we recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;developmental milestone payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 PSP study for BIIB092 and we may pay the former shareholders of iPierian up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$490.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestone payments, and potential royalties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Both the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;developmental milestone payment were recognized as research and development expense in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Alkermes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), for BIIB098 (formerly known as ALKS 8700), an oral monomethyl fumarate prodrug in Phase 3 development for the treatment of relapsing forms of MS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received an exclusive, worldwide license to develop and commercialize BIIB098 and will pay Alkermes a mid-teens percentage royalty on potential worldwide net sales of BIIB098. Royalties payable on net sales of BIIB098 are subject to tiered minimum payment requirements for a period of five years following FDA approval. Alkermes is eligible to receive royalties in the mid-single digits to low-teen percentages of annual net sales upon successful development and commercialization of new product candidates other than BIIB098. Alkermes will maintain responsibility for regulatory interactions with the FDA through the potential approval of the NDA for BIIB098 for the treatment of MS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment to Alkermes representing our share of BIIB098 development costs already incurred in 2017. Beginning in 2018 we are responsible for all development expenses related to BIIB098. In December 2017 we also recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;expense, which is expected to be paid to Alkermes in early 2018, enabling the continuation of the agreement to develop BIIB098. Both the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;continuation payment were recognized as research and development expense in our consolidated financial statements for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may also pay Alkermes up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional future milestone payments upon certain regulatory achievements related to BIIB098 under this collaboration. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$80.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in research and development expense in our consolidated statements of income related to this collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the license and collaboration agreement, we may also enter into a supply agreement with Alkermes for the commercial supply of BIIB098 and other products developed under the license and collaboration agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 we entered into a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). This collaboration is focused on the development of a portfolio of AGTC&#8217;s therapeutic programs, including both a clinical-stage candidate for X-linked Retinoschisis (XLRS) and a pre-clinical candidate for the treatment of X-Linked Retinitis Pigmentosa (XLRP). This agreement also provides us with options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement we received worldwide commercialization rights for the XLRS and XLRP programs. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials and we will support the related clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. AGTC has an option to share development costs and profits after the initial clinical trial data becomes available, and an option to co-promote the second of these products approved in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to AGTC. AGTC is also eligible to receive development, regulatory and commercial milestone payments aggregating in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$467.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;collectively for the two lead programs and up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$592.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;across the discovery programs. AGTC is also eligible to receive royalties in the mid-single digit to mid-teen percentages of annual net sales upon successful development and commercialization of new product candidates. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment reflected a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equity investment in AGTC, prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and total licensing and other fees of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total licensing and other fees were recognized as a charge to research and development expense in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equity investment and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of prepaid research and development expenditures were recorded in investments and other assets in our consolidated balance sheets. These prepaid research and development amounts are being expensed as the services are provided, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains as a prepaid asset as of December 31, 2017. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$54.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which were reflected in research and development expense in our consolidated statements of income related to this collaboration. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we also received a manufacturing license under which we received an exclusive license to use AGTC&#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&#8217;s discretion, in exchange for payment of milestones and royalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">University of Pennsylvania</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 we entered into a collaboration and alliance with the University of Pennsylvania (UPenn) to advance gene therapy and gene editing technologies. The collaboration is primarily focused on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. The alliance is also focused on the research and validation of next-generation gene transfer technology using adeno-associated virus gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to UPenn, which was recorded as research and development expense in our consolidated statements of income, and made prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded in investments and other assets in our consolidated balance sheets. During 2017, we made additional prepaid research and development expenditures to UPenn of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the advancement of these programs. These prepaid research and development amounts are being expensed as the services are provided, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains as a prepaid asset as of December 31, 2017. We also expect to fund an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional research and development costs in seven preclinical research and development programs, as well as the exploration of genome-editing technology.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If all of the collaborations programs are successful and we exercise all of our options under the UPenn collaboration and alliance, we may be required to make future payments of over </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in research funding, options and milestone payments. UPenn is also eligible to receive royalties in the mid-single digit to mid-teens percentages of annual net sales upon successful development and commercialization of new product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$33.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in research and development expense in our consolidated statements of income related to this collaboration.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into several research, discovery and other related arrangements that resulted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, recorded as research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;Samsung Biologics contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;stake in Samsung Bioepis and we contributed approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;ownership interest.&#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control and is based on paying for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the joint venture agreement plus a rate that will represent their return on capital. If we do not exercise this option by mid-2018, this option will expire and Samsung Biologics will have the right to purchase all of Samsung Bioepis&#8217; shares then held by us.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for this investment under the equity method of accounting as we maintain the ability to exercise significant influence over Samsung Bioepis through a presence on the entity&#8217;s Board of Directors and our contractual relationship. Under the equity method, we recorded our original investment at cost and subsequently adjust the carrying value of our investment for our share of equity in the entity&#8217;s income or losses according to our percentage of ownership. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our consolidated statements of income. During the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2013 pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of one anti-TNF biosimilar, Japan.&#160;Under this agreement, we have made total upfront and clinical development milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all of which have been recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in milestone payments, which have been capitalized in intangible assets, net in our consolidated balance sheets as IMRALDI received regulatory approval in the E.U. in August 2017, BENEPALI received regulatory approval in the E.U. in January 2016 and FLIXABI received regulatory approval in the E.U. in May 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of BENEPALI in the E.U. in the first quarter of 2016 and FLIXABI in the E.U. in the third quarter of 2016. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the profit or loss related to our commercial agreement with Samsung Bioepis. This profit sharing with Samsung Bioepis is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration profits. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we will receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis. Under the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development and analytical development. Under our manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;Under limited circumstances, we may also supply Samsung Bioepis with quantities of drug product of biosimilar products for use in clinical trials through arrangements with third-party contract manufacturers. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues in relation to these services, which is reflected as a component of other revenues in our consolidated statements of income. </font></div><div><a name="s6F5D95CC83455E9EAE8CCEC8170AC55C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">21.&#160;&#160;&#160;&#160;Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, a qui tam action filed on behalf of the United States and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in an action filed by a shareholder on October 20, 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Abbreviated New Drug Application (ANDA) Litigation relating to TECFIDERA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June, July, and September 2017 and January 2018, we initiated patent infringement proceedings pursuant to the Hatch-Waxman act in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Caribe Holdings (Cayman) Co. Ltd.&#160;DBA Puracap&#160;Caribe, Puracap International LLC, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Impax Laboratories, Inc., Prinston Pharmaceutical Inc., Slayback Pharma LLC,&#160;Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd., Cipla Limited, Glenmark Pharmaceuticals Ltd., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Shipla Medicare Limited, Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd., Accord Healthcare Inc., Par Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc. and Zydus Pharmaceuticals (USA) Inc. In addition, we initiated patent infringement proceedings pursuant to the Hatch-Waxman act against Stason Pharmaceuticals, Inc. in the U.S. District Court for the Central District of California, Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of New Jersey, Accord Healthcare Inc. in the U.S. District Court for the Middle District of North Carolina, Par Pharmaceutical Inc. in the U.S. District Court for the Southern District of New York, Sandoz Inc. in the U.S. District Court for the District of Colorado and Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cases against Accord Healthcare Inc., Zydus Pharmaceuticals (USA) Inc. and Sandoz Inc. have been dismissed in the North Carolina, New Jersey and Colorado courts but will continue against those parties in Delaware. The cases against Par Pharmaceutical Inc. in both New York and Delaware have been dismissed because Par Pharmaceutical Inc.&#8217;s ANDA application has been withdrawn. The case against Stason Pharmaceuticals, Inc. in California has been dismissed, but the case against its partner Sawai USA, Inc. will proceed in Delaware. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect a trial in the Delaware actions in December 2019, and a trial has been set in the West Virginia action in February 2020.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. In March 2017 the USPTO ruled against Forward Pharma. Forward Pharma has appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. For additional information regarding this matter, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the EPO decided to revoke our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 the EPO announced its decision revoking Forward Pharma&#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Board of Appeal and the Enlarged Board of Appeal, as applicable, to make a final determination. For additional information regarding this matter, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG filed actions in the District Court of The Hague (on January 11, 2016), the German Patents Court (on March 3, 2016) and the Commercial Court of Rome (November 2017) to invalidate the Dutch, German and Italian counterparts of our European Patent Number 1 485 127 (&#8220;Administration of agents to treat inflammation&#8221;) ('127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat MS. The patent expires in February 2023. The Dutch counterpart was ruled invalid and we have appealed. In November 2018 Bioeq gmbh (an entity associated with Swiss Pharma and Polpharma) brought an action in the Polish Patent Office seeking to revoke the Polish counterpart of the &#8216;127 patent. In January 2018 the German court announced that the German counterpart was invalid. No date for a hearing on the merits has yet been set in the Italian action.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees. The trial against EMD Serono and Pfizer commenced in mid-January 2018 and is ongoing. A trial date against Bayer and Novartis has not yet been set.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 1, 2016, we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we learned that the Prosecution Office of Milan is investigating our interactions with certain healthcare providers in Italy.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div><div><a name="sEBCD342DC9105285B4451DCB5ADD1BDA"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">22.&#160;&#160;&#160;&#160;Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013, and Perrigo subsequently sold its rights to these payments to a third party effective January 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN, occurred after January&#160;1, 2009, we recorded the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestones related to these acquisitions. For additional information on our acquisition of Convergence please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013 we paid this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment as TECFIDERA was approved in the U.S. for MS by the FDA. We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2016 and the first, second and third quarters of 2017, respectively, and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products in the fourth quarter of 2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. If the prior 12 months sales of Fumapharm Products are less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, contingent payments remain payable on a decreasing tiered basis. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.7 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in development milestones, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in regulatory milestones and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in commercial milestones as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$460.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$77.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of December 31, 2017, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the Transition Toll Tax, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$78.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is expected to be paid within one year. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015, we purchased land in Solothurn, Switzerland and are building a large-scale biologics manufacturing facility at this site. We expect this facility to be operational by the end of the decade. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$270.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the construction of this facility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense, net of sublease income under these leases, which terminate at various dates through 2028, amounted to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$65.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">72.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">72.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">68.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">271.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">617.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(71.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(188.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">44.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">44.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">199.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">428.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><a name="sFBA6A3D57C105D76AE478F7C4B008F25"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">23.&#160;&#160;&#160;&#160;&#160;&#160;Guarantees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not have significant liabilities recorded for guarantees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><a name="sD7293F7345A85670A9281AFF358B20E3"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">24.&#160;&#160;&#160;&#160;&#160;&#160;Employee Benefit Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">401(k) Savings Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense related to our 401(k) Savings Plan totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$51.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Compensation Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pension Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.00%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. Minimum employee contributions are based on the respective employee&#8217;s age, salary and gender. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the Swiss plan had an unfunded net pension obligation of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and plan assets that totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$83.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized expense totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our Swiss plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The obligations under the German plans are unfunded and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net periodic pension cost related to the German plans totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div><a name="sCCB5AE41FF2A5D5CA6AB5E7E83A4CD78"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">25.&#160;&#160;&#160;&#160;&#160;&#160;Segment Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36"></td></tr><tr><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,294.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">920.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">4,214.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,169.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">798.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,968.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,908.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">730.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,638.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AVONEX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,593.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">557.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,151.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,675.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">638.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,313.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,790.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">840.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,630.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">PLEGRIDY</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">295.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">198.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">494.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">305.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">176.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">481.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">227.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">111.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">338.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,113.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">859.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,973.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,182.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">780.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,963.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,103.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">783.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,886.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">91.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">91.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">84.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">84.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">89.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">89.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">52.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">52.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">657.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">226.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">883.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">42.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">48.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">445.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">68.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">513.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">308.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">11.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">319.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">26.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">268.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">65.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">333.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">208.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">25.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">234.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">39.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">39.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">51.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">51.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">370.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">370.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">7,017.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,337.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7,050.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,767.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9,817.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6,545.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,642.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9,188.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Geographic Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,017.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,844.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">160.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">332.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,475.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">83.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,559.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">249.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">42.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">360.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,226.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,948.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,182.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,050.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,237.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">313.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">224.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,272.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,221.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,501.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,545.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,165.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">333.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">142.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,296.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">881.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,187.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our total revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are derived from our collaboration agreement with Genentech. For additional information on our collaboration with Genentech, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Significant Customers</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recorded revenues from two wholesalers accounting for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,215.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$545.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$161.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$707.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$643.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$684.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><a name="s96D659C9339056F683D0790508A6E48F"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">26.&#160;&#160;&#160;&#160;&#160;&#160;Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b) (c) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (e) (f) (g) (h)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,380.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,639.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,622.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,712.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">340.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">397.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">406.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">415.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,559.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">90.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">41.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">179.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">360.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,810.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,078.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,077.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,307.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,273.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,426.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,712.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,707.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,797.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,643.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">747.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">862.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,226.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(166.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,670.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">747.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">862.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,226.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(297.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.47</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.07</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.80</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.41</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.46</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.07</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.79</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.40</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.92</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(i) (j)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(i) (k) (l)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,309.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,466.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,502.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">329.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">349.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">317.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">318.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,726.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,894.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,955.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,872.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,448.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,413.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,523.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,538.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,493.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,970.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">969.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,048.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,030.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">647.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,695.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">970.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,049.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">649.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.96</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.71</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.99</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">216.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the first, second, third and fourth quarters of 2017 include a pre-tax charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$353.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$29.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$30.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$30.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for an upfront payment to BMS upon the closing of our agreement to exclusively license BIIB092.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to acquired in-process research and development of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for an upfront payment to Remedy upon closing of the asset purchase transaction.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for a developmental milestone that became payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 PSP study for BIIB092.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc., for the fourth quarter of 2017, includes a pre-tax charge to noncontrolling interest of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for a payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in royalty rates payable on potential commercial sales of aducanumab.&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes pre-tax charges to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for an upfront payment and a continuation payment, respectively, to Alkermes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for an upfront payment to Ionis upon entering into a new collaboration agreement to identify new antisense-oligonucleotide drug candidates for the treatment of SMA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,173.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the provisions of the 2017 Tax Act, including a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;expense under the Transition Toll Tax.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second, third and fourth quarters of 2016 includes additional pre-tax depreciation expense totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$15.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$15.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$14.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as part of our decision to cease manufacturing and vacate our small-scale biologics manufacturing facility in Cambridge, MA as well as close and vacate our warehouse space in Somerville, MA. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(j)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the third quarter of 2016 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for a license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(k)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for a milestone payment due to Eisai related to the initiation of a Phase 3 trial for E2609.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(l)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to our January 2017 settlement and license agreement with Forward Pharma.</font></div></td></tr></table><div><a name="s47C98823FD67575EB8529C8CB6E0A2E1"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">27.&#160;&#160;&#160;&#160;&#160;&#160;Subsequent Events</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Karyopharm Therapeutics Inc. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired the exclusive worldwide rights to develop and commercialize Karyopharm Therapeutics Inc.'s (Karyopharm) investigational oral compound BIIB100 (formerly known as KPT-350) for the treatment of certain neurological and neurodegenerative conditions, primarily in ALS. We will pay Karyopharm an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and we may pay Karyopharm up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$207.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestone payments, and potential royalties.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 76</font></div></div><hr style="page-break-after:always"><div><a name="s60DD998B4AB95C689221C5F3DBD8CE23"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">To the Board of Directors and Shareholders of Biogen Inc.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Opinions on the Financial Statements and Internal Control over Financial Reporting</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Biogen Inc. and its subsidiaries (the "Company") as of December 31, 2017 and 2016, and the related consolidated statements of income, comprehensive income, equity and cash flows for each of the three years in the period ended December 31, 2017, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have audited the Company's internal control over financial reporting as of December 31, 2017, based on criteria established in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on criteria established in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(2013) issued by the COSO.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Basis for Opinions</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Definition and Limitations of Internal Control over Financial Reporting</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sF31F0ADD9BBA55B68768652DF7B6557E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/PricewaterhouseCoopers LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston, Massachusetts</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have served as the Company's auditor since 2003.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 78</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>2
<FILENAME>biib-20171231xex1010.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s442fe81c7d8049caaa15fa56d9c83dc0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit 10.10</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Performance Stock Units AWARD AGREEMENT (Cash settled)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Granted Under </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biogen Inc. 2017 Omnibus Equity Plan</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Grant of Performance Stock Units (Cash Settled)</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the Biogen Inc. 2017 Omnibus Equity Plan (as it may be amended from time to time, the &#8220;Plan&#8221;), Biogen Inc. (the &#8220;Company&#8221;) hereby grants to you, an employee of the Company or one of its Affiliates (the &#8220;Participant&#8221;), on each of the grant dates specified on your Fidelity stock plan account</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">(the &#8220;Grant Date&#8221;), the number of cash-settled performance stock units (the &#8220;Granted PSUs&#8221; or the &#8220;Award&#8221;) specified on your Fidelity stock plan account, subject to the terms and conditions of this award agreement (&#8220;Agreement&#8221;) and the Plan.  No Granted PSUs shall be paid unless vested in accordance with this Agreement.  The Participant&#8217;s rights to the Granted PSUs are subject to the restrictions described in this Agreement and the Plan, in addition to such other restrictions, if any, as may be imposed by law.  All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified in this Agreement.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Vesting  </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Participant shall have a non-forfeitable right to a portion of the Award only upon the vesting dates specified on your Fidelity stock plan account, except as otherwise provided herein or determined by the Committee in its sole discretion.  No portion of any Award shall become vested on the vesting date unless the Participant is then, and since the Grant Date has continuously been, employed by the Company or any Affiliate.  If the Participant ceases to be employed by the Company and its Affiliates for any reason, any then outstanding and unvested portion of the Award shall be automatically and immediately forfeited and terminated, except as otherwise provided in this Agreement and the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Award will become eligible to vest upon achievement of each of three annual performance goals (the &#8220;Annual Performance Goals&#8221;), as adopted by the Committee in the first calendar quarter of each of the three years beginning on the first year in which the Award is granted and communicated.  The calculation of the number of Granted PSUs that will vest is specified in the Long-Term Incentive Program Overview for Executives for the year in which the Award is granted (&#8220;LTI Overview&#8221;), which is also found on your Fidelity stock plan account.  Granted PSUs that become eligible to vest upon the achievement of each of the Annual Performance Goals are referred to as the &#8220;Eligible PSUs.&#8221;  In the event and to the extent that the any of the Annual Performance Goals are not satisfied, such Granted PSUs connected to such unachieved Annual Performance Goals shall not become eligible to vest and shall be immediately forfeited.  As specified in each of the Annual Performance Goals, in the event and to the extent that the Annual Performance Goals are exceeded, an additional number of Granted PSUs will become eligible to vest.  In no event shall the number of Eligible PSUs exceed 200% of the number of Granted PSUs.  All Eligible PSUs will vest on the later of</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">the third anniversary of the Grant Date or the date of the Committee&#8217;s determination of the degree to which the Annual Performance Goals have been satisfied</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">(the &#8220;Vesting Date&#8221;). </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Except as otherwise provided in the Plan, upon termination of the Participant&#8217;s employment with the Company and its Affiliates for any reason, any portion of the Award that is not then vested will immediately terminate, except as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">any portion of the Award held by the Participant immediately prior to the Participant&#8217;s termination of employment on account of death or Disability will, to the extent not vested previously, become fully vested upon the later of (a) the date of death or Disability of the Participant or (b) the determination of the Eligible PSUs based on the achievement of the Annual Performance Goals and the Committee&#8217;s approval, even if such determination occurs following the date of death or Disability of the Participant; and</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">any portion of the Award held by the Participant immediately prior to the Participant&#8217;s Retirement, to the extent not vested previously, will become fully vested upon the later of the date of Retirement or determination of the Eligible PSUs based on the achievement of the Annual Performance Goals and the Committee&#8217;s approval for fifty percent (50%) of the number of Eligible PSUs covered by such unvested portion and for an additional ten percent (10%) of the number of Eligible PSUs covered by such unvested portion for every full year of employment by the Company and its Affiliates beyond ten (10) years, up to the remaining amount of the unvested Eligible PSUs of the Award.  For the avoidance of doubt, Retirement means the Participant&#8217;s leaving the employment of the Company and its Affiliates after reaching age 55 with ten (10) consecutive years of service with the Company or its Affiliates, but not including pursuant to any termination For Cause or any termination for insufficient performance, as determined by the Company.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">D.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Notwithstanding anything herein to the contrary, any portion of the Award held by a Participant or a Participant&#8217;s permitted transferee immediately prior to the cessation of the Participant&#8217;s employment For Cause shall terminate at the commencement of business on the date of such termination.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Delivery of Award </font></div></td></tr></table><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:11pt;">With respect to a Participant who is not eligible for Retirement, within 30 days following the date on which Eligible PSUs becomes vested, with respect to, and in satisfaction of, such vested Eligible PSUs (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan), the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, the cash value of one share of common stock of the Company (&#8220;Common Stock&#8221;) in satisfaction of each vested Eligible PSU.  For purposes of this Agreement, the cash value of a share of Common Stock (&#8220;Cash Value&#8221;) will be equal to the 30 calendar-day average of the Company&#8217;s closing stock price ending on the Vesting Date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:11pt;">With respect to a Participant who is or becomes eligible for Retirement at any time during the Vesting Period, the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, the Cash Value in satisfaction of each vested Eligible PSU (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan) within 30 days of the earliest of (i) the date the Eligible PSU otherwise would have vested under Section 2.B. of this Agreement, (ii) the date on which the Participant experiences a separation from service (within the meaning of Section 409A), subject to Section 3.C. of this Agreement or (iii) the date on which a Covered Transaction that satisfies the definition of a &#8220;change in control event&#8221; under Section 409A occurs.  </font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">C.</font><font style="font-family:inherit;font-size:11pt;">If you are a &#8220;specified employee&#8221; (as defined in Section 409A), you will be paid on the earlier of (i) the date which is six months after you separate from service (within the meaning of Section 409A) or (ii) the date of your death or Disability.  The preceding sentence will not apply to any payments that are exempt from or are not subject to the requirements of Section 409A.  For the avoidance of doubt, if payments would be made under Section 3.B.(i) or Section 3.B.(iii) before the six month payment date on account of other than your separation from service, such payment will be made under Section 3.B.(i) or Section 3.B.(iii), as applicable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Cancellation and Rescission of Awards</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The Committee may cancel, rescind, withhold or otherwise limit or restrict the Award prior to payment at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">No Voting, Dividend or Other Rights as a Stockholder</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The Participant shall not have any rights as a stockholder with respect to any shares of Common Stock that are used to calculate the Cash Value to be delivered to the Participant in satisfaction of any vested Eligible PSUs or with respect to any other aspect of the Award.  Accordingly, the Award shall not be interpreted to bestow upon the </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Participant any equity interest or ownership in the Company or any Affiliate.  Furthermore, the Participant is not entitled to vote any Common Stock or to receive or be credited with any dividends declared and payable on any share of Common Stock by reason of the granting of the Award.  </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Unfunded Status</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The obligations of the Company and its Affiliates hereunder shall be contractual only and all such payments shall be made from the general assets of the Company or its Affiliates.  The Participant shall rely solely on the unsecured promise of the Company and nothing herein shall be construed to give the Participant or any other person or persons any right, title, interest or claim in or to any specific asset, fund, reserve, account or property of any kind whatsoever owned by the Company or any Affiliate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Withholding </font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Awards will be subject to income tax withholding and reporting as required under local law.  If statutory withholding of taxes and/or social insurance is required at the time of vesting, the Company will withhold from delivery to the Participant an amount of cash equal in value to the statutory minimum amount required to be withheld.  A similar amount of cash will be paid by the Company on behalf of the Participant to the applicable tax authorities.  The amount of cash to be withheld will be calculated using the closing sales price of a share of Common Stock on the applicable vesting date.  The Cash Value (net of the cash withheld for the payment of withholding taxes, if applicable) will be delivered to the Participant&#8217;s stock plan account upon vesting in accordance with the Plan.  The Company may, in its discretion, permit Participants to make alternative arrangements for payment of any such taxes and/or social insurance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">In certain cases, local law may require that an award be subject to tax earlier than the date of payment.  If that occurs, the Company will notify the Participant and will deduct the required tax amount from the Participant&#8217;s pay in accordance with applicable law.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Provisions of the Plan</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The Award is subject to the provisions of the Plan, which are incorporated herein by reference, and in the event of any inconsistency or conflict between the provisions of this Agreement and the Plan, the provisions of the Plan shall control.  A copy of the Plan as in effect on the Grant Date has been made available electronically to the Participant.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">No Right to Employment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The grant of the Award shall not constitute a contract of employment or confer upon the Participant any right with respect to the continuance of his/her employment by or other service with the Company or any Affiliate, nor shall it or they be construed as affecting the rights of the Company (or any Affiliate) to terminate the service of the Participant at any time or otherwise change the terms of such service, including, without limitation, the right to promote, demote or otherwise re-assign the Participant from one position to another within the Company or any Affiliate.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Governing Law</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The provisions of the Award and this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biogen Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Michel Vounatsos</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Chief Executive Officer </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>biib-20171231xex1011.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4eeac2a41f73410aacdaf35e0890144e"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit 10.11</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Performance STOCK Units AWARD AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Granted Under </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biogen Inc. 2017 Omnibus Equity Plan</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Grant of Performance Stock Units</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the Biogen Inc. 2017 Omnibus Equity Plan (as it may be amended from time to time, the &#8220;Plan&#8221;), Biogen Inc. (the &#8220;Company&#8221;) hereby grants to you, an employee of the Company or one of its Affiliates (the &#8220;Participant&#8221;), on each of the grant dates specified on your Fidelity stock plan account</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">(the &#8220;Grant Date&#8221;), the number of performance stock units (the &#8220;Granted PSUs&#8221; or the &#8220;Award&#8221;) specified on your Fidelity stock plan account, subject to the terms and conditions of this award agreement (&#8220;Agreement&#8221;) and the Plan.  No Granted PSUs shall be paid unless vested in accordance with this Agreement.  The Participant&#8217;s rights to the Granted PSUs are subject to the restrictions described in this Agreement and the Plan, in addition to such other restrictions, if any, as may be imposed by law.  All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified in this Agreement.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Vesting  </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Participant shall have a non-forfeitable right to a portion of the Award only upon the vesting dates specified on your Fidelity stock plan account, except as otherwise provided herein or determined by the Committee in its sole discretion.  No portion of any Award shall become vested on the vesting date unless the Participant is then, and since the Grant Date has continuously been, employed by the Company or any Affiliate.  If the Participant ceases to be employed by the Company and its Affiliates for any reason, any then outstanding and unvested portion of the Award shall be automatically and immediately forfeited and terminated, except as otherwise provided in this Agreement and the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Award will become eligible to vest upon achievement of the Granted PSUs goals (&#8220;Performance Goals&#8221;), as adopted by the Committee in the first calendar quarter of the year in which the Award is granted and communicated.  The calculation of the number of Granted PSUs that will vest is specified in the Long-Term Incentive Program Overview for Executives for the year in which the Award is granted (&#8220;LTI Overview&#8221;), which is also found on your Fidelity stock plan account.  Granted PSUs that become eligible to vest are referred to as the &#8220;Eligible PSUs.&#8221;  In the event and to the extent that the Performance Goals are not satisfied, such Granted PSUs shall not become eligible to vest and shall be immediately forfeited.  As specified in the Performance Goals, in the event and to the extent that the Performance Goals are exceeded, an additional number of Granted PSUs will become eligible to vest.  In no event shall the number of Eligible PSUs exceed 200% of the number of Granted PSUs.  All Eligible PSUs shall vest on the later of</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">the third anniversary of the Grant Date or the date of the Committee&#8217;s determination of the degree to which the Performance Goals have been satisfied (the &#8220;Vesting Date&#8221;). </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Except as otherwise provided in the Plan, upon termination of the Participant&#8217;s employment with the Company and its Affiliates for any reason, any portion of the Award that is not then vested will immediately terminate, except as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">any portion of the Award held by the Participant immediately prior to the Participant&#8217;s termination of employment on account of death or Disability will, to the extent not vested previously, become fully vested upon the later of (a) the date of death or Disability of the Participant or (b) the determination of the Eligible PSUs based on the Performance Goals and the Committee&#8217;s approval, even if such determination occurs following the date of death or Disability of the Participant; and</font></div><div style="line-height:120%;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">any portion of the Award held by the Participant immediately prior to the Participant&#8217;s Retirement, to the extent not vested previously, will become fully vested upon the later of the date of Retirement or determination of the Eligible PSUs based on the Performance Goals and the </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Committee&#8217;s approval for fifty percent (50%) of the number of Eligible PSUs covered by such unvested portion and for an additional ten percent (10%) of the number of Eligible PSUs covered by such unvested portion for every full year of employment by the Company and its Affiliates beyond ten (10) years, up to the remaining amount of the unvested Eligible PSUs of the Award.  For the avoidance of doubt, Retirement means the Participant&#8217;s leaving the employment of the Company and its Affiliates after reaching age 55 with ten (10) consecutive years of service with the Company or its Affiliates, but not including pursuant to any termination For Cause or any termination for insufficient performance, as determined by the Company.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">D.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Notwithstanding anything herein to the contrary, any portion of the Award held by a Participant or a Participant&#8217;s permitted transferee immediately prior to the cessation of the Participant&#8217;s employment For Cause shall terminate at the commencement of business on the date of such termination.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Delivery of Award </font></div></td></tr></table><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:11pt;">With respect to a Participant who is not eligible for Retirement, within 30 days following the date on which Eligible PSUs becomes vested, with respect to, and in satisfaction of, such vested Eligible PSUs (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan), the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of common stock of the Company (&#8220;Common Stock&#8221;) in satisfaction of each vested Eligible PSU.  </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">With respect to a Participant who is or becomes eligible for Retirement at any time after the Grant Date and on or before the Vesting Date, the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of Common Stock in satisfaction of each vested Eligible PSU (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan) within 30 days of the earliest of (i) the date the Eligible PSU otherwise would have vested under Section 2.B. of this Agreement, (ii) the date on which the Participant experiences a separation from service (within the meaning of Section 409A), subject to Section 3.C. of this Agreement or (iii) the date on which a Covered Transaction that satisfies the definition of a &#8220;change in control event&#8221; under Section 409A occurs.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">C.</font><font style="font-family:inherit;font-size:11pt;">If you are a &#8220;specified employee&#8221; (as defined in Section 409A), you will be paid on the earlier of (i) the date which is six months after you separate from service (within the meaning of Section 409A) or (ii) the date of your death or Disability.  The preceding sentence will not apply to any payments that are exempt from or are not subject to the requirements of Section 409A.  For the avoidance of doubt, if payments would be made under Section 3.B.(i) or Section 3.B.(iii) before the six month payment date on account of other than your separation from service, such payment will be made under Section 3.B.(i) or Section 3.B.(iii), as applicable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Cancellation and Rescission of Awards</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The Committee may cancel, rescind, withhold or otherwise limit or restrict the Award prior to payment at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">No Voting, Dividend or Other Rights as a Stockholder</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The Participant shall not have any rights as a stockholder with respect to any shares of Common Stock to be issued under the Award until he or she becomes the holder of such shares.  Accordingly, the Award shall not be interpreted to bestow upon the Participant any equity interest or ownership in the Company or any Affiliate</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">prior to the date on which the Company delivers to the Participant shares of Common Stock.  Furthermore, the Participant is not entitled to vote any Common Stock or to receive or be credited with any dividends declared and payable on any share of Common Stock underlying the Award prior to the payment date with respect to such share.  </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Unfunded Status</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The obligations of the Company and its Affiliates hereunder shall be contractual only and all such payments shall be made from the general assets of the Company or its Affiliates.  The Participant shall rely solely on the </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">unsecured promise of the Company and nothing herein shall be construed to give the Participant or any other person or persons any right, title, interest or claim in or to any specific asset, fund, reserve, account or property of any kind whatsoever owned by the Company or any Affiliate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Withholding </font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Awards will be subject to income tax withholding and reporting as required under local law.  If statutory withholding of taxes and/or social insurance is required at the time of vesting, the Company will withhold from delivery to the Participant an amount of cash equal in value to the statutory minimum amount required to be withheld.  A similar amount of cash will be paid by the Company on behalf of the Participant to the applicable tax authorities.  The amount of cash to be withheld will be calculated using the closing sales price of a share of Common Stock on the applicable vesting date.  The Cash Value (net of the cash withheld for the payment of withholding taxes, if applicable) will be delivered to the Participant&#8217;s stock plan account upon vesting in accordance with the Plan.  The Company may, in its discretion, permit Participants to make alternative arrangements for payment of any such taxes and/or social insurance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">In certain cases, local law may require that an award be subject to tax earlier than the date of payment.  If that occurs, the Company will notify the Participant and will deduct the required tax amount from the Participant&#8217;s pay in accordance with applicable law.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Provisions of the Plan</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The Award is subject to the provisions of the Plan, which are incorporated herein by reference, and in the event of any inconsistency or conflict between the provisions of this Agreement and the Plan, the provisions of the Plan shall control.  A copy of the Plan as in effect on the Grant Date has been made available electronically to the Participant.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">No Right to Employment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The grant of the Award shall not constitute a contract of employment or confer upon the Participant any right with respect to the continuance of his/her employment by or other service with the Company or any Affiliate, nor shall it or they be construed as affecting the rights of the Company (or any Affiliate) to terminate the service of the Participant at any time or otherwise change the terms of such service, including, without limitation, the right to promote, demote or otherwise re-assign the Participant from one position to another within the Company or any Affiliate.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Governing Law</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The provisions of the Award and this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biogen Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Michel Vounatsos</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:336px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Chief Executive Officer </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>4
<FILENAME>biib-20171231xex1028.htm
<DESCRIPTION>EXHIBIT 10.28
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sa6420cbdb7b441958d6f39ffed3ae8ca"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;text-decoration:underline;">Exhibit 10.28</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">Non-Employee Director Compensation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;">The following is a summary of the retainers and meeting fees payable to non-employee directors effective July 1, 2017:</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:79%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#aec2e4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Retainers</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#aec2e4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Annual Board Retainer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$65,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Annual Retainers (in addition to Annual Board Retainer):</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Independent Chairman of the Board</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$75,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Audit Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$25,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Compensation and Management Development Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$20,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Corporate Governance Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$15,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Finance Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$15,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Risk Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$15,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Science and Technology Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$15,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Audit Committee Member (other than Chair)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$5,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#aec2e4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Meeting Fees</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#aec2e4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Board of Directors Meetings (per meeting day):</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In-person attendance</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$2,500</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Telephonic attendance</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$1,500</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Committee Meetings (per meeting attended in person or telephonically)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$1,500</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attendance at Annual Science and Technology Committee Portfolio Review (per day)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$1,500</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Special service fee (for each full day of service other than in connection with Board or Committee meetings)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e1e8f5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$1,000</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>5
<FILENAME>biib-20171231xex1031.htm
<DESCRIPTION>EXHIBIT 10.31
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="seba4edbfd1c74adf81687be552cc0b6b"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;padding-left:112px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;text-decoration:underline;">Exhibit 10.31</font></div><div style="line-height:100%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><img src="biogenlogostandarda06.jpg" alt="biogenlogostandarda06.jpg" style="height:57px;width:173px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:110px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">November 14, 2017</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:110px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Jeffrey Capello</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:110px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">[address]</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:110px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">[address]</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:109px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Dear Jeffrey,</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">I am pleased to extend you this offer of employment to join Biogen with the job title of EVP and Chief Financial Officer. This pos</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#010101;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">tion will report to Michel Vounatsos, Chief Executive Officer. Please note that neither this letter nor any other materials constitute a contract of employment with Biogen. Your employment at Biogen is employment at-will. This means that just as you are free to leave your employment at any time, with or without cause or notice, Biogen also has the same right to terminate your employment at any time, with or without cause or notice. The specific terms of our offer are listed below; please take the time to review the offer, electronically sign and submit by November 18, 2017.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">The position will be based at our Cambridge, MA facility.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:106px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Salary: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">This is a full-time, exempt position and your starting annual salary will be $750,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">00, which will be paid biweekly in accordance with our standard payroll policies.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:106px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Sign-On Bonus: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Upon employment, you will receive $520,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#010101;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">00 as a one-time cash bonus</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">The bonus will be paid to you within two pay periods after your start date provided that you sign the enclosed Cash Sign-On Bonus Agreement, which describes the terms and conditions of the cash sign-on bonus.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:106px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Annual Bonus Plan: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Beginning in 2018,you will be eligible to participate in the Biogen Annual Bonus Plan, with a target bonus opportunity of 70% of your annual base salary. Eligibility details and other terms of the Plan are included in the Annual Bonus Plan document, which will be made available upon your employment with the Company</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:105px;text-indent:1px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Long-Term Incentive (LTl) Plan:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">&#32;You will be granted Performance Stock Units (PSU) in connection with the commencement of your employment. The approximate grant date value of your PSU award </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2d2d2d;">will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">be $1,500,000.00. The number of shares granted to you will be calculated by dividing the grant date value by the closing price of Biogen stock </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2d2d2d;">(NASDAQ) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">on the grant date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">with the resulting number of shares rounded to the nearest five shares. You will also be granted Market Stock Units (MSU) in connection with the commencement of your employment. The approximate grant date value of your MSU award will be $1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">500,000.00. The number of shares granted to you will be calculated by dividing the grant date value by the closing price of Biogen stock (NASDAQ) on the grant date, with the resulting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2d2d2d;">number </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">of shares rounded to the nearest five shares. Your PSU and MSU awards will be granted on the first trading day of the month following your start date. Your PSU award will be subject to three-year cliff vesting and your MSU award will vest ratably over three years beginning on the first anniversary of the grant date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#010101;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Your grant amount has been determined based upon the start date listed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2d2d2d;">in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">this offer letter</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#010101;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">If your start date is delayed, the amount of the grant may decrease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:105px;text-indent:-2px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">The actual terms of your PSU and MSU awards will be communicated to you following </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2d2d2d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">grant date. Your grants will be awarded under the Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2d2d2d;">Inc</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#010101;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">2017 Omnibus Equity Plan </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2d2d2d;">(the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">"2017 Plan"). You are considered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2d2d2d;">"designated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">employee," as defined in the Plan. The Plan and Prospectus will be available on HRConnect: [website]</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#243152;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Please read these documents for information about your Long-term Incentive grants.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:173px;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">225 B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">nney Street</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">Cam</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f67a1;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#567c99;">ridge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#6e7277;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">MA 02142 Phone 781</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">464</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">2000 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4b6991;">www</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">com</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;"><br></font></div><div style="line-height:100%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><img src="biogenlogostandarda06.jpg" alt="biogenlogostandarda06.jpg" style="height:57px;width:173px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:108px;text-indent:1px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Beginning in 2019, we expect that you will be eligible to participate in the Biogen Annual Long Term Incentive (LTI) program. Approved awards would be made under the 2017 Plan. Actual LTl award va</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">ues and details, including, amounts, delivery vehicles and payout percentages and metrics will be determined by the Compensation and Management Development Committee of the Board of Directors (CMDC) in its sole discretion based upon performance</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">future contribution expectations and other considerations. The first time you will be eligible for an annual grant will be February 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:106px;text-indent:1px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Employee Benefits: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Biogen offers a robust and highly competitive employee benefits program. As an employee, you will be able to choose from a menu of options through our flexible benefits program. These benefits include a 401(k) savings plan; group health care, including medical</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">dental, prescription drug and vision coverage; life, dependent life and disability insurance; as well as flexible spending accounts for eligible medi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">al and dependent care expenses</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:106px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">You are also entitled to up to 20 vacation days (160 hours) per year (pro-rated if you work part&#173; time)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Additional benefit offerings include an Employee Stock Purchase Plan (ESPP) and work/life benefits such as a concierge service and access to subsidized back-up dependent care. Please vis</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">t Biogen's Benefits website using the below link and login information to familiarize yourself with Biogen's complete benefit plan offerings.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:152px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">URL: [website]</font></div><div style="line-height:120%;text-align:left;padding-left:152px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Username: [username]</font></div><div style="line-height:120%;text-align:left;padding-left:152px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Password: [password]</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:106px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Additional Executive Benefits</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:128px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Supplemental Savings Plan:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">&#32;You will be entitled to participate in Biogen's Supplemental Savings Plan (SSP)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#525260;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">This plan allows you to make pre-tax deferrals of up to 80% of your base salary and up to 100% of your Annual Bonus payment and certain other eligible incentive payments. Your contributions to this plan may be limited by your contr</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">butions towards other plans (e.g., 401(k), ESPP, medical, etc.). You will be provided with SSP enrollment information upon your employment with the Company</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:128px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Life Insurance: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">You will be provided life insurance coverage equal to three times your annual base salary</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">subject to meeting the medical standards stated in the group term life insurance policy for U.S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">employees</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Biogen pays the premium for this insurance. The IRS requires employers to impute the value of company-paid life insurance for coverage over $50,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">This imputed income will be displayed on your pay stub</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:126px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Severance: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">You will be entitled to severance benefits in accordance with the attached executive severance document, as it may be amended in the future from time to time</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">and should refer to such document fo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">details regarding terms, conditions, eligibility and potential tax implications.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:126px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Tax &amp; Financial Planning and Executive Physicals:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">&#32;You are eligible for annual reimbursement of expenses for qualified services such as federal and state income tax planning and/or preparation, financial and estate planning services, and the purchase of ta</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3d3d;">x </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">and/or financial planning tools. Additionally, the Company will reimburse you for the expenses of an annual comprehensive physical exam when coordinated by the Executive Health Services team at Mass. General Hospital (MGH)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:174px;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d6d93;">225 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3f5b85;">B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4880ac;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3f5b85;">nney St</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#243152;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d6d93;">eet</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#8991a1;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3f5b85;">Cambridge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#727082;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3f5b85;">MA 02142 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4880ac;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3f5b85;">Phone 781</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#727082;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3f5b85;">46</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#28367b;">4 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#727082;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3f5b85;">2000  </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4880ac;">www</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#758789;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3f5b85;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4880ac;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d6d93;">oge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#1c62aa;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#8991a1;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d6d93;">co</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b4b70;">m</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:100%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><img src="biogenlogostandarda06.jpg" alt="biogenlogostandarda06.jpg" style="height:57px;width:173px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:132px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">The combined annual reimbursement you are eligible to receive is $7,500 per calendar year (January 1 - December 31), subject to the guidelines of the Tax </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#1a1a1a;">&amp; </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Financial Planning and Executive Physical Reimbursement Prog</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">am. The details of these benefits are available upon your employment with the Company</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:109px;text-indent:1px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Stock Trading Plan</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;font-weight:bold;">:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Upon employment with the Company, you will become subject to Biogen's Globa</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">l </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Insider Trading Policy</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">a copy of which will be provided to you</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">The Biogen Global Insider Trading Policy sets forth guidelines designed to promote compliance with applicable federal and state securities laws that prohibit persons who are aware of material nonpublic information about the company from trading in securities of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">ompany or providing material nonpublic information to other persons who may trade on the basis of that information</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Upon your employment, you will be assigned, based on your job, to a specific trading group that will determine your obligations and restrictions under the policy, and you will be required to complete training on the policy.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:109px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Share Ownership Requirement:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">&#32;A key object</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">ve of our long-term incentive plans is to ensure strong alignment between the interests of our senior executives and those of our stockholders</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">It is expected that through our annual long-term incentive grants, you will accumulate and retain Biogen shares in an amount equivalent to 3x salary through the first 5 years of employment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:106px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">You are required to satisfy the foll</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">wing contingencies prior to employment at Biogen.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:150px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:128px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Pre</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;font-weight:bold;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">employment screening: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Employment at Biogen is contingent upon your successful completion and passing of both a background check and drug screen. Biogen's background check includes verification of employment history, educational and professional licenses, degrees and/or credentials, a criminal records check, a So</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">ial Security Number search and verification of any other profess</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">onal qualifications that your position responsib</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">lities at Biogen may warrant. Completion of your online Application for Employment authorizes Biogen to conduct these background che</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">ks. If you have any questions about the background check</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">please contact </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#232a4f;">HRConne</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3f4d64;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#232a4f;">t@b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#08344d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#232a4f;">ogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#706499;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#232a4f;">com</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:150px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:128px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Authorization to Work in the United States:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">&#32;Please note that Biogen is an E-Verify employer</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">The Federal government requires you to provide proper identification verifying your eligibility to work in the United States.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:149px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">If you will be working at one of our office locations:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">&#32;Please complete Section 1 of the Employment Eligibility Verification Form 1-9, electronically as specified in your emails from Gua</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">dian</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-style:italic;font-weight:bold;text-decoration:underline;">On your first day of employment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">, please bring original and unexpired documents and a scanned copy of your documents to complete the 1-9 process. A list of acceptable documents can be found on the last page of the Form 1-9 packet.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:149px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">If you are a fleld employee:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">&#32;You will receive a separate email from HR Operations providing you with instructions to complete your 1-9 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">f</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">orm. Please complete per instructions within 3 days of receipt.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:105px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-weight:bold;">Signed Employee Proprietary Information and Inventions and Non-Compete Agreement:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">&#32;Prior to and as a condition of employment with Biogen you will be required to sign Biogen's Propr</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383838;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">etary Information and Inventions and Non-Compete Agreement. This is required to, among other things, protect Biogen's substantial investment in creating and maintaining its </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">confidential </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">and proprietary information, and to maintain goodwill </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">our customers, vendors and other business partners. You </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">receive an email shortly that </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">contains </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">a link </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">this agreement for your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">review </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">and electronic </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">signature.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:174px;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#44628c;">225 B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3874ca;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#44628c;">nney St</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2164ac;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#44628c;">ee</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f4677;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#798993;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#44628c;">Ca</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f4677;">m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#44628c;">bridge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3f4d64;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#44628c;">MA 0</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3f4d64;">2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#44628c;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f4677;">4</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#44628c;">2 Phone 78</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f4677;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#626977;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#44628c;">464-2000 www</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#798993;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#44628c;">blogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#626977;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#44628c;">co</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2164ac;">m</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:100%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><img src="biogenlogostandarda06.jpg" alt="biogenlogostandarda06.jpg" style="height:57px;width:173px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:110px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Jeffrey, we are excited at the prospect of your joining Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#010101;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">To confirm your acceptance of this offer of employment, please electronically sign this letter by November 18, 2017. You will be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">provided with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">a signed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">copy electronically </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">for your personal records. We </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">would </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">anticipate your first day </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">employment to be December 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">2017. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">If you have any questions, please feel free to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">contact </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">me.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Best Regards,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Ginger Gregory</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:109px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Ginger Gregory</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:109px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">EVP</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#010101;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Human Resources</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:109px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Cc: Michel Vounatsos</font></div><div style="line-height:120%;text-align:justify;padding-left:109px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">31947BR</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">I accept this offer of employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">acknowledge the contingencies of employment described above, including the at-will nature of my employment.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:106px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1a1a1a;font-weight:bold;">ACCEPTED:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:106px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;text-decoration:underline;">/s/ Jeffrey Capello</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:106px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#282828;">Signature</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:174px;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">225 B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f4682;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">nney S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#607287;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#1a62aa;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">ee</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f4682;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#607287;">. C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">amb</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f4682;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">idge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#607287;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">MA 0214</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b4f70;">2 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b4f70;">h</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">one </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b4f70;">7</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">81</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b4f70;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">464</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#214b4d;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b4f70;">0</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">00 www</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#878c95;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3f7bb3;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">ogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#607287;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b4f70;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#42608c;">om</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:100%;padding-top:4px;text-align:left;"><img src="biogenlogostandarda06.jpg" alt="biogenlogostandarda06.jpg" style="height:57px;width:173px;"></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:240px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">BIOGEN CASH SIGN-ON BONUS AGREEMENT</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:110px;text-indent:1px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">I have accepted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#313131;">a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">position of employment with Biogen that provides for payment of a cash sign&#173; on bonus of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#313131;">$520,000.00 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">to me following commencement of employment. I understand that the full benefit of this cash sign-on bonus is conditioned upon my remaining an employee of Biogen for at least 36 months. I hereby accept Biogen's offer of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#313131;">cash </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">sign-on bonus according to the following terms:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:110px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">The payment of the cash sign-on bonus by Biogen is taxable income to me and will be taxed at the time of payment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:108px;text-indent:-22px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">I acknowledge and agree </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#313131;">that </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">if, within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#313131;">36 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">months of the effective date of my employment (start date), I voluntarily terminate my employment or Biogen terminates my employment For Cause, as defined in the Biogen Inc. 2017 Omnibus Equity Plan, or for misconduct or poor performance, as determined in good faith by the Company</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#484949;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">I will not have earned the cash sign-on bonus provided to me under this Agreement and I will repay such bonus according to the following schedule:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:174px;text-indent:-44px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">(i)          If my </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#313131;">employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">terminates on or before 12 months from my start date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#484949;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">the full amount of the cash sign-on bonus, net of the applicable proportion of tax withholdings;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:174px;text-indent:-44px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">(ii)         If my employment terminates after 12 months and on or before 24 months from my start date, 70% of the amount of the cash sign-on bonus, net of the applicable proportion of tax withholdings; or</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:174px;text-indent:-46px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">(iii)        If my employment terminates after 24 months and on or before 36 months from my </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#313131;">start </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">date, 35% of the amount of the cash sign</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#484949;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">on bonus, net of the applicable proportion of tax withholdings.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:108px;text-indent:-22px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">I shall pay to Biogen all such repayable amounts within thirty (30) days of the effective date of my employment termination or by the end of the year in which my employment terminates, whichever comes first. I voluntarily authorize Biogen to deduct, withhold and/or retain all or any portion of the amount which I may be required to refund or repay to Biogen hereunder from any wages, salary, vacation pay, severance pay or other pay which may be due and owing to me upon termination of employment, to the extent permitted under applicable law. I shall remain liable to Biogen for any amounts in excess of the sums so deducted, withheld and/or retained by Biogen.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:106px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Except as stated above, I shall have no liability or responsibility to refund or repay to Biogen any amounts paid by Biogen to me in connection with this sign-on bonus.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:106px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Nothing in this Agreement shall alter the at-will emp</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#484949;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">oyment relationship between Biogen and me (e.g</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#484949;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#313131;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Biogen and I can end the employment relationship at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;font-style:italic;">any </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">time with or without cause). Therefore, I understand that nothing in this Agreement guarantees that the Company will employ me for any specific period of time.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:106px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">My signature below acknowledges that I have read and understand this Agreement and agree to be bound by its terms.</font></div><div style="line-height:100%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;text-decoration:underline;">/s/ Jeffrey Capello&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;text-decoration:underline;">Jeffrey Capello&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;text-decoration:underline;">11/18/2017</font></div><div style="line-height:100%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1a1a1a;">Employee Signature&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Employee Name (Please Print)&#160;&#160;&#160;&#160;Date</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>6
<FILENAME>biib-20171231xex1032.htm
<DESCRIPTION>EXHIBIT 10.32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sc32f99c84a154771b4ac7a57366f5857"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:100%;padding-top:4px;text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;text-decoration:underline;">Exhibit 10.3</font></div><div style="line-height:100%;padding-top:4px;text-align:center;"><img src="biogenidec.jpg" alt="biogenidec.jpg" style="font-size:19pt;height:33px;width:141px;"></div><div style="line-height:100%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;padding-top:2px;text-align:left;padding-left:108px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">February 25, 2012</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Greg Covino</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">[address]</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">[address]</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Dear Greg:</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">I am pleased to extend you this offer of employment to join Biogen Idec as Vice President of Finance. You will be appointed as the Company's Chief Accounting Officer as of the day following the filing of the Company's Form 10-Q for Q1 of 2012. This position will report to Paul Clancy, Executive Vice President, and Chief Financial Officer. The position will be based at our Weston, Massachusetts facility. </font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Base Salary:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;Your starting bi-weekly salary will be $11,923.08, which is equivalent to an annual salary of $310,000.08.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">One-time Cash Sign-On Bonus:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;Upon employment, you will receive $35,000.00 as a one-time cash bonus. The bonus will be paid to you within two pay periods after your start date provided that you sign the enclosed Cash Sign-On Bonus Agreement, which describes the terms and conditions of the cash sign-on bonus.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Annual Bonus Plan:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;You will be eligible to participate in the Biogen Idec Annual Bonus Plan, with a target bonus opportunity of 35% of your annualized base salary. Based upon your start date, your target bonus amount may be pro-rated. Eligibility details and other terms of the Plan are included in the current years Plan document which will be made available upon your employment with the Company.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Long-Term Incentive:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;You will be granted Cash-Settled Performance Shares (CSPS) in connection with the commencement of your employment. The approximate grant date value of your CSPS award will be $137,500. You will also be granted Market Stock Units (MSU) in connection with the commencement of your employment. The approximate grant date value of your MSU award will be $137,500. Your CSPS and MSU awards will be granted on the first trading day of the month following your start date.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">The actual terms of your CSPS and MSU awards will be communicated to you following the grant date. Your grants will be awarded under the Biogen Idec Inc. 2008 Omnibus Equity Plan. You are considered a "designated employee," as defined in the 2008 Omnibus Equity Plan. Our 2008 Omnibus Equity Plan and Prospectus are available to you on Biogen Idec's benefits website at [website]. Please read these documents for information about your Long-term Incentive grants.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Stock Trading Plan:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;You have been designated as a member of Trading Group A pursuant to Biogen Idec's Global Insider Trading Policy. As a member of Trading Group A, you are required to enter into a 10b5-1 trading plan for all sales of Biogen Idec stock and you may only purchase Biogen Idec stock on the open market during Biogen Idec's quarterly open trading window periods, as described and in accordance with the requirements outlined in the Global Insider Trading Policy, More information about the Biogen Idec Global Insider Trading Policy, insider trading restrictions, and 10b5-1 trading plans will be made available upon your employment with the Company.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Employee Benefits and Total Rewards:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;Biogen Idec offers a robust and highly competitive employee benefits program. As an employee, you will be able to choose from a menu of options through our flexible Total Rewards program. These benefits include a 401(k) savings plan; group health care, including medical, dental, prescription drug and vision coverage; life, dependent life and disability insurance; as well as flexible spending accounts for eligible medical and dependent care expenses. You are also entitled to 20 vacation days per year, accrued on a per pay period basis. Additional benefit offerings include an Employee Stock Purchase Plan (ESPP) and work/life benefits such as a concierge service and access to subsidized back-up dependent care. Please visit Biogen Idec's Total Rewards website at [website] (user ID = [user ID], password = [password]) to familiarize yourself with Biogen Idec's complete benefit plan offerings.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Additional Executive Benefits</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Supplemental Savings Plan:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;You will be entitled to participate in Biogen Idec's Supplemental Savings Plan (SSP). This plan allows you to make pre-tax deferrals of up to 80% of your base salary and up to 100% of your Annual Bonus payment and certain other eligible incentive payments. Your contributions to this plan may be limited by your contributions towards other plans (e.g., 401(k), ESPP, medical, etc.). You will be provided with SSP enrollment information upon your employment with the Company.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Life Insurance:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;You will be provided life insurance coverage equal to three times your annual base salary, subject to meeting the medical standards stated in the group term life insurance policy for U.S. employees. Biogen Idec pays the premium for this insurance. The IRS requires employers to impute the value of company-paid life insurance for coverage over $50,000. This imputed income will be displayed on your pay stub.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Severance:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;Under certain circumstances, you will be entitled to receive severance benefits. Your severance benefits are explained in detail in the attached executive severance document. If your total severance benefits will trigger 28OG excise taxes, you may elect to have Biogen Idec reduce the amount of your total payment to reduce your total payments to an amount below the 28OG trigger. To facilitate your decision, Biogen Idec will estimate whether any 28OG excise tax will be owed on severance and the amount of that excise tax.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Tax Preparation, Financial and Estate Planning:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;You are entitled to reimbursement of up to $4,500 per calendar year (January 1 - December 31) for expenses incurred due to tax preparation, financial and/or estate planning services, as well as the purchase of tax preparation and/or financial planning software. You will be provided with details of this benefit upon your employment with the Company. Reimbursement must be made no later than the end of the calendar year following the year in which the expense is incurred, and must be requested within the deadlines and processes established in the policy.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">You are required to satisfy the following contingencies prior to employment at Biogen Idec.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Drug Screen:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;A completed drug-screening test is required within one (1) week of accepting this offer of employment. Please see the enclosed information regarding Biogen Idec's Pre-Employment Drug Testing program. Your employment is subject to Biogen Idec receiving negative results (i.e., no drugs found) from your drug test.</font></div></td></tr></table><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Background Check:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;Your employment is subject to satisfactory completion of Biogen Idec's background check, which includes verification of employment history, educational and professional licenses, degrees and/or credentials, a criminal records check, a Social Security Number search and verification of any other professional qualifications that your position responsibilities at Biogen Idec may warrant. Completion of your online Application for Employment authorizes Biogen Idec to conduct these background checks. If you have any questions about the background check, please contact your Biogen idec recruiter.</font></div></td></tr></table><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">New Employee Forms:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;Upon your acceptance of Biogen Idec's offer of employment, please visit our Company website, www.biogenidec.com. Under 'Careers,' click 'New Employees.' This site contains the forms you must complete in order to add you to Biogen Idec's Payroll and Human Resources systems. Completion of these forms is required within 48 hours of accepting this offer of employment at Biogen idec. Your username is [username] and your password is [password].</font></div></td></tr></table><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Authorization to Work in the United States:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;The Federal government requires you to provide proper identification verifying your eligibility to work in the United States. Please bring documents necessary to complete the Employment Eligibility Verification Form 1-9 on your first day of employment.</font></div></td></tr></table><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Signed Proprietary Agreement:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;In order to protect Biogen Idec's substantial investment in creating and maintaining its confidential and proprietary information, and to maintain goodwill with our customers, vendors and other business partners, you will be required to sign our 'Employee Proprietary Information and Inventions and Dispute Resolution Agreement' as a condition of employment. A copy of the Agreement is enclosed with this letter for your reference. Please sign and return this Agreement with your signed acceptance of our offer.</font></div></td></tr></table><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Your employment at Biogen Idec is employment at-will. This means that just as you are free to leave your employment at any time, with or without cause or notice, Biogen Idec also has the same right to terminate your employment at any time, with or without cause or notice.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">To confirm your acceptance of this offer of employment, please sign and return this letter and keep the other copy for your records. Review and complete the enclosed New Employee Checklist with actions required in order to begin your acceptance process. Your new employee paperwork should be completed on line within 48 hours of accepting this offer and the drug screen should be completed within one (1) week of accepting this offer of employment.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Please work with your supervisor or Biogen Idec recruiter to establish a start date. Your start date must be a Monday coinciding with Biogen Idec's New Employee Orientation schedule which is included in your offer package details. (unless it is a holiday, in which case your start date will be on the Tuesday of that week). The New Employee Checklist provides an overview of all required steps and instructions to prepare for your first day of employment.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">We are very excited about the prospect of you joining Biogen Idec. We encourage you to accept this offer of employment, noting your intended start date, by February 29, 2012.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Best regards,</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">/s/ Luci Celona</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Luci Celona</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Vice President, Human Resources</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">cc: Paul Clancy</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">I accept this offer of employment and acknowledge the contingencies of employment described above, including the at-will nature of my employment.</font></div><div style="line-height:120%;padding-top:2px;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">ACCEPTED:</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;text-decoration:underline;">/s/ Greg Covino&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;    2/27/12&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   4/2/12&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Greg Covino&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Signature Date&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Start Date</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>7
<FILENAME>biib-20171231xex1033.htm
<DESCRIPTION>EXHIBIT 10.33
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7670c073e877440b887441d06e850dac"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:100%;padding-top:4px;text-align:right;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;text-decoration:underline;">Exhibit 10.33</font></div><div style="line-height:100%;padding-top:4px;text-align:left;padding-left:108px;"><img src="biogenlogostandarda06.jpg" alt="biogenlogostandarda06.jpg" style="height:57px;width:173px;"></div><div style="line-height:100%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">REVISED</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">April 18</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">2016</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Michael </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">Ehlers</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">[address]</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">[address]</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Dea</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Mike,</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">I </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">am pleased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">to e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">tend </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">this offer of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">to join Biogen with the job title of Executive Vice President, Research </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Development. This position will report to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">George </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Scangos</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Chief Executive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">Officer. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Please note that neither this letter nor </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">any </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">other materials </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">constitute </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">a contract of employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#828585;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">employment at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Biogen is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">at-will</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#626467;">.  </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">This </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">means that </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">just </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">as you are free to leave your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">employment at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">any time</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#707477;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">with or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">without </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">cause or notice, Biogen also has the same right to terminate your employment at any time, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">or without </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">cause or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">not</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">ce</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">The specific terms of our offer </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">listed below; please take the time t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">o </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">review the offer, sign </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">return to me by April 25, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">position </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">will be based </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">at our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Cambridge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">MA facility.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;font-weight:bold;">Salary: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">This is a full-time, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">exempt </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">posi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">ion </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">tarting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">bi-weekly salary will be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">$29,807.70, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">which is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">equivalent </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">to an annual </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">salary of $775,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#626467;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">and which will be paid in accordance with our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">standard </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">payroll policies.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;font-weight:bold;">Sign-On Bonus</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;font-weight:bold;">: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Upon </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">employment, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">re</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">eive $300</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#9c9ca3;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">00 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">as a one-time </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">cash bonus. The bonus </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">be paid to you within two pay periods after your start date provided that you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">sign </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">enclosed Cash Sign-On </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Bonus Agreement</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#707477;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">des</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">ribes the terms </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">and conditions of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">the cash </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">sign&#173; on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">bonus</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#707477;">.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;font-weight:bold;">Annual Bonus Plan</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;font-weight:bold;">: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">You will be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">elig</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">ble to</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">participate </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Annual Bonus Plan</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#425b75;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">target </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">bonus opportunity of 70% </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">of your annual ba</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">e salary. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Based upon </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">start date, your target bonus </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">amount </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">may be pro-rated</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#626467;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">E</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#425b75;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">igibility </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">details </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">and other </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">terms </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">the Plan are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">in the current year's Plan document</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#828585;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">which will be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">mad</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">available </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">upon your employment with the Company</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#828585;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;font-weight:bold;">Long-Term Incentive Plan</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#707477;font-weight:bold;">: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">Yo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">u will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">granted Cash</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#707477;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Settled Performance Units </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">(CSPU) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">onnection </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">commencem</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">nt of your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">employment. The approximate grant date </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">your CSPU </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">award will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">$1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">250</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">000.00. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">number of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">CSPU shares </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">granted to you will be calculated by dividing the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">approximate grant </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">date value by the closing price of Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">stock </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f344f;">(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">NASDAQ) on the date </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">of grant</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#828585;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">with the resulting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">number </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">of share</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">rounded to the nearest five shares</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#707477;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">You will also be granted Market St</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#626467;">oc</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">k Units </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">(MSU) in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">conne</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">tion </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">with the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">commencement </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">of your employment. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">approximate </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">grant </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">date </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">MSU award will be $1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#626467;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">250</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#626467;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">00</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#707477;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">The number of MSU shares granted to you will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">e c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">al</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">ulated by dividing the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">approximate </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">grant date value by the closing price of Biogen stock </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">(N</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">A</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">SDAQ</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#626467;">) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">the MSU </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">accounting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">valuation factor effective </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">the time of grant, with the resulting numb</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">er </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">of shares </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">rounded to the nearest five </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">shares. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Your CSPU and MSU awards will be g</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f344f;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">anted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">the fir</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">t trading day of the month following your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">start </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">dale</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#828585;">.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">ct</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">ual </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">ter</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">ms </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">your CSPU </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">MSU </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">awards will be communicated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">to you following the grant dat</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#828585;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Your gr</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">nts w</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f344f;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">ll be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">awarded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">under the Biogen In</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f5257;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">. Amended and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Restated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#343841;">2008 Omnibus </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23242d;">Equity </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Plan (the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#919393;">'</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">'2008 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Plan</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">You are considered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">designated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">employee,'</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">' </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">as defined in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the Plan</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Plan </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Prospectus </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">are available to you on Biogen's benefits website at [website]. Please </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">read these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">documents for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">informati</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">about your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">L</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Tl grants.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:173px;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">225 B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">nney Street</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">Cam</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f67a1;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#567c99;">ridge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#6e7277;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">MA 02142 Phone 781</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">464</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">2000 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4b6991;">www</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">com</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Each </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">year, typically </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">n February</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">you will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">eligible </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">rece</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">annual </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Long Term </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Incentive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">(L</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Tl) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">award which will be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">based on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">the planning</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">range </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">effect at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">time of grant. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">current planning reference </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">point is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">$2,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">150</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#9caab3;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">00</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Actual L</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Tl </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">award amounts and delivery vehicles will be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">determined </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Compensation and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Manag</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">ent </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Development </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Committee of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the Board of Directors (CMDC) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">based upon performance</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#919393;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">co</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ntributi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">on expectations and other considerations at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the discretion </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">CMDC</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#919393;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;font-weight:bold;">Employee Benefits</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;font-weight:bold;">:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">offer a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">robust </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">nd </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">highly competitive employee benefits </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">program</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">As an employee, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">will be able </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">chose </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">menu </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">of options </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">through </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">flexible benefits </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">program. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">These b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">nefits include </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">401(k) savings </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">plan;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">group </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">health </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">care, including </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">medical</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">dental</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">prescription drug </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">and vision coverage</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">; </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">life </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">dependent life and disability insurance; as well as flexible spending accounts for eligible </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">med</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">ic</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">l </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">and dependent </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">are expenses</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">You are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">also </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">entitled to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">20 vacation days (160 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">hours) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">per year </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">(pro</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">rated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">if yo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">u </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">work </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">part</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">time)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Additional benefit offerings include an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Employee Stock Purchase Plan </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">(ESPP) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">and work/life </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">benefits such </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">a concierge service and a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ccess to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">subsidized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">back-up dependent </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">care</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Please </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">visit </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Biogen's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">benefits </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">websit</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">at [website]</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;font-style:italic;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">(user ID </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">= [user ID]</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">password= [password]) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">familiarize </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">yo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">urself with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Biogen's complete benefit plan offer</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ngs</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;font-weight:bold;">Additional Execut</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;font-weight:bold;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;font-weight:bold;">ve Benefits</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:132px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;font-weight:bold;">Supplemental Savings Plan</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;font-weight:bold;">:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">You will be entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">to p</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">artic</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ipate </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">'</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Supplemental Sav</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ngs </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Plan (SSP)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#9caab3;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">This </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">plan allows you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">ake </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">pr</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">e-tax </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">deferrals </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">up to 80% of your base </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">sa</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ary </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">up </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">to 1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">00</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">% </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">of your Annual Bonus </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">paym</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">en</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">t and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">certain other eligible </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">incentive payments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Your contr</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">butions to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">this plan m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">y </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">be l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">mit</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">ed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">by your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">co</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ntribut</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">io</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ns  towards other plans </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">(e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">g</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">., </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">401(k)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ESPP</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">medical, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">etc</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#919393;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">You </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">w</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ill </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">provided </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">with SSP </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">enrollment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">nformation upon your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">the Company.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:132px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;font-weight:bold;">Life Insurance</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;font-weight:bold;">:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">You will be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">provided l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">ife </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">insurance </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">coverage equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">three times </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">your annual base salary</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">subject </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">meetin</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">g </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">medical </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">standards stated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">the group </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">term life </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">nsurance </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">policy </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">fo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">U</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">employees</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">pays the premium for this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">insuran</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">ce. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">IRS requires employers </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">to impute </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the v</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">alue </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">company-paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">life in</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">sur</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ance for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">coverage over $50</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">This </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">imputed income </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">be disp</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">laye</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">d </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">on your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">pay </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">stub.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:132px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;font-weight:bold;">Severance:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">You </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">be ent</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">tled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">severance </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">benefit</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">accordance with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the atta</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">ched </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Severance </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Plan for U</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#919393;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">E</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">xecutive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Vice </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Presidents effective </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">January 1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#7e8089;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">2014 (the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">EVP </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Severance </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Plan</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#7e8089;">"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">), a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">nd </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">should refer to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the do</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ument </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">for details regarding </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">terms, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">conditions, el</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6e8ea7;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">gibility </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">and potenti</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">al </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">tax </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">implicati</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ns</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#919393;">.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:132px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">If the</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">re </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">a CEO </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Event (defined below) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">any </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">time within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">two </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">(2) years after </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">start date with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">iogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">h</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">you shall be entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">receive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">severance benefits under the EVP Sev</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">er</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">ance Pl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">n and accelerated vest</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">ng of your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">unvested Long </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Term </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Ince</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">tive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Awards under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">2008 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Plan </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">if </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">a Corporate Change </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">in Cont</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">ro</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">l </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Involuntary </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Employment Action </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">occurred under both </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">EVP Severance Plan and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">2008 Plan</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">A </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">CEO Employment Event</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">" </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">shall </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">mean </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">involuntary </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">termination </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">of your employment, other </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">than for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Cause</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">ermination </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">of your employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">with Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">upon </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">occurrence of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the following</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">new </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Chief </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">Exec</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">utive Offi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">cer </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">(CEO) of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Company </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">appointed and as a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">res</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">ult there is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">either (1) a material and substantial </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">hange </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">the financial </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">spend </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">com</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">mitted to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#446475;">h</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Resear</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">ch </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">&amp; </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">evelop</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">nt O</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">rganization </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">(2) a material alteration and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">diminution </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">in your authority, duties or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">responsibilities (othe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">than a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">mere </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">change </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">in titl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f56;">e) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">they </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">existed immediately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">prior to the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">appointment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">of the new </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">CEO</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">; </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">provided</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#67676d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">however, that </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">must </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">notify </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Chief </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#26262d;">Legal </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#383a42;">Officer or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Chief Hum</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Resources Officer of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Company in writing of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">basis for your involuntary or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">vo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">luntary t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">rminati</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">on wi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">45 days of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">occurrence of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">circumstance and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Company does </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">not </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">cure such circumstance within 30 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">days thereafter</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:173px;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">225 B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">nney Street</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">Cam</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f67a1;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#567c99;">ridge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#6e7277;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">MA 02142 Phone 781</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">464</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">2000 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4b6991;">www</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">com</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;font-weight:bold;">Tax &amp; Financial Planning </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;font-weight:bold;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;font-weight:bold;">Executive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;font-weight:bold;">Physicals:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">&#32;You are eligible </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">annual reimbursement of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">expe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">nses for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">qualified services  such as federal and state income </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">tax </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">planning and/or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">preparation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">finan</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">cia</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">l </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">and estate </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">pl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">nning </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">services</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">purchase of tax and/or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">financial planning t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">oo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Additionally, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Company will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">reimburse </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">expenses </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">an annual comprehensive physica</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#565e77;">l </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">exam when coo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">dinated by the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">Exec</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">utive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Health Services </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">team </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">at Mass. General Hospital (MGH)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">combined annual </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">re</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">imbursement you are eligible </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">to receive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">$7</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">500 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">per </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">calendar year (January 1 -</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">ecembe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">r 31</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">), subject to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">guidelines of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the Tax </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">&amp; </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Financia</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">l </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Planning </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">nd </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Executive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Physi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">al </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Reimbursement </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Program</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">The details </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">these benefits </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">avai</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">lable upon </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">your employment with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">Com</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">pa</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">y</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;font-weight:bold;">Stock Trading Plan:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">&#32;Upon </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">employment with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">Co</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">mpany</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">wi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">ll </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">become </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">subject to Biogen's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Global </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Insider Trading </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Policy, a copy of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">will be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">provided to you</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#b5bcbd;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Biogen Global Insider Trad</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">ng Poli</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">cy </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">sets </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">forth </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">guideline</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">designed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">to promote </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">compliance with applicable </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">federal </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">and state securities </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">laws that prohib</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">t </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">persons who </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">aware of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">material </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">nonpublic </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#33315b;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">nformation </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">about </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">company </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">from trading in secu</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">ities </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">company or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">providing material nonpublic </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">information </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">other </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">persons who may trade on the b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">sis </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">that </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">information</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#919191;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Upon </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">your employment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">you will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">assig</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">d, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">based on your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">j</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">a specific </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">trading group that </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">will determine your obligations and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">restrictions under t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">he </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">poli</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">y</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">and you will be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">require</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">d </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">omplete training on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the policy</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;font-weight:bold;">Share Ownership Requirement:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">&#32;A key objective </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">f </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">ng-term </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">incentive plans is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">to ensure </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">strong </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">alignment between the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">interests of our senior exe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">utive</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">those of our stockholders</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">It is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">expected </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">that through our annua</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">l </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">long-term </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">in</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">entive grant</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">accu</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">mulate and retain Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">shares </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">an amount equivalent </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">3x salary through </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the fir</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">t </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">5 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">yea</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">rs o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">f </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">mployment. </font></div><div style="line-height:120%;padding-top:2px;text-align:justify;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Yo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">u </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">are required to satisfy </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">following </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">co</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">nt</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">gen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">ies pr</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">to employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">at B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#565e77;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">ogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:120px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1f2128;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;font-weight:bold;">Pre-employment screening</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;font-weight:bold;">:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Employment at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Bi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">gen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">is contingent </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">upon </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">your successful </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">co</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">mpletion </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">pa</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">ssi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">ng of both </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">a ba</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">kground check </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">and drug screen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">'s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">background </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">h</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">eck </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">verification of employment history</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">educational </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">and professional licenses</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">degrees and/or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">red</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">ntials</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">a criminal </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">records </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">heck</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">a Social Security </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Number </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">search </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">an</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">d </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">verification of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">any other </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">professional qualifi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">ations </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">that </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">position responsibilities at Biogen m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">y warrant. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">Com</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">pl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">on of your online Appli</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">ation </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">authorizes B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">oge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">conduct </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">thes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">backgroun</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">d c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">he</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">k</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">s. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">If you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">hav</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e any </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">questions about </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the background </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">check</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">please contact your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">iogen r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">ec</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">ruit</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">er</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:120px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1f2128;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;font-weight:bold;">New Employee Forms</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;font-weight:bold;">:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Up</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">re</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">eiving </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">your signed offer </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">lette</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">new hire paperwork</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">you will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">receive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">mail containing </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">li</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">nk </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">ew </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">hire </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">form</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#919191;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Please </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">co</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">mplete </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">form </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">soo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">possible </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">upo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">n r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">ece</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">ipt. This </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">form will allow </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">u</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">o </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">begin </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">creating </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">internal resources for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">pr</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">io</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">r to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">y</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">ou</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">tart dat</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#919191;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:120px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1f2128;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;font-weight:bold;">Authorizati</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;font-weight:bold;">on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;font-weight:bold;">to Work in the United States:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">&#32;Pl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">ease </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">note </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">that Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">is an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">E-Verify </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">em</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">p</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">loyer. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">The</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">Fede</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">ral governmen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">t </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">requir</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">es you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">provide proper </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">identification ve</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">ifying </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">ligib</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">lity t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">o </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">work </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">in the United </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">States</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;font-weight:bold;">If you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;font-weight:bold;">w</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;font-weight:bold;">ill </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;font-weight:bold;">be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;font-weight:bold;">working at one of our office locations:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">&#32;Please </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">omplete Section 1 of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">enc</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">osed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">E</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">ligibilit</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">y </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">Verification For</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">m </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">1-9. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;font-weight:bold;text-decoration:underline;">On your first day of employment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">plea</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">se </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">bring with you the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">co</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">mpleted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">Form </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">1-9, your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">original </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">and unexpired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">documents and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">scanned copy of your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">doc</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">um</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">nts</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6d6e72;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">A list of a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4f4f57;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">ceptable documents can </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">found </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">the last </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">page </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313a;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">F</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d4149;">orm </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f2128;">1-9 packet.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:173px;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">225 B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">nney Street</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">Cam</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f67a1;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#567c99;">ridge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#6e7277;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">MA 02142 Phone 781</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">464</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">2000 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4b6991;">www</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">com</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:144px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;font-weight:bold;">If you are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;font-weight:bold;">a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;font-weight:bold;">field </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;font-weight:bold;">employee: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">enclosed you will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">find notary instructions </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">Form 1-9 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">packet</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">You are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">required </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">to complete </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">entire Form </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#5d6269;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">9 of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">the 1-9 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">packet within 3 days of your start at a Notary Public and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">mail your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">original as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">instructed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">in the packet.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:120px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c1c23;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;font-weight:bold;">Signed Proprietary Agreement: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">order </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">o </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">protect Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#5d6269;">'</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">s substantial </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">investment in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">creating and maintaining its conf</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">dential and proprietary </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">information</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">maintain goodwill with our customers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#5d6269;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">vendors and other business partners</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#5d6269;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">you will be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">required to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">sign our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">'Employee Proprietary Information </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">Inventions </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">Dispute </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">Resolution Agreement</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#5d6269;">' </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">as a condition of employment. A copy of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">Agreement is enclosed with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">this letter for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">reference</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#5d6269;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">Please sign and return this Agreement with your signed acceptance of our offer.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;text-indent:1px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">Mike, we are excited at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">prospect of your joining Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#878c8e;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">To confirm your acceptance of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">offer of employment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#878c8e;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">please sign and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">return thi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">letter by April 25</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">20</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">16 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">and keep </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">other copy </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">re</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">ords</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#878c8e;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">Review and complete </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">enclosed New </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">Employee </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">Checklist with actions required in order </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">begin your acceptance process</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">We would anticipate your first day of employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">be on or prior to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">May 16</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#5d6269;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">If you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">have any questions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#878c8e;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">please feel </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">free </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">to contact me</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">Best Regards,</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">/s/ Matt McSherry</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">Matt McSherry</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">Senior Director, Talent Acquisition</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">c: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">George Scangos</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">27669BR</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">I accept </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">thi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">offer of employment and ackn</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#4d5056;">ow</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">led</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#5d6269;">ge </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">contingencies of employment described above</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#878c8e;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">including the at-will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">nature </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1c1c23;">my </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">employment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">ACCEPTED:</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;text-decoration:underline;">/s/ Michael Ehlers&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michael Ehlers&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4/25/16&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f313b;">Signature&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name (Print)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Signature Date</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:173px;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">225 B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">nney Street</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">Cam</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f67a1;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#567c99;">ridge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#6e7277;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">MA 02142 Phone 781</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">464</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">2000 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4b6991;">www</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">com</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:186px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:186px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;color:#23232a;font-weight:bold;">BIOGEN CASH SIGN</font><font style="font-family:inherit;font-size:9pt;color:#42444d;font-weight:bold;">-</font><font style="font-family:Arial;font-size:9pt;color:#23232a;font-weight:bold;">ON BONUS AGREEMENT</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">I have ac</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">ce</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">pted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">position </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">employment with Biogen that provides </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">f</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">payment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">of a cash s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ign</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">-on bo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">nu</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">$300</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6b6b72;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#979799;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">00 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">me </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">following </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">comme</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">cement of employme</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">nt. I </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">understand </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">that th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">fu</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ll </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">benefi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">t o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">f thi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s cash sign-o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">bonus </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s condit</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">up</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">my remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">an emp</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">oyee of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">iogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">fo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">eas</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">24 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">month</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">s. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">I he</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">reby accep</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#797c83;">'</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">offer o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">f </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">a cash sig</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n bo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">us </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">according </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e fo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ll</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">owing </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">te</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">rms</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6b6b72;">:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:108px;text-indent:-2px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">The payment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e cash sig</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">on</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">u</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">Biogen is taxable </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">income to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">me </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">w</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ll </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">taxed at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">time of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">pay</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">I </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">acknowl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">dge </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">agree  t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">hat if</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#979799;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">4 months </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ffec</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">tive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">dat</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e of my emplo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ym</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">en</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">(start date), </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">I </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">voluntarily </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ermina</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">my</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">empl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">y</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">erminates my employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">Cause</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#797c83;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">defined </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">Bi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">In</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">c. 20</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">0</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">8 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">Omnibus </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">Equity </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">Plan</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6b6b72;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">r f</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">misconduct </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">poor performance, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">d</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">rmin</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ed i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">good </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">faith </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">Com</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">pany, I will n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ot </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">h</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ave </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">earned </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">cas</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">h </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ign</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#797c83;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">bonus provided to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">me </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">und</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">er </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">this Agreement </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">nd I </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">repay </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">suc</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">h </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">bonus accordi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ng </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">following </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">sc</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">h</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">edu</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">le</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#979799;">:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:144px;text-indent:-24px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">(i)    </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">If </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">my e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">mpl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">oy</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ent </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">term</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6b6b72;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">nat</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">es on or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">fo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">re </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">2 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">months </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">my </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">tart </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">date, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">full </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e cas</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">h </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">sig</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">bonus</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">net </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">of t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">he </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ppl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ica</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">le </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">proportion </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">of ta</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">x </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">withholdings</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#797c83;">;</font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:144px;text-indent:-24px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">(ii)   </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">If </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">my </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">emp</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">lo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">y</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">me</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">er</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">minat</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">es a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">fter </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">12 mon</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">an</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">d </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">or before </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">24 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">months </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">from m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">y </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">start </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#979799;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">5</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">0% </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">amount </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">f th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e cash </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">sign-on bonus</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">app</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">icab</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">le </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">proportion </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">tax withholdings; or </font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">I </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">shall pay to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">Biog</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">en a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ll </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">u</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ch </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">repayable amounts within thirty </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">(3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">0) days </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">effective </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">d</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">te </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">my </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">employme</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">nt </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">termination </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">end of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e year </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">w</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">h</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ich </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">my</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">emp</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">loym</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">en </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">rmin</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">tes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">whichever </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">comes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">fi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6b6b72;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t. I </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">voluntarily authorize Biogen to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">de</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">du</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#797c83;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">w</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#797c83;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">hold and/or retain </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ll </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">any portion </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e amo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">unt </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">I may </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">req</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">uired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">fun</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">d </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">ep</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">ay to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">Bioge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n hereund</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">from any wages, salary, vacation pay</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#797c83;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">severance pay </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">the</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">pay which may </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6b6b72;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">due </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">nd </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">owing </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">upon </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ter</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">nat</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#6b6b72;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">of emp</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">oyme</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">t, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">tent permitted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">unde</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">applicab</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">le l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">aw. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">I </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">shall </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">remai</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">liable to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">Biogen f</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">any </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">amo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">unt</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s in</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">excess </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">su</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">so deducted</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#979799;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">withhe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">d and/o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">retained by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ioge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#979799;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">Except </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">above</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">I </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">shall </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">h</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ave </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">no </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ia</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">lity </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">re</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">sponsib</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ility  </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">to refund </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">r repay t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">Biogen any </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">amo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">u</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">me </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">in con</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ec</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">ti</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">with this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">sign-on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">nu</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">s.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">Nothing in this Agreement sh</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;font-weight:bold;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">ll alter the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;font-weight:bold;">at-will employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">relationship between Biogen and m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;font-weight:bold;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;font-weight:bold;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">.g</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;font-weight:bold;">., </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;font-weight:bold;">and I can </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;font-weight:bold;">end </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;font-weight:bold;">employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">relationship at any time with or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;font-weight:bold;">without </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">cause)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;font-weight:bold;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">Therefore</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;font-weight:bold;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">I under</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;font-weight:bold;">sta</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">nd that nothing in this Agreement guarantees that the Company will employ me for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;font-weight:bold;">any </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;font-weight:bold;">specific period of time.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">My </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">sig</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">natur</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">belo</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#595b62;">w ac</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">kn</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">owledges </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t I hav</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">e read and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">und</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">ersta</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">nd this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">Agreement </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">agree </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">o </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#34343d;">be bound by its </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#23232a;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#42444d;">erms.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;text-decoration:underline;">/s/ Michael Ehlers&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michael Ehlers&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4/25/16&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Employee Signature&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Employee Name (Please Print)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:173px;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">225 B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">nney Street</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">Cam</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f67a1;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#567c99;">ridge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#6e7277;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">MA 02142 Phone 781</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">464</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">2000 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4b6991;">www</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">com</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:100%;padding-top:4px;text-align:left;padding-left:108px;"><img src="biogenlogostandarda06.jpg" alt="biogenlogostandarda06.jpg" style="height:57px;width:173px;"></div><div style="line-height:120%;text-align:left;padding-left:22px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">April 25</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">016</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Mike Ehlers</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">[address]</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">[address]</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Dear Mike</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#8e8e9a;">:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">s lette</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">hereby confirms </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Biogen's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">agre</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">that in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">vent </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">it is determined that Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">a company </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">that i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ompetit</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">on with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Pfiz</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">and as a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">es</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">ult the Pfizer </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Compensation Committee</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">pursuant to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">its </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">rights </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">under the Executiv</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Long-Term </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">In</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">entive </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Program Po</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">nts </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">I</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">nterest </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">(Part 6, Section 36)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">terminates </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">all or a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">portion </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">outstanding and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">vested TSRUs, PPSs </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">and RSUs </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">that hav</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">not </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">yet been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">paid or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">settled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">in Pfizer </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">common </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">stock (the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#7090a1;">"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Terminated Awards</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">and/or requires </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">to return to Pfizer all </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">a portion </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">of any shares</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">cash </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">paid to or gain </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">realized by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">respe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">t to the grant </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">TSRUs</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">PPSs </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">or RSUs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">one </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">year period </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">descr</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">bed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">in Part </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Section </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">36, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Company will pay </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">the value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">the Term</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">nated Awards </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">and re</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">mb</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">u</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">rse you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">value </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">shares or cash </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">are required </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">return and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">have returned </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Pfizer</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ogen and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">acknowledge </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">that the value </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">reimb</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">u</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">rsement </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">obl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">gation is expected </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">be no </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">more than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">$1,80</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">0</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">,000 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">some consideration </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">for rea</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ona</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">market fluctuations The foregoing obligation </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Biogen is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">conditioned </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">upon </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">your (1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">pr</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">mptly </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">nforming </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">the EVP</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">HR </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">VP, Peopl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Rewards </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">of any </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">ontact or noti</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">ce </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">rece</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">iv</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e from</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">&#32;Pfizer regarding </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">its rights under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Part </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">6, Section 36 (2) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">fir</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">t questioning Pfiz</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">er </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">on </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">ppl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">icability </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Part 6</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Section 36</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">including requesting Pfizer </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">to provide </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">written </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">expla</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">how the provision has been breached</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">, a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">nd </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">(3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">not agreeing or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">conceding with Pfizer </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">as to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">applicability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Part </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Section </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">36 to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">'</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">s employment of you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">without prior </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">consultation with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">wr</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">tten approval </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Biogen,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">which approval </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">will </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">not </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">be unreasonably delayed or withh</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">d</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#9e9ea0;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">F</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">urther </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">agreement is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">not intended to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">and does </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">not </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">imply that Biogen agrees </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">or believ</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">es </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">ha</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">t </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Part </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">6</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#8e8e9a;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Se</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">tion 36 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">enforceable or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">reasonable or that Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">a c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">mpany or em</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">p</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">loyer in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ompetition with Pfiz</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">r for any purpose</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">The foregoing </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">does not affect the at-will statu</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">of your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">employment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">; </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">provided, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">that, if </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">your emp</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">oyment is terminated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">result </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">of your death or Di</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">ability</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">or by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">without Cause or following </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">CEO </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Employment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Event, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">sh</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">ll </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ontinue </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">to owe </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">you </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">any </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">amounts </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">due under this letter</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Any such paym</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">nts shall be m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">de </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">Bio</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">gen promptly </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">after </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">any </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Pfizer awards become </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Termina</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ed Awards and/o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">any shares or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">as</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">h </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">are returned t</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">o </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Pfizer by you</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">If</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">after consultat</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">on with Biogen, it </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">g</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">eed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">that </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">you should d</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">spute a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">determination </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">by Pfi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">z</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">er as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">to the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">appli</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Part </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">6</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Section 3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">6,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">io</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">g</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">n shall </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">pay </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">for or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">imburse </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">you for reasonable </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">attorneys' </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">fees </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">and other </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">reasonabl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">legal </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">costs </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">urr</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">d </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">to d</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">spute such determination</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Notwithstanding anything </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">the immediately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">pre</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ed</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ng </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">sent</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">nce </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">to the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">contrary, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Biog</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">'</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">s </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">obligations </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">to bear the fees </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">costs of disputing th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">det</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">rmination </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">depend upon</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#9e9ea0;">: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">(a) your providing written notice </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">to Biogen </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">within 30 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">days </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">of P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#233b4f;">f</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">ze</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">r </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">inf</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">m</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">g you of an ad</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">v</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">erse </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">determination </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">pursuant </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">to Part </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">6</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">Section 36</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#757980;">; </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">b) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">'</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">s ri</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">g</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ht </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">s</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">ec</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">t and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">reta</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">approp</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">r</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">iate </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ounsel</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">following </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">consultatio</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">n </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">with </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">you</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">; </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">(c) Biogen retain</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">ng </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">right to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">contro</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">l </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">th</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">e </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">defense/prose</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">c</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">ution  </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">of any </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">legal </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">action and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">approve any comprom</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">is</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">settlement or resolution of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">determin</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2a2a31;">ti</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#575960;">; a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#3d3f48;">nd (d) such </font><font style="font-family:Arial;font-size:9pt;color:#3d3f48;">reasonabl</font><font style="font-family:Arial;font-size:9pt;color:#575960;">e </font><font style="font-family:Arial;font-size:9pt;color:#3d3f48;">cooperation </font><font style="font-family:Arial;font-size:9pt;color:#2a2a31;">by </font><font style="font-family:Arial;font-size:9pt;color:#3d3f48;">you in </font><font style="font-family:Arial;font-size:9pt;color:#575960;">a</font><font style="font-family:Arial;font-size:9pt;color:#2a2a31;">ny leg</font><font style="font-family:Arial;font-size:9pt;color:#575960;">a</font><font style="font-family:Arial;font-size:9pt;color:#2a2a31;">l </font><font style="font-family:Arial;font-size:9pt;color:#3d3f48;">proceedings </font><font style="font-family:Arial;font-size:9pt;color:#2a2a31;">to dispute the determination.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:173px;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">225 B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">nney Street</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">Cam</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f67a1;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#567c99;">ridge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#6e7277;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">MA 02142 Phone 781</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">464</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">2000 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4b6991;">www</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">com</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">Pl</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#545b6d;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">ase acknow</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f1f26;">l</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">edge your </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#545b6d;">a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">greement </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f2f36;">to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">the foregoi</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f1f26;">n</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">g </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f2f36;">by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">sign</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f1f26;">in</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">g and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f2f36;">dating </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">below</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#747775;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">Bes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f1f26;">t </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">Regards</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#545b6d;">,</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f1f26;">K</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#545b6d;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f2f36;">n D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#545b6d;">I</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f2f36;">Pietro</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">EVP</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#545b6d;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f1f26;">Hum</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;">an Resource</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#545b6d;">s</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f1f26;font-weight:bold;">Acknowledged </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2f2f36;font-weight:bold;">and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f1f26;font-weight:bold;">Agre</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;font-weight:bold;">e</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#1f1f26;font-weight:bold;">d</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;font-weight:bold;">:</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#41444b;font-weight:bold;text-decoration:underline;">/s/ Michael Ehlers&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;text-decoration:underline;">Michael Ehlers&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4/25/16&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:108px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Signature&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name (Print)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Signature Date</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:173px;font-size:7pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">225 B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">i</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">nney Street</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">Cam</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2f67a1;">b</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#567c99;">ridge</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#6e7277;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">MA 02142 Phone 781</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">464</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">-</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">2000 </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4b6991;">www</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#7285a3;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#4d565b;">.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#3b5b80;">co</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>8
<FILENAME>biib-20171231xex21.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9317C71F09555043AB4250F264ACC5DE"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 21</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a list of subsidiaries of Biogen Inc. as of December 31, 2017, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SUBSIDIARY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Foundation Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen MA Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Realty Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Realty Limited Partnership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Limited Partnership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (RTP) Realty LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Chesapeake LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding I LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding II LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Manufacturing Holding LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen New Ventures Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen SRO Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Therapeutics Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Pacific LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. West Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conforma Therapeutics Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stromedix, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Argentina) SRL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Argentina</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Australia PTY Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Austria GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Austria</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Belgium N.V./S.A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International Holding Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bermuda</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Brasil Produtos Farmaceuticos LTDA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Brazil</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Canada Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Chile Spa</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chile</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Pharmaceutical Consultancy (Shanghai) Co., Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">China</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Biotechnology (Shanghai) Co., Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">China</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Czech Republic) s.r.o.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Czech Republic</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) A/S</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) Manufacturing ApS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding APS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) New Manufacturing ApS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Finland OY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen France S.A.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec (Hong Kong) Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hong Kong</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Hungary KFT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hungary</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Biotech India Pvt. Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">India</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec (Ireland) Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Italia SRL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Japan Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Korea</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Korea</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Luxembourg Holding SARL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Mexico S. DE R.L. DE C.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mexico</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen NZ Biopharma Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">New Zealand</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Norway AS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Norway</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Poland Sp. z.o.o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Poland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Portugal Sociedade Farmaceutica, Unipessoal, Lda.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Singapore) Pte Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Slovakia s.r.o.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Slovak Republic</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Pharma, farmacevtska in biotehnoloska druzba d.o.o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Slovenia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Spain, S.L.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fundacion Biogen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Sweden AB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sweden</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International Neuroscience GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Management Services GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Swiss Investments GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Swiss Manufacturing GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Switzerland AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Switzerland Holdings GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eidetica Biopharma GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Taiwan Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taiwan</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen B.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Netherlands</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Netherlands B.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Netherlands</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Research Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Convergence Pharmaceuticals Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Convergence Pharmaceuticals Holdings Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Old Convergence Pharmaceuticals Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Panion Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Silver Acquisition Co. Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Uruguay SA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Uruguay</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>9
<FILENAME>biib-20171231xex23.htm
<DESCRIPTION>EXHIBIT 23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sC902CC5FCE0356C282CD0E7AE5B6D89B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 23</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-206799) and Registration Statements on Form S-8 (Nos. 333-218799, 333-205254, 333-110432, 333-110433, 333-128339, 333-152456, 333-140817 and 333-170133) of Biogen Inc. of our report dated February 1, 2018 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10&#8209;K.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ PricewaterhouseCoopers LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston, Massachusetts</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February 1, 2018</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>biib-20171231xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7973DC53C85B5CD69052865D35C1B91F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Michel Vounatsos, certify that:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this annual report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">c) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:76%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: February&#160;1, 2018</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>biib-20171231xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7A9A918A03A8525080307B7CAE7ABACB"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Jeffrey Capello, certify that:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this annual report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">d) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:68%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: February&#160;1, 2018</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;Jeffrey Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Finance</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer (principal financial officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>biib-20171231xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCB15FE0BEC505EDC90982DE843343246"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Annual Report on Form 10-K for the year ended December&#160;31, 2017 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: February&#160;1, 2018</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos &#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: February 1, 2018</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Jeffrey Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey Capello</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Finance and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>13
<FILENAME>biib-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:1C4B045CA69257BEA6880541CE344C10,x:3f753fefb5484538b7d2c39d93d504ce-->
<xbrli:xbrl xmlns:biib="http://www.biogenidec.com/20171231" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="biib-20171231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredTaxAssetDomain">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DeferredTaxAssetDomain</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-01</xbrli:startDate>
			<xbrli:endDate>2015-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_RemedyPharmaceuticalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:RemedyPharmaceuticalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_BIIB074Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BIIB074Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2017RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringPlanAxis_biib_A2017RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_FacilityLocationAxis_biib_CambridgeMAMember_us-gaap_RestructuringPlanAxis_biib_A2016RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeMAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2016RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2016RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2016RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringPlanAxis_biib_A2017RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_FacilityLocationAxis_biib_CambridgeMAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeMAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2017RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember_us-gaap_PublicUtilitiesInventoryAxis_biib_FinishedGoodsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:FinishedGoodsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:WorkinprocessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2008-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2010Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-10-01</xbrli:startDate>
			<xbrli:endDate>2010-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_FacilityLocationAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_FacilityLocationAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2006Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2006-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-12-01</xbrli:startDate>
			<xbrli:endDate>2008-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_biib_UndesignatedPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:UndesignatedPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_biib_SeriesXPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:SeriesXPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A1995ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A1995ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A1995ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_DirectorsPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:DirectorsPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember_us-gaap_TitleOfIndividualAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_PlanNameAxis_biib_AttainmentOfPerformanceCriteriain2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:AttainmentOfPerformanceCriteriain2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_ForeignearningstypeAxis_biib_OtherForeignEarningsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:OtherForeignEarningsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_biib_PrepaidtaxesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:PrepaidtaxesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_ForeignearningstypeAxis_biib_ForeignearningsintheformofcashandcashequivalentsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:ForeignearningsintheformofcashandcashequivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SixteenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SixteenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q4_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_FifteenbillionMemberMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:FifteenbillionMemberMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:LeadprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-07-01</xbrli:startDate>
			<xbrli:endDate>2013-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-01</xbrli:startDate>
			<xbrli:endDate>2012-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_OCREVUSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_NewAntiCd20Member_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_DiscoveryprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DiscoveryprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_OCREVUSMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_IPerianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_OCREVUSMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_TypeOfArrangementAxis_biib_IPerianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_NewAntiCd20Member_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_OCREVUSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q3_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q1QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_OCREVUSMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_FutureContingentMilestoneTypesAxis_biib_CommercialMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:CommercialMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_ThreeBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:ThreeBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-04-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_biib_CumulativeSalesLevelAxis_biib_ThirteenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:ThirteenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_OneBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:OneBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_biib_CumulativeSalesLevelAxis_biib_TwelvebillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:TwelvebillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_biib_CumulativeSalesLevelAxis_biib_FourteenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:FourteenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_biib_CumulativeSalesLevelAxis_biib_FourteenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:FourteenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_ElevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:ElevenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2006Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2006-01-01</xbrli:startDate>
			<xbrli:endDate>2006-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementGeographicalAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeMAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeMAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeMAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1SD_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_KaryopharmMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:KaryopharmMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Plan">
		<xbrli:measure>biib:Plan</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Increment">
		<xbrli:measure>biib:Increment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="chf">
		<xbrli:measure>iso4217:CHF</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="EUR">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="KRW">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit>
	<biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch contextRef="FI2017Q4" decimals="-5" id="Fact-9E2A9B2FA4C283D8D0972977947240ED" unitRef="usd">40000000</biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch>
	<biib:AdditionalMilestonePayment contextRef="FI2012Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-4A32465CE62BE90FEC83343597BA7251" unitRef="usd">10000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_DiscoveryprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-7C73C318DA2B86DCBFE42977944C0E28" unitRef="usd">592500000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-221DDC521478950E8F592977944C0447" unitRef="usd">467500000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-C6C94D109199B9A0577E2977944E72FA" unitRef="usd">25000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-8" id="Fact-BF7DA740FBEA9BA651E3297794597EA6" unitRef="usd">1100000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" decimals="-5" id="Fact-79E7A75499FF020D24DE3406AFD6EE03" unitRef="usd">410000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-3B26AC5D800A3096AD8A340D16E1D8B5" unitRef="usd">625000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_IPerianMember" decimals="-5" id="Fact-9D1C9C089043BD0D27173407AB0167F3" unitRef="usd">490000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalPotentialPaymentstoNoncontrollingInterest contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-9CABF640947930C9BBC33348900D18E7" unitRef="usd">50000000</biib:AdditionalPotentialPaymentstoNoncontrollingInterest>
	<biib:Additionalmilestonepaymentsforproductcandidateusingadifferentmodality contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-5D7B0EEA443A040252EF3418284AD4BB" unitRef="usd">90000000</biib:Additionalmilestonepaymentsforproductcandidateusingadifferentmodality>
	<biib:Additionalreductioninroyaltyratepayableoncommercialsales contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="INF" id="Fact-1F669693529A3E9FA30C3348E61E872E" unitRef="number">0.05</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q4YTD" decimals="-5" id="Fact-3375402D20950637B76829779436F4B9" unitRef="usd">32300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-0DBEB5629351FAB58FCF29779435F65D" unitRef="usd">16300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-576393F87FBBD0A81B5A29779435F48B" unitRef="usd">1300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-D7F602C6E477A3AFC97429779435CA61" unitRef="usd">14700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q4YTD" decimals="-5" id="Fact-90C7376A33A0C5B1E9312977945C40A5" unitRef="usd">16700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-6AACF3055A75A3B621512977945CB732" unitRef="usd">-1500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-A209DFA2839B18A8ADCC2977945C052A" unitRef="usd">1400000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-E483E7944C3B7303771E2977945B9AE7" unitRef="usd">16800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3FB5C3038343CF995C80297794719DEB" unitRef="usd">-6000000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-B1A4C4E7358DE4098F202977947053B7" unitRef="usd">-15000000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-94D73A72670F085D106129779469E669" unitRef="usd">100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-0D4FD47F339428F1A83529779470F6AD" unitRef="usd">8900000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-D1CECFC42D137C5F7A852977944A7830" unitRef="usd">277500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2017Q4" decimals="-5" id="Fact-E5CEE9638B3229E991D329779448DAB6" unitRef="usd">327000000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-3792A8CB8F262A32CFE02977944969CD" unitRef="usd">276800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-2AB868F530958EE4D5ED297794480139" unitRef="usd">327300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2016Q4YTD" id="Fact-3012E1B9021EF765790D297794693602">P12M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2017Q4YTD" id="Fact-8B15BB19DD57ABC9AE2B297794693D63">P17M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageStockPriceOnGrantDateInDollarsMaximum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-DCD6F0E2A73811D9324729779432A3E7" unitRef="usd">426.27</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
	<biib:AverageStockPriceOnGrantDateInDollarsMaximum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-47DF9F06EC240583192B2977942CB669" unitRef="usd">304.86</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
	<biib:AverageStockPriceOnGrantDateInDollarsMaximum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-D2AF46546DC99E9A58E3297794336A6A" unitRef="usd">267.88</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
	<biib:AverageStockPriceOnGrantDateInDollarsMinimum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-7605BE10A68FDD333358297794341562" unitRef="usd">227.35</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
	<biib:AverageStockPriceOnGrantDateInDollarsMinimum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-F835166664710BDB9C2C2977942CC42F" unitRef="usd">260.67</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
	<biib:AverageStockPriceOnGrantDateInDollarsMinimum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-91249C4F56AECDA2FD3B2977942C15E6" unitRef="usd">263.18</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="2" id="Fact-9153AE64D79C77B9A5B4340EF1D7DEE4" unitRef="number">0.20</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="2" id="Fact-1BD7632D62793E98F7FD340DDD9A21C0" unitRef="number">0.55</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="3" id="Fact-2E61E9C32782063D43FD340E912C766F" unitRef="number">0.685</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="INF" id="Fact-738558808BC7773C933733C37DD943BD" unitRef="number">0.5</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-0BB9A6DDA9E2BD86CB822977946A7A1B" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
	<biib:CollaborationExpensesinDispute contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-6" id="Fact-1EC8FFD696CBB07A34ED4285F646E1BB" unitRef="usd">120000000</biib:CollaborationExpensesinDispute>
	<biib:CollaborationProfitSharing contextRef="FD2015Q4YTD" decimals="-5" id="Fact-15572A4908434E28B348297794653D5D" unitRef="usd">0</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6C2AF98F8DF9EA05F31029779472D29F" unitRef="usd">10200000</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-7EF4D9463CD32AD6AD5E343A010FBFCC" unitRef="usd">4900000</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-A6F4AE3CC179F12C625633E8BC509BEF" unitRef="usd">15100000</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2017Q4YTD" decimals="-5" id="Fact-FE4EB47E9FA31455F69B297794664A01" unitRef="usd">112300000</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-ECF688F2DBD3592A353929779473D02E" unitRef="usd">1300000</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-FD1284E1D0B279F038B8297794723EE5" unitRef="usd">111000000</biib:CollaborationProfitSharing>
	<biib:Collaborationexpensesaccrual contextRef="FI2016Q4" decimals="-5" id="Fact-23FE27A3184D6CBDC3B42977944D0F9D" unitRef="usd">130900000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationexpensesaccrual contextRef="FI2017Q4" decimals="-5" id="Fact-A2FB8993F84FAF2554EB2977944FCC5F" unitRef="usd">183700000</biib:Collaborationexpensesaccrual>
	<biib:CompensationExpenseOverPurchasePeriod contextRef="FD2017Q4YTD" id="Fact-76CB569D5DBF765E1F5F2977943238FF">The fair value of the look-back provision plus the 15% discount</biib:CompensationExpenseOverPurchasePeriod>
	<biib:ComputerSoftwareAndHardware contextRef="FI2016Q4" decimals="-5" id="Fact-6C4958E211681BBCE642297794504DAD" unitRef="usd">746800000</biib:ComputerSoftwareAndHardware>
	<biib:ComputerSoftwareAndHardware contextRef="FI2017Q4" decimals="-5" id="Fact-8E86E2C04E35ABD46F65297794687436" unitRef="usd">767100000</biib:ComputerSoftwareAndHardware>
	<biib:Copromotionprofitsandlosses contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-E8B6D5A47992047A260233C291BE0A0A" unitRef="usd">43900000</biib:Copromotionprofitsandlosses>
	<biib:Copromotionprofitsandlosses contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-88D385CA53520898E36D2977946B4B96" unitRef="usd">39500000</biib:Copromotionprofitsandlosses>
	<biib:CumulativeSalesLevel contextRef="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_ElevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-B244DF119DA8EC69293629779471F1F8" unitRef="usd">11000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2017Q1_biib_CumulativeSalesLevelAxis_biib_TwelvebillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-CFA321F77169F0E608C029779472739A" unitRef="usd">12000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2017Q2_biib_CumulativeSalesLevelAxis_biib_ThirteenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-0BB094028241B79059142977945CDF44" unitRef="usd">13000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2017Q3_biib_CumulativeSalesLevelAxis_biib_FourteenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-76D2574B8F75FE21B20529779450ECC1" unitRef="usd">14000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-3636945FC8BEBC2F51372977944D2992" unitRef="usd">20000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_FifteenbillionMemberMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-F92C96929E678216A24B3320AF753F02" unitRef="usd">15000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_OneBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-F63C6EF0712C35BB2D39297794463BEC" unitRef="usd">1000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-23AC12B240CB053706742977945E2D88" unitRef="usd">16000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_ThreeBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-77B63E7CE4E26CF52D3029779449B920" unitRef="usd">3000000000</biib:CumulativeSalesLevel>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6729C35BB769CA8C61FC29779473032C" unitRef="usd">2229400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-3B5E5D7584D0D893465829779434D710" unitRef="usd">1732100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-1767D1CD201AA29BC57A29779434792D" unitRef="usd">459700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-453AB2AE138948B9B7082977945A5AC3" unitRef="usd">37600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q4YTD" decimals="-5" id="Fact-139A1C8C648BE32DEBF929779449C378" unitRef="usd">2668000000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-15DCE5BEBB0C2FDB188E2977944BD6F3" unitRef="usd">2044500000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-C9DA11AE50BC50200AD02977945CECE2" unitRef="usd">592600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-788ECBFA4EE3205A21BE2977945CAA19" unitRef="usd">30900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q4YTD" decimals="-5" id="Fact-13EEB9F55F7DC70D49EB2977946A4FA2" unitRef="usd">2917300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-7F1E3F69E663D7458531297794717775" unitRef="usd">2307400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-5FDC5BC6A67AA7C4120529779470A85C" unitRef="usd">583000000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-8F9EE17F3B0FC2E0901329779471B3DF" unitRef="usd">26900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage contextRef="FD2017Q4YTD" decimals="INF" id="Fact-0DF7BCCBAAC6F96DA9C029779450C2F5" unitRef="number">1.01</biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage>
	<biib:DeferredTaxLiabilitiesDepreciationAmortizationOther contextRef="FI2016Q4" decimals="-5" id="Fact-F11B40BC976A4180F4F0297794715B13" unitRef="usd">113500000</biib:DeferredTaxLiabilitiesDepreciationAmortizationOther>
	<biib:DeferredTaxLiabilitiesDepreciationAmortizationOther contextRef="FI2017Q4" decimals="-5" id="Fact-6F5345ABECE039B063622977946A0EBB" unitRef="usd">107900000</biib:DeferredTaxLiabilitiesDepreciationAmortizationOther>
	<biib:DevelopmentalMilestonePayment contextRef="FI2017Q2_us-gaap_TypeOfArrangementAxis_biib_IPerianMember" decimals="-5" id="Fact-20A598BC5212F21F7A693406FC0C07F4" unitRef="usd">60000000</biib:DevelopmentalMilestonePayment>
	<biib:DiscountRateRecognizedInCompensationExpense contextRef="FD2016Q4YTD" decimals="2" id="Fact-5D7E25CAAF7113B9E462297794333122" unitRef="number">0.15</biib:DiscountRateRecognizedInCompensationExpense>
	<biib:DueFromUnconsolidatedJointBusiness contextRef="FI2016Q4" decimals="-5" id="Fact-7473882F6707B333553D29779469976E" unitRef="usd">300600000</biib:DueFromUnconsolidatedJointBusiness>
	<biib:DueFromUnconsolidatedJointBusiness contextRef="FI2017Q4" decimals="-5" id="Fact-0E7B2E0AEC68344FE39429779467F13A" unitRef="usd">532600000</biib:DueFromUnconsolidatedJointBusiness>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2015Q4YTD" decimals="3" id="Fact-BDB882C1F103898A138F29779438A9F9" unitRef="number">-0.018</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2016Q4YTD" decimals="3" id="Fact-D8E3C9CDBFE2AC3A984729779438AAC7" unitRef="number">-0.019</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2017Q4YTD" decimals="3" id="Fact-529014B4E171112C6E502977943362CE" unitRef="number">-0.019</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="0" id="Fact-449636B9E4324DAB10832977945A1661" unitRef="shares">32000</biib:EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards>
	<biib:EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="0" id="Fact-BF4E7555922EBF1B9B31297794594004" unitRef="shares">11000</biib:EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2015Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="2" id="Fact-F0F6658DCA841102AB1429779437DCBF" unitRef="number">0.34</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2015Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="2" id="Fact-F549F3C54629CF81C4E82977943D5208" unitRef="number">0.26</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2016Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="2" id="Fact-190E48B84FEBC76B84802977947DE1A2" unitRef="number">0.35</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2016Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="2" id="Fact-FA8E927E9BE68008AFD429779437FEB5" unitRef="number">0.22</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="2" id="Fact-3CD15A62419D0E7B0ECD297794386B39" unitRef="number">0.34</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="2" id="Fact-03A36208E4AA35E79BFB2977947DE893" unitRef="number">0.21</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EquityMethodInvestmentOwnershipPercentageMaximum contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-1244177A92A6963C89BB2977944B34E2" unitRef="number">0.499</biib:EquityMethodInvestmentOwnershipPercentageMaximum>
	<biib:EquityMethodInvestmentsExpectedProfitShare contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-3E56C57B4FE0949E9EB12977946A6C87" unitRef="number">0.5</biib:EquityMethodInvestmentsExpectedProfitShare>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-1325D78C80370CEAFAC2341304DDE25C" unitRef="usd">260000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="I2018Q1SD_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_KaryopharmMember" decimals="-5" id="Fact-8A3B7040D9ED5EF29DE633996B49D7B3" unitRef="usd">207000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedUsefulLivesOfLeaseholdImprovements contextRef="FD2017Q4YTD" id="Fact-718809A53067B8AF95A42977945DFFAF">Lesser of the useful life or the term of the respective lease</biib:EstimatedUsefulLivesOfLeaseholdImprovements>
	<biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-77BAC615A0FD554689CC3438D922C627" unitRef="usd">15000000</biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold>
	<biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-00457669CA0121423CBC3415E1B3A690" unitRef="usd">800000000</biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold>
	<biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-239438A4472951EBCB3134190219B285" unitRef="usd">130000000</biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-8B820F49F710477743462977942D3E40" unitRef="usd">113800000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-56C280B27D499128957A340A5AA10B1A" unitRef="usd">84100000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-4C780A90588E706B910729779458DB71" unitRef="usd">48600000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-27F7ECF9122CBB99561A340A5AB12832" unitRef="usd">95100000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-FFF1431BD87DF0BAF7C62977945BCC7E" unitRef="usd">39900000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-6D4CED65FCE17A5DC7C1340A5A82842D" unitRef="usd">146200000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-414C82D49E988F3AFB03297794335792" unitRef="usd">74900000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-7346AB62CAF01C6E1A372977943D2A02" unitRef="usd">60800000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-48E41C25BFBA5A1749CA2977945A3FD6" unitRef="usd">30600000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-161E3437D63A3E69C6A3340B528EC11E" unitRef="usd">40400000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-A364F16E12BF20C8555233BDFE576C77" unitRef="usd">22000000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-82ADB00F6BF79FFC22562977943D3518" unitRef="usd">257800000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-A41490122EAA016E84632977943A1140" unitRef="usd">24300000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-4468D3B3353D9CA07ABE29779437F9EA" unitRef="usd">31500000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-A4025DD36439CEFDCC15340B52AEC1AC" unitRef="usd">50500000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-1060AF98CFB8A931300B2977944DA64D" unitRef="usd">234500000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-9451214379323D7919A82977942CA18E" unitRef="usd">19900000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-D511910E8EBAB12C34CD29779472EE07" unitRef="usd">34000000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-23547ADD281BF4418EE1340B529E736E" unitRef="usd">74300000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ForeignSalesRequiredToTriggerMilestone contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-9ED6EDDE646012FB5BE333C01D1C1C57" unitRef="usd">100000000</biib:ForeignSalesRequiredToTriggerMilestone>
	<biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="2" id="Fact-E7D61FD2D7ABBA9429862977944B4F48" unitRef="number">0.25</biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion>
	<biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="2" id="Fact-F77F6C6BCE45D3B394E329779448CE45" unitRef="number">0.18</biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion>
	<biib:FutureContingentPaymentThreshold contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="-8" id="Fact-E2D196F705E7F0C4F74F2977944B9734" unitRef="usd">2000000000</biib:FutureContingentPaymentThreshold>
	<biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_OCREVUSMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-A4283FBA0AB307429520297794398202" unitRef="number">0.24</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
	<biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_OCREVUSMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-205F7FEC77F50C364CDD2977945AAB9C" unitRef="number">0.135</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
	<biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_OCREVUSMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember" decimals="2" id="Fact-7973D6B814F6043991602977947317C7" unitRef="number">0.03</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
	<biib:Futurepercentageofcopromotionoperatingprofits contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_NewAntiCd20Member_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-2B58A0B4B4E86D5805BF297794493F40" unitRef="number">0.375</biib:Futurepercentageofcopromotionoperatingprofits>
	<biib:Futurepercentageofcopromotionoperatingprofits contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_NewAntiCd20Member_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-6423104EB987B94436482977945BBD56" unitRef="number">0.30</biib:Futurepercentageofcopromotionoperatingprofits>
	<biib:Futureresearchanddevelopmentcommitment contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-8" id="Fact-13AC2E52C8C74B73DC1933ED68FA3007" unitRef="usd">0</biib:Futureresearchanddevelopmentcommitment>
	<biib:IncreasedCarryingAmountOfSeniorNotes contextRef="D2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-8B3F334C23AD4D3E4D3D328F74474C10" unitRef="usd">62800000</biib:IncreasedCarryingAmountOfSeniorNotes>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2017Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact-2251CA245A7D489CCB39297794594764">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2017Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" id="Fact-F49C6B278EF099C4FA84297794591EA0">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:InterestInSubsidiary contextRef="FD2017Q4YTD" decimals="2" id="Fact-E3E151A71700DE2F916D29779435CBE7" unitRef="number">1.00</biib:InterestInSubsidiary>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-2C7E9497CF6378D973682977946AA746" unitRef="usd">1039400000</biib:Inventorynetcurrentandnoncurrent>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-ED4FEF91F344410039E92977946A5762" unitRef="usd">925500000</biib:Inventorynetcurrentandnoncurrent>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2016Q4" decimals="-5" id="Fact-6670E8A4B8CDD25CA7DC29779475DE99" unitRef="usd">47400000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2017Q4" decimals="-5" id="Fact-E8A1347385E03E4ECB4E29779475B01D" unitRef="usd">48300000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-A633C8E4B5E0A5F1E5362977945DF32A" unitRef="KRW">280500000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
	<biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-FA8619A599860D533E0B297794339F75" unitRef="usd">250000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
	<biib:JointVentureOwnerShipPercentageByThirdParty contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-C2B9668BCD0E5A2C68CE2977943DABB2" unitRef="number">0.85</biib:JointVentureOwnerShipPercentageByThirdParty>
	<biib:LicenseFee contextRef="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-1275ECDDD547A742485333806C687996" unitRef="usd">75000000</biib:LicenseFee>
	<biib:LicenseFee contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-8C060123E307374DC51F342866CD293B" unitRef="usd">70000000</biib:LicenseFee>
	<biib:LossContingencyAdjustmentRelatedToClaimAmountPercent contextRef="FI2013Q2" decimals="INF" id="Fact-CBA7E2BB7A8B10CC833A334466F3CF73" unitRef="number">0.5</biib:LossContingencyAdjustmentRelatedToClaimAmountPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-201114605D234BE1D571297794677782" unitRef="number">1.50</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="2" id="Fact-646B24EA95465D050C5729779459FF72" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-39DD9408AFE05ACEB6DF297794505160" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="2" id="Fact-5C4F15328AD30B18E84D29779469764E" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MilestonePaymentsMadeDuringPeriod contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-5E3DE4B62DC62399DE1B2EEA724B9B7D" unitRef="usd">6700000</biib:MilestonePaymentsMadeDuringPeriod>
	<biib:MinimumQualifyingAgeForEmployeeBenefitPlan contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember" id="Fact-A72A4440CD65FB61F832297794767CF8">P21Y</biib:MinimumQualifyingAgeForEmployeeBenefitPlan>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-FDDAAF6F344F6CF9255B2977945A00BB" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="2" id="Fact-D54329A9BA6B9716628929779459140D" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-B6F894A4685EA59D49C22977945C5013" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="2" id="Fact-4B12E87B9E6697F4FA17297794451EC0" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:NetMinimumLeasePayments contextRef="FI2017Q4" decimals="-5" id="Fact-D3181F6C65C2505284D22977943D79BC" unitRef="usd">428500000</biib:NetMinimumLeasePayments>
	<biib:NetMinimumLeasePaymentsThereafter contextRef="FI2017Q4" decimals="-5" id="Fact-C68A7956D586ECA6ED872977945E25C9" unitRef="usd">199800000</biib:NetMinimumLeasePaymentsThereafter>
	<biib:NetMinimumLeasePaymentsWithInFiveYear contextRef="FI2017Q4" decimals="-5" id="Fact-729FD290F3CBE2AF620E2977945DCEB7" unitRef="usd">43700000</biib:NetMinimumLeasePaymentsWithInFiveYear>
	<biib:NetMinimumLeasePaymentsWithInFourYear contextRef="FI2017Q4" decimals="-5" id="Fact-95A89700C41DE9FA583C2977943EA63A" unitRef="usd">44600000</biib:NetMinimumLeasePaymentsWithInFourYear>
	<biib:NetMinimumLeasePaymentsWithInOneYear contextRef="FI2017Q4" decimals="-5" id="Fact-B47B55651604A764A6ED2977943FCB7C" unitRef="usd">48300000</biib:NetMinimumLeasePaymentsWithInOneYear>
	<biib:NetMinimumLeasePaymentsWithInThreeYear contextRef="FI2017Q4" decimals="-5" id="Fact-95E28FF8A7916507644C2977945EAD48" unitRef="usd">44500000</biib:NetMinimumLeasePaymentsWithInThreeYear>
	<biib:NetMinimumLeasePaymentsWithInTwoYear contextRef="FI2017Q4" decimals="-5" id="Fact-379CD8FDD08D0492FAB72977944ED9AB" unitRef="usd">47600000</biib:NetMinimumLeasePaymentsWithInTwoYear>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D9C10F2D93DBD5928BDD2977943AEF16" unitRef="usd">1500000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-F43F24A94DB16DB982D1297794726B62" unitRef="usd">1500000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-F041B5C41831C89D40E02977943425DD" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4E058F8AD8386C3B485E29779458EF8A" unitRef="usd">15800000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-96AC7BF41613535AF86729779470B36E" unitRef="usd">15800000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-32FA27616A00998AB8EE29779468F439" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" id="Fact-A317E1E2F53289FD7916297794472617">P60D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" id="Fact-77C7999E8ADD2F51F7152977945AECB6">P60D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" id="Fact-222D56274FDC0C6D7F9E2977945ADD12">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" id="Fact-C4CC60E68F2FE47CA86D297794350DA8">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" id="Fact-800AC10F9AA29B32AD5C297794676220">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-80E5B8B1ABF8D5358FB42977945912F3" unitRef="Increment">4</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-E14244BD9869436E4F8029779466D448" unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-7DBFF2D2F8CFDF3066B92977943560CB" unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-C85568161BB7B2D2997729779468DA02" unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade contextRef="FD2017Q4YTD" decimals="INF" id="Fact-D67119BFBD11773AB968297794489EEA" unitRef="Plan">3</biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade>
	<biib:NumberOfSharesOfCommonStockForIssuance contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_DirectorsPlanMember" decimals="-5" id="Fact-1418525BE8EF5072CA992977945980D6" unitRef="shares">1600000</biib:NumberOfSharesOfCommonStockForIssuance>
	<biib:ParValueOfNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-CAD0FC104BC505A5FA2A2977943D0AE1" unitRef="usd">6000000</biib:ParValueOfNotesPayable>
	<biib:ParValueOfNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-831E263BD10A97FE429F2977945253DE" unitRef="chf">6200000</biib:ParValueOfNotesPayable>
	<biib:ParValueOfNotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-6798DD3FACB413420235297794520EC4" unitRef="chf">3100000</biib:ParValueOfNotesPayable>
	<biib:ParValueOfNotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-2BC388201FAD185F57D329779452947F" unitRef="usd">3200000</biib:ParValueOfNotesPayable>
	<biib:PaymentTermsOfAccountsReceivable contextRef="FD2017Q4YTD" id="Fact-8E81A9814CFE4751A09C29779467D767">30 to 90 days</biib:PaymentTermsOfAccountsReceivable>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q4YTD" decimals="-5" id="Fact-321D55AE2B219FCAE30A2977945E6195" unitRef="usd">1666600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-140EEAE00988B904064229779436BB97" unitRef="usd">1258100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-9FBBF0093133DC3CF28B29779434B45D" unitRef="usd">405900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-6B864F2E28377A4A2EFF2977945BC8A9" unitRef="usd">2600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4E0F919DC908D4DB79DB2977945C51D4" unitRef="usd">2099500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-82E13C53832B4EBC48152977944C1D5E" unitRef="usd">1576000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-F71464C4E0BCDDC4F90A2977944C0536" unitRef="usd">522500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-C381D375366358C9D6182977944BD746" unitRef="usd">1000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q4YTD" decimals="-5" id="Fact-CE86466425175E776C66297794714B52" unitRef="usd">2232800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-1C48D47BF26F303AD5F42977946AF157" unitRef="usd">1756900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-F7EDDF2806102A58CBB029779470DD8F" unitRef="usd">475800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-0551E065A5CFE6C9F4B62977946BEBE7" unitRef="usd">100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2EEBED512BDF38F6AC5729779434B43A" unitRef="usd">351600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-09227D37AD041844DD632977945A5E6D" unitRef="usd">296100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-D5D54B50C856F8953FE129779472F025" unitRef="usd">44000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-6D0A1D7A7A82CA503A7329779434D7BE" unitRef="usd">11500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9455BCBF18C846B488AD2977944A106E" unitRef="usd">609000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-6C0336A078528CEC138F2977945CBED1" unitRef="usd">536000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-6997E52B415EF629D5E52977944DA584" unitRef="usd">53200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-086722449B980B2379022977944AF43B" unitRef="usd">19800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q4YTD" decimals="-5" id="Fact-10FE28A3FE323EEA4DC429779470C831" unitRef="usd">534400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-987301D4BBB6F95DAB8229779471ED6E" unitRef="usd">442200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-1199D43D6C188B9650772977947106E9" unitRef="usd">69100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-4CD5CE6E13571B62FF4629779470F5C0" unitRef="usd">23100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="2" id="Fact-AB8235A67C1A52F6726C2977943C546E" unitRef="number">0.35</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-88029BCA78BEE48C08042977943867FF" unitRef="number">0.30</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-8BFFB149DFA7A19D83492977944C71EB" unitRef="number">0.40</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-90397DF0776CA325F8F3297794490837" unitRef="number">0.400</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-6B9D018AACBE4F5B219B2977944EEEC9" unitRef="number">0.39</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="3" id="Fact-621266F8C0646D9D26AD2977944597F9" unitRef="number">0.390</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-621AB73BBF0BA20138062977944C1183" unitRef="number">0.390</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="3" id="Fact-D467426A9BECB6E6BE6A297794467516" unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-F0787D6C44E36EC80E7F2977944A1E17" unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="3" id="Fact-EA23DE1C7200FD81A5BE297794498E77" unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-F05EB0A40C698D45F68E2977944CF855" unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
	<biib:PercentageOfMarketValuePerShareOfCommonStock contextRef="FD2016Q4YTD" decimals="2" id="Fact-B55ED74EF723AF4E6513297794331E53" unitRef="usdPerShare">0.85</biib:PercentageOfMarketValuePerShareOfCommonStock>
	<biib:PercentageOfMinimumInvestmentReturn contextRef="FD2015Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="4" id="Fact-DE9983C9A8DBABCCAF042977946ACCE8" unitRef="number">0.0175</biib:PercentageOfMinimumInvestmentReturn>
	<biib:PercentageOfMinimumInvestmentReturn contextRef="FD2016Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="4" id="Fact-EBD5F369746E14041754297794762BC8" unitRef="number">0.0125</biib:PercentageOfMinimumInvestmentReturn>
	<biib:PercentageOfMinimumInvestmentReturn contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="4" id="Fact-3896965F1BC859DFE23B2977947CE97A" unitRef="number">0.0100</biib:PercentageOfMinimumInvestmentReturn>
	<biib:PercentageOfRoyaltiesAsPerCollaboration contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="INF" id="Fact-3DEB0B591C0E4B5F262933E2FC188F62" unitRef="number">0.15</biib:PercentageOfRoyaltiesAsPerCollaboration>
	<biib:PercentageOfRoyaltiesAsPerCollaboration contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="INF" id="Fact-7825A7623BB1BAE7663733E2A0F247BA" unitRef="number">0.11</biib:PercentageOfRoyaltiesAsPerCollaboration>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-620418426E3F59760FD6328CFEEA3F02" unitRef="number">0.99294</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-80B1F528DA2E36D9F1E13290D0C5B2CE" unitRef="number">0.99764</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-61AA06542C751EE27BFB32913A2C52AD" unitRef="number">0.9992</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-513342B72A2B0822E449328D638D95AE" unitRef="number">0.99792</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="I2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="5" id="Fact-B2B6BC5C86ACB3D675F632929755DFAF" unitRef="number">0.99184</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2016Q4_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="3" id="Fact-06F4BAA2342EBF393F1E297794743624" unitRef="number">0.372</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2016Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="3" id="Fact-4163EDFB2F02C54DF3722977943D93B5" unitRef="number">0.192</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2017Q4_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="3" id="Fact-95780D783D94FCE9E0A32977943F8F98" unitRef="number">0.265</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2017Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="3" id="Fact-6A6AA6B0CCA9B43D38E0297794357266" unitRef="number">0.190</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageoffuturedevelopmentcostsrelatedtoEisai contextRef="D2018Q2_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="INF" id="Fact-DEB60CA7220B21EB664134103A804CE4" unitRef="number">0.15</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
	<biib:PercentageoffuturedevelopmentcostsrelatedtoEisai contextRef="D2019Q1_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="INF" id="Fact-39229425B26122BBDA53340FA2CA944F" unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
	<biib:PeriodOfCollaborationAgreement contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_OCREVUSMember" id="Fact-F7E823EFB6BA75C38FB229779437B5A6">P11Y</biib:PeriodOfCollaborationAgreement>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1BB8F07D29A4A1B89BC52977945EFEBC" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-10B50A4A7D79369E4D352977943DB8B9" unitRef="usd">34500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DA18A29C1F9870E92AD02977945AABD3" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7CFB995F39FA9DB56E57297794758394" unitRef="usd">34500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-ECE0C6EA04C5F20B6EC72977945E447C" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E14975AE65E58511BB5F2977945DB56B" unitRef="usd">28500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-ABC1D1ABD7AF9A59B6622977945D5349" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B999E5DB59A9A849373D2977945DB5FE" unitRef="usd">28500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2017Q4" decimals="-8" id="Fact-8A93AEE220973DC17C6D2977944D6DB8" unitRef="usd">4200000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2017Q4_biib_FutureContingentMilestoneTypesAxis_biib_CommercialMilestonesMember" decimals="-8" id="Fact-CD1CFD1668DABFEBF99A29779449A34E" unitRef="usd">2000000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2017Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember" decimals="-8" id="Fact-932BD7CFEDBE17C583D529779452EA36" unitRef="usd">700000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2017Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember" decimals="-8" id="Fact-4796C395EB726BA1836B2977944BD52B" unitRef="usd">1500000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" decimals="-5" id="Fact-C0E3701F90AEBC78B6B233F956A1DD6F" unitRef="usd">150000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-8" id="Fact-0C5285D514624C27B27633BB01722BC5" unitRef="usd">2000000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-B8D74331040F99997A142977947DE71E" unitRef="usd">450000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_BIIB074Member" decimals="-5" id="Fact-D11D940A5F0E8F4B17C62977947D839B" unitRef="usd">350000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PurchasePriceOfCommonStockUnderEspp contextRef="FD2017Q4YTD" id="Fact-238659F5515427471FB929779466F3E3">85% of the lower of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date</biib:PurchasePriceOfCommonStockUnderEspp>
	<biib:Purchaseofcommonstock contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-F58839D133824264436233C60E4D949C" unitRef="usd">30000000</biib:Purchaseofcommonstock>
	<biib:RatioOfNumberOfSharesReservedUnderPlan contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember" id="Fact-A292F73C18752CC1992132C48C5A62FA">1.5-to-1</biib:RatioOfNumberOfSharesReservedUnderPlan>
	<biib:RatioOfNumberOfSharesReservedUnderPlan contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_DirectorsPlanMember" id="Fact-49EF502398EA033A678929779433D0AF">1.5-to-1</biib:RatioOfNumberOfSharesReservedUnderPlan>
	<biib:Reductioninroyaltyrate contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_OCREVUSMember" decimals="INF" id="Fact-AD44B485121CCF7D7F5C29779473C368" unitRef="number">0.5</biib:Reductioninroyaltyrate>
	<biib:Reductioninroyaltyratepayableoncommercialsales contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="INF" id="Fact-A5F8B3408A9C1C9855F033483553DDBC" unitRef="number">0.15</biib:Reductioninroyaltyratepayableoncommercialsales>
	<biib:ReimbursementLimitStatedInResolution contextRef="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT" id="Fact-70ACF12136C5CA1B8384333AA35CAE9B">P24M</biib:ReimbursementLimitStatedInResolution>
	<biib:RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement contextRef="FD2017Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-DE1E36E495510A4B9FD43345E73E4CFE" unitRef="usd">275000000</biib:RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement>
	<biib:ResourcesRedirectedthroughRestructuringProgram contextRef="FD2017Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2017RestructuringChargesMember" decimals="-5" id="Fact-0300E09698A2D11BA8E12EC77F5BD2D1" unitRef="usd">400000000</biib:ResourcesRedirectedthroughRestructuringProgram>
	<biib:RestructuringandRelatedCostExpectedCashPayments contextRef="FI2015Q4_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-9396EE636CF5036A21E82EABD2705035" unitRef="usd">120000000</biib:RestructuringandRelatedCostExpectedCashPayments>
	<biib:Restructuringandrelatedcostexpectedpercentageofpositionseliminated contextRef="FD2015Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="2" id="Fact-FCAAEB2275EF5C4370B92EAC9191E4DF" unitRef="number">0.11</biib:Restructuringandrelatedcostexpectedpercentageofpositionseliminated>
	<biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms contextRef="FD2015Q4YTD" decimals="2" id="Fact-3B51ECB62DF9F7F98C1529779438F645" unitRef="number">0.12</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
	<biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms contextRef="FD2016Q4YTD" decimals="2" id="Fact-B21FA3FF054992AF3550297794385C15" unitRef="number">0.11</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
	<biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms contextRef="FD2017Q4YTD" decimals="2" id="Fact-1D9C485F1B25EC80DE712977943A8887" unitRef="number">0.13</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD" decimals="-5" id="Fact-0C5CC197E4C29C55F1E8297794698C6D" unitRef="usd">1339200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-C3CCAB531FD482AD7A682977944856C6" unitRef="usd">65900000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-C590A561F2830D764E032977943EE833" unitRef="usd">1269800000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-C27030078A8D257551362977947CBA28" unitRef="usd">0</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-01D6174068DD80213199297794539F9D" unitRef="usd">3500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-41DA39C1C8314FB12A6829779445C87B" unitRef="usd">1339200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q1QTD" decimals="-5" id="Fact-CEFA2EB3A01D2771CC5D2977942C2F8F" unitRef="usd">329500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q2QTD" decimals="-5" id="Fact-EBE571F5B2F56AF41EBA29779469FB50" unitRef="usd">349200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q3QTD" decimals="-5" id="Fact-C3DA8522637474E939432977947D29DE" unitRef="usd">317600000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4QTD" decimals="-5" id="Fact-C2A8A2C0F0BBCCC4E969297794506FEF" unitRef="usd">318200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C7D7CC8CAC1544F5E0D229779475B57F" unitRef="usd">1314500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-6E3C10FB2BFCA93205342977947C999E" unitRef="usd">63100000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-887686EAF074011CA2A92977947D71E1" unitRef="usd">1249500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-9594EB2BAB6F014FFCAC297794768771" unitRef="usd">0</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-52C50EEF9B80BEE262D72977944AB446" unitRef="usd">1900000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-953EB045E78B333FCEE629779445AEFA" unitRef="usd">1314500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q1QTD" decimals="-5" id="Fact-1D4BBD646A33EAFFEC542977943E8BCE" unitRef="usd">340600000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q2QTD" decimals="-5" id="Fact-B67901813E1DBF32902629779444DFCF" unitRef="usd">397100000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q3QTD" decimals="-5" id="Fact-6ADCB135109842426A572977943F79B9" unitRef="usd">406500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q4QTD" decimals="-5" id="Fact-888B3728AFB641536B012977944CFD76" unitRef="usd">415000000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q4YTD" decimals="-5" id="Fact-007806857C43B7F7B9212977946676C7" unitRef="usd">1559200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-6370F799390DA1A60F4C297794483B94" unitRef="usd">83000000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-0C9DC9EB11EA7B42C1EC2977947617BC" unitRef="usd">1475600000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-827FFE0DE1C144F923E22977943EFE0C" unitRef="usd">0</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-B37622EF3541878DB247297794508643" unitRef="usd">600000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-01DDAAECED292D0AF4CB29779446E34E" unitRef="usd">1559200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage contextRef="FI2017Q4_us-gaap_ProductOrServiceAxis_biib_OCREVUSMember" decimals="-5" id="Fact-8D50C88D0E4E6BD939EC33AD6CF4F2F5" unitRef="usd">900000000</biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage>
	<biib:SalesTriggerGrossSalesThreshold contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-BC85A85C6A894BBF2ECC29779472CB41" unitRef="usd">500000000</biib:SalesTriggerGrossSalesThreshold>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7D64A055EFFAF662B6D8297794339A14" unitRef="usd">196300000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0266F2C2F723D6925AEE2977943EA135" unitRef="usd">189800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2017Q4YTD" decimals="-5" id="Fact-99DE7FB7E3204CB916032977943A2063" unitRef="usd">160100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareOfCoPromotionProfits contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-BA8D0C8C3AB37D98EABD297794457ABE" unitRef="usd">1269800000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-6C7F7A0DD02EE8E0035533C29398A644" unitRef="usd">21900000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-8802EFB9FA50CD03BC7329779446916A" unitRef="usd">1249500000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-5CF11C2D66DCBAF0EABB297794335DEF" unitRef="usd">16900000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-08B0A87124D96551D2FB2977944627ED" unitRef="usd">1316400000</biib:ShareOfCoPromotionProfits>
	<biib:StrategicInvestmentPortfolio contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-EC7151E1628646170C8329779467F848" unitRef="usd">99900000</biib:StrategicInvestmentPortfolio>
	<biib:StrategicInvestmentPortfolio contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-9081E1EAE06D98C60A8529779467B9E9" unitRef="usd">85800000</biib:StrategicInvestmentPortfolio>
	<biib:TermOfLease contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" id="Fact-6F8F089E71A0F58F8E42297794487082">P3Y</biib:TermOfLease>
	<biib:TermofBioverativManufacturingandSupplyAgreement contextRef="FD2017Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" id="Fact-BDE18072891961AAC5F92EA137860162">P5Y</biib:TermofBioverativManufacturingandSupplyAgreement>
	<biib:TermofBioverativTransactionServicesAgreement contextRef="FD2017Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" id="Fact-3A77DD4620054E8F3D6E2EA0032ECB72">P12M</biib:TermofBioverativTransactionServicesAgreement>
	<biib:Termofcollaborationagreement contextRef="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" id="Fact-08B8A774B2C387A2576F33C8387FA93E">P6Y</biib:Termofcollaborationagreement>
	<biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-2A99AE0726FA7BFEAFEA2977947010B9" unitRef="usd">150000000</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
	<biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-42C1C1A1ECDA1C438DAA2977945A6E3A" unitRef="usd">150000000</biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne>
	<biib:Totaldeferredchargesandprepaidtaxes contextRef="FI2016Q4" decimals="-5" id="Fact-6E470FBAFE1F421C0AEA2977945CB0D4" unitRef="usd">989800000</biib:Totaldeferredchargesandprepaidtaxes>
	<biib:Totaldeferredchargesandprepaidtaxes contextRef="FI2017Q4" decimals="-5" id="Fact-FA8294E0D220A2418C61297794721BB9" unitRef="usd">617700000</biib:Totaldeferredchargesandprepaidtaxes>
	<biib:TransitionTollTaxRepatriationTaxRate contextRef="FI2017Q4_biib_ForeignearningstypeAxis_biib_ForeignearningsintheformofcashandcashequivalentsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="INF" id="Fact-52DC0AB4D4F84ED58E8842795D4CB082" unitRef="number">0.155</biib:TransitionTollTaxRepatriationTaxRate>
	<biib:TransitionTollTaxRepatriationTaxRate contextRef="FI2017Q4_biib_ForeignearningstypeAxis_biib_OtherForeignEarningsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="INF" id="Fact-80993D05A38167314D47427A8E36B2EC" unitRef="number">0.08</biib:TransitionTollTaxRepatriationTaxRate>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2012Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-780D06EFD3B50D51DF27343492B9D3FB" unitRef="usd">30000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2013Q3_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-0C60FACD897E3834AB7833C701C72720" unitRef="usd">100000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-D67B41FB21E519662A0533EFB242D8DD" unitRef="usd">124000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" decimals="-5" id="Fact-1023485AB36368362EBE33F58732F050" unitRef="usd">28000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-3EBD37C48E09E5D782DC3389F925FB6C" unitRef="usd">25000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="I2018Q1SD_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_KaryopharmMember" decimals="-5" id="Fact-C72D537ABC730639F3D933976FE52FC4" unitRef="usd">10000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards contextRef="FD2017Q4YTD" id="Fact-5FC6846088BA4466BD7129779469879B">P1Y11M</biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards>
	<dei:AmendmentFlag contextRef="FD2017Q4YTD" id="Fact-F53A6C0F6FE191EA06EB2977944CD0EE">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q4YTD" id="Fact-32ADBC70D272B40AE6A329779449A89C">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q4YTD" id="Fact-4A6B46376702FF0BC27C29779472FA36">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q4YTD" id="Fact-FA91D553CD45002052992977944B9575">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q4YTD" id="Fact-B0239F64B306C9E48DD8297794741832">2017-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q4YTD" id="Fact-DC8EB3951F035C773A6C29779471EAFE">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q4YTD" id="Fact-400DB5109F26FA2533BC2977947233D6">0000875045</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q4SharesOutstanding" decimals="0" id="Fact-F7A5FA067021C1C48A2C2977945958BF" unitRef="shares">211562686</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2017Q4YTD" id="Fact-5A920094E716C6FCB4772977947C4177">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2017Q4YTD" id="Fact-762094E5C856B1C86C5E2977944AFAF5">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2017Q2" decimals="0" id="Fact-2993875908CD72C7FFA92977947613E0" unitRef="usd">57220188450</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2017Q4YTD" id="Fact-C0192D1509E9388C2E6A29779473060E">BIOGEN INC.</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2017Q4YTD" id="Fact-8DB093E959BDB89CF63B2977944C2783">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2017Q4YTD" id="Fact-ABA3A0754E1CB11ACB3829779474F961">Yes</dei:EntityWellKnownSeasonedIssuer>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-8" id="Fact-C1266AF54C8323ECE90E297794661560" unitRef="usd">1100000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-8AF85D06BEA8CA87688E3274FCFCD929" unitRef="usd">675000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-66EBC56D69FD6B4C854A297794521717" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-7B44DE223019AC84EE6A29779452A0C5" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-EFFBBACF2E3F7DF47A6529779453DA0A" unitRef="usd">871700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-B67565C4B8F77D05184E2F0EB97D07E9" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-DD73D8A88D94581D167329779453495E" unitRef="usd">871700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-AA572CD3BC35D86AC0AD2977944DB1A7" unitRef="usd">902100000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-12EC0569BE886E88E35E29779453FE6D" unitRef="usd">83500000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-13E7C07339D2C3AF57F129779452301A" unitRef="usd">88700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-C600D96387B35282448729779453453F" unitRef="usd">1875600000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-9F630EAB7A581C45FF842F0E8A09B5C7" unitRef="usd">150900000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-EE32AED6E4C8BBDFA52729779453739D" unitRef="usd">2198700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-23511342D670135060F9297794521AB9" unitRef="usd">564900000</invest:DerivativeNotionalAmount>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-61780BF606265F8EEA9729779467657C" unitRef="usd">279800000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-FDEA952DC425D95CA8D12977945AF1E2" unitRef="usd">395500000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-5CFF6412901C4286E7B429779467E321" unitRef="usd">1441600000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-2CFEE55A238E8914E767297794666D79" unitRef="usd">1787000000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-9D4AEB74495437D2D7032977945B9B72" unitRef="usd">195800000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-91E3C8EC7464175E07882977946A3BB6" unitRef="usd">206700000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-5" id="Fact-A8C4B42EAA6A967F2812297794651DFD" unitRef="usd">1439300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-5" id="Fact-6F617244DA26D6B2505D297794663E05" unitRef="usd">1559100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4" decimals="-5" id="Fact-1BB1E481F239C72E70E02977945E95AD" unitRef="usd">-59500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-68652282F822AB0EFDA32977945EBA1F" unitRef="usd">-31600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-5A13C72832A6C820E8352977945E4F37" unitRef="usd">71700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-D3856E3CBF29E180845D2977945E5DA3" unitRef="usd">-400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-A0EC63A87F7D1E849FD42977945E3FDB" unitRef="usd">-99200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4" decimals="-5" id="Fact-FC716750F9F8FC24DE632977945EAD38" unitRef="usd">-224000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-A6178C2037A6A2270D5A2977945E9896" unitRef="usd">-37800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-AC1CF0C0EBA3A3C74E172977945EC6A1" unitRef="usd">10200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-CB92F5C2E7E3C774FDE92977945EED71" unitRef="usd">-800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-09B62736A6692F9E14EF2977945EC55B" unitRef="usd">-195600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4" decimals="-5" id="Fact-5D0D819E9FD25C9741EE29779467F4E1" unitRef="usd">-319900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-ABA3DC34B671F8C1D1102977945AB801" unitRef="usd">-32700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-54EC9ACC06F960F927AF2977945B842F" unitRef="usd">57800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-6783DE7D661681F664932977945BAAA4" unitRef="usd">-10800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-CFED6EB3ECBA5A8DF2762977945A7E00" unitRef="usd">-334200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4" decimals="-5" id="Fact-D52AC4F4C31F262F280F2977945B2A70" unitRef="usd">-318400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-5791B890B66DB518B5DF2977947DAEC0" unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-3813259BF00983C8C9FC29779459B9C6" unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-CC269E9C48172176228E2977944BF652" unitRef="usd">-1600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-8CA0B7090FB66000524E297794726C0F" unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-5" id="Fact-8B79160C4D64268D783829779468980A" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q4" decimals="-5" id="Fact-E8E4B0957CB4EF01527E29779459855D" unitRef="usd">97800000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-39D04677BFA9BF82B65629779476C2B0" unitRef="usd">69000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-D0A76B57FF0ACDA24432297794762D56" unitRef="usd">69000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-65FD3D518A17A86DFD6E2977943888FB" unitRef="usd">600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-174EF28032E1DE605E3E29779472A8F7" unitRef="usd">-600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdvertisingExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D5A0AFEE17FDEBE2B4AD2977943586EF" unitRef="usd">108600000</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-DF13FC0BE87D7820DE822977943DF053" unitRef="usd">106300000</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A40852230119B939A2B329779435AB2B" unitRef="usd">75200000</us-gaap:AdvertisingExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-17E5DCDB68E8CA182FD5297794750510" unitRef="usd">183200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-4AB8C9E044A0AF3AE1AD29779438ECFE" unitRef="usd">140500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-2F425D889D09703D81882977942C8804" unitRef="usd">88600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-3686E271676EDD66B88929779435E1E3" unitRef="usd">-8600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-5977EF3DC51C97987FF82977943A1C80" unitRef="usd">127300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-DC5A2179CC336AF10A722977945D1949" unitRef="usd">22400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-D89F696C39FE96EB918E2977945E3687" unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-3D4540EFC4EECAC9C0692977945E6424" unitRef="usd">38100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember" decimals="-5" id="Fact-E903FFFEF32C4E0871C4297794645CBF" unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-DF5598EF82A384DDE8F92977945D7844" unitRef="usd">119000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-73F1AB9FC11465BFC0EB297794768A83" unitRef="usd">183200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0A00360551829D9C7F4D29779469B7ED" unitRef="usd">169400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-FE51B91AB3CBF9B0256E2977943326F2" unitRef="usd">135800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-5730234CAD7C87F486CC2977943E5B51" unitRef="usd">84500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-83FE7488514559A56A742977943BEF4A" unitRef="usd">-1800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-56C757AE8E3B818D674A2977943A4FB7" unitRef="usd">121700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-B4214A65875050CB478B2977945E881E" unitRef="usd">16300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-70BEF11E7F1770520736297794659725" unitRef="usd">11100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-EC0C9417703EBAF8DD6F2977945E04FA" unitRef="usd">38400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember" decimals="-5" id="Fact-18EBBCB4E62DD94EA54B29779464806C" unitRef="usd">18600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-ADA44CFA415A804862172977945D67D7" unitRef="usd">120000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-9450AC202227A959F45129779437B9ED" unitRef="usd">169400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-EB7EBBF7C5C09C328E9629779472478A" unitRef="usd">138100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-D09E7B13E82916BC1CD2297794388C74" unitRef="usd">117300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-E389B131BD485C88B9662977945B4982" unitRef="usd">74000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-E9E59076FC397C09A3C92977942D5520" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-374990D828B947A5540929779437D2D3" unitRef="usd">95700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-C5240301A78F8D4F77B92977945D7C86" unitRef="usd">18400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-468AA54DA6A229720C68297794644409" unitRef="usd">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-8FBC9F89F09F01971A3F2977945E6B43" unitRef="usd">22400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember" decimals="-5" id="Fact-67065B2532000AF4B0032977945D7489" unitRef="usd">12300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-A46D329A7A618996382829779464FFDC" unitRef="usd">107300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-8C1A6EDE0E52BB6BDAD3297794385D22" unitRef="usd">138100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-1B0F3F38ADDC741250002977943DF823" unitRef="usd">207300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9633F97531A870BAEE8E2977943965B7" unitRef="usd">204400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D0DAE5E6D2396199D76B2977943EE31D" unitRef="usd">169700000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C317521FD7DF06E9A3B829779471C1D0" unitRef="usd">382600000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0541EF8AF6CE3DB9F4702977946A4223" unitRef="usd">385600000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q1QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-0AB627D60941A8E8102633F7A8ABA275" unitRef="usd">353600000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-DA263B15CE7661B4417233F7A8B9DF53" unitRef="usd">29400000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-BC1140869972F2984B8433F7A8B03FE3" unitRef="usd">30400000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q4QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-38072C3FBE3BA76855DE33F7A8C4BC57" unitRef="usd">30800000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4E9BE354828FE5120EB0297794759665" unitRef="usd">814700000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-5F2C04CF7A7B066790B82ED37C2E376E" unitRef="usd">444200000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AssetImpairmentCharges contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-AEF7F81DFB1AC54CB6A0343C16B67EB7" unitRef="usd">190800000</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-5" id="Fact-7EFB88FA94DE17F64952297794673D74" unitRef="usd">22876800000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-5" id="Fact-951F8A4825AFB42DDB0C29779465DF33" unitRef="usd">23652600000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-D95E00892584AA0A5923297794677055" unitRef="usd">8732200000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-7D065765B78D9376C344297794659AA7" unitRef="usd">7873300000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F35B1F3E97A39C377D782977947694B3" unitRef="usd">24900000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7E96ECAE60B59C2DEC4C2977947648EA" unitRef="usd">7533100000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2DA62973C30E87F17E1D29779473DE86" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2C587317E535F775F4D92977945D9F31" unitRef="usd">7558000000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8DD734CFED74790017512977945E0DEE" unitRef="usd">11800000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E412283DB82F5114EF532977945DA9C7" unitRef="usd">6433100000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9E2C7D4B4178920BB1B929779475D0C9" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7376CF03B74E42336BAF2977945EEA81" unitRef="usd">6444900000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-26A539B9543CC89C94442E9ABCED83A8" unitRef="usd">1008300000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4" decimals="-5" id="Fact-2194359BB70DCAA755D7297794494895" unitRef="usd">5406300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4" decimals="-5" id="Fact-82214B8222E8B504AA1A2977944B8FE4" unitRef="usd">5173000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4" decimals="-5" id="Fact-44DEC49574B6748C96832977944B12E1" unitRef="usd">5398000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-62EEEEEF7B8DB26FC0E729779446FFCE" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F1A9417281E7B34254C429779473B4E7" unitRef="usd">561700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-29E99B0F2B7D695E3FA22977945E0947" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-23265EBC767A9790F8E82977947550EE" unitRef="usd">561700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-044D1014CEE6595F351D2977945EA299" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A43F2393609DF4AC2FDF2977945DD4A8" unitRef="usd">2663800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7018DCC6CF5EF986272129779473BAFF" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-395637C356AB875DF57B2977947502F3" unitRef="usd">2663800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6B710395C406C2D812DF297794749BDB" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D417B30AE7649E379D222977945D3C32" unitRef="usd">2172500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-355C579EEA9BDC3268E12977947698A7" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9019DFD93A0E21CEB957297794593114" unitRef="usd">2172500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-A882AAF79578BB41BF87297794660F3C" unitRef="usd">1408600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-9D30B36498101ADD8E20297794723404" unitRef="usd">1255200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-FDCA2F2A1431DF41B06C2977945BB519" unitRef="usd">1156000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-4B11D05834B147A4A0F229779446130C" unitRef="usd">1016500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-BFE4144A7733AE4357B52977945A15A6" unitRef="usd">4000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-8CCC9015ECA67945DDAE2977944BEC89" unitRef="usd">557700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-60EFAA04AB89C84C6F3A297794706ABF" unitRef="usd">24900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4" decimals="-5" id="Fact-97872AA7495F98E5C670297794748A5D" unitRef="usd">5172500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4402CB9F9BF23910AF98297794758D1B" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2233ACB9B9E75EE4CF1A2977947318C0" unitRef="usd">643400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C6311FD32D3FE3A861AC29779473BB87" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3832A0AF417876C95C2B2977945EB50F" unitRef="usd">643400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A71FAF052A6B57D906B92977945D5351" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-61AAD49722A502D364CF29779474B46B" unitRef="usd">2609800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BBE50C20DE8E471F6D872977945D9A85" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1A570FEC7B915461994E29779474DEAF" unitRef="usd">2609800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3F6730491D12B320347B2977945DAEE2" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7816B30C3A5D7269F8212977945E8594" unitRef="usd">1919300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-29A97B6ABB4FD09275D72977945EE265" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7F453556AA8549C384A02977945D2F7A" unitRef="usd">1919300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-18CCCBFF9FF8986821192977945D1584" unitRef="usd">1039300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-BC2061E208A8948BA3F12977945A5EDB" unitRef="usd">1570500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-74533D09776CFEE11A0D2977945C5300" unitRef="usd">1075100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-0B7099000015E4FAEB2E2977945BDFEF" unitRef="usd">844200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-66A9191A80B5D96379972977945A02F7" unitRef="usd">800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-7F2F8450501AE694763029779459CDEA" unitRef="usd">642600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-A2099814AE317923CD8229779459D4BB" unitRef="usd">11800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4" decimals="-5" id="Fact-6D962F7DD6938018E3752977947DCECC" unitRef="usd">2900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-94EA8B321781A2499C2A2977947047F6" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-8C625D7F03F041B6DB8329779471F677" unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-CF3E2ADF92D5DADE68C02977946B5623" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-EDBFD782AC41D80CEECF297794717667" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-5D811B9D236CFB217BDB2977945BF826" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-F2BF6F56C226741083E42977947CCE54" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-A343FEA08D0F038182DD2977947213A3" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4" decimals="-5" id="Fact-363887662F092A1D7C322977945AEAC2" unitRef="usd">2300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-449F4ECAF6D6ACC0CB032977945C7204" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-ED267EB49FF5E9B082212977945B20F7" unitRef="usd">900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-103B336B39C7C2924B032977945B30D7" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-20E0CD7EA8BF9607580C2977945AD769" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-A2A23791FEB8CA37A8532977945A6415" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-27EE006AFC439DE329422977945A7899" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-63A2444082706EE5140829779459D75D" unitRef="usd">1800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4" decimals="-5" id="Fact-334E213C8669F48D06F9297794723397" unitRef="usd">11200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-6BF6A9291E4400A2B59329779472171A" unitRef="usd">600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-7187E99946C5BEF8E373297794720AE6" unitRef="usd">4700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-E25D12490244DEC9683829779471C8AF" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-770FE5E79AD73DBAEB4F2977947C7159" unitRef="usd">3400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-D8328AE7083F45ED3E402977945ADD59" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-5B56A6F81203F1696658297794759EF7" unitRef="usd">2200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-E19A499F4E66B51273422977947CA834" unitRef="usd">9300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4" decimals="-5" id="Fact-3A7E0CF9DEDECB9C796A29779459F7D7" unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-5C3486BA4FCBCD7200F42977945BEBB6" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-03E1FAADAFD72A036131297794737E62" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-6EE615CAB6596D7B83772977945A4CD2" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-B85886517C553BDCE7162977945CDFAE" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-EEBC23C8EFBF231E9A282977945BDCE9" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-2D637B1B64AA2A85C4DE2977945AFF10" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-B06C843F9EB27A9DCFBD297794725B91" unitRef="usd">4400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-E5A57B37173C3C41EE4F29779473BBEA" unitRef="usd">5406300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-DD5DEA7FAB659D77004E297794718109" unitRef="usd">1409000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-4C17487E6D2937210240297794710A0E" unitRef="usd">1258700000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-CB38A7AE5BC7C69F528229779472C5E0" unitRef="usd">1156100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-2786578F358175B8FC4B29779471D1CA" unitRef="usd">1019400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-D1EFD86F7632EF808AA72977947C2C6D" unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-74659E67A9CB415227FE297794724C27" unitRef="usd">559100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-F414AFD8EB51024818CB29779472DC5A" unitRef="usd">33500000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4" decimals="-5" id="Fact-B2DDB45BC756678A30792977945AD9DE" unitRef="usd">5173000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-C09C81C94658262695042977945939BC" unitRef="usd">1039500000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-5977112E263FEE4D98BB2977945B6CE1" unitRef="usd">1569600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-9E3E7711CEEE85B49B4B2977945A0803" unitRef="usd">1075700000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-D773F70EC264E37086662977946B0F78" unitRef="usd">845100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-0E89CFC09D00A0031C6529779473C70D" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-142E21A8C286BED0B9172977945AF3C8" unitRef="usd">642300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-7EF9A6B2326BC9309FCF2977945AFA6F" unitRef="usd">14400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-5354696AD2799D05804C297794671D65" unitRef="usd">2568600000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-2B2C791989059851E2722977944E55C4" unitRef="usd">2115200000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-443620A6395CD0E159302977944B777B" unitRef="usd">2559700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2017Q4" decimals="-5" id="Fact-23EA7DDFB222937AB6C02977944A5889" unitRef="usd">2730000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-FE5ECCBD3DA34D68872629779449C7C5" unitRef="usd">2552600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-660CE1E72B652F0454F72977944A0608" unitRef="usd">2730000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-DBA454BB4B7E766812092977944848CD" unitRef="usd">2569100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2017Q4" decimals="-5" id="Fact-D790C81C79EB191C5F35297794482094" unitRef="usd">2116000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-F59767BC7A480D50EBD52977944B2479" unitRef="usd">2568600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-FEC9004653DBC9C6AF1D297794484ADE" unitRef="usd">2115200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2015Q4YTD" decimals="-5" id="Fact-318EC52F0329D38E738F29779448D1B0" unitRef="usd">1500000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AF689E9FB5E7847FBC74297794487448" unitRef="usd">3300000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2017Q4YTD" decimals="-5" id="Fact-6B73D77497C1B7B026E4297794482C00" unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2015Q4YTD" decimals="-5" id="Fact-5352832C517E7389EFE529779449003A" unitRef="usd">3500000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2016Q4YTD" decimals="-5" id="Fact-91ACC7322FAB83746ED2297794482A26" unitRef="usd">4300000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2017Q4YTD" decimals="-5" id="Fact-17C40EC9FA54E44821F029779446C324" unitRef="usd">22400000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-76E9AC25F6E690D2992F29779468FF47" unitRef="usd">2829400000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-8D3848BE747076F5CC252977945A353E" unitRef="usd">3057300000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:BuildingsAndImprovementsGross contextRef="FI2016Q4" decimals="-5" id="Fact-B4160A8E750A7B76F63E297794654666" unitRef="usd">1107800000</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:BuildingsAndImprovementsGross contextRef="FI2017Q4" decimals="-5" id="Fact-1FAE237D34C1186F5C98297794668403" unitRef="usd">1213600000</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2013Q2_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-33C9113C83C71AA0791F29779451610C" unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2017Q4" decimals="-8" id="Fact-E3C34FA18BD1FE2F9ED3297794468269" unitRef="usd">1100000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-B5CA03BB39EAF938279429779465E4EC" unitRef="usd">355000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-6F370D96AE5D6040C51C29779467F654" unitRef="usd">400000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-6A23CDB36F4E892DF48E297794661A4C" unitRef="usd">344000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-E0B1B9537E4912A6BD552EE7A6B03863" unitRef="usd">450000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8385D8D180FE7C80E3E729779468E62F" unitRef="usd">506000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-96DA13B6A4BE704D96A4297794678598" unitRef="usd">75500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-3D1C2749BD080DB43A3D29779466BDDC" unitRef="usd">258900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-FE49E254FB87709AC64829779467E45C" unitRef="usd">133200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E44EA6669A362E5DD1F329779449A80F" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BE6E50E0CA39A9A5C14D2977943EDC66" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7511ACAE6028616B7B98297794747820" unitRef="usd">467600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E0C1491275A7BACDDC26297794754673" unitRef="usd">467600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-DDDB381D31520FB56A8B29779466A0C3" unitRef="usd">102200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember" decimals="-5" id="Fact-BEE0BE9B8F2BF01186D429779465D7C8" unitRef="usd">20000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-4BC9B939A876037848CA29779465D251" unitRef="usd">259000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember" decimals="-5" id="Fact-DEAEDA958851C133EA2329779466DCC2" unitRef="usd">147900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-A8685AAFD80A4A4E9AF92977946593BB" unitRef="usd">162400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember" decimals="-5" id="Fact-47717088A55E3DBE2D70297794669E1E" unitRef="usd">76700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-50EDC7F6FEFD127F99C02977947594EE" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5393F06CC56869D676DE29779474CCBC" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3EBED8A55C9742BC79972977945EC2FE" unitRef="usd">523600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A8BBC6F6A657255B434729779469B42B" unitRef="usd">523600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-165A3EC5C4990AB3136129779451F1F3" unitRef="usd">580800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-97CE77638E6585EEFC6D2977945DE4F3" unitRef="usd">844600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2016Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember" decimals="-5" id="Fact-AEE0FC7C8FB4FD3F0E7C297794656FF1" unitRef="usd">246800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2017Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember" decimals="-5" id="Fact-7CEDDBE43ED414EF86DF29779465A137" unitRef="usd">279000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-2355A55BA495E547C9F52E811CD4FF28" unitRef="usd">424600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-05BB119DB503CDB340202E8084C6B799" unitRef="usd">474600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
	<us-gaap:CapitalLeaseObligations contextRef="FI2015Q3_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" decimals="-5" id="Fact-0870CDC4E68596429CF33284F9EBF756" unitRef="usd">20300000</us-gaap:CapitalLeaseObligations>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-5" id="Fact-32AF636CBF323F043BF92977945141A0" unitRef="usd">1204900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-5" id="Fact-749DE97F4D8A5CAB48B629779474E873" unitRef="usd">1308000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-5" id="Fact-8C3CBFBADB6350CFCBFE2977943D73D2" unitRef="usd">2326500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-5" id="Fact-96321C74DC9970B2018B29779459023D" unitRef="usd">1573800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E4453930AFBD6B20F4A2297794495D4D" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-03DE096281E4A5F5CD0229779475C42B" unitRef="usd">2039600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EDFF54D34D1CBF709F5C297794735E43" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3B30D8C21B90624067F22977947464BF" unitRef="usd">2039600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3D13F9BC91C57C5D709429779474D402" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-15D8F8AD1762A9720EDD2977945D31AE" unitRef="usd">1229400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B570E5A3F6E35BB132822977945EE9E1" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4F3107FE127EF8365C262977945D8CA1" unitRef="usd">1229400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C3AF4732B0D9C207F2462977943851E7" unitRef="usd">148900000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F2F5D00762FCCECB4286297794772256" unitRef="usd">1049800000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q4YTD" decimals="-5" id="Fact-DCFB587B8119DCBE52F52977947348A0" unitRef="usd">-792100000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-5" id="Fact-AF1465E2677E6AF19DC42977945CAA74" unitRef="usd">2039600000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-386A50D3D0D7FCBF0A302977945D94B9" unitRef="usd">31000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-EFBCBA211F586C3B18022977946A57EF" unitRef="usd">1266900000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-8193C9DF09A9F630F45E2977945D8ED6" unitRef="usd">741700000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-4E9AEEEA542EDECD21AC2977946AACC4" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-5" id="Fact-FB9772CA87C8ABDFE0062977945D55E0" unitRef="usd">1229400000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-9905F3552ED5DD18B4DB2977946ABCA5" unitRef="usd">30500000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-1DAA2EBA48D9A09CACA32977945E87AC" unitRef="usd">247300000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-912177A8ABCDC98F65B72977946AD342" unitRef="usd">948000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-F59D6C00676DF7A2153D2977946A02E6" unitRef="usd">3600000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-4CB9886F2F2AD07C19AF297794688B2C" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-86CEF3F5D698FAD9282A297794597B91" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="4" id="Fact-6051AB542EA0F515F1DB2977944A9995" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="4" id="Fact-FC1EDD3FF7752BDDD4D72977944BBCE8" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="-5" id="Fact-8C18716520C1899CC3392977943CA3E5" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="-5" id="Fact-B6209C02DBC39AA635D42977943BB58C" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="-5" id="Fact-64CF98FD6A303B0C1DE62977943B3C53" unitRef="shares">238500000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="-5" id="Fact-A04F4A2AFB6B5972A5C92977943B75B0" unitRef="shares">235300000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="-5" id="Fact-33006B83CCDF4AC793A52977943B6D76" unitRef="shares">215900000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="-5" id="Fact-7C1781B18586007022D72977943CC4FE" unitRef="shares">211500000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-5" id="Fact-D3FDADC976FB204DB49E29779476CAAE" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-5" id="Fact-620DE4D1AB65A880DF39297794669F2B" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-433A72A9D3101DD01D42297794661440" unitRef="usd">3382500000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-42104683CCDB7E9E7AD7297794640A1D" unitRef="usd">3606900000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A2C76ED9199748E5B948297794675F35" unitRef="usd">2540600000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2015Q4YTD" decimals="-5" id="Fact-16FF87025DA546E3CB5B29779466D4E4" unitRef="usd">-46200000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2016Q4YTD" decimals="-5" id="Fact-BF56F67F0B0E911A5452297794682574" unitRef="usd">7100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="-5" id="Fact-BCDE006D214D28B98B5729779469F5D7" unitRef="usd">-131000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D11C165565E6992E1310297794677C17" unitRef="usd">3428700000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A5BB62EFC367E87B982629779466E49A" unitRef="usd">3599800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2EF5AB4A7884BCE57776297794669448" unitRef="usd">2671600000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ConstructionInProgressGross contextRef="FI2016Q4" decimals="-5" id="Fact-E3126683281F8F94A369297794652065" unitRef="usd">658600000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2016Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-261D2A21B70329F2D88829779436DD80" unitRef="usd">481500000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2017Q4" decimals="-5" id="Fact-D19866505A1DAB02C00229779465290D" unitRef="usd">1276000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2017Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-8" id="Fact-30352261721F7213E9802977945912E7" unitRef="usd">1200000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-F2E72B8FF2F4186FB7DF2977945AD96A" unitRef="usd">134000000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2016Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-95ED1B83DC376D13E00133224B6BB95C" unitRef="usd">100000000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-605FAEB881BF06AF964C2977945B3D0D" unitRef="usd">159700000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2017Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-96EABC1C8E962CFEC9052977945DF055" unitRef="usd">150000000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:CostOfGoodsSold contextRef="FD2015Q4YTD" decimals="-5" id="Fact-563C3A37D45B2C1DED5D29779470AC22" unitRef="usd">1240400000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6504DD1E1E778EF842A72977947D9712" unitRef="usd">1478700000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q4YTD" decimals="-5" id="Fact-8501FDE7563A2A961C6C29779475A347" unitRef="usd">1630000000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-7740297F3CCB12769C212EA322448E19" unitRef="usd">15100000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q4YTD" decimals="-5" id="Fact-BF3ECFAE34484FD0CA7D29779471D7A7" unitRef="usd">5872800000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q4YTD" decimals="-5" id="Fact-12F0EAFD2A085BFF3CCA2977947DD99C" unitRef="usd">6298400000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-028DFFADD6095EB9F05233C28FD37BB8" unitRef="usd">50000000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2017Q4YTD" decimals="-5" id="Fact-94D6C831B85AFC9B58D52977946A9681" unitRef="usd">6929700000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-139A3126FA7D8990AF6E297794720871" unitRef="usd">92600000</us-gaap:CostsAndExpenses>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredTaxAssetDomain" decimals="-8" id="Fact-2A6C41FD8D353C51782A330AA14D5291" unitRef="usd">500000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember" decimals="-8" id="Fact-2CB6B33E5C77C52929FA330B9BAEE892" unitRef="usd">500000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-0E778BC2D3E626FBE42E29779464840D" unitRef="usd">1214100000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6C37A7A15DEB6125695E297794521E7B" unitRef="usd">1304300000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-F5D0BCAA390CD472E0C429779465DF81" unitRef="usd">2201400000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-5F7609097B1C92F30156297794665AFE" unitRef="usd">54500000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5E9715A43E9ADF36152529779451F60D" unitRef="usd">52900000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0DDF274D3D5ED0D6C317297794643718" unitRef="usd">108600000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-461F05A321DCD07F7D2A2977945967EB" unitRef="usd">1307200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-474B796AD11DA5206F2E297794517406" unitRef="usd">1412300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-CE7E11BA1EC041064ECA29779452DAD7" unitRef="usd">2367000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-770A990706E12024FB1729779464F6CA" unitRef="usd">38600000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-29FC1A631A006F6127F5297794518784" unitRef="usd">55100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-50DF081A1AACB0CD24C429779464FCF5" unitRef="usd">57000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-08CDBDA4E2FBEEC7A0FA2977945A36AD" unitRef="usd">4700000</us-gaap:DebtCurrent>
	<us-gaap:DebtCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-EC0210164E47194DCB19297794751133" unitRef="usd">3200000</us-gaap:DebtCurrent>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-7" id="Fact-AA8261D4774BA76B26B7328C0567ABC3" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-7" id="Fact-A6B6FF406BF2B55A9050328DF098F2C7" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-8" id="Fact-B2B09EA6C78C34C4043C329008FD8743" unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-8" id="Fact-EBAB4417475399BD5745328FBC478AC3" unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-6BEE2BFE35ECFAC38D822EE2487EC903" unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-F44FD04490A9631A58BF2977946AD352" unitRef="usd">6808400000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-980C4FA8B5B5A76045F12977947179AF" unitRef="usd">6483300000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-6F8F8655454B15CED4BB3273E0E65AA0" unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-D82675FAFAD6FEBAE7343273894485B0" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-F398EA03D0290BDAB3DD328EF163E4CC" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="4" id="Fact-E644106A96DCFCCE5C5D3274D0FAAD16" unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-BD1F933FF9EB03ACF4492977946A03B9" unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-8BB95B18E1ADE2432B09297794698F7B" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="5" id="Fact-1FB869093B2C480DD1332977946A1EC9" unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-4085271482C0F3837292297794697FB3" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-85F28427A75ABF7FD5CB2977946A120F" unitRef="number">0.029</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="5" id="Fact-2D0AC11CBA1410D30F2A2EE1E91FE978" unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentMaturityDateDescription contextRef="FD2017Q4YTD" id="Fact-62B1ABFCCBC4959F48E029779467FE40">less than 90&#160;days</us-gaap:DebtInstrumentMaturityDateDescription>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="FD2017Q4YTD" decimals="INF" id="Fact-451B7B1D1E4728B420F729779452CC13" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="FI2016Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" decimals="-5" id="Fact-45D3DCE0FCA54AF68AFB29779475C269" unitRef="usd">128500000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
	<us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" decimals="-5" id="Fact-4400A6B49E3CA8ED90E12977947CFB2D" unitRef="usd">109800000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-592E60F83F21B3E1EDBE2977946AABF9" unitRef="usd">-129600000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-136029F3CAF182FE25962977946545AA" unitRef="usd">-125600000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E6827430CD8959830AAD29779452B978" unitRef="usd">241000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-1DD384432CDBA36E44E4297794668B7B" unitRef="usd">-14100000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-BF6959CACC8DB83B5D8329779464BFDB" unitRef="usd">-45600000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-C779CB20EB64B5EC5277297794518B83" unitRef="usd">-159200000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-79EF097977E907B284A3297794764F1B" unitRef="usd">-145600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-BDF16AEA186E21E6B06029779474CCC4" unitRef="usd">-175000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D1DAD75DA078AF0DE34029779458668A" unitRef="usd">91700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DC69F4AE32327A0CE9C0297794580CCF" unitRef="usd">-1900000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2BC66D38B785987985622977945206D9" unitRef="usd">-3800000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E3AFFCA127C827FB1FD3297794518277" unitRef="usd">9900000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="FI2016Q4" decimals="-5" id="Fact-77D11AEF1105B533D2B029779470C43E" unitRef="usd">459800000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
	<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="FI2017Q4" decimals="-5" id="Fact-38709599EFFEB2D7C71029779471BFFD" unitRef="usd">378800000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
	<us-gaap:DeferredTaxAssetsGrossNoncurrent contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-A2FB822348F623D0654B42738596EDDB" unitRef="usd">989600000</us-gaap:DeferredTaxAssetsGrossNoncurrent>
	<us-gaap:DeferredTaxAssetsInventory contextRef="FI2016Q4" decimals="-5" id="Fact-6FB1AB2E013F9D6155C12977946A3DF6" unitRef="usd">250600000</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsInventory contextRef="FI2017Q4" decimals="-5" id="Fact-B48D9FFBDB584400463F29779471D334" unitRef="usd">147800000</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2016Q4" decimals="-5" id="Fact-976D57559CB6EDF470902977946B12EA" unitRef="usd">1071800000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2017Q4" decimals="-5" id="Fact-3BDF8DC9683C79B7039B29779471D8D6" unitRef="usd">831800000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2016Q4" decimals="-5" id="Fact-AC69759A135682BE224C2977947120E0" unitRef="usd">65900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2017Q4" decimals="-5" id="Fact-5C043AAA7A2774A56BFA2977946B1F2D" unitRef="usd">209800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-7B8720F6B3D34649C3962977947CB145" unitRef="usd">19300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2016Q4" decimals="-5" id="Fact-E0BE4570D97319F7D78C2977944B0898" unitRef="usd">49000000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2017Q4" decimals="-5" id="Fact-A584706481BDEAAEA35D2977946A37BB" unitRef="usd">25100000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2016Q4" decimals="-5" id="Fact-C58B3620A6B36CBB3FC129779470F6C0" unitRef="usd">201100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2017Q4" decimals="-5" id="Fact-9038D88E459D7571B31C297794713A4D" unitRef="usd">60000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2016Q4" decimals="-5" id="Fact-D26526098E16D35AD8A42977944D9663" unitRef="usd">61500000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2017Q4" decimals="-5" id="Fact-3AB80C0F7CBDD8F880F42977946BB158" unitRef="usd">26900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="FI2017Q4" decimals="-5" id="Fact-84CC483220B5165245A2330E07FD1435" unitRef="usd">48800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_biib_PrepaidtaxesMember" decimals="-5" id="Fact-0C8FE1F29C1141934CE8330E5EB8C49B" unitRef="usd">142600000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-5" id="Fact-E5456BE4ECC1C89645B92977946B3133" unitRef="usd">16100000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-5" id="Fact-53BD8211A4F99B46EE5229779470CDD6" unitRef="usd">16600000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2016Q4" decimals="-5" id="Fact-530707A4D2E5E67C9E1E297794719418" unitRef="usd">490100000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2017Q4" decimals="-5" id="Fact-4DD23FA23FA6F383827F2977944C329D" unitRef="usd">358600000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2016Q4" decimals="-5" id="Fact-605C69847778A2872FFB2977944B659D" unitRef="usd">376600000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2017Q4" decimals="-5" id="Fact-D87B7B0DF71E326A256F2977946BED71" unitRef="usd">250700000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesGrossCurrent contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-263AD6FEC4E8366179914274960F449D" unitRef="usd">78300000</us-gaap:DeferredTaxLiabilitiesGrossCurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-F49EAAABD7770219A2C22977947CA08C" unitRef="usd">93100000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-CDFA05780590B6AF859729779459A952" unitRef="usd">122600000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2016Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-D1DF035E5A83DCA2FB692977947D0841" unitRef="usd">68600000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2016Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-CED2C48BFD86CE631312297794755A39" unitRef="usd">35400000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-7A90964891EFC9F9D8F229779476F7B4" unitRef="usd">83700000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-C6A1A62B52337FF5ED892977947D7727" unitRef="usd">43500000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="FI2016Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-11B9FD237339D98548EB29779476D9DF" unitRef="usd">39100000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
	<us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-DA74FDD6E59491B361332977947CCDF6" unitRef="usd">48300000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2015Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-23C2340B6876ACE163B72977947CA03D" unitRef="usd">4000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2016Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-8A985BEBD2903703A6F729779476DFDE" unitRef="usd">4200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-06DDAA798A426B3BF12A2977947C8A36" unitRef="usd">5200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2015Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember" decimals="-5" id="Fact-CF29FEA7A059A9BC4D6429779473791D" unitRef="usd">51800000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2016Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember" decimals="-5" id="Fact-C4A8AB4EAFC010E66BD8297794766015" unitRef="usd">45200000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember" decimals="-5" id="Fact-0F3F6D1B5E4AEB5D6F60297794756D48" unitRef="usd">42600000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:Depreciation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-76151F20A8FAE249BCD02977942CF964" unitRef="usd">217900000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0404CCBD568309606B262977945830F0" unitRef="usd">309300000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B0265E1BC9E3A2EEF33D29779448A960" unitRef="usd">266300000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q4YTD" decimals="-5" id="Fact-54CF7B6F8B29C21565292977947DFBAC" unitRef="usd">600400000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C9EE6E6636E32B43813529779474C49B" unitRef="usd">682700000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B59F878F0820D27A4962297794526898" unitRef="usd">1081000000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-62667EB325A466ED59C32977945921E0" unitRef="usd">50400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-6A2B119DAE0CADEE80CE29779449746D" unitRef="usd">4000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-AF0746CB0F637CD2DD0E2977944A7586" unitRef="usd">6600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-4510BF765EA42F7A0CF229779468C5F7" unitRef="usd">700000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-72F74ACE1FD39236C6AE297794493D16" unitRef="usd">1800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-DFEDB05C8A4FF88031BB297794587EC5" unitRef="usd">200000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" decimals="-5" id="Fact-CBCE092EE6F8D6D632642977944A6E4E" unitRef="usd">10100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-6ED90AACC5EC79FA05432977945ADCC4" unitRef="usd">9000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-30C636ACA915D7A5801F2977945AFAB7" unitRef="usd">4600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-949788AF561BDF5BA8683278A412DC7F" unitRef="usd">84700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-097FC735A152CAC1FBBC29779453B69D" unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-07B29C65E3B31393869029779458C31A" unitRef="usd">23600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-80DA12F6A411F914A2BB297794690DE1" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-C071B4617B58ED9672AF297794514EDE" unitRef="usd">173200000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-784F5B7D4116CC26370C29779473365B" unitRef="usd">-1500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-A5E496C1C86B8ADDE4CC29779467CECB" unitRef="usd">5300000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-9F599C462F80053BBAD32977946BB26F" unitRef="usd">600000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-310E90009AB0DC481BE529779471694F" unitRef="usd">-32500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-D0F6941155C10462C64129779451BA19" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-8F58FF8D35843BD58EA729779471763D" unitRef="usd">4900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-0B1D039C5C379D859C9E297794695CAD" unitRef="usd">100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-504AC8E429C2F9772210297794679039" unitRef="usd">2900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-8126A9FF938740B9D52229779467B9D5" unitRef="usd">-200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-DD7804E7655FA7B2B6C029779452AF86" unitRef="usd">8900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-FF70ACE44C5FEBFB276629779467038F">P18M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-57305A6F9011A51674D7297794670E5E">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2017Q4QTD" id="Fact-1377EF9F9688E3590ED12F19A1C08DC3">P12M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2017Q4YTD" id="Fact-2295D7D31D916FB0559329779466A7CF">P21M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-ABEEF4161156BCE71BDB297794645ECD">P21M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-D09E999AB123E65344A7297794657CE5">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DirectOperatingCostRoyaltyExpense contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-9A70C2339B4625E91BFE33E37881B887" unitRef="usd">500000</us-gaap:DirectOperatingCostRoyaltyExpense>
	<us-gaap:DirectOperatingCostRoyaltyExpense contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-DE74E0C3271C6CCE50A833E35ACBE3DE" unitRef="usd">112400000</us-gaap:DirectOperatingCostRoyaltyExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-FBD79DC8A4804710C26D2E99CD8760A1" unitRef="usd">144700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-A454E6623A410BA853CD2E9ADD097126" unitRef="usd">87800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-3D4D0FA405B74DD50DCE2E99A3450AF1" unitRef="usd">302700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="FI2016Q4" decimals="-5" id="Fact-94A9C4D48F051BE790522EDC75768257" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-35BD99C406E6B98A82982E9A7F0B2CF3" unitRef="usd">314100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-8A3FE0E2E1D4D1C9E3DD2E9A4ADEA263" unitRef="usd">56800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-62585FB0D9FEA00C6E552E99ECE32924" unitRef="usd">116100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember_us-gaap_PublicUtilitiesInventoryAxis_biib_FinishedGoodsMember" decimals="-5" id="Fact-20D4645F1DA1A8D4BB082ED1B5BCB31B" unitRef="usd">31600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember" decimals="-5" id="Fact-5322FD901936CF6EF3002ED18DF99112" unitRef="usd">84500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-1822F685D1C23B8122AB2E9AA03E507D" unitRef="usd">53700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-39A30B813FEA1F0E9DA12E9AFBFBEC89" unitRef="usd">67700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-957111A7EB0E0E102B862E9A15BABF31" unitRef="usd">20200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q4YTD" decimals="2" id="Fact-DC0C6AEEA1035BEE946A297794707FE6" unitRef="usdPerShare">15.38</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q1QTD" decimals="2" id="Fact-8F4751FF827828502BC22977944E5287" unitRef="usdPerShare">4.44</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q2QTD" decimals="2" id="Fact-1630668AAE5AB0313FE02977945053CD" unitRef="usdPerShare">4.79</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q3QTD" decimals="2" id="Fact-2E8D77B597CA119B94B42977947D42E2" unitRef="usdPerShare">4.72</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q4QTD" decimals="2" id="Fact-CA225FF72250F1F09D812977946A26E7" unitRef="usdPerShare">3.00</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q4YTD" decimals="2" id="Fact-C43C3DF4F099BF36CE8329779476CD8B" unitRef="usdPerShare">16.96</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q1QTD" decimals="2" id="Fact-AA957629D513488EE9CB2977942C53B4" unitRef="usdPerShare">3.47</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q2QTD" decimals="2" id="Fact-D12EA0BB9C5E692A8EFC29779438DA4E" unitRef="usdPerShare">4.07</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q3QTD" decimals="2" id="Fact-144E98CE401F19055B0129779438F1EC" unitRef="usdPerShare">5.80</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q4QTD" decimals="2" id="Fact-25D60BFEF5FA47B95A6229779439F0CB" unitRef="usdPerShare">-1.41</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q4YTD" decimals="2" id="Fact-BDBA2536FD09E79D03E82977945C6A3E" unitRef="usdPerShare">11.94</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-80722327D8E41C49DE8E2977946A38BE" unitRef="usdPerShare">15.34</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q1QTD" decimals="2" id="Fact-8CCC780A6506BFC84EA7297794587247" unitRef="usdPerShare">4.43</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q2QTD" decimals="2" id="Fact-DFC40B25F04AB97BC6322977947D457B" unitRef="usdPerShare">4.79</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-41076F4B1791BCA5BF8029779451CC92" unitRef="usdPerShare">4.71</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q4QTD" decimals="2" id="Fact-B41D7F5DEEBBF095E4232977944FFBFF" unitRef="usdPerShare">2.99</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-53F542F70115EAF3378F297794697503" unitRef="usdPerShare">16.93</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q1QTD" decimals="2" id="Fact-1952959BDA1D57F66EF12977943A9664" unitRef="usdPerShare">3.46</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q2QTD" decimals="2" id="Fact-97FA8E8ECE643FC4C5C32977943999B1" unitRef="usdPerShare">4.07</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-62C7896780F6A010184529779433105B" unitRef="usdPerShare">5.79</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q4QTD" decimals="2" id="Fact-9E0E1DC8D3536072AFFD297794477D9D" unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-CE59779ECD03450D6F9129779468BB1B" unitRef="usdPerShare">11.92</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2015Q4YTD" decimals="-5" id="Fact-B364C7AED7EA9C7FB3242977944BF9FF" unitRef="usd">-45800000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8DAF753A112DAB05A1912977944F57EA" unitRef="usd">-31300000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2017Q4YTD" decimals="-5" id="Fact-C89FBD8F5EC6EEB67DE22977944B2D02" unitRef="usd">39400000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2015Q4YTD" decimals="3" id="Fact-44C5F9CF39373A1C8DC729779472F3FC" unitRef="number">0.244</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q4YTD" decimals="3" id="Fact-E164F70940079CA7FBE4297794722FFB" unitRef="number">0.251</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q4YTD" decimals="3" id="Fact-F36D1EC1EB99874438D92977943636BF" unitRef="number">0.479</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="3" id="Fact-9BD1718B1F10B604556629779437F832" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="3" id="Fact-74E7A4624D401BA99D8729779472476B" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="3" id="Fact-8C14526BD544A54E106B29779435623B" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="2" id="Fact-37CE3C9ED69D9FD2EFF24280304DCCFE" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2015Q4YTD" decimals="3" id="Fact-B16AA7417DB311A19E1833041B8376DD" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2016Q4YTD" decimals="3" id="Fact-73947848C27E9C3082BF330419A17C0B" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="3" id="Fact-57B499DD1A0081977CD03303E0675F72" unitRef="number">0.229</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2015Q4YTD" decimals="3" id="Fact-BE12A72B36252E2A422729779437C9A4" unitRef="number">-0.100</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2016Q4YTD" decimals="3" id="Fact-73A829A93173DB25B4E429779472FE65" unitRef="number">-0.096</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2017Q4YTD" decimals="3" id="Fact-4A9F9F8F2B6428D3BDA329779439882B" unitRef="number">-0.111</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2015Q4YTD" decimals="3" id="Fact-8F9038AE10CB0CA774C5297794339943" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2016Q4YTD" decimals="3" id="Fact-0E8715C7B70DC16803EB29779433D796" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2017Q4YTD" decimals="3" id="Fact-0169E5C162452A0B652F29779437B46E" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses contextRef="FD2015Q4YTD" decimals="3" id="Fact-A67458E6810A905FA2433305E134DF79" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses contextRef="FD2016Q4YTD" decimals="3" id="Fact-6BC56FFC373E5471C7163305DF722FCF" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses contextRef="FD2017Q4YTD" decimals="3" id="Fact-AB22FF6D455792530E5B33056B52C297" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2015Q4YTD" decimals="3" id="Fact-34BE27C6E1A710DFE622297794738923" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2016Q4YTD" decimals="3" id="Fact-A363A7BF8313CB110B8D297794390C22" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2017Q4YTD" decimals="3" id="Fact-F22106FDAB35A67539EB2977943913F1" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2015Q4YTD" decimals="3" id="Fact-6D79876EC3B7626CDC7B29779472DD27" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2016Q4YTD" decimals="3" id="Fact-DFE162DF0C7ECE4BA74329779473B76F" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2017Q4YTD" decimals="3" id="Fact-A151AD4E3676B1DFB0A6297794363355" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q4YTD" decimals="3" id="Fact-137CB8CE2117063DF20629779438EC31" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="3" id="Fact-38626B149A8B86235AA929779437B38B" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="3" id="Fact-A281A7C8F93304E08DCE2977942CF5CE" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2015Q4YTD" decimals="3" id="Fact-64F7101A54D76425C35B29779437FAEB" unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2016Q4YTD" decimals="3" id="Fact-D5CAC1B0E61C20E4F2F92977942D5F21" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2017Q4YTD" decimals="3" id="Fact-77F1C6D03C85C986767E297794387E2B" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-49597BF92A47A5DFFF8129779473DD83" unitRef="usd">282900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-1694C516259550DF6A2E2977943A76C4" unitRef="usd">297700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2015Q4YTD" decimals="-5" id="Fact-045EEBFAB4ECD2D4C7052977943A207F" unitRef="usd">11000000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8DD3F5F0A6D832B2F9862977943EAE77" unitRef="usd">14600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E80E8E58CE006FA5D4F02977943776CD" unitRef="usd">9600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-4BDBFE21674DB965092B297794464B1C" unitRef="usd">79800000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-A14C84C42B82B4AA33E72977945B0EEC" unitRef="usd">12400000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-5987F971EB02C531902E2977946664E6" unitRef="usd">31900000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-22502136D738946AF69932F1CBF35F59" unitRef="usd">8100000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-494ABD040C619DA634D02977945BC8FE" unitRef="usd">16600000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-10849CF9122F5E0B774229779433ADEE" unitRef="usd">11500000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2017Q4" decimals="-5" id="Fact-8E16C032D19D95D8C9D02977943D4DC9" unitRef="usd">168000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6F20E41D849A92EDE3A9297794360339" unitRef="usd">55800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F815A87E9CF4DB1A0B032977945B69A3" unitRef="usd">54000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-249D04300A156431308329779438C054" unitRef="usd">42800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-04EC7D16E6E05454701529779474C6AB" unitRef="usd">11900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5FF05C4CD2FD24BA0EF129779476F535" unitRef="usd">4000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="FD2017Q4YTD" decimals="-5" id="Fact-5B08BCABFC60B212870329779447F895" unitRef="usd">3400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2017Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-807F99B357565F3CC0E02977946A2338" unitRef="number">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-EE56518B70C3F83A4F3F297794337A98" unitRef="number">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestments contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-8AA90C680855589FACA42977947167F9" unitRef="usd">45000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-79DC1AA8B8A6EA9A820A29779471EF37" unitRef="KRW">49500000000</us-gaap:EquityMethodInvestments>
	<us-gaap:ExtinguishmentOfDebtGainLossNetOfTax contextRef="FD2017Q4QTD" decimals="-5" id="Fact-7684B9FB9A87B95E95DB3295AB6FCAAC" unitRef="usd">5200000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
	<us-gaap:ExtinguishmentOfDebtGainLossNetOfTax contextRef="FD2017Q4QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" decimals="-5" id="Fact-FA54D3B28DAE47D1940F329DB9C52DE9" unitRef="usd">2900000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
	<us-gaap:FairValueInputsDiscountRate contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="INF" id="Fact-C74FC8AAAC9AC6D5AAAD2EE4E9BCD4E3" unitRef="number">0.02</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="3" id="Fact-1AE0DBA696F8FB31C46D297794648DE4" unitRef="number">0.028</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="3" id="Fact-FD0378376B8816AA6FCA297794655DDA" unitRef="number">0.024</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="INF" id="Fact-FE68E30F3BBB2D43F05A29779466C09E" unitRef="number">0.024</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2015Q4YTD" decimals="-5" id="Fact-1B4F432A923160889D072977946732A2" unitRef="usd">-30500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D2C5056FC305749FA6AE2977946B4198" unitRef="usd">-14800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3A9DE9700782CB78764F297794681291" unitRef="usd">-62700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-524DE699CF9838D87DF92977947C1EE1" unitRef="usd">274500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2010Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-CA8F7B5CA8504A193DCD29779465BC01" unitRef="usd">81200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2012Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-B0B61A9252CB144EFF452977946664BE" unitRef="usd">122200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A40009C46ECC0357952829779468A324" unitRef="usd">53200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2996FA4DB4FF22B1869C29779469C5A5" unitRef="usd">6700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementsChangesInValuationTechniques contextRef="FD2016Q4YTD" id="Fact-A14935A367E6043A7207297794330DD8">0</us-gaap:FairValueMeasurementsChangesInValuationTechniques>
	<us-gaap:FairValueMeasurementsChangesInValuationTechniques contextRef="FD2017Q4YTD" id="Fact-DA6BE8E39F4B14B21B69297794651E29">0</us-gaap:FairValueMeasurementsChangesInValuationTechniques>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-18C55B7A202690B299D92977945AACAF">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-C4D9EA3857BF0409847E29779459ADF9">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-81F0E4007B61535E1E222977945A2572">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-1778B8D01BFDF77F8D4A2977945AD727">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-AACB8B2A3A109913CCCB2977945AC3C6">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-90BD86EC8E7208EF9A582977945A9176">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4" decimals="-5" id="Fact-9F3F435A80A5FAED5DC32977945CC507" unitRef="usd">3934000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-2173EF9086921BD6A8242977945DA606" unitRef="usd">776100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-2C6B99B5C97E4C80F858297794482624" unitRef="usd">523600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-C92357F876C47F95BED7297794467A69" unitRef="usd">2634300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-AF5D18ECD8C698D8553129779446FA82" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-B811EB95532D4EA66F4729779446C9E7" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4" decimals="-5" id="Fact-B19B6AD23B1327D1C2432977945CA345" unitRef="usd">4385000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-1F241D3DCDFC274065792977944AEC3C" unitRef="usd">1160400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-D6996A17FB5878652C34297794453668" unitRef="usd">535600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-7013EB1F71F8C3CAAA2D2977943BD524" unitRef="usd">2689000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-A92FE7E48E9FC63DC88B2977943BB1EC" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-E111733210D5A94C72D82977943F0E03" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2017Q4" decimals="-5" id="Fact-F417E9F5402B97EFFB9629779464D9C6" unitRef="usd">423500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2017Q4" decimals="-5" id="Fact-9E34938A3D33EF45F65F29779465D5F1" unitRef="usd">242300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2017Q4" decimals="-5" id="Fact-C178072C5A5E79FC0AE92977947345B2" unitRef="usd">254300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2017Q4" decimals="-5" id="Fact-DAC439E6151C70D5249B2977944F94BC" unitRef="usd">381600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2017Q4" decimals="-5" id="Fact-35B629D1EC7834A2A32129779450F9D3" unitRef="usd">401800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-9C85E9E1F477C991B92B2977943FF452" unitRef="usd">3481700000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-18916A414885C99515922977943EA2D4" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-111D20D97BFA9B3E7D1C297794468E92" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-9A3139D91BBF7ECB8BA429779448CCB6" unitRef="usd">3971400000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-40D64DAECDD7692B95E52977944659D0" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-6467E30D5BF1FFC34C9D297794466C23" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-E4738124DCE6B57ECDA92977945D0FCF" unitRef="usd">2705600000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-2515EBBD730F3E085E482977943FA2D9" unitRef="usd">19700000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-7879DF3EBC7D3DA9D95B2977943D9CDE" unitRef="usd">371000000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-9395F9550509B836E0DE29779446CEBD" unitRef="usd">2811000000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember" decimals="-5" id="Fact-F3D621997D1FD0FFFC012977944FE189" unitRef="usd">2236200000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-7AF3752E2BD253346D042977944D51F2" unitRef="usd">7700000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-02747B79910C6CF1F4222977945D897C" unitRef="usd">316300000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-DFEE135D0D103A1C3C3E297794597F1E" unitRef="usd">309500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_BiosimilarsMember" decimals="-5" id="Fact-3C11FCEDA01F8CFA0D7A29779473A662" unitRef="usd">50000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2017Q1QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-4A4C2EFE0474943ABEA92EDB188866F1" unitRef="usd">795200000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_BiosimilarsMember" decimals="-5" id="Fact-10B897C1C804C76357002977945BCB39" unitRef="usd">25000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-CE6E26E9FB8AE49ABA8D297794339C0D" unitRef="usd">90000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-430F66E96AAD25DF9EEA33E132C82505" unitRef="usd">150000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-68B48A7B73FFC925E3152977943F1936" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B3DD333DE69DC9EFD0AD2977945DEB9B" unitRef="usd">61000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E3F33AF697BA02A02A9F2977945D676A" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A3EB3E79F8D2358C17A5297794747062" unitRef="usd">61000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C64A0F5E5DAD2BEEE595297794741BFB" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-413E9CBEA88EDE0477262977947547DE" unitRef="usd">2700000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A0539E001E592D123A3429779473AD9A" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3F2FF35AC9373EC6E6A42977945EEE20" unitRef="usd">2700000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C503208E467BDDAAC8F329779475AC19" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B070F777DC75DCD8E00E2977947D606D" unitRef="usd">13600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E6F9BD4652F8260C66DD2977947D0336" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1A1B4A77BFF6EECB3DC529779472AD44" unitRef="usd">13600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6EF72CF75FD2D62DB5C529779473B2BE" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8957EFF00B7F2C31D28929779464DFDD" unitRef="usd">111300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3FA6B64A6A53FC1F15B22977945DF6A5" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A316DD4199F7747CA767297794745D5C" unitRef="usd">111300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-37D6A1B3D0DBBDDD76112977943C0D9F" unitRef="usd">-32700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0C948D4D95295D1DD02A2977945C0A63" unitRef="usd">-9800000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-85EAA85BCD16CC0C69622977943BA30B" unitRef="usd">6300000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:FurnitureAndFixturesGross contextRef="FI2016Q4" decimals="-5" id="Fact-219B374FCCCF10A36CDB297794518E56" unitRef="usd">60600000</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:FurnitureAndFixturesGross contextRef="FI2017Q4" decimals="-5" id="Fact-E8B54467C1A0FD3E006D297794641F9D" unitRef="usd">55300000</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions contextRef="FI2017Q4" decimals="-5" id="Fact-8318545B204DFF54B5022977943DADCB" unitRef="usd">188500000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter contextRef="FI2017Q4" decimals="-5" id="Fact-D1357532E5663464AD5829779464EE2F" unitRef="usd">71300000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears contextRef="FI2017Q4" decimals="-5" id="Fact-627E5CFC6447882ADD412977943D9EDC" unitRef="usd">22000000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears contextRef="FI2017Q4" decimals="-5" id="Fact-F981D1C3DBAD9B6E0CAC2977943EF75B" unitRef="usd">22300000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear contextRef="FI2017Q4" decimals="-5" id="Fact-721723A9C42D376933A22977943D3A02" unitRef="usd">24300000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears contextRef="FI2017Q4" decimals="-5" id="Fact-192858AE9B513342C93F2977945E9B57" unitRef="usd">23900000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears contextRef="FI2017Q4" decimals="-5" id="Fact-3A30C25794EA07B11E63297794642579" unitRef="usd">24700000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E7B0645038BEC99D761F297794655573" unitRef="usd">23800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4921EEB76A79EAFC7944297794650E1A" unitRef="usd">29200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3AD55BA0BD2EB41A8E8329779468E7A8" unitRef="usd">4500000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-520EA3E4F8BF7DBC1DE52977943C4818" unitRef="usd">-3800000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-B98185A4AB8BB07A81CB2977943BB46F" unitRef="usd">6000000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2017Q4YTD" decimals="-5" id="Fact-AAFE74F2BBDDE2E240C52977943C6922" unitRef="usd">-36300000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:Goodwill contextRef="FI2015Q4" decimals="-5" id="Fact-4FD1C1AA71BDDF13EBC02977943528FD" unitRef="usd">2663800000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2016Q4" decimals="-5" id="Fact-EB83BDE36A29FD6C81E329779465B9BD" unitRef="usd">3669300000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="-5" id="Fact-74234EEB45870205012429779464B0AA" unitRef="usd">4632500000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-0C5A3639F4D69B1DC6642E82586EFD34" unitRef="usd">128300000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2016Q4YTD" decimals="-5" id="Fact-EB86646DE9C5453455A129779451AA00" unitRef="usd">1026900000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-28ECF88A686648FB401A297794765AAB" unitRef="usd">1200000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2017Q4QTD_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-4042CDE4C5F03B4C11232977945D39EE" unitRef="usd">600000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B8E2B4FBB838314C2D3429779452FC24" unitRef="usd">1267300000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2017Q4YTD_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-D5CCEAFC09958151F4632977945048F5" unitRef="usd">300000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2017Q4YTD_biib_CumulativeSalesLevelAxis_biib_FourteenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-F0F6AAA0892B891F7767297794499CF8" unitRef="usd">1200000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-FB8F73F50BFE42E579E8297794488902" unitRef="usd">1500000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="FI2017Q4" decimals="-6" id="Fact-9B9CEB9A45D9252862C32977943754C7" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
	<us-gaap:GoodwillOtherIncreaseDecrease contextRef="FD2016Q4YTD" decimals="-5" id="Fact-ABD870E21482F529746B297794518DDF" unitRef="usd">-21400000</us-gaap:GoodwillOtherIncreaseDecrease>
	<us-gaap:GoodwillOtherIncreaseDecrease contextRef="FD2017Q4YTD" decimals="-5" id="Fact-94A60A11EB323D792788297794522843" unitRef="usd">10000000</us-gaap:GoodwillOtherIncreaseDecrease>
	<us-gaap:GrossProfit contextRef="FD2016Q1QTD" decimals="-5" id="Fact-35CB9BDD4D5B01366B262977947D4BEC" unitRef="usd">2413800000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q2QTD" decimals="-5" id="Fact-2F173E7E40BF8EDEF12E297794588277" unitRef="usd">2523900000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q3QTD" decimals="-5" id="Fact-5D4B2374EDB7D640585B2977947CF54E" unitRef="usd">2538900000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q4QTD" decimals="-5" id="Fact-F29DE4DEA6C03C66602729779451DA63" unitRef="usd">2493500000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-866E975ABB54F75BB8162977944F924F" unitRef="usd">9970100000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q1QTD" decimals="-5" id="Fact-9C65B36DB79172B675C6297794460E63" unitRef="usd">2426100000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q2QTD" decimals="-5" id="Fact-F61A0D8BE3BC28905D5B29779434AD32" unitRef="usd">2712200000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q3QTD" decimals="-5" id="Fact-A74CF05D25811C8B49172977943CD3A2" unitRef="usd">2707800000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q4QTD" decimals="-5" id="Fact-26FD9D561D62DDAC1A7729779439C3CF" unitRef="usd">2797800000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-BADEB7499831E5D4670F2977944DA10F" unitRef="usd">10643900000</us-gaap:GrossProfit>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="FD2017Q4QTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-5A819E259FEA2B6D8CCD2ED5C7F13157" unitRef="usd">31200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2015Q4YTD" decimals="-5" id="Fact-AAB02E029273C34C355A297794519214" unitRef="usd">3386700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A3BE93920CAE2EDC9627297794535BB0" unitRef="usd">3655400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2017Q4YTD" decimals="-5" id="Fact-38D7274C03B61DE41DF1297794644C8B" unitRef="usd">3540400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2015Q4YTD" decimals="-5" id="Fact-297611C750B2BC83717F297794519FEB" unitRef="usd">1380600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4AE8C3AF02A1B0DC8C7B29779452642B" unitRef="usd">1277600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2017Q4YTD" decimals="-5" id="Fact-FC4D6E72D7401124A29929779452FB16" unitRef="usd">1588400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-3438711F983CD4C25561297794698A2C" unitRef="usd">4767300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-809CABEC2C9C54F179C9297794727556" unitRef="usd">4933000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D5A69EC3091B4C0AD497297794764002" unitRef="usd">5128800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-8F5DA7B5B42A1FC412BC2977947472CE" unitRef="usd">-12500000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0D71DECEBEE53B0A38E3297794683F62" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2017Q4YTD" decimals="-5" id="Fact-84F3DAEBAD0D3C60AB9C2977945E2138" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" decimals="-5" id="Fact-DCCD536A43070F8E45C23300BD5B975F" unitRef="usd">60000000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-A1F755A3069661C8669829779470257C" unitRef="usd">1161600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-448E4E04AE59730469D429779469F081" unitRef="usd">-800000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-0FD00B4864E1DCC310B32977943C23CC" unitRef="usd">700000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-99B7571442E6E1E6957E297794751846" unitRef="usd">1237300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-7DE196D8ACC62BABF81C29779468B77D" unitRef="usd">173100000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-D1AB75E7A05DA5D4B5FF297794640878" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-289CCE7245802F77ADE3297794372CB6" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-5557993BB137FE0E7AAF297794678CB1" unitRef="usd">2458700000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-1369058B5DF536AE8F222977943B184C" unitRef="usd">232700000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-3911264152166DC524D8426CC4AF0AD8" unitRef="usd">1173600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-ED9158AE71DF5801A5F929779466A8AC" unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B09607D609B3D264ED7129779467DBD1" unitRef="usd">6800000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability contextRef="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-B05DA06CBF45F6E743B23318BCEF63F9" unitRef="usd">184000000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-5285174FDBBC3939E78F29779433C4FB" unitRef="usd">1674800000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-84347AD5AF2EFF62EC5A297794337A4F" unitRef="usd">1642200000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A1733AAC0D31E48962B82977943318AD" unitRef="usd">1066400000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F80337819A61A64F1DDF297794588948" unitRef="usd">-29000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q4YTD" decimals="-5" id="Fact-86A1D1663FEB1C89059C29779458F65D" unitRef="usd">241400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2099B297458901C42C6F2977947DB07C" unitRef="usd">435600000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2015Q4YTD" decimals="-5" id="Fact-08C36234834C3150AB2C297794745A2F" unitRef="usd">-429400000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D61F347D677A581FECAA297794518862" unitRef="usd">-232600000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2017Q4YTD" decimals="-5" id="Fact-5BBEA5D7775FB5989E88297794748838" unitRef="usd">1303900000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-54C6DEB19E94FDF450BF29779452A7F6" unitRef="usd">199300000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-07E59F271F139C808CD12977947C37AF" unitRef="usd">622300000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4B58D2F2FDBC449B6C51297794582F75" unitRef="usd">-227400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2015Q4YTD" decimals="-5" id="Fact-83E620F8C1B24F4BC5452977947DA33B" unitRef="usd">174400000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5DE295AE4F8FFCB1E6122977947478B5" unitRef="usd">165600000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q4YTD" decimals="-5" id="Fact-5F8E45F5FEAE7D72D5A62977944FA42B" unitRef="usd">94500000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-437DC14C31F431C62FEF29779475C28A" unitRef="usd">127000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C560AEF0C94218DF765329779458DCCB" unitRef="usd">-59100000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0A55F2E0152196EF29742977945272AD" unitRef="usd">76600000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-4A7774D6FB46472245822977947DFE74" unitRef="usd">31100000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E58F5BEAA736153D2353297794521D0D" unitRef="usd">-13900000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2017Q4YTD" decimals="-5" id="Fact-5CF58CDE5742E737ED722977947485A6" unitRef="usd">232000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2B9B25CD65374B2A3ECF2977944F4C9F" unitRef="usd">83200000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F1CEB8266AD95CAB85B12977947393E7" unitRef="usd">69500000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B8A46A4712E4D8BCDD8D297794753AD4" unitRef="usd">-2400000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-59E0CDE1C657DF1C8D452977943D29D1" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-9AC24E7EDA283287B0E42977943F24E4" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-8594BC150F07259668902977943F97F0" unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-EF30F3A687DFA8935CB42977943A6E7D" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-7E165A87A46A98BC018D29779435043D" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-4DC6DCA0F8D05FF6EE022977943F2113" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-8E70E32C7B7BB40813D42977943C84A3" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-5E666928950DF2007173297794369F97" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-01E41F43A72261C104802977943FCDF8" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-FDFC4C2A9B1A55476B882977945CFF66" unitRef="usd">648000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-FA2E7DA13D6F0A8B2F142977945D06E0" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-4A2547BC05493C99BE562977945D3525" unitRef="usd">680600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-2355DF819F962E1F8EF02977945C0E66" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2016Q4" decimals="-5" id="Fact-4F72FC3D34C84F735F0A29779449EEA5" unitRef="usd">7742300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2017Q4" decimals="-5" id="Fact-14896B8F6C00E3A3F83F2977943A905B" unitRef="usd">8264600000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2016Q4" decimals="-5" id="Fact-93C931E6FDA67F9DC1C72977947C6D35" unitRef="usd">3808300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2017Q4" decimals="-5" id="Fact-2361BC03DE77D994E6D02977945A2B79" unitRef="usd">3879600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestCostsCapitalized contextRef="FD2015Q4YTD" decimals="-5" id="Fact-06CE6E6511B5AE5C30B929779439171C" unitRef="usd">10400000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2016Q4YTD" decimals="-5" id="Fact-90CC5BF47AE8E7D70C0A2977947C88BC" unitRef="usd">12900000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2017Q4YTD" decimals="-5" id="Fact-8C82BB669F1F0C78AE88297794599C60" unitRef="usd">30700000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E2024A3F3569F374874B2977943D8D46" unitRef="usd">95500000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-980FFA5352ED2C0773962977943CBCA7" unitRef="usd">260000000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A27AA2863EF4C63F74792977943B85AC" unitRef="usd">250800000</us-gaap:InterestExpense>
	<us-gaap:InterestPaidNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-60D6F39A7A6A21CE0240297794338AB0" unitRef="usd">39100000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C4B4D657AC8276E40D0329779433269C" unitRef="usd">281200000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0BC41638A53F675E13462977943345E0" unitRef="usd">281700000</us-gaap:InterestPaidNet>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2016Q4" decimals="-5" id="Fact-E66BE8F256BF8A4E5F5D2977946AA058" unitRef="usd">170300000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2017Q4" decimals="-5" id="Fact-4435708B271B27550E0E2977944FA720" unitRef="usd">157400000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2016Q4" decimals="-5" id="Fact-17498B8C3F46B584FE2B2977945B6945" unitRef="usd">1001600000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2017Q4" decimals="-5" id="Fact-20E6320DB3B2FF71FF4329779467BA5C" unitRef="usd">902700000</us-gaap:InventoryNet>
	<us-gaap:InventoryNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-531ACCA1800837309F992977945C1D9F" unitRef="usd">37800000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-A12F0F7537CDB1D52D9F297794356D7C" unitRef="usd">22800000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2016Q4" decimals="-5" id="Fact-FC86D3ABC7D7118AC31E2977945B4BB1" unitRef="usd">170400000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2017Q4" decimals="-5" id="Fact-C892CEFDD7D6BD36AF522977946A0034" unitRef="usd">162400000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2016Q4" decimals="-5" id="Fact-7172258271779517F68229779469ABE7" unitRef="usd">698700000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2017Q4" decimals="-5" id="Fact-EE7CC681C01B8D7CB7BA2977946B043A" unitRef="usd">605700000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWriteDown contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C8143D1034C8156501672977944F8123" unitRef="usd">41900000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="FD2016Q4YTD" decimals="-5" id="Fact-89404C4BBAA2E63AD7172977944F9612" unitRef="usd">48200000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="FD2017Q4YTD" decimals="-5" id="Fact-BF9A51F4EB2EABFBE4B629779450F404" unitRef="usd">76900000</us-gaap:InventoryWriteDown>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F46FEAE34237F498A8BA2977943BEF24" unitRef="usd">22100000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A04FB6C690A2383826FB2977943CC068" unitRef="usd">63400000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2017Q4YTD" decimals="-5" id="Fact-5DE3FE4F597D932EB1BA2977945CF5A8" unitRef="usd">78500000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F6B589729EC476E26B672977947465D2" unitRef="usd">24900000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-75E0F30728EA1ACD1B1129779473E0CA" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AC8E1D3A1F813BD75245297794453093" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5CA9035E4A6417CC59E129779475DEC3" unitRef="usd">24900000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CD8D28C3D55E93D0080D2977945E51F6" unitRef="usd">11800000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-16103CC60A14F30401A02977945D9090" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E1A362007901C26231C529779474BBE7" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2F3E8DEE766F733080D229779474745C" unitRef="usd">11800000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:Land contextRef="FI2016Q4" decimals="-5" id="Fact-7CB2076A1AA9F70D2740297794667BB3" unitRef="usd">137800000</us-gaap:Land>
	<us-gaap:Land contextRef="FI2017Q4" decimals="-5" id="Fact-F118CFD9E30B7F836C31297794655C09" unitRef="usd">141200000</us-gaap:Land>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-36D5247DF5965860038429779448DF00" unitRef="usd">68600000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-DEF44D12474BD4DB940F2977944C4C2A" unitRef="usd">68700000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2C265C8D15AAACA94096297794480AB5" unitRef="usd">65300000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseholdImprovementsGross contextRef="FI2016Q4" decimals="-5" id="Fact-2F43148DF959CF66037A297794516D78" unitRef="usd">123700000</us-gaap:LeaseholdImprovementsGross>
	<us-gaap:LeaseholdImprovementsGross contextRef="FI2017Q4" decimals="-5" id="Fact-D165791A51ACC9EE0073297794458E09" unitRef="usd">80600000</us-gaap:LeaseholdImprovementsGross>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" id="Fact-CD05C0678A7FC7A3E4692977947DC990">P10Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-5" id="Fact-77EC9F516BF83333680E297794680251" unitRef="usd">10748200000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-5" id="Fact-5F7801E9091F1B1F13E529779459A105" unitRef="usd">11054500000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-5" id="Fact-40A5BA64CB2BAB6D405A29779467BB4C" unitRef="usd">22876800000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-5" id="Fact-836D19FA0B6976B969272977945907C9" unitRef="usd">23652600000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-D0148AF2804E255C34292977945A8859" unitRef="usd">3419900000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-E41769D3E0615958A1A02977945A9B24" unitRef="usd">3368200000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E6A563F04A4C8E0359A6297794462F2B" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-40D2D2797CC87FC6A0D0297794593D34" unitRef="usd">13600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-84888128E9D75F6BB5162977943F2F9F" unitRef="usd">467600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9357B3AE51AD7653DB882977943CFF2F" unitRef="usd">481200000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3AC01B6B789E763FB5352977945E2925" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AB5B2599BD2FD82FE6332977945E2B85" unitRef="usd">111300000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7B1503BBAC1962152E1F2977945DB608" unitRef="usd">523600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-474F1DA2FA4024BD105B29779475F65F" unitRef="usd">634900000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-07FBB5C3EE4C1E8684832E9B1ADF1F75" unitRef="usd">155500000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-06EA71C5F98781BB236629779449C99B" unitRef="usd">77300000</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
	<us-gaap:LicenseCosts contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-B2C2E09CCE19E712AEF033D53B7052AD" unitRef="usd">35600000</us-gaap:LicenseCosts>
	<us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="FD2015Q4YTD" id="Fact-D6F1C67C1CA3C800B2B6297794505AF7">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
	<us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding contextRef="FI2017Q4" decimals="0" id="Fact-3CB2DB4C19427EFEFD4E29779458C391" unitRef="usd">0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2015Q4" decimals="-8" id="Fact-2BCBC62F3DA3D228753F328B23872846" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LitigationReserve contextRef="FI2016Q4" decimals="-5" id="Fact-9CD694294A9F416E2580297794651686" unitRef="usd">454800000</us-gaap:LitigationReserve>
	<us-gaap:LitigationReserve contextRef="FI2017Q4" decimals="-5" id="Fact-BE075E460842AC3275DC2977946BECBB" unitRef="usd">0</us-gaap:LitigationReserve>
	<us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="FD2017Q1QTD" decimals="-7" id="Fact-917D5641CA23D52D57792EDAF2B02B9A" unitRef="usd">1250000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
	<us-gaap:LitigationSettlementExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-B3C3850E2B978C534A072977945D0D44" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2016Q4QTD" decimals="-5" id="Fact-C5A7C0929E3CAA62BE5E332307B17954" unitRef="usd">454800000</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E7AB1237257619F7534C297794686AAE" unitRef="usd">454800000</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-5005B4EF3BC41CA227222977945DAA1B" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
	<us-gaap:LongTermDebt contextRef="FI2016Q4" decimals="-5" id="Fact-9442C274F02EAC02E4A629779466FF6B" unitRef="usd">6512700000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2017Q4" decimals="-5" id="Fact-EF0AB54A2643BBF208DE29779466EE40" unitRef="usd">5935000000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="FI2016Q4" decimals="-5" id="Fact-203F40745CBB630EFCC52977945C5C24" unitRef="usd">16400000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
	<us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="FI2017Q4" decimals="-5" id="Fact-FFF9E98930E8DD0135AA2977945C0075" unitRef="usd">0</us-gaap:LongTermDebtAndCapitalLeaseObligations>
	<us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-1AC7AF367BF6DFE2A0D02977946A90E3" unitRef="usd">1700000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
	<us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-6245EEB021D28B7AEC062977944A007E" unitRef="usd">0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="FI2017Q4" decimals="-5" id="Fact-CAF3BE03187D985ED3522977943ACBBC" unitRef="usd">3500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="FI2017Q4" decimals="-5" id="Fact-659CCA520BF97CB993A629779437E51F" unitRef="usd">3200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2017Q4" decimals="-5" id="Fact-803BFB13CB3CCC1E853532A16625EF71" unitRef="usd">1000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2017Q4" decimals="-5" id="Fact-E3BD60B001137894ADB02977943A1508" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2017Q4" decimals="-5" id="Fact-F8D3FE15C84166162D502977943B284B" unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2017Q4" decimals="-5" id="Fact-D5D68BE9F6CB412DCC4C2977943A824A" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-655D27BD2D67C2D3CA572977946A3090" unitRef="usd">1721500000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-4D4D2DF9DFA17F4A9A4429779446E674" unitRef="usd">1734800000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-E4F4042B60AFB36B55F92977943D50F7" unitRef="usd">558500000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-8D61F5F513BBB44F6F7E29779434AB9F" unitRef="usd">993200000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-242451CB3BCA78D9442029779471F6BB" unitRef="usd">1485300000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-3B15FEFB448060DB8F042977943C9FDC" unitRef="usd">3000000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q4" decimals="-5" id="Fact-89504752446CDBB6F5782977943A8212" unitRef="usd">6003200000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-D0E4FC1816778951585D297794498397" unitRef="usd">1722000000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-C086E21E709C525D124A297794494C7A" unitRef="usd">1736300000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-6707EBA7A2AB011B9F762977945C041F" unitRef="usd">0</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-F489A3A967C16A7E905329779472E653" unitRef="usd">994300000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-DF30AA56AAFEC5FB2B4C2977945C864A" unitRef="usd">1482400000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-EF904CB1A6822CF8E57B2977946A28EF" unitRef="usd">0</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="I2006Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-CC2B4799CC7D81A17BF42977943C7797" unitRef="chf">61400000</us-gaap:LongTermNotesPayable>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2013Q2_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-D963EAD481CF5BCEB054332811792E7A" unitRef="usd">15400000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="FI2011Q4_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-2428FA6D4BBFCDE04B5D33270228EDD3" unitRef="EUR">30700000</us-gaap:LossContingencyEstimateOfPossibleLoss>
	<us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="FI2013Q2_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-93664893169971CBCC273327B2D77878" unitRef="EUR">33300000</us-gaap:LossContingencyEstimateOfPossibleLoss>
	<us-gaap:MachineryAndEquipmentGross contextRef="FI2016Q4" decimals="-5" id="Fact-02BC99AEA0C45201B60529779465E44D" unitRef="usd">1105800000</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:MachineryAndEquipmentGross contextRef="FI2017Q4" decimals="-5" id="Fact-C1531C68CDA916E2B1DF297794674AB3" unitRef="usd">1207700000</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:MinorityInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-95F1CD3A54F39681D074297794766471" unitRef="usd">5000000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-4D38F5EC088F9293570129779467C591" unitRef="usd">2100000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2016Q4" decimals="-5" id="Fact-203D0B590C8D82704BB22977945E5890" unitRef="usd">-11500000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-1C505FDCAE0AABE9C97C2977945D41EF" unitRef="usd">-11500000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2017Q4" decimals="-5" id="Fact-C0628261F25E885AEE152977946647F8" unitRef="usd">-14700000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-993A2841650D0ED35D352977946AEE08" unitRef="usd">-14700000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FBAA55A0CB129F36FF712977947660C4" unitRef="usd">60000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-C2E8942B672BC284C0DA297794768F80" unitRef="usd">60000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-0F80FAD8B00D1CB1FF27297794750861" unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2017Q4YTD" decimals="-5" id="Fact-56A3144F266AA57B2B1E29779468C822" unitRef="usd">150000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-F71FD027733D5384BF942977945D0CB3" unitRef="usd">150000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-2211794ED17740027A1D2977943A4174" unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7ECD9EB068E664D156A1297794512A93" unitRef="usd">783100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6238AF8F30702CCC924C2977945049C3" unitRef="usd">-1052600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-F8D1B6A7B7D5CA874561297794749A1F" unitRef="usd">-2380000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6B2724A8957F9AE2603E2977947D0B15" unitRef="usd">-4553600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6F5D648E605B7AC9947529779473AC6C" unitRef="usd">-2484800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-539B77F5A03D2953A0AE29779475D80C" unitRef="usd">-2963100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-823B99EFCCDC93A24D062977947CFE0F" unitRef="usd">3919400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-97D09F080514A8538CD729779474CF9E" unitRef="usd">4587200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-9BB88AC86A2B3B606F3F2977944BEEB8" unitRef="usd">4551000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F445A14EA2291652B351297794686864" unitRef="usd">3547000000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-B18177FE3505846BA0BB297794651AB5" unitRef="usd">171000000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-8C344E5F283B7E96BDC1297794765110" unitRef="usd">3547000000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1QTD" decimals="-5" id="Fact-E96EB60D52B9F8C3DD452977945184EB" unitRef="usd">970900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2QTD" decimals="-5" id="Fact-58B39E6971EEB47DE85E297794522902" unitRef="usd">1049800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-5" id="Fact-C84970BC4A74D6BED8C42977945107F7" unitRef="usd">1032900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4QTD" decimals="-5" id="Fact-C91252EF30EE3B8751E92977947D3FEB" unitRef="usd">649200000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E3B5DA0940EDF4E6DBEB297794668089" unitRef="usd">3702800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-1EDA41B270C9EA620E0229779467AC41" unitRef="usd">3400000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-43D0966DF6FDA68F569B29779466101A" unitRef="usd">3702800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1QTD" decimals="-5" id="Fact-85BFBF172AA95E0E3DF42977944DF895" unitRef="usd">747600000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2QTD" decimals="-5" id="Fact-A4A105D27E8BCCCE792F2977944D0FB2" unitRef="usd">862800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-5" id="Fact-0F139BD4B1EC416009F029779439AEC0" unitRef="usd">1226100000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4QTD" decimals="-5" id="Fact-5847CC72681F6402BC302977944B917D" unitRef="usd">-297400000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="-5" id="Fact-AF50A44EDD835A2E0071297794685E44" unitRef="usd">2539100000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-BACC99070230F4F7FBB4297794689938" unitRef="usd">-44200000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-076A1D3E34D25DB35D9E2977945E22B0" unitRef="usd">2539100000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2015Q4YTD" decimals="-5" id="Fact-975BDACE9F526B95F5A62977947227AD" unitRef="usd">46200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-5D3262A2F219E85AFC76297794756B85" unitRef="usd">46200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2016Q4YTD" decimals="-5" id="Fact-13A82BF39E286B06744629779466E70C" unitRef="usd">-7100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-4778F65C8889AB62CDA229779469D83F" unitRef="usd">-7100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2017Q4QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-163CDFF002374C8D06D933F7A8B5C476" unitRef="usd">150000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="-5" id="Fact-26D779EBBC0034813AD7297794682A18" unitRef="usd">131000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-373D3579FA44C672E15A29779472D9C5" unitRef="usd">131000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-EFFD7F62D1CE56ECB87F4229828EB682" unitRef="usd">7500000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
	<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-30CC04FBC3B25B5AA9B84229828B665E" unitRef="usd">7500000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
	<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-802B8DD952FBEAF2530F42D8F7C11E67" unitRef="usd">0</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2015Q4YTD" decimals="-5" id="Fact-1A3160F91B2FE3A5634A2977947DD668" unitRef="usd">10900000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-80C4492EE1EDC1C5E00029779476B76F" unitRef="usd">10900000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-D36889889D3B9AF3FCFB29779476F509" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q4YTD" decimals="-5" id="Fact-155F424D53FD126DC4A829779469ED8C" unitRef="usd">600000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-CDDDBB489BC4CE00DA6F29779464B072" unitRef="usd">600000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-ABD236E73F655B739793297794352FD4" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4" decimals="-5" id="Fact-6609FE8958B2EBC95ED4297794327811" unitRef="usd">2187600000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-98A8B921C0DEE7F2236F2977944B6A01" unitRef="usd">1700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SolothurnMember" decimals="-5" id="Fact-6FFA7C0E5182E6EF6FDE3357BEDB525F" unitRef="usd">161500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_country_DK" decimals="-5" id="Fact-4235464597EA68ABFA2029779438BD66" unitRef="usd">684900000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-0668C86D8CCC81B0CB112977947D333C" unitRef="usd">1296500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-DC0522125D4E2F27E3252977943D2084" unitRef="usd">7700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-483059ACAD223979EA1C2977943E2238" unitRef="usd">881700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4" decimals="-5" id="Fact-D36EDFDE52772FCE7DB62977944E0B5D" unitRef="usd">2501800000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-E6D6876EB66222216F692977946AB159" unitRef="usd">1400000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_biib_SolothurnMember" decimals="-5" id="Fact-F34099F11393FFC4080F2977943A70A8" unitRef="usd">545500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_country_DK" decimals="-5" id="Fact-673360AAD7F2EE129AE229779438A46F" unitRef="usd">643600000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-BBF4EBEDABE026A6C24B2977944A1C88" unitRef="usd">1272300000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-3C042F08E721E3248F222977945E3115" unitRef="usd">7000000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-CBE6CD3FABCAFBB797782977943EAD10" unitRef="usd">1221100000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4" decimals="-5" id="Fact-BBF52B71482BE06F9A502977944DEB9E" unitRef="usd">3182400000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-72A51CFDC550839E52E22977944C471A" unitRef="usd">2100000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4_us-gaap_StatementGeographicalAxis_biib_SolothurnMember" decimals="-5" id="Fact-47D493895B522CBC42DB2977943731DF" unitRef="usd">1215700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4_us-gaap_StatementGeographicalAxis_country_DK" decimals="-5" id="Fact-95A426499E486B22636829779439AE28" unitRef="usd">707100000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-1DEE8ACDC2AFD75E29CC29779459624F" unitRef="usd">1226900000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-F490C78FC46185684F692977944C0005" unitRef="usd">5200000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-FE015E5FDA468544656B2977947C8073" unitRef="usd">1948200000</us-gaap:NoncurrentAssets>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6B3B7A8667461C0DE3B0297794692E34" unitRef="usd">-123700000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-23871A4F80E865664C522977946685FE" unitRef="usd">-100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7CE45CBEC5CFFC55CD36297794694C4D" unitRef="usd">-217400000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-275E0C7C359522BD494629779468F640" unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D373EBD0E6237678335A297794699F23" unitRef="usd">-215400000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-8DD74FFEB393D4FA84DC297794672E58" unitRef="usd">300000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NotesPayableCurrent contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-549DF237A722FF142E4529779470BED1" unitRef="usd">3000000</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-EAC761FB8F86172314E22977945CD0B4" unitRef="usd">3200000</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-A289CA026AE8A429EBD2297794593008" unitRef="usd">6100000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-B68EC04A75FCEA88786C2977947091E0" unitRef="usd">1874500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-A81E0D6F8118E4A70C8D29779470D727" unitRef="usd">1796000000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-6E5565A4DB803674ACC3297794723A10" unitRef="usd">583700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-26C5705805D943BE2DEE29779472358D" unitRef="usd">1026600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-9491FE7F06F31ECD47B72977945B816F" unitRef="usd">1521500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-F48F1EDBC3181699A553297794712B46" unitRef="usd">3200000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-BFD89585BD27981C835D29779459C17D" unitRef="usd">2077600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-9B55B9D7AE2F6EAD16C62977945A455C" unitRef="usd">1851900000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-7FC849EFBD60EFAB99C82977945B16F5" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-683027844BD30F8C07712977945AA736" unitRef="usd">1032900000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-64D21381119F7167A25729779472370D" unitRef="usd">1517700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NumberOfReportableSegments contextRef="FD2017Q4YTD" decimals="0" id="Fact-9E63D0002C8C7B0006FD2977943CC9E2" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-402C7278FD6776E8A76B2977946804AD" unitRef="usd">0</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-B20D59ED18503B8AA58E29779469065E" unitRef="usd">1500000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-02C7BF57B1D36D9B37702977943B9E9C" unitRef="usd">600000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-5" id="Fact-412CC380B0185B1303EF29779469C3C0" unitRef="usd">4891000000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-5" id="Fact-986C45C5092DEF4C336E297794712FF7" unitRef="usd">5150400000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D0E8C7236626C0331A432977947629FC" unitRef="usd">5344200000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2017Q4" decimals="-5" id="Fact-BE95DA055519F56DCA632977943E4D94" unitRef="usd">617000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-5B098C6AB4F8E9AD1F522977946AC9A4" unitRef="usd">72600000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2017Q4" decimals="-5" id="Fact-B8FA6392ABC64D6E74FB2977945CA62C" unitRef="usd">65700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2017Q4" decimals="-5" id="Fact-605E80C61A42882D48402977945E2F31" unitRef="usd">66900000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2017Q4" decimals="-5" id="Fact-A6E3DA866A6AC9AFD7232977943F71FA" unitRef="usd">68400000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2017Q4" decimals="-5" id="Fact-E3975123284DBE3A269D2977943EC040" unitRef="usd">72300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2017Q4" decimals="-5" id="Fact-68A3A277AD0C43AA04132977947CD66F" unitRef="usd">271100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-336DE3CC00531DE2FE582977945052F3" unitRef="usd">1400000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-8" id="Fact-75040CB7E5394F19AF0729779436FE2B" unitRef="usd">2100000000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-A024F1A73E81C1D2405F29779448F24D" unitRef="usd">685700000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-EC33F827CF85C523EC5D29779446035B" unitRef="usd">636900000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-24B253A052A35F7FD37F2977945A73CC" unitRef="usd">1093300000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-3CC47B0B9ECEFA003A63297794664628" unitRef="usd">962000000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q2_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-D36686F5FCC99297989B33D3D8810012" unitRef="usd">15000000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-29306E3C5B9F17C129CB297794685457" unitRef="usd">1335800000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-AD2FC853FCFD16DDCF1529779468484F" unitRef="usd">1027500000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-B5B99B19B0AC0F0045D033D4698399E5" unitRef="usd">29100000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherCommitment contextRef="FI2017Q4" decimals="-5" id="Fact-EB8A6717B05B4FAD6042297794755654" unitRef="usd">460000000</us-gaap:OtherCommitment>
	<us-gaap:OtherCommitment contextRef="FI2017Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-EE8BA78F5BA9C9958C222977944D9158" unitRef="usd">270000000</us-gaap:OtherCommitment>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-5983FBFF5012BF48B05C29779467CAE2" unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1C47590BD649C554D10B297794676578" unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-7B205DCB5094F0E0A4292977947329B2" unitRef="usd">9200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C7C7836D831E96D1B4392977945E3BDC" unitRef="usd">6500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember" decimals="-5" id="Fact-502208552FC6835152C032747D54B3E0" unitRef="usd">8500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-5876B1EA642A676A54842977945E5029" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-1E31A9642A521FECB9DA2977945E1E97" unitRef="usd">110800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-6F6805D692D8AF87C1AB2977945E9B18" unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-C83AB816325AA6F794032977945E0484" unitRef="usd">-96400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-646B69452082879171792977945B875E" unitRef="usd">-92500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-E5F065DA0BCD8318A1572977945B34FB" unitRef="usd">5100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-0CB6CF5BF453201DEDD72977945B5EFA" unitRef="usd">51600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-1B62C248A8BAEEC505842977945AC984" unitRef="usd">-10600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-E01D9CCC008E7A86A0F32977945A136E" unitRef="usd">-138600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4EA6E004CA7EFAE595F4297794722ED1" unitRef="usd">-42700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-EF4D62AB655284C4C2DC29779445172E" unitRef="usd">-4100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-BBBB382A55D5F08C95452977944BCC1B" unitRef="usd">-193800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-2A5198EA071D1517F87429779435FC67" unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-38126960A15A4309190D29779445B92C" unitRef="usd">158700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-9FD26245C34516CD4E8B297794731520" unitRef="usd">-61500000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-29ECAA51B6DDFCB0922A29779464E366" unitRef="usd">47600000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-7185D6DABF4C50ABC483297794675A81" unitRef="usd">-162300000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-081D8D440845054D3C50297794663F0A" unitRef="usd">-96400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4A5513761CA93994A547297794643FA1" unitRef="usd">-138600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3C61855B3F3D117AB20729779468D539" unitRef="usd">158700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-938E2A3B84E98377746B29779475EE7D" unitRef="usd">164500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-1C280C0A3F7300391494297794764BE8" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4B1DE6F73F9A7C48464E2977946651EA" unitRef="usd">-95800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-9A32B991EBB3DFEF0EFF297794695C96" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-6440DB24A0BA105F966429779451A6FB" unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-6BDE31AA8C8406FF515629779468FB8C" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD" decimals="-5" id="Fact-0D5BBCDB0536E315F1C329779467DBFD" unitRef="usd">-164500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-5E0A036BC983F54741FB2977945EF9B8" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-BEAF8C0FA4B32A4A4FCF29779464C52C" unitRef="usd">-61500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-5B124676D87321630C852977945E39A3" unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-1211090927BECCCEFC0029779476B869" unitRef="usd">-164500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-4D7F1706DC1CCAC3DDAD2977945EEAD7" unitRef="usd">-96400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD" decimals="-5" id="Fact-343118333C49F6F8AFD42977946609FA" unitRef="usd">-95900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-3B1394F63934B059D6692977945B905E" unitRef="usd">5100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-708800994370143788C22977945BC916" unitRef="usd">47600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-6BF552108833414F82D72977945B19F9" unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-A5D7CFD8416897A87FAC2977946AC3FF" unitRef="usd">-95900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-E433A8557E02F89884C42977945BB66C" unitRef="usd">-138600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD" decimals="-5" id="Fact-95819A133D1CC30FF7BA2977946685FF" unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-C6F28C8D50C13C416F012977946A6E4E" unitRef="usd">-4100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-594BA78468D42B5684E3297794746545" unitRef="usd">-162300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-6916EF274B35C67D4B562977947DEB57" unitRef="usd">9200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-2D5F59C976A6558D86CF29779433B76D" unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-721D1C3B34674FBC38C929779473F64E" unitRef="usd">158700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-20AAF4569E977AB1EDDD29779468C680" unitRef="usd">6200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E2C2C00994E501136ECC297794669D44" unitRef="usd">-5100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-317B0722486217E3B9012977946663CF" unitRef="usd">4100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C6186B45C9B137A7390E297794673C04" unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C21F278A06AE31B8740229779468B488" unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-F4A0EC4B16CBFD019748297794670275" unitRef="usd">-12700000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-B6C6A75B5AB8BE331D3929779466ABB6" unitRef="usd">172300000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4497D12F493DAC467240297794670AB6" unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0A3BE614AA55452A008C29779466C2EE" unitRef="usd">-31500000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6499824CF878A85F0A14297794649687" unitRef="usd">110800000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-EB44F78106943C14601F2977947434F3" unitRef="usd">51600000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-1D655EAAF1C0DCBCB49529779474A899" unitRef="usd">-193800000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E677A5A4C73B328457B129779467B55F" unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-072A365C83456C52A9032977946450B4" unitRef="usd">-10600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-396866962DBD32505438297794754482" unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherLiabilities contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-BA89FCEF2B876F69F20C297794660A31" unitRef="usd">7900000</us-gaap:OtherLiabilities>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-1DCE525194DF936EFB0529779466F0A1" unitRef="usd">2903500000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-F6A4C82A4D135644809C29779468DF55" unitRef="usd">2901300000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-D4A7BD88C7140A305594297794698AF6" unitRef="usd">722500000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-78C0FC0A78912A7479C3297794696E26" unitRef="usd">1628700000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D00902D3A014132514F429779450E706" unitRef="usd">-129900000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4A4CF8F58F67137CE91029779474F8B9" unitRef="usd">-89000000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-85D9CFDC12473ACCFB65297794529023" unitRef="usd">-162100000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FFF2F8A6A4AC66976C612977943CA1B7" unitRef="usd">-13800000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-14F3F93495B14C31E2052977946A5857" unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D8C82504F348B99C74442977945CC929" unitRef="usd">-17000000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-1995576DDB5BF83817AB29779470B376" unitRef="usd">-900000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B21F268453256F01582E2977943C9F46" unitRef="usd">-13100000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-01004321D9F9F1534D15297794646C58" unitRef="usd">-19500000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonrecurringExpense contextRef="FD2017Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2017RestructuringChargesMember" decimals="-5" id="Fact-97D7FAE93C0068A60DCF2EC364DEFDCB" unitRef="usd">170000000</us-gaap:OtherNonrecurringExpense>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-939EA44E7F35BA325FA9297794646C77" unitRef="usd">236100000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-3F092AE7B43074E752F42977944D26D2" unitRef="usd">62900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-BD9ED3812381E0910FD12977944FA6FD" unitRef="usd">0</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-D6C2E16EB0CD000C0B902977945A87A2" unitRef="usd">142000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-E7466235DCBED107F0AD2977944C9397" unitRef="usd">62900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-117C941D934FDB23C3992977944D5001" unitRef="usd">31200000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q1QTD" decimals="-5" id="Fact-C16469DD22E8754FEB432977942C2D76" unitRef="usd">87900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q2QTD" decimals="-5" id="Fact-07D0920248F6C60313342977947DF414" unitRef="usd">79000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q3QTD" decimals="-5" id="Fact-DA572A9CD302F2209D1C2977946552A6" unitRef="usd">98600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4QTD" decimals="-5" id="Fact-D9B886E07F9DBC15EEFA297794658334" unitRef="usd">50900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-B944513B74726FB42CDC29779475FEE0" unitRef="usd">316400000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-30F4584806292DD696FA33E6E0CDFA26" unitRef="usd">20200000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-3E6EA9CC18ADA12E05EA297794526D9C" unitRef="usd">0</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-2E1352080F833EB759452977944D9EF0" unitRef="usd">224700000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-D15D11C545A390E5050933A52716EA8E" unitRef="usd">21900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-0973B8D74261AF3B19A029779447AA85" unitRef="usd">20200000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-88F8268151DDFBC3C4B5297794691C2C" unitRef="usd">71500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q1QTD" decimals="-5" id="Fact-7ECE5F0D1880EA39877D2977943FAAE8" unitRef="usd">90000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q2QTD" decimals="-5" id="Fact-ABEB5BB74D1F7AA2DBF72977944D38B8" unitRef="usd">41600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q3QTD" decimals="-5" id="Fact-D6BC8C8E71DEB70AE8F22977943AC2E5" unitRef="usd">48800000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q4QTD" decimals="-5" id="Fact-6822BB89A99651FA5BDA2977944BECA4" unitRef="usd">179600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q4YTD" decimals="-5" id="Fact-DD98E064481C262AFBD4297794740145" unitRef="usd">360000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-25635F992C297CCDF37C2EA284E5ED36" unitRef="usd">64800000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-DE1E71FF5AA772825E1629779471AC12" unitRef="usd">42700000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-FE41E9D01850A1D851E3297794489DB0" unitRef="usd">0</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-8B5B496EB32304BDD6312977947D2180" unitRef="usd">249500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-CE117E119EFDD294813929779472DEE1" unitRef="usd">16900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-7E3C6B6825CA6ED75A2C29779453741B" unitRef="usd">42700000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-7F6696AC18C7A3834EF4297794482F70" unitRef="usd">67800000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-389DB9E3B5A036EE68672977944EC39E" unitRef="usd">44500000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0B4D28E6F04E662413C129779452D5BC" unitRef="usd">22800000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-FFA34818596314F616222977947C1908" unitRef="usd">11000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2FE578D175E77F9CD7BC297794509544" unitRef="usd">5000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6166AA29DA0ACC642A32297794520C6A" unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q4YTD" decimals="-5" id="Fact-F2F42C375BFA4D37D4672977947D9145" unitRef="usd">1365400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-6FC9B7B769C4122FB69732B0AC280425" unitRef="usd">365400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-8" id="Fact-058CD4E4D92289E4EC6C2977943AE59D" unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRestructuring contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-C69C8ECB4B25BF84EC8D334057082352" unitRef="usd">9000000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-646BCC2386F77597BBAD3340571769B6" unitRef="usd">31200000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-C5E2AD28832EE9737773334056F8629B" unitRef="usd">40200000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2017Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-5369B5EF2D1AC73B53A6334156C5CCF8" unitRef="usd">2900000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2017Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-B3F1BF326B8C92B0F9913341556D8FF0" unitRef="usd">1700000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2017Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-F2CD6C78F297533849CB33415802E74A" unitRef="usd">4600000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsOfCapitalDistribution contextRef="FD2015Q4YTD" decimals="-5" id="Fact-90324808DFB7597BA9E429E02167C371" unitRef="usd">0</us-gaap:PaymentsOfCapitalDistribution>
	<us-gaap:PaymentsOfCapitalDistribution contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7615E80074A560B2C9D029E000ED2E54" unitRef="usd">0</us-gaap:PaymentsOfCapitalDistribution>
	<us-gaap:PaymentsOfCapitalDistribution contextRef="FD2017Q4YTD" decimals="-5" id="Fact-85D0B249D517B1A0BC8129DFD814C280" unitRef="usd">302700000</us-gaap:PaymentsOfCapitalDistribution>
	<us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="FD2017Q4QTD" decimals="-5" id="Fact-354D055EE4145F9416A83296A2135976" unitRef="usd">7700000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
	<us-gaap:PaymentsOfFinancingCosts contextRef="FD2015Q4YTD" decimals="-5" id="Fact-87FA247837922122D55A297794589844" unitRef="usd">47500000</us-gaap:PaymentsOfFinancingCosts>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F2ECCB6DE32D6F29786A29779473ABFB" unitRef="usd">70900000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-DCF3037D9D373ABC5C9B29779452BEF0" unitRef="usd">8500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-5" id="Fact-380BEBC3649DC6317D6729779475EF36" unitRef="usd">5300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6FEBE3C5F26B84DBA9162977945311AF" unitRef="usd">6864900000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D52465419FA7D6DF379B2977944FA8C4" unitRef="usd">7913200000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2D2502A9F3001D877175297794745B92" unitRef="usd">5355200000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="D2006Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-EDAC83C1914057C748C02977944BC0E6" unitRef="usd">220000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-8236754785E515A019CC2977942C469C" unitRef="usd">200100000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E87E846042D80943E3BD2977945072BB" unitRef="usd">198800000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D4F6340A238492461D7C2977947DFB81" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2017Q4YTD" decimals="-5" id="Fact-12507D188FD2AD8C92182977947397B5" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2015Q4YTD" decimals="-5" id="Fact-8E60B0C5BD9340506C8129E800D8CFC2" unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
	<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2016Q4YTD" decimals="-5" id="Fact-14F6DD4E0DAF44DA36A329E7E05609FC" unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
	<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2017Q4YTD" decimals="-5" id="Fact-7A78323B198598B7EB1629E82A58D4E8" unitRef="usd">120000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-5FB702B1B5C5CDCDFA762977943DB1AA" unitRef="usd">15400000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AF17C39D28B21395A80B2977947CCAAA" unitRef="usd">111600000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-BF278A8D639E1876889E2977944F9965" unitRef="usd">975400000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-4FE6C84471B37AE30D94297794520A9C" unitRef="usd">850000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-05C03B9B31D22A953A4129779447A05B" unitRef="usd">1200000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-22DEE178D86601A77B5A29779475924D" unitRef="usd">1200000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-399983B3A52FAFAEA4A12977945270A3" unitRef="usd">13100000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-956FF15FC31238C4FA332977944B8845" unitRef="usd">38600000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-5F44FAC74C1863A6B2F029779474E1D2" unitRef="usd">3000000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E89F849841E6004E751029779474E480" unitRef="usd">643000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-5" id="Fact-FCAA2CF149219F73A8F52977944EF805" unitRef="usd">616100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="-5" id="Fact-6793D63F528F5258DE2029779474FBB8" unitRef="usd">867400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToMinorityShareholders contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-502473ACB2C0CCAEB4F33347BCA34ED2" unitRef="usd">150000000</us-gaap:PaymentsToMinorityShareholders>
	<us-gaap:PaymentsToMinorityShareholders contextRef="FD2015Q3QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-74E7F6A0311A3147C8ED3346F73423EE" unitRef="usd">60000000</us-gaap:PaymentsToMinorityShareholders>
	<us-gaap:PaymentsToMinorityShareholders contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E3590A2CD3C2707F25A529DD6169AC73" unitRef="usd">56100000</us-gaap:PaymentsToMinorityShareholders>
	<us-gaap:PaymentsToMinorityShareholders contextRef="FD2016Q4YTD" decimals="-5" id="Fact-ADDAFA24E5ED06DEF6B829DE8CD9C1B5" unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
	<us-gaap:PaymentsToMinorityShareholders contextRef="FD2017Q4YTD" decimals="-5" id="Fact-183B015E80FB9802C75A29DEB46EFF5E" unitRef="usd">134100000</us-gaap:PaymentsToMinorityShareholders>
	<us-gaap:PensionExpense contextRef="FD2015Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-052E28834BEB9062436A29779476DF2F" unitRef="usd">12900000</us-gaap:PensionExpense>
	<us-gaap:PensionExpense contextRef="FD2016Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-3D3804D15570AE037AC9297794756101" unitRef="usd">15300000</us-gaap:PensionExpense>
	<us-gaap:PensionExpense contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-A709926C5BBADA33A0FE29779475D4A1" unitRef="usd">12300000</us-gaap:PensionExpense>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="3" id="Fact-62895C1642E2200AAAA529779466B962" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="3" id="Fact-3EC5B9A01D3D040515442977945B22E0" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4" decimals="-5" id="Fact-4508E26F849314F3B5D52977943C2928" unitRef="shares">8000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_biib_SeriesXPreferredStockMember" decimals="-5" id="Fact-357B2D056DB32F9AEF60297794450F39" unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_biib_UndesignatedPreferredStockMember" decimals="-4" id="Fact-E8D18B132C8267966EDC2977943F5E1C" unitRef="shares">5250000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-4" id="Fact-4D0CC5A89B95D9E307552977943F17D7" unitRef="shares">1750000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4" decimals="-5" id="Fact-EA71828C93E7D22B423B297794681C37" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4" decimals="-5" id="Fact-FDE9B58E949C3F0E44E1297794679928" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2013Q3_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-3B8529869443E0BFA92533BD660938D9" unitRef="usd">25000000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-74B7A3ACF010831AC68633C58CB45A62" unitRef="usd">58400000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-0F210FD4C0B14D971BAF33DDB9F8D608" unitRef="usd">11100000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-43398BC12F995A2FBC9F33DFDCDB08B5" unitRef="usd">12700000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:PrepaidTaxes contextRef="FI2016Q4" decimals="-5" id="Fact-2B820B014F00D90AEAD42977945E48F8" unitRef="usd">817000000</us-gaap:PrepaidTaxes>
	<us-gaap:PrepaidTaxes contextRef="FI2017Q4" decimals="-5" id="Fact-E50EF987A3AF197F466B2977945DB771" unitRef="usd">657600000</us-gaap:PrepaidTaxes>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E49C2C2774B0CB5A175329779475B6AA" unitRef="usd">5930500000</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0E5077A273AB80C19B8929779476947F" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A28C59907E1F71A5458D2977945270AD" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-083062F1B665955EFAE529779474F1D5" unitRef="usd">-5200000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-BCFECD2BB41CB6F1C9A5297794742B43" unitRef="usd">-2800000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B2EC7AF8ABFBDA0F34332977944EE23E" unitRef="usd">-8600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D305FA2BF8482A92151A2977944D2AED" unitRef="usd">4063000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1AF97E71C479443CBA622977947454C9" unitRef="usd">7378900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A0CEFB71BEA7A53F97222977944DA8F9" unitRef="usd">5565900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-5" id="Fact-758011F97AC0A073D784297794779301" unitRef="usd">6300000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2130FA78045FFA6E1297297794693399" unitRef="usd">2200000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A383412C6A0AD02DEE7E2977945CDE35" unitRef="usd">700000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProfitLoss contextRef="FD2015Q4YTD" decimals="-5" id="Fact-16A5C34B1E34E74F4684297794719696" unitRef="usd">3593200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q1QTD" decimals="-5" id="Fact-7B1BEEA0D135CFB56F2B2977944DD702" unitRef="usd">969200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q2QTD" decimals="-5" id="Fact-C9FA9B597D40E043519629779452F844" unitRef="usd">1048400000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q3QTD" decimals="-5" id="Fact-4DDEFB8B4AE89A6E69E72977947D7B0E" unitRef="usd">1030200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q4QTD" decimals="-5" id="Fact-81482DFB39943D1A34BC2977944F7B5D" unitRef="usd">647900000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7A59DD466A01EA43104D2977946B5245" unitRef="usd">3695700000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q1QTD" decimals="-5" id="Fact-C4B37D6A0DF45FCA02652977944DD505" unitRef="usd">747500000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q2QTD" decimals="-5" id="Fact-3805CC5D75ED6E24160A2977943AE5DE" unitRef="usd">862800000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q3QTD" decimals="-5" id="Fact-A9116BE50847774894392977944E1C44" unitRef="usd">1226100000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q4QTD" decimals="-5" id="Fact-8D8BD1478B7EC96C41BC2977944D90EA" unitRef="usd">-166300000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E2C654A9F5293A7EF62829779471052B" unitRef="usd">2670100000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" decimals="-5" id="Fact-53B6F06CB95F04F7DCFA327CFA138A40" unitRef="usd">104800000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" decimals="-5" id="Fact-C23662155E38AF73574A327CA575B811" unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-EDB656528E90554C4ACE327BEA70602B" unitRef="usd">20300000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" decimals="-5" id="Fact-9FD0320402963806492C327C48B0BFC4" unitRef="usd">25900000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-C3366DF74581F41FE1EC2977944BD99B" unitRef="chf">64400000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-22AFF54A6EDD1C35373B29779458A5E6" unitRef="usd">62500000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2017Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" decimals="-5" id="Fact-DE7B6DCF4D8B8D119379327E1E9683CB" unitRef="usd">17200000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4" decimals="-5" id="Fact-DDD6A921E1F0C4872F61297794659748" unitRef="usd">3941100000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4" decimals="-5" id="Fact-CDD2F624D8A9B958990E297794659370" unitRef="usd">4741500000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-5" id="Fact-A03A580FAB51AAFCD24829779469E67B" unitRef="usd">2501800000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-5" id="Fact-90B8DF1901722CCCA68829779466053C" unitRef="usd">3182400000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-3A26F01A5DADF988BAEB297794659B5D">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-EEB2F8E4422C1C2ABEA22977942D6051">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-EC26431B9E0E19AEFD4B29779470C7A6">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-AD9B5AA8AC3714F7D0D729779465EE7E">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-EE05B893B6CC5D7C935E2977945D6227">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-E10668EFB4089CD8391A29779465F8BC">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-88A35E4A65C8D6ACDE04297794658AEC">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-50B23F39C3C4532872782977946AE0AF">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E06F128B9571AE91627F2977945E4CE4" unitRef="usd">-171000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-84523D28A82526B3940F2977945EB21E" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-9C91A655807EFFE609272977945EDFF5" unitRef="usd">-172300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-4C66B6422F86F8614CB92977945E4D23" unitRef="usd">1300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-848DD1FF59FF623DB97D2977945EEB90" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-DBFE58E783B744F9DDBD2977945B54FF" unitRef="usd">-3400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-D3CACD3A83E69DAD4B772977945BDFAC" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-4895ADB6E329C4FF89CB2977945BCB83" unitRef="usd">-4000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-A73A1A335E4BE7DB78A82977945BF5D6" unitRef="usd">600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-112C4A527299DB0F645E2977945A2A6E" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2A45AA13DD146AC7415629779473290C" unitRef="usd">44200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-8D73E7775FE856539E5F29779432BCC9" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-E4D12BFF242E9F838596297794333061" unitRef="usd">31500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-E84643D7E20B786CB8C62977943DD5E1" unitRef="usd">12700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-E9BC868E699B74F111722977942C787D" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:RepaymentsOfDebt contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FD9C7CDF1F226710227B2977944FA34C" unitRef="usd">2100000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5D82FF7A0967E7D21E992977944BB5B5" unitRef="usd">2700000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2017Q4YTD" decimals="-5" id="Fact-BC60BAE65FEF8061D1872977945864F2" unitRef="usd">560900000</us-gaap:RepaymentsOfDebt>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2012Q1QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-A06A7F316689641DBCD933E41B940A5B" unitRef="usd">29000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-3ED784FFEA34ADAD3D7D33C7BCA620C7" unitRef="usd">75000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2013Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-41EF727D82E234C814CE29779458218F" unitRef="usd">46000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C0BDF6D38D7CB04985A52977946982CB" unitRef="usd">2012800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-7F1C307AB6E5CDB2144929779459C042" unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-784880CE0601B5A26E4C297794533839" unitRef="usd">42800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-5C90529011EE9F589A6033DED3BD3448" unitRef="usd">54500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-3DB5B76C1BAEBA6F1D2D3436840E964A" unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" decimals="-5" id="Fact-8F16D70F8DE106A61CCE297794333FDF" unitRef="usd">9700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-2BA47A1E178697E18D9133EEDE13D3EB" unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2669FA6DDDB803D09A03297794681FCE" unitRef="usd">1973300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-BA0B0806EFA4AB37819D2977945ABE41" unitRef="usd">5500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-B943CF9D664320D788F4297794734CC4" unitRef="usd">35300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-3EB2EF103C0DAD02ABF833DE9EB48168" unitRef="usd">26500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-2CF1C0E4F8FE5E7275153381F776821A" unitRef="usd">50000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" decimals="-5" id="Fact-B7D66CA9026B7101F97A2977945A2CDC" unitRef="usd">10300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-130A151248C52FCBD2D233EBF7BB388D" unitRef="usd">27800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" decimals="-5" id="Fact-4E0F22B58963FDF22A5834062CEAFD53" unitRef="usd">300000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" decimals="-5" id="Fact-158843523E4EA9B46F7A33F643DDF804" unitRef="usd">50000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3599C65B168642561B9B2977946B8AF2" unitRef="usd">2253600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-54B308D076878DF2D03133DEB447829D" unitRef="usd">27500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" decimals="-5" id="Fact-F7F71062488DEDEA021C340479158BFA" unitRef="usd">80300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-C1ADAE7DD5A6F714CECF3410E3C563B3" unitRef="usd">263400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-452BB5374CB72C37A0172977943B4508" unitRef="usd">12000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" decimals="-5" id="Fact-22BF045F0A2FFF46C9C42977942C6AFA" unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-D55E18059ECB9078087533EB1EC5C4B4" unitRef="usd">33000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2015Q4YTD" decimals="-5" id="Fact-26052C5D49D82CAEA1E729B23722C9EF" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2016Q4YTD" decimals="-5" id="Fact-B6B990DB2BEC2D0952BB29B2641BCFAC" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_RemedyPharmaceuticalMember" decimals="-5" id="Fact-89E0CD1540984FA739F82E7300DF4078" unitRef="usd">120000000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2017Q4YTD" decimals="-5" id="Fact-BB81EFB87C723EC0444929B374D2927C" unitRef="usd">120000000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="FI2015Q4_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-23EF8196BFAFB735E6D92EB35EB929FF" unitRef="usd">102000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
	<us-gaap:RestructuringCharges contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D527EB6E8D32A76AAC2F29779465F893" unitRef="usd">93400000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2015Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-69E08079EF1FC3C69C502EAD8891C65D" unitRef="usd">93400000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD" decimals="-5" id="Fact-B94EEAB640C3FCA62FF72977946548BA" unitRef="usd">33100000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD_biib_FacilityLocationAxis_biib_CambridgeMAMember_us-gaap_RestructuringPlanAxis_biib_A2016RestructuringChargesMember" decimals="-5" id="Fact-EF73FA790FF09C68C2D22977945CF6D0" unitRef="usd">7400000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-5F6661484C8B08ABDDB22EAD3A3CF246" unitRef="usd">8000000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2016RestructuringChargesMember" decimals="-5" id="Fact-D8DB447C6A55D9A281482EAA1530BF2F" unitRef="usd">17700000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q4YTD" decimals="-5" id="Fact-1D457E579C74AF1CD97029779471AA06" unitRef="usd">900000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringPlanAxis_biib_A2017RestructuringChargesMember" decimals="-5" id="Fact-388247B3B91219C67C322EB6DD5F024D" unitRef="usd">900000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringPlanAxis_biib_A2017RestructuringChargesMember" decimals="-5" id="Fact-06E771474CF1231799472EB5FEF9322B" unitRef="usd">18500000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2017RestructuringChargesMember" decimals="-5" id="Fact-4031DA345C12827E2E412EAA457DCEB2" unitRef="usd">19400000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCosts contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-3890F58437E925534C7A333F9E65BE39" unitRef="usd">5400000</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringCosts contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-7119F5854E0B3CB95184333F9E65B99A" unitRef="usd">4900000</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringCosts contextRef="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-F772C4D9E4D73FBE7AFA333F9E652748" unitRef="usd">10300000</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-B7FDED120483CAB2E79B333ECF366235" unitRef="usd">3600000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-31FD04236F129F696783333EA9BC3352" unitRef="usd">33700000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-F8442C3E897C086B0FD0333ED06B635D" unitRef="usd">37300000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-6B8419A74BCA5164CF8F33411B4C39A3" unitRef="usd">2900000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-04843DF93B9A5346BF3633411B60E483" unitRef="usd">2200000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2016Q4_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-7265E306D1E8C389534A33411B402D41" unitRef="usd">5100000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-A25B9249DCC31CC7BD4133418CCD2D60" unitRef="usd">0</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-80D38BCEAD2DBB0C6B0E33418B88F56F" unitRef="usd">500000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2017Q4_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-7640FCDA712809B0396A33418E079F3E" unitRef="usd">500000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="FD2016Q2QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember" decimals="-5" id="Fact-C2D482BCE226CE80BD2B29779459F98A" unitRef="usd">15800000</us-gaap:RestructuringReserveAcceleratedDepreciation>
	<us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="FD2016Q3QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember" decimals="-5" id="Fact-484BDA011C049E722E46297794590F20" unitRef="usd">15700000</us-gaap:RestructuringReserveAcceleratedDepreciation>
	<us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="FD2016Q4QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember" decimals="-5" id="Fact-B5B13E82A9B81BB4EFAC297794599EF3" unitRef="usd">14000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
	<us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="FD2016Q4YTD_biib_FacilityLocationAxis_biib_CambridgeMAMember" decimals="-5" id="Fact-C6D4A3071B0656F717BA29779458D512" unitRef="usd">45500000</us-gaap:RestructuringReserveAcceleratedDepreciation>
	<us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="FD2015Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-AD9D910B22B94451FCA82EB201816C27" unitRef="usd">15900000</us-gaap:RestructuringReserveAccrualAdjustment1>
	<us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-A12F8EFABA66AF9427913340D8124902" unitRef="usd">2900000</us-gaap:RestructuringReserveAccrualAdjustment1>
	<us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-5F82422B0AFC7A7A3E5A3340D832F99F" unitRef="usd">-5200000</us-gaap:RestructuringReserveAccrualAdjustment1>
	<us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-FE4BC147D1C74E6CBC043340D812AB7F" unitRef="usd">-2300000</us-gaap:RestructuringReserveAccrualAdjustment1>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-5" id="Fact-E9C3F035107036BA5CF02977945912E4" unitRef="usd">15071600000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-5" id="Fact-7CE79EAF7D9A9982527F297794674DA2" unitRef="usd">15810400000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2A4939DCA52F1B176EE229779464E5F5" unitRef="usd">10763800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q1QTD" decimals="-5" id="Fact-DB76158BEDACBD47A19E297794685687" unitRef="usd">2726800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q2QTD" decimals="-5" id="Fact-BABD21E6292927E7A21F29779450D3AE" unitRef="usd">2894200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3QTD" decimals="-5" id="Fact-039766644344D6AF844929779450CC47" unitRef="usd">2955800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4QTD" decimals="-5" id="Fact-BB5811C3322F43BB95712977944FBA80" unitRef="usd">2872000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD" decimals="-5" id="Fact-371C9632F0CFE9739E9D29779465A0C0" unitRef="usd">11448800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-67F9AB09C2C9E82BCE2833C28DECDC24" unitRef="usd">6100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q1QTD" decimals="-5" id="Fact-5B3F71C3B7CC4012445F2977943F1E22" unitRef="usd">2810700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD" decimals="-5" id="Fact-FC8AEC3F2E34899E71F12977943A8193" unitRef="usd">3078400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q3QTD" decimals="-5" id="Fact-6BF2435E3C7F4121FD3B2977943839C6" unitRef="usd">3077800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4QTD" decimals="-5" id="Fact-15F28EF2F8B3D54AA8C02977943A1CDB" unitRef="usd">3307000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD" decimals="-5" id="Fact-22CA285B94A55BDDD529297794718D7C" unitRef="usd">12273900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-24231B956AACDEFF9922297794720A04" unitRef="usd">53100000</us-gaap:Revenues>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-5F6169E02EA2D891699E33286D1DF5D0" unitRef="usd">53500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F55C706A4600DB5609AD29779471E919" unitRef="usd">9188500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember" decimals="-5" id="Fact-9B2936F9FD175722A87B297794382AD7" unitRef="usd">234500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-6207024DD48FE851BD4229779458BB64" unitRef="usd">25600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-AA5DDC58F284F661E70B2977943FC5A0" unitRef="usd">208900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-8191728DCD8353B83ACC2977945064CF" unitRef="usd">2630200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-50FFF17E716A4D5C615A2977944BF49A" unitRef="usd">840000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-E1A6184FEEA1F2A117612977944FCECD" unitRef="usd">1790200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-C3DE1D8CC0F84DFCBBEE2977945C800C" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-5C9FE229709C3C456A6A2977945D9308" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-0DBDAD178205F5B8715B2977945D4E53" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-2FD8A46D8ECAC4167CDB2977944EA432" unitRef="usd">319700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-718709E0D327710C23A429779448C162" unitRef="usd">11400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-63223DD4D3CB129F41532977945D1094" unitRef="usd">308300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-A7DC859C72DAF4EB6B3D29779439C219" unitRef="usd">89700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-FBF0BD69C569FCC42ADC2977947D3DD2" unitRef="usd">89700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-1AABB0ADCEE8113E688329779438C695" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-009BBFF044396722CB6E29779453E7A7" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-5D962FD5E887C59F90942977947D6654" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-95EF3CA31ED3593118B82977946A7EAF" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-3858F307DD602AF69E5D29779452A272" unitRef="usd">51400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-C9B418B08B559FDC7B1D2977945BD806" unitRef="usd">51400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-0C88D05938A60FD50FA9297794531AB1" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember" decimals="-5" id="Fact-2DCE8FA900989AB3E4172EA556096347" unitRef="usd">554200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember" decimals="-5" id="Fact-AE767593BABE734FED5C29779448E69D" unitRef="usd">338500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-DD51C05A40D700D3977F2977944EBEF8" unitRef="usd">111400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-6122AF0B735F24A3E1B9297794734361" unitRef="usd">227100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-8BAE8CC5CED7D54B1ED54CA859901C81" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-BAB7E055BD4A394821924CA82B9E50BB" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-6CA246380F79C012BAFC4CA7FEA1DDEE" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-5546ECA08425F998FECD29779438B2B9" unitRef="usd">3638400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-7D203507C10E750BDAE02977943D2E5B" unitRef="usd">730200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-EF55C4362DDF9844DFE329779469E3F8" unitRef="usd">2908200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember" decimals="-5" id="Fact-E543F8B0986D24CFA7092977944EFE69" unitRef="usd">1886100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-2391B08573F3F506DBA029779465E58D" unitRef="usd">783000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-6A62AB8367DEEA4CC05429779433F216" unitRef="usd">1103100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-D45B1F331E0F43A7FD9729779451E2F2" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-CB8C4BD22FB9ED1CA81C2977944DC74E" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-9311CEE8E52BC6F5F94C29779449092B" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-50561A729303789A39FC297794660638" unitRef="usd">173200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-B72BDACA12610D9B8590297794526CFB" unitRef="usd">2642700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-CA4EE2951521081FA59F29779472256C" unitRef="usd">6545800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-BA951DC318A613A548672977945AD000" unitRef="usd">333300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-0146E60D90BF79E8F98B29779476F459" unitRef="usd">6545800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-2C485A541A9E7F2820EA2977944E621F" unitRef="usd">143700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-9EF8ECB43093BB3304752977945095A9" unitRef="usd">2165700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-3E56C2D98325CC566EA4297794450ECD" unitRef="usd">69400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q1QTD" decimals="-5" id="Fact-11CD04C113A1E7FC373329779469EB52" unitRef="usd">2309400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q2QTD" decimals="-5" id="Fact-334DFD126CA1030896E12977942C4C4D" unitRef="usd">2466000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q3QTD" decimals="-5" id="Fact-8E2DFCD4F878C10DAE6C2977947DDD46" unitRef="usd">2539600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4QTD" decimals="-5" id="Fact-36639CDA161C2258750D29779451058F" unitRef="usd">2502900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-CF2221D4B5A410E088AC29779472DD29" unitRef="usd">9817900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember" decimals="-5" id="Fact-31C236EB25B89D4066ED297794338647" unitRef="usd">333700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-C6145590A47B58B9427229779450AE68" unitRef="usd">65700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-8B81EAEA261A434294912977946AE79F" unitRef="usd">268000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-55793ADC05A93805D4ED297794504007" unitRef="usd">2313500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-42269DB313B683CA89702977945D3D81" unitRef="usd">638200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-15497CFD7571DB7DDB832977943EEBA1" unitRef="usd">1675300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-BDE6ACA2C6567C9A97042977945C1AE3" unitRef="usd">100600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-580DD1A5EB0277709EDF297794514860" unitRef="usd">100600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-30E5351B93E5ED2783702977945DE3D8" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-FFEBBA5C2D5A69CBCECE297794736B6C" unitRef="usd">513200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-4C78F945C0EC0EBD0D292977947673FD" unitRef="usd">68000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-09FF6FB06260647E2D5929779466A9EB" unitRef="usd">445200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-27EAA2CAD82C5F2024702977947D810E" unitRef="usd">84900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-71A2E8B1E2F31348C3B32977944B29FE" unitRef="usd">84900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-06CA97FD537A03FE22682977947D5EC9" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-13CBCA53B9450F31EB5A29779477B43B" unitRef="usd">100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-871150CA8628B8C9995529779471FB7D" unitRef="usd">100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-4A8755F774A6CAF96CF42977944BDEE3" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-06ECCEB10B8BF6D6A6AF2977945CF624" unitRef="usd">45900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-8B2FCF656525C1A5925929779472294F" unitRef="usd">45900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-CED57B09F86BD87FAD4729779473E995" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember" decimals="-5" id="Fact-A1F3EA5BAF884E1BC6582EA52D2594F2" unitRef="usd">846900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember" decimals="-5" id="Fact-12F8BE4D573CB70D9AE92977942C6861" unitRef="usd">481700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-9DF5EB05DC4BEE094A122977944DB758" unitRef="usd">176700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-1134BD808D42F0A1CF442977945DF3C9" unitRef="usd">305000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-63F245912C6C492DE1A64CA7C790B99A" unitRef="usd">4600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-A1DC10001BE4FB1877144CA79AD74C16" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-D1D08CEE33EA416A834F4CA76006240E" unitRef="usd">4600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-79C06CFCB1274A9C4EEA33E2267DDD73" unitRef="usd">4600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-06C55751E07B66BB88AC2977944681DF" unitRef="usd">3968100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-F691F365B83E59F4E20C2977945149ED" unitRef="usd">798700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-22B07F385A8D224ABEE929779469E807" unitRef="usd">3169400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember" decimals="-5" id="Fact-451DF82B801B419FE6192977947551B5" unitRef="usd">1963800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-B1457F47469966E58A482977944AB360" unitRef="usd">780900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-93294DF7F78ECB3FBFB92977943FAEBD" unitRef="usd">1182900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-EE7B4BDACD04BAB19424297794587129" unitRef="usd">7800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-1159088D8A69A4C7EAA329779438910C" unitRef="usd">7800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-2B9E9B5BD17F627549B02977944CAD25" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-8A2C40E16EAB2BE928DE297794657EB8" unitRef="usd">5300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-A75E99DDE96BF6FBD06A297794758F5C" unitRef="usd">2767500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-17447A84A63A6FB0FE982977945CF4F4" unitRef="usd">7050400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-FF65B8119A2C9127A7A12977945219CA" unitRef="usd">313000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-48941430AA07EED2486C2977944706EB" unitRef="usd">7050400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-77E844CA21E7F887662E29779458D72F" unitRef="usd">217300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-72E4E462294CB78BC92729779446223D" unitRef="usd">2237200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-E2DA6CF8FD8CF9A855262977943FE0F9" unitRef="usd">65000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1QTD" decimals="-5" id="Fact-83236E263570C417F7542977944D8465" unitRef="usd">2380100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1QTD_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-C655EB17D6ABF874AD953329C796DA69" unitRef="EUR">41800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1QTD_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-8D59CD3DF6042E4CC1F3332AB07556DA" unitRef="usd">45000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q2QTD" decimals="-5" id="Fact-BCB036E795E0F178F9A62977944DCEE8" unitRef="usd">2639700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q3QTD" decimals="-5" id="Fact-2E64408728459F59E3792977944D11FD" unitRef="usd">2622500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4QTD" decimals="-5" id="Fact-BCF59AB50CE0A2DEB9C729779439AF5E" unitRef="usd">2712400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D58747219807B4251CD529779477A109" unitRef="usd">10354700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember" decimals="-5" id="Fact-D35350090B2DED041C85297794738A0D" unitRef="usd">26000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-0E593D3ED863A57D3A3B29779469829C" unitRef="usd">5000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-ADF5139C2090A5C5122B2977945018B7" unitRef="usd">21000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-9CC66BB7A232F7B441932977944A98F1" unitRef="usd">2151500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-C555945A8CE7AB219EF52977944E764F" unitRef="usd">557900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-9B9441DCA62F09B70B29297794759F37" unitRef="usd">1593600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-F260BA5742B0CF613FDB2977944E428E" unitRef="usd">370800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-B04917ACC4EB1698356A29779473755D" unitRef="usd">370800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-806D3BB067B1E920BC0E29779458C339" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-1D066E6F4AB62B597D9F297794729B80" unitRef="usd">48400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-A3BADB416F96692EC97929779459B78F" unitRef="usd">6200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-81A160A6AF529BF342C42977945D2D2F" unitRef="usd">42200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-39A526095A7815057C57297794584F4C" unitRef="usd">91600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-8831B7F004C218F351302977947D911D" unitRef="usd">91600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-06C8D5E1C3AE1B6B1E742977943DE2E1" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-58499A1B514E0DBDEDFC2977944F0785" unitRef="usd">9000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-223344D61C1C9AA817AC2977945A7B02" unitRef="usd">9000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-CDDEB9C4C0B67A13E6612977945CB437" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-B4C81578CF88BFF947142977945CBBA6" unitRef="usd">39600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-5819FDC9F179F072946D2977947DF9A1" unitRef="usd">39600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-F6C45F28C1917DDFF392297794461332" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember" decimals="-5" id="Fact-CF33968ACC4A420162852EA3A482AA64" unitRef="usd">74400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember" decimals="-5" id="Fact-EA9AEA2CEC7D8C2DB96A2977944D6999" unitRef="usd">494300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-0FC7C3EF05E29283CF44297794768ECA" unitRef="usd">198800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-E21302A9816DB9A992B62977943E1778" unitRef="usd">295500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-C494D959DD39586936FB4CA725F7577E" unitRef="usd">883700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-15E09B8BB0CA230ED81C4CA69B5BE006" unitRef="usd">226700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-E99BFA606963722297174CA611BDF7A7" unitRef="usd">657000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-DDC82153877E8EF2D8B033E202B8654C" unitRef="usd">883700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-8B04013287C50B7AD3222977945C346B" unitRef="usd">4214000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-830A41A5CD799F64EB332977945C8B84" unitRef="usd">920000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-8366CB56CFBE32F9AEC729779447DEDB" unitRef="usd">3294000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember" decimals="-5" id="Fact-65B2C255FF823C14A3FE2977944DA61B" unitRef="usd">1973100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-0595C75D14FE7B78111D2977945BC90D" unitRef="usd">859300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-96D71D620DA02CCDE76029779449845D" unitRef="usd">1113800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-C61338FD32E59A4679EB2977943DB9B4" unitRef="usd">52700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-0719E515C4B93E2045792977947DBCC5" unitRef="usd">52700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-CCE4DF50C8A232E0240C29779450FC5E" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-8A044797B4B079C9ABC0297794691CE4" unitRef="usd">32500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-5337FC5B82EC4C179074297794459162" unitRef="usd">3337600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-930AB84F465DD0FD81042977944DEDE9" unitRef="usd">7017100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-5E073FBD3EECC721DB1229779450A582" unitRef="usd">332700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-997A23E1970798A16DAA29779452549C" unitRef="usd">7017100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-4E7171AAEC1538644BCD297794460874" unitRef="usd">160100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-17AA28502C4F0DDFAA352977944EFD51" unitRef="usd">2844800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-1FF66E3942A4B01F481129779445255C" unitRef="usd">242800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D4A347C9825ED8C4E3F529779476E673" unitRef="usd">2113100000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-726153B1A2B44C887EB22977942D9486" unitRef="usd">1947900000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-EC492121965C0CB9E8F82977947253E8" unitRef="usd">1935500000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-189B32C57FE22303B41E2977944B4744" unitRef="usd">161400000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4D203539F2EA1DD8872429779474DBF6" unitRef="usd">154800000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2B4F3FA5E76ACEF6B7B329779475B0FD" unitRef="usd">128000000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-D4E3B9078BD1CAF8D538297794387CED" unitRef="shares">34000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-435FF7CA1F022EF7C8F9297794757F5B" unitRef="shares">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-665A07142FBD5DBBD2A229779471C172" unitRef="shares">182000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-3A49F6DD585653B087CF2977944D4FE2" unitRef="shares">19000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-3BB12036D007171A670229779474E12D" unitRef="usdPerShare">372.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-18565195B3AF6C8D30EF29779471AB54" unitRef="usdPerShare">292.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-FCE06B1876F2B9AEB9BC2977943A0129" unitRef="shares">83000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-DA1702411D2EA703BB55297794745B31" unitRef="shares">94000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_PlanNameAxis_biib_AttainmentOfPerformanceCriteriain2013Member" decimals="INF" id="Fact-6BB0C9D2C4983E6E4EA52977946AB78D" unitRef="shares">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-B28BA22A224E3CEDACE62977947137AB" unitRef="shares">464000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember_us-gaap_TitleOfIndividualAxis_us-gaap_DirectorMember" decimals="INF" id="Fact-E163BE2CB588098624A92977943D70E6" unitRef="shares">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-6110075395A7FE2419072977945902FF" unitRef="shares">40000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-F5426E6BFFF765B5652E297794727C61" unitRef="usdPerShare">493.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-EE4EB50AAEC2EB47B2192977945A73B2" unitRef="usdPerShare">388.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-8232CD6B27527D2B858529779471BE85" unitRef="usdPerShare">328.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-1C19F34CFEE1A36EA5D2297794681823" unitRef="usdPerShare">268.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-2F56B527060CE81A65D229779472D8C4" unitRef="usdPerShare">382.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-97ECB420AC381B93248329779471B0BF" unitRef="usdPerShare">293.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-1BBBCD3F7943F083843629779438BC89" unitRef="shares">122000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-6D55667C74CF65B8EAFC2977947434CF" unitRef="shares">230000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-F6A9B2B7697A910E4BEA297794711182" unitRef="shares">888000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-DB716EA15455C6788A7B297794594345" unitRef="shares">110000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-8D4B775A36A8D77254272977944CE554" unitRef="shares">105000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-7AC362E7FBFB818294BF297794742135" unitRef="shares">171000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-104A82F2AF9ED999D22029779471BC50" unitRef="shares">832000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-5AA7EA28030F1918653C2977944D4265" unitRef="shares">91000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2016Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-BD6F312851E6E77C67EB29779476BF1D" unitRef="usdPerShare">355.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2016Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-957D8EE41AE80F1BF77829779471E862" unitRef="usdPerShare">303.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-629074D468C823F6B045297794752D63" unitRef="usdPerShare">370.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-10E8414BC5951187D9D4297794716941" unitRef="usdPerShare">291.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-3" id="Fact-AD28A2D78AEC20694FBF32EE210F30F3" unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="0" id="Fact-AC0C46EE7ADA45E200DD32E38918F861" unitRef="shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="0" id="Fact-60778CCA0B2B114FB5B932F343566F20" unitRef="shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-3" id="Fact-E40547FA0A430DBC90E132F0CB2F968B" unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-D9766F16102EB4CD629A29779447D278" unitRef="shares">69000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-8A9589EB6FA3D9B41B9329779476BFCA" unitRef="shares">112000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-14D101BCDABE2E57DBAC297794713D58" unitRef="shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-1BEF2B80387B93A5320F2977945941AE" unitRef="shares">43000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-C3DFB3402DC839F1652C2977947D816E" unitRef="usd">109000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-809EF977777AF41E83ED29779464DA1D" unitRef="usd">239700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-2980FBAEF96DAF9281212977945ACBF9" unitRef="usd">39300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-06BD188F0255520B4414297794648E56" unitRef="usd">104600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-CDE3F760C9C823D5EA09297794385419" unitRef="usd">31400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-0935C042163A60E3C3432977945CC564" unitRef="usd">100000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-3B432CB08C325267FC42297794753F5F" unitRef="usdPerShare">311.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-435991E3640EB7AF9AEB29779471A1DB" unitRef="usdPerShare">308.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-2EC05A83B548370C759029779472B5ED" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-63948E0965E08764100429779472E1B5" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-E01B1B471E9B78E2D4E2297794722F60" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-E9D9B3467299C2C71B9D2977942C2E96" unitRef="number">0.332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-50C019A964A06BDC832E2977942C1F41" unitRef="number">0.310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-4DE00A633EF9663C6E552977942C8E6D" unitRef="number">0.407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-499CD2A85D24E81D742229779433825B" unitRef="number">0.382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-40B83B7086BDBF82197F2977942CD682" unitRef="number">0.356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-539789C5799E0F37F98A2977942CE287" unitRef="number">0.330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-01F6CC0BE17BF844F68629779473471D" unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-D8E3F76621CE3309D8C62977943358E3" unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-0985F7F36D939CFD1FFB2977942C16FC" unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-C68AD5E8EC806BC22894297794330525" unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-8B8B49492913C341116E297794344915" unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-5820D927B50395F59C9E29779433D6F9" unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2017Q2_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember" decimals="-5" id="Fact-119368F7D16485FC7C3632C355647A27" unitRef="shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2015Q4" decimals="INF" id="Fact-CE7143A2E5488146F87A297794658216" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2016Q4" decimals="INF" id="Fact-A7C4CB56FB59FEC1693429779465C41D" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q4" decimals="INF" id="Fact-5A4BE6DDB2BFE5027F0F2977945998CC" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q4YTD" decimals="-5" id="Fact-BEBDE07D4AE17C40323A2977943529BB" unitRef="usd">38000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q4YTD" decimals="-5" id="Fact-288BC72DF32C791BD00D29779448F8F9" unitRef="usd">10400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0246B5E69553E396BD552977945A6578" unitRef="usd">3400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2017Q4YTD" decimals="INF" id="Fact-5A179387FCEB9E5E0ECD29779438CC0B" unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2017Q4YTD" decimals="INF" id="Fact-DC21B0F4045C2C5B4C74297794368EBE" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4" decimals="-5" id="Fact-F13504521CB5EE453AF929779436FCFE" unitRef="usd">11100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4" decimals="INF" id="Fact-D37D67E37FEA42140B59297794378C8B" unitRef="shares">66000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4" decimals="INF" id="Fact-81426F1352C661C6CA2D29779436E64D" unitRef="shares">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-F5142A36333EBFCD689E297794381758" unitRef="usdPerShare">54.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" decimals="2" id="Fact-5935C3C94B435206660E29779435C4CE" unitRef="usdPerShare">53.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease contextRef="FD2017Q4YTD" decimals="0" id="Fact-97B1F7CE9E31BFCEDAF332D5D5559083" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD" decimals="2" id="Fact-178734089459F23505B4297794354451" unitRef="usdPerShare">50.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD" decimals="2" id="Fact-1ADA526A2F763E129695297794357731" unitRef="usdPerShare">55.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD" decimals="2" id="Fact-67A370256EC1D646D4182977943600AB" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD" decimals="2" id="Fact-2007D7681A09593354A032D53B856057" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-3B48C77A0FAB6293D8B632E53517F136" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-05652D65AEC727EB57A232F3D67C1637" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q4YTD" id="Fact-724A98BD09C2DE54018829779438E999">P1Y4M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-34543C0219D833E3B0FB297794763F7A" unitRef="shares">257100000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-EAF12C3F360D44B7030D2977947416FF" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-5546C31E5052D0792E012977947C14A7" unitRef="shares">22600000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-E2F1CC51317B4804258329779434EEC5" unitRef="shares">241200000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-82AB067676C59C3C1872297794362B5D" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-364F04D6BBBDA343F25F297794360BB0" unitRef="shares">22600000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-37E9373D983FAA1A04B22977944D6D8B" unitRef="shares">238500000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-4EC0ABE11520BCE7E5532977945C3B96" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-ECE7F8ACEC95BDBE87462977946A1253" unitRef="shares">22600000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-EC60C0D7EEE0C647D45F297794718082" unitRef="shares">235300000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-869DFD196DC141DCCED42977945808FB" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-8E81688BC2960364A621297794729E01" unitRef="shares">23800000</us-gaap:SharesIssued>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="INF" id="Fact-725F7665831CEC700B29297794451042" unitRef="shares">98000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="INF" id="Fact-A44BEECC4315608654B132F6772788B4" unitRef="shares">78000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="INF" id="Fact-F5B6FD531936E2E82A962977944B5B72" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="INF" id="Fact-3220BC20AE915D8D5FDD29779465B7D3" unitRef="shares">190000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2017Q4YTD" decimals="-5" id="Fact-95F34FD6C559E6C41E7B297794594D8A" unitRef="shares">6200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="INF" id="Fact-B4C5C7DB90E693C5C1DE2977945D99CB" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="INF" id="Fact-10B6122044D81DF6F28529779446AAB1" unitRef="shares">167000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-18CC91B9E09C27A1DB2A29779475125E" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-E79CC08BB801351D19B029779434CE67" unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q4YTD" decimals="INF" id="Fact-3EEDCAB3078C1ED0761E29779437DFCE" unitRef="shares">14000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-027D48528CA51A833F662977946BA546" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-0E1899FB3842AA091321297794763459" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-2A005828FC3AE66DBFEB297794365F48" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-F7E7164D6D9983B4D58E2977944AA95F" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="-5" id="Fact-DB947AC1701EB23DE8912977945ADF1D" unitRef="usd">30000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="-5" id="Fact-4979929431C69452C10532F69FDB7531" unitRef="usd">19300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="-5" id="Fact-1440CEA068E4240DB0EF2977945DE88B" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="-5" id="Fact-28046F281DD4379A057C29779436DA37" unitRef="usd">41500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="-5" id="Fact-2C2F4F53365EF032A9B52977944B049D" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="-5" id="Fact-874B1D3CDCABB5AD3BD72977945C8B0D" unitRef="usd">39800000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-5" id="Fact-55DD99480B77467E71A829779477F24B" unitRef="usd">125100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-D248E298B701176CF899297794765B29" unitRef="usd">125100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-6E61E3DD0A78890032952977947640D9" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-5" id="Fact-80388C2CB66133820F35297794661513" unitRef="usd">52100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-2C30847394A6F37D072929779467D72A" unitRef="usd">47600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-67F02E3D1E0ADD703AEE297794349E32" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-EFCA4B3A1815A334B5B04229E4237E01" unitRef="usd">4500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4EF8655F6A0344FA2CDC29779450B96F" unitRef="usd">45800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-839A53FB776382563AE8297794582194" unitRef="usd">44800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-3D6D2A4C9E003C24A4C62977945E203C" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-48F5C88F5EBED58F882029779432E185" unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2015Q4YTD" decimals="-5" id="Fact-CC9DB1118D7A303A6F2B2977947C99CD" unitRef="usd">54200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-67B69DEF44687219F478297794757052" unitRef="usd">54200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-CFCC64D6779813C1DA2929779477E5DC" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4674953D7DC03E00145529779467E7DC" unitRef="usd">43700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-630B375B65CDC055C1E42977946A5A5A" unitRef="usd">43700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-133ED6FDF2B0D54B223F297794330F9C" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0A2F274966A00DFFF966297794582705" unitRef="usd">40500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-C4D9195C73C53D3184832977943B4DBD" unitRef="usd">40500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-B3C29C160510430DFA782977945D01B0" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-D22BB639D3E14E112A4929779471B536" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2015Q2" decimals="-8" id="Fact-3140DD96D18394148A1032B15561738E" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-8" id="Fact-8EAA3682070B63B8C7EE2977943E2508" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2017Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-8" id="Fact-FBA535AD69125C2BBAC18BDF15862A36" unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="FI2011Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-7CC9920A5FC7CF27E04E2977945910C7" unitRef="shares">20000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-357B2E32DA8B41AF70D7422ADE732F42" unitRef="shares">16800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-84F64993EF6A120B1CB629779476B81F" unitRef="shares">16800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-FE2D9A56AFBD738FDFB429779465F706" unitRef="shares">3300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-89758A3E8F2E3B8F22A1297794398263" unitRef="shares">3300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-A252E99E04040746A67629779470A3DB" unitRef="shares">3700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-06EE21A28B11E94F1E3529779439A5F8" unitRef="shares">3700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-5" id="Fact-CEAD49E5D78D6B025F88297794765CAE" unitRef="usd">10809000000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-5" id="Fact-4B7D6B90B2A6FA8A55422977943A4D87" unitRef="usd">9372800000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-5" id="Fact-FC3CE13AB07A0EFAB312297794671F21" unitRef="usd">12140100000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-5" id="Fact-9BA4A8ABF67B733A6CAC2977945A9F87" unitRef="usd">12612800000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4" decimals="-5" id="Fact-D01EF0BBC1A2C50DF58229779477DDA6" unitRef="usd">10814000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-AE18AC3E5EFC93000E5E29779476E3D9" unitRef="usd">-59500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-1E2371E6754E5BD1442629779475CAE9" unitRef="usd">4196200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-F5D503AE219DE2D8FBB52977947591D8" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-5223FEE744CD0460638729779475869E" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-6B5CF6E0F379A5CD75B1297794756C8B" unitRef="usd">9283900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-A986A0F042BB30704537297794756694" unitRef="usd">2611700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4" decimals="-5" id="Fact-8269ED75868880AEFDEB29779467790F" unitRef="usd">9374900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-055E19203345AB18CDC1297794355FCD" unitRef="usd">224000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-41CAEA1C5D3A012FCCE529779469464B" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-121BFC50742E4BEB3666297794340A30" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-26A1F765033153845B972977944B7394" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-87ADA973736C7CF6B5882977943505E7" unitRef="usd">12208400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-0929732FF464C89CF325297794377228" unitRef="usd">2611700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4" decimals="-5" id="Fact-6ECDCC8455E724309C0A29779467437C" unitRef="usd">12128600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-43779C2C7529BCA1732B2977945C950F" unitRef="usd">319900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-B06F5B0FA18EF65AEE1A2977946BE576" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-8AD0B289D647719E9A7B2977946AFA6E" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-37651F7047771496250229779435459C" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-2639AE5DA5297F30A08229779476F1B5" unitRef="usd">15071600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-5B28DD707C0999C97F8B29779473169C" unitRef="usd">2611700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4" decimals="-5" id="Fact-E08F4026059354078E75297794685E57" unitRef="usd">12598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-1DD65244D0703FC658FE29779471D8C7" unitRef="usd">318400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-A71F51ACEE57689D35FE2977945C85D4" unitRef="usd">97800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-8BC9EBB87BAC1455C338297794715500" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-E419CE9483DE39F21EDC2977945119F7" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-E44E6BB81926DB9E40642977945DA908" unitRef="usd">15810400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-0E21A4A70FE377267C6A297794750E24" unitRef="usd">2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="FD2017Q4YTD" decimals="-5" id="Fact-5E673DB18B31F4FED7B3422416BF06E5" unitRef="usd">-852800000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
	<us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-91B8635043147580C7B14223838577C7" unitRef="usd">-852800000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
	<us-gaap:StockholdersEquityOther contextRef="FD2017Q4YTD" decimals="-5" id="Fact-619776336B78457D991D2977944E501F" unitRef="usd">17500000</us-gaap:StockholdersEquityOther>
	<us-gaap:StockholdersEquityOther contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-966D803BD4195CC5D02542285E6C4871" unitRef="usd">17500000</us-gaap:StockholdersEquityOther>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-9AE800CFDDFCE987D169297794696BBB" unitRef="usd">1300000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-CA7FF90FC59DA283E1692977942C0927" unitRef="usd">129700000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxesPayableCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-F8AD4EF8FE31330220E22977946642A6" unitRef="usd">231900000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-8B068AE4A82E0C1883DC29779464FC3D" unitRef="usd">68200000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD" decimals="-5" id="Fact-69983ECCFAAC8723A078297794765E80" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-4E54652459AE3AA1FA9B422AE3480505" unitRef="usd">4377500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-0C23BBDB5D3DB07EF67D422AE74AE40B" unitRef="usd">622500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-0EDDD9E17410FB99FD59297794754413" unitRef="usd">5000000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD" decimals="-5" id="Fact-89E24EFDCC14F7D0D2482977946A0F3E" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-3F3855FFB12697ED88FB2977946A2205" unitRef="usd">164900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-4F93A3EBF243F66B0F6529779467CCD5" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-08DB7112BCD12D186A8F29779466CAA5" unitRef="usd">835100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-7A7EA6D9735CBEBD38E929779438E089" unitRef="usd">1000000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D6AB043879697559212D2977945C7075" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-73DD1761789E30794CCF2977946AEFA9" unitRef="usd">36000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-4D3CED3C968A23E8B5BA2977945DB858" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-8EBCC6E68B0430F60297297794592839" unitRef="usd">964000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-ABEDC68092BAFC59070B2977945C7477" unitRef="usd">1000000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockShares contextRef="FI2016Q4" decimals="-5" id="Fact-36A7232BFE3B6A5054962977946508E1" unitRef="shares">22600000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2017Q4" decimals="-5" id="Fact-CC477C8759E5C2EE1D74297794767EF1" unitRef="shares">23800000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2015Q4YTD" decimals="-5" id="Fact-17C749FC21680F7E668532B25B83B454" unitRef="shares">16800000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-FD9727F06475A85DFC8029EE747AF2A5" unitRef="shares">16800000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2016Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-5" id="Fact-64A27ADCAF4BE55638B832AF6D95C67E" unitRef="shares">3300000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-C0C327CA60E0C17F8B1B297794363E8C" unitRef="shares">3300000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-AF4DF36BEFD6D6B2B1EE32B08342929E" unitRef="shares">1200000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-F50CC0FCDB3FDBE5766E420980E8B3B5" unitRef="shares">1200000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-5" id="Fact-2AFD5E298E80B6499FA42977943FB280" unitRef="shares">3700000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-DFACB9C89C26F9131C802977943564A7" unitRef="shares">3700000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockValue contextRef="FI2016Q4" decimals="-5" id="Fact-29C32E481ABD90856BA6297794654BBF" unitRef="usd">2611700000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2017Q4" decimals="-5" id="Fact-BFB5C32716F13CB88FDF29779468011F" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD" decimals="-5" id="Fact-0D2092CB58F35E205F9529EE750EDCBF" unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-D532D6422CD0F611587D29EE759B23BE" unitRef="usd">-5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3EA151A3C647A41C844C29779439AE98" unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-43B68043A56F9B2C1DD929779439E410" unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-CF32147F60F6DCB96050420987DFF38F" unitRef="usd">365400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-AC6A0E9AC22798EE5DFC420982DD66C4" unitRef="usd">365400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-5" id="Fact-D40D4B87E4EC4A5862132977945C2FDF" unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-748CC977580550D30C3329779471648A" unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-A906B5439522024334DD29779465FE39" unitRef="usd">1800000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-008B5929B67D831E5ECB297794677B9E" unitRef="usd">-49800000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-60C6C7663A8209B5C932297794667E75" unitRef="usd">113000000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2017Q4YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember" decimals="-5" id="Fact-65870A8B68CC3E319A932F1512900349" unitRef="usd">98500000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2014Q4" decimals="-5" id="Fact-D9F758240E5894DA2E4129779459B894" unitRef="usd">131500000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2015Q4" decimals="-5" id="Fact-A04A5DE5586C8495F1EF29779459005E" unitRef="usd">67900000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-5" id="Fact-96E27C32F9C15D61CEF829779459B0A6" unitRef="usd">32400000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4" decimals="-5" id="Fact-3ABE142D787C48B8FEDF29779459306E" unitRef="usd">66800000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-64BB614A2AD8CA9F62BC2977943B0FBB" unitRef="usd">49900000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AE22099004FECE144ECD29779459C9C8" unitRef="usd">13300000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-5" id="Fact-7B5BC3BCBD47C26673FC2977943B954E" unitRef="usd">21800000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-68B2BB93F1736A3168FB2977943A7533" unitRef="usd">42500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2F33E010F48AF8E5552829779459ADDA" unitRef="usd">64300000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-C79E8B94AE6B4A9224A32977943A6B69" unitRef="usd">44600000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-8C416646429FD4DC85862977947CFB42" unitRef="usd">3100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-FBA85265EBDEE5D1431429779470DF7E" unitRef="usd">9100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A477C6328F60E53BBA2729779466EB06" unitRef="usd">4800000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-083DA4240436A1A99C92297794597809" unitRef="usd">10500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D0019E7BED7B852F5F402977943B6884" unitRef="usd">7200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4AC3F04D0BF8EA05B9212977943BEC24" unitRef="usd">5700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-46F98C69C69844F454DD29779459776D" unitRef="usd">19500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8301EC07D417DC623DBB2977943A9248" unitRef="usd">36300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-5" id="Fact-C10FE860F79DC25642882977943BC375" unitRef="usd">7300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="FI2016Q4" decimals="-5" id="Fact-F06CEF5F75DBC18028CF2977947172B0" unitRef="usd">25200000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
	<us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="FI2017Q4" decimals="-5" id="Fact-8C5846B981BE4E4548CC2977946790A6" unitRef="usd">16100000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
	<us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease contextRef="FD2017Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-890C1B31E38213EAA4913314216BB894" unitRef="usd">-93800000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F3C246A0FA339C6EBDF02977943BBD10" unitRef="usd">1200000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D25B7EA2DF8D5BC8F2E229779459A5E4" unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E313AA5A692181B19736297794597B03" unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2015Q4" decimals="-5" id="Fact-10571C9E897BC9FF922829779465685C" unitRef="usd">15700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2016Q4" decimals="-5" id="Fact-806400475646BABBA9D82977944A17FF" unitRef="usd">26900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2017Q4" decimals="-5" id="Fact-0DA3540166D1DB43D4AC2977943E6C25" unitRef="usd">64300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4" decimals="-5" id="Fact-356A706E739696C6AE7D2977945AC0CD" unitRef="usd">483800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-BA483F22232721B5DF47297794333AE0" unitRef="usd">387100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-B86DB5A6CA26B1366BDD29779434EBED" unitRef="usd">47600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-A54FB17143C0391DD3D2297794361831" unitRef="usd">49100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4" decimals="-5" id="Fact-AB24D857951E8D82FF68297794345688" unitRef="usd">662700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-D049F4BA109D58A0AC072977943568CE" unitRef="usd">548700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-C41EA3E97DD71993EDBE29779436695F" unitRef="usd">56100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-B0B71ABA52C1351A5B4629779434FAB5" unitRef="usd">57900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4" decimals="-5" id="Fact-8E4FD24B0E049073003429779473AD63" unitRef="usd">605500000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-FA6352172433E17B0E5A297794732B84" unitRef="usd">166900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-CA33F79ACE7CFB7467E0297794732D1A" unitRef="usd">438600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-917922C8E3AA5FCDBDE72977946A3226" unitRef="usd">482700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-97F137E5801C4ED429792977946A701E" unitRef="usd">71600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-35453FADFF79CADA9DCD29779470280B" unitRef="usd">51200000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4" decimals="-5" id="Fact-18B69F5F8332A5A7774829779473ABF1" unitRef="usd">761600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-29E964D884F2D5F512FF297794734D3B" unitRef="usd">189600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-E0E734ABE73DC3EFA96D297794733AC3" unitRef="usd">572000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-560FDF2F57BFE26A4EA22977946A815F" unitRef="usd">606000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-3958D23366BE865DCBA02977946A16D3" unitRef="usd">109600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-7AFF9C18EF0F9E55265E29779469087A" unitRef="usd">46000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2015Q4YTD" decimals="-5" id="Fact-AF384FE139B426A1A4142977943BEEB3" unitRef="shares">500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2016Q4YTD" decimals="-5" id="Fact-39510A790D0D8825034A2977943F8774" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2017Q4YTD" decimals="-5" id="Fact-50D15A7503431464615D2977943F37E2" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FDEAA1A46EE90732ADB529779469B062" unitRef="shares">231200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q1QTD" decimals="-5" id="Fact-4113143BB7360BB4BDD22977947C1ACF" unitRef="shares">219300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q2QTD" decimals="-5" id="Fact-802F8959C017C1585EE02977945107EA" unitRef="shares">219400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q3QTD" decimals="-5" id="Fact-0A7B99858B532DE157F8297794509AC4" unitRef="shares">219400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q4QTD" decimals="-5" id="Fact-49172C953567A3B2FD5B297794503E92" unitRef="shares">217000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7EFAAAFABDCFE7C412522977946980F4" unitRef="shares">218800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q1QTD" decimals="-5" id="Fact-010AF05CB2896F5DCF2B2977943F9A87" unitRef="shares">215900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q2QTD" decimals="-5" id="Fact-FD4D869E7E935749F5622977943D43FB" unitRef="shares">212200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q3QTD" decimals="-5" id="Fact-E496D2E6ECADACDA29BE2977944D2B1F" unitRef="shares">211800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q4QTD" decimals="-5" id="Fact-1E0D96280632DB0F1D06297794393511" unitRef="shares">212000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0FB65662EF8E96FA4A5D29779470D687" unitRef="shares">213000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-9BD3E3350C07EB308A7E29779450D480" unitRef="shares">4600000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-00FECA03AB5ABA08AA7D29779451F9A9" unitRef="shares">700000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3EF23E99C599B54B35B529779451FEE3" unitRef="shares">3700000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E380236DBAEB31A9F7952977946BE381" unitRef="shares">230700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q1QTD" decimals="-5" id="Fact-C022FA130E75C32490502977947C998D" unitRef="shares">218900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q2QTD" decimals="-5" id="Fact-DED3BBCADA65C98863322977944F22AC" unitRef="shares">219100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q3QTD" decimals="-5" id="Fact-26C1739FF0044E12E5312977947D3BBF" unitRef="shares">218900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q4QTD" decimals="-5" id="Fact-D28DC3F29B6EA76DDBA32977947C37FC" unitRef="shares">216600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q4YTD" decimals="-5" id="Fact-B421033B90048792537529779476E57D" unitRef="shares">218400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q1QTD" decimals="-5" id="Fact-073F08A246653FBE9001297794377185" unitRef="shares">215600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q2QTD" decimals="-5" id="Fact-9E62C525AE950F4B9ED0297794380439" unitRef="shares">211900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q3QTD" decimals="-5" id="Fact-E7A90F33A3E94856BE9B2977943C6B2B" unitRef="shares">211400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q4QTD" decimals="-5" id="Fact-B096DDEB46CA06B387D12977943F054E" unitRef="shares">211500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q4YTD" decimals="-5" id="Fact-059BD000F235E2C0FA96297794690480" unitRef="shares">212600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-50C4B50C19BAFCCD81D029779469B0E8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;583.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,307.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,917.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(475.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,756.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,232.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(69.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(442.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(23.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(534.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;109.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;606.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;592.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,044.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,668.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(522.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,576.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,099.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(53.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(536.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(609.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;387.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;459.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,732.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(405.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,258.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,666.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(44.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(296.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(351.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
	<biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-F1263E41B8938C6EC6A129779448C95F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assumptions used in our valuation are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of expected stock price volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;33.0% - 35.6%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.2% - 40.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.0% - 33.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of risk-free interest rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.9% - 1.6%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6% - 0.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2% - 1.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 calendar day average stock price on grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$263.18 - $267.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$260.67 - $304.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$277.35 - $426.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average per share grant date fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$382.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$328.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$493.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock>
	<biib:BusinessOverviewPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-43C230A767A697DCED9729779434E24A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer&amp;#8217;s disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS and relapsing MS and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), a rare condition that affects movement, speech, vision and cognitive function, Parkinson's disease and ALS.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE in the European Union (E.U.). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these audited consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the spin-off of our hemophilia business, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
	<biib:CoPromotionProfitSharingFormulaTableTextBlock contextRef="FD2017Q4YTD" id="Fact-B48E703F63F3514D1F6729779453A7D4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share of annual co-promotion profits in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until GAZYVA First Non-CLL FDA Approval&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First Non-CLL GAZYVA FDA Approval&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the FDA&amp;#8217;s first approval of GAZYVA in an indication other than CLL.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the earlier of (i)&amp;#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or (ii)&amp;#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;Second GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$500.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:CoPromotionProfitSharingFormulaTableTextBlock>
	<biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="FD2017Q4YTD" id="Fact-F407A91DC3E29798C2B92977946743B8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(535.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,689.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;316.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,634.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;371.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks and trade names&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,971.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,160.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,811.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(776.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,705.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;8,264.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4,385.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,879.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,742.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,934.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,808.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
	<biib:PerformanceunitsactivityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-E58C30ED6267BACEC822297794685D94">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;110,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia spin-off adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(43,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(19,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;91,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:PerformanceunitsactivityTableTextBlock>
	<biib:PretaxProfitSharingFormulaTableTextBlock contextRef="FD2017Q4YTD" id="Fact-D8C1B2866D45B0CF8DE92977944A4BA6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share of annual profits in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:PretaxProfitSharingFormulaTableTextBlock>
	<biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-B84FEC6D4723547A694B297794724DF4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,269.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;242.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;69.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
	<biib:RoyaltyCostofSalesPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-BBEF638C440D67452A40297794356B35">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&amp;#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:RoyaltyCostofSalesPolicyTextBlock>
	<biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-AE45310EE3859F3A96AF29779470091F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our CSPU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;122,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia spin-off adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;83,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(69,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(34,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;105,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock>
	<biib:ScheduleOfMarketStockUnitsActivityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-C64D892CA2053A4F8AA72977945CEFEB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our MSU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;230,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;355.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia spin-off adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;94,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;382.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(112,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;311.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(45,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;372.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;171,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;370.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfMarketStockUnitsActivityTableTextBlock>
	<biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-43A041821ACEAEC15EB3297794355EE1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&amp;#160;Software&amp;#160;and&amp;#160;Hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
	<biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock contextRef="FD2017Q4YTD" id="Fact-C76C4F2DE0A0EEFA8B742977942C9891">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our ESPP activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;167,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;190,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;78,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 1995 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;98,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 1995 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock>
	<biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock contextRef="FD2017Q4YTD" id="Fact-FE816F5AB06EAB69480F2977943F8094">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of activity related to the Eisai Collaboration Agreement is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration in development of BAN2401 and E2609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;146.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;95.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;84.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and E2609 development expense reflected in our consolidated statements of income, excluding upfront and milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;74.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock>
	<biib:SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock contextRef="FD2017Q4YTD" id="Fact-E6F89DDB5E6DA9AB06CD2977942CCBD0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Costs and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;92.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Co-promotion losses in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;43.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of co-promotion losses in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock>
	<biib:SummaryOfCommonStockTableTextBlock contextRef="FD2017Q4YTD" id="Fact-3F6043DAAC977856071B29779435C764">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table describes the number of shares authorized, issued and outstanding of our common stock as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;235.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;238.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfCommonStockTableTextBlock>
	<biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-C15AE2A0D6B543A0048A297794523372">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;189.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;166.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;572.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
	<biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-FC0233A6D3F6EEEE6958297794487200">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our RSU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;888,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;303.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia spin-off adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;464,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;293.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(350,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;308.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(182,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;292.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;832,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;291.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-7C584C3E2204C49BC5132977946414F3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Other Consolidated Financial Statement Detail&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Supplemental Cash Flow Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid during the year for:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;281.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;281.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,066.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,642.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,674.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-cash Operating, Investing and Financing Activity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2017 we accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$600.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon reaching &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 billion&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total cumulative sales of FUMADERM and TECFIDERA (together, the Fumapharm Products). The amount, net of tax benefit, was accounted for as an increase to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm, and is expected to be paid in the first quarter of 2018. For additional information on this transaction, please read Note 22, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our consolidated balance sheets as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. For additional information on this matter, please read Note 11,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Property, Plant and Equipment,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2016 we accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$454.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the settlement and license agreement with Forward Pharma. For additional information on this transaction, please read Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2015 upon completion of our acquisition of Convergence, we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as part of the purchase price. For additional information on this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;78.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(250.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(260.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(95.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(36.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(13.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(17.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(215.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(217.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(123.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; charge recognized in November 2017 upon the redemption of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due March 1, 2018. For additional information on the redemption of these notes, please read Note 12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes other than temporary impairments recorded on strategic investments and marketable debt securities during the year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Current Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets include prepaid taxes totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$657.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$817.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of the Article 20 Procedure of ZINBRYTA, we impaired prepaid tax balances totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$142.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;844.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;580.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;572.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;297.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;282.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;206.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;195.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;183.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;130.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;159.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;134.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued TECFIDERA litigation settlement charge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;454.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;636.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;685.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,901.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,903.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Pricing of TYSABRI in Italy - AIFA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2011 Biogen Italia SRL, our Italian subsidiary, received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 through mid-February 2011 exceeded by EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In January 2012 we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit in the Price Determination Resolution should apply as written to only &amp;#8220;the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months&amp;#8221; of TYSABRI sales, which ended in mid-February 2009. Since being notified in the fourth quarter of 2011 that AIFA believed a reimbursement limit was still in effect, we deferred revenue on sales of TYSABRI as if the reimbursement limit were in effect for each biannual period beginning in mid-February 2009.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2013 we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee that would have resolved all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As a result of this agreement in principle, we recorded a liability and reduction to revenue of EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; at June 30, 2013, which approximated &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the claim related to the period from mid-February 2009 through mid-February 2011. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$53.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of TYSABRI revenues related to the periods February 2013 through June 2014 that were previously deferred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the first quarter of 2017 we reached an agreement with AIFA's Price and Reimbursement Committee resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods. As a result, in the first quarter of 2017, we recognized EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) in revenues for sales that were previously deferred. These amounts were previously accrued for and included in the table above in Other as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2017Q4YTD" id="Fact-B9DD777F6F1028AE8216297794670FDD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,039.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,039.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,570.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,569.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,075.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,075.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;844.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;845.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;642.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;642.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,173.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;14.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,408.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,409.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,255.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,258.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,156.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,156.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,016.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,019.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;557.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;559.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-6E3FE7DF5DA37C3807D42977947DBC4B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Acquisitions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Remedy Pharmaceuticals Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2017 we completed an asset purchase of the Phase 3-ready candidate, BIIB093 (intravenous glibencamide) (formerly known as CIRARA), from Remedy. The target indication for BIIB093 is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) recently granted BIIB093 Orphan Drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 Fast Track designation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we are responsible for the future development and commercialization of BIIB093 and Remedy will share in the cost of development for the target indication for BIIB093 in LHI stroke.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We accounted for this transaction as an asset acquisition as we did not acquire any employees from Remedy nor did we acquire any significant processes required in the development of BIIB093. In connection with the closing of this transaction, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Remedy, which was recorded as acquired in-process research and development in our consolidated statements of income as BIIB093 has not yet reached technological feasibility. We also have agreed to pay Remedy certain development and sales based milestone payments that are substantially payable upon or after regulatory approval, as well as royalties on future commercial sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Convergence Pharmaceuticals&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence&amp;#8217;s lead candidate was a Phase 2 clinical candidate BIIB074 (formerly known as CNV1014802), which had demonstrated clinical activity in proof-of-concept studies for TGN. Additionally, BIIB074 had potential applicability in several other neuropathic pain states, including lumbosacral radiculopathy and erythromelalgia. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price consisted of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$200.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$450.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$350.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is associated with the development and approval of BIIB074 for the treatment of TGN. In connection with the closing of this transaction, we recorded a liability of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; representing the fair value of the contingent consideration resulting in an adjusted purchase price of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$474.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The separately identifiable assets and liabilities acquired were primarily comprised of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$424.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$128.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to in-process research and development and goodwill, respectively.&amp;#160;These amounts were partially offset by the establishment of a deferred tax liability for the acquired IPR&amp;amp;D intangible assets which had no tax basis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&amp;amp;D intangible assets. The goodwill was not tax deductible.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:BusinessCombinationsPolicy contextRef="FD2017Q4YTD" id="Fact-8C6851E740DBCFBCBAF52977943FC308">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&amp;#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-6CCB0A15CB8F05A65CBA29779475CDF2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="FD2017Q4YTD" id="Fact-4285C0A71F8902C4206A29779467DFB7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;less than 90&amp;#160;days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;30.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;948.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;741.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;247.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,266.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,039.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,039.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,570.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,569.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,075.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,075.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;844.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;845.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;642.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;642.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,173.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;14.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,408.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,409.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,255.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,258.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,156.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,156.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,016.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,019.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;557.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;559.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,115.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,116.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,568.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,569.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,730.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,730.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,552.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,559.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;327.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;327.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;276.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;277.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,173.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;months and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,565.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,378.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; primarily relate to impairments recognized on certain of our available-for-sale marketable debt securities as we intend to sell these securities as a result of the Tax Cuts and Jobs Act of 2017 (the 2017 Tax Act), sales of agency mortgage-backed securities, corporate bonds and government securities. Realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$85.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$99.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which are included in investments and other assets in our consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
	<us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-E16E02DE6E96BF50F2202977945AA7AC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax benefit realized for stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received from the exercise of stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-F2AE442CBFDEFA70DBC8297794463273">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depending on the collaborative arrangement, we may record funding receivable or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Genentech (Roche Group)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our collaboration agreement will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&amp;#8217;s offer or purchase Genentech&amp;#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;RITUXAN&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Genentech is responsible for the worldwide manufacturing of RITUXAN. Development and commercialization rights and responsibilities under this collaboration are divided as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We share with Genentech co-exclusive rights to develop, commercialize and market RITUXAN in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Canada&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and Genentech have assigned our rights under our collaboration agreement with respect to Canada to the Roche Group.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;GAZYVA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;OCREVUS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FDA approved OCREVUS, a humanized anti-CD20 monoclonal antibody, for the treatment of RMS and PPMS. Under our agreement with Genentech, we will receive a tiered royalty on U.S. net sales from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and increasing up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if annual net sales exceed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$900.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. There will be a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we will receive a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11 years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS was approved for the treatment of RMS and PPMS in Australia, Switzerland and the E.U. in July 2017, September 2017 and January 2018, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Profit-sharing Formulas&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;RITUXAN Profit Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share on the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until GAZYVA First Non-CLL FDA Approval&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First Non-CLL GAZYVA FDA Approval&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the FDA&amp;#8217;s first approval of GAZYVA in an indication other than CLL.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the earlier of (i)&amp;#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or (ii)&amp;#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;Second GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$500.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share of RITUXAN pre-tax profits in the U.S. decreased to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in February 2016 when GAZYVA was approved by the FDA as a new treatment for follicular lymphoma and was further decreased to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12 month period exceeded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on certain events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2017 the FDA approved RITUXAN HYCELA for subcutaneous injection for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma and CLL. This new treatment includes the same monoclonal antibody as intravenous RITUXAN in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;GAZYVA Profit Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our current pretax profit-sharing formula for GAZYVA provides for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share on the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of operating profits earned each calendar year. Our share of annual profits in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; our share of operating profits on GAZYVA was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,269.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;242.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;69.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; profit-sharing threshold was met during the third quarter and the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; profit-sharing threshold was met during the first quarter. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; profit-sharing threshold was met during the first quarter. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; profit-sharing threshold was met during the first quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as depicted in the table above, excludes certain expenses charged to the collaboration by Genentech that we believe remain the responsibility of Genentech and that we are not obligated to pay under the terms of the collaboration agreement. Accordingly, we did not recognize the effect of those expenses in the determination of our share of pre-tax collaboration profits and Genentech has withheld approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from amounts due to us in relation to collaboration activity for 2017, representing Genentech&amp;#8217;s estimate of our share of these expenses. We remain in discussions with Genentech about a resolution relating to these amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;AbbVie&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with AbbVie for the development and commercialization of ZINBRYTA, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. Under this agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory) where development and commercialization costs and profits are shared equally. Outside of the Collaboration Territory, we are solely responsible for development and commercialization of ZINBRYTA and will pay a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are responsible for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and record these activities within their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures received from AbbVie.&amp;#160;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the collaboration incurred &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$39.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$113.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for research and development activities, respectively, for which we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$19.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to regulatory approval, we also recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$22.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of pre-commercialization expenses within our selling, general and administrative expense, which represented &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the collaboration's pre-commercialization costs for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. After ZINBRYTA was approved by the FDA and European Medicines Agency (EMA) in 2016, we began to recognize our share of the collaboration activities within the U.S., E.U. and Canadian territories as described below under &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;"Co-promotion Profits and Losses."&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Article 20 Procedure of ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2017 the EMA announced that it had provisionally restricted the use of ZINBRYTA to adult patients with highly active relapsing disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) or with rapidly evolving severe relapsing MS who are unsuitable for treatment with other DMTs.&amp;#160;These restrictions followed the initiation of an EMA review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2017, as part of this Article 20 Procedure of ZINBRYTA, the EMA Pharmacovigilance Risk Assessment Committee (PRAC) completed its assessment and recommended a further set of restrictions on the use of ZINBRYTA by MS patients. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 the Committee for Medicinal Products for Human Use (CHMP) adopted an opinion, confirming the PRAC's recommendations, for further restrictions to minimize the risk of serious liver injury with ZINBRYTA, including restriction of its use to adult patients with relapsing forms of MS who have had an inadequate response to at least two DMTs and for whom treatment with any other DMT is contraindicated or otherwise unsuitable. In January 2018 the EC adopted a final and legally-binding decision, which concluded the Article 20 Procedure, confirming the CHMP opinion.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The recommendation of these restrictions by the CHMP resulted in the impairment of substantially all of our assets related to ZINBRYTA as we have determined that these amounts may not be recoverable. As a result, we recorded net impairment charges related to intangible assets, inventory, property, plant and equipment and prepaid tax assets, totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$190.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Inventory related losses are subject to our profit share with AbbVie and are included above net of expected reimbursement. Offsetting these amounts was an unrecorded tax benefit related to certain ZINBRYTA related assets totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$93.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Co-promotion Profits and Losses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the U.S., AbbVie recognizes revenues on sales to third parties and we recognize our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. The collaboration began selling ZINBRYTA in the U.S. in the third quarter of 2016. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net reduction in revenue of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$21.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, to reflect our share of an overall net loss within the collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Costs and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;92.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Co-promotion losses in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;43.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of co-promotion losses in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the E.U. and Canada, we recognize revenues on sales to third parties in product revenues, net in our consolidated statements of income. We also record the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income as these costs are incurred. We reimburse AbbVie for their &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the co-promotion profits or losses in the E.U. and Canada. This reimbursement is recognized in collaboration profit (loss) sharing in our consolidated statements of income. We began to recognize product revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect AbbVie's &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration profits in the E.U. and Canada, as compared to net income recognized of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect AbbVie's &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration losses in the E.U. and Canada in the prior year. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acorda&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&amp;#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. The next expected milestone would be &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, due if ex-U.S. net sales reach &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; over a period of four consecutive quarters. Royalty payments are recognized in cost of sales within our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$34.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Ionis Pharmaceuticals, Inc. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Collaborations &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis to develop and commercialize SPINRAZA for the treatment of SMA. During 2014 we amended this agreement to adjust the amount of potential additional payments and terms of the exercise of our opt-in right to license SPINRAZA, which included providing for additional opt-in scenarios, based on the filing or acceptance of a New Drug Application (NDA) with the FDA or marketing authorization application with the EMA. Consistent with the initial agreement, Ionis remained responsible for conducting the pivotal/Phase 3 trials and we provided input on the clinical trial design and regulatory strategy for the development of SPINRAZA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA was approved for the treatment of SMA in the U.S., E.U. and Japan in December 2016, June 2017 and July 2017, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized product revenues totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$883.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, on our sales of SPINRAZA. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$112.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis. In addition, during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we made milestone payments to Ionis totaling&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;related to the marketing approvals discussed above, which were capitalized in intangible assets, net in our consolidated balance sheets. During the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, upon the exercise of our option to develop and commercialize SPINRAZA, we also paid a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; license fee to Ionis, which was recognized as research and development expense in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; no clinical trial payments were made to Ionis due to the completion of study activities. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we made clinical trial payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to the advancement of the program, which were recorded in investments and other assets in our consolidated balance sheets as they represented prepaid research and development expenditures. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, these prepaid research and development amounts were fully expensed as the services were provided.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$234.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$257.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$74.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, were reflected in total costs and expenses in our consolidated statements of income related to the advancement and commercialization of the program. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Antisense Therapeutics&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three therapeutic targets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, Ionis is responsible for global development of any product candidate&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$70.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to another &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;if we successfully develop the product candidate after option exercise. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis and agreed to make potential additional payments, prior to licensing, of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 we recognized this &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; developmental milestone upon the selection of BIIB080 (also known as IONIS-MAPT&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;Rx&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), which is currently in Phase 1 development. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Research Collaborations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;2013 Long-term Strategic Research Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2013 we entered into a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the treatment of neurological disorders.&amp;#160;Under the collaboration, Ionis will perform research on a set of neurological targets identified within this agreement. Once the research has reached a specific stage of development, we will make a determination whether antisense therapy is the preferred approach to developing a therapeutic candidate or whether another modality is preferred. If an antisense approach is selected, Ionis will continue development and identify a potential product candidate. If another modality is selected, we will assume responsibility for identifying a potential product candidate and assume development responsibility for development in that modality. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as research and development expense representing the value of intellectual property purchased that had not reached technological feasibility.&amp;#160;We recognized the remaining &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as prepaid research and discovery services, representing the value of the Ionis full time equivalent employee resources required by the collaboration to provide research and discovery services over the term of the collaboration.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ionis is also eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us. During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we triggered milestones of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to the advancement of IONIS-SOD1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;Rx&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the treatment of ALS and other neurological targets identified.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$70.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. &amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For product candidates using a different modality, we will be responsible for global development through all stages and will pay Ionis up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$90.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the achievement of certain regulatory milestones and royalties on future sales if we successfully develop the product candidate. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;2017 SMA Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2017 we entered into a new collaboration agreement with Ionis to identify new antisense oligonucleotide drug candidates for the treatment of SMA. Under this agreement, we will have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of these therapies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment to Ionis and we may pay Ionis up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$260.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development and regulatory milestone payments if new drugs advance to marketing approval. Upon commercialization, we may also pay Ionis up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$800.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Co., Ltd. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BAN2401 and E2609 Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2014 we entered into a collaboration agreement with Eisai (Eisai Collaboration Agreement) to jointly develop and commercialize two Eisai product candidates for the treatment of AD, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor. Under the Eisai Collaboration Agreement, Eisai serves as the global operational and regulatory lead for both compounds with all costs, including research, development, sales and marketing expenses shared equally by us and Eisai; and following marketing approval in major markets, such as the U.S., the E.U. and Japan, we and Eisai would co-promote BAN2401 and E2609 and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. In addition, the Eisai Collaboration Agreement provides both parties with certain rights and obligations in the event of a change in control of either party.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The Eisai Collaboration Agreement also provided Eisai with an option to jointly develop and commercialize aducanumab (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, a separate collaboration agreement would be entered into with Eisai on terms and conditions that mirror the Eisai Collaboration Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, both companies will continue to jointly develop BAN2401 and E2609 in accordance with the Eisai Collaboration Agreement; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of activity related to the Eisai Collaboration Agreement is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration in development of BAN2401 and E2609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;146.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;95.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;84.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and E2609 development expense reflected in our consolidated statements of income, excluding upfront and milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;74.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the fourth quarter of 2016 we recognized a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment related to the initiation of a Phase 3 trial for E2609, which is included in research and development expense in our consolidated statements of income. We could pay Eisai up to an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$625.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under the Eisai Collaboration Agreement based on the future achievement of certain development, regulatory and commercial milestones.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Aducanumab Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, we will continue to lead the ongoing Phase 3 development of aducanumab and will remain responsible for 100% of development costs for aducanumab incurred in support of this agreement until April 2018. Eisai will then reimburse us for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of aducanumab development expenses for the period April 2018 through December 2018, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;45%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; thereafter. Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. We will receive a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the potential profits (losses) in the U.S., a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;68.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the potential profits (losses) in the E.U. and a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The companies will continue to share equally in the potential profits (losses) in rest of world markets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and Eisai also agreed to co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai will distribute AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$263.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was reflected in research and development expense in our consolidated statements of income related to the advancement of our aducanumab program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Anti-Tau Option&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Bristol-Myers Squibb Company&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for BIIB092 (formerly known as BMS-986168), a Phase 2-ready experimental medicine with potential in AD and PSP. BIIB092 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we received worldwide rights to BIIB092 and are responsible for the full development and global commercialization of BIIB092 in AD and PSP. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to BMS and we may pay BMS up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$410.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments, and potential royalties. We also assumed all remaining obligations to the former shareholders of iPierian, Inc. (iPierian) related to BMS&amp;#8217;s acquisition of iPierian in 2014. In June 2017 we recognized a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; developmental milestone payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 PSP study for BIIB092 and we may pay the former shareholders of iPierian up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$490.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestone payments, and potential royalties. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Both the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment and the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; developmental milestone payment were recognized as research and development expense in our consolidated statements of income for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Alkermes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), for BIIB098 (formerly known as ALKS 8700), an oral monomethyl fumarate prodrug in Phase 3 development for the treatment of relapsing forms of MS. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we received an exclusive, worldwide license to develop and commercialize BIIB098 and will pay Alkermes a mid-teens percentage royalty on potential worldwide net sales of BIIB098. Royalties payable on net sales of BIIB098 are subject to tiered minimum payment requirements for a period of five years following FDA approval. Alkermes is eligible to receive royalties in the mid-single digits to low-teen percentages of annual net sales upon successful development and commercialization of new product candidates other than BIIB098. Alkermes will maintain responsibility for regulatory interactions with the FDA through the potential approval of the NDA for BIIB098 for the treatment of MS. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment to Alkermes representing our share of BIIB098 development costs already incurred in 2017. Beginning in 2018 we are responsible for all development expenses related to BIIB098. In December 2017 we also recognized a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; expense, which is expected to be paid to Alkermes in early 2018, enabling the continuation of the agreement to develop BIIB098. Both the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; continuation payment were recognized as research and development expense in our consolidated financial statements for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may also pay Alkermes up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional future milestone payments upon certain regulatory achievements related to BIIB098 under this collaboration. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$80.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in research and development expense in our consolidated statements of income related to this collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the license and collaboration agreement, we may also enter into a supply agreement with Alkermes for the commercial supply of BIIB098 and other products developed under the license and collaboration agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Applied Genetic Technologies Corporation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015 we entered into a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). This collaboration is focused on the development of a portfolio of AGTC&amp;#8217;s therapeutic programs, including both a clinical-stage candidate for X-linked Retinoschisis (XLRS) and a pre-clinical candidate for the treatment of X-Linked Retinitis Pigmentosa (XLRP). This agreement also provides us with options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement we received worldwide commercialization rights for the XLRS and XLRP programs. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials and we will support the related clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. AGTC has an option to share development costs and profits after the initial clinical trial data becomes available, and an option to co-promote the second of these products approved in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$124.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to AGTC. AGTC is also eligible to receive development, regulatory and commercial milestone payments aggregating in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.1 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which includes up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$467.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; collectively for the two lead programs and up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$592.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; across the discovery programs. AGTC is also eligible to receive royalties in the mid-single digit to mid-teen percentages of annual net sales upon successful development and commercialization of new product candidates. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$124.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment reflected a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equity investment in AGTC, prepaid research and development expenditures of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and total licensing and other fees of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total licensing and other fees were recognized as a charge to research and development expense in our consolidated statements of income for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equity investment and the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of prepaid research and development expenditures were recorded in investments and other assets in our consolidated balance sheets. These prepaid research and development amounts are being expensed as the services are provided, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; remains as a prepaid asset as of December 31, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$26.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$54.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which were reflected in research and development expense in our consolidated statements of income related to this collaboration. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the collaboration and license agreement, we also received a manufacturing license under which we received an exclusive license to use AGTC&amp;#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&amp;#8217;s discretion, in exchange for payment of milestones and royalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;University of Pennsylvania&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2016 we entered into a collaboration and alliance with the University of Pennsylvania (UPenn) to advance gene therapy and gene editing technologies. The collaboration is primarily focused on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. The alliance is also focused on the research and validation of next-generation gene transfer technology using adeno-associated virus gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to UPenn, which was recorded as research and development expense in our consolidated statements of income, and made prepaid research and development expenditures of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which was recorded in investments and other assets in our consolidated balance sheets. During 2017, we made additional prepaid research and development expenditures to UPenn of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the advancement of these programs. These prepaid research and development amounts are being expensed as the services are provided, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; remains as a prepaid asset as of December 31, 2017. We also expect to fund an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$18.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional research and development costs in seven preclinical research and development programs, as well as the exploration of genome-editing technology.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If all of the collaborations programs are successful and we exercise all of our options under the UPenn collaboration and alliance, we may be required to make future payments of over &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in research funding, options and milestone payments. UPenn is also eligible to receive royalties in the mid-single digit to mid-teens percentages of annual net sales upon successful development and commercialization of new product candidates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$33.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in research and development expense in our consolidated statements of income related to this collaboration.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Research and Discovery Arrangements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we entered into several research, discovery and other related arrangements that resulted in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, recorded as research and development expense in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&amp;#160;Samsung Biologics contributed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;280.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; stake in Samsung Bioepis and we contributed approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for the remaining &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ownership interest.&amp;#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership interest is approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;The exercise of this option is within our control and is based on paying for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the joint venture agreement plus a rate that will represent their return on capital. If we do not exercise this option by mid-2018, this option will expire and Samsung Biologics will have the right to purchase all of Samsung Bioepis&amp;#8217; shares then held by us.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We account for this investment under the equity method of accounting as we maintain the ability to exercise significant influence over Samsung Bioepis through a presence on the entity&amp;#8217;s Board of Directors and our contractual relationship. Under the equity method, we recorded our original investment at cost and subsequently adjust the carrying value of our investment for our share of equity in the entity&amp;#8217;s income or losses according to our percentage of ownership. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our consolidated statements of income. During the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a loss on our investment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Commercial Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2013 pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of one anti-TNF biosimilar, Japan.&amp;#160;Under this agreement, we have made total upfront and clinical development milestone payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$46.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, all of which have been recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. During the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in milestone payments, which have been capitalized in intangible assets, net in our consolidated balance sheets as IMRALDI received regulatory approval in the E.U. in August 2017, BENEPALI received regulatory approval in the E.U. in January 2016 and FLIXABI received regulatory approval in the E.U. in May 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We began to recognize revenues on sales of BENEPALI in the E.U. in the first quarter of 2016 and FLIXABI in the E.U. in the third quarter of 2016. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. We share &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the profit or loss related to our commercial agreement with Samsung Bioepis. This profit sharing with Samsung Bioepis is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$111.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, to reflect Samsung Bioepis's &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration profits. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we will receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis. Under the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development and analytical development. Under our manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&amp;#160;Under limited circumstances, we may also supply Samsung Bioepis with quantities of drug product of biosimilar products for use in clinical trials through arrangements with third-party contract manufacturers. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues in relation to these services, which is reflected as a component of other revenues in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-79BDAAD3E8B6DE0535DF2977947294C5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;TYSABRI Contingent Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on annual worldwide net sales up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on annual worldwide net sales that exceed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013, and Perrigo subsequently sold its rights to these payments to a third party effective January 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration related to Business Combinations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence, Stromedix and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As the acquisitions of Convergence, Stromedix and BIN, occurred after January&amp;#160;1, 2009, we recorded the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.1 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestones related to these acquisitions. For additional information on our acquisition of Convergence please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Fumapharm AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$220.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon closing of the transaction and agreed to pay an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if a Fumapharm Product was approved for MS in the U.S.&amp;#160;or E.U. In the second quarter of 2013 we paid this &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment as TECFIDERA was approved in the U.S. for MS by the FDA. We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent payments as we reached the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$13.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$14.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2016 and the first, second and third quarters of 2017, respectively, and accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$600.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon reaching &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total cumulative sales of Fumapharm Products in the fourth quarter of 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We will owe an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment for every additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, until such time as the cumulative sales level reaches &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, at which time no further contingent payments shall be due. If the prior 12 months sales of Fumapharm Products are less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, contingent payments remain payable on a decreasing tiered basis. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&amp;#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Development, Regulatory and Commercial Milestone Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based on our development plans as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we could make potential future milestone payments to third parties of up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, including approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.7 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in development milestones, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in regulatory milestones and approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in commercial milestones as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Funding Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our consolidated balance sheet for expenditures incurred by CROs as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$460.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cancellable future commitments based on existing CRO contracts as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Related Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$77.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of net liabilities associated with uncertain tax positions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of December 31, 2017, we have accrued income tax liabilities of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$989.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under the Transition Toll Tax, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$78.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is expected to be paid within one year. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2015, we purchased land in Solothurn, Switzerland and are building a large-scale biologics manufacturing facility at this site. We expect this facility to be operational by the end of the decade. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$270.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the construction of this facility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense, net of sublease income under these leases, which terminate at various dates through 2028, amounted to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$65.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$68.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$68.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;72.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;72.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;68.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;65.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;271.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;617.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(24.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(24.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(23.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(22.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(22.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(71.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;48.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;44.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;44.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;43.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;199.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;428.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-B9A965874AFE9CA7AF62297794320006">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&amp;#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&amp;#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
	<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-1961216BE3E8F889844D297794485A06">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&amp;#8217; vesting periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense, net of forfeitures, for RSUs is recognized straight-line over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price of common stock under our ESPP is equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the lesser of (i)&amp;#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&amp;#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; discount is recognized as compensation expense over the 90-day purchase period. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
	<us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="FD2017Q4YTD" id="Fact-BF8F6A6D1F86FD11C005297794680357">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(193.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;158.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(42.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;31.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;44.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(162.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;158.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(318.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(138.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(92.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(138.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(95.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;110.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(172.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(171.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(61.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(164.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(32.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;173.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(44.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;171.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2017Q4YTD" id="Fact-84CFD01042F16B1E673529779445146C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms that generally require payment within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 to 90 days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, two wholesale distributors individually accounted for approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of accounts receivable, net, respectively. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-6B28E4FA4FCC2E81D2AE2977944AA56C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-E44C263841588C7525672977943DF3EB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Indebtedness&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our indebtedness is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financing arrangement for the purchase of the RTP facility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of notes payable and other financing arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Non-current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;558.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,482.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,485.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;994.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;993.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,736.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,734.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,722.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,721.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financing arrangement for the purchase of the RTP facility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of notes payable and other financing arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,935.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,512.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On March&amp;#160;4, 2008, we issued $550.0&amp;#160;million aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;Senior Notes due March&amp;#160;1, 2018 at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;99.184%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par. These notes were senior unsecured obligations. We also entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these contracts, the carrying amount of these notes were increased by &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; with this amount being amortized using the effective interest rate method over the remaining life of the Senior Notes and recognized as a reduction of interest expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 we redeemed these notes prior to their maturity and recognized a net charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the extinguishment of these notes. This charge, which was recognized in interest expense in other income (expense) net in our consolidated statements of income for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflects the payment of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; gain related to the remaining unamortized balance of the interest rate swap liability discussed above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2015 Senior Notes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following is a summary of our principal indebtedness as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2020, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.792%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;3.625%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2022, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.920%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.75 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2025, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.764%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.75 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15,&amp;#160;2045, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.294%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The costs associated with these offerings of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These notes are senior unsecured obligations. These Senior Notes may be redeemed at our option at any time at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued interest and a specified make-whole amount. These Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;101%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes offering due in 2020, we entered into interest rate swap contracts. The carrying value of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes includes approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to changes in the fair value of these contracts. For additional information on our interest rate contracts, please read Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Notes Payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs that are payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica, payable in June 2018, had a carrying value of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Credit Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2015 we entered into a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; outstanding borrowings and were in compliance with all covenants under this facility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Financing Arrangement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2015 we recorded a financing obligation in relation to the amendment of our lease agreement for Eisai's oral solid dose products manufacturing facility in RTP, NC. In December 2017 we completed the purchase of this facility for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and derecognized the remaining unamortized portion of the financing obligation from our consolidated balance sheet as of that date. For additional information on this transaction, please read Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Property, Plant and Equipment,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Maturity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total gross payments, excluding our financing arrangement, due under our debt arrangements are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023 and thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,003.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our debt is disclosed in Note&amp;#160;8, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-14686B1C869E09BFAA422977946621EE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&amp;#160;dollar. The value of revenues and operating expenses measured in U.S.&amp;#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; had durations of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,875.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound sterling&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;150.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss francs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;88.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;83.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,198.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$113.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$49.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect the net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$113.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to be settled over the next &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$98.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is expected to be settled over the next &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&amp;#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="27" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion) (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion) (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(32.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;173.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interest Rate Lock Contracts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2015 we entered into treasury rate locks, with an aggregated notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.1 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, as described in Note 12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements, we settled the treasury rate locks and realized an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interest Rate Swap Contracts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, as described in Note 12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements, we entered into interest rate swaps with an aggregate notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$675.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency contracts was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$564.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$902.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$23.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts were recognized as a component of other income (expense), net, for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance&amp;#160;Sheet&amp;#160;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;84.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;23.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
	<us-gaap:DerivativesPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-28FAC0A4D136FF9EFFFB297794702B43">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q4YTD" id="Fact-153C41549E7671ADA8012977945A1482">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Share-based Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;74.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;84.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;88.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;95.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;121.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;127.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;169.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;204.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;160.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(42.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(54.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(55.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;117.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;135.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;140.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;107.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;119.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;18.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;169.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;204.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;160.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, unrecognized compensation cost related to unvested share-based compensation was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$168.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Spin-off Related Equity Adjustments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pursuant to an employee matters agreement entered into in connection with the spin-off of our hemophilia business and the provisions of our existing share-based compensation arrangements, we made certain adjustments to the number and terms of our outstanding stock options, RSUs, CSPUs and other share-based awards to preserve the intrinsic value of the awards immediately before and after the spin-off. For purposes of the vesting of these equity awards, continued employment or service with Biogen or with Bioverativ was treated as continued employment for purposes of both Biogen&amp;#8217;s and Bioverativ&amp;#8217;s equity awards with the outstanding awards continuing to vest over their respective original vesting periods. Outstanding unvested awards for employees transferring to Bioverativ were converted to unvested Bioverativ awards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments to the number of our share-based compensation awards were made using an adjustment ratio based upon the weighted-average closing price of our common stock for the 10 calendar days prior to the effective date of the spin-off and the volume-weighted average prices for the 10 calendar days of our common stock following the effective date of the spin-off. For stock options, the exercise prices of the awards were modified to maintain the pre-spin intrinsic value of the awards in relation to the post-spin stock price of Biogen. The difference between the fair value of the awards based upon the adjustment ratio and the opening price on the distribution date was not material.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share-based compensation plans pursuant to which awards are currently being made: (i)&amp;#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&amp;#160;Directors Plan); (ii)&amp;#160;the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii)&amp;#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Directors Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2006 our shareholders approved the 2006&amp;#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&amp;#160;Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock for issuance under the 2006&amp;#160;Directors Plan. The 2006&amp;#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5-to-1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Omnibus Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2008 Omnibus Equity Plan as of June 7, 2017 or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017 are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5-to-1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;ratio.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a ten-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options&amp;#8217; vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; grants of stock options made in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, all outstanding options were exercisable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility or both, we have concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January&amp;#160;1, 2006 were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our stock option activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;54.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia spin-off adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;42,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total intrinsic values of options exercised in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$38.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. The aggregate intrinsic values of options outstanding as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The weighted average remaining contractual term for options outstanding as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax benefit realized for stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received from the exercise of stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Market Stock Units (MSUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;MSUs awarded to employees prior to 2014 vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on actual stock performance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;MSUs awarded to employees in 2014 and thereafter vest in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on actual stock performance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The vesting of these awards is subject to the respective employee&amp;#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our MSU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;230,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;355.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia spin-off adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;94,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;382.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(112,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;311.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(45,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;372.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;171,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;370.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;MSUs granted in 2017 include approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;9,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; MSUs issued in 2017 based upon the attainment of performance criteria set for 2013, in relation to awards granted in that year. MSUs granted during 2017 also include awards granted in conjunction with our annual awards made in February 2017 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2017 reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2016, 2015 and 2014.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, including the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price on grant date for MSUs awarded prior to 2014, the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price on the date of grant for MSUs awarded in 2014 and thereafter, expected volatility of our stock price, risk-free rates of return and expected dividend yield.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; The assumptions used in our valuation are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of expected stock price volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;33.0% - 35.6%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.2% - 40.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.0% - 33.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of risk-free interest rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.9% - 1.6%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6% - 0.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2% - 1.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 calendar day average stock price on grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$263.18 - $267.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$260.67 - $304.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$277.35 - $426.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average per share grant date fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$382.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$328.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$493.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of MSUs vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$39.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$109.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Cash Settled Performance Units (CSPUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;CSPUs awarded to employees vest in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&amp;#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&amp;#160;31 of each year. Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs awarded prior to 2014 are settled in cash based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. CSPUs awarded in 2014 and thereafter will be settled in cash based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our CSPU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;122,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia spin-off adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;83,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(69,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(34,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;105,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;CSPUs granted in 2017 include awards granted in conjunction with our annual awards made in February 2017 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. CSPUs granted in 2017 also include CSPUs issued in 2017 based upon the attainment of performance criteria set for 2016 in relation to shares granted in 2016.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The cash paid in settlement of CSPUs vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$79.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Performance-vested Restricted Stock Units (PUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;PUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;110,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia spin-off adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(43,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(19,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;91,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;PUs granted in 2017 include awards granted in conjunction with our annual awards made in February 2017 and PUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; PUs were converted to share settlements, of which approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares were vested and issued. All other PUs that vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; were settled in cash totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All PUs that vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; were settled in cash totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Time-Vested Restricted Stock Units (RSUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;RSUs awarded to employees generally vest no sooner than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one-third per year over three years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our RSU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;888,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;303.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia spin-off adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;464,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;293.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(350,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;308.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(182,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;292.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;832,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;291.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;RSUs granted in 2017 primarily represent RSUs granted in conjunction with our annual awards made in February 2017 and awards made in conjunction with the hiring of new employees. RSUs granted in 2017 also include approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;11,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; RSUs granted to our Board of Directors.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;RSUs granted in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; had weighted average grant date fair values of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$268.52&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$388.88&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of RSUs vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$104.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$239.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan (ESPP)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2015 our shareholders approved the 2015 ESPP. The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&amp;#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our ESPP activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;167,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;190,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;78,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 1995 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;98,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 1995 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-B2E7DF6F7652816328942E843C92810A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. (Sangamo).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the distribution, Biogen and Bioverativ entered into a separation agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward. They also provide for the performance of services by each company for the benefit of the other for a period of time. In addition, under the separation agreement, Bioverativ is obligated to indemnify us for liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The services under these agreements generally commenced on February 1, 2017 (the distribution date), and terminate within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the distribution date, with the exception of the manufacturing and supply agreement, which has an initial term of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, with a 5 year extension at Bioverativ's sole discretion and a further 5 year extension with Bioverativ's and our consent. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the distribution we made a net cash contribution to Bioverativ, during the first quarter of 2017, totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$302.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;302.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;144.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;116.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;56.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;53.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,008.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;87.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;67.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;155.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pursuant to the terms of our agreements with Bioverativ, upon completion of the spin-off, we distributed ALPROLIX and ELOCTATE on behalf of Bioverativ until Bioverativ obtained appropriate regulatory authorizations in certain countries, including a Biologics License Application transfer in the U.S., which was received in September 2017. Accordingly, commencing October 2017, we ceased distribution of ALPROLIX and ELOCTATE on behalf of Bioverativ under this arrangement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the manufacturing and supply agreement, we manufacture and supply certain products and materials to Bioverativ. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$64.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in revenues in relation to these contract manufacturing services, which is reflected as a component of other royalty and corporate revenues in our consolidated statements of income. We also recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as cost of sales in relation to these services during the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts earned under the non-manufacturing and supply related transaction service agreements are recorded as a reduction of costs and expenses in their respective expense line items. These amounts, which were primarily reflected as a reduction to selling, general and administrative expenses in our consolidated statements of income, were not significant for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia related product revenues reflected in our consolidated statements of income for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$74.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$846.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$554.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Results for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; only reflect hemophilia-related product revenues through January 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;"&gt;Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to the spin-off of our hemophilia business, we were awarded various methods of treatment and composition of matter patents related to ELOCTATE and ALPROLIX. Upon completion of the spin-off, these patents were transferred to the patent portfolio of Bioverativ.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-721F5746EDAA2DF2EB9829779473D8D8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2017Q4YTD" id="Fact-0394CAA7C0613A7405A229779451D376">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Earnings&amp;#160;per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,539.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,702.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,547.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;212.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;230.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Earnings per share for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reflects, on a weighted average basis, the repurchase of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares, respectively, of our common stock under our share repurchase authorizations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adjustments related to the spin-off of our hemophilia business did not have a material impact on the potentially dilutive securities to be considered in the calculation of diluted earnings per share of common stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:EquityMethodInvestmentsPolicy contextRef="FD2017Q4YTD" id="Fact-1CE9088B517FDC334CA729779464DDDA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&amp;#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&amp;#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
	<us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="FD2017Q4YTD" id="Fact-14838214A9401938EFEC29779466D5F0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;583.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,517.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,521.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,032.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,026.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,851.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,796.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,077.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,874.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,483.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,808.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2017Q4YTD" id="Fact-4B1F95A0E8D7062EAFA8297794663188">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,609.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,609.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,919.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,919.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;643.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;643.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,444.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,433.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;634.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,558.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,533.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;481.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;583.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,517.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,521.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,032.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,026.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,851.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,796.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,077.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,874.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,483.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,808.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 we redeemed our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due March 1, 2018 with an aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$550.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For information on this redemption please read Note 12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair value of each series of our Senior Notes was determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence, Stromedix and BIN in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;62.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(53.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$279.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$246.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. Changes in the fair value of our contingent consideration obligations are primarily due to changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones and changes in the discount rate. Payments and other for 2016 includes &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of a Convergence milestone converted to a short-term obligation under the acquisition agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or transfers between fair value measurement levels during the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Convergence&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This valuation was based on probability weighted net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$450.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which was the estimated cost of debt financing for market participants. This liability reflected the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For additional information on this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$259.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$258.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon net cash flow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$400.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, probability weighted and discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.4%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net increase in the fair value of this obligation was primarily due to changes in the discount rate, partially offset by changes in the expected timing related to the achievement of certain remaining developmental milestones. Approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$147.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Stromedix Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Stromedix in March 2012 we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$122.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$162.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$133.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$344.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, probability weighted and discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.4%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net increase in the fair value of this obligation was primarily due to an increase in the probability of success related to the achievement of certain remaining developmental milestones, partially offset by changes in the discount rate. Approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$76.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Biogen Idec International Neuroscience GmbH&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$81.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$102.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$355.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, probability weighted and discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.8%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net increase in the fair value of this obligation was primarily due to an increase in the probability of success related to the achievement of certain remaining developmental milestones, partially offset by a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; developmental milestone payment. Approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is reflected as a component of accrued expenses and other in our consolidated balance sheets as we achieved the developmental milestone of dosing our first patient in our Phase 2 SPARK study of BIIB054 in Parkinson's disease in January 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acquired IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence, we also allocated &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$424.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the total purchase price to acquired IPR&amp;amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. These assets will be tested for impairment annually until commercialization, after which time the IPR&amp;amp;D will be amortized over its estimated useful life using the economic consumption method. For additional information on this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2017Q4YTD" id="Fact-CFF79300872F5EFF306E29779464354A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;62.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(53.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2017Q4YTD" id="Fact-9A9FF5F24B97A04382BD2977943329D9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain financial assets and liabilities recorded at fair value which have been classified as Level&amp;#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&amp;#160;and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our financial assets have been classified as Level&amp;#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-B7DB87280EADAE81F94B2977942D37DA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&amp;#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-C16DB5AEA7186760517C297794532E29">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(535.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,689.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;316.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,634.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;371.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks and trade names&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,971.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,160.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,811.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(776.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,705.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;8,264.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4,385.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,879.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,742.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,934.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,808.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of acquired intangible assets totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$814.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$385.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$382.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of acquired intangible assets for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$444.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of amortization and impairment charges related to our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below. Amortization of acquired intangible assets for 2017 also reflects a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment charge related to the Article 20 Procedure of ZINBRYTA in the E.U. For additional information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balances in the table above as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; also reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. For additional information on the spin-off of our hemophilia business, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. In-process research and development balances include adjustments related to foreign currency exchange rate fluctuations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Out-licensed Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Developed Technology&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$309.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired and had not reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life and amortize these amounts based upon an economic consumption method. The carrying value associated with our IPR&amp;amp;D assets as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; relates to the various IPR&amp;amp;D programs we acquired in connection with our acquisitions of Convergence, Stromedix Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN) in 2015, 2012 and 2010, respectively. These amounts have and will be adjusted for foreign exchange rate fluctuations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long-range planning cycle, which was updated in the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&amp;#160;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired and In-licensed Rights and Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2,236.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The net change in acquired and in-licensed rights and patents during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reflects &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$90.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total milestone payments paid to Ionis Pharmaceuticals, Inc. (Ionis) for the approvals of SPINRAZA in the E.U. and Japan in June 2017 and July 2017, respectively, the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment paid to Samsung Bioepis, for the approval of IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the E.U. in August 2017, and the net carrying value recognized in relation to our acquisition of TECFIDERA license rights, as described below. These net increases were in part offset by amortization and the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment charge related to the Article 20 Procedure of ZINBRYTA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our relationships with Ionis and Samsung Bioepis and the European Commission (EC) approved restrictions on the use of ZINBRYTA, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;TECFIDERA License Rights&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.25 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$454.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this agreement and in the first quarter of 2017 we recognized an intangible asset of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$795.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this agreement. The pre-tax charge recognized in the fourth quarter of 2016 represented the fair value of our license to Forward Pharma&amp;#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016. The intangible asset represented the fair value of the U.S. and rest of world licenses to Forward Pharma&amp;#8217;s intellectual property related to TECFIDERA revenues for the period January 2017, the month in which we entered into this agreement, through December 2020, the last month before royalty payments could first commence pursuant to this agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. In January 2018 the European Patent Office (EPO) announced its decision revoking Forward Pharma&amp;#8217;s European Patent No. 2 801 355. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. Based upon our assessment of these rulings, we continue to amortize the remaining net book value of the U.S. and rest of world intangible assets in our consolidated statements of income utilizing an economic consumption model.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on these disputes, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Litigation,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TECFIDERA, AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of TECFIDERA, AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our most recent long-range planning cycle was completed in the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Based upon this analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;423.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;401.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;381.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;254.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;242.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,669.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Elimination of goodwill allocated to our hemophilia business&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,267.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,026.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,632.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,669.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The elimination of goodwill represents an allocation based upon the relative enterprise fair value of the hemophilia business as of the distribution date. For additional information on the spin-off of our hemophilia business, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in goodwill during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent milestones achieved (exclusive of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$232.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$173.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in tax benefits), respectively, and payable to the former shareholders of Fumapharm AG or holders of their rights. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other includes changes related to foreign currency exchange rate fluctuations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; For additional information on future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 22, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="FD2017Q4YTD" id="Fact-371E2D18E80AE0239E262977947C9CB5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&amp;#160;25, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Segment Information,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="FD2017Q4YTD" id="Fact-7B9904517D4BC311E4C22977947565C6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&amp;#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to obtaining the fair value of the U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd. (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TECFIDERA, TYSABRI and AVONEX using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TECFIDERA, TYSABRI and AVONEX is performed annually during our long-range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TECFIDERA, TYSABRI or AVONEX.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
	<us-gaap:GuaranteesTextBlock contextRef="FD2017Q4YTD" id="Fact-5167D976849D9CDD4A3E29779472D77E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Guarantees&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we did not have significant liabilities recorded for guarantees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GuaranteesTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-D56396E46941723757FC297794488D89">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="FD2017Q4YTD" id="Fact-4936305EFD25377BD03E297794354C02">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;amp;D programs have a fair value that is not significantly in excess of carrying value, including treatments for forms of neuropathic pain, such as trigeminal neuralgia (TGN). Such programs could become impaired if assumptions used in determining the fair value change. Impairments are recorded as amortization of acquired intangible assets in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-3A1FEA6BD6BD52D921DA29779438EB57">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Income Tax Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income before income tax provision and the income tax expense consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income before income taxes (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,540.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,655.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,386.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,588.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,277.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,380.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,128.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,933.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,767.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income tax expense (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,201.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,304.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,214.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;57.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;108.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;52.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;54.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,367.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,412.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,307.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;241.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(125.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(129.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(159.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(45.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;91.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(175.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(145.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,458.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,237.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,161.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Tax Reform&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The 2017 Tax Act, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as global intangible low-taxed income (GILTI). These changes are effective beginning in 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The 2017 Tax Act also includes a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in tax rates and tax laws are accounted for in the period of enactment. Therefore, during the year ended December 31, 2017, we recorded a charge totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,173.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to our current estimate of the provisions of the 2017 Tax Act.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Transition Toll Tax&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The 2017 Tax Act eliminates the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on undistributed foreign earnings. The Transition Toll Tax is assessed on the U.S. shareholder's share of the foreign corporation's accumulated foreign earnings that have not previously been taxed. Earnings in the form of cash and cash equivalents will be taxed at a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and all other earnings will be taxed at a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of December 31, 2017, we have accrued income tax liabilities of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$989.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under the Transition Toll Tax, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$78.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is expected to be paid within one year. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;At December 31, 2017, we considered none of our earnings to be permanently reinvested outside the U.S. and have therefore recorded tax liabilities associated with an estimate of the total withholding taxes that may be a result of our repatriation of earnings.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Effect on Deferred Tax Assets and Liabilities and other Adjustments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our deferred tax assets and liabilities are measured at the enacted tax rate expected to apply when these temporary differences are expected to be realized or settled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As our deferred tax assets exceed the balance of our deferred tax liabilities at the date of enactment, we have recorded a tax expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$184.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflecting the decrease in the U.S. corporate income tax rate and other changes to U.S. tax law. It is our current policy to not recognize deferred taxes for basis differences expected to reverse as GILTI is incurred and instead to account for any taxes assessed as period costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Status of our Assessment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our preliminary estimate of the Transition Toll Tax and the remeasurement of our deferred tax assets and liabilities is subject to the finalization of management&amp;#8217;s analysis related to certain matters, such as developing interpretations of the provisions of the 2017 Tax Act, changes to certain estimates and amounts related to the earnings and profits of certain subsidiaries and the filing of our tax returns. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The final determination of the Transition Toll Tax and the remeasurement of our deferred assets and liabilities will be completed as additional information becomes available, but no later than one year from the enactment of the 2017 Tax Act.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Article 20 Procedure of ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of the Article 20 Procedure of ZINBRYTA, we have recognized a net impairment charge on certain tax assets reflected within income tax expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This charge reflects the write off of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$142.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to prepaid taxes, which was partially offset by the recognition of an unrecorded deferred tax benefit of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$93.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Deferred Tax Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Significant components of our deferred tax assets and liabilities are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;201.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory, other reserves and accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;147.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;250.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangibles, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;378.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;459.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;209.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;831.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,071.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(250.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(376.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation, amortization and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(107.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(113.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(358.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(490.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the total deferred charges and prepaid taxes were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$617.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$989.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This new standard becomes effective for us on January 1, 2018.&amp;#160;We will adopt this standard using the modified retrospective method, through a cumulative-effect adjustment directly to retained earnings as of that date.&amp;#160;Based on currently enacted tax rates, upon adoption in 2018, we will record additional deferred tax assets of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and an increase to retained earnings of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017 Tax Act&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;22.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Impairment of ZINBRYTA related tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Changes in Tax Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The most significant factors contributing to the increase in our effective tax rate for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is the effect of the enactment of the 2017 Tax Act and the impairment of certain ZINBRYTA related tax assets, both of which are discussed above. Excluding the effect of these items, our income tax rate would have decreased due to a lower percentage of our earnings being recognized in the U.S., a higher tax jurisdiction. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we earned a lower benefit from the orphan drug credit due to the FDA's approval of SPINRAZA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our effective tax rate for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; increased primarily due to a net state tax benefit in 2015 resulting from the remeasurement of one of our uncertain tax positions, described below, and a higher relative percentage of our earnings being attributed to the U.S., a higher tax jurisdiction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Tax Attributes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which begin to expire in 2020. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$19.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; that begin to expire in 2018. For state income tax purposes, we also had research and investment credit carry forwards of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$129.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; that begin to expire in 2018. For foreign income tax purposes, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.1 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of net operating loss carryforwards that begin to expire in 2021.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at January&amp;#160;1,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;32.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;131.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions based on tax positions related to the current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reductions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(21.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(49.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statute expirations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlement refund (payment)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;44.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(64.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(42.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our 2017 activity above reflects a refund received from a state, related to the settlement of an uncertain tax position.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Included in the balance of unrecognized tax benefits as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; are &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$64.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$26.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we recognized a net interest expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we recognized net interest expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we recognized a net interest expense of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have accrued approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the payment of interest and penalties as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;International Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have made payments totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to the Danish Tax Authority (SKAT) for assessments received for fiscal 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to Danish withholding taxes based on potential European court decisions expected in 2018 on similar matters.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Federal and State Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to our revenues from anti-CD20 therapeutic programs and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-0B3D7F7E3334AED85CFD29779468BD30">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All tax effects associated with intercompany transfers of assets within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&amp;#160;If the asset transferred becomes impaired, for example through the obsolescence of inventory or discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We account for uncertain tax positions using a &amp;#8220;more-likely-than-not&amp;#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-AE6980C0A348471A77FA2977944EC861">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;162.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;605.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;698.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;157.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;925.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;902.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,001.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;22.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;925.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balances in the table above as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. Balances transferred to Bioverativ related to work in process and finished goods inventory totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$84.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. For additional information on the spin-off of our hemophilia business, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$76.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$41.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-DD4F37DD532E9522BE9329779434F51E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventories are stated at the lower of cost or market with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Capitalization of Inventory Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Obsolescence and Unmarketable Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-B032C3D8002DF544D6ED2977943F0BEE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&amp;#8217;s decline and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions and are included in investments and other assets in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Evaluating Investments for Other-than-Temporary Impairments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&amp;#8217;s decline and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="FD2017Q4YTD" id="Fact-00F0B7F62E5B05EEDACC297794678350">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,115.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,116.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,568.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,569.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,730.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,730.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,552.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,559.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;327.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;327.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;276.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;277.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,173.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:LegalMattersAndContingenciesTextBlock contextRef="FD2017Q4YTD" id="Fact-0A3DEFE48AB2B0A3189A29779477FD76">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&amp;#8217; legal theories; and (v) the parties' settlement positions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 6, 2015, a qui tam action filed on behalf of the United States and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&amp;#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Securities Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers are defendants in an action filed by a shareholder on October 20, 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &amp;#167;78j(b) and &amp;#167;78t(a) and 17 C.F.R. &amp;#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Abbreviated New Drug Application (ANDA) Litigation relating to TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June, July, and September 2017 and January 2018, we initiated patent infringement proceedings pursuant to the Hatch-Waxman act in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Caribe Holdings (Cayman) Co. Ltd.&amp;#160;DBA Puracap&amp;#160;Caribe, Puracap International LLC, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Impax Laboratories, Inc., Prinston Pharmaceutical Inc., Slayback Pharma LLC,&amp;#160;Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd., Cipla Limited, Glenmark Pharmaceuticals Ltd., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Shipla Medicare Limited, Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd., Accord Healthcare Inc., Par Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc. and Zydus Pharmaceuticals (USA) Inc. In addition, we initiated patent infringement proceedings pursuant to the Hatch-Waxman act against Stason Pharmaceuticals, Inc. in the U.S. District Court for the Central District of California, Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of New Jersey, Accord Healthcare Inc. in the U.S. District Court for the Middle District of North Carolina, Par Pharmaceutical Inc. in the U.S. District Court for the Southern District of New York, Sandoz Inc. in the U.S. District Court for the District of Colorado and Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The cases against Accord Healthcare Inc., Zydus Pharmaceuticals (USA) Inc. and Sandoz Inc. have been dismissed in the North Carolina, New Jersey and Colorado courts but will continue against those parties in Delaware. The cases against Par Pharmaceutical Inc. in both New York and Delaware have been dismissed because Par Pharmaceutical Inc.&amp;#8217;s ANDA application has been withdrawn. The case against Stason Pharmaceuticals, Inc. in California has been dismissed, but the case against its partner Sawai USA, Inc. will proceed in Delaware. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We expect a trial in the Delaware actions in December 2019, and a trial has been set in the West Virginia action in February 2020.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interference Proceeding with Forward Pharma&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&amp;#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. In March 2017 the USPTO ruled against Forward Pharma. Forward Pharma has appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. For additional information regarding this matter, please read Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles Assets and Goodwill,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2016 the EPO decided to revoke our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2018 the EPO announced its decision revoking Forward Pharma&amp;#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Board of Appeal and the Enlarged Board of Appeal, as applicable, to make a final determination. For additional information regarding this matter, please read Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles Assets and Goodwill,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Patent Revocation Matter&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss Pharma International AG filed actions in the District Court of The Hague (on January 11, 2016), the German Patents Court (on March 3, 2016) and the Commercial Court of Rome (November 2017) to invalidate the Dutch, German and Italian counterparts of our European Patent Number 1 485 127 (&amp;#8220;Administration of agents to treat inflammation&amp;#8221;) ('127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat MS. The patent expires in February 2023. The Dutch counterpart was ruled invalid and we have appealed. In November 2018 Bioeq gmbh (an entity associated with Swiss Pharma and Polpharma) brought an action in the Polish Patent Office seeking to revoke the Polish counterpart of the &amp;#8216;127 patent. In January 2018 the German court announced that the German counterpart was invalid. No date for a hearing on the merits has yet been set in the Italian action.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On May&amp;#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&amp;#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees. The trial against EMD Serono and Pfizer commenced in mid-January 2018 and is ongoing. A trial date against Bayer and Novartis has not yet been set.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 1, 2016, we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&amp;#160;We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2017 we learned that the Prosecution Office of Milan is investigating our interactions with certain healthcare providers in Italy.&amp;#160;We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-D6AB32ABC89C580573C52977944939A3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which supersedes all existing revenue recognition requirements, including most industry-specific guidance. This new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date. These new standards became effective for us on January 1, 2018, and will be adopted using the modified retrospective method through a cumulative-effect adjustment directly to retained earnings as of that date. We have performed a review of these new standards as compared to our current accounting policies for customer contracts and collaborative relationships. During the fourth quarter of 2017 we finalized our assessments over the impact that these new standards will have on our consolidated results of operations, financial position and disclosures. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have not identified any accounting changes that would materially impact the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues; however, the adoption of these new standards may result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we expect to recognize an immaterial adjustment to retained earnings reflecting the cumulative impact for the accounting changes related to certain contract manufacturing arrangements made upon adoption of these new standards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016 the FASB issued ASU No. 2016-01, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. This new standard became effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this new standard is not expected to have a material impact on our consolidated financial position or results of operations; however, it will result in the reclassification of where we recognize changes in fair value related to certain investments prospectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard establishes a right-of-use (ROU) model that requires all lessees recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This new standard will become effective for us on January 1, 2019. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While we are currently evaluating the impact that this new standard may have on our consolidated results of operations, financial position and disclosures, we expect that the adoption of this new standard may materially affect the reported amount of total assets and total liabilities within our consolidated balance sheet with no material impact to our consolidated statement of income. We are unable to quantify the impact at this time as the ultimate impact of adopting this new standard will depend on the total amount of our lease commitments as of the adoption date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016 the FASB issued ASU No. 2016-09, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences and classification of awards as either equity or liabilities in the statement of cash flows. This new standard became effective for us on January 1, 2017. The adoption of this new standard did not have a material impact on our consolidated financial position, results of operations or statement of cash flows; however, it has resulted in the reclassification of certain prior year amounts in our consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. This new standard became effective for us on January 1, 2018. We will adopt this new standard using the modified retrospective method, through a cumulative-effect adjustment directly to retained earnings as of the beginning of that date. Based on currently enacted tax rates, upon adoption, we will record additional deferred tax assets of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and an increase to retained earnings of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-01,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. We elected to early adopt this new standard as of January 1, 2017, with prospective application to any business development transactions, including our recent asset acquisition of BIIB093 from Remedy Pharmaceuticals Inc. (Remedy) in May 2017. For additional information on this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-04, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard eliminates Step 2 from the goodwill impairment test. Under the amendments in ASU No. 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds that reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. We elected to early adopt this new standard as of October 31, 2017, during our annual review of goodwill. The adoption of this new standard resulted in a change to our accounting policy; however, did not have an impact on our consolidated financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. This new standard will become effective for us on January 1, 2019. We are currently evaluating the potential impact that this new standard may have on our consolidated financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2017 the FASB issued ASU No. 2017-12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard is intended to simplify hedge accounting by better aligning how an entity&amp;#8217;s risk management activities and hedging relationships are presented in its financial statements and simplifies the application of hedge accounting guidance in certain situations. This new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This new standard will become effective for us on January 1, 2019; however, early adoption is permitted. For cash flow hedges existing at the adoption date, this new standard requires adoption on a modified retrospective basis with a cumulative-effect adjustment to retained earnings as of the effective date. The amendments to presentation guidance and disclosure requirements are required to be adopted prospectively. We are currently evaluating the date upon which we will adopt this new standard and the impact this new standard may have on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-A3E39DC67349EAB0B5912977947C9D44">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Employee Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;401(k) Savings Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&amp;#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expense related to our 401(k) Savings Plan totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$51.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Deferred Compensation Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$109.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$128.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Pension Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.00%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.25%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.75%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&amp;#8217;s contribution. Minimum employee contributions are based on the respective employee&amp;#8217;s age, salary and gender. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the Swiss plan had an unfunded net pension obligation of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$39.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and plan assets that totaled approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$83.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$68.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized expense totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to our Swiss plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The obligations under the German plans are unfunded and totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$43.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net periodic pension cost related to the German plans totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-F5E37B72F9C56C039B6829779447B784">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;141.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;137.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,213.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,107.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;80.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;123.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,207.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,105.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Computer software and hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;767.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;746.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,276.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;658.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,741.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,941.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,559.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,439.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,182.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,501.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation expense totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$266.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$309.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$217.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we capitalized interest costs related to construction in progress totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. The increase in capitalized interest costs is primarily due to the construction of our Solothurn, Switzerland facility, as discussed below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the first quarter of 2016 we purchased land in Solothurn, Switzerland for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) and are building a large-scale biologics manufacturing facility at this site. We expect this facility to be operational by the end of the decade. Upon completion, the facility will include 393,000&amp;#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$481.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to this facility. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Research Triangle Park Facility Purchase&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2015 we completed the purchase of a drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), NC from Eisai Inc. (Eisai). The &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$104.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; purchase price was comprised of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for buildings, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for machinery and equipment and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for land.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2015 we also amended our existing &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year lease related to Eisai's oral solid dose products manufacturing facility in RTP, NC. The amended lease provided for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year term and our agreement to purchase the facility upon expiration of the lease term or at Eisai's option, their completion of certain activities at the facility. Upon signing, we recognized assets along with a corresponding financing obligation in our consolidated balance sheet of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net present value of the future minimum lease payments. These assets were recorded as a component of buildings and machinery and equipment. In December 2017, upon the earlier than expected completion of Eisai's activities, we completed our purchase of this facility for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-8EE91E16AD5FAACB583A2977943D0A29">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three to five years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&amp;#160;Software&amp;#160;and&amp;#160;Hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2016Q4YTD" id="Fact-DEE74281771264EF8DFE29779448FCCD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of property, plant and equipment, net are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;141.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;137.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,213.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,107.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;80.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;123.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,207.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,105.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Computer software and hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;767.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;746.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,276.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;658.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,741.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,941.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,559.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,439.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,182.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,501.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2017Q4YTD" id="Fact-6C3B3E9372DBEBAB1482297794596186">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Quarterly Financial Data (Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (b) (c) (d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (e) (f) (g) (h)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,380.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,639.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,622.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,712.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,354.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;340.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;397.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;406.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;415.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;90.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;41.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;48.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;179.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;360.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,810.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,078.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,077.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,307.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12,273.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,426.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,712.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,707.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,797.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,643.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;747.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;862.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,226.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(166.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,670.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;747.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;862.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,226.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(297.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,539.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;212.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;212.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;212.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(i)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(i) (j)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(i) (k) (l)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,309.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,466.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,539.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,502.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;329.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;349.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;317.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;318.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;87.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;79.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;98.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,726.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,894.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,955.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,872.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11,448.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,413.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,523.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,538.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,493.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,970.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;969.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,048.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,030.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;647.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,695.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;970.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,049.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,032.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;649.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,702.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;216.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;217.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the first, second, third and fourth quarters of 2017 include a pre-tax charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$353.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$29.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$30.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$30.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment to BMS upon the closing of our agreement to exclusively license BIIB092.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to acquired in-process research and development of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$120.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment to Remedy upon closing of the asset purchase transaction.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a developmental milestone that became payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 PSP study for BIIB092.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc., for the fourth quarter of 2017, includes a pre-tax charge to noncontrolling interest of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a payment to Neurimmune in exchange for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in royalty rates payable on potential commercial sales of aducanumab.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes pre-tax charges to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment and a continuation payment, respectively, to Alkermes.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment to Ionis upon entering into a new collaboration agreement to identify new antisense-oligonucleotide drug candidates for the treatment of SMA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(h)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1,173.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the provisions of the 2017 Tax Act, including a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$989.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; expense under the Transition Toll Tax.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second, third and fourth quarters of 2016 includes additional pre-tax depreciation expense totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$15.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$15.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$14.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, as part of our decision to cease manufacturing and vacate our small-scale biologics manufacturing facility in Cambridge, MA as well as close and vacate our warehouse space in Somerville, MA. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(j)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the third quarter of 2016 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(k)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a milestone payment due to Eisai related to the initiation of a Phase 3 trial for E2609.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(l)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$454.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to our January 2017 settlement and license agreement with Forward Pharma.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-C7F70BF4455398CEB610297794697F2F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,565.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,378.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:ReceivablesPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-B7AEC4D314620242C491297794743825">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&amp;#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&amp;#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
	<us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="FD2017Q4YTD" id="Fact-E0574F4415C7B070039829779468280B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(32.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;173.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(44.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;171.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
	<us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-4B799C7F5BD5D861020F2977942C7C3C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&amp;#160;20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
	<us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-8B7B6CD8B15AB50BE8012977946AC9BE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Restructuring, Business Transformation and Other Cost Saving Initiatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2017 Corporate Strategy&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2017 we announced an updated strategic framework to optimize the value of our MS business while investing for the future across our core growth areas of MS and neuroimmunology, AD and dementia, movement disorders and neuromuscular diseases including SMA and ALS. We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In order to deliver positive results in the near term while investing in the next stages of our growth, we will focus on the following strategic priorities:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;maximizing the resilience of our MS core business;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;accelerating efforts in SMA as a significant new growth opportunity;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;developing and expanding our neuroscience portfolio;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;focusing our capital allocation efforts to drive investment for future growth; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;creating a leaner and simpler operating model to streamline our operations and reallocate resources towards prioritized research and development and commercial value creation opportunities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We expect to make total non-recurring operating and capital expenditures of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$170.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily in 2018, and our goal is to redirect resources of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$400.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; annually by 2020 to prioritized research and development and other value creation opportunities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized charges in our consolidated statements of income totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$19.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this effort, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$18.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is included in selling, general and administrative expense and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is reflected as restructuring charges. These restructuring charges, which were substantially incurred and paid in 2017, were primarily related to severance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2016 Organizational Changes and Cost Saving Initiatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2016 Restructuring Charges&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we initiated cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin-off our hemophilia business, and to achieve further targeted cost reductions. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this effort, which are in addition to, and separate from, the 2015 restructuring charges described below. These amounts, which were substantially incurred and paid by the end of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, were primarily related to severance and are reflected in restructuring charges in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Cambridge, MA Manufacturing Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 following an evaluation of our current and future manufacturing capabilities and capacity needs, we determined that we intended to cease manufacturing and vacate our 67,000 square foot small-scale biologics manufacturing facility in Cambridge, MA and close and vacate our 46,000 square foot warehouse space in Somerville, MA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December&amp;#160;2016 we subleased our rights to the Cambridge, MA manufacturing facility to Brammer Bio MA,&amp;#160;LLC (Brammer). Brammer also purchased from us certain manufacturing equipment, leasehold improvements and other assets in exchange for shares of Brammer common LLC interests and assumed manufacturing operations effective January 1, 2017. In December 2016 we closed and vacated our warehouse space in Somerville, MA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our departure from these facilities shortened the expected useful lives of certain leasehold improvements and other assets at these facilities. As a result, we recorded additional depreciation expense to reflect the assets' new shorter useful lives. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of this additional depreciation, which was recorded as cost of sales in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2016 we also recognized charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for severance costs related to certain employees separated from Biogen in connection with our departure from these facilities. These amounts were substantially incurred and paid by the end of first quarter of 2017 and are reflected in restructuring charges in our consolidated statements of income for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2015 Cost Saving Initiatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2015 Restructuring Charges&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2015, we announced a corporate restructuring, which included the termination of certain pipeline programs and an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in workforce. Under this restructuring, cash payments were estimated to total approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; were related to previously accrued 2015 incentive compensation, resulting in net restructuring charges totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$102.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These amounts were substantially paid by the end of 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$93.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of restructuring charges related to our 2015 restructuring program in our consolidated statements of income.&amp;#160;Our restructuring reserve is included in accrued expenses and other in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the charges and spending related to our 2015 restructuring program during 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Workforce&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Pipeline&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(40.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments to previous estimates, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-3E79C72DED28D035063C2977943F11BA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize revenues when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&amp;#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other governmental rebates, non-US pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs consist of:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i)&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our share of pre-tax profits and losses in the United States (U.S.) for RITUXAN and GAZYVA; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(ii)&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;reimbursement of our selling and development expenses in the U.S. for RITUXAN; and &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(iii)&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech, the Roche Group and us. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information on our collaboration with Genentech, please read Note&amp;#160;20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Royalty Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Multiple-Element Revenue Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&amp;#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenues to the various elements based on their estimated selling price as a component of total revenues.&amp;#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&amp;#8217;s best estimate of a selling price. Revenues allocated to an individual element are recognized when all other revenue recognition criteria are met for that element.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our development and commercialization arrangement with AbbVie Inc. (AbbVie) represents a collaborative arrangement as each party is an active participant and exposed to significant risks and rewards of the arrangement. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenue in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration with AbbVie, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-609E1F53016B61DA42C92977945EFAAB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;844.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;580.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;572.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;297.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;282.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;206.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;195.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;183.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;130.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;159.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;134.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued TECFIDERA litigation settlement charge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;454.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;636.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;685.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,901.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,903.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2017Q4YTD" id="Fact-C987069A0B878111F90E29779467D884">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(193.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;158.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(42.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;31.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;44.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(162.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;158.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(318.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(138.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(92.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(138.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(95.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;110.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(172.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(171.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(61.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(164.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-B089E3C5A993B4076708297794666429">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;less than 90&amp;#160;days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;30.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;948.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;741.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;247.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,266.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="FD2017Q4YTD" id="Fact-EAF2733E86A5986C5C6D2977945D254F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid during the year for:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;281.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;281.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,066.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,642.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,674.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2017Q4YTD" id="Fact-919B22CE5338CCB1F998297794727EB1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;107.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;119.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;18.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;169.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;204.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;160.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2017Q4YTD" id="Fact-5FDEBD319D6D20B77E862977946B082C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income before income tax provision and the income tax expense consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income before income taxes (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,540.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,655.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,386.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,588.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,277.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,380.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,128.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,933.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,767.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income tax expense (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,201.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,304.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,214.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;57.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;108.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;52.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;54.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,367.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,412.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,307.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;241.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(125.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(129.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(159.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(45.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;91.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(175.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(145.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,458.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,237.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,161.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="FD2017Q4YTD" id="Fact-70C8F80064CF4823B7782977944962F9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our indebtedness is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financing arrangement for the purchase of the RTP facility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of notes payable and other financing arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Non-current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;558.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,482.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,485.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;994.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;993.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,736.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,734.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,722.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,721.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financing arrangement for the purchase of the RTP facility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of notes payable and other financing arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,935.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,512.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-D5580A7B0F9154EA18902977946A6D85">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Significant components of our deferred tax assets and liabilities are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;201.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory, other reserves and accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;147.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;250.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangibles, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;378.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;459.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;209.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;831.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,071.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(250.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(376.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation, amortization and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(107.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(113.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(358.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(490.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="FD2017Q4YTD" id="Fact-41D2E9FBC4E5CE3D7C1B29779465ACFA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="27" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion) (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion) (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(32.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;173.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="FD2017Q4YTD" id="Fact-DD94EAB74CC5E4E37A51297794655D87">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance&amp;#160;Sheet&amp;#160;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;84.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;23.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
	<us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="FD2017Q4YTD" id="Fact-A8D3E1B335FA7A8BE9262E83A4844F77">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;302.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;144.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;116.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;56.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;53.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,008.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;87.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;67.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;155.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2017Q4YTD" id="Fact-385F97C5922ED4745AE02977945077EB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,539.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,702.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,547.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;212.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;230.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2017Q4YTD" id="Fact-42EEBC07F94374B3D9B82977945CCEB3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017 Tax Act&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;22.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Impairment of ZINBRYTA related tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2017Q4YTD" id="Fact-101E4BB05CCDCA83B361297794594B35">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;74.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;84.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;88.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;95.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;121.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;127.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;169.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;204.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;160.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(42.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(54.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(55.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;117.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;135.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;140.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="FD2017Q4YTD" id="Fact-AF3F30ABB23F57E3F0B42977943A39B1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="36" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;3,294.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;920.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;4,214.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,169.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;798.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,968.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,908.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;730.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,638.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;AVONEX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,593.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;557.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,151.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,675.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;638.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,313.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,790.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;840.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,630.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;PLEGRIDY&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;295.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;198.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;494.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;305.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;176.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;227.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;111.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;338.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,113.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;859.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,973.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,182.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;780.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,963.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,103.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;783.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,886.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;91.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;91.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;89.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;89.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;52.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;52.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Spinal Muscular Atrophy:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;657.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;226.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;883.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Hemophilia:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ELOCTATE&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;42.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;48.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;445.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;68.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;513.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;308.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;11.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;319.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;26.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;268.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;65.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;333.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;208.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;234.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other product revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;39.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;39.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;45.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;45.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;51.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;51.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;BENEPALI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;370.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;370.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;100.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;100.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FLIXABI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;7,017.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;3,337.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;10,354.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7,050.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,767.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;6,545.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,642.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2017Q4YTD" id="Fact-C77237E4C70F223024BD297794663EB4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,609.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,609.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,919.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,919.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;643.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;643.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,444.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,433.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;634.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,558.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,533.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;481.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-77A3E3B2728B2CC3F56C2977943F7D1F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;72.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;72.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;68.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;65.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;271.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;617.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(24.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(24.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(23.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(22.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(22.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(71.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;48.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;44.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;44.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;43.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;199.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;428.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfGoodwillTextBlock contextRef="FD2017Q4YTD" id="Fact-3CF1C45A599F2BAD7F0C2977946806B2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,669.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Elimination of goodwill allocated to our hemophilia business&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,267.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,026.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,632.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,669.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2017Q4YTD" id="Fact-83F38757E42BD97B82932977944F0429">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;162.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;605.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;698.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;157.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;925.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;902.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,001.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;22.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;925.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2017Q4YTD" id="Fact-9774A1904BEEB27503832977944AA67F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total gross payments, excluding our financing arrangement, due under our debt arrangements are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023 and thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,003.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-A33266DABF30A841D7522977946617D1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,875.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound sterling&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;150.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss francs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;88.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;83.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,198.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
	<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="FD2017Q4YTD" id="Fact-D625127DBA2ACA8D088B2977945EB61B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;78.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(250.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(260.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(95.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(36.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(13.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(17.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(215.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(217.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(123.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2017Q4YTD" id="Fact-87DB8ACC8CDD74E8D0F129779459DA76">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (b) (c) (d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (e) (f) (g) (h)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,380.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,639.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,622.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,712.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,354.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;340.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;397.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;406.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;415.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;90.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;41.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;48.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;179.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;360.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,810.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,078.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,077.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,307.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12,273.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,426.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,712.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,707.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,797.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,643.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;747.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;862.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,226.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(166.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,670.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;747.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;862.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,226.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(297.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,539.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;212.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;212.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;212.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(i)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(i) (j)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(i) (k) (l)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,309.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,466.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,539.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,502.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;329.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;349.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;317.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;318.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;87.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;79.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;98.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,726.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,894.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,955.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,872.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11,448.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,413.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,523.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,538.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,493.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,970.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;969.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,048.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,030.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;647.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,695.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;970.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,049.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,032.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;649.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,702.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;216.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;217.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the first, second, third and fourth quarters of 2017 include a pre-tax charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$353.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$29.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$30.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$30.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment to BMS upon the closing of our agreement to exclusively license BIIB092.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to acquired in-process research and development of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$120.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment to Remedy upon closing of the asset purchase transaction.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a developmental milestone that became payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 PSP study for BIIB092.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc., for the fourth quarter of 2017, includes a pre-tax charge to noncontrolling interest of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a payment to Neurimmune in exchange for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in royalty rates payable on potential commercial sales of aducanumab.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes pre-tax charges to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment and a continuation payment, respectively, to Alkermes.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment to Ionis upon entering into a new collaboration agreement to identify new antisense-oligonucleotide drug candidates for the treatment of SMA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(h)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1,173.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the provisions of the 2017 Tax Act, including a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$989.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; expense under the Transition Toll Tax.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second, third and fourth quarters of 2016 includes additional pre-tax depreciation expense totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$15.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$15.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$14.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, as part of our decision to cease manufacturing and vacate our small-scale biologics manufacturing facility in Cambridge, MA as well as close and vacate our warehouse space in Somerville, MA. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(j)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the third quarter of 2016 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(k)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a milestone payment due to Eisai related to the initiation of a Phase 3 trial for E2609.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(l)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$454.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to our January 2017 settlement and license agreement with Forward Pharma.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="FD2017Q4YTD" id="Fact-8CCF15FAFAAEFCB685FC2977945EE771">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the charges and spending related to our 2015 restructuring program during 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Workforce&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Pipeline&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(40.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments to previous estimates, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
	<us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock contextRef="FD2017Q4YTD" id="Fact-517077AEEE5F2D21360529779438CF24">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables contain certain financial information by geographic area:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,017.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,844.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;160.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;332.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,354.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,475.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;83.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;67.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;42.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;360.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,226.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,948.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,182.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,050.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;217.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;313.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;224.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,272.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,221.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,501.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,545.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,165.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;143.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;333.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,269.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;142.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;62.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,296.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;881.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,187.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-151E42C855BB4CF8C26C29779472784C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our stock option activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;54.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia spin-off adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;42,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="FD2017Q4YTD" id="Fact-25E8A63B3B6265B1387A2977945DDA84">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at January&amp;#160;1,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;32.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;131.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions based on tax positions related to the current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reductions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(21.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(49.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statute expirations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlement refund (payment)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;44.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(64.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(42.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
	<us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-C1E0BC7F80AAEC536C9C2977946AF03D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;583.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,307.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,917.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(475.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,756.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,232.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(69.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(442.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(23.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(534.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;109.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;606.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;592.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,044.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,668.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(522.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,576.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,099.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(53.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(536.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(609.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;387.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;459.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,732.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(405.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,258.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,666.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(44.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(296.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(351.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;189.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;166.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;572.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2017Q4YTD" id="Fact-3E16FDF1A7B5ED04BA9D297794751A37">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based upon this analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;423.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;401.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;381.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;254.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;242.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SegmentReportingDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-A00426CE673817D7EE5F297794648051">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="36" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;3,294.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;920.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;4,214.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,169.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;798.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,968.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,908.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;730.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,638.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;AVONEX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,593.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;557.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,151.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,675.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;638.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,313.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,790.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;840.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,630.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;PLEGRIDY&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;295.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;198.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;494.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;305.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;176.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;227.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;111.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;338.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,113.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;859.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,973.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,182.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;780.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,963.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,103.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;783.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,886.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;91.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;91.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;89.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;89.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;52.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;52.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Spinal Muscular Atrophy:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;657.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;226.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;883.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Hemophilia:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ELOCTATE&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;42.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;48.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;445.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;68.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;513.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;308.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;11.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;319.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;26.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;268.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;65.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;333.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;208.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;234.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other product revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;39.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;39.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;45.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;45.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;51.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;51.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;BENEPALI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;370.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;370.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;100.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;100.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FLIXABI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;7,017.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;3,337.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;10,354.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7,050.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,767.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;6,545.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,642.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Geographic Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables contain certain financial information by geographic area:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,017.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,844.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;160.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;332.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,354.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,475.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;83.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;67.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;42.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;360.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,226.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,948.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,182.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,050.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;217.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;313.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;224.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,272.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,221.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,501.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,545.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,165.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;143.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;333.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,269.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;142.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;62.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,296.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;881.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,187.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our total revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, are derived from our collaboration agreement with Genentech. For additional information on our collaboration with Genentech, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Significant Customers&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recorded revenues from two wholesalers accounting for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,215.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$545.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$161.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$707.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$643.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$684.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Property, Plant and Equipment,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
	<us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-0AB4547883D8282275672977944647D2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Advertising costs are expensed as incurred. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, advertising costs totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$106.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$108.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q4YTD" id="Fact-1B5F87B222F23AE4D45D2977944C28FE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer&amp;#8217;s disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS and relapsing MS and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), a rare condition that affects movement, speech, vision and cognitive function, Parkinson's disease and ALS.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE in the European Union (E.U.). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these audited consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the spin-off of our hemophilia business, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize revenues when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&amp;#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other governmental rebates, non-US pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs consist of:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i)&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our share of pre-tax profits and losses in the United States (U.S.) for RITUXAN and GAZYVA; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(ii)&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;reimbursement of our selling and development expenses in the U.S. for RITUXAN; and &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(iii)&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech, the Roche Group and us. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information on our collaboration with Genentech, please read Note&amp;#160;20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Royalty Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Multiple-Element Revenue Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&amp;#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenues to the various elements based on their estimated selling price as a component of total revenues.&amp;#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&amp;#8217;s best estimate of a selling price. Revenues allocated to an individual element are recognized when all other revenue recognition criteria are met for that element.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our development and commercialization arrangement with AbbVie Inc. (AbbVie) represents a collaborative arrangement as each party is an active participant and exposed to significant risks and rewards of the arrangement. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenue in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration with AbbVie, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain financial assets and liabilities recorded at fair value which have been classified as Level&amp;#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&amp;#160;and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our financial assets have been classified as Level&amp;#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&amp;#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&amp;#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms that generally require payment within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 to 90 days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, two wholesale distributors individually accounted for approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of accounts receivable, net, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Marketable Securities and Other Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&amp;#8217;s decline and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions and are included in investments and other assets in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Evaluating Investments for Other-than-Temporary Impairments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&amp;#8217;s decline and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Equity Method of Accounting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&amp;#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&amp;#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventories are stated at the lower of cost or market with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Capitalization of Inventory Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Obsolescence and Unmarketable Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three to five years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&amp;#160;Software&amp;#160;and&amp;#160;Hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&amp;#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to obtaining the fair value of the U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd. (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TECFIDERA, TYSABRI and AVONEX using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TECFIDERA, TYSABRI and AVONEX is performed annually during our long-range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TECFIDERA, TYSABRI or AVONEX.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired In-process Research and Development (IPR&amp;amp;D)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;amp;D programs have a fair value that is not significantly in excess of carrying value, including treatments for forms of neuropathic pain, such as trigeminal neuralgia (TGN). Such programs could become impaired if assumptions used in determining the fair value change. Impairments are recorded as amortization of acquired intangible assets in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&amp;#160;25, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Segment Information,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&amp;#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Derivative Instruments and Hedging Activities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Translation of Foreign Currencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&amp;#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Royalty Cost of Sales&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&amp;#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Share-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&amp;#8217; vesting periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense, net of forfeitures, for RSUs is recognized straight-line over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price of common stock under our ESPP is equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the lesser of (i)&amp;#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&amp;#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; discount is recognized as compensation expense over the 90-day purchase period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&amp;#160;20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Selling, General and Administrative Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Advertising costs are expensed as incurred. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, advertising costs totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$106.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$108.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All tax effects associated with intercompany transfers of assets within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&amp;#160;If the asset transferred becomes impaired, for example through the obsolescence of inventory or discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We account for uncertain tax positions using a &amp;#8220;more-likely-than-not&amp;#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&amp;#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&amp;#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Earnings per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which supersedes all existing revenue recognition requirements, including most industry-specific guidance. This new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date. These new standards became effective for us on January 1, 2018, and will be adopted using the modified retrospective method through a cumulative-effect adjustment directly to retained earnings as of that date. We have performed a review of these new standards as compared to our current accounting policies for customer contracts and collaborative relationships. During the fourth quarter of 2017 we finalized our assessments over the impact that these new standards will have on our consolidated results of operations, financial position and disclosures. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have not identified any accounting changes that would materially impact the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues; however, the adoption of these new standards may result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we expect to recognize an immaterial adjustment to retained earnings reflecting the cumulative impact for the accounting changes related to certain contract manufacturing arrangements made upon adoption of these new standards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016 the FASB issued ASU No. 2016-01, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. This new standard became effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this new standard is not expected to have a material impact on our consolidated financial position or results of operations; however, it will result in the reclassification of where we recognize changes in fair value related to certain investments prospectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard establishes a right-of-use (ROU) model that requires all lessees recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This new standard will become effective for us on January 1, 2019. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While we are currently evaluating the impact that this new standard may have on our consolidated results of operations, financial position and disclosures, we expect that the adoption of this new standard may materially affect the reported amount of total assets and total liabilities within our consolidated balance sheet with no material impact to our consolidated statement of income. We are unable to quantify the impact at this time as the ultimate impact of adopting this new standard will depend on the total amount of our lease commitments as of the adoption date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016 the FASB issued ASU No. 2016-09, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences and classification of awards as either equity or liabilities in the statement of cash flows. This new standard became effective for us on January 1, 2017. The adoption of this new standard did not have a material impact on our consolidated financial position, results of operations or statement of cash flows; however, it has resulted in the reclassification of certain prior year amounts in our consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. This new standard became effective for us on January 1, 2018. We will adopt this new standard using the modified retrospective method, through a cumulative-effect adjustment directly to retained earnings as of the beginning of that date. Based on currently enacted tax rates, upon adoption, we will record additional deferred tax assets of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and an increase to retained earnings of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-01,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. We elected to early adopt this new standard as of January 1, 2017, with prospective application to any business development transactions, including our recent asset acquisition of BIIB093 from Remedy Pharmaceuticals Inc. (Remedy) in May 2017. For additional information on this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-04, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard eliminates Step 2 from the goodwill impairment test. Under the amendments in ASU No. 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds that reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. We elected to early adopt this new standard as of October 31, 2017, during our annual review of goodwill. The adoption of this new standard resulted in a change to our accounting policy; however, did not have an impact on our consolidated financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. This new standard will become effective for us on January 1, 2019. We are currently evaluating the potential impact that this new standard may have on our consolidated financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2017 the FASB issued ASU No. 2017-12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard is intended to simplify hedge accounting by better aligning how an entity&amp;#8217;s risk management activities and hedging relationships are presented in its financial statements and simplifies the application of hedge accounting guidance in certain situations. This new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This new standard will become effective for us on January 1, 2019; however, early adoption is permitted. For cash flow hedges existing at the adoption date, this new standard requires adoption on a modified retrospective basis with a cumulative-effect adjustment to retained earnings as of the effective date. The amendments to presentation guidance and disclosure requirements are required to be adopted prospectively. We are currently evaluating the date upon which we will adopt this new standard and the impact this new standard may have on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-44B8E6594E6A26EC5B022977945BA646">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of Preferred Stock authorized, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.75 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are authorized as Series A, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are authorized as Series X junior participating and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.25 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table describes the number of shares authorized, issued and outstanding of our common stock as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;235.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;238.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. All share repurchases under this authorization will be retired. Under this authorization, we repurchased and retired &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock during the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for each year. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; remains available for share repurchases under this authorization.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2015 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2015 Share Repurchase Program). All shares repurchased under this authorization were retired. Our 2015 Share Repurchase Program was completed as of December 31, 2015. Under this authorization, we repurchased and retired approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2011 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock (2011 Share Repurchase Program). Shares repurchased under this authorization were principally used to offset common stock issuances under our share-based compensation programs. Our 2011 Share Repurchase Program was completed as of March 31, 2017. Under this authorization, we repurchased &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$365.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We did not repurchase any shares of common stock under this authorization during the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2017Q4YTD" id="Fact-52CC77F5D8B7B6E62ABE297794481717">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Karyopharm Therapeutics Inc. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2018 we acquired the exclusive worldwide rights to develop and commercialize Karyopharm Therapeutics Inc.'s (Karyopharm) investigational oral compound BIIB100 (formerly known as KPT-350) for the treatment of certain neurological and neurodegenerative conditions, primarily in ALS. We will pay Karyopharm an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and we may pay Karyopharm up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$207.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments, and potential royalties.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2017Q4YTD" id="Fact-7353C73607566CC928362977947DFEDA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-042625CF7B99329C455429779476D2C1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2007 we entered into a collaboration and license agreement with Neurimmune Subone AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product, or 12 years from the first commercial sale of any product using such a licensed compound. Our anti-amyloid beta antibody, aducanumab, for the treatment of AD resulted from this collaboration. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&amp;#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. Under this agreement, we are also required to pay royalties on sales of any resulting commercial products and make payments upon the achievement of certain milestone events. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2017 we amended the terms of our collaboration and license agreement with Neurimmune. Under the amended agreement, we made a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune in exchange for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab.&amp;#160;Our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, will now range from the high single digits to low teens.&amp;#160;As we consolidate the results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the fourth quarter of 2017 and treated it as a distribution. Under the amended agreement, we also have an option that will expire in April 2018 to further reduce our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, by an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in exchange for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; amounts reimbursed were immaterial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2015 we recognized a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payable to Neurimmune upon enrollment of the first patient in a Phase 3 trial for aducanumab. We recognized this payment as a charge to noncontrolling interest. Based upon our current development plans for aducanumab, we may pay Neurimmune up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$275.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestone payments. Future milestone payments and royalties, if any, will be reflected in our consolidated statements of income as a charge to noncontrolling interest, net of tax when such milestones are achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of our October 2017 collaboration agreement with Eisai for the joint development and commercialization of aducanumab, Eisai may elect to share in the benefit and cost associated with the royalty reductions discussed above. Eisai has elected to not share in the benefit and cost of the October 2017 royalty reduction. For additional information on our collaboration arrangement with Eisai, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investments in biotechnology companies totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-192858AE9B513342C93F2977945E9B57" xlink:label="Fact-192858AE9B513342C93F2977945E9B57_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-26FD9D561D62DDAC1A7729779439C3CF" xlink:label="Fact-26FD9D561D62DDAC1A7729779439C3CF_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2F173E7E40BF8EDEF12E297794588277" xlink:label="Fact-2F173E7E40BF8EDEF12E297794588277_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2F56B527060CE81A65D229779472D8C4" xlink:label="Fact-2F56B527060CE81A65D229779472D8C4_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-35CB9BDD4D5B01366B262977947D4BEC" xlink:label="Fact-35CB9BDD4D5B01366B262977947D4BEC_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-3A30C25794EA07B11E63297794642579" xlink:label="Fact-3A30C25794EA07B11E63297794642579_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-5D4B2374EDB7D640585B2977947CF54E" xlink:label="Fact-5D4B2374EDB7D640585B2977947CF54E_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-6110075395A7FE2419072977945902FF" xlink:label="Fact-6110075395A7FE2419072977945902FF_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-627E5CFC6447882ADD412977943D9EDC" xlink:label="Fact-627E5CFC6447882ADD412977943D9EDC_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-6BB0C9D2C4983E6E4EA52977946AB78D" xlink:label="Fact-6BB0C9D2C4983E6E4EA52977946AB78D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-721723A9C42D376933A22977943D3A02" xlink:label="Fact-721723A9C42D376933A22977943D3A02_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8318545B204DFF54B5022977943DADCB" xlink:label="Fact-8318545B204DFF54B5022977943DADCB_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-866E975ABB54F75BB8162977944F924F" xlink:label="Fact-866E975ABB54F75BB8162977944F924F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-97ECB420AC381B93248329779471B0BF" xlink:label="Fact-97ECB420AC381B93248329779471B0BF_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-9C65B36DB79172B675C6297794460E63" xlink:label="Fact-9C65B36DB79172B675C6297794460E63_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-A74CF05D25811C8B49172977943CD3A2" xlink:label="Fact-A74CF05D25811C8B49172977943CD3A2_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-B28BA22A224E3CEDACE62977947137AB" xlink:label="Fact-B28BA22A224E3CEDACE62977947137AB_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-BADEB7499831E5D4670F2977944DA10F" xlink:label="Fact-BADEB7499831E5D4670F2977944DA10F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-D1357532E5663464AD5829779464EE2F" xlink:label="Fact-D1357532E5663464AD5829779464EE2F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-DA1702411D2EA703BB55297794745B31" xlink:label="Fact-DA1702411D2EA703BB55297794745B31_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-E163BE2CB588098624A92977943D70E6" xlink:label="Fact-E163BE2CB588098624A92977943D70E6_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F29DE4DEA6C03C66602729779451DA63" xlink:label="Fact-F29DE4DEA6C03C66602729779451DA63_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F61A0D8BE3BC28905D5B29779434AD32" xlink:label="Fact-F61A0D8BE3BC28905D5B29779434AD32_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F981D1C3DBAD9B6E0CAC2977943EF75B" xlink:label="Fact-F981D1C3DBAD9B6E0CAC2977943EF75B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-FCE06B1876F2B9AEB9BC2977943A0129" xlink:label="Fact-FCE06B1876F2B9AEB9BC2977943A0129_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-192858AE9B513342C93F2977945E9B57_lbl" xlink:to="Footnote-47FC4C4F4C9816629A5B297794899152_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-26FD9D561D62DDAC1A7729779439C3CF_lbl" xlink:to="Footnote-25875895BB1B1B69E4D42977948A8AEC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2F173E7E40BF8EDEF12E297794588277_lbl" xlink:to="Footnote-25875895BB1B1B69E4D42977948A8AEC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2F56B527060CE81A65D229779472D8C4_lbl" xlink:to="Footnote-4756B8F28F79BF6DD63329779489EA48_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-35CB9BDD4D5B01366B262977947D4BEC_lbl" xlink:to="Footnote-25875895BB1B1B69E4D42977948A8AEC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-3A30C25794EA07B11E63297794642579_lbl" xlink:to="Footnote-47FC4C4F4C9816629A5B297794899152_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-5D4B2374EDB7D640585B2977947CF54E_lbl" xlink:to="Footnote-25875895BB1B1B69E4D42977948A8AEC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-6110075395A7FE2419072977945902FF_lbl" xlink:to="Footnote-363B2CD5EDEB8129462629779489722A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-627E5CFC6447882ADD412977943D9EDC_lbl" xlink:to="Footnote-47FC4C4F4C9816629A5B297794899152_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-6BB0C9D2C4983E6E4EA52977946AB78D_lbl" xlink:to="Footnote-4756B8F28F79BF6DD63329779489EA48_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-721723A9C42D376933A22977943D3A02_lbl" xlink:to="Footnote-47FC4C4F4C9816629A5B297794899152_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8318545B204DFF54B5022977943DADCB_lbl" xlink:to="Footnote-47FC4C4F4C9816629A5B297794899152_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-866E975ABB54F75BB8162977944F924F_lbl" xlink:to="Footnote-25875895BB1B1B69E4D42977948A8AEC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-97ECB420AC381B93248329779471B0BF_lbl" xlink:to="Footnote-A7396B7BBFE7DED281DB297794898DEA_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-9C65B36DB79172B675C6297794460E63_lbl" xlink:to="Footnote-25875895BB1B1B69E4D42977948A8AEC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-A74CF05D25811C8B49172977943CD3A2_lbl" xlink:to="Footnote-25875895BB1B1B69E4D42977948A8AEC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-B28BA22A224E3CEDACE62977947137AB_lbl" xlink:to="Footnote-A7396B7BBFE7DED281DB297794898DEA_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-BADEB7499831E5D4670F2977944DA10F_lbl" xlink:to="Footnote-25875895BB1B1B69E4D42977948A8AEC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-D1357532E5663464AD5829779464EE2F_lbl" xlink:to="Footnote-47FC4C4F4C9816629A5B297794899152_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-DA1702411D2EA703BB55297794745B31_lbl" xlink:to="Footnote-4756B8F28F79BF6DD63329779489EA48_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-E163BE2CB588098624A92977943D70E6_lbl" xlink:to="Footnote-A7396B7BBFE7DED281DB297794898DEA_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F29DE4DEA6C03C66602729779451DA63_lbl" xlink:to="Footnote-25875895BB1B1B69E4D42977948A8AEC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F61A0D8BE3BC28905D5B29779434AD32_lbl" xlink:to="Footnote-25875895BB1B1B69E4D42977948A8AEC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F981D1C3DBAD9B6E0CAC2977943EF75B_lbl" xlink:to="Footnote-47FC4C4F4C9816629A5B297794899152_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-FCE06B1876F2B9AEB9BC2977943A0129_lbl" xlink:to="Footnote-363B2CD5EDEB8129462629779489722A_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-25875895BB1B1B69E4D42977948A8AEC_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</link:footnote>
		<link:footnote xlink:label="Footnote-363B2CD5EDEB8129462629779489722A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">CSPUs granted in 2017 include awards granted in conjunction with our annual awards made in February 2017 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. CSPUs granted in 2017 also include CSPUs issued in 2017 based upon the attainment of performance criteria set for 2016 in relation to shares granted in 2016.</link:footnote>
		<link:footnote xlink:label="Footnote-4756B8F28F79BF6DD63329779489EA48_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">MSUs granted in 2017 include approximately 9,000 MSUs issued in 2017 based upon the attainment of performance criteria set for 2013, in relation to awards granted in that year. MSUs granted during 2017 also include awards granted in conjunction with our annual awards made in February 2017 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2017 reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2016, 2015 and 2014.</link:footnote>
		<link:footnote xlink:label="Footnote-47FC4C4F4C9816629A5B297794899152_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(1)</link:footnote>
		<link:footnote xlink:label="Footnote-A7396B7BBFE7DED281DB297794898DEA_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">RSUs granted in 2017 primarily represent RSUs granted in conjunction with our annual awards made in February 2017 and awards made in conjunction with the hiring of new employees. RSUs granted in 2017 also include approximately 11,000 RSUs granted to our Board of Directors.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>biib-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20171231" xmlns:biib="http://www.biogenidec.com/20171231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>2117100 - Disclosure - Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2417402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails1" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1">
        <link:definition>2417403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2317301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2102100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDetailsTextual" roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual">
        <link:definition>2402401 - Disclosure - Acquisitions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2123100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails2" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails2">
        <link:definition>2423404 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails">
        <link:definition>2423402 - Disclosure - Collaborative and Other Relationships (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetails1" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1">
        <link:definition>2423403 - Disclosure - Collaborative and Other Relationships (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetailsTextual" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual">
        <link:definition>2423405 - Disclosure - Collaborative and Other Relationships (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables">
        <link:definition>2323301 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies">
        <link:definition>2125100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails">
        <link:definition>2425402 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual">
        <link:definition>2425403 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2325301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets">
        <link:definition>1003000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1003501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1002000 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfEquity" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity">
        <link:definition>1005000 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfIncome" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome">
        <link:definition>1001000 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2113100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2413402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1">
        <link:definition>2413403 - Disclosure - Derivative Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual">
        <link:definition>2413404 - Disclosure - Derivative Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2313301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2118100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2418402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2318301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans">
        <link:definition>2127100 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails1" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1">
        <link:definition>2427402 - Disclosure - Employee Benefit Plans (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansEmployeeBenefitPlansDetails" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails">
        <link:definition>2427401 - Disclosure - Employee Benefit Plans Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2116100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.biogenidec.com/role/EquityDetails">
        <link:definition>2416402 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetailsTextual" roleURI="http://www.biogenidec.com/role/EquityDetailsTextual">
        <link:definition>2416403 - Disclosure - Equity (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.biogenidec.com/role/EquityTables">
        <link:definition>2316301 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2111100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2411402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2411403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2411404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2411405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2311301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2112100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2412402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2412403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2412404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2412405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1">
        <link:definition>2412406 - Disclosure - Financial Instruments (Details Textual 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2">
        <link:definition>2412407 - Disclosure - Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2312301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Guarantees" roleURI="http://www.biogenidec.com/role/Guarantees">
        <link:definition>2126100 - Disclosure - Guarantees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffHemophiliaSpinOff" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff">
        <link:definition>2106100 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffHemophiliaSpinOffDetails" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails">
        <link:definition>2406402 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual">
        <link:definition>2406403 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffHemophiliaSpinOffTables" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables">
        <link:definition>2306301 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2120100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2420402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails1" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1">
        <link:definition>2420403 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails2" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2">
        <link:definition>2420404 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails3" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3">
        <link:definition>2420405 - Disclosure - Income Taxes (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2420406 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2320301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>2115100 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2415402 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails1" roleURI="http://www.biogenidec.com/role/IndebtednessDetails1">
        <link:definition>2415403 - Disclosure - Indebtedness (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetailsTextual" roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual">
        <link:definition>2415404 - Disclosure - Indebtedness (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessTables" roleURI="http://www.biogenidec.com/role/IndebtednessTables">
        <link:definition>2315301 - Disclosure - Indebtedness (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2110100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2410402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2410403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2310301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2109100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2409402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetailsTextual" roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual">
        <link:definition>2409403 - Disclosure - Inventory (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2309301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2122100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2422401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2124100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2121100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2421402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual">
        <link:definition>2421403 - Disclosure - Other Consolidated Financial Statement Detail (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2321301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment">
        <link:definition>2114100 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2414402 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetailsTextual" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual">
        <link:definition>2414403 - Disclosure - Property, Plant and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentTables" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables">
        <link:definition>2314301 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2129100 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetails" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails">
        <link:definition>2429402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetailsTextual" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual">
        <link:definition>2429403 - Disclosure - Quarterly Financial Data (Unaudited) (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2329301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuring" roleURI="http://www.biogenidec.com/role/RestructuringRestructuring">
        <link:definition>2107100 - Disclosure - Restructuring Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringDetails" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails">
        <link:definition>2407402 - Disclosure - Restructuring Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringDetailsTextual" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual">
        <link:definition>2407403 - Disclosure - Restructuring Restructuring (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringTables" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables">
        <link:definition>2307301 - Disclosure - Restructuring Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReserves" roleURI="http://www.biogenidec.com/role/RevenueReserves">
        <link:definition>2108100 - Disclosure - Revenue Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReservesDetails" roleURI="http://www.biogenidec.com/role/RevenueReservesDetails">
        <link:definition>2408402 - Disclosure - Revenue Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReservesDetails1" roleURI="http://www.biogenidec.com/role/RevenueReservesDetails1">
        <link:definition>2408403 - Disclosure - Revenue Reserves (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReservesTables" roleURI="http://www.biogenidec.com/role/RevenueReservesTables">
        <link:definition>2308301 - Disclosure - Revenue Reserves (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.biogenidec.com/role/SegmentInformation">
        <link:definition>2128100 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.biogenidec.com/role/SegmentInformationDetails">
        <link:definition>2428402 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails1" roleURI="http://www.biogenidec.com/role/SegmentInformationDetails1">
        <link:definition>2428403 - Disclosure - Segment Information (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetailsTextual" roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual">
        <link:definition>2428404 - Disclosure - Segment Information (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.biogenidec.com/role/SegmentInformationTables">
        <link:definition>2328301 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2119100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2419402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2419403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails2" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2">
        <link:definition>2419404 - Disclosure - Share-Based Payments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails3" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3">
        <link:definition>2419405 - Disclosure - Share-Based Payments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails4" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4">
        <link:definition>2419406 - Disclosure - Share-Based Payments (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails5" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5">
        <link:definition>2419407 - Disclosure - Share-Based Payments (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails6" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6">
        <link:definition>2419408 - Disclosure - Share-Based Payments (Details 6)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails8" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8">
        <link:definition>2419410 - Disclosure - Share-Based Payments (Details 8)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails9" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9">
        <link:definition>2419411 - Disclosure - Share-Based Payments (Details 9)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetailsTextual" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual">
        <link:definition>2419412 - Disclosure - Share-Based Payments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsShareBasedPaymentsDetails7" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7">
        <link:definition>2419409 - Disclosure - Share-based Payments Share-Based Payments (Details 7)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2319301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsSubsequentEvents" roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents">
        <link:definition>2130100 - Disclosure - Subsequent Events Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsSubsequentEventsDetails" roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails">
        <link:definition>2430401 - Disclosure - Subsequent Events Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401403 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A1995ESPPMember" name="A1995ESPPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2011ShareRepurchaseProgramMember" name="A2011ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2015ESPPMember" name="A2015ESPPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2015RestructuringChargesMember" name="A2015RestructuringChargesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2016RestructuringChargesMember" name="A2016RestructuringChargesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2016ShareRepurchaseProgramYearToDateMember" name="A2016ShareRepurchaseProgramYearToDateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2017OmnibusEquityPlanMember" name="A2017OmnibusEquityPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2017RestructuringChargesMember" name="A2017RestructuringChargesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AGTCMember" name="AGTCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ALPROLIXProductMember" name="ALPROLIXProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AbbVieMember" name="AbbVieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" name="AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_AcordaMember" name="AcordaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_AdditionalPotentialPaymentstoNoncontrollingInterest" name="AdditionalPotentialPaymentstoNoncontrollingInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" name="Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Additionalreductioninroyaltyratepayableoncommercialsales" name="Additionalreductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AlkermesMember" name="AlkermesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" name="AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AttainmentOfPerformanceCriteriain2013Member" name="AttainmentOfPerformanceCriteriain2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AverageStockPriceOnGrantDateInDollarsMaximum" name="AverageStockPriceOnGrantDateInDollarsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_AverageStockPriceOnGrantDateInDollarsMinimum" name="AverageStockPriceOnGrantDateInDollarsMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BENEPALIMember" name="BENEPALIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB074Member" name="BIIB074Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BiogenIdecInternationalNeuroscienceMember" name="BiogenIdecInternationalNeuroscienceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogenshareofcopromotionprofitsorlosses" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiosimilarsMember" name="BiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BioverativMember" name="BioverativMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BristolMyersSquibbMember" name="BristolMyersSquibbMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BusinessTextualAbstract" name="BusinessTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CambridgeMAMember" name="CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesAbstract" name="CashSettledPerformanceSharesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" name="CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CoPromotionProfitSharingFormulaAbstract" name="CoPromotionProfitSharingFormulaAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CoPromotionProfitSharingFormulaTableTextBlock" name="CoPromotionProfitSharingFormulaTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CollaborationExpensesinDispute" name="CollaborationExpensesinDispute" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_CollaborationProfitSharing" name="CollaborationProfitSharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Collaborationexpensesaccrual" name="Collaborationexpensesaccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CollaborationsTextualAbstract" name="CollaborationsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CommercialMilestonesMember" name="CommercialMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CommitmentsAndContingenciesTextualAbstract" name="CommitmentsAndContingenciesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CompensationExpenseOverPurchasePeriod" name="CompensationExpenseOverPurchasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ComputerSoftwareAndHardware" name="ComputerSoftwareAndHardware" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ConvergencePharmaceuticalsMember" name="ConvergencePharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Copromotionprofitsandlosses" name="Copromotionprofitsandlosses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CumulativeSalesLevel" name="CumulativeSalesLevel" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelAxis" name="CumulativeSalesLevelAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelDomain" name="CumulativeSalesLevelDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" name="DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" name="DeferredTaxLiabilitiesDepreciationAmortizationOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DenominatorAbstract" name="DenominatorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityAxis" name="DerivativeMaturityAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityDomain" name="DerivativeMaturityDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DevelopmentalMilestonePayment" name="DevelopmentalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DirectorsPlanMember" name="DirectorsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DiscountRateRecognizedInCompensationExpense" name="DiscountRateRecognizedInCompensationExpense" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DiscoveryprogramsMember" name="DiscoveryprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorOneMember" name="DistributorOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorTwoMember" name="DistributorTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DueFromUnconsolidatedJointBusiness" name="DueFromUnconsolidatedJointBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ELOCTATEMember" name="ELOCTATEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EachAdditionalOneBillionUpToTwentyBillionMember" name="EachAdditionalOneBillionUpToTwentyBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EarningsPerShareTextualAbstract" name="EarningsPerShareTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" name="EffectiveIncomeTaxRateReconciliationManufacturingDeduction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ElevenbillionMember" name="ElevenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeBenefitPlansTextualAbstract" name="EmployeeBenefitPlansTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" name="EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageMaximum" name="EquityMethodInvestmentOwnershipPercentageMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentsExpectedProfitShare" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_EstimatedUsefulLivesOfLeaseholdImprovements" name="EstimatedUsefulLivesOfLeaseholdImprovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" name="ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" name="ExpectedLicenseFeeAndRegulatoryMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ExpenseIncurredByCollaboration" name="ExpenseIncurredByCollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_ExpenseReflectedWithinStatementsOfIncome" name="ExpenseReflectedWithinStatementsOfIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FAMPYRAMember" name="FAMPYRAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FLIXABIMember" name="FLIXABIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FUMADERMMember" name="FUMADERMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FifteenbillionMemberMember" name="FifteenbillionMemberMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FinancialInstrumentsTextualAbstract" name="FinancialInstrumentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FinishedGoodsMember" name="FinishedGoodsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ForeignSalesRequiredToTriggerMilestone" name="ForeignSalesRequiredToTriggerMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ForeignearningsintheformofcashandcashequivalentsMember" name="ForeignearningsintheformofcashandcashequivalentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ForeignearningstypeAxis" name="ForeignearningstypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ForeignearningstypeDomain" name="ForeignearningstypeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FourteenbillionMember" name="FourteenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FumapharmAgMember" name="FumapharmAgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesAxis" name="FutureContingentMilestoneTypesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesDomain" name="FutureContingentMilestoneTypesDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" name="FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" name="FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureContingentPaymentThreshold" name="FutureContingentPaymentThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" name="FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Futurepercentageofcopromotionoperatingprofits" name="Futurepercentageofcopromotionoperatingprofits" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Futureresearchanddevelopmentcommitment" name="Futureresearchanddevelopmentcommitment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_GAZYVAMember" name="GAZYVAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_HemophiliaProductsMember" name="HemophiliaProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IPerianMember" name="IPerianMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IncomeTaxesTextualAbstract" name="IncomeTaxesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IncreasedCarryingAmountOfSeniorNotes" name="IncreasedCarryingAmountOfSeniorNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" name="IntangibleAssetsAndGoodwillAdditionalTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentInVariableInterestEntitiesTextualAbstract" name="InvestmentInVariableInterestEntitiesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" name="InvestmentsByThirdPartyInJointVentureAsPerAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IonisPharmaceuticalsMember" name="IonisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_JointVentureOwnerShipPercentageByThirdParty" name="JointVentureOwnerShipPercentageByThirdParty" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_KaryopharmMember" name="KaryopharmMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_LeadprogramsMember" name="LeadprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_LicenseFee" name="LicenseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_LossContingencyAdjustmentRelatedToClaimAmountPercent" name="LossContingencyAdjustmentRelatedToClaimAmountPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_MajorDistributorAxis" name="MajorDistributorAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MajorDistributorDomain" name="MajorDistributorDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsActivityAbstract" name="MarketStockUnitsActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" name="MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MilestonePaymentsMadeDuringPeriod" name="MilestonePaymentsMadeDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_MinimumQualifyingAgeForEmployeeBenefitPlan" name="MinimumQualifyingAgeForEmployeeBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" name="MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" name="MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NetMinimumLeasePayments" name="NetMinimumLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsThereafter" name="NetMinimumLeasePaymentsThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFiveYear" name="NetMinimumLeasePaymentsWithInFiveYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFourYear" name="NetMinimumLeasePaymentsWithInFourYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInOneYear" name="NetMinimumLeasePaymentsWithInOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInThreeYear" name="NetMinimumLeasePaymentsWithInThreeYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInTwoYear" name="NetMinimumLeasePaymentsWithInTwoYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_NeurimmuneMember" name="NeurimmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NewAntiCd20Member" name="NewAntiCd20Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NotesPayableToFumedicaMember" name="NotesPayableToFumedicaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" name="NumberOfDaysForCalculationOfAverageClosingStockPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfEqualAnnualIncrements" name="NumberOfEqualAnnualIncrements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" name="NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfSharesOfCommonStockForIssuance" name="NumberOfSharesOfCommonStockForIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NumeratorAbstract" name="NumeratorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OCREVUSMember" name="OCREVUSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OneBillionMember" name="OneBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherForeignEarningsMember" name="OtherForeignEarningsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherresearchanddiscoveryMember" name="OtherresearchanddiscoveryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PLEGRIDYMember" name="PLEGRIDYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ParValueOfNotesPayable" name="ParValueOfNotesPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_PaymentTermsOfAccountsReceivable" name="PaymentTermsOfAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" name="PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfMarketValuePerShareOfCommonStock" name="PercentageOfMarketValuePerShareOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfMinimumInvestmentReturn" name="PercentageOfMinimumInvestmentReturn" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfRoyaltiesAsPerCollaboration" name="PercentageOfRoyaltiesAsPerCollaboration" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageParValueOfSeniorNotes" name="PercentageParValueOfSeniorNotes" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" name="PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceUnitsMember" name="PerformanceUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PerformanceunitsactivityTableTextBlock" name="PerformanceunitsactivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PeriodOfCollaborationAgreement" name="PeriodOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PrepaidtaxesMember" name="PrepaidtaxesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PretaxProfitSharingFormulaTableTextBlock" name="PretaxProfitSharingFormulaTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ProceedsFromMarketableDebtSecuritiesAbstract" name="ProceedsFromMarketableDebtSecuritiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PurchasePriceOfCommonStockUnderEspp" name="PurchasePriceOfCommonStockUnderEspp" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Purchaseofcommonstock" name="Purchaseofcommonstock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_RatioOfNumberOfSharesReservedUnderPlan" name="RatioOfNumberOfSharesReservedUnderPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductioninroyaltyrate" name="Reductioninroyaltyrate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductioninroyaltyratepayableoncommercialsales" name="Reductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementLimitStatedInResolution" name="ReimbursementLimitStatedInResolution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" name="RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RemedyPharmaceuticalMember" name="RemedyPharmaceuticalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ResourcesRedirectedthroughRestructuringProgram" name="ResourcesRedirectedthroughRestructuringProgram" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RestOfWorldMember" name="RestOfWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RestrictedStockUnitsActivityAbstract" name="RestrictedStockUnitsActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RestructuringandRelatedCostExpectedCashPayments" name="RestructuringandRelatedCostExpectedCashPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" name="Restructuringandrelatedcostexpectedpercentageofpositionseliminated" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RevenuesFromUnconsolidatedJointBusinessAbstract" name="RevenuesFromUnconsolidatedJointBusinessAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" name="RevenuesInPercentageFromAntiCD20TherapeuticPrograms" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprograms" name="RevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RituxanMember" name="RituxanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RocheGroupGenentechMember" name="RocheGroupGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RoyaltyCostofSalesPolicyTextBlock" name="RoyaltyCostofSalesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" name="Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_SOD1Member" name="SOD1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SPINRAZAMember" name="SPINRAZAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SalesTriggerGrossSalesThreshold" name="SalesTriggerGrossSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" name="ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" name="ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" name="ScheduleOfDevelopmentMilestoneAndCollaborationTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" name="ScheduleOfMarketStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" name="SegmentGeographicalGroupsOfCountriesGroupOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SegmentInformationTextualAbstract" name="SegmentInformationTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" name="SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SeriesXPreferredStockMember" name="SeriesXPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShareBasedPaymentsTextualAbstract" name="ShareBasedPaymentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareOfCoPromotionProfits" name="ShareOfCoPromotionProfits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" name="SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShorttermderivativeMember" name="ShorttermderivativeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SixteenbillionMember" name="SixteenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnMember" name="SolothurnMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionActivityAbstract" name="StockOptionActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StromedixMember" name="StromedixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" name="SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" name="SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfCommonStockTableTextBlock" name="SummaryOfCommonStockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" name="TaxBenefitAndCashReceivedFromStockOptionAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TermOfLease" name="TermOfLease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TermofBioverativManufacturingandSupplyAgreement" name="TermofBioverativManufacturingandSupplyAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TermofBioverativTransactionServicesAgreement" name="TermofBioverativTransactionServicesAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Termofcollaborationagreement" name="Termofcollaborationagreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ThirteenbillionMember" name="ThirteenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ThreeBillionMember" name="ThreeBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" name="ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" name="ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" name="TimeVestedRestrictedStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Totaldeferredchargesandprepaidtaxes" name="Totaldeferredchargesandprepaidtaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_TransitionTollTaxRepatriationTaxRate" name="TransitionTollTaxRepatriationTaxRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_TwelvebillionMember" name="TwelvebillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TysabriMember" name="TysabriMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_U.S.2017TaxActMember" name="U.S.2017TaxActMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_UniversityofPennsylvaniaMember" name="UniversityofPennsylvaniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ValuationOfGrantedStockUnitsAbstract" name="ValuationOfGrantedStockUnitsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" name="WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_WorkinprocessMember" name="WorkinprocessMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>biib-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20171231.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20171231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20171231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20171231.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20171231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20171231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails2" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:href="biib-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20171231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20171231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20171231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20171231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20171231.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20171231.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:href="biib-20171231.xsd#DerivativeInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20171231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20171231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20171231.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20171231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20171231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20171231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:href="biib-20171231.xsd#EmployeeBenefitPlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:href="biib-20171231.xsd#EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20171231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20171231.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20171231.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20171231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20171231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20171231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20171231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20171231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20171231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20171231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20171231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20171231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20171231.xsd#Guarantees" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:href="biib-20171231.xsd#HemophiliaSpinOffHemophiliaSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:href="biib-20171231.xsd#HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:href="biib-20171231.xsd#HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:href="biib-20171231.xsd#HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20171231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20171231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20171231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20171231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20171231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20171231.xsd#Indebtedness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20171231.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20171231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20171231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20171231.xsd#IndebtednessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20171231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20171231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20171231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20171231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20171231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20171231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20171231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20171231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20171231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20171231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20171231.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20171231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20171231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20171231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20171231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20171231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20171231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20171231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20171231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20171231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20171231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20171231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20171231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20171231.xsd#RestructuringRestructuring" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:href="biib-20171231.xsd#RestructuringRestructuringDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20171231.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:href="biib-20171231.xsd#RestructuringRestructuringTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReserves" xlink:href="biib-20171231.xsd#RevenueReserves" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:href="biib-20171231.xsd#RevenueReservesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:href="biib-20171231.xsd#RevenueReservesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesTables" xlink:href="biib-20171231.xsd#RevenueReservesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20171231.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20171231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:href="biib-20171231.xsd#SegmentInformationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20171231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20171231.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20171231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:href="biib-20171231.xsd#ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20171231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20171231.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20171231.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_9a60f89a-212e-b51d-5cad-c5b578edd9d8" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_2b463f4d-0504-7100-db99-2977b50900b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_9a60f89a-212e-b51d-5cad-c5b578edd9d8" xlink:to="loc_biib_ShareOfCoPromotionProfits_2b463f4d-0504-7100-db99-2977b50900b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_9a60f89a-212e-b51d-5cad-c5b578edd9d8" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_191c9581-cfbc-6f63-20ad-2977b7ba3e53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_191c9581-cfbc-6f63-20ad-2977b7ba3e53" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_023cdd1e-7cb9-1c73-2df9-4734cc2b4f27" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_191c9581-cfbc-6f63-20ad-2977b7ba3e53" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_023cdd1e-7cb9-1c73-2df9-4734cc2b4f27" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_765df3f1-7648-baaf-07c7-2977b61f02c2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_5046b63b-148e-eb12-dd52-2a1e8f1e69c0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_765df3f1-7648-baaf-07c7-2977b61f02c2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_5046b63b-148e-eb12-dd52-2a1e8f1e69c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_ee417633-1929-457f-e0e7-85623ffb97c4" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_765df3f1-7648-baaf-07c7-2977b61f02c2" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_ee417633-1929-457f-e0e7-85623ffb97c4" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_3fda730c-ce53-5b3d-66b3-2977b8de6f24" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_3fda730c-ce53-5b3d-66b3-2977b8de6f24" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_f2ca8ae2-c931-2b6e-f9f3-6782994fbb73" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_3fda730c-ce53-5b3d-66b3-2977b8de6f24" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_f2ca8ae2-c931-2b6e-f9f3-6782994fbb73" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_167a760f-cff6-1582-6229-2977b4c750bf" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_167a760f-cff6-1582-6229-2977b4c750bf" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_76a5360a-50e0-868c-0390-587219b43641" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_167a760f-cff6-1582-6229-2977b4c750bf" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_76a5360a-50e0-868c-0390-587219b43641" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4d905a41-66ee-e4c7-1f76-2977b5d74754" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_56f89e4f-d247-3cf0-a749-00554ab475a6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4d905a41-66ee-e4c7-1f76-2977b5d74754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_56f89e4f-d247-3cf0-a749-00554ab475a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_fbc93e34-c9b6-4b08-d15b-e51401874dcd" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4d905a41-66ee-e4c7-1f76-2977b5d74754" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_fbc93e34-c9b6-4b08-d15b-e51401874dcd" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_e319534c-84cd-b670-6da2-2977b5101271" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_e319534c-84cd-b670-6da2-2977b5101271" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_71fd173a-61bb-7942-2be7-d684fb9de3c9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_e319534c-84cd-b670-6da2-2977b5101271" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_71fd173a-61bb-7942-2be7-d684fb9de3c9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_1d9670c1-eacd-b7d2-80e8-2977b4e6c955" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_1d9670c1-eacd-b7d2-80e8-2977b4e6c955" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_911fef2f-adeb-25ae-3cb0-cb8f672a9df8" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_1d9670c1-eacd-b7d2-80e8-2977b4e6c955" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_911fef2f-adeb-25ae-3cb0-cb8f672a9df8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_40678492-c421-af67-b276-f663f9ff2f98" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_TreasuryStockValue_40678492-c421-af67-b276-f663f9ff2f98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_cb565c4d-35c2-d825-4672-f1619e51c133" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_MinorityInterest_cb565c4d-35c2-d825-4672-f1619e51c133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_8544ed0a-bea0-b1fa-ce65-66a1927d2672" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_TaxesPayableCurrent_8544ed0a-bea0-b1fa-ce65-66a1927d2672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_314eb579-3ee1-408c-39f2-e62f2f37befc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_314eb579-3ee1-408c-39f2-e62f2f37befc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_5021b8a7-49e1-51a4-4dec-1be505fea6c4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_5021b8a7-49e1-51a4-4dec-1be505fea6c4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_5328d89f-ab02-69b3-93c2-2977b5ec5f65" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_5328d89f-ab02-69b3-93c2-2977b5ec5f65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1cb4a384-e314-2300-ad55-c1ed289c8f7a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_OtherAssetsCurrent_1cb4a384-e314-2300-ad55-c1ed289c8f7a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_0ab9456b-855b-4b5f-17aa-958b2bf5fece" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_0ab9456b-855b-4b5f-17aa-958b2bf5fece" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_962cfc51-230d-a221-126b-1d12af7a5921" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_962cfc51-230d-a221-126b-1d12af7a5921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ac9066b4-6e40-13ed-8628-1a20304926d8" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ac9066b4-6e40-13ed-8628-1a20304926d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2e0100a2-70c7-ab53-9143-6f416ad2f702" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2e0100a2-70c7-ab53-9143-6f416ad2f702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7e3bb724-19f9-7fc7-d3fb-60f34a11e15a" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7e3bb724-19f9-7fc7-d3fb-60f34a11e15a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d37bab5b-2ef8-8457-799f-b4fea153fb81" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d37bab5b-2ef8-8457-799f-b4fea153fb81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_fec96391-6e35-fdf3-595d-10648487b8fa" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_fec96391-6e35-fdf3-595d-10648487b8fa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4beb4a13-125c-79a5-e70a-88872f47be70" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4beb4a13-125c-79a5-e70a-88872f47be70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_9cebbd9b-269e-5a19-54b8-1c32e2660d83" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_9cebbd9b-269e-5a19-54b8-1c32e2660d83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8bd7b051-5be0-703c-6635-0cad16b52005" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8bd7b051-5be0-703c-6635-0cad16b52005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_a83917b5-0d97-08b8-a37b-5a651675d415" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_a83917b5-0d97-08b8-a37b-5a651675d415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9d35c912-5b2d-89f7-eeb3-812a0511db5e" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9d35c912-5b2d-89f7-eeb3-812a0511db5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3be9d1aa-8098-ddda-91ce-5e44ee6678ae" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3be9d1aa-8098-ddda-91ce-5e44ee6678ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5eaab9ea-3795-2871-0d80-72b9662e37e6" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5eaab9ea-3795-2871-0d80-72b9662e37e6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a1490c4-32d9-5132-1fe2-2675a45abdae" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a1490c4-32d9-5132-1fe2-2675a45abdae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6d67f644-e190-e5ce-9449-e00a27ad7771" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6d67f644-e190-e5ce-9449-e00a27ad7771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_f5111bee-d5f6-1852-97c9-8d4d4881d906" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_f5111bee-d5f6-1852-97c9-8d4d4881d906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_1050dc04-f8c2-03a3-34af-47f0ecaba5f4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_1050dc04-f8c2-03a3-34af-47f0ecaba5f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_6d9b7dce-39b9-34d3-9e48-3b74a3681093" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfDebt_6d9b7dce-39b9-34d3-9e48-3b74a3681093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_96b318db-5cfb-7c2a-3933-0632d73c101c" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_96b318db-5cfb-7c2a-3933-0632d73c101c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_fcdc0031-632d-d703-c30b-13d96fda604e" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_fcdc0031-632d-d703-c30b-13d96fda604e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9c4e2a5c-e841-39a2-fcf8-f80cfa44af11" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9c4e2a5c-e841-39a2-fcf8-f80cfa44af11" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_548688b8-2d34-462c-5a92-aa79f1c44c1a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_548688b8-2d34-462c-5a92-aa79f1c44c1a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_57e8ae74-d8b6-c629-9bee-2d0929cd3999" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_548688b8-2d34-462c-5a92-aa79f1c44c1a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_57e8ae74-d8b6-c629-9bee-2d0929cd3999" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_ab3008c3-c5c2-a86b-0613-39cbd9b94527" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_548688b8-2d34-462c-5a92-aa79f1c44c1a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_ab3008c3-c5c2-a86b-0613-39cbd9b94527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_cc7c59d2-21ac-163e-0898-1c1f212ef02b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_cc7c59d2-21ac-163e-0898-1c1f212ef02b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_6feed690-17e1-a928-d1c5-204f2faa570e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_cc7c59d2-21ac-163e-0898-1c1f212ef02b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_6feed690-17e1-a928-d1c5-204f2faa570e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_aa99f772-8337-cbc2-0b89-25fbb3108271" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_cc7c59d2-21ac-163e-0898-1c1f212ef02b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_aa99f772-8337-cbc2-0b89-25fbb3108271" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2652b636-1a3b-e639-2800-d9ed5b9b4fc0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2652b636-1a3b-e639-2800-d9ed5b9b4fc0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_351eeed0-a987-88e4-c007-095f3644ffff" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_351eeed0-a987-88e4-c007-095f3644ffff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7908f590-67cb-1122-d422-880e24cad7ce" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7908f590-67cb-1122-d422-880e24cad7ce" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_9a60f89a-212e-b51d-5cad-c5b578edd9d8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_9a60f89a-212e-b51d-5cad-c5b578edd9d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_e7cc3a47-5261-0c18-da28-7de072dc978b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_OtherSalesRevenueNet_e7cc3a47-5261-0c18-da28-7de072dc978b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9f968bdd-178b-453d-dcf7-ca4f511341b3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9f968bdd-178b-453d-dcf7-ca4f511341b3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ae796c5c-1c01-d654-6a3c-3b5dd2c89517" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ae796c5c-1c01-d654-6a3c-3b5dd2c89517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_fec96391-6e35-fdf3-595d-10648487b8fa" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_fec96391-6e35-fdf3-595d-10648487b8fa" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_ae8ceecf-eeb6-1774-0e42-2977b86711db" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_biib_CollaborationProfitSharing_ae8ceecf-eeb6-1774-0e42-2977b86711db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d37bab5b-2ef8-8457-799f-b4fea153fb81" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d37bab5b-2ef8-8457-799f-b4fea153fb81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_58ce9b83-14ec-becd-d9b4-8d51ba4f6656" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_LitigationSettlementExpense_58ce9b83-14ec-becd-d9b4-8d51ba4f6656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1c520208-bae2-1c51-b4b4-935e91f5fece" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1c520208-bae2-1c51-b4b4-935e91f5fece" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_baabbf0a-644b-708a-c310-1211f9af2775" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_baabbf0a-644b-708a-c310-1211f9af2775" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cee10fe8-a4bb-491c-22f6-69a723d6a718" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cee10fe8-a4bb-491c-22f6-69a723d6a718" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_61bb41c2-5e2c-2804-d184-f566af2acbb1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f9684315-a9e4-a270-d882-14da209d6338" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_61bb41c2-5e2c-2804-d184-f566af2acbb1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f9684315-a9e4-a270-d882-14da209d6338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_792de6b4-2056-4259-2de2-c302f546025c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_61bb41c2-5e2c-2804-d184-f566af2acbb1" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_792de6b4-2056-4259-2de2-c302f546025c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_169d77af-5216-aa2b-07d9-c5b5792bdf8b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_169d77af-5216-aa2b-07d9-c5b5792bdf8b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c92402e9-bd0b-d11c-b52e-45b5c23d49be" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c92402e9-bd0b-d11c-b52e-45b5c23d49be" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4836856d-11b6-313b-8616-6a2c8b77e26f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4836856d-11b6-313b-8616-6a2c8b77e26f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_065ac417-143a-3361-82a5-1e59ffd9749a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_065ac417-143a-3361-82a5-1e59ffd9749a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6806c6da-7794-6cc2-dea6-0fe1f4c6a026" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6806c6da-7794-6cc2-dea6-0fe1f4c6a026" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_38f7f811-0e73-faf3-e7e6-c5b578fd26c9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_38f7f811-0e73-faf3-e7e6-c5b578fd26c9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_684e73bc-c774-15b7-cfc4-307e06892c2e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_684e73bc-c774-15b7-cfc4-307e06892c2e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_77aad584-eda7-6ab9-9bf4-262b9a6dd394" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_77aad584-eda7-6ab9-9bf4-262b9a6dd394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_36ba223a-0466-98b6-2d31-f243492419f9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_36ba223a-0466-98b6-2d31-f243492419f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_10028fc1-eee3-03f5-6f20-ff5d85e3c0b2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_10028fc1-eee3-03f5-6f20-ff5d85e3c0b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7d48046d-7441-0899-53b0-aaa1e573540a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7d48046d-7441-0899-53b0-aaa1e573540a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_15bb8413-7c16-05ff-0f24-330007bd87a4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_15bb8413-7c16-05ff-0f24-330007bd87a4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_40691c72-4a6d-af64-c37e-f5abe38c6165" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_40691c72-4a6d-af64-c37e-f5abe38c6165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_67cd26b3-6ceb-499c-0dd8-da28cd1ddfc3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_67cd26b3-6ceb-499c-0dd8-da28cd1ddfc3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c63966d8-8cd7-cadc-7cf6-f799677021d3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c63966d8-8cd7-cadc-7cf6-f799677021d3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_211f9603-61ca-7ef7-2141-bb8ed157e3f6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_211f9603-61ca-7ef7-2141-bb8ed157e3f6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e1d12118-f49a-bc63-5339-100c22e4468d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e1d12118-f49a-bc63-5339-100c22e4468d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3541201a-a025-b00d-aec1-2cb167bdef44" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3541201a-a025-b00d-aec1-2cb167bdef44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f7e9e6da-5d57-5f97-5d33-52f319506ef0" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f7e9e6da-5d57-5f97-5d33-52f319506ef0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_91623f44-5f42-408a-f7b7-7a4698afab83" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_91623f44-5f42-408a-f7b7-7a4698afab83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_644ceb1c-07ef-6a89-f014-9d7b5dfbc918" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d1de4f5a-e70f-c355-7179-89a9064c7b88" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_644ceb1c-07ef-6a89-f014-9d7b5dfbc918" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d1de4f5a-e70f-c355-7179-89a9064c7b88" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_c863f688-0c4a-bb70-251b-2977b529c97f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_644ceb1c-07ef-6a89-f014-9d7b5dfbc918" xlink:to="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_c863f688-0c4a-bb70-251b-2977b529c97f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_744a85ef-de6a-dc1b-540c-cd37e4ee0e8e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_744a85ef-de6a-dc1b-540c-cd37e4ee0e8e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bd3fb4a2-dba4-9f41-2b9f-30441850eb67" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bd3fb4a2-dba4-9f41-2b9f-30441850eb67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_b4cebb29-0be8-9a62-3a11-985fb541a531" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_b4cebb29-0be8-9a62-3a11-985fb541a531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_7737f022-7814-d1ba-7a34-4005044fb373" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_7737f022-7814-d1ba-7a34-4005044fb373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e076fca2-751d-53ee-27b4-64a5b6f5b217" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e076fca2-751d-53ee-27b4-64a5b6f5b217" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_d23f3a10-8672-f1d4-6f93-c5b5791c8b49" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_d23f3a10-8672-f1d4-6f93-c5b5791c8b49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8718aa1e-c40a-73dd-11d3-b6a4475e0d37" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8718aa1e-c40a-73dd-11d3-b6a4475e0d37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_4a6633d6-83f5-f01f-e201-56c59db1d76d" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_4a6633d6-83f5-f01f-e201-56c59db1d76d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_cc2cb572-4a61-daed-767d-ea2b10b9fc01" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_07fc9b71-5e9e-f38c-0c73-b038be276f66" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_cc2cb572-4a61-daed-767d-ea2b10b9fc01" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_07fc9b71-5e9e-f38c-0c73-b038be276f66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fd0898b3-8ac6-af74-6eb0-16df5479b1d8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_cc2cb572-4a61-daed-767d-ea2b10b9fc01" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fd0898b3-8ac6-af74-6eb0-16df5479b1d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_afae3a47-9c39-3601-518d-0d7ae5a5a6c2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_cc2cb572-4a61-daed-767d-ea2b10b9fc01" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_afae3a47-9c39-3601-518d-0d7ae5a5a6c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9f5eb2fc-430b-08e9-97ff-7ba73d819a2f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_cc2cb572-4a61-daed-767d-ea2b10b9fc01" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9f5eb2fc-430b-08e9-97ff-7ba73d819a2f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_82b54d4e-a983-1385-5e08-b1962e49d9a0" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_cc2cb572-4a61-daed-767d-ea2b10b9fc01" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_82b54d4e-a983-1385-5e08-b1962e49d9a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ba31165f-5220-17cb-3dfa-506eec2ab044" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_cc2cb572-4a61-daed-767d-ea2b10b9fc01" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ba31165f-5220-17cb-3dfa-506eec2ab044" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_76e8d839-867c-df13-a643-4da04e725367" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_76e8d839-867c-df13-a643-4da04e725367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c3ed8a56-abe0-6418-c541-e6b647d6318a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c3ed8a56-abe0-6418-c541-e6b647d6318a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d62e128-f1a1-954f-82e2-1936cb67d793" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d62e128-f1a1-954f-82e2-1936cb67d793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a6de665e-02e5-e3e1-f0df-a5f7155acc66" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a6de665e-02e5-e3e1-f0df-a5f7155acc66" xlink:type="arc" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c3ed8a56-abe0-6418-c541-e6b647d6318a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20171231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_8ff90a51-3738-a247-ed51-c5b5792b5d90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b077ba6e-d590-fd28-6cc4-ab52e924ed70" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_8ff90a51-3738-a247-ed51-c5b5792b5d90" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b077ba6e-d590-fd28-6cc4-ab52e924ed70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3451b87-a72a-9fff-128b-969b95aecb3a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_8ff90a51-3738-a247-ed51-c5b5792b5d90" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3451b87-a72a-9fff-128b-969b95aecb3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d8866e11-7330-6a9a-9ba0-56d88707d8ec" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_8ff90a51-3738-a247-ed51-c5b5792b5d90" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d8866e11-7330-6a9a-9ba0-56d88707d8ec" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_27459a92-428a-e415-bdb1-176ed2662e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_27459a92-428a-e415-bdb1-176ed2662e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_a2377e00-ed9e-3dc2-4fbd-c7e624463b5d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_a2377e00-ed9e-3dc2-4fbd-c7e624463b5d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_303ce027-35e0-90c6-b665-c64d3c33d4e9" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_303ce027-35e0-90c6-b665-c64d3c33d4e9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0aa54de5-6171-a107-a0ec-dd4686d3f7d1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_0aa54de5-6171-a107-a0ec-dd4686d3f7d1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_a51e8738-e58c-e4f4-3ef7-22747a152cee" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:to="loc_us-gaap_Land_a51e8738-e58c-e4f4-3ef7-22747a152cee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_bfe00325-30ef-aa76-d96c-ca247f562c4f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_bfe00325-30ef-aa76-d96c-ca247f562c4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_f0ea2165-5b3b-6de9-7b02-17c18660730c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_f0ea2165-5b3b-6de9-7b02-17c18660730c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_6b39d457-fc60-0fcb-fae5-ecc070d021fb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_6b39d457-fc60-0fcb-fae5-ecc070d021fb" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_4d2344fa-08d8-e1ee-5d36-2977b53b7390" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:to="loc_biib_ComputerSoftwareAndHardware_4d2344fa-08d8-e1ee-5d36-2977b53b7390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_4cb0d2ac-0cb3-6a50-d84b-44ca2020e7fe" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_4cb0d2ac-0cb3-6a50-d84b-44ca2020e7fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_594f8c62-c8c5-bd85-818c-71da6f0408d7" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:to="loc_us-gaap_ConstructionInProgressGross_594f8c62-c8c5-bd85-818c-71da6f0408d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenueReserves" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>biib-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20171231.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20171231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20171231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20171231.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20171231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20171231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails2" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:href="biib-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20171231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20171231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20171231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20171231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20171231.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20171231.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:href="biib-20171231.xsd#DerivativeInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20171231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20171231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20171231.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20171231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20171231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20171231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:href="biib-20171231.xsd#EmployeeBenefitPlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:href="biib-20171231.xsd#EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20171231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20171231.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20171231.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20171231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20171231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20171231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20171231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20171231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20171231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20171231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20171231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20171231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20171231.xsd#Guarantees" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:href="biib-20171231.xsd#HemophiliaSpinOffHemophiliaSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:href="biib-20171231.xsd#HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:href="biib-20171231.xsd#HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:href="biib-20171231.xsd#HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20171231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20171231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20171231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20171231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20171231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20171231.xsd#Indebtedness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20171231.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20171231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20171231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20171231.xsd#IndebtednessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20171231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20171231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20171231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20171231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20171231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20171231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20171231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20171231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20171231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20171231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20171231.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20171231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20171231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20171231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20171231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20171231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20171231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20171231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20171231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20171231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20171231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20171231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20171231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20171231.xsd#RestructuringRestructuring" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:href="biib-20171231.xsd#RestructuringRestructuringDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20171231.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:href="biib-20171231.xsd#RestructuringRestructuringTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReserves" xlink:href="biib-20171231.xsd#RevenueReserves" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:href="biib-20171231.xsd#RevenueReservesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:href="biib-20171231.xsd#RevenueReservesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesTables" xlink:href="biib-20171231.xsd#RevenueReservesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20171231.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20171231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:href="biib-20171231.xsd#SegmentInformationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20171231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20171231.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20171231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:href="biib-20171231.xsd#ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20171231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20171231.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20171231.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_284F0D228650E58863B129780EA40E94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:to="loc_us-gaap_StatementTable_284F0D228650E58863B129780EA40E94" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_DAE5763AAD56CF55B0B329780EA4BF6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_284F0D228650E58863B129780EA40E94" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_DAE5763AAD56CF55B0B329780EA4BF6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DAE5763AAD56CF55B0B329780EA4BF6A" xlink:to="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DAE5763AAD56CF55B0B329780EA4BF6A" xlink:to="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_86B5D1E24DEFFBDC1D3429780EA48D31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_86B5D1E24DEFFBDC1D3429780EA48D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_EA7E5292F35B5E2AB5F229780EA4D39C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_EA7E5292F35B5E2AB5F229780EA4D39C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2FB0DEF8E11B3BDC278229780EA420DE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2FB0DEF8E11B3BDC278229780EA420DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_98A269FE7FA2B34AA0DD29780EA48473" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_98A269FE7FA2B34AA0DD29780EA48473" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5129DB860DD7FA46B1DF29780EA49D99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5129DB860DD7FA46B1DF29780EA49D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_F8C4D43CC41EDBCB218629780EA47BB2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_F8C4D43CC41EDBCB218629780EA47BB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_156158159A03868FC03029780EA40433" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_156158159A03868FC03029780EA40433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_870709F2DB327297E38C29780EA4A086" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_870709F2DB327297E38C29780EA4A086" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699" xlink:to="loc_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699" xlink:to="loc_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DE2772F8B504194730D48E262A86150" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DE2772F8B504194730D48E262A86150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_FD513C2707569E1C677048E262A8A482" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_FD513C2707569E1C677048E262A8A482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7E6D9FC841D3F01CCF8548E262A8A8B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7E6D9FC841D3F01CCF8548E262A8A8B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C7B9CC150B1901F03A8D48E262A82468" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_C7B9CC150B1901F03A8D48E262A82468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4F103B2463188495B6F248E262A84516" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4F103B2463188495B6F248E262A84516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_E2E6DAC593E7F402C2DE48E262A8E355" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_E2E6DAC593E7F402C2DE48E262A8E355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D79027F9C6B819D188DB48E262A9401D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_OperatingExpenses_D79027F9C6B819D188DB48E262A9401D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_CEB149805C163D3D73B748EC5BF6F61B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_CEB149805C163D3D73B748EC5BF6F61B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BCD77631D7EC3685B0FC48E262A98587" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_NetIncomeLoss_BCD77631D7EC3685B0FC48E262A98587" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:to="loc_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A" xlink:to="loc_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A" xlink:to="loc_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BIIB074Member" xlink:label="loc_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4" xlink:to="loc_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:to="loc_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_103517661A83AFE5DACC434A35CDC947" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_103517661A83AFE5DACC434A35CDC947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_B76F5EBB0808170B0DF2434A35CD857A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_B76F5EBB0808170B0DF2434A35CD857A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_37B72B656B764110E7EE434A35CDA34C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_37B72B656B764110E7EE434A35CDA34C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E3E6FA718F1923E82395434A35CD6C36" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E3E6FA718F1923E82395434A35CD6C36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8FCB4B4736E6F1232937434A35CDAEE6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8FCB4B4736E6F1232937434A35CDAEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_F8889029AAF6B1612892434A35CDCC5E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_Goodwill_F8889029AAF6B1612892434A35CDCC5E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25004B9D146D3807BFAC492867F000A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA29E0DC2212645B2670492867F0DE23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25004B9D146D3807BFAC492867F000A4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA29E0DC2212645B2670492867F0DE23" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_AFA362FB52626C4CEF49492867F08433" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA29E0DC2212645B2670492867F0DE23" xlink:to="loc_us-gaap_TypeOfArrangementAxis_AFA362FB52626C4CEF49492867F08433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD6C8BC2C1ECBF9CB394492867F0ECCA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_AFA362FB52626C4CEF49492867F08433" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD6C8BC2C1ECBF9CB394492867F0ECCA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD6C8BC2C1ECBF9CB394492867F0ECCA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_AFA362FB52626C4CEF49492867F08433" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD6C8BC2C1ECBF9CB394492867F0ECCA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_A01CF521740D1047706E492867F054AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD6C8BC2C1ECBF9CB394492867F0ECCA" xlink:to="loc_biib_EisaiMember_A01CF521740D1047706E492867F054AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25004B9D146D3807BFAC492867F000A4" xlink:to="loc_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25004B9D146D3807BFAC492867F000A4" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6A8FE05987B5D9D1DEF0492867CA5F75" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93C742F19677CE27972D492867C82805" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6A8FE05987B5D9D1DEF0492867CA5F75" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93C742F19677CE27972D492867C82805" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_C099704127665DFE5703492867C9A980" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93C742F19677CE27972D492867C82805" xlink:to="loc_us-gaap_ProductOrServiceAxis_C099704127665DFE5703492867C9A980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_99D3DB3A910C73892F3A492867C99047_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_C099704127665DFE5703492867C9A980" xlink:to="loc_us-gaap_ProductsAndServicesDomain_99D3DB3A910C73892F3A492867C99047_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_99D3DB3A910C73892F3A492867C99047" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_C099704127665DFE5703492867C9A980" xlink:to="loc_us-gaap_ProductsAndServicesDomain_99D3DB3A910C73892F3A492867C99047" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_99D3DB3A910C73892F3A492867C99047" xlink:to="loc_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_99D3DB3A910C73892F3A492867C99047" xlink:to="loc_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_726959358118CB338E52492867C9463D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93C742F19677CE27972D492867C82805" xlink:to="loc_us-gaap_TypeOfArrangementAxis_726959358118CB338E52492867C9463D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE4835A6AFFD60F043F7492867CAF77B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_726959358118CB338E52492867C9463D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE4835A6AFFD60F043F7492867CAF77B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE4835A6AFFD60F043F7492867CAF77B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_726959358118CB338E52492867C9463D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE4835A6AFFD60F043F7492867CAF77B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE4835A6AFFD60F043F7492867CAF77B" xlink:to="loc_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6A8FE05987B5D9D1DEF0492867CA5F75" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6A8FE05987B5D9D1DEF0492867CA5F75" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_AF05E3B9E866EE9FD734492867CB8813" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:to="loc_biib_ShareOfCoPromotionProfits_AF05E3B9E866EE9FD734492867CB8813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7EFEE7C05BE98E11AEDB492867CB0F1E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_7EFEE7C05BE98E11AEDB492867CB0F1E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_4EB31FD49AC6A8CF3907492867CBE0DF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_4EB31FD49AC6A8CF3907492867CBE0DF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3EAF6F3F3D93ACA9107D492867E5D94A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3EAF6F3F3D93ACA9107D492867E5D94A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BE1BC06FED7F3C7873C492867E50D2D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3EAF6F3F3D93ACA9107D492867E5D94A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BE1BC06FED7F3C7873C492867E50D2D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BE1BC06FED7F3C7873C492867E50D2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3EAF6F3F3D93ACA9107D492867E5D94A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BE1BC06FED7F3C7873C492867E50D2D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BE1BC06FED7F3C7873C492867E50D2D" xlink:to="loc_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_0E624C28AA79DBED603A492867E64BD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:to="loc_us-gaap_Revenues_0E624C28AA79DBED603A492867E64BD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_58BCEB58E451F45127C8493564A98BD8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:to="loc_us-gaap_CostsAndExpenses_58BCEB58E451F45127C8493564A98BD8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Copromotionprofitsandlosses" xlink:label="loc_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:to="loc_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:to="loc_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_2BFDC567DCA7781712FE4DAF958CD642" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9" xlink:to="loc_us-gaap_ScenarioForecastMember_2BFDC567DCA7781712FE4DAF958CD642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F49E0C66FFA966B154C94D7427726B97" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F49E0C66FFA966B154C94D7427726B97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA49833433E8811A6E144D74277268B0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F49E0C66FFA966B154C94D7427726B97" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA49833433E8811A6E144D74277268B0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA49833433E8811A6E144D74277268B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F49E0C66FFA966B154C94D7427726B97" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA49833433E8811A6E144D74277268B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_3BD898FF476ED7999D054D742772625F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA49833433E8811A6E144D74277268B0" xlink:to="loc_biib_InLicensedPatentsMember_3BD898FF476ED7999D054D742772625F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_0B8DD339A3A7318AE1024D7427725645" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_StatementGeographicalAxis_0B8DD339A3A7318AE1024D7427725645" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_0B8DD339A3A7318AE1024D7427725645" xlink:to="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_0B8DD339A3A7318AE1024D7427725645" xlink:to="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_52B5D7FFF86E5A84FDDF4D7427721A3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0" xlink:to="loc_country_US_52B5D7FFF86E5A84FDDF4D7427721A3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_DD73FC7841827CC39EBA4D742773A5EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0" xlink:to="loc_us-gaap_ForeignCountryMember_DD73FC7841827CC39EBA4D742773A5EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_7BD293543F43EACE044E4D742773DA2D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0" xlink:to="loc_us-gaap_EuropeanUnionMember_7BD293543F43EACE044E4D742773DA2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_2435909E93E134239CEE4D74277314B1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0" xlink:to="loc_country_JP_2435909E93E134239CEE4D74277314B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1ADE969C4656D899C9204D7427738FBC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1ADE969C4656D899C9204D7427738FBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CAC2F13062B5F31949124D742773EA04_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1ADE969C4656D899C9204D7427738FBC" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_CAC2F13062B5F31949124D742773EA04_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CAC2F13062B5F31949124D742773EA04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1ADE969C4656D899C9204D7427738FBC" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_CAC2F13062B5F31949124D742773EA04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_75BDD951EC5266F76AA24D7427731A8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CAC2F13062B5F31949124D742773EA04" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_75BDD951EC5266F76AA24D7427731A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_CC3AE5FD0F16CAF92B494D742773A460" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CAC2F13062B5F31949124D742773EA04" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_CC3AE5FD0F16CAF92B494D742773A460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_EBADAD41428610F736E24D7427747D78" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_ProductOrServiceAxis_EBADAD41428610F736E24D7427747D78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_EBADAD41428610F736E24D7427747D78" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_EBADAD41428610F736E24D7427747D78" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_12D4C5F4F5B6B15FC58C4D7427742CB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_RituxanMember_12D4C5F4F5B6B15FC58C4D7427742CB1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_A1CE4F6A8E5711F17A734D742774CC75" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_GAZYVAMember_A1CE4F6A8E5711F17A734D742774CC75" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_OCREVUSMember" xlink:label="loc_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_98076790808B70E761E64D7427749093" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_ZINBRYTAMember_98076790808B70E761E64D7427749093" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_36802B5BF32E90F2A6AC4D742774E87E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_SPINRAZAMember_36802B5BF32E90F2A6AC4D742774E87E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_LeadprogramsMember" xlink:label="loc_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DiscoveryprogramsMember" xlink:label="loc_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_4EAC8527DC09458A4A114D7427744221" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_BiosimilarsMember_4EAC8527DC09458A4A114D7427744221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F01854F230619E38A74D4D7427747F5A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F01854F230619E38A74D4D7427747F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F01854F230619E38A74D4D7427747F5A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F01854F230619E38A74D4D7427747F5A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_3994507F1508EB4D2A814D742775A7D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_RocheGroupGenentechMember_3994507F1508EB4D2A814D742775A7D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_E653680DFC413DDB57114D742775F168" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_AbbVieMember_E653680DFC413DDB57114D742775F168" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_8B0A492449565C844FE34D742775643A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_AcordaMember_8B0A492449565C844FE34D742775643A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_4C68076C251B882D27684D742775FDB0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_IonisPharmaceuticalsMember_4C68076C251B882D27684D742775FDB0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_D592A90649FA4B016EEA4D7427752C7A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_EisaiMember_D592A90649FA4B016EEA4D7427752C7A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_02D1F53C8094874050B54D742775BA46" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_BristolMyersSquibbMember_02D1F53C8094874050B54D742775BA46" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_485A294ECAA888BEBFD24D7427752E75" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_IPerianMember_485A294ECAA888BEBFD24D7427752E75" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_78F31A14512F8EFDB07A4D74277582BF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_AlkermesMember_78F31A14512F8EFDB07A4D74277582BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_UniversityofPennsylvaniaMember" xlink:label="loc_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_BD6208807A35E1AC634D4D74277591F1" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_BD6208807A35E1AC634D4D74277591F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8869F518C9C2BDAC7BC24D7427759ECA" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_RangeAxis_8869F518C9C2BDAC7BC24D7427759ECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F6A3DB2B8083F3E32FBD4D742775F0E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8869F518C9C2BDAC7BC24D7427759ECA" xlink:to="loc_us-gaap_RangeMember_F6A3DB2B8083F3E32FBD4D742775F0E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F6A3DB2B8083F3E32FBD4D742775F0E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8869F518C9C2BDAC7BC24D7427759ECA" xlink:to="loc_us-gaap_RangeMember_F6A3DB2B8083F3E32FBD4D742775F0E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_85F260E0E1A822396A864D7427755E31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F6A3DB2B8083F3E32FBD4D742775F0E7" xlink:to="loc_us-gaap_MinimumMember_85F260E0E1A822396A864D7427755E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6A4EB124E5D8736299364D74277589F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F6A3DB2B8083F3E32FBD4D742775F0E7" xlink:to="loc_us-gaap_MaximumMember_6A4EB124E5D8736299364D74277589F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_7773AF92B866BEA5FCE34D742777EBE5" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_ShareOfCoPromotionProfits_7773AF92B866BEA5FCE34D742777EBE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_C9664458088ED0E307914D742777CB69" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_C9664458088ED0E307914D742777CB69" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_33A666F4075CE435C25A4D7427772EDF" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_33A666F4075CE435C25A4D7427772EDF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_401FDEAE8E1C89CD00C24D7427774C4D" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_401FDEAE8E1C89CD00C24D7427774C4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D4BBBD0263A7A808183C4D742777C48E" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D4BBBD0263A7A808183C4D742777C48E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_6ED29557D60A71D830AA4D742778CE46" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_6ED29557D60A71D830AA4D742778CE46" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0927C00B6BFC72AFEEB84D7427787FDD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0927C00B6BFC72AFEEB84D7427787FDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_167551E0B4E977CEFBDB4D742778E974" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_167551E0B4E977CEFBDB4D742778E974" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CollaborationExpensesinDispute" xlink:label="loc_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_823363C92C96D54F78514D7427775AA2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_ExpenseIncurredByCollaboration_823363C92C96D54F78514D7427775AA2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_88C82F8FECA6BC7EE3A64D742777C6C0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_AssetImpairmentCharges_88C82F8FECA6BC7EE3A64D742777C6C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_E3060DAEE763E348EB8F4D742777186E" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_E3060DAEE763E348EB8F4D742777186E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_A8ECCD4F9F5DCFEFBF674D742777D547" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_OtherSalesRevenueNet_A8ECCD4F9F5DCFEFBF674D742777D547" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="loc_us-gaap_DirectOperatingCostRoyaltyExpense_45EFAA868CF98C29A6CF4D7427788C39" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_DirectOperatingCostRoyaltyExpense_45EFAA868CF98C29A6CF4D7427788C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7D541DA3DDAE576177C84D7427788A49" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7D541DA3DDAE576177C84D7427788A49" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_F05D5EB212472A34DD514D74277814F0" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_LicenseFee_F05D5EB212472A34DD514D74277814F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C6D798E3DB10F42355184D74277859C4" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C6D798E3DB10F42355184D74277859C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_96A06E8B60D672BE0C594D7427782923" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_96A06E8B60D672BE0C594D7427782923" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" xlink:label="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_C38AEC85F26D8C35B3E94D7427783191" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_DevelopmentalMilestonePayment_C38AEC85F26D8C35B3E94D7427783191" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_FAF3A98EB56A87FBE31A4D742779AB4C" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_FAF3A98EB56A87FBE31A4D742779AB4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_5A2A7AE5EA2982221A464D7427792FDD" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_LicenseCosts_5A2A7AE5EA2982221A464D7427792FDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_EC744153CC6F9639EF1D4D742779AE25" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_EC744153CC6F9639EF1D4D742779AE25" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Futureresearchanddevelopmentcommitment" xlink:label="loc_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_7EE2EE81C32FF91CCCA34D74277997D9" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_EquityMethodInvestments_7EE2EE81C32FF91CCCA34D74277997D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_B1FF385597D76A31C1F94D74277961A9" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_B1FF385597D76A31C1F94D74277961A9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_57AC91108A46B74F318E4D7427791A8D" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_57AC91108A46B74F318E4D7427791A8D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B" xlink:to="loc_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:to="loc_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:to="loc_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CommercialMilestonesMember" xlink:label="loc_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:to="loc_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_1137234B889C9111064A4C77BC39F998" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_biib_CumulativeSalesLevelAxis_1137234B889C9111064A4C77BC39F998" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_1137234B889C9111064A4C77BC39F998" xlink:to="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_1137234B889C9111064A4C77BC39F998" xlink:to="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FourteenbillionMember" xlink:label="loc_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ElevenbillionMember" xlink:label="loc_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TwelvebillionMember" xlink:label="loc_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ThirteenbillionMember" xlink:label="loc_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_0CFC3EC5743889136A7D4C77BC39B20F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_FifteenbillionMemberMember_0CFC3EC5743889136A7D4C77BC39B20F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_8E57149778F81D5F1A414C7E599B3B45" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_SixteenbillionMember_8E57149778F81D5F1A414C7E599B3B45" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_CE2B6C56747CD5F1106E4C77BC39BED0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_us-gaap_ProductOrServiceAxis_CE2B6C56747CD5F1106E4C77BC39BED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_1347BF80F9FE9A58FA8E4C77BC3A02D4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_CE2B6C56747CD5F1106E4C77BC39BED0" xlink:to="loc_us-gaap_ProductsAndServicesDomain_1347BF80F9FE9A58FA8E4C77BC3A02D4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_1347BF80F9FE9A58FA8E4C77BC3A02D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_CE2B6C56747CD5F1106E4C77BC39BED0" xlink:to="loc_us-gaap_ProductsAndServicesDomain_1347BF80F9FE9A58FA8E4C77BC3A02D4" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_EC545D02544F026262154C77BC3A5D1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_1347BF80F9FE9A58FA8E4C77BC3A02D4" xlink:to="loc_biib_TecfideraMember_EC545D02544F026262154C77BC3A5D1B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_18C5C4D7069A684EACC34C77BC3A408A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_biib_FacilityLocationAxis_18C5C4D7069A684EACC34C77BC3A408A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_D84BEFDDBCAC431F9FE94C77BC3A7FF1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_18C5C4D7069A684EACC34C77BC3A408A" xlink:to="loc_biib_FacilityLocationDomain_D84BEFDDBCAC431F9FE94C77BC3A7FF1_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_D84BEFDDBCAC431F9FE94C77BC3A7FF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_18C5C4D7069A684EACC34C77BC3A408A" xlink:to="loc_biib_FacilityLocationDomain_D84BEFDDBCAC431F9FE94C77BC3A7FF1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_BCE99AAEFD45CA116C154C77BC3A5620" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_D84BEFDDBCAC431F9FE94C77BC3A7FF1" xlink:to="loc_biib_SolothurnMember_BCE99AAEFD45CA116C154C77BC3A5620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_38A68E8266747C7D0D824C77BC3A5846" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_38A68E8266747C7D0D824C77BC3A5846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_439BDF133B6BCECFD1D54C77BC3AA429_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_38A68E8266747C7D0D824C77BC3A5846" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_439BDF133B6BCECFD1D54C77BC3AA429_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_439BDF133B6BCECFD1D54C77BC3AA429" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_38A68E8266747C7D0D824C77BC3A5846" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_439BDF133B6BCECFD1D54C77BC3AA429" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_AD2202BE53472E2ECA2C4C77BC3A72E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_439BDF133B6BCECFD1D54C77BC3AA429" xlink:to="loc_biib_TysabriProductMember_AD2202BE53472E2ECA2C4C77BC3A72E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_989616B222FB16312A194C77BC3AA64F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_439BDF133B6BCECFD1D54C77BC3AA429" xlink:to="loc_biib_FumapharmAgMember_989616B222FB16312A194C77BC3AA64F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4653F2D260B93D891C574C77BC3B4F0E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4653F2D260B93D891C574C77BC3B4F0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2E03C7A9241351E9C35C4C77BC3B5B67" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2E03C7A9241351E9C35C4C77BC3B5B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3E00CCF4D129B562131E4C77BC3B3C8A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3E00CCF4D129B562131E4C77BC3B3C8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_28CF619905020334FEAB4C77BC3BD8AA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_biib_CumulativeSalesLevel_28CF619905020334FEAB4C77BC3BD8AA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_108BE54A21ACEBB1A5824C77BC3B0056" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_108BE54A21ACEBB1A5824C77BC3B0056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_89714369B631F41AEC974C77BC3B9AFB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_OtherCommitment_89714369B631F41AEC974C77BC3B9AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_FC9FED73B15496E3E1CB4C811D5F2D6A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_FC9FED73B15496E3E1CB4C811D5F2D6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossCurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_CDA835E465588F9B6D354C77BC3B8A53" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_CDA835E465588F9B6D354C77BC3B8A53" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_42049A261D4E11C7DB7452C0D5D5A84C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StatementTable_42049A261D4E11C7DB7452C0D5D5A84C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_BD4B0F568D70C877035B52C0D5D51220" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42049A261D4E11C7DB7452C0D5D5A84C" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_BD4B0F568D70C877035B52C0D5D51220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_EDA0A91B8721945D15D852C0D5D52972_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_BD4B0F568D70C877035B52C0D5D51220" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_EDA0A91B8721945D15D852C0D5D52972_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_EDA0A91B8721945D15D852C0D5D52972" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_BD4B0F568D70C877035B52C0D5D51220" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_EDA0A91B8721945D15D852C0D5D52972" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_870DA70D21EB57FF431C52C0D5D6AF1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_EDA0A91B8721945D15D852C0D5D52972" xlink:to="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_870DA70D21EB57FF431C52C0D5D6AF1B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_473F89923149BD4659C952C0D5D65F9C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_EDA0A91B8721945D15D852C0D5D52972" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_473F89923149BD4659C952C0D5D65F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C6D6F6943DB5669DAD4952C0D5D64E8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42049A261D4E11C7DB7452C0D5D5A84C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_C6D6F6943DB5669DAD4952C0D5D64E8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C6D6F6943DB5669DAD4952C0D5D64E8A" xlink:to="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C6D6F6943DB5669DAD4952C0D5D64E8A" xlink:to="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_234812A4D96FB9F24A5552C0D5D6FA0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_PreferredStockMember_234812A4D96FB9F24A5552C0D5D6FA0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_AF68C20C0D4FA279217552C0D5D6B3F4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_CommonStockMember_AF68C20C0D4FA279217552C0D5D6B3F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_D8EC59A7BBC7FA1488F152C0D5D6027D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_D8EC59A7BBC7FA1488F152C0D5D6027D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12231DFDE0C48B9BDBF252C0D5D65775" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12231DFDE0C48B9BDBF252C0D5D65775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2909F56EFBF8E3CAE35252C0D5D6412A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_RetainedEarningsMember_2909F56EFBF8E3CAE35252C0D5D6412A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_5D7F3B944344DAFDA1C952C0D5D647C8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_TreasuryStockMember_5D7F3B944344DAFDA1C952C0D5D647C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_A019DD35F02166EC2C4552C0D5D6571D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_NoncontrollingInterestMember_A019DD35F02166EC2C4552C0D5D6571D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_C8779D4309C56E9D02F052C0D5D7BEEF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_ParentMember_C8779D4309C56E9D02F052C0D5D7BEEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15D6D84E3E97D5FB05B652C0D5D79230" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15D6D84E3E97D5FB05B652C0D5D79230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2662B113F2BC5F8264D952C0D5D7E84A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockholdersEquity_2662B113F2BC5F8264D952C0D5D7E84A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_DB45896898479AF1E95552C0D5D71602" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_MinorityInterest_DB45896898479AF1E95552C0D5D71602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_7A041A63CB32E3985F3D52C0D5D7FC2B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_SharesIssued_7A041A63CB32E3985F3D52C0D5D7FC2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5DC79B0ECEAA06C1E8E152C0D5D7F812" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_NetIncomeLoss_5DC79B0ECEAA06C1E8E152C0D5D7F812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A76137CDBBCF8723142D52C0D5D78B0E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A76137CDBBCF8723142D52C0D5D78B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1EEDD87A71C3A83ECC4752C0D5D77B90" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_ProfitLoss_1EEDD87A71C3A83ECC4752C0D5D77B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2F097F1D912E9D475BBA52C0D5D7A33D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2F097F1D912E9D475BBA52C0D5D7A33D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6B0D72B11DE0989EB07552C0D5D7E777" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6B0D72B11DE0989EB07552C0D5D7E777" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_38515E636856FC364FE352C0D5D85EC0" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_38515E636856FC364FE352C0D5D85EC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_68B3761109F60566C3E952C0D5D8A58E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_68B3761109F60566C3E952C0D5D8A58E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3F2A50C4EE3B823F6EAC52C0D5D881E5" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3F2A50C4EE3B823F6EAC52C0D5D881E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2D54B9B61FEFB474DFFB52C0D5D8251D" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2D54B9B61FEFB474DFFB52C0D5D8251D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_CF3D5121846C10DA27E852C0D5D8F0D9" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_CF3D5121846C10DA27E852C0D5D8F0D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_8ED18F849D4F1BC8619B52C0D5D8B70D" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_8ED18F849D4F1BC8619B52C0D5D8B70D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_10272EF9DDB19C0E1D4052C0D5D8502E" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_10272EF9DDB19C0E1D4052C0D5D8502E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_AF8DE654A9FB71FF84CA52C0D5D825F9" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_AF8DE654A9FB71FF84CA52C0D5D825F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_C22CD8880B209B6F205F52C0D5D8AC29" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_C22CD8880B209B6F205F52C0D5D8AC29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5A1213048D1FED79E1DA52C0D5D8FFD0" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5A1213048D1FED79E1DA52C0D5D8FFD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1843D3461146D478B8252C0D5D8AB6A" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1843D3461146D478B8252C0D5D8AB6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6844893C08938060CA1352C0D5D886F3" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6844893C08938060CA1352C0D5D886F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_98A17F77D17D668BC82952C0D5D8D4F3" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_98A17F77D17D668BC82952C0D5D8D4F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_79847B257F411A946C7852C0D5D9C4B8" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_79847B257F411A946C7852C0D5D9C4B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_D4D0B089D674A7CC88D752C0D5D9FC75" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockholdersEquityOther_D4D0B089D674A7CC88D752C0D5D9FC75" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:to="loc_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86" xlink:to="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86" xlink:to="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_1C0C501C08B017D7CFCD42D5E4139A73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:to="loc_currency_EUR_1C0C501C08B017D7CFCD42D5E4139A73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_FC262194F27359C902CF42D5E414BA36" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:to="loc_currency_GBP_FC262194F27359C902CF42D5E414BA36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_B985C169C15EFD4271FB42D5E4148DA9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:to="loc_currency_CHF_B985C169C15EFD4271FB42D5E4148DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_29E4585609708E7BB70542D5E414C5A5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:to="loc_currency_CAD_29E4585609708E7BB70542D5E414C5A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_652F070033E7542D604742D5E414E240" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_652F070033E7542D604742D5E414E240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F27D62C50683B37D09CE42D5E4141407_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_652F070033E7542D604742D5E414E240" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F27D62C50683B37D09CE42D5E4141407_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F27D62C50683B37D09CE42D5E4141407" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_652F070033E7542D604742D5E414E240" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F27D62C50683B37D09CE42D5E4141407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_DB5C30CB7B78D0FD1EB242D5E4141B5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F27D62C50683B37D09CE42D5E4141407" xlink:to="loc_us-gaap_ForeignExchangeContractMember_DB5C30CB7B78D0FD1EB242D5E4141B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_242A05587B0CDEB75C0542D5E419FB42" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_242A05587B0CDEB75C0542D5E419FB42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_242A05587B0CDEB75C0542D5E419FB42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_242A05587B0CDEB75C0542D5E419FB42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_C88D4CFFDD1C8EE8E61442D5E41A6165" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_C88D4CFFDD1C8EE8E61442D5E41A6165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_2F206D6B8F390965455642D5E41AAA9A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E" xlink:to="loc_us-gaap_OtherInvestmentsMember_2F206D6B8F390965455642D5E41AAA9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_33139AAACC7E6C9F60D142D5E41A7456" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_33139AAACC7E6C9F60D142D5E41A7456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9E29A028A6AC2C9579BB42D5E41AA4BD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9E29A028A6AC2C9579BB42D5E41AA4BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:to="loc_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384" xlink:to="loc_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384" xlink:to="loc_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1406129B11F00BF5C87842D5E41AAED7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1406129B11F00BF5C87842D5E41AAED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_27F3FDDD9972992165E542D5E41AF449" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:to="loc_us-gaap_NondesignatedMember_27F3FDDD9972992165E542D5E41AF449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_7F1846292181A72C9FA142D5E41A07E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:to="loc_invest_DerivativeNotionalAmount_7F1846292181A72C9FA142D5E41A07E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_D88A3AE2CF415E570E2742D5E41A3115" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_D88A3AE2CF415E570E2742D5E41A3115" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A085857E43F3981DFC4642D5E41A7161" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A085857E43F3981DFC4642D5E41A7161" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34" xlink:to="loc_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34" xlink:to="loc_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:to="loc_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:to="loc_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3F87FE3E04150A913BC229780F70B62A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3F87FE3E04150A913BC229780F70B62A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_21114F4595320A286AF229780F704873_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3F87FE3E04150A913BC229780F70B62A" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_21114F4595320A286AF229780F704873_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_21114F4595320A286AF229780F704873" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3F87FE3E04150A913BC229780F70B62A" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_21114F4595320A286AF229780F704873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_2B3D718C2F480A00D82C29780F7008C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_21114F4595320A286AF229780F704873" xlink:to="loc_us-gaap_ForeignExchangeContractMember_2B3D718C2F480A00D82C29780F7008C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9512F679110C3FA6F66F29780F705100" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9512F679110C3FA6F66F29780F705100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9512F679110C3FA6F66F29780F705100" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9512F679110C3FA6F66F29780F705100" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_A11F41C82C7FB81E7DC529780F708A97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:to="loc_us-gaap_SalesMember_A11F41C82C7FB81E7DC529780F708A97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_BE7A4EA42653A755273E29780F709E60" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_BE7A4EA42653A755273E29780F709E60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_8A011FBF93E1DE58C24129780F71D88A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:to="loc_us-gaap_OperatingExpenseMember_8A011FBF93E1DE58C24129780F71D88A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_6608CCBE418745E5743929780F71E1B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_6608CCBE418745E5743929780F71E1B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_7470256E4A8D67DF27B329780F7138DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_7470256E4A8D67DF27B329780F7138DB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:to="loc_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:to="loc_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:to="loc_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9" xlink:to="loc_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2ADCC6B7D214055AED81433E14400768" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:to="loc_us-gaap_RangeAxis_2ADCC6B7D214055AED81433E14400768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_549D4322357A0AFE5097433E14404315_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2ADCC6B7D214055AED81433E14400768" xlink:to="loc_us-gaap_RangeMember_549D4322357A0AFE5097433E14404315_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_549D4322357A0AFE5097433E14404315" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2ADCC6B7D214055AED81433E14400768" xlink:to="loc_us-gaap_RangeMember_549D4322357A0AFE5097433E14404315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9573779765B9FA077DEB433E1440AAF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_549D4322357A0AFE5097433E14404315" xlink:to="loc_us-gaap_MinimumMember_9573779765B9FA077DEB433E1440AAF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_99DEE23E00F9117E0CFA433E1446EC25" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_549D4322357A0AFE5097433E14404315" xlink:to="loc_us-gaap_MaximumMember_99DEE23E00F9117E0CFA433E1446EC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7DC25FF924C4B27594F1433E1446E098" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:to="loc_us-gaap_DebtInstrumentAxis_7DC25FF924C4B27594F1433E1446E098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DBFF134E40011A308E97433E14462A09_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7DC25FF924C4B27594F1433E1446E098" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DBFF134E40011A308E97433E14462A09_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DBFF134E40011A308E97433E14462A09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7DC25FF924C4B27594F1433E1446E098" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DBFF134E40011A308E97433E14462A09" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_1A805B5BA0DADC98D475433E14463EFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DBFF134E40011A308E97433E14462A09" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_1A805B5BA0DADC98D475433E14463EFF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8D2A8AD5D97BB2B07F9E433E1446D35F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DBFF134E40011A308E97433E14462A09" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8D2A8AD5D97BB2B07F9E433E1446D35F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_BB5E0BF14B54F01A3BD6433E1446BEC4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DBFF134E40011A308E97433E14462A09" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_BB5E0BF14B54F01A3BD6433E1446BEC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7231279ABB553DBB3CA7433E144786ED" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7231279ABB553DBB3CA7433E144786ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_33F0BC43F1136398770D433E14474FBA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7231279ABB553DBB3CA7433E144786ED" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_33F0BC43F1136398770D433E14474FBA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_33F0BC43F1136398770D433E14474FBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7231279ABB553DBB3CA7433E144786ED" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_33F0BC43F1136398770D433E14474FBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_42B95A18D362683BE579433E144747EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_33F0BC43F1136398770D433E14474FBA" xlink:to="loc_us-gaap_InterestRateContractMember_42B95A18D362683BE579433E144747EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_C547132BBA09253EF518433E1447E06B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_33F0BC43F1136398770D433E14474FBA" xlink:to="loc_us-gaap_InterestRateSwapMember_C547132BBA09253EF518433E1447E06B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_9D866D547DD4338CB6B9433E1447E733" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:to="loc_us-gaap_HedgingDesignationAxis_9D866D547DD4338CB6B9433E1447E733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_434721EA6F628AB586AF433E14473259_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_9D866D547DD4338CB6B9433E1447E733" xlink:to="loc_us-gaap_HedgingDesignationDomain_434721EA6F628AB586AF433E14473259_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_434721EA6F628AB586AF433E14473259" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_9D866D547DD4338CB6B9433E1447E733" xlink:to="loc_us-gaap_HedgingDesignationDomain_434721EA6F628AB586AF433E14473259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_35D32DE79B644AAE0F54433E1447CC13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_434721EA6F628AB586AF433E14473259" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_35D32DE79B644AAE0F54433E1447CC13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_C809680DFC7680C35E1F433E144CF05F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_434721EA6F628AB586AF433E14473259" xlink:to="loc_us-gaap_NondesignatedMember_C809680DFC7680C35E1F433E144CF05F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D92195E3E5592A13B564433E144DF210" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D92195E3E5592A13B564433E144DF210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_24C97B0E517030B5D8C7433E144DB014" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_24C97B0E517030B5D8C7433E144DB014" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_53C0762DEA9A1A184AD4433E144D71FB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:to="loc_invest_DerivativeNotionalAmount_53C0762DEA9A1A184AD4433E144D71FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2CE60D86BB823D89F913433E144DA9B8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2CE60D86BB823D89F913433E144DA9B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A1168C01C6C44FE4AE2E433E144DFDEC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A1168C01C6C44FE4AE2E433E144DFDEC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E8AD12C00568418262DE29780E9EE1E5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_E8AD12C00568418262DE29780E9EE1E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_F51A7D51255B1BB9D98C29780E9EA952" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:to="loc_biib_MarketStockUnitsMember_F51A7D51255B1BB9D98C29780E9EA952" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:to="loc_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_42F61586B25436133C3229780E9E9CC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC" xlink:to="loc_us-gaap_NetIncomeLoss_42F61586B25436133C3229780E9E9CC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:to="loc_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_51B98C283E2CAB4CF06229780E9EA656" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_51B98C283E2CAB4CF06229780E9EA656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5CEE0CCF133EF0572E2829780E9E833E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5CEE0CCF133EF0572E2829780E9E833E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_93FE4E597CD904ECC12929780E9E09E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_93FE4E597CD904ECC12929780E9E09E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21BCD86C5B61C09003AD29780E9F3A07" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21BCD86C5B61C09003AD29780E9F3A07" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_894C7858F6F63C2609AE4C78A5FA07C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279" xlink:to="loc_us-gaap_ForeignPlanMember_894C7858F6F63C2609AE4C78A5FA07C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:to="loc_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF" xlink:to="loc_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF" xlink:to="loc_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CH" xlink:label="loc_country_CH_16ECDE442E9F463C45DC4C78A6003299" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:to="loc_country_CH_16ECDE442E9F463C45DC4C78A6003299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="loc_country_DE_2CB7D81DE871872DFFF24C78A600948E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:to="loc_country_DE_2CB7D81DE871872DFFF24C78A600948E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891" xlink:to="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:to="loc_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_B4546ACBF305A9D0FE664C78A6010D02" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_B4546ACBF305A9D0FE664C78A6010D02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_908ACDF6A147A8E526524C78A601BABA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_908ACDF6A147A8E526524C78A601BABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_C45D74DDC73DC69F5F1D4C78A6019923" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:to="loc_us-gaap_PensionExpense_C45D74DDC73DC69F5F1D4C78A6019923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_0291323046308F0BBC394C78A601FCB0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_0291323046308F0BBC394C78A601FCB0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:to="loc_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_F61DD44850970846C0D74C78A60ACB4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_F61DD44850970846C0D74C78A60ACB4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_A115D8A6F1D01D1AD16A4C78A60A70DF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_F61DD44850970846C0D74C78A60ACB4D" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_A115D8A6F1D01D1AD16A4C78A60A70DF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_A115D8A6F1D01D1AD16A4C78A60A70DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_F61DD44850970846C0D74C78A60ACB4D" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_A115D8A6F1D01D1AD16A4C78A60A70DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_9B1B651110A79D767E5C4C78A60A999D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_A115D8A6F1D01D1AD16A4C78A60A70DF" xlink:to="loc_us-gaap_DomesticPlanMember_9B1B651110A79D767E5C4C78A60A999D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0B86177A3BE0F23667484C78A60FB722" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_A115D8A6F1D01D1AD16A4C78A60A70DF" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0B86177A3BE0F23667484C78A60FB722" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:to="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_61B16D90B3BF3F35B7384C78A610C951" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_61B16D90B3BF3F35B7384C78A610C951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_CE2B5865AF0E5C4C43444C78A610FACA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_CE2B5865AF0E5C4C43444C78A610FACA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:to="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E" xlink:to="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E" xlink:to="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1794FC13139F027D291F43AA3FFD40C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1794FC13139F027D291F43AA3FFD40C0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:to="loc_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:to="loc_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_C013FCA2E9DA4876012C43AA3FFE4508" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_C013FCA2E9DA4876012C43AA3FFE4508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4AFCEF2677888CF946D643AA3FFE460D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4AFCEF2677888CF946D643AA3FFE460D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_B6F358A74E537A6CC0E743AA3FFE2E40" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_B6F358A74E537A6CC0E743AA3FFE2E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_231B703246AB88ED2F0943AA3FFEDA4C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_231B703246AB88ED2F0943AA3FFEDA4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_17E0B76BBC31333B174C43AA3FFE8DCC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_17E0B76BBC31333B174C43AA3FFE8DCC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FA231860B00DCE0DE67742D5E4CF2CD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_FA231860B00DCE0DE67742D5E4CF2CD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_421422C35BC5C14B312342D5E4CFA157" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_421422C35BC5C14B312342D5E4CFA157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4025503224EC4B79224542D5E4CFA07E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4025503224EC4B79224542D5E4CFA07E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_E903A03968CEA6484FC842D5E4D09AFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_E903A03968CEA6484FC842D5E4D09AFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_A756F3B3C761E8BEC49B42D5E4D0B3BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_A756F3B3C761E8BEC49B42D5E4D0B3BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_2E314A33D12781C0BB3E42D5E4D025F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_2E314A33D12781C0BB3E42D5E4D025F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_FD5F5BE60DB3718A0B9342D5E4D0BB88" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_FD5F5BE60DB3718A0B9342D5E4D0BB88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2F0B93BA0423D082CF5942D5E4D025B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2F0B93BA0423D082CF5942D5E4D025B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_EACF7D2AE29CC93A2A2342D5E4D001CF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="loc_us-gaap_AvailableForSaleSecurities_EACF7D2AE29CC93A2A2342D5E4D001CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_DF9745B01C56C34E91B942D5E4D02EB2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_DF9745B01C56C34E91B942D5E4D02EB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_717A7FBE228794DFFBDB42D5E4D0DC3A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_717A7FBE228794DFFBDB42D5E4D0DC3A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8DF5F140201543FE4E9C42D5E4D1800B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8DF5F140201543FE4E9C42D5E4D1800B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_12D97F2F813AC9346B4642D5E4D18A3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_12D97F2F813AC9346B4642D5E4D18A3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_CC8763BEA1FE6C8F604E42D5E4D18580" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_CC8763BEA1FE6C8F604E42D5E4D18580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_DBDFA4F4AA63E7FBCD5942D5E4D16F87" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_DBDFA4F4AA63E7FBCD5942D5E4D16F87" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_A526C5E6EB700B2D996F4311A5095172" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_39AE5D8DDCE12A2975034311A50825C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A526C5E6EB700B2D996F4311A5095172" xlink:to="loc_us-gaap_DebtInstrumentTable_39AE5D8DDCE12A2975034311A50825C3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_BE495FBB0AEAFFB3C5634311A5087B8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39AE5D8DDCE12A2975034311A50825C3" xlink:to="loc_us-gaap_DebtInstrumentAxis_BE495FBB0AEAFFB3C5634311A5087B8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_BE495FBB0AEAFFB3C5634311A5087B8E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_BE495FBB0AEAFFB3C5634311A5087B8E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:to="loc_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C30F832B50A5F3477B654311A509696C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C30F832B50A5F3477B654311A509696C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_C4582457970A7B1E3EEE4311A509A768" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_C4582457970A7B1E3EEE4311A509A768" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_895EF73FBF3C8B4828AD4311A5099907" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_895EF73FBF3C8B4828AD4311A5099907" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_DACDFC3600A047B94BC24311A5096C22" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_DACDFC3600A047B94BC24311A5096C22" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_252A437E481BAC9302A34311A5094EF0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_252A437E481BAC9302A34311A5094EF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_DB9B536B3B58CEF70BB6437BAD4AF5EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A526C5E6EB700B2D996F4311A5095172" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_DB9B536B3B58CEF70BB6437BAD4AF5EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_7481D893260022446579437BAD6A6901" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A526C5E6EB700B2D996F4311A5095172" xlink:to="loc_us-gaap_DebtInstrumentFairValue_7481D893260022446579437BAD6A6901" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_A9115BDED1EE807D537242D5E4A312D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D7D7E228BCEDC780F63042D5E4A39CFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_A9115BDED1EE807D537242D5E4A312D4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D7D7E228BCEDC780F63042D5E4A39CFA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9D219F91FD00BB7A593942D5E4A30B46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D7D7E228BCEDC780F63042D5E4A39CFA" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9D219F91FD00BB7A593942D5E4A30B46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_55B174D10D5512ABED6542D5E4A3FEC9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9D219F91FD00BB7A593942D5E4A30B46" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_55B174D10D5512ABED6542D5E4A3FEC9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_55B174D10D5512ABED6542D5E4A3FEC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9D219F91FD00BB7A593942D5E4A30B46" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_55B174D10D5512ABED6542D5E4A3FEC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7E9E7C5C6374F947612F42D5E4A3FD2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_55B174D10D5512ABED6542D5E4A3FEC9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7E9E7C5C6374F947612F42D5E4A3FD2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A419484C8BEC0CAF40F442D5E4A3F6B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_A9115BDED1EE807D537242D5E4A312D4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A419484C8BEC0CAF40F442D5E4A3F6B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_00C96585005987B2EB4F42D5E4A35CE4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_A9115BDED1EE807D537242D5E4A312D4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_00C96585005987B2EB4F42D5E4A35CE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0A667C1D10BD914BA06442D5E4A3A7A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_A9115BDED1EE807D537242D5E4A312D4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0A667C1D10BD914BA06442D5E4A3A7A6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_A956F75F4E9E6AD2E53042D5E4922534" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_A956F75F4E9E6AD2E53042D5E4922534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_A99EF515EAE632E6F5F842D5E492CBB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_A99EF515EAE632E6F5F842D5E492CBB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_D9BB80598DCD35879B6542D5E492C7A3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:to="loc_us-gaap_DebtInstrumentAxis_D9BB80598DCD35879B6542D5E492C7A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_D9BB80598DCD35879B6542D5E492C7A3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_D9BB80598DCD35879B6542D5E492C7A3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_13722E3B16E3CA43840642D5E49325B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_13722E3B16E3CA43840642D5E49325B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_7A633863A1D7D7DACDD242D5E493669E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_7A633863A1D7D7DACDD242D5E493669E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_306EAE2CEC009F59606642D5E49336E1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_306EAE2CEC009F59606642D5E49336E1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8BF848A874DAF39B818042D5E4930A76" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8BF848A874DAF39B818042D5E4930A76" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_50E3E98D18A0C9CE633E42D5E49309A2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_50E3E98D18A0C9CE633E42D5E49309A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_59B1727E8AF27EB3994B42D5E493435C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_59B1727E8AF27EB3994B42D5E493435C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D6F6A49A72C6DC1E8F6F42D5E4939055_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59B1727E8AF27EB3994B42D5E493435C" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D6F6A49A72C6DC1E8F6F42D5E4939055_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D6F6A49A72C6DC1E8F6F42D5E4939055" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59B1727E8AF27EB3994B42D5E493435C" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D6F6A49A72C6DC1E8F6F42D5E4939055" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_FA14A9057E93D0575B7642D5E493318C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D6F6A49A72C6DC1E8F6F42D5E4939055" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_FA14A9057E93D0575B7642D5E493318C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D6F6A49A72C6DC1E8F6F42D5E4939055" xlink:to="loc_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D6F6A49A72C6DC1E8F6F42D5E4939055" xlink:to="loc_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4365BEE9AE015008136642D5E4936CCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4365BEE9AE015008136642D5E4936CCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_834E63C6B8011DADD967437EEA8391AD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_834E63C6B8011DADD967437EEA8391AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_95CE23979AB447EF518D42D5E4937027" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_95CE23979AB447EF518D42D5E4937027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_E6304E73DE32FB6437E042D5E4938454" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_OtherLiabilities_E6304E73DE32FB6437E042D5E4938454" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B1136CC640F19BD32DBC42D5E49403EA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B1136CC640F19BD32DBC42D5E49403EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_312673440D296193D9B442D5E494C278" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_312673440D296193D9B442D5E494C278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4724197F226F3D3B8F2842D5E494DDAA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4724197F226F3D3B8F2842D5E494DDAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_48D0B5EC182091F7CCF242D5E494AE21" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_48D0B5EC182091F7CCF242D5E494AE21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_471D4B870B8C2BB33CB142D5E4948F37" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_471D4B870B8C2BB33CB142D5E4948F37" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_7E066314E9EF070876A842D5E494AA6E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_7E066314E9EF070876A842D5E494AA6E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44" xlink:to="loc_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_9666A57449C4F5D99AC429780F79E0BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:to="loc_us-gaap_CommercialPaperMember_9666A57449C4F5D99AC429780F79E0BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_E7B1D9EBC0295B60EA8829780F7A2005" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_E7B1D9EBC0295B60EA8829780F7A2005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9F50748269D3799BF31729780F7AB5CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9F50748269D3799BF31729780F7AB5CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_80E76C5B0C6F9349678929780F7A0618" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:to="loc_us-gaap_DebtSecuritiesMember_80E76C5B0C6F9349678929780F7A0618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_00C05C84D8CA298EC46129780F7AE7FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_00C05C84D8CA298EC46129780F7AE7FD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_917864A38E8F8F6E366942D5E45EA656" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_917864A38E8F8F6E366942D5E45EA656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_917864A38E8F8F6E366942D5E45EA656" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_917864A38E8F8F6E366942D5E45EA656" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_2D3C2506C73380C66724438936B11134" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_us-gaap_EquitySecuritiesMember_2D3C2506C73380C66724438936B11134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_F47BE740AC0EB3FA370842D5E45F66EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:to="loc_us-gaap_AvailableForSaleSecurities_F47BE740AC0EB3FA370842D5E45F66EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2877009FFDC6CAFAB6C542D5E45F6777" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2877009FFDC6CAFAB6C542D5E45F6777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AECFA319D6E1A4FE06F742D5E45F0B53" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AECFA319D6E1A4FE06F742D5E45F0B53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B2606C213A04AB69686442D5E45F2B38" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B2606C213A04AB69686442D5E45F2B38" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_59D47673543B8A61AE8229780FA36C5D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8CA0300114B69849E09829780FA363C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_59D47673543B8A61AE8229780FA36C5D" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8CA0300114B69849E09829780FA363C4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8CA0300114B69849E09829780FA363C4" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0" xlink:to="loc_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_59D47673543B8A61AE8229780FA36C5D" xlink:to="loc_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_FAB15C2516E5BCFA029B4332410D8BF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_FAB15C2516E5BCFA029B4332410D8BF1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9681CE1F9EEDBE4A4CC94332410D3786" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_FAB15C2516E5BCFA029B4332410D8BF1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9681CE1F9EEDBE4A4CC94332410D3786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_54E7F0BB92F5C3A815C24332410D13B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9681CE1F9EEDBE4A4CC94332410D3786" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_54E7F0BB92F5C3A815C24332410D13B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_54E7F0BB92F5C3A815C24332410D13B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9681CE1F9EEDBE4A4CC94332410D3786" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_54E7F0BB92F5C3A815C24332410D13B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_92B5F6DA420497F1FBA84332410DF15F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_54E7F0BB92F5C3A815C24332410D13B5" xlink:to="loc_biib_BioverativMember_92B5F6DA420497F1FBA84332410DF15F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8F702A9E8F9FAFC224334332410D9266" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8F702A9E8F9FAFC224334332410D9266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2A461729B618CC16F5EC4332410D5A15" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2A461729B618CC16F5EC4332410D5A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_DDAE78F096BF447085554332410D58B8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_DDAE78F096BF447085554332410D58B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6074E20F33E74516835B4332410DCFF6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6074E20F33E74516835B4332410DCFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_55727E35EB2AFF50E49E4332410D0489" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_55727E35EB2AFF50E49E4332410D0489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_A698088C004E4C033E8A4332410D5A29" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_A698088C004E4C033E8A4332410D5A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9447A937ABB1492388774332410DE331" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9447A937ABB1492388774332410DE331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_90A0F24B56CE802500404332410D513E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_90A0F24B56CE802500404332410D513E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_840371EF0B21845F42944332410D727D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_840371EF0B21845F42944332410D727D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_4EE0F471694A02081C474332410D8931" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_4EE0F471694A02081C474332410D8931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_AE38E20EC8D3BEBD4FD74332410DE52B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_15697D7703AC21D510884332410D2CE5" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_AE38E20EC8D3BEBD4FD74332410DE52B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18CB3BDD44FF07E7720643329FBEB501" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18CB3BDD44FF07E7720643329FBEB501" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_135FB60EC5225706E59643329FBEF3E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18CB3BDD44FF07E7720643329FBEB501" xlink:to="loc_us-gaap_ProductOrServiceAxis_135FB60EC5225706E59643329FBEF3E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_EAB1C6F7B7FE07637E0443329FBF3B42_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_135FB60EC5225706E59643329FBEF3E4" xlink:to="loc_us-gaap_ProductsAndServicesDomain_EAB1C6F7B7FE07637E0443329FBF3B42_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_EAB1C6F7B7FE07637E0443329FBF3B42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_135FB60EC5225706E59643329FBEF3E4" xlink:to="loc_us-gaap_ProductsAndServicesDomain_EAB1C6F7B7FE07637E0443329FBF3B42" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_C8EBA2A3D5BD646E724C43329FBFE00F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_EAB1C6F7B7FE07637E0443329FBF3B42" xlink:to="loc_biib_HemophiliaProductsMember_C8EBA2A3D5BD646E724C43329FBFE00F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AE98A91A80952A03E6C843329FBF5A7D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18CB3BDD44FF07E7720643329FBEB501" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AE98A91A80952A03E6C843329FBF5A7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_A36ABD53A64B2ED763E943329FBFA4AB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AE98A91A80952A03E6C843329FBF5A7D" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_A36ABD53A64B2ED763E943329FBFA4AB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_A36ABD53A64B2ED763E943329FBFA4AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AE98A91A80952A03E6C843329FBF5A7D" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_A36ABD53A64B2ED763E943329FBFA4AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_7C2F5E3FB62D3E7ABE6443329FBFE083" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_A36ABD53A64B2ED763E943329FBFA4AB" xlink:to="loc_biib_BioverativMember_7C2F5E3FB62D3E7ABE6443329FBFE083" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TermofBioverativTransactionServicesAgreement" xlink:label="loc_biib_TermofBioverativTransactionServicesAgreement_4EA49D5E1C8FE9048A6543329FBF0465" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:to="loc_biib_TermofBioverativTransactionServicesAgreement_4EA49D5E1C8FE9048A6543329FBF0465" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TermofBioverativManufacturingandSupplyAgreement" xlink:label="loc_biib_TermofBioverativManufacturingandSupplyAgreement_4C5939F4E3987E5383FE43329FBF55F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:to="loc_biib_TermofBioverativManufacturingandSupplyAgreement_4C5939F4E3987E5383FE43329FBF55F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8641D799B2C5784A0E8443329FBF63D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8641D799B2C5784A0E8443329FBF63D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_DB279F31BB10453E802E43329FBFEB58" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:to="loc_us-gaap_OtherSalesRevenueNet_DB279F31BB10453E802E43329FBFEB58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_749B9E86D003A14B1C9943329FBF57B0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:to="loc_us-gaap_CostOfGoodsSold_749B9E86D003A14B1C9943329FBF57B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1B492E1DDEC93CAC995243329FBFBF0D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_1B492E1DDEC93CAC995243329FBFBF0D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignearningstypeAxis" xlink:label="loc_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:to="loc_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:to="loc_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:to="loc_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:to="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_OtherForeignEarningsMember" xlink:label="loc_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:to="loc_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_25E6307A36935667C706486D5C08ABED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_25E6307A36935667C706486D5C08ABED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_696C08A0CC1FE98725A8486D5C0823C3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_25E6307A36935667C706486D5C08ABED" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_696C08A0CC1FE98725A8486D5C0823C3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_696C08A0CC1FE98725A8486D5C0823C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_25E6307A36935667C706486D5C08ABED" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_696C08A0CC1FE98725A8486D5C0823C3" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PrepaidtaxesMember" xlink:label="loc_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_696C08A0CC1FE98725A8486D5C0823C3" xlink:to="loc_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_3748DA4BB4AF7F4BA0B5486D5C096DE3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_696C08A0CC1FE98725A8486D5C0823C3" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_3748DA4BB4AF7F4BA0B5486D5C096DE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6D35053DF9C9904A9A05486D5C09C4FE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_696C08A0CC1FE98725A8486D5C0823C3" xlink:to="loc_us-gaap_RetainedEarningsMember_6D35053DF9C9904A9A05486D5C09C4FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_1F2D37091EEC0A6C7F55486D5C09321E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:to="loc_us-gaap_GeneralBusinessMember_1F2D37091EEC0A6C7F55486D5C09321E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_5B751544495326B9ADC4486D5C0991DF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:to="loc_us-gaap_ResearchMember_5B751544495326B9ADC4486D5C0991DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_83AA48419CBD3391807C486D5C09D8B3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_83AA48419CBD3391807C486D5C09D8B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_83AA48419CBD3391807C486D5C09D8B3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_83AA48419CBD3391807C486D5C09D8B3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_10CDA9A9B01FC8703A52486D5C098E01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7" xlink:to="loc_biib_U.S.2017TaxActMember_10CDA9A9B01FC8703A52486D5C098E01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_B2E379A69A99795555F3486D5C0914ED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7" xlink:to="loc_us-gaap_DomesticCountryMember_B2E379A69A99795555F3486D5C0914ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_AB7E0816881CD20BA27A486D5C0E2737" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_AB7E0816881CD20BA27A486D5C0E2737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_F1C787452262C6650ADF486D5C0E73BE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7" xlink:to="loc_us-gaap_ForeignCountryMember_F1C787452262C6650ADF486D5C0E73BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33EF309FA91CD1A2B3344898361EDE9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33EF309FA91CD1A2B3344898361EDE9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5A65D8727E3261C85D46486D5C0F1D68" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5A65D8727E3261C85D46486D5C0F1D68" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TransitionTollTaxRepatriationTaxRate" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_AC26CD60CEDF567946DC489EA24247DD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_AC26CD60CEDF567946DC489EA24247DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossCurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_361172A4A802C733543B486D5C107FDB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_361172A4A802C733543B486D5C107FDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_422FC84C3AE2DE08DC7C486D5C15011D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_422FC84C3AE2DE08DC7C486D5C15011D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_D36257598F6F35767B69486D5C0FD1B3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_D36257598F6F35767B69486D5C0FD1B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_DA02E2147C85E203822C486D5C15D177" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_DA02E2147C85E203822C486D5C15D177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_E234D8AD9B4992888C3F486D5C0F0E69" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_OperatingLossCarryforwards_E234D8AD9B4992888C3F486D5C0F0E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_435BEE37D6492E3CA4EA486D5C0F2F3A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_435BEE37D6492E3CA4EA486D5C0F2F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_159407AE2106846C0014486D5C0F84F9" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_159407AE2106846C0014486D5C0F84F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_A32B7EB823F1D687343E486D5C0F029C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_A32B7EB823F1D687343E486D5C0F029C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_EBF7867D832D1AA69D8E43A9429C58DC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7BDDB06058B3F39EFDB543A9429B034F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EBF7867D832D1AA69D8E43A9429C58DC" xlink:to="loc_us-gaap_DebtInstrumentTable_7BDDB06058B3F39EFDB543A9429B034F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_04392D27772F73E4014243A9429B1F94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7BDDB06058B3F39EFDB543A9429B034F" xlink:to="loc_us-gaap_DebtInstrumentAxis_04392D27772F73E4014243A9429B1F94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_04392D27772F73E4014243A9429B1F94" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_04392D27772F73E4014243A9429B1F94" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_0E02F5ACA9734DBB36BA43AA1DC60470" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_0E02F5ACA9734DBB36BA43AA1DC60470" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_78947E15ECA86F81F29643A9429C056E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_78947E15ECA86F81F29643A9429C056E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_D4CCE350BA7B2C8F495743A9429C017D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_D4CCE350BA7B2C8F495743A9429C017D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_01E2CD6F1D87D2A6A85743A9429C3D66" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_01E2CD6F1D87D2A6A85743A9429C3D66" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C13948B9A0A32835B49D43A9429CBB70" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C13948B9A0A32835B49D43A9429CBB70" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DA10093B86A46CD31E1143A9429CE668" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DA10093B86A46CD31E1143A9429CE668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EBF7867D832D1AA69D8E43A9429C58DC" xlink:to="loc_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_9AF0D8EFD69E3FE1496E43A9429DE34C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:to="loc_us-gaap_NotesPayableCurrent_9AF0D8EFD69E3FE1496E43A9429DE34C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_27EAFBA46F5D39D91E8B43A9429FE9F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_27EAFBA46F5D39D91E8B43A9429FE9F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_AA0CA043F503AF3CEE2643A9429FE5BC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:to="loc_us-gaap_DebtCurrent_AA0CA043F503AF3CEE2643A9429FE5BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EBF7867D832D1AA69D8E43A9429C58DC" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_5EE3852E2A1FA6150BD443A9429FE1D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:to="loc_us-gaap_LongTermNotesPayable_5EE3852E2A1FA6150BD443A9429FE1D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_A722BB9D056786161BC543A942A040DD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_A722BB9D056786161BC543A942A040DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_3308D56009FC67404AD443A942A04462" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:to="loc_us-gaap_LongTermDebt_3308D56009FC67404AD443A942A04462" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_89EF28403E8ED850188F43A944248189" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_89EF28403E8ED850188F43A944248189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59B79265CF4F7B26CE0C43A94424D88E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89EF28403E8ED850188F43A944248189" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59B79265CF4F7B26CE0C43A94424D88E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59B79265CF4F7B26CE0C43A94424D88E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89EF28403E8ED850188F43A944248189" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59B79265CF4F7B26CE0C43A94424D88E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59B79265CF4F7B26CE0C43A94424D88E" xlink:to="loc_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_B648CB147DD20724158543A944252B61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D" xlink:to="loc_us-gaap_InterestRateSwapMember_B648CB147DD20724158543A944252B61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:to="loc_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_994C8A8813303C4106EC43A94425E000" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_994C8A8813303C4106EC43A94425E000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F7D67E032951858E6C2443A94425C535" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F7D67E032951858E6C2443A94425C535" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IncreasedCarryingAmountOfSeniorNotes" xlink:label="loc_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_8B5420A6D6ADEE58998143A9442698A7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_8B5420A6D6ADEE58998143A9442698A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_C816B31F2BED1D6A01A043A94426F83F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_C816B31F2BED1D6A01A043A94426F83F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_11F3CDDDCF6ED2FF33B043A944252F62" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_11F3CDDDCF6ED2FF33B043A944252F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_A6B2DCC0FDB6073A30E943A9442683D8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_A6B2DCC0FDB6073A30E943A9442683D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_D506D90311AE2923A59543A944269810" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_D506D90311AE2923A59543A944269810" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7DCC68D62D0F5D0CD03E43A944268762" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7DCC68D62D0F5D0CD03E43A944268762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_33FDC3002AC396F3BE4743A9442657D6" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_LongTermNotesPayable_33FDC3002AC396F3BE4743A9442657D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ParValueOfNotesPayable" xlink:label="loc_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1B98A454C99A3B93081C43A944265742" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1B98A454C99A3B93081C43A944265742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_C6EB75A3E7ADB889F4F043A944260767" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_C6EB75A3E7ADB889F4F043A944260767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0DF59CA91FAA7C2B1D0743A944265AC8" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0DF59CA91FAA7C2B1D0743A944265AC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_CB2BBB61BD5EF57E86EB43A94427B4EB" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_CB2BBB61BD5EF57E86EB43A94427B4EB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_60E26F71ACAF096C15CE4311A51ACAC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:to="loc_us-gaap_ProductOrServiceAxis_60E26F71ACAF096C15CE4311A51ACAC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_60E26F71ACAF096C15CE4311A51ACAC5" xlink:to="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_60E26F71ACAF096C15CE4311A51ACAC5" xlink:to="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:to="loc_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:to="loc_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_DC0139C8B006A35F45A64311A51BF402" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:to="loc_biib_SPINRAZAMember_DC0139C8B006A35F45A64311A51BF402" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:to="loc_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:to="loc_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_56A27453DD93D03020004311A51B7C0D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:to="loc_biib_TecfideraMember_56A27453DD93D03020004311A51B7C0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_A5C84CDB29AA3B6CC2444311A51BA454" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_A5C84CDB29AA3B6CC2444311A51BA454" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_4D64627D5C191E8D42A44311A51BEF67" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_4D64627D5C191E8D42A44311A51BEF67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:to="loc_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_83606C2E54DCA596926B4311A51BBFCD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_83606C2E54DCA596926B4311A51BBFCD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:to="loc_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_0ADDE484F2DA9763ED154311A51B8B02" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:to="loc_us-gaap_RangeAxis_0ADDE484F2DA9763ED154311A51B8B02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_57926961C69C28C8A6D44311A51CD4AC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_0ADDE484F2DA9763ED154311A51B8B02" xlink:to="loc_us-gaap_RangeMember_57926961C69C28C8A6D44311A51CD4AC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_57926961C69C28C8A6D44311A51CD4AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_0ADDE484F2DA9763ED154311A51B8B02" xlink:to="loc_us-gaap_RangeMember_57926961C69C28C8A6D44311A51CD4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_223442E5926741A2DCF14311A51C3542" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_57926961C69C28C8A6D44311A51CD4AC" xlink:to="loc_us-gaap_MinimumMember_223442E5926741A2DCF14311A51C3542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_09B223B77B7B0AE0D8F44311A51C7ADE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_57926961C69C28C8A6D44311A51CD4AC" xlink:to="loc_us-gaap_MaximumMember_09B223B77B7B0AE0D8F44311A51C7ADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2915C3EE8BFE69F5CA854311A51CC26B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2915C3EE8BFE69F5CA854311A51CC26B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8E32E7757DFFBCFB1C424311A51CE3E1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8E32E7757DFFBCFB1C424311A51CE3E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_94969B9591BAF84FE3E04311A51C9419" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_94969B9591BAF84FE3E04311A51C9419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D131161F7538C0D3AF84311A51CC224" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D131161F7538C0D3AF84311A51CC224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_A364197675100F073F884311A51C46E2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_A364197675100F073F884311A51C46E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_73B436F0E66466C78E324311A51C8AF0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_73B436F0E66466C78E324311A51C8AF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD71245517F7A5A3279C4311A51C31FF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD71245517F7A5A3279C4311A51C31FF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6346F2C4FD957CDD8E5F4311A51DDCBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6346F2C4FD957CDD8E5F4311A51DDCBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_00DFA28AD59E528A481B4311A51D5D2B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_00DFA28AD59E528A481B4311A51D5D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54C8CB51977F760122364311A51DA2EB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54C8CB51977F760122364311A51DA2EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D22C4620967C7AD2C5E44311A51DE6B0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D22C4620967C7AD2C5E44311A51DE6B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_572CD81D7087831309024311A51D3061" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_572CD81D7087831309024311A51D3061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4D8EEE8E6F9AAA57FBE24311A51D91CB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4D8EEE8E6F9AAA57FBE24311A51D91CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0A03DDD30513AB04F06A4311A51D8029" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0A03DDD30513AB04F06A4311A51D8029" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4DECF4267B336476D6B74311A51DA3FD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4DECF4267B336476D6B74311A51DA3FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3BF24D6BC9937D9E02DB4311A51DDE5A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3BF24D6BC9937D9E02DB4311A51DDE5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_617A777EDE7ED37FDFFF4311A51DFA17" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_LitigationSettlementExpense_617A777EDE7ED37FDFFF4311A51DFA17" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1" xlink:to="loc_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CA24E06156652CBFEB604311A50E5581" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CA24E06156652CBFEB604311A50E5581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2C84BDBDB129107E38814311A50E7396_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CA24E06156652CBFEB604311A50E5581" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2C84BDBDB129107E38814311A50E7396_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2C84BDBDB129107E38814311A50E7396" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CA24E06156652CBFEB604311A50E5581" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2C84BDBDB129107E38814311A50E7396" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2C84BDBDB129107E38814311A50E7396" xlink:to="loc_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_8371F932CF4E75ABB5DB4311A50FD53F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:to="loc_us-gaap_ProductOrServiceAxis_8371F932CF4E75ABB5DB4311A50FD53F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_5746CED05F055D015EFA4311A50F17D1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_8371F932CF4E75ABB5DB4311A50FD53F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_5746CED05F055D015EFA4311A50F17D1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_5746CED05F055D015EFA4311A50F17D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_8371F932CF4E75ABB5DB4311A50FD53F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_5746CED05F055D015EFA4311A50F17D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_FE69F127B55BF81EEC994311A50FBD6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_5746CED05F055D015EFA4311A50F17D1" xlink:to="loc_biib_TecfideraMember_FE69F127B55BF81EEC994311A50FBD6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_28AB1D89AEC10680D7074311A50FD1CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_28AB1D89AEC10680D7074311A50FD1CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A7C9CEB87B3313711A4C4311A50F538B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_A7C9CEB87B3313711A4C4311A50F538B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EC8A2FB671F4DC45DF34311A50F9514" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EC8A2FB671F4DC45DF34311A50F9514" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:to="loc_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FinishedGoodsMember" xlink:label="loc_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:to="loc_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6250913748BFF20F6AB34311A523B27E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6250913748BFF20F6AB34311A523B27E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_886066634A2BC95EECB74311A5232765_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6250913748BFF20F6AB34311A523B27E" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_886066634A2BC95EECB74311A5232765_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_886066634A2BC95EECB74311A5232765" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6250913748BFF20F6AB34311A523B27E" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_886066634A2BC95EECB74311A5232765" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_4286B69EDCADE88C57EA4311A523BCBD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_886066634A2BC95EECB74311A5232765" xlink:to="loc_biib_BioverativMember_4286B69EDCADE88C57EA4311A523BCBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3326613D067D5043BB54311A52493FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3326613D067D5043BB54311A52493FD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_BEACBFB021A312FF84C448F12BEE0DA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_BEACBFB021A312FF84C448F12BEE0DA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_090A381F75B1BFFB229148F12BEED18E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_BEACBFB021A312FF84C448F12BEE0DA8" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_090A381F75B1BFFB229148F12BEED18E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_090A381F75B1BFFB229148F12BEED18E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_BEACBFB021A312FF84C448F12BEE0DA8" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_090A381F75B1BFFB229148F12BEED18E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_61AEA92B59944FF779D048F12BEEF0F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_090A381F75B1BFFB229148F12BEED18E" xlink:to="loc_biib_NeurimmuneMember_61AEA92B59944FF779D048F12BEEF0F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_900F335EBBF2F034419248F12BEE9CAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_900F335EBBF2F034419248F12BEE9CAD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_A5F86C446B53C681AEAF48F12BEED1C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_A5F86C446B53C681AEAF48F12BEED1C1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AdditionalPotentialPaymentstoNoncontrollingInterest" xlink:label="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:to="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:to="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A7B5F00662800B03CA2B48EF3C7321C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_48C0398754E67D0990EF48EF3C720359" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_A7B5F00662800B03CA2B48EF3C7321C9" xlink:to="loc_us-gaap_StatementTable_48C0398754E67D0990EF48EF3C720359" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5DA9B07CCE9BA6CA9B8448EF3C72AC62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_48C0398754E67D0990EF48EF3C720359" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5DA9B07CCE9BA6CA9B8448EF3C72AC62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3616E362C47F1A1E8E8148EF3C7230D4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5DA9B07CCE9BA6CA9B8448EF3C72AC62" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3616E362C47F1A1E8E8148EF3C7230D4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3616E362C47F1A1E8E8148EF3C7230D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5DA9B07CCE9BA6CA9B8448EF3C72AC62" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3616E362C47F1A1E8E8148EF3C7230D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_4FDE05A4F9E02CBF8F8348EF3C736A43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3616E362C47F1A1E8E8148EF3C7230D4" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_4FDE05A4F9E02CBF8F8348EF3C736A43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_D9B075179052E16D9CC548EF3C73AC9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A7B5F00662800B03CA2B48EF3C7321C9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_D9B075179052E16D9CC548EF3C73AC9B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_2719AA8F36A6B4EF272948F019069A95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:to="loc_us-gaap_StatementGeographicalAxis_2719AA8F36A6B4EF272948F019069A95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_66D0FF0F6920E636EC3448F01906C295_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_2719AA8F36A6B4EF272948F019069A95" xlink:to="loc_us-gaap_SegmentGeographicalDomain_66D0FF0F6920E636EC3448F01906C295_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_66D0FF0F6920E636EC3448F01906C295" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_2719AA8F36A6B4EF272948F019069A95" xlink:to="loc_us-gaap_SegmentGeographicalDomain_66D0FF0F6920E636EC3448F01906C295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IT" xlink:label="loc_country_IT_2A116609C77783D758FB48F0190750C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_66D0FF0F6920E636EC3448F01906C295" xlink:to="loc_country_IT_2A116609C77783D758FB48F0190750C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_5CA8E2AE6571AA64740348F01907CC94" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:to="loc_us-gaap_ProductOrServiceAxis_5CA8E2AE6571AA64740348F01907CC94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_F911240C383B1179532A48F01907357B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_5CA8E2AE6571AA64740348F01907CC94" xlink:to="loc_us-gaap_ProductsAndServicesDomain_F911240C383B1179532A48F01907357B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_F911240C383B1179532A48F01907357B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_5CA8E2AE6571AA64740348F01907CC94" xlink:to="loc_us-gaap_ProductsAndServicesDomain_F911240C383B1179532A48F01907357B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_EA0025097E13D2418EFA48F019070DDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F911240C383B1179532A48F01907357B" xlink:to="loc_biib_TecfideraMember_EA0025097E13D2418EFA48F019070DDC" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:to="loc_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:to="loc_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:to="loc_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:to="loc_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:to="loc_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_845237C7EB740E9F6DA648F019071FCE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_845237C7EB740E9F6DA648F019071FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BAFCCE83A15847FE239648F01907EDB9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_845237C7EB740E9F6DA648F019071FCE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BAFCCE83A15847FE239648F01907EDB9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BAFCCE83A15847FE239648F01907EDB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_845237C7EB740E9F6DA648F019071FCE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BAFCCE83A15847FE239648F01907EDB9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_85C2F53FCECAE284452D48F01907B39E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BAFCCE83A15847FE239648F01907EDB9" xlink:to="loc_biib_FumapharmAgMember_85C2F53FCECAE284452D48F01907B39E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_F4C89F4F706C859846E748F019072726" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BAFCCE83A15847FE239648F01907EDB9" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_F4C89F4F706C859846E748F019072726" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_AF65584E88349E6F608F48F01908BE7C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:to="loc_biib_FacilityLocationAxis_AF65584E88349E6F608F48F01908BE7C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_E261ECEA2FAE8BF4411B48F019089A4A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_AF65584E88349E6F608F48F01908BE7C" xlink:to="loc_biib_FacilityLocationDomain_E261ECEA2FAE8BF4411B48F019089A4A_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_E261ECEA2FAE8BF4411B48F019089A4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_AF65584E88349E6F608F48F01908BE7C" xlink:to="loc_biib_FacilityLocationDomain_E261ECEA2FAE8BF4411B48F019089A4A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_37CE5E27F457FDAFCAD648F01908D8CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_E261ECEA2FAE8BF4411B48F019089A4A" xlink:to="loc_biib_SolothurnMember_37CE5E27F457FDAFCAD648F01908D8CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_13E70FEEBBBED3CD91FB48F01908E8B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_13E70FEEBBBED3CD91FB48F01908E8B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_D1FCC1613AA993A4AF0348F019088D5B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_D1FCC1613AA993A4AF0348F019088D5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_A9A3D366FBDA8E2E50E548F0190864BA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_LitigationSettlementExpense_A9A3D366FBDA8E2E50E548F0190864BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_83D5202837041A3A4DF848F019088C28" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_83D5202837041A3A4DF848F019088C28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_BAA4F9E6774537B6A82048F01908E7AE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_BAA4F9E6774537B6A82048F01908E7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3A0876FAD0919C3C8D3448F019089A6A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3A0876FAD0919C3C8D3448F019089A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_418A7E697A805ABF9BE548F019088E50" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_PrepaidTaxes_418A7E697A805ABF9BE548F019088E50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_8203E6EF15ABD2655C6C48F01909BE2B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_8203E6EF15ABD2655C6C48F01909BE2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_16F3AF488535E5C7D9C748F01908211C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_16F3AF488535E5C7D9C748F01908211C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_E091D4A1A0CEA5D8361248F01908F8D2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_E091D4A1A0CEA5D8361248F01908F8D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_LossContingencyAdjustmentRelatedToClaimAmountPercent" xlink:label="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_5938C57DB201940A356E48F019094E48" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_5938C57DB201940A356E48F019094E48" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ED1F6E4AEDBCE6DD27B42D5E3B20867" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ED1F6E4AEDBCE6DD27B42D5E3B20867" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885E779F9F4856CB180C42D5E3B235B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ED1F6E4AEDBCE6DD27B42D5E3B20867" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885E779F9F4856CB180C42D5E3B235B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08E99D3465A9EFD085FD42D5E3B20CD5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885E779F9F4856CB180C42D5E3B235B3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08E99D3465A9EFD085FD42D5E3B20CD5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08E99D3465A9EFD085FD42D5E3B20CD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885E779F9F4856CB180C42D5E3B235B3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08E99D3465A9EFD085FD42D5E3B20CD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_35242FBA3A77FDD7A65442D5E3B77372" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08E99D3465A9EFD085FD42D5E3B20CD5" xlink:to="loc_us-gaap_BuildingMember_35242FBA3A77FDD7A65442D5E3B77372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_70C1B2C92BBC304F090942D5E3B7969A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08E99D3465A9EFD085FD42D5E3B20CD5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_70C1B2C92BBC304F090942D5E3B7969A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_33004A8C4FEF66F3F8E442D5E3B751A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08E99D3465A9EFD085FD42D5E3B20CD5" xlink:to="loc_us-gaap_LandMember_33004A8C4FEF66F3F8E442D5E3B751A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A9230B6397F58158D7FC42D5E3B80A8D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ED1F6E4AEDBCE6DD27B42D5E3B20867" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A9230B6397F58158D7FC42D5E3B80A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10CD67796CB4FCF95B1D42D5E3B85EC9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A9230B6397F58158D7FC42D5E3B80A8D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10CD67796CB4FCF95B1D42D5E3B85EC9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10CD67796CB4FCF95B1D42D5E3B85EC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A9230B6397F58158D7FC42D5E3B80A8D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10CD67796CB4FCF95B1D42D5E3B85EC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_D143F9CECCF3A3E5B41942D5E3B84919" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10CD67796CB4FCF95B1D42D5E3B85EC9" xlink:to="loc_biib_EisaiMember_D143F9CECCF3A3E5B41942D5E3B84919" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_3237EC3EE4E505377F6742D5E3B8EB11" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ED1F6E4AEDBCE6DD27B42D5E3B20867" xlink:to="loc_biib_FacilityLocationAxis_3237EC3EE4E505377F6742D5E3B8EB11" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_81525034631A6CF57BC142D5E3B80F1E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_3237EC3EE4E505377F6742D5E3B8EB11" xlink:to="loc_biib_FacilityLocationDomain_81525034631A6CF57BC142D5E3B80F1E_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_81525034631A6CF57BC142D5E3B80F1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_3237EC3EE4E505377F6742D5E3B8EB11" xlink:to="loc_biib_FacilityLocationDomain_81525034631A6CF57BC142D5E3B80F1E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_C08FAD46D2BDDB1950E242D5E3B85E1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_81525034631A6CF57BC142D5E3B80F1E" xlink:to="loc_biib_SolothurnMember_C08FAD46D2BDDB1950E242D5E3B85E1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_34729EAC4F1F26DC243242D5E3B83E6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_Depreciation_34729EAC4F1F26DC243242D5E3B83E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_ABD298651955B627422442D5E3B82C37" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_InterestCostsCapitalized_ABD298651955B627422442D5E3B82C37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_DF496846F7A397164F1A42D5E3B86490" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_DF496846F7A397164F1A42D5E3B86490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_0AD007E7D80E925CF9D242D5E3B85F57" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_ConstructionInProgressGross_0AD007E7D80E925CF9D242D5E3B85F57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D3E1F10B7995992B52A242D5E3B8171A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D3E1F10B7995992B52A242D5E3B8171A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TermOfLease" xlink:label="loc_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_69E8553A3B74AE90929442D5E3B80C62" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_CapitalLeaseObligations_69E8553A3B74AE90929442D5E3B80C62" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20171231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ED927F739F99741762574DC49D27C1CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ED927F739F99741762574DC49D27C1CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BC26541B2A07223C7A464DC49D270421_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ED927F739F99741762574DC49D27C1CE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BC26541B2A07223C7A464DC49D270421_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BC26541B2A07223C7A464DC49D270421" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ED927F739F99741762574DC49D27C1CE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BC26541B2A07223C7A464DC49D270421" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_7904BE817C38C681AEC34DC49D27AEBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BC26541B2A07223C7A464DC49D270421" xlink:to="loc_biib_RemedyPharmaceuticalMember_7904BE817C38C681AEC34DC49D27AEBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_E6004D6520D610DDE0A74DC49D2767AD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:to="loc_us-gaap_ProductOrServiceAxis_E6004D6520D610DDE0A74DC49D2767AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_656F6D8C444BE2F61A8A4DC49D27972A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_E6004D6520D610DDE0A74DC49D2767AD" xlink:to="loc_us-gaap_ProductsAndServicesDomain_656F6D8C444BE2F61A8A4DC49D27972A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_656F6D8C444BE2F61A8A4DC49D27972A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_E6004D6520D610DDE0A74DC49D2767AD" xlink:to="loc_us-gaap_ProductsAndServicesDomain_656F6D8C444BE2F61A8A4DC49D27972A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_656F6D8C444BE2F61A8A4DC49D27972A" xlink:to="loc_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_656F6D8C444BE2F61A8A4DC49D27972A" xlink:to="loc_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:to="loc_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:to="loc_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:to="loc_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281" xlink:to="loc_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31" xlink:to="loc_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:to="loc_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:to="loc_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:to="loc_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:to="loc_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_22ADA7861379F65C7EDF4DC49D29703D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:to="loc_biib_EisaiMember_22ADA7861379F65C7EDF4DC49D29703D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_B6650F5CBA1F7B16BBB84DC49D299D25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_B6650F5CBA1F7B16BBB84DC49D299D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C09C1623F1D6BAE3FBD14DC49D29B113" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C09C1623F1D6BAE3FBD14DC49D29B113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_B65FD8CD89AEC0CB2C5D4DC49D29D74E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_B65FD8CD89AEC0CB2C5D4DC49D29D74E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A1B7462C4FC83A970C644DC49D2981A8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A1B7462C4FC83A970C644DC49D2981A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_496343733AD62C5D396A4DC49D29828F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_496343733AD62C5D396A4DC49D29828F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_68D325E482FE673B88964DC49D298774" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_68D325E482FE673B88964DC49D298774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_17ABFC2AD73E8EDC240D4DC49D2ABC74" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_17ABFC2AD73E8EDC240D4DC49D2ABC74" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_61ADA1ED6750A50D323D4DC49D30CE70" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_LitigationSettlementExpense_61ADA1ED6750A50D323D4DC49D30CE70" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E759547C9E69463C4CB1434A358F7F98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E759547C9E69463C4CB1434A358F7F98" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_6CA476B282D5F915F648434A358F174A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E759547C9E69463C4CB1434A358F7F98" xlink:to="loc_us-gaap_RestructuringPlanAxis_6CA476B282D5F915F648434A358F174A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_8C06AEE25C02F7C93786434A358F5487_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_6CA476B282D5F915F648434A358F174A" xlink:to="loc_us-gaap_RestructuringPlanDomain_8C06AEE25C02F7C93786434A358F5487_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_8C06AEE25C02F7C93786434A358F5487" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_6CA476B282D5F915F648434A358F174A" xlink:to="loc_us-gaap_RestructuringPlanDomain_8C06AEE25C02F7C93786434A358F5487" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_B8E4458F72693E0442EB434A358FAD29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_8C06AEE25C02F7C93786434A358F5487" xlink:to="loc_biib_A2015RestructuringChargesMember_B8E4458F72693E0442EB434A358FAD29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E759547C9E69463C4CB1434A358F7F98" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_E46A588359D0B62207D7434A358F5ACF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:to="loc_us-gaap_EmployeeSeveranceMember_E46A588359D0B62207D7434A358F5ACF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_3D1EBB9F47F450D2A781434A358FCD4B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:to="loc_us-gaap_ContractTerminationMember_3D1EBB9F47F450D2A781434A358FCD4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_0F00E3C07705D7BE657B434A358FC9A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:to="loc_us-gaap_RestructuringReserve_0F00E3C07705D7BE657B434A358FC9A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_D9106C013357ECFB229E434A358FDE81" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:to="loc_us-gaap_RestructuringCosts_D9106C013357ECFB229E434A358FDE81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_B8032CD75BD7C1DA8D79434A358FE67F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:to="loc_us-gaap_PaymentsForRestructuring_B8032CD75BD7C1DA8D79434A358FE67F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_75292AF76B524E4D40C4434A358F821E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_75292AF76B524E4D40C4434A358F821E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B5790C8120D8DC8744BC42D5E53EF585" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B5790C8120D8DC8744BC42D5E53EF585" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4A50429A176D75C2CD6E42D5E53E8F5E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B5790C8120D8DC8744BC42D5E53EF585" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4A50429A176D75C2CD6E42D5E53E8F5E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4A50429A176D75C2CD6E42D5E53E8F5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B5790C8120D8DC8744BC42D5E53EF585" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4A50429A176D75C2CD6E42D5E53E8F5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB3953D56F3EF742501842D5E53E9184" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4A50429A176D75C2CD6E42D5E53E8F5E" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB3953D56F3EF742501842D5E53E9184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_2B8CBB8C759832B5FFDE42D5E53E9182" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4A50429A176D75C2CD6E42D5E53E8F5E" xlink:to="loc_us-gaap_RestructuringChargesMember_2B8CBB8C759832B5FFDE42D5E53E9182" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_8680C5416762A025668F42D5E53EC1BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:to="loc_biib_FacilityLocationAxis_8680C5416762A025668F42D5E53EC1BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_C49A7DE670E0BFAA6C6C42D5E53FAB44_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_8680C5416762A025668F42D5E53EC1BC" xlink:to="loc_biib_FacilityLocationDomain_C49A7DE670E0BFAA6C6C42D5E53FAB44_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_C49A7DE670E0BFAA6C6C42D5E53FAB44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_8680C5416762A025668F42D5E53EC1BC" xlink:to="loc_biib_FacilityLocationDomain_C49A7DE670E0BFAA6C6C42D5E53FAB44" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_10D0FF6AD02F07A5D0F542D5E53F1ECC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_C49A7DE670E0BFAA6C6C42D5E53FAB44" xlink:to="loc_biib_CambridgeMAMember_10D0FF6AD02F07A5D0F542D5E53F1ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:to="loc_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95" xlink:to="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95" xlink:to="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2017RestructuringChargesMember" xlink:label="loc_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:to="loc_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2016RestructuringChargesMember" xlink:label="loc_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:to="loc_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:to="loc_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="loc_us-gaap_OtherNonrecurringExpense_B48131A7EA9A84A032464340BF15C58E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_us-gaap_OtherNonrecurringExpense_B48131A7EA9A84A032464340BF15C58E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ResourcesRedirectedthroughRestructuringProgram" xlink:label="loc_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_8F8FB149203EEDDE0D6C42D5E53F648F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_us-gaap_RestructuringCharges_8F8FB149203EEDDE0D6C42D5E53F648F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_0F1A576082B2C2924F7A42D5E540B004" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_0F1A576082B2C2924F7A42D5E540B004" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" xlink:label="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_BFEB21C5484BA746811742D5E53FF37A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_BFEB21C5484BA746811742D5E53FF37A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_0E3A77DDAEABAA2D721442D5E53FA951" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_0E3A77DDAEABAA2D721442D5E53FA951" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenueReserves" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_1F1FB62DB5BEE3DDDFA6434939532451" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_92D1576807338D4BAAC443493952C1AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_1F1FB62DB5BEE3DDDFA6434939532451" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_92D1576807338D4BAAC443493952C1AE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_E5A83DE80D8BE25380F3434939530357" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_92D1576807338D4BAAC443493952C1AE" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_E5A83DE80D8BE25380F3434939530357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_E5A83DE80D8BE25380F3434939530357" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_E5A83DE80D8BE25380F3434939530357" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_E16DFC482D1D78C9E32143493953787B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_E16DFC482D1D78C9E32143493953787B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_781CCD22D36CE1B6B332434939535753" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74" xlink:to="loc_biib_ContractualAdjustmentsMember_781CCD22D36CE1B6B332434939535753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_0E3094D9355DF7A8600743493953B23C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_0E3094D9355DF7A8600743493953B23C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_1F1FB62DB5BEE3DDDFA6434939532451" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1D4171D49335C2A9337143493953720F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1D4171D49335C2A9337143493953720F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_B239BCC4115F8A446AE6434939532DAD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_B239BCC4115F8A446AE6434939532DAD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_86FF89C37BE69DF0A76043493953BAD1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_86FF89C37BE69DF0A76043493953BAD1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_B0C685E399BF63F8F76243493953AD25" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_B0C685E399BF63F8F76243493953AD25" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_64F7733DCDDCF6BC0B8943493953882C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_64F7733DCDDCF6BC0B8943493953882C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BAE47277BBE589B2E28242D5E5308669" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF" xlink:to="loc_us-gaap_StatementTable_BAE47277BBE589B2E28242D5E5308669" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_BAE47277BBE589B2E28242D5E5308669" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_661C19DBB39AF736E19742D5E5311A1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:to="loc_us-gaap_AccountsReceivableMember_661C19DBB39AF736E19742D5E5311A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_A6B4545BCA536413CDB242D5E5314D5F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_A6B4545BCA536413CDB242D5E5314D5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8A2C4C440D3C5D461A3242D5E5313352" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8A2C4C440D3C5D461A3242D5E5313352" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenueReservesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_32DB2D018DD7C85B5D694C78A5DBB614" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_42729684F05B4A88BA624C78A5D9E718" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_32DB2D018DD7C85B5D694C78A5DBB614" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_42729684F05B4A88BA624C78A5D9E718" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_AC07EBBAD6BF9D7221AD4C78A5D913D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_42729684F05B4A88BA624C78A5D9E718" xlink:to="loc_us-gaap_ProductOrServiceAxis_AC07EBBAD6BF9D7221AD4C78A5D913D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_AC07EBBAD6BF9D7221AD4C78A5D913D2" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_AC07EBBAD6BF9D7221AD4C78A5D913D2" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_8E487505DAB410CF00DD4C78A5D93700" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_TecfideraMember_8E487505DAB410CF00DD4C78A5D93700" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_39F0D0689EF71F0E44D44C78A5DA6079" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_AVONEXMember_39F0D0689EF71F0E44D44C78A5DA6079" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PLEGRIDYMember" xlink:label="loc_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TysabriMember" xlink:label="loc_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_EA372EE3527FDD5AE7CD4C78A5DA57B0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_ZINBRYTAMember_EA372EE3527FDD5AE7CD4C78A5DA57B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_88D5FD1E7928533C146B4C78A5DBDE45" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_SPINRAZAMember_88D5FD1E7928533C146B4C78A5DBDE45" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ALPROLIXProductMember" xlink:label="loc_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_42729684F05B4A88BA624C78A5D9E718" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95" xlink:to="loc_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95" xlink:to="loc_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_3E84DB05BB7F96F662DA4C78A5DBE2C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:to="loc_country_US_3E84DB05BB7F96F662DA4C78A5DBE2C9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RestOfWorldMember" xlink:label="loc_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:to="loc_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetAbstract" xlink:label="loc_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_32DB2D018DD7C85B5D694C78A5DBB614" xlink:to="loc_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_41AA60589FE5922969494C78A5DB58D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_41AA60589FE5922969494C78A5DB58D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_80D3EC4D1E25AA28D3F84C78A5BEBAD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4" xlink:to="loc_us-gaap_StatementGeographicalAxis_80D3EC4D1E25AA28D3F84C78A5BEBAD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_80D3EC4D1E25AA28D3F84C78A5BEBAD5" xlink:to="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_80D3EC4D1E25AA28D3F84C78A5BEBAD5" xlink:to="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_7B8102F90EE619E1FD254C78A5BECAE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8" xlink:to="loc_country_US_7B8102F90EE619E1FD254C78A5BECAE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_BB896068DA76F797B05C4C78A5BECA6D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8" xlink:to="loc_us-gaap_EuropeMember_BB896068DA76F797B05C4C78A5BECA6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AsiaMember" xlink:label="loc_us-gaap_AsiaMember_443039CDA5D7C091E4D64C78A5BE82FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8" xlink:to="loc_us-gaap_AsiaMember_443039CDA5D7C091E4D64C78A5BE82FF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8" xlink:to="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_38450051D7DE8D4E71234C78A5C499FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_38450051D7DE8D4E71234C78A5C499FA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_D104574737097A14E9DD4C78A5C4E027" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_D104574737097A14E9DD4C78A5C4E027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_ADC6272E61062CAA487A4C78A5C45FD0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:to="loc_us-gaap_OtherSalesRevenueNet_ADC6272E61062CAA487A4C78A5C45FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_71888AEFB0EDB3ABB8F84C78A5C454A0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:to="loc_us-gaap_NoncurrentAssets_71888AEFB0EDB3ABB8F84C78A5C454A0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_7F787047C5A263F754294C78A5A9AB98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:to="loc_us-gaap_StatementGeographicalAxis_7F787047C5A263F754294C78A5A9AB98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_20189E80D86F202DBA824C78A5A9F23B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_7F787047C5A263F754294C78A5A9AB98" xlink:to="loc_us-gaap_SegmentGeographicalDomain_20189E80D86F202DBA824C78A5A9F23B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_20189E80D86F202DBA824C78A5A9F23B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_7F787047C5A263F754294C78A5A9AB98" xlink:to="loc_us-gaap_SegmentGeographicalDomain_20189E80D86F202DBA824C78A5A9F23B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_20189E80D86F202DBA824C78A5A9F23B" xlink:to="loc_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DK" xlink:label="loc_country_DK_278C9BCB8D834ABD39834C78A5A9B5B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_20189E80D86F202DBA824C78A5A9F23B" xlink:to="loc_country_DK_278C9BCB8D834ABD39834C78A5A9B5B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:to="loc_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:to="loc_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:to="loc_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:to="loc_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:to="loc_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:to="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_0AA697DCC99C6846F2F54C78A5AAE807" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:to="loc_us-gaap_NoncurrentAssets_0AA697DCC99C6846F2F54C78A5AAE807" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E72D5470EA8F95E009374D82DD0B98A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E72D5470EA8F95E009374D82DD0B98A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2BBB3008D591164600934D82DD0B24FD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2BBB3008D591164600934D82DD0B24FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_CD30800541A694E8F3884D82DD0B33E3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:to="loc_us-gaap_RestructuringChargesMember_CD30800541A694E8F3884D82DD0B33E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_11558621F29E1CDB11264D82DD0BFEA9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:to="loc_us-gaap_ParentMember_11558621F29E1CDB11264D82DD0BFEA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_B3473B0B42962EA867734D82DD0BEF93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_B3473B0B42962EA867734D82DD0BEF93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4964900AA64C422F1FE04D82DD0CB945" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4964900AA64C422F1FE04D82DD0CB945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E5288F555BC9539F88274D82DD0CDBA6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E5288F555BC9539F88274D82DD0CDBA6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_86B6D5DAD3A7277CBBE84D82DD0C08F2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_86B6D5DAD3A7277CBBE84D82DD0C08F2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_709B59E68AFAAC52D85A4D82DD0665CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ECFD38039AD8FF7C30E4D82DD067B76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_709B59E68AFAAC52D85A4D82DD0665CC" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ECFD38039AD8FF7C30E4D82DD067B76" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_FB81CB7D02384A263BB64D82DD06BBD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ECFD38039AD8FF7C30E4D82DD067B76" xlink:to="loc_us-gaap_PlanNameAxis_FB81CB7D02384A263BB64D82DD06BBD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_FB81CB7D02384A263BB64D82DD06BBD9" xlink:to="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_FB81CB7D02384A263BB64D82DD06BBD9" xlink:to="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_7208913081EFCF4F987E4D82DD06659D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:to="loc_biib_MarketStockUnitsMember_7208913081EFCF4F987E4D82DD06659D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_811D9F0F8212D718CDDE4D82DD06731A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_811D9F0F8212D718CDDE4D82DD06731A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:to="loc_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PerformanceUnitsMember" xlink:label="loc_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:to="loc_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_709B59E68AFAAC52D85A4D82DD0665CC" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E80A4A019B70A84E80A04D82DD0785B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_E80A4A019B70A84E80A04D82DD0785B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FFFEE168A607E8F1DBE44D82DD07840F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FFFEE168A607E8F1DBE44D82DD07840F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_794513B36421F9D1E6AE4D82DD07D761" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_794513B36421F9D1E6AE4D82DD07D761" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3B3DEC1FB5785859AC014D82DD076C44" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3B3DEC1FB5785859AC014D82DD076C44" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AC9353661CDB0D007294793EE159269" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5794E8CBEB75B7D275744793EE13111C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AC9353661CDB0D007294793EE159269" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5794E8CBEB75B7D275744793EE13111C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_93E6829A5C74756FA4864793EE133DC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5794E8CBEB75B7D275744793EE13111C" xlink:to="loc_us-gaap_AwardTypeAxis_93E6829A5C74756FA4864793EE133DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72EABA7EDF8D30A36F774793EE148E54_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_93E6829A5C74756FA4864793EE133DC7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72EABA7EDF8D30A36F774793EE148E54_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72EABA7EDF8D30A36F774793EE148E54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_93E6829A5C74756FA4864793EE133DC7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72EABA7EDF8D30A36F774793EE148E54" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_DD59DA3DBD3C6425D7DC4793EE1597A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72EABA7EDF8D30A36F774793EE148E54" xlink:to="loc_biib_MarketStockUnitsMember_DD59DA3DBD3C6425D7DC4793EE1597A9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AC9353661CDB0D007294793EE159269" xlink:to="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03688ACF5080132596FF4793EE154D2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03688ACF5080132596FF4793EE154D2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E8CF9AE09F70543DDBFE4793EE159F82" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E8CF9AE09F70543DDBFE4793EE159F82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D7A1902A9D498BBA522D4793EE155E65" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D7A1902A9D498BBA522D4793EE155E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_47D8D3C0AE91B271E2994793EE150B73" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_47D8D3C0AE91B271E2994793EE150B73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D898B2765507B069F1DF4793EE150A40" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D898B2765507B069F1DF4793EE150A40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C2971B52E7174B81A5BC4793EE1529DA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C2971B52E7174B81A5BC4793EE1529DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3315B6F6F9547F66AEA84793EE16FF01" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3315B6F6F9547F66AEA84793EE16FF01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53F438C709FC7DF72A984793EE16EFF9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53F438C709FC7DF72A984793EE16EFF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_401061E7BDF5D4298AAF4793EE161BE6" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_401061E7BDF5D4298AAF4793EE161BE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_D87CD41446959FC27F7E4793EE16D2C1" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_D87CD41446959FC27F7E4793EE16D2C1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:to="loc_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B" xlink:to="loc_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:to="loc_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A" xlink:to="loc_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A" xlink:to="loc_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9CB5CB890EF4B5F1334329780DA8A7FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:to="loc_us-gaap_MinimumMember_9CB5CB890EF4B5F1334329780DA8A7FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_B7871FF002EEEF11FAFF29780DA83A79" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:to="loc_us-gaap_MaximumMember_B7871FF002EEEF11FAFF29780DA83A79" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037" xlink:to="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7FABABB3139609C1E2C429780DA9BFA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7FABABB3139609C1E2C429780DA9BFA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9811F2328D09E7D75F2329780DA9A52A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9811F2328D09E7D75F2329780DA9A52A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1C507AB96A4B2E105D6629780DA9A901" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1C507AB96A4B2E105D6629780DA9A901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_809BE82AC34C0984878E29780DA9ED89" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_809BE82AC34C0984878E29780DA9ED89" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ACA38214A4B7DBD095E029780DA933D9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ACA38214A4B7DBD095E029780DA933D9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91ED87F53D031972FBB5485EEBBCE059" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28F3456ABBA92E7FC4FE485EEBBCDC6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91ED87F53D031972FBB5485EEBBCE059" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28F3456ABBA92E7FC4FE485EEBBCDC6B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_02F593A9A1BBBBF1DCF9485EEBBCCD58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28F3456ABBA92E7FC4FE485EEBBCDC6B" xlink:to="loc_us-gaap_AwardTypeAxis_02F593A9A1BBBBF1DCF9485EEBBCCD58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F4C90B2A5067DEEF79B485EEBBCF30D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_02F593A9A1BBBBF1DCF9485EEBBCCD58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F4C90B2A5067DEEF79B485EEBBCF30D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F4C90B2A5067DEEF79B485EEBBCF30D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_02F593A9A1BBBBF1DCF9485EEBBCCD58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F4C90B2A5067DEEF79B485EEBBCF30D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_7AFE30FB4C4A4239084B485EEBBC2B21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F4C90B2A5067DEEF79B485EEBBCF30D" xlink:to="loc_biib_CashSettledPerformanceSharesMember_7AFE30FB4C4A4239084B485EEBBC2B21" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91ED87F53D031972FBB5485EEBBCE059" xlink:to="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0B2C4341C01DA7D14634485EEBBCDE0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0B2C4341C01DA7D14634485EEBBCDE0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D265FCE685124A726180485EEBBC8F13" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D265FCE685124A726180485EEBBC8F13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99876EFF774F7EF9B8D7485EEBBD3BDE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99876EFF774F7EF9B8D7485EEBBD3BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F325735A7DD316AE8092485EEBBD785D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F325735A7DD316AE8092485EEBBD785D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A5311ADE740074E0D039485EEBBD5CAF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A5311ADE740074E0D039485EEBBD5CAF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AA7A28E3DA8F4A5F886485EE9D67336" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15E4ED3812E072E2A9D9485EE9D58C9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AA7A28E3DA8F4A5F886485EE9D67336" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15E4ED3812E072E2A9D9485EE9D58C9B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_07CA295A9E20C4BF1638485EE9D63217" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15E4ED3812E072E2A9D9485EE9D58C9B" xlink:to="loc_us-gaap_AwardTypeAxis_07CA295A9E20C4BF1638485EE9D63217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B36A8C8481B435A112D0485EE9D693BD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_07CA295A9E20C4BF1638485EE9D63217" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B36A8C8481B435A112D0485EE9D693BD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B36A8C8481B435A112D0485EE9D693BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_07CA295A9E20C4BF1638485EE9D63217" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B36A8C8481B435A112D0485EE9D693BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B36A8C8481B435A112D0485EE9D693BD" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AA7A28E3DA8F4A5F886485EE9D67336" xlink:to="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1B9503638ACDB04AE193485EE9D627A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1B9503638ACDB04AE193485EE9D627A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_35CED56AA2A30EAA7B0F485EE9D6824F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_35CED56AA2A30EAA7B0F485EE9D6824F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_2F1FCD1A2C008E8F9C3E485EE9D602BD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_2F1FCD1A2C008E8F9C3E485EE9D602BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_80171D83021C33D8705E485EE9D60C84" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_80171D83021C33D8705E485EE9D60C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D8D6B6FCBCCA5FDE18E1485EE9D7711C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D8D6B6FCBCCA5FDE18E1485EE9D7711C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5D98314D694F5B38845E485EE9D7BBE8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5D98314D694F5B38845E485EE9D7BBE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_89690AA2B79C574094D7485EE9D711C4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_89690AA2B79C574094D7485EE9D711C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_F193117B8DCEB980947B485EE9D77BF1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_F193117B8DCEB980947B485EE9D77BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_092ABDD910D8A5623FCF485EE9D79CA6" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_092ABDD910D8A5623FCF485EE9D79CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60497F291F23EC5ADC57485EE9D72D1D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60497F291F23EC5ADC57485EE9D72D1D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299" xlink:to="loc_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B" xlink:to="loc_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B" xlink:to="loc_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:to="loc_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:to="loc_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69F8C6C12242950F83B532F209C509B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69F8C6C12242950F83B532F209C509B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2867DA325E3169120B2132F209C5565B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2867DA325E3169120B2132F209C5565B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D1AC1CE66B0E58E49E52485EE72E19CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:to="loc_us-gaap_PlanNameAxis_D1AC1CE66B0E58E49E52485EE72E19CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1E9AA42D955713198EA0485EE72EE528_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_D1AC1CE66B0E58E49E52485EE72E19CF" xlink:to="loc_us-gaap_PlanNameDomain_1E9AA42D955713198EA0485EE72EE528_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1E9AA42D955713198EA0485EE72EE528" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_D1AC1CE66B0E58E49E52485EE72E19CF" xlink:to="loc_us-gaap_PlanNameDomain_1E9AA42D955713198EA0485EE72EE528" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1E9AA42D955713198EA0485EE72EE528" xlink:to="loc_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2017OmnibusEquityPlanMember" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1E9AA42D955713198EA0485EE72EE528" xlink:to="loc_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AttainmentOfPerformanceCriteriain2013Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1E9AA42D955713198EA0485EE72EE528" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:to="loc_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367" xlink:to="loc_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367" xlink:to="loc_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_767EFCFBB015479ECDD5485EE72F27E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_767EFCFBB015479ECDD5485EE72F27E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:to="loc_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_1D31A907E07D936CE83D485EE72F3166" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6" xlink:to="loc_us-gaap_DirectorMember_1D31A907E07D936CE83D485EE72F3166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_BF38D281F602A344D86B485EE72FCDEF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:to="loc_us-gaap_AwardTypeAxis_BF38D281F602A344D86B485EE72FCDEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_BF38D281F602A344D86B485EE72FCDEF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_BF38D281F602A344D86B485EE72FCDEF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_03F7981F9B68DC085199485EE72F2871" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8" xlink:to="loc_biib_MarketStockUnitsMember_03F7981F9B68DC085199485EE72F2871" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_CF192B02764076CFDC07485EE7301DDF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8" xlink:to="loc_biib_CashSettledPerformanceSharesMember_CF192B02764076CFDC07485EE7301DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_18882D54C559D600D450485EE7308CEB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8" xlink:to="loc_us-gaap_PerformanceSharesMember_18882D54C559D600D450485EE7308CEB" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_EA0C4993AD236C79A271485EE73045DB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_EA0C4993AD236C79A271485EE73045DB" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0E7851DFCC55FBD54855485EE7305F35" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0E7851DFCC55FBD54855485EE7305F35" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04F69A4ED86493E52AAE485EE7302EA8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04F69A4ED86493E52AAE485EE7302EA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6405FA35986F70C8A7CD485EE7306FE7" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6405FA35986F70C8A7CD485EE7306FE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_B7C6F6C9A5F7BDA418C6485EE73049DE" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_B7C6F6C9A5F7BDA418C6485EE73049DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" xlink:label="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4C47C29E77C2C730479E485EE7303504" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4C47C29E77C2C730479E485EE7303504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_51743EBC82AECC25C569485EE7306942" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_51743EBC82AECC25C569485EE7306942" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA6E1B1C82A5F5F9218E485EEBF293E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA6E1B1C82A5F5F9218E485EEBF293E0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F911C432C13AA2680C95485EEBF241E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA6E1B1C82A5F5F9218E485EEBF293E0" xlink:to="loc_us-gaap_AwardTypeAxis_F911C432C13AA2680C95485EEBF241E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D0EF54A6248E3D575DEE485EEBF26FC0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_F911C432C13AA2680C95485EEBF241E8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D0EF54A6248E3D575DEE485EEBF26FC0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D0EF54A6248E3D575DEE485EEBF26FC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_F911C432C13AA2680C95485EEBF241E8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D0EF54A6248E3D575DEE485EEBF26FC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_5D039565B50EBCD902A0485EEBF24FC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D0EF54A6248E3D575DEE485EEBF26FC0" xlink:to="loc_us-gaap_PerformanceSharesMember_5D039565B50EBCD902A0485EEBF24FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8833930F77079F31B974485EEBF3EBDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8833930F77079F31B974485EEBF3EBDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_AA037C619B9C4C02A5E9485EEBF288B7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_AA037C619B9C4C02A5E9485EEBF288B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_292D7B5BA6E6AE4B75A2485EEBF3A10E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_292D7B5BA6E6AE4B75A2485EEBF3A10E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6CFFF11FDDEFACC1A196485EEBF33E91" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6CFFF11FDDEFACC1A196485EEBF33E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C85115F01BB6802C49F6485EEBF31A33" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C85115F01BB6802C49F6485EEBF31A33" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:to="loc_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C4F77114B4EDE2A6493C4C78A533BA75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C4F77114B4EDE2A6493C4C78A533BA75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CE6961151A13635402484C78A533E966_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C4F77114B4EDE2A6493C4C78A533BA75" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CE6961151A13635402484C78A533E966_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CE6961151A13635402484C78A533E966" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C4F77114B4EDE2A6493C4C78A533BA75" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CE6961151A13635402484C78A533E966" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CE6961151A13635402484C78A533E966" xlink:to="loc_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_FE37E008E7C0A9A714954CC112F74FFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8" xlink:to="loc_us-gaap_SubsequentEventMember_FE37E008E7C0A9A714954CC112F74FFB" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_8E7A7044AEA03274A0914C78A534710C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_8E7A7044AEA03274A0914C78A534710C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_600425C6C6F4A7880E1F4311FDB94E4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_600425C6C6F4A7880E1F4311FDB94E4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5D21E9A6E37E65D9F8504311FDC37197_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_600425C6C6F4A7880E1F4311FDB94E4F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5D21E9A6E37E65D9F8504311FDC37197_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5D21E9A6E37E65D9F8504311FDC37197" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_600425C6C6F4A7880E1F4311FDB94E4F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5D21E9A6E37E65D9F8504311FDC37197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_5C3B27D31D83F88BFAE74311FDE40FC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5D21E9A6E37E65D9F8504311FDC37197" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_5C3B27D31D83F88BFAE74311FDE40FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_328DE179D70B59C23B48431225E58DF5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5D21E9A6E37E65D9F8504311FDC37197" xlink:to="loc_us-gaap_RetainedEarningsMember_328DE179D70B59C23B48431225E58DF5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_D42F19AE0ACD9BCB146942D5E56C0653" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:to="loc_biib_MajorDistributorAxis_D42F19AE0ACD9BCB146942D5E56C0653" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_915178A7E8932B32EC8642D5E56CBDC9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_MajorDistributorAxis_D42F19AE0ACD9BCB146942D5E56C0653" xlink:to="loc_biib_MajorDistributorDomain_915178A7E8932B32EC8642D5E56CBDC9_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_915178A7E8932B32EC8642D5E56CBDC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_MajorDistributorAxis_D42F19AE0ACD9BCB146942D5E56C0653" xlink:to="loc_biib_MajorDistributorDomain_915178A7E8932B32EC8642D5E56CBDC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_D96260591B6DB903947742D5E56CFF5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_915178A7E8932B32EC8642D5E56CBDC9" xlink:to="loc_biib_DistributorOneMember_D96260591B6DB903947742D5E56CFF5A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_9BA299D0F94335D5DF6E42D5E56C457B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_915178A7E8932B32EC8642D5E56CBDC9" xlink:to="loc_biib_DistributorTwoMember_9BA299D0F94335D5DF6E42D5E56C457B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_C1772E72FB68B3D87BE142D5E56D92CD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:to="loc_us-gaap_RangeAxis_C1772E72FB68B3D87BE142D5E56D92CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_01544D9B19DEB2A9B88242D5E56DFBEE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_C1772E72FB68B3D87BE142D5E56D92CD" xlink:to="loc_us-gaap_RangeMember_01544D9B19DEB2A9B88242D5E56DFBEE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_01544D9B19DEB2A9B88242D5E56DFBEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_C1772E72FB68B3D87BE142D5E56D92CD" xlink:to="loc_us-gaap_RangeMember_01544D9B19DEB2A9B88242D5E56DFBEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_CC8BF84657A0B5D38D0742D5E56D748D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_01544D9B19DEB2A9B88242D5E56DFBEE" xlink:to="loc_us-gaap_MinimumMember_CC8BF84657A0B5D38D0742D5E56D748D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6C719334D6121E1D87B242D5E56DB73C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_01544D9B19DEB2A9B88242D5E56DFBEE" xlink:to="loc_us-gaap_MaximumMember_6C719334D6121E1D87B242D5E56DB73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_78995F40A37FC9E7307742D5E56D53FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:to="loc_us-gaap_BuildingMember_78995F40A37FC9E7307742D5E56D53FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_AD8C0780B2E963F8722742D5E56D1E2F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_AD8C0780B2E963F8722742D5E56D1E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_C7EEB0EC996584428EC142D5E56D349E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_C7EEB0EC996584428EC142D5E56D349E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_33F9F39C3415DB43A6FC42D5E56DEBDE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:to="loc_us-gaap_ComputerEquipmentMember_33F9F39C3415DB43A6FC42D5E56DEBDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3F8C0D2428980966881843111BEE005F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3F8C0D2428980966881843111BEE005F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:to="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_E77A627A35F3E762192042D5E56DBDFB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_E77A627A35F3E762192042D5E56DBDFB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>biib-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70B14D8C3823998298FF29780D765660_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70B14D8C3823998298FF29780D765660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70B14D8C3823998298FF29780D765660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70B14D8C3823998298FF29780D765660" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70B14D8C3823998298FF29780D765660" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A7D0641025A09BDF10C229780D76111F_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A7D0641025A09BDF10C229780D76111F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A7D0641025A09BDF10C229780D76111F_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A7D0641025A09BDF10C229780D76111F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A7D0641025A09BDF10C229780D76111F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A7D0641025A09BDF10C229780D76111F" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A7D0641025A09BDF10C229780D76111F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_F62A57A5B2409A303393297C21D92E36_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_F62A57A5B2409A303393297C21D92E36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F62A57A5B2409A303393297C21D92E36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F62A57A5B2409A303393297C21D92E36" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_F62A57A5B2409A303393297C21D92E36" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:to="lab_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:to="lab_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_27D579D3780D9CDD6778297C21DAC673_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_27D579D3780D9CDD6778297C21DAC673" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_27D579D3780D9CDD6778297C21DAC673_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_27D579D3780D9CDD6778297C21DAC673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_27D579D3780D9CDD6778297C21DAC673" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_27D579D3780D9CDD6778297C21DAC673" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_27D579D3780D9CDD6778297C21DAC673" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B36E21769057789D9CFF297C21DAC8DD_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B36E21769057789D9CFF297C21DAC8DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B36E21769057789D9CFF297C21DAC8DD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B36E21769057789D9CFF297C21DAC8DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B36E21769057789D9CFF297C21DAC8DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B36E21769057789D9CFF297C21DAC8DD" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B36E21769057789D9CFF297C21DAC8DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3F5DF8388AD8B86184BF297C21DA5D90_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_3F5DF8388AD8B86184BF297C21DA5D90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3F5DF8388AD8B86184BF297C21DA5D90_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_3F5DF8388AD8B86184BF297C21DA5D90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3F5DF8388AD8B86184BF297C21DA5D90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_3F5DF8388AD8B86184BF297C21DA5D90" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_3F5DF8388AD8B86184BF297C21DA5D90" xlink:type="arc" />
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_89E8E86617746770A657297C21DABE2D_verboseLabel_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_89E8E86617746770A657297C21DABE2D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_89E8E86617746770A657297C21DABE2D_label_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_89E8E86617746770A657297C21DABE2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from unconsolidated joint business</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_89E8E86617746770A657297C21DABE2D_documentation_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_89E8E86617746770A657297C21DABE2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_89E8E86617746770A657297C21DABE2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DueFromUnconsolidatedJointBusiness_89E8E86617746770A657297C21DABE2D" xlink:to="lab_biib_DueFromUnconsolidatedJointBusiness_89E8E86617746770A657297C21DABE2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_2DA32586EF29CB56D82D297C21DA22D6_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_2DA32586EF29CB56D82D297C21DA22D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_2DA32586EF29CB56D82D297C21DA22D6_label_en-US" xlink:label="lab_us-gaap_InventoryNet_2DA32586EF29CB56D82D297C21DA22D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2DA32586EF29CB56D82D297C21DA22D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_2DA32586EF29CB56D82D297C21DA22D6" xlink:to="lab_us-gaap_InventoryNet_2DA32586EF29CB56D82D297C21DA22D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_674C228987BAE58620BB297C21DAAA3D_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_674C228987BAE58620BB297C21DAAA3D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_674C228987BAE58620BB297C21DAAA3D_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_674C228987BAE58620BB297C21DAAA3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_674C228987BAE58620BB297C21DAAA3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_674C228987BAE58620BB297C21DAAA3D" xlink:to="lab_us-gaap_OtherAssetsCurrent_674C228987BAE58620BB297C21DAAA3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_35B36A77D5BB8877DE10297C21DA1EFC_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_35B36A77D5BB8877DE10297C21DA1EFC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_35B36A77D5BB8877DE10297C21DA1EFC_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_35B36A77D5BB8877DE10297C21DA1EFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_35B36A77D5BB8877DE10297C21DA1EFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_35B36A77D5BB8877DE10297C21DA1EFC" xlink:to="lab_us-gaap_AssetsCurrent_35B36A77D5BB8877DE10297C21DA1EFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_0908BFF055B3F67B1B9A297C21DAB3F8_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_0908BFF055B3F67B1B9A297C21DAB3F8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_0908BFF055B3F67B1B9A297C21DAB3F8_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_0908BFF055B3F67B1B9A297C21DAB3F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_0908BFF055B3F67B1B9A297C21DAB3F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_0908BFF055B3F67B1B9A297C21DAB3F8" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_0908BFF055B3F67B1B9A297C21DAB3F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_B1EB78A999DF16613F81297C21DA2F7C_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_B1EB78A999DF16613F81297C21DA2F7C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_B1EB78A999DF16613F81297C21DA2F7C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_B1EB78A999DF16613F81297C21DA2F7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_B1EB78A999DF16613F81297C21DA2F7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_B1EB78A999DF16613F81297C21DA2F7C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_B1EB78A999DF16613F81297C21DA2F7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D4B5746749BBE0A08F6D297C21DAAA35_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D4B5746749BBE0A08F6D297C21DAAA35" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D4B5746749BBE0A08F6D297C21DAAA35_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D4B5746749BBE0A08F6D297C21DAAA35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D4B5746749BBE0A08F6D297C21DAAA35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D4B5746749BBE0A08F6D297C21DAAA35" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D4B5746749BBE0A08F6D297C21DAAA35" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_5A5775854B00B9BCEB8F297C21DAC532_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_5A5775854B00B9BCEB8F297C21DAC532" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_5A5775854B00B9BCEB8F297C21DAC532_label_en-US" xlink:label="lab_us-gaap_Goodwill_5A5775854B00B9BCEB8F297C21DAC532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5A5775854B00B9BCEB8F297C21DAC532" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_5A5775854B00B9BCEB8F297C21DAC532" xlink:to="lab_us-gaap_Goodwill_5A5775854B00B9BCEB8F297C21DAC532" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_054AFA0E5D181923C9C2297C21DAAB65_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_054AFA0E5D181923C9C2297C21DAAB65" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_054AFA0E5D181923C9C2297C21DAAB65_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_054AFA0E5D181923C9C2297C21DAAB65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_054AFA0E5D181923C9C2297C21DAAB65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_054AFA0E5D181923C9C2297C21DAAB65" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_054AFA0E5D181923C9C2297C21DAAB65" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_06A64B2C59B8FF1F8BA2297C21DAA66B_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_06A64B2C59B8FF1F8BA2297C21DAA66B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_06A64B2C59B8FF1F8BA2297C21DAA66B_label_en-US" xlink:label="lab_us-gaap_Assets_06A64B2C59B8FF1F8BA2297C21DAA66B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_06A64B2C59B8FF1F8BA2297C21DAA66B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_06A64B2C59B8FF1F8BA2297C21DAA66B" xlink:to="lab_us-gaap_Assets_06A64B2C59B8FF1F8BA2297C21DAA66B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_E95C671EBC9195F5F454297C21DB8D15_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_E95C671EBC9195F5F454297C21DB8D15" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_E95C671EBC9195F5F454297C21DB8D15_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_E95C671EBC9195F5F454297C21DB8D15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_E95C671EBC9195F5F454297C21DB8D15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_E95C671EBC9195F5F454297C21DB8D15" xlink:to="lab_us-gaap_DebtCurrent_E95C671EBC9195F5F454297C21DB8D15" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_DD6962ABC212242E0DD6297C21DBA5EB_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_DD6962ABC212242E0DD6297C21DBA5EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_DD6962ABC212242E0DD6297C21DBA5EB_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_DD6962ABC212242E0DD6297C21DBA5EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_DD6962ABC212242E0DD6297C21DBA5EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_DD6962ABC212242E0DD6297C21DBA5EB" xlink:to="lab_us-gaap_TaxesPayableCurrent_DD6962ABC212242E0DD6297C21DBA5EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_903400E86D123D1EDD6E297C21DBCBCB_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_903400E86D123D1EDD6E297C21DBCBCB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_903400E86D123D1EDD6E297C21DBCBCB_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_903400E86D123D1EDD6E297C21DBCBCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_903400E86D123D1EDD6E297C21DBCBCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_903400E86D123D1EDD6E297C21DBCBCB" xlink:to="lab_us-gaap_AccountsPayableCurrent_903400E86D123D1EDD6E297C21DBCBCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_EFF5FE8E5B6076CA4AB7297C21DB8325_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_EFF5FE8E5B6076CA4AB7297C21DB8325" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_EFF5FE8E5B6076CA4AB7297C21DB8325_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_EFF5FE8E5B6076CA4AB7297C21DB8325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_EFF5FE8E5B6076CA4AB7297C21DB8325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_EFF5FE8E5B6076CA4AB7297C21DB8325" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_EFF5FE8E5B6076CA4AB7297C21DB8325" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_426EE1CF9959E9D10657297C21DBFB52_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_426EE1CF9959E9D10657297C21DBFB52" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_426EE1CF9959E9D10657297C21DBFB52_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_426EE1CF9959E9D10657297C21DBFB52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_426EE1CF9959E9D10657297C21DBFB52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_426EE1CF9959E9D10657297C21DBFB52" xlink:to="lab_us-gaap_LiabilitiesCurrent_426EE1CF9959E9D10657297C21DBFB52" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_6245E2A61C5C55B1AD7F297C21DBFEF7_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_6245E2A61C5C55B1AD7F297C21DBFEF7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_6245E2A61C5C55B1AD7F297C21DBFEF7_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_6245E2A61C5C55B1AD7F297C21DBFEF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6245E2A61C5C55B1AD7F297C21DBFEF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_6245E2A61C5C55B1AD7F297C21DBFEF7" xlink:to="lab_us-gaap_LongTermDebt_6245E2A61C5C55B1AD7F297C21DBFEF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_9A0E1B39A48E9455F1DE297C21DBD978_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_9A0E1B39A48E9455F1DE297C21DBD978" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_9A0E1B39A48E9455F1DE297C21DBD978_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_9A0E1B39A48E9455F1DE297C21DBD978" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_9A0E1B39A48E9455F1DE297C21DBD978" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_9A0E1B39A48E9455F1DE297C21DBD978" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_9A0E1B39A48E9455F1DE297C21DBD978" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4F86C5D5F674E480EE50297C21DB5E1C_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_4F86C5D5F674E480EE50297C21DB5E1C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4F86C5D5F674E480EE50297C21DB5E1C_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_4F86C5D5F674E480EE50297C21DB5E1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4F86C5D5F674E480EE50297C21DB5E1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_4F86C5D5F674E480EE50297C21DB5E1C" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_4F86C5D5F674E480EE50297C21DB5E1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_D1A01FEDEECFD06247E7297C21DBB52A_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_D1A01FEDEECFD06247E7297C21DBB52A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_D1A01FEDEECFD06247E7297C21DBB52A_label_en-US" xlink:label="lab_us-gaap_Liabilities_D1A01FEDEECFD06247E7297C21DBB52A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_D1A01FEDEECFD06247E7297C21DBB52A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_D1A01FEDEECFD06247E7297C21DBB52A" xlink:to="lab_us-gaap_Liabilities_D1A01FEDEECFD06247E7297C21DBB52A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_77AB36004B0CF1BFF77E297C21DBB5F1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_77AB36004B0CF1BFF77E297C21DBB5F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_77AB36004B0CF1BFF77E297C21DBB5F1_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_77AB36004B0CF1BFF77E297C21DBB5F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_77AB36004B0CF1BFF77E297C21DBB5F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_77AB36004B0CF1BFF77E297C21DBB5F1" xlink:to="lab_us-gaap_CommitmentsAndContingencies_77AB36004B0CF1BFF77E297C21DBB5F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_B9860528338F75832B49297C21DB188B_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_B9860528338F75832B49297C21DB188B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_B9860528338F75832B49297C21DB188B_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_B9860528338F75832B49297C21DB188B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_B9860528338F75832B49297C21DB188B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_B9860528338F75832B49297C21DB188B" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_B9860528338F75832B49297C21DB188B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:to="lab_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_417D6DA1C616F9FE655E297C21DBC7E1_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_417D6DA1C616F9FE655E297C21DBC7E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_417D6DA1C616F9FE655E297C21DBC7E1_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_417D6DA1C616F9FE655E297C21DBC7E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_417D6DA1C616F9FE655E297C21DBC7E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_417D6DA1C616F9FE655E297C21DBC7E1" xlink:to="lab_us-gaap_PreferredStockValue_417D6DA1C616F9FE655E297C21DBC7E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_43B71B5D9233C635EA74297C21DBBA84_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_43B71B5D9233C635EA74297C21DBBA84" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_43B71B5D9233C635EA74297C21DBBA84_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_43B71B5D9233C635EA74297C21DBBA84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_43B71B5D9233C635EA74297C21DBBA84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_43B71B5D9233C635EA74297C21DBBA84" xlink:to="lab_us-gaap_CommonStockValue_43B71B5D9233C635EA74297C21DBBA84" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_44772B18E8B835AF25E3297C21DB2856_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_44772B18E8B835AF25E3297C21DB2856" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_44772B18E8B835AF25E3297C21DB2856_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_44772B18E8B835AF25E3297C21DB2856" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_44772B18E8B835AF25E3297C21DB2856" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_44772B18E8B835AF25E3297C21DB2856" xlink:to="lab_us-gaap_AdditionalPaidInCapital_44772B18E8B835AF25E3297C21DB2856" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E71C49AB252AE3E0BA28297C21DC2CD9_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E71C49AB252AE3E0BA28297C21DC2CD9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E71C49AB252AE3E0BA28297C21DC2CD9_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E71C49AB252AE3E0BA28297C21DC2CD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E71C49AB252AE3E0BA28297C21DC2CD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E71C49AB252AE3E0BA28297C21DC2CD9" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E71C49AB252AE3E0BA28297C21DC2CD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A97C8B5C24FCE5A3A41C297C21DCA22F_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A97C8B5C24FCE5A3A41C297C21DCA22F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A97C8B5C24FCE5A3A41C297C21DCA22F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A97C8B5C24FCE5A3A41C297C21DCA22F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_A97C8B5C24FCE5A3A41C297C21DCA22F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_A97C8B5C24FCE5A3A41C297C21DCA22F" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A97C8B5C24FCE5A3A41C297C21DCA22F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_26139A8A784EAE858797297C21DC8E90_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_26139A8A784EAE858797297C21DC8E90" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost; 23.8 million and 22.6 million shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_26139A8A784EAE858797297C21DC8E90_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_26139A8A784EAE858797297C21DC8E90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_26139A8A784EAE858797297C21DC8E90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_26139A8A784EAE858797297C21DC8E90" xlink:to="lab_us-gaap_TreasuryStockValue_26139A8A784EAE858797297C21DC8E90" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_2A63BEE6699AA96B6F61297C21DC57FD_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_2A63BEE6699AA96B6F61297C21DC57FD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2A63BEE6699AA96B6F61297C21DC57FD_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_2A63BEE6699AA96B6F61297C21DC57FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2A63BEE6699AA96B6F61297C21DC57FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_2A63BEE6699AA96B6F61297C21DC57FD" xlink:to="lab_us-gaap_StockholdersEquity_2A63BEE6699AA96B6F61297C21DC57FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_9F8060BEB54263BA9297297C21DCBFDD_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_9F8060BEB54263BA9297297C21DCBFDD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_9F8060BEB54263BA9297297C21DCBFDD_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_9F8060BEB54263BA9297297C21DCBFDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_9F8060BEB54263BA9297297C21DCBFDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_9F8060BEB54263BA9297297C21DCBFDD" xlink:to="lab_us-gaap_MinorityInterest_9F8060BEB54263BA9297297C21DCBFDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_282477FAAD2C189CDE9E297C21DC61FC_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_282477FAAD2C189CDE9E297C21DC61FC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_282477FAAD2C189CDE9E297C21DC61FC_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_282477FAAD2C189CDE9E297C21DC61FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_282477FAAD2C189CDE9E297C21DC61FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_282477FAAD2C189CDE9E297C21DC61FC" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_282477FAAD2C189CDE9E297C21DC61FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_C67CFD691353D2DBCCD3297C21DCD776_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_C67CFD691353D2DBCCD3297C21DCD776" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_C67CFD691353D2DBCCD3297C21DCD776_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_C67CFD691353D2DBCCD3297C21DCD776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_C67CFD691353D2DBCCD3297C21DCD776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_C67CFD691353D2DBCCD3297C21DCD776" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_C67CFD691353D2DBCCD3297C21DCD776" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A401C70972C9A855875042C707F40C9B_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A401C70972C9A855875042C707F40C9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A401C70972C9A855875042C707F40C9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A401C70972C9A855875042C707F40C9B" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A401C70972C9A855875042C707F40C9B" xlink:type="arc" />
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1_terseLabel_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments (Textual)</link:label>
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1_label_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1_documentation_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FinancialInstrumentsTextualAbstract" xlink:label="loc_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1" xlink:to="lab_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_31A9DBC098E72BA9423E42C707F48E30_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_31A9DBC098E72BA9423E42C707F48E30" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Original maturities of commercial paper and short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_31A9DBC098E72BA9423E42C707F48E30_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_31A9DBC098E72BA9423E42C707F48E30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_31A9DBC098E72BA9423E42C707F48E30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateDescription_31A9DBC098E72BA9423E42C707F48E30" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateDescription_31A9DBC098E72BA9423E42C707F48E30" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_F6280430D337B3BD313B42C707F4CAD1_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_F6280430D337B3BD313B42C707F4CAD1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_F6280430D337B3BD313B42C707F4CAD1_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_F6280430D337B3BD313B42C707F4CAD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_F6280430D337B3BD313B42C707F4CAD1_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_F6280430D337B3BD313B42C707F4CAD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_F6280430D337B3BD313B42C707F4CAD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_F6280430D337B3BD313B42C707F4CAD1" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_F6280430D337B3BD313B42C707F4CAD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_BB4E9F2E18D04F91FFBA434A35CD3D84_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_BB4E9F2E18D04F91FFBA434A35CD3D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_BB4E9F2E18D04F91FFBA434A35CD3D84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_BB4E9F2E18D04F91FFBA434A35CD3D84" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_BB4E9F2E18D04F91FFBA434A35CD3D84" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A" xlink:to="lab_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4" xlink:to="lab_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4" xlink:type="arc" />
    <link:label id="lab_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5_terseLabel_en-US" xlink:label="lab_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB074</link:label>
    <link:label id="lab_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5_label_en-US" xlink:label="lab_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB074 [Member]</link:label>
    <link:label id="lab_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5_documentation_en-US" xlink:label="lab_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB074 [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_BIIB074Member" xlink:label="loc_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5" xlink:to="lab_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:type="arc" />
    <link:label id="lab_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20_terseLabel_en-US" xlink:label="lab_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remedy Pharmaceutical [Member]</link:label>
    <link:label id="lab_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20_label_en-US" xlink:label="lab_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remedy Pharmaceutical [Member]</link:label>
    <link:label id="lab_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20_documentation_en-US" xlink:label="lab_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remedy Pharmaceutical [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20" xlink:to="lab_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20" xlink:type="arc" />
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495_terseLabel_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495_label_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495_documentation_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495" xlink:to="lab_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_103517661A83AFE5DACC434A35CDC947_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_103517661A83AFE5DACC434A35CDC947" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_103517661A83AFE5DACC434A35CDC947_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_103517661A83AFE5DACC434A35CDC947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_103517661A83AFE5DACC434A35CDC947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_103517661A83AFE5DACC434A35CDC947" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_103517661A83AFE5DACC434A35CDC947" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_B76F5EBB0808170B0DF2434A35CD857A_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_B76F5EBB0808170B0DF2434A35CD857A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash portion of consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_B76F5EBB0808170B0DF2434A35CD857A_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_B76F5EBB0808170B0DF2434A35CD857A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_B76F5EBB0808170B0DF2434A35CD857A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_B76F5EBB0808170B0DF2434A35CD857A" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_B76F5EBB0808170B0DF2434A35CD857A" xlink:type="arc" />
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_37B72B656B764110E7EE434A35CDA34C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_37B72B656B764110E7EE434A35CDA34C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligation</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_37B72B656B764110E7EE434A35CDA34C_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_37B72B656B764110E7EE434A35CDA34C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_37B72B656B764110E7EE434A35CDA34C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_37B72B656B764110E7EE434A35CDA34C" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_37B72B656B764110E7EE434A35CDA34C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E3E6FA718F1923E82395434A35CD6C36_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E3E6FA718F1923E82395434A35CD6C36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E3E6FA718F1923E82395434A35CD6C36_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E3E6FA718F1923E82395434A35CD6C36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E3E6FA718F1923E82395434A35CD6C36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E3E6FA718F1923E82395434A35CD6C36" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E3E6FA718F1923E82395434A35CD6C36" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8FCB4B4736E6F1232937434A35CDAEE6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8FCB4B4736E6F1232937434A35CDAEE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8FCB4B4736E6F1232937434A35CDAEE6_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8FCB4B4736E6F1232937434A35CDAEE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8FCB4B4736E6F1232937434A35CDAEE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8FCB4B4736E6F1232937434A35CDAEE6" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8FCB4B4736E6F1232937434A35CDAEE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_F8889029AAF6B1612892434A35CDCC5E_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_F8889029AAF6B1612892434A35CDCC5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_F8889029AAF6B1612892434A35CDCC5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_F8889029AAF6B1612892434A35CDCC5E" xlink:to="lab_us-gaap_Goodwill_F8889029AAF6B1612892434A35CDCC5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_81102D8B8370637FA7EB4C77BC437EEA_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_81102D8B8370637FA7EB4C77BC437EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_81102D8B8370637FA7EB4C77BC437EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_81102D8B8370637FA7EB4C77BC437EEA" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_81102D8B8370637FA7EB4C77BC437EEA" xlink:type="arc" />
    <link:label id="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21_verboseLabel_en-US" xlink:label="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under non-cancelable leases</link:label>
    <link:label id="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21_label_en-US" xlink:label="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Rental Commitments Under Noncancellable Leases [Abstract]</link:label>
    <link:label id="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21_documentation_en-US" xlink:label="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under noncancellable leases.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" xlink:label="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_12F2498B665DE8B3250E4C77BC4441E4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_12F2498B665DE8B3250E4C77BC4441E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_12F2498B665DE8B3250E4C77BC4441E4_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_12F2498B665DE8B3250E4C77BC4441E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_12F2498B665DE8B3250E4C77BC4441E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_12F2498B665DE8B3250E4C77BC4441E4" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_12F2498B665DE8B3250E4C77BC4441E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_A1FF95857D1BF5AC6E7C4C77BC4496F0_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_A1FF95857D1BF5AC6E7C4C77BC4496F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_A1FF95857D1BF5AC6E7C4C77BC4496F0_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_A1FF95857D1BF5AC6E7C4C77BC4496F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_A1FF95857D1BF5AC6E7C4C77BC4496F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_A1FF95857D1BF5AC6E7C4C77BC4496F0" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_A1FF95857D1BF5AC6E7C4C77BC4496F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_5A9D870EB0A8168F2DEF4C77BC44A87B_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_5A9D870EB0A8168F2DEF4C77BC44A87B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_5A9D870EB0A8168F2DEF4C77BC44A87B_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_5A9D870EB0A8168F2DEF4C77BC44A87B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_5A9D870EB0A8168F2DEF4C77BC44A87B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_5A9D870EB0A8168F2DEF4C77BC44A87B" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_5A9D870EB0A8168F2DEF4C77BC44A87B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EC018858F60FE94216374C77BC44695A_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EC018858F60FE94216374C77BC44695A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EC018858F60FE94216374C77BC44695A_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EC018858F60FE94216374C77BC44695A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EC018858F60FE94216374C77BC44695A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EC018858F60FE94216374C77BC44695A" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EC018858F60FE94216374C77BC44695A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_0DB951CC6A06BF720D374C77BC446F4E_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_0DB951CC6A06BF720D374C77BC446F4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_0DB951CC6A06BF720D374C77BC446F4E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_0DB951CC6A06BF720D374C77BC446F4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_0DB951CC6A06BF720D374C77BC446F4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_0DB951CC6A06BF720D374C77BC446F4E" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_0DB951CC6A06BF720D374C77BC446F4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F8313CB025B46C8A0E934C77BC449308_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F8313CB025B46C8A0E934C77BC449308" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F8313CB025B46C8A0E934C77BC449308_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F8313CB025B46C8A0E934C77BC449308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F8313CB025B46C8A0E934C77BC449308" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F8313CB025B46C8A0E934C77BC449308" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F8313CB025B46C8A0E934C77BC449308" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4F00FB0032200B83F9504C77BC44D451_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4F00FB0032200B83F9504C77BC44D451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4F00FB0032200B83F9504C77BC44D451_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4F00FB0032200B83F9504C77BC44D451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4F00FB0032200B83F9504C77BC44D451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4F00FB0032200B83F9504C77BC44D451" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4F00FB0032200B83F9504C77BC44D451" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1D60BFD2AF0B4FF9893E4C77BC443024_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1D60BFD2AF0B4FF9893E4C77BC443024" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2018</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1D60BFD2AF0B4FF9893E4C77BC443024_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1D60BFD2AF0B4FF9893E4C77BC443024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1D60BFD2AF0B4FF9893E4C77BC443024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1D60BFD2AF0B4FF9893E4C77BC443024" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1D60BFD2AF0B4FF9893E4C77BC443024" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_2CA2CF9211616DB8DFCE4C77BC456A5C_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_2CA2CF9211616DB8DFCE4C77BC456A5C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2019</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_2CA2CF9211616DB8DFCE4C77BC456A5C_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_2CA2CF9211616DB8DFCE4C77BC456A5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_2CA2CF9211616DB8DFCE4C77BC456A5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_2CA2CF9211616DB8DFCE4C77BC456A5C" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_2CA2CF9211616DB8DFCE4C77BC456A5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_2D956C606A02261BA0024C77BC45DFD5_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_2D956C606A02261BA0024C77BC45DFD5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2020</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_2D956C606A02261BA0024C77BC45DFD5_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_2D956C606A02261BA0024C77BC45DFD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_2D956C606A02261BA0024C77BC45DFD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_2D956C606A02261BA0024C77BC45DFD5" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_2D956C606A02261BA0024C77BC45DFD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_8189CFB0BC3CAF10B56E4C77BC453FAC_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_8189CFB0BC3CAF10B56E4C77BC453FAC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2021</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_8189CFB0BC3CAF10B56E4C77BC453FAC_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_8189CFB0BC3CAF10B56E4C77BC453FAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_8189CFB0BC3CAF10B56E4C77BC453FAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_8189CFB0BC3CAF10B56E4C77BC453FAC" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_8189CFB0BC3CAF10B56E4C77BC453FAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_BC7CD725882EFDAC1A904C77BC459B82_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_BC7CD725882EFDAC1A904C77BC459B82" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2022</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_BC7CD725882EFDAC1A904C77BC459B82_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_BC7CD725882EFDAC1A904C77BC459B82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_BC7CD725882EFDAC1A904C77BC459B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_BC7CD725882EFDAC1A904C77BC459B82" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_BC7CD725882EFDAC1A904C77BC459B82" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_610B1C717F534089A2E44C77BC452551_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_610B1C717F534089A2E44C77BC452551" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, Thereafter</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_610B1C717F534089A2E44C77BC452551_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_610B1C717F534089A2E44C77BC452551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_610B1C717F534089A2E44C77BC452551" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_610B1C717F534089A2E44C77BC452551" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_610B1C717F534089A2E44C77BC452551" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_685ECDA9BAAC923D1B3B4C77BC457281_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_685ECDA9BAAC923D1B3B4C77BC457281" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, Total</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_685ECDA9BAAC923D1B3B4C77BC457281_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_685ECDA9BAAC923D1B3B4C77BC457281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_685ECDA9BAAC923D1B3B4C77BC457281" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_685ECDA9BAAC923D1B3B4C77BC457281" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_685ECDA9BAAC923D1B3B4C77BC457281" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_BFC834D619DCB0C9298A4C77BC453E55_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_BFC834D619DCB0C9298A4C77BC453E55" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2018</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_BFC834D619DCB0C9298A4C77BC453E55_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_BFC834D619DCB0C9298A4C77BC453E55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In One Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_BFC834D619DCB0C9298A4C77BC453E55_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_BFC834D619DCB0C9298A4C77BC453E55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in one year.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_BFC834D619DCB0C9298A4C77BC453E55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_BFC834D619DCB0C9298A4C77BC453E55" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInOneYear_BFC834D619DCB0C9298A4C77BC453E55" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_0D74DF286A36B2E19FD44C77BC454808_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_0D74DF286A36B2E19FD44C77BC454808" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2019</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_0D74DF286A36B2E19FD44C77BC454808_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_0D74DF286A36B2E19FD44C77BC454808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Two Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_0D74DF286A36B2E19FD44C77BC454808_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_0D74DF286A36B2E19FD44C77BC454808" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in two year.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_0D74DF286A36B2E19FD44C77BC454808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_0D74DF286A36B2E19FD44C77BC454808" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_0D74DF286A36B2E19FD44C77BC454808" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_6AA8FD9BAC6BC3983F564C77BC459799_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_6AA8FD9BAC6BC3983F564C77BC459799" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2020</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_6AA8FD9BAC6BC3983F564C77BC459799_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_6AA8FD9BAC6BC3983F564C77BC459799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Three Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_6AA8FD9BAC6BC3983F564C77BC459799_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_6AA8FD9BAC6BC3983F564C77BC459799" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in three year.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_6AA8FD9BAC6BC3983F564C77BC459799" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_6AA8FD9BAC6BC3983F564C77BC459799" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_6AA8FD9BAC6BC3983F564C77BC459799" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_A1B175CE7161D96E1E9B4C77BC45AE37_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_A1B175CE7161D96E1E9B4C77BC45AE37" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2021</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_A1B175CE7161D96E1E9B4C77BC45AE37_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_A1B175CE7161D96E1E9B4C77BC45AE37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Four Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_A1B175CE7161D96E1E9B4C77BC45AE37_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_A1B175CE7161D96E1E9B4C77BC45AE37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in four year.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_A1B175CE7161D96E1E9B4C77BC45AE37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_A1B175CE7161D96E1E9B4C77BC45AE37" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFourYear_A1B175CE7161D96E1E9B4C77BC45AE37" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_99C39A2A7A4EE8E2EA404C77BC460806_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_99C39A2A7A4EE8E2EA404C77BC460806" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2022</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_99C39A2A7A4EE8E2EA404C77BC460806_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_99C39A2A7A4EE8E2EA404C77BC460806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Five Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_99C39A2A7A4EE8E2EA404C77BC460806_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_99C39A2A7A4EE8E2EA404C77BC460806" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in five year.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_99C39A2A7A4EE8E2EA404C77BC460806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_99C39A2A7A4EE8E2EA404C77BC460806" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_99C39A2A7A4EE8E2EA404C77BC460806" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_8BF9CCCBB70F8876CFB54C77BC4632A6_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_8BF9CCCBB70F8876CFB54C77BC4632A6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, Thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_8BF9CCCBB70F8876CFB54C77BC4632A6_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_8BF9CCCBB70F8876CFB54C77BC4632A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments Thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_8BF9CCCBB70F8876CFB54C77BC4632A6_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_8BF9CCCBB70F8876CFB54C77BC4632A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments thereafter.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_8BF9CCCBB70F8876CFB54C77BC4632A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_8BF9CCCBB70F8876CFB54C77BC4632A6" xlink:to="lab_biib_NetMinimumLeasePaymentsThereafter_8BF9CCCBB70F8876CFB54C77BC4632A6" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePayments_9A144A5DE74AFFF0A14C4C77BC4676DF_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_9A144A5DE74AFFF0A14C4C77BC4676DF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, Total</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_9A144A5DE74AFFF0A14C4C77BC4676DF_label_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_9A144A5DE74AFFF0A14C4C77BC4676DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_9A144A5DE74AFFF0A14C4C77BC4676DF_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_9A144A5DE74AFFF0A14C4C77BC4676DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments total.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_9A144A5DE74AFFF0A14C4C77BC4676DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePayments_9A144A5DE74AFFF0A14C4C77BC4676DF" xlink:to="lab_biib_NetMinimumLeasePayments_9A144A5DE74AFFF0A14C4C77BC4676DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_1BB361DEAB255DC9E0B043A944232442_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_1BB361DEAB255DC9E0B043A944232442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1BB361DEAB255DC9E0B043A944232442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1BB361DEAB255DC9E0B043A944232442" xlink:to="lab_us-gaap_DebtDisclosureAbstract_1BB361DEAB255DC9E0B043A944232442" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:to="lab_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5_label_en-US" xlink:label="lab_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5_documentation_en-US" xlink:label="lab_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5" xlink:to="lab_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument Risk [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_B648CB147DD20724158543A944252B61_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_B648CB147DD20724158543A944252B61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_B648CB147DD20724158543A944252B61_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_B648CB147DD20724158543A944252B61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_B648CB147DD20724158543A944252B61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_B648CB147DD20724158543A944252B61" xlink:to="lab_us-gaap_InterestRateSwapMember_B648CB147DD20724158543A944252B61" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113" xlink:to="lab_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579_label_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579_documentation_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.90% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.05% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.20% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_994C8A8813303C4106EC43A94425E000_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_994C8A8813303C4106EC43A94425E000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note payable to Fumedica</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_994C8A8813303C4106EC43A94425E000_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_994C8A8813303C4106EC43A94425E000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_994C8A8813303C4106EC43A94425E000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember_994C8A8813303C4106EC43A94425E000" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember_994C8A8813303C4106EC43A94425E000" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="lab_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_F7D67E032951858E6C2443A94425C535_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_F7D67E032951858E6C2443A94425C535" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_F7D67E032951858E6C2443A94425C535_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_F7D67E032951858E6C2443A94425C535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F7D67E032951858E6C2443A94425C535" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F7D67E032951858E6C2443A94425C535" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_F7D67E032951858E6C2443A94425C535" xlink:type="arc" />
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22_verboseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Redemption percentage par value of senior notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22" xlink:to="lab_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22" xlink:type="arc" />
    <link:label id="lab_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7_terseLabel_en-US" xlink:label="lab_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increased carrying amount of interest rate swap</link:label>
    <link:label id="lab_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7_label_en-US" xlink:label="lab_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increased Carrying Amount Of Senior Notes</link:label>
    <link:label id="lab_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7_documentation_en-US" xlink:label="lab_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increased carrying amount of senior notes.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_IncreasedCarryingAmountOfSeniorNotes" xlink:label="loc_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7" xlink:to="lab_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_8B5420A6D6ADEE58998143A9442698A7_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_8B5420A6D6ADEE58998143A9442698A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net charge upon extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_8B5420A6D6ADEE58998143A9442698A7_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_8B5420A6D6ADEE58998143A9442698A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Gain (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_8B5420A6D6ADEE58998143A9442698A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_8B5420A6D6ADEE58998143A9442698A7" xlink:to="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_8B5420A6D6ADEE58998143A9442698A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_C816B31F2BED1D6A01A043A94426F83F_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_C816B31F2BED1D6A01A043A94426F83F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for debt extinguishment</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_C816B31F2BED1D6A01A043A94426F83F_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_C816B31F2BED1D6A01A043A94426F83F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_C816B31F2BED1D6A01A043A94426F83F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_C816B31F2BED1D6A01A043A94426F83F" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_C816B31F2BED1D6A01A043A94426F83F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_11F3CDDDCF6ED2FF33B043A944252F62_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_11F3CDDDCF6ED2FF33B043A944252F62" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_11F3CDDDCF6ED2FF33B043A944252F62_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_11F3CDDDCF6ED2FF33B043A944252F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_11F3CDDDCF6ED2FF33B043A944252F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_11F3CDDDCF6ED2FF33B043A944252F62" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_11F3CDDDCF6ED2FF33B043A944252F62" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_A6B2DCC0FDB6073A30E943A9442683D8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_A6B2DCC0FDB6073A30E943A9442683D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs associated with the Senior Notes offerings</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_A6B2DCC0FDB6073A30E943A9442683D8_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_A6B2DCC0FDB6073A30E943A9442683D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_A6B2DCC0FDB6073A30E943A9442683D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_A6B2DCC0FDB6073A30E943A9442683D8" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_A6B2DCC0FDB6073A30E943A9442683D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_D506D90311AE2923A59543A944269810_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_D506D90311AE2923A59543A944269810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemptions percentage of 2015 notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_D506D90311AE2923A59543A944269810_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_D506D90311AE2923A59543A944269810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_D506D90311AE2923A59543A944269810" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_D506D90311AE2923A59543A944269810" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_D506D90311AE2923A59543A944269810" xlink:type="arc" />
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption percentage for change in control provision on the 2015 Senior Notes</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B_label_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B_documentation_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B" xlink:to="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_7DCC68D62D0F5D0CD03E43A944268762_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_7DCC68D62D0F5D0CD03E43A944268762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of the interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_7DCC68D62D0F5D0CD03E43A944268762_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_7DCC68D62D0F5D0CD03E43A944268762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7DCC68D62D0F5D0CD03E43A944268762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7DCC68D62D0F5D0CD03E43A944268762" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_7DCC68D62D0F5D0CD03E43A944268762" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_33FDC3002AC396F3BE4743A9442657D6_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_33FDC3002AC396F3BE4743A9442657D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_33FDC3002AC396F3BE4743A9442657D6_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_33FDC3002AC396F3BE4743A9442657D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_33FDC3002AC396F3BE4743A9442657D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_33FDC3002AC396F3BE4743A9442657D6" xlink:to="lab_us-gaap_LongTermNotesPayable_33FDC3002AC396F3BE4743A9442657D6" xlink:type="arc" />
    <link:label id="lab_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7_terseLabel_en-US" xlink:label="lab_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value of notes payable</link:label>
    <link:label id="lab_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7_label_en-US" xlink:label="lab_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par Value Of Notes Payable</link:label>
    <link:label id="lab_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7_documentation_en-US" xlink:label="lab_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Par value of notes payable.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ParValueOfNotesPayable" xlink:label="loc_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7" xlink:to="lab_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1B98A454C99A3B93081C43A944265742_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1B98A454C99A3B93081C43A944265742" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior unsecured revolving credit facility maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1B98A454C99A3B93081C43A944265742_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1B98A454C99A3B93081C43A944265742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1B98A454C99A3B93081C43A944265742" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1B98A454C99A3B93081C43A944265742" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1B98A454C99A3B93081C43A944265742" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_C6EB75A3E7ADB889F4F043A944260767_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_C6EB75A3E7ADB889F4F043A944260767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_C6EB75A3E7ADB889F4F043A944260767_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_C6EB75A3E7ADB889F4F043A944260767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_C6EB75A3E7ADB889F4F043A944260767" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_C6EB75A3E7ADB889F4F043A944260767" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_C6EB75A3E7ADB889F4F043A944260767" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0DF59CA91FAA7C2B1D0743A944265AC8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0DF59CA91FAA7C2B1D0743A944265AC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount outstanding under the credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0DF59CA91FAA7C2B1D0743A944265AC8_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0DF59CA91FAA7C2B1D0743A944265AC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0DF59CA91FAA7C2B1D0743A944265AC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0DF59CA91FAA7C2B1D0743A944265AC8" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0DF59CA91FAA7C2B1D0743A944265AC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_CB2BBB61BD5EF57E86EB43A94427B4EB_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_CB2BBB61BD5EF57E86EB43A94427B4EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Facility purchase</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_CB2BBB61BD5EF57E86EB43A94427B4EB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_CB2BBB61BD5EF57E86EB43A94427B4EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_CB2BBB61BD5EF57E86EB43A94427B4EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions_CB2BBB61BD5EF57E86EB43A94427B4EB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions_CB2BBB61BD5EF57E86EB43A94427B4EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_C6186E7E14747B6E95D44C78A5FA797D_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_C6186E7E14747B6E95D44C78A5FA797D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C6186E7E14747B6E95D44C78A5FA797D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C6186E7E14747B6E95D44C78A5FA797D" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_C6186E7E14747B6E95D44C78A5FA797D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350" xlink:to="lab_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279" xlink:to="lab_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignPlanMember_894C7858F6F63C2609AE4C78A5FA07C4_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_894C7858F6F63C2609AE4C78A5FA07C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_894C7858F6F63C2609AE4C78A5FA07C4_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_894C7858F6F63C2609AE4C78A5FA07C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_894C7858F6F63C2609AE4C78A5FA07C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember_894C7858F6F63C2609AE4C78A5FA07C4" xlink:to="lab_us-gaap_ForeignPlanMember_894C7858F6F63C2609AE4C78A5FA07C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF" xlink:to="lab_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:to="lab_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:type="arc" />
    <link:label id="lab_country_CH_16ECDE442E9F463C45DC4C78A6003299_terseLabel_en-US" xlink:label="lab_country_CH_16ECDE442E9F463C45DC4C78A6003299" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:label id="lab_country_CH_16ECDE442E9F463C45DC4C78A6003299_label_en-US" xlink:label="lab_country_CH_16ECDE442E9F463C45DC4C78A6003299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CH" xlink:label="loc_country_CH_16ECDE442E9F463C45DC4C78A6003299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH_16ECDE442E9F463C45DC4C78A6003299" xlink:to="lab_country_CH_16ECDE442E9F463C45DC4C78A6003299" xlink:type="arc" />
    <link:label id="lab_country_DE_2CB7D81DE871872DFFF24C78A600948E_terseLabel_en-US" xlink:label="lab_country_DE_2CB7D81DE871872DFFF24C78A600948E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:label id="lab_country_DE_2CB7D81DE871872DFFF24C78A600948E_label_en-US" xlink:label="lab_country_DE_2CB7D81DE871872DFFF24C78A600948E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="loc_country_DE_2CB7D81DE871872DFFF24C78A600948E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE_2CB7D81DE871872DFFF24C78A600948E" xlink:to="lab_country_DE_2CB7D81DE871872DFFF24C78A600948E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA_verboseLabel_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA_label_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA_documentation_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee benefit plans.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:to="lab_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of minimum investment return</link:label>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39_label_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Minimum Investment Return</link:label>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39_documentation_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of minimum investment return.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39" xlink:to="lab_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_B4546ACBF305A9D0FE664C78A6010D02_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_B4546ACBF305A9D0FE664C78A6010D02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unfunded net pension</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_B4546ACBF305A9D0FE664C78A6010D02_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_B4546ACBF305A9D0FE664C78A6010D02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_B4546ACBF305A9D0FE664C78A6010D02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_B4546ACBF305A9D0FE664C78A6010D02" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_B4546ACBF305A9D0FE664C78A6010D02" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_908ACDF6A147A8E526524C78A601BABA_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_908ACDF6A147A8E526524C78A601BABA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_908ACDF6A147A8E526524C78A601BABA_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_908ACDF6A147A8E526524C78A601BABA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_908ACDF6A147A8E526524C78A601BABA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation_908ACDF6A147A8E526524C78A601BABA" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation_908ACDF6A147A8E526524C78A601BABA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionExpense_C45D74DDC73DC69F5F1D4C78A6019923_terseLabel_en-US" xlink:label="lab_us-gaap_PensionExpense_C45D74DDC73DC69F5F1D4C78A6019923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Cost (Reversal of Cost)</link:label>
    <link:label id="lab_us-gaap_PensionExpense_C45D74DDC73DC69F5F1D4C78A6019923_label_en-US" xlink:label="lab_us-gaap_PensionExpense_C45D74DDC73DC69F5F1D4C78A6019923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Cost (Reversal of Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_C45D74DDC73DC69F5F1D4C78A6019923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionExpense_C45D74DDC73DC69F5F1D4C78A6019923" xlink:to="lab_us-gaap_PensionExpense_C45D74DDC73DC69F5F1D4C78A6019923" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_0291323046308F0BBC394C78A601FCB0_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_0291323046308F0BBC394C78A601FCB0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Periodic pension cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_0291323046308F0BBC394C78A601FCB0_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_0291323046308F0BBC394C78A601FCB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_0291323046308F0BBC394C78A601FCB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_0291323046308F0BBC394C78A601FCB0" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_0291323046308F0BBC394C78A601FCB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_8D69E35B902EC291FB9148E262A8B80C_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_8D69E35B902EC291FB9148E262A8B80C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_8D69E35B902EC291FB9148E262A8B80C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_8D69E35B902EC291FB9148E262A8B80C" xlink:to="lab_us-gaap_EquityAbstract_8D69E35B902EC291FB9148E262A8B80C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC_label_en-US" xlink:label="lab_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:to="lab_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699_netLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:to="lab_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DE2772F8B504194730D48E262A86150_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DE2772F8B504194730D48E262A86150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains (Losses) on Securities Available for Sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DE2772F8B504194730D48E262A86150_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DE2772F8B504194730D48E262A86150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DE2772F8B504194730D48E262A86150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DE2772F8B504194730D48E262A86150" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DE2772F8B504194730D48E262A86150" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_FD513C2707569E1C677048E262A8A482_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_FD513C2707569E1C677048E262A8A482" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains (Losses) on Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_FD513C2707569E1C677048E262A8A482_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_FD513C2707569E1C677048E262A8A482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_FD513C2707569E1C677048E262A8A482" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_FD513C2707569E1C677048E262A8A482" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_FD513C2707569E1C677048E262A8A482" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7E6D9FC841D3F01CCF8548E262A8A8B7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7E6D9FC841D3F01CCF8548E262A8A8B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7E6D9FC841D3F01CCF8548E262A8A8B7_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7E6D9FC841D3F01CCF8548E262A8A8B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7E6D9FC841D3F01CCF8548E262A8A8B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7E6D9FC841D3F01CCF8548E262A8A8B7" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7E6D9FC841D3F01CCF8548E262A8A8B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_C7B9CC150B1901F03A8D48E262A82468_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_C7B9CC150B1901F03A8D48E262A82468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_C7B9CC150B1901F03A8D48E262A82468_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_C7B9CC150B1901F03A8D48E262A82468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C7B9CC150B1901F03A8D48E262A82468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_C7B9CC150B1901F03A8D48E262A82468" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_C7B9CC150B1901F03A8D48E262A82468" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4F103B2463188495B6F248E262A84516_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4F103B2463188495B6F248E262A84516" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4F103B2463188495B6F248E262A84516_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4F103B2463188495B6F248E262A84516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4F103B2463188495B6F248E262A84516" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4F103B2463188495B6F248E262A84516" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_4F103B2463188495B6F248E262A84516" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_E2E6DAC593E7F402C2DE48E262A8E355_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_E2E6DAC593E7F402C2DE48E262A8E355" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_E2E6DAC593E7F402C2DE48E262A8E355_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_E2E6DAC593E7F402C2DE48E262A8E355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_E2E6DAC593E7F402C2DE48E262A8E355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_E2E6DAC593E7F402C2DE48E262A8E355" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_E2E6DAC593E7F402C2DE48E262A8E355" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_D79027F9C6B819D188DB48E262A9401D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_D79027F9C6B819D188DB48E262A9401D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_D79027F9C6B819D188DB48E262A9401D_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_D79027F9C6B819D188DB48E262A9401D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D79027F9C6B819D188DB48E262A9401D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_D79027F9C6B819D188DB48E262A9401D" xlink:to="lab_us-gaap_OperatingExpenses_D79027F9C6B819D188DB48E262A9401D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_CEB149805C163D3D73B748EC5BF6F61B_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_CEB149805C163D3D73B748EC5BF6F61B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_CEB149805C163D3D73B748EC5BF6F61B_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_CEB149805C163D3D73B748EC5BF6F61B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_CEB149805C163D3D73B748EC5BF6F61B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_CEB149805C163D3D73B748EC5BF6F61B" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_CEB149805C163D3D73B748EC5BF6F61B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_BCD77631D7EC3685B0FC48E262A98587_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_BCD77631D7EC3685B0FC48E262A98587" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_BCD77631D7EC3685B0FC48E262A98587_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_BCD77631D7EC3685B0FC48E262A98587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BCD77631D7EC3685B0FC48E262A98587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_BCD77631D7EC3685B0FC48E262A98587" xlink:to="lab_us-gaap_NetIncomeLoss_BCD77631D7EC3685B0FC48E262A98587" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_4CF0919398215CF48AC0434C2B592EFD_label_en-US" xlink:label="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_4CF0919398215CF48AC0434C2B592EFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts, Returns and Allowances, Goods [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_4CF0919398215CF48AC0434C2B592EFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_4CF0919398215CF48AC0434C2B592EFD" xlink:to="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_4CF0919398215CF48AC0434C2B592EFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_661C19DBB39AF736E19742D5E5311A1A_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_661C19DBB39AF736E19742D5E5311A1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_661C19DBB39AF736E19742D5E5311A1A_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_661C19DBB39AF736E19742D5E5311A1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_661C19DBB39AF736E19742D5E5311A1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_661C19DBB39AF736E19742D5E5311A1A" xlink:to="lab_us-gaap_AccountsReceivableMember_661C19DBB39AF736E19742D5E5311A1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_A6B4545BCA536413CDB242D5E5314D5F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_A6B4545BCA536413CDB242D5E5314D5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_A6B4545BCA536413CDB242D5E5314D5F_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_A6B4545BCA536413CDB242D5E5314D5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_A6B4545BCA536413CDB242D5E5314D5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_A6B4545BCA536413CDB242D5E5314D5F" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_A6B4545BCA536413CDB242D5E5314D5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF" xlink:to="lab_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_8A2C4C440D3C5D461A3242D5E5313352_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_8A2C4C440D3C5D461A3242D5E5313352" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_8A2C4C440D3C5D461A3242D5E5313352_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_8A2C4C440D3C5D461A3242D5E5313352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8A2C4C440D3C5D461A3242D5E5313352" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_8A2C4C440D3C5D461A3242D5E5313352" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_8A2C4C440D3C5D461A3242D5E5313352" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_635604F330654AF1D6DF29780E573BEF_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_635604F330654AF1D6DF29780E573BEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_635604F330654AF1D6DF29780E573BEF_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_635604F330654AF1D6DF29780E573BEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_635604F330654AF1D6DF29780E573BEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_635604F330654AF1D6DF29780E573BEF" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_635604F330654AF1D6DF29780E573BEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_33F0BEE46890CA85B89829780E57D96B_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_33F0BEE46890CA85B89829780E57D96B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_33F0BEE46890CA85B89829780E57D96B_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_33F0BEE46890CA85B89829780E57D96B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_33F0BEE46890CA85B89829780E57D96B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_33F0BEE46890CA85B89829780E57D96B" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_33F0BEE46890CA85B89829780E57D96B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B4B963DA742F3A734612492867D8E111_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B4B963DA742F3A734612492867D8E111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B4B963DA742F3A734612492867D8E111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B4B963DA742F3A734612492867D8E111" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B4B963DA742F3A734612492867D8E111" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_3D64EA46CE8B0C26FC61492867D82E39_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_3D64EA46CE8B0C26FC61492867D82E39" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_3D64EA46CE8B0C26FC61492867D82E39_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_3D64EA46CE8B0C26FC61492867D82E39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_3D64EA46CE8B0C26FC61492867D82E39_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_3D64EA46CE8B0C26FC61492867D82E39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_3D64EA46CE8B0C26FC61492867D82E39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_3D64EA46CE8B0C26FC61492867D82E39" xlink:to="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_3D64EA46CE8B0C26FC61492867D82E39" xlink:type="arc" />
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_5D45B79C13FA7CAF2C16492867D9D78F_terseLabel_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_5D45B79C13FA7CAF2C16492867D9D78F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pretax profit sharing formula</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_5D45B79C13FA7CAF2C16492867D9D78F_label_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_5D45B79C13FA7CAF2C16492867D9D78F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_5D45B79C13FA7CAF2C16492867D9D78F_documentation_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_5D45B79C13FA7CAF2C16492867D9D78F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PretaxProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_5D45B79C13FA7CAF2C16492867D9D78F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxProfitSharingFormulaTableTextBlock_5D45B79C13FA7CAF2C16492867D9D78F" xlink:to="lab_biib_PretaxProfitSharingFormulaTableTextBlock_5D45B79C13FA7CAF2C16492867D9D78F" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F0C64B715162DC2F5602492867D9D321_verboseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F0C64B715162DC2F5602492867D9D321" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F0C64B715162DC2F5602492867D9D321_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F0C64B715162DC2F5602492867D9D321" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F0C64B715162DC2F5602492867D9D321_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F0C64B715162DC2F5602492867D9D321" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F0C64B715162DC2F5602492867D9D321" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F0C64B715162DC2F5602492867D9D321" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F0C64B715162DC2F5602492867D9D321" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_9C8AE4D28FD05657E5C0492867D9FC8C_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_9C8AE4D28FD05657E5C0492867D9FC8C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to collaboration with AbbVie Inc.</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_9C8AE4D28FD05657E5C0492867D9FC8C_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_9C8AE4D28FD05657E5C0492867D9FC8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Seven [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_9C8AE4D28FD05657E5C0492867D9FC8C_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_9C8AE4D28FD05657E5C0492867D9FC8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of activity related to collaboration with company seven.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_9C8AE4D28FD05657E5C0492867D9FC8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_9C8AE4D28FD05657E5C0492867D9FC8C" xlink:to="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_9C8AE4D28FD05657E5C0492867D9FC8C" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_A5B8FA73F695925E4F1C492867D9E950_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_A5B8FA73F695925E4F1C492867D9E950" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to collaboration with Eisai</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_A5B8FA73F695925E4F1C492867D9E950_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_A5B8FA73F695925E4F1C492867D9E950" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_A5B8FA73F695925E4F1C492867D9E950_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_A5B8FA73F695925E4F1C492867D9E950" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_A5B8FA73F695925E4F1C492867D9E950" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_A5B8FA73F695925E4F1C492867D9E950" xlink:to="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_A5B8FA73F695925E4F1C492867D9E950" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B" xlink:to="lab_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_9666A57449C4F5D99AC429780F79E0BB_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_9666A57449C4F5D99AC429780F79E0BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_9666A57449C4F5D99AC429780F79E0BB_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_9666A57449C4F5D99AC429780F79E0BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_9666A57449C4F5D99AC429780F79E0BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_9666A57449C4F5D99AC429780F79E0BB" xlink:to="lab_us-gaap_CommercialPaperMember_9666A57449C4F5D99AC429780F79E0BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_E7B1D9EBC0295B60EA8829780F7A2005_verboseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_E7B1D9EBC0295B60EA8829780F7A2005" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overnight Reverse Repurchase Agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_E7B1D9EBC0295B60EA8829780F7A2005_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_E7B1D9EBC0295B60EA8829780F7A2005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_E7B1D9EBC0295B60EA8829780F7A2005" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_E7B1D9EBC0295B60EA8829780F7A2005" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_E7B1D9EBC0295B60EA8829780F7A2005" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9F50748269D3799BF31729780F7AB5CC_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_9F50748269D3799BF31729780F7AB5CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9F50748269D3799BF31729780F7AB5CC_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_9F50748269D3799BF31729780F7AB5CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9F50748269D3799BF31729780F7AB5CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_9F50748269D3799BF31729780F7AB5CC" xlink:to="lab_us-gaap_MoneyMarketFundsMember_9F50748269D3799BF31729780F7AB5CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_80E76C5B0C6F9349678929780F7A0618_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_80E76C5B0C6F9349678929780F7A0618" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_80E76C5B0C6F9349678929780F7A0618_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_80E76C5B0C6F9349678929780F7A0618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_80E76C5B0C6F9349678929780F7A0618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_80E76C5B0C6F9349678929780F7A0618" xlink:to="lab_us-gaap_DebtSecuritiesMember_80E76C5B0C6F9349678929780F7A0618" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_00C05C84D8CA298EC46129780F7AE7FD_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_00C05C84D8CA298EC46129780F7AE7FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_00C05C84D8CA298EC46129780F7AE7FD_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_00C05C84D8CA298EC46129780F7AE7FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_00C05C84D8CA298EC46129780F7AE7FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_00C05C84D8CA298EC46129780F7AE7FD" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_00C05C84D8CA298EC46129780F7AE7FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322" xlink:to="lab_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623" xlink:to="lab_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A_label_en-US" xlink:label="lab_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A" xlink:to="lab_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F_label_en-US" xlink:label="lab_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:to="lab_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_9CB5CB890EF4B5F1334329780DA8A7FD_verboseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_9CB5CB890EF4B5F1334329780DA8A7FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_9CB5CB890EF4B5F1334329780DA8A7FD_label_en-US" xlink:label="lab_us-gaap_MinimumMember_9CB5CB890EF4B5F1334329780DA8A7FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9CB5CB890EF4B5F1334329780DA8A7FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_9CB5CB890EF4B5F1334329780DA8A7FD" xlink:to="lab_us-gaap_MinimumMember_9CB5CB890EF4B5F1334329780DA8A7FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_B7871FF002EEEF11FAFF29780DA83A79_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_B7871FF002EEEF11FAFF29780DA83A79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_B7871FF002EEEF11FAFF29780DA83A79_label_en-US" xlink:label="lab_us-gaap_MaximumMember_B7871FF002EEEF11FAFF29780DA83A79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_B7871FF002EEEF11FAFF29780DA83A79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_B7871FF002EEEF11FAFF29780DA83A79" xlink:to="lab_us-gaap_MaximumMember_B7871FF002EEEF11FAFF29780DA83A79" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037" xlink:type="arc" />
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4_verboseLabel_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units</link:label>
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4_label_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation of Granted Stock Units [Abstract]</link:label>
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4_documentation_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation of granted stock units.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="lab_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7FABABB3139609C1E2C429780DA9BFA7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7FABABB3139609C1E2C429780DA9BFA7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7FABABB3139609C1E2C429780DA9BFA7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7FABABB3139609C1E2C429780DA9BFA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7FABABB3139609C1E2C429780DA9BFA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7FABABB3139609C1E2C429780DA9BFA7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7FABABB3139609C1E2C429780DA9BFA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9811F2328D09E7D75F2329780DA9A52A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9811F2328D09E7D75F2329780DA9A52A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9811F2328D09E7D75F2329780DA9A52A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9811F2328D09E7D75F2329780DA9A52A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9811F2328D09E7D75F2329780DA9A52A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9811F2328D09E7D75F2329780DA9A52A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9811F2328D09E7D75F2329780DA9A52A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1C507AB96A4B2E105D6629780DA9A901_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1C507AB96A4B2E105D6629780DA9A901" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum range of risk-free interest rates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1C507AB96A4B2E105D6629780DA9A901_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1C507AB96A4B2E105D6629780DA9A901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1C507AB96A4B2E105D6629780DA9A901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1C507AB96A4B2E105D6629780DA9A901" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1C507AB96A4B2E105D6629780DA9A901" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_809BE82AC34C0984878E29780DA9ED89_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_809BE82AC34C0984878E29780DA9ED89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum range of risk-free interest rates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_809BE82AC34C0984878E29780DA9ED89_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_809BE82AC34C0984878E29780DA9ED89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_809BE82AC34C0984878E29780DA9ED89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_809BE82AC34C0984878E29780DA9ED89" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_809BE82AC34C0984878E29780DA9ED89" xlink:type="arc" />
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A_verboseLabel_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average stock price on grant date minimum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A_label_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Stock Price On Grant Date In Dollars Minimum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A_documentation_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average stock price on grant date in dollars minimum.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A" xlink:to="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A" xlink:type="arc" />
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8_verboseLabel_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average stock price on grant date maximum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8_label_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Stock Price On Grant Date In Dollars Maximum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8_documentation_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average stock price on grant date in dollars maximum.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8" xlink:to="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ACA38214A4B7DBD095E029780DA933D9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ACA38214A4B7DBD095E029780DA933D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ACA38214A4B7DBD095E029780DA933D9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ACA38214A4B7DBD095E029780DA933D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ACA38214A4B7DBD095E029780DA933D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ACA38214A4B7DBD095E029780DA933D9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ACA38214A4B7DBD095E029780DA933D9" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units activity</link:label>
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B_label_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units Activity [Abstract]</link:label>
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units activity.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="lab_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03688ACF5080132596FF4793EE154D2E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03688ACF5080132596FF4793EE154D2E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Unvested, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03688ACF5080132596FF4793EE154D2E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03688ACF5080132596FF4793EE154D2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03688ACF5080132596FF4793EE154D2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03688ACF5080132596FF4793EE154D2E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03688ACF5080132596FF4793EE154D2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E8CF9AE09F70543DDBFE4793EE159F82_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E8CF9AE09F70543DDBFE4793EE159F82" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E8CF9AE09F70543DDBFE4793EE159F82_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E8CF9AE09F70543DDBFE4793EE159F82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E8CF9AE09F70543DDBFE4793EE159F82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E8CF9AE09F70543DDBFE4793EE159F82" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E8CF9AE09F70543DDBFE4793EE159F82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D7A1902A9D498BBA522D4793EE155E65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D7A1902A9D498BBA522D4793EE155E65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Hemophilia spin-off adjustment</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D7A1902A9D498BBA522D4793EE155E65_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D7A1902A9D498BBA522D4793EE155E65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D7A1902A9D498BBA522D4793EE155E65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D7A1902A9D498BBA522D4793EE155E65" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D7A1902A9D498BBA522D4793EE155E65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_47D8D3C0AE91B271E2994793EE150B73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_47D8D3C0AE91B271E2994793EE150B73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Hemophilia spin-off adjustment</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_47D8D3C0AE91B271E2994793EE150B73_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_47D8D3C0AE91B271E2994793EE150B73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_47D8D3C0AE91B271E2994793EE150B73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_47D8D3C0AE91B271E2994793EE150B73" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_47D8D3C0AE91B271E2994793EE150B73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D898B2765507B069F1DF4793EE150A40_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D898B2765507B069F1DF4793EE150A40" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D898B2765507B069F1DF4793EE150A40_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D898B2765507B069F1DF4793EE150A40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D898B2765507B069F1DF4793EE150A40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D898B2765507B069F1DF4793EE150A40" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D898B2765507B069F1DF4793EE150A40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C2971B52E7174B81A5BC4793EE1529DA_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C2971B52E7174B81A5BC4793EE1529DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C2971B52E7174B81A5BC4793EE1529DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C2971B52E7174B81A5BC4793EE1529DA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C2971B52E7174B81A5BC4793EE1529DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3315B6F6F9547F66AEA84793EE16FF01_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3315B6F6F9547F66AEA84793EE16FF01" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3315B6F6F9547F66AEA84793EE16FF01_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3315B6F6F9547F66AEA84793EE16FF01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3315B6F6F9547F66AEA84793EE16FF01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3315B6F6F9547F66AEA84793EE16FF01" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3315B6F6F9547F66AEA84793EE16FF01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53F438C709FC7DF72A984793EE16EFF9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53F438C709FC7DF72A984793EE16EFF9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53F438C709FC7DF72A984793EE16EFF9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53F438C709FC7DF72A984793EE16EFF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53F438C709FC7DF72A984793EE16EFF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53F438C709FC7DF72A984793EE16EFF9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53F438C709FC7DF72A984793EE16EFF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_401061E7BDF5D4298AAF4793EE161BE6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_401061E7BDF5D4298AAF4793EE161BE6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_401061E7BDF5D4298AAF4793EE161BE6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_401061E7BDF5D4298AAF4793EE161BE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_401061E7BDF5D4298AAF4793EE161BE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_401061E7BDF5D4298AAF4793EE161BE6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_401061E7BDF5D4298AAF4793EE161BE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_D87CD41446959FC27F7E4793EE16D2C1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_D87CD41446959FC27F7E4793EE16D2C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_D87CD41446959FC27F7E4793EE16D2C1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_D87CD41446959FC27F7E4793EE16D2C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_D87CD41446959FC27F7E4793EE16D2C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_D87CD41446959FC27F7E4793EE16D2C1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_D87CD41446959FC27F7E4793EE16D2C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8841B44307CA900F88F24793EE1671B4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8841B44307CA900F88F24793EE1671B4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Unvested, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8841B44307CA900F88F24793EE1671B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8841B44307CA900F88F24793EE1671B4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8841B44307CA900F88F24793EE1671B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D42631ECB41278A7AC5A4793EE16E6F9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D42631ECB41278A7AC5A4793EE16E6F9" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D42631ECB41278A7AC5A4793EE16E6F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D42631ECB41278A7AC5A4793EE16E6F9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D42631ECB41278A7AC5A4793EE16E6F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_2A5C0C2A543E027C1B5A48E1A9D659AB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_2A5C0C2A543E027C1B5A48E1A9D659AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_2A5C0C2A543E027C1B5A48E1A9D659AB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_2A5C0C2A543E027C1B5A48E1A9D659AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_2A5C0C2A543E027C1B5A48E1A9D659AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_2A5C0C2A543E027C1B5A48E1A9D659AB" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_2A5C0C2A543E027C1B5A48E1A9D659AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7BF657A9D287AE920B0A48E1A9D79236_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7BF657A9D287AE920B0A48E1A9D79236" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7BF657A9D287AE920B0A48E1A9D79236_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7BF657A9D287AE920B0A48E1A9D79236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7BF657A9D287AE920B0A48E1A9D79236" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7BF657A9D287AE920B0A48E1A9D79236" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7BF657A9D287AE920B0A48E1A9D79236" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7A8702DE2A3551A12FFE48E1A9D7A341_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7A8702DE2A3551A12FFE48E1A9D7A341" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7A8702DE2A3551A12FFE48E1A9D7A341_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7A8702DE2A3551A12FFE48E1A9D7A341" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7A8702DE2A3551A12FFE48E1A9D7A341" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7A8702DE2A3551A12FFE48E1A9D7A341" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7A8702DE2A3551A12FFE48E1A9D7A341" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_822705E95870F0E1E1BE297C20CDFFEC_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_822705E95870F0E1E1BE297C20CDFFEC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_822705E95870F0E1E1BE297C20CDFFEC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_822705E95870F0E1E1BE297C20CDFFEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_822705E95870F0E1E1BE297C20CDFFEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_822705E95870F0E1E1BE297C20CDFFEC" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_822705E95870F0E1E1BE297C20CDFFEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_C339D3D81FAA1F99BFC3297C20CD2742_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_C339D3D81FAA1F99BFC3297C20CD2742" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_C339D3D81FAA1F99BFC3297C20CD2742_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_C339D3D81FAA1F99BFC3297C20CD2742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_C339D3D81FAA1F99BFC3297C20CD2742" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_C339D3D81FAA1F99BFC3297C20CD2742" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_C339D3D81FAA1F99BFC3297C20CD2742" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_09394DE3EFF4120DE24B297C20CD1FAE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_09394DE3EFF4120DE24B297C20CD1FAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_09394DE3EFF4120DE24B297C20CD1FAE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_09394DE3EFF4120DE24B297C20CD1FAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_09394DE3EFF4120DE24B297C20CD1FAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_09394DE3EFF4120DE24B297C20CD1FAE" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_09394DE3EFF4120DE24B297C20CD1FAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_8AB42ABB90CFE2BE969F2992D931EEC3_terseLabel_en-US" xlink:label="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_8AB42ABB90CFE2BE969F2992D931EEC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option exercises</link:label>
    <link:label id="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_8AB42ABB90CFE2BE969F2992D931EEC3_label_en-US" xlink:label="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_8AB42ABB90CFE2BE969F2992D931EEC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Proceeds Received and Tax Benefit from Share-based Payment Awards [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:label="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_8AB42ABB90CFE2BE969F2992D931EEC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_8AB42ABB90CFE2BE969F2992D931EEC3" xlink:to="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_8AB42ABB90CFE2BE969F2992D931EEC3" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_A23910516D9F342168DB297C20CDCE0A_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_A23910516D9F342168DB297C20CDCE0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market stock units activity</link:label>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_A23910516D9F342168DB297C20CDCE0A_label_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_A23910516D9F342168DB297C20CDCE0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Market Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_A23910516D9F342168DB297C20CDCE0A_documentation_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_A23910516D9F342168DB297C20CDCE0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Market Stock Units Activity.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_A23910516D9F342168DB297C20CDCE0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_A23910516D9F342168DB297C20CDCE0A" xlink:to="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_A23910516D9F342168DB297C20CDCE0A" xlink:type="arc" />
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F2AC849613CA853521A297C20CDBC63_terseLabel_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F2AC849613CA853521A297C20CDBC63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units</link:label>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F2AC849613CA853521A297C20CDBC63_label_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F2AC849613CA853521A297C20CDBC63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assumptions Used In Valuation Of Market Based Stock Units [Table Text Block]</link:label>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F2AC849613CA853521A297C20CDBC63_documentation_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F2AC849613CA853521A297C20CDBC63" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:label="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F2AC849613CA853521A297C20CDBC63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F2AC849613CA853521A297C20CDBC63" xlink:to="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F2AC849613CA853521A297C20CDBC63" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_D011B3E0B322F480DA28297C20CD609F_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_D011B3E0B322F480DA28297C20CD609F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares activity</link:label>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_D011B3E0B322F480DA28297C20CD609F_label_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_D011B3E0B322F480DA28297C20CD609F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Cash Settled Performance Shares Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_D011B3E0B322F480DA28297C20CD609F_documentation_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_D011B3E0B322F480DA28297C20CD609F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Cash Settled Performance Shares Activity.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_D011B3E0B322F480DA28297C20CD609F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_D011B3E0B322F480DA28297C20CD609F" xlink:to="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_D011B3E0B322F480DA28297C20CD609F" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_6738FAFF0B2F14138E47297C20CD17CF_terseLabel_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_6738FAFF0B2F14138E47297C20CD17CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units activity</link:label>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_6738FAFF0B2F14138E47297C20CD17CF_label_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_6738FAFF0B2F14138E47297C20CD17CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance units activity [Table Text Block]</link:label>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_6738FAFF0B2F14138E47297C20CD17CF_documentation_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_6738FAFF0B2F14138E47297C20CD17CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance units activity [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PerformanceunitsactivityTableTextBlock" xlink:label="loc_biib_PerformanceunitsactivityTableTextBlock_6738FAFF0B2F14138E47297C20CD17CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceunitsactivityTableTextBlock_6738FAFF0B2F14138E47297C20CD17CF" xlink:to="lab_biib_PerformanceunitsactivityTableTextBlock_6738FAFF0B2F14138E47297C20CD17CF" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_86E02193AB134243E12D297C20CD37D4_terseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_86E02193AB134243E12D297C20CD37D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units activity</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_86E02193AB134243E12D297C20CD37D4_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_86E02193AB134243E12D297C20CD37D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_86E02193AB134243E12D297C20CD37D4_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_86E02193AB134243E12D297C20CD37D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units Activity.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_86E02193AB134243E12D297C20CD37D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_86E02193AB134243E12D297C20CD37D4" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_86E02193AB134243E12D297C20CD37D4" xlink:type="arc" />
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_586D2C50324B27DD5724297C20CEC9A8_terseLabel_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_586D2C50324B27DD5724297C20CEC9A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_586D2C50324B27DD5724297C20CEC9A8_label_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_586D2C50324B27DD5724297C20CEC9A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Under Employee Stock Purchase Plan [Table Text Block]</link:label>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_586D2C50324B27DD5724297C20CEC9A8_documentation_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_586D2C50324B27DD5724297C20CEC9A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:label="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_586D2C50324B27DD5724297C20CEC9A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_586D2C50324B27DD5724297C20CEC9A8" xlink:to="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_586D2C50324B27DD5724297C20CEC9A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_E1FB6D70E45F6522768542D5E4CF5F5F_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_E1FB6D70E45F6522768542D5E4CF5F5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E1FB6D70E45F6522768542D5E4CF5F5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E1FB6D70E45F6522768542D5E4CF5F5F" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_E1FB6D70E45F6522768542D5E4CF5F5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_FA231860B00DCE0DE67742D5E4CF2CD9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_FA231860B00DCE0DE67742D5E4CF2CD9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_FA231860B00DCE0DE67742D5E4CF2CD9_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_FA231860B00DCE0DE67742D5E4CF2CD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FA231860B00DCE0DE67742D5E4CF2CD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_FA231860B00DCE0DE67742D5E4CF2CD9" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_FA231860B00DCE0DE67742D5E4CF2CD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_421422C35BC5C14B312342D5E4CFA157_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_421422C35BC5C14B312342D5E4CFA157" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_421422C35BC5C14B312342D5E4CFA157_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_421422C35BC5C14B312342D5E4CFA157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_421422C35BC5C14B312342D5E4CFA157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_421422C35BC5C14B312342D5E4CFA157" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_421422C35BC5C14B312342D5E4CFA157" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4025503224EC4B79224542D5E4CFA07E_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_4025503224EC4B79224542D5E4CFA07E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4025503224EC4B79224542D5E4CFA07E_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_4025503224EC4B79224542D5E4CFA07E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4025503224EC4B79224542D5E4CFA07E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_4025503224EC4B79224542D5E4CFA07E" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_4025503224EC4B79224542D5E4CFA07E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_E903A03968CEA6484FC842D5E4D09AFF_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_E903A03968CEA6484FC842D5E4D09AFF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_E903A03968CEA6484FC842D5E4D09AFF_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_E903A03968CEA6484FC842D5E4D09AFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_E903A03968CEA6484FC842D5E4D09AFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_E903A03968CEA6484FC842D5E4D09AFF" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_E903A03968CEA6484FC842D5E4D09AFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_A756F3B3C761E8BEC49B42D5E4D0B3BD_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_A756F3B3C761E8BEC49B42D5E4D0B3BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_A756F3B3C761E8BEC49B42D5E4D0B3BD_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_A756F3B3C761E8BEC49B42D5E4D0B3BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_A756F3B3C761E8BEC49B42D5E4D0B3BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_A756F3B3C761E8BEC49B42D5E4D0B3BD" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_A756F3B3C761E8BEC49B42D5E4D0B3BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_2E314A33D12781C0BB3E42D5E4D025F3_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_2E314A33D12781C0BB3E42D5E4D025F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_2E314A33D12781C0BB3E42D5E4D025F3_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_2E314A33D12781C0BB3E42D5E4D025F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_2E314A33D12781C0BB3E42D5E4D025F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_2E314A33D12781C0BB3E42D5E4D025F3" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_2E314A33D12781C0BB3E42D5E4D025F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_FD5F5BE60DB3718A0B9342D5E4D0BB88_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_FD5F5BE60DB3718A0B9342D5E4D0BB88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_FD5F5BE60DB3718A0B9342D5E4D0BB88_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_FD5F5BE60DB3718A0B9342D5E4D0BB88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_FD5F5BE60DB3718A0B9342D5E4D0BB88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_FD5F5BE60DB3718A0B9342D5E4D0BB88" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_FD5F5BE60DB3718A0B9342D5E4D0BB88" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2F0B93BA0423D082CF5942D5E4D025B8_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2F0B93BA0423D082CF5942D5E4D025B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2F0B93BA0423D082CF5942D5E4D025B8_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2F0B93BA0423D082CF5942D5E4D025B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2F0B93BA0423D082CF5942D5E4D025B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2F0B93BA0423D082CF5942D5E4D025B8" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2F0B93BA0423D082CF5942D5E4D025B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_EACF7D2AE29CC93A2A2342D5E4D001CF_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_EACF7D2AE29CC93A2A2342D5E4D001CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_EACF7D2AE29CC93A2A2342D5E4D001CF_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_EACF7D2AE29CC93A2A2342D5E4D001CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_EACF7D2AE29CC93A2A2342D5E4D001CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_EACF7D2AE29CC93A2A2342D5E4D001CF" xlink:to="lab_us-gaap_AvailableForSaleSecurities_EACF7D2AE29CC93A2A2342D5E4D001CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_DF9745B01C56C34E91B942D5E4D02EB2_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_DF9745B01C56C34E91B942D5E4D02EB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_DF9745B01C56C34E91B942D5E4D02EB2_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_DF9745B01C56C34E91B942D5E4D02EB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_DF9745B01C56C34E91B942D5E4D02EB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_DF9745B01C56C34E91B942D5E4D02EB2" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_DF9745B01C56C34E91B942D5E4D02EB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_717A7FBE228794DFFBDB42D5E4D0DC3A_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_717A7FBE228794DFFBDB42D5E4D0DC3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_717A7FBE228794DFFBDB42D5E4D0DC3A_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_717A7FBE228794DFFBDB42D5E4D0DC3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_717A7FBE228794DFFBDB42D5E4D0DC3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_717A7FBE228794DFFBDB42D5E4D0DC3A" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_717A7FBE228794DFFBDB42D5E4D0DC3A" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_8DF5F140201543FE4E9C42D5E4D1800B_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_8DF5F140201543FE4E9C42D5E4D1800B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_8DF5F140201543FE4E9C42D5E4D1800B_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_8DF5F140201543FE4E9C42D5E4D1800B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8DF5F140201543FE4E9C42D5E4D1800B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8DF5F140201543FE4E9C42D5E4D1800B" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_8DF5F140201543FE4E9C42D5E4D1800B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_12D97F2F813AC9346B4642D5E4D18A3F_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_12D97F2F813AC9346B4642D5E4D18A3F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_12D97F2F813AC9346B4642D5E4D18A3F_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_12D97F2F813AC9346B4642D5E4D18A3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_12D97F2F813AC9346B4642D5E4D18A3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_12D97F2F813AC9346B4642D5E4D18A3F" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_12D97F2F813AC9346B4642D5E4D18A3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_CC8763BEA1FE6C8F604E42D5E4D18580_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_CC8763BEA1FE6C8F604E42D5E4D18580" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_CC8763BEA1FE6C8F604E42D5E4D18580_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_CC8763BEA1FE6C8F604E42D5E4D18580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_CC8763BEA1FE6C8F604E42D5E4D18580" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_CC8763BEA1FE6C8F604E42D5E4D18580" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_CC8763BEA1FE6C8F604E42D5E4D18580" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_DBDFA4F4AA63E7FBCD5942D5E4D16F87_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_DBDFA4F4AA63E7FBCD5942D5E4D16F87" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_DBDFA4F4AA63E7FBCD5942D5E4D16F87_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_DBDFA4F4AA63E7FBCD5942D5E4D16F87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_DBDFA4F4AA63E7FBCD5942D5E4D16F87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_DBDFA4F4AA63E7FBCD5942D5E4D16F87" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_DBDFA4F4AA63E7FBCD5942D5E4D16F87" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_BA6DDFAB03881C1EA62B2978104657D5_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_BA6DDFAB03881C1EA62B2978104657D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_BA6DDFAB03881C1EA62B2978104657D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_BA6DDFAB03881C1EA62B2978104657D5" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_BA6DDFAB03881C1EA62B2978104657D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_938BE22356DCDAD2D35C297810460A8D_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_938BE22356DCDAD2D35C297810460A8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_938BE22356DCDAD2D35C297810460A8D_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_938BE22356DCDAD2D35C297810460A8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_938BE22356DCDAD2D35C297810460A8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_938BE22356DCDAD2D35C297810460A8D" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_938BE22356DCDAD2D35C297810460A8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_35A613DE1055F6826F9429780E76F212_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_35A613DE1055F6826F9429780E76F212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_35A613DE1055F6826F9429780E76F212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35A613DE1055F6826F9429780E76F212" xlink:to="lab_us-gaap_EarningsPerShareAbstract_35A613DE1055F6826F9429780E76F212" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5BFC67285B5C5C8C2E3E29780E7609D3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_5BFC67285B5C5C8C2E3E29780E7609D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5BFC67285B5C5C8C2E3E29780E7609D3_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_5BFC67285B5C5C8C2E3E29780E7609D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5BFC67285B5C5C8C2E3E29780E7609D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_5BFC67285B5C5C8C2E3E29780E7609D3" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_5BFC67285B5C5C8C2E3E29780E7609D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_C8AA19D774477727FE324DC49D22280F_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_C8AA19D774477727FE324DC49D22280F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_C8AA19D774477727FE324DC49D22280F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_C8AA19D774477727FE324DC49D22280F" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_C8AA19D774477727FE324DC49D22280F" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Table]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08_label_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Table]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08_documentation_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of development milestone and collaboration.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:to="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12_label_en-US" xlink:label="lab_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12_documentation_en-US" xlink:label="lab_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12" xlink:to="lab_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12" xlink:type="arc" />
    <link:label id="lab_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D_label_en-US" xlink:label="lab_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D" xlink:to="lab_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:to="lab_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281" xlink:to="lab_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281" xlink:type="arc" />
    <link:label id="lab_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E_terseLabel_en-US" xlink:label="lab_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cambridge, MA</link:label>
    <link:label id="lab_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E_label_en-US" xlink:label="lab_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cambridge, MA [Member]</link:label>
    <link:label id="lab_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E_documentation_en-US" xlink:label="lab_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cambridge, MA [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E" xlink:to="lab_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56_label_en-US" xlink:label="lab_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56" xlink:to="lab_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:type="arc" />
    <link:label id="lab_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1_terseLabel_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:label id="lab_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1_label_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:label id="lab_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1_documentation_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1" xlink:to="lab_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1" xlink:type="arc" />
    <link:label id="lab_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72_terseLabel_en-US" xlink:label="lab_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">iPerian</link:label>
    <link:label id="lab_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72_label_en-US" xlink:label="lab_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">iPerian [Member]</link:label>
    <link:label id="lab_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72_documentation_en-US" xlink:label="lab_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">iPerian [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72" xlink:to="lab_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72" xlink:type="arc" />
    <link:label id="lab_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8_terseLabel_en-US" xlink:label="lab_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alkermes</link:label>
    <link:label id="lab_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8_label_en-US" xlink:label="lab_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alkermes [Member]</link:label>
    <link:label id="lab_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8_documentation_en-US" xlink:label="lab_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alkermes [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8" xlink:to="lab_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8" xlink:type="arc" />
    <link:label id="lab_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF" xlink:to="lab_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Line Items]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163_label_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Line Items]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163_documentation_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_B6650F5CBA1F7B16BBB84DC49D299D25_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_B6650F5CBA1F7B16BBB84DC49D299D25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_B6650F5CBA1F7B16BBB84DC49D299D25_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_B6650F5CBA1F7B16BBB84DC49D299D25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_B6650F5CBA1F7B16BBB84DC49D299D25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_B6650F5CBA1F7B16BBB84DC49D299D25" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_B6650F5CBA1F7B16BBB84DC49D299D25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C09C1623F1D6BAE3FBD14DC49D29B113_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C09C1623F1D6BAE3FBD14DC49D29B113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C09C1623F1D6BAE3FBD14DC49D29B113_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C09C1623F1D6BAE3FBD14DC49D29B113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C09C1623F1D6BAE3FBD14DC49D29B113" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C09C1623F1D6BAE3FBD14DC49D29B113" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C09C1623F1D6BAE3FBD14DC49D29B113" xlink:type="arc" />
    <link:label id="lab_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98_terseLabel_en-US" xlink:label="lab_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developmental Milestone Payment</link:label>
    <link:label id="lab_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98_label_en-US" xlink:label="lab_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developmental Milestone Payment</link:label>
    <link:label id="lab_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98_documentation_en-US" xlink:label="lab_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developmental Milestone Payment</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98" xlink:to="lab_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A1B7462C4FC83A970C644DC49D2981A8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A1B7462C4FC83A970C644DC49D2981A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A1B7462C4FC83A970C644DC49D2981A8_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A1B7462C4FC83A970C644DC49D2981A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A1B7462C4FC83A970C644DC49D2981A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A1B7462C4FC83A970C644DC49D2981A8" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A1B7462C4FC83A970C644DC49D2981A8" xlink:type="arc" />
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA_label_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA" xlink:to="lab_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA" xlink:type="arc" />
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossNoncurrent_68D325E482FE673B88964DC49D298774_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossNoncurrent_68D325E482FE673B88964DC49D298774" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income tax liability under the Transition Toll Tax</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossNoncurrent_68D325E482FE673B88964DC49D298774_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossNoncurrent_68D325E482FE673B88964DC49D298774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_68D325E482FE673B88964DC49D298774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_68D325E482FE673B88964DC49D298774" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossNoncurrent_68D325E482FE673B88964DC49D298774" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_17ABFC2AD73E8EDC240D4DC49D2ABC74_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_17ABFC2AD73E8EDC240D4DC49D2ABC74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated depreciation</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_17ABFC2AD73E8EDC240D4DC49D2ABC74_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_17ABFC2AD73E8EDC240D4DC49D2ABC74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_17ABFC2AD73E8EDC240D4DC49D2ABC74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_17ABFC2AD73E8EDC240D4DC49D2ABC74" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_17ABFC2AD73E8EDC240D4DC49D2ABC74" xlink:type="arc" />
    <link:label id="lab_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50_terseLabel_en-US" xlink:label="lab_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50_label_en-US" xlink:label="lab_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50_documentation_en-US" xlink:label="lab_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50" xlink:to="lab_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementExpense_61ADA1ED6750A50D323D4DC49D30CE70_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_61ADA1ED6750A50D323D4DC49D30CE70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA litigation settlement charge</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_61ADA1ED6750A50D323D4DC49D30CE70_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_61ADA1ED6750A50D323D4DC49D30CE70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_61ADA1ED6750A50D323D4DC49D30CE70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense_61ADA1ED6750A50D323D4DC49D30CE70" xlink:to="lab_us-gaap_LitigationSettlementExpense_61ADA1ED6750A50D323D4DC49D30CE70" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B" xlink:type="arc" />
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0_verboseLabel_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0_label_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Activity [Abstract]</link:label>
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0_documentation_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted stock units activity.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="lab_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_84D5F989EB3970BFCCCC43AA3FF698C2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_84D5F989EB3970BFCCCC43AA3FF698C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_84D5F989EB3970BFCCCC43AA3FF698C2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_84D5F989EB3970BFCCCC43AA3FF698C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_84D5F989EB3970BFCCCC43AA3FF698C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_84D5F989EB3970BFCCCC43AA3FF698C2" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_84D5F989EB3970BFCCCC43AA3FF698C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_C7FD7C0978C311A42F2B43AA3FF61A7B_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_C7FD7C0978C311A42F2B43AA3FF61A7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_C7FD7C0978C311A42F2B43AA3FF61A7B_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_C7FD7C0978C311A42F2B43AA3FF61A7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_C7FD7C0978C311A42F2B43AA3FF61A7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_C7FD7C0978C311A42F2B43AA3FF61A7B" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_C7FD7C0978C311A42F2B43AA3FF61A7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ACC1C28B5069435C73BE4311A50E5C6D_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ACC1C28B5069435C73BE4311A50E5C6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ACC1C28B5069435C73BE4311A50E5C6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ACC1C28B5069435C73BE4311A50E5C6D" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ACC1C28B5069435C73BE4311A50E5C6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1" xlink:type="arc" />
    <link:label id="lab_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B_terseLabel_en-US" xlink:label="lab_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B_label_en-US" xlink:label="lab_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:label id="lab_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B_documentation_en-US" xlink:label="lab_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B" xlink:to="lab_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B" xlink:type="arc" />
    <link:label id="lab_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42_terseLabel_en-US" xlink:label="lab_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumapharm AG</link:label>
    <link:label id="lab_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42_label_en-US" xlink:label="lab_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:label id="lab_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42_documentation_en-US" xlink:label="lab_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42" xlink:to="lab_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:to="lab_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_28AB1D89AEC10680D7074311A50FD1CE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_28AB1D89AEC10680D7074311A50FD1CE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Elimination of goodwill allocated to our hemophilia business</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_28AB1D89AEC10680D7074311A50FD1CE_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_28AB1D89AEC10680D7074311A50FD1CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_28AB1D89AEC10680D7074311A50FD1CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_28AB1D89AEC10680D7074311A50FD1CE" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_28AB1D89AEC10680D7074311A50FD1CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EC8A2FB671F4DC45DF34311A50F9514_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EC8A2FB671F4DC45DF34311A50F9514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EC8A2FB671F4DC45DF34311A50F9514_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EC8A2FB671F4DC45DF34311A50F9514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EC8A2FB671F4DC45DF34311A50F9514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EC8A2FB671F4DC45DF34311A50F9514" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EC8A2FB671F4DC45DF34311A50F9514" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6" xlink:to="lab_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_A2E683CBA3315338D8704311A50F48DF_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_A2E683CBA3315338D8704311A50F48DF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_A2E683CBA3315338D8704311A50F48DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_A2E683CBA3315338D8704311A50F48DF" xlink:to="lab_us-gaap_Goodwill_A2E683CBA3315338D8704311A50F48DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_E1CCC9C1E92938C5CF394311A50F36F5_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_E1CCC9C1E92938C5CF394311A50F36F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_E1CCC9C1E92938C5CF394311A50F36F5_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_E1CCC9C1E92938C5CF394311A50F36F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E1CCC9C1E92938C5CF394311A50F36F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_E1CCC9C1E92938C5CF394311A50F36F5" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_E1CCC9C1E92938C5CF394311A50F36F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_BBBF2D3A9DE26B0CD0BE4311A50FFCEB_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_BBBF2D3A9DE26B0CD0BE4311A50FFCEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_BBBF2D3A9DE26B0CD0BE4311A50FFCEB_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_BBBF2D3A9DE26B0CD0BE4311A50FFCEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_BBBF2D3A9DE26B0CD0BE4311A50FFCEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_BBBF2D3A9DE26B0CD0BE4311A50FFCEB" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_BBBF2D3A9DE26B0CD0BE4311A50FFCEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_54F5306F95AD1B22AD994311A510F12B_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_54F5306F95AD1B22AD994311A510F12B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_54F5306F95AD1B22AD994311A510F12B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_54F5306F95AD1B22AD994311A510F12B" xlink:to="lab_us-gaap_Goodwill_54F5306F95AD1B22AD994311A510F12B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_29720664EC2DCF0D093329780F089643_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_29720664EC2DCF0D093329780F089643" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_29720664EC2DCF0D093329780F089643_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_29720664EC2DCF0D093329780F089643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_29720664EC2DCF0D093329780F089643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_29720664EC2DCF0D093329780F089643" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_29720664EC2DCF0D093329780F089643" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299" xlink:to="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B" xlink:to="lab_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:to="lab_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:type="arc" />
    <link:label id="lab_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24_terseLabel_en-US" xlink:label="lab_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 ESPP</link:label>
    <link:label id="lab_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24_label_en-US" xlink:label="lab_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:label id="lab_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24_documentation_en-US" xlink:label="lab_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24" xlink:to="lab_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24" xlink:type="arc" />
    <link:label id="lab_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71_terseLabel_en-US" xlink:label="lab_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1995 ESPP</link:label>
    <link:label id="lab_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71_label_en-US" xlink:label="lab_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1995 ESPP [Member]</link:label>
    <link:label id="lab_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71_documentation_en-US" xlink:label="lab_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1995 ESPP [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71" xlink:to="lab_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69F8C6C12242950F83B532F209C509B6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69F8C6C12242950F83B532F209C509B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69F8C6C12242950F83B532F209C509B6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69F8C6C12242950F83B532F209C509B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69F8C6C12242950F83B532F209C509B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69F8C6C12242950F83B532F209C509B6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69F8C6C12242950F83B532F209C509B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2867DA325E3169120B2132F209C5565B_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2867DA325E3169120B2132F209C5565B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2867DA325E3169120B2132F209C5565B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2867DA325E3169120B2132F209C5565B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2867DA325E3169120B2132F209C5565B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2867DA325E3169120B2132F209C5565B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2867DA325E3169120B2132F209C5565B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1ADF63AD5377003EE64629780F37E63F_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_1ADF63AD5377003EE64629780F37E63F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1ADF63AD5377003EE64629780F37E63F_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_1ADF63AD5377003EE64629780F37E63F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1ADF63AD5377003EE64629780F37E63F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_1ADF63AD5377003EE64629780F37E63F" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_1ADF63AD5377003EE64629780F37E63F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_6F2B4BFD63F36705659D4C78A533E22B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_6F2B4BFD63F36705659D4C78A533E22B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_6F2B4BFD63F36705659D4C78A533E22B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_6F2B4BFD63F36705659D4C78A533E22B" xlink:to="lab_us-gaap_SubsequentEventsAbstract_6F2B4BFD63F36705659D4C78A533E22B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:to="lab_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:type="arc" />
    <link:label id="lab_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45_terseLabel_en-US" xlink:label="lab_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Karyopharm</link:label>
    <link:label id="lab_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45_label_en-US" xlink:label="lab_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Karyopharm [Member]</link:label>
    <link:label id="lab_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45_documentation_en-US" xlink:label="lab_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Karyopharm [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45" xlink:to="lab_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_FE37E008E7C0A9A714954CC112F74FFB_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_FE37E008E7C0A9A714954CC112F74FFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_FE37E008E7C0A9A714954CC112F74FFB_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_FE37E008E7C0A9A714954CC112F74FFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_FE37E008E7C0A9A714954CC112F74FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_FE37E008E7C0A9A714954CC112F74FFB" xlink:to="lab_us-gaap_SubsequentEventMember_FE37E008E7C0A9A714954CC112F74FFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:to="lab_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_DC15C60734A3F5B2426E29780F5610C5_verboseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_DC15C60734A3F5B2426E29780F5610C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_DC15C60734A3F5B2426E29780F5610C5_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_DC15C60734A3F5B2426E29780F5610C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_DC15C60734A3F5B2426E29780F5610C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_DC15C60734A3F5B2426E29780F5610C5" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_DC15C60734A3F5B2426E29780F5610C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596" xlink:type="arc" />
    <link:label id="lab_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D_verboseLabel_en-US" xlink:label="lab_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D_label_en-US" xlink:label="lab_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D_documentation_en-US" xlink:label="lab_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D" xlink:to="lab_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements and non-collaborative arrangement transactions</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_0E624C28AA79DBED603A492867E64BD5_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_0E624C28AA79DBED603A492867E64BD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenues, net</link:label>
    <link:label id="lab_us-gaap_Revenues_0E624C28AA79DBED603A492867E64BD5_label_en-US" xlink:label="lab_us-gaap_Revenues_0E624C28AA79DBED603A492867E64BD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_0E624C28AA79DBED603A492867E64BD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_0E624C28AA79DBED603A492867E64BD5" xlink:to="lab_us-gaap_Revenues_0E624C28AA79DBED603A492867E64BD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_58BCEB58E451F45127C8493564A98BD8_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_58BCEB58E451F45127C8493564A98BD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_58BCEB58E451F45127C8493564A98BD8_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_58BCEB58E451F45127C8493564A98BD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_58BCEB58E451F45127C8493564A98BD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_58BCEB58E451F45127C8493564A98BD8" xlink:to="lab_us-gaap_CostsAndExpenses_58BCEB58E451F45127C8493564A98BD8" xlink:type="arc" />
    <link:label id="lab_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C_terseLabel_en-US" xlink:label="lab_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profits and losses</link:label>
    <link:label id="lab_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C_label_en-US" xlink:label="lab_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co-promotion profits and losses</link:label>
    <link:label id="lab_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C_documentation_en-US" xlink:label="lab_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profits and losses</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Copromotionprofitsandlosses" xlink:label="loc_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C" xlink:to="lab_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of co-promotion losses</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B" xlink:to="lab_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_A956F75F4E9E6AD2E53042D5E4922534_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_A956F75F4E9E6AD2E53042D5E4922534" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_A956F75F4E9E6AD2E53042D5E4922534_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_A956F75F4E9E6AD2E53042D5E4922534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_A956F75F4E9E6AD2E53042D5E4922534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_A956F75F4E9E6AD2E53042D5E4922534" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_A956F75F4E9E6AD2E53042D5E4922534" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_A99EF515EAE632E6F5F842D5E492CBB8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_A99EF515EAE632E6F5F842D5E492CBB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_A99EF515EAE632E6F5F842D5E492CBB8_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_A99EF515EAE632E6F5F842D5E492CBB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_A99EF515EAE632E6F5F842D5E492CBB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_A99EF515EAE632E6F5F842D5E492CBB8" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_A99EF515EAE632E6F5F842D5E492CBB8" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_13722E3B16E3CA43840642D5E49325B0_verboseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_13722E3B16E3CA43840642D5E49325B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_13722E3B16E3CA43840642D5E49325B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_13722E3B16E3CA43840642D5E49325B0" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_13722E3B16E3CA43840642D5E49325B0" xlink:type="arc" />
    <link:label id="lab_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA_verboseLabel_en-US" xlink:label="lab_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stromedix, Inc.</link:label>
    <link:label id="lab_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA_label_en-US" xlink:label="lab_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stromedix [Member]</link:label>
    <link:label id="lab_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA_documentation_en-US" xlink:label="lab_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stromedix.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA" xlink:to="lab_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA" xlink:type="arc" />
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436_terseLabel_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec International Neuroscience GmbH</link:label>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436_label_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Idec International Neuroscience Member</link:label>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436_documentation_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen idec international neuroscience.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436" xlink:to="lab_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4365BEE9AE015008136642D5E4936CCE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4365BEE9AE015008136642D5E4936CCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on senior notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4365BEE9AE015008136642D5E4936CCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4365BEE9AE015008136642D5E4936CCE" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4365BEE9AE015008136642D5E4936CCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_834E63C6B8011DADD967437EEA8391AD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_834E63C6B8011DADD967437EEA8391AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes aggregate principal amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_834E63C6B8011DADD967437EEA8391AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_834E63C6B8011DADD967437EEA8391AD" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_834E63C6B8011DADD967437EEA8391AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_95CE23979AB447EF518D42D5E4937027_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_95CE23979AB447EF518D42D5E4937027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_95CE23979AB447EF518D42D5E4937027_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_95CE23979AB447EF518D42D5E4937027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_95CE23979AB447EF518D42D5E4937027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_95CE23979AB447EF518D42D5E4937027" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_95CE23979AB447EF518D42D5E4937027" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilities_E6304E73DE32FB6437E042D5E4938454_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities_E6304E73DE32FB6437E042D5E4938454" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestone converted to short-term obligation</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_E6304E73DE32FB6437E042D5E4938454_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities_E6304E73DE32FB6437E042D5E4938454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_E6304E73DE32FB6437E042D5E4938454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities_E6304E73DE32FB6437E042D5E4938454" xlink:to="lab_us-gaap_OtherLiabilities_E6304E73DE32FB6437E042D5E4938454" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B1136CC640F19BD32DBC42D5E49403EA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B1136CC640F19BD32DBC42D5E49403EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements, changes in valuation techniques</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B1136CC640F19BD32DBC42D5E49403EA_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B1136CC640F19BD32DBC42D5E49403EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Changes in Valuation Techniques</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B1136CC640F19BD32DBC42D5E49403EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B1136CC640F19BD32DBC42D5E49403EA" xlink:to="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B1136CC640F19BD32DBC42D5E49403EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_312673440D296193D9B442D5E494C278_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_312673440D296193D9B442D5E494C278" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_312673440D296193D9B442D5E494C278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_312673440D296193D9B442D5E494C278" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_312673440D296193D9B442D5E494C278" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4724197F226F3D3B8F2842D5E494DDAA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4724197F226F3D3B8F2842D5E494DDAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4724197F226F3D3B8F2842D5E494DDAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4724197F226F3D3B8F2842D5E494DDAA" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4724197F226F3D3B8F2842D5E494DDAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_48D0B5EC182091F7CCF242D5E494AE21_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_48D0B5EC182091F7CCF242D5E494AE21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum contingent consideration in the form of development and approval milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_48D0B5EC182091F7CCF242D5E494AE21_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_48D0B5EC182091F7CCF242D5E494AE21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_48D0B5EC182091F7CCF242D5E494AE21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_48D0B5EC182091F7CCF242D5E494AE21" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_48D0B5EC182091F7CCF242D5E494AE21" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_471D4B870B8C2BB33CB142D5E4948F37_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_471D4B870B8C2BB33CB142D5E4948F37" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discount rate used for net cash outflow projections for fair value measurement</link:label>
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_471D4B870B8C2BB33CB142D5E4948F37_label_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_471D4B870B8C2BB33CB142D5E4948F37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_471D4B870B8C2BB33CB142D5E4948F37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsDiscountRate_471D4B870B8C2BB33CB142D5E4948F37" xlink:to="lab_us-gaap_FairValueInputsDiscountRate_471D4B870B8C2BB33CB142D5E4948F37" xlink:type="arc" />
    <link:label id="lab_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26_verboseLabel_en-US" xlink:label="lab_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments made during period</link:label>
    <link:label id="lab_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26_label_en-US" xlink:label="lab_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Made During Period</link:label>
    <link:label id="lab_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26_documentation_en-US" xlink:label="lab_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payments Made During Period.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26" xlink:to="lab_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_CD21B8FC89EE69FEBAE1486D5C480BB3_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_CD21B8FC89EE69FEBAE1486D5C480BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CD21B8FC89EE69FEBAE1486D5C480BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CD21B8FC89EE69FEBAE1486D5C480BB3" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_CD21B8FC89EE69FEBAE1486D5C480BB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_98CE3B3FA09A6BFBF3EA486D5C481546_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_98CE3B3FA09A6BFBF3EA486D5C481546" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_98CE3B3FA09A6BFBF3EA486D5C481546_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_98CE3B3FA09A6BFBF3EA486D5C481546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_98CE3B3FA09A6BFBF3EA486D5C481546" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_98CE3B3FA09A6BFBF3EA486D5C481546" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_98CE3B3FA09A6BFBF3EA486D5C481546" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_06EF11A6B4ACF68E165B486D5C482153_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_06EF11A6B4ACF68E165B486D5C482153" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_06EF11A6B4ACF68E165B486D5C482153_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_06EF11A6B4ACF68E165B486D5C482153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_06EF11A6B4ACF68E165B486D5C482153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_06EF11A6B4ACF68E165B486D5C482153" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_06EF11A6B4ACF68E165B486D5C482153" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4115116CBC1128101DB3486D5C48AFC1_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4115116CBC1128101DB3486D5C48AFC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4115116CBC1128101DB3486D5C48AFC1_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4115116CBC1128101DB3486D5C48AFC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4115116CBC1128101DB3486D5C48AFC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4115116CBC1128101DB3486D5C48AFC1" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4115116CBC1128101DB3486D5C48AFC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_59E31BC8DB8C0DEA4752486D5C49BC78_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_59E31BC8DB8C0DEA4752486D5C49BC78" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_59E31BC8DB8C0DEA4752486D5C49BC78_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_59E31BC8DB8C0DEA4752486D5C49BC78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_59E31BC8DB8C0DEA4752486D5C49BC78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_59E31BC8DB8C0DEA4752486D5C49BC78" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_59E31BC8DB8C0DEA4752486D5C49BC78" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_FEE3F5F5070F9EEBE2D9486D5C49D7D7_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_FEE3F5F5070F9EEBE2D9486D5C49D7D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_FEE3F5F5070F9EEBE2D9486D5C49D7D7_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_FEE3F5F5070F9EEBE2D9486D5C49D7D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_FEE3F5F5070F9EEBE2D9486D5C49D7D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_FEE3F5F5070F9EEBE2D9486D5C49D7D7" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_FEE3F5F5070F9EEBE2D9486D5C49D7D7" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4AECD495E0C803455470486D5C498B57_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4AECD495E0C803455470486D5C498B57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4AECD495E0C803455470486D5C498B57_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4AECD495E0C803455470486D5C498B57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4AECD495E0C803455470486D5C498B57_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4AECD495E0C803455470486D5C498B57" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4AECD495E0C803455470486D5C498B57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4AECD495E0C803455470486D5C498B57" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4AECD495E0C803455470486D5C498B57" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9EA39E3CB42EB9F768D8486D5C494CCD_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9EA39E3CB42EB9F768D8486D5C494CCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Tax Act</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9EA39E3CB42EB9F768D8486D5C494CCD_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9EA39E3CB42EB9F768D8486D5C494CCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9EA39E3CB42EB9F768D8486D5C494CCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9EA39E3CB42EB9F768D8486D5C494CCD" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9EA39E3CB42EB9F768D8486D5C494CCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_23DC652CD706492202A2486D5C492384_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_23DC652CD706492202A2486D5C492384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of ZINBRYTA related tax assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_23DC652CD706492202A2486D5C492384_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_23DC652CD706492202A2486D5C492384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_23DC652CD706492202A2486D5C492384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_23DC652CD706492202A2486D5C492384" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_23DC652CD706492202A2486D5C492384" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2567DF6A24D5EDC62399486D5C4EC86A_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2567DF6A24D5EDC62399486D5C4EC86A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2567DF6A24D5EDC62399486D5C4EC86A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2567DF6A24D5EDC62399486D5C4EC86A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2567DF6A24D5EDC62399486D5C4EC86A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2567DF6A24D5EDC62399486D5C4EC86A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2567DF6A24D5EDC62399486D5C4EC86A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4CC7A88FFAED17D5237A4881C7AAAD4A_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4CC7A88FFAED17D5237A4881C7AAAD4A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4CC7A88FFAED17D5237A4881C7AAAD4A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4CC7A88FFAED17D5237A4881C7AAAD4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4CC7A88FFAED17D5237A4881C7AAAD4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4CC7A88FFAED17D5237A4881C7AAAD4A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4CC7A88FFAED17D5237A4881C7AAAD4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FD7CFFAA894762A58499486D5C4EDDEB_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FD7CFFAA894762A58499486D5C4EDDEB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FD7CFFAA894762A58499486D5C4EDDEB_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FD7CFFAA894762A58499486D5C4EDDEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FD7CFFAA894762A58499486D5C4EDDEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FD7CFFAA894762A58499486D5C4EDDEB" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FD7CFFAA894762A58499486D5C4EDDEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3A34F36982D954565F6C29780F51586F_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3A34F36982D954565F6C29780F51586F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3A34F36982D954565F6C29780F51586F_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3A34F36982D954565F6C29780F51586F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3A34F36982D954565F6C29780F51586F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3A34F36982D954565F6C29780F51586F" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3A34F36982D954565F6C29780F51586F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_B46FEE3F78E472B5DC0329780E5D54F1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_B46FEE3F78E472B5DC0329780E5D54F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_B46FEE3F78E472B5DC0329780E5D54F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_B46FEE3F78E472B5DC0329780E5D54F1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_B46FEE3F78E472B5DC0329780E5D54F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_BEDC349D592B23B8F77A29780E5E4DCB_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_BEDC349D592B23B8F77A29780E5E4DCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_BEDC349D592B23B8F77A29780E5E4DCB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_BEDC349D592B23B8F77A29780E5E4DCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_BEDC349D592B23B8F77A29780E5E4DCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_BEDC349D592B23B8F77A29780E5E4DCB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_BEDC349D592B23B8F77A29780E5E4DCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_250D0CC338ECB51B992329780EE4E134_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_250D0CC338ECB51B992329780EE4E134" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_250D0CC338ECB51B992329780EE4E134_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_250D0CC338ECB51B992329780EE4E134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_250D0CC338ECB51B992329780EE4E134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_250D0CC338ECB51B992329780EE4E134" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_250D0CC338ECB51B992329780EE4E134" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1FD7FBFE225FE7E15C2529780DD73B82_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1FD7FBFE225FE7E15C2529780DD73B82" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1FD7FBFE225FE7E15C2529780DD73B82_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1FD7FBFE225FE7E15C2529780DD73B82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1FD7FBFE225FE7E15C2529780DD73B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1FD7FBFE225FE7E15C2529780DD73B82" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1FD7FBFE225FE7E15C2529780DD73B82" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_325F6B948BDC61BB3BF329780F3331C3_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_325F6B948BDC61BB3BF329780F3331C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_325F6B948BDC61BB3BF329780F3331C3_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_325F6B948BDC61BB3BF329780F3331C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_325F6B948BDC61BB3BF329780F3331C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_325F6B948BDC61BB3BF329780F3331C3" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_325F6B948BDC61BB3BF329780F3331C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_68113B249A725AE3C66029780F0618DF_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_68113B249A725AE3C66029780F0618DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_68113B249A725AE3C66029780F0618DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_68113B249A725AE3C66029780F0618DF" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_68113B249A725AE3C66029780F0618DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ECD0E6AB9F3D85CADE3E29780F07E828_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ECD0E6AB9F3D85CADE3E29780F07E828" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges and spending related to our 2015 restructuring program</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ECD0E6AB9F3D85CADE3E29780F07E828_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ECD0E6AB9F3D85CADE3E29780F07E828" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ECD0E6AB9F3D85CADE3E29780F07E828" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ECD0E6AB9F3D85CADE3E29780F07E828" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ECD0E6AB9F3D85CADE3E29780F07E828" xlink:type="arc" />
    <link:label id="lab_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4_verboseLabel_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable to Fumedica</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4_label_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable To Fumedica [Member]</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4_documentation_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes payable.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4" xlink:to="lab_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_DB9B536B3B58CEF70BB6437BAD4AF5EB_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_DB9B536B3B58CEF70BB6437BAD4AF5EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_DB9B536B3B58CEF70BB6437BAD4AF5EB_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_DB9B536B3B58CEF70BB6437BAD4AF5EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_DB9B536B3B58CEF70BB6437BAD4AF5EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_DB9B536B3B58CEF70BB6437BAD4AF5EB" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_DB9B536B3B58CEF70BB6437BAD4AF5EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_7481D893260022446579437BAD6A6901_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_7481D893260022446579437BAD6A6901" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_7481D893260022446579437BAD6A6901_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_7481D893260022446579437BAD6A6901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_7481D893260022446579437BAD6A6901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_7481D893260022446579437BAD6A6901" xlink:to="lab_us-gaap_DebtInstrumentFairValue_7481D893260022446579437BAD6A6901" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_2646B489F52E7277C69A29780E95C90A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_2646B489F52E7277C69A29780E95C90A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_2646B489F52E7277C69A29780E95C90A_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_2646B489F52E7277C69A29780E95C90A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_2646B489F52E7277C69A29780E95C90A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_2646B489F52E7277C69A29780E95C90A" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_2646B489F52E7277C69A29780E95C90A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_851B7E2CB33F705A5D6B29780E95E8B6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_851B7E2CB33F705A5D6B29780E95E8B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes (benefit):</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_851B7E2CB33F705A5D6B29780E95E8B6_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_851B7E2CB33F705A5D6B29780E95E8B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_851B7E2CB33F705A5D6B29780E95E8B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_851B7E2CB33F705A5D6B29780E95E8B6" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_851B7E2CB33F705A5D6B29780E95E8B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2FC40063F706ED8F564F29780E95E3DB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2FC40063F706ED8F564F29780E95E3DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2FC40063F706ED8F564F29780E95E3DB_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2FC40063F706ED8F564F29780E95E3DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2FC40063F706ED8F564F29780E95E3DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2FC40063F706ED8F564F29780E95E3DB" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2FC40063F706ED8F564F29780E95E3DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89949E504C912CD0C74C29780E95B283_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89949E504C912CD0C74C29780E95B283" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89949E504C912CD0C74C29780E95B283_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89949E504C912CD0C74C29780E95B283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89949E504C912CD0C74C29780E95B283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89949E504C912CD0C74C29780E95B283" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89949E504C912CD0C74C29780E95B283" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_846A4CACE34A952CAE2729780E9545A3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_846A4CACE34A952CAE2729780E9545A3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_846A4CACE34A952CAE2729780E9545A3_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_846A4CACE34A952CAE2729780E9545A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_846A4CACE34A952CAE2729780E9545A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_846A4CACE34A952CAE2729780E9545A3" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_846A4CACE34A952CAE2729780E9545A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_A327C1864ED3C81E8F7D29780E966963_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_A327C1864ED3C81E8F7D29780E966963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit):</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_A327C1864ED3C81E8F7D29780E966963_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_A327C1864ED3C81E8F7D29780E966963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_A327C1864ED3C81E8F7D29780E966963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_A327C1864ED3C81E8F7D29780E966963" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_A327C1864ED3C81E8F7D29780E966963" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_F116A71F680ACCA037D929780E96F572_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_F116A71F680ACCA037D929780E96F572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_F116A71F680ACCA037D929780E96F572_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_F116A71F680ACCA037D929780E96F572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_F116A71F680ACCA037D929780E96F572" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_F116A71F680ACCA037D929780E96F572" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_F116A71F680ACCA037D929780E96F572" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_DAF3C3EBAF0D26B2492E29780E96EA2F_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_DAF3C3EBAF0D26B2492E29780E96EA2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_DAF3C3EBAF0D26B2492E29780E96EA2F_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_DAF3C3EBAF0D26B2492E29780E96EA2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_DAF3C3EBAF0D26B2492E29780E96EA2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_DAF3C3EBAF0D26B2492E29780E96EA2F" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_DAF3C3EBAF0D26B2492E29780E96EA2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_C96A76AC4AC20561F4A429780E96AA17_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_C96A76AC4AC20561F4A429780E96AA17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_C96A76AC4AC20561F4A429780E96AA17_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_C96A76AC4AC20561F4A429780E96AA17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_C96A76AC4AC20561F4A429780E96AA17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_C96A76AC4AC20561F4A429780E96AA17" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_C96A76AC4AC20561F4A429780E96AA17" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_523C44148697A23233FD29780E96BABC_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_523C44148697A23233FD29780E96BABC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_523C44148697A23233FD29780E96BABC_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_523C44148697A23233FD29780E96BABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_523C44148697A23233FD29780E96BABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_523C44148697A23233FD29780E96BABC" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_523C44148697A23233FD29780E96BABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_B909F11E2BAB0F1C2B0D29780E9699F4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_B909F11E2BAB0F1C2B0D29780E9699F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_B909F11E2BAB0F1C2B0D29780E9699F4_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_B909F11E2BAB0F1C2B0D29780E9699F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_B909F11E2BAB0F1C2B0D29780E9699F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_B909F11E2BAB0F1C2B0D29780E9699F4" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_B909F11E2BAB0F1C2B0D29780E9699F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A94BD9DEB56641D7FDF629780E960449_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A94BD9DEB56641D7FDF629780E960449" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A94BD9DEB56641D7FDF629780E960449_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A94BD9DEB56641D7FDF629780E960449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A94BD9DEB56641D7FDF629780E960449" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A94BD9DEB56641D7FDF629780E960449" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A94BD9DEB56641D7FDF629780E960449" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AB692503EB6263862D0029780E97B2ED_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AB692503EB6263862D0029780E97B2ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AB692503EB6263862D0029780E97B2ED_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AB692503EB6263862D0029780E97B2ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AB692503EB6263862D0029780E97B2ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AB692503EB6263862D0029780E97B2ED" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AB692503EB6263862D0029780E97B2ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_985465D308584FECA43129780E970C2C_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_985465D308584FECA43129780E970C2C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_985465D308584FECA43129780E970C2C_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_985465D308584FECA43129780E970C2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_985465D308584FECA43129780E970C2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_985465D308584FECA43129780E970C2C" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_985465D308584FECA43129780E970C2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_CDAAB56FD6AECAB896EC29780E973A98_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_CDAAB56FD6AECAB896EC29780E973A98" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CDAAB56FD6AECAB896EC29780E973A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_CDAAB56FD6AECAB896EC29780E973A98" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_CDAAB56FD6AECAB896EC29780E973A98" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_E9F7A3B8E51504993B9229780F46EDF3_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_E9F7A3B8E51504993B9229780F46EDF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E9F7A3B8E51504993B9229780F46EDF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E9F7A3B8E51504993B9229780F46EDF3" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_E9F7A3B8E51504993B9229780F46EDF3" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_B4CA3DAC549DD823DDE329780F46F80D_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_B4CA3DAC549DD823DDE329780F46F80D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment estimated useful lives</link:label>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_B4CA3DAC549DD823DDE329780F46F80D_label_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_B4CA3DAC549DD823DDE329780F46F80D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_B4CA3DAC549DD823DDE329780F46F80D_documentation_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_B4CA3DAC549DD823DDE329780F46F80D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of property plant and equipment useful lives.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_B4CA3DAC549DD823DDE329780F46F80D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_B4CA3DAC549DD823DDE329780F46F80D" xlink:to="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_B4CA3DAC549DD823DDE329780F46F80D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_C141BED1E8A7179BBAF8328B3CB1E003_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_C141BED1E8A7179BBAF8328B3CB1E003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_C141BED1E8A7179BBAF8328B3CB1E003_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_C141BED1E8A7179BBAF8328B3CB1E003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_C141BED1E8A7179BBAF8328B3CB1E003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_C141BED1E8A7179BBAF8328B3CB1E003" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_C141BED1E8A7179BBAF8328B3CB1E003" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_15F881AE2277AB69338732A6DEA31D67_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_15F881AE2277AB69338732A6DEA31D67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_15F881AE2277AB69338732A6DEA31D67_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_15F881AE2277AB69338732A6DEA31D67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_15F881AE2277AB69338732A6DEA31D67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_15F881AE2277AB69338732A6DEA31D67" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_15F881AE2277AB69338732A6DEA31D67" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7CDF293472BD63870F7732A7557DC20E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7CDF293472BD63870F7732A7557DC20E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7CDF293472BD63870F7732A7557DC20E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7CDF293472BD63870F7732A7557DC20E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7CDF293472BD63870F7732A7557DC20E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7CDF293472BD63870F7732A7557DC20E" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7CDF293472BD63870F7732A7557DC20E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C4E87C4598E3A503B9F832A7D5996D8D_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C4E87C4598E3A503B9F832A7D5996D8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C4E87C4598E3A503B9F832A7D5996D8D_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C4E87C4598E3A503B9F832A7D5996D8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C4E87C4598E3A503B9F832A7D5996D8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C4E87C4598E3A503B9F832A7D5996D8D" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C4E87C4598E3A503B9F832A7D5996D8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_63D28D3D8604BEDC8B2432A9E1126362_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_63D28D3D8604BEDC8B2432A9E1126362" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_63D28D3D8604BEDC8B2432A9E1126362_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_63D28D3D8604BEDC8B2432A9E1126362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_63D28D3D8604BEDC8B2432A9E1126362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_63D28D3D8604BEDC8B2432A9E1126362" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_63D28D3D8604BEDC8B2432A9E1126362" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_C152D8A645566B9B7719328B3CB1DBFF_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_C152D8A645566B9B7719328B3CB1DBFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 and thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_C152D8A645566B9B7719328B3CB1DBFF_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_C152D8A645566B9B7719328B3CB1DBFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_C152D8A645566B9B7719328B3CB1DBFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_C152D8A645566B9B7719328B3CB1DBFF" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_C152D8A645566B9B7719328B3CB1DBFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_9D6EC60343C0774FFB25328B3CB20EB8_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_9D6EC60343C0774FFB25328B3CB20EB8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_9D6EC60343C0774FFB25328B3CB20EB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_9D6EC60343C0774FFB25328B3CB20EB8" xlink:to="lab_us-gaap_LongTermNotesPayable_9D6EC60343C0774FFB25328B3CB20EB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0_terseLabel_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0_label_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:to="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_6B6981A0853A6B4A9FCC29780DB1CD9C_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_6B6981A0853A6B4A9FCC29780DB1CD9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_6B6981A0853A6B4A9FCC29780DB1CD9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_6B6981A0853A6B4A9FCC29780DB1CD9C" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_6B6981A0853A6B4A9FCC29780DB1CD9C" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_E20CC7621BEE4B5EF01529780DB15B19_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_E20CC7621BEE4B5EF01529780DB15B19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_E20CC7621BEE4B5EF01529780DB15B19_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_E20CC7621BEE4B5EF01529780DB15B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_E20CC7621BEE4B5EF01529780DB15B19_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_E20CC7621BEE4B5EF01529780DB15B19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_E20CC7621BEE4B5EF01529780DB15B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_E20CC7621BEE4B5EF01529780DB15B19" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprograms_E20CC7621BEE4B5EF01529780DB15B19" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_29BA00988BB5531F679E29780DB11F26_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_29BA00988BB5531F679E29780DB11F26" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_29BA00988BB5531F679E29780DB11F26_label_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_29BA00988BB5531F679E29780DB11F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_29BA00988BB5531F679E29780DB11F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_29BA00988BB5531F679E29780DB11F26" xlink:to="lab_us-gaap_OtherSalesRevenueNet_29BA00988BB5531F679E29780DB11F26" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_8FEF921F1574862C185E29780DB1B0F3_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_8FEF921F1574862C185E29780DB1B0F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8FEF921F1574862C185E29780DB1B0F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_8FEF921F1574862C185E29780DB1B0F3" xlink:to="lab_us-gaap_Revenues_8FEF921F1574862C185E29780DB1B0F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_E3DC1F9596342DC6AC3229780DB16BF9_verboseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_E3DC1F9596342DC6AC3229780DB16BF9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_E3DC1F9596342DC6AC3229780DB16BF9_label_en-US" xlink:label="lab_us-gaap_GrossProfit_E3DC1F9596342DC6AC3229780DB16BF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_E3DC1F9596342DC6AC3229780DB16BF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_E3DC1F9596342DC6AC3229780DB16BF9" xlink:to="lab_us-gaap_GrossProfit_E3DC1F9596342DC6AC3229780DB16BF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_4E41CC528E31B6006C0929780DB1EC74_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_4E41CC528E31B6006C0929780DB1EC74" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_4E41CC528E31B6006C0929780DB1EC74_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_4E41CC528E31B6006C0929780DB1EC74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_4E41CC528E31B6006C0929780DB1EC74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_4E41CC528E31B6006C0929780DB1EC74" xlink:to="lab_us-gaap_ProfitLoss_4E41CC528E31B6006C0929780DB1EC74" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_83380F047BC4AA3D064C29780DB1D7B6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_83380F047BC4AA3D064C29780DB1D7B6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Idec Inc</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_83380F047BC4AA3D064C29780DB1D7B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_83380F047BC4AA3D064C29780DB1D7B6" xlink:to="lab_us-gaap_NetIncomeLoss_83380F047BC4AA3D064C29780DB1D7B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_C0CAFCB73C299AA9E92429780DB1AD90_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_C0CAFCB73C299AA9E92429780DB1AD90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_C0CAFCB73C299AA9E92429780DB1AD90_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_C0CAFCB73C299AA9E92429780DB1AD90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_C0CAFCB73C299AA9E92429780DB1AD90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_C0CAFCB73C299AA9E92429780DB1AD90" xlink:to="lab_us-gaap_EarningsPerShareBasic_C0CAFCB73C299AA9E92429780DB1AD90" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_A2F15F9C113DF35C792E29780DB12F3F_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_A2F15F9C113DF35C792E29780DB12F3F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_A2F15F9C113DF35C792E29780DB12F3F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_A2F15F9C113DF35C792E29780DB12F3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_A2F15F9C113DF35C792E29780DB12F3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_A2F15F9C113DF35C792E29780DB12F3F" xlink:to="lab_us-gaap_EarningsPerShareDiluted_A2F15F9C113DF35C792E29780DB12F3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1278622E6158E46138D629780DB11D45_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1278622E6158E46138D629780DB11D45" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1278622E6158E46138D629780DB11D45_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1278622E6158E46138D629780DB11D45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1278622E6158E46138D629780DB11D45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1278622E6158E46138D629780DB11D45" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1278622E6158E46138D629780DB11D45" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576832FFCC609BF505E729780DB11292_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576832FFCC609BF505E729780DB11292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576832FFCC609BF505E729780DB11292_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576832FFCC609BF505E729780DB11292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576832FFCC609BF505E729780DB11292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576832FFCC609BF505E729780DB11292" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576832FFCC609BF505E729780DB11292" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0AB5F4BF5AC2C8E37E812978105853DD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0AB5F4BF5AC2C8E37E812978105853DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income tax provision and the income tax expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0AB5F4BF5AC2C8E37E812978105853DD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0AB5F4BF5AC2C8E37E812978105853DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0AB5F4BF5AC2C8E37E812978105853DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0AB5F4BF5AC2C8E37E812978105853DD" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0AB5F4BF5AC2C8E37E812978105853DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_24D22210BC5473293A2C29781059B05D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_24D22210BC5473293A2C29781059B05D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_24D22210BC5473293A2C29781059B05D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_24D22210BC5473293A2C29781059B05D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_24D22210BC5473293A2C29781059B05D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_24D22210BC5473293A2C29781059B05D" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_24D22210BC5473293A2C29781059B05D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_51BA099215807AC5094229781059CAB2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_51BA099215807AC5094229781059CAB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_51BA099215807AC5094229781059CAB2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_51BA099215807AC5094229781059CAB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_51BA099215807AC5094229781059CAB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_51BA099215807AC5094229781059CAB2" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_51BA099215807AC5094229781059CAB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CD1263A8EFC826D641CC297810591734_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CD1263A8EFC826D641CC297810591734" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of beginning and ending amount of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CD1263A8EFC826D641CC297810591734_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CD1263A8EFC826D641CC297810591734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CD1263A8EFC826D641CC297810591734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CD1263A8EFC826D641CC297810591734" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CD1263A8EFC826D641CC297810591734" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E72D5470EA8F95E009374D82DD0B98A7_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E72D5470EA8F95E009374D82DD0B98A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E72D5470EA8F95E009374D82DD0B98A7_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E72D5470EA8F95E009374D82DD0B98A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E72D5470EA8F95E009374D82DD0B98A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E72D5470EA8F95E009374D82DD0B98A7" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E72D5470EA8F95E009374D82DD0B98A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2BBB3008D591164600934D82DD0B24FD_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2BBB3008D591164600934D82DD0B24FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2BBB3008D591164600934D82DD0B24FD_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2BBB3008D591164600934D82DD0B24FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2BBB3008D591164600934D82DD0B24FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2BBB3008D591164600934D82DD0B24FD" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2BBB3008D591164600934D82DD0B24FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringChargesMember_CD30800541A694E8F3884D82DD0B33E3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_CD30800541A694E8F3884D82DD0B33E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_CD30800541A694E8F3884D82DD0B33E3_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_CD30800541A694E8F3884D82DD0B33E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_CD30800541A694E8F3884D82DD0B33E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember_CD30800541A694E8F3884D82DD0B33E3" xlink:to="lab_us-gaap_RestructuringChargesMember_CD30800541A694E8F3884D82DD0B33E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_11558621F29E1CDB11264D82DD0BFEA9_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_11558621F29E1CDB11264D82DD0BFEA9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_11558621F29E1CDB11264D82DD0BFEA9_label_en-US" xlink:label="lab_us-gaap_ParentMember_11558621F29E1CDB11264D82DD0BFEA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_11558621F29E1CDB11264D82DD0BFEA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_11558621F29E1CDB11264D82DD0BFEA9" xlink:to="lab_us-gaap_ParentMember_11558621F29E1CDB11264D82DD0BFEA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_B3473B0B42962EA867734D82DD0BEF93_negatedLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_B3473B0B42962EA867734D82DD0BEF93" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_B3473B0B42962EA867734D82DD0BEF93_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_B3473B0B42962EA867734D82DD0BEF93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_B3473B0B42962EA867734D82DD0BEF93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_B3473B0B42962EA867734D82DD0BEF93" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_B3473B0B42962EA867734D82DD0BEF93" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4964900AA64C422F1FE04D82DD0CB945_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4964900AA64C422F1FE04D82DD0CB945" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4964900AA64C422F1FE04D82DD0CB945_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4964900AA64C422F1FE04D82DD0CB945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4964900AA64C422F1FE04D82DD0CB945" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4964900AA64C422F1FE04D82DD0CB945" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4964900AA64C422F1FE04D82DD0CB945" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E5288F555BC9539F88274D82DD0CDBA6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E5288F555BC9539F88274D82DD0CDBA6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E5288F555BC9539F88274D82DD0CDBA6_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E5288F555BC9539F88274D82DD0CDBA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E5288F555BC9539F88274D82DD0CDBA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E5288F555BC9539F88274D82DD0CDBA6" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E5288F555BC9539F88274D82DD0CDBA6" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_86B6D5DAD3A7277CBBE84D82DD0C08F2_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_86B6D5DAD3A7277CBBE84D82DD0C08F2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_86B6D5DAD3A7277CBBE84D82DD0C08F2_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_86B6D5DAD3A7277CBBE84D82DD0C08F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_86B6D5DAD3A7277CBBE84D82DD0C08F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_86B6D5DAD3A7277CBBE84D82DD0C08F2" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_86B6D5DAD3A7277CBBE84D82DD0C08F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the beginning and ending of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_FF6965FB5BFF4D30F945430791055099_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_FF6965FB5BFF4D30F945430791055099" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_FF6965FB5BFF4D30F945430791055099_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_FF6965FB5BFF4D30F945430791055099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_FF6965FB5BFF4D30F945430791055099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_FF6965FB5BFF4D30F945430791055099" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_FF6965FB5BFF4D30F945430791055099" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23B8031CCB9D0548F12443079105901A_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23B8031CCB9D0548F12443079105901A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions based on tax positions related to the current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23B8031CCB9D0548F12443079105901A_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23B8031CCB9D0548F12443079105901A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23B8031CCB9D0548F12443079105901A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23B8031CCB9D0548F12443079105901A" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23B8031CCB9D0548F12443079105901A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C1CF387BC294644738F9430791058052_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C1CF387BC294644738F9430791058052" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions for tax positions of prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C1CF387BC294644738F9430791058052_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C1CF387BC294644738F9430791058052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C1CF387BC294644738F9430791058052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C1CF387BC294644738F9430791058052" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C1CF387BC294644738F9430791058052" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B99E7986E06A1762DF41430791058A25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B99E7986E06A1762DF41430791058A25" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reductions for tax positions of prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B99E7986E06A1762DF41430791058A25_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B99E7986E06A1762DF41430791058A25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B99E7986E06A1762DF41430791058A25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B99E7986E06A1762DF41430791058A25" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B99E7986E06A1762DF41430791058A25" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B87057D34A8AC8C2D62B43079105207B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B87057D34A8AC8C2D62B43079105207B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Statute expirations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B87057D34A8AC8C2D62B43079105207B_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B87057D34A8AC8C2D62B43079105207B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B87057D34A8AC8C2D62B43079105207B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B87057D34A8AC8C2D62B43079105207B" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B87057D34A8AC8C2D62B43079105207B" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1D85534625F3029D87B143079105AB80_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1D85534625F3029D87B143079105AB80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1D85534625F3029D87B143079105AB80_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1D85534625F3029D87B143079105AB80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1D85534625F3029D87B143079105AB80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1D85534625F3029D87B143079105AB80" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1D85534625F3029D87B143079105AB80" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_54EBAC3E43EA76C0330643079105898E_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_54EBAC3E43EA76C0330643079105898E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_54EBAC3E43EA76C0330643079105898E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_54EBAC3E43EA76C0330643079105898E" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_54EBAC3E43EA76C0330643079105898E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_6D660B7013E33F74C4A829780DCD1E73_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_6D660B7013E33F74C4A829780DCD1E73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_6D660B7013E33F74C4A829780DCD1E73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_6D660B7013E33F74C4A829780DCD1E73" xlink:to="lab_us-gaap_SegmentReportingAbstract_6D660B7013E33F74C4A829780DCD1E73" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_04495ED3FE3A25C1725929780DCD9C71_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_04495ED3FE3A25C1725929780DCD9C71" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_04495ED3FE3A25C1725929780DCD9C71_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_04495ED3FE3A25C1725929780DCD9C71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_04495ED3FE3A25C1725929780DCD9C71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_04495ED3FE3A25C1725929780DCD9C71" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_04495ED3FE3A25C1725929780DCD9C71" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance units</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6" xlink:to="lab_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D_terseLabel_en-US" xlink:label="lab_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:label id="lab_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D_label_en-US" xlink:label="lab_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:label id="lab_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D_documentation_en-US" xlink:label="lab_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PerformanceUnitsMember" xlink:label="loc_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D" xlink:to="lab_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_E80A4A019B70A84E80A04D82DD0785B1_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_E80A4A019B70A84E80A04D82DD0785B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E80A4A019B70A84E80A04D82DD0785B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_E80A4A019B70A84E80A04D82DD0785B1" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_E80A4A019B70A84E80A04D82DD0785B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0682D4DA6A376927B09A4300ABE4C58D_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0682D4DA6A376927B09A4300ABE4C58D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0682D4DA6A376927B09A4300ABE4C58D_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0682D4DA6A376927B09A4300ABE4C58D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0682D4DA6A376927B09A4300ABE4C58D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0682D4DA6A376927B09A4300ABE4C58D" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0682D4DA6A376927B09A4300ABE4C58D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95" xlink:to="lab_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:to="lab_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:type="arc" />
    <link:label id="lab_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011_terseLabel_en-US" xlink:label="lab_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Restructuring Charges [Member]</link:label>
    <link:label id="lab_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011_label_en-US" xlink:label="lab_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Restructuring Charges [Member]</link:label>
    <link:label id="lab_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011_documentation_en-US" xlink:label="lab_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_A2017RestructuringChargesMember" xlink:label="loc_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011" xlink:to="lab_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011" xlink:type="arc" />
    <link:label id="lab_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F_terseLabel_en-US" xlink:label="lab_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Restructuring Charges</link:label>
    <link:label id="lab_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F_label_en-US" xlink:label="lab_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Restructuring Charges [Member]</link:label>
    <link:label id="lab_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F_documentation_en-US" xlink:label="lab_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_A2016RestructuringChargesMember" xlink:label="loc_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F" xlink:to="lab_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F" xlink:type="arc" />
    <link:label id="lab_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF_terseLabel_en-US" xlink:label="lab_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Restructuring Charges</link:label>
    <link:label id="lab_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF_label_en-US" xlink:label="lab_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 Restructuring Charges [Member]</link:label>
    <link:label id="lab_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF_documentation_en-US" xlink:label="lab_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF" xlink:to="lab_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonrecurringExpense_B48131A7EA9A84A032464340BF15C58E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonrecurringExpense_B48131A7EA9A84A032464340BF15C58E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total non-recurring operation and capital expenditures</link:label>
    <link:label id="lab_us-gaap_OtherNonrecurringExpense_B48131A7EA9A84A032464340BF15C58E_label_en-US" xlink:label="lab_us-gaap_OtherNonrecurringExpense_B48131A7EA9A84A032464340BF15C58E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonrecurring Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="loc_us-gaap_OtherNonrecurringExpense_B48131A7EA9A84A032464340BF15C58E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringExpense_B48131A7EA9A84A032464340BF15C58E" xlink:to="lab_us-gaap_OtherNonrecurringExpense_B48131A7EA9A84A032464340BF15C58E" xlink:type="arc" />
    <link:label id="lab_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C_terseLabel_en-US" xlink:label="lab_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redirection of resources</link:label>
    <link:label id="lab_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C_label_en-US" xlink:label="lab_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Resources Redirected through Restructuring Program</link:label>
    <link:label id="lab_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C_documentation_en-US" xlink:label="lab_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Resources Redirected through Restructuring Program</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ResourcesRedirectedthroughRestructuringProgram" xlink:label="loc_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C" xlink:to="lab_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_8F8FB149203EEDDE0D6C42D5E53F648F_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_8F8FB149203EEDDE0D6C42D5E53F648F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_8F8FB149203EEDDE0D6C42D5E53F648F_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_8F8FB149203EEDDE0D6C42D5E53F648F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_8F8FB149203EEDDE0D6C42D5E53F648F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_8F8FB149203EEDDE0D6C42D5E53F648F" xlink:to="lab_us-gaap_RestructuringCharges_8F8FB149203EEDDE0D6C42D5E53F648F" xlink:type="arc" />
    <link:label id="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1_terseLabel_en-US" xlink:label="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected percentage of positions eliminated</link:label>
    <link:label id="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1_label_en-US" xlink:label="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected percentage of positions eliminated</link:label>
    <link:label id="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1_documentation_en-US" xlink:label="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected percentage of positions eliminated</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" xlink:label="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1" xlink:to="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1" xlink:type="arc" />
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9_terseLabel_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously accrued incentive compensation</link:label>
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9_label_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cash Payments</link:label>
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9_documentation_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cash Payments</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9" xlink:to="lab_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_BFEB21C5484BA746811742D5E53FF37A_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1_BFEB21C5484BA746811742D5E53FF37A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to previous estimates, net</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_BFEB21C5484BA746811742D5E53FF37A_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1_BFEB21C5484BA746811742D5E53FF37A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_BFEB21C5484BA746811742D5E53FF37A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment1_BFEB21C5484BA746811742D5E53FF37A" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment1_BFEB21C5484BA746811742D5E53FF37A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_0E3A77DDAEABAA2D721442D5E53FA951_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_0E3A77DDAEABAA2D721442D5E53FA951" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total restructuring charges expected</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_0E3A77DDAEABAA2D721442D5E53FA951_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_0E3A77DDAEABAA2D721442D5E53FA951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_0E3A77DDAEABAA2D721442D5E53FA951" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_0E3A77DDAEABAA2D721442D5E53FA951" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_0E3A77DDAEABAA2D721442D5E53FA951" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_92D1576807338D4BAAC443493952C1AE_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_92D1576807338D4BAAC443493952C1AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_92D1576807338D4BAAC443493952C1AE_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_92D1576807338D4BAAC443493952C1AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_92D1576807338D4BAAC443493952C1AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_92D1576807338D4BAAC443493952C1AE" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_92D1576807338D4BAAC443493952C1AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_E5A83DE80D8BE25380F3434939530357_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_E5A83DE80D8BE25380F3434939530357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_E5A83DE80D8BE25380F3434939530357_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_E5A83DE80D8BE25380F3434939530357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_E5A83DE80D8BE25380F3434939530357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_E5A83DE80D8BE25380F3434939530357" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_E5A83DE80D8BE25380F3434939530357" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_4FDFE935AA946F943198434939539E74" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_E16DFC482D1D78C9E32143493953787B_verboseLabel_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_E16DFC482D1D78C9E32143493953787B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_E16DFC482D1D78C9E32143493953787B_label_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_E16DFC482D1D78C9E32143493953787B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discount [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_E16DFC482D1D78C9E32143493953787B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReserveForCashDiscountMember_E16DFC482D1D78C9E32143493953787B" xlink:to="lab_us-gaap_ReserveForCashDiscountMember_E16DFC482D1D78C9E32143493953787B" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_781CCD22D36CE1B6B332434939535753_verboseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_781CCD22D36CE1B6B332434939535753" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contractual Adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_781CCD22D36CE1B6B332434939535753_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_781CCD22D36CE1B6B332434939535753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_781CCD22D36CE1B6B332434939535753_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_781CCD22D36CE1B6B332434939535753" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_781CCD22D36CE1B6B332434939535753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_781CCD22D36CE1B6B332434939535753" xlink:to="lab_biib_ContractualAdjustmentsMember_781CCD22D36CE1B6B332434939535753" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_0E3094D9355DF7A8600743493953B23C_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_0E3094D9355DF7A8600743493953B23C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_0E3094D9355DF7A8600743493953B23C_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_0E3094D9355DF7A8600743493953B23C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_0E3094D9355DF7A8600743493953B23C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_0E3094D9355DF7A8600743493953B23C" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_0E3094D9355DF7A8600743493953B23C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_1F1FB62DB5BEE3DDDFA6434939532451_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_1F1FB62DB5BEE3DDDFA6434939532451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_1F1FB62DB5BEE3DDDFA6434939532451_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_1F1FB62DB5BEE3DDDFA6434939532451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_1F1FB62DB5BEE3DDDFA6434939532451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_1F1FB62DB5BEE3DDDFA6434939532451" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_1F1FB62DB5BEE3DDDFA6434939532451" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in, reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Abstract]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_DA977C494D3B640C09E1434939536098" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_1D4171D49335C2A9337143493953720F_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_1D4171D49335C2A9337143493953720F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1D4171D49335C2A9337143493953720F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_1D4171D49335C2A9337143493953720F" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_1D4171D49335C2A9337143493953720F" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_B239BCC4115F8A446AE6434939532DAD_verboseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_B239BCC4115F8A446AE6434939532DAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current provisions relating to sales in current year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_B239BCC4115F8A446AE6434939532DAD_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_B239BCC4115F8A446AE6434939532DAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_B239BCC4115F8A446AE6434939532DAD_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_B239BCC4115F8A446AE6434939532DAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_B239BCC4115F8A446AE6434939532DAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_B239BCC4115F8A446AE6434939532DAD" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_B239BCC4115F8A446AE6434939532DAD" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_86FF89C37BE69DF0A76043493953BAD1_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_86FF89C37BE69DF0A76043493953BAD1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments relating to prior years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_86FF89C37BE69DF0A76043493953BAD1_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_86FF89C37BE69DF0A76043493953BAD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_86FF89C37BE69DF0A76043493953BAD1_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_86FF89C37BE69DF0A76043493953BAD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_86FF89C37BE69DF0A76043493953BAD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_86FF89C37BE69DF0A76043493953BAD1" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_86FF89C37BE69DF0A76043493953BAD1" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_B0C685E399BF63F8F76243493953AD25_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_B0C685E399BF63F8F76243493953AD25" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/returns relating to sales in current year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_B0C685E399BF63F8F76243493953AD25_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_B0C685E399BF63F8F76243493953AD25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_B0C685E399BF63F8F76243493953AD25_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_B0C685E399BF63F8F76243493953AD25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_B0C685E399BF63F8F76243493953AD25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_B0C685E399BF63F8F76243493953AD25" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_B0C685E399BF63F8F76243493953AD25" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_64F7733DCDDCF6BC0B8943493953882C_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_64F7733DCDDCF6BC0B8943493953882C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/returns relating to sales in prior years</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_64F7733DCDDCF6BC0B8943493953882C_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_64F7733DCDDCF6BC0B8943493953882C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_64F7733DCDDCF6BC0B8943493953882C_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_64F7733DCDDCF6BC0B8943493953882C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_64F7733DCDDCF6BC0B8943493953882C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_64F7733DCDDCF6BC0B8943493953882C" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_64F7733DCDDCF6BC0B8943493953882C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4B547EBD87F96D23288843493953FC7E_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_4B547EBD87F96D23288843493953FC7E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4B547EBD87F96D23288843493953FC7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_4B547EBD87F96D23288843493953FC7E" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_4B547EBD87F96D23288843493953FC7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558" xlink:to="lab_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B" xlink:to="lab_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA" xlink:to="lab_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401_terseLabel_en-US" xlink:label="lab_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of expense reflected within our consolidation statements of income</link:label>
    <link:label id="lab_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401_label_en-US" xlink:label="lab_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Reflected Within Statements Of Income</link:label>
    <link:label id="lab_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401_documentation_en-US" xlink:label="lab_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen Idec's share of expense reflected within our consolidated statements of income.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401" xlink:to="lab_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_0D50DE037D2FBBBEE6E029780F57A116_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_0D50DE037D2FBBBEE6E029780F57A116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0D50DE037D2FBBBEE6E029780F57A116" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0D50DE037D2FBBBEE6E029780F57A116" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_0D50DE037D2FBBBEE6E029780F57A116" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_331F8E152C697EE221E729780F57E3D2_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_331F8E152C697EE221E729780F57E3D2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_331F8E152C697EE221E729780F57E3D2_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_331F8E152C697EE221E729780F57E3D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_331F8E152C697EE221E729780F57E3D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_331F8E152C697EE221E729780F57E3D2" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_331F8E152C697EE221E729780F57E3D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4" xlink:type="arc" />
    <link:label id="lab_country_US_7B8102F90EE619E1FD254C78A5BECAE5_verboseLabel_en-US" xlink:label="lab_country_US_7B8102F90EE619E1FD254C78A5BECAE5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S</link:label>
    <link:label id="lab_country_US_7B8102F90EE619E1FD254C78A5BECAE5_label_en-US" xlink:label="lab_country_US_7B8102F90EE619E1FD254C78A5BECAE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_7B8102F90EE619E1FD254C78A5BECAE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_7B8102F90EE619E1FD254C78A5BECAE5" xlink:to="lab_country_US_7B8102F90EE619E1FD254C78A5BECAE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeMember_BB896068DA76F797B05C4C78A5BECA6D_verboseLabel_en-US" xlink:label="lab_us-gaap_EuropeMember_BB896068DA76F797B05C4C78A5BECA6D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_us-gaap_EuropeMember_BB896068DA76F797B05C4C78A5BECA6D_label_en-US" xlink:label="lab_us-gaap_EuropeMember_BB896068DA76F797B05C4C78A5BECA6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_BB896068DA76F797B05C4C78A5BECA6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeMember_BB896068DA76F797B05C4C78A5BECA6D" xlink:to="lab_us-gaap_EuropeMember_BB896068DA76F797B05C4C78A5BECA6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AsiaMember_443039CDA5D7C091E4D64C78A5BE82FF_verboseLabel_en-US" xlink:label="lab_us-gaap_AsiaMember_443039CDA5D7C091E4D64C78A5BE82FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asia</link:label>
    <link:label id="lab_us-gaap_AsiaMember_443039CDA5D7C091E4D64C78A5BE82FF_label_en-US" xlink:label="lab_us-gaap_AsiaMember_443039CDA5D7C091E4D64C78A5BE82FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AsiaMember" xlink:label="loc_us-gaap_AsiaMember_443039CDA5D7C091E4D64C78A5BE82FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AsiaMember_443039CDA5D7C091E4D64C78A5BE82FF" xlink:to="lab_us-gaap_AsiaMember_443039CDA5D7C091E4D64C78A5BE82FF" xlink:type="arc" />
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502_verboseLabel_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502_label_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Geographical Groups Of Countries Group Other [Member]</link:label>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502_documentation_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment geographical groups of countries group other.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502" xlink:to="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Geographic information</link:label>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E_label_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments, Geographical Areas [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:to="lab_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_ADC6272E61062CAA487A4C78A5C45FD0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_ADC6272E61062CAA487A4C78A5C45FD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_ADC6272E61062CAA487A4C78A5C45FD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_ADC6272E61062CAA487A4C78A5C45FD0" xlink:to="lab_us-gaap_OtherSalesRevenueNet_ADC6272E61062CAA487A4C78A5C45FD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncurrentAssets_71888AEFB0EDB3ABB8F84C78A5C454A0_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_71888AEFB0EDB3ABB8F84C78A5C454A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_71888AEFB0EDB3ABB8F84C78A5C454A0_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_71888AEFB0EDB3ABB8F84C78A5C454A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_71888AEFB0EDB3ABB8F84C78A5C454A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_71888AEFB0EDB3ABB8F84C78A5C454A0" xlink:to="lab_us-gaap_NoncurrentAssets_71888AEFB0EDB3ABB8F84C78A5C454A0" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_EFE407BD1033447F0924434903612406_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_EFE407BD1033447F0924434903612406" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the change in reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_EFE407BD1033447F0924434903612406_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_EFE407BD1033447F0924434903612406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_EFE407BD1033447F0924434903612406_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_EFE407BD1033447F0924434903612406" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_EFE407BD1033447F0924434903612406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_EFE407BD1033447F0924434903612406" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_EFE407BD1033447F0924434903612406" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_FF8688758B241D8405D243490361D8BD_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_FF8688758B241D8405D243490361D8BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total reserves, included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_FF8688758B241D8405D243490361D8BD_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_FF8688758B241D8405D243490361D8BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_FF8688758B241D8405D243490361D8BD_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_FF8688758B241D8405D243490361D8BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_FF8688758B241D8405D243490361D8BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_FF8688758B241D8405D243490361D8BD" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_FF8688758B241D8405D243490361D8BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_2D3C2506C73380C66724438936B11134_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_2D3C2506C73380C66724438936B11134" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_2D3C2506C73380C66724438936B11134_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_2D3C2506C73380C66724438936B11134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_2D3C2506C73380C66724438936B11134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_2D3C2506C73380C66724438936B11134" xlink:to="lab_us-gaap_EquitySecuritiesMember_2D3C2506C73380C66724438936B11134" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_F47BE740AC0EB3FA370842D5E45F66EF_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_F47BE740AC0EB3FA370842D5E45F66EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_F47BE740AC0EB3FA370842D5E45F66EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_F47BE740AC0EB3FA370842D5E45F66EF" xlink:to="lab_us-gaap_AvailableForSaleSecurities_F47BE740AC0EB3FA370842D5E45F66EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2877009FFDC6CAFAB6C542D5E45F6777_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2877009FFDC6CAFAB6C542D5E45F6777" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2877009FFDC6CAFAB6C542D5E45F6777_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2877009FFDC6CAFAB6C542D5E45F6777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2877009FFDC6CAFAB6C542D5E45F6777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2877009FFDC6CAFAB6C542D5E45F6777" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2877009FFDC6CAFAB6C542D5E45F6777" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AECFA319D6E1A4FE06F742D5E45F0B53_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AECFA319D6E1A4FE06F742D5E45F0B53" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AECFA319D6E1A4FE06F742D5E45F0B53_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AECFA319D6E1A4FE06F742D5E45F0B53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AECFA319D6E1A4FE06F742D5E45F0B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AECFA319D6E1A4FE06F742D5E45F0B53" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AECFA319D6E1A4FE06F742D5E45F0B53" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B2606C213A04AB69686442D5E45F2B38_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B2606C213A04AB69686442D5E45F2B38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B2606C213A04AB69686442D5E45F2B38_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B2606C213A04AB69686442D5E45F2B38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B2606C213A04AB69686442D5E45F2B38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B2606C213A04AB69686442D5E45F2B38" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B2606C213A04AB69686442D5E45F2B38" xlink:type="arc" />
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078_verboseLabel_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Marketable Debt Securities</link:label>
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078_label_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Marketable Debt Securities [Abstract]</link:label>
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078_documentation_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ProceedsFromMarketableDebtSecuritiesAbstract" xlink:label="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078" xlink:to="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_DC1B33D15A47F5695A2029780EC2901F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_DC1B33D15A47F5695A2029780EC2901F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_DC1B33D15A47F5695A2029780EC2901F_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_DC1B33D15A47F5695A2029780EC2901F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_DC1B33D15A47F5695A2029780EC2901F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_DC1B33D15A47F5695A2029780EC2901F" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_DC1B33D15A47F5695A2029780EC2901F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_ABED15F7CA729599AB8829780EC278E3_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_ABED15F7CA729599AB8829780EC278E3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_ABED15F7CA729599AB8829780EC278E3_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_ABED15F7CA729599AB8829780EC278E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_ABED15F7CA729599AB8829780EC278E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_ABED15F7CA729599AB8829780EC278E3" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_ABED15F7CA729599AB8829780EC278E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_A6D67BC30418CE3AE43D29780EC244E9_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_A6D67BC30418CE3AE43D29780EC244E9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_A6D67BC30418CE3AE43D29780EC244E9_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_A6D67BC30418CE3AE43D29780EC244E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_A6D67BC30418CE3AE43D29780EC244E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_A6D67BC30418CE3AE43D29780EC244E9" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_A6D67BC30418CE3AE43D29780EC244E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_DAE5763AAD56CF55B0B329780EA4BF6A_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_DAE5763AAD56CF55B0B329780EA4BF6A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_DAE5763AAD56CF55B0B329780EA4BF6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DAE5763AAD56CF55B0B329780EA4BF6A" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_DAE5763AAD56CF55B0B329780EA4BF6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2FB0DEF8E11B3BDC278229780EA420DE_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2FB0DEF8E11B3BDC278229780EA420DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded Status of Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2FB0DEF8E11B3BDC278229780EA420DE_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2FB0DEF8E11B3BDC278229780EA420DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2FB0DEF8E11B3BDC278229780EA420DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2FB0DEF8E11B3BDC278229780EA420DE" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2FB0DEF8E11B3BDC278229780EA420DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_98A269FE7FA2B34AA0DD29780EA48473_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_98A269FE7FA2B34AA0DD29780EA48473" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_98A269FE7FA2B34AA0DD29780EA48473_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_98A269FE7FA2B34AA0DD29780EA48473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_98A269FE7FA2B34AA0DD29780EA48473" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_98A269FE7FA2B34AA0DD29780EA48473" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_98A269FE7FA2B34AA0DD29780EA48473" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5129DB860DD7FA46B1DF29780EA49D99_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5129DB860DD7FA46B1DF29780EA49D99" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5129DB860DD7FA46B1DF29780EA49D99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5129DB860DD7FA46B1DF29780EA49D99" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5129DB860DD7FA46B1DF29780EA49D99" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_F8C4D43CC41EDBCB218629780EA47BB2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_F8C4D43CC41EDBCB218629780EA47BB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_F8C4D43CC41EDBCB218629780EA47BB2_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_F8C4D43CC41EDBCB218629780EA47BB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_F8C4D43CC41EDBCB218629780EA47BB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_F8C4D43CC41EDBCB218629780EA47BB2" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_F8C4D43CC41EDBCB218629780EA47BB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_156158159A03868FC03029780EA40433_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_156158159A03868FC03029780EA40433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_156158159A03868FC03029780EA40433_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_156158159A03868FC03029780EA40433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_156158159A03868FC03029780EA40433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_156158159A03868FC03029780EA40433" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_156158159A03868FC03029780EA40433" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_870709F2DB327297E38C29780EA4A086_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_870709F2DB327297E38C29780EA4A086" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net current period other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_870709F2DB327297E38C29780EA4A086_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_870709F2DB327297E38C29780EA4A086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_870709F2DB327297E38C29780EA4A086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_870709F2DB327297E38C29780EA4A086" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_870709F2DB327297E38C29780EA4A086" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6DA4561176322A11579629780EA5C178_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6DA4561176322A11579629780EA5C178" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6DA4561176322A11579629780EA5C178" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6DA4561176322A11579629780EA5C178" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6DA4561176322A11579629780EA5C178" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892_label_en-US" xlink:label="lab_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892_documentation_en-US" xlink:label="lab_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892" xlink:to="lab_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0_label_en-US" xlink:label="lab_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0" xlink:to="lab_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0" xlink:type="arc" />
    <link:label id="lab_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92_label_en-US" xlink:label="lab_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92" xlink:to="lab_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1" xlink:to="lab_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_A5C84CDB29AA3B6CC2444311A51BA454_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_A5C84CDB29AA3B6CC2444311A51BA454" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_A5C84CDB29AA3B6CC2444311A51BA454_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_A5C84CDB29AA3B6CC2444311A51BA454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_A5C84CDB29AA3B6CC2444311A51BA454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_A5C84CDB29AA3B6CC2444311A51BA454" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_A5C84CDB29AA3B6CC2444311A51BA454" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_4D64627D5C191E8D42A44311A51BEF67_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_4D64627D5C191E8D42A44311A51BEF67" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and trade names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_4D64627D5C191E8D42A44311A51BEF67_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_4D64627D5C191E8D42A44311A51BEF67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_4D64627D5C191E8D42A44311A51BEF67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_4D64627D5C191E8D42A44311A51BEF67" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_4D64627D5C191E8D42A44311A51BEF67" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB" xlink:to="lab_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_83606C2E54DCA596926B4311A51BBFCD_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_83606C2E54DCA596926B4311A51BBFCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_83606C2E54DCA596926B4311A51BBFCD_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_83606C2E54DCA596926B4311A51BBFCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_83606C2E54DCA596926B4311A51BBFCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_83606C2E54DCA596926B4311A51BBFCD" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_83606C2E54DCA596926B4311A51BBFCD" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4" xlink:to="lab_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2915C3EE8BFE69F5CA854311A51CC26B_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2915C3EE8BFE69F5CA854311A51CC26B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (In Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2915C3EE8BFE69F5CA854311A51CC26B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2915C3EE8BFE69F5CA854311A51CC26B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2915C3EE8BFE69F5CA854311A51CC26B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2915C3EE8BFE69F5CA854311A51CC26B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2915C3EE8BFE69F5CA854311A51CC26B" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8E32E7757DFFBCFB1C424311A51CE3E1_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8E32E7757DFFBCFB1C424311A51CE3E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8E32E7757DFFBCFB1C424311A51CE3E1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8E32E7757DFFBCFB1C424311A51CE3E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8E32E7757DFFBCFB1C424311A51CE3E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8E32E7757DFFBCFB1C424311A51CE3E1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8E32E7757DFFBCFB1C424311A51CE3E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_94969B9591BAF84FE3E04311A51C9419_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_94969B9591BAF84FE3E04311A51C9419" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_94969B9591BAF84FE3E04311A51C9419_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_94969B9591BAF84FE3E04311A51C9419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_94969B9591BAF84FE3E04311A51C9419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_94969B9591BAF84FE3E04311A51C9419" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_94969B9591BAF84FE3E04311A51C9419" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D131161F7538C0D3AF84311A51CC224_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D131161F7538C0D3AF84311A51CC224" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D131161F7538C0D3AF84311A51CC224_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D131161F7538C0D3AF84311A51CC224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D131161F7538C0D3AF84311A51CC224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D131161F7538C0D3AF84311A51CC224" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D131161F7538C0D3AF84311A51CC224" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_A364197675100F073F884311A51C46E2_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_A364197675100F073F884311A51C46E2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_A364197675100F073F884311A51C46E2_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_A364197675100F073F884311A51C46E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_A364197675100F073F884311A51C46E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_A364197675100F073F884311A51C46E2" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_A364197675100F073F884311A51C46E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_73B436F0E66466C78E324311A51C8AF0_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_73B436F0E66466C78E324311A51C8AF0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_73B436F0E66466C78E324311A51C8AF0_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_73B436F0E66466C78E324311A51C8AF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_73B436F0E66466C78E324311A51C8AF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_73B436F0E66466C78E324311A51C8AF0" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_73B436F0E66466C78E324311A51C8AF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD71245517F7A5A3279C4311A51C31FF_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD71245517F7A5A3279C4311A51C31FF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD71245517F7A5A3279C4311A51C31FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD71245517F7A5A3279C4311A51C31FF" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD71245517F7A5A3279C4311A51C31FF" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Additional Textual)</link:label>
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356_label_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets And Goodwill (Additional Textual) [Abstract]</link:label>
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill additional.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:to="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6346F2C4FD957CDD8E5F4311A51DDCBB_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6346F2C4FD957CDD8E5F4311A51DDCBB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2018</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6346F2C4FD957CDD8E5F4311A51DDCBB_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6346F2C4FD957CDD8E5F4311A51DDCBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6346F2C4FD957CDD8E5F4311A51DDCBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6346F2C4FD957CDD8E5F4311A51DDCBB" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6346F2C4FD957CDD8E5F4311A51DDCBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_00DFA28AD59E528A481B4311A51D5D2B_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_00DFA28AD59E528A481B4311A51D5D2B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_00DFA28AD59E528A481B4311A51D5D2B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_00DFA28AD59E528A481B4311A51D5D2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_00DFA28AD59E528A481B4311A51D5D2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_00DFA28AD59E528A481B4311A51D5D2B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_00DFA28AD59E528A481B4311A51D5D2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54C8CB51977F760122364311A51DA2EB_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54C8CB51977F760122364311A51DA2EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54C8CB51977F760122364311A51DA2EB_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54C8CB51977F760122364311A51DA2EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54C8CB51977F760122364311A51DA2EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54C8CB51977F760122364311A51DA2EB" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54C8CB51977F760122364311A51DA2EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D22C4620967C7AD2C5E44311A51DE6B0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D22C4620967C7AD2C5E44311A51DE6B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D22C4620967C7AD2C5E44311A51DE6B0_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D22C4620967C7AD2C5E44311A51DE6B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D22C4620967C7AD2C5E44311A51DE6B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D22C4620967C7AD2C5E44311A51DE6B0" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D22C4620967C7AD2C5E44311A51DE6B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_572CD81D7087831309024311A51D3061_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_572CD81D7087831309024311A51D3061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_572CD81D7087831309024311A51D3061_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_572CD81D7087831309024311A51D3061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_572CD81D7087831309024311A51D3061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_572CD81D7087831309024311A51D3061" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_572CD81D7087831309024311A51D3061" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_4D8EEE8E6F9AAA57FBE24311A51D91CB_negatedLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_4D8EEE8E6F9AAA57FBE24311A51D91CB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4D8EEE8E6F9AAA57FBE24311A51D91CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_4D8EEE8E6F9AAA57FBE24311A51D91CB" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_4D8EEE8E6F9AAA57FBE24311A51D91CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0A03DDD30513AB04F06A4311A51D8029_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0A03DDD30513AB04F06A4311A51D8029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of out-licensed patent</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0A03DDD30513AB04F06A4311A51D8029_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0A03DDD30513AB04F06A4311A51D8029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0A03DDD30513AB04F06A4311A51D8029" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0A03DDD30513AB04F06A4311A51D8029" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0A03DDD30513AB04F06A4311A51D8029" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4DECF4267B336476D6B74311A51DA3FD_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4DECF4267B336476D6B74311A51DA3FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4DECF4267B336476D6B74311A51DA3FD_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4DECF4267B336476D6B74311A51DA3FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4DECF4267B336476D6B74311A51DA3FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4DECF4267B336476D6B74311A51DA3FD" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4DECF4267B336476D6B74311A51DA3FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3BF24D6BC9937D9E02DB4311A51DDE5A_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3BF24D6BC9937D9E02DB4311A51DDE5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment made to Forward Pharma</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3BF24D6BC9937D9E02DB4311A51DDE5A_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3BF24D6BC9937D9E02DB4311A51DDE5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3BF24D6BC9937D9E02DB4311A51DDE5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3BF24D6BC9937D9E02DB4311A51DDE5A" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3BF24D6BC9937D9E02DB4311A51DDE5A" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_E2F2EC4B203A5440516029780E771081_terseLabel_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_E2F2EC4B203A5440516029780E771081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of common stock</link:label>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_E2F2EC4B203A5440516029780E771081_label_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_E2F2EC4B203A5440516029780E771081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Common Stock [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_E2F2EC4B203A5440516029780E771081_documentation_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_E2F2EC4B203A5440516029780E771081" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of common stock.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SummaryOfCommonStockTableTextBlock" xlink:label="loc_biib_SummaryOfCommonStockTableTextBlock_E2F2EC4B203A5440516029780E771081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfCommonStockTableTextBlock_E2F2EC4B203A5440516029780E771081" xlink:to="lab_biib_SummaryOfCommonStockTableTextBlock_E2F2EC4B203A5440516029780E771081" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8D93AFC5EE4CC005CBFB29780E8C67BC_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8D93AFC5EE4CC005CBFB29780E8C67BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8D93AFC5EE4CC005CBFB29780E8C67BC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8D93AFC5EE4CC005CBFB29780E8C67BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8D93AFC5EE4CC005CBFB29780E8C67BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8D93AFC5EE4CC005CBFB29780E8C67BC" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8D93AFC5EE4CC005CBFB29780E8C67BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0B6C2A46C28A71E3889429780E8CF293_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0B6C2A46C28A71E3889429780E8CF293" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0B6C2A46C28A71E3889429780E8CF293_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0B6C2A46C28A71E3889429780E8CF293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0B6C2A46C28A71E3889429780E8CF293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0B6C2A46C28A71E3889429780E8CF293" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0B6C2A46C28A71E3889429780E8CF293" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3F6A9EF9FE057462394429780E8C419A_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3F6A9EF9FE057462394429780E8C419A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3F6A9EF9FE057462394429780E8C419A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3F6A9EF9FE057462394429780E8C419A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3F6A9EF9FE057462394429780E8C419A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3F6A9EF9FE057462394429780E8C419A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3F6A9EF9FE057462394429780E8C419A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B4CFC891CA6FAC0946FC29780E8C1393_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B4CFC891CA6FAC0946FC29780E8C1393" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B4CFC891CA6FAC0946FC29780E8C1393_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B4CFC891CA6FAC0946FC29780E8C1393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B4CFC891CA6FAC0946FC29780E8C1393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B4CFC891CA6FAC0946FC29780E8C1393" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B4CFC891CA6FAC0946FC29780E8C1393" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_039509697EB10B40002429780E8C5E1C_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_039509697EB10B40002429780E8C5E1C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, Estimated Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_039509697EB10B40002429780E8C5E1C_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_039509697EB10B40002429780E8C5E1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_039509697EB10B40002429780E8C5E1C_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_039509697EB10B40002429780E8C5E1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_039509697EB10B40002429780E8C5E1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_039509697EB10B40002429780E8C5E1C" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_039509697EB10B40002429780E8C5E1C" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_D36B7EA677949B355A8829780E8C186A_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_D36B7EA677949B355A8829780E8C186A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_D36B7EA677949B355A8829780E8C186A_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_D36B7EA677949B355A8829780E8C186A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_D36B7EA677949B355A8829780E8C186A_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_D36B7EA677949B355A8829780E8C186A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_D36B7EA677949B355A8829780E8C186A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_D36B7EA677949B355A8829780E8C186A" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_D36B7EA677949B355A8829780E8C186A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_E77F936D6E4670AF26AE29780E8C2BDE_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_E77F936D6E4670AF26AE29780E8C2BDE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_E77F936D6E4670AF26AE29780E8C2BDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_E77F936D6E4670AF26AE29780E8C2BDE" xlink:to="lab_us-gaap_AvailableForSaleSecurities_E77F936D6E4670AF26AE29780E8C2BDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA638F5E35B070DCA61129780E8C2B40_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA638F5E35B070DCA61129780E8C2B40" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA638F5E35B070DCA61129780E8C2B40_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA638F5E35B070DCA61129780E8C2B40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA638F5E35B070DCA61129780E8C2B40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA638F5E35B070DCA61129780E8C2B40" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA638F5E35B070DCA61129780E8C2B40" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_5D039565B50EBCD902A0485EEBF24FC9_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_5D039565B50EBCD902A0485EEBF24FC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_5D039565B50EBCD902A0485EEBF24FC9_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_5D039565B50EBCD902A0485EEBF24FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_5D039565B50EBCD902A0485EEBF24FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_5D039565B50EBCD902A0485EEBF24FC9" xlink:to="lab_us-gaap_PerformanceSharesMember_5D039565B50EBCD902A0485EEBF24FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2C0746EF47AC63D23E1429780FB90895_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2C0746EF47AC63D23E1429780FB90895" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2C0746EF47AC63D23E1429780FB90895_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2C0746EF47AC63D23E1429780FB90895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2C0746EF47AC63D23E1429780FB90895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2C0746EF47AC63D23E1429780FB90895" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2C0746EF47AC63D23E1429780FB90895" xlink:type="arc" />
    <link:label id="lab_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272_terseLabel_en-US" xlink:label="lab_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GAZYVA</link:label>
    <link:label id="lab_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272_label_en-US" xlink:label="lab_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:label id="lab_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272_documentation_en-US" xlink:label="lab_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272" xlink:to="lab_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272" xlink:type="arc" />
    <link:label id="lab_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF_verboseLabel_en-US" xlink:label="lab_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RITUXAN</link:label>
    <link:label id="lab_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF_label_en-US" xlink:label="lab_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RITUXAN [Member]</link:label>
    <link:label id="lab_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF_documentation_en-US" xlink:label="lab_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RITUXAN.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF" xlink:to="lab_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2_verboseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Roche Group - Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2" xlink:to="lab_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Abstract]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:to="lab_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Until GAZYVA First Non-CLL FDA Approval</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option one.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After First GA101 Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two [Abstract]</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Until First GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option one.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After First Threshold Date and until Second Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option two.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After Second Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option three.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777_verboseLabel_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777_label_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues From Unconsolidated Joint Business [Abstract]</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777_documentation_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:to="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_AF05E3B9E866EE9FD734492867CB8813_verboseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_AF05E3B9E866EE9FD734492867CB8813" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_AF05E3B9E866EE9FD734492867CB8813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_AF05E3B9E866EE9FD734492867CB8813" xlink:to="lab_biib_ShareOfCoPromotionProfits_AF05E3B9E866EE9FD734492867CB8813" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_7EFEE7C05BE98E11AEDB492867CB0F1E_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_7EFEE7C05BE98E11AEDB492867CB0F1E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue on sales in the rest of world for RITUXAN</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7EFEE7C05BE98E11AEDB492867CB0F1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_7EFEE7C05BE98E11AEDB492867CB0F1E" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_7EFEE7C05BE98E11AEDB492867CB0F1E" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_4EB31FD49AC6A8CF3907492867CBE0DF_totalLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_4EB31FD49AC6A8CF3907492867CBE0DF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_4EB31FD49AC6A8CF3907492867CBE0DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_4EB31FD49AC6A8CF3907492867CBE0DF" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprograms_4EB31FD49AC6A8CF3907492867CBE0DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B110BD490AE2A71BF64229780DF0455F_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B110BD490AE2A71BF64229780DF0455F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B110BD490AE2A71BF64229780DF0455F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B110BD490AE2A71BF64229780DF0455F" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B110BD490AE2A71BF64229780DF0455F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_3BBC35D2C835039D2FA329780DF06E16_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_3BBC35D2C835039D2FA329780DF06E16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_3BBC35D2C835039D2FA329780DF06E16_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_3BBC35D2C835039D2FA329780DF06E16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_3BBC35D2C835039D2FA329780DF06E16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_3BBC35D2C835039D2FA329780DF06E16" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_3BBC35D2C835039D2FA329780DF06E16" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2BAFDDD67EBEF2A2B10F29780DF0F8E6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2BAFDDD67EBEF2A2B10F29780DF0F8E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on our consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2BAFDDD67EBEF2A2B10F29780DF0F8E6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2BAFDDD67EBEF2A2B10F29780DF0F8E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2BAFDDD67EBEF2A2B10F29780DF0F8E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2BAFDDD67EBEF2A2B10F29780DF0F8E6" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2BAFDDD67EBEF2A2B10F29780DF0F8E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_CCA5C0363CE94C0622F029780DF0DEEE_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_CCA5C0363CE94C0622F029780DF0DEEE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the fair value for our outstanding derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_CCA5C0363CE94C0622F029780DF0DEEE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_CCA5C0363CE94C0622F029780DF0DEEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_CCA5C0363CE94C0622F029780DF0DEEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_CCA5C0363CE94C0622F029780DF0DEEE" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_CCA5C0363CE94C0622F029780DF0DEEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86_label_en-US" xlink:label="lab_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86" xlink:to="lab_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:to="lab_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:type="arc" />
    <link:label id="lab_currency_EUR_1C0C501C08B017D7CFCD42D5E4139A73_verboseLabel_en-US" xlink:label="lab_currency_EUR_1C0C501C08B017D7CFCD42D5E4139A73" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_1C0C501C08B017D7CFCD42D5E4139A73_label_en-US" xlink:label="lab_currency_EUR_1C0C501C08B017D7CFCD42D5E4139A73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_1C0C501C08B017D7CFCD42D5E4139A73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_1C0C501C08B017D7CFCD42D5E4139A73" xlink:to="lab_currency_EUR_1C0C501C08B017D7CFCD42D5E4139A73" xlink:type="arc" />
    <link:label id="lab_currency_GBP_FC262194F27359C902CF42D5E414BA36_terseLabel_en-US" xlink:label="lab_currency_GBP_FC262194F27359C902CF42D5E414BA36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound sterling</link:label>
    <link:label id="lab_currency_GBP_FC262194F27359C902CF42D5E414BA36_label_en-US" xlink:label="lab_currency_GBP_FC262194F27359C902CF42D5E414BA36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_FC262194F27359C902CF42D5E414BA36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_FC262194F27359C902CF42D5E414BA36" xlink:to="lab_currency_GBP_FC262194F27359C902CF42D5E414BA36" xlink:type="arc" />
    <link:label id="lab_currency_CHF_B985C169C15EFD4271FB42D5E4148DA9_terseLabel_en-US" xlink:label="lab_currency_CHF_B985C169C15EFD4271FB42D5E4148DA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss francs</link:label>
    <link:label id="lab_currency_CHF_B985C169C15EFD4271FB42D5E4148DA9_label_en-US" xlink:label="lab_currency_CHF_B985C169C15EFD4271FB42D5E4148DA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_B985C169C15EFD4271FB42D5E4148DA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_B985C169C15EFD4271FB42D5E4148DA9" xlink:to="lab_currency_CHF_B985C169C15EFD4271FB42D5E4148DA9" xlink:type="arc" />
    <link:label id="lab_currency_CAD_29E4585609708E7BB70542D5E414C5A5_verboseLabel_en-US" xlink:label="lab_currency_CAD_29E4585609708E7BB70542D5E414C5A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_29E4585609708E7BB70542D5E414C5A5_label_en-US" xlink:label="lab_currency_CAD_29E4585609708E7BB70542D5E414C5A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_29E4585609708E7BB70542D5E414C5A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_29E4585609708E7BB70542D5E414C5A5" xlink:to="lab_currency_CAD_29E4585609708E7BB70542D5E414C5A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_DB5C30CB7B78D0FD1EB242D5E4141B5B_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_DB5C30CB7B78D0FD1EB242D5E4141B5B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_DB5C30CB7B78D0FD1EB242D5E4141B5B_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_DB5C30CB7B78D0FD1EB242D5E4141B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_DB5C30CB7B78D0FD1EB242D5E4141B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_DB5C30CB7B78D0FD1EB242D5E4141B5B" xlink:to="lab_us-gaap_ForeignExchangeContractMember_DB5C30CB7B78D0FD1EB242D5E4141B5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_C88D4CFFDD1C8EE8E61442D5E41A6165_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_C88D4CFFDD1C8EE8E61442D5E41A6165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_C88D4CFFDD1C8EE8E61442D5E41A6165_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_C88D4CFFDD1C8EE8E61442D5E41A6165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_C88D4CFFDD1C8EE8E61442D5E41A6165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_C88D4CFFDD1C8EE8E61442D5E41A6165" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_C88D4CFFDD1C8EE8E61442D5E41A6165" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherInvestmentsMember_2F206D6B8F390965455642D5E41AAA9A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_2F206D6B8F390965455642D5E41AAA9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_2F206D6B8F390965455642D5E41AAA9A_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_2F206D6B8F390965455642D5E41AAA9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_2F206D6B8F390965455642D5E41AAA9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember_2F206D6B8F390965455642D5E41AAA9A" xlink:to="lab_us-gaap_OtherInvestmentsMember_2F206D6B8F390965455642D5E41AAA9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384" xlink:to="lab_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:to="lab_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_1406129B11F00BF5C87842D5E41AAED7_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_1406129B11F00BF5C87842D5E41AAED7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_1406129B11F00BF5C87842D5E41AAED7_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_1406129B11F00BF5C87842D5E41AAED7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1406129B11F00BF5C87842D5E41AAED7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1406129B11F00BF5C87842D5E41AAED7" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_1406129B11F00BF5C87842D5E41AAED7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_27F3FDDD9972992165E542D5E41AF449_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_27F3FDDD9972992165E542D5E41AF449" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_27F3FDDD9972992165E542D5E41AF449_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_27F3FDDD9972992165E542D5E41AF449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_27F3FDDD9972992165E542D5E41AF449" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_27F3FDDD9972992165E542D5E41AF449" xlink:to="lab_us-gaap_NondesignatedMember_27F3FDDD9972992165E542D5E41AF449" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_7F1846292181A72C9FA142D5E41A07E5_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_7F1846292181A72C9FA142D5E41A07E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate notional amount</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_7F1846292181A72C9FA142D5E41A07E5_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_7F1846292181A72C9FA142D5E41A07E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_7F1846292181A72C9FA142D5E41A07E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_7F1846292181A72C9FA142D5E41A07E5" xlink:to="lab_invest_DerivativeNotionalAmount_7F1846292181A72C9FA142D5E41A07E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_D88A3AE2CF415E570E2742D5E41A3115_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_D88A3AE2CF415E570E2742D5E41A3115" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset derivatives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_D88A3AE2CF415E570E2742D5E41A3115" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_D88A3AE2CF415E570E2742D5E41A3115" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_D88A3AE2CF415E570E2742D5E41A3115" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A085857E43F3981DFC4642D5E41A7161_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A085857E43F3981DFC4642D5E41A7161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A085857E43F3981DFC4642D5E41A7161_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A085857E43F3981DFC4642D5E41A7161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A085857E43F3981DFC4642D5E41A7161" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A085857E43F3981DFC4642D5E41A7161" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A085857E43F3981DFC4642D5E41A7161" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F_terseLabel_en-US" xlink:label="lab_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn</link:label>
    <link:label id="lab_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F_label_en-US" xlink:label="lab_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn [Member]</link:label>
    <link:label id="lab_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F_documentation_en-US" xlink:label="lab_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F" xlink:to="lab_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F" xlink:type="arc" />
    <link:label id="lab_country_DK_278C9BCB8D834ABD39834C78A5A9B5B6_terseLabel_en-US" xlink:label="lab_country_DK_278C9BCB8D834ABD39834C78A5A9B5B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DENMARK</link:label>
    <link:label id="lab_country_DK_278C9BCB8D834ABD39834C78A5A9B5B6_label_en-US" xlink:label="lab_country_DK_278C9BCB8D834ABD39834C78A5A9B5B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DENMARK</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DK" xlink:label="loc_country_DK_278C9BCB8D834ABD39834C78A5A9B5B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DK_278C9BCB8D834ABD39834C78A5A9B5B6" xlink:to="lab_country_DK_278C9BCB8D834ABD39834C78A5A9B5B6" xlink:type="arc" />
    <link:label id="lab_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C_terseLabel_en-US" xlink:label="lab_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Distributor [Axis]</link:label>
    <link:label id="lab_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C_label_en-US" xlink:label="lab_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Distributor [Axis]</link:label>
    <link:label id="lab_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C_documentation_en-US" xlink:label="lab_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Distributor.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:to="lab_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:type="arc" />
    <link:label id="lab_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019_terseLabel_en-US" xlink:label="lab_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Distributor [Domain]</link:label>
    <link:label id="lab_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019_label_en-US" xlink:label="lab_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Distributor [Domain]</link:label>
    <link:label id="lab_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019_documentation_en-US" xlink:label="lab_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Distributor.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:to="lab_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F_verboseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F_label_en-US" xlink:label="lab_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F_documentation_en-US" xlink:label="lab_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F" xlink:to="lab_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157_verboseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157_label_en-US" xlink:label="lab_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157" xlink:to="lab_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8_verboseLabel_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs in percentage</link:label>
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8_label_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues In Percentage From Anti-CD20 Therapeutic Programs</link:label>
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8_documentation_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues In Percentage From Anti-CD20 Therapeutic Programs</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8" xlink:to="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8" xlink:type="arc" />
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586_verboseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncurrentAssets_0AA697DCC99C6846F2F54C78A5AAE807_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_0AA697DCC99C6846F2F54C78A5AAE807" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets related to operations in Denmark</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_0AA697DCC99C6846F2F54C78A5AAE807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_0AA697DCC99C6846F2F54C78A5AAE807" xlink:to="lab_us-gaap_NoncurrentAssets_0AA697DCC99C6846F2F54C78A5AAE807" xlink:type="arc" />
    <link:label id="lab_biib_SegmentInformationTextualAbstract_60F7BDC19C2FB98EE7534C78A5AFF0B7_verboseLabel_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_60F7BDC19C2FB98EE7534C78A5AFF0B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_SegmentInformationTextualAbstract_60F7BDC19C2FB98EE7534C78A5AFF0B7_label_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_60F7BDC19C2FB98EE7534C78A5AFF0B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Information (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_SegmentInformationTextualAbstract_60F7BDC19C2FB98EE7534C78A5AFF0B7_documentation_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_60F7BDC19C2FB98EE7534C78A5AFF0B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment Information.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SegmentInformationTextualAbstract" xlink:label="loc_biib_SegmentInformationTextualAbstract_60F7BDC19C2FB98EE7534C78A5AFF0B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SegmentInformationTextualAbstract_60F7BDC19C2FB98EE7534C78A5AFF0B7" xlink:to="lab_biib_SegmentInformationTextualAbstract_60F7BDC19C2FB98EE7534C78A5AFF0B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_9239B76FA3AE740594D84C78A5AFFE6A_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_9239B76FA3AE740594D84C78A5AFFE6A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segment</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_9239B76FA3AE740594D84C78A5AFFE6A_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_9239B76FA3AE740594D84C78A5AFFE6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_9239B76FA3AE740594D84C78A5AFFE6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_9239B76FA3AE740594D84C78A5AFFE6A" xlink:to="lab_us-gaap_NumberOfReportableSegments_9239B76FA3AE740594D84C78A5AFFE6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_5C3B27D31D83F88BFAE74311FDE40FC8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain_5C3B27D31D83F88BFAE74311FDE40FC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_5C3B27D31D83F88BFAE74311FDE40FC8_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain_5C3B27D31D83F88BFAE74311FDE40FC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_5C3B27D31D83F88BFAE74311FDE40FC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_5C3B27D31D83F88BFAE74311FDE40FC8" xlink:to="lab_us-gaap_DeferredTaxAssetDomain_5C3B27D31D83F88BFAE74311FDE40FC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_328DE179D70B59C23B48431225E58DF5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_328DE179D70B59C23B48431225E58DF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_328DE179D70B59C23B48431225E58DF5_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_328DE179D70B59C23B48431225E58DF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_328DE179D70B59C23B48431225E58DF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_328DE179D70B59C23B48431225E58DF5" xlink:to="lab_us-gaap_RetainedEarningsMember_328DE179D70B59C23B48431225E58DF5" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_D96260591B6DB903947742D5E56CFF5A_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_D96260591B6DB903947742D5E56CFF5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_D96260591B6DB903947742D5E56CFF5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_D96260591B6DB903947742D5E56CFF5A" xlink:to="lab_biib_DistributorOneMember_D96260591B6DB903947742D5E56CFF5A" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_9BA299D0F94335D5DF6E42D5E56C457B_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_9BA299D0F94335D5DF6E42D5E56C457B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_9BA299D0F94335D5DF6E42D5E56C457B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_9BA299D0F94335D5DF6E42D5E56C457B" xlink:to="lab_biib_DistributorTwoMember_9BA299D0F94335D5DF6E42D5E56C457B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_78995F40A37FC9E7307742D5E56D53FA_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_78995F40A37FC9E7307742D5E56D53FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_78995F40A37FC9E7307742D5E56D53FA_label_en-US" xlink:label="lab_us-gaap_BuildingMember_78995F40A37FC9E7307742D5E56D53FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_78995F40A37FC9E7307742D5E56D53FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_78995F40A37FC9E7307742D5E56D53FA" xlink:to="lab_us-gaap_BuildingMember_78995F40A37FC9E7307742D5E56D53FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_AD8C0780B2E963F8722742D5E56D1E2F_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_AD8C0780B2E963F8722742D5E56D1E2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_AD8C0780B2E963F8722742D5E56D1E2F_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_AD8C0780B2E963F8722742D5E56D1E2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_AD8C0780B2E963F8722742D5E56D1E2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_AD8C0780B2E963F8722742D5E56D1E2F" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_AD8C0780B2E963F8722742D5E56D1E2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_C7EEB0EC996584428EC142D5E56D349E_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_C7EEB0EC996584428EC142D5E56D349E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_C7EEB0EC996584428EC142D5E56D349E_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_C7EEB0EC996584428EC142D5E56D349E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_C7EEB0EC996584428EC142D5E56D349E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_C7EEB0EC996584428EC142D5E56D349E" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_C7EEB0EC996584428EC142D5E56D349E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_33F9F39C3415DB43A6FC42D5E56DEBDE_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_33F9F39C3415DB43A6FC42D5E56DEBDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_33F9F39C3415DB43A6FC42D5E56DEBDE_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_33F9F39C3415DB43A6FC42D5E56DEBDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_33F9F39C3415DB43A6FC42D5E56DEBDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_33F9F39C3415DB43A6FC42D5E56DEBDE" xlink:to="lab_us-gaap_ComputerEquipmentMember_33F9F39C3415DB43A6FC42D5E56DEBDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3F8C0D2428980966881843111BEE005F_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3F8C0D2428980966881843111BEE005F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3F8C0D2428980966881843111BEE005F_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3F8C0D2428980966881843111BEE005F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3F8C0D2428980966881843111BEE005F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3F8C0D2428980966881843111BEE005F" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3F8C0D2428980966881843111BEE005F" xlink:type="arc" />
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D_terseLabel_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage receivables of wholesale distributor accounted in consolidated receivables</link:label>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D_label_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Receivables Of Wholesale Distributor Accounted In Consolidated Receivables</link:label>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D_documentation_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage receivables of wholesale distributor accounted in consolidated receivables.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D" xlink:to="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_E77A627A35F3E762192042D5E56DBDFB_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_E77A627A35F3E762192042D5E56DBDFB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_E77A627A35F3E762192042D5E56DBDFB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_E77A627A35F3E762192042D5E56DBDFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_E77A627A35F3E762192042D5E56DBDFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_E77A627A35F3E762192042D5E56DBDFB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_E77A627A35F3E762192042D5E56DBDFB" xlink:type="arc" />
    <link:label id="lab_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027_terseLabel_en-US" xlink:label="lab_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business (Textual)</link:label>
    <link:label id="lab_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027_label_en-US" xlink:label="lab_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027_documentation_en-US" xlink:label="lab_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_BusinessTextualAbstract" xlink:label="loc_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:to="lab_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_F818541532E5004AFA3642D5E56D837C_terseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_F818541532E5004AFA3642D5E56D837C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_F818541532E5004AFA3642D5E56D837C_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_F818541532E5004AFA3642D5E56D837C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_F818541532E5004AFA3642D5E56D837C_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_F818541532E5004AFA3642D5E56D837C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_F818541532E5004AFA3642D5E56D837C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_F818541532E5004AFA3642D5E56D837C" xlink:to="lab_biib_InterestInSubsidiary_F818541532E5004AFA3642D5E56D837C" xlink:type="arc" />
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_F4282FADDFAF328A782342D5E56E26AA_verboseLabel_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_F4282FADDFAF328A782342D5E56E26AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment terms of accounts receivable arising from product sales</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_F4282FADDFAF328A782342D5E56E26AA_label_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_F4282FADDFAF328A782342D5E56E26AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Terms Of Accounts Receivable</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_F4282FADDFAF328A782342D5E56E26AA_documentation_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_F4282FADDFAF328A782342D5E56E26AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment  terms of accounts receivable.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PaymentTermsOfAccountsReceivable" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_F4282FADDFAF328A782342D5E56E26AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentTermsOfAccountsReceivable_F4282FADDFAF328A782342D5E56E26AA" xlink:to="lab_biib_PaymentTermsOfAccountsReceivable_F4282FADDFAF328A782342D5E56E26AA" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_FE717A4328CB8488036842D5E56E2D8F_terseLabel_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_FE717A4328CB8488036842D5E56E2D8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives of leasehold improvements</link:label>
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_FE717A4328CB8488036842D5E56E2D8F_label_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_FE717A4328CB8488036842D5E56E2D8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives Of Leasehold Improvements</link:label>
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_FE717A4328CB8488036842D5E56E2D8F_documentation_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_FE717A4328CB8488036842D5E56E2D8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated useful lives of leasehold improvements.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EstimatedUsefulLivesOfLeaseholdImprovements" xlink:label="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_FE717A4328CB8488036842D5E56E2D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_FE717A4328CB8488036842D5E56E2D8F" xlink:to="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_FE717A4328CB8488036842D5E56E2D8F" xlink:type="arc" />
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_1A139CDCE0F06B9884DE42D5E56EB7F8_terseLabel_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_1A139CDCE0F06B9884DE42D5E56EB7F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock under ESPP</link:label>
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_1A139CDCE0F06B9884DE42D5E56EB7F8_label_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_1A139CDCE0F06B9884DE42D5E56EB7F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Price Of Common Stock Under ESPP</link:label>
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_1A139CDCE0F06B9884DE42D5E56EB7F8_documentation_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_1A139CDCE0F06B9884DE42D5E56EB7F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Price Of Common Stock Under ESPP.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PurchasePriceOfCommonStockUnderEspp" xlink:label="loc_biib_PurchasePriceOfCommonStockUnderEspp_1A139CDCE0F06B9884DE42D5E56EB7F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PurchasePriceOfCommonStockUnderEspp_1A139CDCE0F06B9884DE42D5E56EB7F8" xlink:to="lab_biib_PurchasePriceOfCommonStockUnderEspp_1A139CDCE0F06B9884DE42D5E56EB7F8" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_4FE45370AC96F51F4CAA42D5E56EF9F8_terseLabel_en-US" xlink:label="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_4FE45370AC96F51F4CAA42D5E56EF9F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of market value per share of common stock</link:label>
    <link:label id="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_4FE45370AC96F51F4CAA42D5E56EF9F8_label_en-US" xlink:label="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_4FE45370AC96F51F4CAA42D5E56EF9F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Market Value Per Share Of Common Stock</link:label>
    <link:label id="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_4FE45370AC96F51F4CAA42D5E56EF9F8_documentation_en-US" xlink:label="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_4FE45370AC96F51F4CAA42D5E56EF9F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of market value per share of common stock.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfMarketValuePerShareOfCommonStock" xlink:label="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_4FE45370AC96F51F4CAA42D5E56EF9F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_4FE45370AC96F51F4CAA42D5E56EF9F8" xlink:to="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_4FE45370AC96F51F4CAA42D5E56EF9F8" xlink:type="arc" />
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_10CDAF6E79466212804B42D5E56EDD37_terseLabel_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_10CDAF6E79466212804B42D5E56EDD37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense over purchase period</link:label>
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_10CDAF6E79466212804B42D5E56EDD37_label_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_10CDAF6E79466212804B42D5E56EDD37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Expense Over Purchase Period</link:label>
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_10CDAF6E79466212804B42D5E56EDD37_documentation_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_10CDAF6E79466212804B42D5E56EDD37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation expense over purchase period.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CompensationExpenseOverPurchasePeriod" xlink:label="loc_biib_CompensationExpenseOverPurchasePeriod_10CDAF6E79466212804B42D5E56EDD37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CompensationExpenseOverPurchasePeriod_10CDAF6E79466212804B42D5E56EDD37" xlink:to="lab_biib_CompensationExpenseOverPurchasePeriod_10CDAF6E79466212804B42D5E56EDD37" xlink:type="arc" />
    <link:label id="lab_biib_DiscountRateRecognizedInCompensationExpense_61CB54AF5762FE9A594B42D5E56E562D_terseLabel_en-US" xlink:label="lab_biib_DiscountRateRecognizedInCompensationExpense_61CB54AF5762FE9A594B42D5E56E562D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate recognized in compensation expense</link:label>
    <link:label id="lab_biib_DiscountRateRecognizedInCompensationExpense_61CB54AF5762FE9A594B42D5E56E562D_label_en-US" xlink:label="lab_biib_DiscountRateRecognizedInCompensationExpense_61CB54AF5762FE9A594B42D5E56E562D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount Rate Recognized In Compensation Expense</link:label>
    <link:label id="lab_biib_DiscountRateRecognizedInCompensationExpense_61CB54AF5762FE9A594B42D5E56E562D_documentation_en-US" xlink:label="lab_biib_DiscountRateRecognizedInCompensationExpense_61CB54AF5762FE9A594B42D5E56E562D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discount rate recognized in compensation expense.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DiscountRateRecognizedInCompensationExpense" xlink:label="loc_biib_DiscountRateRecognizedInCompensationExpense_61CB54AF5762FE9A594B42D5E56E562D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DiscountRateRecognizedInCompensationExpense_61CB54AF5762FE9A594B42D5E56E562D" xlink:to="lab_biib_DiscountRateRecognizedInCompensationExpense_61CB54AF5762FE9A594B42D5E56E562D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingExpense_328F0B9A55E82CB71EDA42D5E56E56C5_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_328F0B9A55E82CB71EDA42D5E56E56C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_328F0B9A55E82CB71EDA42D5E56E56C5_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_328F0B9A55E82CB71EDA42D5E56E56C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_328F0B9A55E82CB71EDA42D5E56E56C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_328F0B9A55E82CB71EDA42D5E56E56C5" xlink:to="lab_us-gaap_AdvertisingExpense_328F0B9A55E82CB71EDA42D5E56E56C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_531D473CE40B871F5A4229780D9AB999_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_531D473CE40B871F5A4229780D9AB999" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_531D473CE40B871F5A4229780D9AB999_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_531D473CE40B871F5A4229780D9AB999" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_531D473CE40B871F5A4229780D9AB999" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_531D473CE40B871F5A4229780D9AB999" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_531D473CE40B871F5A4229780D9AB999" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_A7050801E79A968C778329780D9AEC66_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_A7050801E79A968C778329780D9AEC66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_A7050801E79A968C778329780D9AEC66_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_A7050801E79A968C778329780D9AEC66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_A7050801E79A968C778329780D9AEC66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_A7050801E79A968C778329780D9AEC66" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_A7050801E79A968C778329780D9AEC66" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ACDE92B09296A3ED6D0829780D9B505F_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ACDE92B09296A3ED6D0829780D9B505F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ACDE92B09296A3ED6D0829780D9B505F_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ACDE92B09296A3ED6D0829780D9B505F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ACDE92B09296A3ED6D0829780D9B505F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ACDE92B09296A3ED6D0829780D9B505F" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ACDE92B09296A3ED6D0829780D9B505F" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216_verboseLabel_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216_label_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Activity [Abstract]</link:label>
    <link:label id="lab_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216_documentation_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock option activity.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_StockOptionActivityAbstract" xlink:label="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="lab_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B36067BB3334F23FC89A4793E6DB424D_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B36067BB3334F23FC89A4793E6DB424D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B36067BB3334F23FC89A4793E6DB424D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B36067BB3334F23FC89A4793E6DB424D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B36067BB3334F23FC89A4793E6DB424D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B36067BB3334F23FC89A4793E6DB424D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B36067BB3334F23FC89A4793E6DB424D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C792A5E0056BA51668274793E6DB0B74_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C792A5E0056BA51668274793E6DB0B74" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C792A5E0056BA51668274793E6DB0B74_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C792A5E0056BA51668274793E6DB0B74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C792A5E0056BA51668274793E6DB0B74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C792A5E0056BA51668274793E6DB0B74" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C792A5E0056BA51668274793E6DB0B74" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_AE22BE3DAC80ED5D0E6D47E7487217DE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_AE22BE3DAC80ED5D0E6D47E7487217DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Hemophilia spin-off adjustment</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_AE22BE3DAC80ED5D0E6D47E7487217DE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_AE22BE3DAC80ED5D0E6D47E7487217DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Share Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_AE22BE3DAC80ED5D0E6D47E7487217DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_AE22BE3DAC80ED5D0E6D47E7487217DE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_AE22BE3DAC80ED5D0E6D47E7487217DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FBA4649A56DBCEB6E4A94793E6DB4A3C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FBA4649A56DBCEB6E4A94793E6DB4A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FBA4649A56DBCEB6E4A94793E6DB4A3C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FBA4649A56DBCEB6E4A94793E6DB4A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FBA4649A56DBCEB6E4A94793E6DB4A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FBA4649A56DBCEB6E4A94793E6DB4A3C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FBA4649A56DBCEB6E4A94793E6DB4A3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D308C4D3C57F6FA4FB6D4793E6DBF5FB_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D308C4D3C57F6FA4FB6D4793E6DBF5FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D308C4D3C57F6FA4FB6D4793E6DBF5FB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D308C4D3C57F6FA4FB6D4793E6DBF5FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D308C4D3C57F6FA4FB6D4793E6DBF5FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D308C4D3C57F6FA4FB6D4793E6DBF5FB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D308C4D3C57F6FA4FB6D4793E6DBF5FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E8736C719CBA6839336B4793E6DB84B4_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E8736C719CBA6839336B4793E6DB84B4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E8736C719CBA6839336B4793E6DB84B4_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E8736C719CBA6839336B4793E6DB84B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E8736C719CBA6839336B4793E6DB84B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E8736C719CBA6839336B4793E6DB84B4" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E8736C719CBA6839336B4793E6DB84B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D5A889F0CE240547A5C04793E6DB3B04_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D5A889F0CE240547A5C04793E6DB3B04" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D5A889F0CE240547A5C04793E6DB3B04_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D5A889F0CE240547A5C04793E6DB3B04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D5A889F0CE240547A5C04793E6DB3B04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D5A889F0CE240547A5C04793E6DB3B04" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D5A889F0CE240547A5C04793E6DB3B04" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409F366526AF3667CC44793E6DC1FC5_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409F366526AF3667CC44793E6DC1FC5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409F366526AF3667CC44793E6DC1FC5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409F366526AF3667CC44793E6DC1FC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409F366526AF3667CC44793E6DC1FC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409F366526AF3667CC44793E6DC1FC5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409F366526AF3667CC44793E6DC1FC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B47BEC4E4E5DB8090EE44793E6DC7466_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B47BEC4E4E5DB8090EE44793E6DC7466" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B47BEC4E4E5DB8090EE44793E6DC7466_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B47BEC4E4E5DB8090EE44793E6DC7466" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B47BEC4E4E5DB8090EE44793E6DC7466" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B47BEC4E4E5DB8090EE44793E6DC7466" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B47BEC4E4E5DB8090EE44793E6DC7466" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_228AC188D017A548AD4D4793E6DC2B6F_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_228AC188D017A548AD4D4793E6DC2B6F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Outstanding shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_228AC188D017A548AD4D4793E6DC2B6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_228AC188D017A548AD4D4793E6DC2B6F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_228AC188D017A548AD4D4793E6DC2B6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9CB1FF0CA2314DFD45034793E6DC5F22_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9CB1FF0CA2314DFD45034793E6DC5F22" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9CB1FF0CA2314DFD45034793E6DC5F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9CB1FF0CA2314DFD45034793E6DC5F22" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9CB1FF0CA2314DFD45034793E6DC5F22" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_41E98E91B2957D5B683629780F50FC28_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_41E98E91B2957D5B683629780F50FC28" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_41E98E91B2957D5B683629780F50FC28_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_41E98E91B2957D5B683629780F50FC28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_41E98E91B2957D5B683629780F50FC28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_41E98E91B2957D5B683629780F50FC28" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_41E98E91B2957D5B683629780F50FC28" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A" xlink:to="lab_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6605733F5E5F20085AF329780F548128_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6605733F5E5F20085AF329780F548128" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6605733F5E5F20085AF329780F548128_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6605733F5E5F20085AF329780F548128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6605733F5E5F20085AF329780F548128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6605733F5E5F20085AF329780F548128" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6605733F5E5F20085AF329780F548128" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_B8727026BF70F6C6DEA329780F54EC83_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_B8727026BF70F6C6DEA329780F54EC83" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_B8727026BF70F6C6DEA329780F54EC83_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_B8727026BF70F6C6DEA329780F54EC83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_B8727026BF70F6C6DEA329780F54EC83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_B8727026BF70F6C6DEA329780F54EC83" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_B8727026BF70F6C6DEA329780F54EC83" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_76CDAE75558AA78DA45C29780F5419FD_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_76CDAE75558AA78DA45C29780F5419FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_76CDAE75558AA78DA45C29780F5419FD_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_76CDAE75558AA78DA45C29780F5419FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_76CDAE75558AA78DA45C29780F5419FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_76CDAE75558AA78DA45C29780F5419FD" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_76CDAE75558AA78DA45C29780F5419FD" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_A5F28BAEB8EA853EFC0329780F5459C9_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_A5F28BAEB8EA853EFC0329780F5459C9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_A5F28BAEB8EA853EFC0329780F5459C9_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_A5F28BAEB8EA853EFC0329780F5459C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_A5F28BAEB8EA853EFC0329780F5459C9_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_A5F28BAEB8EA853EFC0329780F5459C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_A5F28BAEB8EA853EFC0329780F5459C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_A5F28BAEB8EA853EFC0329780F5459C9" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_A5F28BAEB8EA853EFC0329780F5459C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_A65BBC3EB36942D18AFF29780F546988_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_A65BBC3EB36942D18AFF29780F546988" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_A65BBC3EB36942D18AFF29780F546988" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_A65BBC3EB36942D18AFF29780F546988" xlink:to="lab_us-gaap_InventoryNet_A65BBC3EB36942D18AFF29780F546988" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_F6B710D31F5B4766BDED29780F541192_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_F6B710D31F5B4766BDED29780F541192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_F6B710D31F5B4766BDED29780F541192_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_F6B710D31F5B4766BDED29780F541192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_F6B710D31F5B4766BDED29780F541192" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_F6B710D31F5B4766BDED29780F541192" xlink:to="lab_us-gaap_InventoryNoncurrent_F6B710D31F5B4766BDED29780F541192" xlink:type="arc" />
    <link:label id="lab_us-gaap_Land_96EDCA08A67FC83023EE29780E44C4A1_terseLabel_en-US" xlink:label="lab_us-gaap_Land_96EDCA08A67FC83023EE29780E44C4A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_96EDCA08A67FC83023EE29780E44C4A1_label_en-US" xlink:label="lab_us-gaap_Land_96EDCA08A67FC83023EE29780E44C4A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_96EDCA08A67FC83023EE29780E44C4A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land_96EDCA08A67FC83023EE29780E44C4A1" xlink:to="lab_us-gaap_Land_96EDCA08A67FC83023EE29780E44C4A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_C5FF1B60C30E745A44B329780E44DB23_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross_C5FF1B60C30E745A44B329780E44DB23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_C5FF1B60C30E745A44B329780E44DB23_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross_C5FF1B60C30E745A44B329780E44DB23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_C5FF1B60C30E745A44B329780E44DB23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross_C5FF1B60C30E745A44B329780E44DB23" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross_C5FF1B60C30E745A44B329780E44DB23" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_3279CBA14E5DEBB60CE529780E45EDBB_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross_3279CBA14E5DEBB60CE529780E45EDBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_3279CBA14E5DEBB60CE529780E45EDBB_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross_3279CBA14E5DEBB60CE529780E45EDBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_3279CBA14E5DEBB60CE529780E45EDBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross_3279CBA14E5DEBB60CE529780E45EDBB" xlink:to="lab_us-gaap_LeaseholdImprovementsGross_3279CBA14E5DEBB60CE529780E45EDBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_E36FBB3953C5E643B84D29780E45409A_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross_E36FBB3953C5E643B84D29780E45409A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_E36FBB3953C5E643B84D29780E45409A_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross_E36FBB3953C5E643B84D29780E45409A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_E36FBB3953C5E643B84D29780E45409A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross_E36FBB3953C5E643B84D29780E45409A" xlink:to="lab_us-gaap_MachineryAndEquipmentGross_E36FBB3953C5E643B84D29780E45409A" xlink:type="arc" />
    <link:label id="lab_biib_ComputerSoftwareAndHardware_D2F1C601AFFE4997C76F29780E456275_terseLabel_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_D2F1C601AFFE4997C76F29780E456275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_D2F1C601AFFE4997C76F29780E456275_label_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_D2F1C601AFFE4997C76F29780E456275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_D2F1C601AFFE4997C76F29780E456275_documentation_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_D2F1C601AFFE4997C76F29780E456275" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_D2F1C601AFFE4997C76F29780E456275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ComputerSoftwareAndHardware_D2F1C601AFFE4997C76F29780E456275" xlink:to="lab_biib_ComputerSoftwareAndHardware_D2F1C601AFFE4997C76F29780E456275" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_CA0D15F187C5CB2CA30C29780E4508EF_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_CA0D15F187C5CB2CA30C29780E4508EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_CA0D15F187C5CB2CA30C29780E4508EF_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_CA0D15F187C5CB2CA30C29780E4508EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_CA0D15F187C5CB2CA30C29780E4508EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesGross_CA0D15F187C5CB2CA30C29780E4508EF" xlink:to="lab_us-gaap_FurnitureAndFixturesGross_CA0D15F187C5CB2CA30C29780E4508EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_B085AAF256A90A5114F329780E45491C_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_B085AAF256A90A5114F329780E45491C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_B085AAF256A90A5114F329780E45491C_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_B085AAF256A90A5114F329780E45491C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_B085AAF256A90A5114F329780E45491C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_B085AAF256A90A5114F329780E45491C" xlink:to="lab_us-gaap_ConstructionInProgressGross_B085AAF256A90A5114F329780E45491C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_D79193B9649FEE2C41F629780E452579_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_D79193B9649FEE2C41F629780E452579" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_D79193B9649FEE2C41F629780E452579_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_D79193B9649FEE2C41F629780E452579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_D79193B9649FEE2C41F629780E452579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_D79193B9649FEE2C41F629780E452579" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_D79193B9649FEE2C41F629780E452579" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_849A53E00C3F7C4F678829780E45FB3F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_849A53E00C3F7C4F678829780E45FB3F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_849A53E00C3F7C4F678829780E45FB3F_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_849A53E00C3F7C4F678829780E45FB3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_849A53E00C3F7C4F678829780E45FB3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_849A53E00C3F7C4F678829780E45FB3F" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_849A53E00C3F7C4F678829780E45FB3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_53B6544954966C3D257B29780E46FC3A_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_53B6544954966C3D257B29780E46FC3A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_53B6544954966C3D257B29780E46FC3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_53B6544954966C3D257B29780E46FC3A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_53B6544954966C3D257B29780E46FC3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0" xlink:to="lab_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_2BFDC567DCA7781712FE4DAF958CD642_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_2BFDC567DCA7781712FE4DAF958CD642" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of development expenses to be reimbursed</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_2BFDC567DCA7781712FE4DAF958CD642_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_2BFDC567DCA7781712FE4DAF958CD642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_2BFDC567DCA7781712FE4DAF958CD642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_2BFDC567DCA7781712FE4DAF958CD642" xlink:to="lab_us-gaap_ScenarioForecastMember_2BFDC567DCA7781712FE4DAF958CD642" xlink:type="arc" />
    <link:label id="lab_country_US_52B5D7FFF86E5A84FDDF4D7427721A3F_terseLabel_en-US" xlink:label="lab_country_US_52B5D7FFF86E5A84FDDF4D7427721A3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_52B5D7FFF86E5A84FDDF4D7427721A3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_52B5D7FFF86E5A84FDDF4D7427721A3F" xlink:to="lab_country_US_52B5D7FFF86E5A84FDDF4D7427721A3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_DD73FC7841827CC39EBA4D742773A5EE_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_DD73FC7841827CC39EBA4D742773A5EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outside the U.S</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_DD73FC7841827CC39EBA4D742773A5EE_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_DD73FC7841827CC39EBA4D742773A5EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_DD73FC7841827CC39EBA4D742773A5EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_DD73FC7841827CC39EBA4D742773A5EE" xlink:to="lab_us-gaap_ForeignCountryMember_DD73FC7841827CC39EBA4D742773A5EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeanUnionMember_7BD293543F43EACE044E4D742773DA2D_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_7BD293543F43EACE044E4D742773DA2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_7BD293543F43EACE044E4D742773DA2D_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_7BD293543F43EACE044E4D742773DA2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_7BD293543F43EACE044E4D742773DA2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember_7BD293543F43EACE044E4D742773DA2D" xlink:to="lab_us-gaap_EuropeanUnionMember_7BD293543F43EACE044E4D742773DA2D" xlink:type="arc" />
    <link:label id="lab_country_JP_2435909E93E134239CEE4D74277314B1_terseLabel_en-US" xlink:label="lab_country_JP_2435909E93E134239CEE4D74277314B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:label id="lab_country_JP_2435909E93E134239CEE4D74277314B1_label_en-US" xlink:label="lab_country_JP_2435909E93E134239CEE4D74277314B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_2435909E93E134239CEE4D74277314B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_2435909E93E134239CEE4D74277314B1" xlink:to="lab_country_JP_2435909E93E134239CEE4D74277314B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_75BDD951EC5266F76AA24D7427731A8E_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_75BDD951EC5266F76AA24D7427731A8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_75BDD951EC5266F76AA24D7427731A8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_75BDD951EC5266F76AA24D7427731A8E" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_75BDD951EC5266F76AA24D7427731A8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B" xlink:to="lab_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B" xlink:type="arc" />
    <link:label id="lab_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903_verboseLabel_en-US" xlink:label="lab_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">New Anti-CD20</link:label>
    <link:label id="lab_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903_label_en-US" xlink:label="lab_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Anti Cd20 [Member]</link:label>
    <link:label id="lab_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903_documentation_en-US" xlink:label="lab_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Anti-CD20.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903" xlink:to="lab_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903" xlink:type="arc" />
    <link:label id="lab_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C_verboseLabel_en-US" xlink:label="lab_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">OCREVUS</link:label>
    <link:label id="lab_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C_label_en-US" xlink:label="lab_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCREVUS [Member]</link:label>
    <link:label id="lab_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C_documentation_en-US" xlink:label="lab_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OCREVUS</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_OCREVUSMember" xlink:label="loc_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C" xlink:to="lab_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C" xlink:type="arc" />
    <link:label id="lab_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174_terseLabel_en-US" xlink:label="lab_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOD1</link:label>
    <link:label id="lab_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174_label_en-US" xlink:label="lab_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SOD1 [Member]</link:label>
    <link:label id="lab_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174_documentation_en-US" xlink:label="lab_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SOD1 [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174" xlink:to="lab_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174" xlink:type="arc" />
    <link:label id="lab_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B_terseLabel_en-US" xlink:label="lab_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lead programs</link:label>
    <link:label id="lab_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B_label_en-US" xlink:label="lab_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lead programs [Member]</link:label>
    <link:label id="lab_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B_documentation_en-US" xlink:label="lab_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lead programs [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_LeadprogramsMember" xlink:label="loc_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B" xlink:to="lab_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B" xlink:type="arc" />
    <link:label id="lab_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218_terseLabel_en-US" xlink:label="lab_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discovery programs</link:label>
    <link:label id="lab_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218_label_en-US" xlink:label="lab_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discovery programs [Member]</link:label>
    <link:label id="lab_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218_documentation_en-US" xlink:label="lab_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discovery programs [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DiscoveryprogramsMember" xlink:label="loc_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218" xlink:to="lab_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218" xlink:type="arc" />
    <link:label id="lab_biib_AcordaMember_8B0A492449565C844FE34D742775643A_terseLabel_en-US" xlink:label="lab_biib_AcordaMember_8B0A492449565C844FE34D742775643A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acorda</link:label>
    <link:label id="lab_biib_AcordaMember_8B0A492449565C844FE34D742775643A_label_en-US" xlink:label="lab_biib_AcordaMember_8B0A492449565C844FE34D742775643A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acorda [Member]</link:label>
    <link:label id="lab_biib_AcordaMember_8B0A492449565C844FE34D742775643A_documentation_en-US" xlink:label="lab_biib_AcordaMember_8B0A492449565C844FE34D742775643A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acorda.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_8B0A492449565C844FE34D742775643A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcordaMember_8B0A492449565C844FE34D742775643A" xlink:to="lab_biib_AcordaMember_8B0A492449565C844FE34D742775643A" xlink:type="arc" />
    <link:label id="lab_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9_terseLabel_en-US" xlink:label="lab_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGTC</link:label>
    <link:label id="lab_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9_label_en-US" xlink:label="lab_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGTC [Member]</link:label>
    <link:label id="lab_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9_documentation_en-US" xlink:label="lab_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGTC [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9" xlink:to="lab_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9" xlink:type="arc" />
    <link:label id="lab_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D_terseLabel_en-US" xlink:label="lab_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">University of Pennsylvania</link:label>
    <link:label id="lab_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D_label_en-US" xlink:label="lab_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">University of Pennsylvania [Member]</link:label>
    <link:label id="lab_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D_documentation_en-US" xlink:label="lab_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">University of Pennsylvania [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_UniversityofPennsylvaniaMember" xlink:label="loc_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D" xlink:to="lab_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D" xlink:type="arc" />
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48" xlink:to="lab_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48" xlink:type="arc" />
    <link:label id="lab_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318_verboseLabel_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships (Textual)</link:label>
    <link:label id="lab_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318_label_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborations (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318_documentation_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborations.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="lab_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:type="arc" />
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E_verboseLabel_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of ocrelizumab</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E_label_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Percentage To Be Received On Sale Of Product</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E_documentation_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of product.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E" xlink:to="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E" xlink:type="arc" />
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8_terseLabel_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8_label_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8_documentation_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8" xlink:to="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8" xlink:type="arc" />
    <link:label id="lab_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D_label_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D" xlink:to="lab_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D" xlink:type="arc" />
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071_verboseLabel_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Period of collaboration agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071_label_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071_documentation_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071" xlink:to="lab_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Co promotion Operating Profits first fifty million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits First Fifty Million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits first fifty million.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C_label_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C_documentation_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C" xlink:to="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C" xlink:type="arc" />
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1" xlink:to="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1" xlink:type="arc" />
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales to be achieved in any twelve consecutive months under option one.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89" xlink:to="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89" xlink:type="arc" />
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE_terseLabel_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE_label_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE_documentation_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales trigger gross sales threshold.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE" xlink:to="lab_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE" xlink:type="arc" />
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168_terseLabel_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168_label_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168_documentation_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168" xlink:to="lab_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07_verboseLabel_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments when certain sales threshold is met</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07_label_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Additional Milestone Payments When Meeting Certain Sales Threshold</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07_documentation_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments when meeting certain sales threshold.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07" xlink:to="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07" xlink:type="arc" />
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2_verboseLabel_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign sales required to trigger milestone</link:label>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2_label_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Sales Required To Trigger Milestone</link:label>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2_documentation_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign sales required to trigger milestone.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2" xlink:to="lab_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_401FDEAE8E1C89CD00C24D7427774C4D_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_401FDEAE8E1C89CD00C24D7427774C4D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_401FDEAE8E1C89CD00C24D7427774C4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_401FDEAE8E1C89CD00C24D7427774C4D" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_401FDEAE8E1C89CD00C24D7427774C4D" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D4BBBD0263A7A808183C4D742777C48E_verboseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D4BBBD0263A7A808183C4D742777C48E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D4BBBD0263A7A808183C4D742777C48E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D4BBBD0263A7A808183C4D742777C48E" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D4BBBD0263A7A808183C4D742777C48E" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_6ED29557D60A71D830AA4D742778CE46_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_6ED29557D60A71D830AA4D742778CE46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Until First GAZYVA Threshold Date</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_6ED29557D60A71D830AA4D742778CE46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_6ED29557D60A71D830AA4D742778CE46" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_6ED29557D60A71D830AA4D742778CE46" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0927C00B6BFC72AFEEB84D7427787FDD_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0927C00B6BFC72AFEEB84D7427787FDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Until GAZYVA First Non-CLL FDA Approval</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0927C00B6BFC72AFEEB84D7427787FDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0927C00B6BFC72AFEEB84D7427787FDD" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0927C00B6BFC72AFEEB84D7427787FDD" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_167551E0B4E977CEFBDB4D742778E974_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_167551E0B4E977CEFBDB4D742778E974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After First Threshold Date and until Second Threshold Date</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_167551E0B4E977CEFBDB4D742778E974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_167551E0B4E977CEFBDB4D742778E974" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_167551E0B4E977CEFBDB4D742778E974" xlink:type="arc" />
    <link:label id="lab_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D_terseLabel_en-US" xlink:label="lab_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Expenses in Dispute</link:label>
    <link:label id="lab_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D_label_en-US" xlink:label="lab_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Expenses in Dispute</link:label>
    <link:label id="lab_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D_documentation_en-US" xlink:label="lab_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Expenses in Dispute</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CollaborationExpensesinDispute" xlink:label="loc_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D" xlink:to="lab_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D" xlink:type="arc" />
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_88C82F8FECA6BC7EE3A64D742777C6C0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_88C82F8FECA6BC7EE3A64D742777C6C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_88C82F8FECA6BC7EE3A64D742777C6C0_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_88C82F8FECA6BC7EE3A64D742777C6C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_88C82F8FECA6BC7EE3A64D742777C6C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_88C82F8FECA6BC7EE3A64D742777C6C0" xlink:to="lab_us-gaap_AssetImpairmentCharges_88C82F8FECA6BC7EE3A64D742777C6C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_E3060DAEE763E348EB8F4D742777186E_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_E3060DAEE763E348EB8F4D742777186E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_E3060DAEE763E348EB8F4D742777186E_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_E3060DAEE763E348EB8F4D742777186E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_E3060DAEE763E348EB8F4D742777186E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_E3060DAEE763E348EB8F4D742777186E" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_E3060DAEE763E348EB8F4D742777186E" xlink:type="arc" />
    <link:label id="lab_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84_terseLabel_en-US" xlink:label="lab_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84_label_en-US" xlink:label="lab_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84_documentation_en-US" xlink:label="lab_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84" xlink:to="lab_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6_terseLabel_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Of Royalties As Per Collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6_label_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Royalties As Per Collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6_documentation_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of royalties as per collaboration.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6" xlink:to="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectOperatingCostRoyaltyExpense_45EFAA868CF98C29A6CF4D7427788C39_terseLabel_en-US" xlink:label="lab_us-gaap_DirectOperatingCostRoyaltyExpense_45EFAA868CF98C29A6CF4D7427788C39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty cost of sales</link:label>
    <link:label id="lab_us-gaap_DirectOperatingCostRoyaltyExpense_45EFAA868CF98C29A6CF4D7427788C39_label_en-US" xlink:label="lab_us-gaap_DirectOperatingCostRoyaltyExpense_45EFAA868CF98C29A6CF4D7427788C39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Operating Cost, Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="loc_us-gaap_DirectOperatingCostRoyaltyExpense_45EFAA868CF98C29A6CF4D7427788C39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectOperatingCostRoyaltyExpense_45EFAA868CF98C29A6CF4D7427788C39" xlink:to="lab_us-gaap_DirectOperatingCostRoyaltyExpense_45EFAA868CF98C29A6CF4D7427788C39" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2_terseLabel_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected License Fee And Regulatory Milestone Payments</link:label>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2_label_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected License Fee And Regulatory Milestone Payments</link:label>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2_documentation_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected license fee and regulatory milestone payments.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2" xlink:to="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D" xlink:to="lab_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D" xlink:type="arc" />
    <link:label id="lab_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F" xlink:to="lab_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_96A06E8B60D672BE0C594D7427782923_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_96A06E8B60D672BE0C594D7427782923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and discovery services</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_96A06E8B60D672BE0C594D7427782923_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_96A06E8B60D672BE0C594D7427782923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_96A06E8B60D672BE0C594D7427782923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_96A06E8B60D672BE0C594D7427782923" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets_96A06E8B60D672BE0C594D7427782923" xlink:type="arc" />
    <link:label id="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3_terseLabel_en-US" xlink:label="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payments for product candidate using a different modality</link:label>
    <link:label id="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3_label_en-US" xlink:label="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional milestone payments for product candidate using a different modality</link:label>
    <link:label id="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3_documentation_en-US" xlink:label="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payments for product candidate using a different modality</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" xlink:label="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3" xlink:to="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3" xlink:type="arc" />
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD" xlink:type="arc" />
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_FAF3A98EB56A87FBE31A4D742779AB4C_verboseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_FAF3A98EB56A87FBE31A4D742779AB4C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment, approximately</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_FAF3A98EB56A87FBE31A4D742779AB4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_FAF3A98EB56A87FBE31A4D742779AB4C" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_FAF3A98EB56A87FBE31A4D742779AB4C" xlink:type="arc" />
    <link:label id="lab_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647_terseLabel_en-US" xlink:label="lab_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647_label_en-US" xlink:label="lab_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647_documentation_en-US" xlink:label="lab_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647" xlink:to="lab_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseCosts_5A2A7AE5EA2982221A464D7427792FDD_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseCosts_5A2A7AE5EA2982221A464D7427792FDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total licensing and other fees</link:label>
    <link:label id="lab_us-gaap_LicenseCosts_5A2A7AE5EA2982221A464D7427792FDD_label_en-US" xlink:label="lab_us-gaap_LicenseCosts_5A2A7AE5EA2982221A464D7427792FDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_5A2A7AE5EA2982221A464D7427792FDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseCosts_5A2A7AE5EA2982221A464D7427792FDD" xlink:to="lab_us-gaap_LicenseCosts_5A2A7AE5EA2982221A464D7427792FDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_EC744153CC6F9639EF1D4D742779AE25_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_EC744153CC6F9639EF1D4D742779AE25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_EC744153CC6F9639EF1D4D742779AE25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_EC744153CC6F9639EF1D4D742779AE25" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_EC744153CC6F9639EF1D4D742779AE25" xlink:type="arc" />
    <link:label id="lab_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9_terseLabel_en-US" xlink:label="lab_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future research and development commitment</link:label>
    <link:label id="lab_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9_label_en-US" xlink:label="lab_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future research and development commitment</link:label>
    <link:label id="lab_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9_documentation_en-US" xlink:label="lab_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future research and development commitment</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Futureresearchanddevelopmentcommitment" xlink:label="loc_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9" xlink:to="lab_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75_terseLabel_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75_label_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75_documentation_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments by third party in joint venture as per agreement</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75" xlink:to="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75" xlink:type="arc" />
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE_terseLabel_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint Venture Owner Ship Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE_label_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint Venture Owner Ship Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE_documentation_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Joint venture owner ship percentage by third party.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE" xlink:to="lab_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_7EE2EE81C32FF91CCCA34D74277997D9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_7EE2EE81C32FF91CCCA34D74277997D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_7EE2EE81C32FF91CCCA34D74277997D9_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_7EE2EE81C32FF91CCCA34D74277997D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_7EE2EE81C32FF91CCCA34D74277997D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_7EE2EE81C32FF91CCCA34D74277997D9" xlink:to="lab_us-gaap_EquityMethodInvestments_7EE2EE81C32FF91CCCA34D74277997D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_B1FF385597D76A31C1F94D74277961A9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_B1FF385597D76A31C1F94D74277961A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of equity interest to the portion of total capital stock</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_B1FF385597D76A31C1F94D74277961A9_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_B1FF385597D76A31C1F94D74277961A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_B1FF385597D76A31C1F94D74277961A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_B1FF385597D76A31C1F94D74277961A9" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_B1FF385597D76A31C1F94D74277961A9" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment Ownership Percentage Maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment Ownership Percentage Maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment ownership percentage maximum.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_57AC91108A46B74F318E4D7427791A8D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_57AC91108A46B74F318E4D7427791A8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_57AC91108A46B74F318E4D7427791A8D_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_57AC91108A46B74F318E4D7427791A8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_57AC91108A46B74F318E4D7427791A8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_57AC91108A46B74F318E4D7427791A8D" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_57AC91108A46B74F318E4D7427791A8D" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3CDA6E7A227AE8485A3651D3A7DA5EBB_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3CDA6E7A227AE8485A3651D3A7DA5EBB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3CDA6E7A227AE8485A3651D3A7DA5EBB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3CDA6E7A227AE8485A3651D3A7DA5EBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3CDA6E7A227AE8485A3651D3A7DA5EBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3CDA6E7A227AE8485A3651D3A7DA5EBB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3CDA6E7A227AE8485A3651D3A7DA5EBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7E481BB8BE4FD9EC1EF451D3A7E4D8B8_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_7E481BB8BE4FD9EC1EF451D3A7E4D8B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7E481BB8BE4FD9EC1EF451D3A7E4D8B8_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_7E481BB8BE4FD9EC1EF451D3A7E4D8B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7E481BB8BE4FD9EC1EF451D3A7E4D8B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_7E481BB8BE4FD9EC1EF451D3A7E4D8B8" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_7E481BB8BE4FD9EC1EF451D3A7E4D8B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_00E84B33450469DDB04951D3A7E41729_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_00E84B33450469DDB04951D3A7E41729" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_00E84B33450469DDB04951D3A7E41729_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_00E84B33450469DDB04951D3A7E41729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_00E84B33450469DDB04951D3A7E41729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_00E84B33450469DDB04951D3A7E41729" xlink:to="lab_us-gaap_ShareBasedCompensation_00E84B33450469DDB04951D3A7E41729" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_FA105F9D4CDDE09C447151D3A7E50F76_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_FA105F9D4CDDE09C447151D3A7E50F76" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_FA105F9D4CDDE09C447151D3A7E50F76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_FA105F9D4CDDE09C447151D3A7E50F76" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_FA105F9D4CDDE09C447151D3A7E50F76" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EA2172A3209D706C78551D3A7E5B2E7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EA2172A3209D706C78551D3A7E5B2E7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EA2172A3209D706C78551D3A7E5B2E7_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EA2172A3209D706C78551D3A7E5B2E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EA2172A3209D706C78551D3A7E5B2E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EA2172A3209D706C78551D3A7E5B2E7" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EA2172A3209D706C78551D3A7E5B2E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_653717BBFA7A8C70525351D3A7E58C13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_653717BBFA7A8C70525351D3A7E58C13" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_653717BBFA7A8C70525351D3A7E58C13_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_653717BBFA7A8C70525351D3A7E58C13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_653717BBFA7A8C70525351D3A7E58C13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_653717BBFA7A8C70525351D3A7E58C13" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_653717BBFA7A8C70525351D3A7E58C13" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B875CEA97C26691EA2C451D3A7E57045_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B875CEA97C26691EA2C451D3A7E57045" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B875CEA97C26691EA2C451D3A7E57045_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B875CEA97C26691EA2C451D3A7E57045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B875CEA97C26691EA2C451D3A7E57045" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B875CEA97C26691EA2C451D3A7E57045" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B875CEA97C26691EA2C451D3A7E57045" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_D70F0092DA7C4FAA96DC51D3A7E51CD4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_D70F0092DA7C4FAA96DC51D3A7E51CD4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_D70F0092DA7C4FAA96DC51D3A7E51CD4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_D70F0092DA7C4FAA96DC51D3A7E51CD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_D70F0092DA7C4FAA96DC51D3A7E51CD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_D70F0092DA7C4FAA96DC51D3A7E51CD4" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_D70F0092DA7C4FAA96DC51D3A7E51CD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_42FC14712B3FCBA8CB8251D3A7E6F066_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_42FC14712B3FCBA8CB8251D3A7E6F066" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_42FC14712B3FCBA8CB8251D3A7E6F066_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_42FC14712B3FCBA8CB8251D3A7E6F066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_42FC14712B3FCBA8CB8251D3A7E6F066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_42FC14712B3FCBA8CB8251D3A7E6F066" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_42FC14712B3FCBA8CB8251D3A7E6F066" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_E22B4B2EE509A733A92251D3A7E68ABD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_E22B4B2EE509A733A92251D3A7E68ABD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_E22B4B2EE509A733A92251D3A7E68ABD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_E22B4B2EE509A733A92251D3A7E68ABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_E22B4B2EE509A733A92251D3A7E68ABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_E22B4B2EE509A733A92251D3A7E68ABD" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_E22B4B2EE509A733A92251D3A7E68ABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4126C1A1B82EA10C1ADC51D3A7E60AFC_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4126C1A1B82EA10C1ADC51D3A7E60AFC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4126C1A1B82EA10C1ADC51D3A7E60AFC_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4126C1A1B82EA10C1ADC51D3A7E60AFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4126C1A1B82EA10C1ADC51D3A7E60AFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4126C1A1B82EA10C1ADC51D3A7E60AFC" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4126C1A1B82EA10C1ADC51D3A7E60AFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_94D22BF01152FE3E482251D3A7E69845_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_94D22BF01152FE3E482251D3A7E69845" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_94D22BF01152FE3E482251D3A7E69845_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_94D22BF01152FE3E482251D3A7E69845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_94D22BF01152FE3E482251D3A7E69845" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_94D22BF01152FE3E482251D3A7E69845" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_94D22BF01152FE3E482251D3A7E69845" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_56EE7CCF6896202E52A151D3A7E63F37_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_56EE7CCF6896202E52A151D3A7E63F37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_56EE7CCF6896202E52A151D3A7E63F37_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_56EE7CCF6896202E52A151D3A7E63F37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_56EE7CCF6896202E52A151D3A7E63F37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_56EE7CCF6896202E52A151D3A7E63F37" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_56EE7CCF6896202E52A151D3A7E63F37" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4039207E6266ECB434DF51D3A7E77B34_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4039207E6266ECB434DF51D3A7E77B34" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4039207E6266ECB434DF51D3A7E77B34_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4039207E6266ECB434DF51D3A7E77B34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4039207E6266ECB434DF51D3A7E77B34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4039207E6266ECB434DF51D3A7E77B34" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4039207E6266ECB434DF51D3A7E77B34" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EB1B186733CB06E267F751D3A7E79DFD_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EB1B186733CB06E267F751D3A7E79DFD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EB1B186733CB06E267F751D3A7E79DFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EB1B186733CB06E267F751D3A7E79DFD" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EB1B186733CB06E267F751D3A7E79DFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_DA2150C3767FF4A3E1AB51D3A7E82538_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_DA2150C3767FF4A3E1AB51D3A7E82538" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_DA2150C3767FF4A3E1AB51D3A7E82538_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_DA2150C3767FF4A3E1AB51D3A7E82538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_DA2150C3767FF4A3E1AB51D3A7E82538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_DA2150C3767FF4A3E1AB51D3A7E82538" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_DA2150C3767FF4A3E1AB51D3A7E82538" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_513B43893B6D6B8D6E6651D3A7E88847_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_513B43893B6D6B8D6E6651D3A7E88847" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_513B43893B6D6B8D6E6651D3A7E88847_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_513B43893B6D6B8D6E6651D3A7E88847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_513B43893B6D6B8D6E6651D3A7E88847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_513B43893B6D6B8D6E6651D3A7E88847" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_513B43893B6D6B8D6E6651D3A7E88847" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_E998F1044A26856CE67151D3A7E8A3BB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_E998F1044A26856CE67151D3A7E8A3BB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_E998F1044A26856CE67151D3A7E8A3BB_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_E998F1044A26856CE67151D3A7E8A3BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_E998F1044A26856CE67151D3A7E8A3BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_E998F1044A26856CE67151D3A7E8A3BB" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_E998F1044A26856CE67151D3A7E8A3BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD57E0BB7305A8D532FF51D3A7E8A6CE_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD57E0BB7305A8D532FF51D3A7E8A6CE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD57E0BB7305A8D532FF51D3A7E8A6CE_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD57E0BB7305A8D532FF51D3A7E8A6CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD57E0BB7305A8D532FF51D3A7E8A6CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD57E0BB7305A8D532FF51D3A7E8A6CE" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD57E0BB7305A8D532FF51D3A7E8A6CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_333064277E284C8BEF9A51D3A7ED7287_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_333064277E284C8BEF9A51D3A7ED7287" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_333064277E284C8BEF9A51D3A7ED7287_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_333064277E284C8BEF9A51D3A7ED7287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_333064277E284C8BEF9A51D3A7ED7287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_333064277E284C8BEF9A51D3A7ED7287" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_333064277E284C8BEF9A51D3A7ED7287" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_C8EAC76C1DF76A9BE04851D3A7EDA6D8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_C8EAC76C1DF76A9BE04851D3A7EDA6D8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_C8EAC76C1DF76A9BE04851D3A7EDA6D8_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_C8EAC76C1DF76A9BE04851D3A7EDA6D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_C8EAC76C1DF76A9BE04851D3A7EDA6D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_C8EAC76C1DF76A9BE04851D3A7EDA6D8" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_C8EAC76C1DF76A9BE04851D3A7EDA6D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BEE9824F19C715151C7351D3A7EE3C0F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BEE9824F19C715151C7351D3A7EE3C0F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BEE9824F19C715151C7351D3A7EE3C0F_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BEE9824F19C715151C7351D3A7EE3C0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BEE9824F19C715151C7351D3A7EE3C0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BEE9824F19C715151C7351D3A7EE3C0F" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BEE9824F19C715151C7351D3A7EE3C0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F29CAB637C3DF05041E351D3A7EEC0FB_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F29CAB637C3DF05041E351D3A7EEC0FB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F29CAB637C3DF05041E351D3A7EEC0FB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F29CAB637C3DF05041E351D3A7EEC0FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F29CAB637C3DF05041E351D3A7EEC0FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F29CAB637C3DF05041E351D3A7EEC0FB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F29CAB637C3DF05041E351D3A7EEC0FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_FB67F0E2F55E6258A5A851D3A7EE07F1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_FB67F0E2F55E6258A5A851D3A7EE07F1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_FB67F0E2F55E6258A5A851D3A7EE07F1_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_FB67F0E2F55E6258A5A851D3A7EE07F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_FB67F0E2F55E6258A5A851D3A7EE07F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_FB67F0E2F55E6258A5A851D3A7EE07F1" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_FB67F0E2F55E6258A5A851D3A7EE07F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_CBA57A0F6BB1A1A6AAB451D3A7EE31B7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_CBA57A0F6BB1A1A6AAB451D3A7EE31B7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_CBA57A0F6BB1A1A6AAB451D3A7EE31B7_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_CBA57A0F6BB1A1A6AAB451D3A7EE31B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_CBA57A0F6BB1A1A6AAB451D3A7EE31B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_CBA57A0F6BB1A1A6AAB451D3A7EE31B7" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_CBA57A0F6BB1A1A6AAB451D3A7EE31B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_2BD76F6996D963D1F05151D3A7EE2F44_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_2BD76F6996D963D1F05151D3A7EE2F44" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_2BD76F6996D963D1F05151D3A7EE2F44_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_2BD76F6996D963D1F05151D3A7EE2F44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_2BD76F6996D963D1F05151D3A7EE2F44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_2BD76F6996D963D1F05151D3A7EE2F44" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_2BD76F6996D963D1F05151D3A7EE2F44" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_9E42BDAABBF5CA68F3DB51D3A7EF100A_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_9E42BDAABBF5CA68F3DB51D3A7EF100A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_9E42BDAABBF5CA68F3DB51D3A7EF100A_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_9E42BDAABBF5CA68F3DB51D3A7EF100A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_9E42BDAABBF5CA68F3DB51D3A7EF100A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_9E42BDAABBF5CA68F3DB51D3A7EF100A" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_9E42BDAABBF5CA68F3DB51D3A7EF100A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_71E88FB79D90F213220B51D3A7EF5EEB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_71E88FB79D90F213220B51D3A7EF5EEB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_71E88FB79D90F213220B51D3A7EF5EEB_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_71E88FB79D90F213220B51D3A7EF5EEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_71E88FB79D90F213220B51D3A7EF5EEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_71E88FB79D90F213220B51D3A7EF5EEB" xlink:to="lab_us-gaap_RepaymentsOfDebt_71E88FB79D90F213220B51D3A7EF5EEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_D27F335695EE528DE57251D3A7F03B1B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution_D27F335695EE528DE57251D3A7F03B1B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net cash contribution to Bioverativ, Inc.</link:label>
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_D27F335695EE528DE57251D3A7F03B1B_label_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution_D27F335695EE528DE57251D3A7F03B1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Capital Distribution</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_D27F335695EE528DE57251D3A7F03B1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfCapitalDistribution_D27F335695EE528DE57251D3A7F03B1B" xlink:to="lab_us-gaap_PaymentsOfCapitalDistribution_D27F335695EE528DE57251D3A7F03B1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_ADF9ED6DC877F18485AC51D3A7F09B6A_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_ADF9ED6DC877F18485AC51D3A7F09B6A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_ADF9ED6DC877F18485AC51D3A7F09B6A_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_ADF9ED6DC877F18485AC51D3A7F09B6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_ADF9ED6DC877F18485AC51D3A7F09B6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets_ADF9ED6DC877F18485AC51D3A7F09B6A" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets_ADF9ED6DC877F18485AC51D3A7F09B6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2F3EB3617660E306190351D3A7F068E2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2F3EB3617660E306190351D3A7F068E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2F3EB3617660E306190351D3A7F068E2_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2F3EB3617660E306190351D3A7F068E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2F3EB3617660E306190351D3A7F068E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2F3EB3617660E306190351D3A7F068E2" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2F3EB3617660E306190351D3A7F068E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CA7F0346AB1FDF2EE53F51D3A7F0B4FF_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CA7F0346AB1FDF2EE53F51D3A7F0B4FF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CA7F0346AB1FDF2EE53F51D3A7F0B4FF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CA7F0346AB1FDF2EE53F51D3A7F0B4FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CA7F0346AB1FDF2EE53F51D3A7F0B4FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CA7F0346AB1FDF2EE53F51D3A7F0B4FF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CA7F0346AB1FDF2EE53F51D3A7F0B4FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_74C0AFA13CF3D5AA92DC51D3A7F03054_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_74C0AFA13CF3D5AA92DC51D3A7F03054" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_74C0AFA13CF3D5AA92DC51D3A7F03054_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_74C0AFA13CF3D5AA92DC51D3A7F03054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_74C0AFA13CF3D5AA92DC51D3A7F03054" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_74C0AFA13CF3D5AA92DC51D3A7F03054" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_74C0AFA13CF3D5AA92DC51D3A7F03054" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_62EA5396A852558E016B51D3A7F0D9EF_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_62EA5396A852558E016B51D3A7F0D9EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_62EA5396A852558E016B51D3A7F0D9EF_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_62EA5396A852558E016B51D3A7F0D9EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_62EA5396A852558E016B51D3A7F0D9EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_62EA5396A852558E016B51D3A7F0D9EF" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_62EA5396A852558E016B51D3A7F0D9EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E694926A90DB1846400451D3A7F06936_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E694926A90DB1846400451D3A7F06936" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E694926A90DB1846400451D3A7F06936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E694926A90DB1846400451D3A7F06936" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E694926A90DB1846400451D3A7F06936" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8988E05D3678D0F2EFBF51D3A7F1E9A7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8988E05D3678D0F2EFBF51D3A7F1E9A7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8988E05D3678D0F2EFBF51D3A7F1E9A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8988E05D3678D0F2EFBF51D3A7F1E9A7" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8988E05D3678D0F2EFBF51D3A7F1E9A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_18D5E4AD6DCF08C0D12629780F051F9B_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_18D5E4AD6DCF08C0D12629780F051F9B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_18D5E4AD6DCF08C0D12629780F051F9B_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_18D5E4AD6DCF08C0D12629780F051F9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_18D5E4AD6DCF08C0D12629780F051F9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_18D5E4AD6DCF08C0D12629780F051F9B" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_18D5E4AD6DCF08C0D12629780F051F9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_E3E2EF21691DACA3426E29780F05ED32_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_E3E2EF21691DACA3426E29780F05ED32" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_E3E2EF21691DACA3426E29780F05ED32_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_E3E2EF21691DACA3426E29780F05ED32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_E3E2EF21691DACA3426E29780F05ED32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_E3E2EF21691DACA3426E29780F05ED32" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_E3E2EF21691DACA3426E29780F05ED32" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_EF52D2F370B859BBB87029780F05AD37_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_EF52D2F370B859BBB87029780F05AD37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_EF52D2F370B859BBB87029780F05AD37_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_EF52D2F370B859BBB87029780F05AD37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_EF52D2F370B859BBB87029780F05AD37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_EF52D2F370B859BBB87029780F05AD37" xlink:to="lab_us-gaap_TreasuryStockShares_EF52D2F370B859BBB87029780F05AD37" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1AFFC68EF4F264CFF65129780DEE029F_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1AFFC68EF4F264CFF65129780DEE029F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1AFFC68EF4F264CFF65129780DEE029F_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1AFFC68EF4F264CFF65129780DEE029F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1AFFC68EF4F264CFF65129780DEE029F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1AFFC68EF4F264CFF65129780DEE029F" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1AFFC68EF4F264CFF65129780DEE029F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E378B8876A1E0DC51CF229780D733479_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E378B8876A1E0DC51CF229780D733479" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E378B8876A1E0DC51CF229780D733479_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E378B8876A1E0DC51CF229780D733479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E378B8876A1E0DC51CF229780D733479" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E378B8876A1E0DC51CF229780D733479" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E378B8876A1E0DC51CF229780D733479" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:to="lab_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_E46A588359D0B62207D7434A358F5ACF_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_E46A588359D0B62207D7434A358F5ACF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Workforce reduction</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_E46A588359D0B62207D7434A358F5ACF_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_E46A588359D0B62207D7434A358F5ACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_E46A588359D0B62207D7434A358F5ACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember_E46A588359D0B62207D7434A358F5ACF" xlink:to="lab_us-gaap_EmployeeSeveranceMember_E46A588359D0B62207D7434A358F5ACF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractTerminationMember_3D1EBB9F47F450D2A781434A358FCD4B_terseLabel_en-US" xlink:label="lab_us-gaap_ContractTerminationMember_3D1EBB9F47F450D2A781434A358FCD4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pipeline programs</link:label>
    <link:label id="lab_us-gaap_ContractTerminationMember_3D1EBB9F47F450D2A781434A358FCD4B_label_en-US" xlink:label="lab_us-gaap_ContractTerminationMember_3D1EBB9F47F450D2A781434A358FCD4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Termination [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_3D1EBB9F47F450D2A781434A358FCD4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractTerminationMember_3D1EBB9F47F450D2A781434A358FCD4B" xlink:to="lab_us-gaap_ContractTerminationMember_3D1EBB9F47F450D2A781434A358FCD4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_0F00E3C07705D7BE657B434A358FC9A2_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_0F00E3C07705D7BE657B434A358FC9A2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve, beginning period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_0F00E3C07705D7BE657B434A358FC9A2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_0F00E3C07705D7BE657B434A358FC9A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_0F00E3C07705D7BE657B434A358FC9A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_0F00E3C07705D7BE657B434A358FC9A2" xlink:to="lab_us-gaap_RestructuringReserve_0F00E3C07705D7BE657B434A358FC9A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCosts_D9106C013357ECFB229E434A358FDE81_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts_D9106C013357ECFB229E434A358FDE81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_D9106C013357ECFB229E434A358FDE81_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts_D9106C013357ECFB229E434A358FDE81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_D9106C013357ECFB229E434A358FDE81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts_D9106C013357ECFB229E434A358FDE81" xlink:to="lab_us-gaap_RestructuringCosts_D9106C013357ECFB229E434A358FDE81" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRestructuring_B8032CD75BD7C1DA8D79434A358FE67F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_B8032CD75BD7C1DA8D79434A358FE67F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_B8032CD75BD7C1DA8D79434A358FE67F_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_B8032CD75BD7C1DA8D79434A358FE67F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_B8032CD75BD7C1DA8D79434A358FE67F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring_B8032CD75BD7C1DA8D79434A358FE67F" xlink:to="lab_us-gaap_PaymentsForRestructuring_B8032CD75BD7C1DA8D79434A358FE67F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_61A5FED91DA6BCBF850F434A358FCB73_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_61A5FED91DA6BCBF850F434A358FCB73" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve, ending period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_61A5FED91DA6BCBF850F434A358FCB73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_61A5FED91DA6BCBF850F434A358FCB73" xlink:to="lab_us-gaap_RestructuringReserve_61A5FED91DA6BCBF850F434A358FCB73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_10B5EA596F9B4C1E9C9529780DB9EE06_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_10B5EA596F9B4C1E9C9529780DB9EE06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_10B5EA596F9B4C1E9C9529780DB9EE06_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_10B5EA596F9B4C1E9C9529780DB9EE06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_10B5EA596F9B4C1E9C9529780DB9EE06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_10B5EA596F9B4C1E9C9529780DB9EE06" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_10B5EA596F9B4C1E9C9529780DB9EE06" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_42050BBD022ABAEE8D6729780DB99F48_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_42050BBD022ABAEE8D6729780DB99F48" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities including strategic investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_42050BBD022ABAEE8D6729780DB99F48_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_42050BBD022ABAEE8D6729780DB99F48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_42050BBD022ABAEE8D6729780DB99F48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_42050BBD022ABAEE8D6729780DB99F48" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_42050BBD022ABAEE8D6729780DB99F48" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0ACCA60DC4211F11B37229780DB91365_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0ACCA60DC4211F11B37229780DB91365" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: Available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0ACCA60DC4211F11B37229780DB91365_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0ACCA60DC4211F11B37229780DB91365" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0ACCA60DC4211F11B37229780DB91365" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0ACCA60DC4211F11B37229780DB91365" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0ACCA60DC4211F11B37229780DB91365" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DBD0604F7B5BF0B112B829780DB9A209_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DBD0604F7B5BF0B112B829780DB9A209" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable securities, excluding strategic investments</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DBD0604F7B5BF0B112B829780DB9A209_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DBD0604F7B5BF0B112B829780DB9A209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DBD0604F7B5BF0B112B829780DB9A209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DBD0604F7B5BF0B112B829780DB9A209" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DBD0604F7B5BF0B112B829780DB9A209" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD" xlink:to="lab_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticPlanMember_9B1B651110A79D767E5C4C78A60A999D_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember_9B1B651110A79D767E5C4C78A60A999D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_9B1B651110A79D767E5C4C78A60A999D_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember_9B1B651110A79D767E5C4C78A60A999D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_9B1B651110A79D767E5C4C78A60A999D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember_9B1B651110A79D767E5C4C78A60A999D" xlink:to="lab_us-gaap_DomesticPlanMember_9B1B651110A79D767E5C4C78A60A999D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0B86177A3BE0F23667484C78A60FB722_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0B86177A3BE0F23667484C78A60FB722" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0B86177A3BE0F23667484C78A60FB722_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0B86177A3BE0F23667484C78A60FB722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0B86177A3BE0F23667484C78A60FB722" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0B86177A3BE0F23667484C78A60FB722" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0B86177A3BE0F23667484C78A60FB722" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:type="arc" />
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE_terseLabel_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum Qualifying Age For Employee Benefit Plan</link:label>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE_label_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Qualifying Age For Employee Benefit Plan</link:label>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE_documentation_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum qualifying age for employee benefit plan.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE" xlink:to="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_61B16D90B3BF3F35B7384C78A610C951_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_61B16D90B3BF3F35B7384C78A610C951" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses related to savings plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_61B16D90B3BF3F35B7384C78A610C951_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_61B16D90B3BF3F35B7384C78A610C951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_61B16D90B3BF3F35B7384C78A610C951" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_61B16D90B3BF3F35B7384C78A610C951" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_61B16D90B3BF3F35B7384C78A610C951" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_CE2B5865AF0E5C4C43444C78A610FACA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_CE2B5865AF0E5C4C43444C78A610FACA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_CE2B5865AF0E5C4C43444C78A610FACA_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_CE2B5865AF0E5C4C43444C78A610FACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_CE2B5865AF0E5C4C43444C78A610FACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_CE2B5865AF0E5C4C43444C78A610FACA" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_CE2B5865AF0E5C4C43444C78A610FACA" xlink:type="arc" />
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A_label_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A_documentation_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="lab_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_D46069358FF370F8D48A29780DD6625A_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_D46069358FF370F8D48A29780DD6625A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_D46069358FF370F8D48A29780DD6625A_label_en-US" xlink:label="lab_dei_EntityRegistrantName_D46069358FF370F8D48A29780DD6625A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_D46069358FF370F8D48A29780DD6625A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_D46069358FF370F8D48A29780DD6625A" xlink:to="lab_dei_EntityRegistrantName_D46069358FF370F8D48A29780DD6625A" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_064C7BC3C76EF35E7ACC29780DD657E8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_064C7BC3C76EF35E7ACC29780DD657E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_064C7BC3C76EF35E7ACC29780DD657E8_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_064C7BC3C76EF35E7ACC29780DD657E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_064C7BC3C76EF35E7ACC29780DD657E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_064C7BC3C76EF35E7ACC29780DD657E8" xlink:to="lab_dei_EntityCentralIndexKey_064C7BC3C76EF35E7ACC29780DD657E8" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_F966B2E1BA8D463A3DA929780DD6354C_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_F966B2E1BA8D463A3DA929780DD6354C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_F966B2E1BA8D463A3DA929780DD6354C_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_F966B2E1BA8D463A3DA929780DD6354C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_F966B2E1BA8D463A3DA929780DD6354C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_F966B2E1BA8D463A3DA929780DD6354C" xlink:to="lab_dei_CurrentFiscalYearEndDate_F966B2E1BA8D463A3DA929780DD6354C" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_D5654A8447144A798D4A29780DD64224_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_D5654A8447144A798D4A29780DD64224" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_D5654A8447144A798D4A29780DD64224_label_en-US" xlink:label="lab_dei_EntityFilerCategory_D5654A8447144A798D4A29780DD64224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D5654A8447144A798D4A29780DD64224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_D5654A8447144A798D4A29780DD64224" xlink:to="lab_dei_EntityFilerCategory_D5654A8447144A798D4A29780DD64224" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_2087A90B613896CFB5D529780DD6E020_terseLabel_en-US" xlink:label="lab_dei_DocumentType_2087A90B613896CFB5D529780DD6E020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_2087A90B613896CFB5D529780DD6E020_label_en-US" xlink:label="lab_dei_DocumentType_2087A90B613896CFB5D529780DD6E020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2087A90B613896CFB5D529780DD6E020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_2087A90B613896CFB5D529780DD6E020" xlink:to="lab_dei_DocumentType_2087A90B613896CFB5D529780DD6E020" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_CDF94021AE8F5141E11F29780DD6C555_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_CDF94021AE8F5141E11F29780DD6C555" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_CDF94021AE8F5141E11F29780DD6C555_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_CDF94021AE8F5141E11F29780DD6C555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_CDF94021AE8F5141E11F29780DD6C555" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_CDF94021AE8F5141E11F29780DD6C555" xlink:to="lab_dei_DocumentPeriodEndDate_CDF94021AE8F5141E11F29780DD6C555" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_6EDE8F03AF8B1A4F52DD29780DD647FD_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_6EDE8F03AF8B1A4F52DD29780DD647FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6EDE8F03AF8B1A4F52DD29780DD647FD_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_6EDE8F03AF8B1A4F52DD29780DD647FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6EDE8F03AF8B1A4F52DD29780DD647FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_6EDE8F03AF8B1A4F52DD29780DD647FD" xlink:to="lab_dei_DocumentFiscalYearFocus_6EDE8F03AF8B1A4F52DD29780DD647FD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_D05626F323CC211A679529780DD60495_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_D05626F323CC211A679529780DD60495" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_D05626F323CC211A679529780DD60495_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_D05626F323CC211A679529780DD60495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_D05626F323CC211A679529780DD60495" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_D05626F323CC211A679529780DD60495" xlink:to="lab_dei_DocumentFiscalPeriodFocus_D05626F323CC211A679529780DD60495" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_2F81AA6B9128DC1E304829780DD6A1A6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_2F81AA6B9128DC1E304829780DD6A1A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_2F81AA6B9128DC1E304829780DD6A1A6_label_en-US" xlink:label="lab_dei_AmendmentFlag_2F81AA6B9128DC1E304829780DD6A1A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_2F81AA6B9128DC1E304829780DD6A1A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_2F81AA6B9128DC1E304829780DD6A1A6" xlink:to="lab_dei_AmendmentFlag_2F81AA6B9128DC1E304829780DD6A1A6" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_32967DFF61FE3A3F4B7629780DD6D902_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_32967DFF61FE3A3F4B7629780DD6D902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_32967DFF61FE3A3F4B7629780DD6D902_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_32967DFF61FE3A3F4B7629780DD6D902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_32967DFF61FE3A3F4B7629780DD6D902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_32967DFF61FE3A3F4B7629780DD6D902" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_32967DFF61FE3A3F4B7629780DD6D902" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_D05E013FDBCD4947AD3629780DD62B2C_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_D05E013FDBCD4947AD3629780DD62B2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_D05E013FDBCD4947AD3629780DD62B2C_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_D05E013FDBCD4947AD3629780DD62B2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_D05E013FDBCD4947AD3629780DD62B2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_D05E013FDBCD4947AD3629780DD62B2C" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_D05E013FDBCD4947AD3629780DD62B2C" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_09A53B23AE3BD22021B429780DD63622_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_09A53B23AE3BD22021B429780DD63622" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_09A53B23AE3BD22021B429780DD63622_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_09A53B23AE3BD22021B429780DD63622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_09A53B23AE3BD22021B429780DD63622" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_09A53B23AE3BD22021B429780DD63622" xlink:to="lab_dei_EntityVoluntaryFilers_09A53B23AE3BD22021B429780DD63622" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_EBFBF2E470F4E70AE1F729780DD6CCEF_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_EBFBF2E470F4E70AE1F729780DD6CCEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_EBFBF2E470F4E70AE1F729780DD6CCEF_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_EBFBF2E470F4E70AE1F729780DD6CCEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_EBFBF2E470F4E70AE1F729780DD6CCEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_EBFBF2E470F4E70AE1F729780DD6CCEF" xlink:to="lab_dei_EntityCurrentReportingStatus_EBFBF2E470F4E70AE1F729780DD6CCEF" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_D300DAB6FC40E4B33CEA29780DD68B7E_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_D300DAB6FC40E4B33CEA29780DD68B7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_D300DAB6FC40E4B33CEA29780DD68B7E_label_en-US" xlink:label="lab_dei_EntityPublicFloat_D300DAB6FC40E4B33CEA29780DD68B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_D300DAB6FC40E4B33CEA29780DD68B7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_D300DAB6FC40E4B33CEA29780DD68B7E" xlink:to="lab_dei_EntityPublicFloat_D300DAB6FC40E4B33CEA29780DD68B7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_BEACBFB021A312FF84C448F12BEE0DA8_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_BEACBFB021A312FF84C448F12BEE0DA8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities by Classification of Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_BEACBFB021A312FF84C448F12BEE0DA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_BEACBFB021A312FF84C448F12BEE0DA8" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_BEACBFB021A312FF84C448F12BEE0DA8" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_61AEA92B59944FF779D048F12BEEF0F7_verboseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_61AEA92B59944FF779D048F12BEEF0F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_61AEA92B59944FF779D048F12BEEF0F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_61AEA92B59944FF779D048F12BEEF0F7" xlink:to="lab_biib_NeurimmuneMember_61AEA92B59944FF779D048F12BEEF0F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_900F335EBBF2F034419248F12BEE9CAD_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_900F335EBBF2F034419248F12BEE9CAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment to Neurimmune</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_900F335EBBF2F034419248F12BEE9CAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_900F335EBBF2F034419248F12BEE9CAD" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_900F335EBBF2F034419248F12BEE9CAD" xlink:type="arc" />
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D_terseLabel_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D_label_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D_documentation_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D" xlink:to="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF_terseLabel_en-US" xlink:label="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional potential payment to Neurimmune</link:label>
    <link:label id="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF_label_en-US" xlink:label="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Potential Payments to Noncontrolling Interest</link:label>
    <link:label id="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF_documentation_en-US" xlink:label="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Potential Payments to Noncontrolling Interest</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AdditionalPotentialPaymentstoNoncontrollingInterest" xlink:label="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF" xlink:to="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual)</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6_label_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6_documentation_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:to="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:type="arc" />
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F_verboseLabel_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement</link:label>
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F_label_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Potential Development Milestone Payments And Royalties On Commercial Sales Under Terms Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F_documentation_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F" xlink:to="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B65B8000D63A2F74BBF64331EFF1A3EB_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B65B8000D63A2F74BBF64331EFF1A3EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B65B8000D63A2F74BBF64331EFF1A3EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B65B8000D63A2F74BBF64331EFF1A3EB" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B65B8000D63A2F74BBF64331EFF1A3EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_B1899A89FE2DAA8175824331F009219C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_B1899A89FE2DAA8175824331F009219C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities charged against equity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_B1899A89FE2DAA8175824331F009219C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_B1899A89FE2DAA8175824331F009219C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_B1899A89FE2DAA8175824331F009219C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_B1899A89FE2DAA8175824331F009219C" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_B1899A89FE2DAA8175824331F009219C" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4_verboseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Settled Performance Shares [Abstract]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:to="lab_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2CB276880926DAD607B14348CCF95E4E_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2CB276880926DAD607B14348CCF95E4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reserves for Discounts and Allowances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2CB276880926DAD607B14348CCF95E4E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2CB276880926DAD607B14348CCF95E4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2CB276880926DAD607B14348CCF95E4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2CB276880926DAD607B14348CCF95E4E" xlink:to="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2CB276880926DAD607B14348CCF95E4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_FAE966769938F600D7D629780E90184C_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_FAE966769938F600D7D629780E90184C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_FAE966769938F600D7D629780E90184C_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_FAE966769938F600D7D629780E90184C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_FAE966769938F600D7D629780E90184C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_FAE966769938F600D7D629780E90184C" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_FAE966769938F600D7D629780E90184C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_D9B075179052E16D9CC548EF3C73AC9B_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_D9B075179052E16D9CC548EF3C73AC9B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_D9B075179052E16D9CC548EF3C73AC9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_D9B075179052E16D9CC548EF3C73AC9B" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_D9B075179052E16D9CC548EF3C73AC9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_298E84494373A0D5EF3D48EF3C730223_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_298E84494373A0D5EF3D48EF3C730223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Paid During the Year</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_298E84494373A0D5EF3D48EF3C730223_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_298E84494373A0D5EF3D48EF3C730223" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_298E84494373A0D5EF3D48EF3C730223" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_298E84494373A0D5EF3D48EF3C730223" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_298E84494373A0D5EF3D48EF3C730223" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_124DC46ED582F34CC24E48EF3C73A25F_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_124DC46ED582F34CC24E48EF3C73A25F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_124DC46ED582F34CC24E48EF3C73A25F_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_124DC46ED582F34CC24E48EF3C73A25F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_124DC46ED582F34CC24E48EF3C73A25F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_124DC46ED582F34CC24E48EF3C73A25F" xlink:to="lab_us-gaap_InterestPaidNet_124DC46ED582F34CC24E48EF3C73A25F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_5BC808695BA6C5BBE8F048EF3C73EEDB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_5BC808695BA6C5BBE8F048EF3C73EEDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_5BC808695BA6C5BBE8F048EF3C73EEDB_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_5BC808695BA6C5BBE8F048EF3C73EEDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_5BC808695BA6C5BBE8F048EF3C73EEDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_5BC808695BA6C5BBE8F048EF3C73EEDB" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_5BC808695BA6C5BBE8F048EF3C73EEDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_BEE433BCD875D85972D848EF3C7357B1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_BEE433BCD875D85972D848EF3C7357B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_BEE433BCD875D85972D848EF3C7357B1_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_BEE433BCD875D85972D848EF3C7357B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_BEE433BCD875D85972D848EF3C7357B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_BEE433BCD875D85972D848EF3C7357B1" xlink:to="lab_us-gaap_InvestmentIncomeInterest_BEE433BCD875D85972D848EF3C7357B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_4DD9B863E411B786E2D448EF3C735868_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_4DD9B863E411B786E2D448EF3C735868" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_4DD9B863E411B786E2D448EF3C735868_label_en-US" xlink:label="lab_us-gaap_InterestExpense_4DD9B863E411B786E2D448EF3C735868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4DD9B863E411B786E2D448EF3C735868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_4DD9B863E411B786E2D448EF3C735868" xlink:to="lab_us-gaap_InterestExpense_4DD9B863E411B786E2D448EF3C735868" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_438B4F5C3FF117C3CDDB48EF3C732E89_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_438B4F5C3FF117C3CDDB48EF3C732E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_438B4F5C3FF117C3CDDB48EF3C732E89_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_438B4F5C3FF117C3CDDB48EF3C732E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_438B4F5C3FF117C3CDDB48EF3C732E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments_438B4F5C3FF117C3CDDB48EF3C732E89" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments_438B4F5C3FF117C3CDDB48EF3C732E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01661C6DA6B41759720248EF3C7453D0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01661C6DA6B41759720248EF3C7453D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01661C6DA6B41759720248EF3C7453D0_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01661C6DA6B41759720248EF3C7453D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01661C6DA6B41759720248EF3C7453D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01661C6DA6B41759720248EF3C7453D0" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01661C6DA6B41759720248EF3C7453D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8F6FDE545AFB450B166748EF3C74DF0F_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_8F6FDE545AFB450B166748EF3C74DF0F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8F6FDE545AFB450B166748EF3C74DF0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8F6FDE545AFB450B166748EF3C74DF0F" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_8F6FDE545AFB450B166748EF3C74DF0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5109C7EEC0C3555B184848EF3C7442C3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5109C7EEC0C3555B184848EF3C7442C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5109C7EEC0C3555B184848EF3C7442C3_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5109C7EEC0C3555B184848EF3C7442C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5109C7EEC0C3555B184848EF3C7442C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5109C7EEC0C3555B184848EF3C7442C3" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5109C7EEC0C3555B184848EF3C7442C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_95822109E5C0FC5EE88848EF3C74F9BD_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_95822109E5C0FC5EE88848EF3C74F9BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_95822109E5C0FC5EE88848EF3C74F9BD_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_95822109E5C0FC5EE88848EF3C74F9BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_95822109E5C0FC5EE88848EF3C74F9BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_95822109E5C0FC5EE88848EF3C74F9BD" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_95822109E5C0FC5EE88848EF3C74F9BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_87EDCB1047C774919B0E48EF3C744E3D_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_87EDCB1047C774919B0E48EF3C744E3D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_87EDCB1047C774919B0E48EF3C744E3D_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_87EDCB1047C774919B0E48EF3C744E3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_87EDCB1047C774919B0E48EF3C744E3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_87EDCB1047C774919B0E48EF3C744E3D" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_87EDCB1047C774919B0E48EF3C744E3D" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationexpensesaccrual_A4EB392AB80A62B713C548EF3C75FAFD_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_A4EB392AB80A62B713C548EF3C75FAFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_A4EB392AB80A62B713C548EF3C75FAFD_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_A4EB392AB80A62B713C548EF3C75FAFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_A4EB392AB80A62B713C548EF3C75FAFD_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_A4EB392AB80A62B713C548EF3C75FAFD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_A4EB392AB80A62B713C548EF3C75FAFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual_A4EB392AB80A62B713C548EF3C75FAFD" xlink:to="lab_biib_Collaborationexpensesaccrual_A4EB392AB80A62B713C548EF3C75FAFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_781F52857AA5DE041BD448EF3C7524FA_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_781F52857AA5DE041BD448EF3C7524FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_781F52857AA5DE041BD448EF3C7524FA_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_781F52857AA5DE041BD448EF3C7524FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_781F52857AA5DE041BD448EF3C7524FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_781F52857AA5DE041BD448EF3C7524FA" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_781F52857AA5DE041BD448EF3C7524FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationReserve_4F38C3624DA3520EB8D648EF3C7536DE_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve_4F38C3624DA3520EB8D648EF3C7536DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued TECFIDERA litigation settlement and license charges</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_4F38C3624DA3520EB8D648EF3C7536DE_label_en-US" xlink:label="lab_us-gaap_LitigationReserve_4F38C3624DA3520EB8D648EF3C7536DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationReserve" xlink:label="loc_us-gaap_LitigationReserve_4F38C3624DA3520EB8D648EF3C7536DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve_4F38C3624DA3520EB8D648EF3C7536DE" xlink:to="lab_us-gaap_LitigationReserve_4F38C3624DA3520EB8D648EF3C7536DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D2D332B55A918723115748EF3C75385E_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D2D332B55A918723115748EF3C75385E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D2D332B55A918723115748EF3C75385E_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D2D332B55A918723115748EF3C75385E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_D2D332B55A918723115748EF3C75385E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_D2D332B55A918723115748EF3C75385E" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D2D332B55A918723115748EF3C75385E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_7A08521CD6121BF5184848EF3C757381_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_7A08521CD6121BF5184848EF3C757381" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7A08521CD6121BF5184848EF3C757381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_7A08521CD6121BF5184848EF3C757381" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_7A08521CD6121BF5184848EF3C757381" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:type="arc" />
    <link:label id="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795_terseLabel_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795_label_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program Year To Date [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795_documentation_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program Year To Date</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795" xlink:to="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795" xlink:type="arc" />
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F_terseLabel_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F_label_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F_documentation_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F" xlink:to="lab_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E" xlink:to="lab_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:to="lab_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_1794FC13139F027D291F43AA3FFD40C0_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_1794FC13139F027D291F43AA3FFD40C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_1794FC13139F027D291F43AA3FFD40C0_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_1794FC13139F027D291F43AA3FFD40C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1794FC13139F027D291F43AA3FFD40C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_1794FC13139F027D291F43AA3FFD40C0" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_1794FC13139F027D291F43AA3FFD40C0" xlink:type="arc" />
    <link:label id="lab_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111_terseLabel_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series X junior participating</link:label>
    <link:label id="lab_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111_label_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series X Preferred Stock [Member]</link:label>
    <link:label id="lab_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111_documentation_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series X preferred stock.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111" xlink:to="lab_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111" xlink:type="arc" />
    <link:label id="lab_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF_terseLabel_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated</link:label>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF_label_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF_documentation_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF" xlink:to="lab_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:to="lab_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_C013FCA2E9DA4876012C43AA3FFE4508_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_C013FCA2E9DA4876012C43AA3FFE4508" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_C013FCA2E9DA4876012C43AA3FFE4508_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_C013FCA2E9DA4876012C43AA3FFE4508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_C013FCA2E9DA4876012C43AA3FFE4508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_C013FCA2E9DA4876012C43AA3FFE4508" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_C013FCA2E9DA4876012C43AA3FFE4508" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4AFCEF2677888CF946D643AA3FFE460D_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4AFCEF2677888CF946D643AA3FFE460D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized amount of share repurchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4AFCEF2677888CF946D643AA3FFE460D_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4AFCEF2677888CF946D643AA3FFE460D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4AFCEF2677888CF946D643AA3FFE460D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4AFCEF2677888CF946D643AA3FFE460D" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4AFCEF2677888CF946D643AA3FFE460D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_B6F358A74E537A6CC0E743AA3FFE2E40_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_B6F358A74E537A6CC0E743AA3FFE2E40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares authorized for repurchase</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_B6F358A74E537A6CC0E743AA3FFE2E40_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_B6F358A74E537A6CC0E743AA3FFE2E40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_B6F358A74E537A6CC0E743AA3FFE2E40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_B6F358A74E537A6CC0E743AA3FFE2E40" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_B6F358A74E537A6CC0E743AA3FFE2E40" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_231B703246AB88ED2F0943AA3FFEDA4C_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_231B703246AB88ED2F0943AA3FFEDA4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_231B703246AB88ED2F0943AA3FFEDA4C_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_231B703246AB88ED2F0943AA3FFEDA4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_231B703246AB88ED2F0943AA3FFEDA4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_231B703246AB88ED2F0943AA3FFEDA4C" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_231B703246AB88ED2F0943AA3FFEDA4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_17E0B76BBC31333B174C43AA3FFE8DCC_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_17E0B76BBC31333B174C43AA3FFE8DCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_17E0B76BBC31333B174C43AA3FFE8DCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_17E0B76BBC31333B174C43AA3FFE8DCC" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_17E0B76BBC31333B174C43AA3FFE8DCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7E9E7C5C6374F947612F42D5E4A3FD2D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_7E9E7C5C6374F947612F42D5E4A3FD2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7E9E7C5C6374F947612F42D5E4A3FD2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_7E9E7C5C6374F947612F42D5E4A3FD2D" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_7E9E7C5C6374F947612F42D5E4A3FD2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A419484C8BEC0CAF40F442D5E4A3F6B7_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A419484C8BEC0CAF40F442D5E4A3F6B7" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A419484C8BEC0CAF40F442D5E4A3F6B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A419484C8BEC0CAF40F442D5E4A3F6B7" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A419484C8BEC0CAF40F442D5E4A3F6B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_00C96585005987B2EB4F42D5E4A35CE4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_00C96585005987B2EB4F42D5E4A35CE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on fair value remeasurement of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_00C96585005987B2EB4F42D5E4A35CE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_00C96585005987B2EB4F42D5E4A35CE4" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_00C96585005987B2EB4F42D5E4A35CE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0A667C1D10BD914BA06442D5E4A3A7A6_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0A667C1D10BD914BA06442D5E4A3A7A6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0A667C1D10BD914BA06442D5E4A3A7A6_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0A667C1D10BD914BA06442D5E4A3A7A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0A667C1D10BD914BA06442D5E4A3A7A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0A667C1D10BD914BA06442D5E4A3A7A6" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0A667C1D10BD914BA06442D5E4A3A7A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_727611B356D693495E7142D5E4A3D751_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_727611B356D693495E7142D5E4A3D751" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_727611B356D693495E7142D5E4A3D751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_727611B356D693495E7142D5E4A3D751" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_727611B356D693495E7142D5E4A3D751" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_241ED74C3734CDAED53C29780E092114_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_241ED74C3734CDAED53C29780E092114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Indebtedness</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_241ED74C3734CDAED53C29780E092114_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_241ED74C3734CDAED53C29780E092114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_241ED74C3734CDAED53C29780E092114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_241ED74C3734CDAED53C29780E092114" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_241ED74C3734CDAED53C29780E092114" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_21DC11B03523603D59B629780E09C923_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_21DC11B03523603D59B629780E09C923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_21DC11B03523603D59B629780E09C923_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_21DC11B03523603D59B629780E09C923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_21DC11B03523603D59B629780E09C923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_21DC11B03523603D59B629780E09C923" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_21DC11B03523603D59B629780E09C923" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_87563215B594E8D1DB7529780D943B6B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_87563215B594E8D1DB7529780D943B6B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue by product</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_87563215B594E8D1DB7529780D943B6B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_87563215B594E8D1DB7529780D943B6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_87563215B594E8D1DB7529780D943B6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_87563215B594E8D1DB7529780D943B6B" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_87563215B594E8D1DB7529780D943B6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_A8830AE3A4A59B136E3F29780D94D398_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_A8830AE3A4A59B136E3F29780D94D398" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Geographic information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_A8830AE3A4A59B136E3F29780D94D398_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_A8830AE3A4A59B136E3F29780D94D398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_A8830AE3A4A59B136E3F29780D94D398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_A8830AE3A4A59B136E3F29780D94D398" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_A8830AE3A4A59B136E3F29780D94D398" xlink:type="arc" />
    <link:label id="lab_country_IT_2A116609C77783D758FB48F0190750C1_terseLabel_en-US" xlink:label="lab_country_IT_2A116609C77783D758FB48F0190750C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
    <link:label id="lab_country_IT_2A116609C77783D758FB48F0190750C1_label_en-US" xlink:label="lab_country_IT_2A116609C77783D758FB48F0190750C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IT" xlink:label="loc_country_IT_2A116609C77783D758FB48F0190750C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT_2A116609C77783D758FB48F0190750C1" xlink:to="lab_country_IT_2A116609C77783D758FB48F0190750C1" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:to="lab_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:to="lab_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:type="arc" />
    <link:label id="lab_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24_terseLabel_en-US" xlink:label="lab_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fifteen billion</link:label>
    <link:label id="lab_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24_label_en-US" xlink:label="lab_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fifteen billion [Member] [Member]</link:label>
    <link:label id="lab_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24_documentation_en-US" xlink:label="lab_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fifteen billion [Member] [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24" xlink:to="lab_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24" xlink:type="arc" />
    <link:label id="lab_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F_terseLabel_en-US" xlink:label="lab_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sixteen billion</link:label>
    <link:label id="lab_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F_label_en-US" xlink:label="lab_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sixteen billion [Member]</link:label>
    <link:label id="lab_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F_documentation_en-US" xlink:label="lab_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sixteen billion [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F" xlink:to="lab_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_13E70FEEBBBED3CD91FB48F01908E8B5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_13E70FEEBBBED3CD91FB48F01908E8B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_13E70FEEBBBED3CD91FB48F01908E8B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_13E70FEEBBBED3CD91FB48F01908E8B5" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_13E70FEEBBBED3CD91FB48F01908E8B5" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33_label_en-US" xlink:label="lab_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33" xlink:to="lab_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3A0876FAD0919C3C8D3448F019089A6A_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3A0876FAD0919C3C8D3448F019089A6A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3A0876FAD0919C3C8D3448F019089A6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3A0876FAD0919C3C8D3448F019089A6A" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3A0876FAD0919C3C8D3448F019089A6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidTaxes_418A7E697A805ABF9BE548F019088E50_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_418A7E697A805ABF9BE548F019088E50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_418A7E697A805ABF9BE548F019088E50_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_418A7E697A805ABF9BE548F019088E50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_418A7E697A805ABF9BE548F019088E50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes_418A7E697A805ABF9BE548F019088E50" xlink:to="lab_us-gaap_PrepaidTaxes_418A7E697A805ABF9BE548F019088E50" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_8203E6EF15ABD2655C6C48F01909BE2B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_8203E6EF15ABD2655C6C48F01909BE2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net impairment on certain tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_8203E6EF15ABD2655C6C48F01909BE2B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_8203E6EF15ABD2655C6C48F01909BE2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_8203E6EF15ABD2655C6C48F01909BE2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_8203E6EF15ABD2655C6C48F01909BE2B" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_8203E6EF15ABD2655C6C48F01909BE2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_16F3AF488535E5C7D9C748F01908211C_negatedLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_16F3AF488535E5C7D9C748F01908211C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Proposed settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_16F3AF488535E5C7D9C748F01908211C_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_16F3AF488535E5C7D9C748F01908211C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_16F3AF488535E5C7D9C748F01908211C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_16F3AF488535E5C7D9C748F01908211C" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_16F3AF488535E5C7D9C748F01908211C" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B_terseLabel_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement Limit Stated In Resolution</link:label>
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B_label_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Limit Stated In Resolution</link:label>
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B_documentation_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement limit stated in the resolution.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B" xlink:to="lab_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_E091D4A1A0CEA5D8361248F01908F8D2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_E091D4A1A0CEA5D8361248F01908F8D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_E091D4A1A0CEA5D8361248F01908F8D2_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_E091D4A1A0CEA5D8361248F01908F8D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_E091D4A1A0CEA5D8361248F01908F8D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_E091D4A1A0CEA5D8361248F01908F8D2" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_E091D4A1A0CEA5D8361248F01908F8D2" xlink:type="arc" />
    <link:label id="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72_terseLabel_en-US" xlink:label="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, adjustment related to claim amount, percent</link:label>
    <link:label id="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72_label_en-US" xlink:label="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Adjustment Related To Claim Amount, Percent</link:label>
    <link:label id="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72_documentation_en-US" xlink:label="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Adjustment Related To Claim Amount, Percent</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_LossContingencyAdjustmentRelatedToClaimAmountPercent" xlink:label="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72" xlink:to="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72" xlink:type="arc" />
    <link:label id="lab_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051_terseLabel_en-US" xlink:label="lab_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PLEGRIDY</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051_label_en-US" xlink:label="lab_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PLEGRIDY [Member]</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051_documentation_en-US" xlink:label="lab_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PLEGRIDY [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PLEGRIDYMember" xlink:label="loc_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051" xlink:to="lab_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051" xlink:type="arc" />
    <link:label id="lab_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28_verboseLabel_en-US" xlink:label="lab_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28_label_en-US" xlink:label="lab_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI [Member]</link:label>
    <link:label id="lab_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28_documentation_en-US" xlink:label="lab_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tysabri.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_TysabriMember" xlink:label="loc_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28" xlink:to="lab_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28" xlink:type="arc" />
    <link:label id="lab_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D_label_en-US" xlink:label="lab_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D" xlink:to="lab_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D" xlink:type="arc" />
    <link:label id="lab_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3_terseLabel_en-US" xlink:label="lab_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ELOCTATE</link:label>
    <link:label id="lab_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3_label_en-US" xlink:label="lab_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:label id="lab_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3_documentation_en-US" xlink:label="lab_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3" xlink:to="lab_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3" xlink:type="arc" />
    <link:label id="lab_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3_terseLabel_en-US" xlink:label="lab_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALPROLIX</link:label>
    <link:label id="lab_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3_label_en-US" xlink:label="lab_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALPROLIX Product [Member]</link:label>
    <link:label id="lab_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3_documentation_en-US" xlink:label="lab_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ALPROLIX Product [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ALPROLIXProductMember" xlink:label="loc_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3" xlink:to="lab_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3" xlink:type="arc" />
    <link:label id="lab_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C_label_en-US" xlink:label="lab_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C_documentation_en-US" xlink:label="lab_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C" xlink:to="lab_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C" xlink:type="arc" />
    <link:label id="lab_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C_label_en-US" xlink:label="lab_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C_documentation_en-US" xlink:label="lab_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C" xlink:to="lab_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C" xlink:type="arc" />
    <link:label id="lab_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272_label_en-US" xlink:label="lab_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272_documentation_en-US" xlink:label="lab_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272" xlink:to="lab_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Business Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068_label_en-US" xlink:label="lab_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:to="lab_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:type="arc" />
    <link:label id="lab_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE_verboseLabel_en-US" xlink:label="lab_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE_label_en-US" xlink:label="lab_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE_documentation_en-US" xlink:label="lab_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rest of world.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RestOfWorldMember" xlink:label="loc_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE" xlink:to="lab_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue by product</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetAbstract" xlink:label="loc_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43" xlink:to="lab_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_068F2D5280C837B635474C78A5393E6C_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_068F2D5280C837B635474C78A5393E6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_068F2D5280C837B635474C78A5393E6C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_068F2D5280C837B635474C78A5393E6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_068F2D5280C837B635474C78A5393E6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_068F2D5280C837B635474C78A5393E6C" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_068F2D5280C837B635474C78A5393E6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18CB3BDD44FF07E7720643329FBEB501_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18CB3BDD44FF07E7720643329FBEB501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18CB3BDD44FF07E7720643329FBEB501_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18CB3BDD44FF07E7720643329FBEB501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18CB3BDD44FF07E7720643329FBEB501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18CB3BDD44FF07E7720643329FBEB501" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18CB3BDD44FF07E7720643329FBEB501" xlink:type="arc" />
    <link:label id="lab_biib_HemophiliaProductsMember_C8EBA2A3D5BD646E724C43329FBFE00F_terseLabel_en-US" xlink:label="lab_biib_HemophiliaProductsMember_C8EBA2A3D5BD646E724C43329FBFE00F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia Products</link:label>
    <link:label id="lab_biib_HemophiliaProductsMember_C8EBA2A3D5BD646E724C43329FBFE00F_label_en-US" xlink:label="lab_biib_HemophiliaProductsMember_C8EBA2A3D5BD646E724C43329FBFE00F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hemophilia Products [Member]</link:label>
    <link:label id="lab_biib_HemophiliaProductsMember_C8EBA2A3D5BD646E724C43329FBFE00F_documentation_en-US" xlink:label="lab_biib_HemophiliaProductsMember_C8EBA2A3D5BD646E724C43329FBFE00F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hemophilia Products</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_C8EBA2A3D5BD646E724C43329FBFE00F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HemophiliaProductsMember_C8EBA2A3D5BD646E724C43329FBFE00F" xlink:to="lab_biib_HemophiliaProductsMember_C8EBA2A3D5BD646E724C43329FBFE00F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Distributed to Bioverativ [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_B6EE6D0BAD5DD807AB7943329FBFA3B3" xlink:type="arc" />
    <link:label id="lab_biib_TermofBioverativTransactionServicesAgreement_4EA49D5E1C8FE9048A6543329FBF0465_terseLabel_en-US" xlink:label="lab_biib_TermofBioverativTransactionServicesAgreement_4EA49D5E1C8FE9048A6543329FBF0465" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Transaction Services Agreement</link:label>
    <link:label id="lab_biib_TermofBioverativTransactionServicesAgreement_4EA49D5E1C8FE9048A6543329FBF0465_label_en-US" xlink:label="lab_biib_TermofBioverativTransactionServicesAgreement_4EA49D5E1C8FE9048A6543329FBF0465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Transaction Services Agreement</link:label>
    <link:label id="lab_biib_TermofBioverativTransactionServicesAgreement_4EA49D5E1C8FE9048A6543329FBF0465_documentation_en-US" xlink:label="lab_biib_TermofBioverativTransactionServicesAgreement_4EA49D5E1C8FE9048A6543329FBF0465" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Transaction Services Agreement</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_TermofBioverativTransactionServicesAgreement" xlink:label="loc_biib_TermofBioverativTransactionServicesAgreement_4EA49D5E1C8FE9048A6543329FBF0465" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermofBioverativTransactionServicesAgreement_4EA49D5E1C8FE9048A6543329FBF0465" xlink:to="lab_biib_TermofBioverativTransactionServicesAgreement_4EA49D5E1C8FE9048A6543329FBF0465" xlink:type="arc" />
    <link:label id="lab_biib_TermofBioverativManufacturingandSupplyAgreement_4C5939F4E3987E5383FE43329FBF55F1_terseLabel_en-US" xlink:label="lab_biib_TermofBioverativManufacturingandSupplyAgreement_4C5939F4E3987E5383FE43329FBF55F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Manufacturing and Supply Agreement</link:label>
    <link:label id="lab_biib_TermofBioverativManufacturingandSupplyAgreement_4C5939F4E3987E5383FE43329FBF55F1_label_en-US" xlink:label="lab_biib_TermofBioverativManufacturingandSupplyAgreement_4C5939F4E3987E5383FE43329FBF55F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Manufacturing and Supply Agreement</link:label>
    <link:label id="lab_biib_TermofBioverativManufacturingandSupplyAgreement_4C5939F4E3987E5383FE43329FBF55F1_documentation_en-US" xlink:label="lab_biib_TermofBioverativManufacturingandSupplyAgreement_4C5939F4E3987E5383FE43329FBF55F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Manufacturing and Supply Agreement</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_TermofBioverativManufacturingandSupplyAgreement" xlink:label="loc_biib_TermofBioverativManufacturingandSupplyAgreement_4C5939F4E3987E5383FE43329FBF55F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermofBioverativManufacturingandSupplyAgreement_4C5939F4E3987E5383FE43329FBF55F1" xlink:to="lab_biib_TermofBioverativManufacturingandSupplyAgreement_4C5939F4E3987E5383FE43329FBF55F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8641D799B2C5784A0E8443329FBF63D4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8641D799B2C5784A0E8443329FBF63D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8641D799B2C5784A0E8443329FBF63D4_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8641D799B2C5784A0E8443329FBF63D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8641D799B2C5784A0E8443329FBF63D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8641D799B2C5784A0E8443329FBF63D4" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8641D799B2C5784A0E8443329FBF63D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_749B9E86D003A14B1C9943329FBF57B0_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_749B9E86D003A14B1C9943329FBF57B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_749B9E86D003A14B1C9943329FBF57B0_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_749B9E86D003A14B1C9943329FBF57B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_749B9E86D003A14B1C9943329FBF57B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_749B9E86D003A14B1C9943329FBF57B0" xlink:to="lab_us-gaap_CostOfGoodsSold_749B9E86D003A14B1C9943329FBF57B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63F27B49AEE15A701B80297C21E140A0_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63F27B49AEE15A701B80297C21E140A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63F27B49AEE15A701B80297C21E140A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63F27B49AEE15A701B80297C21E140A0" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63F27B49AEE15A701B80297C21E140A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6990037710E12A6813AE297C21E1B7B9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6990037710E12A6813AE297C21E1B7B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6990037710E12A6813AE297C21E1B7B9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6990037710E12A6813AE297C21E1B7B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6990037710E12A6813AE297C21E1B7B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6990037710E12A6813AE297C21E1B7B9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6990037710E12A6813AE297C21E1B7B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_011879FB8F37CF9BEC23297C21E1191B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_011879FB8F37CF9BEC23297C21E1191B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: reclassification adjustment for (gains) losses included in net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_011879FB8F37CF9BEC23297C21E1191B_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_011879FB8F37CF9BEC23297C21E1191B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_011879FB8F37CF9BEC23297C21E1191B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_011879FB8F37CF9BEC23297C21E1191B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_011879FB8F37CF9BEC23297C21E1191B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_BB42DE502584A8509F59297C21E171CD_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_BB42DE502584A8509F59297C21E171CD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_BB42DE502584A8509F59297C21E171CD_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_BB42DE502584A8509F59297C21E171CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_BB42DE502584A8509F59297C21E171CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_BB42DE502584A8509F59297C21E171CD" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_BB42DE502584A8509F59297C21E171CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_6FC04F16F548445D5C32297C21E1C678_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_6FC04F16F548445D5C32297C21E1C678" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_6FC04F16F548445D5C32297C21E1C678_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_6FC04F16F548445D5C32297C21E1C678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_6FC04F16F548445D5C32297C21E1C678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_6FC04F16F548445D5C32297C21E1C678" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_6FC04F16F548445D5C32297C21E1C678" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_ADAC5EC4BC1516DF8405297C21E14AF4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_ADAC5EC4BC1516DF8405297C21E14AF4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: reclassification adjustment for (gains) losses included in net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_ADAC5EC4BC1516DF8405297C21E14AF4_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_ADAC5EC4BC1516DF8405297C21E14AF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_ADAC5EC4BC1516DF8405297C21E14AF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_ADAC5EC4BC1516DF8405297C21E14AF4" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_ADAC5EC4BC1516DF8405297C21E14AF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_D7CA549924F0E7624288297C21E1876E_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_D7CA549924F0E7624288297C21E1876E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_D7CA549924F0E7624288297C21E1876E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_D7CA549924F0E7624288297C21E1876E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_D7CA549924F0E7624288297C21E1876E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_D7CA549924F0E7624288297C21E1876E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_D7CA549924F0E7624288297C21E1876E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_73B0465FB59FB0FA4400297C21E142D2_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_73B0465FB59FB0FA4400297C21E142D2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_73B0465FB59FB0FA4400297C21E142D2_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_73B0465FB59FB0FA4400297C21E142D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_73B0465FB59FB0FA4400297C21E142D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_73B0465FB59FB0FA4400297C21E142D2" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_73B0465FB59FB0FA4400297C21E142D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_018C33C681F1EA6CA0BB297C21E13DB5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_018C33C681F1EA6CA0BB297C21E13DB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_018C33C681F1EA6CA0BB297C21E13DB5_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_018C33C681F1EA6CA0BB297C21E13DB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_018C33C681F1EA6CA0BB297C21E13DB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_018C33C681F1EA6CA0BB297C21E13DB5" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_018C33C681F1EA6CA0BB297C21E13DB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_650873BED1C0FF5A27FD297C21E1C1EE_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_650873BED1C0FF5A27FD297C21E1C1EE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_650873BED1C0FF5A27FD297C21E1C1EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_650873BED1C0FF5A27FD297C21E1C1EE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_650873BED1C0FF5A27FD297C21E1C1EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_DEAD4431C606B77158FD297C21E1D09D_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_DEAD4431C606B77158FD297C21E1D09D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_DEAD4431C606B77158FD297C21E1D09D_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_DEAD4431C606B77158FD297C21E1D09D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_DEAD4431C606B77158FD297C21E1D09D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_DEAD4431C606B77158FD297C21E1D09D" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_DEAD4431C606B77158FD297C21E1D09D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_626F6F59C992A916F792297C21E2E6DC_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_626F6F59C992A916F792297C21E2E6DC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_626F6F59C992A916F792297C21E2E6DC_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_626F6F59C992A916F792297C21E2E6DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_626F6F59C992A916F792297C21E2E6DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_626F6F59C992A916F792297C21E2E6DC" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_626F6F59C992A916F792297C21E2E6DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6F653E6961A0ECD87BAA297C21E2E9DF_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6F653E6961A0ECD87BAA297C21E2E9DF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6F653E6961A0ECD87BAA297C21E2E9DF_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6F653E6961A0ECD87BAA297C21E2E9DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6F653E6961A0ECD87BAA297C21E2E9DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6F653E6961A0ECD87BAA297C21E2E9DF" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6F653E6961A0ECD87BAA297C21E2E9DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:to="lab_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA" xlink:to="lab_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F" xlink:to="lab_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9512F679110C3FA6F66F29780F705100_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_9512F679110C3FA6F66F29780F705100" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9512F679110C3FA6F66F29780F705100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9512F679110C3FA6F66F29780F705100" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_9512F679110C3FA6F66F29780F705100" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_A11F41C82C7FB81E7DC529780F708A97_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_A11F41C82C7FB81E7DC529780F708A97" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_A11F41C82C7FB81E7DC529780F708A97_label_en-US" xlink:label="lab_us-gaap_SalesMember_A11F41C82C7FB81E7DC529780F708A97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_A11F41C82C7FB81E7DC529780F708A97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_A11F41C82C7FB81E7DC529780F708A97" xlink:to="lab_us-gaap_SalesMember_A11F41C82C7FB81E7DC529780F708A97" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_BE7A4EA42653A755273E29780F709E60_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_BE7A4EA42653A755273E29780F709E60" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_BE7A4EA42653A755273E29780F709E60_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_BE7A4EA42653A755273E29780F709E60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_BE7A4EA42653A755273E29780F709E60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_BE7A4EA42653A755273E29780F709E60" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_BE7A4EA42653A755273E29780F709E60" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_8A011FBF93E1DE58C24129780F71D88A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_8A011FBF93E1DE58C24129780F71D88A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_8A011FBF93E1DE58C24129780F71D88A_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_8A011FBF93E1DE58C24129780F71D88A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_8A011FBF93E1DE58C24129780F71D88A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_8A011FBF93E1DE58C24129780F71D88A" xlink:to="lab_us-gaap_OperatingExpenseMember_8A011FBF93E1DE58C24129780F71D88A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_6608CCBE418745E5743929780F71E1B5_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_6608CCBE418745E5743929780F71E1B5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount Reclassified from Accumulated Other Comprehensive Income into Income Gain/(Loss) (Effective Portion)</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_6608CCBE418745E5743929780F71E1B5_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_6608CCBE418745E5743929780F71E1B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_6608CCBE418745E5743929780F71E1B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_6608CCBE418745E5743929780F71E1B5" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_6608CCBE418745E5743929780F71E1B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_7470256E4A8D67DF27B329780F7138DB_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_7470256E4A8D67DF27B329780F7138DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in earnings of foreign currency forward contracts due to hedge ineffectiveness</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_7470256E4A8D67DF27B329780F7138DB_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_7470256E4A8D67DF27B329780F7138DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_7470256E4A8D67DF27B329780F7138DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_7470256E4A8D67DF27B329780F7138DB" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_7470256E4A8D67DF27B329780F7138DB" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_0D290B1F74E99641CF0F29780DA3EA89_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_0D290B1F74E99641CF0F29780DA3EA89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_0D290B1F74E99641CF0F29780DA3EA89_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_0D290B1F74E99641CF0F29780DA3EA89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_0D290B1F74E99641CF0F29780DA3EA89_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_0D290B1F74E99641CF0F29780DA3EA89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_0D290B1F74E99641CF0F29780DA3EA89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_0D290B1F74E99641CF0F29780DA3EA89" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_0D290B1F74E99641CF0F29780DA3EA89" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_62650E53009B1488E5FB29780DA32125_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_62650E53009B1488E5FB29780DA32125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_62650E53009B1488E5FB29780DA32125_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_62650E53009B1488E5FB29780DA32125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_62650E53009B1488E5FB29780DA32125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_62650E53009B1488E5FB29780DA32125" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_62650E53009B1488E5FB29780DA32125" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0CE270FC47C8542CD26E29780DA35B2C_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_0CE270FC47C8542CD26E29780DA35B2C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0CE270FC47C8542CD26E29780DA35B2C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_0CE270FC47C8542CD26E29780DA35B2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_0CE270FC47C8542CD26E29780DA35B2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_0CE270FC47C8542CD26E29780DA35B2C" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_0CE270FC47C8542CD26E29780DA35B2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandMember_33004A8C4FEF66F3F8E442D5E3B751A6_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember_33004A8C4FEF66F3F8E442D5E3B751A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_33004A8C4FEF66F3F8E442D5E3B751A6_label_en-US" xlink:label="lab_us-gaap_LandMember_33004A8C4FEF66F3F8E442D5E3B751A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_33004A8C4FEF66F3F8E442D5E3B751A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember_33004A8C4FEF66F3F8E442D5E3B751A6" xlink:to="lab_us-gaap_LandMember_33004A8C4FEF66F3F8E442D5E3B751A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_34729EAC4F1F26DC243242D5E3B83E6B_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_34729EAC4F1F26DC243242D5E3B83E6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_34729EAC4F1F26DC243242D5E3B83E6B_label_en-US" xlink:label="lab_us-gaap_Depreciation_34729EAC4F1F26DC243242D5E3B83E6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_34729EAC4F1F26DC243242D5E3B83E6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_34729EAC4F1F26DC243242D5E3B83E6B" xlink:to="lab_us-gaap_Depreciation_34729EAC4F1F26DC243242D5E3B83E6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestCostsCapitalized_ABD298651955B627422442D5E3B82C37_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_ABD298651955B627422442D5E3B82C37" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest cost capitalization related to construction in progress</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_ABD298651955B627422442D5E3B82C37_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_ABD298651955B627422442D5E3B82C37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_ABD298651955B627422442D5E3B82C37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized_ABD298651955B627422442D5E3B82C37" xlink:to="lab_us-gaap_InterestCostsCapitalized_ABD298651955B627422442D5E3B82C37" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D3E1F10B7995992B52A242D5E3B8171A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D3E1F10B7995992B52A242D5E3B8171A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of original lease</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D3E1F10B7995992B52A242D5E3B8171A_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D3E1F10B7995992B52A242D5E3B8171A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D3E1F10B7995992B52A242D5E3B8171A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D3E1F10B7995992B52A242D5E3B8171A" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D3E1F10B7995992B52A242D5E3B8171A" xlink:type="arc" />
    <link:label id="lab_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68_terseLabel_en-US" xlink:label="lab_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of amended lease</link:label>
    <link:label id="lab_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68_label_en-US" xlink:label="lab_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Of Lease</link:label>
    <link:label id="lab_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68_documentation_en-US" xlink:label="lab_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Of Lease.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_TermOfLease" xlink:label="loc_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68" xlink:to="lab_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligations_69E8553A3B74AE90929442D5E3B80C62_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligations_69E8553A3B74AE90929442D5E3B80C62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital lease obligation</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligations_69E8553A3B74AE90929442D5E3B80C62_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligations_69E8553A3B74AE90929442D5E3B80C62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_69E8553A3B74AE90929442D5E3B80C62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligations_69E8553A3B74AE90929442D5E3B80C62" xlink:to="lab_us-gaap_CapitalLeaseObligations_69E8553A3B74AE90929442D5E3B80C62" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CC7B94D8D0F4BFD125424331A7B785EA_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CC7B94D8D0F4BFD125424331A7B785EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia Spin-Off</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CC7B94D8D0F4BFD125424331A7B785EA_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CC7B94D8D0F4BFD125424331A7B785EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CC7B94D8D0F4BFD125424331A7B785EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CC7B94D8D0F4BFD125424331A7B785EA" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_CC7B94D8D0F4BFD125424331A7B785EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C_terseLabel_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C_label_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:to="lab_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:type="arc" />
    <link:label id="lab_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA_terseLabel_en-US" xlink:label="lab_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA_label_en-US" xlink:label="lab_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work-in-process [Member]</link:label>
    <link:label id="lab_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA_documentation_en-US" xlink:label="lab_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA" xlink:to="lab_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA" xlink:type="arc" />
    <link:label id="lab_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49_terseLabel_en-US" xlink:label="lab_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished Goods</link:label>
    <link:label id="lab_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49_label_en-US" xlink:label="lab_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished Goods [Member]</link:label>
    <link:label id="lab_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49_documentation_en-US" xlink:label="lab_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finished Goods</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FinishedGoodsMember" xlink:label="loc_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49" xlink:to="lab_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7" xlink:to="lab_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3326613D067D5043BB54311A52493FD_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3326613D067D5043BB54311A52493FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3326613D067D5043BB54311A52493FD_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3326613D067D5043BB54311A52493FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3326613D067D5043BB54311A52493FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3326613D067D5043BB54311A52493FD" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3326613D067D5043BB54311A52493FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_B26A74FE1E8868C1BD2B4311A524D216_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_B26A74FE1E8868C1BD2B4311A524D216" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Write-downs on excess, obsolete, unmarketable or other inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_B26A74FE1E8868C1BD2B4311A524D216_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_B26A74FE1E8868C1BD2B4311A524D216" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_B26A74FE1E8868C1BD2B4311A524D216" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_B26A74FE1E8868C1BD2B4311A524D216" xlink:to="lab_us-gaap_InventoryWriteDown_B26A74FE1E8868C1BD2B4311A524D216" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DD9A7783F62D59BE256929780F4F4678_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DD9A7783F62D59BE256929780F4F4678" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DD9A7783F62D59BE256929780F4F4678_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DD9A7783F62D59BE256929780F4F4678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DD9A7783F62D59BE256929780F4F4678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DD9A7783F62D59BE256929780F4F4678" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DD9A7783F62D59BE256929780F4F4678" xlink:type="arc" />
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3_verboseLabel_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option</link:label>
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3_label_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Benefit And Cash Received From Stock Option [Abstract]</link:label>
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3_documentation_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" xlink:label="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3" xlink:to="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_D075590D3CA95BBA4E774252BB84D82B_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_D075590D3CA95BBA4E774252BB84D82B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit realized for stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_D075590D3CA95BBA4E774252BB84D82B_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_D075590D3CA95BBA4E774252BB84D82B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_D075590D3CA95BBA4E774252BB84D82B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_D075590D3CA95BBA4E774252BB84D82B" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_D075590D3CA95BBA4E774252BB84D82B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_FEBAB95E657ECFA187D04236E1E64DF8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_FEBAB95E657ECFA187D04236E1E64DF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_FEBAB95E657ECFA187D04236E1E64DF8_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_FEBAB95E657ECFA187D04236E1E64DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_FEBAB95E657ECFA187D04236E1E64DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_FEBAB95E657ECFA187D04236E1E64DF8" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_FEBAB95E657ECFA187D04236E1E64DF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B60CC9DEAC0915D84CF229780E16C245_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B60CC9DEAC0915D84CF229780E16C245" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B60CC9DEAC0915D84CF229780E16C245_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B60CC9DEAC0915D84CF229780E16C245" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B60CC9DEAC0915D84CF229780E16C245" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B60CC9DEAC0915D84CF229780E16C245" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B60CC9DEAC0915D84CF229780E16C245" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9A9FFE56F297285E651929780F7C666D_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9A9FFE56F297285E651929780F7C666D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9A9FFE56F297285E651929780F7C666D_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9A9FFE56F297285E651929780F7C666D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9A9FFE56F297285E651929780F7C666D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9A9FFE56F297285E651929780F7C666D" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9A9FFE56F297285E651929780F7C666D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3346131037658CDD3CB429780F7CFA59_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_3346131037658CDD3CB429780F7CFA59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3346131037658CDD3CB429780F7CFA59_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_3346131037658CDD3CB429780F7CFA59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3346131037658CDD3CB429780F7CFA59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_3346131037658CDD3CB429780F7CFA59" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_3346131037658CDD3CB429780F7CFA59" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_81618527063936B8185429780F7CAD9A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_81618527063936B8185429780F7CAD9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_81618527063936B8185429780F7CAD9A_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_81618527063936B8185429780F7CAD9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_81618527063936B8185429780F7CAD9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_81618527063936B8185429780F7CAD9A" xlink:to="lab_us-gaap_CommonStockSharesIssued_81618527063936B8185429780F7CAD9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_005F50E546F3808F2D7629780F7CD498_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_005F50E546F3808F2D7629780F7CD498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_005F50E546F3808F2D7629780F7CD498_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_005F50E546F3808F2D7629780F7CD498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_005F50E546F3808F2D7629780F7CD498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_005F50E546F3808F2D7629780F7CD498" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_005F50E546F3808F2D7629780F7CD498" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:to="lab_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_9AF0D8EFD69E3FE1496E43A9429DE34C_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_9AF0D8EFD69E3FE1496E43A9429DE34C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable to Fumedica</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_9AF0D8EFD69E3FE1496E43A9429DE34C_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_9AF0D8EFD69E3FE1496E43A9429DE34C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_9AF0D8EFD69E3FE1496E43A9429DE34C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_9AF0D8EFD69E3FE1496E43A9429DE34C" xlink:to="lab_us-gaap_NotesPayableCurrent_9AF0D8EFD69E3FE1496E43A9429DE34C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_27EAFBA46F5D39D91E8B43A9429FE9F1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_27EAFBA46F5D39D91E8B43A9429FE9F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing arrangement for the purchase of the RTP facility</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_27EAFBA46F5D39D91E8B43A9429FE9F1_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_27EAFBA46F5D39D91E8B43A9429FE9F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_27EAFBA46F5D39D91E8B43A9429FE9F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_27EAFBA46F5D39D91E8B43A9429FE9F1" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_27EAFBA46F5D39D91E8B43A9429FE9F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_AA0CA043F503AF3CEE2643A9429FE5BC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_AA0CA043F503AF3CEE2643A9429FE5BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable and other financing arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_AA0CA043F503AF3CEE2643A9429FE5BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_AA0CA043F503AF3CEE2643A9429FE5BC" xlink:to="lab_us-gaap_DebtCurrent_AA0CA043F503AF3CEE2643A9429FE5BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_5EE3852E2A1FA6150BD443A9429FE1D3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_5EE3852E2A1FA6150BD443A9429FE1D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current notes payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_5EE3852E2A1FA6150BD443A9429FE1D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_5EE3852E2A1FA6150BD443A9429FE1D3" xlink:to="lab_us-gaap_LongTermNotesPayable_5EE3852E2A1FA6150BD443A9429FE1D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_A722BB9D056786161BC543A942A040DD_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_A722BB9D056786161BC543A942A040DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing arrangement for the purchase of the RTP facility</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_A722BB9D056786161BC543A942A040DD_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_A722BB9D056786161BC543A942A040DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_A722BB9D056786161BC543A942A040DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_A722BB9D056786161BC543A942A040DD" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_A722BB9D056786161BC543A942A040DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_3308D56009FC67404AD443A942A04462_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_3308D56009FC67404AD443A942A04462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of notes payable and other financing arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_3308D56009FC67404AD443A942A04462" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_3308D56009FC67404AD443A942A04462" xlink:to="lab_us-gaap_LongTermDebt_3308D56009FC67404AD443A942A04462" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:to="lab_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9" xlink:to="lab_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9" xlink:type="arc" />
    <link:label id="lab_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74" xlink:to="lab_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateContractMember_42B95A18D362683BE579433E144747EE_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember_42B95A18D362683BE579433E144747EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate lock</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_42B95A18D362683BE579433E144747EE_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember_42B95A18D362683BE579433E144747EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_42B95A18D362683BE579433E144747EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember_42B95A18D362683BE579433E144747EE" xlink:to="lab_us-gaap_InterestRateContractMember_42B95A18D362683BE579433E144747EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_35D32DE79B644AAE0F54433E1447CC13_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_35D32DE79B644AAE0F54433E1447CC13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_35D32DE79B644AAE0F54433E1447CC13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_35D32DE79B644AAE0F54433E1447CC13" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_35D32DE79B644AAE0F54433E1447CC13" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D92195E3E5592A13B564433E144DF210_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D92195E3E5592A13B564433E144DF210" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D92195E3E5592A13B564433E144DF210_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D92195E3E5592A13B564433E144DF210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D92195E3E5592A13B564433E144DF210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D92195E3E5592A13B564433E144DF210" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D92195E3E5592A13B564433E144DF210" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_24C97B0E517030B5D8C7433E144DB014_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_24C97B0E517030B5D8C7433E144DB014" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_24C97B0E517030B5D8C7433E144DB014_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_24C97B0E517030B5D8C7433E144DB014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_24C97B0E517030B5D8C7433E144DB014" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_24C97B0E517030B5D8C7433E144DB014" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_24C97B0E517030B5D8C7433E144DB014" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A1168C01C6C44FE4AE2E433E144DFDEC_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A1168C01C6C44FE4AE2E433E144DFDEC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on treasury rate lock settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A1168C01C6C44FE4AE2E433E144DFDEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A1168C01C6C44FE4AE2E433E144DFDEC" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A1168C01C6C44FE4AE2E433E144DFDEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_A05F015583AC3BA31058433E144DFD04_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_A05F015583AC3BA31058433E144DFD04" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_A05F015583AC3BA31058433E144DFD04_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_A05F015583AC3BA31058433E144DFD04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_A05F015583AC3BA31058433E144DFD04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_A05F015583AC3BA31058433E144DFD04" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_A05F015583AC3BA31058433E144DFD04" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteesAbstract_66A283201608A86DA17829780DE706CC_label_en-US" xlink:label="lab_us-gaap_GuaranteesAbstract_66A283201608A86DA17829780DE706CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="loc_us-gaap_GuaranteesAbstract_66A283201608A86DA17829780DE706CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesAbstract_66A283201608A86DA17829780DE706CC" xlink:to="lab_us-gaap_GuaranteesAbstract_66A283201608A86DA17829780DE706CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteesTextBlock_8D0CDA64CA664477EA5329780DE7BA64_verboseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock_8D0CDA64CA664477EA5329780DE7BA64" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteesTextBlock_8D0CDA64CA664477EA5329780DE7BA64_label_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock_8D0CDA64CA664477EA5329780DE7BA64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GuaranteesTextBlock" xlink:label="loc_us-gaap_GuaranteesTextBlock_8D0CDA64CA664477EA5329780DE7BA64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesTextBlock_8D0CDA64CA664477EA5329780DE7BA64" xlink:to="lab_us-gaap_GuaranteesTextBlock_8D0CDA64CA664477EA5329780DE7BA64" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A9A7AA61F2854F87537242D5E576E140_terseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_A9A7AA61F2854F87537242D5E576E140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A9A7AA61F2854F87537242D5E576E140_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_A9A7AA61F2854F87537242D5E576E140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A9A7AA61F2854F87537242D5E576E140_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_A9A7AA61F2854F87537242D5E576E140" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_A9A7AA61F2854F87537242D5E576E140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_A9A7AA61F2854F87537242D5E576E140" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_A9A7AA61F2854F87537242D5E576E140" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_78835960756EAB59BCB042D5E576E6E7_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_78835960756EAB59BCB042D5E576E6E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_78835960756EAB59BCB042D5E576E6E7_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_78835960756EAB59BCB042D5E576E6E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_78835960756EAB59BCB042D5E576E6E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_78835960756EAB59BCB042D5E576E6E7" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_78835960756EAB59BCB042D5E576E6E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_0937DF205B02C98BB0AE42D5E576950B_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_0937DF205B02C98BB0AE42D5E576950B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_0937DF205B02C98BB0AE42D5E576950B_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_0937DF205B02C98BB0AE42D5E576950B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_0937DF205B02C98BB0AE42D5E576950B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_0937DF205B02C98BB0AE42D5E576950B" xlink:to="lab_us-gaap_UseOfEstimates_0937DF205B02C98BB0AE42D5E576950B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_FC51E31B9EFF836C990742D5E5761A00_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_FC51E31B9EFF836C990742D5E5761A00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_FC51E31B9EFF836C990742D5E5761A00_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_FC51E31B9EFF836C990742D5E5761A00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_FC51E31B9EFF836C990742D5E5761A00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_FC51E31B9EFF836C990742D5E5761A00" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_FC51E31B9EFF836C990742D5E5761A00" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9137957F776AF5978EFA42D5E5769615_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9137957F776AF5978EFA42D5E5769615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9137957F776AF5978EFA42D5E5769615_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9137957F776AF5978EFA42D5E5769615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9137957F776AF5978EFA42D5E5769615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9137957F776AF5978EFA42D5E5769615" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9137957F776AF5978EFA42D5E5769615" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_BE13E46D6A9E21A8601A42D5E576B490_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_BE13E46D6A9E21A8601A42D5E576B490" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_BE13E46D6A9E21A8601A42D5E576B490_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_BE13E46D6A9E21A8601A42D5E576B490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_BE13E46D6A9E21A8601A42D5E576B490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_BE13E46D6A9E21A8601A42D5E576B490" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_BE13E46D6A9E21A8601A42D5E576B490" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_75AA5E2E5243C828CFE342D5E5765E18_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_75AA5E2E5243C828CFE342D5E5765E18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_75AA5E2E5243C828CFE342D5E5765E18_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_75AA5E2E5243C828CFE342D5E5765E18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_75AA5E2E5243C828CFE342D5E5765E18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock_75AA5E2E5243C828CFE342D5E5765E18" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock_75AA5E2E5243C828CFE342D5E5765E18" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_FEB592CBBC7AEA43817D42D5E576C9ED_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_FEB592CBBC7AEA43817D42D5E576C9ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_FEB592CBBC7AEA43817D42D5E576C9ED_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_FEB592CBBC7AEA43817D42D5E576C9ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_FEB592CBBC7AEA43817D42D5E576C9ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_FEB592CBBC7AEA43817D42D5E576C9ED" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_FEB592CBBC7AEA43817D42D5E576C9ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_EA0C9AFBBBC0358D957A42D5E5763390_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_EA0C9AFBBBC0358D957A42D5E5763390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Other Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_EA0C9AFBBBC0358D957A42D5E5763390_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_EA0C9AFBBBC0358D957A42D5E5763390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_EA0C9AFBBBC0358D957A42D5E5763390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_EA0C9AFBBBC0358D957A42D5E5763390" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_EA0C9AFBBBC0358D957A42D5E5763390" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_E7D843EDAA396B2DDE3142D5E5768934_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_E7D843EDAA396B2DDE3142D5E5768934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method of Accounting</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_E7D843EDAA396B2DDE3142D5E5768934_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_E7D843EDAA396B2DDE3142D5E5768934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_E7D843EDAA396B2DDE3142D5E5768934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy_E7D843EDAA396B2DDE3142D5E5768934" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy_E7D843EDAA396B2DDE3142D5E5768934" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_9C0BCE130D14CF3E62D842D5E576CED8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_9C0BCE130D14CF3E62D842D5E576CED8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_9C0BCE130D14CF3E62D842D5E576CED8_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_9C0BCE130D14CF3E62D842D5E576CED8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_9C0BCE130D14CF3E62D842D5E576CED8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_9C0BCE130D14CF3E62D842D5E576CED8" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_9C0BCE130D14CF3E62D842D5E576CED8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3E5C4F83D6712A03638242D5E576D639_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3E5C4F83D6712A03638242D5E576D639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3E5C4F83D6712A03638242D5E576D639_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3E5C4F83D6712A03638242D5E576D639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3E5C4F83D6712A03638242D5E576D639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3E5C4F83D6712A03638242D5E576D639" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3E5C4F83D6712A03638242D5E576D639" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_04059D3D8294D9C36CDC42D5E576F8D7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_04059D3D8294D9C36CDC42D5E576F8D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_04059D3D8294D9C36CDC42D5E576F8D7_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_04059D3D8294D9C36CDC42D5E576F8D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_04059D3D8294D9C36CDC42D5E576F8D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_04059D3D8294D9C36CDC42D5E576F8D7" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_04059D3D8294D9C36CDC42D5E576F8D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_C264E9CC833D195A2A8C42D5E5764B50_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_C264E9CC833D195A2A8C42D5E5764B50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired In-process Research and Development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_C264E9CC833D195A2A8C42D5E5764B50_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_C264E9CC833D195A2A8C42D5E5764B50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_C264E9CC833D195A2A8C42D5E5764B50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_C264E9CC833D195A2A8C42D5E5764B50" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_C264E9CC833D195A2A8C42D5E5764B50" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D214210717A7B124686E42D5E5766903_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D214210717A7B124686E42D5E5766903" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D214210717A7B124686E42D5E5766903_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D214210717A7B124686E42D5E5766903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D214210717A7B124686E42D5E5766903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D214210717A7B124686E42D5E5766903" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D214210717A7B124686E42D5E5766903" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_408B15AFF1BDDECA299D42D5E5769121_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_408B15AFF1BDDECA299D42D5E5769121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_408B15AFF1BDDECA299D42D5E5769121_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_408B15AFF1BDDECA299D42D5E5769121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_408B15AFF1BDDECA299D42D5E5769121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_408B15AFF1BDDECA299D42D5E5769121" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_408B15AFF1BDDECA299D42D5E5769121" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_F12BF02E0161EB712C0E42D5E577EEB1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_F12BF02E0161EB712C0E42D5E577EEB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_F12BF02E0161EB712C0E42D5E577EEB1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_F12BF02E0161EB712C0E42D5E577EEB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_F12BF02E0161EB712C0E42D5E577EEB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_F12BF02E0161EB712C0E42D5E577EEB1" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_F12BF02E0161EB712C0E42D5E577EEB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_90D63814FB4053D8B55542D5E577306A_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_90D63814FB4053D8B55542D5E577306A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_90D63814FB4053D8B55542D5E577306A_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_90D63814FB4053D8B55542D5E577306A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_90D63814FB4053D8B55542D5E577306A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_90D63814FB4053D8B55542D5E577306A" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_90D63814FB4053D8B55542D5E577306A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1D6030445E630461C8B642D5E5776782_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1D6030445E630461C8B642D5E5776782" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation of Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1D6030445E630461C8B642D5E5776782_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1D6030445E630461C8B642D5E5776782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1D6030445E630461C8B642D5E5776782" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1D6030445E630461C8B642D5E5776782" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1D6030445E630461C8B642D5E5776782" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B46544C6B81CC8F4F9F742D5E5777EC7_terseLabel_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B46544C6B81CC8F4F9F742D5E5777EC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales</link:label>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B46544C6B81CC8F4F9F742D5E5777EC7_label_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B46544C6B81CC8F4F9F742D5E5777EC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales [Policy Text Block]</link:label>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B46544C6B81CC8F4F9F742D5E5777EC7_documentation_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B46544C6B81CC8F4F9F742D5E5777EC7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales [Policy Text Block]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RoyaltyCostofSalesPolicyTextBlock" xlink:label="loc_biib_RoyaltyCostofSalesPolicyTextBlock_B46544C6B81CC8F4F9F742D5E5777EC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyCostofSalesPolicyTextBlock_B46544C6B81CC8F4F9F742D5E5777EC7" xlink:to="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B46544C6B81CC8F4F9F742D5E5777EC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_05CD588A3FBDEFF674DC42D5E577C552_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_05CD588A3FBDEFF674DC42D5E577C552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting for Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_05CD588A3FBDEFF674DC42D5E577C552_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_05CD588A3FBDEFF674DC42D5E577C552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_05CD588A3FBDEFF674DC42D5E577C552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_05CD588A3FBDEFF674DC42D5E577C552" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_05CD588A3FBDEFF674DC42D5E577C552" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_93C749BDCD2DE26AA5FC42D5E577789E_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_93C749BDCD2DE26AA5FC42D5E577789E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_93C749BDCD2DE26AA5FC42D5E577789E_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_93C749BDCD2DE26AA5FC42D5E577789E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_93C749BDCD2DE26AA5FC42D5E577789E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_93C749BDCD2DE26AA5FC42D5E577789E" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_93C749BDCD2DE26AA5FC42D5E577789E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_B8C6287635ABC36CDA9F42D5E577EFCA_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_B8C6287635ABC36CDA9F42D5E577EFCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_B8C6287635ABC36CDA9F42D5E577EFCA_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_B8C6287635ABC36CDA9F42D5E577EFCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_B8C6287635ABC36CDA9F42D5E577EFCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_B8C6287635ABC36CDA9F42D5E577EFCA" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_B8C6287635ABC36CDA9F42D5E577EFCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_D68284AC54F9D2704E3E42D5E5775B5B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_D68284AC54F9D2704E3E42D5E5775B5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_D68284AC54F9D2704E3E42D5E5775B5B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_D68284AC54F9D2704E3E42D5E5775B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_D68284AC54F9D2704E3E42D5E5775B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_D68284AC54F9D2704E3E42D5E5775B5B" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_D68284AC54F9D2704E3E42D5E5775B5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_17834CF67ECE8976829D42D5E577E9AD_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_17834CF67ECE8976829D42D5E577E9AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_17834CF67ECE8976829D42D5E577E9AD_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_17834CF67ECE8976829D42D5E577E9AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_17834CF67ECE8976829D42D5E577E9AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_17834CF67ECE8976829D42D5E577E9AD" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_17834CF67ECE8976829D42D5E577E9AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_0B6422F7098DC420F89C42D5E577A64E_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0B6422F7098DC420F89C42D5E577A64E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_0B6422F7098DC420F89C42D5E577A64E_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0B6422F7098DC420F89C42D5E577A64E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0B6422F7098DC420F89C42D5E577A64E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_0B6422F7098DC420F89C42D5E577A64E" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0B6422F7098DC420F89C42D5E577A64E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2AD1C047789DDE6F248842D5E57747CD_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2AD1C047789DDE6F248842D5E57747CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2AD1C047789DDE6F248842D5E57747CD_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2AD1C047789DDE6F248842D5E57747CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2AD1C047789DDE6F248842D5E57747CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2AD1C047789DDE6F248842D5E57747CD" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2AD1C047789DDE6F248842D5E57747CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_F5AC66CC9D599748D1A729780EB97783_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_F5AC66CC9D599748D1A729780EB97783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_F5AC66CC9D599748D1A729780EB97783_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_F5AC66CC9D599748D1A729780EB97783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_F5AC66CC9D599748D1A729780EB97783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_F5AC66CC9D599748D1A729780EB97783" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_F5AC66CC9D599748D1A729780EB97783" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_0089ACBDBC7D3E79563929780EB983AA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_0089ACBDBC7D3E79563929780EB983AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, other reserves, and accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_0089ACBDBC7D3E79563929780EB983AA_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_0089ACBDBC7D3E79563929780EB983AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_0089ACBDBC7D3E79563929780EB983AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory_0089ACBDBC7D3E79563929780EB983AA" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory_0089ACBDBC7D3E79563929780EB983AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5D6EE2B0909ADFEE4CC029780EB933E0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5D6EE2B0909ADFEE4CC029780EB933E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5D6EE2B0909ADFEE4CC029780EB933E0_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5D6EE2B0909ADFEE4CC029780EB933E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5D6EE2B0909ADFEE4CC029780EB933E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5D6EE2B0909ADFEE4CC029780EB933E0" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5D6EE2B0909ADFEE4CC029780EB933E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A571F33EA8930D262BA529780EB9E9B2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A571F33EA8930D262BA529780EB9E9B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A571F33EA8930D262BA529780EB9E9B2_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A571F33EA8930D262BA529780EB9E9B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A571F33EA8930D262BA529780EB9E9B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A571F33EA8930D262BA529780EB9E9B2" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A571F33EA8930D262BA529780EB9E9B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_25763347D6D3D85E26B729780EB9D426_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_25763347D6D3D85E26B729780EB9D426" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_25763347D6D3D85E26B729780EB9D426_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_25763347D6D3D85E26B729780EB9D426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_25763347D6D3D85E26B729780EB9D426" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_25763347D6D3D85E26B729780EB9D426" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_25763347D6D3D85E26B729780EB9D426" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_7AB1C9DE75E94B234DC729780EB99E4B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_7AB1C9DE75E94B234DC729780EB99E4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_7AB1C9DE75E94B234DC729780EB99E4B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_7AB1C9DE75E94B234DC729780EB99E4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_7AB1C9DE75E94B234DC729780EB99E4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_7AB1C9DE75E94B234DC729780EB99E4B" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_7AB1C9DE75E94B234DC729780EB99E4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_57451C1F3F5FF529F43B29780EB98A95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_57451C1F3F5FF529F43B29780EB98A95" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_57451C1F3F5FF529F43B29780EB98A95_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_57451C1F3F5FF529F43B29780EB98A95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_57451C1F3F5FF529F43B29780EB98A95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_57451C1F3F5FF529F43B29780EB98A95" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_57451C1F3F5FF529F43B29780EB98A95" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_FC19DF377DFD9D978F6A29780EB941BC_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_FC19DF377DFD9D978F6A29780EB941BC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_FC19DF377DFD9D978F6A29780EB941BC_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_FC19DF377DFD9D978F6A29780EB941BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_FC19DF377DFD9D978F6A29780EB941BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_FC19DF377DFD9D978F6A29780EB941BC" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_FC19DF377DFD9D978F6A29780EB941BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_DDFA8EA2873AEA37E55729780EBA560B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_DDFA8EA2873AEA37E55729780EBA560B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_DDFA8EA2873AEA37E55729780EBA560B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_DDFA8EA2873AEA37E55729780EBA560B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_DDFA8EA2873AEA37E55729780EBA560B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_DDFA8EA2873AEA37E55729780EBA560B" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_DDFA8EA2873AEA37E55729780EBA560B" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_DB3C6A94B0AE9BB802CE29780EBAF397_negatedTerseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_DB3C6A94B0AE9BB802CE29780EBAF397" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and other</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_DB3C6A94B0AE9BB802CE29780EBAF397_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_DB3C6A94B0AE9BB802CE29780EBAF397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Depreciation Amortization Other</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_DB3C6A94B0AE9BB802CE29780EBAF397_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_DB3C6A94B0AE9BB802CE29780EBAF397" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities depreciation amortization other.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_DB3C6A94B0AE9BB802CE29780EBAF397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_DB3C6A94B0AE9BB802CE29780EBAF397" xlink:to="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_DB3C6A94B0AE9BB802CE29780EBAF397" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_BE8FCD3E12B093B9F91129780EBAF726_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_BE8FCD3E12B093B9F91129780EBAF726" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_BE8FCD3E12B093B9F91129780EBAF726_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_BE8FCD3E12B093B9F91129780EBAF726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_BE8FCD3E12B093B9F91129780EBAF726" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_BE8FCD3E12B093B9F91129780EBAF726" xlink:to="lab_us-gaap_DeferredTaxLiabilities_BE8FCD3E12B093B9F91129780EBAF726" xlink:type="arc" />
    <link:label id="lab_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB_verboseLabel_en-US" xlink:label="lab_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Directors Plan</link:label>
    <link:label id="lab_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB_label_en-US" xlink:label="lab_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Directors Plan [Member]</link:label>
    <link:label id="lab_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB_documentation_en-US" xlink:label="lab_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Directors plan.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB" xlink:to="lab_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB" xlink:type="arc" />
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF_terseLabel_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Omnibus Equity Plan [Member]</link:label>
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF_label_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Omnibus Equity Plan [Member]</link:label>
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF_documentation_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Omnibus Equity Plan</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_A2017OmnibusEquityPlanMember" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF" xlink:to="lab_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF" xlink:type="arc" />
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB_terseLabel_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2013</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB_label_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2013 [Member]</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB_documentation_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2013</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AttainmentOfPerformanceCriteriain2013Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB" xlink:to="lab_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367_label_en-US" xlink:label="lab_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367" xlink:to="lab_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A_label_en-US" xlink:label="lab_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A" xlink:to="lab_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_767EFCFBB015479ECDD5485EE72F27E5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_767EFCFBB015479ECDD5485EE72F27E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of PUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_767EFCFBB015479ECDD5485EE72F27E5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_767EFCFBB015479ECDD5485EE72F27E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_767EFCFBB015479ECDD5485EE72F27E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_767EFCFBB015479ECDD5485EE72F27E5" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_767EFCFBB015479ECDD5485EE72F27E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69" xlink:to="lab_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectorMember_1D31A907E07D936CE83D485EE72F3166_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember_1D31A907E07D936CE83D485EE72F3166" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</link:label>
    <link:label id="lab_us-gaap_DirectorMember_1D31A907E07D936CE83D485EE72F3166_label_en-US" xlink:label="lab_us-gaap_DirectorMember_1D31A907E07D936CE83D485EE72F3166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_1D31A907E07D936CE83D485EE72F3166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember_1D31A907E07D936CE83D485EE72F3166" xlink:to="lab_us-gaap_DirectorMember_1D31A907E07D936CE83D485EE72F3166" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF_verboseLabel_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total number of shares of common stock for issuance</link:label>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF_label_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Of Common Stock For Issuance</link:label>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF_documentation_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total number of shares of common stock for issuance.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF" xlink:to="lab_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF" xlink:type="arc" />
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12_verboseLabel_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ratio of total number of shares reserved under the plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12_label_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ratio Of Number Of Shares Reserved Under Plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12_documentation_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ratio of total number of shares reserved under the plan.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12" xlink:to="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0E7851DFCC55FBD54855485EE7305F35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0E7851DFCC55FBD54855485EE7305F35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omnibus Plan number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0E7851DFCC55FBD54855485EE7305F35_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0E7851DFCC55FBD54855485EE7305F35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0E7851DFCC55FBD54855485EE7305F35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0E7851DFCC55FBD54855485EE7305F35" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0E7851DFCC55FBD54855485EE7305F35" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075_verboseLabel_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of equal annual increments</link:label>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075_label_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Equal Annual Increments</link:label>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075_documentation_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of equal annual increments.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075" xlink:to="lab_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075" xlink:type="arc" />
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D_verboseLabel_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D_label_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D_documentation_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D" xlink:to="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D" xlink:type="arc" />
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9_verboseLabel_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9_label_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9_documentation_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9" xlink:to="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04F69A4ED86493E52AAE485EE7302EA8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04F69A4ED86493E52AAE485EE7302EA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04F69A4ED86493E52AAE485EE7302EA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04F69A4ED86493E52AAE485EE7302EA8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04F69A4ED86493E52AAE485EE7302EA8" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007_verboseLabel_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of days for calculation of average closing stock price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007_label_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Days For Calculation Of Average Closing Stock Price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007_documentation_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of days for calculation of average closing stock price.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007" xlink:to="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6405FA35986F70C8A7CD485EE7306FE7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6405FA35986F70C8A7CD485EE7306FE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of vested awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6405FA35986F70C8A7CD485EE7306FE7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6405FA35986F70C8A7CD485EE7306FE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6405FA35986F70C8A7CD485EE7306FE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6405FA35986F70C8A7CD485EE7306FE7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6405FA35986F70C8A7CD485EE7306FE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_B7C6F6C9A5F7BDA418C6485EE73049DE_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_B7C6F6C9A5F7BDA418C6485EE73049DE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash in settlement of CSPS awards upon vesting</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_B7C6F6C9A5F7BDA418C6485EE73049DE_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_B7C6F6C9A5F7BDA418C6485EE73049DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Cash Flow Effect, Cash Used to Settle Awards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_B7C6F6C9A5F7BDA418C6485EE73049DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_B7C6F6C9A5F7BDA418C6485EE73049DE" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_B7C6F6C9A5F7BDA418C6485EE73049DE" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028_terseLabel_en-US" xlink:label="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PUs converted to share settlements</link:label>
    <link:label id="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028_label_en-US" xlink:label="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Shares Used to Settle Awards</link:label>
    <link:label id="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028_documentation_en-US" xlink:label="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Shares Used to Settle Awards</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" xlink:label="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028" xlink:to="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0_terseLabel_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payments (Textual)</link:label>
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0_label_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0_documentation_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Payments.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareBasedPaymentsTextualAbstract" xlink:label="loc_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:to="lab_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5865E73796E7A902C453485EE7319AC2_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5865E73796E7A902C453485EE7319AC2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to unvested share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5865E73796E7A902C453485EE7319AC2_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5865E73796E7A902C453485EE7319AC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5865E73796E7A902C453485EE7319AC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5865E73796E7A902C453485EE7319AC2" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5865E73796E7A902C453485EE7319AC2" xlink:type="arc" />
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_5CD941DE3F35731E074B485EE73182B2_verboseLabel_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_5CD941DE3F35731E074B485EE73182B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period to recognize the cost of unvested awards</link:label>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_5CD941DE3F35731E074B485EE73182B2_label_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_5CD941DE3F35731E074B485EE73182B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Period To Recognize Cost Of Nonvested Awards</link:label>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_5CD941DE3F35731E074B485EE73182B2_documentation_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_5CD941DE3F35731E074B485EE73182B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-average period to recognize the cost of nonvested awards.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_5CD941DE3F35731E074B485EE73182B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_5CD941DE3F35731E074B485EE73182B2" xlink:to="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_5CD941DE3F35731E074B485EE73182B2" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_444BA88A69747EF47AE0485EE731DEA6_verboseLabel_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_444BA88A69747EF47AE0485EE731DEA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of share-based compensation plans pursuant to which awards are currently being made</link:label>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_444BA88A69747EF47AE0485EE731DEA6_label_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_444BA88A69747EF47AE0485EE731DEA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Based Compensation Plans Pursuant To Which Awards Are Currently Being Made</link:label>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_444BA88A69747EF47AE0485EE731DEA6_documentation_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_444BA88A69747EF47AE0485EE731DEA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of share-based compensation plans pursuant to which awards are currently being made.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_444BA88A69747EF47AE0485EE731DEA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_444BA88A69747EF47AE0485EE731DEA6" xlink:to="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_444BA88A69747EF47AE0485EE731DEA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_A472A20BB34F7AC687C2485EE7313B56_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_A472A20BB34F7AC687C2485EE7313B56" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares granted under stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_A472A20BB34F7AC687C2485EE7313B56_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_A472A20BB34F7AC687C2485EE7313B56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_A472A20BB34F7AC687C2485EE7313B56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_A472A20BB34F7AC687C2485EE7313B56" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_A472A20BB34F7AC687C2485EE7313B56" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_93AAA5BD6E66EDDDD8D5485EE731AD36_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_93AAA5BD6E66EDDDD8D5485EE731AD36" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_93AAA5BD6E66EDDDD8D5485EE731AD36_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_93AAA5BD6E66EDDDD8D5485EE731AD36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_93AAA5BD6E66EDDDD8D5485EE731AD36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_93AAA5BD6E66EDDDD8D5485EE731AD36" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_93AAA5BD6E66EDDDD8D5485EE731AD36" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E967EE4CAC89375254AD485EE7319CB3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E967EE4CAC89375254AD485EE7319CB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic values of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E967EE4CAC89375254AD485EE7319CB3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E967EE4CAC89375254AD485EE7319CB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E967EE4CAC89375254AD485EE7319CB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E967EE4CAC89375254AD485EE7319CB3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E967EE4CAC89375254AD485EE7319CB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1D3A03E104ADD6D9F8A1485EE7317907_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1D3A03E104ADD6D9F8A1485EE7317907" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1D3A03E104ADD6D9F8A1485EE7317907_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1D3A03E104ADD6D9F8A1485EE7317907" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1D3A03E104ADD6D9F8A1485EE7317907" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1D3A03E104ADD6D9F8A1485EE7317907" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1D3A03E104ADD6D9F8A1485EE7317907" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1FF893A5457CE60FEC5329780E711EC8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1FF893A5457CE60FEC5329780E711EC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1FF893A5457CE60FEC5329780E711EC8_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1FF893A5457CE60FEC5329780E711EC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1FF893A5457CE60FEC5329780E711EC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1FF893A5457CE60FEC5329780E711EC8" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1FF893A5457CE60FEC5329780E711EC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_207377A668975A39685743AA3FF8BB71_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_207377A668975A39685743AA3FF8BB71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_207377A668975A39685743AA3FF8BB71_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_207377A668975A39685743AA3FF8BB71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_207377A668975A39685743AA3FF8BB71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_207377A668975A39685743AA3FF8BB71" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_207377A668975A39685743AA3FF8BB71" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B" xlink:type="arc" />
    <link:label id="lab_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C_terseLabel_en-US" xlink:label="lab_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Tax Act</link:label>
    <link:label id="lab_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C_label_en-US" xlink:label="lab_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. 2017 Tax Act [Member]</link:label>
    <link:label id="lab_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C_documentation_en-US" xlink:label="lab_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">U.S. 2017 Tax Act</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C" xlink:to="lab_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:type="arc" />
    <link:label id="lab_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440_terseLabel_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440_label_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440_documentation_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440" xlink:to="lab_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440" xlink:type="arc" />
    <link:label id="lab_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5" xlink:to="lab_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5" xlink:type="arc" />
    <link:label id="lab_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992_terseLabel_en-US" xlink:label="lab_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992_label_en-US" xlink:label="lab_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992_documentation_en-US" xlink:label="lab_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CommercialMilestonesMember" xlink:label="loc_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992" xlink:to="lab_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992" xlink:type="arc" />
    <link:label id="lab_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094_terseLabel_en-US" xlink:label="lab_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fourteen billion</link:label>
    <link:label id="lab_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094_label_en-US" xlink:label="lab_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fourteen billion [Member]</link:label>
    <link:label id="lab_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094_documentation_en-US" xlink:label="lab_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fourteen billion [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FourteenbillionMember" xlink:label="loc_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094" xlink:to="lab_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094" xlink:type="arc" />
    <link:label id="lab_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661_terseLabel_en-US" xlink:label="lab_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eleven billion</link:label>
    <link:label id="lab_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661_label_en-US" xlink:label="lab_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eleven billion [Member]</link:label>
    <link:label id="lab_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661_documentation_en-US" xlink:label="lab_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eleven billion [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ElevenbillionMember" xlink:label="loc_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661" xlink:to="lab_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661" xlink:type="arc" />
    <link:label id="lab_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED_terseLabel_en-US" xlink:label="lab_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Twelve billion</link:label>
    <link:label id="lab_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED_label_en-US" xlink:label="lab_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twelve billion [Member]</link:label>
    <link:label id="lab_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED_documentation_en-US" xlink:label="lab_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twelve billion [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_TwelvebillionMember" xlink:label="loc_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED" xlink:to="lab_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED" xlink:type="arc" />
    <link:label id="lab_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604_terseLabel_en-US" xlink:label="lab_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thirteen billion</link:label>
    <link:label id="lab_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604_label_en-US" xlink:label="lab_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thirteen billion [Member]</link:label>
    <link:label id="lab_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604_documentation_en-US" xlink:label="lab_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Thirteen billion [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ThirteenbillionMember" xlink:label="loc_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604" xlink:to="lab_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604" xlink:type="arc" />
    <link:label id="lab_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E_terseLabel_en-US" xlink:label="lab_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One billion</link:label>
    <link:label id="lab_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E_label_en-US" xlink:label="lab_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One billion [Member]</link:label>
    <link:label id="lab_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E_documentation_en-US" xlink:label="lab_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One billion [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E" xlink:to="lab_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E" xlink:type="arc" />
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6_terseLabel_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6_label_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6_documentation_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6" xlink:to="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6" xlink:type="arc" />
    <link:label id="lab_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA_terseLabel_en-US" xlink:label="lab_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Three billion</link:label>
    <link:label id="lab_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA_label_en-US" xlink:label="lab_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three billion [Member]</link:label>
    <link:label id="lab_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA_documentation_en-US" xlink:label="lab_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Three billion [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA" xlink:to="lab_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313" xlink:to="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D_label_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D" xlink:to="lab_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB" xlink:to="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_2E03C7A9241351E9C35C4C77BC3B5B67_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_2E03C7A9241351E9C35C4C77BC3B5B67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount paid in cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2E03C7A9241351E9C35C4C77BC3B5B67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_2E03C7A9241351E9C35C4C77BC3B5B67" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_2E03C7A9241351E9C35C4C77BC3B5B67" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_89714369B631F41AEC974C77BC3B9AFB_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_89714369B631F41AEC974C77BC3B9AFB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cancellable future commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_89714369B631F41AEC974C77BC3B9AFB_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_89714369B631F41AEC974C77BC3B9AFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_89714369B631F41AEC974C77BC3B9AFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_89714369B631F41AEC974C77BC3B9AFB" xlink:to="lab_us-gaap_OtherCommitment_89714369B631F41AEC974C77BC3B9AFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGrossCurrent_CDA835E465588F9B6D354C77BC3B8A53_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGrossCurrent_CDA835E465588F9B6D354C77BC3B8A53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income tax liability under the Transition Toll Tax, current</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGrossCurrent_CDA835E465588F9B6D354C77BC3B8A53_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGrossCurrent_CDA835E465588F9B6D354C77BC3B8A53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossCurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_CDA835E465588F9B6D354C77BC3B8A53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_CDA835E465588F9B6D354C77BC3B8A53" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGrossCurrent_CDA835E465588F9B6D354C77BC3B8A53" xlink:type="arc" />
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9_terseLabel_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies (Textual)</link:label>
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9_label_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9_documentation_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9" xlink:to="lab_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9" xlink:type="arc" />
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F01E8DA5F9E93F7A4104C77BC3B0996_verboseLabel_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F01E8DA5F9E93F7A4104C77BC3B0996" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F01E8DA5F9E93F7A4104C77BC3B0996_label_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F01E8DA5F9E93F7A4104C77BC3B0996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses On Funding Commitment Related To Clinical Research</link:label>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F01E8DA5F9E93F7A4104C77BC3B0996_documentation_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F01E8DA5F9E93F7A4104C77BC3B0996" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued expenses on funding commitment related to clinical research.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F01E8DA5F9E93F7A4104C77BC3B0996" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F01E8DA5F9E93F7A4104C77BC3B0996" xlink:to="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F01E8DA5F9E93F7A4104C77BC3B0996" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_0A5078174D656234C7E44C77BC3B8D5D_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_0A5078174D656234C7E44C77BC3B8D5D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities associated with uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_0A5078174D656234C7E44C77BC3B8D5D_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_0A5078174D656234C7E44C77BC3B8D5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_0A5078174D656234C7E44C77BC3B8D5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_0A5078174D656234C7E44C77BC3B8D5D" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_0A5078174D656234C7E44C77BC3B8D5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_CED01B902A4AFA4765C24C77BC3B0C8B_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_CED01B902A4AFA4765C24C77BC3B0C8B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease rent expense which terminates at various dates through 2028</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_CED01B902A4AFA4765C24C77BC3B0C8B_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_CED01B902A4AFA4765C24C77BC3B0C8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_CED01B902A4AFA4765C24C77BC3B0C8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_CED01B902A4AFA4765C24C77BC3B0C8B" xlink:to="lab_us-gaap_LeaseAndRentalExpense_CED01B902A4AFA4765C24C77BC3B0C8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="lab_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508" xlink:to="lab_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_8BEC058B7BFE9CA88F7348E2641D7B36_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_8BEC058B7BFE9CA88F7348E2641D7B36" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8BEC058B7BFE9CA88F7348E2641D7B36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_8BEC058B7BFE9CA88F7348E2641D7B36" xlink:to="lab_us-gaap_Revenues_8BEC058B7BFE9CA88F7348E2641D7B36" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_C381B75C17F0F60F7AB148E2641D5C34_negatedLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_C381B75C17F0F60F7AB148E2641D5C34" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization of acquired intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_C381B75C17F0F60F7AB148E2641D5C34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_C381B75C17F0F60F7AB148E2641D5C34" xlink:to="lab_us-gaap_CostOfGoodsSold_C381B75C17F0F60F7AB148E2641D5C34" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EEBEC8175FE358B0F4F948E2641DDCF1_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EEBEC8175FE358B0F4F948E2641DDCF1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EEBEC8175FE358B0F4F948E2641DDCF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EEBEC8175FE358B0F4F948E2641DDCF1" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EEBEC8175FE358B0F4F948E2641DDCF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_BBA0E00FAFBFEC9CB7D048E2641D5133_negatedLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_BBA0E00FAFBFEC9CB7D048E2641D5133" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_BBA0E00FAFBFEC9CB7D048E2641D5133_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_BBA0E00FAFBFEC9CB7D048E2641D5133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_BBA0E00FAFBFEC9CB7D048E2641D5133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_BBA0E00FAFBFEC9CB7D048E2641D5133" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_BBA0E00FAFBFEC9CB7D048E2641D5133" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_E13155A5523A4F16A83F48E2641E05E4_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_E13155A5523A4F16A83F48E2641E05E4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_E13155A5523A4F16A83F48E2641E05E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_E13155A5523A4F16A83F48E2641E05E4" xlink:to="lab_us-gaap_RestructuringCharges_E13155A5523A4F16A83F48E2641E05E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_8A5288C21D0F5D6F065448E2641E602A_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_8A5288C21D0F5D6F065448E2641E602A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8A5288C21D0F5D6F065448E2641E602A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_8A5288C21D0F5D6F065448E2641E602A" xlink:to="lab_us-gaap_CostsAndExpenses_8A5288C21D0F5D6F065448E2641E602A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9884B44765BF295681F648E2641EC3D0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_9884B44765BF295681F648E2641EC3D0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9884B44765BF295681F648E2641EC3D0_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_9884B44765BF295681F648E2641EC3D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9884B44765BF295681F648E2641EC3D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_9884B44765BF295681F648E2641EC3D0" xlink:to="lab_us-gaap_OperatingIncomeLoss_9884B44765BF295681F648E2641EC3D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_660B4C07CB2B0EA4DF1048EBC4F3B72B_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_660B4C07CB2B0EA4DF1048EBC4F3B72B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_660B4C07CB2B0EA4DF1048EBC4F3B72B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_660B4C07CB2B0EA4DF1048EBC4F3B72B" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_660B4C07CB2B0EA4DF1048EBC4F3B72B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_BA311796DC3581DB8DE848E2641EEF8B_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_BA311796DC3581DB8DE848E2641EEF8B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_BA311796DC3581DB8DE848E2641EEF8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_BA311796DC3581DB8DE848E2641EEF8B" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_BA311796DC3581DB8DE848E2641EEF8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5D48B28479DE75CC7B5E48E2641E83A7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5D48B28479DE75CC7B5E48E2641E83A7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5D48B28479DE75CC7B5E48E2641E83A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5D48B28479DE75CC7B5E48E2641E83A7" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5D48B28479DE75CC7B5E48E2641E83A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_6E633932B938DB2200A348E2641EF523_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_6E633932B938DB2200A348E2641EF523" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_6E633932B938DB2200A348E2641EF523" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_6E633932B938DB2200A348E2641EF523" xlink:to="lab_us-gaap_ProfitLoss_6E633932B938DB2200A348E2641EF523" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_1F37851B68DE0712E96D48E2641E1E6B_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1F37851B68DE0712E96D48E2641E1E6B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1F37851B68DE0712E96D48E2641E1E6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1F37851B68DE0712E96D48E2641E1E6B" xlink:to="lab_us-gaap_NetIncomeLoss_1F37851B68DE0712E96D48E2641E1E6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_88040D355C6879C5340948E2641E64CF_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_88040D355C6879C5340948E2641E64CF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_88040D355C6879C5340948E2641E64CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88040D355C6879C5340948E2641E64CF" xlink:to="lab_us-gaap_EarningsPerShareAbstract_88040D355C6879C5340948E2641E64CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_920C45D2CF7EE83025F148E2641E70F5_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_920C45D2CF7EE83025F148E2641E70F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_920C45D2CF7EE83025F148E2641E70F5_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_920C45D2CF7EE83025F148E2641E70F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_920C45D2CF7EE83025F148E2641E70F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_920C45D2CF7EE83025F148E2641E70F5" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_920C45D2CF7EE83025F148E2641E70F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B8A2764E90109FA3900029780D74757A_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B8A2764E90109FA3900029780D74757A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B8A2764E90109FA3900029780D74757A_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B8A2764E90109FA3900029780D74757A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B8A2764E90109FA3900029780D74757A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B8A2764E90109FA3900029780D74757A" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B8A2764E90109FA3900029780D74757A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:type="arc" />
    <link:label id="lab_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8_terseLabel_en-US" xlink:label="lab_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:label id="lab_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8_label_en-US" xlink:label="lab_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:label id="lab_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8_documentation_en-US" xlink:label="lab_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignearningstypeAxis" xlink:label="loc_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:to="lab_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:type="arc" />
    <link:label id="lab_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E_terseLabel_en-US" xlink:label="lab_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Domain]</link:label>
    <link:label id="lab_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E_label_en-US" xlink:label="lab_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Domain]</link:label>
    <link:label id="lab_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E_documentation_en-US" xlink:label="lab_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Foreign earnings type [Axis]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:to="lab_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:type="arc" />
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82_terseLabel_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings in the form of cash and cash equivalents</link:label>
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82_label_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign earnings in the form of cash and cash equivalents [Member]</link:label>
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82_documentation_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign earnings in the form of cash and cash equivalents [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82" xlink:to="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82" xlink:type="arc" />
    <link:label id="lab_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6_terseLabel_en-US" xlink:label="lab_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Foreign Earnings</link:label>
    <link:label id="lab_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6_label_en-US" xlink:label="lab_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Foreign Earnings [Member]</link:label>
    <link:label id="lab_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6_documentation_en-US" xlink:label="lab_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Foreign Earnings [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_OtherForeignEarningsMember" xlink:label="loc_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6" xlink:to="lab_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6" xlink:type="arc" />
    <link:label id="lab_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388_terseLabel_en-US" xlink:label="lab_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388_label_en-US" xlink:label="lab_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid taxes [Member]</link:label>
    <link:label id="lab_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388_documentation_en-US" xlink:label="lab_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid taxes [Member]</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_PrepaidtaxesMember" xlink:label="loc_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388" xlink:to="lab_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralBusinessMember_1F2D37091EEC0A6C7F55486D5C09321E_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember_1F2D37091EEC0A6C7F55486D5C09321E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Business</link:label>
    <link:label id="lab_us-gaap_GeneralBusinessMember_1F2D37091EEC0A6C7F55486D5C09321E_label_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember_1F2D37091EEC0A6C7F55486D5C09321E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Business Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_1F2D37091EEC0A6C7F55486D5C09321E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralBusinessMember_1F2D37091EEC0A6C7F55486D5C09321E" xlink:to="lab_us-gaap_GeneralBusinessMember_1F2D37091EEC0A6C7F55486D5C09321E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_5B751544495326B9ADC4486D5C0991DF_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_5B751544495326B9ADC4486D5C0991DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research</link:label>
    <link:label id="lab_us-gaap_ResearchMember_5B751544495326B9ADC4486D5C0991DF_label_en-US" xlink:label="lab_us-gaap_ResearchMember_5B751544495326B9ADC4486D5C0991DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_5B751544495326B9ADC4486D5C0991DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_5B751544495326B9ADC4486D5C0991DF" xlink:to="lab_us-gaap_ResearchMember_5B751544495326B9ADC4486D5C0991DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_B2E379A69A99795555F3486D5C0914ED_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_B2E379A69A99795555F3486D5C0914ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Country</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_B2E379A69A99795555F3486D5C0914ED_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_B2E379A69A99795555F3486D5C0914ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_B2E379A69A99795555F3486D5C0914ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_B2E379A69A99795555F3486D5C0914ED" xlink:to="lab_us-gaap_DomesticCountryMember_B2E379A69A99795555F3486D5C0914ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_AB7E0816881CD20BA27A486D5C0E2737_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_AB7E0816881CD20BA27A486D5C0E2737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_AB7E0816881CD20BA27A486D5C0E2737_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_AB7E0816881CD20BA27A486D5C0E2737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_AB7E0816881CD20BA27A486D5C0E2737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_AB7E0816881CD20BA27A486D5C0E2737" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_AB7E0816881CD20BA27A486D5C0E2737" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_F1C787452262C6650ADF486D5C0E73BE_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_F1C787452262C6650ADF486D5C0E73BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_F1C787452262C6650ADF486D5C0E73BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_F1C787452262C6650ADF486D5C0E73BE" xlink:to="lab_us-gaap_ForeignCountryMember_F1C787452262C6650ADF486D5C0E73BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33EF309FA91CD1A2B3344898361EDE9D_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33EF309FA91CD1A2B3344898361EDE9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33EF309FA91CD1A2B3344898361EDE9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33EF309FA91CD1A2B3344898361EDE9D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33EF309FA91CD1A2B3344898361EDE9D" xlink:type="arc" />
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B_terseLabel_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition Toll Tax repatriation tax rate</link:label>
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B_label_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transition Toll Tax Repatriation Tax Rate</link:label>
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B_documentation_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transition Toll Tax Repatriation Tax Rate</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_TransitionTollTaxRepatriationTaxRate" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B" xlink:to="lab_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_422FC84C3AE2DE08DC7C486D5C15011D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_422FC84C3AE2DE08DC7C486D5C15011D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_422FC84C3AE2DE08DC7C486D5C15011D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_422FC84C3AE2DE08DC7C486D5C15011D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_422FC84C3AE2DE08DC7C486D5C15011D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_422FC84C3AE2DE08DC7C486D5C15011D" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_422FC84C3AE2DE08DC7C486D5C15011D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_E234D8AD9B4992888C3F486D5C0F0E69_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_E234D8AD9B4992888C3F486D5C0F0E69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_E234D8AD9B4992888C3F486D5C0F0E69_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_E234D8AD9B4992888C3F486D5C0F0E69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_E234D8AD9B4992888C3F486D5C0F0E69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_E234D8AD9B4992888C3F486D5C0F0E69" xlink:to="lab_us-gaap_OperatingLossCarryforwards_E234D8AD9B4992888C3F486D5C0F0E69" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_435BEE37D6492E3CA4EA486D5C0F2F3A_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_435BEE37D6492E3CA4EA486D5C0F2F3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_435BEE37D6492E3CA4EA486D5C0F2F3A_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_435BEE37D6492E3CA4EA486D5C0F2F3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_435BEE37D6492E3CA4EA486D5C0F2F3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_435BEE37D6492E3CA4EA486D5C0F2F3A" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_435BEE37D6492E3CA4EA486D5C0F2F3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_159407AE2106846C0014486D5C0F84F9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_159407AE2106846C0014486D5C0F84F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_159407AE2106846C0014486D5C0F84F9_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_159407AE2106846C0014486D5C0F84F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_159407AE2106846C0014486D5C0F84F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_159407AE2106846C0014486D5C0F84F9" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_159407AE2106846C0014486D5C0F84F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_A32B7EB823F1D687343E486D5C0F029C_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_A32B7EB823F1D687343E486D5C0F029C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notice of assessment of corporate withholding tax including penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_A32B7EB823F1D687343E486D5C0F029C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_A32B7EB823F1D687343E486D5C0F029C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_A32B7EB823F1D687343E486D5C0F029C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_A32B7EB823F1D687343E486D5C0F029C" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_A32B7EB823F1D687343E486D5C0F029C" xlink:type="arc" />
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8_verboseLabel_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes (Textual)</link:label>
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8_label_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8_documentation_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_IncomeTaxesTextualAbstract" xlink:label="loc_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:to="lab_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:type="arc" />
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_5D31B949967D92320C0E486D5C1545F1_terseLabel_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_5D31B949967D92320C0E486D5C1545F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_5D31B949967D92320C0E486D5C1545F1_label_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_5D31B949967D92320C0E486D5C1545F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_5D31B949967D92320C0E486D5C1545F1_documentation_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_5D31B949967D92320C0E486D5C1545F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Totaldeferredchargesandprepaidtaxes" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_5D31B949967D92320C0E486D5C1545F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Totaldeferredchargesandprepaidtaxes_5D31B949967D92320C0E486D5C1545F1" xlink:to="lab_biib_Totaldeferredchargesandprepaidtaxes_5D31B949967D92320C0E486D5C1545F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95CB868D5B78E1765311486D5C15DD17_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95CB868D5B78E1765311486D5C15DD17" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95CB868D5B78E1765311486D5C15DD17_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95CB868D5B78E1765311486D5C15DD17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95CB868D5B78E1765311486D5C15DD17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95CB868D5B78E1765311486D5C15DD17" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95CB868D5B78E1765311486D5C15DD17" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_76B08A55556B05D4830F486D5C1665DF_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_76B08A55556B05D4830F486D5C1665DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_76B08A55556B05D4830F486D5C1665DF_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_76B08A55556B05D4830F486D5C1665DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_76B08A55556B05D4830F486D5C1665DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_76B08A55556B05D4830F486D5C1665DF" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_76B08A55556B05D4830F486D5C1665DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_DA298946F894A915224B486D5C16C327_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_DA298946F894A915224B486D5C16C327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_DA298946F894A915224B486D5C16C327_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_DA298946F894A915224B486D5C16C327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_DA298946F894A915224B486D5C16C327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_DA298946F894A915224B486D5C16C327" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_DA298946F894A915224B486D5C16C327" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_860A5E779CE5F1015BCD52C0D5D59F0B_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_860A5E779CE5F1015BCD52C0D5D59F0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_860A5E779CE5F1015BCD52C0D5D59F0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_860A5E779CE5F1015BCD52C0D5D59F0B" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_860A5E779CE5F1015BCD52C0D5D59F0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_C6D6F6943DB5669DAD4952C0D5D64E8A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_C6D6F6943DB5669DAD4952C0D5D64E8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C6D6F6943DB5669DAD4952C0D5D64E8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C6D6F6943DB5669DAD4952C0D5D64E8A" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_C6D6F6943DB5669DAD4952C0D5D64E8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_234812A4D96FB9F24A5552C0D5D6FA0C_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_234812A4D96FB9F24A5552C0D5D6FA0C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_234812A4D96FB9F24A5552C0D5D6FA0C_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_234812A4D96FB9F24A5552C0D5D6FA0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_234812A4D96FB9F24A5552C0D5D6FA0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_234812A4D96FB9F24A5552C0D5D6FA0C" xlink:to="lab_us-gaap_PreferredStockMember_234812A4D96FB9F24A5552C0D5D6FA0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_AF68C20C0D4FA279217552C0D5D6B3F4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_AF68C20C0D4FA279217552C0D5D6B3F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_AF68C20C0D4FA279217552C0D5D6B3F4_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_AF68C20C0D4FA279217552C0D5D6B3F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_AF68C20C0D4FA279217552C0D5D6B3F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_AF68C20C0D4FA279217552C0D5D6B3F4" xlink:to="lab_us-gaap_CommonStockMember_AF68C20C0D4FA279217552C0D5D6B3F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_D8EC59A7BBC7FA1488F152C0D5D6027D_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_D8EC59A7BBC7FA1488F152C0D5D6027D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_D8EC59A7BBC7FA1488F152C0D5D6027D_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_D8EC59A7BBC7FA1488F152C0D5D6027D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_D8EC59A7BBC7FA1488F152C0D5D6027D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_D8EC59A7BBC7FA1488F152C0D5D6027D" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_D8EC59A7BBC7FA1488F152C0D5D6027D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12231DFDE0C48B9BDBF252C0D5D65775_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12231DFDE0C48B9BDBF252C0D5D65775" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12231DFDE0C48B9BDBF252C0D5D65775_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12231DFDE0C48B9BDBF252C0D5D65775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12231DFDE0C48B9BDBF252C0D5D65775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12231DFDE0C48B9BDBF252C0D5D65775" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12231DFDE0C48B9BDBF252C0D5D65775" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_2909F56EFBF8E3CAE35252C0D5D6412A_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_2909F56EFBF8E3CAE35252C0D5D6412A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2909F56EFBF8E3CAE35252C0D5D6412A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_2909F56EFBF8E3CAE35252C0D5D6412A" xlink:to="lab_us-gaap_RetainedEarningsMember_2909F56EFBF8E3CAE35252C0D5D6412A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_5D7F3B944344DAFDA1C952C0D5D647C8_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_5D7F3B944344DAFDA1C952C0D5D647C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_5D7F3B944344DAFDA1C952C0D5D647C8_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_5D7F3B944344DAFDA1C952C0D5D647C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_5D7F3B944344DAFDA1C952C0D5D647C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_5D7F3B944344DAFDA1C952C0D5D647C8" xlink:to="lab_us-gaap_TreasuryStockMember_5D7F3B944344DAFDA1C952C0D5D647C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_A019DD35F02166EC2C4552C0D5D6571D_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_A019DD35F02166EC2C4552C0D5D6571D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_A019DD35F02166EC2C4552C0D5D6571D_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_A019DD35F02166EC2C4552C0D5D6571D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_A019DD35F02166EC2C4552C0D5D6571D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_A019DD35F02166EC2C4552C0D5D6571D" xlink:to="lab_us-gaap_NoncontrollingInterestMember_A019DD35F02166EC2C4552C0D5D6571D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_C8779D4309C56E9D02F052C0D5D7BEEF_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_C8779D4309C56E9D02F052C0D5D7BEEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_C8779D4309C56E9D02F052C0D5D7BEEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_C8779D4309C56E9D02F052C0D5D7BEEF" xlink:to="lab_us-gaap_ParentMember_C8779D4309C56E9D02F052C0D5D7BEEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15D6D84E3E97D5FB05B652C0D5D79230_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15D6D84E3E97D5FB05B652C0D5D79230" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15D6D84E3E97D5FB05B652C0D5D79230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15D6D84E3E97D5FB05B652C0D5D79230" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15D6D84E3E97D5FB05B652C0D5D79230" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_2662B113F2BC5F8264D952C0D5D7E84A_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_2662B113F2BC5F8264D952C0D5D7E84A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2662B113F2BC5F8264D952C0D5D7E84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_2662B113F2BC5F8264D952C0D5D7E84A" xlink:to="lab_us-gaap_StockholdersEquity_2662B113F2BC5F8264D952C0D5D7E84A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_DB45896898479AF1E95552C0D5D71602_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_DB45896898479AF1E95552C0D5D71602" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_DB45896898479AF1E95552C0D5D71602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_DB45896898479AF1E95552C0D5D71602" xlink:to="lab_us-gaap_MinorityInterest_DB45896898479AF1E95552C0D5D71602" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_7A041A63CB32E3985F3D52C0D5D7FC2B_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_7A041A63CB32E3985F3D52C0D5D7FC2B" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesIssued_7A041A63CB32E3985F3D52C0D5D7FC2B_label_en-US" xlink:label="lab_us-gaap_SharesIssued_7A041A63CB32E3985F3D52C0D5D7FC2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_7A041A63CB32E3985F3D52C0D5D7FC2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_7A041A63CB32E3985F3D52C0D5D7FC2B" xlink:to="lab_us-gaap_SharesIssued_7A041A63CB32E3985F3D52C0D5D7FC2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2F097F1D912E9D475BBA52C0D5D7A33D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2F097F1D912E9D475BBA52C0D5D7A33D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2F097F1D912E9D475BBA52C0D5D7A33D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2F097F1D912E9D475BBA52C0D5D7A33D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2F097F1D912E9D475BBA52C0D5D7A33D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6B0D72B11DE0989EB07552C0D5D7E777_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6B0D72B11DE0989EB07552C0D5D7E777" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6B0D72B11DE0989EB07552C0D5D7E777_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6B0D72B11DE0989EB07552C0D5D7E777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6B0D72B11DE0989EB07552C0D5D7E777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6B0D72B11DE0989EB07552C0D5D7E777" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6B0D72B11DE0989EB07552C0D5D7E777" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_38515E636856FC364FE352C0D5D85EC0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_38515E636856FC364FE352C0D5D85EC0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_38515E636856FC364FE352C0D5D85EC0_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_38515E636856FC364FE352C0D5D85EC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_38515E636856FC364FE352C0D5D85EC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_38515E636856FC364FE352C0D5D85EC0" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_38515E636856FC364FE352C0D5D85EC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_68B3761109F60566C3E952C0D5D8A58E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_68B3761109F60566C3E952C0D5D8A58E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_68B3761109F60566C3E952C0D5D8A58E_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_68B3761109F60566C3E952C0D5D8A58E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_68B3761109F60566C3E952C0D5D8A58E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_68B3761109F60566C3E952C0D5D8A58E" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_68B3761109F60566C3E952C0D5D8A58E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3F2A50C4EE3B823F6EAC52C0D5D881E5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3F2A50C4EE3B823F6EAC52C0D5D881E5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3F2A50C4EE3B823F6EAC52C0D5D881E5_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3F2A50C4EE3B823F6EAC52C0D5D881E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3F2A50C4EE3B823F6EAC52C0D5D881E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3F2A50C4EE3B823F6EAC52C0D5D881E5" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3F2A50C4EE3B823F6EAC52C0D5D881E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2D54B9B61FEFB474DFFB52C0D5D8251D_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2D54B9B61FEFB474DFFB52C0D5D8251D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2D54B9B61FEFB474DFFB52C0D5D8251D_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2D54B9B61FEFB474DFFB52C0D5D8251D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2D54B9B61FEFB474DFFB52C0D5D8251D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2D54B9B61FEFB474DFFB52C0D5D8251D" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2D54B9B61FEFB474DFFB52C0D5D8251D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_CF3D5121846C10DA27E852C0D5D8F0D9_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_CF3D5121846C10DA27E852C0D5D8F0D9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_CF3D5121846C10DA27E852C0D5D8F0D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_CF3D5121846C10DA27E852C0D5D8F0D9" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_CF3D5121846C10DA27E852C0D5D8F0D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_8ED18F849D4F1BC8619B52C0D5D8B70D_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_8ED18F849D4F1BC8619B52C0D5D8B70D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_8ED18F849D4F1BC8619B52C0D5D8B70D_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_8ED18F849D4F1BC8619B52C0D5D8B70D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_8ED18F849D4F1BC8619B52C0D5D8B70D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_8ED18F849D4F1BC8619B52C0D5D8B70D" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_8ED18F849D4F1BC8619B52C0D5D8B70D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_10272EF9DDB19C0E1D4052C0D5D8502E_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_10272EF9DDB19C0E1D4052C0D5D8502E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_10272EF9DDB19C0E1D4052C0D5D8502E_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_10272EF9DDB19C0E1D4052C0D5D8502E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_10272EF9DDB19C0E1D4052C0D5D8502E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_10272EF9DDB19C0E1D4052C0D5D8502E" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_10272EF9DDB19C0E1D4052C0D5D8502E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_AF8DE654A9FB71FF84CA52C0D5D825F9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_AF8DE654A9FB71FF84CA52C0D5D825F9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_AF8DE654A9FB71FF84CA52C0D5D825F9_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_AF8DE654A9FB71FF84CA52C0D5D825F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_AF8DE654A9FB71FF84CA52C0D5D825F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_AF8DE654A9FB71FF84CA52C0D5D825F9" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_AF8DE654A9FB71FF84CA52C0D5D825F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_C22CD8880B209B6F205F52C0D5D8AC29_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_C22CD8880B209B6F205F52C0D5D8AC29" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_C22CD8880B209B6F205F52C0D5D8AC29_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_C22CD8880B209B6F205F52C0D5D8AC29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_C22CD8880B209B6F205F52C0D5D8AC29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_C22CD8880B209B6F205F52C0D5D8AC29" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_C22CD8880B209B6F205F52C0D5D8AC29" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5A1213048D1FED79E1DA52C0D5D8FFD0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5A1213048D1FED79E1DA52C0D5D8FFD0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5A1213048D1FED79E1DA52C0D5D8FFD0_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5A1213048D1FED79E1DA52C0D5D8FFD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5A1213048D1FED79E1DA52C0D5D8FFD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5A1213048D1FED79E1DA52C0D5D8FFD0" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5A1213048D1FED79E1DA52C0D5D8FFD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1843D3461146D478B8252C0D5D8AB6A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1843D3461146D478B8252C0D5D8AB6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1843D3461146D478B8252C0D5D8AB6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1843D3461146D478B8252C0D5D8AB6A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1843D3461146D478B8252C0D5D8AB6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6844893C08938060CA1352C0D5D886F3_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_6844893C08938060CA1352C0D5D886F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6844893C08938060CA1352C0D5D886F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_6844893C08938060CA1352C0D5D886F3" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_6844893C08938060CA1352C0D5D886F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_98A17F77D17D668BC82952C0D5D8D4F3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_98A17F77D17D668BC82952C0D5D8D4F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia spin-off adjustment</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_98A17F77D17D668BC82952C0D5D8D4F3_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_98A17F77D17D668BC82952C0D5D8D4F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Spinoff Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_98A17F77D17D668BC82952C0D5D8D4F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_98A17F77D17D668BC82952C0D5D8D4F3" xlink:to="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_98A17F77D17D668BC82952C0D5D8D4F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_79847B257F411A946C7852C0D5D9C4B8_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_79847B257F411A946C7852C0D5D9C4B8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from share-based payments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_79847B257F411A946C7852C0D5D9C4B8_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_79847B257F411A946C7852C0D5D9C4B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_79847B257F411A946C7852C0D5D9C4B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_79847B257F411A946C7852C0D5D9C4B8" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_79847B257F411A946C7852C0D5D9C4B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityOther_D4D0B089D674A7CC88D752C0D5D9FC75_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_D4D0B089D674A7CC88D752C0D5D9FC75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_D4D0B089D674A7CC88D752C0D5D9FC75_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_D4D0B089D674A7CC88D752C0D5D9FC75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_D4D0B089D674A7CC88D752C0D5D9FC75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther_D4D0B089D674A7CC88D752C0D5D9FC75" xlink:to="lab_us-gaap_StockholdersEquityOther_D4D0B089D674A7CC88D752C0D5D9FC75" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8AF5AC61E2125993041B52C0D5D96466_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8AF5AC61E2125993041B52C0D5D96466" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8AF5AC61E2125993041B52C0D5D96466" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8AF5AC61E2125993041B52C0D5D96466" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8AF5AC61E2125993041B52C0D5D96466" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_B23422665E60E6CAFF9452C0D5D9FD0D_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B23422665E60E6CAFF9452C0D5D9FD0D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B23422665E60E6CAFF9452C0D5D9FD0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_B23422665E60E6CAFF9452C0D5D9FD0D" xlink:to="lab_us-gaap_StockholdersEquity_B23422665E60E6CAFF9452C0D5D9FD0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_F6C65962F4E5ED613F9C52C0D5D9CDED_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_F6C65962F4E5ED613F9C52C0D5D9CDED" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_F6C65962F4E5ED613F9C52C0D5D9CDED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_F6C65962F4E5ED613F9C52C0D5D9CDED" xlink:to="lab_us-gaap_MinorityInterest_F6C65962F4E5ED613F9C52C0D5D9CDED" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_6E3EA7FC0F06B1ACE90352C0D5D96769_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_6E3EA7FC0F06B1ACE90352C0D5D96769" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_6E3EA7FC0F06B1ACE90352C0D5D96769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_6E3EA7FC0F06B1ACE90352C0D5D96769" xlink:to="lab_us-gaap_SharesIssued_6E3EA7FC0F06B1ACE90352C0D5D96769" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_33C2BFD4ADC35E8180CF431B93738C79_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_33C2BFD4ADC35E8180CF431B93738C79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_33C2BFD4ADC35E8180CF431B93738C79_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_33C2BFD4ADC35E8180CF431B93738C79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_33C2BFD4ADC35E8180CF431B93738C79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_33C2BFD4ADC35E8180CF431B93738C79" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_33C2BFD4ADC35E8180CF431B93738C79" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:type="arc" />
    <link:label id="lab_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC_verboseLabel_en-US" xlink:label="lab_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC_label_en-US" xlink:label="lab_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC_documentation_en-US" xlink:label="lab_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC" xlink:to="lab_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC" xlink:type="arc" />
    <link:label id="lab_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84_verboseLabel_en-US" xlink:label="lab_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84_label_en-US" xlink:label="lab_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84_documentation_en-US" xlink:label="lab_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:to="lab_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_51B98C283E2CAB4CF06229780E9EA656_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_51B98C283E2CAB4CF06229780E9EA656" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_51B98C283E2CAB4CF06229780E9EA656" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_51B98C283E2CAB4CF06229780E9EA656" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_51B98C283E2CAB4CF06229780E9EA656" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5CEE0CCF133EF0572E2829780E9E833E_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5CEE0CCF133EF0572E2829780E9E833E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5CEE0CCF133EF0572E2829780E9E833E_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5CEE0CCF133EF0572E2829780E9E833E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5CEE0CCF133EF0572E2829780E9E833E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5CEE0CCF133EF0572E2829780E9E833E" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5CEE0CCF133EF0572E2829780E9E833E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_93FE4E597CD904ECC12929780E9E09E6_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_93FE4E597CD904ECC12929780E9E09E6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_93FE4E597CD904ECC12929780E9E09E6_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_93FE4E597CD904ECC12929780E9E09E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_93FE4E597CD904ECC12929780E9E09E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_93FE4E597CD904ECC12929780E9E09E6" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_93FE4E597CD904ECC12929780E9E09E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21BCD86C5B61C09003AD29780E9F3A07_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21BCD86C5B61C09003AD29780E9F3A07" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21BCD86C5B61C09003AD29780E9F3A07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21BCD86C5B61C09003AD29780E9F3A07" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21BCD86C5B61C09003AD29780E9F3A07" xlink:type="arc" />
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_552D28680CEC9FBFA64E29780E9FA636_terseLabel_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_552D28680CEC9FBFA64E29780E9FA636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share (Textual)</link:label>
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_552D28680CEC9FBFA64E29780E9FA636_label_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_552D28680CEC9FBFA64E29780E9FA636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_552D28680CEC9FBFA64E29780E9FA636_documentation_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_552D28680CEC9FBFA64E29780E9FA636" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings per share.</link:label>
    <link:loc xlink:href="biib-20171231.xsd#biib_EarningsPerShareTextualAbstract" xlink:label="loc_biib_EarningsPerShareTextualAbstract_552D28680CEC9FBFA64E29780E9FA636" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EarningsPerShareTextualAbstract_552D28680CEC9FBFA64E29780E9FA636" xlink:to="lab_biib_EarningsPerShareTextualAbstract_552D28680CEC9FBFA64E29780E9FA636" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_E79BE7755C74AD23AFCD29780E9FDD3E_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_E79BE7755C74AD23AFCD29780E9FDD3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_E79BE7755C74AD23AFCD29780E9FDD3E_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_E79BE7755C74AD23AFCD29780E9FDD3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_E79BE7755C74AD23AFCD29780E9FDD3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_E79BE7755C74AD23AFCD29780E9FDD3E" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_E79BE7755C74AD23AFCD29780E9FDD3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2A461729B618CC16F5EC4332410D5A15_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2A461729B618CC16F5EC4332410D5A15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2A461729B618CC16F5EC4332410D5A15_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2A461729B618CC16F5EC4332410D5A15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2A461729B618CC16F5EC4332410D5A15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2A461729B618CC16F5EC4332410D5A15" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2A461729B618CC16F5EC4332410D5A15" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6074E20F33E74516835B4332410DCFF6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6074E20F33E74516835B4332410DCFF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6074E20F33E74516835B4332410DCFF6_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6074E20F33E74516835B4332410DCFF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6074E20F33E74516835B4332410DCFF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6074E20F33E74516835B4332410DCFF6" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6074E20F33E74516835B4332410DCFF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_55727E35EB2AFF50E49E4332410D0489_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_55727E35EB2AFF50E49E4332410D0489" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_55727E35EB2AFF50E49E4332410D0489_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_55727E35EB2AFF50E49E4332410D0489" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_55727E35EB2AFF50E49E4332410D0489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_55727E35EB2AFF50E49E4332410D0489" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_55727E35EB2AFF50E49E4332410D0489" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_A698088C004E4C033E8A4332410D5A29_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_A698088C004E4C033E8A4332410D5A29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_A698088C004E4C033E8A4332410D5A29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_A698088C004E4C033E8A4332410D5A29" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_A698088C004E4C033E8A4332410D5A29" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9447A937ABB1492388774332410DE331_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9447A937ABB1492388774332410DE331" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9447A937ABB1492388774332410DE331_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9447A937ABB1492388774332410DE331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9447A937ABB1492388774332410DE331" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9447A937ABB1492388774332410DE331" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9447A937ABB1492388774332410DE331" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_90A0F24B56CE802500404332410D513E_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_90A0F24B56CE802500404332410D513E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Transfered, net</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_90A0F24B56CE802500404332410D513E_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_90A0F24B56CE802500404332410D513E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_90A0F24B56CE802500404332410D513E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_90A0F24B56CE802500404332410D513E" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_90A0F24B56CE802500404332410D513E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_840371EF0B21845F42944332410D727D_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_840371EF0B21845F42944332410D727D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_840371EF0B21845F42944332410D727D_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_840371EF0B21845F42944332410D727D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_840371EF0B21845F42944332410D727D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_840371EF0B21845F42944332410D727D" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_840371EF0B21845F42944332410D727D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_4EE0F471694A02081C474332410D8931_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_4EE0F471694A02081C474332410D8931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_4EE0F471694A02081C474332410D8931_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_4EE0F471694A02081C474332410D8931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_4EE0F471694A02081C474332410D8931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_4EE0F471694A02081C474332410D8931" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_4EE0F471694A02081C474332410D8931" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_AE38E20EC8D3BEBD4FD74332410DE52B_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_AE38E20EC8D3BEBD4FD74332410DE52B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities Transferred, net</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_AE38E20EC8D3BEBD4FD74332410DE52B_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_AE38E20EC8D3BEBD4FD74332410DE52B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_AE38E20EC8D3BEBD4FD74332410DE52B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_AE38E20EC8D3BEBD4FD74332410DE52B" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_AE38E20EC8D3BEBD4FD74332410DE52B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_77DDFA8F05FEFD6C654D29780EF534D5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_77DDFA8F05FEFD6C654D29780EF534D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_77DDFA8F05FEFD6C654D29780EF534D5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_77DDFA8F05FEFD6C654D29780EF534D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_77DDFA8F05FEFD6C654D29780EF534D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_77DDFA8F05FEFD6C654D29780EF534D5" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_77DDFA8F05FEFD6C654D29780EF534D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_6841785C10D431338F1642C706A7B9E8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_6841785C10D431338F1642C706A7B9E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under non-cancelable leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_6841785C10D431338F1642C706A7B9E8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_6841785C10D431338F1642C706A7B9E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_6841785C10D431338F1642C706A7B9E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_6841785C10D431338F1642C706A7B9E8" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_6841785C10D431338F1642C706A7B9E8" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>biib-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20171231.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20171231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20171231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20171231.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20171231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20171231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails2" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20171231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:href="biib-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20171231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20171231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20171231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20171231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20171231.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20171231.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:href="biib-20171231.xsd#DerivativeInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20171231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20171231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20171231.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20171231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20171231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20171231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:href="biib-20171231.xsd#EmployeeBenefitPlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:href="biib-20171231.xsd#EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20171231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20171231.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20171231.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20171231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20171231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20171231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20171231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20171231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20171231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20171231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20171231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20171231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20171231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20171231.xsd#Guarantees" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:href="biib-20171231.xsd#HemophiliaSpinOffHemophiliaSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:href="biib-20171231.xsd#HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:href="biib-20171231.xsd#HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:href="biib-20171231.xsd#HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20171231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20171231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20171231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20171231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20171231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20171231.xsd#Indebtedness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20171231.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20171231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20171231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20171231.xsd#IndebtednessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20171231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20171231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20171231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20171231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20171231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20171231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20171231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20171231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20171231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20171231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20171231.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20171231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20171231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20171231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20171231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20171231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20171231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20171231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20171231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20171231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20171231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20171231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20171231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20171231.xsd#RestructuringRestructuring" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:href="biib-20171231.xsd#RestructuringRestructuringDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20171231.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:href="biib-20171231.xsd#RestructuringRestructuringTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReserves" xlink:href="biib-20171231.xsd#RevenueReserves" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:href="biib-20171231.xsd#RevenueReservesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:href="biib-20171231.xsd#RevenueReservesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesTables" xlink:href="biib-20171231.xsd#RevenueReservesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20171231.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20171231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:href="biib-20171231.xsd#SegmentInformationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20171231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20171231.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20171231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20171231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:href="biib-20171231.xsd#ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20171231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20171231.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20171231.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_C2C1E369DD6C6554718043AA3FF85A1F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_207377A668975A39685743AA3FF8BB71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C2C1E369DD6C6554718043AA3FF85A1F" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_207377A668975A39685743AA3FF8BB71" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7F3A74453E5B2C044CC929780EA34886" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_284F0D228650E58863B129780EA40E94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7F3A74453E5B2C044CC929780EA34886" xlink:to="loc_us-gaap_StatementTable_284F0D228650E58863B129780EA40E94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_DAE5763AAD56CF55B0B329780EA4BF6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_284F0D228650E58863B129780EA40E94" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_DAE5763AAD56CF55B0B329780EA4BF6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DAE5763AAD56CF55B0B329780EA4BF6A" xlink:to="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_86B5D1E24DEFFBDC1D3429780EA48D31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_86B5D1E24DEFFBDC1D3429780EA48D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_EA7E5292F35B5E2AB5F229780EA4D39C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_EA7E5292F35B5E2AB5F229780EA4D39C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2FB0DEF8E11B3BDC278229780EA420DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2FB0DEF8E11B3BDC278229780EA420DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_98A269FE7FA2B34AA0DD29780EA48473" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ECF9774C200DA930AC4329780EA4D5E7" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_98A269FE7FA2B34AA0DD29780EA48473" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_284F0D228650E58863B129780EA40E94" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5129DB860DD7FA46B1DF29780EA49D99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5129DB860DD7FA46B1DF29780EA49D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_F8C4D43CC41EDBCB218629780EA47BB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_F8C4D43CC41EDBCB218629780EA47BB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_156158159A03868FC03029780EA40433" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_156158159A03868FC03029780EA40433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_870709F2DB327297E38C29780EA4A086" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_870709F2DB327297E38C29780EA4A086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6DA4561176322A11579629780EA5C178" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33DF0CE27FCB63AB237029780EA4F844" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6DA4561176322A11579629780EA5C178" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_8D69E35B902EC291FB9148E262A8B80C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8D69E35B902EC291FB9148E262A8B80C" xlink:to="loc_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6BF35E702A30988CA46F48E262A88699" xlink:to="loc_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DE2772F8B504194730D48E262A86150" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6DE2772F8B504194730D48E262A86150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_FD513C2707569E1C677048E262A8A482" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57CFFB30D413207160C748E262A87B18" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_FD513C2707569E1C677048E262A8A482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47FA32D4515E43EF305648E262A8939D" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7E6D9FC841D3F01CCF8548E262A8A8B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8FBBDA33FE730161C2BF48E262A84D30" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7E6D9FC841D3F01CCF8548E262A8A8B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4745F7AE0988CDFE299548E262A8DCDC" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C7B9CC150B1901F03A8D48E262A82468" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_C7B9CC150B1901F03A8D48E262A82468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4F103B2463188495B6F248E262A84516" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4F103B2463188495B6F248E262A84516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_E2E6DAC593E7F402C2DE48E262A8E355" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_E2E6DAC593E7F402C2DE48E262A8E355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D79027F9C6B819D188DB48E262A9401D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_OperatingExpenses_D79027F9C6B819D188DB48E262A9401D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_CEB149805C163D3D73B748EC5BF6F61B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_CEB149805C163D3D73B748EC5BF6F61B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BCD77631D7EC3685B0FC48E262A98587" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_BA199242E5D9D1F02A0E48E262A82DD5" xlink:to="loc_us-gaap_NetIncomeLoss_BCD77631D7EC3685B0FC48E262A98587" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7BC4C8285C72F3057FDF43AA3FF62137" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_84D5F989EB3970BFCCCC43AA3FF698C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7BC4C8285C72F3057FDF43AA3FF62137" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_84D5F989EB3970BFCCCC43AA3FF698C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_C7FD7C0978C311A42F2B43AA3FF61A7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7BC4C8285C72F3057FDF43AA3FF62137" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_C7FD7C0978C311A42F2B43AA3FF61A7B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_93A85C46B4C237F607AB42D5E5667EAC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_33C2BFD4ADC35E8180CF431B93738C79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_93A85C46B4C237F607AB42D5E5667EAC" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_33C2BFD4ADC35E8180CF431B93738C79" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_BB4E9F2E18D04F91FFBA434A35CD3D84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_BB4E9F2E18D04F91FFBA434A35CD3D84" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:to="loc_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_263121FF1F3F7BB99D8A434A35CDD81A" xlink:to="loc_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BIIB074Member" xlink:label="loc_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_C1641344018893A8E2C5434A35CD9DC4" xlink:to="loc_biib_BIIB074Member_B74A047528C23B143F27434A35CD13E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_28287EF02A0C7DBAD241434A35CD696E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:to="loc_biib_RemedyPharmaceuticalMember_AD564FDD1EE497506C69434A35CDFF20" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490861D5CA8CD6678BE6434A35CD0062" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_975D7933AED57D20C48B434A35CDC495" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0A31007AD148F675BA07434A35CD92FA" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_103517661A83AFE5DACC434A35CDC947" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_103517661A83AFE5DACC434A35CDC947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_B76F5EBB0808170B0DF2434A35CD857A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_B76F5EBB0808170B0DF2434A35CD857A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_818BD116EB78C852BC3C434A35CD1607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_37B72B656B764110E7EE434A35CDA34C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_37B72B656B764110E7EE434A35CDA34C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E3E6FA718F1923E82395434A35CD6C36" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E3E6FA718F1923E82395434A35CD6C36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8FCB4B4736E6F1232937434A35CDAEE6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8FCB4B4736E6F1232937434A35CDAEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_F8889029AAF6B1612892434A35CDCC5E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83FA39D9B0D4F0A05183434A35CD9BCB" xlink:to="loc_us-gaap_Goodwill_F8889029AAF6B1612892434A35CDCC5E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4E179F4F431E2802C1F329780F510A42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3A34F36982D954565F6C29780F51586F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4E179F4F431E2802C1F329780F510A42" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3A34F36982D954565F6C29780F51586F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7467479A1FC84D5738CD492867EF6131" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA29E0DC2212645B2670492867F0DE23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7467479A1FC84D5738CD492867EF6131" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA29E0DC2212645B2670492867F0DE23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_AFA362FB52626C4CEF49492867F08433" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA29E0DC2212645B2670492867F0DE23" xlink:to="loc_us-gaap_TypeOfArrangementAxis_AFA362FB52626C4CEF49492867F08433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD6C8BC2C1ECBF9CB394492867F0ECCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_AFA362FB52626C4CEF49492867F08433" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD6C8BC2C1ECBF9CB394492867F0ECCA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_A01CF521740D1047706E492867F054AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD6C8BC2C1ECBF9CB394492867F0ECCA" xlink:to="loc_biib_EisaiMember_A01CF521740D1047706E492867F054AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25004B9D146D3807BFAC492867F000A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA29E0DC2212645B2670492867F0DE23" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25004B9D146D3807BFAC492867F000A4" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25004B9D146D3807BFAC492867F000A4" xlink:to="loc_biib_ExpenseIncurredByCollaboration_6CE4D79654E6745A90C3492867F0DCBA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25004B9D146D3807BFAC492867F000A4" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_AB8AFAFFCCF21F9C284B492867F18401" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_154D0F8EEF1F701BAC62492867C769D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93C742F19677CE27972D492867C82805" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_154D0F8EEF1F701BAC62492867C769D0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93C742F19677CE27972D492867C82805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_C099704127665DFE5703492867C9A980" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93C742F19677CE27972D492867C82805" xlink:to="loc_us-gaap_ProductOrServiceAxis_C099704127665DFE5703492867C9A980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_99D3DB3A910C73892F3A492867C99047" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_C099704127665DFE5703492867C9A980" xlink:to="loc_us-gaap_ProductsAndServicesDomain_99D3DB3A910C73892F3A492867C99047" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_99D3DB3A910C73892F3A492867C99047" xlink:to="loc_biib_GAZYVAMember_60CB7F1A8D2A27A0BB28492867C91272" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_99D3DB3A910C73892F3A492867C99047" xlink:to="loc_biib_RituxanMember_3EA950FAF68FC04F4B3C492867C98DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_726959358118CB338E52492867C9463D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93C742F19677CE27972D492867C82805" xlink:to="loc_us-gaap_TypeOfArrangementAxis_726959358118CB338E52492867C9463D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE4835A6AFFD60F043F7492867CAF77B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_726959358118CB338E52492867C9463D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE4835A6AFFD60F043F7492867CAF77B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE4835A6AFFD60F043F7492867CAF77B" xlink:to="loc_biib_RocheGroupGenentechMember_7045355647CE0E13800C492867CA71B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6A8FE05987B5D9D1DEF0492867CA5F75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93C742F19677CE27972D492867C82805" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6A8FE05987B5D9D1DEF0492867CA5F75" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6A8FE05987B5D9D1DEF0492867CA5F75" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_A42F9AAA774A95153D27492867CB0056" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_07B41126EB21FFC7AB6E492867CA8066" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_B42294EC03CBD5720BFE492867CBE84B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_E59BCEB8B28A4A9AF9B4492867CBFB85" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_5FC6A65FD84B0738166D492867CB1322" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_1F7F174F77E6E7AFA072492867CB121A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6A8FE05987B5D9D1DEF0492867CA5F75" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_AF05E3B9E866EE9FD734492867CB8813" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:to="loc_biib_ShareOfCoPromotionProfits_AF05E3B9E866EE9FD734492867CB8813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7EFEE7C05BE98E11AEDB492867CB0F1E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_7EFEE7C05BE98E11AEDB492867CB0F1E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_4EB31FD49AC6A8CF3907492867CBE0DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_E00123D7F70F01D02FDB492867CBB777" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_4EB31FD49AC6A8CF3907492867CBE0DF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3CB9C5D9033DDAF95526492867E5CCE6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3CB9C5D9033DDAF95526492867E5CCE6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3EAF6F3F3D93ACA9107D492867E5D94A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3EAF6F3F3D93ACA9107D492867E5D94A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BE1BC06FED7F3C7873C492867E50D2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3EAF6F3F3D93ACA9107D492867E5D94A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BE1BC06FED7F3C7873C492867E50D2D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BE1BC06FED7F3C7873C492867E50D2D" xlink:to="loc_biib_AbbVieMember_C6FF9413F63A8EC9C6F7492867E6896D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46A3155E69D4518CEAED492867E53596" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_0E624C28AA79DBED603A492867E64BD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:to="loc_us-gaap_Revenues_0E624C28AA79DBED603A492867E64BD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_58BCEB58E451F45127C8493564A98BD8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:to="loc_us-gaap_CostsAndExpenses_58BCEB58E451F45127C8493564A98BD8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Copromotionprofitsandlosses" xlink:label="loc_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:to="loc_biib_Copromotionprofitsandlosses_F83DBD9A347600823563492867E6410C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CAB12C084DC19419D94F492867E64458" xlink:to="loc_biib_ShareOfCoPromotionProfits_749CB7FF09C5E3A58AE7492867E6254B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FB2C98C7CA57996191B84D74276E20A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FB2C98C7CA57996191B84D74276E20A3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_EACEF357AD253C80B0264DAF5D7253B0" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_2BFDC567DCA7781712FE4DAF958CD642" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6CDBE98503DC130A2B0F4DAF5D7672C9" xlink:to="loc_us-gaap_ScenarioForecastMember_2BFDC567DCA7781712FE4DAF958CD642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F49E0C66FFA966B154C94D7427726B97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F49E0C66FFA966B154C94D7427726B97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA49833433E8811A6E144D74277268B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F49E0C66FFA966B154C94D7427726B97" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA49833433E8811A6E144D74277268B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_3BD898FF476ED7999D054D742772625F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA49833433E8811A6E144D74277268B0" xlink:to="loc_biib_InLicensedPatentsMember_3BD898FF476ED7999D054D742772625F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_0B8DD339A3A7318AE1024D7427725645" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_StatementGeographicalAxis_0B8DD339A3A7318AE1024D7427725645" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_0B8DD339A3A7318AE1024D7427725645" xlink:to="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_52B5D7FFF86E5A84FDDF4D7427721A3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0" xlink:to="loc_country_US_52B5D7FFF86E5A84FDDF4D7427721A3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_DD73FC7841827CC39EBA4D742773A5EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0" xlink:to="loc_us-gaap_ForeignCountryMember_DD73FC7841827CC39EBA4D742773A5EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_7BD293543F43EACE044E4D742773DA2D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0" xlink:to="loc_us-gaap_EuropeanUnionMember_7BD293543F43EACE044E4D742773DA2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_2435909E93E134239CEE4D74277314B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0EF2CB32544FB95CC7A84D74277254D0" xlink:to="loc_country_JP_2435909E93E134239CEE4D74277314B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1ADE969C4656D899C9204D7427738FBC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1ADE969C4656D899C9204D7427738FBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CAC2F13062B5F31949124D742773EA04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1ADE969C4656D899C9204D7427738FBC" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_CAC2F13062B5F31949124D742773EA04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_75BDD951EC5266F76AA24D7427731A8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CAC2F13062B5F31949124D742773EA04" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_75BDD951EC5266F76AA24D7427731A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_CC3AE5FD0F16CAF92B494D742773A460" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CAC2F13062B5F31949124D742773EA04" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_CC3AE5FD0F16CAF92B494D742773A460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9E2F4E9B430B4AB647B54D7427737D67" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_E129E8DA1C65E42920704D742773745B" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_EBADAD41428610F736E24D7427747D78" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_ProductOrServiceAxis_EBADAD41428610F736E24D7427747D78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_EBADAD41428610F736E24D7427747D78" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_12D4C5F4F5B6B15FC58C4D7427742CB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_RituxanMember_12D4C5F4F5B6B15FC58C4D7427742CB1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_A1CE4F6A8E5711F17A734D742774CC75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_GAZYVAMember_A1CE4F6A8E5711F17A734D742774CC75" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_NewAntiCd20Member_305AF56820637DC374464D7427747903" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_OCREVUSMember" xlink:label="loc_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_OCREVUSMember_09A47E1321E7B2B2F9794D742774DC7C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_98076790808B70E761E64D7427749093" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_ZINBRYTAMember_98076790808B70E761E64D7427749093" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_36802B5BF32E90F2A6AC4D742774E87E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_SPINRAZAMember_36802B5BF32E90F2A6AC4D742774E87E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_SOD1Member_9B5B9C104C4AB88DE1A44D7427742174" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_LeadprogramsMember" xlink:label="loc_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_LeadprogramsMember_6B49E81AA1BCE29650194D742774520B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DiscoveryprogramsMember" xlink:label="loc_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_DiscoveryprogramsMember_F59232C6DFBBB3D2D8FE4D7427744218" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_4EAC8527DC09458A4A114D7427744221" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3295DBEAC261F24942384D742774B07F" xlink:to="loc_biib_BiosimilarsMember_4EAC8527DC09458A4A114D7427744221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F01854F230619E38A74D4D7427747F5A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F01854F230619E38A74D4D7427747F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F01854F230619E38A74D4D7427747F5A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_3994507F1508EB4D2A814D742775A7D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_RocheGroupGenentechMember_3994507F1508EB4D2A814D742775A7D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_E653680DFC413DDB57114D742775F168" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_AbbVieMember_E653680DFC413DDB57114D742775F168" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_8B0A492449565C844FE34D742775643A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_AcordaMember_8B0A492449565C844FE34D742775643A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_4C68076C251B882D27684D742775FDB0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_IonisPharmaceuticalsMember_4C68076C251B882D27684D742775FDB0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_D592A90649FA4B016EEA4D7427752C7A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_EisaiMember_D592A90649FA4B016EEA4D7427752C7A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_02D1F53C8094874050B54D742775BA46" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_BristolMyersSquibbMember_02D1F53C8094874050B54D742775BA46" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_485A294ECAA888BEBFD24D7427752E75" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_IPerianMember_485A294ECAA888BEBFD24D7427752E75" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_78F31A14512F8EFDB07A4D74277582BF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_AlkermesMember_78F31A14512F8EFDB07A4D74277582BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_AGTCMember_37BDC852A1FDD5BCCCDB4D74277529C9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_UniversityofPennsylvaniaMember" xlink:label="loc_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_UniversityofPennsylvaniaMember_AE843FC729801D549B904D742775D26D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_OtherresearchanddiscoveryMember_8A4918F09C4FE86EB17B4D742775AB48" xlink:type="arc" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AA39506B102FB44138C94D742774BFC7" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_C4AF4569730E5583DCAB4D742774223B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8869F518C9C2BDAC7BC24D7427759ECA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_RangeAxis_8869F518C9C2BDAC7BC24D7427759ECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F6A3DB2B8083F3E32FBD4D742775F0E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8869F518C9C2BDAC7BC24D7427759ECA" xlink:to="loc_us-gaap_RangeMember_F6A3DB2B8083F3E32FBD4D742775F0E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_85F260E0E1A822396A864D7427755E31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F6A3DB2B8083F3E32FBD4D742775F0E7" xlink:to="loc_us-gaap_MinimumMember_85F260E0E1A822396A864D7427755E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6A4EB124E5D8736299364D74277589F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F6A3DB2B8083F3E32FBD4D742775F0E7" xlink:to="loc_us-gaap_MaximumMember_6A4EB124E5D8736299364D74277589F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_33258CCADC734179DF014D7427711CBA" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_FEE64734BE32B18F983D4D742776B32E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_F7B71329D6129B2985B64D7427761CB8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_Reductioninroyaltyrate_2ED52FA9DE0FACA9572F4D742776A80D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_PeriodOfCollaborationAgreement_8D1753A086237A4952C04D7427760071" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_7C3E82D3571FD9A1D3854D742776A832" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_B30DAA2F3A294D218C804D742776861C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_1CDFF72C798190DF8FB14D742776B3F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_B3A7610FEEC960A25C934D7427765A89" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_29171EF5A9C0A32B90EE4D74277622FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_Futurepercentageofcopromotionoperatingprofits_8929C82B5C4B04CFF7B44D7427769168" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_7773AF92B866BEA5FCE34D742777EBE5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_ShareOfCoPromotionProfits_7773AF92B866BEA5FCE34D742777EBE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_C9664458088ED0E307914D742777CB69" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_C9664458088ED0E307914D742777CB69" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_33A666F4075CE435C25A4D7427772EDF" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_33A666F4075CE435C25A4D7427772EDF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_F2B93FF463D71B786F9E4D7427777E07" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_ForeignSalesRequiredToTriggerMilestone_BFBB9000C66A4D1EEFE44D742777D5F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_401FDEAE8E1C89CD00C24D7427774C4D" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_401FDEAE8E1C89CD00C24D7427774C4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D4BBBD0263A7A808183C4D742777C48E" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_DFC8F12BAC6C3A7452FA4D742776A318" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D4BBBD0263A7A808183C4D742777C48E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_6ED29557D60A71D830AA4D742778CE46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_6ED29557D60A71D830AA4D742778CE46" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0927C00B6BFC72AFEEB84D7427787FDD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_0927C00B6BFC72AFEEB84D7427787FDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_167551E0B4E977CEFBDB4D742778E974" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_167551E0B4E977CEFBDB4D742778E974" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CollaborationExpensesinDispute" xlink:label="loc_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_CollaborationExpensesinDispute_17BFA9BC0C5A96918FBB4D742777227D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_823363C92C96D54F78514D7427775AA2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_ExpenseIncurredByCollaboration_823363C92C96D54F78514D7427775AA2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_29F3A1F8D332D6AC7B724D742777B861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_88C82F8FECA6BC7EE3A64D742777C6C0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_AssetImpairmentCharges_88C82F8FECA6BC7EE3A64D742777C6C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_E3060DAEE763E348EB8F4D742777186E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_E3060DAEE763E348EB8F4D742777186E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_A8ECCD4F9F5DCFEFBF674D742777D547" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_OtherSalesRevenueNet_A8ECCD4F9F5DCFEFBF674D742777D547" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_CollaborationProfitSharing_99322B30C5D1339143DB4D7427781A84" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_28E561D980AE81559DC24D74277877A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="loc_us-gaap_DirectOperatingCostRoyaltyExpense_45EFAA868CF98C29A6CF4D7427788C39" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_DirectOperatingCostRoyaltyExpense_45EFAA868CF98C29A6CF4D7427788C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7D541DA3DDAE576177C84D7427788A49" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7D541DA3DDAE576177C84D7427788A49" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_F05D5EB212472A34DD514D74277814F0" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_LicenseFee_F05D5EB212472A34DD514D74277814F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_1FA2747B6936E0BB5B744D74277891F2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C6D798E3DB10F42355184D74277859C4" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C6D798E3DB10F42355184D74277859C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_AdditionalMilestonePayment_49BB99C305E918F2D1814D7427782D4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_Termofcollaborationagreement_65AE00D7CEF16AB5E70B4D742778192F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_96A06E8B60D672BE0C594D7427782923" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_96A06E8B60D672BE0C594D7427782923" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" xlink:label="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_17CD4B1A448F72E432704D742778F4D3" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_407ECB88F08F437C19354D742778BDAD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_C38AEC85F26D8C35B3E94D7427783191" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_DevelopmentalMilestonePayment_C38AEC85F26D8C35B3E94D7427783191" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_FAF3A98EB56A87FBE31A4D742779AB4C" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_FAF3A98EB56A87FBE31A4D742779AB4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_Purchaseofcommonstock_E90AE22EEFBB7E82CE424D7427799647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_5A2A7AE5EA2982221A464D7427792FDD" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_LicenseCosts_5A2A7AE5EA2982221A464D7427792FDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_EC744153CC6F9639EF1D4D742779AE25" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_EC744153CC6F9639EF1D4D742779AE25" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Futureresearchanddevelopmentcommitment" xlink:label="loc_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_Futureresearchanddevelopmentcommitment_B12F553ED26B4A8C9D2C4D74277994E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3DA8220E694BF4796C404D7427794D75" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_83B453576441AB61D1354D74277952FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_7EE2EE81C32FF91CCCA34D74277997D9" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_EquityMethodInvestments_7EE2EE81C32FF91CCCA34D74277997D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_B1FF385597D76A31C1F94D74277961A9" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_B1FF385597D76A31C1F94D74277961A9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E87E46CD926A3D4D47A94D742779C998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_57AC91108A46B74F318E4D7427791A8D" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_57AC91108A46B74F318E4D7427791A8D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09381488EA35056A97754D742776BD5F" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_037BA48BB2BF5A5CE8F14D742779410E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B4B963DA742F3A734612492867D8E111" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_3D64EA46CE8B0C26FC61492867D82E39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B4B963DA742F3A734612492867D8E111" xlink:to="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_3D64EA46CE8B0C26FC61492867D82E39" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PretaxProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_5D45B79C13FA7CAF2C16492867D9D78F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B4B963DA742F3A734612492867D8E111" xlink:to="loc_biib_PretaxProfitSharingFormulaTableTextBlock_5D45B79C13FA7CAF2C16492867D9D78F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F0C64B715162DC2F5602492867D9D321" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B4B963DA742F3A734612492867D8E111" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_F0C64B715162DC2F5602492867D9D321" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_9C8AE4D28FD05657E5C0492867D9FC8C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B4B963DA742F3A734612492867D8E111" xlink:to="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_9C8AE4D28FD05657E5C0492867D9FC8C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_A5B8FA73F695925E4F1C492867D9E950" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B4B963DA742F3A734612492867D8E111" xlink:to="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_A5B8FA73F695925E4F1C492867D9E950" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_02E1F7B103617855CB9829780D739F4A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E378B8876A1E0DC51CF229780D733479" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_02E1F7B103617855CB9829780D739F4A" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E378B8876A1E0DC51CF229780D733479" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_81102D8B8370637FA7EB4C77BC437EEA" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" xlink:label="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_81102D8B8370637FA7EB4C77BC437EEA" xlink:to="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_12F2498B665DE8B3250E4C77BC4441E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_12F2498B665DE8B3250E4C77BC4441E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_A1FF95857D1BF5AC6E7C4C77BC4496F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_A1FF95857D1BF5AC6E7C4C77BC4496F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_5A9D870EB0A8168F2DEF4C77BC44A87B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_5A9D870EB0A8168F2DEF4C77BC44A87B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EC018858F60FE94216374C77BC44695A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EC018858F60FE94216374C77BC44695A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_0DB951CC6A06BF720D374C77BC446F4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_0DB951CC6A06BF720D374C77BC446F4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F8313CB025B46C8A0E934C77BC449308" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F8313CB025B46C8A0E934C77BC449308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4F00FB0032200B83F9504C77BC44D451" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4F00FB0032200B83F9504C77BC44D451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1D60BFD2AF0B4FF9893E4C77BC443024" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1D60BFD2AF0B4FF9893E4C77BC443024" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_2CA2CF9211616DB8DFCE4C77BC456A5C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_2CA2CF9211616DB8DFCE4C77BC456A5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_2D956C606A02261BA0024C77BC45DFD5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_2D956C606A02261BA0024C77BC45DFD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_8189CFB0BC3CAF10B56E4C77BC453FAC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_8189CFB0BC3CAF10B56E4C77BC453FAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_BC7CD725882EFDAC1A904C77BC459B82" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_BC7CD725882EFDAC1A904C77BC459B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_610B1C717F534089A2E44C77BC452551" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_610B1C717F534089A2E44C77BC452551" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_685ECDA9BAAC923D1B3B4C77BC457281" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_685ECDA9BAAC923D1B3B4C77BC457281" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_BFC834D619DCB0C9298A4C77BC453E55" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInOneYear_BFC834D619DCB0C9298A4C77BC453E55" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_0D74DF286A36B2E19FD44C77BC454808" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_0D74DF286A36B2E19FD44C77BC454808" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_6AA8FD9BAC6BC3983F564C77BC459799" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_6AA8FD9BAC6BC3983F564C77BC459799" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_A1B175CE7161D96E1E9B4C77BC45AE37" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFourYear_A1B175CE7161D96E1E9B4C77BC45AE37" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_99C39A2A7A4EE8E2EA404C77BC460806" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_99C39A2A7A4EE8E2EA404C77BC460806" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_8BF9CCCBB70F8876CFB54C77BC4632A6" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_biib_NetMinimumLeasePaymentsThereafter_8BF9CCCBB70F8876CFB54C77BC4632A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_9A144A5DE74AFFF0A14C4C77BC4676DF" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_93422487BC41A3387E7C4C77BC446E21" xlink:to="loc_biib_NetMinimumLeasePayments_9A144A5DE74AFFF0A14C4C77BC4676DF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3BB5F1E81629B2BBBA494C77BC377016" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3BB5F1E81629B2BBBA494C77BC377016" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_BCCC8672A6845AF2E4184C77BC3816BE" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_BC8B30A4DF018CC6AAEA4C77BC38502B" xlink:to="loc_biib_U.S.2017TaxActMember_45AF2A4AD67D427C07E94C77BC38763C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_8D4E2B4CFA6ACBBD8EEB4C77BC3869A6" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:to="loc_biib_DevelopmentMilestonesMember_8A4947C20B24C6BC667F4C77BC38E440" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:to="loc_biib_RegulatoryMilestonesMember_9E4EEB8A59F0EA64E7604C77BC38CAC5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CommercialMilestonesMember" xlink:label="loc_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A86099E54C459E167A4D4C77BC389A7D" xlink:to="loc_biib_CommercialMilestonesMember_CF96C9403CCDDFB916D54C77BC38D992" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_1137234B889C9111064A4C77BC39F998" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_biib_CumulativeSalesLevelAxis_1137234B889C9111064A4C77BC39F998" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_1137234B889C9111064A4C77BC39F998" xlink:to="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FourteenbillionMember" xlink:label="loc_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_FourteenbillionMember_7E0781F57F56B9B592A14C77BC39D094" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ElevenbillionMember" xlink:label="loc_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_ElevenbillionMember_29CF8CED8F7F84AE55A24C77BC395661" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TwelvebillionMember" xlink:label="loc_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_TwelvebillionMember_F4008D93E0396770CDC64C77BC398CED" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ThirteenbillionMember" xlink:label="loc_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_ThirteenbillionMember_42C59EB4292F44EF03EE4C77BC390604" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_0CFC3EC5743889136A7D4C77BC39B20F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_FifteenbillionMemberMember_0CFC3EC5743889136A7D4C77BC39B20F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_8E57149778F81D5F1A414C7E599B3B45" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_SixteenbillionMember_8E57149778F81D5F1A414C7E599B3B45" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_OneBillionMember_8F625AA542EA19479BCB4C77BC394D8E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6F8FEBDF754930F979B74C77BC398FB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_77E827DF31E18A2DA6814C77BC39C591" xlink:to="loc_biib_ThreeBillionMember_F4E5ADF97F31513DBCFC4C77BC39A3CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_CE2B6C56747CD5F1106E4C77BC39BED0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_us-gaap_ProductOrServiceAxis_CE2B6C56747CD5F1106E4C77BC39BED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_1347BF80F9FE9A58FA8E4C77BC3A02D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_CE2B6C56747CD5F1106E4C77BC39BED0" xlink:to="loc_us-gaap_ProductsAndServicesDomain_1347BF80F9FE9A58FA8E4C77BC3A02D4" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_EC545D02544F026262154C77BC3A5D1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_1347BF80F9FE9A58FA8E4C77BC3A02D4" xlink:to="loc_biib_TecfideraMember_EC545D02544F026262154C77BC3A5D1B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_18C5C4D7069A684EACC34C77BC3A408A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_biib_FacilityLocationAxis_18C5C4D7069A684EACC34C77BC3A408A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_D84BEFDDBCAC431F9FE94C77BC3A7FF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_18C5C4D7069A684EACC34C77BC3A408A" xlink:to="loc_biib_FacilityLocationDomain_D84BEFDDBCAC431F9FE94C77BC3A7FF1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_BCE99AAEFD45CA116C154C77BC3A5620" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_D84BEFDDBCAC431F9FE94C77BC3A7FF1" xlink:to="loc_biib_SolothurnMember_BCE99AAEFD45CA116C154C77BC3A5620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_38A68E8266747C7D0D824C77BC3A5846" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_38A68E8266747C7D0D824C77BC3A5846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_439BDF133B6BCECFD1D54C77BC3AA429" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_38A68E8266747C7D0D824C77BC3A5846" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_439BDF133B6BCECFD1D54C77BC3AA429" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_AD2202BE53472E2ECA2C4C77BC3A72E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_439BDF133B6BCECFD1D54C77BC3AA429" xlink:to="loc_biib_TysabriProductMember_AD2202BE53472E2ECA2C4C77BC3A72E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_989616B222FB16312A194C77BC3AA64F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_439BDF133B6BCECFD1D54C77BC3AA429" xlink:to="loc_biib_FumapharmAgMember_989616B222FB16312A194C77BC3AA64F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2544BBEBD631A0456B134C77BC3790FF" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_6BB87BCEC3F8774197C14C77BC3A8313" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_biib_FutureContingentPaymentThreshold_86D0DD8C6C20AEFFA9774C77BC3AE18D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_135FCD3CD90BC30B13E84C77BC3A0ECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4653F2D260B93D891C574C77BC3B4F0E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4653F2D260B93D891C574C77BC3B4F0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2E03C7A9241351E9C35C4C77BC3B5B67" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2E03C7A9241351E9C35C4C77BC3B5B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3E00CCF4D129B562131E4C77BC3B3C8A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3E00CCF4D129B562131E4C77BC3B3C8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_28CF619905020334FEAB4C77BC3BD8AA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_biib_CumulativeSalesLevel_28CF619905020334FEAB4C77BC3BD8AA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_108BE54A21ACEBB1A5824C77BC3B0056" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_108BE54A21ACEBB1A5824C77BC3B0056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_89714369B631F41AEC974C77BC3B9AFB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_OtherCommitment_89714369B631F41AEC974C77BC3B9AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_FC9FED73B15496E3E1CB4C811D5F2D6A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_FC9FED73B15496E3E1CB4C811D5F2D6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossCurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_CDA835E465588F9B6D354C77BC3B8A53" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_38F49504CE3DF43D3F7B4C77BC3AA512" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_CDA835E465588F9B6D354C77BC3B8A53" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3BB5F1E81629B2BBBA494C77BC377016" xlink:to="loc_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F01E8DA5F9E93F7A4104C77BC3B0996" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9" xlink:to="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F01E8DA5F9E93F7A4104C77BC3B0996" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_0A5078174D656234C7E44C77BC3B8D5D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_0A5078174D656234C7E44C77BC3B8D5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_CED01B902A4AFA4765C24C77BC3B0C8B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_CBA147769AFF21A78CA54C77BC3B2CC9" xlink:to="loc_us-gaap_LeaseAndRentalExpense_CED01B902A4AFA4765C24C77BC3B0C8B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_703A667B49FEE0C9638D42C706A722A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_6841785C10D431338F1642C706A7B9E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_703A667B49FEE0C9638D42C706A722A1" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_6841785C10D431338F1642C706A7B9E8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F62A57A5B2409A303393297C21D92E36" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F62A57A5B2409A303393297C21D92E36" xlink:to="loc_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_27D579D3780D9CDD6778297C21DAC673" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_27D579D3780D9CDD6778297C21DAC673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B36E21769057789D9CFF297C21DAC8DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B36E21769057789D9CFF297C21DAC8DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3F5DF8388AD8B86184BF297C21DA5D90" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3F5DF8388AD8B86184BF297C21DA5D90" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_89E8E86617746770A657297C21DABE2D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_89E8E86617746770A657297C21DABE2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2DA32586EF29CB56D82D297C21DA22D6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:to="loc_us-gaap_InventoryNet_2DA32586EF29CB56D82D297C21DA22D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_674C228987BAE58620BB297C21DAAA3D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:to="loc_us-gaap_OtherAssetsCurrent_674C228987BAE58620BB297C21DAAA3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_35B36A77D5BB8877DE10297C21DA1EFC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_968F40CFCCADFD9DEB40297C21DA725E" xlink:to="loc_us-gaap_AssetsCurrent_35B36A77D5BB8877DE10297C21DA1EFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_0908BFF055B3F67B1B9A297C21DAB3F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_0908BFF055B3F67B1B9A297C21DAB3F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_B1EB78A999DF16613F81297C21DA2F7C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_B1EB78A999DF16613F81297C21DA2F7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D4B5746749BBE0A08F6D297C21DAAA35" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D4B5746749BBE0A08F6D297C21DAAA35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5A5775854B00B9BCEB8F297C21DAC532" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:to="loc_us-gaap_Goodwill_5A5775854B00B9BCEB8F297C21DAC532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_054AFA0E5D181923C9C2297C21DAAB65" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_054AFA0E5D181923C9C2297C21DAAB65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_06A64B2C59B8FF1F8BA2297C21DAA66B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18F414A503C9DC42B289297C21D904B6" xlink:to="loc_us-gaap_Assets_06A64B2C59B8FF1F8BA2297C21DAA66B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F62A57A5B2409A303393297C21D92E36" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_E95C671EBC9195F5F454297C21DB8D15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7" xlink:to="loc_us-gaap_DebtCurrent_E95C671EBC9195F5F454297C21DB8D15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_DD6962ABC212242E0DD6297C21DBA5EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7" xlink:to="loc_us-gaap_TaxesPayableCurrent_DD6962ABC212242E0DD6297C21DBA5EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_903400E86D123D1EDD6E297C21DBCBCB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7" xlink:to="loc_us-gaap_AccountsPayableCurrent_903400E86D123D1EDD6E297C21DBCBCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_EFF5FE8E5B6076CA4AB7297C21DB8325" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_EFF5FE8E5B6076CA4AB7297C21DB8325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_426EE1CF9959E9D10657297C21DBFB52" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D3A8D1A4C05D476F3497297C21DB36A7" xlink:to="loc_us-gaap_LiabilitiesCurrent_426EE1CF9959E9D10657297C21DBFB52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6245E2A61C5C55B1AD7F297C21DBFEF7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:to="loc_us-gaap_LongTermDebt_6245E2A61C5C55B1AD7F297C21DBFEF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_9A0E1B39A48E9455F1DE297C21DBD978" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_9A0E1B39A48E9455F1DE297C21DBD978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4F86C5D5F674E480EE50297C21DB5E1C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4F86C5D5F674E480EE50297C21DB5E1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_D1A01FEDEECFD06247E7297C21DBB52A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:to="loc_us-gaap_Liabilities_D1A01FEDEECFD06247E7297C21DBB52A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_77AB36004B0CF1BFF77E297C21DBB5F1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:to="loc_us-gaap_CommitmentsAndContingencies_77AB36004B0CF1BFF77E297C21DBB5F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_B9860528338F75832B49297C21DB188B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_B9860528338F75832B49297C21DB188B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_B9860528338F75832B49297C21DB188B" xlink:to="loc_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_417D6DA1C616F9FE655E297C21DBC7E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:to="loc_us-gaap_PreferredStockValue_417D6DA1C616F9FE655E297C21DBC7E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_43B71B5D9233C635EA74297C21DBBA84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:to="loc_us-gaap_CommonStockValue_43B71B5D9233C635EA74297C21DBBA84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_44772B18E8B835AF25E3297C21DB2856" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:to="loc_us-gaap_AdditionalPaidInCapital_44772B18E8B835AF25E3297C21DB2856" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E71C49AB252AE3E0BA28297C21DC2CD9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E71C49AB252AE3E0BA28297C21DC2CD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_A97C8B5C24FCE5A3A41C297C21DCA22F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_A97C8B5C24FCE5A3A41C297C21DCA22F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_26139A8A784EAE858797297C21DC8E90" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:to="loc_us-gaap_TreasuryStockValue_26139A8A784EAE858797297C21DC8E90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2A63BEE6699AA96B6F61297C21DC57FD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A3343B5C16009EBEABD2297C21DB8A19" xlink:to="loc_us-gaap_StockholdersEquity_2A63BEE6699AA96B6F61297C21DC57FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_9F8060BEB54263BA9297297C21DCBFDD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_B9860528338F75832B49297C21DB188B" xlink:to="loc_us-gaap_MinorityInterest_9F8060BEB54263BA9297297C21DCBFDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_282477FAAD2C189CDE9E297C21DC61FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_B9860528338F75832B49297C21DB188B" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_282477FAAD2C189CDE9E297C21DC61FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_C67CFD691353D2DBCCD3297C21DCD776" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D0AA8E051F0A8FD048F2297C21DAFD76" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_C67CFD691353D2DBCCD3297C21DCD776" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_AA65A0A21B0750BD99A729780F052375" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_18D5E4AD6DCF08C0D12629780F051F9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_AA65A0A21B0750BD99A729780F052375" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_18D5E4AD6DCF08C0D12629780F051F9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_E3E2EF21691DACA3426E29780F05ED32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_AA65A0A21B0750BD99A729780F052375" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_E3E2EF21691DACA3426E29780F05ED32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_EF52D2F370B859BBB87029780F05AD37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_AA65A0A21B0750BD99A729780F052375" xlink:to="loc_us-gaap_TreasuryStockShares_EF52D2F370B859BBB87029780F05AD37" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3CDA6E7A227AE8485A3651D3A7DA5EBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3CDA6E7A227AE8485A3651D3A7DA5EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_B287E137A743D9A2508451D3A7DEB367" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3CDA6E7A227AE8485A3651D3A7DA5EBB" xlink:to="loc_us-gaap_ProfitLoss_B287E137A743D9A2508451D3A7DEB367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3CDA6E7A227AE8485A3651D3A7DA5EBB" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7E481BB8BE4FD9EC1EF451D3A7E4D8B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7E481BB8BE4FD9EC1EF451D3A7E4D8B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_F5B8BB4F3E03816E028A51D3A7E84C60" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_F5B8BB4F3E03816E028A51D3A7E84C60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_00E84B33450469DDB04951D3A7E41729" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:to="loc_us-gaap_ShareBasedCompensation_00E84B33450469DDB04951D3A7E41729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_FA105F9D4CDDE09C447151D3A7E50F76" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_FA105F9D4CDDE09C447151D3A7E50F76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EA2172A3209D706C78551D3A7E5B2E7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EA2172A3209D706C78551D3A7E5B2E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_653717BBFA7A8C70525351D3A7E58C13" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_653717BBFA7A8C70525351D3A7E58C13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B875CEA97C26691EA2C451D3A7E57045" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B875CEA97C26691EA2C451D3A7E57045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_D70F0092DA7C4FAA96DC51D3A7E51CD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_D70F0092DA7C4FAA96DC51D3A7E51CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_42FC14712B3FCBA8CB8251D3A7E6F066" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_42FC14712B3FCBA8CB8251D3A7E6F066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_E22B4B2EE509A733A92251D3A7E68ABD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_E22B4B2EE509A733A92251D3A7E68ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4126C1A1B82EA10C1ADC51D3A7E60AFC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4126C1A1B82EA10C1ADC51D3A7E60AFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_94D22BF01152FE3E482251D3A7E69845" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_94D22BF01152FE3E482251D3A7E69845" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_56EE7CCF6896202E52A151D3A7E63F37" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51128B173305B801FBF451D3A7E58E57" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_56EE7CCF6896202E52A151D3A7E63F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4039207E6266ECB434DF51D3A7E77B34" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C48BF234D81158EECDA751D3A7E40E9F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4039207E6266ECB434DF51D3A7E77B34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EB1B186733CB06E267F751D3A7E79DFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EB1B186733CB06E267F751D3A7E79DFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_DA2150C3767FF4A3E1AB51D3A7E82538" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_DA2150C3767FF4A3E1AB51D3A7E82538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_513B43893B6D6B8D6E6651D3A7E88847" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_513B43893B6D6B8D6E6651D3A7E88847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_E998F1044A26856CE67151D3A7E8A3BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_E998F1044A26856CE67151D3A7E8A3BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD57E0BB7305A8D532FF51D3A7E8A6CE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD57E0BB7305A8D532FF51D3A7E8A6CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_333064277E284C8BEF9A51D3A7ED7287" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_333064277E284C8BEF9A51D3A7ED7287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_C8EAC76C1DF76A9BE04851D3A7EDA6D8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_C8EAC76C1DF76A9BE04851D3A7EDA6D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BEE9824F19C715151C7351D3A7EE3C0F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BEE9824F19C715151C7351D3A7EE3C0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F29CAB637C3DF05041E351D3A7EEC0FB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3D484241F48043EB3A2351D3A7E759A3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F29CAB637C3DF05041E351D3A7EEC0FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_FB67F0E2F55E6258A5A851D3A7EE07F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_FB67F0E2F55E6258A5A851D3A7EE07F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_CBA57A0F6BB1A1A6AAB451D3A7EE31B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_CBA57A0F6BB1A1A6AAB451D3A7EE31B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_2BD76F6996D963D1F05151D3A7EE2F44" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_2BD76F6996D963D1F05151D3A7EE2F44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_9E42BDAABBF5CA68F3DB51D3A7EF100A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_9E42BDAABBF5CA68F3DB51D3A7EF100A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_71E88FB79D90F213220B51D3A7EF5EEB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:to="loc_us-gaap_RepaymentsOfDebt_71E88FB79D90F213220B51D3A7EF5EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_D27F335695EE528DE57251D3A7F03B1B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_D27F335695EE528DE57251D3A7F03B1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_ADF9ED6DC877F18485AC51D3A7F09B6A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_ADF9ED6DC877F18485AC51D3A7F09B6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2F3EB3617660E306190351D3A7F068E2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2F3EB3617660E306190351D3A7F068E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CA7F0346AB1FDF2EE53F51D3A7F0B4FF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FEFDCB0C9F7C7E87206851D3A7EE6443" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CA7F0346AB1FDF2EE53F51D3A7F0B4FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_74C0AFA13CF3D5AA92DC51D3A7F03054" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_74C0AFA13CF3D5AA92DC51D3A7F03054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_62EA5396A852558E016B51D3A7F0D9EF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_62EA5396A852558E016B51D3A7F0D9EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E694926A90DB1846400451D3A7F06936" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E694926A90DB1846400451D3A7F06936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8988E05D3678D0F2EFBF51D3A7F1E9A7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_333BAA88A47F4B458E2551D3A7D22B35" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8988E05D3678D0F2EFBF51D3A7F1E9A7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63F27B49AEE15A701B80297C21E140A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7855F155B55D314A4435297C21E1F42D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63F27B49AEE15A701B80297C21E140A0" xlink:to="loc_us-gaap_NetIncomeLoss_7855F155B55D314A4435297C21E1F42D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_63F27B49AEE15A701B80297C21E140A0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6990037710E12A6813AE297C21E1B7B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6990037710E12A6813AE297C21E1B7B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_011879FB8F37CF9BEC23297C21E1191B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_011879FB8F37CF9BEC23297C21E1191B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_BB42DE502584A8509F59297C21E171CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_BB42DE502584A8509F59297C21E171CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_6FC04F16F548445D5C32297C21E1C678" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_6FC04F16F548445D5C32297C21E1C678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_ADAC5EC4BC1516DF8405297C21E14AF4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_ADAC5EC4BC1516DF8405297C21E14AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_D7CA549924F0E7624288297C21E1876E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_D7CA549924F0E7624288297C21E1876E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_73B0465FB59FB0FA4400297C21E142D2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_73B0465FB59FB0FA4400297C21E142D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_018C33C681F1EA6CA0BB297C21E13DB5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_018C33C681F1EA6CA0BB297C21E13DB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_650873BED1C0FF5A27FD297C21E1C1EE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_650873BED1C0FF5A27FD297C21E1C1EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_DEAD4431C606B77158FD297C21E1D09D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_DEAD4431C606B77158FD297C21E1D09D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_626F6F59C992A916F792297C21E2E6DC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_626F6F59C992A916F792297C21E2E6DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6F653E6961A0ECD87BAA297C21E2E9DF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9258C5676064298B3E5E297C21E11308" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6F653E6961A0ECD87BAA297C21E2E9DF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_860A5E779CE5F1015BCD52C0D5D59F0B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_42049A261D4E11C7DB7452C0D5D5A84C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_860A5E779CE5F1015BCD52C0D5D59F0B" xlink:to="loc_us-gaap_StatementTable_42049A261D4E11C7DB7452C0D5D5A84C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_BD4B0F568D70C877035B52C0D5D51220" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42049A261D4E11C7DB7452C0D5D5A84C" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_BD4B0F568D70C877035B52C0D5D51220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_EDA0A91B8721945D15D852C0D5D52972" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_BD4B0F568D70C877035B52C0D5D51220" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_EDA0A91B8721945D15D852C0D5D52972" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_870DA70D21EB57FF431C52C0D5D6AF1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_EDA0A91B8721945D15D852C0D5D52972" xlink:to="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_870DA70D21EB57FF431C52C0D5D6AF1B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_473F89923149BD4659C952C0D5D65F9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_EDA0A91B8721945D15D852C0D5D52972" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_473F89923149BD4659C952C0D5D65F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C6D6F6943DB5669DAD4952C0D5D64E8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42049A261D4E11C7DB7452C0D5D5A84C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_C6D6F6943DB5669DAD4952C0D5D64E8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C6D6F6943DB5669DAD4952C0D5D64E8A" xlink:to="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_234812A4D96FB9F24A5552C0D5D6FA0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_PreferredStockMember_234812A4D96FB9F24A5552C0D5D6FA0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_AF68C20C0D4FA279217552C0D5D6B3F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_CommonStockMember_AF68C20C0D4FA279217552C0D5D6B3F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_D8EC59A7BBC7FA1488F152C0D5D6027D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_D8EC59A7BBC7FA1488F152C0D5D6027D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12231DFDE0C48B9BDBF252C0D5D65775" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12231DFDE0C48B9BDBF252C0D5D65775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2909F56EFBF8E3CAE35252C0D5D6412A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_RetainedEarningsMember_2909F56EFBF8E3CAE35252C0D5D6412A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_5D7F3B944344DAFDA1C952C0D5D647C8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_TreasuryStockMember_5D7F3B944344DAFDA1C952C0D5D647C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_A019DD35F02166EC2C4552C0D5D6571D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_NoncontrollingInterestMember_A019DD35F02166EC2C4552C0D5D6571D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_C8779D4309C56E9D02F052C0D5D7BEEF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27E35FC8C2D1F5CA7CBA52C0D5D62772" xlink:to="loc_us-gaap_ParentMember_C8779D4309C56E9D02F052C0D5D7BEEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42049A261D4E11C7DB7452C0D5D5A84C" xlink:to="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15D6D84E3E97D5FB05B652C0D5D79230" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15D6D84E3E97D5FB05B652C0D5D79230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2662B113F2BC5F8264D952C0D5D7E84A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockholdersEquity_2662B113F2BC5F8264D952C0D5D7E84A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_DB45896898479AF1E95552C0D5D71602" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_MinorityInterest_DB45896898479AF1E95552C0D5D71602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_7A041A63CB32E3985F3D52C0D5D7FC2B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_SharesIssued_7A041A63CB32E3985F3D52C0D5D7FC2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5DC79B0ECEAA06C1E8E152C0D5D7F812" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_NetIncomeLoss_5DC79B0ECEAA06C1E8E152C0D5D7F812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A76137CDBBCF8723142D52C0D5D78B0E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A76137CDBBCF8723142D52C0D5D78B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1EEDD87A71C3A83ECC4752C0D5D77B90" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_ProfitLoss_1EEDD87A71C3A83ECC4752C0D5D77B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2F097F1D912E9D475BBA52C0D5D7A33D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2F097F1D912E9D475BBA52C0D5D7A33D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6B0D72B11DE0989EB07552C0D5D7E777" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6B0D72B11DE0989EB07552C0D5D7E777" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_77EA0697E4A3ECA2A6B552C0D5D78C9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_38515E636856FC364FE352C0D5D85EC0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_38515E636856FC364FE352C0D5D85EC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_68B3761109F60566C3E952C0D5D8A58E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_68B3761109F60566C3E952C0D5D8A58E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3F2A50C4EE3B823F6EAC52C0D5D881E5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3F2A50C4EE3B823F6EAC52C0D5D881E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2D54B9B61FEFB474DFFB52C0D5D8251D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2D54B9B61FEFB474DFFB52C0D5D8251D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_CF3D5121846C10DA27E852C0D5D8F0D9" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_CF3D5121846C10DA27E852C0D5D8F0D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_8ED18F849D4F1BC8619B52C0D5D8B70D" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_8ED18F849D4F1BC8619B52C0D5D8B70D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_10272EF9DDB19C0E1D4052C0D5D8502E" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_10272EF9DDB19C0E1D4052C0D5D8502E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_AF8DE654A9FB71FF84CA52C0D5D825F9" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_AF8DE654A9FB71FF84CA52C0D5D825F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_C22CD8880B209B6F205F52C0D5D8AC29" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_C22CD8880B209B6F205F52C0D5D8AC29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5A1213048D1FED79E1DA52C0D5D8FFD0" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5A1213048D1FED79E1DA52C0D5D8FFD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1843D3461146D478B8252C0D5D8AB6A" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1843D3461146D478B8252C0D5D8AB6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6844893C08938060CA1352C0D5D886F3" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6844893C08938060CA1352C0D5D886F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_98A17F77D17D668BC82952C0D5D8D4F3" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_98A17F77D17D668BC82952C0D5D8D4F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_79847B257F411A946C7852C0D5D9C4B8" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_79847B257F411A946C7852C0D5D9C4B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_D4D0B089D674A7CC88D752C0D5D9FC75" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockholdersEquityOther_D4D0B089D674A7CC88D752C0D5D9FC75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8AF5AC61E2125993041B52C0D5D96466" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8AF5AC61E2125993041B52C0D5D96466" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B23422665E60E6CAFF9452C0D5D9FD0D" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_StockholdersEquity_B23422665E60E6CAFF9452C0D5D9FD0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_F6C65962F4E5ED613F9C52C0D5D9CDED" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_MinorityInterest_F6C65962F4E5ED613F9C52C0D5D9CDED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_6E3EA7FC0F06B1ACE90352C0D5D96769" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7839D0B4208490938C2A52C0D5D7F388" xlink:to="loc_us-gaap_SharesIssued_6E3EA7FC0F06B1ACE90352C0D5D96769" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="loc_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_8CED5444D92708EE3D6C48E2641D704E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_8CED5444D92708EE3D6C48E2641D704E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_02269281517CE63FDDC448E2641D1A1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_02269281517CE63FDDC448E2641D1A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_EDA072FF4C0D8ED9E52548E2641D7784" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508" xlink:to="loc_us-gaap_OtherSalesRevenueNet_EDA072FF4C0D8ED9E52548E2641D7784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8BEC058B7BFE9CA88F7348E2641D7B36" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_833B3E74347AD9730E6348E2641DA508" xlink:to="loc_us-gaap_Revenues_8BEC058B7BFE9CA88F7348E2641D7B36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_C381B75C17F0F60F7AB148E2641D5C34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:to="loc_us-gaap_CostOfGoodsSold_C381B75C17F0F60F7AB148E2641D5C34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EEBEC8175FE358B0F4F948E2641DDCF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EEBEC8175FE358B0F4F948E2641DDCF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_BBA0E00FAFBFEC9CB7D048E2641D5133" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_BBA0E00FAFBFEC9CB7D048E2641D5133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3DB952FC855DFB7CEE5E48E2641D36B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3DB952FC855DFB7CEE5E48E2641D36B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_24AA17806CCA1D632B4448E2641D1E51" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_24AA17806CCA1D632B4448E2641D1E51" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_DFB10E9CBAD23812D07F48E2641D66A7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:to="loc_biib_CollaborationProfitSharing_DFB10E9CBAD23812D07F48E2641D66A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BA97FC0F1B03FDDFBA8548E2641E2A77" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BA97FC0F1B03FDDFBA8548E2641E2A77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_E13155A5523A4F16A83F48E2641E05E4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:to="loc_us-gaap_RestructuringCharges_E13155A5523A4F16A83F48E2641E05E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_5A67CED9E84E7EA8B03D48E2641E3A64" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:to="loc_us-gaap_LitigationSettlementExpense_5A67CED9E84E7EA8B03D48E2641E3A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8A5288C21D0F5D6F065448E2641E602A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8CFE3870D5FD3C9E843D48E2641D6560" xlink:to="loc_us-gaap_CostsAndExpenses_8A5288C21D0F5D6F065448E2641E602A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9884B44765BF295681F648E2641EC3D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="loc_us-gaap_OperatingIncomeLoss_9884B44765BF295681F648E2641EC3D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_660B4C07CB2B0EA4DF1048EBC4F3B72B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_660B4C07CB2B0EA4DF1048EBC4F3B72B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F036E2B3EBB446B17D6F48E2641E8E13" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F036E2B3EBB446B17D6F48E2641E8E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_BA311796DC3581DB8DE848E2641EEF8B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_BA311796DC3581DB8DE848E2641EEF8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5D48B28479DE75CC7B5E48E2641E83A7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5D48B28479DE75CC7B5E48E2641E83A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_6E633932B938DB2200A348E2641EF523" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="loc_us-gaap_ProfitLoss_6E633932B938DB2200A348E2641EF523" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5B9A662844FF6570276D48E2641EE4F1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5B9A662844FF6570276D48E2641EE4F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1F37851B68DE0712E96D48E2641E1E6B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="loc_us-gaap_NetIncomeLoss_1F37851B68DE0712E96D48E2641E1E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_88040D355C6879C5340948E2641E64CF" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="loc_us-gaap_EarningsPerShareAbstract_88040D355C6879C5340948E2641E64CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_EA15BE9F50884391226F48E2641E9229" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88040D355C6879C5340948E2641E64CF" xlink:to="loc_us-gaap_EarningsPerShareBasic_EA15BE9F50884391226F48E2641E9229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_61374CD0E0084632B56F48E2641EF00D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88040D355C6879C5340948E2641E64CF" xlink:to="loc_us-gaap_EarningsPerShareDiluted_61374CD0E0084632B56F48E2641EF00D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_920C45D2CF7EE83025F148E2641E70F5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_062D7B41A3EB851A7BB448E2641DA131" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_920C45D2CF7EE83025F148E2641E70F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_111C3C0ACCAAC84A059D48E2641F1513" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_920C45D2CF7EE83025F148E2641E70F5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_111C3C0ACCAAC84A059D48E2641F1513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_324DBA1441AFA89EE85A48E2641F3135" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_920C45D2CF7EE83025F148E2641E70F5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_324DBA1441AFA89EE85A48E2641F3135" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_CA6E64CD10E32364AA6F29780D74035F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B8A2764E90109FA3900029780D74757A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_CA6E64CD10E32364AA6F29780D74035F" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B8A2764E90109FA3900029780D74757A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C9F6D0850D007947966142D5E41394C6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C9F6D0850D007947966142D5E41394C6" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:to="loc_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencyAxis_E6E363C5C06C9157BDEC42D5E413AC86" xlink:to="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_1C0C501C08B017D7CFCD42D5E4139A73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:to="loc_currency_EUR_1C0C501C08B017D7CFCD42D5E4139A73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_FC262194F27359C902CF42D5E414BA36" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:to="loc_currency_GBP_FC262194F27359C902CF42D5E414BA36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_B985C169C15EFD4271FB42D5E4148DA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:to="loc_currency_CHF_B985C169C15EFD4271FB42D5E4148DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_29E4585609708E7BB70542D5E414C5A5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_0EDA6EEAC9950013026642D5E4139838" xlink:to="loc_currency_CAD_29E4585609708E7BB70542D5E414C5A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_652F070033E7542D604742D5E414E240" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_652F070033E7542D604742D5E414E240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F27D62C50683B37D09CE42D5E4141407" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_652F070033E7542D604742D5E414E240" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F27D62C50683B37D09CE42D5E4141407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_DB5C30CB7B78D0FD1EB242D5E4141B5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F27D62C50683B37D09CE42D5E4141407" xlink:to="loc_us-gaap_ForeignExchangeContractMember_DB5C30CB7B78D0FD1EB242D5E4141B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_242A05587B0CDEB75C0542D5E419FB42" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_242A05587B0CDEB75C0542D5E419FB42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_242A05587B0CDEB75C0542D5E419FB42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_C88D4CFFDD1C8EE8E61442D5E41A6165" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_C88D4CFFDD1C8EE8E61442D5E41A6165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_2F206D6B8F390965455642D5E41AAA9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E" xlink:to="loc_us-gaap_OtherInvestmentsMember_2F206D6B8F390965455642D5E41AAA9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_33139AAACC7E6C9F60D142D5E41A7456" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_33139AAACC7E6C9F60D142D5E41A7456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9E29A028A6AC2C9579BB42D5E41AA4BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D2B0C78B89B47C96A3DE42D5E419839E" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9E29A028A6AC2C9579BB42D5E41AA4BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:to="loc_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_68AB134C6C9B102B2E5642D5E41AE384" xlink:to="loc_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1406129B11F00BF5C87842D5E41AAED7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1406129B11F00BF5C87842D5E41AAED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_27F3FDDD9972992165E542D5E41AF449" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_B76A6B0F2ECE6DB02CF142D5E41A3F73" xlink:to="loc_us-gaap_NondesignatedMember_27F3FDDD9972992165E542D5E41AF449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_440431D431EB633A483342D5E413BF65" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_7F1846292181A72C9FA142D5E41A07E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:to="loc_invest_DerivativeNotionalAmount_7F1846292181A72C9FA142D5E41A07E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F08FD2A463A26407786642D5E41AA44D" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_D88A3AE2CF415E570E2742D5E41A3115" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_D88A3AE2CF415E570E2742D5E41A3115" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A085857E43F3981DFC4642D5E41A7161" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_5B92AAF6702D5C17347242D5E41ACECF" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A085857E43F3981DFC4642D5E41A7161" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_FFA93AD57E22D555D21529780F7044CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_FFA93AD57E22D555D21529780F7044CB" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D64F0E6936C6BBB98FF429780F70CE34" xlink:to="loc_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:to="loc_biib_CashflowsrevenueMember_7F74E28F543EDD098FA429780F7072EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_60B5195ADDF61B44240129780F70EA48" xlink:to="loc_biib_CashflowsoperatingexpensesMember_048E51A886D534A859CA29780F701A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3F87FE3E04150A913BC229780F70B62A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3F87FE3E04150A913BC229780F70B62A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_21114F4595320A286AF229780F704873" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3F87FE3E04150A913BC229780F70B62A" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_21114F4595320A286AF229780F704873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_2B3D718C2F480A00D82C29780F7008C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_21114F4595320A286AF229780F704873" xlink:to="loc_us-gaap_ForeignExchangeContractMember_2B3D718C2F480A00D82C29780F7008C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9512F679110C3FA6F66F29780F705100" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9512F679110C3FA6F66F29780F705100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9512F679110C3FA6F66F29780F705100" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_A11F41C82C7FB81E7DC529780F708A97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:to="loc_us-gaap_SalesMember_A11F41C82C7FB81E7DC529780F708A97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_BE7A4EA42653A755273E29780F709E60" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_BE7A4EA42653A755273E29780F709E60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_8A011FBF93E1DE58C24129780F71D88A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DB46DFE33110CE5DEC0A29780F70C14E" xlink:to="loc_us-gaap_OperatingExpenseMember_8A011FBF93E1DE58C24129780F71D88A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58A11A9C559AE36BF63829780F70DF97" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6B0AE973DED3EF9A053829780F71AC45" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_6608CCBE418745E5743929780F71E1B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_6608CCBE418745E5743929780F71E1B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_7470256E4A8D67DF27B329780F7138DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_000CCD0F0DC152BA613129780F71C5EB" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_7470256E4A8D67DF27B329780F7138DB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_91DBBA0C7604F47B6605433E1440B08F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_91DBBA0C7604F47B6605433E1440B08F" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:to="loc_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_BC323DA5BE4D2DCB9FA5433E1440BB69" xlink:to="loc_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_CDC8D847EA058F40C79A433E1440B2E9" xlink:to="loc_biib_ShorttermderivativeMember_D2E3F251B2A768652967433E1440EA74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2ADCC6B7D214055AED81433E14400768" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:to="loc_us-gaap_RangeAxis_2ADCC6B7D214055AED81433E14400768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_549D4322357A0AFE5097433E14404315" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2ADCC6B7D214055AED81433E14400768" xlink:to="loc_us-gaap_RangeMember_549D4322357A0AFE5097433E14404315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9573779765B9FA077DEB433E1440AAF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_549D4322357A0AFE5097433E14404315" xlink:to="loc_us-gaap_MinimumMember_9573779765B9FA077DEB433E1440AAF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_99DEE23E00F9117E0CFA433E1446EC25" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_549D4322357A0AFE5097433E14404315" xlink:to="loc_us-gaap_MaximumMember_99DEE23E00F9117E0CFA433E1446EC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7DC25FF924C4B27594F1433E1446E098" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:to="loc_us-gaap_DebtInstrumentAxis_7DC25FF924C4B27594F1433E1446E098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DBFF134E40011A308E97433E14462A09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7DC25FF924C4B27594F1433E1446E098" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DBFF134E40011A308E97433E14462A09" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_1A805B5BA0DADC98D475433E14463EFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DBFF134E40011A308E97433E14462A09" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_1A805B5BA0DADC98D475433E14463EFF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8D2A8AD5D97BB2B07F9E433E1446D35F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DBFF134E40011A308E97433E14462A09" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8D2A8AD5D97BB2B07F9E433E1446D35F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_BB5E0BF14B54F01A3BD6433E1446BEC4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DBFF134E40011A308E97433E14462A09" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_BB5E0BF14B54F01A3BD6433E1446BEC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7231279ABB553DBB3CA7433E144786ED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7231279ABB553DBB3CA7433E144786ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_33F0BC43F1136398770D433E14474FBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7231279ABB553DBB3CA7433E144786ED" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_33F0BC43F1136398770D433E14474FBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_42B95A18D362683BE579433E144747EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_33F0BC43F1136398770D433E14474FBA" xlink:to="loc_us-gaap_InterestRateContractMember_42B95A18D362683BE579433E144747EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_C547132BBA09253EF518433E1447E06B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_33F0BC43F1136398770D433E14474FBA" xlink:to="loc_us-gaap_InterestRateSwapMember_C547132BBA09253EF518433E1447E06B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_9D866D547DD4338CB6B9433E1447E733" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:to="loc_us-gaap_HedgingDesignationAxis_9D866D547DD4338CB6B9433E1447E733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_434721EA6F628AB586AF433E14473259" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_9D866D547DD4338CB6B9433E1447E733" xlink:to="loc_us-gaap_HedgingDesignationDomain_434721EA6F628AB586AF433E14473259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_35D32DE79B644AAE0F54433E1447CC13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_434721EA6F628AB586AF433E14473259" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_35D32DE79B644AAE0F54433E1447CC13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_C809680DFC7680C35E1F433E144CF05F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_434721EA6F628AB586AF433E14473259" xlink:to="loc_us-gaap_NondesignatedMember_C809680DFC7680C35E1F433E144CF05F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E6028CFEAFE263BC3C29433E14400295" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D92195E3E5592A13B564433E144DF210" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D92195E3E5592A13B564433E144DF210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_24C97B0E517030B5D8C7433E144DB014" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_24C97B0E517030B5D8C7433E144DB014" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_53C0762DEA9A1A184AD4433E144D71FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:to="loc_invest_DerivativeNotionalAmount_53C0762DEA9A1A184AD4433E144D71FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2CE60D86BB823D89F913433E144DA9B8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2CE60D86BB823D89F913433E144DA9B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A1168C01C6C44FE4AE2E433E144DFDEC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_D70F49298AC7945B8C59433E144C71C4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A1168C01C6C44FE4AE2E433E144DFDEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_A05F015583AC3BA31058433E144DFD04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_91DBBA0C7604F47B6605433E1440B08F" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_A05F015583AC3BA31058433E144DFD04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B110BD490AE2A71BF64229780DF0455F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_3BBC35D2C835039D2FA329780DF06E16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B110BD490AE2A71BF64229780DF0455F" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_3BBC35D2C835039D2FA329780DF06E16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2BAFDDD67EBEF2A2B10F29780DF0F8E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B110BD490AE2A71BF64229780DF0455F" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2BAFDDD67EBEF2A2B10F29780DF0F8E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_CCA5C0363CE94C0622F029780DF0DEEE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B110BD490AE2A71BF64229780DF0455F" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_CCA5C0363CE94C0622F029780DF0DEEE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="biib-20171231.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_D46069358FF370F8D48A29780DD6625A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_EntityRegistrantName_D46069358FF370F8D48A29780DD6625A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_064C7BC3C76EF35E7ACC29780DD657E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_EntityCentralIndexKey_064C7BC3C76EF35E7ACC29780DD657E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_F966B2E1BA8D463A3DA929780DD6354C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_CurrentFiscalYearEndDate_F966B2E1BA8D463A3DA929780DD6354C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D5654A8447144A798D4A29780DD64224" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_EntityFilerCategory_D5654A8447144A798D4A29780DD64224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2087A90B613896CFB5D529780DD6E020" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_DocumentType_2087A90B613896CFB5D529780DD6E020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_CDF94021AE8F5141E11F29780DD6C555" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_DocumentPeriodEndDate_CDF94021AE8F5141E11F29780DD6C555" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6EDE8F03AF8B1A4F52DD29780DD647FD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_DocumentFiscalYearFocus_6EDE8F03AF8B1A4F52DD29780DD647FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_D05626F323CC211A679529780DD60495" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_DocumentFiscalPeriodFocus_D05626F323CC211A679529780DD60495" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_2F81AA6B9128DC1E304829780DD6A1A6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_AmendmentFlag_2F81AA6B9128DC1E304829780DD6A1A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_32967DFF61FE3A3F4B7629780DD6D902" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_32967DFF61FE3A3F4B7629780DD6D902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_D05E013FDBCD4947AD3629780DD62B2C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_D05E013FDBCD4947AD3629780DD62B2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_09A53B23AE3BD22021B429780DD63622" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_EntityVoluntaryFilers_09A53B23AE3BD22021B429780DD63622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_EBFBF2E470F4E70AE1F729780DD6CCEF" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_EntityCurrentReportingStatus_EBFBF2E470F4E70AE1F729780DD6CCEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_D300DAB6FC40E4B33CEA29780DD68B7E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_186936316E55D7876C3E29780DD5F54A" xlink:to="loc_dei_EntityPublicFloat_D300DAB6FC40E4B33CEA29780DD68B7E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_35A613DE1055F6826F9429780E76F212" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5BFC67285B5C5C8C2E3E29780E7609D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35A613DE1055F6826F9429780E76F212" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_5BFC67285B5C5C8C2E3E29780E7609D3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B77144AB20CD05AD22A929780E9D2B37" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B77144AB20CD05AD22A929780E9D2B37" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EC59709D994FE44EFBBB29780E9D6C53" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_82CA9B2BB351D9E1069729780E9ED0E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E8AD12C00568418262DE29780E9EE1E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_E8AD12C00568418262DE29780E9EE1E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_F51A7D51255B1BB9D98C29780E9EA952" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B873F9E604F23B35B14C29780E9D4157" xlink:to="loc_biib_MarketStockUnitsMember_F51A7D51255B1BB9D98C29780E9EA952" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97E1E3AAF4A47A38379A29780E9D6033" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_611292AA7585F62402E829780E9EF309" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:to="loc_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_42F61586B25436133C3229780E9E9CC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_NumeratorAbstract_6D844CCAFD32C43408F129780E9E8BBC" xlink:to="loc_us-gaap_NetIncomeLoss_42F61586B25436133C3229780E9E9CC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_92F3D22F83E9C326420D29780E9E0443" xlink:to="loc_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_51B98C283E2CAB4CF06229780E9EA656" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_51B98C283E2CAB4CF06229780E9EA656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5CEE0CCF133EF0572E2829780E9E833E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5CEE0CCF133EF0572E2829780E9E833E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_93FE4E597CD904ECC12929780E9E09E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_80CA05EE3EC2EB7CB73C29780E9EDB01" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_93FE4E597CD904ECC12929780E9E09E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21BCD86C5B61C09003AD29780E9F3A07" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_992709A4BD1D4103B04029780E9E9E84" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21BCD86C5B61C09003AD29780E9F3A07" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EarningsPerShareTextualAbstract" xlink:label="loc_biib_EarningsPerShareTextualAbstract_552D28680CEC9FBFA64E29780E9FA636" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B77144AB20CD05AD22A929780E9D2B37" xlink:to="loc_biib_EarningsPerShareTextualAbstract_552D28680CEC9FBFA64E29780E9FA636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_E79BE7755C74AD23AFCD29780E9FDD3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EarningsPerShareTextualAbstract_552D28680CEC9FBFA64E29780E9FA636" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_E79BE7755C74AD23AFCD29780E9FDD3E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6AF8FD77D258FB02A3FB29780F08E689" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_29720664EC2DCF0D093329780F089643" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6AF8FD77D258FB02A3FB29780F08E689" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_29720664EC2DCF0D093329780F089643" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_28679A2F9EACA572E15629780FB9F455" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2C0746EF47AC63D23E1429780FB90895" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_28679A2F9EACA572E15629780FB9F455" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2C0746EF47AC63D23E1429780FB90895" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C6186E7E14747B6E95D44C78A5FA797D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C6186E7E14747B6E95D44C78A5FA797D" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_E394A033202A0F068D804C78A5FAA350" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_894C7858F6F63C2609AE4C78A5FA07C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_F0CDD81F5F3C38301CCA4C78A5FA7279" xlink:to="loc_us-gaap_ForeignPlanMember_894C7858F6F63C2609AE4C78A5FA07C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:to="loc_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_FE9896EA88D6842686654C78A5FAB0AF" xlink:to="loc_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CH" xlink:label="loc_country_CH_16ECDE442E9F463C45DC4C78A6003299" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:to="loc_country_CH_16ECDE442E9F463C45DC4C78A6003299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="loc_country_DE_2CB7D81DE871872DFFF24C78A600948E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_C5E0BED86DD4F7EB80084C78A60077A7" xlink:to="loc_country_DE_2CB7D81DE871872DFFF24C78A600948E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D4D596BEA1E86BF21A984C78A5FA96C9" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5701FE9410E067BFDFAD4C78A600D891" xlink:to="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:to="loc_biib_PercentageOfMinimumInvestmentReturn_0AE35FEEB8F5FC89ED1F4C78A6017F39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_B4546ACBF305A9D0FE664C78A6010D02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_B4546ACBF305A9D0FE664C78A6010D02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_908ACDF6A147A8E526524C78A601BABA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_908ACDF6A147A8E526524C78A601BABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_C45D74DDC73DC69F5F1D4C78A6019923" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:to="loc_us-gaap_PensionExpense_C45D74DDC73DC69F5F1D4C78A6019923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_0291323046308F0BBC394C78A601FCB0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_63A048141E8070B273B34C78A60052BA" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_0291323046308F0BBC394C78A601FCB0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_177633782F07778F7F174C78A60A4DD0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_177633782F07778F7F174C78A60A4DD0" xlink:to="loc_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_F61DD44850970846C0D74C78A60ACB4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_F61DD44850970846C0D74C78A60ACB4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_A115D8A6F1D01D1AD16A4C78A60A70DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_F61DD44850970846C0D74C78A60ACB4D" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_A115D8A6F1D01D1AD16A4C78A60A70DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_9B1B651110A79D767E5C4C78A60A999D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_A115D8A6F1D01D1AD16A4C78A60A70DF" xlink:to="loc_us-gaap_DomesticPlanMember_9B1B651110A79D767E5C4C78A60A999D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0B86177A3BE0F23667484C78A60FB722" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_A115D8A6F1D01D1AD16A4C78A60A70DF" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0B86177A3BE0F23667484C78A60FB722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_481DCBEBDA7F1E3DED824C78A60A12AD" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:to="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_7454D3A63DD5C8C483274C78A610A7BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_61B16D90B3BF3F35B7384C78A610C951" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_61B16D90B3BF3F35B7384C78A610C951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_CE2B5865AF0E5C4C43444C78A610FACA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_E85BFF4F42055A8CE4C84C78A60F1DEE" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_CE2B5865AF0E5C4C43444C78A610FACA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_983D4CE1EC0BE662213A29780E719FF2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1FF893A5457CE60FEC5329780E711EC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_983D4CE1EC0BE662213A29780E719FF2" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1FF893A5457CE60FEC5329780E711EC8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1B823D13F9C6EC8427ED29780F7C88B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9A9FFE56F297285E651929780F7C666D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1B823D13F9C6EC8427ED29780F7C88B3" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9A9FFE56F297285E651929780F7C666D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3346131037658CDD3CB429780F7CFA59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9A9FFE56F297285E651929780F7C666D" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3346131037658CDD3CB429780F7CFA59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_81618527063936B8185429780F7CAD9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9A9FFE56F297285E651929780F7C666D" xlink:to="loc_us-gaap_CommonStockSharesIssued_81618527063936B8185429780F7CAD9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_005F50E546F3808F2D7629780F7CD498" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9A9FFE56F297285E651929780F7C666D" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_005F50E546F3808F2D7629780F7CD498" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_297429EB1D6B9F0C566943AA3FFD18F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_297429EB1D6B9F0C566943AA3FFD18F8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ECE84535C2EC190669BD43AA3FFDD988" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:to="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_1FE561E387793806409A43AA3FFDD795" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_2D4C9685EAFB814231E143AA3FFD9427" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_77C7A9A562409D5B937743AA3FFDE37F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F6666FF25AC6F2A7FAC143AA3FFD969E" xlink:to="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1794FC13139F027D291F43AA3FFD40C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1794FC13139F027D291F43AA3FFD40C0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:to="loc_biib_SeriesXPreferredStockMember_F6BE59223C7DEFC4A43A43AA3FFE4111" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_247225879C558072A9C343AA3FFD2D64" xlink:to="loc_biib_UndesignatedPreferredStockMember_2617E55F9C4B18F3B5BE43AA3FFE85DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4844D1AE9174E956CD5E43AA3FFDD374" xlink:to="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_C013FCA2E9DA4876012C43AA3FFE4508" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_C013FCA2E9DA4876012C43AA3FFE4508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4AFCEF2677888CF946D643AA3FFE460D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4AFCEF2677888CF946D643AA3FFE460D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_B6F358A74E537A6CC0E743AA3FFE2E40" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_B6F358A74E537A6CC0E743AA3FFE2E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_231B703246AB88ED2F0943AA3FFEDA4C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_231B703246AB88ED2F0943AA3FFEDA4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_17E0B76BBC31333B174C43AA3FFE8DCC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78AE9BB28ED5026BB6C843AA3FFE9B79" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_17E0B76BBC31333B174C43AA3FFE8DCC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4AAB314B02C1BE54F6FA29780E77D529" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SummaryOfCommonStockTableTextBlock" xlink:label="loc_biib_SummaryOfCommonStockTableTextBlock_E2F2EC4B203A5440516029780E771081" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4AAB314B02C1BE54F6FA29780E77D529" xlink:to="loc_biib_SummaryOfCommonStockTableTextBlock_E2F2EC4B203A5440516029780E771081" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D037E9CEBA49B6CF055D29780F3702BD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1ADF63AD5377003EE64629780F37E63F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D037E9CEBA49B6CF055D29780F3702BD" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1ADF63AD5377003EE64629780F37E63F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E1FB6D70E45F6522768542D5E4CF5F5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E1FB6D70E45F6522768542D5E4CF5F5F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_FEDEB076519238F0500342D5E4CF10EA" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FA231860B00DCE0DE67742D5E4CF2CD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_FA231860B00DCE0DE67742D5E4CF2CD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_421422C35BC5C14B312342D5E4CFA157" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_421422C35BC5C14B312342D5E4CFA157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4025503224EC4B79224542D5E4CFA07E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56DF8012A225EE70635A42D5E4CF6B38" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4025503224EC4B79224542D5E4CFA07E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_D32E16FF26093C9B60F942D5E4CF8348" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_E903A03968CEA6484FC842D5E4D09AFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_B4D4D2A96A742CA6F71442D5E4D086AC" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_E903A03968CEA6484FC842D5E4D09AFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4E8E4D3C0410298A7E7A42D5E4D0D0A4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_A756F3B3C761E8BEC49B42D5E4D0B3BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_A756F3B3C761E8BEC49B42D5E4D0B3BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_2E314A33D12781C0BB3E42D5E4D025F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_2E314A33D12781C0BB3E42D5E4D025F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_FD5F5BE60DB3718A0B9342D5E4D0BB88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8C6A27E0DFC681138AC142D5E4D0E24B" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_FD5F5BE60DB3718A0B9342D5E4D0BB88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E4F333B523A34A4EE0942D5E4CF1603" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_338A09030677A04221B042D5E4D06DA5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2F0B93BA0423D082CF5942D5E4D025B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2F0B93BA0423D082CF5942D5E4D025B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_EACF7D2AE29CC93A2A2342D5E4D001CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="loc_us-gaap_AvailableForSaleSecurities_EACF7D2AE29CC93A2A2342D5E4D001CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_DF9745B01C56C34E91B942D5E4D02EB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_DF9745B01C56C34E91B942D5E4D02EB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_717A7FBE228794DFFBDB42D5E4D0DC3A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_717A7FBE228794DFFBDB42D5E4D0DC3A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_71C3047A2643C14D563C42D5E4D1F65E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8DF5F140201543FE4E9C42D5E4D1800B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_273F0C7D989487F2A7DB42D5E4D0BDF4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8DF5F140201543FE4E9C42D5E4D1800B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_59FAFF091B07BD1847A042D5E4D0EBC8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_12D97F2F813AC9346B4642D5E4D18A3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_12D97F2F813AC9346B4642D5E4D18A3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_CC8763BEA1FE6C8F604E42D5E4D18580" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_CC8763BEA1FE6C8F604E42D5E4D18580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_DBDFA4F4AA63E7FBCD5942D5E4D16F87" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F962F182350399F406E342D5E4D1C29E" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_DBDFA4F4AA63E7FBCD5942D5E4D16F87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_EE795FD0A8D70A579D894311A5087830" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_39AE5D8DDCE12A2975034311A50825C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_EE795FD0A8D70A579D894311A5087830" xlink:to="loc_us-gaap_DebtInstrumentTable_39AE5D8DDCE12A2975034311A50825C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_BE495FBB0AEAFFB3C5634311A5087B8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39AE5D8DDCE12A2975034311A50825C3" xlink:to="loc_us-gaap_DebtInstrumentAxis_BE495FBB0AEAFFB3C5634311A5087B8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_BE495FBB0AEAFFB3C5634311A5087B8E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:to="loc_biib_NotesPayableToFumedicaMember_C39BEE37DC41EC44A0134311A508D0E4" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C30F832B50A5F3477B654311A509696C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C30F832B50A5F3477B654311A509696C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_C4582457970A7B1E3EEE4311A509A768" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_C4582457970A7B1E3EEE4311A509A768" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_895EF73FBF3C8B4828AD4311A5099907" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_895EF73FBF3C8B4828AD4311A5099907" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_DACDFC3600A047B94BC24311A5096C22" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_DACDFC3600A047B94BC24311A5096C22" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_252A437E481BAC9302A34311A5094EF0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652F4CCA0201F76850964311A508DB76" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_252A437E481BAC9302A34311A5094EF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_A526C5E6EB700B2D996F4311A5095172" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39AE5D8DDCE12A2975034311A50825C3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_A526C5E6EB700B2D996F4311A5095172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_38AFA7F85B481A3F61F54311A509AFF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A526C5E6EB700B2D996F4311A5095172" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_38AFA7F85B481A3F61F54311A509AFF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_2F04205719C738EFB3A54311A509B914" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A526C5E6EB700B2D996F4311A5095172" xlink:to="loc_us-gaap_DebtInstrumentFairValue_2F04205719C738EFB3A54311A509B914" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_FB6F3FD73D08BC24A0A342D5E4A3D4D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D7D7E228BCEDC780F63042D5E4A39CFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FB6F3FD73D08BC24A0A342D5E4A3D4D6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D7D7E228BCEDC780F63042D5E4A39CFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9D219F91FD00BB7A593942D5E4A30B46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D7D7E228BCEDC780F63042D5E4A39CFA" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9D219F91FD00BB7A593942D5E4A30B46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_55B174D10D5512ABED6542D5E4A3FEC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9D219F91FD00BB7A593942D5E4A30B46" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_55B174D10D5512ABED6542D5E4A3FEC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7E9E7C5C6374F947612F42D5E4A3FD2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_55B174D10D5512ABED6542D5E4A3FEC9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7E9E7C5C6374F947612F42D5E4A3FD2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_A9115BDED1EE807D537242D5E4A312D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D7D7E228BCEDC780F63042D5E4A39CFA" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_A9115BDED1EE807D537242D5E4A312D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A419484C8BEC0CAF40F442D5E4A3F6B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_A9115BDED1EE807D537242D5E4A312D4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A419484C8BEC0CAF40F442D5E4A3F6B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_00C96585005987B2EB4F42D5E4A35CE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_A9115BDED1EE807D537242D5E4A312D4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_00C96585005987B2EB4F42D5E4A35CE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0A667C1D10BD914BA06442D5E4A3A7A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_A9115BDED1EE807D537242D5E4A312D4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0A667C1D10BD914BA06442D5E4A3A7A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_727611B356D693495E7142D5E4A3D751" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_A9115BDED1EE807D537242D5E4A312D4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_727611B356D693495E7142D5E4A3D751" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_76B8337EC502C12680CB42D5E492BA58" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_76B8337EC502C12680CB42D5E492BA58" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_394166407B98C84B2D3142D5E4927A2E" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_A956F75F4E9E6AD2E53042D5E4922534" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_A956F75F4E9E6AD2E53042D5E4922534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_A99EF515EAE632E6F5F842D5E492CBB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_B1BDAC94C4E969F9B01242D5E4923E51" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_A99EF515EAE632E6F5F842D5E492CBB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_D9BB80598DCD35879B6542D5E492C7A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:to="loc_us-gaap_DebtInstrumentAxis_D9BB80598DCD35879B6542D5E492C7A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_D9BB80598DCD35879B6542D5E492C7A3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_13722E3B16E3CA43840642D5E49325B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_13722E3B16E3CA43840642D5E49325B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_7A633863A1D7D7DACDD242D5E493669E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_7A633863A1D7D7DACDD242D5E493669E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_306EAE2CEC009F59606642D5E49336E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_306EAE2CEC009F59606642D5E49336E1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8BF848A874DAF39B818042D5E4930A76" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8BF848A874DAF39B818042D5E4930A76" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_50E3E98D18A0C9CE633E42D5E49309A2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46E1350E8175A023166B42D5E4933A89" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_50E3E98D18A0C9CE633E42D5E49309A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_59B1727E8AF27EB3994B42D5E493435C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_59B1727E8AF27EB3994B42D5E493435C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D6F6A49A72C6DC1E8F6F42D5E4939055" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59B1727E8AF27EB3994B42D5E493435C" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D6F6A49A72C6DC1E8F6F42D5E4939055" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_FA14A9057E93D0575B7642D5E493318C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D6F6A49A72C6DC1E8F6F42D5E4939055" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_FA14A9057E93D0575B7642D5E493318C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D6F6A49A72C6DC1E8F6F42D5E4939055" xlink:to="loc_biib_StromedixMember_5C5FF60E4C9B61BECF7142D5E4932FCA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D6F6A49A72C6DC1E8F6F42D5E4939055" xlink:to="loc_biib_BiogenIdecInternationalNeuroscienceMember_1BCEF58E2C057776111942D5E493A436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_59822EC5ADF5E9BC941242D5E492792B" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4365BEE9AE015008136642D5E4936CCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4365BEE9AE015008136642D5E4936CCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_834E63C6B8011DADD967437EEA8391AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_834E63C6B8011DADD967437EEA8391AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_95CE23979AB447EF518D42D5E4937027" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_95CE23979AB447EF518D42D5E4937027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_E6304E73DE32FB6437E042D5E4938454" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_OtherLiabilities_E6304E73DE32FB6437E042D5E4938454" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B1136CC640F19BD32DBC42D5E49403EA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B1136CC640F19BD32DBC42D5E49403EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_312673440D296193D9B442D5E494C278" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_312673440D296193D9B442D5E494C278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4724197F226F3D3B8F2842D5E494DDAA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4724197F226F3D3B8F2842D5E494DDAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_48D0B5EC182091F7CCF242D5E494AE21" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_48D0B5EC182091F7CCF242D5E494AE21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_471D4B870B8C2BB33CB142D5E4948F37" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_471D4B870B8C2BB33CB142D5E4948F37" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_C4ACF0F84D43E6BE29C842D5E494FC26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_7E066314E9EF070876A842D5E494AA6E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6AD9FF37949BE44CAB4442D5E493C566" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_7E066314E9EF070876A842D5E494AA6E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_52D45AEF1194AE189F0D29780D9A3BE9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_531D473CE40B871F5A4229780D9AB999" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52D45AEF1194AE189F0D29780D9A3BE9" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_531D473CE40B871F5A4229780D9AB999" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_A7050801E79A968C778329780D9AEC66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52D45AEF1194AE189F0D29780D9A3BE9" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_A7050801E79A968C778329780D9AEC66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ACDE92B09296A3ED6D0829780D9B505F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52D45AEF1194AE189F0D29780D9A3BE9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ACDE92B09296A3ED6D0829780D9B505F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D28FCF2ADACF58DCE06529780DEE0AEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1AFFC68EF4F264CFF65129780DEE029F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D28FCF2ADACF58DCE06529780DEE0AEC" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1AFFC68EF4F264CFF65129780DEE029F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_EE6495296BECFB911DA429780F798FDD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_EE6495296BECFB911DA429780F798FDD" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44" xlink:to="loc_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_7F720BFB161A22AB956F29780F79152B" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_9666A57449C4F5D99AC429780F79E0BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:to="loc_us-gaap_CommercialPaperMember_9666A57449C4F5D99AC429780F79E0BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_E7B1D9EBC0295B60EA8829780F7A2005" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_E7B1D9EBC0295B60EA8829780F7A2005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9F50748269D3799BF31729780F7AB5CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9F50748269D3799BF31729780F7AB5CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_80E76C5B0C6F9349678929780F7A0618" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_18A882E10DDEF8D067B629780F793019" xlink:to="loc_us-gaap_DebtSecuritiesMember_80E76C5B0C6F9349678929780F7A0618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_DC920C60E0709A5B817F29780F791C44" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F6CE28310C5789CB605729780F7A827E" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_00C05C84D8CA298EC46129780F7AE7FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_94653A91B18724CE58E429780F7A57C3" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_00C05C84D8CA298EC46129780F7AE7FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9B2ACAA0B94A5D7EA8C542D5E45EF611" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9B2ACAA0B94A5D7EA8C542D5E45EF611" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_917864A38E8F8F6E366942D5E45EA656" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_917864A38E8F8F6E366942D5E45EA656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_917864A38E8F8F6E366942D5E45EA656" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_3D3924E1ED471A2F0E5E42D5E45E21DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_9FCBAE8974FA23394D7F42D5E45EC15D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_7A2AF7AF0665938D202142D5E45E59E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_3CB2523FC2066B6F7C5942D5E45EA97C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6DEC129C0BD78900EE1342D5E45F6DD6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_34D5EE69C8106F389ADD42D5E45F4A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_2D3C2506C73380C66724438936B11134" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_308D3F9AFC2C2BB634BE42D5E45E34A5" xlink:to="loc_us-gaap_EquitySecuritiesMember_2D3C2506C73380C66724438936B11134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E3F74FCD370A3C39D19E42D5E45E9718" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4CF5286B142634C9FE7842D5E45FE437" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_F47BE740AC0EB3FA370842D5E45F66EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:to="loc_us-gaap_AvailableForSaleSecurities_F47BE740AC0EB3FA370842D5E45F66EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2877009FFDC6CAFAB6C542D5E45F6777" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2877009FFDC6CAFAB6C542D5E45F6777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AECFA319D6E1A4FE06F742D5E45F0B53" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AECFA319D6E1A4FE06F742D5E45F0B53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B2606C213A04AB69686442D5E45F2B38" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3579AEDEAC9A1A15CF2542D5E45F89F7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B2606C213A04AB69686442D5E45F2B38" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_6B5C6D0AD300DC24983829780E8B01B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_6B5C6D0AD300DC24983829780E8B01B8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8D93AFC5EE4CC005CBFB29780E8C67BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8D93AFC5EE4CC005CBFB29780E8C67BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0B6C2A46C28A71E3889429780E8CF293" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0B6C2A46C28A71E3889429780E8CF293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3F6A9EF9FE057462394429780E8C419A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3F6A9EF9FE057462394429780E8C419A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B4CFC891CA6FAC0946FC29780E8C1393" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B4CFC891CA6FAC0946FC29780E8C1393" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_039509697EB10B40002429780E8C5E1C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_039509697EB10B40002429780E8C5E1C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_D36B7EA677949B355A8829780E8C186A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_D36B7EA677949B355A8829780E8C186A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_E77F936D6E4670AF26AE29780E8C2BDE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:to="loc_us-gaap_AvailableForSaleSecurities_E77F936D6E4670AF26AE29780E8C2BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA638F5E35B070DCA61129780E8C2B40" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8FF95273CB25F85DC21329780E8B65AA" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA638F5E35B070DCA61129780E8C2B40" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_635A18EFE9378CE790BF29780EC2382D" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ProceedsFromMarketableDebtSecuritiesAbstract" xlink:label="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_635A18EFE9378CE790BF29780EC2382D" xlink:to="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_DC1B33D15A47F5695A2029780EC2901F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_DC1B33D15A47F5695A2029780EC2901F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_ABED15F7CA729599AB8829780EC278E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_ABED15F7CA729599AB8829780EC278E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_A6D67BC30418CE3AE43D29780EC244E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_BAE19D0ADDEABA64330F29780EC2A078" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_A6D67BC30418CE3AE43D29780EC244E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A401C70972C9A855875042C707F40C9B" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FinancialInstrumentsTextualAbstract" xlink:label="loc_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A401C70972C9A855875042C707F40C9B" xlink:to="loc_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_31A9DBC098E72BA9423E42C707F48E30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_31A9DBC098E72BA9423E42C707F48E30" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_F6280430D337B3BD313B42C707F4CAD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_9416999B2D0CD29B15FD42C707F4F5D1" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_F6280430D337B3BD313B42C707F4CAD1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_F1A495CC0608FD438F7229780FA33635" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8CA0300114B69849E09829780FA363C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_F1A495CC0608FD438F7229780FA33635" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8CA0300114B69849E09829780FA363C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8CA0300114B69849E09829780FA363C4" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_E80FDD4EABE83BFB8A1429780FA36B84" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED92AEBCEEDFE105A5C029780FA39BD0" xlink:to="loc_biib_StrategicInvestmentsMember_BD864264A8770D56618729780FA36558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_59D47673543B8A61AE8229780FA36C5D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8CA0300114B69849E09829780FA363C4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_59D47673543B8A61AE8229780FA36C5D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_59D47673543B8A61AE8229780FA36C5D" xlink:to="loc_biib_StrategicInvestmentPortfolio_E486FCB79E620EE6CDB229780FA3A25B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_72FE943CF6688F173D5529780DB844DC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_10B5EA596F9B4C1E9C9529780DB9EE06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_72FE943CF6688F173D5529780DB844DC" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_10B5EA596F9B4C1E9C9529780DB9EE06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_42050BBD022ABAEE8D6729780DB99F48" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_72FE943CF6688F173D5529780DB844DC" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_42050BBD022ABAEE8D6729780DB99F48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0ACCA60DC4211F11B37229780DB91365" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_72FE943CF6688F173D5529780DB844DC" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0ACCA60DC4211F11B37229780DB91365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DBD0604F7B5BF0B112B829780DB9A209" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_72FE943CF6688F173D5529780DB844DC" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DBD0604F7B5BF0B112B829780DB9A209" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="loc_us-gaap_GuaranteesAbstract_66A283201608A86DA17829780DE706CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GuaranteesTextBlock" xlink:label="loc_us-gaap_GuaranteesTextBlock_8D0CDA64CA664477EA5329780DE7BA64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteesAbstract_66A283201608A86DA17829780DE706CC" xlink:to="loc_us-gaap_GuaranteesTextBlock_8D0CDA64CA664477EA5329780DE7BA64" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_F1DCAF7169FF57EC086B4331A7B380BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_859D53528449E5BB95DC42D5E5567BAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_F1DCAF7169FF57EC086B4331A7B380BB" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_859D53528449E5BB95DC42D5E5567BAF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_BE2EAA3C56CE9A5852C643324108E8D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03A598384C7FFBF800F242D5E5514A46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_BE2EAA3C56CE9A5852C643324108E8D8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03A598384C7FFBF800F242D5E5514A46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E496BE01CEBA32245E0F42D5E551071B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03A598384C7FFBF800F242D5E5514A46" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E496BE01CEBA32245E0F42D5E551071B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_A6F154294BD75BEE2C7442D5E5514413" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E496BE01CEBA32245E0F42D5E551071B" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_A6F154294BD75BEE2C7442D5E5514413" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_BE5C1EB8F3656EB6197442D5E5518B2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_A6F154294BD75BEE2C7442D5E5514413" xlink:to="loc_biib_BioverativMember_BE5C1EB8F3656EB6197442D5E5518B2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03A598384C7FFBF800F242D5E5514A46" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_D48C12E2C39D4E487E7D42D5E551F6C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_D48C12E2C39D4E487E7D42D5E551F6C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CAF5F431480D67D00AFB42D5E5516025" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CAF5F431480D67D00AFB42D5E5516025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_10D7D3A4BFB770739DE942D5E551C519" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_10D7D3A4BFB770739DE942D5E551C519" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6299017F8A0526F5FB9A42D5E551AF4B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6299017F8A0526F5FB9A42D5E551AF4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_DCA9138E1BD27529066542D5E551EB75" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_DCA9138E1BD27529066542D5E551EB75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_88A08149AAAC1386B8F842D5E5525669" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_88A08149AAAC1386B8F842D5E5525669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_C781E102E590AA90C3A042D5E552E1A8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_C781E102E590AA90C3A042D5E552E1A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_FE4F69B12A33A397D75442D5E55220E7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_FE4F69B12A33A397D75442D5E55220E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_46763BBF412147FCF03D42D5E55275C2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_46763BBF412147FCF03D42D5E55275C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_5D541F7D784F051CEB1242D5E5523136" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_5D541F7D784F051CEB1242D5E5523136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_A574CD1414A2AF728B1042D5E5524187" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F755B6220A0D8D9FADC842D5E5514882" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_A574CD1414A2AF728B1042D5E5524187" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_E83482F61D49640D175943329FBB4C7B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_096EA2EDC86F9F8F384342D5E54C15C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_E83482F61D49640D175943329FBB4C7B" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_096EA2EDC86F9F8F384342D5E54C15C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_7B9B6420B318C0A75CA142D5E54C23A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_096EA2EDC86F9F8F384342D5E54C15C1" xlink:to="loc_us-gaap_ProductOrServiceAxis_7B9B6420B318C0A75CA142D5E54C23A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_69EA639C9C2BCEDA92E042D5E54C0FF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_7B9B6420B318C0A75CA142D5E54C23A8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_69EA639C9C2BCEDA92E042D5E54C0FF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_995A260148A344B0BE2D42D5E54C3254" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_69EA639C9C2BCEDA92E042D5E54C0FF2" xlink:to="loc_biib_HemophiliaProductsMember_995A260148A344B0BE2D42D5E54C3254" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_CDAB3B7B537F6AFC751F42D5E54CA865" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_096EA2EDC86F9F8F384342D5E54C15C1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_CDAB3B7B537F6AFC751F42D5E54CA865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DDC518F1D540E6A842E742D5E54C0443" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_CDAB3B7B537F6AFC751F42D5E54CA865" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DDC518F1D540E6A842E742D5E54C0443" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_0A6F461B8B3B360D8F5D42D5E54C9E88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DDC518F1D540E6A842E742D5E54C0443" xlink:to="loc_biib_BioverativMember_0A6F461B8B3B360D8F5D42D5E54C9E88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42F3DB70253D8546758A42D5E54C7DDA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_096EA2EDC86F9F8F384342D5E54C15C1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42F3DB70253D8546758A42D5E54C7DDA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TermofBioverativTransactionServicesAgreement" xlink:label="loc_biib_TermofBioverativTransactionServicesAgreement_A46A9A7C6FA30FC7730C42D5E54CDB98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42F3DB70253D8546758A42D5E54C7DDA" xlink:to="loc_biib_TermofBioverativTransactionServicesAgreement_A46A9A7C6FA30FC7730C42D5E54CDB98" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TermofBioverativManufacturingandSupplyAgreement" xlink:label="loc_biib_TermofBioverativManufacturingandSupplyAgreement_3221BF79FAE350A9302042D5E54DB8E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42F3DB70253D8546758A42D5E54C7DDA" xlink:to="loc_biib_TermofBioverativManufacturingandSupplyAgreement_3221BF79FAE350A9302042D5E54DB8E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_BEBB85FDB65E56C6F58E42D5E54D46BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42F3DB70253D8546758A42D5E54C7DDA" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_BEBB85FDB65E56C6F58E42D5E54D46BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_DD60D32D9D054B16E71542D5E54C06B4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42F3DB70253D8546758A42D5E54C7DDA" xlink:to="loc_us-gaap_OtherSalesRevenueNet_DD60D32D9D054B16E71542D5E54C06B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_46B0E6F5B99DECA964CA42D5E54D9D14" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42F3DB70253D8546758A42D5E54C7DDA" xlink:to="loc_us-gaap_CostOfGoodsSold_46B0E6F5B99DECA964CA42D5E54D9D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7B0995AA2B6828AC916B42D5E54DFB56" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42F3DB70253D8546758A42D5E54C7DDA" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_7B0995AA2B6828AC916B42D5E54DFB56" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B65B8000D63A2F74BBF64331EFF1A3EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_B73F108CA23AB48FB71E42D5E554AF83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B65B8000D63A2F74BBF64331EFF1A3EB" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_B73F108CA23AB48FB71E42D5E554AF83" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_78433662DD619533A3E729780F507AD9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_41E98E91B2957D5B683629780F50FC28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78433662DD619533A3E729780F507AD9" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_41E98E91B2957D5B683629780F50FC28" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A9B042550C4A37D7BEAE29780E95EF1D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_2646B489F52E7277C69A29780E95C90A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A9B042550C4A37D7BEAE29780E95EF1D" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_2646B489F52E7277C69A29780E95C90A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_851B7E2CB33F705A5D6B29780E95E8B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_2646B489F52E7277C69A29780E95C90A" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_851B7E2CB33F705A5D6B29780E95E8B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2FC40063F706ED8F564F29780E95E3DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_851B7E2CB33F705A5D6B29780E95E8B6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2FC40063F706ED8F564F29780E95E3DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89949E504C912CD0C74C29780E95B283" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_851B7E2CB33F705A5D6B29780E95E8B6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89949E504C912CD0C74C29780E95B283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_846A4CACE34A952CAE2729780E9545A3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_851B7E2CB33F705A5D6B29780E95E8B6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_846A4CACE34A952CAE2729780E9545A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_A327C1864ED3C81E8F7D29780E966963" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_2646B489F52E7277C69A29780E95C90A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_A327C1864ED3C81E8F7D29780E966963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_A327C1864ED3C81E8F7D29780E966963" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_F116A71F680ACCA037D929780E96F572" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_F116A71F680ACCA037D929780E96F572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_DAF3C3EBAF0D26B2492E29780E96EA2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_DAF3C3EBAF0D26B2492E29780E96EA2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_C96A76AC4AC20561F4A429780E96AA17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_C96A76AC4AC20561F4A429780E96AA17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_523C44148697A23233FD29780E96BABC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_949DAC6F2F7A7EA9BEFF29780E96AB7B" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_523C44148697A23233FD29780E96BABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_A327C1864ED3C81E8F7D29780E966963" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_B909F11E2BAB0F1C2B0D29780E9699F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_B909F11E2BAB0F1C2B0D29780E9699F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A94BD9DEB56641D7FDF629780E960449" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A94BD9DEB56641D7FDF629780E960449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AB692503EB6263862D0029780E97B2ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_AB692503EB6263862D0029780E97B2ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_985465D308584FECA43129780E970C2C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8F8E7B0188B948E0B30329780E9639F8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_985465D308584FECA43129780E970C2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CDAAB56FD6AECAB896EC29780E973A98" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_2646B489F52E7277C69A29780E95C90A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_CDAAB56FD6AECAB896EC29780E973A98" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B30A9DE461C0D0179AE129780EB93C10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B30A9DE461C0D0179AE129780EB93C10" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_F5AC66CC9D599748D1A729780EB97783" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_F5AC66CC9D599748D1A729780EB97783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_0089ACBDBC7D3E79563929780EB983AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_0089ACBDBC7D3E79563929780EB983AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5D6EE2B0909ADFEE4CC029780EB933E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5D6EE2B0909ADFEE4CC029780EB933E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A571F33EA8930D262BA529780EB9E9B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A571F33EA8930D262BA529780EB9E9B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_25763347D6D3D85E26B729780EB9D426" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_25763347D6D3D85E26B729780EB9D426" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_7AB1C9DE75E94B234DC729780EB99E4B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_7AB1C9DE75E94B234DC729780EB99E4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_57451C1F3F5FF529F43B29780EB98A95" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_57451C1F3F5FF529F43B29780EB98A95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_FC19DF377DFD9D978F6A29780EB941BC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_FC19DF377DFD9D978F6A29780EB941BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_DDFA8EA2873AEA37E55729780EBA560B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_DDFA8EA2873AEA37E55729780EBA560B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_DB3C6A94B0AE9BB802CE29780EBAF397" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:to="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_DB3C6A94B0AE9BB802CE29780EBAF397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_BE8FCD3E12B093B9F91129780EBAF726" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_622CDAEDE2C33639E79C29780EB98C62" xlink:to="loc_us-gaap_DeferredTaxLiabilities_BE8FCD3E12B093B9F91129780EBAF726" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CD21B8FC89EE69FEBAE1486D5C480BB3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CD21B8FC89EE69FEBAE1486D5C480BB3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_98CE3B3FA09A6BFBF3EA486D5C481546" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_98CE3B3FA09A6BFBF3EA486D5C481546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_06EF11A6B4ACF68E165B486D5C482153" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_06EF11A6B4ACF68E165B486D5C482153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4115116CBC1128101DB3486D5C48AFC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4115116CBC1128101DB3486D5C48AFC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_59E31BC8DB8C0DEA4752486D5C49BC78" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_59E31BC8DB8C0DEA4752486D5C49BC78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_FEE3F5F5070F9EEBE2D9486D5C49D7D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_FEE3F5F5070F9EEBE2D9486D5C49D7D7" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4AECD495E0C803455470486D5C498B57" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4AECD495E0C803455470486D5C498B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9EA39E3CB42EB9F768D8486D5C494CCD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9EA39E3CB42EB9F768D8486D5C494CCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_23DC652CD706492202A2486D5C492384" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_23DC652CD706492202A2486D5C492384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2567DF6A24D5EDC62399486D5C4EC86A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2567DF6A24D5EDC62399486D5C4EC86A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4CC7A88FFAED17D5237A4881C7AAAD4A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4CC7A88FFAED17D5237A4881C7AAAD4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FD7CFFAA894762A58499486D5C4EDDEB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_EC8D965A9C782BF14CC7486D5C48EE25" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FD7CFFAA894762A58499486D5C4EDDEB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FE8C1D5FDDA001DB5E43430791053004" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FE8C1D5FDDA001DB5E43430791053004" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_FF6965FB5BFF4D30F945430791055099" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_FF6965FB5BFF4D30F945430791055099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23B8031CCB9D0548F12443079105901A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23B8031CCB9D0548F12443079105901A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C1CF387BC294644738F9430791058052" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C1CF387BC294644738F9430791058052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B99E7986E06A1762DF41430791058A25" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B99E7986E06A1762DF41430791058A25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B87057D34A8AC8C2D62B43079105207B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B87057D34A8AC8C2D62B43079105207B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1D85534625F3029D87B143079105AB80" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1D85534625F3029D87B143079105AB80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_54EBAC3E43EA76C0330643079105898E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_578CAEC18656BE89035B430791057087" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_54EBAC3E43EA76C0330643079105898E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3C151A38C5D36A16470A486D5C021B71" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3C151A38C5D36A16470A486D5C021B71" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignearningstypeAxis" xlink:label="loc_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:to="loc_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeAxis_47E9313F10FD9B0FF9F8486D5C03F3F8" xlink:to="loc_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:to="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_AC82273EA4D314D3C198486D5C08EA82" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_OtherForeignEarningsMember" xlink:label="loc_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeDomain_796C171776F905561F81486D5C03568E" xlink:to="loc_biib_OtherForeignEarningsMember_D9996412EA0CC63C0BD5486D5C0840A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_25E6307A36935667C706486D5C08ABED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_25E6307A36935667C706486D5C08ABED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_696C08A0CC1FE98725A8486D5C0823C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_25E6307A36935667C706486D5C08ABED" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_696C08A0CC1FE98725A8486D5C0823C3" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PrepaidtaxesMember" xlink:label="loc_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_696C08A0CC1FE98725A8486D5C0823C3" xlink:to="loc_biib_PrepaidtaxesMember_9C019B74D2050108C31D486D5C08A388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_3748DA4BB4AF7F4BA0B5486D5C096DE3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_696C08A0CC1FE98725A8486D5C0823C3" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_3748DA4BB4AF7F4BA0B5486D5C096DE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6D35053DF9C9904A9A05486D5C09C4FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_696C08A0CC1FE98725A8486D5C0823C3" xlink:to="loc_us-gaap_RetainedEarningsMember_6D35053DF9C9904A9A05486D5C09C4FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1848A073555AA6A135A6486D5C09FC12" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_1F2D37091EEC0A6C7F55486D5C09321E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:to="loc_us-gaap_GeneralBusinessMember_1F2D37091EEC0A6C7F55486D5C09321E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_5B751544495326B9ADC4486D5C0991DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_77537214EE1460ADCA78486D5C09B692" xlink:to="loc_us-gaap_ResearchMember_5B751544495326B9ADC4486D5C0991DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_83AA48419CBD3391807C486D5C09D8B3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_83AA48419CBD3391807C486D5C09D8B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_83AA48419CBD3391807C486D5C09D8B3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_10CDA9A9B01FC8703A52486D5C098E01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7" xlink:to="loc_biib_U.S.2017TaxActMember_10CDA9A9B01FC8703A52486D5C098E01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_B2E379A69A99795555F3486D5C0914ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7" xlink:to="loc_us-gaap_DomesticCountryMember_B2E379A69A99795555F3486D5C0914ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_AB7E0816881CD20BA27A486D5C0E2737" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_AB7E0816881CD20BA27A486D5C0E2737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_F1C787452262C6650ADF486D5C0E73BE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_639B17CB61979AC77653486D5C0938E7" xlink:to="loc_us-gaap_ForeignCountryMember_F1C787452262C6650ADF486D5C0E73BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7FE4A7AFBF205A8E40AC486D5C033205" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33EF309FA91CD1A2B3344898361EDE9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33EF309FA91CD1A2B3344898361EDE9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5A65D8727E3261C85D46486D5C0F1D68" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5A65D8727E3261C85D46486D5C0F1D68" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TransitionTollTaxRepatriationTaxRate" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_biib_TransitionTollTaxRepatriationTaxRate_F9FFAE7070802819791C486D5C10932B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_AC26CD60CEDF567946DC489EA24247DD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_AC26CD60CEDF567946DC489EA24247DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossCurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_361172A4A802C733543B486D5C107FDB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_361172A4A802C733543B486D5C107FDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_422FC84C3AE2DE08DC7C486D5C15011D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_422FC84C3AE2DE08DC7C486D5C15011D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_D36257598F6F35767B69486D5C0FD1B3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_D36257598F6F35767B69486D5C0FD1B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_DA02E2147C85E203822C486D5C15D177" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_DA02E2147C85E203822C486D5C15D177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_E234D8AD9B4992888C3F486D5C0F0E69" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_OperatingLossCarryforwards_E234D8AD9B4992888C3F486D5C0F0E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_435BEE37D6492E3CA4EA486D5C0F2F3A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_435BEE37D6492E3CA4EA486D5C0F2F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_159407AE2106846C0014486D5C0F84F9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_159407AE2106846C0014486D5C0F84F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_A32B7EB823F1D687343E486D5C0F029C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5D37ADDF6AFD79956DD3486D5C0F5295" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_A32B7EB823F1D687343E486D5C0F029C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IncomeTaxesTextualAbstract" xlink:label="loc_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3C151A38C5D36A16470A486D5C021B71" xlink:to="loc_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Totaldeferredchargesandprepaidtaxes" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_5D31B949967D92320C0E486D5C1545F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:to="loc_biib_Totaldeferredchargesandprepaidtaxes_5D31B949967D92320C0E486D5C1545F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_0FD17E9E89C94D46421C486D5C15473F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_0FD17E9E89C94D46421C486D5C15473F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95CB868D5B78E1765311486D5C15DD17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95CB868D5B78E1765311486D5C15DD17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_76B08A55556B05D4830F486D5C1665DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_76B08A55556B05D4830F486D5C1665DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_DA298946F894A915224B486D5C16C327" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_09F59EB3DB62987E5C6C486D5C154DD8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_DA298946F894A915224B486D5C16C327" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_53D3D78069B8809CD2C929781058B11D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0AB5F4BF5AC2C8E37E812978105853DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_53D3D78069B8809CD2C929781058B11D" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0AB5F4BF5AC2C8E37E812978105853DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_24D22210BC5473293A2C29781059B05D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_53D3D78069B8809CD2C929781058B11D" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_24D22210BC5473293A2C29781059B05D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_51BA099215807AC5094229781059CAB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_53D3D78069B8809CD2C929781058B11D" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_51BA099215807AC5094229781059CAB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CD1263A8EFC826D641CC297810591734" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_53D3D78069B8809CD2C929781058B11D" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_CD1263A8EFC826D641CC297810591734" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_29E76A7FE4CA70E9832029780EE401AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_250D0CC338ECB51B992329780EE4E134" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_29E76A7FE4CA70E9832029780EE401AF" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_250D0CC338ECB51B992329780EE4E134" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_B72FD475B510C5D0DD4B43A9429B9EEA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7BDDB06058B3F39EFDB543A9429B034F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_B72FD475B510C5D0DD4B43A9429B9EEA" xlink:to="loc_us-gaap_DebtInstrumentTable_7BDDB06058B3F39EFDB543A9429B034F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_04392D27772F73E4014243A9429B1F94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7BDDB06058B3F39EFDB543A9429B034F" xlink:to="loc_us-gaap_DebtInstrumentAxis_04392D27772F73E4014243A9429B1F94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_04392D27772F73E4014243A9429B1F94" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_0E02F5ACA9734DBB36BA43AA1DC60470" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_0E02F5ACA9734DBB36BA43AA1DC60470" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_78947E15ECA86F81F29643A9429C056E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_78947E15ECA86F81F29643A9429C056E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_D4CCE350BA7B2C8F495743A9429C017D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_D4CCE350BA7B2C8F495743A9429C017D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_01E2CD6F1D87D2A6A85743A9429C3D66" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_01E2CD6F1D87D2A6A85743A9429C3D66" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C13948B9A0A32835B49D43A9429CBB70" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C13948B9A0A32835B49D43A9429CBB70" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DA10093B86A46CD31E1143A9429CE668" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A4B0921785D564CE35543A9429C7252" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DA10093B86A46CD31E1143A9429CE668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_EBF7867D832D1AA69D8E43A9429C58DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7BDDB06058B3F39EFDB543A9429B034F" xlink:to="loc_us-gaap_DebtInstrumentLineItems_EBF7867D832D1AA69D8E43A9429C58DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EBF7867D832D1AA69D8E43A9429C58DC" xlink:to="loc_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_9AF0D8EFD69E3FE1496E43A9429DE34C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:to="loc_us-gaap_NotesPayableCurrent_9AF0D8EFD69E3FE1496E43A9429DE34C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_27EAFBA46F5D39D91E8B43A9429FE9F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_27EAFBA46F5D39D91E8B43A9429FE9F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_AA0CA043F503AF3CEE2643A9429FE5BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_CF3A9E55543FCF1F6AE943A9429D6D29" xlink:to="loc_us-gaap_DebtCurrent_AA0CA043F503AF3CEE2643A9429FE5BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EBF7867D832D1AA69D8E43A9429C58DC" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_5EE3852E2A1FA6150BD443A9429FE1D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:to="loc_us-gaap_LongTermNotesPayable_5EE3852E2A1FA6150BD443A9429FE1D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_A722BB9D056786161BC543A942A040DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_A722BB9D056786161BC543A942A040DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_3308D56009FC67404AD443A942A04462" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_B1A5238495D1CB30EF1143A9429FA020" xlink:to="loc_us-gaap_LongTermDebt_3308D56009FC67404AD443A942A04462" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_C0A903A9ECF18DF8C224328B3CB1A582" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C0A903A9ECF18DF8C224328B3CB1A582" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_C141BED1E8A7179BBAF8328B3CB1E003" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_C141BED1E8A7179BBAF8328B3CB1E003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_15F881AE2277AB69338732A6DEA31D67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_15F881AE2277AB69338732A6DEA31D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7CDF293472BD63870F7732A7557DC20E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7CDF293472BD63870F7732A7557DC20E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C4E87C4598E3A503B9F832A7D5996D8D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C4E87C4598E3A503B9F832A7D5996D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_63D28D3D8604BEDC8B2432A9E1126362" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_63D28D3D8604BEDC8B2432A9E1126362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_C152D8A645566B9B7719328B3CB1DBFF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_C152D8A645566B9B7719328B3CB1DBFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_9D6EC60343C0774FFB25328B3CB20EB8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_F7A34B16525E7AAD7231328B3CB16C45" xlink:to="loc_us-gaap_LongTermNotesPayable_9D6EC60343C0774FFB25328B3CB20EB8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1BB361DEAB255DC9E0B043A944232442" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1BB361DEAB255DC9E0B043A944232442" xlink:to="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_89EF28403E8ED850188F43A944248189" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_89EF28403E8ED850188F43A944248189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59B79265CF4F7B26CE0C43A94424D88E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89EF28403E8ED850188F43A944248189" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59B79265CF4F7B26CE0C43A94424D88E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59B79265CF4F7B26CE0C43A94424D88E" xlink:to="loc_biib_EisaiMember_65A8108F3DE4B533DB2343A9442471F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_C796D1E00643A8A7B6AA43A94424A3E0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_B648CB147DD20724158543A944252B61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F77E11537CAFC0C1035F43A94425D34D" xlink:to="loc_us-gaap_InterestRateSwapMember_B648CB147DD20724158543A944252B61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:to="loc_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_EFEE10EEF6193103A19A43A944251113" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CDFF3E4B1D219B66C8CD43A944253579" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_12D4BDAF589352C7839D43A94425D720" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4111BEC4A7E6C236AAC43A94425C4F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E89D5B5E0986FC31B17A43A944253343" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1BC718347C257EC777E143A94425FA53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_994C8A8813303C4106EC43A94425E000" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C759A8A3EF5E08FFBB1E43A944255A09" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_994C8A8813303C4106EC43A94425E000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_84B45084E47A1D310C4043A9442442D4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F7D67E032951858E6C2443A94425C535" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F7D67E032951858E6C2443A94425C535" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_08C8B20C835E0A2DABD943A944269F22" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IncreasedCarryingAmountOfSeniorNotes" xlink:label="loc_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_biib_IncreasedCarryingAmountOfSeniorNotes_D7A53C0C335426F0A7BD43A9442617B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_8B5420A6D6ADEE58998143A9442698A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_8B5420A6D6ADEE58998143A9442698A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_C816B31F2BED1D6A01A043A94426F83F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_C816B31F2BED1D6A01A043A94426F83F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_11F3CDDDCF6ED2FF33B043A944252F62" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_11F3CDDDCF6ED2FF33B043A944252F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_A6B2DCC0FDB6073A30E943A9442683D8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_A6B2DCC0FDB6073A30E943A9442683D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_D506D90311AE2923A59543A944269810" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_D506D90311AE2923A59543A944269810" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E85F6FFFD858D4E1F9FF43A94426C84B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7DCC68D62D0F5D0CD03E43A944268762" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7DCC68D62D0F5D0CD03E43A944268762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_33FDC3002AC396F3BE4743A9442657D6" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_LongTermNotesPayable_33FDC3002AC396F3BE4743A9442657D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ParValueOfNotesPayable" xlink:label="loc_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_biib_ParValueOfNotesPayable_239F292CA7AB28D422B143A944268AE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1B98A454C99A3B93081C43A944265742" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1B98A454C99A3B93081C43A944265742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_C6EB75A3E7ADB889F4F043A944260767" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_C6EB75A3E7ADB889F4F043A944260767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0DF59CA91FAA7C2B1D0743A944265AC8" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0DF59CA91FAA7C2B1D0743A944265AC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_CB2BBB61BD5EF57E86EB43A94427B4EB" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_06999E180A7D90553BDB43A94425E9FD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_CB2BBB61BD5EF57E86EB43A94427B4EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_81865869DF1F67CE273A29780E099F56" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_241ED74C3734CDAED53C29780E092114" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_81865869DF1F67CE273A29780E099F56" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_241ED74C3734CDAED53C29780E092114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_21DC11B03523603D59B629780E09C923" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_81865869DF1F67CE273A29780E099F56" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_21DC11B03523603D59B629780E09C923" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C6477F6F6817266935C029780F333638" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_325F6B948BDC61BB3BF329780F3331C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C6477F6F6817266935C029780F333638" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_325F6B948BDC61BB3BF329780F3331C3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B55FA9075B1EABA039564311A51A9560" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B55FA9075B1EABA039564311A51A9560" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_60E26F71ACAF096C15CE4311A51ACAC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:to="loc_us-gaap_ProductOrServiceAxis_60E26F71ACAF096C15CE4311A51ACAC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_60E26F71ACAF096C15CE4311A51ACAC5" xlink:to="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:to="loc_biib_AVONEXMember_90BAFA009F61B41A75974311A51AE892" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:to="loc_biib_TysabriProductMember_A8B291A0EDC30FC450524311A51BC4D0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_DC0139C8B006A35F45A64311A51BF402" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:to="loc_biib_SPINRAZAMember_DC0139C8B006A35F45A64311A51BF402" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:to="loc_biib_BiosimilarsMember_B6EF8657A0B38D5583DE4311A51B2E92" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:to="loc_biib_ZINBRYTAMember_CFE025B11DFA1CEE7FF54311A51BB2E1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_56A27453DD93D03020004311A51B7C0D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_993F4DB343567544A6844311A51A234F" xlink:to="loc_biib_TecfideraMember_56A27453DD93D03020004311A51B7C0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_D7214A2BDA8FAF2A0B304311A51BBCD0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_A5C84CDB29AA3B6CC2444311A51BA454" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_A5C84CDB29AA3B6CC2444311A51BA454" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_4D64627D5C191E8D42A44311A51BEF67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_CEA4336769A981246FFC4311A51BFC9B" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_4D64627D5C191E8D42A44311A51BEF67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_915511205C27ABCEAFC64311A51B71B3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:to="loc_biib_OutLicensedPatentsMember_2952B82263F0972575FA4311A51B60AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_83606C2E54DCA596926B4311A51BBFCD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_83606C2E54DCA596926B4311A51BBFCD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C971BD19A000CCDEAE0F4311A51B28D8" xlink:to="loc_biib_InLicensedPatentsMember_5D4EFB18D883500C65724311A51BBAC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_0ADDE484F2DA9763ED154311A51B8B02" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:to="loc_us-gaap_RangeAxis_0ADDE484F2DA9763ED154311A51B8B02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_57926961C69C28C8A6D44311A51CD4AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_0ADDE484F2DA9763ED154311A51B8B02" xlink:to="loc_us-gaap_RangeMember_57926961C69C28C8A6D44311A51CD4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_223442E5926741A2DCF14311A51C3542" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_57926961C69C28C8A6D44311A51CD4AC" xlink:to="loc_us-gaap_MinimumMember_223442E5926741A2DCF14311A51C3542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_09B223B77B7B0AE0D8F44311A51C7ADE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_57926961C69C28C8A6D44311A51CD4AC" xlink:to="loc_us-gaap_MaximumMember_09B223B77B7B0AE0D8F44311A51C7ADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5F38D0BC797263A367174311A51A10CC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2915C3EE8BFE69F5CA854311A51CC26B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2915C3EE8BFE69F5CA854311A51CC26B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_6A11EA15159E86FF04CD4311A51C1CC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8E32E7757DFFBCFB1C424311A51CE3E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8E32E7757DFFBCFB1C424311A51CE3E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_94969B9591BAF84FE3E04311A51C9419" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_94969B9591BAF84FE3E04311A51C9419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D131161F7538C0D3AF84311A51CC224" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D131161F7538C0D3AF84311A51CC224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_A364197675100F073F884311A51C46E2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_A364197675100F073F884311A51C46E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_73B436F0E66466C78E324311A51C8AF0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_73B436F0E66466C78E324311A51C8AF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD71245517F7A5A3279C4311A51C31FF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_328D4D4E2A24EB95A3134311A51CB12C" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD71245517F7A5A3279C4311A51C31FF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6346F2C4FD957CDD8E5F4311A51DDCBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6346F2C4FD957CDD8E5F4311A51DDCBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_00DFA28AD59E528A481B4311A51D5D2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_00DFA28AD59E528A481B4311A51D5D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54C8CB51977F760122364311A51DA2EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54C8CB51977F760122364311A51DA2EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D22C4620967C7AD2C5E44311A51DE6B0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D22C4620967C7AD2C5E44311A51DE6B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_572CD81D7087831309024311A51D3061" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_FDD05A90E876FEEA89A14311A51C8356" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_572CD81D7087831309024311A51D3061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4D8EEE8E6F9AAA57FBE24311A51D91CB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4D8EEE8E6F9AAA57FBE24311A51D91CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0A03DDD30513AB04F06A4311A51D8029" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0A03DDD30513AB04F06A4311A51D8029" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4DECF4267B336476D6B74311A51DA3FD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4DECF4267B336476D6B74311A51DA3FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3BF24D6BC9937D9E02DB4311A51DDE5A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3BF24D6BC9937D9E02DB4311A51DDE5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_617A777EDE7ED37FDFFF4311A51DFA17" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0808DBDB9AD2DD5812434311A51CE1F3" xlink:to="loc_us-gaap_LitigationSettlementExpense_617A777EDE7ED37FDFFF4311A51DFA17" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ACC1C28B5069435C73BE4311A50E5C6D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ACC1C28B5069435C73BE4311A50E5C6D" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A43182CAE326E6DB981E4311A50E250F" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3CDC7F07189816B727DB4311A50E93A1" xlink:to="loc_biib_BioverativMember_FECBC03FE861E59D8C174311A50E598B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CA24E06156652CBFEB604311A50E5581" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CA24E06156652CBFEB604311A50E5581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2C84BDBDB129107E38814311A50E7396" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CA24E06156652CBFEB604311A50E5581" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2C84BDBDB129107E38814311A50E7396" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2C84BDBDB129107E38814311A50E7396" xlink:to="loc_biib_FumapharmAgMember_F4ACA1C2ECBFD2EA3A5F4311A50F9A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_8371F932CF4E75ABB5DB4311A50FD53F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:to="loc_us-gaap_ProductOrServiceAxis_8371F932CF4E75ABB5DB4311A50FD53F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_5746CED05F055D015EFA4311A50F17D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_8371F932CF4E75ABB5DB4311A50FD53F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_5746CED05F055D015EFA4311A50F17D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_FE69F127B55BF81EEC994311A50FBD6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_5746CED05F055D015EFA4311A50F17D1" xlink:to="loc_biib_TecfideraMember_FE69F127B55BF81EEC994311A50FBD6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5F610621696C0F6A58F44311A50EA522" xlink:to="loc_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_28AB1D89AEC10680D7074311A50FD1CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_28AB1D89AEC10680D7074311A50FD1CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A7C9CEB87B3313711A4C4311A50F538B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_A7C9CEB87B3313711A4C4311A50F538B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EC8A2FB671F4DC45DF34311A50F9514" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7BAB9B773BC6F30843E94311A50FBA43" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EC8A2FB671F4DC45DF34311A50F9514" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ACC1C28B5069435C73BE4311A50E5C6D" xlink:to="loc_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_A2E683CBA3315338D8704311A50F48DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6" xlink:to="loc_us-gaap_Goodwill_A2E683CBA3315338D8704311A50F48DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E1CCC9C1E92938C5CF394311A50F36F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_E1CCC9C1E92938C5CF394311A50F36F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_BBBF2D3A9DE26B0CD0BE4311A50FFCEB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_BBBF2D3A9DE26B0CD0BE4311A50FFCEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_54F5306F95AD1B22AD994311A510F12B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_EFA1F3D74A998D39ED714311A50F8AD6" xlink:to="loc_us-gaap_Goodwill_54F5306F95AD1B22AD994311A510F12B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8C6F1FD365D2310D0C5929780DA33D00" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_0D290B1F74E99641CF0F29780DA3EA89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8C6F1FD365D2310D0C5929780DA33D00" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_0D290B1F74E99641CF0F29780DA3EA89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_62650E53009B1488E5FB29780DA32125" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8C6F1FD365D2310D0C5929780DA33D00" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_62650E53009B1488E5FB29780DA32125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_0CE270FC47C8542CD26E29780DA35B2C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8C6F1FD365D2310D0C5929780DA33D00" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_0CE270FC47C8542CD26E29780DA35B2C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0D50DE037D2FBBBEE6E029780F57A116" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_331F8E152C697EE221E729780F57E3D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0D50DE037D2FBBBEE6E029780F57A116" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_331F8E152C697EE221E729780F57E3D2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_B28C9640D327491429C729780F5428C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B28C9640D327491429C729780F5428C1" xlink:to="loc_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6605733F5E5F20085AF329780F548128" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6605733F5E5F20085AF329780F548128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_B8727026BF70F6C6DEA329780F54EC83" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_B8727026BF70F6C6DEA329780F54EC83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_76CDAE75558AA78DA45C29780F5419FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_76CDAE75558AA78DA45C29780F5419FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_A5F28BAEB8EA853EFC0329780F5459C9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_698AFA220879B97EB49729780F54884A" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_A5F28BAEB8EA853EFC0329780F5459C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_A65BBC3EB36942D18AFF29780F546988" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B28C9640D327491429C729780F5428C1" xlink:to="loc_us-gaap_InventoryNet_A65BBC3EB36942D18AFF29780F546988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_F6B710D31F5B4766BDED29780F541192" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B28C9640D327491429C729780F5428C1" xlink:to="loc_us-gaap_InventoryNoncurrent_F6B710D31F5B4766BDED29780F541192" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_405237423323DBC909644311A523B862" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_405237423323DBC909644311A523B862" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_B817EBBB6DCB8A8794764311A52340D3" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:to="loc_biib_WorkinprocessMember_5BF3B549BC7E6E8C1D934311A523ACAA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FinishedGoodsMember" xlink:label="loc_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4503932D41E736E9774F4311A523C7E7" xlink:to="loc_biib_FinishedGoodsMember_9E2FFCA22DB6FFECE5544311A523AD49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6250913748BFF20F6AB34311A523B27E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6250913748BFF20F6AB34311A523B27E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_886066634A2BC95EECB74311A5232765" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6250913748BFF20F6AB34311A523B27E" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_886066634A2BC95EECB74311A5232765" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_4286B69EDCADE88C57EA4311A523BCBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_886066634A2BC95EECB74311A5232765" xlink:to="loc_biib_BioverativMember_4286B69EDCADE88C57EA4311A523BCBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_CB83455F07F5BAFDAD6D4311A5238B8C" xlink:to="loc_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3326613D067D5043BB54311A52493FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_8551F003DAFCA2A950164311A524D0C7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3326613D067D5043BB54311A52493FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_B26A74FE1E8868C1BD2B4311A524D216" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_405237423323DBC909644311A523B862" xlink:to="loc_us-gaap_InventoryWriteDown_B26A74FE1E8868C1BD2B4311A524D216" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3790CE6298D254036ED529780EF53394" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_77DDFA8F05FEFD6C654D29780EF534D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3790CE6298D254036ED529780EF53394" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_77DDFA8F05FEFD6C654D29780EF534D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:href="biib-20171231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_635604F330654AF1D6DF29780E573BEF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_33F0BEE46890CA85B89829780E57D96B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_635604F330654AF1D6DF29780E573BEF" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_33F0BEE46890CA85B89829780E57D96B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20171231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_5D6F65C199E33292C90E48F12BEE55A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_5D6F65C199E33292C90E48F12BEE55A9" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_BEACBFB021A312FF84C448F12BEE0DA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_BEACBFB021A312FF84C448F12BEE0DA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_090A381F75B1BFFB229148F12BEED18E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_BEACBFB021A312FF84C448F12BEE0DA8" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_090A381F75B1BFFB229148F12BEED18E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_61AEA92B59944FF779D048F12BEEF0F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_090A381F75B1BFFB229148F12BEED18E" xlink:to="loc_biib_NeurimmuneMember_61AEA92B59944FF779D048F12BEEF0F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_D854192B85318765561B48F12BEE2D2F" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_900F335EBBF2F034419248F12BEE9CAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_900F335EBBF2F034419248F12BEE9CAD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_A5F86C446B53C681AEAF48F12BEED1C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_A5F86C446B53C681AEAF48F12BEED1C1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_71940A8EBF7B56BBBCAC48F12BEF306D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AdditionalPotentialPaymentstoNoncontrollingInterest" xlink:label="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:to="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_1D6D54929549CF7E805548F12BEF85EF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6B007B6DA330B8429F5248F12BEEBCE5" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:to="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_C830416C5CA8726248B848F12BEF715F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_FCE03111B2292BE4777648F12BEF81D6" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_DC05736163BB28F725F548F12BEF7023" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_BA6DDFAB03881C1EA62B2978104657D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_938BE22356DCDAD2D35C297810460A8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_BA6DDFAB03881C1EA62B2978104657D5" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_938BE22356DCDAD2D35C297810460A8D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BEB197D76389241F396A29780E90E982" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_FAE966769938F600D7D629780E90184C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BEB197D76389241F396A29780E90E982" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_FAE966769938F600D7D629780E90184C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17DD83D461567B9EE9CE48EF3C710234" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_48C0398754E67D0990EF48EF3C720359" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17DD83D461567B9EE9CE48EF3C710234" xlink:to="loc_us-gaap_StatementTable_48C0398754E67D0990EF48EF3C720359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5DA9B07CCE9BA6CA9B8448EF3C72AC62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48C0398754E67D0990EF48EF3C720359" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5DA9B07CCE9BA6CA9B8448EF3C72AC62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3616E362C47F1A1E8E8148EF3C7230D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5DA9B07CCE9BA6CA9B8448EF3C72AC62" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3616E362C47F1A1E8E8148EF3C7230D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_4FDE05A4F9E02CBF8F8348EF3C736A43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3616E362C47F1A1E8E8148EF3C7230D4" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_4FDE05A4F9E02CBF8F8348EF3C736A43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A7B5F00662800B03CA2B48EF3C7321C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48C0398754E67D0990EF48EF3C720359" xlink:to="loc_us-gaap_StatementLineItems_A7B5F00662800B03CA2B48EF3C7321C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_D9B075179052E16D9CC548EF3C73AC9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A7B5F00662800B03CA2B48EF3C7321C9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_D9B075179052E16D9CC548EF3C73AC9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_298E84494373A0D5EF3D48EF3C730223" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17DD83D461567B9EE9CE48EF3C710234" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_298E84494373A0D5EF3D48EF3C730223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_124DC46ED582F34CC24E48EF3C73A25F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_298E84494373A0D5EF3D48EF3C730223" xlink:to="loc_us-gaap_InterestPaidNet_124DC46ED582F34CC24E48EF3C73A25F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_5BC808695BA6C5BBE8F048EF3C73EEDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_298E84494373A0D5EF3D48EF3C730223" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_5BC808695BA6C5BBE8F048EF3C73EEDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D" xlink:type="locator" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17DD83D461567B9EE9CE48EF3C710234" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_BEE433BCD875D85972D848EF3C7357B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D" xlink:to="loc_us-gaap_InvestmentIncomeInterest_BEE433BCD875D85972D848EF3C7357B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4DD9B863E411B786E2D448EF3C735868" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D" xlink:to="loc_us-gaap_InterestExpense_4DD9B863E411B786E2D448EF3C735868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_438B4F5C3FF117C3CDDB48EF3C732E89" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_438B4F5C3FF117C3CDDB48EF3C732E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01661C6DA6B41759720248EF3C7453D0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01661C6DA6B41759720248EF3C7453D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C0D01EDBE0BB836277F748EF3C7471CF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_C0D01EDBE0BB836277F748EF3C7471CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8F6FDE545AFB450B166748EF3C74DF0F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_54E64E824C02A7C00D4F48EF3C73DF4D" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8F6FDE545AFB450B166748EF3C74DF0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:type="locator" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17DD83D461567B9EE9CE48EF3C710234" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5109C7EEC0C3555B184848EF3C7442C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5109C7EEC0C3555B184848EF3C7442C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_95822109E5C0FC5EE88848EF3C74F9BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_95822109E5C0FC5EE88848EF3C74F9BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_87EDCB1047C774919B0E48EF3C744E3D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_87EDCB1047C774919B0E48EF3C744E3D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_A4EB392AB80A62B713C548EF3C75FAFD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:to="loc_biib_Collaborationexpensesaccrual_A4EB392AB80A62B713C548EF3C75FAFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_781F52857AA5DE041BD448EF3C7524FA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_781F52857AA5DE041BD448EF3C7524FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationReserve" xlink:label="loc_us-gaap_LitigationReserve_4F38C3624DA3520EB8D648EF3C7536DE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:to="loc_us-gaap_LitigationReserve_4F38C3624DA3520EB8D648EF3C7536DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_D2D332B55A918723115748EF3C75385E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_D2D332B55A918723115748EF3C75385E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7A08521CD6121BF5184848EF3C757381" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A7684A4F93C0DD364C2C48EF3C7414C1" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_7A08521CD6121BF5184848EF3C757381" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7145C157192B2E8B2EB048F019065E27" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7145C157192B2E8B2EB048F019065E27" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_2719AA8F36A6B4EF272948F019069A95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:to="loc_us-gaap_StatementGeographicalAxis_2719AA8F36A6B4EF272948F019069A95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_66D0FF0F6920E636EC3448F01906C295" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_2719AA8F36A6B4EF272948F019069A95" xlink:to="loc_us-gaap_SegmentGeographicalDomain_66D0FF0F6920E636EC3448F01906C295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IT" xlink:label="loc_country_IT_2A116609C77783D758FB48F0190750C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_66D0FF0F6920E636EC3448F01906C295" xlink:to="loc_country_IT_2A116609C77783D758FB48F0190750C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_5CA8E2AE6571AA64740348F01907CC94" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:to="loc_us-gaap_ProductOrServiceAxis_5CA8E2AE6571AA64740348F01907CC94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_F911240C383B1179532A48F01907357B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_5CA8E2AE6571AA64740348F01907CC94" xlink:to="loc_us-gaap_ProductsAndServicesDomain_F911240C383B1179532A48F01907357B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_EA0025097E13D2418EFA48F019070DDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F911240C383B1179532A48F01907357B" xlink:to="loc_biib_TecfideraMember_EA0025097E13D2418EFA48F019070DDC" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:to="loc_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_697209185E45931213A648F019076C8F" xlink:to="loc_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:to="loc_biib_FifteenbillionMemberMember_323C60363938BAAF3EEC48F019076F24" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_FC006462CE93C5D4FAD748F01907C96A" xlink:to="loc_biib_SixteenbillionMember_0286E23946972EABF78648F01907972F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_845237C7EB740E9F6DA648F019071FCE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_845237C7EB740E9F6DA648F019071FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BAFCCE83A15847FE239648F01907EDB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_845237C7EB740E9F6DA648F019071FCE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BAFCCE83A15847FE239648F01907EDB9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_85C2F53FCECAE284452D48F01907B39E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BAFCCE83A15847FE239648F01907EDB9" xlink:to="loc_biib_FumapharmAgMember_85C2F53FCECAE284452D48F01907B39E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_F4C89F4F706C859846E748F019072726" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BAFCCE83A15847FE239648F01907EDB9" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_F4C89F4F706C859846E748F019072726" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_AF65584E88349E6F608F48F01908BE7C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:to="loc_biib_FacilityLocationAxis_AF65584E88349E6F608F48F01908BE7C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_E261ECEA2FAE8BF4411B48F019089A4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_AF65584E88349E6F608F48F01908BE7C" xlink:to="loc_biib_FacilityLocationDomain_E261ECEA2FAE8BF4411B48F019089A4A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_37CE5E27F457FDAFCAD648F01908D8CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_E261ECEA2FAE8BF4411B48F019089A4A" xlink:to="loc_biib_SolothurnMember_37CE5E27F457FDAFCAD648F01908D8CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_464C917B460D986C281748F019060CBA" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_13E70FEEBBBED3CD91FB48F01908E8B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_13E70FEEBBBED3CD91FB48F01908E8B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_biib_CumulativeSalesLevel_1BCD86028D3F38181C4C48F019087A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_D1FCC1613AA993A4AF0348F019088D5B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_D1FCC1613AA993A4AF0348F019088D5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_A9A3D366FBDA8E2E50E548F0190864BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_LitigationSettlementExpense_A9A3D366FBDA8E2E50E548F0190864BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_83D5202837041A3A4DF848F019088C28" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_83D5202837041A3A4DF848F019088C28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_BAA4F9E6774537B6A82048F01908E7AE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_BAA4F9E6774537B6A82048F01908E7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3A0876FAD0919C3C8D3448F019089A6A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3A0876FAD0919C3C8D3448F019089A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_418A7E697A805ABF9BE548F019088E50" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_PrepaidTaxes_418A7E697A805ABF9BE548F019088E50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_8203E6EF15ABD2655C6C48F01909BE2B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_8203E6EF15ABD2655C6C48F01909BE2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_16F3AF488535E5C7D9C748F01908211C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_16F3AF488535E5C7D9C748F01908211C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_FEDA17C97FE805A9040D48F01908051B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_E091D4A1A0CEA5D8361248F01908F8D2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_E091D4A1A0CEA5D8361248F01908F8D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_LossContingencyAdjustmentRelatedToClaimAmountPercent" xlink:label="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_009F933C91D3C893D5D548F019093B72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_5938C57DB201940A356E48F019094E48" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B47F6790BF3F9AF5EA748F019087C4D" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_5938C57DB201940A356E48F019094E48" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A3E209E5DF4D019F417548E1A9D355EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_2A5C0C2A543E027C1B5A48E1A9D659AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A3E209E5DF4D019F417548E1A9D355EA" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_2A5C0C2A543E027C1B5A48E1A9D659AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7BF657A9D287AE920B0A48E1A9D79236" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A3E209E5DF4D019F417548E1A9D355EA" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7BF657A9D287AE920B0A48E1A9D79236" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7A8702DE2A3551A12FFE48E1A9D7A341" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A3E209E5DF4D019F417548E1A9D355EA" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7A8702DE2A3551A12FFE48E1A9D7A341" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57D4A48BF3678F6E24A629780E165648" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B60CC9DEAC0915D84CF229780E16C245" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57D4A48BF3678F6E24A629780E165648" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B60CC9DEAC0915D84CF229780E16C245" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0434C2659A3B68F979EE29780E4458BE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_96EDCA08A67FC83023EE29780E44C4A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0434C2659A3B68F979EE29780E4458BE" xlink:to="loc_us-gaap_Land_96EDCA08A67FC83023EE29780E44C4A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_C5FF1B60C30E745A44B329780E44DB23" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0434C2659A3B68F979EE29780E4458BE" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_C5FF1B60C30E745A44B329780E44DB23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_3279CBA14E5DEBB60CE529780E45EDBB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0434C2659A3B68F979EE29780E4458BE" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_3279CBA14E5DEBB60CE529780E45EDBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_E36FBB3953C5E643B84D29780E45409A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0434C2659A3B68F979EE29780E4458BE" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_E36FBB3953C5E643B84D29780E45409A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_D2F1C601AFFE4997C76F29780E456275" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0434C2659A3B68F979EE29780E4458BE" xlink:to="loc_biib_ComputerSoftwareAndHardware_D2F1C601AFFE4997C76F29780E456275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_CA0D15F187C5CB2CA30C29780E4508EF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0434C2659A3B68F979EE29780E4458BE" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_CA0D15F187C5CB2CA30C29780E4508EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_B085AAF256A90A5114F329780E45491C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0434C2659A3B68F979EE29780E4458BE" xlink:to="loc_us-gaap_ConstructionInProgressGross_B085AAF256A90A5114F329780E45491C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_D79193B9649FEE2C41F629780E452579" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0434C2659A3B68F979EE29780E4458BE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_D79193B9649FEE2C41F629780E452579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_849A53E00C3F7C4F678829780E45FB3F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0434C2659A3B68F979EE29780E4458BE" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_849A53E00C3F7C4F678829780E45FB3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_53B6544954966C3D257B29780E46FC3A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0434C2659A3B68F979EE29780E4458BE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_53B6544954966C3D257B29780E46FC3A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1BD57CF7D4E5CA4F760142D5E3B17478" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ED1F6E4AEDBCE6DD27B42D5E3B20867" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1BD57CF7D4E5CA4F760142D5E3B17478" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ED1F6E4AEDBCE6DD27B42D5E3B20867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885E779F9F4856CB180C42D5E3B235B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ED1F6E4AEDBCE6DD27B42D5E3B20867" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885E779F9F4856CB180C42D5E3B235B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08E99D3465A9EFD085FD42D5E3B20CD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885E779F9F4856CB180C42D5E3B235B3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08E99D3465A9EFD085FD42D5E3B20CD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_35242FBA3A77FDD7A65442D5E3B77372" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08E99D3465A9EFD085FD42D5E3B20CD5" xlink:to="loc_us-gaap_BuildingMember_35242FBA3A77FDD7A65442D5E3B77372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_70C1B2C92BBC304F090942D5E3B7969A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08E99D3465A9EFD085FD42D5E3B20CD5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_70C1B2C92BBC304F090942D5E3B7969A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_33004A8C4FEF66F3F8E442D5E3B751A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08E99D3465A9EFD085FD42D5E3B20CD5" xlink:to="loc_us-gaap_LandMember_33004A8C4FEF66F3F8E442D5E3B751A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A9230B6397F58158D7FC42D5E3B80A8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ED1F6E4AEDBCE6DD27B42D5E3B20867" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A9230B6397F58158D7FC42D5E3B80A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10CD67796CB4FCF95B1D42D5E3B85EC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A9230B6397F58158D7FC42D5E3B80A8D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10CD67796CB4FCF95B1D42D5E3B85EC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_D143F9CECCF3A3E5B41942D5E3B84919" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10CD67796CB4FCF95B1D42D5E3B85EC9" xlink:to="loc_biib_EisaiMember_D143F9CECCF3A3E5B41942D5E3B84919" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_3237EC3EE4E505377F6742D5E3B8EB11" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ED1F6E4AEDBCE6DD27B42D5E3B20867" xlink:to="loc_biib_FacilityLocationAxis_3237EC3EE4E505377F6742D5E3B8EB11" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_81525034631A6CF57BC142D5E3B80F1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_3237EC3EE4E505377F6742D5E3B8EB11" xlink:to="loc_biib_FacilityLocationDomain_81525034631A6CF57BC142D5E3B80F1E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_C08FAD46D2BDDB1950E242D5E3B85E1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_81525034631A6CF57BC142D5E3B80F1E" xlink:to="loc_biib_SolothurnMember_C08FAD46D2BDDB1950E242D5E3B85E1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ED1F6E4AEDBCE6DD27B42D5E3B20867" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_34729EAC4F1F26DC243242D5E3B83E6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_Depreciation_34729EAC4F1F26DC243242D5E3B83E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_ABD298651955B627422442D5E3B82C37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_InterestCostsCapitalized_ABD298651955B627422442D5E3B82C37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_DF496846F7A397164F1A42D5E3B86490" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_DF496846F7A397164F1A42D5E3B86490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_0AD007E7D80E925CF9D242D5E3B85F57" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_ConstructionInProgressGross_0AD007E7D80E925CF9D242D5E3B85F57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D3E1F10B7995992B52A242D5E3B8171A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D3E1F10B7995992B52A242D5E3B8171A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TermOfLease" xlink:label="loc_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_biib_TermOfLease_09F372DDDE9A25609F2342D5E3B88C68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_69E8553A3B74AE90929442D5E3B80C62" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928C4C1DD32DA8079B6C42D5E3B8F459" xlink:to="loc_us-gaap_CapitalLeaseObligations_69E8553A3B74AE90929442D5E3B80C62" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_B46FEE3F78E472B5DC0329780E5D54F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_BEDC349D592B23B8F77A29780E5E4DCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_B46FEE3F78E472B5DC0329780E5D54F1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_BEDC349D592B23B8F77A29780E5E4DCB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6D144562237C4F6B595E29780F56DCAB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_DC15C60734A3F5B2426E29780F5610C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6D144562237C4F6B595E29780F56DCAB" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_DC15C60734A3F5B2426E29780F5610C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_745096F192BD5CD28ADA29780DB1991E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_745096F192BD5CD28ADA29780DB1991E" xlink:to="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_6B6981A0853A6B4A9FCC29780DB1CD9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_6B6981A0853A6B4A9FCC29780DB1CD9C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_E20CC7621BEE4B5EF01529780DB15B19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_E20CC7621BEE4B5EF01529780DB15B19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_29BA00988BB5531F679E29780DB11F26" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:to="loc_us-gaap_OtherSalesRevenueNet_29BA00988BB5531F679E29780DB11F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8FEF921F1574862C185E29780DB1B0F3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:to="loc_us-gaap_Revenues_8FEF921F1574862C185E29780DB1B0F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_E3DC1F9596342DC6AC3229780DB16BF9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:to="loc_us-gaap_GrossProfit_E3DC1F9596342DC6AC3229780DB16BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_4E41CC528E31B6006C0929780DB1EC74" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:to="loc_us-gaap_ProfitLoss_4E41CC528E31B6006C0929780DB1EC74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_83380F047BC4AA3D064C29780DB1D7B6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:to="loc_us-gaap_NetIncomeLoss_83380F047BC4AA3D064C29780DB1D7B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_C0CAFCB73C299AA9E92429780DB1AD90" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:to="loc_us-gaap_EarningsPerShareBasic_C0CAFCB73C299AA9E92429780DB1AD90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_A2F15F9C113DF35C792E29780DB12F3F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_A2F15F9C113DF35C792E29780DB12F3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1278622E6158E46138D629780DB11D45" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1278622E6158E46138D629780DB11D45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576832FFCC609BF505E729780DB11292" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_D7072ABD61E4185C110829780DB156E0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576832FFCC609BF505E729780DB11292" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_C8AA19D774477727FE324DC49D22280F" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_C8AA19D774477727FE324DC49D22280F" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ED927F739F99741762574DC49D27C1CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ED927F739F99741762574DC49D27C1CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BC26541B2A07223C7A464DC49D270421" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ED927F739F99741762574DC49D27C1CE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BC26541B2A07223C7A464DC49D270421" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_7904BE817C38C681AEC34DC49D27AEBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BC26541B2A07223C7A464DC49D270421" xlink:to="loc_biib_RemedyPharmaceuticalMember_7904BE817C38C681AEC34DC49D27AEBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_E6004D6520D610DDE0A74DC49D2767AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:to="loc_us-gaap_ProductOrServiceAxis_E6004D6520D610DDE0A74DC49D2767AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_656F6D8C444BE2F61A8A4DC49D27972A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_E6004D6520D610DDE0A74DC49D2767AD" xlink:to="loc_us-gaap_ProductsAndServicesDomain_656F6D8C444BE2F61A8A4DC49D27972A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_656F6D8C444BE2F61A8A4DC49D27972A" xlink:to="loc_biib_TecfideraMember_B6C7EA19A431958B9ED34DC49D275F12" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_656F6D8C444BE2F61A8A4DC49D27972A" xlink:to="loc_biib_SPINRAZAMember_D9E5DEEEA81855A2A8D54DC49D28950D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:to="loc_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_BE88F5862167984D5DDE4DC49D2897DE" xlink:to="loc_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_E6B20ADBCBE009C72FC54DC49D281281" xlink:to="loc_biib_CambridgeMAMember_73AF475FDC05F0631B4D4DC49D28556E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4EC497AF3BA86EBFCA394DC49D28A635" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_E0F4B7336C7D59451BF64DC49D28FE31" xlink:to="loc_biib_NeurimmuneMember_A100CF72D07B8226A36A4DC49D28DD56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0D759676E89745D15F764DC49D284CBA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:to="loc_biib_BristolMyersSquibbMember_A1970A56C91AA2BDCE3A4DC49D296CC1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:to="loc_biib_IPerianMember_4616C8C4E00C549736484DC49D294A72" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:to="loc_biib_AlkermesMember_00232AB7C13F9C67C5474DC49D29D2A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:to="loc_biib_IonisPharmaceuticalsMember_EE76163FA1DB66B1E5824DC49D2906EF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_22ADA7861379F65C7EDF4DC49D29703D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAA33ED0957E3CAB5B384DC49D286B1A" xlink:to="loc_biib_EisaiMember_22ADA7861379F65C7EDF4DC49D29703D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DC2A8FDC8C8D82BB8B404DC49D22BE08" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_B6650F5CBA1F7B16BBB84DC49D299D25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_B6650F5CBA1F7B16BBB84DC49D299D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C09C1623F1D6BAE3FBD14DC49D29B113" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C09C1623F1D6BAE3FBD14DC49D29B113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_B65FD8CD89AEC0CB2C5D4DC49D29D74E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_B65FD8CD89AEC0CB2C5D4DC49D29D74E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_biib_DevelopmentalMilestonePayment_5D704FC532F0021C20CB4DC49D292D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A1B7462C4FC83A970C644DC49D2981A8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A1B7462C4FC83A970C644DC49D2981A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_629B195F7E18BA5B441F4DC49D29DBEA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2F1E93B586AB2468DF1C4DC49D292845" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_496343733AD62C5D396A4DC49D29828F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_496343733AD62C5D396A4DC49D29828F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_68D325E482FE673B88964DC49D298774" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossNoncurrent_68D325E482FE673B88964DC49D298774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_17ABFC2AD73E8EDC240D4DC49D2ABC74" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_17ABFC2AD73E8EDC240D4DC49D2ABC74" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_biib_LicenseFee_3487E9A013FA96F327DC4DC49D2A8F50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_61ADA1ED6750A50D323D4DC49D30CE70" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_B67F5B68A83DAF2D10434DC49D290163" xlink:to="loc_us-gaap_LitigationSettlementExpense_61ADA1ED6750A50D323D4DC49D30CE70" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3A3FF11B0F1F7BFA8CAD29780DD787C6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1FD7FBFE225FE7E15C2529780DD73B82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3A3FF11B0F1F7BFA8CAD29780DD787C6" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1FD7FBFE225FE7E15C2529780DD73B82" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5A1E436545004A66F4E029780F4EB38E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DD9A7783F62D59BE256929780F4F4678" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5A1E436545004A66F4E029780F4EB38E" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DD9A7783F62D59BE256929780F4F4678" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_28088098999E991EA6F0434A358FEB19" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E759547C9E69463C4CB1434A358F7F98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_28088098999E991EA6F0434A358FEB19" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E759547C9E69463C4CB1434A358F7F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_6CA476B282D5F915F648434A358F174A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E759547C9E69463C4CB1434A358F7F98" xlink:to="loc_us-gaap_RestructuringPlanAxis_6CA476B282D5F915F648434A358F174A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_8C06AEE25C02F7C93786434A358F5487" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_6CA476B282D5F915F648434A358F174A" xlink:to="loc_us-gaap_RestructuringPlanDomain_8C06AEE25C02F7C93786434A358F5487" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_B8E4458F72693E0442EB434A358FAD29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_8C06AEE25C02F7C93786434A358F5487" xlink:to="loc_biib_A2015RestructuringChargesMember_B8E4458F72693E0442EB434A358FAD29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E759547C9E69463C4CB1434A358F7F98" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_DC2F53E86C3CEA49C65F434A358FB10C" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_E46A588359D0B62207D7434A358F5ACF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:to="loc_us-gaap_EmployeeSeveranceMember_E46A588359D0B62207D7434A358F5ACF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_3D1EBB9F47F450D2A781434A358FCD4B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_DA9E3E39C883EFEF5E64434A358F901B" xlink:to="loc_us-gaap_ContractTerminationMember_3D1EBB9F47F450D2A781434A358FCD4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E759547C9E69463C4CB1434A358F7F98" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_0F00E3C07705D7BE657B434A358FC9A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:to="loc_us-gaap_RestructuringReserve_0F00E3C07705D7BE657B434A358FC9A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_D9106C013357ECFB229E434A358FDE81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:to="loc_us-gaap_RestructuringCosts_D9106C013357ECFB229E434A358FDE81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_B8032CD75BD7C1DA8D79434A358FE67F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:to="loc_us-gaap_PaymentsForRestructuring_B8032CD75BD7C1DA8D79434A358FE67F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_75292AF76B524E4D40C4434A358F821E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_75292AF76B524E4D40C4434A358F821E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_61A5FED91DA6BCBF850F434A358FCB73" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3A6F58082BC823ED239C434A358FEF30" xlink:to="loc_us-gaap_RestructuringReserve_61A5FED91DA6BCBF850F434A358FCB73" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_B2423F532F386966532742D5E53EFAB4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_B2423F532F386966532742D5E53EFAB4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B5790C8120D8DC8744BC42D5E53EF585" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B5790C8120D8DC8744BC42D5E53EF585" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4A50429A176D75C2CD6E42D5E53E8F5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B5790C8120D8DC8744BC42D5E53EF585" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4A50429A176D75C2CD6E42D5E53E8F5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB3953D56F3EF742501842D5E53E9184" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4A50429A176D75C2CD6E42D5E53E8F5E" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB3953D56F3EF742501842D5E53E9184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_2B8CBB8C759832B5FFDE42D5E53E9182" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4A50429A176D75C2CD6E42D5E53E8F5E" xlink:to="loc_us-gaap_RestructuringChargesMember_2B8CBB8C759832B5FFDE42D5E53E9182" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_8680C5416762A025668F42D5E53EC1BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:to="loc_biib_FacilityLocationAxis_8680C5416762A025668F42D5E53EC1BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_C49A7DE670E0BFAA6C6C42D5E53FAB44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_8680C5416762A025668F42D5E53EC1BC" xlink:to="loc_biib_FacilityLocationDomain_C49A7DE670E0BFAA6C6C42D5E53FAB44" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_10D0FF6AD02F07A5D0F542D5E53F1ECC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_C49A7DE670E0BFAA6C6C42D5E53FAB44" xlink:to="loc_biib_CambridgeMAMember_10D0FF6AD02F07A5D0F542D5E53F1ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:to="loc_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_F62C9919609C44CEDB4642D5E53F4A95" xlink:to="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2017RestructuringChargesMember" xlink:label="loc_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:to="loc_biib_A2017RestructuringChargesMember_9EEDD796A9C6AA0FC7E042D5E53F0011" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2016RestructuringChargesMember" xlink:label="loc_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:to="loc_biib_A2016RestructuringChargesMember_0C96086C9D17C465CEC942D5E53FEB5F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_CD2629E740EB4FA149A742D5E53FCC57" xlink:to="loc_biib_A2015RestructuringChargesMember_7F1EFCE477F16C9AF9FA42D5E53F1FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9067679905F86A58D41142D5E53EADA8" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="loc_us-gaap_OtherNonrecurringExpense_B48131A7EA9A84A032464340BF15C58E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_us-gaap_OtherNonrecurringExpense_B48131A7EA9A84A032464340BF15C58E" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ResourcesRedirectedthroughRestructuringProgram" xlink:label="loc_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_biib_ResourcesRedirectedthroughRestructuringProgram_7CF3C76600898967C81742D5E53F370C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_8F8FB149203EEDDE0D6C42D5E53F648F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_us-gaap_RestructuringCharges_8F8FB149203EEDDE0D6C42D5E53F648F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_0F1A576082B2C2924F7A42D5E540B004" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_0F1A576082B2C2924F7A42D5E540B004" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" xlink:label="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_9FB65FCD9FEAE5B52FF042D5E53FE7C1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_biib_RestructuringandRelatedCostExpectedCashPayments_E9B44548704C7AF0AC0242D5E53F42E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_BFEB21C5484BA746811742D5E53FF37A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_BFEB21C5484BA746811742D5E53FF37A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_0E3A77DDAEABAA2D721442D5E53FA951" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A6EC0BA5CA4EB4E0E53D42D5E53F1119" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_0E3A77DDAEABAA2D721442D5E53FA951" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_68113B249A725AE3C66029780F0618DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ECD0E6AB9F3D85CADE3E29780F07E828" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_68113B249A725AE3C66029780F0618DF" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ECD0E6AB9F3D85CADE3E29780F07E828" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenueReserves" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_32B82CA34F554E0A4AC54348CCF12762" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_10E014C29149C2B9E9DF42D5E53A7454" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_32B82CA34F554E0A4AC54348CCF12762" xlink:to="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_10E014C29149C2B9E9DF42D5E53A7454" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_D5EDF8D76E73B2B5B464434939443C16" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_762C9F5EB4D0198DD6D842D5E535DA17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_D5EDF8D76E73B2B5B464434939443C16" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_762C9F5EB4D0198DD6D842D5E535DA17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0A67ACD611EFBDB2B4DA42D5E535C9D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_762C9F5EB4D0198DD6D842D5E535DA17" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0A67ACD611EFBDB2B4DA42D5E535C9D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_5ECE9A6C3A514A3F958E42D5E535DA44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0A67ACD611EFBDB2B4DA42D5E535C9D0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_5ECE9A6C3A514A3F958E42D5E535DA44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_918529930D620558B4A842D5E535AF01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5ECE9A6C3A514A3F958E42D5E535DA44" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_918529930D620558B4A842D5E535AF01" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_BBDC1D8DDEA232CE7CDF42D5E535728D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5ECE9A6C3A514A3F958E42D5E535DA44" xlink:to="loc_biib_ContractualAdjustmentsMember_BBDC1D8DDEA232CE7CDF42D5E535728D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_A2653B3CA867C060E54F42D5E535D3AF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5ECE9A6C3A514A3F958E42D5E535DA44" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_A2653B3CA867C060E54F42D5E535D3AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_5ED18CE099BBD90FAE1B42D5E535C4B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_762C9F5EB4D0198DD6D842D5E535DA17" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_5ED18CE099BBD90FAE1B42D5E535C4B1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_8D886C2C541AC6A99AC842D5E5352581" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_5ED18CE099BBD90FAE1B42D5E535C4B1" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_8D886C2C541AC6A99AC842D5E5352581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_5BD44A88CBB85AB0B4E742D5E5357526" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_8D886C2C541AC6A99AC842D5E5352581" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_5BD44A88CBB85AB0B4E742D5E5357526" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_3FD0FFF1936B5563B1C142D5E5352695" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_8D886C2C541AC6A99AC842D5E5352581" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_3FD0FFF1936B5563B1C142D5E5352695" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_5F66D94E34304A64A78E42D5E5354431" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_8D886C2C541AC6A99AC842D5E5352581" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_5F66D94E34304A64A78E42D5E5354431" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_19FCF56625026710757842D5E536F9D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_8D886C2C541AC6A99AC842D5E5352581" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_19FCF56625026710757842D5E536F9D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_CBFC3E085875585A71E842D5E5364011" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_8D886C2C541AC6A99AC842D5E5352581" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_CBFC3E085875585A71E842D5E5364011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_69F2E71911E830C01F2F42D5E53611AA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_8D886C2C541AC6A99AC842D5E5352581" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_69F2E71911E830C01F2F42D5E53611AA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_4CF0919398215CF48AC0434C2B592EFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BAE47277BBE589B2E28242D5E5308669" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_4CF0919398215CF48AC0434C2B592EFD" xlink:to="loc_us-gaap_StatementTable_BAE47277BBE589B2E28242D5E5308669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BAE47277BBE589B2E28242D5E5308669" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5962957E1A1325B3BC4B42D5E5301414" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_661C19DBB39AF736E19742D5E5311A1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:to="loc_us-gaap_AccountsReceivableMember_661C19DBB39AF736E19742D5E5311A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_A6B4545BCA536413CDB242D5E5314D5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5C67350B4772075E57B042D5E531FA1B" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_A6B4545BCA536413CDB242D5E5314D5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BAE47277BBE589B2E28242D5E5308669" xlink:to="loc_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8A2C4C440D3C5D461A3242D5E5313352" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F07B5C1C30A10A462D4542D5E5311CBF" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8A2C4C440D3C5D461A3242D5E5313352" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_661D3E29BF69F495760843490354A330" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_93ADFE29E72F9AF6A73042D5E5381C87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_661D3E29BF69F495760843490354A330" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_93ADFE29E72F9AF6A73042D5E5381C87" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B656484105553FE2038142D5E538CFC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_661D3E29BF69F495760843490354A330" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B656484105553FE2038142D5E538CFC4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_6D660B7013E33F74C4A829780DCD1E73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_04495ED3FE3A25C1725929780DCD9C71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6D660B7013E33F74C4A829780DCD1E73" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_04495ED3FE3A25C1725929780DCD9C71" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_D5A9B51FAB525AA3D30D4C78A5D9B560" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_42729684F05B4A88BA624C78A5D9E718" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_D5A9B51FAB525AA3D30D4C78A5D9B560" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_42729684F05B4A88BA624C78A5D9E718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_AC07EBBAD6BF9D7221AD4C78A5D913D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_42729684F05B4A88BA624C78A5D9E718" xlink:to="loc_us-gaap_ProductOrServiceAxis_AC07EBBAD6BF9D7221AD4C78A5D913D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_AC07EBBAD6BF9D7221AD4C78A5D913D2" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_8E487505DAB410CF00DD4C78A5D93700" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_TecfideraMember_8E487505DAB410CF00DD4C78A5D93700" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_39F0D0689EF71F0E44D44C78A5DA6079" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_AVONEXMember_39F0D0689EF71F0E44D44C78A5DA6079" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PLEGRIDYMember" xlink:label="loc_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_PLEGRIDYMember_A458F0E80FD3430475104C78A5DAE051" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TysabriMember" xlink:label="loc_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_TysabriMember_2753C7408AF4027325DE4C78A5DAAA28" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_FAMPYRAMember_9EA9A5C5B9A3DB957B124C78A5DAA84D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_EA372EE3527FDD5AE7CD4C78A5DA57B0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_ZINBRYTAMember_EA372EE3527FDD5AE7CD4C78A5DA57B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_88D5FD1E7928533C146B4C78A5DBDE45" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_SPINRAZAMember_88D5FD1E7928533C146B4C78A5DBDE45" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_ELOCTATEMember_1E00AD432F7733748C4F4C78A5DA2FB3" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ALPROLIXProductMember" xlink:label="loc_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_ALPROLIXProductMember_A59F8A948D5C8FCDA3C04C78A5DAB8E3" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_FUMADERMMember_6AFB3C21FFA6B442FF914C78A5DA8A5C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_BENEPALIMember_B2B8F7B82DB298DA99BE4C78A5DB230C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D2C501DF4EDF901B72254C78A5D90522" xlink:to="loc_biib_FLIXABIMember_78F732304A93DF8AFF1F4C78A5DB8272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_42729684F05B4A88BA624C78A5D9E718" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D0F8AD5410821CDC499F4C78A5DBDC95" xlink:to="loc_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_3E84DB05BB7F96F662DA4C78A5DBE2C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:to="loc_country_US_3E84DB05BB7F96F662DA4C78A5DBE2C9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RestOfWorldMember" xlink:label="loc_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_930208214FB2D2458CD94C78A5DBE068" xlink:to="loc_biib_RestOfWorldMember_A78AE77F7522D8779AF84C78A5DB54FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_32DB2D018DD7C85B5D694C78A5DBB614" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_42729684F05B4A88BA624C78A5D9E718" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_32DB2D018DD7C85B5D694C78A5DBB614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetAbstract" xlink:label="loc_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_32DB2D018DD7C85B5D694C78A5DBB614" xlink:to="loc_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_41AA60589FE5922969494C78A5DB58D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesRevenueGoodsNetAbstract_3277024C9E59402AFD7A4C78A5DB0F43" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_41AA60589FE5922969494C78A5DB58D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_B4A373B5967095A3C0644C78A5BE9FD9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_B4A373B5967095A3C0644C78A5BE9FD9" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_80D3EC4D1E25AA28D3F84C78A5BEBAD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4" xlink:to="loc_us-gaap_StatementGeographicalAxis_80D3EC4D1E25AA28D3F84C78A5BEBAD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_80D3EC4D1E25AA28D3F84C78A5BEBAD5" xlink:to="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_7B8102F90EE619E1FD254C78A5BECAE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8" xlink:to="loc_country_US_7B8102F90EE619E1FD254C78A5BECAE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_BB896068DA76F797B05C4C78A5BECA6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8" xlink:to="loc_us-gaap_EuropeMember_BB896068DA76F797B05C4C78A5BECA6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AsiaMember" xlink:label="loc_us-gaap_AsiaMember_443039CDA5D7C091E4D64C78A5BE82FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8" xlink:to="loc_us-gaap_AsiaMember_443039CDA5D7C091E4D64C78A5BE82FF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_7C1B5B93EEB1E39D39134C78A5BEAEB8" xlink:to="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_FF346C0BD8C0A4FD94604C78A5BFD502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_52818BC0BA0EBEEFB5FB4C78A5BEB0E4" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_488E729D1498123C43684C78A5BF6DF1" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_38450051D7DE8D4E71234C78A5C499FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_38450051D7DE8D4E71234C78A5C499FA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_D104574737097A14E9DD4C78A5C4E027" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_D104574737097A14E9DD4C78A5C4E027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_ADC6272E61062CAA487A4C78A5C45FD0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:to="loc_us-gaap_OtherSalesRevenueNet_ADC6272E61062CAA487A4C78A5C45FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_71888AEFB0EDB3ABB8F84C78A5C454A0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_C57525D3834DAC46CD3C4C78A5BFD94E" xlink:to="loc_us-gaap_NoncurrentAssets_71888AEFB0EDB3ABB8F84C78A5C454A0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_92CBD54EF17C0CA13F864C78A5A9761D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_92CBD54EF17C0CA13F864C78A5A9761D" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_7F787047C5A263F754294C78A5A9AB98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:to="loc_us-gaap_StatementGeographicalAxis_7F787047C5A263F754294C78A5A9AB98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_20189E80D86F202DBA824C78A5A9F23B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_7F787047C5A263F754294C78A5A9AB98" xlink:to="loc_us-gaap_SegmentGeographicalDomain_20189E80D86F202DBA824C78A5A9F23B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_20189E80D86F202DBA824C78A5A9F23B" xlink:to="loc_biib_SolothurnMember_3A480E35F9ADCD35BB734C78A5A9BE8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DK" xlink:label="loc_country_DK_278C9BCB8D834ABD39834C78A5A9B5B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_20189E80D86F202DBA824C78A5A9F23B" xlink:to="loc_country_DK_278C9BCB8D834ABD39834C78A5A9B5B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:to="loc_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorAxis_92692256B104058C37844C78A5A9A37C" xlink:to="loc_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:to="loc_biib_DistributorOneMember_80AA2EBC3B14234F86FC4C78A5AAAF2F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_7723802AF5A587ECDA214C78A5A9F019" xlink:to="loc_biib_DistributorTwoMember_9C74EA5AAB765453DC7B4C78A5AAA157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_AC4E32B5033BE1F58BCD4C78A5A96103" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:to="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_08380BDBDAFCC8D709494C78A5AAD7A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_72AD33615E03D1D276794C78A5AAA586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_0AA697DCC99C6846F2F54C78A5AAE807" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C2E25ACEC73F18ABCCCF4C78A5AAC6B5" xlink:to="loc_us-gaap_NoncurrentAssets_0AA697DCC99C6846F2F54C78A5AAE807" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SegmentInformationTextualAbstract" xlink:label="loc_biib_SegmentInformationTextualAbstract_60F7BDC19C2FB98EE7534C78A5AFF0B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_92CBD54EF17C0CA13F864C78A5A9761D" xlink:to="loc_biib_SegmentInformationTextualAbstract_60F7BDC19C2FB98EE7534C78A5AFF0B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_9239B76FA3AE740594D84C78A5AFFE6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SegmentInformationTextualAbstract_60F7BDC19C2FB98EE7534C78A5AFF0B7" xlink:to="loc_us-gaap_NumberOfReportableSegments_9239B76FA3AE740594D84C78A5AFFE6A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_2DEF9924121631187C4629780D94ED75" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_87563215B594E8D1DB7529780D943B6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2DEF9924121631187C4629780D94ED75" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_87563215B594E8D1DB7529780D943B6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_A8830AE3A4A59B136E3F29780D94D398" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2DEF9924121631187C4629780D94ED75" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_A8830AE3A4A59B136E3F29780D94D398" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70B14D8C3823998298FF29780D765660" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A7D0641025A09BDF10C229780D76111F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70B14D8C3823998298FF29780D765660" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A7D0641025A09BDF10C229780D76111F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4F05D7C30C4CDA83CD634D82DD0B8AE3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4F05D7C30C4CDA83CD634D82DD0B8AE3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7EB7E6FD462D8794D3374D82DD0B7D9A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E72D5470EA8F95E009374D82DD0B98A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E72D5470EA8F95E009374D82DD0B98A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2BBB3008D591164600934D82DD0B24FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2BBB3008D591164600934D82DD0B24FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_CD30800541A694E8F3884D82DD0B33E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:to="loc_us-gaap_RestructuringChargesMember_CD30800541A694E8F3884D82DD0B33E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_11558621F29E1CDB11264D82DD0BFEA9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1288A6FDB84DB95390334D82DD0BB686" xlink:to="loc_us-gaap_ParentMember_11558621F29E1CDB11264D82DD0BFEA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_DA42C140BFF5ACE934E84D82DD0BDC2B" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_C5D57EAE78C3B1F97E134D82DD0B2618" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_B3473B0B42962EA867734D82DD0BEF93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_B3473B0B42962EA867734D82DD0BEF93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4964900AA64C422F1FE04D82DD0CB945" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4964900AA64C422F1FE04D82DD0CB945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E5288F555BC9539F88274D82DD0CDBA6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E5288F555BC9539F88274D82DD0CDBA6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_ED879BF5BC4D1CFB37B74D82DD0C4579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_86B6D5DAD3A7277CBBE84D82DD0C08F2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7B32F0E0DEBD89CFC00E4D82DD0BBEB2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_86B6D5DAD3A7277CBBE84D82DD0C08F2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06049DC2ABAEB7A4B7664D82DD068D56" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ECFD38039AD8FF7C30E4D82DD067B76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06049DC2ABAEB7A4B7664D82DD068D56" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ECFD38039AD8FF7C30E4D82DD067B76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_FB81CB7D02384A263BB64D82DD06BBD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ECFD38039AD8FF7C30E4D82DD067B76" xlink:to="loc_us-gaap_PlanNameAxis_FB81CB7D02384A263BB64D82DD06BBD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_FB81CB7D02384A263BB64D82DD06BBD9" xlink:to="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_7208913081EFCF4F987E4D82DD06659D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:to="loc_biib_MarketStockUnitsMember_7208913081EFCF4F987E4D82DD06659D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_811D9F0F8212D718CDDE4D82DD06731A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_811D9F0F8212D718CDDE4D82DD06731A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:to="loc_biib_CashSettledPerformanceSharesMember_4A9B2D1A7E8AC1F87A234D82DD0665A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PerformanceUnitsMember" xlink:label="loc_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:to="loc_biib_PerformanceUnitsMember_0FEC37319B0B7E8B152A4D82DD06294D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1E76AA376FBCCFD25AFA4D82DD067D90" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_40A04BB3955A84F885EF4D82DD0612BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_709B59E68AFAAC52D85A4D82DD0665CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ECFD38039AD8FF7C30E4D82DD067B76" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_709B59E68AFAAC52D85A4D82DD0665CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_709B59E68AFAAC52D85A4D82DD0665CC" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E80A4A019B70A84E80A04D82DD0785B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_E80A4A019B70A84E80A04D82DD0785B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FFFEE168A607E8F1DBE44D82DD07840F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FFFEE168A607E8F1DBE44D82DD07840F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_794513B36421F9D1E6AE4D82DD07D761" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_794513B36421F9D1E6AE4D82DD07D761" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3B3DEC1FB5785859AC014D82DD076C44" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_D348C0B53D2CC440C4994D82DD07BDE0" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3B3DEC1FB5785859AC014D82DD076C44" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A65E8D2989EADA0B81104793E6DB1B46" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_StockOptionActivityAbstract" xlink:label="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A65E8D2989EADA0B81104793E6DB1B46" xlink:to="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B36067BB3334F23FC89A4793E6DB424D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B36067BB3334F23FC89A4793E6DB424D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C792A5E0056BA51668274793E6DB0B74" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C792A5E0056BA51668274793E6DB0B74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_AE22BE3DAC80ED5D0E6D47E7487217DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_AE22BE3DAC80ED5D0E6D47E7487217DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_72C1964A5AF8603864DA47E6FB703527" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_72C1964A5AF8603864DA47E6FB703527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FBA4649A56DBCEB6E4A94793E6DB4A3C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FBA4649A56DBCEB6E4A94793E6DB4A3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D308C4D3C57F6FA4FB6D4793E6DBF5FB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D308C4D3C57F6FA4FB6D4793E6DBF5FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E8736C719CBA6839336B4793E6DB84B4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E8736C719CBA6839336B4793E6DB84B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D5A889F0CE240547A5C04793E6DB3B04" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_D5A889F0CE240547A5C04793E6DB3B04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409F366526AF3667CC44793E6DC1FC5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409F366526AF3667CC44793E6DC1FC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B47BEC4E4E5DB8090EE44793E6DC7466" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B47BEC4E4E5DB8090EE44793E6DC7466" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_228AC188D017A548AD4D4793E6DC2B6F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_228AC188D017A548AD4D4793E6DC2B6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9CB1FF0CA2314DFD45034793E6DC5F22" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_797E7D77C2809CF24A784793E6DBC216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9CB1FF0CA2314DFD45034793E6DC5F22" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EC3756D6238ECCEAAD8F4236E1E6C9E8" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" xlink:label="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EC3756D6238ECCEAAD8F4236E1E6C9E8" xlink:to="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_D075590D3CA95BBA4E774252BB84D82B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_D075590D3CA95BBA4E774252BB84D82B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_FEBAB95E657ECFA187D04236E1E64DF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_D6CF2A58F2D847C680284236E1E6C6C3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_FEBAB95E657ECFA187D04236E1E64DF8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_648068A850BB4F6963F04793EE0C9B77" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5794E8CBEB75B7D275744793EE13111C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_648068A850BB4F6963F04793EE0C9B77" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5794E8CBEB75B7D275744793EE13111C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_93E6829A5C74756FA4864793EE133DC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5794E8CBEB75B7D275744793EE13111C" xlink:to="loc_us-gaap_AwardTypeAxis_93E6829A5C74756FA4864793EE133DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72EABA7EDF8D30A36F774793EE148E54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_93E6829A5C74756FA4864793EE133DC7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72EABA7EDF8D30A36F774793EE148E54" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_DD59DA3DBD3C6425D7DC4793EE1597A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72EABA7EDF8D30A36F774793EE148E54" xlink:to="loc_biib_MarketStockUnitsMember_DD59DA3DBD3C6425D7DC4793EE1597A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AC9353661CDB0D007294793EE159269" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5794E8CBEB75B7D275744793EE13111C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AC9353661CDB0D007294793EE159269" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AC9353661CDB0D007294793EE159269" xlink:to="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03688ACF5080132596FF4793EE154D2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03688ACF5080132596FF4793EE154D2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E8CF9AE09F70543DDBFE4793EE159F82" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E8CF9AE09F70543DDBFE4793EE159F82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D7A1902A9D498BBA522D4793EE155E65" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D7A1902A9D498BBA522D4793EE155E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_47D8D3C0AE91B271E2994793EE150B73" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_47D8D3C0AE91B271E2994793EE150B73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D898B2765507B069F1DF4793EE150A40" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D898B2765507B069F1DF4793EE150A40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C2971B52E7174B81A5BC4793EE1529DA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C2971B52E7174B81A5BC4793EE1529DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3315B6F6F9547F66AEA84793EE16FF01" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3315B6F6F9547F66AEA84793EE16FF01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53F438C709FC7DF72A984793EE16EFF9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53F438C709FC7DF72A984793EE16EFF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_401061E7BDF5D4298AAF4793EE161BE6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_401061E7BDF5D4298AAF4793EE161BE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_D87CD41446959FC27F7E4793EE16D2C1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_D87CD41446959FC27F7E4793EE16D2C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8841B44307CA900F88F24793EE1671B4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8841B44307CA900F88F24793EE1671B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D42631ECB41278A7AC5A4793EE16E6F9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4E5189116BC5FC47D274793EE15B50B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D42631ECB41278A7AC5A4793EE16E6F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631622A6106469DE91FC29780DA87CE9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631622A6106469DE91FC29780DA87CE9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:to="loc_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_D1C8615F2C038CAADB9029780DA84322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48297FB569F906E47A2629780DA8569B" xlink:to="loc_biib_MarketStockUnitsMember_3F26D557EEF3D7FCEBC729780DA80623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:to="loc_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_C04A212513FFB6B2AC8129780DA80E6A" xlink:to="loc_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9CB5CB890EF4B5F1334329780DA8A7FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:to="loc_us-gaap_MinimumMember_9CB5CB890EF4B5F1334329780DA8A7FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_B7871FF002EEEF11FAFF29780DA83A79" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F797C58FF0D07FD16D9D29780DA8B32F" xlink:to="loc_us-gaap_MaximumMember_B7871FF002EEEF11FAFF29780DA83A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632AE8B70FF20E19505D29780DA80F86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C010F58D677510D2FAA729780DA82037" xlink:to="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7FABABB3139609C1E2C429780DA9BFA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7FABABB3139609C1E2C429780DA9BFA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9811F2328D09E7D75F2329780DA9A52A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9811F2328D09E7D75F2329780DA9A52A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1C507AB96A4B2E105D6629780DA9A901" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1C507AB96A4B2E105D6629780DA9A901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_809BE82AC34C0984878E29780DA9ED89" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_809BE82AC34C0984878E29780DA9ED89" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_C6A072F0069B008EDCE829780DA92B5A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_2B8B7D5517AF2A76567A29780DA9DFB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ACA38214A4B7DBD095E029780DA933D9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_5AB398ABA76347DA264529780DA99FB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ACA38214A4B7DBD095E029780DA933D9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2E0557451D2428DE487F485EEBBB772C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28F3456ABBA92E7FC4FE485EEBBCDC6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2E0557451D2428DE487F485EEBBB772C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28F3456ABBA92E7FC4FE485EEBBCDC6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_02F593A9A1BBBBF1DCF9485EEBBCCD58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28F3456ABBA92E7FC4FE485EEBBCDC6B" xlink:to="loc_us-gaap_AwardTypeAxis_02F593A9A1BBBBF1DCF9485EEBBCCD58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F4C90B2A5067DEEF79B485EEBBCF30D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_02F593A9A1BBBBF1DCF9485EEBBCCD58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F4C90B2A5067DEEF79B485EEBBCF30D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_7AFE30FB4C4A4239084B485EEBBC2B21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F4C90B2A5067DEEF79B485EEBBCF30D" xlink:to="loc_biib_CashSettledPerformanceSharesMember_7AFE30FB4C4A4239084B485EEBBC2B21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91ED87F53D031972FBB5485EEBBCE059" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28F3456ABBA92E7FC4FE485EEBBCDC6B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91ED87F53D031972FBB5485EEBBCE059" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91ED87F53D031972FBB5485EEBBCE059" xlink:to="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0B2C4341C01DA7D14634485EEBBCDE0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0B2C4341C01DA7D14634485EEBBCDE0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D265FCE685124A726180485EEBBC8F13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_D265FCE685124A726180485EEBBC8F13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99876EFF774F7EF9B8D7485EEBBD3BDE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99876EFF774F7EF9B8D7485EEBBD3BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F325735A7DD316AE8092485EEBBD785D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F325735A7DD316AE8092485EEBBD785D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A5311ADE740074E0D039485EEBBD5CAF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A5311ADE740074E0D039485EEBBD5CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_349B3F1FBD21F6D9177E485EEBBD10C0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_D1BAFFB22E934884DD63485EEBBC1DD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_349B3F1FBD21F6D9177E485EEBBD10C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60BF73225E3D96288D19485EE9D4D613" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15E4ED3812E072E2A9D9485EE9D58C9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60BF73225E3D96288D19485EE9D4D613" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15E4ED3812E072E2A9D9485EE9D58C9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_07CA295A9E20C4BF1638485EE9D63217" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15E4ED3812E072E2A9D9485EE9D58C9B" xlink:to="loc_us-gaap_AwardTypeAxis_07CA295A9E20C4BF1638485EE9D63217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B36A8C8481B435A112D0485EE9D693BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_07CA295A9E20C4BF1638485EE9D63217" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B36A8C8481B435A112D0485EE9D693BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B36A8C8481B435A112D0485EE9D693BD" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_E61256D8B685F1EE2D76485EE9D69C3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AA7A28E3DA8F4A5F886485EE9D67336" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15E4ED3812E072E2A9D9485EE9D58C9B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AA7A28E3DA8F4A5F886485EE9D67336" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AA7A28E3DA8F4A5F886485EE9D67336" xlink:to="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1B9503638ACDB04AE193485EE9D627A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1B9503638ACDB04AE193485EE9D627A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_35CED56AA2A30EAA7B0F485EE9D6824F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_35CED56AA2A30EAA7B0F485EE9D6824F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_2F1FCD1A2C008E8F9C3E485EE9D602BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_2F1FCD1A2C008E8F9C3E485EE9D602BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_80171D83021C33D8705E485EE9D60C84" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_80171D83021C33D8705E485EE9D60C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D8D6B6FCBCCA5FDE18E1485EE9D7711C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D8D6B6FCBCCA5FDE18E1485EE9D7711C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5D98314D694F5B38845E485EE9D7BBE8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5D98314D694F5B38845E485EE9D7BBE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_89690AA2B79C574094D7485EE9D711C4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_89690AA2B79C574094D7485EE9D711C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_F193117B8DCEB980947B485EE9D77BF1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_F193117B8DCEB980947B485EE9D77BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_092ABDD910D8A5623FCF485EE9D79CA6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_092ABDD910D8A5623FCF485EE9D79CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60497F291F23EC5ADC57485EE9D72D1D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60497F291F23EC5ADC57485EE9D72D1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AA529B4134918834730C485EE9D7120E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AA529B4134918834730C485EE9D7120E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9316F764E00C1BB13D92485EE9D7BC6A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_9BAC5D0991C665E3B324485EE9D67ED0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9316F764E00C1BB13D92485EE9D7BC6A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4EF9A4480BE149D97C1C32F209C51079" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4EF9A4480BE149D97C1C32F209C51079" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299" xlink:to="loc_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_407EA9EAECC2BC59E37932F209C5483B" xlink:to="loc_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:to="loc_biib_A2015ESPPMember_29B5276690B809A26EDB32F209C51A24" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_C8623D54F95075B452CC32F209C57FFD" xlink:to="loc_biib_A1995ESPPMember_F4D056F741B68D4BB5E932F209C5DF71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_1235172D190BF124F72832F209C56299" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69F8C6C12242950F83B532F209C509B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69F8C6C12242950F83B532F209C509B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2867DA325E3169120B2132F209C5565B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_61D66C8C1D38C7D6E78C32F209C50E60" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2867DA325E3169120B2132F209C5565B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9601B150E065C69CC318485EE72DC8F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9601B150E065C69CC318485EE72DC8F8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D1AC1CE66B0E58E49E52485EE72E19CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:to="loc_us-gaap_PlanNameAxis_D1AC1CE66B0E58E49E52485EE72E19CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1E9AA42D955713198EA0485EE72EE528" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_D1AC1CE66B0E58E49E52485EE72E19CF" xlink:to="loc_us-gaap_PlanNameDomain_1E9AA42D955713198EA0485EE72EE528" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1E9AA42D955713198EA0485EE72EE528" xlink:to="loc_biib_DirectorsPlanMember_F5AA067C4304901985FE485EE72F14BB" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_A2017OmnibusEquityPlanMember" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1E9AA42D955713198EA0485EE72EE528" xlink:to="loc_biib_A2017OmnibusEquityPlanMember_0506F1B28F9E261CB15C485EE72E3ECF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AttainmentOfPerformanceCriteriain2013Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1E9AA42D955713198EA0485EE72EE528" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2013Member_0D4DE9B2867047B755A4486D27D6A2BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:to="loc_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_21BCE2CD657FA85B8BC4485EE72E8367" xlink:to="loc_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_767EFCFBB015479ECDD5485EE72F27E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_B94B8F5AE46AF8E2A359485EE72FA58A" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_767EFCFBB015479ECDD5485EE72F27E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:to="loc_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3E72776F6EEADD9B1D16485EE72FAB69" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_1D31A907E07D936CE83D485EE72F3166" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_75CD41FAE6F4C8F86D35485EE72F2CD6" xlink:to="loc_us-gaap_DirectorMember_1D31A907E07D936CE83D485EE72F3166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_BF38D281F602A344D86B485EE72FCDEF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:to="loc_us-gaap_AwardTypeAxis_BF38D281F602A344D86B485EE72FCDEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_BF38D281F602A344D86B485EE72FCDEF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_03F7981F9B68DC085199485EE72F2871" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8" xlink:to="loc_biib_MarketStockUnitsMember_03F7981F9B68DC085199485EE72F2871" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_CF192B02764076CFDC07485EE7301DDF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8" xlink:to="loc_biib_CashSettledPerformanceSharesMember_CF192B02764076CFDC07485EE7301DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_18882D54C559D600D450485EE7308CEB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8" xlink:to="loc_us-gaap_PerformanceSharesMember_18882D54C559D600D450485EE7308CEB" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_EA0C4993AD236C79A271485EE73045DB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04CC1C349B6D0B100C76485EE72F73F8" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_EA0C4993AD236C79A271485EE73045DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416ADE9A5A888802CFC2485EE72E3601" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_NumberOfSharesOfCommonStockForIssuance_C46CEE93DBB95B4B388B485EE730CCAF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_356EAF576F04AFF5E270485EE7307E12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0E7851DFCC55FBD54855485EE7305F35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0E7851DFCC55FBD54855485EE7305F35" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_NumberOfEqualAnnualIncrements_2EAA0BD1DC318447A030485EE730E075" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_B474D4BD7319C25B60B9485EE730380D" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_D700728C7B25490E1F9C485EE730EEE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04F69A4ED86493E52AAE485EE7302EA8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04F69A4ED86493E52AAE485EE7302EA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_72B7A23146A1CBD446EC485EE730D007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6405FA35986F70C8A7CD485EE7306FE7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6405FA35986F70C8A7CD485EE7306FE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_B7C6F6C9A5F7BDA418C6485EE73049DE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_B7C6F6C9A5F7BDA418C6485EE73049DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" xlink:label="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_4C09F208CEF9BD253268485EE730E028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4C47C29E77C2C730479E485EE7303504" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4C47C29E77C2C730479E485EE7303504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_51743EBC82AECC25C569485EE7306942" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79498958FAD0CB0FACE5485EE7309EEB" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_51743EBC82AECC25C569485EE7306942" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ShareBasedPaymentsTextualAbstract" xlink:label="loc_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9601B150E065C69CC318485EE72DC8F8" xlink:to="loc_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5865E73796E7A902C453485EE7319AC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5865E73796E7A902C453485EE7319AC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_5CD941DE3F35731E074B485EE73182B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:to="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_5CD941DE3F35731E074B485EE73182B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_444BA88A69747EF47AE0485EE731DEA6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:to="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_444BA88A69747EF47AE0485EE731DEA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_A472A20BB34F7AC687C2485EE7313B56" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_A472A20BB34F7AC687C2485EE7313B56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_93AAA5BD6E66EDDDD8D5485EE731AD36" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_93AAA5BD6E66EDDDD8D5485EE731AD36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E967EE4CAC89375254AD485EE7319CB3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E967EE4CAC89375254AD485EE7319CB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1D3A03E104ADD6D9F8A1485EE7317907" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_52433755CF668D8D0622485EE7310FF0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1D3A03E104ADD6D9F8A1485EE7317907" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_329E08032F40B830203E485EEBF1441C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA6E1B1C82A5F5F9218E485EEBF293E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_329E08032F40B830203E485EEBF1441C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA6E1B1C82A5F5F9218E485EEBF293E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F911C432C13AA2680C95485EEBF241E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA6E1B1C82A5F5F9218E485EEBF293E0" xlink:to="loc_us-gaap_AwardTypeAxis_F911C432C13AA2680C95485EEBF241E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D0EF54A6248E3D575DEE485EEBF26FC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_F911C432C13AA2680C95485EEBF241E8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D0EF54A6248E3D575DEE485EEBF26FC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_5D039565B50EBCD902A0485EEBF24FC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D0EF54A6248E3D575DEE485EEBF26FC0" xlink:to="loc_us-gaap_PerformanceSharesMember_5D039565B50EBCD902A0485EEBF24FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA6E1B1C82A5F5F9218E485EEBF293E0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8833930F77079F31B974485EEBF3EBDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8833930F77079F31B974485EEBF3EBDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_AA037C619B9C4C02A5E9485EEBF288B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_AA037C619B9C4C02A5E9485EEBF288B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_292D7B5BA6E6AE4B75A2485EEBF3A10E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_292D7B5BA6E6AE4B75A2485EEBF3A10E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6CFFF11FDDEFACC1A196485EEBF33E91" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6CFFF11FDDEFACC1A196485EEBF33E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C85115F01BB6802C49F6485EEBF31A33" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C85115F01BB6802C49F6485EEBF31A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D49A1086105D59523FC0485EEBF374C4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57D59FE2293026ED7FE8485EEBF20534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D49A1086105D59523FC0485EEBF374C4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7683854BE1C793EFB39B297C20CD167B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_822705E95870F0E1E1BE297C20CDFFEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7683854BE1C793EFB39B297C20CD167B" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_822705E95870F0E1E1BE297C20CDFFEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_C339D3D81FAA1F99BFC3297C20CD2742" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7683854BE1C793EFB39B297C20CD167B" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_C339D3D81FAA1F99BFC3297C20CD2742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_09394DE3EFF4120DE24B297C20CD1FAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7683854BE1C793EFB39B297C20CD167B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_09394DE3EFF4120DE24B297C20CD1FAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:label="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_8AB42ABB90CFE2BE969F2992D931EEC3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7683854BE1C793EFB39B297C20CD167B" xlink:to="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_8AB42ABB90CFE2BE969F2992D931EEC3" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_A23910516D9F342168DB297C20CDCE0A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7683854BE1C793EFB39B297C20CD167B" xlink:to="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_A23910516D9F342168DB297C20CDCE0A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:label="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F2AC849613CA853521A297C20CDBC63" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7683854BE1C793EFB39B297C20CD167B" xlink:to="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F2AC849613CA853521A297C20CDBC63" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_D011B3E0B322F480DA28297C20CD609F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7683854BE1C793EFB39B297C20CD167B" xlink:to="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_D011B3E0B322F480DA28297C20CD609F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PerformanceunitsactivityTableTextBlock" xlink:label="loc_biib_PerformanceunitsactivityTableTextBlock_6738FAFF0B2F14138E47297C20CD17CF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7683854BE1C793EFB39B297C20CD167B" xlink:to="loc_biib_PerformanceunitsactivityTableTextBlock_6738FAFF0B2F14138E47297C20CD17CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_86E02193AB134243E12D297C20CD37D4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7683854BE1C793EFB39B297C20CD167B" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_86E02193AB134243E12D297C20CD37D4" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:label="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_586D2C50324B27DD5724297C20CEC9A8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7683854BE1C793EFB39B297C20CD167B" xlink:to="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_586D2C50324B27DD5724297C20CEC9A8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5FEA84F3BB4148D4629E4C78A539373E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_068F2D5280C837B635474C78A5393E6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5FEA84F3BB4148D4629E4C78A539373E" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_068F2D5280C837B635474C78A5393E6C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_6F2B4BFD63F36705659D4C78A533E22B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_6F2B4BFD63F36705659D4C78A533E22B" xlink:to="loc_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C4F77114B4EDE2A6493C4C78A533BA75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C4F77114B4EDE2A6493C4C78A533BA75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CE6961151A13635402484C78A533E966" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C4F77114B4EDE2A6493C4C78A533BA75" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CE6961151A13635402484C78A533E966" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CE6961151A13635402484C78A533E966" xlink:to="loc_biib_KaryopharmMember_0DA1F237DBCF81CB83174C78A5330B45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_DE5C2A6DDEDE96FCE2024C78A5349E76" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_FE37E008E7C0A9A714954CC112F74FFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_B97785D3B651AC08E5564C78A534BCA8" xlink:to="loc_us-gaap_SubsequentEventMember_FE37E008E7C0A9A714954CC112F74FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4C2B18CC61FEEC13F7284C78A533F23D" xlink:to="loc_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_8E7A7044AEA03274A0914C78A534710C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_8E7A7044AEA03274A0914C78A534710C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6BF9C54F0A4DBC6FF6774C78A5344034" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_22B76CEFCCDA8E4402954C78A535CFFC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_810ACADBD2AFD63B59C242D5E57ABD71" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0682D4DA6A376927B09A4300ABE4C58D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_810ACADBD2AFD63B59C242D5E57ABD71" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0682D4DA6A376927B09A4300ABE4C58D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_034762F38F5FBEF18E2C42D5E56C111A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_034762F38F5FBEF18E2C42D5E56C111A" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_600425C6C6F4A7880E1F4311FDB94E4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_600425C6C6F4A7880E1F4311FDB94E4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5D21E9A6E37E65D9F8504311FDC37197" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_600425C6C6F4A7880E1F4311FDB94E4F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5D21E9A6E37E65D9F8504311FDC37197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_5C3B27D31D83F88BFAE74311FDE40FC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5D21E9A6E37E65D9F8504311FDC37197" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_5C3B27D31D83F88BFAE74311FDE40FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_328DE179D70B59C23B48431225E58DF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5D21E9A6E37E65D9F8504311FDC37197" xlink:to="loc_us-gaap_RetainedEarningsMember_328DE179D70B59C23B48431225E58DF5" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_D42F19AE0ACD9BCB146942D5E56C0653" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:to="loc_biib_MajorDistributorAxis_D42F19AE0ACD9BCB146942D5E56C0653" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_915178A7E8932B32EC8642D5E56CBDC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorAxis_D42F19AE0ACD9BCB146942D5E56C0653" xlink:to="loc_biib_MajorDistributorDomain_915178A7E8932B32EC8642D5E56CBDC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_D96260591B6DB903947742D5E56CFF5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_915178A7E8932B32EC8642D5E56CBDC9" xlink:to="loc_biib_DistributorOneMember_D96260591B6DB903947742D5E56CFF5A" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_9BA299D0F94335D5DF6E42D5E56C457B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_915178A7E8932B32EC8642D5E56CBDC9" xlink:to="loc_biib_DistributorTwoMember_9BA299D0F94335D5DF6E42D5E56C457B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_C1772E72FB68B3D87BE142D5E56D92CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:to="loc_us-gaap_RangeAxis_C1772E72FB68B3D87BE142D5E56D92CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_01544D9B19DEB2A9B88242D5E56DFBEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_C1772E72FB68B3D87BE142D5E56D92CD" xlink:to="loc_us-gaap_RangeMember_01544D9B19DEB2A9B88242D5E56DFBEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_CC8BF84657A0B5D38D0742D5E56D748D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_01544D9B19DEB2A9B88242D5E56DFBEE" xlink:to="loc_us-gaap_MinimumMember_CC8BF84657A0B5D38D0742D5E56D748D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6C719334D6121E1D87B242D5E56DB73C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_01544D9B19DEB2A9B88242D5E56DFBEE" xlink:to="loc_us-gaap_MaximumMember_6C719334D6121E1D87B242D5E56DB73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E0724C8F4ABD1D201A642D5E56DD541" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_78995F40A37FC9E7307742D5E56D53FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:to="loc_us-gaap_BuildingMember_78995F40A37FC9E7307742D5E56D53FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_AD8C0780B2E963F8722742D5E56D1E2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_AD8C0780B2E963F8722742D5E56D1E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_C7EEB0EC996584428EC142D5E56D349E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_C7EEB0EC996584428EC142D5E56D349E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_33F9F39C3415DB43A6FC42D5E56DEBDE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B3F1202E6642E72BF8442D5E56DC077" xlink:to="loc_us-gaap_ComputerEquipmentMember_33F9F39C3415DB43A6FC42D5E56DEBDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_76643347FD7BCF527E8F42D5E56C14FD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3F8C0D2428980966881843111BEE005F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3F8C0D2428980966881843111BEE005F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:to="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_623333B46119DDBA1F4D42D5E56D3D9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_E77A627A35F3E762192042D5E56DBDFB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7351DC002EC7E2EF9E6D42D5E56D8447" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_E77A627A35F3E762192042D5E56DBDFB" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BusinessTextualAbstract" xlink:label="loc_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_034762F38F5FBEF18E2C42D5E56C111A" xlink:to="loc_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_F818541532E5004AFA3642D5E56D837C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:to="loc_biib_InterestInSubsidiary_F818541532E5004AFA3642D5E56D837C" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PaymentTermsOfAccountsReceivable" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_F4282FADDFAF328A782342D5E56E26AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:to="loc_biib_PaymentTermsOfAccountsReceivable_F4282FADDFAF328A782342D5E56E26AA" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_EstimatedUsefulLivesOfLeaseholdImprovements" xlink:label="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_FE717A4328CB8488036842D5E56E2D8F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:to="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_FE717A4328CB8488036842D5E56E2D8F" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PurchasePriceOfCommonStockUnderEspp" xlink:label="loc_biib_PurchasePriceOfCommonStockUnderEspp_1A139CDCE0F06B9884DE42D5E56EB7F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:to="loc_biib_PurchasePriceOfCommonStockUnderEspp_1A139CDCE0F06B9884DE42D5E56EB7F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_PercentageOfMarketValuePerShareOfCommonStock" xlink:label="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_4FE45370AC96F51F4CAA42D5E56EF9F8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:to="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_4FE45370AC96F51F4CAA42D5E56EF9F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_CompensationExpenseOverPurchasePeriod" xlink:label="loc_biib_CompensationExpenseOverPurchasePeriod_10CDAF6E79466212804B42D5E56EDD37" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:to="loc_biib_CompensationExpenseOverPurchasePeriod_10CDAF6E79466212804B42D5E56EDD37" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_DiscountRateRecognizedInCompensationExpense" xlink:label="loc_biib_DiscountRateRecognizedInCompensationExpense_61CB54AF5762FE9A594B42D5E56E562D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:to="loc_biib_DiscountRateRecognizedInCompensationExpense_61CB54AF5762FE9A594B42D5E56E562D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_328F0B9A55E82CB71EDA42D5E56E56C5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_8154A3205D2A1967710642D5E56D1027" xlink:to="loc_us-gaap_AdvertisingExpense_328F0B9A55E82CB71EDA42D5E56E56C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_A9A7AA61F2854F87537242D5E576E140" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_A9A7AA61F2854F87537242D5E576E140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_78835960756EAB59BCB042D5E576E6E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_78835960756EAB59BCB042D5E576E6E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_0937DF205B02C98BB0AE42D5E576950B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_UseOfEstimates_0937DF205B02C98BB0AE42D5E576950B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_FC51E31B9EFF836C990742D5E5761A00" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_FC51E31B9EFF836C990742D5E5761A00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9137957F776AF5978EFA42D5E5769615" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9137957F776AF5978EFA42D5E5769615" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_BE13E46D6A9E21A8601A42D5E576B490" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_BE13E46D6A9E21A8601A42D5E576B490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_75AA5E2E5243C828CFE342D5E5765E18" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_75AA5E2E5243C828CFE342D5E5765E18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_FEB592CBBC7AEA43817D42D5E576C9ED" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_FEB592CBBC7AEA43817D42D5E576C9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_EA0C9AFBBBC0358D957A42D5E5763390" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_EA0C9AFBBBC0358D957A42D5E5763390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_E7D843EDAA396B2DDE3142D5E5768934" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_E7D843EDAA396B2DDE3142D5E5768934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_9C0BCE130D14CF3E62D842D5E576CED8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_9C0BCE130D14CF3E62D842D5E576CED8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3E5C4F83D6712A03638242D5E576D639" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3E5C4F83D6712A03638242D5E576D639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_04059D3D8294D9C36CDC42D5E576F8D7" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_04059D3D8294D9C36CDC42D5E576F8D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_C264E9CC833D195A2A8C42D5E5764B50" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_C264E9CC833D195A2A8C42D5E5764B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D214210717A7B124686E42D5E5766903" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_D214210717A7B124686E42D5E5766903" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_408B15AFF1BDDECA299D42D5E5769121" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_408B15AFF1BDDECA299D42D5E5769121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_F12BF02E0161EB712C0E42D5E577EEB1" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_F12BF02E0161EB712C0E42D5E577EEB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_90D63814FB4053D8B55542D5E577306A" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_90D63814FB4053D8B55542D5E577306A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1D6030445E630461C8B642D5E5776782" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1D6030445E630461C8B642D5E5776782" xlink:type="arc" />
    <link:loc xlink:href="biib-20171231.xsd#biib_RoyaltyCostofSalesPolicyTextBlock" xlink:label="loc_biib_RoyaltyCostofSalesPolicyTextBlock_B46544C6B81CC8F4F9F742D5E5777EC7" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_biib_RoyaltyCostofSalesPolicyTextBlock_B46544C6B81CC8F4F9F742D5E5777EC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_05CD588A3FBDEFF674DC42D5E577C552" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_05CD588A3FBDEFF674DC42D5E577C552" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_93C749BDCD2DE26AA5FC42D5E577789E" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_93C749BDCD2DE26AA5FC42D5E577789E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_B8C6287635ABC36CDA9F42D5E577EFCA" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_B8C6287635ABC36CDA9F42D5E577EFCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_D68284AC54F9D2704E3E42D5E5775B5B" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_D68284AC54F9D2704E3E42D5E5775B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_17834CF67ECE8976829D42D5E577E9AD" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_17834CF67ECE8976829D42D5E577E9AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0B6422F7098DC420F89C42D5E577A64E" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_0B6422F7098DC420F89C42D5E577A64E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2AD1C047789DDE6F248842D5E57747CD" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_697AEE4735A115F5858242D5E575454E" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2AD1C047789DDE6F248842D5E57747CD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E9F7A3B8E51504993B9229780F46EDF3" xlink:type="locator" />
    <link:loc xlink:href="biib-20171231.xsd#biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_B4CA3DAC549DD823DDE329780F46F80D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E9F7A3B8E51504993B9229780F46EDF3" xlink:to="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_B4CA3DAC549DD823DDE329780F46F80D" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>acquiredinprocessrdchart.jpg
<TEXT>
begin 644 acquiredinprocessrdchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MX=ZEI\WCM_!\FEZQ8:A/(NF1^(586^I16$/D?PI_X*(ZG#X-^!/CS]JWX>^
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M6VTCXI6<ID^'<_BFY3[$^9\(?^"D7[//Q(^$/@;XC:[J>O\ @SQ1XM^%_P
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M:ZO_ /)]?> ;]%8'_",Z3_SSN_\ P:ZO_P#)]'_",Z3_ ,\[O_P:ZO\ _)]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/Q _X*3_ /*23_@A3_V=;^U!_P"L<_$&OU2^.'_(H:7_ -ANT_\ 3?J%?E;_
M ,%)_P#E))_P0I_[.M_:@_\ 6.?B#7ZI?'#_ )%#2_\ L-VG_IOU"OE^-?\
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M!87R[5DE159SNR$!R55FZ+7Y?_\ !2?_ )22?\$*?^SK?VH/_6.?B#7ZI?'
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ME_R);?\ 8:U+_P!H5^B>&'_)3O\ [%N+_P#3V%'T?JORD>O4445_1@@HHHH
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M/Q+\:ZMJWBK5K36_#?C[Q!8OX9TNPM?!\OA_Y?\ BI_P6"_X-[/C=XQ^&7Q
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M !$0?\$;?^CW/!W_ (;;X\?_ #J* /VGHK\6/^(B#_@C;_T>YX._\-M\>/\
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MD+_\31M'^0O_ ,33J* &[1_D+_\ $T;1_D+_ /$TZC(SC(SZ=_RH ^</C/\
M#OQ5XP^+'[(OBG0+&*ZT3X4?''QKXU\<7,E[96KZ9X=UG]F#]H#X:6%W#;7$
ML4^I22^,/'GAC3VM-/CN+J**]DU"6);&RNYX?HW:/\A?_B:=D'H>G!]CZ4A9
M0,EE /0D@ _CTH 3:/\ (7_XFC:/\A?_ (FG @C(.0>01T(]:* &[1_D+_\
M$TH&/_U ?R I:* "BBB@ HHHH **** "BBB@ HHHH **** "L[6(]4ETG4X]
M#N[&QUF33[V/2;W4["?5--M-3>UE73[G4--M;[2[K4+*WO##-=V-MJ6GSWEN
MDEM#?6DDJW$>C67K>BZ5XCT;5O#VN6-OJ>BZ[IE_HVKZ==*7MK_3-4M)K#4+
M*X0,I:"[L[B:WF4,I:.1@&!.: /Q.\3?&K]I3X=Z;\6KCP!^T'XM^+GPHMC^
MS7\'?$/[1_Q!\"_#JST7PE^T1\8/VH/ WP8^*_BSX"MI'ACPKX3\0> ?A/\
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M<-I<7EY96$LEE!&8=(L;W4M3O[#1+3[-HUC?ZIJE]:6$-WJ5[-/['0 4444
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MK=];7QT,2Z=I7A8ZG=1_IM!^R'^S+9Z#\1_#.F?!'X>:+HGQ<ELY/B+9>']
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>amortofacqintanassetschart.jpg
<TEXT>
begin 644 amortofacqintanassetschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR>$_A[I7BS4_#6@7WC/Q)%IE_K$FC>'K?4YK9[^[33]-O)69 MN)UMM/\_\
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ML;S_ !#_ - O1O\ P>WW_P SE'G^(?\ H%Z-_P"#V^_^9R@#9HK&\_Q#_P!
MO1O_  >WW_S.4>?XA_Z!>C?^#V^_^9R@#9HK&\_Q#_T"]&_\'M]_\SE'G^(?
M^@7HW_@]OO\ YG* -FBL;S_$/_0+T;_P>WW_ ,SE'G^(?^@7HW_@]OO_ )G*
M -FBL;S_ !#_ - O1O\ P>WW_P SE'G^(?\ H%Z-_P"#V^_^9R@#9HK&\_Q#
M_P! O1O_  >WW_S.4>?XA_Z!>C?^#V^_^9R@#9HK&\_Q#_T"]&_\'M]_\SE'
MG^(?^@7HW_@]OO\ YG* -FBL;S_$/_0+T;_P>WW_ ,SE7;234'\S[?:V5MC;
MY7V2_GO=^=V_S/.T[3_+V_+MV^;NRV=FT;@"Y1110 4444 %%%% !1110 44
M44 ?B!_P4G_Y22?\$*?^SK?VH/\ UCGX@U^J7QP_Y%#2_P#L-VG_ *;]0K\K
M?^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]4OCA_R*&E_P#8;M/_ $WZA7R_&O\
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M5?#NK^)(+Z>]^)M^]Y?1VE_=?L;M7.=HSC&<#./3/7%(J(IRJ*I/!*J <>G
M%=U3/*U6[EAZ"?LJ%-1ASQI.5#%/%PJ5:7,U6FJCY%.JY5'2<HU*E24Y39?R
MU\M/G_PUEMIW_.;]A#0OB]\$/AYK'PR^)_P!?P"?&O[8_P"V%J7@VT^%$M[X
MK^'W@#X=ZY\0?&_Q#\)^)_&&I>(-)\"WWA?X<>(K2&S\+_"35-/T77M3\41Z
MCX7?Q#H_A*^U.^M=-^G/@CH'BR37/C?\2_B'I.I:7XN\>_&/QCH7AZTUDJ]W
MI7P-^%6J77@3X+:=INV:=;;1/$>FV7B'XN>7$ZG4-8^*&I:G>H+J2.*V]^VK
MQP."2.!P3G)'N<G)ZG)]:7 '08ZG\2<D_B>3[UPXC&RQ%3%5?94Z<\9+FK.#
MJ._[YUI1C[2<VHSFJ3ES.3<J47=7E<;OTZ;_ '?+R6GWA7UU\$O^1+;_ +#6
MI?\ M"OD6OKKX)?\B6W_ &&M2_\ :%?;^&'_ "4[_P"Q;B__ $]A0Z/U7Y2/
M7J***_HP04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%>3WOQY^!^F^)&\&ZC\8_A58>+TN_L#>%;WXB>#[7
MQ&M[YBP_9&T2?68]26Z,KK$+9K99S(0@C+$"O6* /Q _X*3_ /*23_@A3_V=
M;^U!_P"L<_$&OU2^.'_(H:7_ -ANT_\ 3?J%?E1_P4N\_P#X>/\ _!"S[+Y'
MG_\ #5G[3_E_:?,\G_DSOX@;M_E?O,[-VS'&_;N^3=7ZB?&3^V/^$6T[[?\
MV9Y']LVNS[%]N\SS/L-_C/VGY/*VYSG]YNVXXW5\OQK_ ,DKG?\ V!O_ -.4
MQQW7JOS/F>BBBOY7$%%%% !1110 5]=?!+_D2V_[#6I?^T*^1:^I?@__ &S_
M ,(BWV#^S/L_]KZA_P ??VWSO,S#OSY'[O9]W;_%USVK]$\+_P#DIW_V+<7_
M .G<*/H_5?E(]SHKG_\ BIO^H'_Y4Z/^*F_Z@?\ Y4Z_HP1T%%<__P 5-_U
M_P#RIT?\5-_U _\ RIT =!17/_\ %3?]0/\ \J='_%3?]0/_ ,J= '045S__
M !4W_4#_ /*G1_Q4W_4#_P#*G0!T%%<__P 5-_U _P#RIT?\5-_U _\ RIT
M=!17/_\ %3?]0/\ \J='_%3?]0/_ ,J= '045S__ !4W_4#_ /*G1_Q4W_4#
M_P#*G0!T%%<__P 5-_U _P#RIT?\5-_U _\ RIT =!17/_\ %3?]0/\ \J='
M_%3?]0/_ ,J= '045S__ !4W_4#_ /*G6A8?VG^]_M'[#_!Y/V+[5_M;_-^T
M_P# =FS_ &MW:@#0HHHH **** "BBB@ J*>&.X@F@FC6:*:*2*2)QE)(Y$9'
MC8?W75BK>Q-2TC=#SC@\YQCCKGMCU[4 ?CS\2OB%^TM8_%K6/@Q\._@)I6C_
M  A\#_%[PK:W7ABW_9IUK5_ OQ.^&WC76_V?_"'AKP_#X[N / DL&L6'BW]I
M7XH^/_&GA+3Y!\&K/X2>#?#_ (_MK0:G<GQM^O&EZ;8:/IMCI.E65MIVF:;:
M6]AIVGV4*6]G96-I$L%I:VMO&%C@MX((XXH8$54BC58T554 ?@UX_P!*\)V'
M[=7Q!U[Q'\*OV;/BQI\O[0OPEM'^-_Q4^%_[2WC76/@KXDU+1_A9IFA?#-OC
M;9_"_P 0?!?P%KUM>7/A_5? /@^S\3:-X<\,^)?%.DP>+-8T_P 2>+(FNOWS
M'([=3T^IZ].?4=CF@#\0?^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]4OCA_R*&E
M_P#8;M/_ $WZA7Y6_P#!2?\ Y22?\$*?^SK?VH/_ %CGX@U^J7QP_P"10TO_
M +#=I_Z;]0KY?C7_ ))7._\ L#?_ *<ICCNO5?F?*E%%%?RN(**** "BBB@
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M48N;C"4E%._+&3M9,1ZM17BW_"V]#_Z&:P_\([7O_EW1_P +;T/_ *&>P_\
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M-8^$=*M[>RTW2X?UF'X]3UQZGT[>G?&,\T ?B#_P4G_Y22?\$*?^SK?VH/\
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M (Q67PX"?8(/'L\-]>WXN3?R>'H/$UY=^-K;PW#XVN9?$3?08    P   !T
M' 'X5PX^K@JLJ#P5.=*$:$8U(34$_:*4G\4$G-J+2E.5Y2:OS-626FGXO^NW
M]=W]!? /_C^\2_\ 7IIG_HZ]KZ7KYH^ 7_']XF_Z]-,_]'7M?2]?T3X<_P#)
M(Y;_ -?,?_ZGXD04445]P 4444 %%%% !52_LXM0LKRPG6-X+VUN+29)H(+J
M)HKF%X)%DMKJ.:VN(V21E>"XAE@E4F.:.2-F1K=% 'YHZ9^P/X8\,>(])N?"
MG[/W_!.O3I-#OM/U30_B1'^QOX>TOQ]H6I:9<P7>FZM::/H.K6&D?\)%IMS;
MQ7=IK6F>)?#\$6HQ0WUIHUBD268_1_2K:[LM,T^TU#4'U:^MK.V@O-4EMK6R
MDU&ZBA1+B^>TLDCM+5KJ8/.;>VC2"$OY<2[%%7Z* /Q _P""D_\ RDD_X(4_
M]G6_M0?^L<_$&OU2^.'_ "*&E_\ 8;M/_3?J%?E1_P %+DED_P""C_\ P0L2
M"?[-*W[5G[3^R;RDGV8_8[^(!/[J0A&W*"F2<INWKEE K]1/C):ZC!X6TY[O
M4_ML3:S:A8O[/M;3:_V&_(DWPNS<*"OEXV'=G.57/R_&O_)*YW_V!O\ ].4Q
MQW7JOS/F>BBBOY7$%%%% !1110 5]=?!+_D2V_[#6I?^T*^1:^I?@_::E/X1
M9[35/L<7]KZ@OD_8+:Y^<&'<_FRNK_-D?+C"XXZU^B>%_P#R4[_[%N+_ /3N
M%'T?JORD>YU\4?%3_D?O$/\ UUL?_378U];_ -G:W_T'O_*39?\ QROD'XEQ
MS1>-]=CN)_M4RR6(DG\F.W\P_P!F61!\F(M&FU2%^4G=MWMAF(K[SQ8_Y$&!
M_P"QQ1_]0L>(X6BBBOY_ **** "BBB@"]IG_ "$M._["%A_Z605^A5?GIIH)
MU&P"G:QO[(*V VUC=P@-M/#;3@[3P<8/!K[K_L[6_P#H/?\ E(LO_CE?MGA%
M_"S[_KYEO_I.-'T7J_RB9?Q%_P"1&\3_ /8)N/Y+7PXW4_4_SK[)\>V6K1^#
M?$<D^L^?"NEW!DA_LRTB\U<#*>8DA>//'SJ"R]0*^-FZGZG^=>1XL_\ (YRW
M_L6?^[6(#HO5_E$2BBBORH04444 %%%% 'T#\ O^/[Q-_P!>FF?^CKVOI>OE
MKX(P7MQ>>(19WWV%EMM-,A^R077FJ9;P*/WS+Y>PY.5SNW<_=%?2MA;WUOYO
MVR_^W;]GE_Z)!:^5MW;O]2S>9OROWL;=O'4U_3'AS_R2.6_]?,?_ .I^) T*
M***^X **** "BBB@ HHHH **** /Q _X*3_\I)/^"%/_ &=;^U!_ZQS\0:_5
M+XX?\BAI?_8;M/\ TWZA7Y6_\%)_^4DG_!"G_LZW]J#_ -8Y^(-?JE\</^10
MTO\ [#=I_P"F_4*^7XU_Y)7._P#L#?\ Z<ICCNO5?F?*E%%%?RN(**** "BB
MB@ KZZ^"7_(EM_V&M2_]H5\BU]=?!+_D2V_[#6I?^T*_1/##_DIW_P!BW%_^
MGL*/H_5?E(]>KXH^*G_(_>(?^NMC_P"FNQK[7KXH^*G_ "/WB'_KK8_^FNQK
M[SQ8_P"1!@?^QQ1_]0L>(\^HHHK^?P"BBB@ HHHH O:9_P A+3O^PA8?^ED%
M?H57YZZ9_P A+3O^PA8?^ED%?H57[9X1?PL^_P"OF6_^DXT?1>K_ "B<7\1?
M^1&\3_\ 8)N/Y+7PXW4_4_SK[C^(O_(C>)_^P3<?R6OAQNI^I_G7D>+/_(YR
MW_L6?^[6(#HO5_E$2BBBORH04444 %%%% 'T#\ O^/[Q-_UZ:9_Z.O:^EZ^:
M/@%_Q_>)O^O33/\ T=>U]+U_3'AS_P DCEO_ %\Q_P#ZGXD HHHK[@ HHHH
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M>-UD1U_;3T$,CHP='4_\*:R&5@&4]B :VO\ AS+>_P#26O\ X+4?^)L:!_\
M.7K[_@GA3%\+PS&.*Q6'Q+QLL+*'U=55R+#QKJ7/[2$?B]LK<M_A=^EW?2WF
MW]]O\C]<OB*Z?\(-XG^9?^03<?Q#T7WKX<9TR?F7J?XAZ_6OFN;_ ((OSW,,
MMO<?\%9_^"TTT$R-%-$_[;&@%)(W!5T<#X,#*LI(89Y!(/%9'_#C_2O^DJ/_
M  68_P#$T]!_^<U7%QIP5C>)\?A,7AL9A<-##X3ZO*.(59RE+VU2IS1]G"2Y
M;32UL[I^0=$O-_C;_(^JMZ?WE_[Z'^-&]/[R_P#?0_QKY5_X<?Z5_P!)4?\
M@LQ_XFGH/_SFJ/\ AQ_I7_25'_@LQ_XFGH/_ ,YJOC?^(2YM_P!#3+?_  '%
M?_*OZL_*Z/JK>G]Y?^^A_C1O3^\O_?0_QK\UOB[_ ,$D+OP)\3_V6/!NC_\
M!4O_ (+!2:9\:OC-XN^'WBM]1_;*T:>^AT30OV<?CI\6[23098_A' EGJ3>)
M?AKH$-Q//%>QOHTFJVJVR2W,5Y:^_P#_  X_TK_I*C_P68_\33T'_P"<U1_Q
M"7-O^AIEO_@.*_\ E7]6?E</JK>G]Y?^^A_C1O3^\O\ WT/\:^5?^''^E?\
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MOC;6-+\,?$K4?BKXR\&>"-3\"^/]5\,2:'JGB[1[FZU>;3+/Q/>^'LWXF?\
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MXCUS4=5TJW\(^#O$7CNRDM=6;5+B^O/%DT]K=6$=HL<WU3110 4444 %%%%
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EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>anticd20revenueschart.jpg
<TEXT>
begin 644 anticd20revenueschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %N 3T# 2(  A$! Q$!_\0
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M\>OB"WCW7="T#Q%XZ^%7P'@\,ZI>>*OA]\')]=&K?%/5-;\8^%-5TGPMX?\
M&GBBSTB?2?#^FR>)[/[/W[#O@;]GKXD:/\1_"VOL9],^ %M\"CX9T?P-\/OA
M_P"#U@;XT>/?CCJWB;2O#'P[T'PUX?T"YU+Q3\0=7M!I.EZ3':QV$%O=7UYJ
MVNSZGJ]_I_&+]DS5?C3XR2;Q3\;?&S_"*Y\?_#3XF:C\)_\ A'O!<TUEXD^%
M.O\ @[Q7X=TSP3\3#I,/CKP/X1U;Q/X'T?7O%.DZ?<W^NW%_=:XOACQ7X2L]
M7GM(P"?X!?M6:E\;?CW^T]\%=0^$?B/X:Q_L]M\'IM(UKQ7K>DSZS\0=&^+&
MA>,=5M?$+^%-(%X/!FGQW'@Z\71M/UC7+OQ'J>DW=GJNMZ-X5NIAHT?LOQ;\
M7?%;PW#X6TWX0?"_2_B-XD\3:Y<:;=WGBOQN/A]X!\%:39:+J6K7'B#Q?XAL
M?#GC;Q.\=[=6=GX=T'2?"O@CQ%?ZAKVKV;:BVB:#:ZIK=G\B>#_V._C[X&^-
M7[2?QWTS]JU+_P 5_M"^"=/\.W.EO\"_!FF6/A?6?A]X4\:>'/@MKFCWTOB/
M7?-D\%2^,9=1U^UU?2-5L?&5Q8VR75IIEFUQ93^L_M+_ +.?Q4_: ^%7@OX9
MZ7^T/JOPYBL[S39/BW<V'P\\/>(-.^.6A6N@2Z?JO@7QAIIU;PY?:)X'\4ZW
M)'K/BO1_!VN:%/XATV!_!>HWLO@W5-=T;5@#Y@T[_@IGJWB[X>ZI\2_ 'P&&
MM>'_ (4? 2;]H[]HR+5OBIH^EW?A+X>P?$#XR> (X_@_/I_A?7-.^,6HZ_'^
MS[\6_'W@G4M4NOAGX6\6> -*\(ZG;ZU8W_CFUL=&^E-"_:WG\2_M>Z1^S+I7
MPNUF'PIXC_9P\<?'[PG\;-6U_2K30/&Z^#/%WP2\.2Z/X0\+V4>I:Y=^'I+7
MXV:1=7/C;6Y-!B;5-,OM(T+0M=MX;O6+;S3Q#^P1J'BSPZNCZG\<=7\/W'C?
MX':;^S3^T"/AO\,_ '@?PW\6/@AX>UCQK=>$_"^@>$_)URR^$>L>%_#GQ"\9
M> M(\1^$+R\:V\(^*=:@BTJ+5[;PEJ_A/HM2_9#^)LW[7/@;]IC1?VA;?0/#
M?P]^'NN_!CP[\'K;X+^%Y])@^#?C#Q+\+/%WB[PD_BY_%$6L?VO>ZW\)/#G]
MB^*(M-B;0--FOK%-'OY'BNT .N^ GQK_ &@/'GQB^+'PR^*?PS^#>@:/\*=%
M\*)K/C#X4?%GX@^/H(/B#XNMU\16?P[O;'QI\$?A? NJ:=\/KK0O&VN7>G:G
MJ*Z79^+_  A926LDNKS2V/H'QX^)_P 6_A[%8O\ ##X4^%O&UG;^&O&7C+QE
MXO\ B/\ %:V^$7P[\'Z)X-M],N?[+O?$,/A'Q]K$_B?Q/'>WL^C ^&+;PEI&
MD^'_ !#K/BWQ7HHMM(TW7LK3?@+XC\!?#3X[Z!\*/B1J'ASXE_&'Q[\6/B=I
MWQ+U;0M"U^Z\*>,?B/J(FT6==!U6TOM$US3? 6C6>@^&M%L-5M)H[[1/#NGV
M]\GF,[CB_P!KO]E_X@?M-IX"T;1?CD/AY\/_  U=:QJ7CCX6:M\*O#'Q-\ ?
M&/4)CIK>%8_B3INLZWX?U#6?#?@R>UO]3M/ QU,^"_$^L7MI>>.=#\2VVA:3
M8P '@3_\%+[35O!^H_&'PC\)9;CX)?#+X1?LW_&/]H;7?%WC>'PQ\1/AIH7[
M2'A;2_']AI.@> K+PSXBTKQ;KWPL^'.MZ1X\^*%KK/C;P1 ND:E;Z=X(N/%F
MNI<V,'JFH_MV:9X7^/?[2'PL^(/PM\4^ /A_^SE^S%_PTWJGQ2\0:II+W/C+
MPKI7C7XH^$_%DWAKP)IC7VIVOA[2XOAE>WV@:]X@U72=3\8/=2-8>%K+1(]*
MU_78/&_["</Q%U'6;CQ/\7_$L>C_ !A\*?"GPW^U?X5T#PIX6TGP_P#M!3_"
M0!-+U15N4U75?A@WBS3=O@SQ[9>%=4OH=<^'UKIOA[3I-"U:P3Q1)SOBW]@W
MQ5\1/VC?BO\ &'XA_'>+Q5\-_C3\$M<_9C\?_!&3X1:'IFF:K^SYJ^J?$36U
M\%Q^.;'Q>OB*UU]-0^)6N1WOC*&S6;4--CM;0:/9W >^(!Z9^R9^UEJ?[26I
M^.--U3PW\+]"F\*Z#X \2"V^'7QUT'XM:OH2>/8-<N(?"'Q+T&'PUX0U7PCX
MST6'2(S<ZAH-MXT^&'B"YEU;3O"/Q#UK4?"NOVUOK>,_V\/V8_AU-X]3Q_XW
MUWP1:?#KPG\2/'&LZSXM^&?Q0\.^']:\+?!Z[MK/XIZQX!U_5_!UGI'Q*M?
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M^F:IX^OM&\,:CJ7A+PI-J$6D06>B7]Q=^)+3Q9XK2T\46OUQ0 4444 %%%%
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M?^%DZCX0\+>J_L?_ +-G[3/[+W[//P*_9SU/XI_"3Q;I'PRU>?PKK/C3PO\
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M'B66#5=;\3_$/7OBAX[^(?C/QS\2_$7B.;5]4\4>-M7\0O/K7GV2-:P?9 M
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M<[O^%2_'S=R2W]C?#G.3G)S_ ,+"SR,Y_&OXH?\ A>VM_P#0 T7_ ,"=3_\
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MRK9K')$8Y'97#LJH0I.Y@!EB ?\ .GE^(/C<22 >*M;P'<?\?G^T?^F=?:>
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M(/)_^ON9_P#JTQ@4445\&?I(4444 %%%% !2, 00<X((..N,=L<Y]*6D;H<
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M56.)J5O;4_K&(4:4%2PD*/U)^U3^R5X9^$WPMU;XF^'O!7Q#^&$?A3]H^^^
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M._@3X7? _P"*OA'X/6\/PC\+A_#WQ%N/#_B_X@?"WX_#4M0\3_M!P^%?A_\
M'#PG\7-%UK2M.\6:WJ/PVN]/UGXI>$H[ZZTB[\'^-_#VEZ#;^'[CX8FR^,OV
MO?"/P^^'7[7'QV\$^#= B\/?#;P=\49=/TWPIH&L7-S_ &!X7%AH.HW&AZ=K
M>O2ZU>QRP6UY>P6&J^()-2GCG>&\U%;S;)#)@:U^U5^T;XC?X9RZ_P#&;Q[K
M<WP>TF\T;X<2ZWK<NO?\(W:7[:N+RX2#7UU6SU/5I[/6[W1WUS6;74=7&@1Z
M?H27J:9I>GV]NNN?M3?'[Q5J?B+7?%WQ.\1>*_$7B?PS9>$=1\1Z^=/N=<&B
M6'CSPG\28(8KVVL;,37/_"7>"?#FI?;M2BU"[06 @AEBC?Y?OL!@<RPDJ3JU
MXXF$:>,IS]KC\7*<OK.+HU:-249T)4IU:%*G47M8QHRM6=&,.6G[2M^;9CF.
M48V-94</+"3G4P%6'LLMP481>%P-6A7IQ=/$1JTZ.(K3I/V,I5XWP_UB<^:M
M[&C]_?#_ ."?[/WQ2U_X>Z5\0/A-\/O@%XSO;OXT_&+PQ\'M'\:_$9]?\0_L
MO_"_X >,_B7X:'[1$=UXA\5^+M$U[QGXS\/>'8O#WB/P[I?A#XC?$+P"OQ"U
MS2?!>GZ;>_#S43S5[\./@+%H%Q\6-$\,?LKZC>>.?@'X*\:_ NV\;^(?C!\(
M/V;_ !O=Z3\;/&?PZ^-_B+Q!X;^(?C73=8^'OQ!T"Q\/Z9HGA/P#J?Q8O_!7
MC,1^(/''@*]UCQ4]GX-L/B7Q5^U9^TEXWUK1O$GBSXV>/]:\2^'O%<?CK1/$
MTNHV-AXGTWQG%#-;Q^*;?Q+HVF:9KS:VMO<3P->W&HSM+#*\4RR1G:(+;]J/
M]HZS\:WGQ%M?C?\ $FW\;ZAX>L/"-[XBB\12+<W'A32;R/4=(\,M8&$Z%'H&
MCZG%'JNC:/!I,6GZ/K"#6=+M[/5BUZW/_96:<RE]=<5R0O06/QDZ"E"O4K2I
MQJ3H_6)4ZT94:=6I4G*:I4JM-0FZ]*KA.EYUD_+*FLOC).I-K$O+<!'$N,\-
M0HQJ.G"O]6C4H3CB*M*C3A"FZU6C5=2,</6H8W[%N_V;_@IX9_X**^//A)=6
M-OJ7[/?P\T[Q#\1?%;ZMK7B0>&?A]X1LO@5IWQ(U.^\9W\E_X:^(.O?#WX4^
M-?$FG67BC0]/OM,^*OBGPCI+>'K-!XSU)DD^??VNOA_X'\(:A\%O$WPY'PXU
M'PM\4/@]%XN_X3+X,P>--)^$/C3Q#I?CSQEX2\1W7@3PG\2]4U/XB^#O^$9G
MT:Q\)>+=%\61Z0]SXOTK5M;T+1+'P_JEB]QXQI_QT^-&DW&FWFF?%?X@6-]I
M'CKQ1\3M.U"W\4:HNHV_Q$\;Z99Z+XS\:-J3S/J%WXA\7:/I]GI7B:]O[J[7
M7M/@6SU2&Z@DG27#^('Q-^(?Q6UR'Q)\2O&GB+QQKMMIEIHMGJ/B+4&O)-/T
M73VF>QT;2[9$@L-(TBTDN+B:WTO2;.RL(Y[FYN!;_:+F>63MPV!S"EB<'5K8
MQU:=#!4L+6BZM1K$5*4*T98B5)TTO;5ISIU:E1U7&*@Z3I5I*EB:7!BLQRRK
MA,=1H8"-&KBLPKXRA-4*,7A:-:IAYPPD*RJRE]7PT(5J-.DJ*E-U%65:A%UL
M-6_I<_X-@_\ DIG[7_\ V(7P5_\ 4G^)5?V%U_'I_P &P?\ R4S]K_\ [$+X
M*_\ J3_$JO["Z_G3Q+_Y++-/^O>7_P#JOPI_5'A)_P D'D__ %]S/_U:8P**
M**^#/TD**** "BBB@ HHHH \ZN_A!\*;_P 4Q^.+[X9_#Z]\:12I-%XNN_!7
MABY\41RQLK)*GB"?2I-82161661;T.K*I# J"/10,<?Y_P ^]%% 'X@?\%)_
M^4DG_!"G_LZW]J#_ -8Y^(->*?\ !RK_ ,F2?"#_ +.<\)?^JO\ BK7L_P#P
M4M:1/^"D'_!"IHH_-?\ X:O_ &G!LWK'E6_8]\?J[;G^7Y$+/MZOMV+\S"O!
M?^#D>ZU"?]B?X0K=Z8;)!^TUX4(D^VVUSN8?##XHA4VP@$;@SG=T&S!^\N/J
M^!O^2MR+_L-7_IJH?%^(G_)$\1_]B^7_ *=I'\3E%%%?UJ?Q&%%%% !1110
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MRMIYD3']A%A<WUQYOVS3S8[-GEYNX+KS=V[=_J%&S9A?O?>W<?=-?RWXE_\
M)8YI_P!>\O\ _5=A?Z_X9G]C^$G_ "0>3_\ 7W,__5IC#0HHHKX,_20HHHH
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M_877\M^)?_)99I_U[R__ -5^%/['\)/^2#R?_K[F?_JTQ@4445\&?I(4444
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M^BBBOZ*/Y8"BBB@ HHHH ]!^$O\ R5?X5_\ 94?AI_ZGOAVO]5R/[I_WY/\
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MK1HPGR2<8N4>:TG%-IM(_%;_ (8>_P""PI_YSBQ?^*ROV7__ )LJ_-KXY_\
M!M=^TE^TC\5?%OQK^,'_  5NUWQ%\1_',^EW'B76K+]A?X,Z#:WTNC:)IOAW
M3VBTG2?B3;Z?9B'2-(L+=Q;PH)I(FN)-TLLC'^LZBN?!9AC\MJRK9?C<5@:T
MZ;I3JX3$5</4E3<HS=.4Z4X2<'.$).+=N:$7:\4UU8_+,NS6E'#YG@,%F-"%
M15H4<=A:.+I0JQC.$:L:=>%2$:BA.<%-)249SC>TFG_&Q_Q"??$C_I*GXG_\
M0O\ A5_\]"C_ (A/OB1_TE3\3_\ B%_PJ_\ GH5_9/17I_ZU<3?]%#G?_ATQ
MO_R[R7W'D_ZG<)?]$OP]_P"&;+O_ )G\OS[L_C7/_!J!\2%P3_P53\3D;D!_
MXPO^%0X9PIY_X6>>@/H?I7B'[-7_  ;/_$[]H#X"?"7XU7'_  4T\0^%9_B;
MX&T/QC-X<M_V0/A?J\.C2:Q 9SI\6I3_ !$L9KU+?&T7$EI;O)U,2?=']RQ
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M_P#B%_PJ_P#GH4?\0GWQ(_Z2I^)__$+_ (5?_/0K^R>BNW_6KB;_ **'._\
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M%_B2TE@^'VFV4VLZ/X:\3^(KK2GT0 -8_;W_ &9=*M/!&LV_C35?$/A+QIX
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M_;H_9M\<V'B'6(O&M[X2T+1/!EC\3M.U_P"(_A?Q'\.M%\<?"G5M6A\/Z/\
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MV@K-!>ZY/IFI> ?B/\//$^EW^G0CQ%I6LZ5XCTK28;L _8WPGX@'BSPQX?\
M$RZ/K_A]?$&C:=K T+Q5I,NA>)M'&HVL=T--U_19Y)9])UBR$GV?4=.FD>6S
MNDE@=BR$UT->!?LO?"_QA\&/@+\-_AEX[\3Q^+?$_A/1;FQO]2MK_7=6T^P@
MN=9U34]*\*Z/J_B>:;Q)K.@^!M&O].\$:!K6O^3K.KZ+X=L-2U.ULKRZFL[?
MWV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***9YD?]]/^^E_QH ?130Z$X#J2>@# D_@#3J "BBOG
M[]HK]I'P+^S/X8\(^)/&VE^-O$$WC[XD>%/A+X)\,?#SPI=^,?%?B;QWXT75
M)="T;3=(M;BT4":WT74[FYO;N[M;*T@M'DGG7*!@#Z!HKYM^$/[4WPU^-5Q!
M9>$[/QMI]_;CXE67BNP\7>#M3\)7WP\\4_"?5?!&E^,/!'CZTU@PS>'O%42_
M$#P]K.C6FV\TWQ'X:EF\2:'JU]HPM[NY]5U;XJ?#30O",/C[6?B!X*TOP/<Q
M3SVWB^_\5:%:^&;J&VM[R[GDM==FOTTN[6&UT^^N'%K=3,(K.[?:5MIB@!WM
M%<E:^//!5Y))#:^+/#DUQ#X;M?&,ULNMZ8+JW\)WL336GB6YM'NEN;70;B-6
M:+5[F&'3WVN!<;D<+QGB[XZ?#KP?)X)CN=6GUO\ X3SXJZ)\&=)D\(6,WBZ&
MP\<Z]IFJZO:67B2;03>1^&[*"QTBXEU+4M7:VM=--QIZWAC.H6ID /8**PM(
M\3^'/$%QK%IH>O:-J]WX?OSI6O6FF:I8:A=:'JBQ),VFZQ;V=Q--I>H+$Z2-
M8WZ6]TJ,',(4@GROXQ_M&?"/X%^ OB9\1/'GBNTCT3X0:+9:_P#$"QT$Q^(_
M$OA[3-2N+2VT^:\\,:5-/K437SWL#64<UK"UU"6FM_,C1FH ]QHKC[WXA> ]
M.TA-?U#QIX3L-"EUF7P[%K-[XDT6TTF77X=1GTB718]2N+Z.R?5H]4M;G3GT
MQ9S?+?P36;6XN8I(EM:CXT\(:0VJ)JOBCP[IK:)8WFI:RNH:YI5DVDZ=IT.F
M7-_?ZFMU=Q'3[*QM]9TB>\NKP06]K%JFFR7$D:7]HTP!TU%4XM1L)]/BU6"]
MM)M,GM$U"'48KB&6QEL9(1<1WL5VCM;R6CVY$Z722- \!$RR&,AJ^>_''[6'
MP/\  WC+X%_#VX\8V/B+QK^T;K]]H_PF\.^#Y[#Q)>>)=/T2!;KQ5XOCEL[]
M;&+P7X1M9(9-?\0?:Y(HI[FUTW3H-2U>YAT]@#Z0HK G\5>&;;5[70+CQ#H<
M&NWT_P!ELM&FU?3H]6O+D6$NJFWM=->Y6]N)QID$VHF&&!Y!8Q2WFW[-&\JY
MY^('@4+9N?&7A4)J.K:?H.GN?$>B[;[6]6LDU'2]'LV^W;;K5=2T^1+[3]-M
MS)>WUFZW5K!-;LLA .OHKRCQ!\<_A%X5^+7@'X$^(?B!X;TCXO?%'PWXP\7>
M / %Y?I%XA\4>'? -QH-IXLU/3;7:4:+2I_$NDIY,TL-UJ DOI-+@OHM&UI]
M.ZC2_B#X$UNT2_T;QGX4U:QDN]6L([S3/$>BZA:27V@PR7.MV:7-G?3P/=Z/
M;PRSZK;+(9].AC>6]C@C5F !U]%<_JWBSPOH6G1ZOK?B/0=(TJ6UGO8]3U36
M=-T[3Y+.VLGU*XNTO;RZ@MGMH-/CDOIKA93%%9H]U(ZP*T@;-XO\*V]P]I/X
MET"&ZCM9KZ2VEUG3([B.RM[%-4GO'A>Z65+6'39(]0FN&00Q6+I>2.MLZRD
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MQWE\!Z7\$+#X"?%GXL>)O%?AWP9I=UH7@7Q3X(A\:_LM_LX_"#6?%.EZO>_
MCXGVGAZSN_''PS^)&L>._ ?@&T\*:W\1SK?@[Q+JOQ)#V.K^%YO+/#'_  2F
M_:+L/A%?0^)_'/@O5/C'IWC_ /87\:S:QI/B>)Y_BCHG[,O[$OP4^ OC[P+X
ME\6?$7X0_$[2=&T[6OC?X'USXQ>&8==^&OC_ $/6=9\.>!]5\3:=IFJW<M_X
M9_23]E']J3Q'^T-\6?C+I.H6*>&M(\"?#/\ 9_N=2^'MW#:2^(?AC\7]>UOX
M_>&OC7X!\2ZQ##!+J6H>&?$GPUTW3()'06%UI]I:^(]%,FD>)+2YN/F?4/\
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MZ%X2\9S^([40W6FQP\M\??\ @HKXF^$1^$OB[5/BG\.?"GA'Q7\>/'_Q+O\
M0]<T6W_M;Q5^Q[X ^*O@_P#9WA\-^$Y;E4DF\6^,+CQA>_M':-XGBD:[?PMX
M,U/PY&$TRZ=X0#W+]MCX9?%;XA>//^"=5_X:^ _A+XF-X)^-WQ*\1_$SX=^(
MK^_E^$&C:;>_L5?M!^'K?2_%OC2V\ ^)+/2?#@\=ZQX>\.^%_$&M> IM+O\
MQ%+X<MFT:SO+ZT6T^6OA_P#\$KOC!X/\#_%72-:UGX2^,/$&H^ ?V"- \$VF
MKWFL2^%_$.C?LQ>.+[X@_%GX >)KB[\%7VI^%_@=\0K!-"^#FGR:9IFO7.J?
M#_0?#USXO\*WEKH<?A6;][5)(&>2,@G&W)4D$@<X!()')X(YIU '\^GQ*_X)
M2?%;XA67Q6\16VA? #PQXC^)?[-O_!4KP-X2\$6EW=W7A?X&>._VS?"7[./A
MOX.>&_!/B-?AW874GA72-4^%_P 4/'_Q)\3:5X=\/3:3XW^+?BZ3PKX;URTU
MS4;VZ])\7?\ !.SXCV?B?XZWGA?X8?!K7[+Q[^U1X3_:P\(>*++XA6OP_P#%
MUAKEQ^R_X9_9Z\6^%=1\/>(_V?/C!\+]>FT#4=$\5^(-,?XE>#OB+X1\5:1\
M3M=OK;2? ?Q"TFRUZ;]PJ* /S<\5_LK?&KQ5^RA^R3\&]6U7X4-\0_@A\=?V
M+/B-XUN/"VE2>!_AX?"O[.GQX\!_$/Q-I7@K1-'\.6]E:WD7@KPH^D^';&Q\
M->#_  ]JFN0Q-::-X%T6\@TO1_(OV#_V _B;^RQXF_9FUK7G^&5HO@#]BOXG
M? SXUW'@J_U"74?'/Q<U[XX?#+XB> _$DEQ<>&-'G\5:-X<\.:1\1K.WUKQ!
M<VNJ:'>>)9+#2=*:RU?4;B#]@** /PVT/_@F%XKM/VNG\;Z_X-^!/B+X!R?M
M2?M9?M*:HFH$76M>*5_:<_9WT/X76GA;7?AO=^ I/#]Q?^"/%ND:I+-J=_XF
MU>RUC0=?35K:*RU9+S2%XO\ 9Y_X)@?M%_#3QE^SGK?Q)\?Z?XT_X0OP;^Q-
M)XTUC2OB9I>FMX*\3_LJ?"?P?X"UOPCX4BU7]F_Q!\2O&/@OQ-K_ (>USQ+8
M?V5\:?A)HWB*W^(GC;2/B!X2NH)+N3QA^_M% 'YW?'G]GKXW7'[0OBWXY_!C
M3/AMXM;XL?LHM^RQXKT3X@^-_$7@$>"6TKQQXW\:>%?B!I,^A> ?'H\6Z>&^
M(WB6Q\1^&77PWJ:_V9H4ND:I<"]U$:?2\>_LW_$_6O@AH7[-T_PE^ 7Q9^%'
MP?T+]G32O!!^)'C[QYX>\4_$N+X=>%+_ $GQ9J-OJGA+P:]]^SM\1?!GB#1O
M!7B3X6_$+PWJ_P 1IM5<Z_I6H67@=YK7Q#;?H]10!\+_ ++?PX_:>^"^E>'_
M  7XUF\/^,? ?B#QW\7/$]ZOB?XZ_$7XG^-O@#X#O+'PW+\)/A1X7\<>._ L
MOBOX_P!NNMQ^*[G7O%7C_P 0>$=2\$Z;J>G>&]!?QGHVBZ;,OW1110 4444
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MWEKWU% 'SAHO[(_[._A[6]9\1:-\-K*PU;7_  K\8_ ^I3PZWXI,#>$?C_\
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M^U">ZO[V6.V@B22[O;FXN[EPTUS/-/))(VG110 4444 %%%% !1110 4444
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M7K[PIH.E^,3JU]I7C&YUC;^&/_!3KXY> _@O\!_!OQ-^&]M\1/C)\3_V=/\
M@GCX]\$>+_"2^/\ X@OJ2_M8>$/BGIGB'Q#\5O#'A'P;'XEOO$WAK7O@!XV\
M3S:7\.["2T\9W/B_P[X7TZX\.SVM_P"()@#]_J*_,CX!?MM_%KXV?'+X>?!V
M_P#@YI7P\^V_ ?7/C5\1[KQ9J'B:P\1Z7!X:^/7Q.^ 0TSP[X1OM)L-4MCXQ
MU'P;H?CG1(/&:Z+K7ACPSJ=]I'BK2SXG@2SA\]^*_P#P40^*O@OQ]\5_!WA[
MX0:;K5CX7_;#T']C'P7JFDZ7\3?B'KM]XOU?]F'P=^U;K'Q \0^!?AWX>U+7
MYO#/AKP)JNM>';/PYX=>;7_%_B]]*BAO/#6AV6K:O, ?KS17Y!P_\%-/%>A^
M&+_4_B%\#;WPMXI'P]TSXR:+X%-_?CQ5K/PO\$:3\9[W]H/4;/1=1M+/4VUS
MP9+\ _$;^&M(NK33[]XOBG\%=/\ &6G^'M>U[5M,MN3\._\ !2KX\:SHGPSM
M[S]GK3]!\4?%WXU?LV_#;PKJ/B^V^*/P_P#"$6G_ +2/@WXQ>(LP0>-_"6C>
M+_%5Y\)KSX70)K7B?1-'M_!?Q&TO7[&Y\)7.B:@NI6&B@'[445^'4/\ P5C\
M=OX)^(^O77P@\'6>L?#7P1\'CJ$1\7:]+H>L?$SQ-_P4:^-__!/WXC:;I-_-
MH]C>-X7TW5O@['XY\(R36@UZXC\4:?HFN6ZS(EQ<]AX5_P""E_QE\<Z9\5?$
MW@O]EOQ%K6AV?ASXVZK\(;;Q'!XM^%L6HZM\'OC)I/P?T[P[XM\=?$/0M(\!
M:]KGQ&_M&[\4Z7I7PRU+6I_#&I:1_P *SU.?5/$OB#P_JUT ?LK2 @C(((Y&
M001D<$<>AZU^?GAO]J'XA^.?V4_VEO'NA-\/['XY? K2OBKI#:5>>&OC!X;T
MO2/&?A;X;6?Q&\&-\0_AG\5?"7@+XF>"YM9T'7O#NO7?AAG\16-SH>I:;JOA
M[QOXATO5HIK?\^/V7/\ @H%^T-H'P*TW3/&^A^&OB;XO\)_!_P#8"\3>)OB'
MXN\<^*X7\7_%[_@I!J>D:=X,_M6Z3P]>VW@3X9_#[Q/X@FU7QEJ$%G/:Z+X9
M2P\+^!?#4:);'3P#^@NBOQ(\?_\ !3OXS^ G^-'AIO@_\,M<\9?LR?"#]L;X
MO_%N\MO&OBZQ\%^+='_8PU']FG7O%FG?"_4V\.WVH)JWCOX>?M"VUG9VWB&W
MNK7X?_$_P[K/AG7M4\0Z3IK:IJ/UQ\(/VS=2\0VG[8L?Q8T'P3X%O?V36T7Q
M3JVNVOBK6F\#7?PW\;? G1/C]X;U?Q%K%WX;N=7\/7_AK0-5OM"\=3V&AZ_8
MH^BOXCT*UN(M17P]8@'W_2$@#)( '4DX _$U^'6D_P#!4?XTW7Q$T?X)7GP2
M\-V?Q+\5?$;]E+0_#VJ^($^(W@'PH_@C]K/0?VG9_#_B+^P_%NCIX^N3X&UO
M]F[4OM%SJ6C^%YO&^D:S&+?PWX(U.VGBA^:_BQ_P4O\ VFM9DU_Q?;0>'/"?
MPCT/]BSXW>+/&O@7PAK&J:-XR'[0?P(_;YL_V1?%6M>"/BW/H<^H:;X0N[S2
M[K4]#BU'0'N1X6U:YM-;TG^VS::Q  ?TLEE7EB "< D@9)Z#GN?2DWINV[EW
M?W=PW?EG/Z5^6OC?XM>,/C_^TGI?P=M/B#\:_P!E[X7Z#\ ?BU\5;;6T\/VO
MPF\=^./'_@3XP:9\-[[5GF^)GAG4KNZ^&OPKT232_&OV6UTJ+PIXZM_B1X8U
M#Q3=:GX:LTTBZ^/M1^+WQAC\)_\ !1?]J#1OVN/'/B?6OV6+[X!R? ZRTBXT
M33_V?OB_'?\ [$7[*WQBMO#2?"&]M]3L3;_M,?$OXCZUIND_V7XD?QAI5S\1
M]'M/!7B2&^T_1Y)0#^@S(R5R-P&2,C(!Z$CK@T @YP0<'!P0<'T..AK\B?B#
M\0OCMX$^,?BOQ!\&?B=\3OVA_$7P]T3]HCXB?M$?#BXTKPM'\!_ 7A;3OA'X
M\\2_L_?L_P#AM=*TF*2R^/T7Q"E^%-@UEX>\:ZOXPU_P+#\0_&_Q5BT73_%_
MPKL(NF_9"^)7Q*@^+?PL\$:S\9?%/QY\,_'']AWPI^U7XI\1>*7\*W:^"?B+
MJ7BSP=HUO-X.?PMINCPZ#X!^+VF^,?$ESX6\(2P7^@:+_P *DO'\,7<)G\1_
M;0#]4,@$ D GH,\G')QZX%+7\[7@C]K7]O/Q3\<OAMX1O/&7PRU36]2_;H_X
M*A_!C0O#BVFL>$?A]J7PT_9[^'&LW'PMT[X@MIFD:MXEU:7PSX@L(;K3KK1D
MM]4U*WN+>^U;4[RZCF\WW[]G7_@JQXS_ &E?%OPON_!O[.'C&P^&WC"7X!>&
M_$M_)H/CW5YM!\1?'3X%^ _C7<^)8?B+'X8TGX31^#?AVGQ%\.>';K2-5UJV
M\;>.[1=9\4^&M/LEL=+\.Z^ ?M/17X*>(/\ @K;\6/#G[+7@C]IZY^#_ ($U
M6*\_9/\ #_[;GCWX6^$;WXF^*?%OA;X'>(M*DN-'@USQ)'X7TSP!X(N==F\,
M^/I](\5^(/$6K)<W>B3^'=/\"ZU!H.N^,6[#XA?\%8O&GPKT3XG?%#7_ (+>
M'?%OPN\$_'3]L;]G32="\">+/$-_\6;_ ,=?LQ>'_'_CC0?$NK:'_P (QJ.E
M:;X'\8^'/ SZ9XHGC:;4_ =WJND>*/*US1M1.D60!^W=!('4XZ#GU)P!^)X'
MO7Y6?#W]O+XL:EXW^#/@#XB?!:;PE<^/?CW\0/A%XA\5ZUX?^(OPZTDZ)X9_
M9&^(?[3.G>*/#?A;XEZ1H_C2P:VUGP/<_#[6(_%VGV.FZG:0MXR\+WU[8Z@N
MGZ3\2?#S_@H?^U#\59+SXF>+D\*:-\%_&OPN_P""('Q,\"^ _AW?:YHOC;PC
MXB_;U_:&L/"'CFWD\<R:5>S>+O#ODVVJ6>N>'[FQ">(=!T[1?#NDW/A^XU[Q
M1J<H!_1=17Q#^R!^TQX^_:,T;1?'7B;P[\+_  SX+^*7PZTCXO\ PJT;P[\0
MKK6?B=HO@[6M>U+1K71_B?X.U/2M.DM-;M[:VT^XU76O#SR:!I7BBXU[X?S0
MRWWAB'Q!XC^WJ "BBB@ HHHH **** "BBB@!K=!_O)_Z&M?YV7Q:_P"2J_$_
M_LH_CW_U+M9K_1.(S^8/Y$$?RK\6/$?_  0Q_9:\3>(=>\27WQ&^/45[XAUS
M6->O(K7Q!X!2VBNM:U.[U2YBMUD^'LLBV\4]W)' LDLL@A5!)+(X:1OZ-^CW
MXE\+^'.+XHK<35L91AFN'RJEA'A,'4Q;E+"5<=*M[14VG!)5Z?*W\5W;9G\;
M?2_\%..O&;+>!L+P1ALNQ%7(<;GU?,/[0S&CE\84\?0RJGAO9.JG[5REA*W,
MH_ E%OXD?@S_ ,$L/^3_ ']F_P#[&3Q7_P"JT\;5_<8GW%_W5_D*_*/]G[_@
MD%^SO^SG\8?!'QJ\&^.OC+JOB;P'?:C?Z5I_B76O!EUH=S+J6A:KH$R:A!IO
M@C2[Z2-+35[B6(6U_;,+B.%G=X@\4GZN@8  [ #\J\7Q]X]X>\0^+,JS?ANK
MBJN#PG#V'RZM+%X6>%J+$T\QS+$RC&G4;<H*EBJ3YUHY.45\)]%]$KPFXP\'
M^ ,]X>XTH8'#YEC^+\9G.'A@,=2Q]*6!KY-D>"A*56DE&%3V^ Q$73?O*,8R
MVDA:YGQCX.\(_$#PSJ_@WQYX8T'QGX1U^U^Q:YX8\4:-8^(- UBS\V.<6VIZ
M/J=O=V-[ L\,,Z)<6\@CGAAGCV311NO35^97_!3:P\3ZGX?_ &0+#PYX2\0^
M/+2\_;L^ ]MXR\&>'KMK!_%'@.XT#XG0>+-#U:ZFN;'1_P"Q-2TZ3[)?V/BG
M4=,\):T98-"\2:GIVE:G<7D/X8?U.?8NH?LW?L]:KX \-?"O4?@E\++SX:^#
M]6C\0>$_ EQX!\.2>%?#6NQ/J$AUK0]#.F"RTK6)7U;5S=:E9PP7]Z=8U5;R
M>X&JWRW,>N_L_?LYW7AK4])\1_!SX2S>$V^&_A'X9:M8:QX%\+G0T^%/PNO]
M0\0^!?!5[#>Z=]BM_!/P]U6_U'7?">D2B+2O"FHW-UJVD)873O<#\5=+_8&_
M:YNM+^*%\NG3>'E/[._AW2?@/X-O?C/-(?A[9W?[;7[2_P 5O$'[-MAXKTG6
M-3N_#GB:S_8Z^(/A7]FNV^+VE"XTGPQIOBG5/#?@OQ5<>%=$NKR?YI_; ^&7
MB'PAK1^'_C?P/<?"'X%?$UOVF_%WP_\ @9XO\:^ &T+X%>!O%O@C]FWX=P3?
M":;7?BWX*^!5Y^U>_CSP=\8?BI\(?AUX)^)?Q.TCX6Z?\2]8M;3P!K-AXYU^
M[TH _I?\#?"7X+^#)M$\0_#CX<?#KPS+8^!K'P+X>UGP9X3\/Z4;7X=+JUSX
MJT_PKI%]H=C"D?A+^V]2N_$5MI5G(-+?4[^?5DB:ZNY+B2'Q'\"?@EXOT;QQ
MX=\5?"7X=>(M"^)OB>R\;?$+2-9\%:#J>G^-?&6F:/X>T#3/%GBBVN].FBUC
MQ/INB^$?"VE:=KU\LFK6%CX<T*UM+N%-*L5A_&*Y_9-^.GC_ %#QSX\U7X-7
M7BGP'\</VM_%'Q)>TUV\^'^H?%SPW^SGXC_9\^&47PIT_2?A?\;M>@^">@6.
MC_%H>,K_ .)G@KX@^&?$7B+P;J7VSQ-X(^'>J>*WTS4M.\Y^%/[ G[;:>%?!
M4_QEM]0\1_$SP?>?\$MM)3Q=_P +@TRXU-M ^#OQ9\=>%OVT)[;5],UO2)73
MQ?\ LU:[:^%_%Q>QT^[^*OA^\;P_%I]]?P'3[, _?32?A#\)=!O/!>H:%\,O
M >BWWP[\)Z]X$^']WI7@S0M-N/!'@GQ3/H-QXD\(^%);/38&\.>&M?N/"WAJ
M?6=#TLV>FZG+X?T>6\MIFTZU:+DO"_[+O[-O@F"RM?!WP$^#OA6VTWQMIGQ)
MT^#P]\-_".C16'C_ $2TU.PT3QE91Z=I-LMKXDT73]9U;3]&U:$)=Z38:C>V
M6G26MK<RPM^+NH_L3?M5^%IM)F\)_"V;Q1K'P]^)?[06G_L\Z5XH^)?@K6O@
MQ\-?AC<_MF_$/XI_ Q=4TUO&_@CXO?!9+#X1:QX2T2T^(G[/_B[Q?X^A\"V-
MA\(/&'PHN?#_ (+TC2-5_H8 P/Q8]^Y)[D_X#L .* /!]2_9;_9LUE=(35O@
M'\'=23P_=>,+[0UO_AQX2NQI%Y\0?&4GQ#\<W6G>?I4AL[CQ?X]FE\:^(Y;<
MQOK'BN23Q#>F757:Z-H?LS_L[?VM\1-=/P)^#[ZQ\7+/4-.^*6I2?#;P=+>?
M$73]6NH;[5K'QM-+H[MXFL]6OK>"^U:UU?[7!JE]!#?:C'=7D4<Z^WT4 >9^
M#?@O\(_AYX(O_AKX$^&?@3PA\/\ 55U5=5\&>'/"NBZ/X:U3^W;06&M/JFCV
M-G#9:E+J]D!::I/?17$U_;*MO=22PHB+EVG[/GP)L-$\2^&K/X-_"^V\.^,_
M!WA/X>^+M!A\"^&ET;Q1X#\!Z/<^'_!7@SQ!IATTV6L>%_"6A7EWH_AO0K^"
M?3=%TVYFLM/M[>"1D/L%% 'B5M^S7^SW9^'X_"=K\$/A1;^&8OAYX\^$J:!#
MX \,1:0/AA\4K_3M6^)?P_;3X]-6V?PA\0M5TG3=4\;Z!)&VG>*]2L;74-=A
MOKR%9AV>G?##X<:1=^,;[2_ ?@_3[SXAP:5:^/+FS\.:1!-XSMM"\.P^$=&M
M_%+I: Z_!I7A6W@\-V$.J?:HK70H8]*B1;%! .ZHH \ \+?LI?LR^!Y-&E\&
M_L_?!GPM-X=U/0=:T&7P_P##;PCI$NC:OX5G\4W'AG4],EL-)@DL[[P[-XX\
M8MH5U R3:0/%&NQZ>]O'J=VDB>(?V4OV9?%FEZ'HGB;]G_X.:]H_AK4/&^J^
M']+U;X<^%+ZPT?4/B7X@NO%OQ$NM.M;C2WBM9?'7BJ\N/$WB[RE5/$7B&3^V
MM62ZU)(KF/Z HH \P^)7P4^#WQELM)TWXM_"WX??$W3]"U&35]%LO'O@[P_X
MLM=*U.>(P7-[I\&NZ??1VEQ=VQ:TO6@5!?6CR6EZMQ;.T1XZY_91_9GO/BL_
MQSO/@'\(+OXQ27OA_4Y/B9=?#WPQ<>-7U7PII6FZ'X7U=O$$VFO?'5_#>BZ-
MI.D:!JPD&HZ-IFFV%AIMU:VUG;QQ_0%% 'S7X3_8X_94\!_$>3XO>"OV>?@_
MX3^)TWB/Q5XPF\=>'/ >@Z-XFF\6>.9-1F\9^)I=4L+2">77_%D^KZG<>(]7
M<M?ZU<7]W<:A/<33NY])^'GP9^$?PDD\2R_"[X8^ ?AU)XRU,:SXL?P1X1T'
MPNWB/55-PR7^M-HMA9'4KF-KR\>)[HR"%[R\>%8WN[EI?2Z* /(;3X ? ^P^
M(-W\6++X1?#>T^)E_JMUKMYX^MO!F@0>+KG7+[PV_@V_UJ;7HK%-1DU?4/"3
MGPSJ&IM.;Z_T%8M)O+B>QABA3+T/]F3]G3PSX@\$>+/#OP)^$.A>)_AKX6TG
MP1\/?$.D_#KPE8:SX(\'Z!I\VD:%X9\*:E;:3'>:#HFAZ3=7FE:-I^FS6\&D
MZ9?7VGZ>MM9WUW#-[E10!\]ZS^R7^R]XATKP?H6N_L\?!35]&^'O@FX^&W@7
M2]2^&/@V]T_P?\/;K36T>X\#^&[.YT>6#1_"4FF.UD?#MDD6DK!A8[5" U<O
M\*OV*_V=/A'K/Q(\3:%\.O#FN>*_BIXU^,?C+Q9XM\7>&_">N>*)X/CGXE?Q
M1X[\#P:Z/#UI?GX=SW9AL;'PG>RWUK'H]I::=?3:C' K'ZLHH \&T_\ 9:_9
MKTKP3:_#;3?@%\&[#X?V7BS3_'EIX+M/AMX0@\,6_C;2C%_9GBV'14T@6*>)
M-/2W@M[+6A#_ &C:V<$5C#<)91K;B2Y_9@_9RN[SP;J%S\"OA)->_#S0/#/A
M7P+=2?#[PP9_"/AGP7XIT?QQX-\/^'I!IH?2M&\(^,] T;Q9X7TVU*6?A[Q)
MIMGK6D0V>HQ"X/NM% 'G'@GX/_"GX:ZQXP\0?#WX;>!? ^N_$'53KGCG6/"?
MA/0O#VI^+]8-Q>7;:EXDOM)L+2YUB\:]U+4KYI[Z29FO]3U.^.;S4;V>X]'H
MHH **** "BBB@ HHHH **** "BBB@ HHHH *0C..O!SP2/SP1D>QR/:EHH *
M0J#UST(X9EZ]?ND<\<'J.Q&32T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>avonex.jpg
<TEXT>
begin 644 avonex.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !5 .(# 2(  A$! Q$!_\0
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M0JJ.PJ6N&M5=27,Q-B8HI:*R$(.E+2#I6=X@U-='T.ZO6(!B0E<]V[4TFW9
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M*** $'2O./BUJVV"TTN-N7/G2 >@X'ZYKT?M7.:OX$TK6]0>\O?/:5@!Q)@
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M&JS<?$;48,7;>'[A=-)XF?()'KTQ6TJ4IPAR]@/0**Q7\5Z:GAO^V_,)M2.
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>benepalia02.jpg
<TEXT>
begin 644 benepalia02.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !S -\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MJG?:I;:>/WSY<]$7DFHJ5(TX\TW9";MN7**Y:X\3W,A(MXTB7U/S'_"J3:Q?
ML<FZ<?3 KRYYSAXNT4W_ %YD.JCMJ*XN/6]0C.1<LWLP!K0M?%#@A;N$$?WH
M^OY55+.,/-VE=>O_   56+.DHJ&VNX;R+S+>0.O?'4?45-7J1DI*\7=&@444
M4P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***J:E>BPLGFZMT
M0>I/2IG.,(N4MD#=BCK6M?8\V]N09R.6_N#_ !KEF9G<L[%F8Y))R32N[2.S
MNQ9F.23W--KXS%XN>)GS2VZ(Y92<F%3VUE<7AQ;PL_N.@_&MC2/#_FJL]Z#M
M/*Q>ON?\*Z)$6-0J*%4= !@"N["91.JE.J[+\?\ @%1IWU9R\?AB[89DDB3V
MY-/;PM< ?+<1$^X(KIZ*]191A;6L_O-/9Q.0^P:GI,OGQH>.K1G<"/<>E=%I
MFI1ZE;[U^61>'3T/^%7:J/81BZ6YAQ',.&(Z./0C^M51P<L+*]*5XO=/\T-1
MY=BW1117HEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<SXHN"
MUQ#;@\(N\_4__JKIJXW7V)UF;V"C]!7E9Q-QPUEU:7Z_H9U7[IG5L>']-%W<
M&>5<Q1'@'^)O_K5C]*[C2[86FFPQXYV[F^IY->/E6&5:M>6T=?\ (RIQNRW7
M.^+?%?\ PC"6I%K]H:X+#!DV[<8]CZUT5>:?%67.H:=%_=B=OS(']*^SP\%.
MHHO8Z13\5;G/&EPX]YC_ (5O^'/'UIKMVMG- UK<O]P%MRN?0'UK-\%^%M)U
M+PM'<7]G'++*S_O"2" &(&#VZ5Q&B)M\4V"0,6"WB!&]0'Z_E77[*C/FC%6:
M ]THJ*YN8;.W>>YE2*&,99W. !7,R_$C08Y2BRW$@!^^D)Q^M<,:<I_"K@=7
M15'2M8L=:MC/I]PLR X8#@J?0@\BJ4OC#1X=6.FR7+"Z$@B*^6V-Q]\8[TE"
M3=K ;=%<Q>?$+0K.X:'SY)BIP6AC+*#]>_X5M:7J]GK5F+FPF$L><'C!4^A!
MZ&G*G.*NT!=HK-U?7].T.-6U"Y6,O]U "S-] .:QX/B-H,TH1IIX@3]^2(A?
MS%.-*<E=(#JJ*KSWUO;6#WLD@-LD9D+K\PVXSD8ZUDVWC70[J">9+T+'  7+
MHR]>F,CD\=!4J$FKI ;U%<O;?$/0;BY$/GRQ;C@/)$57\^WXUTX.1D=*)0E#
MXE8!:*Y[4O'.AZ9.T,ET994.&6%"^#Z9Z?K5>#XC:!*V'GFA]Y(3C],U2HU&
MK\K V]9U(:/I%S?M'Y@@3=LSC=[9K#\,>-O^$DU*2T%@8 D1D+F7=W QC ]:
MD\=72-X(NI(V#),(PK#N"P/\JYCX5Q9U34)?[L*K^;'_  K:%*+HRFUJ!O\
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M/7H?I5*'Q/!)>0PS6MU;I<'$,TJ860]OSK*U(.? NGK,I#;H58,,'KBM'QD
M-&B?H8[F-@?3F@"IXHOF74M.C^R7#""Z5PP7B3C[J^IKHK*Z-Y;"5K>:W))&
MR9<-61XF_P"/S1?^OU:WZ "BBB@ HHHH **** "BBB@ HHHH *Q?%_\ R*]Y
M]%_]"%;517%O%=PM#<1K)&W56&0: *5IJM@MG K7ML"(U!!E7T^M4?%Q\NUL
M;A@?*@NXWD('1?6KW_".Z3_T#K;_ +X%:#HDB%'561A@JPR"* .<\57,%UHU
MK-'(DUH+J,RE#D;??]*9XFOK67^RX()HW8W4;@(P.%'&>/K6_'IUI%:O;1VT
M2P.26C"C:<]>*@AT'3+=0(K&!0'#_=YW#H: *&L_\C1H?^]+_P"@T:I_R-^C
M?[LO\JV9+6":>*:2)&EBSY;D<KGKBA[6"6XCG>)&FBR$<CE<]<4 8<,T=CXU
MOEN'6,74$;1EC@,1P:OV&L+J.IWEO @:"VVCSU;(9CU'X59O=-L]20)>6\<P
M7IN'(^AJ2UM(+* 0VL*11C^%!@4 8WA#_D'WG_7Y+_2H]+GBL?$NLP7$BQM*
MZ3)O.-PQSBMVWM8+1&6WB2-68NP48R3U-0WVE66I;?MEM',5Z%AR/QH STU
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21D=#4U%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biogenidec.jpg
<TEXT>
begin 644 biogenidec.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !F :L# 2(  A$! Q$!_\0
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M% !1110 4444 %%%% !1110 4444 )7*?%?_ ))=XP_[ ]Y_Z)>NKKE/BO\
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M_9-_;,F^(VJ6_@[QL88]?E&+'4XU$:7C 9,;J.%DP"1@ -C& <9^@OB_\(=
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M"KD#&< D<"OQ)D_UC # R?YU]GE+I5Z3A*"O'J>)C%.G-24M&?M3\.[V?4?
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M<;HX;MXP?[WV=Q^>"?RK]4.M?C5\$?B"/A;\5_#/BAPQM["[!N%098PL#'(
M.YV.V!ZXK]B=)U2TUS3;74+"XCN[*ZC6:">%@R2(PR&![@@U.>0E[:,^C16
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M/^3E/$/_ %[VG_I.E?J/#;QVT2QQ1K%&HP%10 /PK\N/V[/^3E/$'_7O:?\
MI.E8Y3/VF-E.VZ;_ !1IBX\M!1['U'_P3A_Y(=J__8?G_P#2>WKZI[5\K?\
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MRG*G7FI+J>C1DI4XM'YE_P#!0C_DX$_]@FV_]"DKVO\ X)I?\B1XR_[",/\
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MT!? & <A0"?J*_2?Q=\,_"?CZ,+XC\.:7K14862\M4D=?]UR-P_ UP:_L?\
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M-='3QF(^LUG52L*C2]E#D;N?EQ^U!^RCK7P<UV\U?1;2;4?!5PYDAN(E+M9
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M(?\ KWM/_2=*_4WUKD]<^%?@SQ1J4FHZSX1T/5M0D #W5]IL,TK    LRDG
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M4UE1O*]SI;*.2&SMXY9/-E2-5:3^\0 "?Q-6***\YLZ@HHHI %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biogenlogostandarda06.jpg
<TEXT>
begin 644 biogenlogostandarda06.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                        9&5S
M8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="                             &1E
M<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V
M,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ                                  !V
M:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,
M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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MQQMEM;KJT---(4XZZXI*&VVT)-2UK6HR2A"$D9F9GH1#Z 7$-:*N*^$@"IV
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MC)(CTM-?,>D'L-"L[%<JI 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MIH;9K7%C2 YW$]K-A.S>ZOF4*_\ 2'=FOF[;G?QIQ7^]#87]E74'TK9_BY%
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MUOC/M9\HF/";O#S[T[+U-S[!ZAKGY[LKSUUO[9BI!#HNN?R B B B B B B
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M_81+HOR9]V6)]5)[>52("*E)Z B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MMO.ZN1LZ1OV[2VGX-_G:.$G>7-<3O6LO,+!'"9UT\+:6-U61G4'5_"-\SCQ
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M>V9ME0EXR"U[6]>U7K6D>,_A1NF_]-G(WFGRK0LV]&ZX?L[?J%>T/B@MG?\
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MJZZZ^ZX^^XX\\\XMUYYU:G'777%&MQQQQ9FM;BUF9F9F9F9ZF)3:T- :T -
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M;3#'3W>/?/9MWR6Y$[:=)+6?A6@;R71M%.G?22]/<X.7^I'M@M;]D%V[='<
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M6S;N9$QK&^4AH%2>EQJ2=I)*U?R>6RF:NG7V7N)KF\=O?(]SW>0%Q- .@"@
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MCY.\.'3#DC[K,/ZF3V\JYS\Y?>;EO71^QB4=XE51B@(KE_D+?R'[;_3KGO\
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M>J'$NQW'F'(^YB<N<)S$PQL,@!'D8P3!<  OB?\ 4XHW?+C)HX;06O#7#/-
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M"*RTN::TG.I-*3-,9E]6BR,M=%]OOC_$#RNOY.Z??26[R:#O8)6@_P )K'M
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MH.:&;K<D^;4FHV-TGJ22N<C9^ E<=MPQHVM>>F9@VUWR,!)]-KB^? :QK8]
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M]KFU-*KFD9>L40$4AOEB<JY_%/E=@M[-LE1=M]Q)\';?=*(ZZ2(!8YD4]B-
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M6.4V2YTJ.I78:6)DV46&1DOH(U$OP?A#9*3HE:R/N* \EXI],P3%F*QM[<1
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M/.YSYWN+G.<27.<34N<3M))VDG:3M*WXBBB@B;#"UK(6-#6M: &M:!0  ;
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MCJ=):QLH'8XJ ?$7A(\AH9N6#1\XL+ICN*FT1S'NGM[ Y[HB>UH5-D;^K1=
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M+*,/<=[I(QW;W'[9["?.N9?,/$1X+7&4Q<(#;>.\D+ -S6//>,:/(UP'F7*
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M /@KOI_R6 ?CB+3^RSJ_Z1QO_'_JE=/VF=)_^0R/_!_K4_I"?&?_ ,%=]/\
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MI_+UQ_\ T8[D?Y.AB!?$A[LI?[9!_**G#P]^\>+^R3_R0KJPYZ+?9 1 1 1
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M_P XB_PUVMAO#3_WU=_Y3+_B+57"!H8MX$!$!$!$!%1<\X[Z1_D9_JB^0C;
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MQ)FRW&X[*W%$VA1DA"E'T(S$F\F[NUL>9F*N[V6.&U9-(7/>X,8VL,H%7.(
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M)\1QY:42K1Y"'GTH2W'CQ^>?-;FOD^9&1;&UKK?3EN\F&&NUQW=[+389"W8
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M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(HT>=_P#@3OT;?^"L?RX?^*1^P?\
MZ?\ \T2_RT_G!_W=\8__ (C_ %__ .7G44<Q?YL_]J[A_P#EO)T?ZO,JE')O
M_"+7^15_<OY,G^#_ /O*'_[J_P#2_P#9O$&\FCOBL_[AZ?\ \AO^*?C?ZOLJ
M+2W5OQG_ /X#^X;OC#XO^GQ:KBH2$L"0$0$6Q-KO^M\#_N\_N?\ WH_]4/\
M#(G^'_\ I?\  ^(+5F?^@=_U?]W_ )W<?B_Z;Z*YXC_KF_\ 2_WC^:WC?_IN
MJK,? S_"<?\ H9_\*K_^I'_?S^QI_9O_ &K_ -1_PWBC3_F9\27W@;G?SW_1
M>;LZ^SA6V/+GX\?_ &)O;_-?]9Y^WJ[:JQ<Q^PL_L7[$W^P?L/O"_8?^"_L?
MM#5%WQCOW]._S]JVA;\4;MW1N\R^4?E?4!$!$!$!$!$!$!$!$!$!$!$!$!$!
C$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biosimilarschart.jpg
<TEXT>
begin 644 biosimilarschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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M_FTK\5:*/]6LB_Z%N'_\J?\ R?E^?=A_KAQ+_P!#?%?=2_\ E?E^?=G[5?\
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M[_Z@/Q KV^&_^1[EG_83'_TF1\[Q;_R3F;_]@K_].0/Y9****_=3^:0HHHH
M**** "OZSO\ @BK_ ,F:2?\ 98OB5_Z%H%?R8U_6=_P15_Y,TD_[+%\2O_0M
M KX_CC_D2+_L,P__ *35/O?#C_DHW_V+L7_Z<PQ^N5%%%?CY^]A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY^]G045S_P#84G_0<U[_ ,#H?_D.C^PI/^@YKW_@=#_\AT =!17/_P!A2?\
M0<U[_P #H?\ Y#H_L*3_ *#FO?\ @=#_ /(= '045S_]A2?]!S7O_ Z'_P"0
MZ/["D_Z#FO?^!T/_ ,AT =!17/\ ]A2?]!S7O_ Z'_Y#H_L*3_H.:]_X'0__
M "'0!T%%<_\ V%)_T'->_P# Z'_Y#H_L*3_H.:]_X'0__(= '045S_\ 84G_
M $'->_\  Z'_ .0Z/["D_P"@YKW_ ('0_P#R'0!T%%<__84G_0<U[_P.A_\
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M(%>WPW_R/<L_["8_^DR/G>+?^2<S?_L%?_IR!_+)1117[J?S2%%%% !1110
M5_6=_P $5?\ DS23_LL7Q*_]"T"OY,:_K._X(J_\F:2?]EB^)7_H6@5\?QQ_
MR)%_V&8?_P!)JGWOAQ_R4;_[%V+_ /3F&/URHHHK\?/WL**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CF3S(I8]TB
M;XW3?$YCE7>I7=&Z\I(N<HPY5@&'(%24AS@XZX..G7MUX_/B@#\*/BQ\7_A#
MH/[0.K?"GP]^S9\*/$OB/X?_ !I\'^%OBAXI\8^,/$U]^T6_@[Q]KO[/?@GP
M-KWAO6X+"?QGHWQ ^*/CSXW>)=<^$4.M>.?[/\8^!O@+X]U?3[^TOKF6/PA^
MY6F64>F:=8:;%->W,6GV=O8Q7&I7MUJ6H3Q6D201S7VHWTL][?W<J1J]Q>WD
M\]W=RL\]S-+-(\C?B%X_^(36/[??B+X=>/\ 5OB;XE\3:K\8/A?=?"K2/"W_
M  4)\*?!?2=(\&7?A[P9+IV@ZE^S/H/Q/\+'6A9ZK;>*O$<.E^*=%UGQ]\7-
M'U/6DM=.OM"2RTQ?W*'3\^^>,\'/H>H]!Q0!^(/_  4G_P"4DG_!"G_LZW]J
M#_UCGX@UM?\ !</_ )-8^&__ &77P[_Z@/Q K%_X*3_\I)/^"%/_ &=;^U!_
MZQS\0:VO^"X?_)K'PW_[+KX=_P#4!^(%>WPW_P CW+/^PF/_ *3(^=XM_P"2
M<S?_ +!7_P"G('\LE%%%?NI_-(4444 %%%% !7]9W_!%7_DS23_LL7Q*_P#0
MM K^3&OZSO\ @BK_ ,F:2?\ 98OB5_Z%H%?'\<?\B1?]AF'_ /2:I][X<?\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$#_@I/\
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MB@ HHHH **** "BBB@ HHHH _$#_ (*3_P#*23_@A3_V=;^U!_ZQS\0:VO\
M@N'_ ,FL?#?_ ++KX=_]0'X@5B_\%)_^4DG_  0I_P"SK?VH/_6.?B#6U_P7
M#_Y-8^&__9=?#O\ Z@/Q KV^&_\ D>Y9_P!A,?\ TF1\[Q;_ ,DYF_\ V"O_
M -.0/Y9****_=3^:0HHHH **** "OZSO^"*O_)FDG_98OB5_Z%H%?R8U_6=_
MP15_Y,TD_P"RQ?$K_P!"T"OC^./^1(O^PS#_ /I-4^]\./\ DHW_ -B[%_\
MIS#'ZXMT/T/\J_B^_P""H_\ R?C\?O\ L)>"/_58^"J_M!;H?H?Y5_%]_P %
M1_\ D_'X_?\ 82\$?^JQ\%5\MP%_R-L5_P!BZK_ZDX0^T\3O^1'@O^QK2_\
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M% 'X@?\ !2?_ )22?\$*?^SK?VH/_6.?B#6U_P %P_\ DUCX;_\ 9=?#O_J
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M'B981TK5J-7F]G&OS_PISY>7GBO>M>^E[.W[%45^.O\ PGG_  7B_P"C:/\
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M7AG3/"F@SZ[=V]]K$NF:5%Y-L^I7EK9Z?;W-VR']]-#96L;MRL*=*77/C/\
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MO%IMV]S);VT]E=>BUYYX+^+GPK^)%WXLL/A[\2? ?CJ^\!ZHVA^-K+P?XO\
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M/N/-\-Z5I&N>&]2\.^*DFF\+Z=9)8>$_"D]L;*UT6+]S-B?+\J_+]WY1\O\
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M#;X0_"K4K#2_@K-\5?V7OBCHGPX_9F_8,L?V8?C]X'@^'L?B2\^-7Q&7XB_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>collabprofitsharechart.jpg
<TEXT>
begin 644 collabprofitsharechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN:[OHFE<#K****^A **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\/?] >P_\!T_PH_X1CP]_P! >P_\!T_PK=HH PO^$8\/?] >P_\  =/\*/\
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MXU_1@C#_ .$G\/?]!BP_\"$_QH_X2?P]_P!!BP_\"$_QK<P/?\S_ (T8'O\
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M\: ,/_A)_#W_ $&+#_P(3_&C_A)_#W_08L/_  (3_&MS ]_S/^-&![_F?\:
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M_0OZY_WZTS_Y;5_1@C>HK!_MFY_Z%_7/^_6F?_+:C^V;G_H7]<_[]:9_\MJ
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MT/\ \&&H_P#RIH\WQ+_SYZ'_ .##4?\ Y4UO4UW6-&=L[5!)(!. .IP 2?H
M2>@!) (!A^;XE_Y\]#_\&&H__*FCS?$O_/GH?_@PU'_Y4U^=/PY_X*<^ ?B)
MX8^,7CFR^"WQFMO!/@#QWX!\ ?#7Q':0> ]=MOCOXB^*FF?!,_#GPSX3CTKQ
MK*/!OCSQ;XB^.GA#2[/P9\29O"\^E:1=KK_B74M#FTKQOH?@G[ ^!OQQL?C-
M9^-K*Z\)>(OAUX_^%OC!? /Q-^'7BRY\/7^M>%/$L_A;PUXWTHQZMX4UC7?#
MGB#0?$G@WQ?X;\3>'=>T;4YH+S3M4^R7UOI>NZ=K.CZ< >K>;XE_Y\]#_P#!
MAJ/_ ,J:/-\2_P#/GH?_ (,-1_\ E36]10!@^;XE_P"?/0__  8:C_\ *FK]
MB^IMYO\ :,-C"!L\G[%<7-QNSNW^9]HM+79CY=NS?NRV[;@9OT4 %%%% !11
M10 4444 %%%% !1110!^('_!2@@?\%(_^"%)) '_  U;^U!R>!_R9S\0:_5#
MXX.G_"(:7\R_\ANT_B'_ $#]0]Z^=/VX?^">?PU_;JN_@=KOB[XO_M'? SQQ
M^SKXP\4^./A7\2?V9?B3I?PP\?Z!KGC/PE+X'\0,FOZEX1\6[;>]\-7-YIC+
M:6UG/]GOKV%KAX+J6%OD>\_X(K_VA$L-]_P5A_X+17<*N)5CG_;6T!D$BJRJ
MX ^# ^8*[J#Z,:\C/LNJ9OD^/RVC4A2J8R@Z4*E52=.#<XRO)03E:T>B;\AI
MV:?9W/IC>G]Y?^^A_C1O3^\O_?0_QKY5_P"''^E?])4?^"S'_B:>@_\ SFJ/
M^''^E?\ 25'_ (+,?^)IZ#_\YJOQW_B$N;?]#3+?_ <5_P#*OZL_*Z/JK>G]
MY?\ OH?XT;T_O+_WT/\ &OE7_AQ_I7_25'_@LQ_XFGH/_P YJOF[3O\ @DY?
M7?[6_BOX%2?\%2O^"OP\(Z'^SIX!^+%I.G[96D#Q"WB3Q1\4OB9X*U&*XO#\
M)3;OHR:7X.TN2SM5L(Y(KU[Z5[N83)%"?\0ES;_H:9=_X#BO_E0'Z=[T_O+_
M -]#_&C>G]Y?^^A_C7RK_P ./]*_Z2H_\%F/_$T]!_\ G-4?\./]*_Z2H_\
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M)'N WQNN4/XN_P##F6]_Z2U_\%J/_$V- _\ G+T?\.9;W_I+7_P6H_\ $V-
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MQS?5-%% !1110 4444 %?&?[97P@_:-^-WA?PKX&^"7Q-^'_ ( \%W^H:O\
M\+LTCQ9H_P 1$\0?$7PJ]C;P:5X)\.>/_AKXT\)>)?AWHNHW<NH/XZU'0O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>corporatestrategy.jpg
<TEXT>
begin 644 corporatestrategy.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MO&$(WDX7O.246[^2;LC;"X>5"4YNT5*UH1;:5O-VNST:O)/4"@ H * "@ H
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MF$C$$9PR@*.<XYZ=>] ':T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % %(:;:J_FB&(29SNV+NSZYQG- %V@ H K7%E;W6//CCEQTWH
MK8^F0: )HHD@4)&H11T50 !] .* 'T % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 (2%Z\4 -\Q.F1^8IV$/'M2&% !0 4 % !0 4 % !0 4 % !0 4
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M]>L-1MM4A%Q9RI/$W1D8,/H<=#Z@X(]*\R47!\LDT^S/2C)25XM->1=J"@H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MN8X/OD ^G?\ *@#/?5E'W%)^IQ_C0!7.K2=E4?G_ (T .75G'WE'X$C_ !H
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MU6V4)#>$B4#H)QR6QV\Q>3_M*Q_BKW\'5YHNE+>.WI_P#PL72Y&JD=GOZ_\
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MAA4*BCL!_,GJ3U)))YKY*4G-N4M6SZF,5!*,=$B>>>.UC::9A''&I9F8X55
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M]%LV(<@\23#@GCJL?*K_ +6X^F.S"4?9Q]I+XI;>2_X)R8JMSR]G'X8_B_\
M@'D%>F>:% 'L'P4MEEUF:8C)@MCM]C(Z@D>^ 1]"?6O+QSM!175_DCT\&O?;
M[+\SZCKY\]T\/^-^NO96$.F1-M-X[-+CC]U%@[3[,[#/LI%>O@*?--U']E:>
MK_X!YF,GRQ4%UW]$<IX7\(ZOX6AL?$NFP_;Y9XW^T6N0C+%+@QE">^T L>2#
MQ@KFNFK6IUG/#U'RI-<LM]5O<PITITE&M!<S:=X[:/:Q[UX8U:ZUJR%U?6QL
M9B[H8BX<@(Q7.0!C.#D$<$>F*\:K"-.7+"7,K+6UMSU*<G.-Y1Y7=Z'*_%NU
M6X\.SR$<P/#(/8^8J?R<BM\(^6K%+K=?A?\ 0PQ2O2?E9_B?(]?3'S@4 *K%
M"&4E64@@C@@CD$'L0>0: /5-=^*%QK&B1:4,I=,-MW*.-Z+C;MQ_SUZR=,8(
M'#&O.IX54ZCJ?9^RNS_X'0]">)<Z:I[2^T_+_@]3RJO1//"@#M/AU:K>>(K*
M-AD+(TF#ZQQNX_(KFN3$OEI2MZ?>SKPRO5BOG]R/LN::.V0R2LL:+U9B%4=N
M2< <U\NDWHMSZ1M+5Z(R;S7+>W 2)EFE;[JJV0,]"Q7<0/0 ,[=%4\XTC3;W
M5E_7]=NY#FEHM6<5JT[3R.+IG+Q0NZ1N J!BA*S>5Y@0+&<!%E\R1W/0$ #K
M@N5+EMJTKK??:]KZ];621S2>OO=%HNFV]KVT\[MLB5KJR:*([(GD E@D)WMM
M^4.I<;648S+L;<FTLI8D "O=E=ZV6C6WII^%UKU%K&RVZI_\'\3T1"NJ60+
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MH 56*'*\$=* .DLKL7"X/#KU]_>@"X[B-2S< =: .9NKIKEO11T']3[T 5*
M)8(3/((QWZ^P'6@#J<"WCP@ "C@$X'XGG&>YP?6FNP;&1;WUU-%;R!8"97*R
M;9"5"X8_NR%(+8&2"<<8SSD:N,4Y+71::?F9)NR>FN^OY%BXO)HKV"U1$:*9
M)6=BQ#KLVXVJ%(()8 DL.O'O*BN5RN[IJVFFI3;4E%;._J9^H6PMW!7A7SCV
M/<?U%9EE"@":"=K=MR?B.Q% '40S+,@=>G\CZ4 8M_>^8?+C/R#J?7_ZW\Z
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M%0Y_"O,QL;TTUT?YZ'I8.5IM=U^6I]6U\\>\5TM(8S(50 S',A[OQCYCU/'
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M==_30=KER&DCM5ZY\QO8#(7\R2?PKG-BA0 4 9,K[V)_*@#1@?>@/<<4 2T
M0RS&V*3CI$P8_P"[T;]": .CU.Q_M6W'DN(Y5VR0RX#!6&&4D'JIXR/3D$$
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MM[7NMC#F6K;V>FEG;MKOZ;[&QH\,=Q>W%ZA,D1V+$[)MP?G9P#A2VTOM#8R
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M93!HMZXXQ;2_JI']:WHJ]2"_O(PK.U.7^%GP^*^N/EA:0!0 4 % !0 F* #
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M.'Q[&@#1H * &LBN,,,B@#,DT6UD.XQKGZ4 6X+*&V_U:A?H* +5 !0 4 %
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M%J,+GU-9LM%D\4BCW6YT7PS;W]IH4MC,LU_!"PNH[B3Y'E4X/ENY4_,O.00
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MJ *\=K'#*\Z#$DN-S9)R%Z#!. !Z#% %5M'M63RRF%WF089@0S=2I!!7/HI
M]J &MHMFR)'Y>!%G;M9E(SUR003GODG/>@!?['M1&D00A(F+)AG!4GK@AL\^
MF<4 /BTJVAE\]$P^21RV 6ZE5)VJ3W( - &A0 4 % %RP3?,OMS^5 '3T %
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MH)!$)A)N)4-]W!& >_)XH REU.]FA3RR"RR2)(T:(SL$P%9(V(!!YW;>F.U
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M0!U% &WI,. TI[_*/ZT ;% !0!XA\9_#QNK2+6(5R]J?+EQ_SR<_*Q]D<_\
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M]L'/S$\^] %ZZT^WO<?:(U?;TSD$9ZC((./;I0 HL+<$L$4%D\LXX^0?PX'
M'T H C&F6H&/+7&SRL<GY/[O)Z?K[T )'I-I$K*D2@.NQAS\RYS@\\\]^OO0
M!)!80VF6MT5'*[0>3P.5!YZ _C0!7TW3VLS++*5:6=]S; 0H] ,\^YSW/XT
M:#6IG.]1PG+?3_/Z4 -GMX[E/*E4,AP<'...1TQ0 UK2%Y1<,@,H4J&[[3U'
MH1R>HH @ATNUM]WE1(N\%6XSD'J.<X'L,"@!D6CV<&3'$JY4H<9Y5NHZ]#^G
M:@">2Q@EB%NZ*T28"J<\8Z8.<C'KG- #5TZV1418U"Q-O0#/RM_>Z\GW.:
M:;:K-]H$2B7.=V._KCIGWQGWH Q9=!>:<R.80AE$A94(EP#D+UV<GJP&3U/I
M0!HV^GNMX][.4+%0B! 1A0>K9ZL> <<4 ;,<9E8(O4T =9%&(4"+T H DH *
M *]W:Q7L+VTZAXI59'4]"K#!'Y&J3<6I1T:U0FE).+V>A\5>+?#4WA74'L9<
MF/[\+XX>(D[3]1]UAV8&OJZ-55H*:WZKLSY>K3=&3@]NC[HYFMS * "@ H *
M "@ H * "@ H <B-(P1 69B%50,DDG  '<D\ 4;:L>^B.M\3^!KOPA';RW&&
M6Z0,Q4<1RXRT)/J!@@]&^;'0US4J\:SDH_9?WKN=%6A*BDWU7W/L<A72<QTW
MA+Q"OA>_%^T7VE1')&8]_EY#C!.[:_3Z<^HK"M3]K'D3MJG>U]ON-Z53V4N>
MU]&K7MN=!-X]BLXXX="L8]-C6XCN909&G,KQ'**S,%(0=<#OR".<X+#MMNM-
MS=G%:<MD]_F;.NHI*C!05TWK>[6WR-&;XG%[N"Z2WFVPW#7$D<M[-*&8HRJD
M:LOEPHNYB!Y;L.@8"H6%M%QYEJN5-02MKN^K?S1;Q/O*23T=VG)OY+HE\C(A
M\<B%;=?L^?LVIR:C_K<;MY8^5_J^,;OO\YQ]RM'0OS>]O34-NW7?\/Q,U6MR
MKEVFY[]^FWXFM#\3W1)$D@EQ]HGN(1#>2VX7SBSF.?RE4S(KMN&#&>P(R:S>
M%6C37PI.\4]M+J^SMZFBQ-KII[MJTG'?H[;Z^ABV_C<PIIJO 7;2[J>Z9O,/
M[XS2-(5Y5BF"V-Q:0GJ:U=#6I9VYXJ.VUE;^MC)5K<EU\$G+?>[O\OQ+4'CN
M)5C$UH7>VU%]0@99]H4R2^8T;KY3;^"RALKC(;:<8,O#O6TK)P4'IV5KK70I
M5TK7CM-S6MMW=K;4U+#XH+:'<]F7VWL]Y&$N&C7]^S$K*JQD3,@9@CM@ X.S
MC!SEA;[2M[JB_=OMVUTOU7XFD<3R[Q^TY*TK;]]-?)_@>67<PN)I)E!42.[A
M2<D;F+8S@9QG&<#/I7HI62796.!N[;7<@IDGT5\'/";6Z-KMTN&E!2V!'(3^
M.3VW_=4_W03T:O$QE:_[F/367KT7R/:PE*W[V772/IU?S.!^)WA ^'-0-S N
M+*\9G3 XCD/+Q^W/S)_LG ^Z:[,+6]K#E?Q1T?FNC_S./$TO92YE\,MO)]5_
MD>9UWG"% !0 4 % !0 4 % !0 4 '2F!W>K_  [O=%TB'6I <S<SQ8YA5L>4
MS?[W\?3:Q4>M<4,1&=1TETV??O\ \ ZYX>5."JOKNNW;_@G"5V'(;>@>(+OP
MS<F\L=@E*-&?,7>NUB">,CG@5E4IQJKEG>U[Z:&M.I*D^:%KVMJ;5_X_U;4)
M('D:)%M)1/'''$$C,HZ.Z@_.0.!DX )QR<UE'#TX)I7]Y6;;N[=EV-95YR:;
MLN5W22LK]V-A\>:E#*\Y6VDD>9KA6EMXW,,S?>>$GYHR3SU."!COD>'A9+WD
MK6TDU==GW!5YIM^ZW>^L4[-]5V&6'CK5;!=@:*<K*\T;W$*2O#+)DO)$S#*,
MQ))QD9Z #(+E0A+HUHDTFTFELGW%&O..FCUNKI-IO=KL9EWXDOKVUCLIG#)#
M.]PKXQ)YLA)9B^>>3D<#!K14HQDYI:M*-NEEY&;J2:46]$V_.[\S:NOB#JMY
M!-!)]G'VJ-8YI5@5)I H 5GD4@EU P#T'8"L5AX1::YO==TKZ*_9=C5UYM-.
MVJLW:S?S*UYXWU*^"^;Y </%(\JP1K+,T.#'YT@&YPI ./ES]*J-"$=KVLTE
M=V5][+H)UIRWM>Z;=E=VVN^I OBV^6\N+]Q!*]]Q/%+"LD#],9B?(XQD'.>O
M4&J]C'EC!77+LT[-?-$^UDI.>CYMTU=/Y&=K6M7.O7'VN[*[PBQJ$4(B(@PJ
M(HX"CG'7K5PA&DN6&V^NKN^I$YNH^:6^VFB2,FM#,]J^&/A1XA_;=TN%<%;8
M$=1T>7\>57U&XC@BO%QE;_ES'UE^B_5GL82E;]]+TC^K_1'LU>*>P% !0 4
M% !0 4 21QM*P1!DF@#I8+588_+ZY^][_P">U &!=6QMFQ_">A_I]10!5H *
M "@ H * "@ H * -W3K3RQYKC#'H/0>OU/\ *@#1EB652C=#_G- ',7%NULV
MUNG8^HH @H * "@ H * "@ H DBB:5@B#)- '36]NMNFP<YZGU- &)>V9MVW
M+]P]/;V_PH H4 % !0 4 % !0 4 *!G@=: .AL;3[.NYOOG]!Z?XT :%, H
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M<?SI 0&SF'\#4 .6PG;^$CZX% %N+2F_Y:,![#FF!J0VT=N/D'/J>OYT 6*
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MJ?:/G>?=R1_LBO(JXR<_=A[L?Q^_I\CU*6$A3UG[S_!?+_,]9 "@ # '  X
MKS3T1: "@ H * $90X*L 5(P0>00>Q'I1L(\L\0_"72=8+36F;"=N?W0!B)]
MXC@#_@!7Z&O1IXNI3TE[R\]_O_S."IA83UC[K\MON_R/(=4^$6NZ?DVZQWB#
MO$X5L?[DFW\E+5Z<,92EO>+\U^J/.EA*D?AM)>3_ $9QESX6U>R.V:SN4/\
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M "@ H * "@ H * "@ H * "@ H * "@!U(84 % !0 4 % !0 4 % !0 4 %
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00 4 % !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>costofsaleschart.jpg
<TEXT>
begin 644 costofsaleschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MY:=9XN@J<Y7J12C-T;.\J->,6G:4J%>,6Y4:BC_1=_PD>E?\];G_ ,%NJ?\
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MI_\ R%6\&4YP1QSU[>OTYZ_XBE!!&>WN"/YX- &!_P )/HW_ #\3?^"_4_\
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MDYE5P%26'>7TY4HQHVJ)J<6GSR=.,^:<_:5Z=+DA6K0<:=623A!-2G/]$_\
M@GO;376O_%%8]0O;$KHOA/+6GV,M)NU'7L!_MEI=@;=ORF,(?F8,6& /U/LK
M.:T\SS=1OM0\S9M^VBR'E;=V?+^QV5I]_<-_F>9]U=NWYMWY=_\ !.O_ )&'
MXJ?]@7PC_P"G'Q!7ZI5_.'B5_P E?F7_ %[P'_JNPA_97@Q_R;O)?*OF_P#Z
MM\:%%%%?!GZF%%%% !1110 4AZ'OP?4_RR?R&:6JM[=16-G=WLXG,%G;7%U,
M+6UNKZY\JWB>:3[/964-S>7<^Q&\FUM+>>YN)-L-O#+,Z1L ?B+XU\-1ZO\
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M:R_]1,*?._2!_P"2ER;_ +$B_P#4[%"4445^KGX(%%%% !1110!^CW_!.O\
MY&'XJ?\ 8%\(_P#IQ\05^J5?E%_P3VN9K;Q!\43#87=^6T7PGN6T>Q1H]NHZ
M]@O]NO;-3OW';Y;.?E;<%&W=^J%G=SW/F>=IM[I^S;M^V/I[^;NW9\O[#?WN
M-FT;O-\O.Y=F_P";;_,?B5_R5^9?]>\!_P"J["']N^#'_)N\E_Z_YO\ ^K?&
MEVBBBO@S]3"BBB@ HHHH *QO$0W:!K8Q(<Z1J8Q#9ZIJ$QS8W Q%8Z)-;ZS>
MR<_)::5/#J5R^(+"6.[DA==FD;[K?0]#@]/7M]>U '\ZG@CX'ZSX+^+WPXT_
M4+GQ-=7&F>,_AIJ<LVB?L8?\%IY?#S1:A>^'/$$"-XZU_P#:U\5_"[1WBM;^
M&'7;WQK:ZUX;\'ZI'J=A\0])F&A^(M(7^BL?U/J.Y]?_ -1ZCC%?ST^.9/A)
M)_P4#^):^.;;]B=O&4?[17PI7PY-^T5X;^)WQ0_:">+_ (1CX6II#_#'Q9H3
M6G@WP'HL>IQRP_#;P*HOT\'^*HM4\1^(KHW/BJ:PLOZ%AT[=3T^I_7U]3F@#
M\0?^"D__ "DD_P""%/\ V=;^U!_ZQS\0:_5/XWDKX1TLJ2#_ &W:<@D'_D'Z
MAZ5^5G_!2?\ Y22?\$*?^SK?VH/_ %CGX@U^J7QP_P"10TO_ +#=I_Z;]0KY
M?C7_ ))7._\ L#?_ *<ICC\2]4?*_F2?\]'_ .^F_P :^"?VIOVS/$7P ^-/
M[/7PAT+P5X,UB7XQ>)+:RO-8^)OQ1B^$6E:U97>@_%&Y3PG\,/$NL:'?^$=1
M^(]GJ_@31CJ%EXNUK1=.C3QGX(T&VMKJZ\:KX@\*_>=?'7[4G['VE?M3ZAX
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MPJ5?;3IPJVHNK7INES4ZE6%'"RC>EB<?><)5SNVC?WN^ENO-KLMDMF]#T_\
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M_P#8&_\ TY3''=>J_,^9Z***_E<04444 %%%% !7US\$C_Q1;=?^0UJ78_\
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M_P"()< ?] &.Z?\ ,TQGEO\ O/+6U]WW1^AG_#-7BOI_PD7AO)Z#;JO..O\
MRY4@_9K\5'IXC\-'OP-4/!S@\67?!_(U\2?'?]M/6/#G[9GPT.H>*?CW\)OA
MAX:'[;G@2X\%Q?L_?'*[\/>)K3X6_LYZCXNMOCCKVB3>!8/#OQ--C\0K![SX
M9:)9^([[2/#G@3PO#XC\1:CI#_$N_NM,]&_8K^+?Q/T/QQ+X/_:.\6ZAH%[?
M?LL_#KXM7&H^,/VG/#7[0'@WQ_K>H^/-+\&^(?C&GBQKC3='_9PNM=U77O#V
M@V'P)M&F\%:S+XH5O ^OZY/X"O3.I^/GC'3PGUN>;Y.D\-2Q,:7]A9>JDE4K
M5:4J<%*C%U9TO9*5;V*J^S]I%U.2F_:,_P"((\ 6O]0QV]FO[4QG3E[5+:^=
MM>9'TM_PS5XKZ?\ "1>&\GH-NJ\XZ_\ +E1_PS5XK_Z&+PW_ -\ZK_\ (5?+
M?B7]J7Q-JO\ P46_9O\  <FK_&_P-X$NO''[5?P47X87?PD^-'A_P=\0YO!7
MP=M]1L/BSXJUF[\!0>$/%%K>_$J.2/X<ZC9Z_?:!X"^'FAP^.M;O-)?XB7DF
MG_KA_GT_G7!B_I&>+V"6%]MFN57Q.&CB8I9#EZY(NM6I<C<J"4IQ=%N7+>*Y
MK*3U;7_$$N /^@#'=/\ F:8SR_Z>>6OJS1_8I^%^L?#W6OB#<:GJ6F7Z:II7
MAN&$:>MYNC:SO=8DD,OVF"(89;A FPL<JVX 8)_0?.?7\01_.OEKX(:=9ZC>
M>(EO(?.$=KII0>9+'M+37@8_NI(R<A1U)QCCO7TM8Z99:=YOV.$0^=L\S]Y-
M)NV;MO\ K99,8WM]W&<\YP,?89)Q5G'&>6T.(<^K4J^9XV5:%>K0P]+"TY1P
ME6>$H\M&C&-./+0H4XMI+FDG)ZML_0<@R'+N&LKP^3Y33J4L#AI5I4H5:LZ\
MU+$5JF(JWJ5&YRO5JS:N]$TE9(OT445ZQ[(4444 %%%% !1110 W8F=VU=W7
M.T9SZYQFG444 ?B!_P %)_\ E))_P0I_[.M_:@_]8Y^(-?JE\</^10TO_L-V
MG_IOU"ORM_X*3_\ *23_ ((4_P#9UO[4'_K'/Q!K]4OCA_R*&E_]ANT_]-^H
M5\OQK_R2N=_]@;_].4QQW7JOS/E2BBBOY7$%%%% !1110 5]=?!+_D2V_P"P
MUJ7_ +0KY%KZZ^"7_(EM_P!AK4O_ &A7Z)X8?\E._P#L6XO_ -/84?1^J_*1
MZ]7Q1\5/^1^\0_\ 76Q_]-=C7VO7Q1\5/^1^\0_]=;'_ --=C7WGBQ_R(,#_
M -CBC_ZA8\1Y]1117\_@%%%% !1110!>TS_D):=_V$+#_P!+(*_0JOSUTS_D
M):=_V$+#_P!+(*_0JOVSPB_A9]_U\RW_ -)QH^B]7^43B_B+_P B-XG_ .P3
M<?R6OAQNI^I_G7W'\1?^1&\3_P#8)N/Y+7PXW4_4_P Z\CQ9_P"1SEO_ &+/
M_=K$!T7J_P HG(^._ 7@GXH>$-<\ ?$?PGX?\<^"/$UK'9^(/"GBG2[;6-"U
M>VBGBNH8[RPNT>-V@N88I[>>/R[FWE0/!-&Q8EVM> O GB74?#&K^(_ O@CQ
M!JW@B[^W>"=3USP;X8U?4/!=Z%B1;KP=>:CI-S/X3FC6WMEA?P])IOD"UL_)
M$?V.U\GJZ*_+8U*D4E&I.*BYRBHSDE&52*A-I)V3G",8S:UE&*B[I)"*%UI.
MEWVI:-K-]IFGWNL>'&U1_#NK7EE:W6J>'WURQ&EZV^A:A<127FCOK6E@:;J[
M:;-;-J>G#[#?&>U_=5P=M\%O@S9:1XE\/67P>^$MEX?\:7]CJOC+0;+X8^!+
M+1/%^IZ7J$&K:7J/BK2+7P_#IWB.]TO5K6VU72[K6;:]FTW4X(=0L'M[R-9Q
MZ711&I4BK1J3BO=TC*27N2<X[-?#-N<>TFY*S=P*%[I6EZEJ>D:UJ6FZ?J.L
M^'WU:70=7O[*VO-5T.37[(:;KTFBZC<Q2WNE/KFG :?K+Z?/;MJM@!9WYN+8
M"*K]%%1=V2N[)62Z)7;LNRNV[+JV^H'T#\ O^/[Q-_UZ:9_Z.O:^EZ^:/@%_
MQ_>)O^O33/\ T=>U]+U_3'AS_P DCEO_ %\Q_P#ZGXD HHHK[@ HHHH ****
M "BBB@ HHHH _#S_ (*6F8?\%(/^"%1@6-I/^&K_ -IS"RNZ(5_X8]\?B3+H
MDC!A'O*?(PWA0V%)(_4/XR/K#>%=-&H0Z;'#_;%ML:SN+N64R?8+[:&6>T@0
M)MWDD.6W;0%QN(_,#_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K]4OCA_R*&E_]ANT
M_P#3?J%?+\:_\DKG?_8&_P#TY3''=>J_,^5****_E<04444 %%%% !7U-\'G
MUE?"!%A!IDD']KZ@2UY<W<4OF8@W )!9SIL!^Z2^X]U&.?EFOKKX)?\ (EM_
MV&M2_P#:%?HGAA_R4[_[%N+_ /3V%'T?JOU._P#-\3_\^NA?^!NI?_*ZOD#X
MEFY/CC7C=K EQYMGYJVSR20@_P!FV878\L<,C IM)+1KAB0,@ G[>KXH^*G_
M "/WB'_KK8_^FNQK[SQ8_P"1!@?^QQ1_]0L>(\^HHHK^?P"BBB@ HHHH N:=
MN_M"PV8+?;K+:&R%+?:H=H8@$A2V-Q )"Y(!.!7W<9/$V3BUT+&>/]-U$_RT
MW'Y5\)Z9_P A+3O^PA8?^ED%?H57[9X1?PL^_P"OF6_^DXT?1>K_ $/,_'LF
MOGP;XD%U;Z0MN=+G\UK>[OGF5/ER8TEL8XV;'16D0$]6%?&AZG/J:^X_B+_R
M(WB?_L$W'\EKX<;J?J?YUY'BS_R.<M_[%G_NUB Z+U?Z"4445^5""BBB@ HH
MHH ]S^"#:DMYXB.G1V4C?9=.\T7LUQ"H'G7>SRS;V]P6).[<&"@84@G)Q]*V
M+:HWF_VC%81XV>3]BFN9L_>W^9]HMK?;CY-FS?G+;L8&?GCX!?\ ']XF_P"O
M33/_ $=>U]+U_3'AS_R2.6_]?,?_ .I^) ****^X **** "BBB@ HHHH ***
M* /Q _X*3_\ *23_ ((4_P#9UO[4'_K'/Q!K]4OCA_R*&E_]ANT_]-^H5^+W
M_!9CXR?#W]G#]KW_ ((U_M"?&/5M3\+_  ?^%7[3_P"T1J7Q!\96/A+QCXRA
M\,V&O?LL>,/#&D7-[I'@;0/$OB"9+[7=6L-/A6RTFZD\R<S.BVUO<SPZOQ3_
M ."_/_!)GQ)X<L+#1_VI-5NKJ'5+>YEC'[-W[64>V&.SO(F?<_P)4'$DJ+@$
M]<]*^<XOHUL1PUG%##T:M>M4PCC3HT:<ZM6I+VD'RPIP4IR=DW:*;LF-;KU7
MYGW#17Y0?\/P?^"7W_1RNJ_^(Y_M6_\ SBZ/^'X/_!+[_HY75?\ Q'/]JW_Y
MQ=?S3_J]G_\ T(\Y_P##7CO_ )1Y_GV86]/O7]=?S[,_5^BOR@_X?@_\$OO^
MCE=5_P#$<_VK?_G%U%_P_(_X)<&8VP_:;OS<+$MPUN/V>?VJ#<+;O(\*7#6X
M^!WGK;O-')"EPT8A>:.2))&DC=5/]7L__P"A'G/_ (:\=_\ *//\^S"WI]Z_
MKK^?9GZR45^4'_#\'_@E]_T<KJO_ (CG^U;_ /.+H_X?@_\ !+[_ *.5U7_Q
M'/\ :M_^<71_J]G_ /T(\Y_\->._^4>?Y]F%O3[U_77\^S/U?KZZ^"7_ ");
M?]AK4O\ VA7\\W_#\'_@E]_T<KJO_B.?[5O_ ,XNOHKX7_\ !?[_ ()*^'/#
M!T[5_P!J;5;6\.IWUSY1_9M_:SD_<S>5Y;;H_@2R_-M;C.1CFOO?#C*<UP?$
M3KXS+,QPE'^S\3#VN)P6)P]+GE5PSC'VE6E"/,TFU&]W9V6CL='ZK\G_ )K^
MDS][:^*/BI_R/WB'_KK8_P#IKL:^+O\ B(<_X)!?]'7:I_XC5^UM_P#.'KY@
M\??\%UO^"5^M^+M8U33/VF]5N+&[DM6@F_X9Q_:O3>(K"U@?Y7^!088DB=>0
M.G'&"?M?$[!8S'9'@J6"PF)QE6.:T:DJ>%P]7$5(TUA,;%SE"C"<E!2E&+DT
MHIRBF[M"/TOHK\H/^'X/_!+[_HY75?\ Q'/]JW_YQ='_  _!_P""7W_1RNJ_
M^(Y_M6__ #BZ_#?]7L__ .A'G/\ X:\=_P#*//\ /LQV]/O7]=?S[,_5^BOR
M@_X?@_\ !+XD ?M*:L22  /V<_VKB23P  /@7DDG@ <DU%!_P7(_X);W,,=Q
M;?M-W]S;S()(;BV_9Z_:HN;>:-ONR0W$'P.DAFC;^&2*1T.#AC@T?ZO9_P#]
M"/.?_#7CO_E'G^?9A;T^]?UU_/LS]9**_*#_ (?@_P#!+[_HY75?_$<_VK?_
M )Q='_#\'_@E]_T<KJO_ (CG^U;_ /.+H_U>S_\ Z$><_P#AKQW_ ,H\_P ^
MS"WI]Z_KK^?9GZVZ9_R$M._["%A_Z605^A5?S)6/_!<;_@EW#>V4TG[2VJK'
M%>6DLC?\,Y_M6_+'%<Q2.W_)"^<(K' Y.,"OL7_B(<_X) _]'7ZI_P"(U?M;
M?_.'K]@\+,OQ^ I9TL=@<9@G5GE[I+%X:MAG44(XSG<%6A!SY>:/-RWY>97M
M=!T2\V_O2/UT^(O_ "(WB?\ [!-Q_):^'&ZGZG^=?)'C/_@X+_X)&:OX5UW3
M;#]JK59KR]TZ:"VB'[-G[6B^9*^-J[F^!"JN?4D 5\KG_@N%_P $OB2?^&E=
M5Y)_YMS_ &K?_G%UY?B?E>9X[-LOJ8++L=C*<,NY)SPN$Q&(A&?UFO+DE*C3
MG&,N5J7*VG9IVL[AT2\W^-C]7J*_*#_A^#_P2^_Z.5U7_P 1S_:M_P#G%T?\
M/P?^"7W_ $<KJO\ XCG^U;_\XNOS/_5[/_\ H1YS_P"&O'?_ "CS_/LPMZ?>
MOZZ_GV9^K]%?DX__  7'_P""7$3PQR_M-W\4EQ(T5O'+^SS^U1%)<RK%).\5
MM')\#E>XE2"&:=XH%DD6"&:=E$,,KI)_P_!_X)??]'*ZK_XCG^U;_P#.+H_U
M>S__ *$><_\ AKQW_P H\_S[,+>GWK^NOY]F?J_17Y0?\/P?^"7W_1RNJ_\
MB.?[5O\ \XNC_A^#_P $OO\ HY75?_$<_P!JW_YQ='^KV?\ _0CSG_PUX[_Y
M1Y_GV86]/O7]=?S[,_>#X!?\?WB;_KTTS_T=>U]+U_/1\(_^"]?_  2B\+7>
MN2ZW^U#JMFEY;6*6Y/[-_P"UC)YCPRW+2#]W\"6(VK(AR0,YP.AK]0?V0?\
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M#]:6@!NT>K?]]O\ _%4;1ZM_WV__ ,53J* &[1ZM_P!]O_\ %4;1ZM_WV_\
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M:3P=X<\+7-SXHGCL;OQ-KFB?#_PYXNM]9^Q*\-^,O[,W[/\ ^T-/X3N_C?\
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MZI#I/Q UKQ)^U1;:%^^=O#_@;P?X1UGQUX@M=7-K_8%V ?K/17Y_?L6?%_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>equityinlossofinvesteechart.jpg
<TEXT>
begin 644 equityinlossofinvesteechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_"-Z7Z7W_@XUK_Y8T ;U%8/_"-Z7Z7W_@XUK_Y8T?\ "-Z7Z7W_ (.-:_\
MEC0!O45@_P#"-Z7Z7W_@XUK_ .6-7['3;73_ #3;"<>;LW^=>7MW]S=MV_;+
MFX\O[QSY>S=QNW87 !?HHHH **** "BBB@ HHHH **** /Q _P""D_\ RDD_
MX(4_]G6_M0?^L<_$&OV\C_U<?^XO_H(K\0_^"D__ "DD_P""%/\ V=;^U!_Z
MQS\0:_;R/_5Q_P"XO_H(H ?1110 4444 %%%% !1110 4444 %%%% !1110
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M -S(]1^8HR/4?F*P_P"P+?\ Z"&N_P#@]U3_ .2:/[ M_P#H(:[_ .#W5/\
MY)H W,CU'YBC(]1^8K#_ + M_P#H(:[_ .#W5/\ Y)H_L"W_ .@AKO\ X/=4
M_P#DF@#<R/4?F*,CU'YBL/\ L"W_ .@AKO\ X/=4_P#DFC^P+?\ Z"&N_P#@
M]U3_ .2: -S(]1^8HR/4?F*P_P"P+?\ Z"&N_P#@]U3_ .2:/[ M_P#H(:[_
M .#W5/\ Y)H W,CU'YBC(]1^8K#_ + M_P#H(:[_ .#W5/\ Y)H_L"W_ .@A
MKO\ X/=4_P#DF@#<R/4?F*,CU'YBL/\ L"W_ .@AKO\ X/=4_P#DFC^P+?\
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M?_!D?_C%']A'_H,:[_X,C_\ &* -[(]1^8HR/4?F*P?["/\ T&-=_P#!D?\
MXQ1_81_Z#&N_^#(__&* -[(]1^8HR/4?F*P?["/_ $&-=_\ !D?_ (Q1_81_
MZ#&N_P#@R/\ \8H WLCU'YBC(]1^8K!_L(_]!C7?_!D?_C%']A'_ *#&N_\
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M@_\ !2?_ )22?\$*?^SK?VH/_6.?B#7[>1_ZN/\ W%_]!%?B'_P4G_Y22?\
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M% !1110 4444 %%%% 'X@?\ !2?_ )22?\$*?^SK?VH/_6.?B#7[>1_ZN/\
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M/AQX<\6Z[%X>_;/T6ST2/4M7M?/N4TNTG^$5]-;V:O\ ZF*2\N65,!IG(+$
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MQS?5-%% !1110 4444 %?&?[97P@_:-^-WA?PKX&^"7Q-^'_ ( \%W^H:O\
M\+LTCQ9H_P 1$\0?$7PJ]C;P:5X)\.>/_AKXT\)>)?AWHNHW<NH/XZU'0O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>fampyra.jpg
<TEXT>
begin 644 fampyra.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  C 'X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#JHKVT\0>*
M[I=2M[N:WB");P-$P5">K,.Q]S72OK]M9E%GMKN"#<(Q-)$0@/09/4?4U4TN
MSNH/$FN7'D,JS;/*=A\KD+6)J%G?ZAH#Q7%GJ4VJ;@9"Q(B7#9.T9P1CH*Q3
M<49)M(Z>7Q':I=W%K'%<SW%N0)(XHMQ QG/TJ+_A+-/:T^U0K<S0*,R21Q$B
M+U#>A'<=J-$M)H-9UJ66)D2:6,QLP^\ @!Q^-0:)8W%OX;OX)H&2222=@A'+
M!LX_.JO(J\B[/XCL8+B& &266>(30K$F[S%]J8/$UD([HRI<12VJ>9+"\9#A
M/[P'<?2N<T\W&EZUHPELY9)(]+VR1H/G3YN>.];4-O+J_B,:A):2P6L-LT $
MRX:4L>>.P%"DV)2;-.ZUBTL]/BO)&9HIBJQ[!DL6Z "H(?$-I<:@]E EQ)/'
M*8I L>0GN3V%8>B6,LNL#3Y2)++1I&,39SN9ON ^Z@FM/1;2YM;G7)/(*/-<
ML\)<</\ +@'Z9H4FQJ39//XB@M2#<6MY%$S!!*\6%)/ Y[9/K5VZB6]TZ19%
MD0.IR =K?I7&WEG?:AHH2>TU*;5-ZF1G)$:X8$[1G!&.@KN) QMV"_>VG'UQ
M1=R33'3D[W..T^22;2M*TZ.1HUN9'\QE.#M!)(!]ZT[RTBT*^L9[$&..:803
M1@DJP/0X]156TTJ]ATG3KF. _:;21F,+<%E).1]:OS+<:W?6?^C2P6MM)YKM
M*,%F'0 5R0BU';72QW2DN;1Z:W-&]U."PDBCFW[YLA%522Q':JZZ_;,SQK%<
M&=#S#Y1W_7'I[T:A;2RZUILJ1EHXBY=NRY'%+#:NOB.ZN#&1&T"*'[$Y.1_*
MNEN=]#!*%AXUNR-B+KS&V%_+"[3NW?W<=<U7N?$MG9[1<1W$;MR$:,@X]:S_
M .S;R*9KM+=G\F^>41< NA&,CWJCXLN)+V2UQ;2Q *V/,&&/3MZ5A4KSC!RZ
MFU.C"4U'H=8VH0)(R%FW#C 4TR/5;>3."PYP/E//I5<7=O%-,)K=5#3% < E
MNG)]LFG)?V>X'[.5X&&*#H<X_D:ZN==SFY63G5+4?\M#Z_=/2A=3@* L64DD
M;<<\'%5OM=FK';;GS'7=RF>,$Y^F,TC:E"/*5(%\L@C<4XR". /J:.==PY6(
MLVGRWT>HMO6X5#",YP 3G'UJS/>6]Q;O&))0K?(7CX*YSR#^!J(W]CP6@ )(
MVYC&6ZC(_(U<6. P;O*18V&X@J!^=--/83C8SM/N=/T^W6WM498PQ^8Y)8XR
M6)[DG^=:%O>Q7+%8R<C/!&,X.*P+GQEX;LW*"1)2.#Y,61^=4;SX@Z4ML[:>
MKBY/0O#@8[U+J1BMR%*-[7.T)P,FL75M=CM76.&0%B.2.1^=<>?%-UJ=K*IN
M@T?\4> #^76JRW0$3 D[@>/4UPUL;]F*L>GA\&I>\W=>1U/_  D$J'*L2>^X
M5MZ7JB:A&<[5D'\.[D^]<%9++J%PMO 0)&/ 9L9KN-#TR2P@)N4A\XGAD'./
M<U6%J5*COT%BZ5.FK=35HHHKT#SR&YMUNH3&SR(,@[HV*D?C4%OI-M;RM*=\
MTK#;OE<L<>@STJ[14N*;NQJ36Q"]I!(P9HE)!W ^_P#D"H[BWB6UDVQJ-J''
MM@''\S110T@N%I:01VT>V-1\H_EBG?8;<.7\I=Q&,_Y^@HHH458&W<<;2!@
M8EP.F.,=_P"M2A0%VXXQC%%%.PC#U#PIHMR&EDTZ'>3DE<K_ "(K.M_!VAM,
M U@I&>AD?_&BBLY15]C*45?8WK70=,LHFCM[&!$?AAMSG\34,GAS26<$V,0/
MMD#\J**)PBUJC>$G'X78M6>E65B=UM:Q1M_> Y_.KE%%:122T$VV[L****8@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>financialhighlightschart.jpg
<TEXT>
begin 644 financialhighlightschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &Q 3T# 2(  A$! Q$!_\0
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M/B]<>"_&C^%E\*_$>;X77S?9/'UE\/\ 5_$MYX7N(;V'4X87TS5!9>'>#_\
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M.D:3XF^'O@#QW?\ CT20_#;2-/\ #FNZ-\6M0T/P?\,_%OQ5%_=^(_A_X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\8H_L'1/^@1I?_@NLO\ XQ0!>^UVG_/S;_\ ?Z/_ .*H^UVG_/S;_P#?Z/\
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MAA:E2@X5.9*HHS]E4=*510;/U^^UVG_/S;_]_H__ (JC[7:?\_-O_P!_H_\
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M;PA:?$35?"&H:=K=CH$VI*LIU31M#:\3Q1K6DZ%>_30((!!R" 01T(/(/XT
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M-<7Q\4:M;ZOI/ZTJ20"<9(&<'(SWP>,CT..1S0 R;_52_P#7-_\ T$U^)/\
MP2^_Y/F_X+A_]GW?#+_UDWX2U^MGQ!^,OPE^%SV5I\2?B7X&\!7.L6UW/I4'
MB[Q/I&@2ZA!:-'#=36<>I7=N]S%;2SPQSO"KB-Y45L,P!_&C_@E+X[\%>(_V
MRO\ @MAXE\/^+?#NM>'M:_;G^&=UI&MZ7J]E>Z7J=NO[*?PKMVGL;ZWF>VNH
MEN+>X@:2&1T$L$R;MR$4 ?O+16)_PDOA[_H-Z5_X'VW_ ,<H_P"$E\/?]!O2
MO_ ^V_\ CE &W5>[DN8K2YEL[=+N[CMYI+6UEG^RQW-PD3-!;R7)BG%NDTH2
M-YS#+Y*L9/*DV[&S/^$E\/?]!O2O_ ^V_P#CE'_"2^'O^@WI7_@?;?\ QRFG
M9IM)I--IWL[='9IV>SLT^S3U%)-II2<6TTI1Y;Q;ZKF4HW6ZYHM=TUH?@7\=
MO&/Q'\9?$C7;GXH6]SI?B+2[F73$\-2!TLO#%DC^;!IFEQLS))9R(R70U1&D
M.N&1-2::2.6!8OH+]C'XD?$WPQKU_HNDZ!XA\7?#'S%N?%=IIFFWVKMX4N[R
M.4VNLZ3!91SW#7M]+"L=[HUI#,VI6^[4#!%):-=/]P?'_P""'PT^.=G8W4OB
M32?#?B_3&AALO%%JUG=S2:69PUUI6I6AN8!J%KY;S3:>9)DETZ](EA<VTUY:
MW/K/P[\/_#3X7>%=/\(>$;O2+'2[$%Y)7U"TEOM3OI OVK5=5NMRM>:C>,H:
M:=@JHJQV]M'!:P001_L69\?9%B^$Z.5PRBE+$U:<<)4RWEE3P> C1C&V*P]9
M)RYFVY8-1;K4ZJG+$2E&"^M?SMDOA1Q3@./<3G=7B"O'!4*LL=1SE3A5S#-)
MXB4O]@Q>';45&*CR9@Y1C0JT'3C@U"=5O!/M/C3\,;BX%G<^+;#0;TD*+#Q;
M#?\ @V_+]/+6S\5VFC3N^?EQ&C[C]TG(->CVE]9ZA EU875M>VTF?+N+2>*Y
M@?'7;- \D;8R,X8]:Q;O6/"5_!):WVHZ%>VTHQ+;W=Q8W,$@YX>&=I(F&"1A
ME(P:\WN_AW\#KJ?[7!I?AC0[WK]O\)ZE)X-U#?V<WOA2_P!&N'8'!R\CY(YR
M.*_+/^$JI_T'X3_PGQ]]%_V+N17O_P _'Y'[G_PNTO\ H4X^_P#V%Y4XZK_L
M<JH[7_Y]*[VTU]LR/6BO"3X:&G!V\,?'/Q3INXY2S\0:IX<\<Z<H!R%9O$FG
M3Z^RYX)3Q#%(5X\P$YIP\0_$W2G0+XD^#_C.WC4AO/GUOP#J$N,XS-%=>.M.
M,C# R+6UASV0<@^I4)_P,QPDY/X:595\+4V3M.=:BL)!WNK?6VK_ &FM1_VE
MB:?^\Y1F%.*MSUL.\+C:*;=KTX8?$2Q]2*6M_J,7TY3W2BO#!\9KS3E/_"2?
M#[Q!;A6P]WX3U?POX[L HX+B+2=6M?$)7N ?#H=A_ #Q6MI_QX^$]^XCE\8V
M.B2YVM#XKM=3\'R)(!EHF_X2BQTE#(I!&$D<,5.PL!FD\LQS3=/#RQ,5=N>#
ME3QU.-K/WJF#G7IQWVE)/<:SO*E95L9#!RE91IYC"KEE6=]N2EF%/#5)W[Q@
MT>NT5S=CXQ\):I"+G2_$^@:G;'.+C3=7L+^#@X/[ZTN)H^#_ +56?^$F\.]/
M[<TK/I]OMLCZCS,BN%IQDXR3C*+M*+34D^S3U3\F>I&49QC.#4H32E&46G&2
M>SBUHT^Z-NBL3_A)?#W_ $&]*_\  ^V_^.52U'QMX/TBQN]3U/Q/H5AI]A!)
M=7E[=ZI9P6UM!$,O+-+)*%11PHR<L[*B!G95+C&4Y1A",ISG)1A"*<I2E)VC
M&,4FY2DVDDDVV[)7%.<*<)U*DXTZ=.,ISG.2C"$(IRE.<I-1C&,4W*3:22;;
M21U%%<];^+?"UY!#=6GB+1;FVN88[BWN(-3LY8)X)D$D,T,J3,DL4L;*\<B,
MR.I#*2#4W_"2^'O^@WI7_@?;?_'*333::::;335FFM&FGJFGHT]AIJ24HM2C
M))QDFFFFKIIK1IK5-:-&W16)_P )+X>_Z#>E?^!]M_\ '*/^$E\/?]!O2O\
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MUS3_  HFB-/I5E^RE^TM:75W_;7B;1/#4?EW$W[14\40@FUJ*Y<M$Y=(6C4
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MVTG3['3+-62TTZSM;&U1Y&E=;>SMX[:!7D<EY&6*) SN2SD%F))-7:\%T_\
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M"WXN>*M6\-7>O>*-%UG4O#\=EX=GTA](D^WZU?:-J=R=.;[!_9)^'7C+X;?
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M*M4^%_AS0?$FGS:+>Z+Z%\3_ -B']K?2/$_[07_"I?!LMQ\.-9L_^"@?P>^
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MF3&WY<;>*M44TVKV;5U9V=KKL^Z\A-)VND[.ZNKV?==F%%%%(84444 %%%%
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M_'L  ?M%VH    ^#7A,  <  ?VQP!V':E/PY^/F#C]HRV!['_A37A,X_\K%
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M%X:\,^/_  [X=ET?5=!\):WK_B'1M,T[3]8U2W\*VW]I>)?$GC+4O[5'A!-
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MT.1GGJ :6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:YI6M0/I]Q>1);WL<5Q)#=+);I^5?P&_9$_:%^&7[1'PD^+,NAG2TO?VEO\
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M5A:<+OEDKL****P.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 0C/7/7/!(_D1Q[=#WH P,<_B23^9)/^<=*6B@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
LB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>flixabi.jpg
<TEXT>
begin 644 flixabi.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !U .H# 2(  A$! Q$!_\0
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M^BBBMC **** "O,?C1 IL=*GP-RRR)GV*@_TKTZO+_C3<@6NDVV?F:220CV
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MI6IZ)=>(-5MM/MD74;,@7;K %9B>1\W\72N=^#?_ "+&H?\ 82F_DM-\%?\
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MWUKH:@N;6*ZCV2KD Y!'!4^H/8UR5L-S5%6AI)?BNS)<=;DU<3\8/^2=WO\
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M[DDF@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>fumaderm.jpg
<TEXT>
begin 644 fumaderm.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_P 8H^N4?YG_ . 3_P#D0^L4OYOPE_D'_"56'_3Q_P" EW_\8H^N4?YG_P"
M3_\ D0^L4OYOPE_D'_"56'_3Q_X"7?\ \8H^N4?YG_X!/_Y$/K%+^;\)?Y!_
MPE5A_P!/'_@)=_\ QBCZY1_F?_@$_P#Y$/K%+^;\)?Y!_P )58?]/'_@)=__
M !BCZY1_F?\ X!/_ .1#ZQ2_F_"7^0?\)58?]/'_ ("7?_QBCZY1_F?_ (!/
M_P"1#ZQ2_F_"7^0?\)58?]/'_@)=_P#QBCZY1_F?_@$__D0^L4OYOPE_D'_"
M56'_ $\?^ EW_P#&*/KE'^9_^ 3_ /D0^L4OYOPE_D'_  E5A_T\?^ EW_\
M&*/KE'^9_P#@$_\ Y$/K%+^;\)?Y&U:W45Y$EQ VZ.55=#@C*L RG! (R"#@
M@$=QFNV,E-*<=4TFO1ZHZ4U)*2V:NOF<9XID*W5H.PF8_P#DO<#^M>9COX</
M\:_])F<&+^!?XE^3*GFBO!/&#S10 >:* #S10 >:* #S10 >:* #S10 >:*
M#S10 >:* #S10!J^#Y"VF6^>T,0_)!7U5#^#3_P0_P#24?24O@A_AC^2,KQF
M_E3VK>DS?^B)JXL?I3C_ (U_Z3,Y,7I37^)?DSG_ +:/6OGKGAW-_P /2I<2
MR!@C;8F8>8 4!!')ST [GTS7J85*4:LFH7BE9S7NK??LNYV89*53E:37++1J
MZZ%PJE[,(6-MA8GDS:$=1CAR0?P'ZT2@JGM&^3]W2<U[+X6[[2\_NT:.CD52
M<*;]G9\W\+?1=?T^9'8V$-S'"[LX\Y96;!''E],?+^?7\*I8>G92DY)>Q=1V
MMNG%::;6;T_$SHT8U%!MN\IRCI;HFUT\B6*RLY?)*R3 7081@A,AESDMVQZ
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MT4 'V2+^Z* #[)%_=% !]DB_NB@ ^R1?W10 ?9(O[HH /LD7]T4 'V2+^Z*
C#[)%_=% !]DB_NB@ ^R1?W10 HM(O[HH O1(J#"C H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>gazyva.jpg
<TEXT>
begin 644 gazyva.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^_9:WC/HS\ZS#()X=.MA/?ANX]5Z=SVY'5P&4@J1D$<@CVK4^&:<79Z-=!U
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MH0!V/>L)QMJC]1R+,_:Q^IXF7O17N2;W7:YXC_9]S_SRD_[X;_"LC[?VE/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P!V/)_I5G@2WT.OH)"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?$;7=/4)#<O@>H#?SJ^9H\:IE."JN\Z6OD[%UOBKXA88-R1]%4?THYF8K),
MO^77_DS.<U#Q9JFI_P#'Q<2,/0,5'Z8I79Z-+ X;#_PJ<5ZI,YYG+G+$DGKF
MI/0VT6B[(85S03*-]#IO"7@B[\6W2PPJ5A!_>2D?*H[\^OM6D5?8^7S'$4\#
M!RFUSOX8]3[7\/Z#;>'+-+&S4*D8Y/0L>['W-="5M#\DK595YNI/=_@;5,YP
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2^=CIHWO>]/0X]2[&;GO2T*U+J&3O2 G%(84 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 &* # H ,"@ QB@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M^A4]?TS7H+5'F[.W8^SO VO#Q!I4-P3F55"2?[X'-<$X\KL>C!W5SKZS- H
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MES+S.2<>1V6QZ9\%O$7^LTB4_P#32/)Z8X*C\>:QJQ^T;4I?9/H6N4ZPH *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M/S'^\.2,>E>EBY^QKQFDG9;'S&3T'C,!4P[DX\TOBZHD_P"%=X_Y>3_WS_\
M7I?VA_T[17^K?_43/[C@[S33#J'V&UD,S;@F1D?,>O?MFO5A4O2]M.*BK;'R
M-;"NGBE@L/4E4?,E?S.C\8!H;ZWCR05C0'GN&7-<6$LZ=1VZL]W..:&)P\+M
M6C%/7L>P6O\ J4_W5_D*^;E\3]6?IM+X(_X5^1Y!XF=AKR $@;HN_P#O5])A
MDOJTM.Y^9YFVLT@DW;W=+^9!XP\UM6"0DAB$"\XY(-5A.54&Y+1-F.<<[Q\8
MTFU)I):][&O+\/F:W,K3,UP5W8/()QG;7,L?:7*HI0O8].?#W-2=2=1RK6OK
MWWL<MHJW^J-_9$<A2+<6;D\!3SCG./:N^M[.BOK+C=]/F?/X)8G%MY7"HXPN
MW)WU26]C8U_P6-'M?M<,C/Y9&X'CJ>HQT_"N>AC/;3]G.*2>QZ>89(L%1^LT
M)MN-K]'ZG;>#M1DU+3MLAS)'E,]R,<&O+Q=-4JNFSU/JLFQ,L7A/??O1O&_Y
M&&/ #73M+=3-DL2 .3R?7/\ *NKZ_P B4:<5HM]CR5P^ZLY5,35;NVU'>QSG
MB'PU)X:V75M(Q4MC/0JPY'U'UKMP^(6*O3J15['A9CELLHY<3AYOEYDNUF;7
MB._.IZ%!<'[S.H/U!P:YL-3]EB9071,]7,\1];RNG7>[:3]49OA[P@^M6PN+
MB5DCR0BCV[^U:U\6J$^2G%7ZLX\ORB6/HJMB*C4-HQ6WJ4=0L+GP;>I)$Y*$
MY5NFX?Q*1T/%;4YPQM-QDK2.+$8>KD.(A.E)NFVK/9/NFCVRRNEO8$G3[LBA
MA^-?+SBX2<'T=C]6HU57IQK1VDDRU4'0% !0 4 % !0 4 % !0 4 % !0 4
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M_(T_'O\ R"G_ -]/YUA@?XR]&>AGW^XS_P 4?U(/ G_()/\ UTE_G5X[^/\
M)&&0_P"X?]O3.1\,?\AQ_J_\S7H8G_=H^B/G,K_Y&53U9Z?XA_Y!UQ_US/\
M2O"H?Q8>I]_F'^ZUO\#.'^&IPDX]T_\ 017JYCO#T/D>&OAK+^\CJ_%__(,E
M^E>=A?XL3Z3-O]SJ&%\/#BTD)[.:[,P_B+T/%X<TPTO\3.7\27C^(M46RM^4
M1MBCL3_$WY5W8>"PM%U9Z-JYX&95I9IC8X.CK"+Y?*_5_<>OZ=9)IUNEM$,+
M&H'^-?.5)NI)S>[9^F8>C'#4HT(*RBK'D_CGC4XCTX'_ *$M?0X+^#,_.L\T
MQE'Y'KMK_J4_W%_D*^=E\3]6?I-+^'#_  K\CQ[Q/_R'D_WHO_9J^CPW^ZR^
M9^9YG_R-8?\ ;GYB^)O^0Y']8_Y&C#?[M+YAF?\ R,Z?_;OZ'LB_<'T_I7S7
M4_3U\/R_0\8\&_\ (;?_ +;_ /H5?38S_=X_]NGY=DW_ ",JG_<3\V>D^*?^
M0;-_NUXF&_BQ]3[O-/\ =*GH>=>'[I[+1KN:/AQA1_P+BO:Q$%/$4X/8^%RZ
ML\/EV(JPT:T7ST+7@70;>_62[N5$I5MJAN@. 2?K6>.K2I-4J;LK7=CIR' T
ML3&>*KQYGS-)/[[FEX[TZVM+!6AC5&\U1D#''-88&I*56TFVK,]#/L/2HX52
MI047SI71@7?_ "+</_7<_P#H5=L/]\EZ'AUO^1+2_P ?ZG?>"O\ D%Q?4UXV
M+_C2/M<F_P!SA\S+^(4HCLHT[O)@?A@UT9>OWC?9'F\124<-&/>7Z&GX)C,>
MEQ$_Q#(K#&.]:7D>ADL7'!TV^JN<EJMU*DVI ,0$(V\]..U=]**Y:.A\]BJL
MU4QJ4GI:VNWH/O\ 23IEA!JD4KF=3&6))PP;D@C-*%7VE25"45R^];RL77PG
MU3#4L?3J2=5<C;;W3W19FU>6VO;BY!/%LA5>P9AUJ%24J<(?WW]R-IXN=*O6
MK7_Y<Q:71-K<SY+);;3UU5+AC>\2-\W7)Y7&?2M5-RJ/#N"]GJMO+<XY452P
ML<PC6?UG2;UWN]8VOV-.6YE\47<5FKM% L0DEV\%CZ5BHK"0E4M>3E:/D=\J
MD\VKT\,I.%)4U.=M&WV-#5_#D%EIEPD3.%"[^23R.WT-8TL1*=6#:6]OO.S%
MY=3H8.M&G*5DN;?JC#BT\6&A&[B=P[H#UX'TKJ<^?$>SDE9,\F&'6'RYXBG*
M7-**ZZ+T++&369K33&=EA6!9)<'EB1WJ%:A&I627-S-1\C=\^-J8? N35-4H
MSG;>5T!\SP]=RZ>CLT$T)= Q^ZW/2C3$0C5:2E&5G;J@?-EM>I@X2;I3IN44
M_LLI6VB_:-(.HM+)YZ!G0Y.%PW3KTK65;DK^Q45RNR?W'+3P?M<#]==2?M8I
MRB[[6>QZ%H%V][80SR?>92#_ ,!8K_2O'KQ5.I**V3_-)GV> JRKX:G5G\33
MO\I./Z&Q7.>D% !0!QGC;2'U*S#Q#,D!W #J01@C\J]/!552J6EM+0^7SO!O
M%X>]->_3?,EU?D<WX8\8PV%N+2]#KY7"L%+9'H?0BNW$X.52?M*.J>IX&69U
M2PU)8;&7BX:)VN_F8VL7\GB^_CAMU81K\J\'."1ECZ=ZZJ5-8*FYS?O,\S&8
MB6>8F%'#I^SB[7\GNV=3XUMQ::7# O\ RS9%'X8KS\$^:LY=[L^ASRFJ&!A2
M6T;+[C*\)^+[?3;86EVK+LR595)R#["NC$X2=6?/2U[KL>?E><4<)16'Q5XI
M:QE:]S)\0:Q)XINX[>U5O+!PH(())X+$=L"NBA16#@YU-'_6AYF88QYS7AA\
M*FX)Z>>N[[:'8^*;,:?H:VR]$"C\?_UFO,PTO:8AS[W/JLTI+#9<J*VC9'.P
M''AJ7VD/\Z[9_P"]KT/"H-?V-+_$=+\/1BR<=/WC?SKCS#2K\CV^'/\ =7;^
M9D_CW_CP'^^/YBHP'\5&_$&F#?J4O#MF;_07MAUD5E_'_(K3$2]GB5/LSGRZ
ME]9RR5%?:BT<IX4UU?#LTMO=A@C'YB 2591CI[UZ&*H/$QC4I:M(^:RK'QRJ
MI4P^*3C%O735-:;%_P 7>+(=4M_LEHK,I*LSLI7&#P,>]8X7"2HSYZFCZ([<
MVS>EC*+P^%3E&Z<IVM:W0ZCP"/\ B5[3_P ]9!^M<./TK?)'O\/ZX%+^](X5
M;D^'=;:293L#MG Y*MG!%>KR_6<.HPWM^)\BJO\ 9693J5DU!R?_ ("^J/3H
M-6M/$<,MO;%ON8.Y2O4<<&O"E1GA91E45M3[^EC*&:TZE+#R;7*T[JQYAX>U
M4^&+Z2*Y5A&<JP )(QT./3%>]7I?6J<94]UL?G^7XO\ LC$U*6)3C!MW\M=&
M;?BGQC;WMJ;6S5F\P?,S*5V@>U<F&P<Z4U.K96V7<]C,\YHXFB\/A+RON[6Y
M45-#OGTW1+B1.'+[![;N/ZUK7I^UQ,(/:U_N./ 8AX3+*U6&][+YZ&1X5U6V
MTB5[BY5WD(PN%)QZG/J:Z<51J5DH4](K<\S*L;A\#.5?$:S>WEYG>CX@6?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
8 * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>geographicsaleschart.jpg
<TEXT>
begin 644 geographicsaleschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '\ 3T# 2(  A$! Q$!_\0
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M#]C:Z/A[POK]I\*?%7B7XJ:O?>-I],^(]QX!\%^*8/B%#K-]XF8^"/$$GAP
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M*PU1S4*]&2G3FX3<)J,EH^6<91?9IKH(OT445U %%%% !1110 4444 %%%%
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M\B-XG_[!-Q_):^'&ZGZG^=>1XL_\CG+?^Q9_[M8@.B]7^41****_*A!1110
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MZ_[.UO\ Z#W_ )2++_XY7PKIG_(2T[_L(6'_ *605^A5?MGA%_"S[_KYEO\
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M1E#,<@M.<,.\5.K&4LBC!8>.&C.NZLI17LH\]GHI>I'Q<\0WB%A9Y5PM2K/
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M_P"%[_#'_H,:C_X(=4_^,4?\0L\2O^B!XQZ?\TYF_6W_ %"?WE^(?Z\\%_\
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M)H_PC^&^@:;H&DZ5X5M+>S\->.3\3M+:>^UG4M1;XBO;:G9S>.-7UO5M3O\
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M;"SE?Q_I<;2VMG;V\C(?#WB)BC/#&C%"RJQ4D@E0<9 KZK@C_DK,B_[#H?\
MI$SX7Q,_Y(+B?_L6R_\ 3U(_)&BBBOZN/X)"BBB@ HHHH *_9S]@O_DA3?\
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MQW'M0!^"?CW0OAQ9?M]>/Y?%7AC]B?XE^([OXL?#'QII_C#XT:!\?O$OQ?\
MAKIT=]\#?AU#X9\-_$-?A;KWP@\/ZGX:\6>-?AU<^%? 6C^,=(3P;J_Q&\.Z
MQXJ6S/BU]8D_>P=.W4]/J>N<<^OOFOQ%^*GP*TGQ#^W$?&/A3P?\9_C=IA\>
MZ+:_$#X9> &\5_"SX,^#[C5?$/P0\8>+/%_C_P 6?$KP_=?"GXA7ECJGP?\
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M-9X8_P"1G\,_]C)X?_\ 3S8U_2F.GXM_,U^'^,/\7(/^O>9?^E8$_IWZ._\
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MUU[_ (*+>*X#^U/^S9X"U2T\9^&/".I)\3/VA+[P+^TGH%M>?$+]E/XJ^"O
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MG\B!1110 4444 ;GAC_D9_#/_8R>'_\ T\V-?TICI^+?S-?S6>&/^1G\,_\
M8R>'_P#T\V-?TICI^+?S-?A_C#_%R#_KWF7_ *5@3^G?H[_P.*_^ON3_ /I&
M9'AG[3/_ "0+XL?]B7JW_H$=?@(W4_4_SK]^_P!IG_D@7Q8_[$O5O_0(Z_ 1
MNI^I_G7L^$?_ "(\R_[&LO\ U$PI\[]('_DI<F_[$B_]3L4)1117ZN?@@444
M4 %%%% 'Z/?\$Z_^1A^*G_8%\(_^G'Q!7ZI5^5O_  3K_P"1A^*G_8%\(_\
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M_P#*23_@A3_V=;^U!_ZQS\0:^S/^"@7_ "1WPG_V4'2O_4=\25\9_P#!2?\
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M"4445^KGX(%%%% !1110!^CW_!.O_D8?BI_V!?"/_IQ\05^J5?E;_P $Z_\
MD8?BI_V!?"/_ *<?$%?JE7\Q^)7_ "5^9?\ 7O ?^J["']N^#'_)N\E_Z_YO
M_P"K?&A1117P9^IA1110 4444 %9NLS:G;:3JEQHMC;:GK$&G7LVE:=>WK:;
M9W^I1VLKV%E=ZBMK>M86UU=K#;W%ZMG=&UAD>X%M.8Q"^E2'H><<'D<$>^:
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M'3\6_F:_FK\,G;XE\-L0Q"^(] 8A5+,0-8L3A5'+,<851RQP!R:_HW&OV_\
MT#]=ZG_F!:IZG_IVK\/\8?XN0?\ 7O,O_2L"?T[]'?\ @<5_]?<G_P#2,R/*
M?VF?^2!?%C_L2]6_] CK\!&ZGZG^=?O)^TEK,%Q\"/BI"MEK$;2>#=54//H^
MH00J2B',DTL"QQJ,<L[!0,DGBOP;;J?J?YU[/A'_ ,B/,O\ L:R_]1,*?._2
M"_Y*7)O^Q(O_ %.Q:$HHHK]7/P0**** "BBB@#]'O^"=?_(P_%3_ + OA'_T
MX^(*_5*OR@_X)\7T=CK_ ,4&DM[Z<2:-X3 %E8W-Z5*ZAKYS(+:.0Q@Y^4N
M&PVW.TBOU0LM0COO,\NWOX/*V9^VV%U9;M^['E_:8H_,QM._9NV97=C<,_S'
MXE?\E?F7_7O+_P#U783_ "/[=\&/^3=Y+_U_S?\ ]6^-+]%%%?!GZF%%%% !
M1110 5F:U,;?1]5N%MM2O6ATZ^E%GHS*NKW1CM97%MI;-/;*-1N-ODV):XMU
M%T\),\(S*FG10!^-/@C1?C1\=_&?@_Q_XILOB%KO@OX;>)?#.AZ?=:/=6L/Q
M,\-1W6IZ?XDEE:_\=^"_A/IU[XA\,7-K_P (?\9_$/@/1M*\8)X<:3PO%/\
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MG8H2BBBOU<_! HHHH **** /T>_X)V 'Q#\5,C/_ !)?"/\ Z<?$%?JE@#H
M*_*W_@G7_P C#\5/^P+X1_\ 3CX@K]4J_F/Q*_Y*_,O^O> _]5V$/[=\&/\
MDW>2_P#7_-__ %;XT****^#/U,**** "BBB@ HHHH **** /Q _X*3_\I)/^
M"%/_ &=;^U!_ZQS\0:^S/^"@7_)'?"?_ &4'2O\ U'?$E?&?_!2?_E))_P $
M*?\ LZW]J#_UCGX@U]F?\% O^2.^$_\ LH.E?^H[XDKZK@C_ )*S(O\ L.A_
MZ1,^%\3/^2"XG_[%LO\ T]2/R"HHHK^KC^"0HHHH **** "OV<_8+_Y(4W_8
M\>*OYZ;7XQU^SG[!?_)"F_['CQ5_/3:_./%/_DE?^ZG@O_3>)/V3P+_Y+E_]
MB7,/_3^!/M2OPA_:\_Y.*^)'_7UH'_J)Z#7[O5^$/[7G_)Q7Q(_Z^M _]1/0
M:^!\)/\ DH<?_P!B:O\ ^IV /U?Z0'_)(Y5_V4>&_P#59FI\VT445_0I_(@4
M444 %%%% &YX8_Y&?PS_ -C)X?\ _3S8U_2F.GXM_,U_-9X8_P"1G\,_]C)X
M?_\ 3S8U_2F.GXM_,U^'^,/\7(/^O>9?^E8$_IWZ._\  XK_ .ON3_\ I&9'
MAG[3/_) OBQ_V)>K?^@1U^ C=3]3_.OW[_:9_P"2!?%C_L2]6_\ 0(Z_ 1NI
M^I_G7L^$?_(CS+_L:R_]1,*?._2!_P"2ER;_ +$B_P#4[%"4445^KGX(%%%%
M !1110!^CW_!.O\ Y&'XJ?\ 8%\(_P#IQ\05^J5?E;_P3K_Y&'XJ?]@7PC_Z
M<?$%?JE7\Q^)7_)7YE_U[P'_ *KL(?V[X,?\F[R7_K_F_P#ZM\:%%%%?!GZF
M%%%% !1110 4444 %%%% 'X@?\%)_P#E))_P0I_[.M_:@_\ 6.?B#7V9_P %
M O\ DCOA/_LH.E?^H[XDKXS_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K[,_P""
M@7_)'?"?_90=*_\ 4=\25]5P1_R5F1?]AT/_ $B9\+XF?\D%Q/\ ]BV7_IZD
M?D%1117]7'\$A1110 4444 %?LY^P7_R0IO^QX\5?STVOQCK]G/V"_\ DA3?
M]CQXJ_GIM?G'BG_R2O\ W4\%_P"F\2?LG@7_ ,ER_P#L2YA_Z?P)]J5^$/[7
MG_)Q7Q(_Z^M _P#43T&OW>K\(?VO/^3BOB1_U]:!_P"HGH-? ^$G_)0X_P#[
M$U?_ -3L ?J_T@/^21RK_LH\-_ZK,U/FVBBBOZ%/Y$"BBB@ HHHH W/#'_(S
M^&?^QD\/_P#IYL:_I3'3\6_F:_FL\,?\C/X9_P"QD\/_ /IYL:_I3'3\6_F:
M_#_&'^+D'_7O,O\ TK G]._1W_@<5_\ 7W)__2,R/#/VF?\ D@7Q8_[$O5O_
M $".OP$;J?J?YU^_?[3/_) OBQ_V)>K?^@1U^ C=3]3_ #KV?"/_ )$>9?\
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MCOB2OJN"/^2LR+_L.A_Z1,^%\3/^2"XG_P"Q;+_T]2/R"HHHK^KC^"0HHHH
M**** "OV<_8+_P"2%-_V/'BK^>FU^,=?LY^P7_R0IO\ L>/%7\]-K\X\4_\
MDE?^ZG@O_3>)/V3P+_Y+E_\ 8ES#_P!/X$^U*_"']KS_ ).*^)'_ %]:!_ZB
M>@U^[U?A#^UY_P G%?$C_KZT#_U$]!KX'PD_Y*''_P#8FK_^IV /U?Z0'_)(
MY5_V4>&_]5F:GS;1117]"G\B!1110 4444 ;GAC_ )&?PS_V,GA__P!/-C7]
M*8Z?BW\S7\UGAC_D9_#/_8R>'_\ T\V-?TICI^+?S-?A_C#_ !<@_P"O>9?^
ME8$_IWZ._P# XK_Z^Y/_ .D9D>&?M,_\D"^+'_8EZM_Z!'7X"-U/U/\ .OW[
M_:9_Y(%\6/\ L2]6_P#0(Z_ 1NI^I_G7L^$?_(CS+_L:R_\ 43"GSOT@?^2E
MR;_L2+_U.Q0E%%%?JY^"!1110 4444 ?H]_P3K_Y&'XJ?]@7PC_Z<?$%?JE7
MY6_\$Z_^1A^*G_8%\(_^G'Q!7ZI5_,?B5_R5^9?]>\!_ZKL(?V[X,?\ )N\E
M_P"O^;_^K?&A1117P9^IA1110 4444 %%%% !1110!^'7_!2X3G_ (*/?\$+
M!;-"DY_:M_:?\MKA))(1_P 8=_$#=O2*2&1ODW!=LBX?:6RH*G[!_;V35E^$
M7A8W\^F2PGQ_I>Q;.UO() __  CWB/!+W%]<H8]NX%2@D+%"' #!OD3_ (*3
M_P#*23_@A3_V=;^U!_ZQS\0:^S/^"@7_ "1WPG_V4'2O_4=\25]5P1_R5F1?
M]AT/_2)GPOB9_P D%Q/_ -BV7_IZD?D%1117]7'\$A1110 4444 %?L3^PO'
MK#? ]C87&F10?\)KXH&V[M+R:;?G3]QWP7UM'L(VX7R]P[L>WX[5^SG[!?\
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M?BW\S7X?XP_Q<@_Z]YE_Z5@3^G?H[_P.*_\ K[D__I&9'AG[3/\ R0+XL?\
M8EZM_P"@1U^ C=3]3_.OW[_:9_Y(%\6/^Q+U;_T".OP$;J?J?YU[/A'_ ,B/
M,O\ L:R_]1,*?._2!_Y*7)O^Q(O_ %.Q0E%%%?JY^"!1110 4444 ?H]_P $
MZ_\ D8?BI_V!?"/_ *<?$%?JE7Y6_P#!.O\ Y&'XJ?\ 8%\(_P#IQ\05^J5?
MS'XE?\E?F7_7O ?^J["']N^#'_)N\E_Z_P";_P#JWQH4445\&?J84444 %%%
M% !1110 4444 ?B!_P %)_\ E))_P0I_[.M_:@_]8Y^(-?9G_!0+_DCOA/\
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M=Z5-?KX?UB^LUT^]OM*N;2[L;RSEO;)([>[6*Y$5S'# )XW,$13X?_X< _\
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M_;3J?^7JW]3_ --:_(?_ (<!?\$</^D?7[/_ /X)_$?_ ,TU)_PX!_X(X?\
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MM_X%6W_QZON__AP%_P $</\ I'U^S_\ ^"CQ'_\ --1_PX"_X(X?](^OV?\
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M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 F!Z#\J,#T'Y4M% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>glonfvcontconsideration.jpg
<TEXT>
begin 644 glonfvcontconsideration.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &
M1Z]>GO17Y#?M\_%[XH> ?V]O^".?@+P5X_\ %GA;P5\8_P!I']H?PU\5/"VA
M:S=:?H7Q"T#P]^RSXU\5Z%I'BW3X&$.M:?I'B.PM-:T^UNP\5MJ4$5VBB:.-
MU_7>,DHA/)**2?4D"@!U%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDK!;2_FE]]_\CW*BL'RO$O\ S^:'_P""_4?_ );4>5XE_P"?S0__  7ZC_\
M+:OU(1O45@^5XE_Y_-#_ /!?J/\ \MJ/*\2_\_FA_P#@OU'_ .6U &]16#Y7
MB7_G\T/_ ,%^H_\ RVH\KQ+_ ,_FA_\ @OU'_P"6U &]16#Y7B7_ )_-#_\
M!?J/_P MJ/*\2_\ /YH?_@OU'_Y;4 ;U%8/E>)?^?S0__!?J/_RVH\KQ+_S^
M:'_X+]1_^6U &]16#Y7B7_G\T/\ \%^H_P#RVH\KQ+_S^:'_ ."_4?\ Y;4
M;U%8/E>)?^?S0_\ P7ZC_P#+:CRO$O\ S^:'_P""_4?_ );4 ;U%8/E>)?\
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MO!-Q\.M-T7P\GA)_"ETEO=Z%I/B9-5?Q#:B^:^G["&BZ)KGPIU3X??'SXV>
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M+<7_ .G<*/H_5?E(]>HI,CW_ "/^%&1[_D?\*_HP0M%)D>_Y'_"C(]_R/^%
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M_&O_ "2N=_\ 8&__ $Y3''=>J_,^5****_E<04444 %%%% !7U/\'M%TF_\
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M;V6[\WS-/OK'R]FW[:EJOF[MV?+^S7=UG9M&_?L^\NW=SCYW^ 7_ !_>)O\
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M'+A:V)J5>>I.C*+Y:N$HQY4J;3?/=75DPTM;S7X)_P"9ZC7Q1\5/^1^\0_\
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MOC;6-+\,?$K4?BKXR\&>"-3\"^/]5\,2:'JGB[1[FZU>;3+/Q/>^'LWXF?\
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MXCUS4=5TJW\(^#O$7CNRDM=6;5+B^O/%DT]K=6$=HL<WU3110 4444 %%%%
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EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>incometaxprovisionchart.jpg
<TEXT>
begin 644 incometaxprovisionchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %2 3T# 2(  A$! Q$!_\0
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M_P *V^(?@+P%X\^"5EXP^#_P4^&W@+P]_P *$\>ZKX>UE_A]I?PWNF\4>'M
MU?P9JOAG3M9\ ^-K"\DO-%UJ34I]7T?Q'IFL:MH][2\5?L%>+/\ A:?[+'C'
MX4?'P?"_P!^QYX6_X0KX-_"U_A'H'C2SM/#6J?#W1OA;XIT[Q!XKU;Q9IVM:
MQ_:?@S1+6UTJX2VL[C0]1:7499-8W"V !K_LN_MK:W^T%\5O$7@W5['X%>%M
M$CC^)5QX/T;0_BSXY\2_%O6;7X?_ !%N? \\VH>&=7^#7A'X?S/IT%HMWX_L
M_!'Q-\;WWP[UC5M#\/Z[;[[];X?H?7R1X9_9AURW^+/A+XD_$7XW^./BK8_"
MJ\\>W_P=\,Z_H/@K0SX3O/B/I]WHFM7OB7Q%X7T?3-4\?7VC>&-1U+PEX4FU
M&+2H+/0[^XN_$EIXL\5I:>*+7ZWH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&=._])KRORE_X*3_ /*23_@A3_V=;^U!_P"L<_$&OU:^-G_(D6O_ &&=._\
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M1D@^F!FEI#T/..#SZ>_/''6@#\2O'.B:I?\ [4'Q6^'FM)\2?#O@GQ=^U/\
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M_&OQ6\ ^)/"GB6V^'][\2?BI/^TGX;^ GBOQKX?^(]@MQXYU/39_A'XY\/\
MA;P9XBT30-,A^'WC._U/7-1US^B#P[KEKXFT#1/$=C;:Q9V6OZ3IVLV=IXAT
M'6O"VO6MKJ=I%>V]OK?AKQ'8:7X@\/:M##,D>HZ)KFFZ?J^E7:S6.HV5K=P2
MPH ?BI_P4MD>/_@I!_P0J=(7G8?M7?M.@11M$KL&_8\\?JQ!FDBC^127(:12
MP4JNYRJG]3/C!?7ESX.MHY](O+%!J^GMY\]SIDL986]YB,+9WUS-N;D@F,(
MIW,IP#^7'_!2?_E))_P0I_[.M_:@_P#6.?B#7ZM?&S_D2+7_ +#.G?\ I->5
M\UQC_P DOGG_ & 5OTU^0'R91117\J %%%)D>H_,4 +11D'H<T4 %>T?!.YG
MMM<UE[>PN+]CI$:M%;RV<3(OVV,AV:\N;:,J2=N$=GS@[=IR/%Z]T^ __(P:
MW_V!8O\ TO2OJN"/^2LR3_L*J?\ J+7&NOI^J/H;^UM2_P"A;U+_ ,#="_\
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MXF2TMQ>Q_P"EZGX-BU"T\2VT0.XRRZ&?$JQA<M;QQ9E7"KW3X#C_ (J#6_\
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M7_V$8'_U+HB/S;_;=\ Z_P#$C]FGXD^'/"G@;7/B!XGCT;5M8\.:1X1\=_\
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MI/\ \I)/^"%/_9UO[4'_ *QS\0:_5KXV?\B1:_\ 89T[_P!)KRORE_X*3_\
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M_P#A'QLM/L8C+&UJM6IXZFK>C;O;2UVOL2OEKX\_\C#H?_8&E_\ 2Z2O5O\
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M\\(S2S2:@KC6KY +75M5L8L+!9D'R;*]MX2YR=TACWL,!F(50/EJOK;X'_\
M(F3?]AR__P#1%E7U?AC_ ,E1'_L7XO\ ]+PXSUFUM(K.(PPM<,A=GS=7EW?2
M;F !'G7L]Q,%X&$$FQ3DJH+'-FBBOZ. **** "BBB@ I"2 2.H!(Z]?P!/Y
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MU17Y0_\ #\/_ ();?]'1R?\ A@_VHO\ YR%'_#\/_@EM_P!'1R?^&#_:B_\
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M\*YKA\+0K8FO46"]G1P]*=:M/ES#"3ER4Z<93ERPC*<N6+M&,I.R38+?Y/\
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M#W_,_P"-&![_ )G_ !I"Z* 6=5#<@E@ 1QR,GGJ.GJ*<"",@Y!Y!'0CUH 3
M]_S/^-&![_F?\:6B@!,#W_,_XT8'O^9_QI:* $P/?\S_ (T8'O\ F?\ &EHH
M 3 ]_P S_C7RT/A;XP_X;.?XR_8K?_A C^S)'\,QJ']HVOVO_A+5^+\OB\V?
M]F>9]M^S_P!AL+C[?Y?V7S?]&WF8;1]2@@YP0<'!P<X/H?0T9&-V1MQG.1C
MZG/3% !@>_YG_&C ]_S/^-!(&,D#)P,G&3Z#U-+0 F![_F?\:,#W_,_XTM%
M"8'O^9_QHP/?\S_C2T4 )@>_YG_&C ]_S/\ C2T4 )@>_P"9_P :^6_A%\+O
M&'A+]HC]J[XAZW96]OX7^*NK?!2[\&7<6HVMS<7T'@KX46GA37VNK*&1KG3C
M;:S$\$*W:1M=Q 7,&^$AJ^I-RXSN&!U.1@8Z\].*,C .1@XP<\'/3'KGMZT
M&![_ )G_ !HP/?\ ,_XTA= VTLH8]%+#<?PSFG4 )@>_YG_&C ]_S/\ C2T4
M &,?_K)_G1110 4444 %%%% !1110 4444 %%%% !2'IUQTY]L\]QC(R,]NO
MM2TA /!&>0>?4$$'\" 1[B@#\5_BY\7/VE?@WKGQ\\;_  B^,?BW]HQ_@G\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %037-M;[?M%Q!!OSL\Z6.+=MQNV[V7=MR,XSC(SU%3U\X_'X
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M=%T?X=GQM\(-/\,ZEXX^/VI?LS1:CXJL_B-\-;<^*]6TCX>^)/ /Q?N?!/Q
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M\/\ 5/#WBGX0_M+_ !&\ :'X;\<^))M;M=7_ &4OVD_!7P#\;Z'X\FO/#_\
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MM+5KJ9'G%I:6EHKK;6MO%'Z'110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>interferonchart.jpg
<TEXT>
begin 644 interferonchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-/C/\ $,_"/X0_
M%/XJ#1W\0GX:_#CQUX_&@QW?V"36CX+\*ZMXF&DI?"VO39OJ7]E_8ENA9W7V
M9IQ-]FG\ORG^!/V=O^"D?A?XA_"3PM\7/BKK7P$:S^(VG>%+CP%X._9(^)?Q
M&_;!\?+K&H_#P?$_QKX:\8^$/ GP8TGQ!H>I^ /"5YIFJZW+I^F:Q:VMC+)=
M:N^C&ZT2#5OT#^+GP\LOBW\*_B5\*]2U"[TG3OB5X \:> +_ %2PCAFO=-LO
M&GAG5/#5U?V<5R#;RW5E;ZI)<V\<X,+S1(DH\LM7S)KW[&%NGAK]FQ/AK\5/
M$OPQ^)/[,'@.Y^&?@?XE:;X9\'^))]2\&:]X \(?#[QAIOB#PGXDL+KP_=3Z
MS9^ _!WB'3;VW%O-H7B;POHKXU3PW_;/AG6@#UKX6?M3? WXV^+M>\%_"CQH
M?'>J^&/#W@_Q5KM_X?\ #_B>[\*Z=H7Q"\#^#/B1X!O)?&AT>/PF[^-? _CW
MP]XD\*V4.L2:AKFFMJ\UA:2CP]KHT_X/\*_\%>OA+XEUGX<37GPN^+W@_P "
M^,]5_;ST/6=;\4_#CXGKXST.^_89^(7@KP/K][H_PRT/X>ZQXG\7Z!XJM_$V
MKZ[J6KZ7''%\.O\ A%M7\.^*E7Q%IVO6.B_67[)W[&7P]_8_7XB:=\-M:\0W
M_A[QP/@U;66D>(#I\\OAW3O@O\!OAW\!M$MX]1LK:SDU6YUC2/AY:>)-;OKJ
MVMVEU[5M1%K!;V(MX(_&= _X)P>%] \=W/B6+XI^*[GPSI\O[<;>!_"$N@>'
MHV\*6_[?7BOPQ\1?C!97'B*$K?\ B.WT7XAZ+JNN>!Y-0M+>]TW2==;P[JUW
MK,6EV5^P!]'^&OVP/V>_&/CK2/ 'A?QV^NZEK]WI.D:)XBTWPMXQN?AMJWB;
M7OA_:?%;1O!.G_%=- _X5K=>/=2^&E_9^.K/P/#XI;Q1-X8N8=3&EA)%2O-?
MC1^V-<?!;XO7'P5UGX</J7C'XB>$_#&J?LKI:>)?L]K\>?&5WXB/A?XA^ )9
M;G0U'A#5/A M_P"&_B/XZO8#XF@M?@KJ^K?$2"!X?!7BO3M/\2_9V_X)2?!+
M]G'XA> /'/A>YT#6I/ ]KX,U9KSQ#\&/@[J/Q"U3XA^$_@SX=^"D_B>W^,%]
MX6O_ (B^&]!U[1_#=MXLO?!GAW5K%;#QC=Z@-&\16'@R]N?!DOV'\8?V;?"W
MQG^)GP ^(WB35-1A'P%UWXI:Q9>';:"W;3?%<'Q5^#GB[X-:UIFLW3-'?V5M
M:Z)XOO=0MIM+EAN7O((8G=8&<T <7H?[=7[.?B;2KK5?#.O^.O$H6TT#5="T
M[P_\%OC/JVN^/_#?BJXU.S\.>.?A?H%GX"FU?XE?#G6;O1]0BM/B+X+M-:\$
M1I';W5YK]K9:CI=U?8<__!1?]CRWM/M[_%V-[*'X;-\6]3N8/!?Q!NH_#W@.
M/QCX^^'$^J^*5MO"DLWAB^MOB5\-/%WPSN/#FNPV'B:+XCV=AX$_L=O%&MZ-
MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MA[\=;WP[H5S\0]<\3Z1\(? _B?QV]M\0_&NE2:=XZ\<Z3+X#^'-S\/[BYTT
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M,HR5KQDFFKJZNG9[,TC*,XJ4)1E%[2BTT[:/5::/1]F%%%%24%%%% !1110
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MW5X8+>^OH8L1R^N^$?A#X$U+Q#X?\(:CH6A6E_XE\;ZCH7BD:G\5%FUWX?\
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M$/$5UXJ32? GC73]<2VU5-%T'POKVOR63::A@ TS4]0O- '_  DWB&XN#/\
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M,T^VU&_.J7]M9VUO>ZF;6&Q.H7<$*17-ZUG;$V]HUU,CSM;VY\B$R&.$"-5
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M^L^BO_R2/$/_ &4<O_59EY\M])G_ )*S(?\ LGU_ZL<8-HHHK^H3^;0HHHH
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M -V)G=M7=USM&<^N<9IU%% 'X@?\%)_^4DG_  0I_P"SK?VH/_6.?B#7._\
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M%::WJ"-;K#*\J2R20Q?V/?\ !!K_ ),7D_[+?\4__0O#M?QF5_9G_P $&O\
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M_P#0;\8_^&;^-?\ \[NC_AJ#X+_]!OQC_P"&;^-?_P [NC_B(' ?_1;<(_\
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MCHK%T:3JJG[2GSN',H<\.:W-&_V!_P %,_\ DP7]K#_LC'BO_P!%V]?P)/\
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M$9_&DVCU;_OM_P#XJG44 -VCU;_OM_\ XJC:/5O^^W_^*IU% #=H]6_[[?\
M^*KY@TWX7>+;;]LCQ?\ &.6TMQX%U?\ 9H^'?PTL;\:C;M>R>*_#WQ:^*?BW
M5+1]-#_;(K:+1?%.CSQW[J+>>6:6VC8RV\JCZ@!!S@@X.#@@X(Z@^A'O1N7&
M[<-N,[LC&/7/3% ";1ZM_P!]O_\ %4;1ZM_WV_\ \50SHIPSJI/(#, 2.F<$
MYZTZ@!NT>K?]]O\ _%4;1ZM_WV__ ,53J* &[1ZM_P!]O_\ %4;1ZM_WV_\
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M8 'Z$G!H -H]6_[[?_XJC:/5O^^W_P#BJ4$$ @@@\@@Y!'J".M+0 W:/5O\
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MKJTND1>('TK5/$FC_"_X5ZF\-[_8UQ=:9I7A6"^:/]3A^RG^S6F@_$;PQ;_
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MCA@BCC15&G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDMO$OAI-=TVWM9H+B:XTF5R)H()XZ^!-=_X*1_&7X167QX">$_"WQ/T/X'^
M_P!L#]K'Q3XA\4^+-4TC6=1^#?PH_;V_:!^#NF?#GP3%H&AZCI\FHQ_"KP)I
M<O@?7=5+Z7'+IUM::S'?6]__ &A: '[O@@]"#R1QZCJ/J.]%?SW7_P#P4,_:
M%^&GQ;\:^,A86GBC]F[X5?#W_@L+\1?'_P .+R36O%OQ6\9^(?V,OVO/ /PG
M\&P>#?%R:/;P>%M)-GXXTBTT+PS_ &=J.C^$O"&H^*VUD>*+O0/"=[!]5^"?
MVZ_C]XO\3_#KX.3? [3?"WQ7^('Q=U7PCIWBCXB:3\5OA?\ #2[\'^$?A"OQ
MG\8W&FZ#XR\+P?$Z3QA;6Z3>!M!T[4M(T[1/$T<&H_$[2=1N=!T;4O"40!^L
MN1C=D;<9SD8P.ISTQ0"& *D$'H000?H1Q7XQ?!#XR_M&?%O_ ()'_!7XFZ/\
M8-!TS]HCXFZ;X&MHO&WC+QEX:\+2^,+_ %SX[#1=7\">$_B!K7A+7_#.A>/O
MB'X,AU'X=_"CQ=?^ ];L[;QCJ_AG4SX>>7;Y'D>G?M?_ +0_P]^.G[.WPFC\
M7^*?!O@SP[\=?V@?"_[6/A+]K=?A]XK\>>#?"?A/]C>S_:;\$Z+HGQN^#E[X
M@\+^)O!Z^'DU'QOI'CJ^O;GQ]9?:[;PW\1=/G@T*[TB] /WZHK^>?XB?\%,?
MVK_%(T7X>?"SPM\/OA]\2-6\=_\ !/#XC:#XQ\4>#_B/_P (+XK_ &?OVM?V
MM],_9TUG0[#1O&^FZ%XWN3_:,^GA/B/<^&_!=QJ_A#6]9O-"\(^#?%NDZ7</
M]%>'/^"EGQ?\73_%[5_"O[+_ (CUGPYH.D_M/V_POAU^'Q3\++75_%_[-7CC
M4OAU9Z7XN^*/Q(T71OA;Y/Q?\1Z+K2:/;>#-3UJ_^'5S!I&A^+9-3N];DU#1
MP#]CJ*^4?V3OC_JOQS\.>.[3Q@OAS3OB)\,O'(\'^+O#NC^'OBMX(UC2H]2\
M*^'/&7ARZ\4_#WXS^#_"7C3P7J>KZ+XBCN;2RCF\8^&]5TJ&SU[0?&NIQZE<
MZ9HOU=0 5E:EKNBZ,81J^KZ7I9N Y@&HZA9V)F$6P2&$74T1E$9D0.4W;-Z[
ML;ESJU^0'_!4>.-]3^"V^.-\6/C[!=$<C-UX2S@L#C.!G'7%?4<&\/0XJXCP
M&15,5+!0QJQ<GB845B)4_JV#Q&+25)U:*ESNA[-_O(\JES:VY7\WQ;GT^&<@
MQV=0PT<9/!RPB6'E5="-3ZSC</A7>JJ=5QY%7<]*;YG'ETOS+]5_^$W\&_\
M0V>&?_!_I/\ \F5T-M=6U[;PW=G<07=K<1K+!<VTT<\$T3C*R131,\<B,/NN
MC,I[$U_)4L$&1^X@ZC_EC%Z_[E?TL_LH@+^S?\%@H"J/A[X> 50%4#[+T"@
M #L  !7V7B#X9T.",MP6/I9Q5S&6+QOU1TJF!CA5!*A4J\ZG'%8AR=Z=N7E7
MQ7YM+/Y+@3Q#K\8YAC,%5RJE@%A<']:52&,EB7-^VI4>1QEA:'*OWCES*3VM
MRZZ?0=%%,D)"@@X.^(?@9$!'X@D5^2GZB*'1B0KJQ'4!@2.W(!R.:=7\L_P-
M_;=_:"^%?P^\$_M#^-[K]J+QFL7AK]O;XU?$NT^)WC[X9^)OA'^T'\-OV?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>noncontrollinginterestchart.jpg
<TEXT>
begin 644 noncontrollinginterestchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@JT\-VMW<>,/[4\6ZK;>&;/PG/>>&?$>C;V\7ZA-)I5K]EG[KX"?!_XPZ?\
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M^-4?V3IG_0/L?_ .V_\ C5 !_:VF?]!"Q_\  RV_^.T?VMIG_00L?_ RV_\
MCM']DZ9_T#['_P  [;_XU1_9.F?] ^Q_\ [;_P"-4 ']K:9_T$+'_P #+;_X
M[1_:VF?]!"Q_\#+;_P".T?V3IG_0/L?_  #MO_C5']DZ9_T#['_P#MO_ (U0
M ?VMIG_00L?_  ,MO_CM']K:9_T$+'_P,MO_ ([1_9.F?] ^Q_\  .V_^-4?
MV3IG_0/L?_ .V_\ C5 !_:VF?]!"Q_\  RV_^.T?VMIG_00L?_ RV_\ CM']
MDZ9_T#['_P  [;_XU1_9.F?] ^Q_\ [;_P"-4 ']K:9_T$+'_P #+;_X[1_:
MVF?]!"Q_\#+;_P".T?V3IG_0/L?_  #MO_C5']DZ9_T#['_P#MO_ (U0 ?VM
MIG_00L?_  ,MO_CM6(+NUNM_V:X@GV8W^3-%-LW9V[O+=MN[!QNQG!QG!JO_
M &3IG_0/L?\ P#MO_C56(+2UM=_V:W@@WXW^3#%#OVYV[O+1=VW)QNSC)QC)
MH L4444 %%%% !1110 4444 %%>3WOQY^!^F^)&\&ZC\8_A58>+TN_L#>%;W
MXB>#[7Q&M[YBP_9&T2?68]26Z,KK$+9K99S(0@C+$"O6* /Q _X*3_\ *23_
M ((4_P#9UO[4'_K'/Q!K]4OCA_R*&E_]ANT_]-^H5^4__!2Z>&U_X*/?\$+)
MYW\N*/\ :M_:?W.5=L;OV._B BC;&KL=S,JC"D G)(4$C]1?C)K&G:AX6TV"
MTN1-(FL6LA417"?(+&_4L#-!&N-S*,9W<CY< D?+\:_\DKG?_8&__3E,<=UZ
MK\SYGHHHK^5Q!1110 4444 %?77P2_Y$MO\ L-:E_P"T*^1:^IO@_K6FV'A%
MK>ZN1%+_ &OJ$FSRKA_D?R=IW10R)SM/&[([@5^B>&'_ "4[_P"Q;B__ $[A
M1]'ZK\I'N5%8'_"3Z+_S^C_P'O/_ )&H_P"$GT7_ )_1_P" ]Y_\C5_1@C?H
MK _X2?1?^?T?^ ]Y_P#(U'_"3Z+_ ,_H_P# >\_^1J -^BL#_A)]%_Y_1_X#
MWG_R-1_PD^B_\_H_\![S_P"1J -^BL#_ (2?1?\ G]'_ (#WG_R-1_PD^B_\
M_H_\![S_ .1J -^BL#_A)]%_Y_1_X#WG_P C4?\ "3Z+_P _H_\  >\_^1J
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M,_\ EM6]10!@_P!LW/\ T+^N?]^M,_\ EM1_;-S_ -"_KG_?K3/_ );5O44
M8/\ ;-S_ -"_KG_?K3/_ );4?VS<_P#0OZY_WZTS_P"6U;U% &#_ &S<_P#0
MOZY_WZTS_P"6U']LW/\ T+^N?]^M,_\ EM6]10!@_P!LW/\ T+^N?]^M,_\
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MK4:>'J8B6(C*E2E*4(^QQ-6@FG+WO>5-2:>S;2NK,"_1117T !1110 4444
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M;MA_\Z&LZU&CB*4Z.(I4Z]&HN6I2K4XU:52._+.G-2A)72=I)K0#]8/^%9>
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M'ZP?\*R\ ?\ 0O67_@1>?_)5'_"LO '_ $+UE_X$7G_R57X0?%W_ ()>>)_
MGQ._98\&Z/\ \%6O^"Q+Z9\:OC-XN^'WBM[_ /;6LYKR+0]!_9P^.GQ;M&T2
M1?A3"MIJ3>)OAMX?CGN)([M&T=M5M/LX>ZCNK7W_ /X<UW'_ $E>_P""SO\
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MBQS?5-%% !1110 4444 %?&?[97P@_:-^-WA?PKX&^"7Q-^'_@#P7?ZAJ_\
MPNS2/%FC_$1/$'Q%\*O8V\&E>"?#GC_X:^-/"7B7X=Z+J-W+J#^.M1T+_BJM
M>T9+7P_X?\1^$HKO6+Z\^S** /RX\6?L#^-_$VA>-?#FA>-/A%\+O#'[1G[.
MGPY_9G_:<\'^"?A1JT^@P^ ?ASI/CKPK8_\ #/:WGC.PB\!7%]\./B#KGPUC
MLO&6F>,M&T+3;3PKXBTC3XKWP[?:1XFF\0_L<?'7QK^UA\2?BIXM\7_ N7X"
M?$[]G.Z_9&USX<Z/X0^)EA\0H/@F?$7CWQ#!>6/C"7QO/X:@\:W"^.)=(NV'
MA<Z)!:V*7=C"D\ODI^H-% 'YR?LD_L+ZM^SMX]\->-_$'C'P!JDOPY_9UT7]
ME[PC!\,_A?+\-KGQSX*T'7/#>NVGQ!^.=_<^*_$\GCKXG12^&;>VT26R73-$
M\*2^(OB5J6F+</\ $6[L]%_1NBB@ HHHH ****  YQP<'UQG].*_-6Z_97_:
M)\>_M*^)?B7\=?%_P"^*7PGNS\0/!7P]\)'P=\4]#\0?"/X-^-_#U_X7U/2O
M"%F/'VH>!KGXM>+-'N6T_P"(7QBU?1[G7-4T/4=4\(>$K3P;X-N+G0-1_2JB
M@#\VOAI^R#\<_A:G@SQ#;?%;X5^-/&_[//[/4_[,7[,AUSX9>)?#_AZQ\ ZQ
MKOPIOO%?BKXP?V+XZOM7\2>._$&A?!WP%HA3P--X-\+:=?:)JFM6VD&W\62Z
M'X?XS]G?]C+]I;X(_LU? /X,ZAX^_99\8^*/V;)KC2O VM>(/@%XM\0>'-<\
M-7_AV]T*XU&XAUSXCOXM\!>/+>36-5=-<\%>(FTO5-!N+WPMJVD2VVJG4=,_
M5BB@#P[]F_X*6O[/'P7\$?"&TUT^)$\)6NK^?J\>C6?AK3KB_P#$'B36O%>I
MP^'_  MI\]W8^$_"=AJ6O7>G>#_"-G>7UMX5\*V>C>'H;Z]CTU;N;W&BB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>ocrevusmultiplesclerosislogo.jpg
<TEXT>
begin 644 ocrevusmultiplesclerosislogo.jpg
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ME^A.<G?,5.!GC8W8MO1R59]G)O$6P.&(-;=&];49*;D1QBT*25R!4T(1R>^
M__.=OMDPG>>3924%^DQW0L9(M)J'X2D2<UZA";Y7]3RO)#ZA83@2159FF$XQ
M(G(G)&,@1!C'J50<\S0:]-P"9 [<;9C.Q\@<& 04!=HJ(TE&3YKPNQ-K:9 ^
M*I!W78P$O50A,<-[O'4X!&&>$G*RQ%K<",%V@H!_2[D/)B!B8QA_[HF$@H41
M:RVR>I^53OJ4(HZQA+N/<A Q:RCAQ/H1<)1MZ2FU]21XA'B7T^XT0'V Z/M^
M?&);^G^;THAMZ5.!*XBW#X"\Z ,))]9)).:\>BK2Y23JB(6(U'4FB<1:"9SC
ME\*: 7]5BQH:?DL-8F/9@:3.K4+*DK8Y:)%8%2%^[*PLE\[Y22L5@;+^)T0Z
MV99>95OZ+Y':.UYYC<90A7#%(MO2;VN*_F);^CK;TL<C%>W2L?9]@Y3Y.*HE
M$T,M*+<'3N\6 Y2RM 8CG](U-@7;>HKDBZ ?RY"LJ?/L)+NJV9;^/D(<CQ(2
M>!_ =. PV]+?:=J($^#7J[UYYR*97UNZ%&S=BBS@2T@,]FE+2 BUU'!IE]/H
M3RJ$1G:?MBW]/\"9RNAT K*B]D>XT39@-;+*S4I662)=V%+E[U65_S<.,7AU
M1U[45H0#18%Y888L'^XA7B0+IHCY\1*)$4EA2]RA-&^#I:982A\A7A=LKN2
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MK!S!@*YKF;;DZ!HD3;4:B1WV!\8L#5;-]'38XX$98?J/#Z\"-QFF,U!-J''
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E2Q!"70S,W1F<-(,,,M@+\/]-B-N*SJ]\_@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>oiechart.jpg
<TEXT>
begin 644 oiechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-?C-\0_P#A4?PA
M^*?Q4_L>3Q#_ ,*U^''CKQ__ &##=BPEUO\ X0OPKJWB;^R(KXVUX+.34_[+
M^PI=&UN1;M.)OL\^SRG^#/V?/^"COA/X@?"KPK\6/BMK7P$MK#XCV/AJ?P%X
M0_94^*/Q%_; ^("ZK>> [CXD>-?#?C3P;X"^".C>(= U?X?^$VL=4\0?V9IF
MO6MC:-=W&K3:0&T>/6/OCXO_  [M/B[\*/B;\*K_ %.[T6Q^)?P]\;?#^\UC
M3X;>XOM*M/&GAC5?#-SJ5E!=@VLUW80ZH]W;17(,$DT*),#&S5\O:M^Q5:V7
MAG]FM?A?\4==^%_Q+_9B\ W?PR\'?$K3/!_@K7VUWPAXB\%>#_!?C2Q\4>#=
M<L'\/7MUKO\ P@7@_P 4V&H6[6]UH7BCPUI3*VI>')=:\-ZR >Q_"[]J;X%?
M&SQ;KW@OX3^.8_'VK^&/#WA'Q3KUWX;T+Q-?^&-.T+X@>"?!OQ&\!WTOC1=&
M7PBY\:>"/'GAWQ)X5M(=:DO]>TQ]5FTZUG_X1[7AIWPGX9_X*\?!_P 0ZW\.
M'OOAA\8O!?@7QIJW[=^AZSK_ (P^&OQ,M_&&@WG[#?Q*\&> ?$5_I'PQT+P#
MKGBCQCX=\3V?B75_$VJ:QI21+\-8?"FN>'/&,$/BG2M?TK1/JC]DK]B[P!^Q
MVOQ(TWX<>(?$NJ>&?'+?!F#3=&\2?V;<3^&=-^"WP"^''P#T>W35;&VLYM9N
M]=TOX=6OB?7=1OK:"237M7U&.T@MM.CM+>+QK0O^"<.@:%X\;Q+;_%SQ7)X8
MTB+]NJ'P5X0/AKPU%)X=A_;^\:^'?B=\6XK_ ,2PE=0\2KX=^(FDZGJW@22^
MM+6XT_1=8C\.ZO/K":19:BX!]+>&OVO?V>_&/C?2/ 7A;Q^NO:EK]YI.D:)K
M^E^&O&%W\.=5\2Z]\/[/XK:-X,T_XKQZ ?AG=^.]4^&E_9>.[+P-#XK?Q5/X
M6NH-672?)E0'S;XR_MCO\%_B[<_!;7OAQ->^,/'WA/PYJ_[+JVWB9+>S^/OB
MV[U\>&/B!X $UQHG_%&ZK\'WO_#/Q"\?WX_X22"R^"NN:G\2K6WFM? _C#3M
M-\%_9P_X)/?!C]FWX@?#WQOX<U+0_$4_@:R\&:G)J7B7X,?"'4/B)JOQ \)_
M![P]\'+CQ%:?%J[\.WOC;PKX;U[3_#L'C&[\&>&[FRDTWQE?:FNC>*++P=?W
M/@^3[%^,W[-'ACXV?$_]GKXC^(]9U&V3X Z_\5=:M?#5K:V<FG>+X?BO\%_&
M/P5UC3-8O9-FHZ;!9:+XSOM2M;C1Y8+J6[@CMII!:RR@@')Z/^W9^S;K^CW.
ML:#XI\8>($6QT'5]$L/#_P &_C1K&M>/O#WB<ZM'H'C/X5Z!9?#Z76_BE\/M
M7GT+54LOB%X$L->\$^5;1WMQKT%A>Z==WF'>?\%&/V-;&R?4KCXT6*Z=;?#A
M_BUJE\GA+Q_-;^'O ,7C'Q[\.)]8\5&'PI)+X5N[?XE_#7Q;\,KGP[XABTWQ
M-!\2K.P^'[Z/_P );KFB:1?_ "5X8_X(Y?"?P+X2T;PGX*\8:%H-EX+NO!>G
M^$K6/]GOX%'2/%/@7P1I/B#0],\(?M%Z98^&=,N/VCTEM==LM;GNO&FK:;I2
M>/?!'@'XB6WAJ+Q;H-YJ.L>B?!G_ ()9_#_X&Z)\3O#_ (,^*7BF+3?B+\'O
M$'P>CM;OX??!N^TCP_H^O_M1_M)?M1SRP>"M3\#:E\-M5TL:Y^TEX@\"R>"]
M0\$?\(>_@;0].L+32=/N+N>6  ^]_!7QJ^'WCKP5K?Q T_4-:\.>&O"\NKP>
M*Y?B5X-\9_"75?"DF@:;!K&M-XG\/?$_0/"6O:%:Z?I5S#JDFHZCIT.F3:7(
MFIVE[<6#K<GPM/V_/V6/[$T?7KGQ[X@TZ#Q'XJ^'_@[PUI>K?"CXOZ/XI\3Z
MQ\6M.\5:I\)YO#/@W5/ EGXL\1:#\4+;P3XHB^'WBG1M%OO#GBW4]%O]%T?4
M[C6;6?3XZ/PB_8G\'^ /@3\:O@+XM\4:KXX\%_'L>,;/QEX;TS3K7X>^ /"O
MAWQS\/=,^&NO^#/@]X T"[OM.^%?A&_T;3KG7[K1M$U&ZCE\=^(O%/BN-[>;
M639V_@GPZ_X)8?#;X>0?#@:5XNTS2K[X<?'3X'_&&WOO GP1^#/PMF\6V?P"
MT/XDZ)X0\/\ CN3P'X;TJ\\4:KJZ_$_7]2\4>*[Z^*-J?[WPGX:\(6^HZW:Z
MD =+\?O^"HW[/GPH^!?C+XN?#ZXU7XQZYX:^'(^(EMX'T?PQ\2-%^RV<OQ#U
MCX566D_$OQ&?A]J]K\$]9U'XA>%_&7@K3](^)UEX?UJ[\7>#?%'A^+2S?:#J
MRV?O=Q^W%^S'8IXZNM3^)#:3I7P_T_QSJFJ^(M5\&^/]-\*Z_9_#/Q=8> /'
M_P#PK?Q1>>%8=!^+5WX0\=ZMI'@G7M-^%]_XNU&S\7ZOI7AQ;6;5-3L;>X^.
MM2_X)+^&_P#A"OC/X#\+?'_XC>$M$_:-D\>M\<#:>%O FJ7?BU=;_:&^,O[0
MO@+^RKC5;"=O"T_@?4OC7XC\!ZG-8_:1XW\"Z;HD-]'HWB*VFU^;2T+_ ()%
M? 3PZ/B/8Z+>Z?X?T_Q++KNI^ M<\,?";X1:)\5?A_XCU?XQ^'/CUI.NW_Q?
M/A6^\9_$1O ?Q'\)>'Y?!NC^*9H]#N?#=A%H7Q#L/B#/%9ZO9@'O_P -_P!M
MO1?B;;_MHZEHG@+7['2OV1M>L-#"^)(/$?@_Q)XTFN/V:OA[^T'>1:QX.\8^
M$_#_ (D^'FI:?-XY;P?)I>LV&H32#3(_$2N+?4HK"'R/X6_\%$[^'PA\"_'?
M[5/P[\$? OP9^T;\!;CX]?#;QAX+^*.O_%;0;.VT_P &>%/B%J7PV\:6FI_"
MKX<^)=/^(<GA#Q=:ZCX7M?"FB^--+\8WFC^(-!TZZM/$$6@:9XD]S^''[(3^
M$M,_:J;Q=\5O$GQ \5_M=:A8ZS\1?$ESX;\,>&8=&U2S^ ?@W]G]4\'Z#HD1
ML=/TB+PUX)TK4K/3]2N-5NXM2DNS>ZKJ7GO.WR]!_P $I=$\;_!KP1\%_P!H
MSXY^)?C5X=^#WP9T;X+_  2AMOAS\/O >D^ [/0C\.S8^/\ 5?#L4'BRP\?_
M !%\OX6>$=*FN_%,LO@UO#4GBKP['X*AL?&7B!KD ^MM5_;H_9JT31;/6-5\
M8>)[&ZN-3\5:5>>#YOA+\7S\3/#D_@/1/#_B?QW>^,_A7%X$D^(O@G0?!?AC
MQ9X4\3>)?$_BOPSI/AS3/#_BOPGJ\FJ/9>*_#LNIR:S^W1^RYX?E^(1U?XFB
MRTKX8^'?B3XF\3^*Y/"'CL^ Y[+X.>'[OQ5\5]/\(_$!?#!\$_$#Q+\.O#UA
M?ZIXQ\)^!=?\0^)=#@TW5X[O2UN-#UR'3?!/"'_!./3/AK%X:\1_"3XK1_!7
MXJZ9'\4M$UWQI\'?@9\$/ 7AW5/!/QCB^%<?C#P_I?PVL/"TWA[2M7T^Y^"?
MPTUSP=XWU>\\6>)M%US0[B+5[GQ-X3U!O"-MP>L?\$B/@G?+^T98:5K>G:#I
MOQ[\%?M/:"FM6_P;^#FH?%?PIXF_:T\.^-=%^*/B=_C3J/A:7XA>)[2VOOB%
MXOUKPOX=O=2TR.R;7+G0-:U?Q!X5M]+T73@#W_Q1_P %&/V9-(LO%-KH?B_4
M=;\:Z!=:UX=M/".H^!_B7X56Y\>Q?#B_^*/@?PAK?B#7?!$&C^#W^+GA*R75
MOA)K7B*:TTCXG6$K3?#^X\3W$36C9WPB_P""D'[._P 2?A!X$^)&M:QK/@[Q
M/XO^%_P$^(Y^&#^"OB7K/B[4_P#AH31OM7@C3_A3I4?@2QU_XY:9J.OV7B+P
MQIGB?X8^']<TN_O?#.LW-P--M;2=XN#^(G_!,CP5\1-6^)6J7_Q5\:V/_"R_
MBQ^S%\5=0MK;1_#DL6GW?[,WPKM?A9I.B6KSQF2:P\76%L-6UJYN";RQOW\O
M3&2!%KA-<_X)%_#/Q?X:\!:1\0/B7KGQ-U7X%>!?A'\,?V=M0^(GP^^&WB?0
MO '@3X/VFI6=AI/C/P1<:/#X<^+EYXYL]4DTWXB:GXBBTIK_ $_2_#TWA*V\
M&>(-,N/$&I 'W!X1_:^_9]\>^.O"?PT\'>-[SQ#XY\9^$;GQWI'ANP\%>/3J
M-EX4T_Q5XO\  FM:MXLCG\,0+X#'AOQSX&\2>!_%5EXX;P[J/A?QI:6WA+7;
M.Q\0:IIFG7?E_P :_P!KOQ+\%_C3X!^'&I?#GP/J&@?$/Q_\-/A[X4MG^.GA
MRR^//CV3Q_K^@:!K_CGX6_ *#PUJE]XL^'GP>DUN36/BMJNL^,_"6LZ-X4\.
M^-/%>GZ'>Z/X=L9O$<G[/W[#?@K]GKXG:3\2_"_B-B^G?L_6GP*;PEHW@3X?
M_#_P:H/QK\?_ !TUCQ7I7ASP!H?A_1]"NM3\4_$36+,:186'V9+""WO=0OM8
M\0W.JZUJ&C\9_P!D75/C?XPB?Q9\</&S?"2?QW\-_B7?_"]?#/@9]2TSQ-\+
M/$7A#Q9X<T[P%\4TT>V\<^!?!^J>)/!&CZSXITBUEU77;VZOO$46@>+/#%EK
M'V.T +_P#_:LO_C;\>?VF_@K?_"+Q/\ #-/V>S\(9M,UCQ?K.D2ZWX_TGXK:
M/XTU&VU^3PCI/VQ_!-A#<>"[R/2-/UO6KGQ%JNDW=CK6JZ/X:>ZBTL>R_%KQ
M?\5/#4/A?3_A%\++#XE>(_$NMW.G7=UXF\<1?#WP%X)TBST;4-3G\1>,?$5K
MX>\:^)F@N[RVL?#^B:3X3\#^)M4U'6]6M6O5T;0K75-;L?D#P9^QU^T!X$^-
M?[2GQVTW]JVTO_$W[0G@?3/#3Z,WP"\%:5I_A+6/A]X5\:^'_@YKND:D?$NM
M2W4GA"Z\8R:EK]MK>F:M9>+GT^WMY[72[.2XMY?6_P!IG]G3XK?'_P"%'@_X
M9:/^T3J?PWCMKK36^+5Y8?#O0]=L/C=H5KH;V.J^"/%>G1Z[X8U+0/!7BG66
M35_%.D^#?$6B7.NZ;$_@S4+^7PCJ6N:3JH!\QZ?_ ,%,]3\5?#W5_B5X#^ D
MFN:!\)/@3/\ M$?M'0ZG\5M!TR\\(> +7XA?&?X=A/@]/IOAO7M,^-.H:Z?V
M>OB]X]\$:I=WOPX\(>,/A[H_@_5K/Q#9WWQ!TRQTSZ2T']KB7Q/^UUI'[,VD
M_"S78?"WB+]G/QU\?/"?QMUC7]&L_#OC=?!7BWX(^')]'\'^%K-=3\07WAV:
MU^-^BWDGCK63H%I)J.F:AHVA:-KZVU_J=CYIXA_8*U+Q7X=.C7_QPU+PO+X[
M^!^F?LS_ +04/PS^%OP_\%>%_BK\#?#FI^.Y/"'A;PWX3G3Q%;_![6/"GACX
MD>-/ NC>)/!^HWC6_AGQ-J@CTJ+5['PCJGA3?U']D/XH2?M=>!/VEM#_ &@]
M/\/^%?AW\._$/P8\._!JU^"'A>;3(?A#XT\2_"7Q9XN\-2>-3XL@UTZU<ZK\
M'O#L6@>)(]/CB\/:;=ZE:#0M3E>&[B .U^ _QJ^/OCSXO_%7X9_%'X8?!WP]
MI'PKT?PNFL^,?A3\7_'GQ$MH/'_BRWA\067P[OK'QE\#OA5%%K&G> ;O1O&N
MNW&GZCJ2Z7I_BWP9;R6\DNN2OI_??'3XG?%OX?I8#X7_  D\-^.[>+P[XM\7
M>+O%WQ%^+-A\'?ASX/T;PC#IMP=,O_$O_"*>/=7E\3^)HKR]FT1'\+6O@_2M
M+T'7]9\8>,- BM=*L=<Q-*^ 7B7P!\-?CQH'PJ^)=_H'Q-^,?Q!^+/Q0T[XF
M:UX?T+7I_"7B_P"(^IK+H4O_  C^H6UUHVO:7\/="LO#_A?1++5;>0:AH7AO
M3K>__>M)(.*_:^_9=^(G[3B> M%T/XZI\//AYX<O-5U/QU\*=9^%'ASXG> /
MC+?NVFOX6@^)&G:GXA\,:EK'A?PE-:W^H)X$?59/!?BS5+VTN/&^B>(;31--
ML$ /!_\ AYC8:QX-U'XQ>$/A%>W7P2^&OPB_9Q^,G[06O^+/&EKX5^(7PR\/
M_M&^%M*^(-CI6B_#ZV\.^(+#Q;K_ ,+?AMKFC^/?BA9ZMXR\%PIH^I6VF^!;
MCQAX@6YTV#U74?V[='\+_';]H[X6_$#X6>+OA_X$_9Q_9GD_::UCXI>(M0TI
MI_&7A'2O&7Q+\*^*)_"_@+33?:O!X>TR+X::CJ&@>(-=U+2[_P :&Z9M+\,V
MVC0Z=KNMT_&_["$7Q%U#7I_$_P 7M?AT?XS>%/A9X;_:Q\*^'?!WA71_#_Q\
MF^$\*V^FZC9I<G5M4^%P\7Z2%\$^/[+P[J>KIK?P[M-*\/:5<>']7TY?%,O-
M^,?V"O%WQ*_:,^+OQ>^(OQYM?%'PS^-WP.UC]F'Q]\#_ /A3/AW2K#4O@%J6
MJ_$;6$\)0_$"S\6GQ-:^(?M7Q,UNWU'Q?'9[M2L8+2-=$L;I7O6 /5?V4?VK
M]3_:.U3QMIFI>&?AEH,OA70/ GB)[?X??'CPW\7-7T&3QPFO2#P9\2=!LO#_
M (5U3PCXST./15-U?Z%!XT^%WB&XFU.P\%_$;Q!?>&-?@M=#QA^WI^R]\/+C
MQU%X^\?:QX)M_A[X4^(WCC6]6\6?#3XI>'=!U/PG\(;R*R^*.M^"-?U?P99Z
M/\1;/P%)<0W'B1_ E[X@-GISOJL0N-+M[F]AJ_L__LA)\&_'3_$KQ7\4O$OQ
M8\9Z5\'_  ?^SUX)U/5O#?A'P9:^&?@UX%UF[\0:-HUWI?@K3].L/$?BK4M7
MNTNO$7BF]BM+*1;"TMO"OA?P?:7.MP:S\3_$;_@C#\-_B7-XSN]>^-'C)M9\
M2>&OVI?!UKXW?P%\-;OXH7?AW]JG1-=TWQ'!\1OB=<Z2?&7Q6O/ %SK@C^&D
MOB34K73?#_AO2],\.3Z/>&V35P ?=5S^W/\ LV0/-8+XQ\13^)H?&VM?#^;P
M+!\*_BY<?$2TU_P]X/T'XAZO>ZE\/+7P)<>.-+\'6'@#Q7X5\;W'Q OO#\'@
MA?"OBCPYJT>O21Z[I45WF?"K]I[X@?'']D+]G+]I#X6_!(:_XN_:,^'OPB\=
M:;\/KOX@Z?I/A;P%:?$_PS9>*]0U/QG\1)]!FU"7PIX-TV>=+G4?#/@+7O$W
MB&_.E:?HOA%IM5:73^"US]@>W;]I7XC?M5^!/C1XQ\ ?%;XB^([*:[OK+POX
M-\0Z;IG@&\^$GPD^%7C/P!:Z?XAL[N"XA\0/\%? GCO2O$EPO]K>&/&&EA8X
MM8\,WFJ^'M2U[W]C/Q=X>_8J^$/[''P4_:,\<?"*V^%'@?X8_#$_%6P\,Z%K
M?C;Q3\/OAYH5OX?OO#]\4O\ 0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35]
M U*[@U6Q /.?#W[?WCOX@78\ _#'X Z1XI^-WAQ?VE+[XB>#+_XRVNB>"K/1
MOV8_B9I7PF\0W?PY^(B^ -3F\>W/Q$\;ZJ= ^'*ZQX0\"Z7:ZGX>\<:=\1M6
M\$ZKX1N--O\ MM"_;ZT3QK\9/V-_ '@;X4^,=3^&W[8GPV\2_$SPG\:=>U+1
M?#NAV.GZ=\(=&^,6@Z)HWAA)M7\0>+-6O= UA+;Q5>A="\.^$-16#3(=8\1Z
MM/=Z?I>7I?["7B31/#_P\D\+_'.#X8?$;P!X"\;_  3L_&'P<^"/PZ\#>'7^
M _CG5/#VMS>!-.^&^IW/B_0=#UWPCKGAFQU[P'XVM;^XGT;6+O69=6T+Q%IV
MMZII=UF^*OV"?& ^*/[*GB[X2_'Z'X6?#W]CKPDW@;X/?"V3X-^'/&\$'AK4
M_AYI/PO\16'B#QEK'BS3M=U5KWPGH]O%I5S#;64^D7[/>7#ZPN+>@#=_9>_;
M7U;]H3XI^(_!NIV?P&\+Z- GQ'F\)Z)H7QC\:^)_C#J]MX"^($O@N6XU3P?J
MWP6\'^!,V$$ NO'EMX*^)_CFZ^'NLZEHOA[6XFEOQ>I^AM?(WAK]F+Q'%\6/
M!WQ)^)7QS\;?%:P^$][X[O\ X/\ AK7/#7@7P])X9O?B'I5[X?UG4/%7B+PG
MHNEW_C[4-'\+ZGJ?A7PQ-=6FA00:3J5UJ'BBT\6^+5M/$UK]<T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$'T_6OU2^.&?^$1TO@C&N6@.01@_V?J'!R!SP>.O!]*^7XU_Y)7._P#L#?\
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M %/Q(!1117W !1110 4444 %%%% !17D][\>?@?IOB1O!NH_&/X56'B]+O[
MWA6]^(G@^U\1K>^8L/V1M$GUF/4ENC*ZQ"V:V6<R$((RQ KUB@#\.O\ @I=;
MP77_  4>_P""%D%S$DT,G[5O[3V^*0;D;;^QW\0'7([[756'N!7ZC?&31]*T
M_P *Z;-8Z?:VLKZQ:QM)!$$8QFPOV*$CJI95.#DY4<]<_E__ ,%)_P#E))_P
M0I_[.M_:@_\ 6.?B#7ZI?'#_ )%#2_\ L-VG_IOU"OE^-?\ DE<[_P"P-_\
MIRF..Z]5^9\J4445_*X@HHHH **** "OJ?X/:+I-_P"$6N+W3[6YG_M?4(_-
MFB5WV)Y&Q=QYPN3@=!D^IKY8KZZ^"7_(EM_V&M2_]H5^B>&'_)3O_L6XO_T[
MA1]'ZK]3T'_A&/#W_0'L/_ =/\*^/OB7;6]GXXUVVM88[>WBDLA'#$NV- VF
M63MM4<#<[,QQW8U]O5\4?%3_ )'[Q#_UUL?_ $UV-?>>+'_(@P/_ &.*/_J%
MCQ'GU%%%?S^ 4444 %%%% %W30&U"P5@&5KZR5E/1E:[A5E/L5)!]C7W=_PC
M'A[_ * ]A_X#I_A7PEIG_(2T[_L(6'_I9!7Z%5^V>$7\+/O^OF6_^DXT?1>K
M_0\T\?>']$M?!OB.XM]+LH9X=+N'BE2%5>-P!AE8<AAV-?&;=3]3_.ON/XB_
M\B-XG_[!-Q_):^'&ZGZG^=>1XL_\CG+?^Q9_[M8@.B]7^@E%%%?E0@HHHH *
M*** /=/@?IMAJ-[XB6_M(+M8K73FB$\8D$9>6\#E0>A8*H)[X%?2MEI>G:;Y
MAL+.WM/.V>;Y$8C\S9NV;L==NYL9Z9-?._P"_P"/[Q-_UZ:9_P"CKVOI>OZ8
M\.?^21RW_KYC_P#U/Q(!1117W !1110 4444 %13PQW$$T$T:S1312121.,I
M)'(C(\;#^ZZL5;V)J6D;H><<'G.,<=<]L>O:@#\>?B5\0OVEK'XM:Q\&/AW\
M!-*T?X0^!_B]X5M;KPQ;_LTZUJ_@7XG?#;QKK?[/_A#PUX?A\=W '@26#6+#
MQ;^TK\4?'_C3PEI\@^#5G\)/!OA_Q_;6@U.Y/C;]>-+TVPT?3;'2=*LK;3M,
MTVTM[#3M/LH4M[.RL;2)8+2UM;>,+'!;P01QQ0P(JI%&JQHJJH _!KQ_I7A.
MP_;J^(.O>(_A5^S9\6-/E_:%^$MH_P ;_BI\+_VEO&NL?!7Q)J6C_"S3-"^&
M;?&VS^%_B#X+^ M>MKRY\/ZKX!\'V?B;1O#GAGQ+XITF#Q9K&G^)/%D377[Y
MCD=NIZ?4]>G/J.QS0!^(/_!2?_E))_P0I_[.M_:@_P#6.?B#7ZI?'#_D4-+_
M .PW:?\ IOU"ORM_X*3_ /*23_@A3_V=;^U!_P"L<_$&OU2^.'_(H:7_ -AN
MT_\ 3?J%?+\:_P#)*YW_ -@;_P#3E,<=UZK\SY4HHHK^5Q!1110 4444 %?7
M7P2_Y$MO^PUJ7_M"OD6OKKX)?\B6W_8:U+_VA7Z)X8?\E._^Q;B__3V%'T?J
MORD>O5\4?%3_ )'[Q#_UUL?_ $UV-?:]?%'Q4_Y'[Q#_ -=;'_TUV-?>>+'_
M "(,#_V.*/\ ZA8\1Y]1117\_@%%%% !1110!>TS_D):=_V$+#_TL@K]"J_/
M73/^0EIW_80L/_2R"OT*K]L\(OX6??\ 7S+?_2<:/HO5_E$XOXB_\B-XG_[!
M-Q_):^'&ZGZG^=?<?Q%_Y$;Q/_V";C^2U\.-U/U/\Z\CQ9_Y'.6_]BS_ -VL
M0'1>K_*(E%%%?E0@HHHH **** /H'X!?\?WB;_KTTS_T=>U]+U\T? +_ (_O
M$W_7IIG_ *.O:^EZ_ICPY_Y)'+?^OF/_ /4_$@%%%%?< %%%% !1110 5FZS
M>3:?I&J7UO'!+/9Z=?74$=T]W';236UK-/&EQ)8V6HWJ0.\:K,]I87MTL99K
M>SNI@D$FE6;K,%S=:1JEM9^4;NXTZ^@M?.O+[3X?M$MK-'!YM]IC+J5E'YK)
MYEW8,M[;)F>T87$<9H _GUO/BMX0^)W[1N@:A8Z)I#^"_B'\4/A!XL\:_#Z#
MXM_M]^%/ASXT^)FEOX&MU\:^(?A)=?L"Q>$-2UG0/$&A:;)IMK>?%7P5X!\?
M-X4\+^(OBGI-K>7&MFV_H;7IQV)'Y$\G(')ZD^O<]3^ EKINL>&OVD],\"^%
MXOB/XQM/ 'Q'^&'AKQMJ/AGX^_\ !;/XR:!X8\73:7X&\2>)_#_B+Q-HB>+_
M -GM[C27U];ZXT/QQXH;0;+PW>Z1_P +/@TB"\UFSM_W[']3Z^I]?_U>G&*
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M]OLMN[.W=]KAV[MO.W.-V.<9QS7W7_Q4_?\ L/\ \J=?"NF?\A+3O^PA8?\
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MOLW?.[?OXQMV]Z^E;#^T_P![_:/V'^#R?L7VK_:W^;]I_P" [-G^UN[5\\?
M+_C^\3?]>FF?^CKVOI>OZ,\.?^21RW_KYC__ %/Q(@HHHK[@ HHHH **** "
MD/0XZX./\GC\Z6FNP568L%"JS%F("J "2Q)(  ZDD@8ZD#F@#\GM?^!G[0$'
M[5GC;QNO@#XJ>*_ WB;XN>"?$^C>)_"_[>WC3X&^$M&\*Z9H?@S2+NSU3]G'
MX>Z)I/A3QBNDW.BZI?:E-XON]>\2?$>UNO[$\2:LNCVFBZ=8_K$/ZGOGN?\
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ML%_97OE;?-^R74%SY>_=L\SR9'V;MK;=V-VUL9P:N44 %%%% !1110 4444
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M=/FJ0HQ<TDW!2JU*=*+E:]2<(*\I13=OT_'_ (<]PKZZ^"7_ ");?]AK4O\
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M\0O"UAHGC'XQS:]\06M?"WBM]&TWP_\ HWX]63X[^)/V:K"Q^'_BS_A4VO\
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M+^F[7_(WJ*P?[*U3_H8[[_P T7_Y7T?V5JG_ $,=]_X :+_\KZ^\$;U%8/\
M96J?]#'??^ &B_\ ROH_LK5/^ACOO_ #1?\ Y7T ;U%?*'QJ\7>//!_Q9_9
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MU7R-:NKJRC&FVVB#4M2N;JWL]#U>YM?KT'< 1T/3W'8\=B.1['G'2@!:***
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M^%;/1O#T-]>QZ:MW-[C110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>otherrevenueschart.jpg
<TEXT>
begin 644 otherrevenueschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MY4&2,8S(@R,C+KR.F1SR,@C(H ?102 ,D@ =2> /QHH **** "BBB@ HHHH
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M??7N[_\ #]5\PKZE^#]SJL/A I9:7'>1?VOJ!,SZC':MO/D;D\IK:4D+V<,
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M^0J/MWB#_H P_P#@Y@_^0JN#7-%8A5UC2V9B%51J%H2S,0%4 39))(  Y)(
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M605^A&U3U5?R'^%?MGA%_"S[_KYEO_I.-'T7J_RB9'_"1^'O^@[HW_@TL?\
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MO[*]\K;YOV2Z@N?+W[MGF>3(^S?M;;NQNVMC.#BWL3^ZO_?(_P *4 #H /H
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M !1110 5]=?!+_D2V_[#6I?^T*^1:^NO@E_R);?]AK4O_:%?HGAA_P E._\
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MQ9^V1H_@[XF?LM?"K7/@]\9M'\1_M.>,-0\&QW&N^'-)T[0/A7J]G\-OB_\
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MTV235-1O5;6+9!%>-8F)2;"^(D7[-86LF\!2HW2,H5F^4D@CY?C7_DE<[_[
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M\-HA\5#P?-J_]@0^+&\/"8ZNGAJ?7LZ+;ZZ]FNEW&K+)IT%U)=Q20ISW@?\
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M*3_\I)/^"%/_ &=;^U!_ZQS\0:^S/^"@7_)'?"?_ &4'2O\ U'?$E?5<#_\
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ME_\ #K@/+_I_YH_B7_4[B_\ Z)3B7_PQ9I_\R^?Y]F?H?17YX?\ #UK]@O\
MZ+3XA_\ # ?M+?\ SG:B_P"'L/[ AG-L/C?K9N5A6X:V'P&_:1-RMN\CPI<-
M;#X/^>MN\T<D*7#1B%YHY(DD:2-U4_UCX>?_ #/LE_\ #K@?+_I_YH/]3N+_
M /HE.)?_  Q9I_\ ,OG^?9GZ*45^>'_#UK]@O_HM/B'_ ,,!^TM_\YVC_AZU
M^P7_ -%I\0_^& _:6_\ G.T?ZQ\/?]#[)?\ PZX#R_Z?^:#_ %.XO_Z)3B7_
M ,,6:?\ S+Y_GV9^A]?LY^P7_P D*;_L>/%7\]-K^53_ (>M?L%_]%I\0_\
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MT>K?]]O_ /%4H((!!!!Y!!R"/4$=:6@!NT>K?]]O_P#%4H '3/XDG^9-+10
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MRDM46U6U%L!%3?%'[$_[(WC7X<Z)\(?%G[-_P9\0?"[P[JNHZ[I'P]U3X?\
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MCW1_"&FZ;XEO?'?BL7*^)_&-[J%I'$]WXF\0K=W UK6[A9-0U/S/],GEV1[
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M%2PSP]J$JKHJ?ML50P[O44*CCRJLY+W'=Q2TO=!]!_VKI?\ T$K#_P #+?\
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M$6D,'A#2=0A:^\1:WXIT7^B]3D ^O(Z@X[9! (..H(!4Y!Z4 +1110 4444
M%%%% !1110!YA\:/!FJ_$/X6^-O!6B36-OJWB/1)M-L9M2EFAL8YY)H)%:ZE
MM[>ZG2("-LF.WE;. %Y)'YB'_@G_ /&<DD:_\.N23_R%_$'_ ,S-?L517U61
M<8YSPYAJN$RV6&C1K5WB)JOAU6E[1PITW:3DK1Y:45:W?N?"\4^'?#?&&-P^
M/SFGC)XC#8982F\/BI4(>Q56I62E&,7>7/5G[U]FE;37XM_90_9W\;_ V_\
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M2>)]:;3K/3=.DU[Q7XEU75_$NO3:?ING6,VL:M?2V=A96S16T7I=% !1110
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M-4/ASQQX;TCQ1HO]I6+2-9Z@--UFTO+5+ZU,TP@NXXUN(EGGC601SS))WM%
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H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>part1researchanddevchart.jpg
<TEXT>
begin 644 part1researchanddevchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #& 3T# 2(  A$! Q$!_\0
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MOX3+7'B#P=IVC72V^B>-=/M_%\(!ZY\8?^"H?[+OPI^'GQU\;6FI^-O'>I?
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M-S8VEQ91&V:.TFMH);5&LY(Y;1DMY(VA4VLL,,ML0@,$D4<D.QXT90#\R?V
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MS'_AJ?\ 9X_Z*]X*_P#!H?\ XS0![_17@'_#4_[/'_17O!7_ (-#_P#&:/\
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MLK&QMK:QLK:,;8+2VABW,5+M^S?_  3\&?@&W7_D>_%G<C_H&>AK\2:_:?\
M8%U;2K'X#M#>ZGI]G*?'/BMA%=7MM;R%3_9N&V2RHVT]CC![&@#[O8#!Z]#W
M/I]:_ K]L6YNH_VD?B8D=W=QH+OP]A([JXC1<^$?#Y.U$D51DY)P!R2>M?NZ
M?$?A[!_XGNC=#_S%+'_X_7X+?M@7$%U^T;\2I[:>&Y@DN_#^R:"1)HGV^$M
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M$'(((."",$<&OZ;?[,TXDDV%D268DFTMR22Q)))B))]SS7\R?A;_ )&GPO\
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M-^)4%M!#;01W?A_9#!&D,2;O"6@,VR.-51=S,S' &6))Y)-?M"?VA/@1@_\
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MQ)X>=V/Q#\$@*B:U8LS$_P!O=%4$GV%?TI?\-!_ A2P/QH^$V0S _P#%RO!
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M_P#L2?\ B-/PH_\ F9I1_P $<O\ @E"./^';_P"Q'^/[,_PF/ZGPP37Z344
M?FU_PYR_X)0_](W_ -B+_P 1F^$O_P S%(?^"./_  2@)S_P[?\ V(_P_9H^
M$X'Y#PR!7Z344 ?FQ_PYP_X)0?\ 2-_]B3_Q&GX4?_,S1_PYP_X)0?\ 2-_]
MB3_Q&GX4?_,S7Z3T4 ?FQ_PYR_X)0HR.O_!-[]B,E)(F /[,_P )G4[9%)#(
M_A=D=2 =RNK(RY#J5)!^9_V-?^".7_!.MOV5O@&/C'_P3?\ V41\45^&'AI?
M'?\ PGO[,_PX7QF?$IMW;4SXF.K>&!JC:SYS8NVU$M=A@JR$*J*O[?T4 ?FQ
M_P .</\ @E!_TC?_ &)/_$:?A1_\S-'_  YP_P""4'_2-_\ 8D_\1I^%'_S,
MU^D]% 'YL?\ #G#_ ()0?](W_P!B3_Q&GX4?_,S3O^'.7_!*'_I&_P#L1?\
MB,WPE_\ F8K]):* /S:/_!'+_@E">/\ AV_^Q%^'[,_PF'ZCPQFF_P##G#_@
ME!_TC?\ V)/_ !&GX4?_ #,U^D]% 'YL?\.</^"4'_2-_P#8D_\ $:?A1_\
M,S1_PYP_X)0?](W_ -B3_P 1I^%'_P S-?I/10!^)OQE_P""./\ P3D_X6M^
MR./!W_!-_P#9._X17_A>'C3_ (6U_8/[-'PW_L7_ (0D_LQ?'W^QO^$W-GX8
M^S?\(Z/B8/ /]G_VL?L(\7_\(UY&-3-B3]%_\.</^"4'_2-_]B3_ ,1I^%'_
M ,S-?I/10!^;'_#G#_@E!_TC?_8D_P#$:?A1_P#,S1_PYP_X)0?](W_V)/\
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M/&7A_P 2Z3H/A>;4=%TBWOCXCTCQ;KNHZ+HWASP_?:Y<:+X2\)6.A<_\*_V
MO!OP;^#7@GX)^!?CG^TWIGA_X8:C+<?#/6T^*.DVWB;P7HMWI/\ 9&H>#K>?
M2_!&FZ#XI\)7T+W%Z=-^(?ASQG<Z=K,ZZWH>H:5JECI=U8@'TY\"_B'IWQ6^
M$G@+Q[IOBO2_&Z:_X?MI+[Q-H_A'7?A_9:CKMA+/I'B11X!\4:IK?B;P+=V'
MB+3]5TS4O!?B/5]2U_PIJ5E>:#K-Y<:CI]S(WK%<!\+?ACX-^#?@+PY\-O .
MFS:5X6\,6D]OI\%UJ.HZSJ-Q/?7]YJ^K:MK&M:Q=7NKZYKNNZUJ.I:YKVMZK
M>76IZSK.HW^IW]Q-=74LC=_0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>plegridy.jpg
<TEXT>
begin 644 plegridy.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "6 /H# 2(  A$! Q$!_\0
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MMO#:P+%;":2<'!9L!<>W?K66FL^,[E4ECTRW2*3!''8_C5/XH_\ 'QIOT?\
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M[:>ZB/\ L28_I4I-$Q4HZ&U6?J6LV^GH06#S=HP>?Q]*GFL_.B"-<3@ 8RK
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M@>QR*W:* .-3X9:4'!>XNV4?P[@/Z5T^FZ7::3:BWL85BCZG'4GU)[U;I"<
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M]MCTSXA7;78D1;N"-(6"$ACQZ?2@#-@N],URYO[G6=3>&19FCMXA,4\I1T8
M=:CGU>\N_ -O*+E_M$=ZL/G \L!T)]>"*M:5>:=X<;4+'680LJSM+"SP[O-4
M] IQST_6EUK[9<>#+62ZM4@FDNT?RHDQM7G&1ZT 6]=T5=+\):O(;F>XGN(U
M,KR-D%LCH.U5=1D&B>&M-MX+R: 7[1B29WSY:[06P>U;WC!6?PGJ"JI9C&,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>principalproductschart.jpg
<TEXT>
begin 644 principalproductschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )] 3T# 2(  A$! Q$!_\0
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M^SIXQ^%'A#XL>"O^%A_#*7]HKXO>%_A-:>,_&'A."YU?7]/L?"5SXIL];O\
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M-\1O%-MI=]X)N9;.]^P'^S9XIM+?_@FK\)_'_C']N[3_ (L?LC:SX6U[QO\
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MR!_9T_:X_:8USXL?\$M?&OQ$^)]KXM\%?\%/?V7O'_Q8\3?!:W\">#-$\%_
M/QAH?P*^&?[0?A=?A'XLTW2K7XF:OI5OIOB7Q!X'\51?%'Q/XYE\3SS:9XGT
M<>"C8R:'<._X+07/B*S\<_\ !)RZ\)?"W3/C5XCA_P""E&EOI/POUCQ%X8\)
M:=XONA^R/^U/C3KGQ%XQT[5O#NEK%'OU!)M1L+A99;*.VMA'>SVTL8!^P'PO
M^,OP?^-VAW'B7X,_%3X<?%OPU;7?V&Y\1?#'QWX7\?:)!?"))OL<^L>$M7U>
MQANQ"R2?9Y;E)_*97V;"#7I0"CD'ID9+%B,XR,L21G R,]A7\H_BO]H_XE?
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MX?\ A?1Y>Z_9J_81^)=SX@N?%G[66O\ B/5O"W@3XZ_"3]H+]E?X(ZC^U/\
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M-_A_J_Q?\;>,[SP5X,N=2T31+S5=+\/R64WB*?0M ?Q+>:S_ &!HOV#ZTHH
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M.G?$#QKXELO"7PQC\(^)+RSMO FC0VN@QW.G^&KV2WFG\(^%FTC[RHH ^&O
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M$UOX6\&>%_V>;#XS^$_%]WXILM4\8>.9W^*6J?#J^D3PSI+7.B>'/"UR=/\
MM'AEM4U^3Q3JK^?/KFB^%;=;2&\9^U=^P]X%_:WU_P"'M_XW^)7Q5\.^%?#5
M_K,'C[X<^%/%SVW@GXM>#->^&/Q;^&&J^$->TB_BOHO#$FJZ'\8/$NFZWXP\
M#_V#XNUKPO<W?A:_U22+_A']3\+OL/V-GTW]J=_VJ;;]H_XS)KA\ Q?".#X;
M#1?@&OPVL_A/9>([_P 7:3X$MEC^#*^.A::3XDU!]0M=?E\;R^+)XX+>PO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?D)^WU\7/BAX"_;X_P""./@/P5X_\6^%?!?QA_:2_:(\-_%3PKH.MWFFZ%\0
MM!\/?LL^-?%6A:1XOTZW=;?7-.TCQ%86FM:?:7JR0VNIP17D:B>*-U\Q_P""
M]G[07QM_9S_9+^&'C3X$_$_Q9\*O%>K?M ^&O#6IZ_X0NK.UU&^T"[^'OQ&U
M.YTFXDO;'4(FLY]0TO3KN1%A5S-9PL) H96M?\%)_P#E))_P0I_[.M_:@_\
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M^U&:#P7\389;Z\CL[33DN[R6+P"CW5RFGV%C8K<3M),ME96EH'%O;011V?\
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MAEX;\*?#*U\1>-)/$WB'P, ?N=17Y4?LQ>&OV;/V<=*_:;_:RN/A]\//V>/
MFM?&#7/@GHJ^$O <?A72M.^&WP7^*E_\#/#=S?Z'X6T%;O4-2^(7QGD\9>*S
MKSZ;-<7?A_Q)X)T^6;^Q/#5G=UV>D_ 7X,>*O^"B'B'QWI?P9^'OASQ#\ _A
MSX>^(.H?$/2_ 5CHWB_QY\:/VA9_B)X9EU+5O&=M8V][KR> /A?X(U6!K*6]
MN[*YU/XN?;]1A?5/#>A360!^DE%%% !1110 4444 %%%% !1110 4444 ?B!
M_P %)_\ E))_P0I_[.M_:@_]8Y^(->*?\'*O_)DGP@_[.<\)?^JO^*M>U_\
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M?A+Q;XWL;/7]!T7R-8\2Z'H6M0G3=,DY?]IOX5>&/A-XA^'5IX<MO&'A>_\
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MJ2Z_X>_\E"^'_P#V/_@7_P!2[1J_T#UZ'_>?_P!#:O\ /P^'O_)0?A]_V/\
MX%_]2[1:_P! ]>A_WG_]#:O@?$#^+EG^'&?^ZI^G>%O\/.?\>!_])Q1^>7_!
M67_E&]^V9_V0;QG_ .BK6O\ -SF!\V7@_P"L?L?[QK_3 _X*0:;8:Q^PK^U+
MIFIVT=Y87WP=\4VUW:REQ'/!)';AXW,;QR!6P,['5O0BOX47^#WPS+N?^$/T
MSEF_Y:ZCZG_I^KZWPMS2A@,IS"G5IU9RGF+FG34&E%X;#1=^:<'?W6]FMO0^
M+\9<HQ&89[E=6E4HPC#*O9M5743;^MUY77)3FK6DMVGH]-K_ )TX/H?R-&#Z
M'\C7ZK_##]DG3/C%XKM?!GP_^&FG:UK=S&;B4S:C-I>E:99+)' =0UK6=2U2
MWTW2;%KJ>VLHKB[G3[1?75K96T<]S/'&>AT?]AK7-=N==L+#X&RKJ?AS6KCP
MSJ6DZEJ-GHFK2^*;31F\177A30M-UKQ+87GB[Q/!X?7^W'T#PA%KNIG2);34
M([>2UU#3I;O])GQ5EM.4HU.>$H1C.<9RP\7&,FHJ4E*NK)OF2;T;2757_)J?
M!^;58PG2C3J0J3E"$J<,5.,YP2E.$7'#M2E&+3DE=I:['Y#X/H?R-&#Z'\C7
MZU-^Q=<+X/LO'?\ PIV%O#5_IVA:W!<)JUE)JR>'O%&L1^'_  UXIO/"L?B1
M_%NF^$O$&MS6^E:-XJU'0[7P_J%Y<VB6^HNEY9O/C^.?V4_#GPZN5LO%/@_P
M+'?C4=2TBXL-!^(?A3QG?:=J>CR^1J5AK%EX,\9Z_<Z)<VMP'MGCU:*R+W,4
M]O%YDT$R1D>*<NG)1C[24G*4>6,L.Y<T%%SCRJNWS04KRC:\4U=*ZNI<(9K"
M//-4X0Y83YY0Q48\E1M0GS/#I<LVI*$KVDXR46['Y6X/H?R-&#Z'\C7ZRS_L
M:/;^"&^(DWPBM$\*)HEAXHFNQK5A)JMKX2U74H]'TOQA>^%(O$S^+['P?J6J
MS06%CXJN]!AT*YN+FU,5^8;NUFF\N_X4[\,_^A/TS_O[J7_R?5PXFP-2[A"M
M/EERRY/8RY9)1;C*U=\LDFVXNS6FFNL5.%,RI<OM9T*?/!5(>T6(ASPE\,X\
MV'7-!V=I*Z=G9L_8'_@V#!'Q,_:_R"/^*"^"O7_L9_B37]A5?S#_ /!O[X+\
M+>%/'_[3DOAW1;72I+WP=\*([I[=[IC.D&O^.WB5Q<7$P C:60KM"G+G)(P!
M_3Q7\Z^(&)AC.*LQKTXRC&=/ KEFDI)QP&&B[\LI+=.VKT/ZJ\+\+4P7!658
M>K*$IPJ9BVX.3B^?,<5)6<HQ>S5]-PHHHKXP_0 HHHH **** "BBB@ HHHH
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M\"^D!_O/"_\ UZS?_P!*RP_;O W^#Q)W]IE7_I./_P" >+?M9\_LV_&? /\
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MX*N<YZ<8R<_L18Z78:;YOV&V2W\[9YNUI&W^7NV9WNV-N]L8QU.:_B[QBO\
M\1 SGM[+*K?^&C W/ZZ\*/\ DALI_P"OV9_^K/%E^BBBOS _1@HHHH ****
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M >F1^1Z#V'0>V.O6@#\0?^"D_P#RDD_X(4_]G6_M0?\ K'/Q!KZE_P""EO\
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MTJ6\E;1O!FCW_B'7;VS\/QW33W6NV^F:;=:>GAU-0)/B9#H[:B($DU!=NY^
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M=:IW/[!\)9PJ<"93.G.,XNMFEI0DI1=LTQB=FFUHU9]GH%%%%?EQ^D!1110
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MW]S:-WF>7]Y=N[G'\*>/7_)T,_\ ^O.2_P#JCRT_M/P2_P"3<9'_ -?\X_\
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M -G6_M0?^L<_$&O7_P#@KQ_R;GX"_P"RQ:#_ .H;XTKR#_@I/_RDD_X(4_\
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MHKFXNH(I(1^TQJ9.T>%M'+;F3;_;-]G>@#/&!]FR9$4AG0?,BD,P"D$_9_[
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M?(/[;&GW\7[)_P ?9)==U"YC7X:Z^S02VNCK'( D/RN\&FPS*IZ'RY4;N&!
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ML.N:HXX.RP\%.A15:M&BZ?L+>TDZD)I4XT_Z,?\ @W;_ .2A?M3?]B7\(_\
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MA"BBB@ HHHH [;X9_P#)2_AK_P!E(^'W_J9Z'7^E O0_[S_^AM7^:_\ #/\
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M/_51G1^;U%%%?WD?Q"%%%% !1110!VWPS_Y*7\-?^RD?#[_U,]#K_2@7H?\
M>?\ ]#:O\U_X9_\ )2_AK_V4CX??^IGH=?Z4"]#_ +S_ /H;5_&7TK_][X(_
MZ\<0?^EY*?UW]%[_ ';C+_K_ )'_ .F\T/AC_@IG_P F"_M8?]D8\5_^B[>O
MX$G^^W^\W\S7]]O_  4S_P"3!?VL/^R,>*__ $7;U_ D_P!]O]YOYFOK/HK_
M /)(\0_]E'+_ -5F7GRWTF?^2LR'_LGU_P"K'&#:***_J$_FT**** "BBB@#
M^CC_ (-V_P#DH7[4W_8E_"/_ -2'Q_7]4%?RO_\ !NW_ ,E"_:F_[$OX1_\
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MXR^E?_O?!'_7CB#_ -+R4_KOZ+W^[<9?]?\ (_\ TWFA\,?\%,_^3!?VL/\
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M#>;^[S/S8HK]B/\ B'._X*._]'E_L;_^(]_&#_YX]'_$.=_P4=_Z/+_8W_\
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M=1HWS&%B%(_)\_\ !N?_ ,%'223^V7^QODDDX_9Z^,&.3G_HH]>[X'>*_"?
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MZC>F.!Y=6_;1_9=\/_!K6?C_ .)?C/X0\+?"CPYKY\)^(O$OBN34O"UQX?\
M&'VVSL$\&:[X8\0Z;IGC#2/&DUSJ.FBW\(:AX>M_$MS!J>FWEOI<ME?VEQ*
M?4%%?-GQI_:V^!W[/FKV>C?%?7?%_A^6]T_3=334M-^$/QE\9^&;:VU?6I/#
MVFKJ7C#P+\/O$WA+2+R[UF-;&/3=6UNRU(27%D[VB0ZA8RW/TGG/3W'Y'!_6
M@ HHHH **** "BBO'OB]\?/A+\"K30KKXH>,+;P[+XGO+ZQ\-Z1;Z;KWB3Q+
MX@FTJQ;5-9DT7PIX2TG7O$^J66@Z8O\ :?B'4K'1Y].\/Z:4O]:N["UDCE<
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M3HO$NAV&MQV,US$D<5Q+9I?+;R3QQI'*\;2(BJP4=E7B?[-?_)NWP%_[(O\
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MBK:>(ET"R&K?!G4=<\*^)+MHA!\6/#=Y)X3M9-:M'%D>,ZC^AKPAXV\(>/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:[>:!9^'?"FGCQ!H/QN_MZY?6M?T7QKJJ '[4@Y&1T/(HI%!"J#U"@'Z@4M
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MU9Z\8QC&,8Q48Q2C&,4E&,4K*,4K))))))62T04445(PHHHH **** "BBB@
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MQ/I5G>-%^J5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%(84444 &,X]OP__6/8\4$9_P _Y_$=^AXHHH **** "BBB@ HHHH ****
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M5?';X8_M2R_!KX>>)?!'Q$F^*'_!7_P=:?%K5_BL?#.J?&'PWXZ^.WQW\+?
M/X0Z7I&KZI9:SX6TGPEXXN/"GQ1\*^*]7L-/\&^#M+\#Z5KOP[UW5+CXB:O%
M;?9_Q<_9/^)_@7XQ^,O&?@+X;:HWAKP[\1/@'\4_@U\;O!/CO4+GQ!^S_P#
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!",^OYD?R-&![_\ ?3?XTM%
M!1110 4444 %%%% !1110 4444 %%%% " 8SUY.>23^62<#V&![4M%% !111
M0 @&/7J3R2>ISW)X]!T X  I:** &A0O0MT Y9FZ?[Q//J>I[DTZBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>rdpiechart2015.jpg
<TEXT>
begin 644 rdpiechart2015.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 3T# 2(  A$! Q$!_\0
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M\_9^2T\3>%]0U71+.YMM9\)?$'6+^X;3]7M)[/5H+*6VE>".2.0 CT/_ (*
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M*8/CIJ/Q7^(&O^ OC%XA\'Z;XY_:=N_'NF:/\.K[P_JFB> 8/@IX;_:2\/\
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M%:5O;P6D$-K:PQ6]M;0QV]O;P1I#!!!"BQPPPPQ*D<444:JD<<:JB(JHBA0
M ":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\P1^AYHK^7OX#?M1_M5_#+]D#X*>$K_X\_$+4/BCX _8ZU[Q!HC>/OAYX?\
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M+ZQK.J^)-/\ ">D>))H-4TG1K_7;W5H=/MH[6;4I;G]^>>\,_"3QA\._A_\
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M06&H2:U-:Z?<VL8^T;/0-,\)^+;/4+.ZO/B9XAU6TMYUDN--NM$\(P07L0#
MV\T]EHT%U$C$@L]M+%("N%8 D'_/U_9E_:J^-7[(WQ"C^(OP5\4?V+?7(M[;
MQ/X>U&W&H^$?'&DP3+,='\6:*S1B\APK+::I936.OZ.SM+I&J6F^:.;^U_\
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M\]>:-BXQ\W_?39[=\YP<#<,X8\L":=10 THIR>1D8X9EQ]-I&#V)&"1P3BE
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M#P.*_P#DEN)O^R>SO_U68H_"1NI^I_G24K=3]3_.DK_66.R]%^1_EL%%%%,
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MIQ'CX6D\1G;A7PRFK-^RRNG&&!]FVKQCBZ>-J0Z5F]3F?!_@KP=\/=$A\->
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M  5.\1^$;76?"WC^ZN]%;_@F9\?KWX=3VGBC[#\2K"+79?C;X5N-*L'72O\
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M4"Q:]\2+2Z_7;:N<[1GUP,\=.:6@!!T&?UQG\<<9]<<>E+110 4444 %%%%
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21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>rdpiechart2016.jpg
<TEXT>
begin 644 rdpiechart2016.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 3T# 2(  A$! Q$!_\0
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M\_9^2T\3>%]0U71+.YMM9\)?$'6+^X;3]7M)[/5H+*6VE>".2.0 CT/_ (*
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M]N[JI6*YA($EK>P9ZV][;-%<PD9 60H3N1@,"@ KQO\ :'_Y(5\6?^Q'U?\
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MISZ187EU9Z?<ZAY"ZE=V.G7MY%;/-/!:75PJ0R?YZW[,G[5WQN_9&\?+X_\
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M\U6E%1]E7C5C&$:+HN3Z***_)S]3"BBB@ HHHH **** "BBB@ HHHH ****
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MCXM_$34HOB?JNJ^"(IO#H\4?$3Q=X7U[5]4\!ZO8S^*K"7Q3HIT[PQ#+IMS
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M5':W7Z!CCOGK^6>!^ XSWZT >:6WPLT2VFCF37?'S-'G D^('BUU.5*_,O\
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MBYX4\:B*U2?^QM<< '1M2EC5YI,#(TV\&RWOUSDK&IBO-HR]H.I_.'2I?]9
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MP[T"+Q=;:_\ #[5OV1_VKM,^ ^G:U\3=6'CK5F_X1KXI:%J-O9R);^&- N_
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M"_\ :.^('@?2-1\>^+[>PUK0-'\-V^HVVN77Q!\4?"*>_P#'WP>U/XB_$_\
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M6'PR-)G^%_CGQ7I.M#3O$%W^G_[)OQF\>_&SX<:UK?Q)\$3^"/%7A;XA>,?
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M+Z#!\6?"?Q:^+^G^$OB1K?@.VN/!'C_XF_%>S\$>#M0NKCQ'K_@S7/@KX/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>rdpiechart2017.jpg
<TEXT>
begin 644 rdpiechart2017.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 3T# 2(  A$! Q$!_\0
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M\_9^2T\3>%]0U71+.YMM9\)?$'6+^X;3]7M)[/5H+*6VE>".2.0 CT/_ (*
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M1IEV+B^L-4G%SI]G/YVI:4ULVF:A+YL#^;?:<UE9M87DFZYLVM;9K:6(P1%
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MV>ZDM[>"![V?[5>/##'$]U<B""U^T7+(JM<3_9[:W@\Z8O+Y,$,6_P N*-5
M/YR?V>/$C?LX+\3+7P1XOT_X3VWQ+_X*4_M9?LTZO^T3\<_%GC3XG> /@?\
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MH^H^+- LM5TO5/BAJ[>'_AKIFHZ?<ZA%=V.H?$+7D?1/ ]E<PQ7/BW5T?3=
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M>(OV?O#&GZQX/UK3/'?PV^&'Q+\;^"/&^J>.;GQA9:'X9N?!_A?1(NA\??\
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M5W>C:-XNDDM]!EL;!]-T'5-!\5^'_$'@Z*2.6XD\$ZUX<N+ZYGU&6\D/T-0
M5\^?&?\ :8^&/P3MY;?Q!JAU7Q4UN)K'P9HC1W6N7(<[8I+S<RV>BV;'YOM>
MJSVWF1JYM(;N4")OD_\ :@_;8_L2?4?A]\&+^&;6+>66R\0>/(EANK72YHB\
M5SIOAA)8Y;:^U*-P8[G6W6>PL'22"QCO+O=<67Y17=W=7]W=7]]<W%[?7L\E
MU>WMY/+=7EY=3,7FN;NZG>2>YN)7):2::1Y')RS&@#ZX^*7[;/QF^(4UU::'
MJ8^'/AN9984TOPO)G5YH'+ '4/$\\*ZDTYC.TMI":-$HR!&YQ)7R+<W%Q>7,
MM[>3SWE[.Q:>\NYI;J\G8]6FNKAY+B9CW,DC'@<X J&B@ KQO]H?_DA7Q9_[
M$?5_YP5[)7C?[0__ "0KXL_]B/J_\X*^BX0_Y*WA7_LI,B_]6F$/ XK_ .26
MXF_[)[.__59BC\)&ZGZG^=)DC.">1@^X]#ZBE;J?J?YTE?ZRK9>B/\MCTWX4
M?&CXL_ KQ%9>*_@[\1/%GPXUW3YY;BWN?"^JR6=H\L\#6UQ]MT25;C0-42XM
MF-O<1:II5['-#B-U(5=O[Y_LD?\ !>WQ/I-QH_@W]L#PE%XCTIY;>RD^,GP]
MTZ.QUVPB=BC:CXP^'ULHL-:BB++)>7_@I],OEA1S:^$M0GX;^;^BOB^+?#SA
M#C:A.GG^387$8B4.6GF=&$<-FN':3Y)4L?2C&NXTV^:-"O*MA92_BX>HO=/L
M>%N/N+.#JT*F19OB:%",^:IEU:;Q.65U=<RJX&JY44YJ*@ZU%4L3&/\ "K4W
M9K^ZGQMX/\6?MH?$#]F#]IW]F/\ :A^ 1^&?P&\7^)/B#X-LK[X)^,/BA>>(
M?%GB[X3?$GX*^+-.\4>(M&_:!^&1T:TM?"?Q*U"\TWPY)X/TWQ%H?BC2[6?6
M[O4].EFT@=UH_P"S3^T7IG[7'Q5_:7;X\_!W^Q_B5\'_  O\$;?P/:?L[>,(
M=;\-^%/ACXB^.7C+X5ZPOC.[_:+OM,UGQ3IWB?XV7$GCF:X\$6>B>+=$\.6^
MF:'HW@J\U.75K/\ CG_85^,7[47PH^/7ABU_94U2Y;QMXUU&STW5O!EZC7O@
M7QEI%DXN;YOB!I;NMNFAZ)IZ7-[>>*8'LM>\-6"7,VCZI!),;.]_O0\ ^.+3
MQGI%O*YMK;7K:UMO[<TRWDEE@MKQHE%Q)ITUQ%;SWFE/<B065W+;P3O#Y8O+
M:UNB\"_Y[>+O N7^&'$^7Y#'B+ 9C+.\)B,QRK U:L*6=TL'AZL:4GCL)'W.
M64W4IX7%4W"&/>$QLZ6'I/"8BE1_N?PM\19>(F3XC&5LIKY;C,NJTL+C:D5*
M>5XFO.#G?+\1/WW*,%&IB,+44JF$5:@I5:T:L*L_AWQM^P=XD^(*>-K#Q-\9
M]&FT7]HSP!\$O"/[95AIWPCBT]OC+J_PCT^WT?6/$OPVED^(%Y'\&X_BGX<A
M_P"$(\9:'K5M\7(=.\#6VE67A&_T+Q387'B[4.L^(O[$K?$7XE-\4;WXGWVE
M^(Y?'MMK*/I7AY;9- \#:3J'@O5_#F@>#RFNI_8/C70=8\,^)M4M_B)*FI37
M-U\7?BFEWX>FM-7T2UT'[SHK\U/U 0#'<GDGGW)./H,X'L!2T49Y(YXQV..?
M0]#TYP>._44 %%'^?SZ44 %%%'7I0 4444 %%%% !1110 4444 >.>,/V??@
MMX^^('A7XI^,OAKX3\1?$'P6-,'AWQ5J>EQSZI9+H6K2^(/#J3N&2'54\+^(
M9I_$7A2/6(-13PKXBGGU[PZNF:O-+>/XC\6OV"?V=?BW8_#73+[PA:^&-.^&
M_CWX.>-8K/PO8Z5:Q^*+/X&:I\1==\!>#?%#W]CJ$MYX;TW7OBIXVUZ.6UDM
M/$-MK6MWVJ6.MVU[=W4TOVC10!\TQ_L=?LO1#X:B+X&?#>(?".PL]+\!+!X;
MM($T73]/UMO%-C9S10>7%KEM9^+I)?&=K#XC36([?QI-/XQA5/$]Q/JTE_5O
MV3/V;->TVTT?7?@I\/-;TBROOC+J5OI>L>'K;4].6^_:%UN_\2?&NYDLK[S[
M:>7XEZ_J=]K'BLW$4HU#4;A[L"*8(R?0]% 'RM/^Q%^RA=>%].\'7OP)\ 7^
MAZ;XAU3Q5''J&F3W^I7NNZ]I6F:!XAO=:\07EY/XB\1#Q)X=T71/#7B2T\0:
MOJEAXA\,Z)HOAW6K2_T32-.L+7I;K]E']G*]^(-U\4Y_@YX$/CR]C<77B"+1
M8[>::]?PJ_@3^W&LK9X=*'BB/P/(_@N'Q:NGKXIM_")_X1JWUB+10+$?0E%
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M]T;1KV[M/$<NDZ=!J<NNW.EZ7J.CWUMK;6,#V=C>Z9=Q:@8KBRN%BH6/Q'^
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M(;9$588[:&!5AB@2,*(HX56)4P$4+@4 6J*** "BBB@ HHHH **** "BBB@
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MKX(;48["_P!->PM_"?B9[-O%HUBT0:CI6G6D,=RWU)I?[4WQ=^''QM3X>?M
M^--*\/>'EU"V\;^)-<TW3/#VOVVGZ.VJ?$6RA\,^'V\'Z3JLWA_X6ZUHLWPR
M\9#Q5\27M/'/A/P_X<\>S^*[NRM/&W@#4E_6<$$<'/49]P2#G'&000<<9Z4
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M\/Z:UVNHZKIJVKK+<75G:2QVF'2[:"2*5$ /1Z*\SD^,_P )(M7\2Z#)\2_
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M33RWPO\ \%8+7Q=X4TWQ'H_[-WQ&N[GQE\%D^,?P]T73]<M/$5_>Z5X6^/\
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M&I37RY:OWG"T445_GX?%$T$\ENX=#]5.=K#T8#MUY'*YRO(KI+>>.X3<G##
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MKZVOP_O9M,\>-I.G:?K4]YJ0\%ZC;7%AXK^R0S'P]>6\T.K?9)()0GXCR_\
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M>I/'#XV\.'14L@#^C%6##(Z99?Q5BI_4&EIJ*5!!Q]^1N/1G9A^.",^_K3J
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M%_'UC:W]_>067BO2M:\3^(-836K5(;VZU;6-0U*_DN[VYDG(!^5OP=_:2_;
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M$B*VL[.WA@A3)(1!DLQ+$ W**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>researchanddevelopmentchart.jpg
<TEXT>
begin 644 researchanddevelopmentchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" += 3T# 2(  A$! Q$!_\0
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M'XK_  8\8_!;6-,UB\DV:EIUO9Z)XSOM2M;C1YH+J2\@CMYI!:RR@@'(Z/\
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MTMO"OQ"^&6@?M&^%M*^(-EI6B?#^V\.>(+#Q;K_PM^&NN:/X]^*%GJWC+P7
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MUL+?US(/0YH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _$#_ (*3_P#*23_@A3_V=;^U!_ZQ
MS\0:^\_VV/B-XW^&7PL\-:YX#\0W?AO5;SQOINEW-[9P6%Q)-I\V@Z_=26K)
MJ-G>PA'N+2VE+)$LH:)0) I=6^#/^"D__*23_@A3_P!G6_M0?^L<_$&OKW_@
MHG_R1?PC_P!E&TG_ -1KQ/0!^>O_  UO^T=_T5;7/_!;X8_^4->8>/O^"D'C
M?X6:OX-T'XB?M*6W@[5OB!JSZ)X3L]<3PK:-J5['8ZCJ#R32MH!@TG2UBTJ[
MMSKFLRZ?HO\ :7V;2OM_]H7<%N_!5\!_M=?#3XP>)OB'\&O%/P3\)ZD/%]AK
MSV'_  L#3_%F@CPMI<=I\.?CK!H]E\:?AYXMTG4=(UKX=Z;X@\96VS7M)MM5
M\12Z9XO\;>#=.BT76=?\.:A< 'ZL:G^WQ\5]&\;^&?AKJOQ^DL/'WC+1O$_B
M+POX1N;7PTFM:UH/@M;1_%6KVL \.-%%I^A+>VQO;B\GM5):5;;[0UI>BVS?
M O\ P4/^(?Q-FO[?X?\ [1B^+9],@L;V\BTFTT#S!IFJS75OI.MVBWWA>S.J
M^&]7N+*]@TCQ5H_]H>&=5FL[J+3M7N7@D5?RE\1_L]?'K7/VC_ 'C/Q1/\)/
M&OP\U67]IW3?B+JFDV'COPUXETSX??$OX6Z/\//!O@$-?^+[U(8[/P]%>Z#X
M7O\ PYI\\&E^(KWQ5XU\3PS77B&L;2/V??VA/$U_9WK>)=6\%)X-_9XT[]F[
M1%^+(\'WW]M>"KKX@>!M?\2^'5@^ .OPR7%E!X*\ 1^$8?BO-J7AOQ%K]WXP
MU/4M&\!>$DTHRW0!^PG@3]OCXL?$_03XI^'GQ]E\8^'!KGB'PT-:T*T\-W.G
M/KOA/6KKP[XCTR.>3PW#YL^D:W8W6G7,D2O;230F2UN+BV>*=Z7@G_@H5\2/
MB1)JL7@+]HD>+)-%^ROJ2Z1:>'W,-K?37MOIVJ6YN?#%LNJ:#J=QINI6^E>)
M='.H^&]5N-.OX--U:ZEL[E(_S&^!?PX^-O@_X5_$/X4?$#PIHFFW'Q;^-/[7
M/V+Q5\*[BUTO0/A7X*^)E[X[UKPAXYOM)\1^*+_6+O2-5O=2TZR\$>'/"D5[
MXB\,VEWHUKXML+4Z?JFHP]Q\'/ _Q#3QE\-/$/C#PC/X M/A#^S'8_L_SV+>
M(?#6N6?C;Q%_;OP_O[G6/#:^';R^DB^'_ART^'9N/"]UK\?AW6KN]\;:C;/X
M3TPZ7J$]T ?I_P#\-;_M'?\ 15M<_P#!;X8_^4-?JW^QEX^\8?$CX.MXB\;Z
M[=>(M;'B_P 1Z?\ VA=PV4$OV*S^P?9;?986MG!LA\V3:WD^8=YWNV!C\&*_
M;?\ X)]_\D#;_L>_%G\]-H ^X:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$#_@I/_P I)/\
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M233=>\-ZQIVO:+J$<4KP2O9:KI-S>6%VD<\4D,C6]Q(J2QO&Q#HR@ WJ***
M"BBB@ HHHH **** "BBB@ HHHH _$#_@I/\ \I)/^"%/_9UO[4'_ *QS\0:^
MO?\ @HG_ ,D7\(_]E&TG_P!1KQ/7Q]_P4MFAM_\ @I!_P0KFGEB@B3]JW]I_
M?+-(D4:[OV._B J[I)&5%W,0JY(W,0HR2 ?K/_@H5J>FWOP;\)Q6>H6-W*GQ
M$TIVCMKRVN'5!X;\3*7*0RNVP,R@OC:"R@G++D _'>BBB@ HHHH **** "OV
MW_X)]_\ ) V_['OQ9_/3:_$BOVH_8%U73++X#M#>:C86LO\ PG/BI_*N;RV@
MDVL=.VMY<LJ/M;!P=N#C@T ?>%%8_P#PD.@_]!K2?_!E8_\ R11_PD.@_P#0
M:TG_ ,&5C_\ )% 'EGQ1_:0^ GP2\2?#GPA\7/B]\/\ X<^)OBWX@G\+_#C1
M?%_B;3-$OO%>MVVD:MK<UKI\=[/$(H%L]&O(5U&^:TTN35Y=,T"*]?7M;T;3
M;_K[7XH?#F]^(^K?""S\<>%KKXIZ!X3TKQWKGP]MM;L)_&.C>#==U2^T30_%
M&K>'XIWU+3M#UG5M,U+3M)U&\@AM]2NM.OHK-YC:3E/QZ_X*4_#3XS^,?CM^
MSMXZ_9M\ :IK7CY-7N_#S^/8/%?PI\4?!.]CTSX(?M9Q>&_"W[3?PM^(Z[M*
M^&>D>)/B +:7X@>##?>(K[PY\2O'/A?0VT_XF#X56^J]SX TW7O"/_!4#QY\
M3='_ &7?B3X0^%7CC]GS2/A7XD^,NEZ!\+=.^'_B7XN6'QH\=_$/Q+\0=8O[
M?XFOXUU+PYK.AZEHMMI7BW5?#$]_.#9Z.;&QAL%MX #])/'G[0WP,^%_C#PM
MX ^(GQ9^'_@KQGXT-G_PC/AKQ-XHTK2-6U5-2U,Z'I,T5K>7$;6]OK.O8\/:
M)=7IM;;6O$++H.E37FKL+*N0L?VO_P!FO4?BZ?@/:_%[PH?BW_;'B/0(_!$[
MZG9ZM<:SX1TK5-<\2Z=:27NFV^G7ESHNC:+JVJ:@EK?S""PTV]NRQAMY''Y2
M?M:_"CXL?M*:!\6-4^!_@KXO^ G_ &_OV2?AY\+?BC8>,%^ %WHO@&^M+?XA
MV7A"X\7^*K[XL7OB;X+^(?ACIGQ*U37/&K>#O"/QFT;QU9+96'PL7P_\3H+[
M7=3_ $2M=&\6ZI^T1\7/'OBC2[+Q#X3\ _ WP;\-_@)9^(/&.@6V@^-O$/B>
M/Q1XH^-NLSP)-J\>DW/B>_TWX3^ M0U/5=#9M.T_PWJ;Z9:76F:QJ<5Z >[_
M  L_:'^!?QNN_$%C\(?BW\/OB1=^%A92Z[;^#?%.E:]-86.IO=1:1K#1V-Q(
MUQH&M2V&HQ:)XBLQ<Z#K,NFZC%IFI7<EA=K#%I/[1_P%U[XIW_P2T;XP?#K5
M/BSI9U&.^^']CXLTBY\407>CVXO-:TW^S(KEI)=8T.Q:._US18&EU?1=/FAO
M]5L;.SFCG;\XOA7;_%?P5^T=XV_:,N?@)\:=:\-7WP;\)_"RU\ ^/-<_9@?X
MD_#[5-6^-OABXB^'W[-@^'_COPSX,NOV;_AWX8UWQ/XW^).L>/M3N/$NJ6/@
M/P8OPVUCQCJ-KJOAI>E\2^&?BCXZ_:U^ 7BVP^'/C?PIX/\ A!\;/B%XG\0Z
M9XT\3? .\_9=M/#^L^!/CAX/_P"%Y?".\\$76G_&34/VC/''_";V,,EAXNL9
M]#T'2O'_ ,2[/Q+H\-^VE^+KL _6*BL8>(="P,ZSI&<#.-2L<9[X_?\ 3TI?
M^$AT'_H-:3_X,K'_ .2* -BH;DL()BD;RN(W*11NL3R,%)5$E=D6)G("K(64
M1DARRA<CB?&'Q*\'^"?#&N>+=8U>VDTOP_I\^IWR:;-;:C?M;6X!D%K8P7'G
M74W(V0Q_,QX%?,1_;]_9]!(^U>,^/^I/OO\ X_0!^)O[//AC2/@IXD_;@;QQ
M^Q=\6_C+\"/"/B_PFU]9:M^RW-:_M.WOQ"\/>$?V*M5^%'P?\0S?"^[U+PW^
MU+X?UCQ$FO>-O'7CR/0;[P-X9G^'NH?%[XC^-_&]M\:M8%E^EG[+M_;^'O@_
M\2KGP]'XB\!_%7]KWX^?$=]&\.>&OV?OC?\ #KX8_ _XKZK^S_'/X=TK0M'^
M)/PS^'&M)X%T3PO\(M.\0>,OC3>^$/#OA;XG?&_6/$VI06VBZ_XQLO"]C]"C
M]OS]GP9(N?&8XY(\'WPP![B?@9YP,#))ZDU&_P"WO^SQ(\4DDOB]Y+=V>%Y/
M!EX[PN\;PNT3-,6C9HG>-BA4M&[H259@0#\]O@/\,?#FAV'PDF\8? GXR?"K
MX<_"']@J'X'?MG6>E_"#XN>'=>^)?QIE^(7P*N?!_AW28_A=I[^._C\WAO4?
M"OQWU_Q1XZ^'MKX]\*:QX6^+M_\ ;O%FK:7\0?%4$?F/[._CGPE\+/\ @G!^
MQ#X9\3?L@?%[Q]\<OA7X9U#X2^$O!/Q$_9)_:4C\!? WQ?>Z!,?$GB[XE^'+
M'X.ZS>Z;X)TCP=>V^B:;K7@_P/XJUG7YM4O_ (;_  ]NK"?6?%EWI7ZM_P##
M?G[/@Z7/C,<8X\'WPX'0<3\#VZ<GU-'_  W[^S[_ ,_?C3_PD+__ .2* /B#
MX@> H%_X)_>"OV,?A/X9^//Q-30? ?[-NM7_ ,4M?^ GQ/\ #=AX9\(_\+T-
M[>^/]%^%WC3PO;1?$'5?A%KOP\N/%=U^Q-=17NI7GPH'@_P1XFT#6/A]XFLH
M=?\ IK_@G%X=\>^'?#?[0?\ PF>BZK-IVO?'NX\2>#/B?JOP@U;]F^7XN^'+
M_P"%OPRM%U^#]G'6;2PN_A1!X1O=-N/AHTXL+!/B==^#KGXIR645YXLNY)?1
M?^&_?V?>]UXS/3KX/OCT.0>9^H/.>N:4?M^_L^CI=>,^>O\ Q1]]SP!D_O\
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M=44Q0W2&=!&E\L+>9RSQLR_*5K[L;H?H?Y5^ ?[9'_)R7Q-_Z^_#W_J(>'Z
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MB&OUHH **** "BBB@ HHHH **** "BBB@#\0/^"D_P#RDD_X(4_]G6_M0?\
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M_08Z_GE;J?J?YU_2;\8=$T_Q)\,?&^@ZJDTFG:KX>OK.\2WG:VF:"4)N$<Z
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M %CGX@U]>_\ !1/_ )(OX1_[*-I/_J->)Z^0O^"D_P#RDD_X(4_]G6_M0?\
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M7O EG\1?AMK&DZ-J^H^';'39M1^Y@2"""00<@@D$'U!&"#]#28'' XZ>WTH
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MX*60Q3_\%(/^"%<4\4<T3_M6_M/AXYHTEC;'['7Q 8;DD5D.& 9<J=K ,,,
M1^I?QETW3[/PKIDMI865K(^M6JM);6EM Y4Z?J#%"\,2-L+ $IG:2JDC*K@
M^9Z*** "BBB@ HHHH *^K_@S<6\7@YEEGAC;^V-1.V25$;!,.#M9@<''!QS7
MRA7U/\'M+TV\\(&:[T^RN91J^HIYMQ:6TTFQ3#M7?+$[;1DX&<#/ % 'L'VV
MS_Y^[;_O_%_\77QK\3W23QUK[QNKHTMD0R,KJ?\ B660.&4D'!!!P>""#R#7
MU[_8.B?] C2__!=9?_&*^/\ XEP0VWC?78;>&*"&.2R"10QQPQ(#IMDQVQQJ
MB+EB6;"C<Q+'+$D@'"T444 %%%% !1110!=T[C4+ D@ 7]B22<  7<)))/
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M "DD_P""%/\ V=;^U!_ZQS\0:_53XW?\BEI7_8;M?_3=J-?E7_P4G_Y22?\
M!"G_ +.M_:@_]8Y^(-?JI\;O^12TK_L-VO\ Z;M1H ^6J*** "BBB@ HHHH
M*^M?@K_R)C?]AG4OYP5\E5]:_!7_ )$QO^PSJ7\X* /6Z^+OBC_R/GB#_KK8
M_P#IKL:^T:^+OBC_ ,CYX@_ZZV/_ *:[&@#@**** "BBB@ HHHH NZ;_ ,A'
M3_\ K_L?_2R"OT"'3\6_F:_/W3?^0CI__7_8_P#I9!7Z!#I^+?S- '&_$/\
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M7X*_\B8W_89U+^<%?)5?6OP5_P"1,;_L,ZE_."@#UNOB[XH_\CYX@_ZZV/\
MZ:[&OM&OB[XH_P#(^>(/^NMC_P"FNQH X"BBB@ HHHH **** +NF_P#(1T__
M *_['_TL@K] AT_%OYFOS]TW_D(Z?_U_V/\ Z605^@0Z?BW\S0!QOQ#_ .1*
M\3?]@BZ_DE?$;=3]3_.OMSXA_P#(E>)O^P1=?R2OB-NI^I_G0 E%%% !1110
M 4444 >^? ;_ )"'B7_KSTO_ -'WU?2E?-?P&_Y"'B7_ *\]+_\ 1]]7TI0
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M?^&C_A3_ -!76/\ PG-2_P */^&C_A5_T%=8_P#"<U+_ .)KX/\ XC)X3?\
M1R>"/_$FR?R_ZB_/^M+\7]JY9_T'X/\ \**7_P EYK[SW:BO"?\ AH_X4_\
M05UC_P )S4O\*/\ AH_X4_\ 05UC_P )S4O\*/\ B,OA-_T<G@C_ ,2;)_+_
M *B_/^KJY_:N6?\ 0?@__"BE_P#)>:^\]VHKPG_AH_X4_P#05UC_ ,)S4O\
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M16O*^1M1@[RJR^%2?^$H\,<G_D9O#?<_]!W3Z_I_7H?]Y_\ T-J_E_\ "O\
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MJ7E[2<;WJ0DUI%*RT^]GVW_PUCH7_0EZW_X.-+_7_1^*/^&L="! /@O6@3D
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M /V(VL_^@PU_/ _WV_WF_F:^&^FO_P E[PI_V22_]7&8G'Q9_ON&_P"P5?\
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M &=;^U!_ZQS\0:^S/^"@7_)'?"?_ &4'2O\ U'?$E?&?_!2?_E))_P $*?\
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M4"!/P>\)X&?^+@Z5_P"H[XDKZK@C_DK,B_[#H_\ I$SX7Q,_Y(/B?_L6R_\
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MA%7=W:,4DKO5V6KU"BBBOM"PHHHH **** "BBB@ HHHH _$#_@I/_P I)/\
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M_98!(/AGXV$@D'_BC_#7K_V.U?L1_P %,_\ DP7]K#_LC'BO_P!%V]?P)/\
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M(VC:1I&"?JC8Z>MCYNVZO[GS=F?MUY-=[-F[_5>:3Y>[=\^W&["YZ"OY;O\
M@W;_ .2A?M3?]B7\(_\ U(?']?U05^!>(G 7#_AGQ9F/!O#$<9#)LLIX&IA8
MX_$_6\4I9AE^%S'$>TK^SI\Z>)Q=5P7(N2GRPUY;O^H/"SB7,^+N",JS[.)4
M)9AC*V90K/#4?847'"YEB\+2Y:7-/E:I48*3YGS2O+2]@HHHKX@_0PHHHH *
M*** "BBB@ HHHH _$#_@I/\ \I)/^"%/_9UO[4'_ *QS\0:_5+XX?\BAI?\
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M$/\ UXR/_P!4.6'^@/@+_P FOR#_ +",[_\ 5WF 4445^*'[$%%%% !1110
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M,O/VD;H?H?Y5_"3_ ,%=?^4BG[2/_83^'W_JIO =?W;-T/T/\J_A)_X*Z_\
M*13]I'_L)_#[_P!5-X#K\/\ HM?\EYG7_9(XW_U<Y$?L_P!)C_DB,G_[*K"?
M^JC.C\WJ***_O(_B$**** "BBB@#MOAG_P E+^&O_92/A]_ZF>AU_I0+T/\
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MGV^?8:II=]X<FM+ZSGVJ);>XBDBD PRD5\]?\0NW["1Z_M#?\%$__$N]4_\
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ML]3GNAH>A?LV?'CXL6HT>0^#8S::B?$WPX\/&6Y"S[M)75+0P?Z6+BV^@?\
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MO ?CW0[&Y30=4MV@U:YUO3/$^A>'_L*@ HHHH **** "B@G )P3@9P.I]AG
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M7Q&^+_BWXD?!2\^"?Q-_9XN?V3?$'PETSX2_$'3/&"_!!O$7CKQ% +3XA?\
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M-JMSKS>']<T;Q-8V$-F\NJ^%M4L/$^D_;M NH=2;XR^*_P"PS\3]*_X)]?\
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MQ_XB\):UIUCH\EDEO<Z7]JE%S:?:',WVN>'*MYT>U=D:_+@\Y.>:\Q;XT^.
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M+!K&N75SIGAZY\0W6F0>)M5TO4]'\//J6IV-W;6_QY\*?^"5'B/X4^ ?@?\
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M9=,\21ZA\+==U^YT'2X_%I>^^W: "BBB@ HHHH **** "BBB@ HHHH ****
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M6-;\=W'BWX :F&\/:7I-Y?RZQK]MX0TVVU'7-(U'=[KJ7[8_[,&D3^ K>_\
MC;X"@E^)5CIVJ>% -5>99=,U;Q _A#3-3UN2WMI8O"&G7_C*&Y\%VE_XRD\/
M6D_C.RU#PBDQ\1Z?>Z9;_FK_ ,.:-/:,7EW\<FU76]#7PGJO@PW'@SQ5HFBV
M?BKPG^U!^VE^T!%=>)4\$?%OPAXLU;0M2\._ME^(/A[)8>'O&/A/6M,U+PAI
M7CO3M?$MV_AJ#UO7/^"9^O)X?\!Z1\,OC-X8^#.N>&M!\0:1J?Q'^&_PR\>^
M'_B?I>H>*?BMXV^,&OZY\//&]G^T)'K5S%J7BOQG?7=SX._:)NOVC_!%]K#W
MGBS6=$U76/$7C:'Q: >Y^ ?^"EG[(/CWP%XK^) ^),O@OPUX0^-?Q1^ =\?B
M%X<\0^%-5U+QW\(==\0:/XN;P]HMUILNJ:]H4%CX:U3Q:VK:;:3IHOA"&35O
M&$/AB:QU:QT[V2S_ &O_ -F/4/B%I_PKT_XX_#G4/'>J:GI.C6&A6/B*VO&N
MM5\1?#[1OBMX8T^+4K82Z,;OQ9\.=?TSQCX2B;4E;Q5H4L][X=_M-;#4%M/D
MW1_V _B9X#^(4OQ'^%O[0'AK0-?T#XP_M7?$?X<R>+_@[J/C6TT7P_\ MK^-
M8_B;\;?"7BRPMOBQX6A\2WVA?$;2_#&O_"GQ1H<O@]]#T31[WPEXNT;Q?;>(
M=3U0>8Z9_P $A/">A_#75_A!I7QCUY/ >I?&K]D+XC1)<^&Q_P ).G@S]EO]
MG;X3?L]W?@BZ\0:=XBT]9M9\?:7\-+OQ%'XOL]/L+7P=?^(DLM.\+ZA::-#]
MJ /TR^%/Q[^#_P ;X=8N/A3X_P! \;PZ$]B;^31IKAD:PU=;I]#U_3S=VUK_
M &SX5\1)8W[^&O%^C?VAX6\2+I^H-H.L:B+&[,/G6H?MJ_LL:0_CO^V/C=X'
MTBU^&VF:YK?B_5-5O;S3=#T_1?"OB'3_  EXOUBSU^]L(-#U_2O!GB?5M+\/
M^--1\-ZCK%GX/UC4;&P\2S:5<74*/X]^Q+^PIIO[(*:O(_B/PWXOU67X?_#G
MX5:1XATOPUX_TC7G\$?#1M;?1H/$>H>/OC'\6S/=W<VLR7DVC>"HO ?@#2+Y
MK^X\.^#M._M6Z5/C?XF_\$;]=^+!\0WOC']IZXUOQ1J7P_\ VD/AC'\0-;^&
M^OZ[X[\3>&/V@=>\&>([>?XEZAK/QAU'P]K.H_#J?P?;Z+X>TWX?^&/ACX,N
M-$N6B3PMIOV;3[?3@#]'->_;@_9:T'PJ?%=Q\9_!,EM)XJ\4>!;33EU*>/6Y
M_&7@[1;?Q%XCT&;0Y++^VM,;1O#]_H_B+5M4U73;/1-+\,:_X?\ %%_J4'A[
M7='U*^U/A?\ M6_#'Q[\"/V6/CGXBU"#X:V/[6WAGX.ZG\,_#/BK4+675[GQ
M7\:/AZOQ&\-?#U+K3%GT[4?$R:/#JJ.UE(+"Z?1[V:VG,(B+_-NM_L"^*[?]
MI;XU?M0_#SXX6'A?QO\ &;5/$.DWVF>)/AG+XU\/Z+\+?&_P/_9A^$_BWPS8
MV2^/_#AD\:Q>(OV7O"7Q \+^.'<:5:1ZIJ?@SQ+X+\3Z6MIJ%OU=Q^PS);?L
MM_L8_ 3P_P#$R&R\8?L1R_LXZQ\-_B%K7@R36=!\1^)/V>_ ;?#>*X\7^ ]/
M\6>';R?1_&'A?4-?AN]-TGQGIEWHNI:E8ZE9ZC=C2OL=Z >F1_MX?L@2R>'X
MH_V@_AJS>)SI#:,QUMXX9[;7OB'XW^$ND:A<W,EJEMI>D7_Q.^'7C'P#!K6K
MS6&D?\);HSZ')?)?7NF17WC_ ,"_^"FO[.'QNUWQO91^)+#P+I.D_%SXA?![
MX>S^-[O4M"\2?$_6_@]XHT[P)\5]9TKP?J7AW3KW1_#?A'Q?J^EV\VHWE_>&
M#0+^'Q)XFB\)VMOJ-M8?$_@[_@E'\6_#GBKXE?!P_%W3V_9W^(O[(WP\^!/Q
M!^(5[X$T>Z\;^/TU#]KO]M'X\_$WPWX3TFP\;Z=+\,/$NG^%/CMX=\/Z9XVO
MK#Q?X7?_ (2"_P!4TKPQ_;?ARS@L_IQO^"86A:SJ.J1^+_BOJ>K^%_$.B_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>reserveschart.jpg
<TEXT>
begin 644 reserveschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %( 3T# 2(  A$! Q$!_\0
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MZ[_X<^Q_^6-(?C7(!S\)M<P!_P!%.L, =S_R$> .I/0#DUV?V=7_ .?V6_\
MAWRG_P";?-?>>?\ VOA?^@?-_P#PP9[Y?]2[S1\Y:O\ !P3?LJ^$/V3/AK\
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M_9H^-U_X65)I/[=$WPFT[5)H4D94N[?P)K/Q0T[QKY#QXF%E>Z18>(B@9%T
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M:X<(-/U!2Y2&5VV!B 7QM!903EES^6__  4I57_X*1?\$*E9593^U;^U!E6
M8''['7Q!(R""#@X(]" 1S7ZH_&N**/PGI9CBBC)UNU!*1HA(_L[43C*J#C/.
M.G XX% 'R^"5(93@C/8$$$$,K*059'4E'1PR2(S(ZLC,I\L_X4;\$V\*>%_
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M9X+$8#%QE+#8JFZ5:,)RIR<&T[1G%J47=+5.X+1I]C^='_ALK]K_ /Z0S_\
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M_P *]7)^#,BR+&?7LOH5X8CV,Z'-4Q-:K'V=1P<ER5).-VZ::=KKH%]+:?\
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MPKYC_B&G"G_0+BO_  NQ/E_T\\G]_D%_)?=Z?Y?B^Y_.C_PV5^U__P!(9_\
M@H=R0/\ D8_V2NYQ_P!%RX'J3P!R>*Y7P/\ \% ?VEOB3X/\-^/O!'_!'_\
MX*#^(/"'B_1[+7O#FN6NO_LIPVVJZ1J$0FLKZ".\^-=K=)#<1,LD8GMX9"C*
MQC 89_I6:")ACRX_O*?N+_"P;T[XQ7AO[,OP:F^ /P ^$?P7OM9L_%%Y\,_
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M:^)OBBQ^$WPRN_BAX5^&D=K);:QXN^%&B_%1=?\ $>E>$/ NH0^!]3\=VWQ
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MH3C\.E+10 @4#/7GU9CWSQDG'X8[#H!2;01C+8Z_>8'\P<_AG'?J!3J*  #
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M-?AGXYOO ?B72-'T?3+G4/%WC*P\7?#[X9Z_\8/">M?'G3]:^&OAGP'-X?\
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,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>restructuringchargeschart.jpg
<TEXT>
begin 644 restructuringchargeschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_!&W_P N*/LGB'_H-6/_ ((V_P#EQ6]10!@_9/$/_0:L?_!&W_RXH^R>(?\
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MMW'SO\ O^/[Q-_UZ:9_Z.O:^EZ_ICPY_Y)'+?^OF/_\ 4_$@%%%%?< %%%%
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MGXFT;PYX9\2^*=)@\6:QI_B3Q9$UU^^8Y';J>GU/7ISZCL<T ?B#_P %)_\
ME))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7_T$5^'W_!2YY8_^"C__  0L>"#[
M3*O[5G[3^R'S4@WY_8[^( /[V0%%VJ2^",OMV+AF!K]HDU#6PB#^P?X5_P"8
MO8GL.XCP?J.#U% '145S_P#:.M_] '_RK67_ ,;H_M'6_P#H _\ E6LO_C=
M'045S_\ :.M_] '_ ,JUE_\ &Z/[1UO_ * /_E6LO_C= '045S_]HZW_ - '
M_P JUE_\;H_M'6_^@#_Y5K+_ .-T =!17/\ ]HZW_P! '_RK67_QNC^T=;_Z
M /\ Y5K+_P"-T =!17/_ -HZW_T ?_*M9?\ QNC^T=;_ .@#_P"5:R_^-T =
M!17/_P!HZW_T ?\ RK67_P ;H_M'6_\ H _^5:R_^-T =!17/_VCK?\ T ?_
M "K67_QNC^T=;_Z /_E6LO\ XW0!T%%<_P#VCK?_ $ ?_*M9?_&Z/[1UO_H
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M_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\ N+_Z"*_$/_@I/_RDD_X(4_\
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M_P"$GT7_ )_1_P" ]Y_\C5O8'O\ F?\ &C ]_P S_C0!@_\ "3Z+_P _H_\
M >\_^1J/^$GT7_G]'_@/>?\ R-6]@>_YG_&C ]_S/^- &#_PD^B_\_H_\![S
M_P"1J/\ A)]%_P"?T?\ @/>?_(U;V![_ )G_ !J![BUC8I)<0HZXRKSJK#(!
M&59P1D$$9'0@TI2C%7DU%72NVDKO9:@9'_"3Z+_S^C_P'O/_ )&H_P"$GT7_
M )_1_P" ]Y_\C5J_:[/_ )^[?_P)C_\ BZ/M=G_S]V__ ($Q_P#Q=1[:E_S\
MA_X$O+S\T!E?\)/HO_/Z/_ >\_\ D:C_ (2?1?\ G]'_ (#WG_R-6K]KL_\
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MKZ7KYH^ ?_']XF/./LFEC@$_\MKWT^AKZ7SGU_$$?SK^F/#G_DD<M_Z^8_\
M]3\2 4445]P 4444 %%%% !1110 4444 ?AU_P %+K>"Z_X*/?\ !"R"YB2:
M&3]JW]I[?%(-R-M_8[^(#KD=]KJK#W K]I8_#'A[RT_XD]@/D7C[.OH/7FOQ
M@_X*3_\ *23_ ((4_P#9UO[4'_K'/Q!K]O(_]7'_ +B_^@B@#%_X1CP]_P!
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M!T_PK=HH PO^$8\/?] >P_\  =/\*^/OB7;6]GXXUVVM88[>WBDLA'#$NV-
MVF63MM4<#<[,QQW8U]O5\4?%3_D?O$/_ %UL?_378U^7^+'_ "(,#_V.*/\
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M00/^"D?_  0I)( _X:M_:@Y/ _Y,Y^(-?MU&Z>7'\R_<7^(?W1[U\%?MP_\
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M3Q#HOA4>(-9UOP=X%\7?$?Q!X$\*>*]2E\4Z-X=M]8T[P]/H?UN&0  ,H
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MWLK*UA7Y8K>V@BAC7A$ K\_)/^"E'PFO_">B_$GP;X ^*OC7X76OP/\ A_\
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M\<ZK$GA@^)W^)>D^![[P]\,_&T_AKXDZSX-LO"GB)]!DO;2YB\-ZQX7\0Z^
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+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>rituxan.jpg
<TEXT>
begin 644 rituxan.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!<17AI9@  34T *@    @ ! ,"  (
M   6    /E$0  $    ! 0   %$1  0    !   7$E$2  0    !   7$@
M  !0:&]T;W-H;W @24-#('!R;V9I;&4 _^(,6$E#0U]04D]&24Q%  $!   ,
M2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M245#('-21T(               $  /;6  $     TRU(4" @
M                                                   18W!R=
M 5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA9
M6@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P
M9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@
M   4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M!#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@
M2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#
M-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                         %A9
M6B        #S40 !     1;,6%E:(                     !865H@
M    ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@
M   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                        9&5S8P         N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="                             &1E<V,         +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ                                  !V:65W       3I/X
M%%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE
M87,          0                        */     G-I9R      0U)4
M(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
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M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\  $0@
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M,"#P?4'U![BK_LZ,H7C*_P"1'UZ2E:4;'UA/J%E:S1PW%Y;PRR?<224*S=N
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MCF?;\O\ ,.5=_P RQ15?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y3_XFCF?;\O\
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HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>sellinggeneraladminchart.jpg
<TEXT>
begin 644 sellinggeneraladminchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &
M1Z]>GO17Y#?M\_%[XH> ?V]O^".?@+P5X_\ %GA;P5\8_P!I']H?PU\5/"VA
M:S=:?H7Q"T#P]^RSXU\5Z%I'BW3X&$.M:?I'B.PM-:T^UNP\5MJ4$5VBB:.-
MU_7>,DHA/)**2?4D"@!U%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD_\ RDD_X(4_]G6_M0?^L<_$&OU2^.'_ "*&E_\ 8;M/_3?J%?E;_P %)_\
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MO_(C>)_^P3<?R6OAQNI^I_G7D>+/_(YRW_L6?^[6(#HO5_H)1117Y4(****
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MLE.^WNHH9XSD$@21J67#+E64G[SQ8_Y$&!_['%'_ -0L>(X2BBBOY_ ****
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M7^41****_*A!1110 4444 ?0/P"_X_O$W_7IIG_HZ]KZ7KYH^ 7_ !_>)O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>spinrazachart.jpg
<TEXT>
begin 644 spinrazachart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-/C/\ $,_"/X0_
M%/XJ#1W\0GX:_#CQUX_&@QW?V"36CX+\*ZMXF&DI?"VO39OJ7]E_8ENA9W7V
M9IQ-]FG\ORG^!/V=O^"D?A?XA_"3PM\7/BKK7P$:S^(VG>%+CP%X._9(^)?Q
M&_;!\?+K&H_#P?$_QKX:\8^$/ GP8TGQ!H>I^ /"5YIFJZW+I^F:Q:VMC+)=
M:N^C&ZT2#5OT#^+GP\LOBW\*_B5\*]2U"[TG3OB5X \:> +_ %2PCAFO=-LO
M&GAG5/#5U?V<5R#;RW5E;ZI)<V\<X,+S1(DH\LM7S)KW[&%NGAK]FQ/AK\5/
M$OPQ^)/[,'@.Y^&?@?XE:;X9\'^))]2\&:]X \(?#[QAIOB#PGXDL+KP_=3Z
MS9^ _!WB'3;VW%O-H7B;POHKXU3PW_;/AG6@#UKX6?M3? WXV^+M>\%_"CQH
M?'>J^&/#W@_Q5KM_X?\ #_B>[\*Z=H7Q"\#^#/B1X!O)?&AT>/PF[^-? _CW
MP]XD\*V4.L2:AKFFMJ\UA:2CP]KHT_X/\*_\%>OA+XEUGX<37GPN^+W@_P "
M^,]5_;ST/6=;\4_#CXGKXST.^_89^(7@KP/K][H_PRT/X>ZQXG\7Z!XJM_$V
MKZ[J6KZ7''%\.O\ A%M7\.^*E7Q%IVO6.B_67[)W[&7P]_8_7XB:=\-M:\0W
M_A[QP/@U;66D>(#I\\OAW3O@O\!OAW\!M$MX]1LK:SDU6YUC2/AY:>)-;OKJ
MVMVEU[5M1%K!;V(MX(_&= _X)P>%] \=W/B6+XI^*[GPSI\O[<;>!_"$N@>'
MHV\*6_[?7BOPQ\1?C!97'B*$K?\ B.WT7XAZ+JNN>!Y-0M+>]TW2==;P[JUW
MK,6EV5^P!]'^&OVP/V>_&/CK2/ 'A?QV^NZEK]WI.D:)XBTWPMXQN?AMJWB;
M7OA_:?%;1O!.G_%=- _X5K=>/=2^&E_9^.K/P/#XI;Q1-X8N8=3&EA)%2O-?
MC1^V-<?!;XO7'P5UGX</J7C'XB>$_#&J?LKI:>)?L]K\>?&5WXB/A?XA^ )9
M;G0U'A#5/A M_P"&_B/XZO8#XF@M?@KJ^K?$2"!X?!7BO3M/\2_9V_X)2?!+
M]G'XA> /'/A>YT#6I/ ]KX,U9KSQ#\&/@[J/Q"U3XA^$_@SX=^"D_B>W^,%]
MX6O_ (B^&]!U[1_#=MXLO?!GAW5K%;#QC=Z@-&\16'@R]N?!DOV'\8?V;?"W
MQG^)GP ^(WB35-1A'P%UWXI:Q9>';:"W;3?%<'Q5^#GB[X-:UIFLW3-'?V5M
M:Z)XOO=0MIM+EAN7O((8G=8&<T <7H?[=7[.?B;2KK5?#.O^.O$H6TT#5="T
M[P_\%OC/JVN^/_#?BJXU.S\.>.?A?H%GX"FU?XE?#G6;O1]0BM/B+X+M-:\$
M1I';W5YK]K9:CI=U?8<__!1?]CRWM/M[_%V-[*'X;-\6]3N8/!?Q!NH_#W@.
M/QCX^^'$^J^*5MO"DLWAB^MOB5\-/%WPSN/#FNPV'B:+XCV=AX$_L=O%&MZ-
MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
M[3?[1G[3ES);>$-4\$ZE\-]2T\Z[^T;XB\%S>$+_ ,#GP?+X*T;3].M]'L6N
M)3  ?=W@GXV?#_QUX'USXAV5YKOACPUX6GUNW\5R?$WP;XP^$NJ>%9/#=A%J
MNN2>)-"^)FA>%=9T:RT_2YHM4?5;RQ329]+==2L[^YL6%Q7A*?\ !0']ELZ+
MI6MS^-?%%A'X@\6?#WP7X:T?5OA)\7M'\6>*-8^+FG>*]3^$UQX9\&:KX%L_
M%>OZ!\3[?P1XIA\ >)]*T:[\/^*=2T2_T;3-1FUBWEL4B^$/[%7@OX>_ WXT
M? CQ/X@OO&7@SX\OXS@\9>&M(TG3OAQ\/_#'A_QUX!TSX<:_X,^$'P\\+RRZ
M-\+/"%]HVG7&N76D:'=W/VCQQX@\4>+&G2[UE[>#P?X;_P#!+/X8?#JW^'BZ
M9XFTG3;OX<_'#X'_ !?LKKP'\$/@G\)V\2P? #0OB+H/@O1/&_\ PKCPGH-S
MXJU;4X_B5KNI>*?%>J7DPFU7]]X5\.^$+6_U6SO@#<^/O_!4;X!?"OX$^,OB
M[\/&UKXO:[X;^&J?$BU\$:=X2^)NAK9VD_Q'U+X3V>C?$WQ'_P *\U>T^"FN
M7_Q \-^-?"%EHWQ.L_#^MW7BCP/XLT.'2WO=!U);;WJ?]N7]F2R'CR?4OB'<
MZ5I?P]T_QQJFI>(M5\$?$'3O"WB2S^&GBZP^'_C[_A67B>[\*Q:)\7+SPEX\
MU?1O!&M:;\+[WQ;J-OXOUG2/#L-K<:GJ=E!/\B:G_P $FO"+>#?C%X$\,?'/
MXA^$_#W[1+>-C\<(++PUX&U*X\9C5_VA_C!^T3X%>PN]6TVXN?#%QX'UGXS^
M)?!-Y+ILTL?C'P/9Z1;W]OI/B"T/B!]+1/\ @D=\ - 3XG:?H\VE>']+\6'Q
M+?>!-5\+_"'X,Z%\3_AWK_B'XR^'?C[8Z[<_&%?!EYX\^(LW@GXE^%-!N/!V
MF^,K^;1I_#MDNA_$&P^(,Z6FKV@![M\-?VW-'^)]M^VCJFB> M?T[2_V1]=T
M[1$C\46OB;P9XF\92W7[,WP[_:&O(M;\&^,O"7A_Q)\/-2T^;QVWA"33-6L-
M2FE33(O$22?9]3BL(?(OA3_P41U6#P9\"/'G[5WP^\ _ [PA^T=\ KGX]_#G
MQ;X&^*'B+XIZ)91:=X+\'_$+4_AGXNL=6^%?P[\2VWQ D\)>,K:^\)P>$M(\
M96'C6_T77O#]BVG>(O\ A'-*\3>]?#;]D0>$-+_:D;Q=\4O$?Q"\6_M;ZC9Z
MW\2_$]WX?\.>&X]/U:U^!'@_X!@>$]!T2,V.F:1#X8\%:3>V.G7T^IW4%Z9_
MMNJZF\LER_R_;_\ !*?P_P"-/@UX+^"_[17QN\3_ !L\-_"/X*Z/\$O@M;+\
M/?AYX+T;P'IVB)\.EL_'>H^'/L7BVP\?_$.2+X5^$-,N;OQA->^#9/#G_"2^
M'8O!,-CXQ\2-?@'U;J?[=?[-NC:'9:UJGBCQA9W5UJ_BS1;[P:_PA^+\GQ-\
M,S^ =$\.>)_'E]XT^%MOX%F^(7@O0/!GACQAX0\2^)?$GB;PWIF@:;H'B_PA
MJKZE):^*O#SZE)K/[=?[+WA^;XB?VO\ $EK+2OAAX>^)GB3Q)XM?P?XY;P'>
M6GP8\/7GBOXLZ;X-\?KX:/@SX@^)OAUX>T_4-3\6^$_ VN^(/$>DPZ9K$<VF
MFXT+7(=-\)\+?\$XM'^'D/AGQ#\)_BDOP5^*FE#XJZ1K/C7X,_ [X%_#KP_J
M'@SXSP_#*'QIX=TKX;:)X/'AS2-1L+CX._#O7?!GC/5+GQ5XIT3Q!H;-K5[X
MJ\,W;^%(N+U?_@D=\#;YOVAK32]1TK0=-^/'@S]IO0/[8M/@W\&;OXK^&->_
M:R\.^+M$^*.OR?&^]\)2?$WQ186MWXY\5:SX5\.ZCK=BNGRZ[?:)K>L>(O"]
MOHNB:0 >Y^)?^"C'[-6EV?BBTT+Q/J^K^,]!O->\.6WA;5_ ?Q+\(0R^.K?X
M;:E\4O WA;7_ !#K_@FVTGP@GQ>\*V U'X0Z[K\MMI/Q1M)2_P /I_$]VGV)
M\SX0_P#!2/\ 9Z^(_P (? OQ%UW4?$'@SQ5XN^%_P#^(O_"KY/ ?Q0U;Q;K!
M_:$\/Q:CX)L?A)IA\!:=KOQUTF_UVW\0>&;#Q3\,-!UW2;J\\-:O=7K:7:6T
MSQ\C\0?^"9G@#XA:K\1]4U#XC^,;(_$CXJ_LS_%/4K>VTS0GBL;W]FGX6V_P
MLT31[1I5\Q[#Q/ID']I:S/,?M5I>NT>GD0!:\_UC_@D;\+_%?AKP-I'Q ^(F
MK_$_5?@?X(^#WPS_ &=[WXD?#GX7^+/#WP[\!?!FVU&WTK0O%O@6\T!/#7Q:
MD\9PZM<6/Q U'Q/#87%_I^F^'Y/":>#/$.E3>)-1 /MGP9^V!\ /B%XZ\(_#
M3P7XPU+Q%XX\:>#[KQ[I?AVP\$>._MVF^$]-\6>+_ 6N:KXP^T>&H(_ ?_"-
M>/? WB/P+XILO&KZ!J/AOQK;6GA/6;2SU_5=+L+OS'XV_M=^)?@O\;?AW\-=
M1\ _#Z]T+XC_ ! ^&OP^\)6-Q\<]!T_X]_$(^/==T+0/$?CKX5_ >#PSJEWX
MI^'_ ,&Y]<&K?%/5-;\8^%-5TKPKX?\ &GBBSTF;2M TN3Q19_9__8=\#?L]
M_$C2/B/X6U]S<:9\ ;;X%'PSH_@?X??#_P 'K;M\:/'GQQU;Q+I7A?X=Z!X9
M\/Z!<ZCXI^(.KVHTG2])CM([""VNKZ[U;79]3U>_U/C#^R;JGQH\9)-XI^-O
MC=_A%<^/_AG\3-1^$W_"/^"II+/Q)\*/$'@_Q7X=TWP5\2SI$/COP/X1U7Q/
MX'T?7O%&DZ?=WVN7&H76N#PSXJ\)V>L7%H@!-\ OVK-2^-OQ[_:>^"NH_"/Q
M%\-8_P!GMO@]-I&L^*M;TBXUKX@Z-\6-"\8ZK:^(7\*Z0+T>#-/CN/!UVNC:
M?J^N7?B/4M)N[/5=;T;PK=S_ -BQ^R_%OQ=\5O#D'A;3?A!\,-+^(OB3Q-KE
MQIUW>>+/&X^'W@'P5I%EHNHZM<:_XO\ $%CX<\;>)Y$O;JSLO#N@Z3X5\$^(
M;_4->U>S?47T30;35-;L_D3P?^QU\?/ WQJ_:3^.^F?M7"_\5_M"^"M/\.W.
MEO\  SP5IMAX8UCX?^%/&GASX+:YH][+X@USS9?!4OC&;4=>M=7TG5+'QE<6
M-LEW::;9-<64_K/[2W[.?Q3_ &@/A5X+^&>F?M#ZM\.HK.\TV3XMW-A\/?#N
MOZ=\<M"M= FT_5? OC#3&U7P[>Z+X'\4ZW)'K7BK1O!VMZ%-XATZ!O!>I7DW
M@S5->T75@#Y?T[_@IGJWB[X>ZI\2_ 'P&76O#_PG^ DO[1_[1D6J_%31]+NO
M"?P]@^('QD\ QQ_!^XT_POK>G?&'4-?B_9]^+?C_ ,$ZGJMS\,_"WBWP!I7A
M#4K?6;&_\=6MEHWTKH7[6]QXE_:]TC]F72OA;K,/A3Q'^SAXX^/_ (2^-FK>
M(-)M- \<+X,\7?!+PY+I'A#PO91ZEKEWX=DM?C9I%U<>-=<DT"-M4TN^TC0]
M!UVWANM8MO-?$7[!%_XL\.IH^J?''6?#]QXV^!^F_LT_M ?\*W^&OP_\#^'/
MBS\$/#VL>-;OPGX7T+PG]GURQ^$FK^%_#GQ!\9> ](\1^#[NZ>W\(>*=:MXM
M+BU>V\):OX3Z'4OV0_B9-^USX'_:9T7]H6+0/#GP]^'VN_!CP[\'K7X,>%9]
M'@^#GC#Q)\+/%WB[PD_BU_$L6L_VM?:W\)/#G]B^)XM/B?P_ILU]8QZ1?N\5
MV@!UWP$^-7[0'CSXQ?%CX9?%/X:?!K0='^%.B^%(]9\8?"CXK_$'Q[!!\0O%
MUNOB*S^'=[8^-/@G\,(%U33OA]=:%XVUR[T[4]172[3Q?X1LI+62;5IY;'T#
MX\?$_P"+?P\BL7^&'PJ\*^-;.V\->,O&7C+QA\2/BM;?"+X=^#]$\&V^F7/]
MEWOB&'PCX^UB;Q-XGCOKR?1MWABV\):1I'A[Q%K/BSQ7HWV;2-,U[+T[X"^(
M_ ?PT^.WA_X4?$C4?#?Q+^,'CWXL?$[3_B7JVA:#K]UX4\8_$?4A-HUPN@ZM
M9W^B:YIO@+1;30?#6BV&K6<T=]H?AW3[>^0R%Y!Q7[7?[+WC_P#:<3P%H^C?
M',_#SX?^&KK6-2\;_"S5/A7X6^)O@#XQZC,=-;PJGQ)TW6]8T'4-9\.>#+BU
MOM3M/ [:FW@OQ-K%[:7GCG0O$MOH6D6-N >!/_P4OM=6\'ZC\8?"7PDEG^"7
MPR^$7[.'QB_:&USQ=XWA\,?$3X::%^TAX6TKQ_8:3H'@*R\->(=*\6:]\+/A
MQK>D>//BA:ZUXU\$0#2-2M].\$7/BO74N;*#U34?V[-,\+_'O]I#X6_$#X6^
M*/ 'P_\ V<OV8O\ AIO5/BEX@U329+GQEX5TKQK\4?"?BR;PUX%TQKW4K7P]
MI<7PROK[0-=\0:KI.J>+VNG>Q\+V.B)I>O:Y!XW_ &$X?B+J.LW'BCXO^)DT
M?XP>%/A3X<_:O\*Z!X6\*Z1X?_:#G^$@V:7J@6XCU35?ABWBS3=O@WQ]9^%-
M4O(==^'UKIOA[3I-#U6P3Q/)SWBS]@SQ3\1/VC/BO\8OB)\=T\5_#CXT_!+7
M/V8_'_P0D^$>@:9I6J_L^:OJOQ%UM?!2>.+#Q8OB.UUY-0^)6N1WOC&&T6?4
M--BM;0:19W >^8 ]*_9+_:RU/]I+4_'.F:IX<^%^A3>%=!\ >)!;?#KXZ:%\
M6M7T)/'L&N7$7A'XEZ%#X:\(:KX2\9:+%I$?VG4= M_&GPP\074NK:;X1^(>
MLZEX5U^V@UO&?[>/[,?PYG\?1_$#QOKW@BT^'7A/XD>.=8UGQ;\,_BAX=\/Z
MUX5^#UU;6GQ3UCP#KVK^#K/2?B3:^ GO+6Y\1GP'=^(#;:7(^M6XNM&MKO4+
M>O\ L_?LB1?!KQN_Q&\4_%+Q3\6O&6E?"+PA^S[X(U37- \(^$H/"WP;\#:Q
M=Z]H^AW&F>"M,TNQ\1>*-3U:YAO/$OBS4(H8+DZ?96_AKPYX1M)M7MM6^+/B
M#_P1E^%WQ(NO&=]XA^+GBV?5_$GAS]J/P?:>,7\"?#:;XF3^'/VJ]$U33?%=
MO\0OB>VC)XU^*U[X+GU*&'X?77BG58K/1?#FCZ+X?N=+OY;$:TX!]N7'[=?[
M.$+36">)_%L_BF#QOKWP^F\ 1?"3XOR?$BUU[PUX2T/Q]J^H:A\.XO DOC73
M?!5GX%\4^%?&4GQ$O=!@\"MX9\4^&]4A\02IKFF1W.=\*_VGOB'\;_V/_P!G
M']I'X7?!./7_ !C^T9\/?A!XYT[X?W?Q L]*\)^ K7XH^&;+Q3?ZGXR^(<WA
M^?5)O"?@ZPN)8[G4/#/@'7?$OB"^;2['2?"B-J<MSIO$^(OV!]/N/VC?B'^U
M+X&^,'C#X??%CXA^)+6XOM3T_P .>$=?L;#P)?\ PA^%GPC\:> ;;3_$5E>6
MTL'B&#X/>"/&NE^(94&J>&O&.CPLL.L^&[G5O#NJ[.H?L:>*-!_8N^$7['7P
M4_:'\=?!VQ^%/@OX8?#1?B=I7AW0=:\:>)_AW\.M%MM!OO#-\[W>CR>'Y?'&
MF6-K8>(/$W@W5= \6:;9R7Y\)ZUH&HW4.IV0!YCH'[?GQ \?W$/@3X8? ;P_
MXJ^-GAZ/]I74_B+X1OOC%_8G@6'0/V8?B?IGP@\17_PR^(:_#K4[OQ[+\1O'
M>I3:!\./[9\&^!].M=2\,^.-.^(6H^#]3\+FQU/N-#_;XTCQI\9OV,_ 7@;X
M5>+=3^&?[8WPS\4_$SPM\:=>U70M T6QL]*^$6A?&#0M"T7PQ;SZUKWBG5;S
M0=;6V\4WS_V!X<\*Z@D&FV.L^*-6?4;#1\O2_P!A+Q+HWASP /#GQW/PW^(?
M@+P'X\^"=EXP^#WP5^&G@'P__P *$\>ZKX>UE_A[I?PWNO\ A*/#N@:MX-U7
MPSIVL^ /&UA=O>Z+K4FI3ZMH_B+2]8U;1KVGXI_8*\5_\+3_ &6/&/PH^/A^
M%_@']CSPM_PA?P;^%K_"3P_XTL[3PUJGP]T;X6^*=.\0>*]6\5Z=K6KC5/!F
MB6MKI5PMO9W&AZBTNHRR:QN%L #5_9=_;6US]H+XK>(O!NKV/P*\*Z)''\2I
M_!VC:'\6/'7B3XMZS:_#_P"(ESX'GGO_  UK'P:\(_#Z=].@M%O/']EX'^)O
MC>^^'>L:MH>@:[;E[\7P_1"OD?PQ^S#KEO\ %CPE\2?B+\;_ !S\5;'X57GC
MV_\ @[X8\0:%X*T0^$[SXCZ?=Z)K5]XD\1^%]&TS5?'U]HWAC4=2\)>%)M2B
MTJ"ST2_N;OQ':>+/%:6GBBU^N* "BBB@ HHHH **** "BBB@ HHHH ***^:/
MCC^U_P#L\?LX^*OAKX,^,7Q(TGP=K_Q5UTZ%X:M;JWU"[AL_^)1XCU===\6W
MNG6EW9^"O"3Q^%M9LH_%GBJ?2M ?4[62R6^+P7KV8!]+T5\\Z;^U7\!=7^(=
M_P###3_'L5QXGTWQ)XB\%W5Y_P ([XOB\#?\)QX1T:\\0>*_ =K\4I_#T7PO
MO_'WAC1]-U;4/$7@:P\8W/BO0[;1M9?4])MFT?5$M.5T7]N#]F#7_#.M>,-/
M^)JQ^&]&\.Z#XOAU35?!GQ$T"'Q;X4\5:]8>%O"OBCX8Q:]X0TVZ^+OAOQ5X
MEU?1/#WAC7?A9;^,=+\1:[K_ (>TG1[J]O\ Q!HL%^ ?6%%>5_#+XU?#;XP^
M&M:\5_#W7[C6]-\,Z_K7A3Q187/AWQ1X>\6>%/%7AZ&VNM7\+>+/ GB?1-%\
M;^%_%%G97VG7[>'-?\/:?K,VGZII.H6UE/8ZKIUQ=<9\)OVI/A#\:O%^O^ O
M!$GQ,M?%WAGPQHWC+6=$^(?P'^.WP=N+;PSXAU;5M"T358)/B[\-_ ]MJ$6I
M:KH&MV=K#I\]U=2-I&HR>0(;.XEC /H>BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK\
M>/\ @H-\3?B/X1_;U_X(U^ ?"?C[QEX7\$_%K]IG]H;0OBCX4\.^)M9T30/B
M)H?AW]E3QUXET+1?&NEZ9>6MIXFTG2?$5K:Z[I^FZQ%=V5KJ]K;:C% +NWAE
M3]"/C%XLTSX3^%],\0IX?GUYK_6+?23:OXCU?3A'YUA?7AN//5KXN5-EY?E^
M4N?,W;QMVMY^:YI@<ER_%YKF59X? X*E[;$UU2JUG3IJ48N7LJ$*E:=G):4Z
M<I:['-C,7A\!AJV,Q=3V6'P\/:5:G).?)"Z5^2G&<Y:M:1BWY'O]?CO_ ,%&
M_P!F_P#:6^*OQM_9B\??LS>%8='\:>&?&T4*_'+1/BK?^%KGX?M8_";]I/3]
M*F^,/PSUCPIXJ\#?$GX4Z-XD\?Z)<Z<PTC7O& _X2/X@_#_3+'PY8_$:X\66
MONW_  U=9?\ 1-&_\+W6?_E91_PU=8\?\6S;CD?\5YK/!P1D?\2ST)'T)K\]
M_P"(T>&__10R_P##1G?E_P!2[S_!]CYG_7SA;_H9O_PBQ_E_U"^?X/L?']G^
MQ;^UAIGQVE\;^&[6RTKQA=_&7]HCXJ^*_%_B'Q[%K/[$NO6?Q,^'OQ*\(^!M
M2\(_L?0ZK=:]X2^,:7&K_#Z7QSXNCL]-UJ_O+OXSZSK?Q7^)(\?ZCI&OWOV;
M?V4OVF/V?M2UO5/"?PV\;WWAC1OV=/"OP9NO ?Q?_:>TGQEX@O?$%AXYT&ZU
M6\_9&\8:;8ZO#^SY\.M"\#_\)7-X=\!73_#7PEX@\4:1\&](MO!'PHTGP$/$
M,/UE_P -767_ $31O_"]UG_Y64?\-767_1-&_P#"]UG_ .5E'_$:/#?_ **&
M7_AHSOR_ZEWG^#[!_KYPM_T,W_X18_R_ZA?/\'V*O['WPX^._P "(M8T'6/A
M9KEUX0^-'[0_CCQM?ZMXW^+_ (9\>?&/X3^!F^"OAJUTSQ%\</'C37]W\<?&
M?BGXF>"7\(:#::#KGBO4_A_\.=:\":)?>,];\/\ @?[)I?T/^SM\-?%_A"]^
M.7C?XD06:^//BS\=OB'XD\ZWN+._-O\ ##PUJ9\ ? O28;RUW"WM(?A1X7\.
M^(;C10Z+IGB?Q7XJDN(5U6_U2:?P+_AJZR_Z)HW_ (7NL_\ RLH_X:NLO^B:
M-_X7NL__ "LH_P"(T>&__10R_P##1G?E_P!2[S_!]@_U\X6_Z&;_ /"+'^7_
M %"^?X/L?HE17YV_\-767_1-&_\ "]UG_P"5E?4/P@\1:9\4_"1\42:%/HC?
MVMJ.F?8D\0ZMJ Q8& >=]H,EF<R^=RGDX3;]]L\>WD'B-P=Q1C_[+R/-I8W'
M>PJ8GV+P&98;]S2=.-2?M,5@Z%+W958+EY^9W=DTFUZ&6\49'F^)^J9?C77Q
M'LYUO9O#8JE^[@X*4N:M1IPT<XJW-=ZV3L>XT5@?\(SI'_/&Y_\ !GJO_P G
M4?\ ",Z1_P \;G_P9ZK_ /)U?;GOF_16!_PC.D?\\;G_ ,&>J_\ R=1_PC.D
M?\\;G_P9ZK_\G4 ;]%8'_",Z1_SQN?\ P9ZK_P#)U'_",Z1_SQN?_!GJO_R=
M0!OT5@?\(SI'_/&Y_P#!GJO_ ,G4?\(SI'_/&Y_\&>J__)U &_16!_PC.D?\
M\;G_ ,&>J_\ R=1_PC.D?\\;G_P9ZK_\G4 ;]%8'_",Z1_SQN?\ P9ZK_P#)
MU'_",Z1_SQN?_!GJO_R=0!OT5@?\(SI'_/&Y_P#!GJO_ ,G4?\(SI'_/&Y_\
M&>J__)U &_16!_PC.D?\\;G_ ,&>J_\ R=1_PC.D?\\;G_P9ZK_\G4 ;]%8'
M_",Z1_SQN?\ P9ZK_P#)U'_",Z1_SQN?_!GJO_R=0!OT5@?\(SI'_/&Y_P#!
MGJO_ ,G5?L=,L].\W[*DJ>=LW^9<W=QG9NVX^U3S;,;VSLV[N-V<# !H4444
M %%%% !1110 4444 %%%% 'X@?\ !2?_ )22?\$*?^SK?VH/_6.?B#7Z#_MA
M?\DU\._]CA8?^F/7*_/C_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OT'_;"_P"2
M:^'?^QPL/_3'KE?!>*'_ ";_ (I_[%DO_3U$^<XN_P"2:SC_ +!)?^EP/S?H
MHKU_X<>&/#7B'2/$2WMH=6\1B )I>DMKJ^';AXGU'0+2WN-!N+NQGTO4=7FN
M]0GL3:W]W'B233K"&QG?61<VW\&97EM;-<7'!X>I1IU94JU2+K.I:7L:4JGL
MZ<*-*M7JUJG+R4J5&E4G.<E[JBI27\YX3"U,;65"E*$9N%2:YW*S]G!S<8QI
MPJ5)SE;EA"$)2E)K1*[7D%%>FPZ5X6G\*ZAJ5SI&K:1#ID6DVEKXBN=3+7WB
M'Q0;ZR3Q#HEEHDJKICVUEITNIW4<EJRRZ.+"P.N7KS:D;2NGTWP9X5UX:7=-
MI=QX760>*=<@TF]\1RO<Z]X'\.>'[C5;?6;^YO+=GT%[W48$L'U*W@^PWUF=
M2O-&TXC3HI+CTJ'#6,Q,Z5.AB<%.I7I8:M3AS8N+=/$XMX*+E*>#C3AR5DKR
MG.-/$1G2^H3QDJD8'53RJO5E"$*N'E*I"E4A&]=7C5K>P3;E048\L[7<I*-1
M2C]6E7<DCPNBNS\8Z7I^F7>AW>FVME'IFM:/!J-L^G:Q?ZMI.H/#?7EA?OIM
MQJMK8:Y9Q)<V4EK<Z=JL37]G=17#)<26LELZS^*H=%MM)\-_9?#\&C:SJUJ^
MOW0M=5UF^A@T2]9X-#M6BU:\NR+J]CMY]7EEC,?E6EQIT(5V>9QPU<JJ4?KZ
MGB<,G@(4:DM,5RXF&(E1C1EA)O"J%15(UX5J?M9474P]Z])3IQG*//+"2@\2
MI5:*^K1IS;_?6K1JN"A*@W1M)252,X\[IN=)NI!2@I-<+7Z<?LC_ /))S_V-
M7B'_ -"LJ_,>OTX_9'_Y).?^QJ\0_P#H5E7ZKX"_\EX_^Q)F/_I_ GV7AQ_R
M4;_[%V+_ /3F&/J"BBBO[7/WL**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0/^"D__ "DD_P""%/\
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M&_\ %6N:F+I+V[@EBNM.LM(,":;I=O;6FF:?>#4+2RTNWMK*&'1X8[P-._\
M926;W#RSBY>9+B=9,S4-2O=4FBN+^<W$T%E8:=$Y2./R[+2[.&PL+=5B2--M
MO:010JQ4NX3?(SR,SM1HKFK8S%XBZQ&*Q%=2<7)5J]6KS.,JLXM\\I7<9UJT
MHM[2JU9+6I)O.=>M5O[2M5J7M?GJ3G>SG)7YF[VE4FU?9SFUK)W*_3C]D?\
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MT^VU&_.J7]M9VUO>ZF;6&Q.H7<$*17-ZUG;$V]HUU,CSM;VY\B$R&.$"-5
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M^46OZNO^",?_ "9U)_V5[XC_ ,]!K]!\,_\ DIO^Z=BO_3N%/I>$_P#D;/\
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M#G_LN/A[_P!0/Q[7*_\ !2UWC_X*0?\ !"MTADN&'[5W[3P$41A61@W['GQ
M4D&>6&+"*2[;I%)52$#.51MO_@M9>7-Q^S!\.DFTJ^L5'QO\/L);J73'1B/
MOCL! ++4;N3<P8L"T:H C;G#%5;YKC'_ ))C.?\ L$?_ *<IGDY[_P BC'?]
M>?\ V^!_,/7TO\(OV>$^)?PU^)'Q.UCQO#X,T#P-#+;0W;>$O%7BO3XM6@N_
M" DG\:7?A?3M1D\'^&9+'Q7']CU26VO;Z]GL]6O[739='\,:_/'\T5]/?L]_
MM%VOP$M_%5Y9> ;/6O%VH:?''X<\4P>)_%'AR:.>/Q)X.UU=#\:V&BZG;67B
M_P $(_A9Y_[%>&SO;AM2UC0+V^NO#7B75[6'^:\M6">*2Q[BL.Z=:[G[=QC/
MV<O9R<</:K-J=G&FITU.22E4A%MGY;AO8>U7UBWL^6=V_:-*7*^1M4K3E:5F
MHJ4$W92G&-V-U7]F?6M"^'.E^--9UG6-/U?5=&\!:_;Z0_PV\7W'@Y;7XD7^
MEQ^%_#\OQ6M#/X:@\>7.AZSIOBN;P_=Z=:Z-%I5R-)/BD^*5_L5E^+'P!T;X
M.>(K#2O&.N_%;2M%DU[Q9H.H>*-6^!G]D6,DOA82PM/X7MYOB=/_ ,)&]W=I
M#++IU_=^&=4T_1+RSUR2TN8[F*T>QJ'[3VH:GX=O([[P;;WGCW5OA+X5^!FL
M^+;OQ;KS>&[[X:^$-7T/4M,M+?X;6L%GIFE^()[/PUHNB76KV.OII]M:V]SK
M&BZ#I/B>]DUF+!U'XV^&1'I>G>&?A7#H7AV7XQ>'?C7XVT;5O'VO^-7\6>(?
M#@NK>TT&TU36M+M[K0?#!T[5=<L9#=Q^)O$^H+J<+Z[XDUA-*LH#W5?[%Y)*
MCR<WLZ#A.H\>YJ<:E7G52FHQISG4I^R^L\E:C2I*\L(ZT[Q>\_J-G[.W-RT[
M.;Q#::E+FYH)*$I2CR>UY9PA!)NASRYD^9^(_P ++?PC\1M)^&OA77K_ ,8Z
M_J4'A"RN[/4?#<?A'4]%\9^+S:_9_ ^I6*^(O$UHNLZ5_:>CVVLS0ZM);Z?J
ME[=:3.J7>DWN-7XF?!BQ\#Z)JVO>&_'EEX^L/"/Q'O?A'X\EMO#6I^&DT#QW
M:Z?J6H6W]DMJ-]?'Q+X0UM-!\2V^A^)531[NXNO#UZM_X?TZ*[TV6YY)_B&;
MGQ;XT^(%_I=U<^.M?\5KXZ\*^(8M>N;4>#/%S>/8O&L^KS:<ME+;^+$DC6;2
M(+#49-/M[226/5T:2:V2S?KOB7\:+'QQHFL:%X=\!V/@*S\8_$>Z^+OCU+7Q
M)JGB-->\=W&G:IIUL-'CU*RLCX8\(Z,OB'Q/=Z/X;$NM7D-YXANS>^(+ZWLM
M,@MN5O+G3QDDHPE.3EA::>*E4I4TZD:4(RE>E*HVJ<\2Z\YQ=&=\.U74J<,7
M]6<:SLHMMNE%.LY1C>2@DW>#D[1E5=24E[-_NVJG-&/A%?U=?\$8_P#DSJ3_
M +*]\1_YZ#7\HM?U5?\ !&V\N;?]CYTATF_OE/Q=^(Q,MK+I:1@DZ#\I%[J5
MI+D=#B,KD<$C!KZ[PS_Y*;_NG8K_ -.X8]SA3_D;?]RE?_TNB?KM16+_ &I?
M_P#0MZQ_X$>'_P#Y>4?VI?\ _0MZQ_X$>'__ )>5_0Y^EFU16+_:E_\ ]"WK
M'_@1X?\ _EY1_:E__P!"WK'_ ($>'_\ Y>4 ;5%8O]J7_P#T+>L?^!'A_P#^
M7E']J7__ $+>L?\ @1X?_P#EY0!M45B_VI?_ /0MZQ_X$>'_ /Y>4?VI?_\
M0MZQ_P"!'A__ .7E &U16+_:E_\ ]"WK'_@1X?\ _EY1_:E__P!"WK'_ ($>
M'_\ Y>4 ;5%8O]J7_P#T+>L?^!'A_P#^7E']J7__ $+>L?\ @1X?_P#EY0!M
M45B_VI?_ /0MZQ_X$>'_ /Y>4?VI?_\ 0MZQ_P"!'A__ .7E &U16+_:E_\
M]"WK'_@1X?\ _EY1_:E__P!"WK'_ ($>'_\ Y>4 ;5%8O]J7_P#T+>L?^!'A
M_P#^7E']J7__ $+>L?\ @1X?_P#EY0!M45B_VI?_ /0MZQ_X$>'_ /Y>5=L[
MJXN?,\_3;S3]FW;]KDT^3S=V[/E_8;Z]QLP-WF^7G>NS?AMH!=HHHH ****
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MP6V_Y-=^'/\ V7'P]_Z@?CVN9_X*3_\ *23_ ((4_P#9UO[4'_K'/Q!KIO\
M@MM_R:[\.?\ LN/A[_U _'M?-<8_\DQG/_8(_P#TY3/)SW_D48[_ *\_^WP/
MY>****_EP_)0HHHH **** "OZNO^",?_ "9U)_V5[XC_ ,]!K^46OZNO^",?
M_)G4G_97OB/_ #T&OT'PS_Y*;_NG8K_T[A3Z7A/_ )&S_P"P2O\ ^ET3]9J*
M**_H<_2PHHH) &20 .I/ 'XT %%(&4@D'@=>Q!]"#R#[$9]J7( R>![\?SH
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M.$ZDY4K1A"+G.3YXZ1C%-M^23/R^HKY4_P"&V/V;?^AR\6_^&2^/'_SLJ/\
MAMC]FW_H<O%O_ADOCQ_\[*OYO_U?S[_H29O_ .&W&_\ RD_,/[-S'_H QO\
MX2U__E9]5T5\J?\ #;'[-O\ T.7BW_PR7QX_^=E47_#;_P"S,9S;#QQXG-RL
M*W+6P^#'QS-RML\KPI<M;#X:^>ML\T<D,=PT8@>:.2%)&EC=%/\ 5_/O^A)F
M_P#X;<;_ /*0_LW,?^@#&_\ A+7_ /E9]845\J?\-L?LV_\ 0Y>+?_#)?'C_
M .=E1_PVQ^S;_P!#EXM_\,E\>/\ YV5'^K^??]"3-_\ PVXW_P"4A_9N8_\
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M>@#]J*BGD2*&6621(4CC>1Y9"!'&B*6>20EE 1%!9SN7"@_,O4?BY_Q$.?\
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M5.HH ;M'JW_?;_\ Q5&T>K?]]O\ _%4ZB@!NT>K?]]O_ /%4;1ZM_P!]O_\
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M7%E=^)M+\-SF-[C2K'Q!<Z=I\^L6]K*D>H26-HUT)#;Q;/3J "BBB@ HHHH
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M>/X@GQ)P?P>\6?M2_M*_L*_\$YM1TWXL^)=5^)OQ-\-ZQXD^*WB.W^-?A?\
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MTVQAM[+3]/L;6**VL[*T@AMK6WCCA@BCC15&G0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(2 "20
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M+0 _=\$'H0>2./4=1]1WHK^>Z_\ ^"AG[0OPT^+?C7QD+"T\4?LW?"KX>_\
M!87XB^/_ (<7DFM>+?BMXS\0_L9?M>> ?A/X-@\&^+DT>W@\+:2;/QQI%IH7
MAG^SM1T?PEX0U'Q6VLCQ1=Z!X3O8/JOP3^W7\?O%_B?X=?!R;X':;X6^*_Q
M^+NJ^$=.\4?$32?BM\+_ (:7?@_PC\(5^,_C&XTW0?&7A>#XG2>,+:W2;P-H
M.G:EI&G:)XFC@U'XG:3J-SH.C:EX2B /UER,;LC;C.<C&!U.>F* 0P!4@@]"
M""#]".*_&+X(?&7]HSXM_P#!(_X*_$W1_C!H.F?M$?$W3? UM%XV\9>,O#7A
M:7QA?ZY\=AHNK^!/"?Q UKPEK_AG0O'WQ#\&0ZC\._A1XNO_  'K=G;>,=7\
M,ZF?#SR[?(\CT[]K_P#:'^'OQT_9V^$T?B_Q3X-\&>'?CK^T#X7_ &L?"7[6
MZ_#[Q7X\\&^$_"?[&]G^TWX)T71/C=\'+WQ!X7\3>#U\/)J/C?2/'5]>W/CZ
MR^UVWAOXBZ?/!H5WI%Z ?OU17\\_Q$_X*8_M7^*1HOP\^%GA;X??#[XD:MX[
M_P"">'Q&T'QCXH\'_$?_ (07Q7^S]^UK^UOIG[.FLZ'8:-XWTW0O&]R?[1GT
M\)\1[GPWX+N-7\(:WK-YH7A'P;XMTG2[A_HKPY_P4L^+_BZ?XO:OX5_9?\1Z
MSX<T'2?VG[?X7PZ_#XI^%EKJ_B_]FKQQJ7PZL]+\7?%'XD:+HWPM\GXO^(]%
MUI-'MO!FIZU?_#JY@TC0_%LFIW>MR:AHX!^QU%?*/[)WQ_U7XY^'/'=IXP7P
MYIWQ$^&7CD>#_%WAW1_#WQ6\$:QI4>I>%?#GC+PY=>*?A[\9_!_A+QIX+U/5
M]%\11W-I91S>,?#>JZ5#9Z]H/C74X]2N=,T7ZNH *I7FI:=IYC%]?V5D90QB
M%W=6]L9 FW>4$\D>\+N7=MSMW+G&1F[7P1^VJJ->_#O<B-BU\3XW(K8S-H6<
M;@<9P,X]!7R?''$L^$.&<QX@IX2..G@98)+"SK/#QJK%8_#8-WK*E6<.15W4
M7[N7,XJ/NWYEXW$&:RR3*<5F<:"Q,L.Z"5&51TE+VV(I4'>:A4:Y54<E[KNU
M;2]U]N_\))X?_P"@YH__ (-+#_Y(K5AFAN8HY[>6.>"50\4T,B2Q2(W(>.2,
MLCJ>S*Q![&OPJ$41(_=1=1_RR3_XFOV%^!P ^$7P[   'A32<   #]R>@& /
MPKXCPV\4Z_'N9X_+ZN2TLLC@L!]<56GCYXMU'[>A0]FX2PF'45^]<N92EM;E
MUNOG^%>,*G$>+Q.&G@(818?#>WYXXB59R?M84^7E=&E9>^W>[V6FNGJM%%,D
M)"@@X.^(?@9$!'X@D5^QGW(H=&)"NK$=0&!([<@'(YIU?RS_  -_;=_:"^%?
MP^\$_M#^-[K]J+QFL7AK]O;XU?$NT^)WC[X9^)OA'^T'\-OV?_&_Q+\%>'_A
MW^SGX2\,W_B_QYX ^(N@>+->^#7B![K6?#'P^@TKX.>%/BKX@U#2/')TA]/'
MZ0/^W=^TS-X22SM/V<[B'QS9_%J7P3K6N:MX'^-6GZ8OA3_A4TGQ)@\5^'/@
M.WAQOVE_&$=OXH-I\+=?'AGP?JRZ%#J%A\7$M-4\'SSZ)9 'Z\45^6G[%/[4
MGQJ_:,_:>_:<BUGQ-\,-<_9QTCX/?L<?$;X'67@BTUJ[OK*?XZ?#'7/%OB:X
M'C'5]"\+7_BO0KG5]&U2VBO-;\,Z%JL']GZ;%_PCOA>[_M[18_FS]JW_ (*2
M_M"^$O@3\?/'OPK\(?#3PK]M\'_\%"_#WP&UG5]5\0^(O'O@OQ]^P=X>^*%_
MXK\6?%;P)<:'8Z%;Z)XNB^$_C";PM96][-'X1U^_^%=CXO'BJS\=ZC:^'@#]
MW000"""#T(.0?H12U^<OCOXX?$C]C[]F3]G[5?%5M;?%CQ+K%C8_#KQ1K6M^
M+O$MW?:U\8/%_P //$VH_"2RA\0ZQ8W.HW5M\3_C59^%?A+;W&KPP7&GW_CW
MP^;:W\NV^S'RK0_^"AGQ(^*,/@#1_A+X#^%MKXH\?Z?\9=6MM3^)GCCQ%HO@
M+1YOV8/ 7P@N/C_X,O\ 6]$T*_OIO%^A_&SXFZS\(+98;2.RT2Q^&7Q(\=:G
M'K'_  C<?A;5 #];R0.I R<#/<^GUHR,XR,XSCOCUQZ5_/\ ^)O^"E?Q:^,.
MF?#;X@> _#.I?"KX8Z-^V'^PSX0UJRL;JZU?XH>/?"?QY_9B^%W[5'B?P)J'
MAR32X]/@@A\.?$\>#REA<_VAXJUBRTN?38M'M7>2^]\_94_:C^/OQL_;#^&5
MM\0+OPEX<^'?Q5_X)O\ AG]J#PU\-O ?BF_\5:/IDWQ&^-FDQ^%=0\0WNL>'
M=#O;CQ7I7@B_B\/7FMZ9L\.:_<#59=*TO3H;%!, ?L)1110 4444 %%%% !1
M110 4444 %5[N)I[6XA0@-+!-$I;(4-)$Z*20"< L,X!.,X!Z58HH>J:[AN?
MRRR_\$4?VK'DD<>-/@7AY)'&?%'C0'#R,PS_ ,4 ><$9]Z^S/V"/^":OQX_9
M@_:&T_XK?$#Q)\+]3\.6G@SQAX>DM?"FN>)+_5S?:^FE+9R);ZGX3T>U-M']
MAF^T.;T2)NC\N*7+;?W.HKXK!< \/8#%X;&X>GBU7PM:G7I.>)<HJI3DI1<H
M\BYE=*ZOKKW9X%#AO+,-6I5Z4:ZJ49QJ0O6DXJ4&G&ZMJKQU76[[A1117VI[
MYP?Q&^%OPV^+_AT^$?BIX"\'_$;PN;^TU0>'_&WAW2?$VDQZIIYD.GZI!8ZO
M:W<%OJ=@TTK66HVZQ7MHTLAMYX_,<-RUU^SK\ KW2[_1+OX*?"FXT75?AD_P
M6U+2)/ 'A8Z7??""2ZN[Y_A==:>NEK9S?#YKR^O;IO"#PG03<7=S,;'S)Y&;
MV6B@#QN\_9W^ VH7&CWE[\&OAA<W?A[Q?XZ^(&AW4W@;PW)<Z3XW^*$VHW'Q
M)\5:?.VG&6VUWX@SZOJ<WC?4(V$WBN6_NI->:_:4FL.R_91_9CT[P.GPSL/V
M>_@M9?#V/Q/9>-H_!-K\,O!L'A=/&&FHD.G>*%T2/1UL!K]A:QQV-EJXA^W6
MFG1IIEO/'IRBU'T!10!YTOP@^%"_#M_A$OPT\!?\*JEL)M*E^&Q\(Z _@.32
M[F]DU*XTZ3PB^GMH#V$VH2RWTEHVGF W<C7(C$QWCCK7]E[]G&R\):%X"L_@
M3\)+3P7X9\8VGQ$\/>&+?X?>%H=%T7Q]8J$MO&VFV":6(;7Q:D6ZW?Q%&HU>
M>TDEL[B\EM)9(']VHH ^<K/]C_\ 92T[P[XA\(Z?^S;\"['POXLT*;PQXF\/
MV?PK\$VVCZ]X<GUU/$[:%JNGPZ*EM>Z1'XBBAURUT^>-[6QU6WMK^QCMKFUM
MY(MZT_9G_9VL-8\9>(;7X%_"*+7?B)X?N/"?C[6/^%=>$9-3\:^%[RTM+&_\
M/>++V72))_$.C:E9:?I]KJFG:J]U:ZK!I]A'J4=VMC:B'V^B@#SWX:_"7X7_
M  :\/R>%/A-\/?!?PV\-3:A/JT^A>!_#6D>&-+N-5NHH(+C4[JST>TM(KK4)
MK>UM;:2]N5EN6MK6UMO-\BV@CC]"HHH *^8_VAO@UXI^*]QX4E\.7FB6JZ'#
MK,=V-7N;RW9VU"33&@,'V6PO0X46<OF;S&5)3;NRVWZ<HKQ>(<@R_B?*,5DF
M:QJSP.,=!UHT*KHU6\-B:6*I<M1)N/[VC!RLM8WCU.#,\MPV;X*M@,8IO#UW
M3=14YNG/]U5A6A:23M[].-]-5==3\U1^Q]\3@0?[6\&<'_H):O\ _**OO3X<
M>'+[PCX%\*>&=3DMI;_0]$L=-NY+-Y)+5Y[:/;(T$DT4$KQ$_=9X8V(ZHM=M
M17SW"GAUPUP9B\3C<DIXR%?%8;ZK6>)Q<L1%TO:4ZONQE&/++GI1?-?:ZMJ>
M9DW"^59%7JXC+XUXU*U+V,_:UG5BX<\9Z)I6?-%:]KKJ%! /4 \@\\\@Y!^H
M(!'H1FBBONSZ(\KM_@9\&+30O"_A>T^%/P[MO#7@G4/%&J^$/#\'@WP_'HOA
MG4?&^F^*-'\97NAZ8MA]BTRX\6:3XW\8Z9XE>T@B_MVP\4^(;/5!=6^KW\<_
M$M^R'^RLW@2#X8']G'X'_P#"NK7Q$_B^U\$CX6^"QX8M?%4ED-,?Q+;:.-&%
MI!KS:2JZ.VK11I?G1@-'-Q_98%I7T510!YQI'P>^%&@>*]*\=:#\-O VA^,M
M"\"6OPNT;Q/HWA71-*US3/AM87-O>:=X"L=1L+*WN;?P=IEU;0SZ9X<C==(T
MV16:PM+;S)0_.7O[-W[/NI:Q\1_$&H?!#X3WNN_&#PUJ_@WXK:S=?#[PI/JG
MQ(\)^(;&#3/$'AOQQ?R:4;KQ/H>O:=:V=CK>F:Q+=VFL6EC8P:E%=1V-HL'M
M5% '/:WX1\+>)=+L=$\0^&]"UW1],U;PUKVG:5K&DV.I:=8:WX,UO3?$OA'6
M+.SO()K>VU3POXBT;2-=\/W\,:76CZQIFGZEI\MO>6=O-'YWXH_9V^ ?C;PO
M:>"/&/P6^%7BGP;8>*]=\=67A7Q!X \*ZQX>M/&?BC5M:U[Q-XJMM'U#2KBP
M@\0>)-8\2>(M2\0:M' M[KEWX@UR759;LZMJ N/9:* /,)_@G\'KJ^N-3N?A
M;\/KC4;OQ[X6^*=U?3>#]!DN[CXE>!_#NC>$/!OCZ:=K'S)/&/A3PKX=T'PW
MX=\1LQU71=#T72]*T^YM[*PM88J'@']G_P"!GPJUF^\1?#/X._#'X?:]J<&I
MVNH:SX+\"^&O#.J7MIK6K6^NZK:7-]HVFV=S-::AK5K;:M=6CR&VDU&"*[\H
M3H'KUZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>spinrazalogonewa01.jpg
<TEXT>
begin 644 spinrazalogonewa01.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[@ .061O8F4 9      !_^$0C$5X:68
M $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    )    '(!,@ "    %    ):':0 $
M 0   *H   $N  K\@   )Q  "OR    G$$%D;V)E(%!H;W1O<VAO<"!#0R R
M,#$U("A-86-I;G1O<V@I #(P,38Z,3 Z,C@@,#@Z-# Z-#,   >0 P "
M%    020!  "    %    1B2D0 "     S P  "2D@ "     S P  "@ 0 #
M     0 !  "@ @ $     0   >"@ P $     0   /      ,C Q-CHQ,#HR
M." P.#HT,#HP,  R,#$V.C$P.C(X(# X.C0P.C P      8! P #     0 &
M   !&@ %     0   7P!&P %     0   80!*  #     0 "   " 0 $
M 0   8P" @ $     0  #O<         2     $   !(     ?_8_^T #$%D
M;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5
M#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !0 * # 2(  A$! Q$!_]T
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M[1AB4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M.$))300Z      $+    $     $       MP<FEN=$]U='!U=     4
M4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    4 $, 00!-
M %  4@!) $X 5  Q "T 1@!/ $P 3 !/ %< +0!" %<       ]P<FEN=%!R
M;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP
M<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )
M<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/=71P
M=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G
M<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"
M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q 4@            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ !(     0 ! $@    !  $X0DE-!"8       X
M/X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          $X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300        "   X0DE-! (       (
M #A"24T$,        0$ .$))300M       &  $    ".$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      U<
M   &              #P   !X    !$ 4P!0 $D 3@!2 $$ 6@!! %\ ; !O
M &< ;P!? &X 90!W     0                         !
M  '@    \                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    \     !29VAT;&]N9P   >     &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   /      4F=H
M=&QO;F<   '@     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 4 "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M300A      !=     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(               $  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\
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M>W/Z>QY[ZC_D+;5_TL4_ZLS]9(_W9'_3[>>/_%1N/^[EM?5.'\I_CY-[T_\
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M 2B#$3.B_I#GW+?L/S-#[.>UUCR1>V;7V\Q7-U*9(B$@;QYGD05D/B JK!6
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MYD_Y[I?^/=?3U]WG_IQ?LQ_XKMA_U:7K:(_EL?\ ,H?C7_X@7$?^X-'[Q_\
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M\BYID<ZQ2HH/*M;'O[O-CO'NU]Y;:N:ELVCL;.Y>_G\Q!;PQ-#:Q,PQK:0Q
M#\6F9EJ%-.%'WA?<J?GK=>>.=MR@$%SO%QI@@)!,4("1PQ$^9BMXQXA&/$)/
M!AU:;[[.]88=4S?SN>^O]&GQ:Q_4F)KOM]R_('<T6VIX8I(Q4KU_M;[?<6^*
MEHV!<T5:R4&*E*_\[-5/#>X>]Z-]_=O+$>U1/2YOY-'_ #:2C2'[#VH?]/3S
MZZ!_W='MD.;_ 'INN>;ZVU[/RM9FX!(.GZVYU06:UX:TK-<J#_RCD^75$7\L
MOJV;L+Y08W=LM%+5X;I3;M=O^I,<32P#<V1$FVMD4TRZ'$JM7UM35%19@*0-
M]![YU^_',(V;D.?;4D"W>ZSK;C.?"6DDY&10Z51:GCK(ZZ7??%YU3E;V:N]B
M2X6._P"8;M+):FA^G2EQ>,/0Z%CCKP/BE>/1M_YO'0V1QVUND/DW38VJ2'*9
M++]-[RG:&<HM$GW>;Z[R]3IC*4XEKX<G0^21EUI+"BCZ7.O8?D_=-M]EK'G2
MZ>3]W;IO5QX*T!1(4584E0C-)YXI:UQ14*CNKU!/W#O<ZTN=Z]Q_9R6\C,D,
M46ZVBU7XSIBOHES5J(;>;2H-"LA/01?RB^[:GKWO/</6LM3(M'V+C*;=VVJ4
MR.J/OOKN.2HK,? &)1)]S[(J*N"RKJDDI%O[+/=>:^Y8FY)]U]FC8[KRWN4<
MC!31GMI'76A;)TE@8C4$!9VQQZ'GW[?;J+FGVWVGG!809]IF:UN&\Q9WQ"JY
M\RMO=K&^2 HD-./6XC05U-DZ&CR-'():2OI8*RFE7Z205,2S1.+\^I'!]]6M
MDWBPYAV;:M^VJ<2[9>VT<\3C@T<J!T;\U8'K@?=6TMG<W%I.FF>)V1AZ,I((
M_:.I?LTZ8Z07:'9>S>G.O=W]H]@Y>+![-V/@Z[<&?R4JM(T5'11E_#34\8::
MLKZV8K!301AI)YY$C0%F ]H=SW&SVBPN]SOY0EG"A9C\AY >9/  9)( R>A-
MR;RAO_/W-6P\F<K6#7._[E<I!#&*"KN:59CA$05>1V(5$5F8@ GK0^^5/R2W
M?\INZ][=X;[,N.&9E6BVQMMZ@U=-L38.)>H_NSM"C>/4D]10PSR5%=+& *S+
M5=3*BJCQHN#W,N_WW->^W>[7%?$E.F..N(XP:)&#P%*DNW N6.!0#Z8O9/VC
MV'V6]N^7?;CEH"7Z92]S< :6O+V4#ZBZ<'X0Y54A5C6*UBA1B65F-XO\N/XG
M9'J#8,.Z-PX1X>[.[J3&2U]#51D5VR]BR,N0VQLB2RLU'7UVI,KFB!Z)&BA;
MBG/O!WW"WS=?=OGS:.1.3$-S90W7@6RK73<W;562<D _I1@,B.<+$DDIH">N
M;WWMO?&TY\YHEV3:MP!]N^77D".I[+N\'9<7@X!D3-M9@\5#R#,HZV#ME[4H
M]F[>HL)26=XE\U;4V]5972@&HJ&)YL2 J#^RBJ!]/?8/V@]LMI]I.1-HY/VR
MCRQKKN)O.>Y<#Q93PP2 J"@"QJB@ "G7+/F'>I]_W6YW&;",:(O\"#X5_P I
M]22>E7[D[HDZH3_GN]])MKJ+K?XZXBM*Y;M3<B[VW=3PR$,NQ^O*JFJ\52U:
M^,@1YC?DU#/%ZEUC$S*;K<>X+]\=]6VVC;^7XW_4NI/$D'_"XB"H/^FE*D>O
MAGKIS_=H>V)WCGOFWW7O[:MCLEI]):L0#_CE\K+(RYXQ68F1L&AN8S@T/56/
M\J/JRIW7WEO+M:HH9YL5T_LJ7'XV=:>=X_[Y]BF7$4X21%:"62@VS2UKR(3K
MC\R/;F_OG+]X?F)-NY2VSEY)U6XW.[#.*@?HVU)"?4!I2@!X'21UFG]]_G6'
M8_;?E_D>*Y5;W?MQ#R D _26%)6J"=0#W#1!3P;0P\J=#A_.!^,\NS9NE_DY
MCZ6N3_2CBVV!V"LFDT5%N/ 8LY7KZK1$HHY::KSNTJ7(1U)GE<%\?$L84DWF
M?VZ]NKSD[V2]NM[N7E,N["6Y=6(*PBY/C6R1T12JO /$8.7(D+ &A $;_<)]
MX8]_C]P?9VYFB/[EE^ML:5#O;S2>%?(27(98;IH&CT(#IG<L304Q?R9^^7VA
MOW?'3^1JM,%2]-VUM"*27AI:!:;;?9&(I8O&X#UFWZBFK;*1ZZ9G/]?<?\[[
MI/[<\]^V7O+9CLVV^6TO: =UI,6#$G.?#>=%QAF2AQU?^\%]L1OO+?+7/UI!
M^H@;;+H@>3EKBPE8U'P3"2+/DX ZVS(I(YHXYHF5XI422-U-U>-U#(RD<%64
MW'OK#;W$-W;P75M('MY45U89#*P!4@^8(((ZX=.C1NR.*.I((]"./7/V]U7K
MWOW7NO>_=>Z][]U[K__5W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]UPD1)4>.10\
M<B,CHPNK(X*LI'Y# V]^X9'6F4,"K"JD=4X?,KX\9_8-3D=_;/H:G+;&RE1-
M4Y"&DI_)/M&IE#2R0U45-'?^ R/J,-1IM#<12_1'<<\O[A%=>':3,%G'"OXO
M]GY>?$>?6,ON/R-=;-/-O.V1-)M4C5(45,)/D0!_9_PMY?"WD6ID[!W/X5F)
MD"!;VN1<<$C@\D^Y8VNSULM!_P 5Y]8Y[S?B)':N1PZV$OY5&_<OOWX:[+ES
M$[U3[3W5O_8^-J'N2<%MS=-?%A:17))>/%8^=*-2;$+3@?BYBCW&L([#FFY6
M, "6**0C^DZ M^T]WY]9=?=\WJXWKVTVY[ARQMKFXMU/]"*5@B_8BD(/DO1"
M?^%(?R.JNI?@7FNJ-H96?'=@]YY2AP=75XRH^VS.$Z@Q>6Q)[5R5)51.E90K
MGL;7P8!Y(M+FGRT]CZ&!.?:KEY]TWJ;=Y8@UC8*&-1@R,:1CT.DUD_V@]>C;
MW'YKV#;=TY-Y1W *V\;O<R?3J:=IMX7E+&N1J8+&I R6H32H/SS52."-(XXX
MX(H45(H8D6***.)="1QQJ D4<:"P L%46^GO)"I-34_ZN/0?J2?F?\O^7J]?
M^65M#(3]F_"S;=/'-!D,SW+UYG+%6$\*9/?<&;:0H#K BQM/Y">"$&H\>][_
M "+:\F[[))\ L9CG^DI _F1^=.L"]YO#S-]ZNV2VEJ%WZRMD*FH_Q41JY%./
M<'!I@4.>OHV>\&^NM?7O?NO=>]^Z]T@NQ^K>N>X-KUNRNTMD;8W_ +4R _RG
M!;KPU#F<>9 "$J(8:V&7[:KBO>.:(I+&>58'V1\P<M[+S38-MN^6*S6]:J:E
M7C8<'BD4J\;CR9&4TJ":$@B;E+G/FSD/>;?F'DSF.\VO>XOAFMI7B>GFI*$:
ME/FC55N!!ZH;^7_\D384>W-R=B_%3<==LO+X3'Y+.574^[*ZLS>S<Y2T4,M;
M44.V\]5-4Y[:F1%/$PIEE:MHY'TQLL*DR+CWO?L9NFW_ %%SLG,0NMO52?"N
MD G0"I[+B(!90!0:9H3(QSXXX'IG[#?WC',[;MM'*?O9M4>X6%S+'"NY6R+#
M=PLY"*]Q"NF&Y3409"HAE458&0C0=:W"[JS&T<IMS?FU,C48O<.T\MB-W[9R
MU-))!54&4Q-5#D*&HC=&25 X71(MQKC=D-U8@P:UO;[A#-97 U6T\91OL88(
M/$.IHRD4*L 5((!ZZ];ELEAOUGNW+.^6JS[3?6\MK<1L 5>.561U(-1\P:&C
M ,,@$;^O0'95;O[:])_%V#9-,)M[-(_^['H<]BX*Y8I& 42/15$C1!OU,@4M
M=KLTB?<[]X]YY_V#F'DKFS<6N^8]AE"I<./U9[1GD2)I2  \D1C,;2?$ZZ&D
MK(6=_EZ]S^4;?EC>9_H!_B1N9XOD'AD9"1Z!U :G &M,4 )5_.@_[=_=F?\
MA\](_P#OXME>Y]]X_P#E0MR_YKVW_:1'UD3_ '>__B4?)W_2NW?_ +M5WUJ4
M='=4Y#O3MS9?4&)SF/VUDM[U&6IZ3/Y:CJLCC<8V(PM;FY7JJ*ADBJYQ/%0F
M-=!!5F!/'O"#FOF&'E+EO=>9;BT>>"U5"8T8*S:W5!1FP*:JYXTIUW.]R.>+
M7VUY$Y@Y\OMMEO+3;EB9H(V5'D$LR1=KN"JZ2X8U&0*#/5G.)_DS]KY,1U [
MIV_/C7E,;UNW^L-X962R&THA,U?!223Q?ZEI  1S;W&VV^[7,._V W+EOV;Y
M@O[,EE$D*/+"64T9?$AA<$J<, 25X$=8;7W]X)R39:X3[?72W@6H2?<+6(9X
M5HA8 ^H7[.CO] ?RE>NNM<WC]S9G;6].Z=X8RKAJL17=CXN@V_L;"UL15X,E
M2;(O'B\C64DJ>2-\A/6)$X#+&6 ]EMY8_>=]RE?:-@]KMQVC;)NUSX36SLK8
M(:[O#!I33\?@A6(Q4DA3CC[H_?EYMYPVZZV?;]XV_E[89D*R)82O/>2H<&-K
MO,D:,#I98$B++4%Z=7.=9]/G;%:-R;FJ8<EN'UM2PPEI:3&/,A2:?SRJKUF0
M=&9?)I18T8JJ\ECEA]V[[I<7M;N%OSOSS=V]YSG&A%O#""UM9:UTLZNP5I[@
MJ63Q=$:1HS+&I),C<^^;^?!O%L=HVB%H=JQJ)PT@!J!I%="5H=-26(!)\@.W
MO-OJ->M!7YJ?]E;?*'_Q-O9/_NZJ?>"?-W_*W<R?\]TO_'NOI]^[S_TXOV8_
M\5VP_P"K2];1'\MC_F4/QK_\0+B/_<&C]X__ ':?_$O>8?\ FCNW_'K?KB_]
M[G_E?/>#_P 6>7_C[=6Q>^MG6$77SQ_D'_S.#OC_ ,2?VK_[U>>]X#[K_P K
M#N?_ #W2_P#5UNOJN]K/^5#]L_\ I2[;_P!HT/6Y=\()F&V>NZ7TM%/T-L:6
M0,+DM!@]HH@%_P"SIJ7N/SQ[A[[E5W-']X#W&L0%\";;+]V%,ZHMRM52GH*2
MO44SCTZ^??[Q<:G=^;)LB1>9[P#_ &TUR3_QT=:]_P#-B^$0^,'< [-V'B&I
M^D.ZLYD:S%0T<4G\.V'V#40-E,[L>3TF.DQ^X/'5Y3#J&T"-:JE5$2EA$F3W
MNIR7_5G=_P!YV$1&RWCDJ ,12GN:/Y!NYXQPH&4 :5KU1^X]]XT^\O(?]3N9
MK\/[D<O6T:2%R/$O;%3X<-X/-I(*QV]T:5+&&9F9II"A0JOY0[QSGQ I?BGG
M\C7UF(VCVEMW>6Q:QDAJ85V?38K/4]=L[)S2JU3"VV<O6Q38N2-E!HI7IF],
M,8]P;:;;N6U<Q;O>[9N)CY=W6/Q+ZTH/#>_B,:P7J5!*R/"&BGT$:RJ,^K&F
M=[?V7V#;??J7WMVFTBCOK_99[2\7(/U;2PLEU& =)$\2LEPI!I,JS#+OT8C^
M4_\ ]E-[T_\ $#[I_P#>HVM_O7N)?O%FO(>V?]+>+_JU+U%'WX?^G.<O_P#B
MS6__ &CW'6XSUO\ \>%M+_M1T/\ UJ'OI-]WW_IR7M=_TIK;_C@ZX%<V_P#*
MS;Y_STO_ (>J%?\ A0'_ ,>=\8/_  ^]^_\ O'I]/\?8?]^L6G+)'^_Y?^K8
MZZ;?W7.>8/>0?](RR_[2CU2]\-_C'A?E1O;?6T,YO;-;$I]G;)Q^[8<CA,10
M9F>OFKMQQ8%J"HI\E-!%%!#'+Y0ZG46X/'O";W0Y^N?;W:=IW&UVJ*[:YNFB
M*R.R!0L9D+ K4GA0@CAGCUT)^\![R[A[*<N<L[[MO+MON4NX;C):F.:62(1A
M+<S:PT88DD]M#@#/V#G\SOY:^_/BGL#;/;.W\MN3L+K2NJEQF\,[E<1AL55;
M,K<G/2Q[6R4U/AZ^L\^V]PR5(I3.ZHU-6&-7LLJ^Q?RE'[D[KM%QOG.'MU+M
M.SM%#+;W"S1S03Q2@:?AD:2-LJ5UHJLK4J'P8V^[W][WEOWNYHW?D;=+&TVK
MG&.,R6D,<LLBW21AC<Q@RHE+B +X@120\6HK4H>F/^6_\C\=TOV[4]=;QFIJ
M/K[O&LPF!J\\\5+#4;8WU2S&GVK65>2D5)O[M[@\[8^J@DD-/!5205(4$2-[
MC;WGY(_K3L=GO5M'(^X;2QD:-"2TUH2#<B)/A^HC0&2(G+4:-C0CHQ^]U[1W
M?N%R)#S9L,;R<T\N)-,L/<1<6C+6Y58Q4>/#I$\;A=;QB6*I!0=;F/7VV]L;
M>V_3?W8C+4^01*FHKYR'KZV< HYKGL"DT#ZD,("K"P*A18^^@WL#R5[8<I^W
MFS7WM:!-LNZ01W+7;'5/=%E^.=J JR$LG@@*L#!HPBD$=?/SS1NN\;GNDPWA
MJ2Q$JJ+A$''L'F&%"&R7%"2>ES[F[H.=:77\W+OO_3=\R]XXC&UZUNT.CZ&#
MJ3;BPSQST1S5%*N5[&R4!0D1U-3NJH7&5 _(P<1_'O#KW7WT[US?=Q125M+(
M"!,X+ ZI2/F9#H/_ #3'7T)_<4]LC[<?=^V&^N[0Q[]S)*=SG)%'\%AX=A&:
M_A6V4W"?.[?JN/;O9&ZMDMD$V?OS=NS7R+P?Q8;3W#FMOC)O1+*E,,@V(GIQ
M7&C$SB,2%A'K:W)/N*K[9=MW40'<]IMKKPZZ/%CCDT!J5TZP2M:"M*5H*]99
M[KREL7,GTK;_ ,LV&X"(-X7U,$4_AAJ:O#\4-HU4&JE-5!6M.GO</>7:6[=O
MG:.[NX^S]V;2>:DJ3M3<^^MVY_;)J*"4ST%3_ <G75.,^XH)R7A?Q:HW)*D$
MGV;6[7EMML&R6LCQ;)$ ([=&TP( 25"1*1&M#4C2HH:GCGHNVGVVY*V'=!OF
MP\@;-8[Z R_4V]G;0W&EQ1U\:-%DTN,,-5&&"".F_8^^,QUGO;9?9FW&89OK
M_<V&WAC!&3>I.&K(ZJIHC8W:/)8XRT[J/U+*5_-O9+NNUVV_;7NFPW@_Q2\@
M>!OEK! ;[4;2P/D17I7S'RUM_./+G,/)V[#_ '6[I936LE?P^*I56^V.32X]
M"H/$=;YWQF[%PO8W6F'R^!JTK,/5X[%[@V_.DL<HDVQNNACSN% ,1* 40JI*
M72.$^WT_4$"4ON3\Y7>Y>W&Z>W>]2D\P<K7TEJP)[OII'=X#3B%1A-#&",1Q
M)3KYE/>#E3<.4^;]PL=R@,=^DLD$ZD$4N+9S#+QSW:5DKYZZ\".C$>\S.HJZ
MU4/YSWS5_P!*?8"_%GKW)QS]>=5YB'(=EY*BG26'=G:%#Y$@VT)(97C?#]=>
M2]0K -)FV*$#[$&3%WWBYQ_>E]_5C;Y0=OM7K,0?CF'X/]+#Y^LF*=F>V?\
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M2/\ [^+97O/+WC_Y4+<O^:]M_P!I$?4T_P!WO_XE'R=_TKMW_P"[5=]:R?\
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M,;JWCL[>VR]MY#:RMM2HPE/3;IP53D8\O0T68.7Q.19:K!UK51H9$>.-!7U
MD#:E9(+]ZN0>:>9]MCWGD3Z%^:;:)E$%WK$5RGQ!/%1@8I%:OANP:/O8.!4,
MN7_W:_O>\W_=XVC?>5=OV3;]PY=W&[2Y/U*S,UM,L9B=XO"EC&F9!&)E8,3X
M,14BA# '\7OY<N<^).Y-R;FZYR_9^X6W5182')8+>67V#)AAD-N9 Y'"YV!,
M0]'4)EZ02S4I8N5:DG="#Q; #F/VS^]7S)=<L;J_LY;VV[;1>+=6TL5W8Z@Z
ME7$;ZK]AX1=$+*,U&#0GJ3?>?[V>W^^FT[/M'-EALUJ+*28QS6D5Z)?#N(_#
MEA)EUJ8FHLE* B1%8'CU=#1335%'25%132451/302ST<S1O+2S21*\M-(\+R
M0O) Y*DHS*2."1[ZQ;/=W=_M.UWU_M\EI?36\;R0.49X9&0,\3M&SQLT;$HQ
M1F0D$JQ%#USYN(XXKB>**821*Y <5 8 T# $ @$9%0#ZBO4KV8],]>]^Z]U[
MW[KW7__0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0!=T_*7X\_'?'O7]R
M]N[)V*XC66#$9/,T\NY:Y7#F/^';7H35;@KQ(8R T5,R@_4CV>;/RUOV_2"/
M:-JFG_I!3H'VN:*/S/0,YK]Q.2.1X&GYJYFM+.@'8\@\4UK33$M9&K3!"T^?
M6O'\S?YY>:WIC\KUY\3,?D.OL)7I/CZ[N/=HHZ/>U?2R&>GG78FU9?N4VTM5
M R&/)5[G(Q,Q$5)#(J3B>^4/9:*T>'<.:I%FE&1 A)0'C^H_XJ'BB]AIEF!(
MZP;]UOOB7.ZPW>P^UUO);0NI5KV4 3$$D'P(<^'5:4E?]0$FB(0&ZJ<ZQ^(/
MRT[_ ,D]9L/HSM?=;YNMDR5=O#<>$R>W,'7U.4J?N*S,UV]-\G$T>9FJJBH,
M]1-!-63N7UL"3<RCN/-G*NQ1".]WBUB5!I$:,'84'PB./45]!4 #UZQAY?\
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MIIV9HB8G4 %0205!^*F:4X'UQY]<?DIOW([GVW\+_DG+U+WCB]B==?),;V[
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M\KAG;^6I\!6=F=S\./CCJ9F+,3_HCVI]6:Y/MCFT4YIYB X?73?]7&ZMM/\
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M3PTE'3P4M+31)#3TU-%'!3P0QJ%CBAAB58XHHU%@J@ #Z>VB2Q)8U)ZL
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..[KW7O?NO=>]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>stockperformancechart.jpg
<TEXT>
begin 644 stockperformancechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '@ F4# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6O\ Y8T?\(WI?I??^#C6O_EC6]10!@_\(WI?I??^#C6O_EC1_P (WI?I??\
M@XUK_P"6-;U% &#_ ,(WI?I??^#C6O\ Y8T?\(WI?I??^#C6O_EC6]10!@_\
M(WI?I??^#C6O_EC7,ZGI%K!XB\-6D4NHI;7JZX;J%=9UH)/]FL8)8/,']H\^
M4[,R8(P237HE<?K/_(U^$/\ =\1_^FVWH TO^$;TOTOO_!QK7_RQH_X1O2_2
M^_\ !QK7_P L:WJ* ,'_ (1O2_2^_P#!QK7_ ,L:/^$;TOTOO_!QK7_RQK>H
MH P?^$;TOTOO_!QK7_RQH_X1O2_2^_\ !QK7_P L:WJ* ,'_ (1O2_2^_P#!
MQK7_ ,L:/^$;TOTOO_!QK7_RQK>HH P?^$;TOTOO_!QK7_RQH_X1O2_2^_\
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M;73_ #3;"<>;LW^=>7MW]S=MV_;+FX\O[QSY>S=QNW87%^BB@ HHHH ****
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OSN_P""NW_**K_@I/\
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M^"DXW+G_ (80_:R&-PSG_A1GCCC&<Y_KQUH ]4_X)\_\F&?L3_\ 9H_[-?\
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MC_A'/#W_ $ M&_\ !78__&*V:* ,;_A'/#W_ $ M&_\ !78__&*/^$<\/?\
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M-% &-_PCGA[_ * 6C?\ @KL?_C%'_".>'O\ H!:-_P""NQ_^,5LT4 >=^-]
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M7B6V8R0:]\1K_P#X262RE+!_,T?19(H/"WA\K)EXSH6A:>Z' \QMJD>QA54
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MHH **** .0T7_D9_&'_770/_ $SBNOKD-%_Y&?QA_P!== _],XKKZ "BBB@
MHHHH ***Y?Q=XU\*^ ](?7?%VMV6AZ8LL=O'-=NS37EY,2(-/TVR@2:^U74[
ME@5M=-TVVNKZY<%(+=VXH ZBO$OB+\<_"_@9]6TJP5/%'BG1M+N-:UC2+74]
M/TK1_"6C6UO-=W'B'XC>,-4EB\._#_PY:VT+W-QJ&OW4=Y);*\FFZ9J++LKX
MR^-W[7VNW?BR'X/> _#?CS5_B;K%C!?Z3\!/A=_9K_M!:KHU\L/V#Q5\4_$F
MH2GP-^R7\++Q[J R>+OB+JD7C34[031^%M(&MK%ITL_P[_84U3XA_P!E>(/V
MQ;WPIXHT/3]4B\2>&?V2_ATVKM^S1X0UF.<3VVM?$>X\0K%XJ_:F^(L316]Q
M>>,_BW#%X2AU,/=>'/AOI$\<6HR>E2R]1IPQ./JO!X:I%3I+D53&8J#VEA<*
MY0<J<G>V)K3HX5\LU"M4JP]C+R:V:<]6>$RRC]?Q=.7)6DI^SP.#FOBCC,8H
MU(QJQ5KX3#PQ&,3E3E4H4J,_;Q_EL_X+0Z?\3?VB_B5H7[8GA'2O%GQ,_9^L
M/!.A?":7XS>%OA_XDTOX*67B/1_$'BW6&T[X<^(-;5-=\;^ 6&MF$_&*?1]-
M\$>*/%8OM-\.:G=10VD*?+__  2,_9K^+?Q__;?^ 6N_#W0=:;PA\'_BCX-^
M*?Q'\?06MU'X:\*^'O!>JQZ^;&ZUU8C8'7?%4^GIX=T31(9WU&^:_NKIK=--
ML;^ZA_T6Q8V:6:V"6MNMBENMFMFL,0M5M!&(1:BV"" 6PA_="W$8A$8"",*
M*Y#X;Z=I^F>#=%MM-T^PTVV\B646NFV-II]J)'N9P\BVME#!;K(^!O=8@SGE
MRQR:^^PWB75P?#\LBPV4PCR86I@L+BJN,=1TJ%2#@I5Z,<+3C7KQC*3<X3H4
MI3<6Z*BG&7YGBO"2CCN)X<1XO.ZDN?&4<PQN#HX%4HUL52G&I*.'KRQ=26'P
MTYPBN2<,16A!2BJ\I24X=R.@[>W7'M]!T%+117Y>?L04444 %%%% !1110 4
M444 %%%% !1110 4444 %?G=_P %=O\ E%5_P4G_ .S$/VLO_5&>.*_1&OSN
M_P""NW_**K_@I/\ ]F(?M9?^J,\<4 >I_P#!/G_DPS]B?_LT?]FO_P!4MX(K
MZ^KY!_X)\_\ )AG[$_\ V:/^S7_ZI;P17U]0 4444 %<AI'_ "-GBS_KAX;_
M /2*_KKZY#2/^1L\6?\ 7#PW_P"D5_0!U]%%% !1110 4444 %%%% !2'I^*
M_P Q2TAZ?BO\Q0!R/@3_ )%?3O\ ?U'_ -.U_77UR'@3_D5]._W]1_\ 3M?U
MU] !1110 445Y[\4/BQ\-?@IX+UCXB?%GQQX9^'O@G0HU?4_$GBO5K72-,AE
MDW"UL89;EU>^U74)0+;2]'T^.[U;5;R2*RTVRN[N:*%[A3G5G"G2A.I4J24(
M4X1<YSG)VC&$8IRE*3:2BDVV[)7(J5*=&G.K5J0I4J<93J5*DHPITX13<ISG
M)J,8Q2;E*3223;=CT+IUKY?^.W[6OPM^!>JZ5X&G7Q#\3/C;XJM)+KP+^S]\
M)]*'C'XO>+H8Y%B;4E\/PW%M8^$?"-NY8ZE\0O'^J>%/ >DI%*;WQ"DRI;R^
M"GX@?M5?M>8MO@QI?B#]D3]GN].V;XY?$CPO;_\ #1_Q'T>8 &?X,_!CQ/:3
MZ?\ "72+Z%)#8_$/XV6%[XJ,%U!=Z1\(;?\ T;6:^G_@3^S1\(/V==+U>T^&
M_AN9-?\ %=W'JOQ ^(OBC5=2\9?%/XFZ\J%9/$'Q'^(WB.XO_%?B_5)&:5X%
MU/47TW2HY6LM#T[2].2*SC]/ZKA<#KF$W6Q"VR[#5(WA)=,=BH\\*%OM8>@J
MN)TG2K2P-2TSQ_KN-S'W<KIK#X5[YIC*4K3B[:Y?@Y<E3$W7,H8K$.C@_>IU
M\.LPI.4#YA7]G3X\?M6,NK?MG^)(/ ?PGNOWEE^QM\%_%.I#P[JEDS>=!;_M
M&_&;3AH_B'XMW)$GEZE\/?!$7@[X3*\)LM77XC6A%]+][^&_#/A7P%X;TKPQ
MX2T'0?!_A'PUIT6GZ)X>\/:7I^@>'= TFSC(ALM+TK3H+33=+T^UB4[+>U@@
MMX4!.U0":M:_X@T3PKHVI>(O$>J66BZ'H]K)>ZGJFHW"6ME96L0^:6>>0A5!
M)5(U&9)962*%))71&^9H['Q9^TJ\5SKEMJ_@?X %X[BS\/3"XTGQE\8;8.LD
M%WXB ,5]X6^'UVJ)+;Z$A@UOQ+:R>;JCV5A+';/RXK'5\5&%.7)2PU)MT<)0
MC[/#46U9RC3NW.JXI1GB*TJN)JJ,?;5JC29V8/+L/@Y3JQYZ^+K)*OC<3)5<
M772=U&56T53HJ3E.GA:$:6%HRE+V%"FI-'QU^V/;0?&L'XF?#'PMJ&N>&_AM
M$?#'B3XBV[(FE>+'OM8AM+32_"%J8S<>)K/PQJUQ<QW_ (BM"-,ADU*:UM);
MU(Y)H?M?]G3]G/PC\)O!7AB?4O#.B77Q(:PAO_$/B6YL;>\U2VU>]#7-Q8:=
M>W G>QM=+69-+C_L]K<7*68N)M\DK-7L?BG3-.TCP-<:5I=C::=IFGVFFV=C
MI]E;Q6UE9VEO?6,<%M;6L*)##!"BJD<4:*B*  *[L=/Q;^9KC.\7 '^>?SJO
M=6EK>VUQ9WEO!=6EW#-;W5K<11SVUS!.ABGAN+>57AGBEC9DDBE1T=&*LI4D
M&Q11ML)I/1I-;6:OIV/B3Q#_ ,$_OV>9=9OO%OPGL/%_[,'CO4)8Y[SQE^S!
MXNU#X.R:A.AWO/XA\#Z*ES\)O&<L\FV2X;QM\//$1N'7=(Q+.6PSHO\ P4%^
M#@,FB^+?@W^V-X4MEEE.E>/M/?\ 9P^-QAWA(K:W\:>"]/\ %OP;\6:@L>V1
M1?\ P]^%]K<2;UFU*W#+(/O>BO26:XN24,4Z>/II**ACZ:Q$U!))0IXEN.,H
M05E[N'Q-%:'DRR7!1DYX/VV656^;GRZH\-!S;3=2KA$I8'$U'_/BL+7>K\CX
M1C_;\^&W@VXATS]I;X??&#]DK4I)8;,ZM\;?!JO\*I[]\++%9?'KX=:AXZ^#
M"P*_^IDU[QEX=NYHBDK6$6_8OV;X7\7>%?&^AV'B?P9XET#Q=X:U2+S],\0^
M&-9T[7]"U& XQ-8ZOI-S>:?=Q'((D@N9%.>M;<UO!<PS6]Q#%/;W$<D,\$T:
M20SQ3(8Y8IHG#1RQR(S))'(K(ZDJP()%?%_BC]@']G/4-;OO&/PUT7Q/^S9\
M0M0D2:[\>_LQ^+-4^"NJW]P&+O<>(O#?A<K\-_&\LSG=.OCSP-XHBN"#YR.&
M;+YLJQ'Q0Q67U'NZ3CC<*V]+*G4E0Q-"FMW)U\=4M>T&[(7+G6&^&>#S2DM$
MJJEE^,459\TJM*.(PF)JRU2C'#Y=23LW-*]OM:BO@D^&_P#@H#\'<R>&O'WP
M@_; \)VOF2_V%\5M);]GOXTFVC.R*UMOB/\ #K2?$OPF\3WYBP5_M7X3> (;
MB4'[3J\(8RB:#]OSX=>#9X=*_:<^'?Q<_9'U=IHK)M5^-'A-;KX27-\^ RZ;
M\?\ X=WOC7X-?9B2#"WB'Q;X8U"1"K3:7;N3&!Y5B*FN#G0S&-KI8*HZE=V^
M)_4JL*./48_:F\*J:W4VM1K.L+3=L?3Q.52ZO,*2I8=7MRK^T*4ZV6N<_LTU
MC'5;5G!2T/O"N/UG_D:_"'^[XC_]-MO5_P +^+O"OC?0[#Q/X,\2Z!XN\-:I
M$)],\0^&-8T[Q!H>I0-C;-8:OI%S>:?>1-D;7M[B16R,$Y%?G-\6_P#@JS_P
M3W^%?QDT_P"''C?]IWP/IWBOPIJ&OZ/XIM].L/%?B;1_#.K2V5O;G3?$'BCP
MQX?UCPUI=];W(>VU"VGU4RZ5<1RPZJMB\4@7##9=F&-J5*.#P.,Q=:DG*K2P
MV&KUZE.*?*Y5(4H3E!*6C<DDGIN=&+S7+,OI4J^/S' X*A6DHT:V+Q>'PU*K
M*2YHQIU*U2$)R<?>2BVW'6UM3].J*Q/#7B7P[XRT#1_%?A+7-(\3>&?$.G6F
MKZ#XAT#4;35]$UK2K^%;BRU+2M4L)I[*_L;N!TFM[JUFEAEC8,CFMNN1IQ;C
M).,HMJ46FFFG9IIZIIZ-/5,[HRC*,91DI1DE*,HM.,HM74HM7333333LUJ@H
MHHI#/+OB5\)_#WQ)@L+JXGO_  ]XO\/M)<^$/'GAV5;+Q1X6O7P2]C>;62[T
MZY*B/5-"U&.YTG5+<M%=6V_RYHN"\+?%CQ%X1U[3_AQ\=H-.T;Q#J,@M/!_Q
M%TV-[3P'\2'4[8[6)I2R>$_&CH ]UX5U"80WDN^;P_>7D++;Q_1U<_XI\*>'
M/&VA:AX9\5Z/8Z]H.JPF"_TS481-;SID,CCE9(9X) LUM=6\D5U:SHD]M-%,
MBN #H**^4EU/QQ^SD5M_$EQK7Q&^!D3&.U\5LD^K^/\ X66F4$5OXLCC#7?C
M'P79J2(_$EM'+X@T2V0IJ]O?VD27:_3FD:OI>OZ98ZUHFH6>K:3J=M%>:=J6
MGW,5W97MI,H>*XM;F!GBFAD4@JZ,1V.&!  -&BBB@#D-%_Y&?QA_UUT#_P!,
MXKKZY#1?^1G\8?\ 770/_3.*Z^@ HHHH *0D*"20  223@ #J3[ <D] .3Q7
MGGCCXG^&/ CV.GWS7VL^)]960^'O!/AJT;6/%_B Q$^8^G:/"Z-%8P8)O=9U
M*;3]#TY 9+_4K9!D_F=XU_:)^)O[1?BO6_A5\"O"NF?&+Q!HM_+HWB[1M%\4
MWFD?LM?"&]"A7A_:,_:"\/Q3WWQ3\9:9+,CWW[/OP(MM4N8Y[=],\<:KI5C)
M_;$75A<'B,9*2HP3C3BIUJU24:5"A!NRG7KU'&E2BW[L7.:<YM0@I3E&+Y,7
MCL-@8PEB*C4ZLG"A0IPG6Q.(J)7=/#X>E&=:O-1]Z2IPE[."E4J.%.,IKZV^
M-'[7/@/X;>%M>\2V/B+PG8>&?#UPVG>(/BSXVU.72OA-X<U8AUAT*RU*S275
MOB9XYNIE2TTGX=_#BVU?6]5U*6+3)+K3KN1$;Y)\(^!/VFOVJ]9B\76]_P"/
M?V;_ (77D4L1^-GC_0],T_\ :W^(.@WB-;W>G_!7X5ZI!J_A/]CWP%JD3W)M
MO$GBO2]=^.VJ64D,USH'A._:WUD?2OP7_8F\,^$?%&@?%[XX>)YOV@_CSX?M
MS%X8\5^(-"T_P[\-O@] ZK"=%_9U^"^FR7/@_P"$.E0VD<-DVO0'7?B9K4"R
M'Q)X]U43M!']P 8Z?Y_SWKL]O@L K86,,=BUOC:])O"T7L_J>$K17MGVQ&.I
MVM+W,#1JPA7?G_5\?F6N-E/+L$]LOPU9+&5EHU]?QU"35&+VEA<NJO6/OYAB
M*-2>'CXS\$/V?OA'^SKX3D\'?"/P;8^%].OKZ36/$.IM/>ZQXK\:^([GF^\5
M^/O&>MW.H>*?'/BS4'^:^\2>*=6U35I\+']I2".*%/9J**\VK5JUZDZU:I4K
M5:DG*I5JSE4J3D]Y3G)N4F^[;9ZU&A1PU*G0P]*G0H4HJ%*C1A&G2IQ6T80@
ME&,5V22$/3\5_F*Y+P)_R*>B_P#7J_\ Z57%=:>GXK_,5R/@,@^$]%(((-J^
M"""#_I5QT(R#^%9_U_7WHU.OHHHH **** "BBB@ HHHH **** "BBB@ HHKX
M*^,W[0/Q^^$OQ<^']M=^&/A%<_#7XB?'OX9_ SP/\/8=7\5:E\>?B-I?C3^R
MD\:_%_P]=::P\)Z'I/P>L[[Q'XY\7> -2\.:Q/+\+/ASXE\7WWQ!\-ZEJFC>
M&U /O6BOQ=U7_@I[X[\#?"GP?^T;XU\!>!=3^$?[0WP^^-/BS]G+PQX=O?%.
MF>.['7OA_#+J_P ,?#'Q2U[4?[7T6Y@^+_A6&?6]8UWP_P"&="3X3:I"/#<V
MG?$&"8>(XONWX"?&'XGZY\4_C!\ ?C9:> 9_B5\)_"_PA^(R^*/A?:^)-+\&
M^)? ?QH_X6%I>@%=!\6:IK^M:'X@T#Q=\)?'^AZG;OX@U>SU72(/#?B:W;2I
M]:OO#NB@'UK7YW?\%=O^457_  4G_P"S$/VLO_5&>.*_1&OR?_X*[_&WX-#_
M ()I?\%)O!#?%KX8)XR_X8F_:QT >$Y?B#X/B\2G7C\$_&]JNB#0I-:353K,
MEV5M(M*%H=0ENW2TBMGN)$B8 ^HO^"?/_)AG[$__ &:/^S7_ .J6\$5]?5\6
M_P#!/[6]'A_8/_8ICEU;3(Y$_9(_9L5XWU"S5T8?!?P2"KHTX96!'*L >^,$
M5]=_V_H?_09TK_P967_Q^@#7HK(_M_0_^@SI7_@RLO\ X_1_;^A_]!G2O_!E
M9?\ Q^@#7KD-(_Y&SQ9_UP\-_P#I%?UL?V_H?_09TK_P967_ ,?KD]*UO1E\
M4^*9&U;2PDD'AW8QU&S"OLM+X.%;S\,5)&X*3C(SC- 'H=%9']OZ'_T&=*_\
M&5E_\?H_M_0_^@SI7_@RLO\ X_0!KT5D?V_H?_09TK_P967_ ,?H_M_0_P#H
M,Z5_X,K+_P"/T :]%9']OZ'_ -!G2O\ P967_P ?H_M_0_\ H,Z5_P"#*R_^
M/T :]%9']OZ'_P!!G2O_  967_Q^C^W]#_Z#.E?^#*R_^/T :](>GXK_ #%9
M/]OZ'_T&=*_\&5E_\?I#K^A_]!G2NH_YB5EZC_IO0!D>!/\ D5]._P!_4?\
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M^(;SXHQ:3I_CVU\6WEO=:#\/-5\.RR:A>C3;^5X;N*#]P?!'[=G[(WC[5?\
MA'M)^//@/1?%@E\@^!OB'?7?PF^("SA@C0/X"^*=GX.\7+.C':\0T=F4D=0R
MD_0/ANW\ >#M T;PKX3B\)>&?#/AW3K32- \/Z!_8VD:+HNE6,*V]EINDZ98
M-!9Z?8VD"+#;6MK#%##&H5$'.<;QOX5^#_Q-TDZ#\2/#GPX^(.A$NS:+XXTG
MPMXMTEC(NR3=I_B"WU&T.]/E?$0W+\IXXKY+-LURW.,SQV85LNKX26,Q-6M_
MLF+@U%3E=2JT:V'J*K6:LZKIU\-"=1RDHQO8^VR3)<VR+*<NRRAFF&QL,!A*
M.'?UW!U.:<J<(Q<*->AB:;H4$[JBJN'Q=2G34(RG.UST>*>&:*.:&5)89466
M.:-@\,D;J&22.5"8W1E(*LK%6!!!(J4$'D'(]17P+<?L)_LL:1+=7WPAU'QI
M^S=JUU.9S>?LY?&OQE\)])1V(+A_A]I'B*X^%=[&[*K/#J7@.\@9E4F/KE@^
M&O[77@-I)/AM^VQX(^)^G6\2PV7AK]J#X/\ A#6+^6-6.U'^(_P)UWX-:A#.
M(L1M?ZGX+\1S/)B>6&4ATD\_ZI@*O\#,XTWI[N/PM;#2DW;2#PKS"E:[^*K5
MHJR;:2/4^N9E1_WG*)U?[^6XS#XJ"BMW..,665N;JH4:-=O9-L^_:*^!(?VC
M/VKO \J6OQ-_9.T/XC6-M"S7GB?]ECX]^!?&<UR4P?/B^'7QLC^"'B6%G4X_
MLW2=<\5W:R*R1270VR-H:?\ \%'/V6;:_M-$^)OBKQ3^SUXCNI%C_L3]H[X=
M^-O@Q%&[A=H7Q;XNT6V^'MZF\F,SZ9XQOK;>IQ,5:-G7]DX^2O1HK%I)M_4:
MU''.,?YJD,)4K3I+9_O8P:OJD] 6=Y;'3$5Y8%WLO[2H5\NC*6GNTYXVE0IU
M6F[7HSJ1=FTVK-_=+HKJ4=0RL"K*P# A@00000002"""""0002*^9-8^&OBS
MX2:E?^,O@1;PWFA7MW+J?B[X'W-RECX?UF69@][K/P[NI ;?P;XKD >273=J
M^&=?E(6YM["\V7;>T>$OB3\/?'NFIK7@;QUX-\9Z/)&LL>K>%/%.@^(]-DB<
M921+_1M0O;5HV RKB4JPY!-;O_"0:"21_;.DDC@C^TK$D>Q'VCC\:\^490E*
M$XN,XNTHR3C*+[2B[-/R:/4A*-2$9PE&<)J\)P:E"2[QDFU)>:;1R_P[^)GA
M7XG:/-JGANZN%N-.N3IWB#0-5MI-,\2^%M81<SZ-XDT:XQ=:9J$)# +(K6]T
M@%Q8W%S;.DS>@5\]_$7X>Z#XBUB'Q_X#\9:7X ^+&FVHMK/Q7:7-C<:=XAL8
ML-'X;\>Z,MS%%XF\/2LJK&9F75=';%UH]Y!(AAEP=$_:B\&Z/Y_A_P"--UI7
MPM\=:6L2WEE=Z@VH^&/$,#@B/7_!/B*VBEAU;1;ID8O;W(M]7T>8FQU2V654
MFF11[GHO_(S^,/\ KKH'_IG%=?7RMIG[4/[/MOKWB>\F^+/@]+>\?2&MY#>S
MA95M=,$,[*3:X(CDRC8/!!!P< ]!XZ_:4\ ^&-/NWT#4]&\4:G9:"GB;4Y)?
M$6D^&_"'@[P[)!'=#Q+\2?'.N30:%X%T*.UD6X8ZF\FMW*,B:?HMW(X :3DU
M&*;DVDDDVVV[))+5MO1):MBE*,8N4FHQBG*4I-*,8I7;;>B26K;T2U9[SJVK
MZ7H.FWNL:WJ-CI&DZ=;O=:AJ>I74%E865M'R\]U=W+QP01)W>615[ DD"O@?
MX]?MJZ#X+M-$LM%OM2T%O&T[Z?\ #Z#3O"MWXV^.'QCOU#$V/[/GP&ME'B+Q
M3 W[E;CXC^,K;1/ASX?BN%U74Y[G24:\7YJLOB3\9_VQ]4M;WX*ZCX<7P+'=
MM)#^U-\5O#\EO\#=!\J(Q7$W[*_[//B"ZT[Q#\?/$^GW%PRZ7\;?C!)HOPQM
MKNU.J>$['Q;:C^R#]W_ ;]G'X(? *[USQ5I.KW?CWXO>,X88_B+\>?BCXHLO
M&/QB\?\ D2&6"TUKQ5<?9XM(\-6+[1HO@/P=I_AGP#X?B1(M$\,V0#,_J_4J
M&!][-)3]LMLLH2BL3?MC:S4X8%)WYJ+A5QMXN%3#X>,X5SQ?[0Q.8/DRB$/J
M[^+-L3"3PC7? 4%*G4S%M6<:\9T<!RR4Z>*Q,H3P[^4? _[)?QB_: CO=6_:
M2NM7^"?PB\2F&YU7]GGP7XYGUSXS?%>W58D1?VL?VCM#DM-1OM,NHEN!<_ O
MX(WFA?#S38;HZ3JWC'QGIPET]?TS\%>"/!WPW\*Z'X'^'_A;P]X*\&^&;"/3
M/#OA7PKH]AH'A[0].B9G2STK2-+@MK"QMP[O(8[>! \CO+(7E=W;2_M_0_\
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M[\4/@I\16^'W@[3_  I_9VH>!]-U=-7U33]4N=9L[[5[K7;&2>RE@U>UL/\
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M>3'@9L[XG V\9(YQ7:UR&D?\C9XL_P"N'AO_ -(K^@#J/LMM_P ^\'_?F/\
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M.AAZ&%HPP^&HTL/0IIJG2HPC3IP3;;Y812BKR;E)VNY-R=VVR#[-:CK;P?\
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MH A^RVW_ #[P?]^8_P#XFC[+;?\ /O!_WYC_ /B:GHH @^RVW_/O!_WYC_\
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MX4_#SP+\,/"%M)9^%/AWX/\ #?@?PU:S2+-/!H/A71[/0])CN)E2,3W*V-C
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M>>G==_Z_IK[Q:*,Y]?Q!'\Z,@=3BD%UW_K^F@HI,CU'YBC(]1^8HL^W]?TT
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MC@,]PN*J4HPE*C1IXF6(FYOEA"AA_8*MB:LI72HX>%6J[-J'*KGV22%!+$
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M>.*_1'I7Y _\%>/VB_@XG_!.'_@I-\.I/&4<7B\_L8?M8>%AI+:!XN;.O/\
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MIOPV\-#6-5,+*05;Q;X[%[:[P21YEMX)M'  9'5AFO4?^$FT3_G\'_@/>?\
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M_'CQGIHE;1K;4[2TDM?"OPK\ FZS=6/PG^#VB7#>$_ MC(4DU)QKGC758O\
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M%J,/B[QQXET^_P#&>PF'QO\ %?Q3;:WXODP5.S0O[7ECBT=#A0NG>#M(TJU
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MP/?\S_C2T4 <AHV3XF\7@EL"70?XCWT@$]^YYKKL#W_,_P"-<CHO_(S^,/\
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MI/\ ]F(?M9?^J,\<4 >I_P#!/G_DPS]B?_LT?]FO_P!4MX(KZ^KY!_X)\_\
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M[-'@;5-?@BE>UO/B/K%@EOI%EC<#+IMAJLEC80NZC?:W/BF^L[@;3/!X4UJ
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M65E9&[16%_;]O_T#]=_\$6J?_(U']OV__0/UW_P1:I_\C59Z!NT5A?V_;_\
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M^W_Z!^N_^"+5/_D:@#=HK"_M^W_Z!^N_^"+5/_D:C^W[?_H'Z[_X(M4_^1J
M-VBL+^W[?_H'Z[_X(M4_^1J/[?M_^@?KO_@BU3_Y&H W:X_6?^1K\(?[OB/_
M --MO6G_ &_;_P#0/UW_ ,$6J?\ R-7)ZMK<#>)_"D@L-; C7Q!D'1-2#MOT
M^W4;$-N&?&/FV@[?XL#F@#TFBL+^W[?_ *!^N_\ @BU3_P"1J/[?M_\ H'Z[
M_P""+5/_ )&H W:*PO[?M_\ H'Z[_P""+5/_ )&H_M^W_P"@?KO_ ((M4_\
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MPY\*ZQX]L+W04TV/1[FR\5WVF3ZU:2Z='HVD):M;WD?E+I>G 9%E;>7]$T4
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M<EX$_P"13T7_ *]7_P#2JXH ZW ]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:* #
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MIZ+_ ->K_P#I5<4 ==1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?G=_P %=O\ E%5_P4G_ .S$/VLO_5&>.*_1&OSN_P""NW_**K_@I/\ ]F(?
MM9?^J,\<4 >I_P#!/G_DPS]B?_LT?]FO_P!4MX(KZ^KY!_X)\_\ )AG[$_\
MV:/^S7_ZI;P17U]0 4444 %<AI'_ "-GBS_KAX;_ /2*_KKZY#2/^1L\6?\
M7#PW_P"D5_0!U]%%% !1110 4444 %%%% !2'I^*_P Q2TAZ?BO\Q0!R/@3_
M )%?3O\ ?U'_ -.U_77UR'@3_D5]._W]1_\ 3M?UU] !1110 4444 %%%% !
M1110!R/CK_D5M4_W;3_TXV==:.GXM_,UR7CK_D5M4_W;3_TXV==:.GXM_,T
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MZ\OO^"F^A:7=2OI'BK7=#U$26)_97OS"L6JZ9?0PM]JD$\,:7 V>;Y4?K/\
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M_%H^A?\ T)='_#5__!9__I$=^SK_ .+1]"_^A+H _92BOQK_ .&K_P#@L_\
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M'7/^$E&JK9?"3X7?\(>/#PL]#-F9#K?]O'6;H(-/_LAC>_9= !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ%\9(/C'_P *Q_:/DT?PW\//!?Q>O+$>-+CXPZ$_[.]W\&?%_BWQ/=?!Z5]
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MA;KFB_:;/XD^&_C%\6SX(\>> _VA=5U?Q[H#"T\=^'O$FK^ [WQ%\*/AS/\
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MU_'8QL\5GY$3,A]_^"GP)^#_ .SGX!TWX8? _P"'GAGX9^!-)FN;JU\/>%[
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M0 .@ QC& .,=/RR<>F:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/P8A^-GQ3.HZ?K?Q,U&&;3?"TVH6][HWA_2/ ^C:9\-[G4O#1TZ>YT>7P_\
M$GQ;X3\6?%K0=1T^XG&H>%_'?ASS9F^S1QQ 'VE1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
E44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>tecfidera.jpg
<TEXT>
begin 644 tecfidera.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !2 7(# 2(  A$! Q$!_\0
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M.BJO:4XJ75HYW5]=U/Q7JBF>1W:1]L,(.%3/8"NMM/A',]INNM2BCG(SL7D
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>tecfiderachart.jpg
<TEXT>
begin 644 tecfiderachart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MA_3[3P1H'A_1QI/V'4H]7_L>VO/$]SKUX3.OY_?\-2_M&_\ 1:/'O_@TM_\
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M!_ZQS\0:^I?^"EO_ "0WP;_V4S1__47\55\M?\%)_P#E))_P0I_[.M_:@_\
M6.?B#6__ ,%OOB;XH^%G[+7PWUWPHVF+?WOQT\.:3.=4T\:E!]CF\!^/[N0)
M"9H DIFLX=LN\[5WKM.[(^^\+L//%>('"N'I.*J5<SA"#FVHW=&J]6DVEIV9
M\1XDUZ>%X%XEQ%7F]G2RYRER)2E;VU):)M)O7JUZGYCT5^4O_#8OQH_Y[^#_
M /PE(_\ Y84?\-B_&C_GOX/_ /"4C_\ EA7^@O\ JOFG_4+_ .#I?_*O7^GI
M_"?^M.5]L5_X)AY?]/?-_=YGZM45^4O_  V+\:/^>_@__P )2/\ ^6%'_#8O
MQH_Y[^#_ /PE(_\ Y84?ZKYI_P!0O_@Z7_RKU_IZ'^M.5]L5_P""8>7_ $]\
MW]WF?JU17Y2_\-B_&C_GOX/_ /"4C_\ EA1_PV+\:/\ GOX/_P#"4C_^6%'^
MJ^:?]0O_ (.E_P#*O7^GH?ZTY7VQ7_@F'E_T]\W]WF?JU7[P_P#!.+_DW9O^
MR@^,?_0M+K^,3_AL7XT?\]_!_P#X2D?_ ,L*_K%_X(M_$/Q'\3?V-I/$OBEM
M/;4_^%P?$C3LZ98C3[;[-9-H/D#[.)I_W@\U][^9\_&0,5^)^/F28W+^ EB,
M1['V?]MY=3_=U)2ES3I8QK1PCI[KN[]N^GZ_X'YW@LPXW]AAU7519+F$_P!Y
M3C&/+&O@;ZJ<G>[LE:W6Z/UL;H?H?Y5_.E^VW_R=#\5/^OSPU_ZAGAROZ+6Z
M'Z'^5?S,_MX_$[X<Z#^UC\7=(UOQWX2TC5+.]\++=Z=J.N65I>VQF\#>&+B(
M3V\L@DC,D,L<J!@-T;HXX8&OQGP#IU*G%V9QIPG4DN',2VH1E-I?VGE*O:*;
MM=I7[L_7O&^I3I\,9;*I.%.+S[#Q3G*,$V\OS)I)R:3;2>GD>'J2I##&5(89
M56&5((RK JPR!E6#*PRK*RD@^W^(_C7-KGASPCX6LO!GAKP_HN@:II.OZSI>
MEMJHTK7M8T;7O$VL6BVFGW>HWEMX:T>5/%.J0W>FZ/%$\TEY*IN3I=GH^F:?
M\B_\+E^$G_13? O_ (4FG_\ QRC_ (7+\)/^BF^!?_"DT_\ ^.5_5>)R;ZY/
M#U,3@<15EA:CJT+PQ$8PJ.+@IN$'&$Y14N:FZD9.E4Y:E/EJ1C)?S/A\W6%C
M7AA\;0IQQ--4JUIX>4IT^>,W!3ES3A&;4545.4?:P;IU.:G)Q?TUHWQ/O=,\
M9^+/&EUIDE]?^+[G6KN^%AXI\5^$K^RDUW6#K%XNFZ]X7U/3]3C@D9FT^YMK
MO[9;7NG'8\4-W';WD';)^T9XCFUK2O$FK^'=&U37?#&OZEXB\&W4.K>*=#L?
M#UUJ$=A"EE<Z/I&KQ6GB;2]-@TK3K6P@UN1[V2PM1IFJZCJ>FRRVI^+_ /A<
MOPD_Z*;X%_\ "DT__P".4?\ "Y?A)_T4WP+_ .%)I_\ \<KEK<,X3$2YZV5U
MIS5%8>,DL9!PH>R]@Z-+DG'V5.I1?LJT:?*J].3IUO:0?*=-+B+$4(\E+,Z,
M(NM]8<>;"24ZWM8UHU:G/&7M)PJJ-2E*IS.C4M.BZ<[2/H30_&J^'-9TO7=(
M\/Z=:ZEI_AC7M"N)_MNI2?VCJVOZ3K^C7'BUXY96CT[5;:TUT&ST_2TMM(@F
MTVTECMT:6Y9^$50JJH& BJ@ [!0%'Z 5YM_PN7X2?]%-\"_^%)I__P <H_X7
M+\)/^BF^!?\ PI-/_P#CE>A3RZK3G*I#"8GGG"%.4Y0KSE*G3G6J4X7GS/EA
M/$57!+2*J<JM%12X9YA1J0C3EB\.X0G.I&"J4(14ZD*-.<DH<OO3A1HJ3=W)
MP4G>4I2E[5X2_P"1M\)_]C5X9_\ 3[I]?U;CI^+?S-?R ^#OC#\)YO&/@^&+
MXE>")99O%WA6&**/Q%I[R2RS>(=-CBC11+EGDD=411DLS!0,D5_7\.GXM_,U
M_-7TA*56EB>%O:TZE/FHYPX\\)0NE+++VYDKVTO;NNY_0?@35I5:/$OLZE.I
M:IE5^2<9VO''VORMVO9VOO9GSQ^UI_R;;\9_^Q#UG_T&*OYL&ZGZG^=?TG_M
M:?\ )MOQG_[$/6?_ $&*OYL&ZGZG^=>[X"?\D[G'_8ZE_P"H."/&\;?^2@RK
M_L4+_P!3,2>T_ 3PKX*\8>/[+1_&]Q ;25(O[+TB[UO_ (1FQ\0:F]U#&^F7
M7B$V-\M@8=--[J5M;'["VJSV:V2:G9Y83:VG^%O!VCZA\1+;Q9\/M=33/ VG
M-K-Q<ZEX[EM]?C.NPZ;9>"?#T+^&K63PKK,FLZSJEM=VOB.S4V.H^&%NM:AM
MRJ00MYKX#^(/B7X<:VNN^&KBU69ECBO=/U*QM-4TC5;>&47$%OJ6G7L4T$Z6
M]TL=U;3((KNTN8UEM;B$M()*FH>./%.JVWB.VU/5I+]?%M]H&H^();FWLS/?
MW/AB*\AT()+%;Q"QM-.AOIX+;3M/2UTZ*W6UMX[5(+*TCA_5L1@,SK9EBZD<
M2X9?7PV I4X0Q^-H5J52GBXO&3HPPRHTZ3E@Y5^64Y5IU<2\/SU%0A[&C^:8
M?&Y=1P&%IRP\9XZCB,=4G*>"P=:C5IU,+_LD*T\1[6I54<7&BFHJC"EAU7Y(
M.O/VM7V'P!\./!OQ#\*W5OIT,NG^);*V\-V[ZO)XUT_4=9FU_5/&'A_P_J]S
M/\,K>P2>Q^'.FZ?KLEVWB5]1^VV,ME!-J%S,E\;.WYSQYX4\&P^'-:\0^$-/
MUC1(_"?Q0OOAIJ%IK>MC69=<@_LW5=0TCQ&'.GZ>-)U20^']3AUO1[=9]-M_
MM6FO8M%LG$_+-\4/&9T9M$74+&"-]'L_#LVK6N@Z':>*KGP[I\EM)8Z#=>+;
M;3XO$4^DVS65DB6SZ@7>WLK.TFFEM+:*!;.I?%GQMK%[I]_J5WHMU+I]_J^L
M>0_A/PPNG:EKVO:>VEZQXCU_2XM*CT_Q!XCO[,JDNMZO;W5]'+'%<VTD%PID
M;*G@<\AC9XAXFG*A]9JUJ6'EF&,G&G"5*DG1FJF'E&K#$3A.,8.,:67\[KX6
ME.3=%:3QF3SPD*'U>HJZP].E5Q"P.$A*<U4J-58.GB%*E.A&<).2E.IC^3V.
M)JQBE4?1VOAGP-J?PX\2^(+;1_$NE2^&M$T-+;QOJVM0KIWBGXC7M_IRZEX#
MTWPPM@;5[6+2KK4]0M+S3M5GU?2['15UGQ&L%OJT&GQ>)UZ#J_Q,\2:YX;TC
MPKJ=IX3N-+T#18M T.0>#/#L&JZ3IL<J3N+#5X+*.]MKV\G3[1JFJ(XU'5KA
MY9M2N;F20L//J]3+J.+HQQ3Q<W*57%U*E&'UBKBE3H\E.$$JM:%.2=1PE6E2
MIPIT*$JLJ5&FH04I^;CJN&JO#+#025/"TZ=:?U>EAG4K*52<I.G2G.,E",X4
M8U:DYUZT::JUIN<W&/ZG?\$O?^1F^,/_ & ?!7_IS\25^Q5?CK_P2]_Y&;XP
M_P#8!\%?^G/Q)7[%5_'_ (Q?\E_G/_7K*O\ U48 _JSPH_Y(;*?^OV9_^K/%
MA1117Y@?HP4444 %%%% !114<PD,4HBD6*3RW\N1X_-6-RC!':/?'YBHV&*>
M8F\ KO7.X #MZ;MNY=W]W<-WY9S3J_(GXC_'GP1X.^*5KX9G^)7[8?B3Q1I_
MQ0N?A[XT\>^&?%7PTT'X?^!+72KOX#:%X@\;2?#O56L/#7B/P;X<\>?M(_"3
MP#=:;IGPZ\4^+[C4M2\3W5G8:[I/A+5]<D_6?2X+RUTS3[;4;\ZI?VUG;6][
MJ9M8;$ZA=P0I%<WK6=L3;VC74R/.UO;GR(3(8X0(U4  _$O_ (*6-*O_  4@
M_P""%1AC663_ (:O_:< 1Y/*7:W['OC]78OLD(V1EGP$)<KL&"P8<?\ \%^)
M]3E_9%^%JWNG0V<8_:%\,E7COUNV9Q\._B,%4HMK!@,"YW;S@I@@[@1VG_!2
M?_E))_P0I_[.M_:@_P#6.?B#7._\' O_ ":#\+/^SA_"_P#ZKGXDU^E>#W_)
MSN#/^QQ3_P#3-8_._%G_ )-QQ;_V*W_ZD4#^0BBBBO\ 3X_S;"BBB@ HHHH
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M^&H]7_;E^)FK>(]#\:^ ]1O/C)\"X;"X\ _\$WOB1\5/#GQ9\,_#N+X?^)?
M_B?QM^TK=_#O6=&FU+PQXW^WPWOB;3-2TGPG\+VT'PKJ4EQ>:KX1M_$D/[AC
MI^)[8[G_ #GOU[U^"/Q)\/Z+XA_:ZO=4L/#)N]9\=_'7X _$OP_^TOKW[+7[
M:LO[07P8\,Z;IWPPNY?@IX!\1V'[,.H_#&T\!^(++2+[1]4U'4/C5X"\&^#;
M'XE>/['XM?#SQ)KFD^*6UO\ >Y>!^?X<G@<#@= <<C!H _$'_@I/_P I)/\
M@A3_ -G6_M0?^L<_$&N=_P"#@7_DT'X6?]G#^%__ %7/Q)KHO^"D_P#RDD_X
M(4_]G6_M0?\ K'/Q!KG?^#@7_DT'X6?]G#^%_P#U7/Q)K]*\'O\ DYW!G_8X
MI_\ IFL?G?BS_P FXXM_[%;_ /4B@?R$4445_I\?YMA1110 4444 %?V9_\
M!!K_ ),7D_[+?\4__0O#M?QF5_9G_P $&O\ DQ>3_LM_Q3_]"\.U_/OTE_\
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M5-0F.;&X&(K'1)K?6;V3GY+32IX=2N7Q!82QW<D+KLTC?=;Z'H<'IZ]OKVH
M_G4\$? _6?!?Q>^'&GZA<^)KJXTSQG\--3EFT3]C#_@M/+X>:+4+WPYX@@1O
M'6O_ +6OBOX7:.\5K?PPZ[>^-;76O#?@_5(]3L/B'I,PT/Q%I"_T5C^I]1W/
MK_\ J/4<8K^>GQS)\))/^"@?Q+7QS;?L3MXRC_:*^%*^')OVBO#?Q.^*'[03
MQ?\ ",?"U-(?X8^+-":T\&^ ]%CU..6'X;>!5%^G@_Q5%JGB/Q%=&Y\536%E
M_0L.G;J>GU/Z^OJ<T ?B#_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-<[_P ' O\
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M^L^BO_R2/$/_ &4<O_59EY\M])G_ )*S(?\ LGU_ZL<8-HHHK^H3^;0HHHH
M**** /Z./^#=O_DH7[4W_8E_"/\ ]2'Q_7]4%?RO_P#!NW_R4+]J;_L2_A'_
M .I#X_K^J"O\XOI"_P#)UN(?^O&1_P#JARP_T&\!?^37Y!_V$9W_ .KO, HH
MHK\4/V(**** "BBB@ I"< GT!/Y4M5+^.XELKR*UFEM[F2UN([>XA-L)H)WA
MD6&:(WEO=VGF12E'C^TVMS;[U7S[>:+?$X!^=^M_MI>)'_:,\6_!K0;C]D#P
MUIO@;XD^#_A[JVG_ !E_:^_X0/XYZ\?$.C^$]=FUWPG\%O#_ ,+/&<$MIJD'
MB>73/A]IVN>-M*U/QGJVD72W<'AVVN863]&QSZ=3T.>AQ^?J.QXK\=;?X2^.
MK/XBZ/KWBWQ[^V;XT\=:;XET36[S2=4_8_\ V#=4M?$\NCW^G3BVO?C+X<_9
MVT[PS96VI0V<5JVMVOQ.\,:YI]G_ *387>AZA:V[VGZ^:7<7=WIMA=7]@VE7
MUS9VUQ>:8]S;WCZ==30I)/8O=VA:UNGM)6:![BV9[>9HS)#))&RNP!^)W_!2
M?_E))_P0I_[.M_:@_P#6.?B#7._\' O_ ":#\+/^SA_"_P#ZKGXDUO?\%+8V
ME_X*0?\ !"I%ED@8_M7_ +3K"2+R]XV?L>^/W('FQRH5<*4<,ARC, 58AAR'
M_!?BPFM?V1/A:\FIZA>@_M"^&E$=XUFT:EOAW\1B'7[/96S[EVD+ERH#ME22
M"OZ5X._\G.X,_P"QQ#_TQ6/SOQ9_Y-QQ;_V*W_ZD4#^7+X$W!M/B_P" KI=!
M\.^*9+76+FX@\.>*?$'ASPKI&M746BZJ;*Q7Q#XQL]1\(Z7KAO#!/X1E\4Z?
M?^'9_&,&@6FLV-W87$]O+^KO[0FE?%'3?VI?%>O^!-=\>^)]3U/PO81?$+PQ
M\+M,_9YT/]L#P3X>MO&.I0Z%9Z?JD5KK-OKUIKM]96>IWWBI-*M/&D/P_O?#
MV@?$'2]+\,G1FO?Q'=$D1XY%5XY%9'1U#HZ."KHZ,"KHZDJRL"K*2"""14MW
M))?W$UW?N]]=7$S7%Q=7KM>7-Q<.H1[B>XN3+--<.@"//*[2L@",Y4 #_1/.
M>&I9KFN'S)8C"4U2RS%9;4H8K+GCHUX8C$4*Z<G+&4%2C3E2=2+PT*&(=>%&
M57$U:%/ZL_X"RCB)97EM?+W0Q<W5S+#9C3K8;'K!2HSH4*U%I*.$JRJRJ*HH
M26(G6PZHRK1I8:E7J?65^AGBKX?_ !5UK]MGQ[KG[/GA+P'X@O-7^,OC#PUX
M'U33K#P?_P *X\,>+[_X>CQ;J[JE[J5YX1TKQ/\ ##0=2U#Q)JVMVJZIX7T?
MQQH6IZUX8@U,6VD:4WT6TOCZ7Q!XL\ :58?&32_CKI'P4^%NF)^T_HGPHT*3
MXK_$B7P[\5/%]_XMU32O 7C/6O OC2]\!>(8O$7AGX<V?Q(+OXO?P_\ #+0-
M0^+MEI7@SQ%J5II/XVM=W+Z;%H[3R-I,-])J<.FDC[#'J$MK;V4EZEOCRQ<M
M9VEM:B4@LD$*11[%W!J;0PL,-!"PR6VM#&R[B"I;:5(W%25)QDJ2I."17%B>
M$:^+IX*E6Q^!:R_+L#@:%264*MB*L\#5ISIU\94GCE'$X>2IW>5U*3P$JM:O
M5Q5/&/ZLL+V8?BNCA9XRI1P.-3Q^/QF-K4XYK[*A2AC:4H3H82G#!.6&KQE-
MVS.%3Z_&E2H4\-4PB^LO%?MSX4M?V;X_VFOV@KKX;?$;X.Z1J'Q$G_:(\*7.
MBZY9ZV;+P?X$TO\ 9K\22^)+GP/<^%/ .O?#ZY/CWXQ'6=<U35_#&KVMOHG@
M;P6-%\#V=ZWB^.QD^*_@#X3^*OA#X>?%]/A=87MI^T9XC\&? [Q?\&+K1#HL
MWB[Q%\%M6\6^*H?'GB/X:C56,X36;[3? DVN0K;6/B4^ 8=>&JZ;::"?$$1^
M'=J[0FU=@QA,#:-N-N%Q@;<#;@?+@8Q@4QHHF!#11,&<R,&C1@TA&#(P*D&0
M@X+D%B."<5>'X/GA:-:A'-JF,A7PW#^'JK-,)3QBJ+A_$SKTHU8TJN#]MA\7
M3=/"8NA5<IU</"HYUYU\15K$U^+(8BM1KO*J6$G0Q&?5Z;RW%U,(Z;SW#TZ-
M65)U:6+='$86I&IBL+7I\L:5>5-0H0HT*=)?0/[4R^#D_:(^+B^ O["'AH>*
MHRB^%39'PJGB%M"T5O'<?A<Z;_Q+#X;C^()\51Z)_9>=)&FK;C2?^):+2OZM
MO^"#7_)B\G_9;_BG_P"A>':_C+             &  !@  #  X X%?V1?\$)
MK":Z_8:=H]3U&R4?&_XJ?N[1K-4))\-C+?:+&Y<GY<@;PH+,0/FP/RCZ1.&^
MI>%&!P7M9U_JF;Y#A77J:U*WU?!8RC[:HVW>I5Y.>;N[SD]3]/\  +$_7/%#
M&XOV4*'UK*LZQ/L:?\.C[?'8*K[*GHOW=/GY(*RM&*/VV;H?H?Y5_"3_ ,%=
M?^4BG[2/_83^'W_JIO =?W,-HUS@_P#%0:YT/_+73/3_ +!-?PP_\%;HFA_X
M*'_M'QO/-<,NJ> 29I_*\U]WPI\"L-WDQ0Q *&"*$B4!%4')!8_C/T6O^2\S
MK_LD<;_ZN<B/U[Z3'_)$9/\ ]E5A/_51G1S7[)GP2^$'Q<^'?Q=_M_2=0\=_
M%RSTY(O!_@'3/B9H_P +_$\-A/XK^%^BZ3K_ ,-AXJ\/7GA'X@>+M6UCQ-KO
MAR7P[K/B"T*W,7A_PK8>'[W5_B#I>NZ-QNB?#3X2^+OV=_B9XNT;0)].\>_"
M[P9X:UBXF'Q>M]>^)&K>)T\:^'/#OCW4/$WP)CT.TMO!_P $].T_7KEM,\7P
M:C)XBT'4+?P\GB"\U@^(;RVT[S#X7_M)_&7X-^&?%7A'X?>+Y-&T7Q7"Q>.7
M3-(U.[\-:M+J7AW4+GQ/X)U#4[&[O/"/BB[7PMH]C=:QHLUM++;VEI=[%UK2
M=!U;2:.I_M!?%C6/"%WX(U#Q'8RZ3J?AS1?!FMZI!X2\&V7CCQ%X+\.RZ?+H
M?@[Q+\1K3P_#XZ\0^&=,;2=(6WTC6->O;>:/1]'M]1%_:Z78V\']>5,IXEEF
M>/KPQE-8.KG.5XW!\V;YG&K1P6&5#Z_AGA*5"&"=#$4Z<Z5+!\JA*I.I6Q=:
MO4G3JT?Y3IYIP]'+L#1E@YO%TLHS/!XOERK+I4ZV,Q+K?4L2L75KSQBK8><H
M5:F+OSQA&%'"TJ%.-2E5Z7X4^!/A;XM^#_[1GB#6Y?&=W\3/AS\+F\?>$+;3
MWT[3O!&E6-E\2OA5X1GOM5N5FNM8\4ZUK$'C?5[6ST2.VTG1="@T]-5N[[6K
M^^L[+2OH[7?V7?A7X>\'6&@ZEJ&D?\)GI_PJ^ WQG^('CC3OBY)/XJ\%>"?B
MMJ?@'4?%_C.]^"T_A1O"^H?"KP!X0^(%C:2#3O&@^+#:O9P>.+_2O^$&U(V-
MO\V:?^TW\0M#U+XEWOAW0OA-I=G\5]1UFY\6:3>?!GX8>)+2YTC6-:T?7W\(
MQ2^(/"U[/!X0L]5\/:%J-EX=MC:Z1;:CID-_;V4$SR X-Q^T-\7KGP8O@-_%
M4$.A#1M'\,27=GX8\)67BRX\(>'-;B\2>&_ UYX[M="C\:7W@3P[KEO9ZCH?
M@V[UV;0-/?3]+M8K(Z=I6FV5H8C+>*<3BG5IXVGA,-+,</C/8/,L4YTJ/U?+
MJ=2BG0P=.G.GAI8?'>SP,O:8+&U,7#$8N;G2DJAA\QX9P^&]E4P<\57CE]?"
M>V_L[#*%2M]8Q]2G6?M\9.I&IB(U\$IXV/)C,'3PDZ&%CR58.E]#_M)_L\^"
M_ /PNU7XD^'/#$GP[7PW^T#<_!_3=.NOC'H/Q=@^)7P]U7PAX@\5^!_B]%J.
MD@6V@SZO#X6O/-33I8O#'B*RU>UO?#NE:9'I-R]_4U']ED^%?V4O&OQ*\4>#
M?B,OQ4TU_@?XZM;O^Q_$=GX-\*?##XJ:EXJL[+3-20Z2-.UCQ'J>A:1I?CW7
M=3-_]D\#:%K_ (1TNZ$6J:IJZ6WAFL?M&_%?7KW2[S4=1\(>7I%WXRU6#1]/
M^%OPOT;PO>^(_B#H$OAGQEXRUSPEHWA"P\->(/'.N:-*+63QEK6EWWB#3Y+>
MRN]&O=-NK*WECXNQ^*7Q%T_P5XF^'=OXU\2MX,\8'PM_PD.@W>LZCJ%I?)X+
MN=1O/#L$;7US<2V-I:7&JWK75G8/;6NJH\,6JPWD5I:I#6&RKBJ&!P&'K9IA
M56P^:8+&8F<,1F->5?!T\?1J8G+_ *UBG/%RI3PE*M4?MYU7B*V)6"<L-@,*
M_K4XC,^&)XW'8BEEF)=+$99C,)AH3H8"A&AC*F"J0PV.^K8:*PL:D<5.E#]S
M3I*A1P\L8HXC&XFV&K_#/_DI?PU_[*1\/O\ U,]#K_2@7H?]Y_\ T-J_S7OA
MJ"WQ*^&XR5+?$;X?KN7&Y2WC+0QN7((W+G<N01D#((X/^D*=(N79V_M[6EW2
M2-M233 J[I&.U1_91PHSA1DX  R>M?S-]*__ 'O@C_KQQ!_Z7DI_1?T7O]VX
MR_Z_Y'_Z;S0^-/\ @IG_ ,F"_M8?]D8\5_\ HNWK^!)_OO\ [S?AR<DGL!W-
M?WK_ /!2K3)[?]@K]J^1]8U6Y4?!CQ3F*X>P:-L"U?!\K3H9!NV[&*R*=C,
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MF!?HHHK\4/V(**** "BBB@ HHHH ;L3.[:N[KG:,Y]<XS3J** /Q _X*3_\
M*23_ ((4_P#9UO[4'_K'/Q!KG?\ @X%_Y-!^%G_9P_A?_P!5S\2:Z+_@I/\
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MHSH_-ZBBBO[R/XA"BBB@ HHHH [;X9_\E+^&O_92/A]_ZF>AU_I0+T/^\_\
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M\MP6)Q]>G0CE>;TY5ITL+2JU(TE4JTZ;J2BH*=2$6^:<4_(J*\ _X:@^"_\
MT&_&/_AF_C7_ /.[H_X:@^"__0;\8_\ AF_C7_\ .[K^UO\ B(' ?_1;<(_^
M))DW_P VG\=_ZA\<_P#1&<6?^([G'_S'YK[SW^BO /\ AI_X+D@#6_&1)(
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ML(5.249<DI*7+*,K6DF_?J*\ _X:@^"__0;\8_\ AF_C7_\ .[H_X:@^"_\
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MMN$?_$DR;_YM#_4/CG_HC.+/_$=SC_YC\U]Y_5O_ ,&[?_)0OVIO^Q+^$?\
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ME^B]H]6_[[?_ .*I00<X(.#@X(.#Z'T/L:0N@ 8LH4]"6 !^A)P: #:/5O\
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MI\=ZI9VZ_#_P/\.GOM&\5:M?:G;7%KK>K2>#O#GA:YN?%$\=C=^)M<T3X?\
MASQ=;ZS]B5X;\9?V9OV?_P!H:?PG=_&_X._#WXIWO@-]>D\%7WC;PSI^N7_A
M-_%-I9V'B4^';ZZC-WH__"06&GV5AK0L9H1JEC;16EZ)K=?+(!^17CGXW?MA
M^'?A[\:/$7Q=^*>K?"[XW_L7_L&_L_\ Q\;P/X:A^'47@KXV_'#Q?9_&;5?'
M%CXXTY;#4(O%>@>(]9^&.@? ZWTCP;K'ASP]IGC'6?&.N>![E=5O?!%WX?\
MH35/CE^T1\/OVU?VG=)USQ1-\0?!GA7_ ()[6G[1OPS^!6A^%[+0K#0_%6E?
M%+XMZ1::%)J,=UKGB3Q3XW\3Z;X6TG0_$FM3:U!HDUS':P>%/"GAZ.&[GU7[
ML_X9?_9T,7PPAF^"'PMNE^"UO:6GPF:^\$Z!J$WP\M;"XM[VQMO"5S?V-S<Z
M-!9ZA9V.I6D5K,L=MJEA8:I L>HV-I=08%G^QO\ LKV'QBD_:$LO@#\*[7XX
M3:M=:W-\5X?"&F1^/9=3O3>/=7,GB58QJ3B:74+Z=K=IC;"YO+FY6$7$TDK
M'P[^P#\</BCXM^('@_2/BYXW^+'B#5/C[^R)X _:H\(6GBO5?A-XA\#:KINJ
M:CX5L_%WB7PYIO@?PYH7B7X)W$>J>/\ 0-&TCX4:IJWCSPGJ7@U=%US1/%]U
MX[T?XF0M^O%>4_#CX%?!CX/WWB;4_A5\*?AY\.=1\9W4-[XKOO!/@_0?#-UX
M@N+>6[N+8ZK/H]C:27<5M=:CJ5W:VTC?9+:[U/4KNW@BN-0O99_5J "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ3>!M!T[4M(T[1/$T<&H_$[2=1N=!T;4O"40!^LN1C=D;<9SD8P.ISTQ0"&
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M^S'RK0_^"AGQ(^*,/@#1_A+X#^%MKXH\?Z?\9=6MM3^)GCCQ%HO@+1YOV8/
M7P@N/C_X,O\ 6]$T*_OIO%^A_&SXFZS\(+98;2.RT2Q^&7Q(\=:G'K'_  C<
M?A;5 #];R0.I R<#/<^GUHR,XR,XSCOCUQZ5_/\ ^)O^"E?Q:^,.F?#;X@>
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MU:VVK75H\AMI-1@BN_*$Z!Z]>HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>teclitigationchart.jpg
<TEXT>
begin 644 teclitigationchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*6=-7XG8&,HPED6>QG*;IQ@Z%!2E4BVI0C%UTW.+C-2BES)Q::33L6_K[O\
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MAR/?\C_A1D>_Y'_"L'_A&-%_Y\A_X$7G_P DT?\ ",:+_P ^0_\  B\_^2:
M-[(]_P C_A1D>_Y'_"L'_A&-%_Y\A_X$7G_R31_PC&B_\^0_\"+S_P"2: -[
M(]_R/^%&1[_D?\*P?^$8T7_GR'_@1>?_ "31_P (QHO_ #Y#_P "+S_Y)H W
MLCW_ "/^%&1[_D?\*P?^$8T7_GR'_@1>?_)-'_",:+_SY#_P(O/_ ))H WLC
MW_(_X5\4_%3_ )'[Q#P1^]L#R"#@Z58D'!]1R/4<U]<?\(QHO_/D/_ B\_\
MDFOD#XEVT%GXWUVVMHQ%#%)9!$#.^T'3+)C\TCNYRS,QRQP3@84 #\O\6/\
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M7AB__9\M-,\'_$G2?&/CS7O &C^$/VPO!GQO\7WEM\:&^*7@73_B!KUM\/\
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MN#I8%TZ,*%&<:D'"-3GYH^W>LIU9QM*6)JRERPBW^[C=0IQB%W:VEO\ AO\
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MB_\ H(K\0_\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"* 'T444
M%%%% !1110 4444 %?%'Q4_Y'[Q#_P!=;'_TUV-?:]?%'Q4_Y'[Q#_UUL?\
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M=K\7/^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(H R?[4OO\
MH7-9_P"__A[_ .7M']J7W_0N:S_W_P##W_R]K9HH QO[4OO^A<UG_O\ ^'O_
M )>T?VI??]"YK/\ W_\ #W_R]K9HH QO[4OO^A<UG_O_ .'O_E[1_:E]_P!"
MYK/_ '_\/?\ R]K9HH QO[4OO^A<UG_O_P"'O_E[1_:E]_T+FL_]_P#P]_\
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M_P#@]U3_ .2:W:* ,+^P+?\ Z"&N_P#@]U3_ .2:/[ M_P#H(:[_ .#W5/\
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M_P#H'Z[_ ."+5/\ Y&H W:*PO[?M_P#H'Z[_ ."+5/\ Y&H_M^W_ .@?KO\
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MXDT!_$>N:CJNE6_A'P=XB\=V4EKJS:I<7UYXLFGM;JPCM%CF^J:** "BBB@
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C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>tysabri.jpg
<TEXT>
begin 644 tysabri.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !W -@# 2(  A$! Q$!_\0
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M)T!2444 +2444 +2444 +2444 +1110 E+110 E+110 4E%% !1110 M%%%
M!4%X\J6<S6Z!Y@AV*3C)[444UN)['/>!M->ST^>XG&)KB0YYS@+D?SS1116E
..>3E4DV8X:"IT8Q78_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>tysabrichart.jpg
<TEXT>
begin 644 tysabrichart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MZ-XNO_%NB+HNMKJ6CVTNBZM'9 'T#1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%?C_ /M_?%;XF^!_V^O^"-?@;P9\0/&/
MA7P;\6?VE_VB= ^*'A;P]XBU72/#_P 0]"T#]E+QWXCT/1O&FDV-U!9>)=*T
MCQ#;6NNZ=I^KPW=I9ZQ:VNIP0I>VT$\?VI^UM\=_%'[/WPYT#QAX5TG0=9U#
M5?%UAX>GM_$2:B]FEI=:-K6HR3Q#3;VQG^TB;3844O*T7ER2YC+[&7T<IRO%
MYUF6$RK 1A/&8ZJJ.'C4J1I0=1QE)*527NP5HO5Z'!FF987*,OQ69XV4X83!
MTG6KRA"52:@FHWC"/O2=Y+1:GKOQF\&:G\0OAAXQ\&:1:> ]1O?$.E"P&E?$
M_P +S^,O .LVK7EK-J.A^*O#]KJ.EW5WI.MZ=%=Z3-<VMTUUI,EY%K-M9ZE/
MI\>FW?X?>#?^">G[:?AW_@F#X\_8\LI_A3?>,/C%H$'A>#P9X\^.'Q';X?\
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M708+3PMI-M)87VD^--58SZ=#\Y?\/-?C+_T(OPP_\!_%G_S0T?\ #S7XR_\
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M7]I7QSX@^-'Q*\_1/AM\0_'/@WX?^(M0^'/@?4_#'[/.AZ]I'BJSTO2/"?\
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M[_P[YA_\T>2^X^JO^&V_VH?^BJ7G_A-^#/\ YG*/^&V_VH?^BJ7G_A-^#/\
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M9E[:"JQC&I[-TG]<E5DY2DH)0C_9\:<(TXR]I+%-UJ\7"&%R/"7_ "-OA/\
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MOJ&\^$?A6T^&<?B!H)6UNS^&^@>-];6'QC"WCVRU#4M<M+:]CN/A-/I:?8/
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M^'>LZ--J7ACQO]OAO?$VF:EI/A/X7MH/A74I+B\U7PC;^)(?W#'3\3VQW/\
MG/?KWK\$?B3X?T7Q#^UU>ZI8>&3=ZSX[^.OP!^)?A_\ :7U[]EK]M67]H+X,
M>&=-T[X87<OP4\ ^([#]F'4?AC:> _$%EI%]H^J:CJ'QJ\!>#?!MC\2O']C\
M6OAYXDUS2?%+:W^]R\#\_P .3P.!P.@..1@T ?A[_P %+7>/_@I!_P $*G2%
MYV'[5W[3H$4;1*[!OV//'ZL09I(H_D4ER&=2P4JN7*J?IC_@I#>7=S\$?!Z3
MZ5=V*CXE:0PEGN-.E1F'AGQ0 @%I>W$@8ABV6C5 %(+!BH/S7_P4G_Y22?\
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MW$_] E#_ ,#J?UW_ *6O[C_\+2^&7_11? W_ (5>A_\ R;1_PM+X9?\ 11?
MW_A5Z'_\FU^'&Q/[J_\ ?(_PHV)_=7_OD?X4?ZHX?_H-K_\ @NG_ )_U=^5C
M_6W$_P#0)0_\#J?UW_I:_O1X0^)_PVD\7>$8X?B#X)FFD\6>%XX88O%.B-+-
M+)K^G)%#&OVWYI)9&6.->[LH[U_6J=4U$%@OA[46 =P&^V:(,@,0#@ZKD9ZX
M/(Z&O\WCX9JO_"R_AK\J_P#)2/A]V'_0YZ'[5_I1+T/^\_\ Z&U?R5])K*:>
M5XK@Y4ZTZOMJ&>.7/&,;.G/*+6Y>_/KZ?=_4GT<\VJ9IA^+)5*,*3HULF2Y)
M2ES<\,R;OS;6Y58^8_VJ]0OIOV<OC+'+HE]:HW@36 9Y+K29(T!$(+.MOJ,L
MVU5)8[(W8XP%)(K^<9NI^I_G7]%?[<?BC3_!7[(_[07BO58KN?3M!^&?B#4K
MR*QCBEO)(+=(2ZV\<TUO$\IR-JO-&I[N*_D8;]M3X4AF']B^.^&(_P"03H_K
M_P!AZO0^CY@,9BN&\ZGAL/5K1CGDHR<$FHR> P+L]5T:?H<7CKC\'A.(LIAB
M<13HREDRE&,VTY1^NXI7T3TNFOD?7=%?(7_#:OPH_P"@+X[_ /!3H_\ \OJ/
M^&U?A1_T!?'?_@IT?_Y?5^^_V/FG_0!B/_ %Y>?G^#['X?\ VUE7_0=0^^7_
M ,CY_GV9]>T5\A?\-J_"C_H"^.__  4Z/_\ +ZC_ (;5^%'_ $!?'?\ X*='
M_P#E]1_8^:?] &(_\ 7EY^?X/L']M95_T'4/OE_\CY_GV9]>T5\A?\-J_"C_
M * OCO\ \%.C_P#R^H_X;5^%'_0%\=_^"G1__E]1_8^:?] &(_\  %Y>?G^#
M[!_;65?]!U#[Y?\ R/G^?9G[_P#_  3)N9[;Q)\7V@L+B_9M!\&92WELXBF-
M4\0@%S>7-LI#!FQL+D%"&"[E)_8>RN[FY\S[1IMSI^S9L^T3V,WF[MV[;]BN
MKG;LVC/F;,[AMW8;'X._\$:OCIX0^+WC#X]6?AFQ\06DNA^&?AY<W9UJSLK9
M)(]0UCQ=#"+<VFH7I9U>SD,@=8P%9"I8D@?OC7\0^-%"MA_$/.J5>G.E4C1R
MERIS24HJ63X"2NE?>+3WZ]#^R?"&O1Q/ 63UJ%2-2E*MFJC.-[/ES7&1>_9I
MI^@4445^5GZ6%%%% !1110 5C>(ANT#6QB0YTC4QB&SU34)CFQN!B*QT2:WU
MF]DY^2TTJ>'4KE\06$L=W)"Z[-(WW6^AZ'!Z>O;Z]J /YU/!'P/UGP7\7OAQ
MI^H7/B:ZN-,\9_#34Y9M$_8P_P""T\OAYHM0O?#GB"!&\=:_^UKXK^%VCO%:
MW\,.NWOC6UUKPWX/U2/4[#XAZ3,-#\1:0O\ 16/ZGU'<^O\ ^H]1QBOYZ?',
MGPDD_P""@?Q+7QS;?L3MXRC_ &BOA2OAR;]HKPW\3OBA^T$\7_",?"U-(?X8
M^+-":T\&^ ]%CU..6'X;>!5%^G@_Q5%JGB/Q%=&Y\536%E_0L.G;J>GU/Z^O
MJ<T ?B#_ ,%)_P#E))_P0I_[.M_:@_\ 6.?B#7._\' O_)H/PL_[.'\+_P#J
MN?B36]_P4M\W_AY!_P $*O(\OS/^&K_VG,>;OV;/^&/?'_F9V?-N\O?L[;]N
M[Y<UQW_!??\ M?\ X9$^%W]HC3O*_P"&A/#.W[&;LOO_ .%=_$;;N^T +LV^
M9G'.=N.-U?I7@[_R<[@S_L<0_P#3%8_._%G_ )-QQ;_V*W_ZD4#^1NBBBO\
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M(R?_ +*K"?\ JHSH_.2BBBO[R/XA"BBB@ HHHH [;X9_\E+^&O\ V4CX??\
MJ9Z'7^E O0_[S_\ H;5_FO?#7=_PLGX;[,;_ /A8WP_V;L[=_P#PF6A[=V.=
MN[&['.,XYK_2#;_A)-\GEC1/+\V7R]YU+?L\QMF_:-N[;C=M^7.<<8K^,OI7
M_P"]\$?]>.(/_2\E/Z[^B]_NO&?_ %_R/_TWFA\;?\%,_P#DP7]K#_LC'BO_
M -%V]?P)/]]O]YOYFO[U?^"E/]N_\,%_M7_;!I/D_P#"F/%.?LQOO-_Y=-V/
M. 3_ %?F;?\ ;V9^7=7\%3_?;_>;^9KZSZ*__)(\1?\ 91R_]5F7GRWTFO\
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M2>Q>[M"UK=/:2LT#W%LSV\S1F2&22-E=@#\3O^"D_P#RDD_X(4_]G6_M0?\
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MC^OZH*_E?_X-V_\ DH7[4W_8E_"/_P!2'Q_7]4%?YQ?2%_Y.MQ#_ ->,C_\
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MY5OKE#,&J4<!0I2Q=&&!C*HZ<,#K&N\OHNK"<YW4JT5)*J[;4>*\3AJ#PU#
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M?S-?6?17_P"21XA_[*.7_JLR\^6^DS_R5F0_]D^O_5CC!M%%%?U"?S:%%%%
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M,F_^;3_/[_4/CG_HC.+/_$=SC_YC\U]Y[_17@'_#4'P7_P"@WXQ_\,W\:_\
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M^&;^-?\ \[NO[6_XB!P'_P!%MPC_ .))DW_S:?QW_J'QS_T1G%G_ (CN<?\
MS'YK[SW^BO /^&G_ (+D@#6_&1)(  ^#?QK))/   ^'>22> !R34-O\ M3_!
M"Z@BN;7Q%XJNK:=!)!<VWPB^,US;SQM]V2"X@^'TD,T;?PR12.C<X8T?\1 X
M#_Z+;A'_ ,23)O\ YM#_ %#XY_Z(SBO_ ,1W./+_ *@_-?>NY]"T5X!_PU!\
M%_\ H-^,?_#-_&O_ .=W1_PU!\%_^@WXQ_\ #-_&O_YW='_$0. _^BVX1_\
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M,?\ PS?QK_\ G=T?\1 X#_Z+;A'_ ,23)O\ YM#_ %#XY_Z(SBS_ ,1W./\
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MSJI/(#, 2.F<$YZTZ@!NT>K?]]O_ /%4;1ZM_P!]O_\ %4ZB@!NT>K?]]O\
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MU9Z7XN^*/Q(T71OA;Y/Q?\1Z+K2:/;>#-3UJ_P#AU<P:1H?BV34[O6Y-0T<
M_8ZBOE']D[X_ZK\<_#GCNT\8+X<T[XB?#+QR/!_B[P[H_A[XK>"-8TJ/4O"O
MASQEX<NO%/P]^,_@_P )>-/!>IZOHOB*.YM+*.;QCX;U72H;/7M!\:ZG'J5S
MIFB_5U !65J6NZ+HQA&KZOI>EFX#F :CJ%G8F81;!(81=31&41F1 Y3=LWKN
MQN7.K7Y ?\%1XXWU/X+;XXWQ8^/L%T1R,W7A+."P.,X&<=<5]1P;P]#BKB/
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M^(O'O@OQ]^P=X>^*%_XK\6?%;P)<:'8Z%;Z)XNB^$_C";PM96][-'X1U^_\
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M\VDJNCMJT4:7YT8#1S<?V6!:5]%44 ><:1\'OA1H'BO2O'6@_#;P-H?C+0O
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LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>zinbryta.jpg
<TEXT>
begin 644 zinbryta.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !: /$# 2(  A$! Q$!_\0
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M0O.*G$5*=&3YG;6QGAY.=*,GNTOR+-%,65'9E1U9E.& .2/K3Z9JG?8****
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MN\,BJ#(2Q4@<L,<^]5?B3IMWJ'C#3X;6)R\\2HC8.,[CW[8K)_!\ROM'J0
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MV8*^#].CU&.^ADNXKA%V,R3MF49S\YZFGWOA:VOM734Y+N^2YC&(S'-M"#N
M,=#6W11RKL%V8^J>&K;5KVVNI[F\26V_U1BEVA3W.,=33=4\,6NKR6DEU<WH
M>TP8C'-MPP_BZ?>]ZVJ*.5!=F)J'A6SU&:VGEGO([JV38MQ%-MD*^A..::O@
M_3HM0BO87NXIT38S).V91G/SGJ:W:*.5=@NS'O\ PW;WVJ#45N;RVNA'Y6^W
MEVY7.<$$&K&FZ+:Z6\LL7F2W$V/,GF??(^.@)]/85H44^57N%V96FV,YU"YU
C*_55N)1Y448.1%$#P,^I/)_"M6BBA*P@HHHI@)1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>zinbrytachart.jpg
<TEXT>
begin 644 zinbrytachart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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M $WBC]4\'4EQCHDO^$C';)+_ )?8)?EH?>]%%%?Q^?U<%%%% !1110 4444
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MQ#_T"-*_\'MS_P#*&MNB@#$^T^(?^@1I7_@]N?\ Y0T?:?$/_0(TK_P>W/\
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M?>]%%%?Q^?U:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%_M6]_Z%S6O^_P!H'_R]H_M6]_Z%S6O^_P!H'_R]H VJ*Q?[5O?^A<UK_O\
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MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *0G )] 3^5+52_CN);*\BM9I;>YDM;B.WN(3;":"=X9%AFB-Y;W=IYD
M4I1X_M-K<V^]5\^WFBWQ. ?G?K?[:7B1_P!HSQ;\&M!N/V0/#6F^!OB3X/\
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M ,K:WJ* ,'_A)-,_ZB'_ ()=;_\ E;1_PDFF?]1#_P $NM__ "MK>HH P?\
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M &4S1_\ U%_%5?+7_!2?_E))_P $*?\ LZW]J#_UCGX@U]2_\%+?^2&^#?\
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M_P %0?V&KJ&.XM_C%KEU;3HLL,]O\"_VB;JVGC)RDL$\'PEE@F0D K+$[H2
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MXMZY\,_VB?B%\3?@E&?V;?@_X@_:2^)/AWX?G3M*^.OQ6_:A\"?"+XR?$_\
M9\GA\,^'_"M[\//A7\+/%.OZ[XI,]IXP^#_ACXBV'A;0?!USK4WA7XO::F5^
MT[\9_P!J#X5?LP?\%&=%^&'QZ\46DG['7C;P4WA#XS^*/#OA3QM\2=?\.^*?
MA1\)_B1JGPI_X241:;X>MO$/A/Q'XPN;/5_&NO\ @KQ%XG;X=^(]'T6**T\7
MPP_$"']2/AK^Q5^R7\';'7]*^%_[.OP@\#:/XI\&#X=>(M$\/>!M$LM"UCP
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MP[10:K>ZAJ44:WNH7T]QRWA_]AW]CWPK\/Y/A1X=_9G^"6C_  TD\1V_B]/
M=C\.O#<7A2U\3VFG'1[?7M/T0V+6.EZI'I#2:4+S38K29M-N+JP=FM+NZAF
M.@_9-^).F?%K]G?X5^-M*/BXPW?AV31+UO'>OZ;XL\6/K?@S5]3\$>(Y-8\7
M:/C2?%\TGB+PYJKP>+M,C@L/%-FUMK]G:VL&H);0_1-9FBZ)H_AO1]+\/>'M
M)TW0M!T/3[/2-%T31K"TTO2-(TK3K>.TT_3-+TVQAM[+3]/L;6**VL[*T@AM
MK6WCCA@BCC15&G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<TT5O%+/
M/+'#!!&\TTTKK'%%%$I>2661RJ1QQHI=W=E5%!9B ":DKS3XT 'X._%@$ @_
M#3QV"",@@^%]5!!!X((X(/6NC"4%B<5AL,Y<BQ&(HT'-+F<%5J1I\W+=7Y>:
M]KJ]K76YABJSP^&Q&(45-T*%:LHM\JDZ5.4U%NSLI<MKV=KWL]CH_P#A-_!O
M_0V^&?\ P?Z3_P#)E:.G>(-"UB62'2=:TG4YHHQ++%I^I65[)'$6V"22.UGE
M=$+G:'8!2WRYSQ7\F\=O;B.,"W@ \N/@0Q?W%_V*_2__ ()B1QI\5/B24BB0
MGX>Z>"4C1"1_PDT!P2J@D9[$D5^Y<4^#.&X=X?S/.X<05\7++Z-.K'#RRV%&
M-5SQ%"ARNJL=4<+>U<KJG*]K6ZK\9X:\6\3G^>9;D\\BHX6&/K2I/$1S"=:5
M+EH5*JDJ;P5-3NZ?+;GCO>^R/VPHHHK\%/VT:SHF-SJN>FY@,_3)%.K\8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822505616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 26, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,562,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,220,188,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823039696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 10,354.7<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">1,559.2<span></span>
</td>
<td class="nump">1,314.5<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">360.0<span></span>
</td>
<td class="nump">316.4<span></span>
</td>
<td class="nump">236.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">12,273.9<span></span>
</td>
<td class="nump">11,448.8<span></span>
</td>
<td class="nump">10,763.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales, excluding amortization of acquired intangible assets</a></td>
<td class="num">(1,630.0)<span></span>
</td>
<td class="num">(1,478.7)<span></span>
</td>
<td class="num">(1,240.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="num">(2,253.6)<span></span>
</td>
<td class="num">(1,973.3)<span></span>
</td>
<td class="num">(2,012.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="num">(1,935.5)<span></span>
</td>
<td class="num">(1,947.9)<span></span>
</td>
<td class="num">(2,113.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="num">(814.7)<span></span>
</td>
<td class="num">(385.6)<span></span>
</td>
<td class="num">(382.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">112.3<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="nump">62.7<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(33.1)<span></span>
</td>
<td class="num">(93.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement charge</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">6,929.7<span></span>
</td>
<td class="nump">6,298.4<span></span>
</td>
<td class="nump">5,872.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">5,344.2<span></span>
</td>
<td class="nump">5,150.4<span></span>
</td>
<td class="nump">4,891.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(215.4)<span></span>
</td>
<td class="num">(217.4)<span></span>
</td>
<td class="num">(123.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">5,128.8<span></span>
</td>
<td class="nump">4,933.0<span></span>
</td>
<td class="nump">4,767.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">2,458.7<span></span>
</td>
<td class="nump">1,237.3<span></span>
</td>
<td class="nump">1,161.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,670.1<span></span>
</td>
<td class="nump">3,695.7<span></span>
</td>
<td class="nump">3,593.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">131.0<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 2,539.1<span></span>
</td>
<td class="nump">$ 3,702.8<span></span>
</td>
<td class="nump">$ 3,547.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 11.94<span></span>
</td>
<td class="nump">$ 16.96<span></span>
</td>
<td class="nump">$ 15.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 11.92<span></span>
</td>
<td class="nump">$ 16.93<span></span>
</td>
<td class="nump">$ 15.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">212.6<span></span>
</td>
<td class="nump">218.4<span></span>
</td>
<td class="nump">230.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">213.0<span></span>
</td>
<td class="nump">218.8<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823026480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 2,539.1<span></span>
</td>
<td class="nump">$ 3,702.8<span></span>
</td>
<td class="nump">$ 3,547.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) recognized during the period, net of tax</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Less: reclassification adjustment for (gains) losses included in net income, net of tax</a></td>
<td class="nump">12.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">9.2<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) recognized during the period, net of tax</a></td>
<td class="num">(193.8)<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
<td class="nump">110.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax', window );">Less: reclassification adjustment for (gains) losses included in net income, net of tax</a></td>
<td class="nump">31.5<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(172.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(162.3)<span></span>
</td>
<td class="nump">47.6<span></span>
</td>
<td class="num">(61.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">158.7<span></span>
</td>
<td class="num">(138.6)<span></span>
</td>
<td class="num">(96.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="num">(95.9)<span></span>
</td>
<td class="num">(164.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">2,540.6<span></span>
</td>
<td class="nump">3,606.9<span></span>
</td>
<td class="nump">3,382.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">131.0<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 2,671.6<span></span>
</td>
<td class="nump">$ 3,599.8<span></span>
</td>
<td class="nump">$ 3,428.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4613674-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph c<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41638-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822934992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,573.8<span></span>
</td>
<td class="nump">$ 2,326.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,115.2<span></span>
</td>
<td class="nump">2,568.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,787.0<span></span>
</td>
<td class="nump">1,441.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DueFromUnconsolidatedJointBusiness', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">532.6<span></span>
</td>
<td class="nump">300.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">902.7<span></span>
</td>
<td class="nump">1,001.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">962.0<span></span>
</td>
<td class="nump">1,093.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,873.3<span></span>
</td>
<td class="nump">8,732.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">3,057.3<span></span>
</td>
<td class="nump">2,829.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,182.4<span></span>
</td>
<td class="nump">2,501.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,879.6<span></span>
</td>
<td class="nump">3,808.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,632.5<span></span>
</td>
<td class="nump">3,669.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,027.5<span></span>
</td>
<td class="nump">1,335.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">23,652.6<span></span>
</td>
<td class="nump">22,876.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable and other financing arrangements</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">68.2<span></span>
</td>
<td class="nump">231.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">395.5<span></span>
</td>
<td class="nump">279.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,901.3<span></span>
</td>
<td class="nump">2,903.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,368.2<span></span>
</td>
<td class="nump">3,419.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable and other financing arrangements</a></td>
<td class="nump">5,935.0<span></span>
</td>
<td class="nump">6,512.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">122.6<span></span>
</td>
<td class="nump">93.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,628.7<span></span>
</td>
<td class="nump">722.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,054.5<span></span>
</td>
<td class="nump">10,748.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">97.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(318.4)<span></span>
</td>
<td class="num">(319.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">15,810.4<span></span>
</td>
<td class="nump">15,071.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 23.8 million and 22.6 million shares, respectively</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,611.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">12,612.8<span></span>
</td>
<td class="nump">12,140.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(14.7)<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">12,598.1<span></span>
</td>
<td class="nump">12,128.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 23,652.6<span></span>
</td>
<td class="nump">$ 22,876.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DueFromUnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DueFromUnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803068576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost, shares</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">22.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821107856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,670.1<span></span>
</td>
<td class="nump">$ 3,695.7<span></span>
</td>
<td class="nump">$ 3,593.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,081.0<span></span>
</td>
<td class="nump">682.7<span></span>
</td>
<td class="nump">600.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">128.0<span></span>
</td>
<td class="nump">154.8<span></span>
</td>
<td class="nump">161.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">91.7<span></span>
</td>
<td class="num">(175.0)<span></span>
</td>
<td class="num">(145.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="nump">62.7<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">162.1<span></span>
</td>
<td class="nump">89.0<span></span>
</td>
<td class="nump">129.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(435.6)<span></span>
</td>
<td class="num">(241.4)<span></span>
</td>
<td class="nump">29.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="num">(232.0)<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
<td class="num">(31.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(94.5)<span></span>
</td>
<td class="num">(165.6)<span></span>
</td>
<td class="num">(174.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(76.6)<span></span>
</td>
<td class="nump">59.1<span></span>
</td>
<td class="num">(127.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(227.4)<span></span>
</td>
<td class="nump">622.3<span></span>
</td>
<td class="nump">199.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">1,303.9<span></span>
</td>
<td class="num">(232.6)<span></span>
</td>
<td class="num">(429.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(2.4)<span></span>
</td>
<td class="nump">69.5<span></span>
</td>
<td class="nump">83.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">4,551.0<span></span>
</td>
<td class="nump">4,587.2<span></span>
</td>
<td class="nump">3,919.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">5,565.9<span></span>
</td>
<td class="nump">7,378.9<span></span>
</td>
<td class="nump">4,063.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(5,355.2)<span></span>
</td>
<td class="num">(7,913.2)<span></span>
</td>
<td class="num">(6,864.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration related to Fumapharm AG acquisition</a></td>
<td class="num">(1,200.0)<span></span>
</td>
<td class="num">(1,200.0)<span></span>
</td>
<td class="num">(850.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to Acquire in Process Research and Development</a></td>
<td class="num">(120.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(198.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(867.4)<span></span>
</td>
<td class="num">(616.1)<span></span>
</td>
<td class="num">(643.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(975.4)<span></span>
</td>
<td class="num">(111.6)<span></span>
</td>
<td class="num">(15.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(11.0)<span></span>
</td>
<td class="num">(22.8)<span></span>
</td>
<td class="num">(44.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(2,963.1)<span></span>
</td>
<td class="num">(2,484.8)<span></span>
</td>
<td class="num">(4,553.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(1,365.4)<span></span>
</td>
<td class="num">(1,000.0)<span></span>
</td>
<td class="num">(5,000.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(5.3)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(70.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Net distribution to noncontrolling interest</a></td>
<td class="num">(134.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(56.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5,930.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings</a></td>
<td class="num">(560.9)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfCapitalDistribution', window );">Net cash contribution to Bioverativ, Inc.</a></td>
<td class="num">(302.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Contingent consideration payments</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(38.6)<span></span>
</td>
<td class="num">(13.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by (used in) financing activities</a></td>
<td class="num">(2,380.0)<span></span>
</td>
<td class="num">(1,052.6)<span></span>
</td>
<td class="nump">783.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="num">(792.1)<span></span>
</td>
<td class="nump">1,049.8<span></span>
</td>
<td class="nump">148.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">39.4<span></span>
</td>
<td class="num">(31.3)<span></span>
</td>
<td class="num">(45.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the year</a></td>
<td class="nump">2,326.5<span></span>
</td>
<td class="nump">1,308.0<span></span>
</td>
<td class="nump">1,204.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the year</a></td>
<td class="nump">$ 1,573.8<span></span>
</td>
<td class="nump">$ 2,326.5<span></span>
</td>
<td class="nump">$ 1,308.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfCapitalDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfCapitalDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=96949009&amp;loc=SL79513924-113897<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827606960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>2016 Share Repurchase Program</div></th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>2011 Share Repurchase Program</div></th>
<th class="th">
<div>2011 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2014</a></td>
<td class="num">$ (10,814.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (4,196.2)<span></span>
</td>
<td class="nump">$ 59.5<span></span>
</td>
<td class="num">$ (9,283.9)<span></span>
</td>
<td class="num">$ (2,611.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2014</a></td>
<td class="nump">10,809.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning Balance at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(257,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">3,547.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,547.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">46.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,593.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(164.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(164.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Acquisition of noncontrolling interest</a></td>
<td class="num">(10.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(60.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="num">(16,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,377.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622.5<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">54.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">54.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(125.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(125.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">183.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefit from share-based payments</a></td>
<td class="num">(69.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2015</a></td>
<td class="num">(9,374.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(224.0)<span></span>
</td>
<td class="num">(12,208.4)<span></span>
</td>
<td class="num">$ (2,611.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2015</a></td>
<td class="nump">9,372.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending Balance at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(241,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">3,702.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,702.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(7.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,695.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(95.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">95.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Acquisition of noncontrolling interest</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of noncontrolling interest</a></td>
<td class="num">(7.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="num">(1,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">164.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835.1<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(52.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(47.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">169.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefit from share-based payments</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="num">(12,128.6)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(319.9)<span></span>
</td>
<td class="num">(15,071.6)<span></span>
</td>
<td class="num">$ (2,611.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="nump">12,140.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="num">(11.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(238,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">2,539.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,539.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">131.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,670.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(150.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000.0)<span></span>
</td>
<td class="num">$ (1,000.0)<span></span>
</td>
<td class="num">$ (365.4)<span></span>
</td>
<td class="num">$ (365.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,700,000)<span></span>
</td>
<td class="num">(3,700,000)<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">36.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">964.0<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">40.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">$ (45.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(44.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">$ 138.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Hemophilia spin-off adjustment</a></td>
<td class="num">(852.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(852.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Tax benefit</a></td>
<td class="nump">17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="num">(12,598.1)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (97.8)<span></span>
</td>
<td class="num">$ (318.4)<span></span>
</td>
<td class="num">$ (15,810.4)<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="nump">12,612.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="num">$ (14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(235,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79981250&amp;loc=d3e23524-113945<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of treasury stock (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramYearToDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramYearToDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813308736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer&#8217;s disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS and relapsing MS and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), a rare condition that affects movement, speech, vision and cognitive function, Parkinson's disease and ALS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE in the European Union (E.U.). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these audited consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenues when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates, non-US pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the United States (U.S.) for RITUXAN and GAZYVA; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160; </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">reimbursement of our selling and development expenses in the U.S. for RITUXAN; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(iii)&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech, the Roche Group and us. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information on our collaboration with Genentech, please read Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Multiple-Element Revenue Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenues to the various elements based on their estimated selling price as a component of total revenues.&#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&#8217;s best estimate of a selling price. Revenues allocated to an individual element are recognized when all other revenue recognition criteria are met for that element.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangement with AbbVie Inc. (AbbVie) represents a collaborative arrangement as each party is an active participant and exposed to significant risks and rewards of the arrangement. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenue in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration with AbbVie, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms that generally require payment within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of accounts receivable, net, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Marketable Securities and Other Investments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions and are included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Investments for Other-than-Temporary Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Equity Method of Accounting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or market with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three to five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to obtaining the fair value of the U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd. (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TECFIDERA, TYSABRI and AVONEX using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TECFIDERA, TYSABRI and AVONEX is performed annually during our long-range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TECFIDERA, TYSABRI or AVONEX.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired In-process Research and Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including treatments for forms of neuropathic pain, such as trigeminal neuralgia (TGN). Such programs could become impaired if assumptions used in determining the fair value change. Impairments are recorded as amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&#160;25, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Translation of Foreign Currencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Share-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&#8217; vesting periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense, net of forfeitures, for RSUs is recognized straight-line over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price of common stock under our ESPP is equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the lesser of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> discount is recognized as compensation expense over the 90-day purchase period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$106.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$108.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All tax effects associated with intercompany transfers of assets within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&#160;If the asset transferred becomes impaired, for example through the obsolescence of inventory or discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Earnings per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry-specific guidance. This new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date. These new standards became effective for us on January 1, 2018, and will be adopted using the modified retrospective method through a cumulative-effect adjustment directly to retained earnings as of that date. We have performed a review of these new standards as compared to our current accounting policies for customer contracts and collaborative relationships. During the fourth quarter of 2017 we finalized our assessments over the impact that these new standards will have on our consolidated results of operations, financial position and disclosures. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have not identified any accounting changes that would materially impact the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues; however, the adoption of these new standards may result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we expect to recognize an immaterial adjustment to retained earnings reflecting the cumulative impact for the accounting changes related to certain contract manufacturing arrangements made upon adoption of these new standards.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. This new standard became effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this new standard is not expected to have a material impact on our consolidated financial position or results of operations; however, it will result in the reclassification of where we recognize changes in fair value related to certain investments prospectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard establishes a right-of-use (ROU) model that requires all lessees recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This new standard will become effective for us on January 1, 2019. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While we are currently evaluating the impact that this new standard may have on our consolidated results of operations, financial position and disclosures, we expect that the adoption of this new standard may materially affect the reported amount of total assets and total liabilities within our consolidated balance sheet with no material impact to our consolidated statement of income. We are unable to quantify the impact at this time as the ultimate impact of adopting this new standard will depend on the total amount of our lease commitments as of the adoption date. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences and classification of awards as either equity or liabilities in the statement of cash flows. This new standard became effective for us on January 1, 2017. The adoption of this new standard did not have a material impact on our consolidated financial position, results of operations or statement of cash flows; however, it has resulted in the reclassification of certain prior year amounts in our consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. This new standard became effective for us on January 1, 2018. We will adopt this new standard using the modified retrospective method, through a cumulative-effect adjustment directly to retained earnings as of the beginning of that date. Based on currently enacted tax rates, upon adoption, we will record additional deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and an increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-01,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. We elected to early adopt this new standard as of January 1, 2017, with prospective application to any business development transactions, including our recent asset acquisition of BIIB093 from Remedy Pharmaceuticals Inc. (Remedy) in May 2017. For additional information on this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-04, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates Step 2 from the goodwill impairment test. Under the amendments in ASU No. 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds that reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. We elected to early adopt this new standard as of October 31, 2017, during our annual review of goodwill. The adoption of this new standard resulted in a change to our accounting policy; however, did not have an impact on our consolidated financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. This new standard will become effective for us on January 1, 2019. We are currently evaluating the potential impact that this new standard may have on our consolidated financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard is intended to simplify hedge accounting by better aligning how an entity&#8217;s risk management activities and hedging relationships are presented in its financial statements and simplifies the application of hedge accounting guidance in certain situations. This new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This new standard will become effective for us on January 1, 2019; however, early adoption is permitted. For cash flow hedges existing at the adoption date, this new standard requires adoption on a modified retrospective basis with a cumulative-effect adjustment to retained earnings as of the effective date. The amendments to presentation guidance and disclosure requirements are required to be adopted prospectively. We are currently evaluating the date upon which we will adopt this new standard and the impact this new standard may have on our consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976005344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Remedy Pharmaceuticals Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 we completed an asset purchase of the Phase 3-ready candidate, BIIB093 (intravenous glibencamide) (formerly known as CIRARA), from Remedy. The target indication for BIIB093 is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) recently granted BIIB093 Orphan Drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 Fast Track designation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we are responsible for the future development and commercialization of BIIB093 and Remedy will share in the cost of development for the target indication for BIIB093 in LHI stroke.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as we did not acquire any employees from Remedy nor did we acquire any significant processes required in the development of BIIB093. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Remedy, which was recorded as acquired in-process research and development in our consolidated statements of income as BIIB093 has not yet reached technological feasibility. We also have agreed to pay Remedy certain development and sales based milestone payments that are substantially payable upon or after regulatory approval, as well as royalties on future commercial sales. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Convergence Pharmaceuticals</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence&#8217;s lead candidate was a Phase 2 clinical candidate BIIB074 (formerly known as CNV1014802), which had demonstrated clinical activity in proof-of-concept studies for TGN. Additionally, BIIB074 had potential applicability in several other neuropathic pain states, including lumbosacral radiculopathy and erythromelalgia. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price consisted of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$350.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is associated with the development and approval of BIIB074 for the treatment of TGN. In connection with the closing of this transaction, we recorded a liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> representing the fair value of the contingent consideration resulting in an adjusted purchase price of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$474.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The separately identifiable assets and liabilities acquired were primarily comprised of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to in-process research and development and goodwill, respectively.&#160;These amounts were partially offset by the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets which had no tax basis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&amp;D intangible assets. The goodwill was not tax deductible.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813328864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hemophilia Spin-Off Hemophilia Spin-Off<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Hemophilia Spin-Off</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. (Sangamo).</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution, Biogen and Bioverativ entered into a separation agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward. They also provide for the performance of services by each company for the benefit of the other for a period of time. In addition, under the separation agreement, Bioverativ is obligated to indemnify us for liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The services under these agreements generally commenced on February 1, 2017 (the distribution date), and terminate within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the distribution date, with the exception of the manufacturing and supply agreement, which has an initial term of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5 years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with a 5 year extension at Bioverativ's sole discretion and a further 5 year extension with Bioverativ's and our consent. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution we made a net cash contribution to Bioverativ, during the first quarter of 2017, totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">155.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the terms of our agreements with Bioverativ, upon completion of the spin-off, we distributed ALPROLIX and ELOCTATE on behalf of Bioverativ until Bioverativ obtained appropriate regulatory authorizations in certain countries, including a Biologics License Application transfer in the U.S., which was received in September 2017. Accordingly, commencing October 2017, we ceased distribution of ALPROLIX and ELOCTATE on behalf of Bioverativ under this arrangement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the manufacturing and supply agreement, we manufacture and supply certain products and materials to Bioverativ. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in revenues in relation to these contract manufacturing services, which is reflected as a component of other royalty and corporate revenues in our consolidated statements of income. We also recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as cost of sales in relation to these services during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts earned under the non-manufacturing and supply related transaction service agreements are recorded as a reduction of costs and expenses in their respective expense line items. These amounts, which were primarily reflected as a reduction to selling, general and administrative expenses in our consolidated statements of income, were not significant for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia related product revenues reflected in our consolidated statements of income for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$846.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$554.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Results for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> only reflect hemophilia-related product revenues through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to the spin-off of our hemophilia business, we were awarded various methods of treatment and composition of matter patents related to ELOCTATE and ALPROLIX. Upon completion of the spin-off, these patents were transferred to the patent portfolio of Bioverativ.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6975978752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Restructuring, Business Transformation and Other Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2017 Corporate Strategy</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we announced an updated strategic framework to optimize the value of our MS business while investing for the future across our core growth areas of MS and neuroimmunology, AD and dementia, movement disorders and neuromuscular diseases including SMA and ALS. We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to deliver positive results in the near term while investing in the next stages of our growth, we will focus on the following strategic priorities:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">maximizing the resilience of our MS core business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">accelerating efforts in SMA as a significant new growth opportunity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">developing and expanding our neuroscience portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">focusing our capital allocation efforts to drive investment for future growth; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">creating a leaner and simpler operating model to streamline our operations and reallocate resources towards prioritized research and development and commercial value creation opportunities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We expect to make total non-recurring operating and capital expenditures of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$170.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily in 2018, and our goal is to redirect resources of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$400.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> annually by 2020 to prioritized research and development and other value creation opportunities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges in our consolidated statements of income totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this effort, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is included in selling, general and administrative expense and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is reflected as restructuring charges. These restructuring charges, which were substantially incurred and paid in 2017, were primarily related to severance.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2016 Organizational Changes and Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2016 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we initiated cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin-off our hemophilia business, and to achieve further targeted cost reductions. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this effort, which are in addition to, and separate from, the 2015 restructuring charges described below. These amounts, which were substantially incurred and paid by the end of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were primarily related to severance and are reflected in restructuring charges in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cambridge, MA Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 following an evaluation of our current and future manufacturing capabilities and capacity needs, we determined that we intended to cease manufacturing and vacate our 67,000 square foot small-scale biologics manufacturing facility in Cambridge, MA and close and vacate our 46,000 square foot warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December&#160;2016 we subleased our rights to the Cambridge, MA manufacturing facility to Brammer Bio MA,&#160;LLC (Brammer). Brammer also purchased from us certain manufacturing equipment, leasehold improvements and other assets in exchange for shares of Brammer common LLC interests and assumed manufacturing operations effective January 1, 2017. In December 2016 we closed and vacated our warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our departure from these facilities shortened the expected useful lives of certain leasehold improvements and other assets at these facilities. As a result, we recorded additional depreciation expense to reflect the assets' new shorter useful lives. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of this additional depreciation, which was recorded as cost of sales in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2016 we also recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for severance costs related to certain employees separated from Biogen in connection with our departure from these facilities. These amounts were substantially incurred and paid by the end of first quarter of 2017 and are reflected in restructuring charges in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2015 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2015, we announced a corporate restructuring, which included the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in workforce. Under this restructuring, cash payments were estimated to total approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were related to previously accrued 2015 incentive compensation, resulting in net restructuring charges totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These amounts were substantially paid by the end of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of restructuring charges related to our 2015 restructuring program in our consolidated statements of income.&#160;Our restructuring reserve is included in accrued expenses and other in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our 2015 restructuring program during 2017:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(40.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813326400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract', window );"><strong>Sales Discounts, Returns and Allowances, Goods [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Reserves for Discounts and Allowances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">482.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">605.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">583.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,307.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">26.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,917.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(475.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,756.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,232.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(69.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(442.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(534.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">109.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">606.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">548.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">592.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,044.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,668.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(522.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,576.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,099.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(536.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(609.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">482.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">387.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">459.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,732.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,229.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(405.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,258.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,666.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(44.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(296.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(351.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">548.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">189.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">572.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813276976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">162.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">605.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">698.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">157.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">902.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,001.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances in the table above as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. Balances transferred to Bioverativ related to work in process and finished goods inventory totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$84.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$76.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976047968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(535.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(523.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,689.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,634.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">680.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">680.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,971.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,160.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,811.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,481.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(776.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,705.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,264.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,385.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,879.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,742.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,934.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,808.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$814.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$385.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$382.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$444.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of amortization and impairment charges related to our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below. Amortization of acquired intangible assets for 2017 also reflects a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge related to the Article 20 Procedure of ZINBRYTA in the E.U. For additional information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances in the table above as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> also reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. In-process research and development balances include adjustments related to foreign currency exchange rate fluctuations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Out-licensed Patents</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$309.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired and had not reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life and amortize these amounts based upon an economic consumption method. The carrying value associated with our IPR&amp;D assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of Convergence, Stromedix Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN) in 2015, 2012 and 2010, respectively. These amounts have and will be adjusted for foreign exchange rate fluctuations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long-range planning cycle, which was updated in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&#160;&#160; </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,236.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net change in acquired and in-licensed rights and patents during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflects </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total milestone payments paid to Ionis Pharmaceuticals, Inc. (Ionis) for the approvals of SPINRAZA in the E.U. and Japan in June 2017 and July 2017, respectively, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment paid to Samsung Bioepis, for the approval of IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the E.U. in August 2017, and the net carrying value recognized in relation to our acquisition of TECFIDERA license rights, as described below. These net increases were in part offset by amortization and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge related to the Article 20 Procedure of ZINBRYTA.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationships with Ionis and Samsung Bioepis and the European Commission (EC) approved restrictions on the use of ZINBRYTA, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this agreement and in the first quarter of 2017 we recognized an intangible asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this agreement. The pre-tax charge recognized in the fourth quarter of 2016 represented the fair value of our license to Forward Pharma&#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016. The intangible asset represented the fair value of the U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property related to TECFIDERA revenues for the period January 2017, the month in which we entered into this agreement, through December 2020, the last month before royalty payments could first commence pursuant to this agreement. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. In January 2018 the European Patent Office (EPO) announced its decision revoking Forward Pharma&#8217;s European Patent No. 2 801 355. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. Based upon our assessment of these rulings, we continue to amortize the remaining net book value of the U.S. and rest of world intangible assets in our consolidated statements of income utilizing an economic consumption model.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on these disputes, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TECFIDERA, AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of TECFIDERA, AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon this analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">423.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">401.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">381.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">254.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">242.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,669.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to our hemophilia business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,267.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,026.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,632.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,669.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The elimination of goodwill represents an allocation based upon the relative enterprise fair value of the hemophilia business as of the distribution date. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$232.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$173.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in tax benefits), respectively, and payable to the former shareholders of Fumapharm AG or holders of their rights. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other includes changes related to foreign currency exchange rate fluctuations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 22, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813312400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,229.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,229.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,609.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,609.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,919.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,919.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">643.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">643.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,444.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,433.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">111.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">111.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">634.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">111.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,558.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,533.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">481.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,517.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,521.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,032.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,026.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,851.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,796.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,077.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,874.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,483.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,808.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we redeemed our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due March 1, 2018 with an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For information on this redemption please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair value of each series of our Senior Notes was determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix and BIN in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">62.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$279.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$246.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. Changes in the fair value of our contingent consideration obligations are primarily due to changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones and changes in the discount rate. Payments and other for 2016 includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of a Convergence milestone converted to a short-term obligation under the acquisition agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or transfers between fair value measurement levels during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Convergence</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was based on probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was the estimated cost of debt financing for market participants. This liability reflected the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For additional information on this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$259.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$258.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash flow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$400.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in the fair value of this obligation was primarily due to changes in the discount rate, partially offset by changes in the expected timing related to the achievement of certain remaining developmental milestones. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$147.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Stromedix Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Stromedix in March 2012 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$122.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$162.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$133.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$344.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in the fair value of this obligation was primarily due to an increase in the probability of success related to the achievement of certain remaining developmental milestones, partially offset by changes in the discount rate. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$76.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen Idec International Neuroscience GmbH</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$355.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in the fair value of this obligation was primarily due to an increase in the probability of success related to the achievement of certain remaining developmental milestones, partially offset by a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone payment. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is reflected as a component of accrued expenses and other in our consolidated balance sheets as we achieved the developmental milestone of dosing our first patient in our Phase 2 SPARK study of BIIB054 in Parkinson's disease in January 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we also allocated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the total purchase price to acquired IPR&amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. These assets will be tested for impairment annually until commercialization, after which time the IPR&amp;D will be amortized over its estimated useful life using the economic consumption method. For additional information on this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6975912464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">948.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">741.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">247.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,266.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,229.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available for sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,039.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,039.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,570.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,569.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,075.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,075.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">844.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">845.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">642.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">642.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,408.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,409.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,255.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,258.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,016.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,019.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">557.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,115.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,116.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,569.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,730.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,730.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,552.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,559.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">327.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">327.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">276.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">277.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;months and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,565.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,378.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,063.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> primarily relate to impairments recognized on certain of our available-for-sale marketable debt securities as we intend to sell these securities as a result of the Tax Cuts and Jobs Act of 2017 (the 2017 Tax Act), sales of agency mortgage-backed securities, corporate bonds and government securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -URI http://asc.fasb.org/topic&amp;trid=2122426<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813379696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,875.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">150.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">88.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">83.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,198.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$98.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is expected to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion) (in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion) (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Lock Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we entered into treasury rate locks, with an aggregated notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, as described in Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements, we settled the treasury rate locks and realized an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Swap Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, as described in Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$564.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$902.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recognized as a component of other income (expense), net, for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">84.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">23.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6975951344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">141.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">137.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,213.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,107.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">80.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">123.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,207.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,105.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">767.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">746.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,276.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">658.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,741.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,941.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,439.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,182.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,501.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation expense totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$266.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$309.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$217.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we capitalized interest costs related to construction in progress totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The increase in capitalized interest costs is primarily due to the construction of our Solothurn, Switzerland facility, as discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2016 we purchased land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and are building a large-scale biologics manufacturing facility at this site. We expect this facility to be operational by the end of the decade. Upon completion, the facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$481.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research Triangle Park Facility Purchase</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we completed the purchase of a drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), NC from Eisai Inc. (Eisai). The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> purchase price was comprised of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for buildings, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for machinery and equipment and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for land.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we also amended our existing </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year lease related to Eisai's oral solid dose products manufacturing facility in RTP, NC. The amended lease provided for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year term and our agreement to purchase the facility upon expiration of the lease term or at Eisai's option, their completion of certain activities at the facility. Upon signing, we recognized assets along with a corresponding financing obligation in our consolidated balance sheet of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net present value of the future minimum lease payments. These assets were recorded as a component of buildings and machinery and equipment. In December 2017, upon the earlier than expected completion of Eisai's activities, we completed our purchase of this facility for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976047968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Indebtedness</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">558.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,482.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">994.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">993.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,736.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,734.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,722.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,935.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,512.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">6.875% Senior Notes due March 1, 2018</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March&#160;4, 2008, we issued $550.0&#160;million aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Senior Notes due March&#160;1, 2018 at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99.184%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par. These notes were senior unsecured obligations. We also entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these contracts, the carrying amount of these notes were increased by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> with this amount being amortized using the effective interest rate method over the remaining life of the Senior Notes and recognized as a reduction of interest expense.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we redeemed these notes prior to their maturity and recognized a net charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the extinguishment of these notes. This charge, which was recognized in interest expense in other income (expense) net in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the payment of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> gain related to the remaining unamortized balance of the interest rate swap liability discussed above.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Senior Notes</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The costs associated with these offerings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These notes are senior unsecured obligations. These Senior Notes may be redeemed at our option at any time at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued interest and a specified make-whole amount. These Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes offering due in 2020, we entered into interest rate swap contracts. The carrying value of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to changes in the fair value of these contracts. For additional information on our interest rate contracts, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Notes Payable to Fumedica</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs that are payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica, payable in June 2018, had a carrying value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financing Arrangement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we recorded a financing obligation in relation to the amendment of our lease agreement for Eisai's oral solid dose products manufacturing facility in RTP, NC. In December 2017 we completed the purchase of this facility for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and derecognized the remaining unamortized portion of the financing obligation from our consolidated balance sheet as of that date. For additional information on this transaction, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Maturity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments, excluding our financing arrangement, due under our debt arrangements are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,500.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,003.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our debt is disclosed in Note&#160;8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813315984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares of Preferred Stock authorized, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are authorized as Series A, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are authorized as Series X junior participating and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.25 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. All share repurchases under this authorization will be retired. Under this authorization, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for each year. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remains available for share repurchases under this authorization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2015 Share Repurchase Program). All shares repurchased under this authorization were retired. Our 2015 Share Repurchase Program was completed as of December 31, 2015. Under this authorization, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock (2011 Share Repurchase Program). Shares repurchased under this authorization were principally used to offset common stock issuances under our share-based compensation programs. Our 2011 Share Repurchase Program was completed as of March 31, 2017. Under this authorization, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We did not repurchase any shares of common stock under this authorization during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976001408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(334.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(319.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(193.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">158.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">44.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(162.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">158.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(104.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(318.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(92.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(334.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(172.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(171.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(61.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(19.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(44.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">171.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813381072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Earnings per share for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflects, on a weighted average basis, the repurchase of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares, respectively, of our common stock under our share repurchase authorizations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adjustments related to the spin-off of our hemophilia business did not have a material impact on the potentially dilutive securities to be considered in the calculation of diluted earnings per share of common stock.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813201680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">74.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">95.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">121.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">169.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">160.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(54.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">117.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">135.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">140.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">107.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">119.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">169.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">160.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, unrecognized compensation cost related to unvested share-based compensation was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$168.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spin-off Related Equity Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to an employee matters agreement entered into in connection with the spin-off of our hemophilia business and the provisions of our existing share-based compensation arrangements, we made certain adjustments to the number and terms of our outstanding stock options, RSUs, CSPUs and other share-based awards to preserve the intrinsic value of the awards immediately before and after the spin-off. For purposes of the vesting of these equity awards, continued employment or service with Biogen or with Bioverativ was treated as continued employment for purposes of both Biogen&#8217;s and Bioverativ&#8217;s equity awards with the outstanding awards continuing to vest over their respective original vesting periods. Outstanding unvested awards for employees transferring to Bioverativ were converted to unvested Bioverativ awards.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to the number of our share-based compensation awards were made using an adjustment ratio based upon the weighted-average closing price of our common stock for the 10 calendar days prior to the effective date of the spin-off and the volume-weighted average prices for the 10 calendar days of our common stock following the effective date of the spin-off. For stock options, the exercise prices of the awards were modified to maintain the pre-spin intrinsic value of the awards in relation to the post-spin stock price of Biogen. The difference between the fair value of the awards based upon the adjustment ratio and the opening price on the distribution date was not material.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Directors Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2006 our shareholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Omnibus Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2008 Omnibus Equity Plan as of June 7, 2017 or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017 are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;ratio.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a ten-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options&#8217; vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> grants of stock options made in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all outstanding options were exercisable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility or both, we have concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January&#160;1, 2006 were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.06</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.89</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.11</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">42,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total intrinsic values of options exercised in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic values of options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The weighted average remaining contractual term for options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Market Stock Units (MSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees prior to 2014 vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">four</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees in 2014 and thereafter vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">355.60</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">94,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">382.59</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(112,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">311.17</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(45,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">372.35</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">171,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">370.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted in 2017 include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">9,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> MSUs issued in 2017 based upon the attainment of performance criteria set for 2013, in relation to awards granted in that year. MSUs granted during 2017 also include awards granted in conjunction with our annual awards made in February 2017 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2017 reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2016, 2015 and 2014.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, including the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price on grant date for MSUs awarded prior to 2014, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price on the date of grant for MSUs awarded in 2014 and thereafter, expected volatility of our stock price, risk-free rates of return and expected dividend yield.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> The assumptions used in our valuation are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.0% - 35.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.2% - 40.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0% - 33.2%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9% - 1.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6% - 0.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2% - 1.0%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$263.18 - $267.88</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$260.67 - $304.86</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$277.35 - $426.27</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$382.59</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$328.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$493.43</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of MSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Settled Performance Units (CSPUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CSPUs awarded to employees vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs awarded prior to 2014 are settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. CSPUs awarded in 2014 and thereafter will be settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">122,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">83,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(69,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(34,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">105,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">CSPUs granted in 2017 include awards granted in conjunction with our annual awards made in February 2017 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. CSPUs granted in 2017 also include CSPUs issued in 2017 based upon the attainment of performance criteria set for 2016 in relation to shares granted in 2016.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cash paid in settlement of CSPUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$79.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance-vested Restricted Stock Units (PUs)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">PUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">110,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(43,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(19,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PUs granted in 2017 include awards granted in conjunction with our annual awards made in February 2017 and PUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> PUs were converted to share settlements, of which approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares were vested and issued. All other PUs that vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were settled in cash totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All PUs that vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were settled in cash totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Time-Vested Restricted Stock Units (RSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs awarded to employees generally vest no sooner than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one-third per year over three years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">888,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">303.49</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">464,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">293.41</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(350,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">308.04</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(182,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">292.57</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">832,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">291.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2017 primarily represent RSUs granted in conjunction with our annual awards made in February 2017 and awards made in conjunction with the hiring of new employees. RSUs granted in 2017 also include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">11,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> RSUs granted to our Board of Directors.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs granted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> had weighted average grant date fair values of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$268.52</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$388.88</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of RSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$239.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015 our shareholders approved the 2015 ESPP. The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">167,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">190,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 1995 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 1995 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813307072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Tax Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,540.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,655.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,386.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,588.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,277.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,380.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,128.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,933.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,767.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,201.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,304.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,214.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">108.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,367.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,412.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,307.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">241.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(125.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(129.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(159.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(45.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(145.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,458.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,237.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,161.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Reform</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as global intangible low-taxed income (GILTI). These changes are effective beginning in 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in tax rates and tax laws are accounted for in the period of enactment. Therefore, during the year ended December 31, 2017, we recorded a charge totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,173.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our current estimate of the provisions of the 2017 Tax Act.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Transition Toll Tax</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminates the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on undistributed foreign earnings. The Transition Toll Tax is assessed on the U.S. shareholder's share of the foreign corporation's accumulated foreign earnings that have not previously been taxed. Earnings in the form of cash and cash equivalents will be taxed at a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and all other earnings will be taxed at a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of December 31, 2017, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the Transition Toll Tax, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$78.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is expected to be paid within one year. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At December 31, 2017, we considered none of our earnings to be permanently reinvested outside the U.S. and have therefore recorded tax liabilities associated with an estimate of the total withholding taxes that may be a result of our repatriation of earnings.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Effect on Deferred Tax Assets and Liabilities and other Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our deferred tax assets and liabilities are measured at the enacted tax rate expected to apply when these temporary differences are expected to be realized or settled.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As our deferred tax assets exceed the balance of our deferred tax liabilities at the date of enactment, we have recorded a tax expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$184.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflecting the decrease in the U.S. corporate income tax rate and other changes to U.S. tax law. It is our current policy to not recognize deferred taxes for basis differences expected to reverse as GILTI is incurred and instead to account for any taxes assessed as period costs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Status of our Assessment</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our preliminary estimate of the Transition Toll Tax and the remeasurement of our deferred tax assets and liabilities is subject to the finalization of management&#8217;s analysis related to certain matters, such as developing interpretations of the provisions of the 2017 Tax Act, changes to certain estimates and amounts related to the earnings and profits of certain subsidiaries and the filing of our tax returns. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates.  </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The final determination of the Transition Toll Tax and the remeasurement of our deferred assets and liabilities will be completed as additional information becomes available, but no later than one year from the enactment of the 2017 Tax Act.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Article 20 Procedure of ZINBRYTA</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the Article 20 Procedure of ZINBRYTA, we have recognized a net impairment charge on certain tax assets reflected within income tax expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This charge reflects the write off of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$142.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to prepaid taxes, which was partially offset by the recognition of an unrecorded deferred tax benefit of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">201.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">147.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">250.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">378.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">459.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">209.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">26.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">831.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,071.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(250.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(376.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(107.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(113.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(358.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(490.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total deferred charges and prepaid taxes were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$617.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This new standard becomes effective for us on January 1, 2018.&#160;We will adopt this standard using the modified retrospective method, through a cumulative-effect adjustment directly to retained earnings as of that date.&#160;Based on currently enacted tax rates, upon adoption in 2018, we will record additional deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and an increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 Tax Act</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment of ZINBRYTA related tax assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Changes in Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The most significant factors contributing to the increase in our effective tax rate for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is the effect of the enactment of the 2017 Tax Act and the impairment of certain ZINBRYTA related tax assets, both of which are discussed above. Excluding the effect of these items, our income tax rate would have decreased due to a lower percentage of our earnings being recognized in the U.S., a higher tax jurisdiction. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we earned a lower benefit from the orphan drug credit due to the FDA's approval of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increased primarily due to a net state tax benefit in 2015 resulting from the remeasurement of one of our uncertain tax positions, described below, and a higher relative percentage of our earnings being attributed to the U.S., a higher tax jurisdiction.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Attributes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which begin to expire in 2020. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that begin to expire in 2018. For state income tax purposes, we also had research and investment credit carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$129.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that begin to expire in 2018. For foreign income tax purposes, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net operating loss carryforwards that begin to expire in 2021.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">32.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(21.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(49.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement refund (payment)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">44.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(64.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our 2017 activity above reflects a refund received from a state, related to the settlement of an uncertain tax position.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in the balance of unrecognized tax benefits as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recognized a net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recognized net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recognized a net interest expense of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have accrued approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the payment of interest and penalties as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">International Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to the Danish Tax Authority (SKAT) for assessments received for fiscal 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to Danish withholding taxes based on potential European court decisions expected in 2018 on similar matters.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Federal and State Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to our revenues from anti-CD20 therapeutic programs and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6718810784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Supplemental Cash Flow Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">281.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,066.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,642.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,674.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-cash Operating, Investing and Financing Activity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2017 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 billion</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of FUMADERM and TECFIDERA (together, the Fumapharm Products). The amount, net of tax benefit, was accounted for as an increase to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm, and is expected to be paid in the first quarter of 2018. For additional information on this transaction, please read Note 22, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated balance sheets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information on this matter, please read Note 11,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Property, Plant and Equipment,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the settlement and license agreement with Forward Pharma. For additional information on this transaction, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2015 upon completion of our acquisition of Convergence, we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as part of the purchase price. For additional information on this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">78.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(250.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(260.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(215.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(217.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> charge recognized in November 2017 upon the redemption of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due March 1, 2018. For additional information on the redemption of these notes, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes other than temporary impairments recorded on strategic investments and marketable debt securities during the year.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets include prepaid taxes totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$657.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$817.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the Article 20 Procedure of ZINBRYTA, we impaired prepaid tax balances totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$142.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on the Article 20 Procedure of ZINBRYTA and resulting impairment of ZINBRYTA related assets, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">844.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">572.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">297.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">282.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">206.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">195.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">183.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">130.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">159.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued TECFIDERA litigation settlement charge</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">636.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">685.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,901.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011 Biogen Italia SRL, our Italian subsidiary, received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 through mid-February 2011 exceeded by EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In January 2012 we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit in the Price Determination Resolution should apply as written to only &#8220;the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months&#8221; of TYSABRI sales, which ended in mid-February 2009. Since being notified in the fourth quarter of 2011 that AIFA believed a reimbursement limit was still in effect, we deferred revenue on sales of TYSABRI as if the reimbursement limit were in effect for each biannual period beginning in mid-February 2009.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2013 we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee that would have resolved all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As a result of this agreement in principle, we recorded a liability and reduction to revenue of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> at June 30, 2013, which approximated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the claim related to the period from mid-February 2009 through mid-February 2011. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of TYSABRI revenues related to the periods February 2013 through June 2014 that were previously deferred.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2017 we reached an agreement with AIFA's Price and Reimbursement Committee resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods. As a result, in the first quarter of 2017, we recognized EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) in revenues for sales that were previously deferred. These amounts were previously accrued for and included in the table above in Other as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813359072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2007 we entered into a collaboration and license agreement with Neurimmune Subone AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product, or 12 years from the first commercial sale of any product using such a licensed compound. Our anti-amyloid beta antibody, aducanumab, for the treatment of AD resulted from this collaboration. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. Under this agreement, we are also required to pay royalties on sales of any resulting commercial products and make payments upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of our collaboration and license agreement with Neurimmune. Under the amended agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab.&#160;Our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, will now range from the high single digits to low teens.&#160;As we consolidate the results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the fourth quarter of 2017 and treated it as a distribution. Under the amended agreement, we also have an option that will expire in April 2018 to further reduce our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> amounts reimbursed were immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015 we recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payable to Neurimmune upon enrollment of the first patient in a Phase 3 trial for aducanumab. We recognized this payment as a charge to noncontrolling interest. Based upon our current development plans for aducanumab, we may pay Neurimmune up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$275.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestone payments. Future milestone payments and royalties, if any, will be reflected in our consolidated statements of income as a charge to noncontrolling interest, net of tax when such milestones are achieved.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our October 2017 collaboration agreement with Eisai for the joint development and commercialization of aducanumab, Eisai may elect to share in the benefit and cost associated with the royalty reductions discussed above. Eisai has elected to not share in the benefit and cost of the October 2017 royalty reduction. For additional information on our collaboration arrangement with Eisai, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813322592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depending on the collaborative arrangement, we may record funding receivable or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration agreement will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#8217;s offer or purchase Genentech&#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is responsible for the worldwide manufacturing of RITUXAN. Development and commercialization rights and responsibilities under this collaboration are divided as follows:</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share with Genentech co-exclusive rights to develop, commercialize and market RITUXAN in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Canada</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Genentech have assigned our rights under our collaboration agreement with respect to Canada to the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">OCREVUS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FDA approved OCREVUS, a humanized anti-CD20 monoclonal antibody, for the treatment of RMS and PPMS. Under our agreement with Genentech, we will receive a tiered royalty on U.S. net sales from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and increasing up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if annual net sales exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$900.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. There will be a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we will receive a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11 years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS was approved for the treatment of RMS and PPMS in Australia, Switzerland and the E.U. in July 2017, September 2017 and January 2018, respectively. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Profit-sharing Formulas</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">RITUXAN Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</font></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN pre-tax profits in the U.S. decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in February 2016 when GAZYVA was approved by the FDA as a new treatment for follicular lymphoma and was further decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12 month period exceeded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on certain events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 the FDA approved RITUXAN HYCELA for subcutaneous injection for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma and CLL. This new treatment includes the same monoclonal antibody as intravenous RITUXAN in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GAZYVA Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax profit-sharing formula for GAZYVA provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating profits earned each calendar year. Our share of annual profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> our share of operating profits on GAZYVA was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,316.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">242.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,559.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> profit-sharing threshold was met during the third quarter and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> profit-sharing threshold was met during the first quarter. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> profit-sharing threshold was met during the first quarter. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> profit-sharing threshold was met during the first quarter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as depicted in the table above, excludes certain expenses charged to the collaboration by Genentech that we believe remain the responsibility of Genentech and that we are not obligated to pay under the terms of the collaboration agreement. Accordingly, we did not recognize the effect of those expenses in the determination of our share of pre-tax collaboration profits and Genentech has withheld approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from amounts due to us in relation to collaboration activity for 2017, representing Genentech&#8217;s estimate of our share of these expenses. We remain in discussions with Genentech about a resolution relating to these amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie for the development and commercialization of ZINBRYTA, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. Under this agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory) where development and commercialization costs and profits are shared equally. Outside of the Collaboration Territory, we are solely responsible for development and commercialization of ZINBRYTA and will pay a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are responsible for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and record these activities within their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures received from AbbVie.&#160;For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the collaboration incurred </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for research and development activities, respectively, for which we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we also recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of pre-commercialization expenses within our selling, general and administrative expense, which represented </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the collaboration's pre-commercialization costs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. After ZINBRYTA was approved by the FDA and European Medicines Agency (EMA) in 2016, we began to recognize our share of the collaboration activities within the U.S., E.U. and Canadian territories as described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Co-promotion Profits and Losses."</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Article 20 Procedure of ZINBRYTA</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 the EMA announced that it had provisionally restricted the use of ZINBRYTA to adult patients with highly active relapsing disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) or with rapidly evolving severe relapsing MS who are unsuitable for treatment with other DMTs.&#160;These restrictions followed the initiation of an EMA review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, as part of this Article 20 Procedure of ZINBRYTA, the EMA Pharmacovigilance Risk Assessment Committee (PRAC) completed its assessment and recommended a further set of restrictions on the use of ZINBRYTA by MS patients. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 the Committee for Medicinal Products for Human Use (CHMP) adopted an opinion, confirming the PRAC's recommendations, for further restrictions to minimize the risk of serious liver injury with ZINBRYTA, including restriction of its use to adult patients with relapsing forms of MS who have had an inadequate response to at least two DMTs and for whom treatment with any other DMT is contraindicated or otherwise unsuitable. In January 2018 the EC adopted a final and legally-binding decision, which concluded the Article 20 Procedure, confirming the CHMP opinion.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The recommendation of these restrictions by the CHMP resulted in the impairment of substantially all of our assets related to ZINBRYTA as we have determined that these amounts may not be recoverable. As a result, we recorded net impairment charges related to intangible assets, inventory, property, plant and equipment and prepaid tax assets, totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$190.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Inventory related losses are subject to our profit share with AbbVie and are included above net of expected reimbursement. Offsetting these amounts was an unrecorded tax benefit related to certain ZINBRYTA related assets totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie recognizes revenues on sales to third parties and we recognize our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. The collaboration began selling ZINBRYTA in the U.S. in the third quarter of 2016. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenue of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect our share of an overall net loss within the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">92.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, we recognize revenues on sales to third parties in product revenues, net in our consolidated statements of income. We also record the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income as these costs are incurred. We reimburse AbbVie for their </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the co-promotion profits or losses in the E.U. and Canada. This reimbursement is recognized in collaboration profit (loss) sharing in our consolidated statements of income. We began to recognize product revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits in the E.U. and Canada, as compared to net income recognized of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration losses in the E.U. and Canada in the prior year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. The next expected milestone would be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due if ex-U.S. net sales reach </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over a period of four consecutive quarters. Royalty payments are recognized in cost of sales within our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Collaborations </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis to develop and commercialize SPINRAZA for the treatment of SMA. During 2014 we amended this agreement to adjust the amount of potential additional payments and terms of the exercise of our opt-in right to license SPINRAZA, which included providing for additional opt-in scenarios, based on the filing or acceptance of a New Drug Application (NDA) with the FDA or marketing authorization application with the EMA. Consistent with the initial agreement, Ionis remained responsible for conducting the pivotal/Phase 3 trials and we provided input on the clinical trial design and regulatory strategy for the development of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA was approved for the treatment of SMA in the U.S., E.U. and Japan in December 2016, June 2017 and July 2017, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized product revenues totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$883.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, on our sales of SPINRAZA. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$112.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis. In addition, during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we made milestone payments to Ionis totaling&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;related to the marketing approvals discussed above, which were capitalized in intangible assets, net in our consolidated balance sheets. During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, upon the exercise of our option to develop and commercialize SPINRAZA, we also paid a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> license fee to Ionis, which was recognized as research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> no clinical trial payments were made to Ionis due to the completion of study activities. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we made clinical trial payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of the program, which were recorded in investments and other assets in our consolidated balance sheets as they represented prepaid research and development expenditures. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, these prepaid research and development amounts were fully expensed as the services were provided.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$234.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$257.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reflected in total costs and expenses in our consolidated statements of income related to the advancement and commercialization of the program. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Antisense Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three therapeutic targets. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, Ionis is responsible for global development of any product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to another </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if we successfully develop the product candidate after option exercise. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis and agreed to make potential additional payments, prior to licensing, of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 we recognized this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone upon the selection of BIIB080 (also known as IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), which is currently in Phase 1 development. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Research Collaborations</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">2013 Long-term Strategic Research Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2013 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the treatment of neurological disorders.&#160;Under the collaboration, Ionis will perform research on a set of neurological targets identified within this agreement. Once the research has reached a specific stage of development, we will make a determination whether antisense therapy is the preferred approach to developing a therapeutic candidate or whether another modality is preferred. If an antisense approach is selected, Ionis will continue development and identify a potential product candidate. If another modality is selected, we will assume responsibility for identifying a potential product candidate and assume development responsibility for development in that modality. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense representing the value of intellectual property purchased that had not reached technological feasibility.&#160;We recognized the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as prepaid research and discovery services, representing the value of the Ionis full time equivalent employee resources required by the collaboration to provide research and discovery services over the term of the collaboration.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis is also eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered milestones of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the treatment of ALS and other neurological targets identified.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. &#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For product candidates using a different modality, we will be responsible for global development through all stages and will pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the achievement of certain regulatory milestones and royalties on future sales if we successfully develop the product candidate. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">2017 SMA Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2017 we entered into a new collaboration agreement with Ionis to identify new antisense oligonucleotide drug candidates for the treatment of SMA. Under this agreement, we will have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of these therapies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment to Ionis and we may pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$260.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and regulatory milestone payments if new drugs advance to marketing approval. Upon commercialization, we may also pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$800.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and E2609 Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2014 we entered into a collaboration agreement with Eisai (Eisai Collaboration Agreement) to jointly develop and commercialize two Eisai product candidates for the treatment of AD, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor. Under the Eisai Collaboration Agreement, Eisai serves as the global operational and regulatory lead for both compounds with all costs, including research, development, sales and marketing expenses shared equally by us and Eisai; and following marketing approval in major markets, such as the U.S., the E.U. and Japan, we and Eisai would co-promote BAN2401 and E2609 and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. In addition, the Eisai Collaboration Agreement provides both parties with certain rights and obligations in the event of a change in control of either party.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Eisai Collaboration Agreement also provided Eisai with an option to jointly develop and commercialize aducanumab (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, a separate collaboration agreement would be entered into with Eisai on terms and conditions that mirror the Eisai Collaboration Agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, both companies will continue to jointly develop BAN2401 and E2609 in accordance with the Eisai Collaboration Agreement; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of activity related to the Eisai Collaboration Agreement is as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration in development of BAN2401 and E2609</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">146.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and E2609 development expense reflected in our consolidated statements of income, excluding upfront and milestone payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">74.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2016 we recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment related to the initiation of a Phase 3 trial for E2609, which is included in research and development expense in our consolidated statements of income. We could pay Eisai up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$625.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the Eisai Collaboration Agreement based on the future achievement of certain development, regulatory and commercial milestones.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, we will continue to lead the ongoing Phase 3 development of aducanumab and will remain responsible for 100% of development costs for aducanumab incurred in support of this agreement until April 2018. Eisai will then reimburse us for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of aducanumab development expenses for the period April 2018 through December 2018, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> thereafter. Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. We will receive a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in the U.S., a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in the E.U. and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The companies will continue to share equally in the potential profits (losses) in rest of world markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai also agreed to co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai will distribute AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$263.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was reflected in research and development expense in our consolidated statements of income related to the advancement of our aducanumab program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-Tau Option</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for BIIB092 (formerly known as BMS-986168), a Phase 2-ready experimental medicine with potential in AD and PSP. BIIB092 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received worldwide rights to BIIB092 and are responsible for the full development and global commercialization of BIIB092 in AD and PSP. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to BMS and we may pay BMS up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$410.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments, and potential royalties. We also assumed all remaining obligations to the former shareholders of iPierian, Inc. (iPierian) related to BMS&#8217;s acquisition of iPierian in 2014. In June 2017 we recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 PSP study for BIIB092 and we may pay the former shareholders of iPierian up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$490.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestone payments, and potential royalties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Both the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone payment were recognized as research and development expense in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Alkermes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), for BIIB098 (formerly known as ALKS 8700), an oral monomethyl fumarate prodrug in Phase 3 development for the treatment of relapsing forms of MS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received an exclusive, worldwide license to develop and commercialize BIIB098 and will pay Alkermes a mid-teens percentage royalty on potential worldwide net sales of BIIB098. Royalties payable on net sales of BIIB098 are subject to tiered minimum payment requirements for a period of five years following FDA approval. Alkermes is eligible to receive royalties in the mid-single digits to low-teen percentages of annual net sales upon successful development and commercialization of new product candidates other than BIIB098. Alkermes will maintain responsibility for regulatory interactions with the FDA through the potential approval of the NDA for BIIB098 for the treatment of MS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment to Alkermes representing our share of BIIB098 development costs already incurred in 2017. Beginning in 2018 we are responsible for all development expenses related to BIIB098. In December 2017 we also recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> expense, which is expected to be paid to Alkermes in early 2018, enabling the continuation of the agreement to develop BIIB098. Both the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> continuation payment were recognized as research and development expense in our consolidated financial statements for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may also pay Alkermes up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional future milestone payments upon certain regulatory achievements related to BIIB098 under this collaboration. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$80.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in research and development expense in our consolidated statements of income related to this collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the license and collaboration agreement, we may also enter into a supply agreement with Alkermes for the commercial supply of BIIB098 and other products developed under the license and collaboration agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 we entered into a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). This collaboration is focused on the development of a portfolio of AGTC&#8217;s therapeutic programs, including both a clinical-stage candidate for X-linked Retinoschisis (XLRS) and a pre-clinical candidate for the treatment of X-Linked Retinitis Pigmentosa (XLRP). This agreement also provides us with options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement we received worldwide commercialization rights for the XLRS and XLRP programs. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials and we will support the related clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. AGTC has an option to share development costs and profits after the initial clinical trial data becomes available, and an option to co-promote the second of these products approved in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to AGTC. AGTC is also eligible to receive development, regulatory and commercial milestone payments aggregating in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$467.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> collectively for the two lead programs and up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$592.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> across the discovery programs. AGTC is also eligible to receive royalties in the mid-single digit to mid-teen percentages of annual net sales upon successful development and commercialization of new product candidates. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment reflected a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equity investment in AGTC, prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and total licensing and other fees of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total licensing and other fees were recognized as a charge to research and development expense in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equity investment and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of prepaid research and development expenditures were recorded in investments and other assets in our consolidated balance sheets. These prepaid research and development amounts are being expensed as the services are provided, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remains as a prepaid asset as of December 31, 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$54.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which were reflected in research and development expense in our consolidated statements of income related to this collaboration. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we also received a manufacturing license under which we received an exclusive license to use AGTC&#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&#8217;s discretion, in exchange for payment of milestones and royalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">University of Pennsylvania</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 we entered into a collaboration and alliance with the University of Pennsylvania (UPenn) to advance gene therapy and gene editing technologies. The collaboration is primarily focused on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. The alliance is also focused on the research and validation of next-generation gene transfer technology using adeno-associated virus gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to UPenn, which was recorded as research and development expense in our consolidated statements of income, and made prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded in investments and other assets in our consolidated balance sheets. During 2017, we made additional prepaid research and development expenditures to UPenn of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the advancement of these programs. These prepaid research and development amounts are being expensed as the services are provided, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remains as a prepaid asset as of December 31, 2017. We also expect to fund an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional research and development costs in seven preclinical research and development programs, as well as the exploration of genome-editing technology.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If all of the collaborations programs are successful and we exercise all of our options under the UPenn collaboration and alliance, we may be required to make future payments of over </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in research funding, options and milestone payments. UPenn is also eligible to receive royalties in the mid-single digit to mid-teens percentages of annual net sales upon successful development and commercialization of new product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$33.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in research and development expense in our consolidated statements of income related to this collaboration.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into several research, discovery and other related arrangements that resulted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, recorded as research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;Samsung Biologics contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> stake in Samsung Bioepis and we contributed approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ownership interest.&#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control and is based on paying for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the joint venture agreement plus a rate that will represent their return on capital. If we do not exercise this option by mid-2018, this option will expire and Samsung Biologics will have the right to purchase all of Samsung Bioepis&#8217; shares then held by us.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for this investment under the equity method of accounting as we maintain the ability to exercise significant influence over Samsung Bioepis through a presence on the entity&#8217;s Board of Directors and our contractual relationship. Under the equity method, we recorded our original investment at cost and subsequently adjust the carrying value of our investment for our share of equity in the entity&#8217;s income or losses according to our percentage of ownership. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our consolidated statements of income. During the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2013 pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of one anti-TNF biosimilar, Japan.&#160;Under this agreement, we have made total upfront and clinical development milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all of which have been recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in milestone payments, which have been capitalized in intangible assets, net in our consolidated balance sheets as IMRALDI received regulatory approval in the E.U. in August 2017, BENEPALI received regulatory approval in the E.U. in January 2016 and FLIXABI received regulatory approval in the E.U. in May 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of BENEPALI in the E.U. in the first quarter of 2016 and FLIXABI in the E.U. in the third quarter of 2016. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis. This profit sharing with Samsung Bioepis is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we will receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis. Under the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development and analytical development. Under our manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;Under limited circumstances, we may also supply Samsung Bioepis with quantities of drug product of biosimilar products for use in clinical trials through arrangements with third-party contract manufacturers. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues in relation to these services, which is reflected as a component of other revenues in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976001408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, a qui tam action filed on behalf of the United States and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in an action filed by a shareholder on October 20, 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Abbreviated New Drug Application (ANDA) Litigation relating to TECFIDERA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June, July, and September 2017 and January 2018, we initiated patent infringement proceedings pursuant to the Hatch-Waxman act in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Caribe Holdings (Cayman) Co. Ltd.&#160;DBA Puracap&#160;Caribe, Puracap International LLC, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Impax Laboratories, Inc., Prinston Pharmaceutical Inc., Slayback Pharma LLC,&#160;Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd., Cipla Limited, Glenmark Pharmaceuticals Ltd., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Shipla Medicare Limited, Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd., Accord Healthcare Inc., Par Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc. and Zydus Pharmaceuticals (USA) Inc. In addition, we initiated patent infringement proceedings pursuant to the Hatch-Waxman act against Stason Pharmaceuticals, Inc. in the U.S. District Court for the Central District of California, Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of New Jersey, Accord Healthcare Inc. in the U.S. District Court for the Middle District of North Carolina, Par Pharmaceutical Inc. in the U.S. District Court for the Southern District of New York, Sandoz Inc. in the U.S. District Court for the District of Colorado and Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cases against Accord Healthcare Inc., Zydus Pharmaceuticals (USA) Inc. and Sandoz Inc. have been dismissed in the North Carolina, New Jersey and Colorado courts but will continue against those parties in Delaware. The cases against Par Pharmaceutical Inc. in both New York and Delaware have been dismissed because Par Pharmaceutical Inc.&#8217;s ANDA application has been withdrawn. The case against Stason Pharmaceuticals, Inc. in California has been dismissed, but the case against its partner Sawai USA, Inc. will proceed in Delaware. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect a trial in the Delaware actions in December 2019, and a trial has been set in the West Virginia action in February 2020.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. In March 2017 the USPTO ruled against Forward Pharma. Forward Pharma has appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. For additional information regarding this matter, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the EPO decided to revoke our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 the EPO announced its decision revoking Forward Pharma&#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Board of Appeal and the Enlarged Board of Appeal, as applicable, to make a final determination. For additional information regarding this matter, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG filed actions in the District Court of The Hague (on January 11, 2016), the German Patents Court (on March 3, 2016) and the Commercial Court of Rome (November 2017) to invalidate the Dutch, German and Italian counterparts of our European Patent Number 1 485 127 (&#8220;Administration of agents to treat inflammation&#8221;) ('127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat MS. The patent expires in February 2023. The Dutch counterpart was ruled invalid and we have appealed. In November 2018 Bioeq gmbh (an entity associated with Swiss Pharma and Polpharma) brought an action in the Polish Patent Office seeking to revoke the Polish counterpart of the &#8216;127 patent. In January 2018 the German court announced that the German counterpart was invalid. No date for a hearing on the merits has yet been set in the Italian action.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees. The trial against EMD Serono and Pfizer commenced in mid-January 2018 and is ongoing. A trial date against Bayer and Novartis has not yet been set.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 1, 2016, we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we learned that the Prosecution Office of Milan is investigating our interactions with certain healthcare providers in Italy.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813318384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013, and Perrigo subsequently sold its rights to these payments to a third party effective January 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN, occurred after January&#160;1, 2009, we recorded the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestones related to these acquisitions. For additional information on our acquisition of Convergence please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013 we paid this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment as TECFIDERA was approved in the U.S. for MS by the FDA. We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2016 and the first, second and third quarters of 2017, respectively, and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of Fumapharm Products in the fourth quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. If the prior 12 months sales of Fumapharm Products are less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, contingent payments remain payable on a decreasing tiered basis. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.7 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in development milestones, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in regulatory milestones and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in commercial milestones as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$460.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$77.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of December 31, 2017, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the Transition Toll Tax, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$78.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is expected to be paid within one year. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015, we purchased land in Solothurn, Switzerland and are building a large-scale biologics manufacturing facility at this site. We expect this facility to be operational by the end of the decade. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$270.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the construction of this facility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense, net of sublease income under these leases, which terminate at various dates through 2028, amounted to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$65.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">72.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">72.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">68.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">271.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">617.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(71.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(188.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">44.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">44.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">199.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">428.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813180960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Guarantees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesAbstract', window );"><strong>Guarantees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesTextBlock', window );">Guarantees</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Guarantees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not have significant liabilities recorded for guarantees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI http://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813309824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Employee Benefit Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">401(k) Savings Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense related to our 401(k) Savings Plan totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$51.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Compensation Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pension Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.00%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. Minimum employee contributions are based on the respective employee&#8217;s age, salary and gender. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the Swiss plan had an unfunded net pension obligation of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and plan assets that totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$83.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized expense totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our Swiss plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The obligations under the German plans are unfunded and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net periodic pension cost related to the German plans totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976047968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,294.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">920.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">4,214.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,169.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">798.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,968.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,908.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">730.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,638.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AVONEX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,593.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">557.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,151.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,675.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">638.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,313.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,790.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">840.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,630.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">PLEGRIDY</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">295.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">198.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">494.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">305.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">176.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">481.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">227.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">111.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">338.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,113.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">859.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,973.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,182.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">780.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,963.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,103.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">783.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,886.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">91.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">91.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">84.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">84.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">89.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">89.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">52.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">52.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">657.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">226.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">883.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">42.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">48.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">445.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">68.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">513.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">308.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">11.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">319.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">26.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">268.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">65.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">333.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">208.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">25.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">234.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">39.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">39.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">51.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">51.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">370.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">370.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">7,017.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,337.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7,050.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,767.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9,817.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6,545.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,642.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9,188.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Geographic Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,017.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,844.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">160.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">332.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,475.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">83.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,559.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">249.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">42.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">360.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,226.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,948.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,182.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,050.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,237.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">313.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">224.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,272.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,221.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,501.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,545.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,165.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">333.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">142.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,296.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">881.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,187.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our total revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are derived from our collaboration agreement with Genentech. For additional information on our collaboration with Genentech, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Significant Customers</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recorded revenues from two wholesalers accounting for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,215.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$545.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$161.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$707.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$643.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$684.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813318384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b) (c) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (e) (f) (g) (h)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,380.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,639.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,622.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,712.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">340.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">397.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">406.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">415.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,559.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">90.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">41.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">179.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">360.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,810.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,078.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,077.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,307.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,273.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,426.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,712.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,707.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,797.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,643.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">747.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">862.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,226.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(166.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,670.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">747.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">862.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,226.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(297.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.47</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.07</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.80</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.41</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.46</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.07</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.79</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.40</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.92</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(i) (j)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(i) (k) (l)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,309.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,466.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,502.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">329.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">349.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">317.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">318.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,726.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,894.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,955.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,872.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,448.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,413.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,523.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,538.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,493.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,970.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">969.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,048.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,030.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">647.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,695.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">970.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,049.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">649.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.96</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.99</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">216.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the first, second, third and fourth quarters of 2017 include a pre-tax charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$353.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$29.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$30.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$30.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment to BMS upon the closing of our agreement to exclusively license BIIB092.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to acquired in-process research and development of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment to Remedy upon closing of the asset purchase transaction.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a developmental milestone that became payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 PSP study for BIIB092.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc., for the fourth quarter of 2017, includes a pre-tax charge to noncontrolling interest of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in royalty rates payable on potential commercial sales of aducanumab.&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes pre-tax charges to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment and a continuation payment, respectively, to Alkermes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment to Ionis upon entering into a new collaboration agreement to identify new antisense-oligonucleotide drug candidates for the treatment of SMA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,173.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the provisions of the 2017 Tax Act, including a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> expense under the Transition Toll Tax.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second, third and fourth quarters of 2016 includes additional pre-tax depreciation expense totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$15.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$15.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$14.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as part of our decision to cease manufacturing and vacate our small-scale biologics manufacturing facility in Cambridge, MA as well as close and vacate our warehouse space in Somerville, MA. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(j)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the third quarter of 2016 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(k)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a milestone payment due to Eisai related to the initiation of a Phase 3 trial for E2609.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(l)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our January 2017 settlement and license agreement with Forward Pharma.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6715933264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Karyopharm Therapeutics Inc. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired the exclusive worldwide rights to develop and commercialize Karyopharm Therapeutics Inc.'s (Karyopharm) investigational oral compound BIIB100 (formerly known as KPT-350) for the treatment of certain neurological and neurodegenerative conditions, primarily in ALS. We will pay Karyopharm an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and we may pay Karyopharm up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$207.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments, and potential royalties.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805334704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Business Overview</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer&#8217;s disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS and relapsing MS and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), a rare condition that affects movement, speech, vision and cognitive function, Parkinson's disease and ALS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE in the European Union (E.U.). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these audited consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenues when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates, non-US pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the United States (U.S.) for RITUXAN and GAZYVA; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160; </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">reimbursement of our selling and development expenses in the U.S. for RITUXAN; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(iii)&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech, the Roche Group and us. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information on our collaboration with Genentech, please read Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Multiple-Element Revenue Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenues to the various elements based on their estimated selling price as a component of total revenues.&#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&#8217;s best estimate of a selling price. Revenues allocated to an individual element are recognized when all other revenue recognition criteria are met for that element.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangement with AbbVie Inc. (AbbVie) represents a collaborative arrangement as each party is an active participant and exposed to significant risks and rewards of the arrangement. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenue in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration with AbbVie, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms that generally require payment within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of accounts receivable, net, respectively. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Marketable Securities and Other Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions and are included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Investments for Other-than-Temporary Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method of Accounting</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or market with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three to five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to obtaining the fair value of the U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd. (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TECFIDERA, TYSABRI and AVONEX using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TECFIDERA, TYSABRI and AVONEX is performed annually during our long-range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TECFIDERA, TYSABRI or AVONEX.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-process Research and Development (IPR&amp;D)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including treatments for forms of neuropathic pain, such as trigeminal neuralgia (TGN). Such programs could become impaired if assumptions used in determining the fair value change. Impairments are recorded as amortization of acquired intangible assets in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&#160;25, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Contingent Consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation of Foreign Currencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyCostofSalesPolicyTextBlock', window );">Royalty Cost of Sales</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Accounting for Share-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&#8217; vesting periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense, net of forfeitures, for RSUs is recognized straight-line over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price of common stock under our ESPP is equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the lesser of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> discount is recognized as compensation expense over the 90-day purchase period. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$106.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$108.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All tax effects associated with intercompany transfers of assets within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&#160;If the asset transferred becomes impaired, for example through the obsolescence of inventory or discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry-specific guidance. This new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date. These new standards became effective for us on January 1, 2018, and will be adopted using the modified retrospective method through a cumulative-effect adjustment directly to retained earnings as of that date. We have performed a review of these new standards as compared to our current accounting policies for customer contracts and collaborative relationships. During the fourth quarter of 2017 we finalized our assessments over the impact that these new standards will have on our consolidated results of operations, financial position and disclosures. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have not identified any accounting changes that would materially impact the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues; however, the adoption of these new standards may result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we expect to recognize an immaterial adjustment to retained earnings reflecting the cumulative impact for the accounting changes related to certain contract manufacturing arrangements made upon adoption of these new standards.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. This new standard became effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this new standard is not expected to have a material impact on our consolidated financial position or results of operations; however, it will result in the reclassification of where we recognize changes in fair value related to certain investments prospectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard establishes a right-of-use (ROU) model that requires all lessees recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This new standard will become effective for us on January 1, 2019. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While we are currently evaluating the impact that this new standard may have on our consolidated results of operations, financial position and disclosures, we expect that the adoption of this new standard may materially affect the reported amount of total assets and total liabilities within our consolidated balance sheet with no material impact to our consolidated statement of income. We are unable to quantify the impact at this time as the ultimate impact of adopting this new standard will depend on the total amount of our lease commitments as of the adoption date. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences and classification of awards as either equity or liabilities in the statement of cash flows. This new standard became effective for us on January 1, 2017. The adoption of this new standard did not have a material impact on our consolidated financial position, results of operations or statement of cash flows; however, it has resulted in the reclassification of certain prior year amounts in our consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. This new standard became effective for us on January 1, 2018. We will adopt this new standard using the modified retrospective method, through a cumulative-effect adjustment directly to retained earnings as of the beginning of that date. Based on currently enacted tax rates, upon adoption, we will record additional deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and an increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-01,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. We elected to early adopt this new standard as of January 1, 2017, with prospective application to any business development transactions, including our recent asset acquisition of BIIB093 from Remedy Pharmaceuticals Inc. (Remedy) in May 2017. For additional information on this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-04, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates Step 2 from the goodwill impairment test. Under the amendments in ASU No. 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds that reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. We elected to early adopt this new standard as of October 31, 2017, during our annual review of goodwill. The adoption of this new standard resulted in a change to our accounting policy; however, did not have an impact on our consolidated financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. This new standard will become effective for us on January 1, 2019. We are currently evaluating the potential impact that this new standard may have on our consolidated financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard is intended to simplify hedge accounting by better aligning how an entity&#8217;s risk management activities and hedging relationships are presented in its financial statements and simplifies the application of hedge accounting guidance in certain situations. This new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This new standard will become effective for us on January 1, 2019; however, early adoption is permitted. For cash flow hedges existing at the adoption date, this new standard requires adoption on a modified retrospective basis with a cumulative-effect adjustment to retained earnings as of the effective date. The amendments to presentation guidance and disclosure requirements are required to be adopted prospectively. We are currently evaluating the date upon which we will adopt this new standard and the impact this new standard may have on our consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyCostofSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Cost of Sales [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyCostofSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41620-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579240-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579245-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41675-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41638-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75025870&amp;loc=d3e40691-111596<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e4975-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6389767&amp;loc=d3e17916-109280<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6975934784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Property, plant and equipment estimated useful lives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976199680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hemophilia Spin-Off Hemophilia Spin-Off (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Assets and liabilities charged against equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">155.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=SL51724579-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6975957488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Charges and spending related to our 2015 restructuring program</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our 2015 restructuring program during 2017:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(40.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813213168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Reserves (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract', window );"><strong>Sales Discounts, Returns and Allowances, Goods [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of the change in reserves</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">482.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">605.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">583.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,307.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">26.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,917.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(475.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,756.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,232.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(69.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(442.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(534.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">109.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">606.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">548.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">592.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,044.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,668.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(522.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,576.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,099.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(536.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(609.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">482.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">387.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">459.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,732.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,229.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(405.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,258.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,666.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(44.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(296.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(351.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">548.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves, included in consolidated balance sheets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">189.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">572.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813400784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">162.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">605.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">698.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">157.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">902.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,001.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802627536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(535.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(523.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,689.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,634.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">680.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">680.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,971.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,160.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,811.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,481.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(776.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,705.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,264.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,385.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,879.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,742.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,934.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,808.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization of intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon this analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">423.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">401.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">381.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">254.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">242.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,669.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to our hemophilia business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,267.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,026.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,632.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,669.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805566608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,229.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,229.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,609.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,609.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,919.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,919.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">643.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">643.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,444.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,433.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">111.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">111.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">634.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">111.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,558.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,533.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">481.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,517.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,521.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,032.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,026.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,851.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,796.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,077.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,874.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,483.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,808.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">62.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13476-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13467-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75026489&amp;loc=d3e13220-108610<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14172-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6716952896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">948.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">741.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">247.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,266.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,229.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable securities including strategic investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available for sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,039.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,039.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,570.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,569.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,075.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,075.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">844.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">845.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">642.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">642.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,408.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,409.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,255.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,258.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,016.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,019.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">557.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: Available-for-sale securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,115.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,116.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,569.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,730.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,730.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,552.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,559.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">327.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">327.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">276.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">277.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable securities, excluding strategic investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,565.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,378.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,063.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6716169984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,875.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">150.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">88.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">83.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,198.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of derivatives designated as hedging instruments on our consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion) (in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion) (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of the fair value for our outstanding derivatives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">84.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">23.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813394416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of property, plant and equipment, net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of property, plant and equipment, net are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">141.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">137.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,213.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,107.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">80.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">123.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,207.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,105.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">767.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">746.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,276.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">658.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,741.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,941.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,439.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,182.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,501.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976006928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Indebtedness</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">558.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,482.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">994.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">993.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,736.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,734.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,722.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,935.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,512.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Total debt maturities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments, excluding our financing arrangement, due under our debt arrangements are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,500.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,003.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813340720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfCommonStockTableTextBlock', window );">Summary of common stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813224576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of accumulated other comprehensive income (loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(334.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(319.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(193.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">158.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">44.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(162.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">158.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(104.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(318.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(92.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(334.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(172.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(171.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(61.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of accumulated other comprehensive income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(19.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(44.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">171.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976048976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823136992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">74.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">95.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">121.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">169.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">160.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(54.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">117.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">135.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">140.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">107.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">119.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">169.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">160.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.06</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.89</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.11</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">42,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock', window );">Tax benefit and cash received from stock option exercises</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock', window );">Market stock units activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">355.60</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">94,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">382.59</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(112,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">311.17</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(45,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">372.35</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">171,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">370.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock', window );">Assumptions used in valuation of market based stock units</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assumptions used in our valuation are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.0% - 35.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.2% - 40.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0% - 33.2%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9% - 1.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6% - 0.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2% - 1.0%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$263.18 - $267.88</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$260.67 - $304.86</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$277.35 - $426.27</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$382.59</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$328.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$493.43</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock', window );">Cash settled performance shares activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">122,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">83,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(69,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(34,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">105,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceunitsactivityTableTextBlock', window );">Performance units activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">110,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(43,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(19,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock', window );">Time-vested restricted stock units activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">888,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">303.49</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">464,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">293.41</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(350,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">308.04</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(182,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">292.57</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">832,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">291.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock', window );">Shares issued under employee stock purchase plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">167,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">190,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 1995 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 1995 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumptions used in valuation of market based stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceunitsactivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance units activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceunitsactivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Cash Settled Performance Shares Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Market Stock Units Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfMarketStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time Vested Restricted Stock Units Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6972386912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Income before income tax provision and the income tax expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,540.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,655.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,386.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,588.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,277.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,380.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,128.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,933.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,767.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,201.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,304.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,214.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">108.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,367.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,412.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,307.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">241.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(125.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(129.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(159.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(45.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(145.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,458.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,237.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,161.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of deferred tax assets and liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">201.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">147.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">250.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">378.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">459.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">209.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">26.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">831.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,071.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(250.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(376.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(107.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(113.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(358.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(490.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 Tax Act</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment of ZINBRYTA related tax assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of beginning and ending amount of unrecognized tax benefits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">32.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(21.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(49.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement refund (payment)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">44.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(64.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=96868398&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976199680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental cash flow information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">281.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,066.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,642.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,674.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">78.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(250.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(260.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(215.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(217.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">844.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">572.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">297.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">282.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">206.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">195.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">183.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">130.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">159.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued TECFIDERA litigation settlement charge</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">636.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">685.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,901.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805303120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaTableTextBlock', window );">Co-promotion profit sharing formula</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of annual co-promotion profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</font></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PretaxProfitSharingFormulaTableTextBlock', window );">Pretax profit sharing formula</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of annual profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,316.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">242.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,559.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock', window );">Summary of activity related to collaboration with AbbVie Inc.</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">92.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock', window );">Summary of activity related to collaboration with Eisai</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of activity related to the Eisai Collaboration Agreement is as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration in development of BAN2401 and E2609</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">146.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and E2609 development expense reflected in our consolidated statements of income, excluding upfront and milestone payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">74.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pretax Profit Sharing Formula [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of activity related to collaboration with company seven.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813183168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Minimum rental commitments under non-cancelable leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">72.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">72.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">68.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">271.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">617.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(71.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(188.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">44.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">44.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">199.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">428.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"></font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976040288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Revenue by product</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,294.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">920.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">4,214.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,169.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">798.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,968.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,908.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">730.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,638.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AVONEX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,593.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">557.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,151.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,675.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">638.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,313.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,790.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">840.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,630.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">PLEGRIDY</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">295.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">198.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">494.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">305.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">176.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">481.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">227.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">111.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">338.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,113.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">859.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,973.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,182.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">780.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,963.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,103.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">783.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,886.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">91.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">91.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">84.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">84.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">89.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">89.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">52.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">52.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">657.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">226.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">883.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">42.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">48.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">445.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">68.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">513.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">308.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">11.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">319.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">26.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">268.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">65.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">333.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">208.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">25.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">234.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">39.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">39.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">51.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">51.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">370.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">370.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">7,017.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,337.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7,050.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,767.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9,817.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6,545.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,642.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9,188.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Geographic information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,017.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,844.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">160.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">332.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,475.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">83.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,559.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">249.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">42.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">360.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,226.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,948.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,182.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,050.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,237.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">313.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">224.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,272.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,221.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,501.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,545.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,165.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">333.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">142.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,296.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">881.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,187.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976149376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b) (c) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (e) (f) (g) (h)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,380.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,639.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,622.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,712.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,354.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">340.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">397.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">406.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">415.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,559.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">90.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">41.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">179.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">360.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,810.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,078.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,077.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,307.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,273.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,426.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,712.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,707.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,797.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,643.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">747.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">862.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,226.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(166.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,670.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">747.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">862.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,226.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(297.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.47</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.07</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.80</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.41</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.46</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.07</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.79</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.40</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.92</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">212.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(i) (j)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(i) (k) (l)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,309.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,466.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,502.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">329.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">349.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">317.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">318.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,726.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,894.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,955.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,872.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,448.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,413.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,523.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,538.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,493.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,970.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">969.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,048.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,030.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">647.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,695.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">970.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,049.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">649.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.96</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.99</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">216.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the first, second, third and fourth quarters of 2017 include a pre-tax charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$353.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$29.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$30.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$30.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment to BMS upon the closing of our agreement to exclusively license BIIB092.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to acquired in-process research and development of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment to Remedy upon closing of the asset purchase transaction.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a developmental milestone that became payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 PSP study for BIIB092.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc., for the fourth quarter of 2017, includes a pre-tax charge to noncontrolling interest of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in royalty rates payable on potential commercial sales of aducanumab.&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes pre-tax charges to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment and a continuation payment, respectively, to Alkermes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment to Ionis upon entering into a new collaboration agreement to identify new antisense-oligonucleotide drug candidates for the treatment of SMA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,173.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the provisions of the 2017 Tax Act, including a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> expense under the Transition Toll Tax.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second, third and fourth quarters of 2016 includes additional pre-tax depreciation expense totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$15.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$15.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$14.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as part of our decision to cease manufacturing and vacate our small-scale biologics manufacturing facility in Cambridge, MA as well as close and vacate our warehouse space in Somerville, MA. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(j)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the third quarter of 2016 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(k)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a milestone payment due to Eisai related to the initiation of a Phase 3 trial for E2609.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(l)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our January 2017 settlement and license agreement with Forward Pharma.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826694320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessTextualAbstract', window );"><strong>Business (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentTermsOfAccountsReceivable', window );">Payment terms of accounts receivable arising from product sales</a></td>
<td class="text">30 to 90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedUsefulLivesOfLeaseholdImprovements', window );">Estimated useful lives of leasehold improvements</a></td>
<td class="text">Lesser of the useful life or the term of the respective lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PurchasePriceOfCommonStockUnderEspp', window );">Purchase price of common stock under ESPP</a></td>
<td class="text">85% of the lower of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfMarketValuePerShareOfCommonStock', window );">Percentage of market value per share of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CompensationExpenseOverPurchasePeriod', window );">Compensation expense over purchase period</a></td>
<td class="text">The fair value of the look-back provision plus the 15% discount<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DiscountRateRecognizedInCompensationExpense', window );">Discount rate recognized in compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">$ 75.2<span></span>
</td>
<td class="nump">$ 106.3<span></span>
</td>
<td class="nump">$ 108.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables', window );">Percentage receivables of wholesale distributor accounted in consolidated receivables</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">37.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables', window );">Percentage receivables of wholesale distributor accounted in consolidated receivables</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredTaxAssetDomain', window );">Deferred Tax Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CompensationExpenseOverPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation expense over purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CompensationExpenseOverPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DiscountRateRecognizedInCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate recognized in compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DiscountRateRecognizedInCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedUsefulLivesOfLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated useful lives of leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedUsefulLivesOfLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentTermsOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment  terms of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentTermsOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfMarketValuePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of market value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfMarketValuePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage receivables of wholesale distributor accounted in consolidated receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PurchasePriceOfCommonStockUnderEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Common Stock Under ESPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PurchasePriceOfCommonStockUnderEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredTaxAssetDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredTaxAssetDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825745472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,632.5<span></span>
</td>
<td class="nump">$ 3,669.3<span></span>
</td>
<td class="nump">$ 2,663.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember', window );">Remedy Pharmaceutical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="nump">$ 200.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BIIB074Member', window );">BIIB074 | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=84160947&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BIIB074Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BIIB074Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824146752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Hemophilia Spin-Off Hemophilia Spin-Off (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash</a></td>
<td class="nump">$ 302.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts Receivable</a></td>
<td class="nump">144.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="nump">116.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, Plant and Equipment, net</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible Assets, net</a></td>
<td class="nump">56.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="nump">314.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other, net</a></td>
<td class="nump">53.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets Transfered, net</a></td>
<td class="nump">1,008.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="nump">87.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other Long-Term Liabilities</a></td>
<td class="nump">67.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Liabilities Transferred, net</a></td>
<td class="nump">$ 155.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2510-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823493024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hemophilia Spin-Off Hemophilia Spin-Off (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues</a></td>
<td class="nump">$ 179.6<span></span>
</td>
<td class="nump">$ 48.8<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="nump">$ 50.9<span></span>
</td>
<td class="nump">$ 98.6<span></span>
</td>
<td class="nump">$ 79.0<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="nump">$ 360.0<span></span>
</td>
<td class="nump">$ 316.4<span></span>
</td>
<td class="nump">$ 236.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,630.0<span></span>
</td>
<td class="nump">1,478.7<span></span>
</td>
<td class="nump">1,240.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,712.4<span></span>
</td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="nump">$ 2,639.7<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
<td class="nump">$ 2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">10,354.7<span></span>
</td>
<td class="nump">9,817.9<span></span>
</td>
<td class="nump">9,188.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TermofBioverativTransactionServicesAgreement', window );">Term of Bioverativ Transaction Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TermofBioverativManufacturingandSupplyAgreement', window );">Term of Bioverativ Manufacturing and Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_HemophiliaProductsMember', window );">Hemophilia Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74.4<span></span>
</td>
<td class="nump">$ 846.9<span></span>
</td>
<td class="nump">$ 554.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TermofBioverativManufacturingandSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of Bioverativ Manufacturing and Supply Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TermofBioverativManufacturingandSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TermofBioverativTransactionServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of Bioverativ Transaction Services Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TermofBioverativTransactionServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_HemophiliaProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_HemophiliaProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806433456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Details) - 2015 Restructuring Charges - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="nump">$ 37.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
<td class="num">(40.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="nump">$ 15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending period</a></td>
<td class="nump">37.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember', window );">Workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">33.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(31.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending period</a></td>
<td class="nump">33.7<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember', window );">Pipeline programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending period</a></td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826968816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 33.1<span></span>
</td>
<td class="nump">$ 93.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2017RestructuringChargesMember', window );">2017 Restructuring Charges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonrecurringExpense', window );">Total non-recurring operation and capital expenditures</a></td>
<td class="nump">$ 170.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResourcesRedirectedthroughRestructuringProgram', window );">Redirection of resources</a></td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2016RestructuringChargesMember', window );">2016 Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember', window );">2015 Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">93.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated', window );">Restructuring and related cost, expected percentage of positions eliminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RestructuringandRelatedCostExpectedCashPayments', window );">Previously accrued incentive compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Total restructuring charges expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_CambridgeMAMember', window );">Cambridge, MA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_CambridgeMAMember', window );">Cambridge, MA | 2016 Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | 2017 Restructuring Charges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges | 2017 Restructuring Charges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResourcesRedirectedthroughRestructuringProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Resources Redirected through Restructuring Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResourcesRedirectedthroughRestructuringProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestructuringandRelatedCostExpectedCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Cash Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestructuringandRelatedCostExpectedCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and related cost, expected percentage of positions eliminated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64828382&amp;loc=d3e15138-107781<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2017RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2017RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2016RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2016RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_CambridgeMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_CambridgeMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825493472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Reserves (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 605.5<span></span>
</td>
<td class="nump">$ 662.7<span></span>
</td>
<td class="nump">$ 483.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">2,917.3<span></span>
</td>
<td class="nump">2,668.0<span></span>
</td>
<td class="nump">2,229.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
<td class="num">(32.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(2,232.8)<span></span>
</td>
<td class="num">(2,099.5)<span></span>
</td>
<td class="num">(1,666.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(534.4)<span></span>
</td>
<td class="num">(609.0)<span></span>
</td>
<td class="num">(351.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">761.6<span></span>
</td>
<td class="nump">605.5<span></span>
</td>
<td class="nump">662.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">71.6<span></span>
</td>
<td class="nump">56.1<span></span>
</td>
<td class="nump">47.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">583.0<span></span>
</td>
<td class="nump">592.6<span></span>
</td>
<td class="nump">459.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(475.8)<span></span>
</td>
<td class="num">(522.5)<span></span>
</td>
<td class="num">(405.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(69.1)<span></span>
</td>
<td class="num">(53.2)<span></span>
</td>
<td class="num">(44.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
<td class="nump">56.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">482.7<span></span>
</td>
<td class="nump">548.7<span></span>
</td>
<td class="nump">387.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">2,307.4<span></span>
</td>
<td class="nump">2,044.5<span></span>
</td>
<td class="nump">1,732.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="num">(16.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(1,756.9)<span></span>
</td>
<td class="num">(1,576.0)<span></span>
</td>
<td class="num">(1,258.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(442.2)<span></span>
</td>
<td class="num">(536.0)<span></span>
</td>
<td class="num">(296.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">606.0<span></span>
</td>
<td class="nump">482.7<span></span>
</td>
<td class="nump">548.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">51.2<span></span>
</td>
<td class="nump">57.9<span></span>
</td>
<td class="nump">49.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">30.9<span></span>
</td>
<td class="nump">37.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(8.9)<span></span>
</td>
<td class="num">(16.8)<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(23.1)<span></span>
</td>
<td class="num">(19.8)<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="nump">$ 57.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of the amount of, and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823287120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Reserves (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 761.6<span></span>
</td>
<td class="nump">$ 605.5<span></span>
</td>
<td class="nump">$ 662.7<span></span>
</td>
<td class="nump">$ 483.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">189.6<span></span>
</td>
<td class="nump">166.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 572.0<span></span>
</td>
<td class="nump">$ 438.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828158960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 162.4<span></span>
</td>
<td class="nump">$ 170.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">605.7<span></span>
</td>
<td class="nump">698.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">157.4<span></span>
</td>
<td class="nump">170.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">925.5<span></span>
</td>
<td class="nump">1,039.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">902.7<span></span>
</td>
<td class="nump">1,001.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">$ 22.8<span></span>
</td>
<td class="nump">$ 37.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824146896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs on excess, obsolete, unmarketable or other inventory</a></td>
<td class="nump">$ 76.9<span></span>
</td>
<td class="nump">$ 48.2<span></span>
</td>
<td class="nump">$ 41.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember', window );">Work-in-process | Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=biib_FinishedGoodsMember', window );">Finished Goods | Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=biib_FinishedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=biib_FinishedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826632400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">$ 8,264.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742.3<span></span>
</td>
<td class="nump">$ 8,264.6<span></span>
</td>
<td class="nump">$ 7,742.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,385.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,934.0)<span></span>
</td>
<td class="num">(4,385.0)<span></span>
</td>
<td class="num">(3,934.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,879.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,808.3<span></span>
</td>
<td class="nump">3,879.6<span></span>
</td>
<td class="nump">3,808.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2018</a></td>
<td class="nump">423.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2019</a></td>
<td class="nump">401.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">381.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">254.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">242.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(814.7)<span></span>
</td>
<td class="num">(385.6)<span></span>
</td>
<td class="num">$ (382.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Payment made to Forward Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(535.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(523.6)<span></span>
</td>
<td class="num">(535.6)<span></span>
</td>
<td class="num">(523.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
<td class="nump">$ 3,005.3<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,689.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,634.3)<span></span>
</td>
<td class="num">(2,689.0)<span></span>
</td>
<td class="num">(2,634.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">316.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371.0<span></span>
</td>
<td class="nump">$ 316.3<span></span>
</td>
<td class="nump">371.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,971.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,481.7<span></span>
</td>
<td class="nump">$ 3,971.4<span></span>
</td>
<td class="nump">3,481.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,160.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(776.1)<span></span>
</td>
<td class="num">(1,160.4)<span></span>
</td>
<td class="num">(776.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,811.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,705.6<span></span>
</td>
<td class="nump">$ 2,811.0<span></span>
</td>
<td class="nump">2,705.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648.0<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="nump">648.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">309.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,236.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of out-licensed patent</a></td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="num">$ (30.8)<span></span>
</td>
<td class="num">$ (30.4)<span></span>
</td>
<td class="num">$ (29.4)<span></span>
</td>
<td class="num">(353.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (444.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets and goodwill additional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827381952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Elimination of goodwill allocated to our hemophilia business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 2,458.7<span></span>
</td>
<td class="nump">1,237.3<span></span>
</td>
<td class="nump">$ 1,161.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">3,669.3<span></span>
</td>
<td class="nump">2,663.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">1,267.3<span></span>
</td>
<td class="nump">1,026.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="num">(21.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">4,632.5<span></span>
</td>
<td class="nump">3,669.3<span></span>
</td>
<td class="nump">$ 2,663.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">Fumapharm AG | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">232.7<span></span>
</td>
<td class="nump">173.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Elimination of goodwill allocated to our hemophilia business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (314.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a,h)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824078304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 5,172.5<span></span>
</td>
<td class="nump">$ 5,398.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,229.4<span></span>
</td>
<td class="nump">2,039.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">61.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">28.5<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,444.9<span></span>
</td>
<td class="nump">7,558.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">111.3<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">523.6<span></span>
</td>
<td class="nump">467.6<span></span>
</td>
<td class="nump">$ 506.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">634.9<span></span>
</td>
<td class="nump">481.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,609.8<span></span>
</td>
<td class="nump">2,663.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,919.3<span></span>
</td>
<td class="nump">2,172.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">643.4<span></span>
</td>
<td class="nump">561.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,229.4<span></span>
</td>
<td class="nump">2,039.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">61.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">28.5<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,433.1<span></span>
</td>
<td class="nump">7,533.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">111.3<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">111.3<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,609.8<span></span>
</td>
<td class="nump">2,663.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,919.3<span></span>
</td>
<td class="nump">2,172.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">643.4<span></span>
</td>
<td class="nump">561.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">523.6<span></span>
</td>
<td class="nump">467.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">523.6<span></span>
</td>
<td class="nump">467.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82895926&amp;loc=d3e24584-111560<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826719504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value</a></td>
<td class="nump">$ 6,483.3<span></span>
</td>
<td class="nump">$ 6,808.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember', window );">Notes Payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">583.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,517.7<span></span>
</td>
<td class="nump">1,521.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,032.9<span></span>
</td>
<td class="nump">1,026.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,851.9<span></span>
</td>
<td class="nump">1,796.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 2,077.6<span></span>
</td>
<td class="nump">$ 1,874.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805091248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="num">$ (62.7)<span></span>
</td>
<td class="num">$ (14.8)<span></span>
</td>
<td class="num">$ (30.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(6.7)<span></span>
</td>
<td class="num">(53.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">467.6<span></span>
</td>
<td class="nump">506.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 523.6<span></span>
</td>
<td class="nump">$ 467.6<span></span>
</td>
<td class="nump">$ 506.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823749696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Mar. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
<th class="th"><div>Mar. 04, 2008</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques', window );">Fair value measurements, changes in valuation techniques</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0<span></span>
</td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Milestone converted to short-term obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259.0<span></span>
</td>
<td class="nump">258.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate used for net cash outflow projections for fair value measurement</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_StromedixMember', window );">Stromedix, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162.4<span></span>
</td>
<td class="nump">133.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate used for net cash outflow projections for fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember', window );">Biogen Idec International Neuroscience GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102.2<span></span>
</td>
<td class="nump">75.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 355.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate used for net cash outflow projections for fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MilestonePaymentsMadeDuringPeriod', window );">Milestone payments made during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">6.875% Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">6.875% Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">6.875% Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">6.875% Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">6.875% Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279.0<span></span>
</td>
<td class="nump">$ 246.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Stromedix, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Biogen Idec International Neuroscience GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MilestonePaymentsMadeDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made During Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MilestonePaymentsMadeDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the changes in valuation technique(s) and related inputs used to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsChangesInValuationTechniques</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_StromedixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_StromedixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976178080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,229.4<span></span>
</td>
<td class="nump">$ 2,039.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">30.5<span></span>
</td>
<td class="nump">31.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight Reverse Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">948.0<span></span>
</td>
<td class="nump">741.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 247.3<span></span>
</td>
<td class="nump">$ 1,266.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805167968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 5,172.5<span></span>
</td>
<td class="nump">$ 5,398.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(11.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">5,173.0<span></span>
</td>
<td class="nump">5,406.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,039.3<span></span>
</td>
<td class="nump">1,408.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,039.5<span></span>
</td>
<td class="nump">1,409.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,570.5<span></span>
</td>
<td class="nump">1,255.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,569.6<span></span>
</td>
<td class="nump">1,258.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,075.1<span></span>
</td>
<td class="nump">1,156.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,075.7<span></span>
</td>
<td class="nump">1,156.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">844.2<span></span>
</td>
<td class="nump">1,016.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">845.1<span></span>
</td>
<td class="nump">1,019.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">642.6<span></span>
</td>
<td class="nump">557.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">642.3<span></span>
</td>
<td class="nump">559.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4.4)<span></span>
</td>
<td class="num">(9.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="nump">$ 33.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6717563584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, Estimated Fair Value</a></td>
<td class="nump">$ 2,115.2<span></span>
</td>
<td class="nump">$ 2,568.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, Amortized Cost</a></td>
<td class="nump">2,116.0<span></span>
</td>
<td class="nump">2,569.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Estimated Fair Value</a></td>
<td class="nump">2,730.0<span></span>
</td>
<td class="nump">2,552.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">2,730.0<span></span>
</td>
<td class="nump">2,559.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, Estimated Fair Value</a></td>
<td class="nump">327.3<span></span>
</td>
<td class="nump">276.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, Amortized Cost</a></td>
<td class="nump">327.0<span></span>
</td>
<td class="nump">277.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total available-for-sale securities, Fair Value</a></td>
<td class="nump">5,172.5<span></span>
</td>
<td class="nump">5,398.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total available-for-sale securities, Amortized Cost</a></td>
<td class="nump">$ 5,173.0<span></span>
</td>
<td class="nump">$ 5,406.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6960725168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ProceedsFromMarketableDebtSecuritiesAbstract', window );"><strong>Proceeds from Marketable Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 5,565.9<span></span>
</td>
<td class="nump">$ 7,378.9<span></span>
</td>
<td class="nump">$ 4,063.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gains</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses</a></td>
<td class="num">$ (22.4)<span></span>
</td>
<td class="num">$ (4.3)<span></span>
</td>
<td class="num">$ (3.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ProceedsFromMarketableDebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from marketable debt securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ProceedsFromMarketableDebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813352560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FinancialInstrumentsTextualAbstract', window );"><strong>Financial Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Original maturities of commercial paper and short-term debt securities</a></td>
<td class="text">less than 90&#160;days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">17 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FinancialInstrumentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FinancialInstrumentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813327488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 85.8<span></span>
</td>
<td class="nump">$ 99.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806813344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 2,198.7<span></span>
</td>
<td class="nump">$ 871.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">564.9<span></span>
</td>
<td class="nump">902.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other current assets | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other current assets | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Investments and other assets | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Accrued expenses and other | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">84.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Accrued expenses and other | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other long-term liabilities | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_EUR', window );">Euro | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,875.6<span></span>
</td>
<td class="nump">871.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_GBP', window );">British pound sterling | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">150.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CHF', window );">Swiss francs | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">88.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CAD', window );">Canadian dollar | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 83.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806188048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details 1) - Foreign Exchange Contract - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember', window );">Cash flows, revenue | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount Reclassified from Accumulated Other Comprehensive Income into Income Gain/(Loss) (Effective Portion)</a></td>
<td class="num">$ (32.5)<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="nump">$ 173.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember', window );">Cash flows, revenue | Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in earnings of foreign currency forward contracts due to hedge ineffectiveness</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember', window );">Cash flows, operating expenses | Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in earnings of foreign currency forward contracts due to hedge ineffectiveness</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember', window );">Cash flows, operating expenses | Operating Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount Reclassified from Accumulated Other Comprehensive Income into Income Gain/(Loss) (Effective Portion)</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624177-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806628960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (113.0)<span></span>
</td>
<td class="nump">$ 49.8<span></span>
</td>
<td class="num">$ (1.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Gain on treasury rate lock settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (42.7)<span></span>
</td>
<td class="num">(92.5)<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 2,198.7<span></span>
</td>
<td class="nump">2,198.7<span></span>
</td>
<td class="nump">871.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 564.9<span></span>
</td>
<td class="nump">$ 564.9<span></span>
</td>
<td class="nump">$ 902.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate lock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Gain on treasury rate lock settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate lock | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 months<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (98.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806169168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 141.2<span></span>
</td>
<td class="nump">$ 137.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">1,213.6<span></span>
</td>
<td class="nump">1,107.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">80.6<span></span>
</td>
<td class="nump">123.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">1,207.7<span></span>
</td>
<td class="nump">1,105.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ComputerSoftwareAndHardware', window );">Computer software and hardware</a></td>
<td class="nump">767.1<span></span>
</td>
<td class="nump">746.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">55.3<span></span>
</td>
<td class="nump">60.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,276.0<span></span>
</td>
<td class="nump">658.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">4,741.5<span></span>
</td>
<td class="nump">3,941.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,559.1)<span></span>
</td>
<td class="num">(1,439.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">$ 3,182.4<span></span>
</td>
<td class="nump">$ 2,501.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ComputerSoftwareAndHardware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Computer software and hardware</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ComputerSoftwareAndHardware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807121568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details Textual)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266.3<span></span>
</td>
<td class="nump">$ 309.3<span></span>
</td>
<td class="nump">$ 217.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest cost capitalization related to construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.7<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
<td class="nump">$ 10.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">$ 1,276.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,276.0<span></span>
</td>
<td class="nump">658.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="nump">$ 481.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Term of original lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TermOfLease', window );">Term of amended lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land | Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.5<span></span>
</td>
<td class="nump">SFr 64.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TermOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Of Lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TermOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828184400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness (Details)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2006 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Financing arrangement for the purchase of the RTP facility</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable and other financing arrangements</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">6,003.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Financing arrangement for the purchase of the RTP facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">16.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Non-current portion of notes payable and other financing arrangements</a></td>
<td class="nump">5,935.0<span></span>
</td>
<td class="nump">6,512.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Note payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable to Fumedica</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">SFr 61.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">558.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">1,482.4<span></span>
</td>
<td class="nump">1,485.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">994.3<span></span>
</td>
<td class="nump">993.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">1,736.3<span></span>
</td>
<td class="nump">1,734.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">$ 1,722.0<span></span>
</td>
<td class="nump">$ 1,721.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6975943952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness (Details 1)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Total debt maturities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2018</a></td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2019</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2020</a></td>
<td class="nump">1,500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2021</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2022</a></td>
<td class="nump">1,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2023 and thereafter</a></td>
<td class="nump">3,500.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total</a></td>
<td class="nump">$ 6,003.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825469680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details Textual)<br> SFr in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2008 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Mar. 04, 2008 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2006 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax', window );">Net charge upon extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment for debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Costs associated with the Senior Notes offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemptions percentage of 2015 notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage', window );">Redemption percentage for change in control provision on the 2015 Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,003,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,003,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior unsecured revolving credit facility maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Amount outstanding under the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.184%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncreasedCarryingAmountOfSeniorNotes', window );">Increased carrying amount of interest rate swap</a></td>
<td class="nump">$ 62,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 558,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,482,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,482,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,485,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 994,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 994,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">993,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.764%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,736,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,736,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,734,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.294%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,722,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,722,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,721,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Note payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 61.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ParValueOfNotesPayable', window );">Par value of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 3.1<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="nump">SFr 6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax', window );">Net charge upon extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | 2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value of the interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,200,000<span></span>
</td>
<td class="nump">$ 104,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Make Whole Provision Redemption Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncreasedCarryingAmountOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increased carrying amount of senior notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncreasedCarryingAmountOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ParValueOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Par value of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ParValueOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976076928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">235.3<span></span>
</td>
<td class="nump">238.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">211.5<span></span>
</td>
<td class="nump">215.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823996816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Textual) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 1,365.4<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember', window );">Series X junior participating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember', window );">Undesignated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramYearToDateMember', window );">2016 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember', window );">2011 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock shares authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 365.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramYearToDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramYearToDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822647440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">$ (319.9)<span></span>
</td>
<td class="num">$ (224.0)<span></span>
</td>
<td class="num">$ (59.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="num">(42.7)<span></span>
</td>
<td class="num">(92.5)<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">44.2<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(171.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="num">(95.9)<span></span>
</td>
<td class="num">(164.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(318.4)<span></span>
</td>
<td class="num">(319.9)<span></span>
</td>
<td class="num">(224.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Securities Available for Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(10.8)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">12.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">9.2<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="num">(10.8)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="num">(193.8)<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
<td class="nump">110.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">31.5<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(172.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(162.3)<span></span>
</td>
<td class="nump">47.6<span></span>
</td>
<td class="num">(61.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(104.5)<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded Status of Postretirement Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(32.7)<span></span>
</td>
<td class="num">(37.8)<span></span>
</td>
<td class="num">(31.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(36.8)<span></span>
</td>
<td class="num">(32.7)<span></span>
</td>
<td class="num">(37.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(334.2)<span></span>
</td>
<td class="num">(195.6)<span></span>
</td>
<td class="num">(99.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="nump">158.7<span></span>
</td>
<td class="num">(138.6)<span></span>
</td>
<td class="num">(96.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">158.7<span></span>
</td>
<td class="num">(138.6)<span></span>
</td>
<td class="num">(96.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (175.5)<span></span>
</td>
<td class="num">$ (334.2)<span></span>
</td>
<td class="num">$ (195.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825660896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13.1)<span></span>
</td>
<td class="num">$ (17.0)<span></span>
</td>
<td class="num">$ (13.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,458.7<span></span>
</td>
<td class="nump">1,237.3<span></span>
</td>
<td class="nump">1,161.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="num">$ (2,712.4)<span></span>
</td>
<td class="num">$ (2,622.5)<span></span>
</td>
<td class="num">$ (2,639.7)<span></span>
</td>
<td class="num">$ (2,380.1)<span></span>
</td>
<td class="num">$ (2,502.9)<span></span>
</td>
<td class="num">$ (2,539.6)<span></span>
</td>
<td class="num">$ (2,466.0)<span></span>
</td>
<td class="num">$ (2,309.4)<span></span>
</td>
<td class="num">(10,354.7)<span></span>
</td>
<td class="num">(9,817.9)<span></span>
</td>
<td class="num">(9,188.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(215.4)<span></span>
</td>
<td class="num">(217.4)<span></span>
</td>
<td class="num">(123.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="num">$ (297.4)<span></span>
</td>
<td class="nump">$ 1,226.1<span></span>
</td>
<td class="nump">$ 862.8<span></span>
</td>
<td class="nump">$ 747.6<span></span>
</td>
<td class="nump">$ 649.2<span></span>
</td>
<td class="nump">$ 1,032.9<span></span>
</td>
<td class="nump">$ 1,049.8<span></span>
</td>
<td class="nump">$ 970.9<span></span>
</td>
<td class="nump">2,539.1<span></span>
</td>
<td class="nump">3,702.8<span></span>
</td>
<td class="nump">3,547.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44.2)<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">171.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Securities Available for Sale | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.5)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.5)<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
<td class="num">(173.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824068368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Idec Inc</a></td>
<td class="num">$ (297.4)<span></span>
</td>
<td class="nump">$ 1,226.1<span></span>
</td>
<td class="nump">$ 862.8<span></span>
</td>
<td class="nump">$ 747.6<span></span>
</td>
<td class="nump">$ 649.2<span></span>
</td>
<td class="nump">$ 1,032.9<span></span>
</td>
<td class="nump">$ 1,049.8<span></span>
</td>
<td class="nump">$ 970.9<span></span>
</td>
<td class="nump">$ 2,539.1<span></span>
</td>
<td class="nump">$ 3,702.8<span></span>
</td>
<td class="nump">$ 3,547.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">211.5<span></span>
</td>
<td class="nump">211.4<span></span>
</td>
<td class="nump">211.9<span></span>
</td>
<td class="nump">215.6<span></span>
</td>
<td class="nump">216.6<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">219.1<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
<td class="nump">218.4<span></span>
</td>
<td class="nump">230.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">212.0<span></span>
</td>
<td class="nump">211.8<span></span>
</td>
<td class="nump">212.2<span></span>
</td>
<td class="nump">215.9<span></span>
</td>
<td class="nump">217.0<span></span>
</td>
<td class="nump">219.4<span></span>
</td>
<td class="nump">219.4<span></span>
</td>
<td class="nump">219.3<span></span>
</td>
<td class="nump">213.0<span></span>
</td>
<td class="nump">218.8<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EarningsPerShareTextualAbstract', window );"><strong>Earnings per share (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EarningsPerShareTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EarningsPerShareTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808587792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (138.1)<span></span>
</td>
<td class="num">$ (169.4)<span></span>
</td>
<td class="num">$ (183.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">169.7<span></span>
</td>
<td class="nump">204.4<span></span>
</td>
<td class="nump">207.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(9.6)<span></span>
</td>
<td class="num">(14.6)<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">160.1<span></span>
</td>
<td class="nump">189.8<span></span>
</td>
<td class="nump">196.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(42.8)<span></span>
</td>
<td class="num">(54.0)<span></span>
</td>
<td class="num">(55.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(74.0)<span></span>
</td>
<td class="num">(84.5)<span></span>
</td>
<td class="num">(88.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(95.7)<span></span>
</td>
<td class="num">(121.7)<span></span>
</td>
<td class="num">(127.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (117.3)<span></span>
</td>
<td class="num">$ (135.8)<span></span>
</td>
<td class="num">$ (140.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824250944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 138.1<span></span>
</td>
<td class="nump">$ 169.4<span></span>
</td>
<td class="nump">$ 183.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">169.7<span></span>
</td>
<td class="nump">204.4<span></span>
</td>
<td class="nump">207.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(9.6)<span></span>
</td>
<td class="num">(14.6)<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">160.1<span></span>
</td>
<td class="nump">189.8<span></span>
</td>
<td class="nump">196.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">107.3<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">119.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">16.3<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_PerformanceUnitsMember', window );">Performance Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">12.3<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823302064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 2)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StockOptionActivityAbstract', window );"><strong>Stock Option Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance, Outstanding shares | shares</a></td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 54.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease', window );">Shares, Hemophilia spin-off adjustment | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Hemophilia spin-off adjustment | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised | shares</a></td>
<td class="num">(14,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 50.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Cancelled | shares</a></td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled | $ / shares</a></td>
<td class="nump">$ 55.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance, Outstanding shares | shares</a></td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 53.83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813219328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract', window );"><strong>Tax benefit and cash received from stock option</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit realized for stock options</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 11.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from the exercise of stock options</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax benefit and cash received from stock option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TaxBenefitAndCashReceivedFromStockOptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809058976">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 4) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MarketStockUnitsActivityAbstract', window );"><strong>Market stock units activity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Hemophilia spin-off adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MarketStockUnitsActivityAbstract', window );"><strong>Market stock units activity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">230,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 355.60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Shares, Hemophilia spin-off adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Hemophilia spin-off adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">94,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 382.59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 328.03<span></span>
</td>
<td class="nump">$ 493.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(112,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 311.17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(45,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 372.35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">171,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 370.83<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 355.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted in 2017 include approximately 9,000 MSUs issued in 2017 based upon the attainment of performance criteria set for 2013, in relation to awards granted in that year. MSUs granted during 2017 also include awards granted in conjunction with our annual awards made in February 2017 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2017 reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2016, 2015 and 2014.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MarketStockUnitsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market stock units activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MarketStockUnitsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807437168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 5) - Market stock units - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Minimum range of risk-free interest rates</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Maximum range of risk-free interest rates</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageStockPriceOnGrantDateInDollarsMinimum', window );">Average stock price on grant date minimum</a></td>
<td class="nump">$ 263.18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 260.67<span></span>
</td>
<td class="nump">$ 227.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageStockPriceOnGrantDateInDollarsMaximum', window );">Average stock price on grant date maximum</a></td>
<td class="nump">$ 267.88<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 304.86<span></span>
</td>
<td class="nump">$ 426.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 382.59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 328.03<span></span>
</td>
<td class="nump">$ 493.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Range of expected stock price volatility</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">38.20%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Range of expected stock price volatility</a></td>
<td class="nump">35.60%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">40.70%<span></span>
</td>
<td class="nump">33.20%<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted in 2017 include approximately 9,000 MSUs issued in 2017 based upon the attainment of performance criteria set for 2013, in relation to awards granted in that year. MSUs granted during 2017 also include awards granted in conjunction with our annual awards made in February 2017 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2017 reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2016, 2015 and 2014.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageStockPriceOnGrantDateInDollarsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price on grant date in dollars maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageStockPriceOnGrantDateInDollarsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageStockPriceOnGrantDateInDollarsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price on grant date in dollars minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageStockPriceOnGrantDateInDollarsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ValuationOfGrantedStockUnitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation of granted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ValuationOfGrantedStockUnitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976164880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 6) - Cash settled performance units<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CashSettledPerformanceSharesAbstract', window );"><strong>Cash settled performance shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="nump">122,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Shares, Hemophilia spin-off adjustment</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">83,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(69,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(34,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="nump">105,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">CSPUs granted in 2017 include awards granted in conjunction with our annual awards made in February 2017 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. CSPUs granted in 2017 also include CSPUs issued in 2017 based upon the attainment of performance criteria set for 2016 in relation to shares granted in 2016.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CashSettledPerformanceSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash settled performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CashSettledPerformanceSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6975251424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments Share-Based Payments (Details 7) - Performance units<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="nump">110,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Shares, Hemophilia spin-off adjustment</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(43,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(19,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="nump">91,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">CSPUs granted in 2017 include awards granted in conjunction with our annual awards made in February 2017 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. CSPUs granted in 2017 also include CSPUs issued in 2017 based upon the attainment of performance criteria set for 2016 in relation to shares granted in 2016.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809182448">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 8) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RestrictedStockUnitsActivityAbstract', window );"><strong>Time-vested restricted stock units</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Hemophilia spin-off adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RestrictedStockUnitsActivityAbstract', window );"><strong>Time-vested restricted stock units</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">888,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 303.49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Shares, Hemophilia spin-off adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Hemophilia spin-off adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">464,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 293.41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 268.52<span></span>
</td>
<td class="nump">$ 388.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(350,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 308.04<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(182,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 292.57<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">832,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 291.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 303.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">RSUs granted in 2017 primarily represent RSUs granted in conjunction with our annual awards made in February 2017 and awards made in conjunction with the hiring of new employees. RSUs granted in 2017 also include approximately 11,000 RSUs granted to our Board of Directors.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestrictedStockUnitsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestrictedStockUnitsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6717707072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 9) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember', window );">2015 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">167,000<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">78,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Cash received under ESPP</a></td>
<td class="nump">$ 39.8<span></span>
</td>
<td class="nump">$ 41.5<span></span>
</td>
<td class="nump">$ 19.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A1995ESPPMember', window );">1995 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Cash received under ESPP</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2015ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A1995ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A1995ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808525056">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details Textual)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>Increment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>Increment</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedPaymentsTextualAbstract', window );"><strong>Share-Based Payments (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested share-based compensation | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 168.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards', window );">Weighted-average period to recognize the cost of unvested awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year 11 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade', window );">Number of share-based compensation plans pursuant to which awards are currently being made | Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares granted under stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="nump">$ 38.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic values of options outstanding | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term for options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year 4 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">94,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested awards | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 31.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 39.3<span></span>
</td>
<td class="nump">$ 109.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 382.59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 328.03<span></span>
</td>
<td class="nump">$ 493.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">83,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash in settlement of CSPS awards upon vesting | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 31.9<span></span>
</td>
<td class="nump">$ 79.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash in settlement of CSPS awards upon vesting | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards', window );">PUs converted to share settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">464,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested awards | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 104.6<span></span>
</td>
<td class="nump">$ 239.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 293.41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 268.52<span></span>
</td>
<td class="nump">$ 388.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director | Time-vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">11,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Settlement of PUs | Performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards', window );">PUs converted to share settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_DirectorsPlanMember', window );">Directors Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSharesOfCommonStockForIssuance', window );">Total number of shares of common stock for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1.5-to-1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember', window );">2017 Omnibus Equity Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1.5-to-1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Omnibus Plan number of shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_AttainmentOfPerformanceCriteriain2013Member', window );">Attainment Of Performance Criteria in 2013 | Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted in 2017 include approximately 9,000 MSUs issued in 2017 based upon the attainment of performance criteria set for 2013, in relation to awards granted in that year. MSUs granted during 2017 also include awards granted in conjunction with our annual awards made in February 2017 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2017 reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2016, 2015 and 2014.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">CSPUs granted in 2017 include awards granted in conjunction with our annual awards made in February 2017 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. CSPUs granted in 2017 also include CSPUs issued in 2017 based upon the attainment of performance criteria set for 2016 in relation to shares granted in 2016.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">RSUs granted in 2017 primarily represent RSUs granted in conjunction with our annual awards made in February 2017 and awards made in conjunction with the hiring of new employees. RSUs granted in 2017 also include approximately 11,000 RSUs granted to our Board of Directors.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share-based Compensation, Shares Used to Settle Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days for calculation of average closing stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfDaysForCalculationOfAverageClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfEqualAnnualIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal annual increments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfEqualAnnualIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share-based compensation plans pursuant to which awards are currently being made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSharesOfCommonStockForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of common stock for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSharesOfCommonStockForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RatioOfNumberOfSharesReservedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of total number of shares reserved under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RatioOfNumberOfSharesReservedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedPaymentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedPaymentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period to recognize the cost of nonvested awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_DirectorsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_DirectorsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_AttainmentOfPerformanceCriteriain2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_AttainmentOfPerformanceCriteriain2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807438224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income before income taxes (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 3,540.4<span></span>
</td>
<td class="nump">$ 3,655.4<span></span>
</td>
<td class="nump">$ 3,386.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">1,588.4<span></span>
</td>
<td class="nump">1,277.6<span></span>
</td>
<td class="nump">1,380.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">5,128.8<span></span>
</td>
<td class="nump">4,933.0<span></span>
</td>
<td class="nump">4,767.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">2,201.4<span></span>
</td>
<td class="nump">1,304.3<span></span>
</td>
<td class="nump">1,214.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">57.0<span></span>
</td>
<td class="nump">55.1<span></span>
</td>
<td class="nump">38.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">108.6<span></span>
</td>
<td class="nump">52.9<span></span>
</td>
<td class="nump">54.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">2,367.0<span></span>
</td>
<td class="nump">1,412.3<span></span>
</td>
<td class="nump">1,307.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">241.0<span></span>
</td>
<td class="num">(125.6)<span></span>
</td>
<td class="num">(129.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(159.2)<span></span>
</td>
<td class="num">(45.6)<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">91.7<span></span>
</td>
<td class="num">(175.0)<span></span>
</td>
<td class="num">(145.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 2,458.7<span></span>
</td>
<td class="nump">$ 1,237.3<span></span>
</td>
<td class="nump">$ 1,161.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6717886880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of deferred tax assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="nump">$ 201.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory, other reserves, and accruals</a></td>
<td class="nump">147.8<span></span>
</td>
<td class="nump">250.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles, net</a></td>
<td class="nump">378.8<span></span>
</td>
<td class="nump">459.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">209.8<span></span>
</td>
<td class="nump">65.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">61.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">25.1<span></span>
</td>
<td class="nump">49.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(16.6)<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">831.8<span></span>
</td>
<td class="nump">1,071.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Purchased intangible assets</a></td>
<td class="num">(250.7)<span></span>
</td>
<td class="num">(376.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther', window );">Depreciation, amortization and other</a></td>
<td class="num">(107.9)<span></span>
</td>
<td class="num">(113.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">$ 358.6<span></span>
</td>
<td class="nump">$ 490.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation amortization other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesDepreciationAmortizationOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976007312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(11.10%)<span></span>
</td>
<td class="num">(9.60%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction', window );">Manufacturing deduction</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">2017 Tax Act</a></td>
<td class="nump">22.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Impairment of ZINBRYTA related tax assets</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">47.90%<span></span>
</td>
<td class="nump">25.10%<span></span>
</td>
<td class="nump">24.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation manufacturing deduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825774224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract', window );"><strong>Reconciliation of the beginning and ending of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1</a></td>
<td class="nump">$ 32.4<span></span>
</td>
<td class="nump">$ 67.9<span></span>
</td>
<td class="nump">$ 131.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current period</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior periods</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">36.3<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior periods</a></td>
<td class="num">(21.8)<span></span>
</td>
<td class="num">(13.3)<span></span>
</td>
<td class="num">(49.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Statute expirations</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">44.6<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 66.8<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
<td class="nump">$ 67.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809623872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 2,458.7<span></span>
</td>
<td class="nump">$ 1,237.3<span></span>
</td>
<td class="nump">$ 1,161.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Net impairment on certain tax assets</a></td>
<td class="nump">48.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Totaldeferredchargesandprepaidtaxes', window );">Total deferred charges and prepaid taxes</a></td>
<td class="nump">617.7<span></span>
</td>
<td class="nump">989.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefit</a></td>
<td class="nump">64.3<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Net interest expense</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</a></td>
<td class="nump">$ 16.1<span></span>
</td>
<td class="nump">$ 25.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember', window );">2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 1,173.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossNoncurrent', window );">Accrued income tax liability under the Transition Toll Tax</a></td>
<td class="nump">989.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGrossCurrent', window );">Accrued income tax liability under the Transition Toll Tax, current</a></td>
<td class="nump">78.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Income tax expense (benefit)</a></td>
<td class="nump">184.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Notice of assessment of corporate withholding tax including penalties and interest</a></td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | Domestic Country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</a></td>
<td class="nump">19.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">129.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_PrepaidtaxesMember', window );">Prepaid taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Net impairment on certain tax assets</a></td>
<td class="nump">142.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredTaxAssetDomain', window );">Deferred Tax Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember', window );">Earnings in the form of cash and cash equivalents | 2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TransitionTollTaxRepatriationTaxRate', window );">Transition Toll Tax repatriation tax rate</a></td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember', window );">Other Foreign Earnings | 2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TransitionTollTaxRepatriationTaxRate', window );">Transition Toll Tax repatriation tax rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Totaldeferredchargesandprepaidtaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total deferred charges and prepaid taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Totaldeferredchargesandprepaidtaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TransitionTollTaxRepatriationTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transition Toll Tax Repatriation Tax Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TransitionTollTaxRepatriationTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences and carryforwards, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_PrepaidtaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_PrepaidtaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredTaxAssetDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredTaxAssetDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807832592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 761.6<span></span>
</td>
<td class="nump">$ 605.5<span></span>
</td>
<td class="nump">$ 662.7<span></span>
</td>
<td class="nump">$ 483.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash Paid During the Year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">281.7<span></span>
</td>
<td class="nump">281.2<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">1,066.4<span></span>
</td>
<td class="nump">1,642.2<span></span>
</td>
<td class="nump">1,674.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">78.5<span></span>
</td>
<td class="nump">63.4<span></span>
</td>
<td class="nump">22.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">250.8<span></span>
</td>
<td class="nump">260.0<span></span>
</td>
<td class="nump">95.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (loss) on investments, net</a></td>
<td class="num">(36.3)<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="num">(9.8)<span></span>
</td>
<td class="num">(32.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(13.1)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(13.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(215.4)<span></span>
</td>
<td class="num">(217.4)<span></span>
</td>
<td class="num">$ (123.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">844.6<span></span>
</td>
<td class="nump">580.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">297.7<span></span>
</td>
<td class="nump">282.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">206.7<span></span>
</td>
<td class="nump">195.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses</a></td>
<td class="nump">183.7<span></span>
</td>
<td class="nump">130.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Accrued construction in progress</a></td>
<td class="nump">159.7<span></span>
</td>
<td class="nump">134.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Accrued TECFIDERA litigation settlement and license charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">636.9<span></span>
</td>
<td class="nump">685.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,901.3<span></span>
</td>
<td class="nump">2,903.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 572.0<span></span>
</td>
<td class="nump">$ 438.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827196400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details Textual)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="10">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2013 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,267.3<span></span>
</td>
<td class="nump">$ 1,026.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Accrued construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159.7<span></span>
</td>
<td class="nump">134.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax', window );">Net charge upon extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657.6<span></span>
</td>
<td class="nump">817.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Net impairment on certain tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent', window );">Loss contingency, adjustment related to claim amount, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,712.4<span></span>
</td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="nump">$ 2,639.7<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,354.7<span></span>
</td>
<td class="nump">9,817.9<span></span>
</td>
<td class="nump">9,188.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Accrued construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,214.0<span></span>
</td>
<td class="nump">3,968.1<span></span>
</td>
<td class="nump">$ 3,638.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fifteen billion | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Sixteen billion | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IT', window );">ITALY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Proposed settlement | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (33.3)<span></span>
</td>
<td class="num">&#8364; (30.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementLimitStatedInResolution', window );">Reimbursement Limit Stated In Resolution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">&#8364; 41.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Adjustment Related To Claim Amount, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LossContingencyAdjustmentRelatedToClaimAmountPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementLimitStatedInResolution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement limit stated in the resolution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementLimitStatedInResolution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_FifteenbillionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_FifteenbillionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_SixteenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_SixteenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976933664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payment to Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 56.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
<td class="nump">$ 47.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payment to Neurimmune</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalPotentialPaymentstoNoncontrollingInterest', window );">Additional potential payment to Neurimmune</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement', window );">Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalPotentialPaymentstoNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Potential Payments to Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalPotentialPaymentstoNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInVariableInterestEntitiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825456048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="nump">$ 2,712.4<span></span>
</td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="nump">$ 2,639.7<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
<td class="nump">$ 2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">$ 10,354.7<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 415.0<span></span>
</td>
<td class="nump">$ 406.5<span></span>
</td>
<td class="nump">$ 397.1<span></span>
</td>
<td class="nump">$ 340.6<span></span>
</td>
<td class="nump">$ 318.2<span></span>
</td>
<td class="nump">$ 317.6<span></span>
</td>
<td class="nump">$ 349.2<span></span>
</td>
<td class="nump">$ 329.5<span></span>
</td>
<td class="nump">1,559.2<span></span>
</td>
<td class="nump">1,314.5<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember', window );">Roche Group - Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,316.4<span></span>
</td>
<td class="nump">1,249.5<span></span>
</td>
<td class="nump">1,269.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242.8<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
<td class="nump">69.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,559.2<span></span>
</td>
<td class="nump">$ 1,314.5<span></span>
</td>
<td class="nump">$ 1,339.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract', window );"><strong>After First GA101 Threshold Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaAbstract', window );"><strong>Co-promotion profit sharing formula</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne', window );">Until GAZYVA First Non-CLL FDA Approval</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract', window );"><strong>After First GA101 Threshold Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from unconsolidated joint business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesFromUnconsolidatedJointBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823778448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues, net</a></td>
<td class="nump">$ 3,307.0<span></span>
</td>
<td class="nump">$ 3,077.8<span></span>
</td>
<td class="nump">$ 3,078.4<span></span>
</td>
<td class="nump">$ 2,810.7<span></span>
</td>
<td class="nump">$ 2,872.0<span></span>
</td>
<td class="nump">$ 2,955.8<span></span>
</td>
<td class="nump">$ 2,894.2<span></span>
</td>
<td class="nump">$ 2,726.8<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
<td class="nump">$ 11,448.8<span></span>
</td>
<td class="nump">$ 10,763.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,929.7<span></span>
</td>
<td class="nump">6,298.4<span></span>
</td>
<td class="nump">$ 5,872.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.1<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.6<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Copromotionprofitsandlosses', window );">Co-promotion profits and losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
<td class="nump">43.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of co-promotion losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="nump">$ 21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Copromotionprofitsandlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profits and losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Copromotionprofitsandlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813219328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships (Details 2) - Eisai - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total expense incurred by collaboration</a></td>
<td class="nump">$ 146.2<span></span>
</td>
<td class="nump">$ 95.1<span></span>
</td>
<td class="nump">$ 84.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="nump">$ 74.3<span></span>
</td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="nump">$ 40.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseReflectedWithinStatementsOfIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen Idec's share of expense reflected within our consolidated statements of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseReflectedWithinStatementsOfIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911690880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details Textual)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,712.4<span></span>
</td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="nump">$ 2,639.7<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
<td class="nump">$ 2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,354.7<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,253.6<span></span>
</td>
<td class="nump">1,973.3<span></span>
</td>
<td class="nump">2,012.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179.6<span></span>
</td>
<td class="nump">$ 48.8<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="nump">50.9<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
<td class="nump">316.4<span></span>
</td>
<td class="nump">236.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Prepaid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,027.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,335.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,027.5<span></span>
</td>
<td class="nump">1,335.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember', window );">Roche Group - Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,316.4<span></span>
</td>
<td class="nump">1,249.5<span></span>
</td>
<td class="nump">1,269.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242.8<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
<td class="nump">69.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationExpensesinDispute', window );">Collaboration Expenses in Dispute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AcordaMember', window );">Acorda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="nump">31.5<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold', window );">Expected additional milestone payments when certain sales threshold is met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignSalesRequiredToTriggerMilestone', window );">Foreign sales required to trigger milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold', window );">Expected additional milestone payments when certain sales threshold is met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments', window );">Expected License Fee And Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality', window );">Additional milestone payments for product candidate using a different modality</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
<td class="nump">50.5<span></span>
</td>
<td class="nump">40.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263.4<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total expense incurred by collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146.2<span></span>
</td>
<td class="nump">95.1<span></span>
</td>
<td class="nump">84.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember', window );">Bristol-Myers Squibb [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember', window );">iPerian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DevelopmentalMilestonePayment', window );">Developmental Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember', window );">Alkermes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember', window );">AGTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="nump">54.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Purchaseofcommonstock', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">Total licensing and other fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_UniversityofPennsylvaniaMember', window );">University of Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.0<span></span>
</td>
<td class="nump">27.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Prepaid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futureresearchanddevelopmentcommitment', window );">Future research and development commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Biosimilar Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.0<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Equity Method Investments, Expected Profit Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of Co promotion Operating Profits first fifty million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne', window );">Until GAZYVA First Non-CLL FDA Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of Co promotion Operating Profits first fifty million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment', window );">Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SalesTriggerGrossSalesThreshold', window );">Sales Trigger Gross Sales Threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti-CD20 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti-CD20 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage', window );">Royalty operating profit threshold for highest royalty rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyrate', window );">Reduction in royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PeriodOfCollaborationAgreement', window );">Period of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.7<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Net impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecorded tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.9<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">883.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Ionis Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234.5<span></span>
</td>
<td class="nump">257.8<span></span>
</td>
<td class="nump">74.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCostRoyaltyExpense', window );">Royalty cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Ionis Pharmaceuticals, Inc. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage Of Royalties As Per Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Ionis Pharmaceuticals, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage Of Royalties As Per Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SOD1Member', window );">SOD1 | Ionis Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_LeadprogramsMember', window );">Lead programs | AGTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 467.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_DiscoveryprogramsMember', window );">Discovery programs | AGTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Biosimilar Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.7<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">62.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement', window );">Investments By Third Party In Joint Venture As Per Agreement.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 280.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_JointVentureOwnerShipPercentageByThirdParty', window );">Joint Venture Owner Ship Percentage By Third Party.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 49.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of equity interest to the portion of total capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum', window );">Equity Method Investment Ownership Percentage Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total expense incurred by collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.9<span></span>
</td>
<td class="nump">48.6<span></span>
</td>
<td class="nump">113.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | ZINBRYTA | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,017.1<span></span>
</td>
<td class="nump">7,050.4<span></span>
</td>
<td class="nump">6,545.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249.5<span></span>
</td>
<td class="nump">224.7<span></span>
</td>
<td class="nump">$ 142.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S | SPINRAZA | Ionis Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 883.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember', window );">Outside the U.S | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember', window );">Outside the U.S | OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember', window );">European Union | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_JP', window );">JAPAN | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Ionis Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Percentage of development expenses to be reimbursed | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payments for product candidate using a different modality</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationExpensesinDispute">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Expenses in Dispute</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationExpensesinDispute</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DevelopmentalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Developmental Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DevelopmentalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment ownership percentage maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected additional milestone payments when meeting certain sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected license fee and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseReflectedWithinStatementsOfIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen Idec's share of expense reflected within our consolidated statements of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseReflectedWithinStatementsOfIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignSalesRequiredToTriggerMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign sales required to trigger milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignSalesRequiredToTriggerMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future royalties percentage to be received on sale of product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Futurepercentageofcopromotionoperatingprofits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future percentage of co-promotion operating profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Futurepercentageofcopromotionoperatingprofits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Futureresearchanddevelopmentcommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future research and development commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Futureresearchanddevelopmentcommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments by third party in joint venture as per agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_JointVentureOwnerShipPercentageByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint venture owner ship percentage by third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_JointVentureOwnerShipPercentageByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits first fifty million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfRoyaltiesAsPerCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfRoyaltiesAsPerCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PeriodOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PeriodOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Purchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Purchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyrate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyrate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty operating profit threshold for highest royalty rate percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SalesTriggerGrossSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales trigger gross sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SalesTriggerGrossSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales to be achieved in any twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCostRoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty expense incurred and are directly related to goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectOperatingCostRoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AcordaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AcordaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IPerianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AlkermesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AGTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UniversityofPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UniversityofPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_NewAntiCd20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_NewAntiCd20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_OCREVUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_OCREVUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SOD1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SOD1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_LeadprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_LeadprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_DiscoveryprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_DiscoveryprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976067184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract', window );"><strong>Minimum rental commitments under non-cancelable leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Minimum lease payments, 2018</a></td>
<td class="nump">$ 72.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Minimum lease payments, 2019</a></td>
<td class="nump">72.3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Minimum lease payments, 2020</a></td>
<td class="nump">68.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Minimum lease payments, 2021</a></td>
<td class="nump">66.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Minimum lease payments, 2022</a></td>
<td class="nump">65.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Minimum lease payments, Thereafter</a></td>
<td class="nump">271.1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Minimum lease payments, Total</a></td>
<td class="nump">617.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear', window );">Less: income from subleases, 2018</a></td>
<td class="num">(24.3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears', window );">Less: income from subleases, 2019</a></td>
<td class="num">(24.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears', window );">Less: income from subleases, 2020</a></td>
<td class="num">(23.9)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears', window );">Less: income from subleases, 2021</a></td>
<td class="num">(22.3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears', window );">Less: income from subleases, 2022</a></td>
<td class="num">(22.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter', window );">Less: income from subleases, Thereafter</a></td>
<td class="num">(71.3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions', window );">Less: income from subleases, Total</a></td>
<td class="num">(188.5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInOneYear', window );">Net minimum lease payments, 2018</a></td>
<td class="nump">48.3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInTwoYear', window );">Net minimum lease payments, 2019</a></td>
<td class="nump">47.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInThreeYear', window );">Net minimum lease payments, 2020</a></td>
<td class="nump">44.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFourYear', window );">Net minimum lease payments, 2021</a></td>
<td class="nump">44.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFiveYear', window );">Net minimum lease payments, 2022</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsThereafter', window );">Net minimum lease payments, Thereafter</a></td>
<td class="nump">199.8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePayments', window );">Net minimum lease payments, Total</a></td>
<td class="nump">$ 428.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1)</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum rental commitments under noncancellable leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFiveYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in five year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFiveYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFourYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in four year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFourYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInThreeYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in three year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInThreeYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in two year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821033920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2006</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>Apr. 02, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="nump">$ 1,100.0<span></span>
</td>
<td class="nump">$ 1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,267.3<span></span>
</td>
<td class="nump">$ 1,026.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">4,200.0<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Cancellable future commitments</a></td>
<td class="nump">460.0<span></span>
</td>
<td class="nump">460.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments And Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch', window );">Accrued expenses</a></td>
<td class="nump">40.0<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liabilities associated with uncertain tax positions</a></td>
<td class="nump">77.3<span></span>
</td>
<td class="nump">77.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease rent expense which terminates at various dates through 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.3<span></span>
</td>
<td class="nump">68.7<span></span>
</td>
<td class="nump">$ 68.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion', window );">Future contingent payment for annual worldwide net sales up to $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentThreshold', window );">Future contingent payment threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion', window );">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Amount paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Cancellable future commitments</a></td>
<td class="nump">270.0<span></span>
</td>
<td class="nump">270.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_FourteenbillionMember', window );">Fourteen billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_ElevenbillionMember', window );">Eleven billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_TwelvebillionMember', window );">Twelve billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_ThirteenbillionMember', window );">Thirteen billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_FifteenbillionMemberMember', window );">Fifteen billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">15,000.0<span></span>
</td>
<td class="nump">15,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_SixteenbillionMember', window );">Sixteen billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">16,000.0<span></span>
</td>
<td class="nump">16,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_OneBillionMember', window );">One billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember', window );">Each additional one billion up to twenty billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">20,000.0<span></span>
</td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember', window );">Three billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">3,000.0<span></span>
</td>
<td class="nump">3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember', window );">Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">700.0<span></span>
</td>
<td class="nump">700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">1,500.0<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember', window );">Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">2,000.0<span></span>
</td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember', window );">2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossNoncurrent', window );">Accrued income tax liability under the Transition Toll Tax</a></td>
<td class="nump">989.6<span></span>
</td>
<td class="nump">989.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGrossCurrent', window );">Accrued income tax liability under the Transition Toll Tax, current</a></td>
<td class="nump">$ 78.3<span></span>
</td>
<td class="nump">$ 78.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses on funding commitment related to clinical research.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales that exceed $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales up to $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences and carryforwards, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_FourteenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_FourteenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_ElevenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_ElevenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_TwelvebillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_TwelvebillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_ThirteenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_ThirteenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_FifteenbillionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_FifteenbillionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_SixteenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_SixteenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_OneBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_OneBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6975251424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember', window );">Domestic Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumQualifyingAgeForEmployeeBenefitPlan', window );">Minimum Qualifying Age For Employee Benefit Plan</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses related to savings plan</a></td>
<td class="nump">$ 42.6<span></span>
</td>
<td class="nump">$ 45.2<span></span>
</td>
<td class="nump">$ 51.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Deferred Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation liability</a></td>
<td class="nump">$ 109.8<span></span>
</td>
<td class="nump">$ 128.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumQualifyingAgeForEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum qualifying age for employee benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumQualifyingAgeForEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806436240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details 1) - Foreign Plan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_ForeignPlanMember', window );">SWITZERLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfMinimumInvestmentReturn', window );">Percentage of minimum investment return</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Unfunded net pension</a></td>
<td class="nump">$ 48.3<span></span>
</td>
<td class="nump">$ 39.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Employee Benefit Plan obligations</a></td>
<td class="nump">83.7<span></span>
</td>
<td class="nump">68.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">Pension Cost (Reversal of Cost)</a></td>
<td class="nump">12.3<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_ForeignPlanMember', window );">GERMANY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Employee Benefit Plan obligations</a></td>
<td class="nump">43.5<span></span>
</td>
<td class="nump">35.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Periodic pension cost</a></td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EmployeeBenefitPlansTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EmployeeBenefitPlansTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfMinimumInvestmentReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum investment return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfMinimumInvestmentReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64852052&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6901823312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,712.4<span></span>
</td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="nump">$ 2,639.7<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
<td class="nump">$ 2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">$ 10,354.7<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=country_US', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,017.1<span></span>
</td>
<td class="nump">7,050.4<span></span>
</td>
<td class="nump">6,545.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=biib_RestOfWorldMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,337.6<span></span>
</td>
<td class="nump">2,767.5<span></span>
</td>
<td class="nump">2,642.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,214.0<span></span>
</td>
<td class="nump">3,968.1<span></span>
</td>
<td class="nump">3,638.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,294.0<span></span>
</td>
<td class="nump">3,169.4<span></span>
</td>
<td class="nump">2,908.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920.0<span></span>
</td>
<td class="nump">798.7<span></span>
</td>
<td class="nump">730.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,151.5<span></span>
</td>
<td class="nump">2,313.5<span></span>
</td>
<td class="nump">2,630.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,593.6<span></span>
</td>
<td class="nump">1,675.3<span></span>
</td>
<td class="nump">1,790.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557.9<span></span>
</td>
<td class="nump">638.2<span></span>
</td>
<td class="nump">840.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494.3<span></span>
</td>
<td class="nump">481.7<span></span>
</td>
<td class="nump">338.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295.5<span></span>
</td>
<td class="nump">305.0<span></span>
</td>
<td class="nump">227.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198.8<span></span>
</td>
<td class="nump">176.7<span></span>
</td>
<td class="nump">111.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,973.1<span></span>
</td>
<td class="nump">1,963.8<span></span>
</td>
<td class="nump">1,886.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriMember', window );">TYSABRI | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,113.8<span></span>
</td>
<td class="nump">1,182.9<span></span>
</td>
<td class="nump">1,103.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriMember', window );">TYSABRI | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">859.3<span></span>
</td>
<td class="nump">780.9<span></span>
</td>
<td class="nump">783.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.6<span></span>
</td>
<td class="nump">84.9<span></span>
</td>
<td class="nump">89.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.6<span></span>
</td>
<td class="nump">84.9<span></span>
</td>
<td class="nump">89.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">883.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657.0<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
<td class="nump">513.2<span></span>
</td>
<td class="nump">319.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.2<span></span>
</td>
<td class="nump">445.2<span></span>
</td>
<td class="nump">308.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">68.0<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember', window );">ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
<td class="nump">333.7<span></span>
</td>
<td class="nump">234.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember', window );">ALPROLIX | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">268.0<span></span>
</td>
<td class="nump">208.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember', window );">ALPROLIX | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">65.7<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
<td class="nump">51.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
<td class="nump">51.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370.8<span></span>
</td>
<td class="nump">100.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370.8<span></span>
</td>
<td class="nump">100.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=biib_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=biib_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TysabriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TysabriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805401824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,712.4<span></span>
</td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="nump">$ 2,639.7<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
<td class="nump">$ 2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">$ 10,354.7<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">415.0<span></span>
</td>
<td class="nump">406.5<span></span>
</td>
<td class="nump">397.1<span></span>
</td>
<td class="nump">340.6<span></span>
</td>
<td class="nump">318.2<span></span>
</td>
<td class="nump">317.6<span></span>
</td>
<td class="nump">349.2<span></span>
</td>
<td class="nump">329.5<span></span>
</td>
<td class="nump">1,559.2<span></span>
</td>
<td class="nump">1,314.5<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues</a></td>
<td class="nump">179.6<span></span>
</td>
<td class="nump">$ 48.8<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="nump">50.9<span></span>
</td>
<td class="nump">$ 98.6<span></span>
</td>
<td class="nump">$ 79.0<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
<td class="nump">316.4<span></span>
</td>
<td class="nump">236.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">3,182.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,501.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,182.4<span></span>
</td>
<td class="nump">2,501.8<span></span>
</td>
<td class="nump">2,187.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,017.1<span></span>
</td>
<td class="nump">7,050.4<span></span>
</td>
<td class="nump">6,545.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475.6<span></span>
</td>
<td class="nump">1,249.5<span></span>
</td>
<td class="nump">1,269.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249.5<span></span>
</td>
<td class="nump">224.7<span></span>
</td>
<td class="nump">142.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">1,226.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,272.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226.9<span></span>
</td>
<td class="nump">1,272.3<span></span>
</td>
<td class="nump">1,296.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,844.8<span></span>
</td>
<td class="nump">2,237.2<span></span>
</td>
<td class="nump">2,165.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.8<span></span>
</td>
<td class="nump">71.5<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">1,948.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,221.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,948.2<span></span>
</td>
<td class="nump">1,221.1<span></span>
</td>
<td class="nump">881.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_AsiaMember', window );">Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160.1<span></span>
</td>
<td class="nump">217.3<span></span>
</td>
<td class="nump">143.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.7<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">62.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332.7<span></span>
</td>
<td class="nump">313.0<span></span>
</td>
<td class="nump">333.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
<td class="nump">63.1<span></span>
</td>
<td class="nump">65.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentsGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentsGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826668832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms', window );">Revenues from anti-CD20 therapeutic programs in percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 3,182.4<span></span>
</td>
<td class="nump">$ 2,501.8<span></span>
</td>
<td class="nump">$ 2,187.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SegmentInformationTextualAbstract', window );"><strong>Segment Information (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Entity wide percentage of revenue from major distributors</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Entity wide percentage of revenue from major distributors</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 1,215.7<span></span>
</td>
<td class="nump">$ 545.5<span></span>
</td>
<td class="nump">$ 161.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_DK', window );">DENMARK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 707.1<span></span>
</td>
<td class="nump">$ 643.6<span></span>
</td>
<td class="nump">$ 684.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues In Percentage From Anti-CD20 Therapeutic Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SegmentInformationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SegmentInformationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807834320">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,712.4<span></span>
</td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="nump">$ 2,639.7<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
<td class="nump">$ 2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">$ 10,354.7<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">415.0<span></span>
</td>
<td class="nump">406.5<span></span>
</td>
<td class="nump">397.1<span></span>
</td>
<td class="nump">340.6<span></span>
</td>
<td class="nump">318.2<span></span>
</td>
<td class="nump">317.6<span></span>
</td>
<td class="nump">349.2<span></span>
</td>
<td class="nump">329.5<span></span>
</td>
<td class="nump">1,559.2<span></span>
</td>
<td class="nump">1,314.5<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">179.6<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="nump">50.9<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
<td class="nump">87.9<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
<td class="nump">316.4<span></span>
</td>
<td class="nump">236.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,307.0<span></span>
</td>
<td class="nump">3,077.8<span></span>
</td>
<td class="nump">3,078.4<span></span>
</td>
<td class="nump">2,810.7<span></span>
</td>
<td class="nump">2,872.0<span></span>
</td>
<td class="nump">2,955.8<span></span>
</td>
<td class="nump">2,894.2<span></span>
</td>
<td class="nump">2,726.8<span></span>
</td>
<td class="nump">12,273.9<span></span>
</td>
<td class="nump">11,448.8<span></span>
</td>
<td class="nump">10,763.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,797.8<span></span>
</td>
<td class="nump">2,707.8<span></span>
</td>
<td class="nump">2,712.2<span></span>
</td>
<td class="nump">2,426.1<span></span>
</td>
<td class="nump">2,493.5<span></span>
</td>
<td class="nump">2,538.9<span></span>
</td>
<td class="nump">2,523.9<span></span>
</td>
<td class="nump">2,413.8<span></span>
</td>
<td class="nump">10,643.9<span></span>
</td>
<td class="nump">9,970.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(166.3)<span></span>
</td>
<td class="nump">1,226.1<span></span>
</td>
<td class="nump">862.8<span></span>
</td>
<td class="nump">747.5<span></span>
</td>
<td class="nump">647.9<span></span>
</td>
<td class="nump">1,030.2<span></span>
</td>
<td class="nump">1,048.4<span></span>
</td>
<td class="nump">969.2<span></span>
</td>
<td class="nump">2,670.1<span></span>
</td>
<td class="nump">3,695.7<span></span>
</td>
<td class="nump">3,593.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Idec Inc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (297.4)<span></span>
</td>
<td class="nump">$ 1,226.1<span></span>
</td>
<td class="nump">$ 862.8<span></span>
</td>
<td class="nump">$ 747.6<span></span>
</td>
<td class="nump">$ 649.2<span></span>
</td>
<td class="nump">$ 1,032.9<span></span>
</td>
<td class="nump">$ 1,049.8<span></span>
</td>
<td class="nump">$ 970.9<span></span>
</td>
<td class="nump">$ 2,539.1<span></span>
</td>
<td class="nump">$ 3,702.8<span></span>
</td>
<td class="nump">$ 3,547.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.41)<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="nump">$ 3.47<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 4.72<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="nump">$ 11.94<span></span>
</td>
<td class="nump">$ 16.96<span></span>
</td>
<td class="nump">$ 15.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.40)<span></span>
</td>
<td class="nump">$ 5.79<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="nump">$ 4.43<span></span>
</td>
<td class="nump">$ 11.92<span></span>
</td>
<td class="nump">$ 16.93<span></span>
</td>
<td class="nump">$ 15.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">211.5<span></span>
</td>
<td class="nump">211.4<span></span>
</td>
<td class="nump">211.9<span></span>
</td>
<td class="nump">215.6<span></span>
</td>
<td class="nump">216.6<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">219.1<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
<td class="nump">218.4<span></span>
</td>
<td class="nump">230.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">212.0<span></span>
</td>
<td class="nump">211.8<span></span>
</td>
<td class="nump">212.2<span></span>
</td>
<td class="nump">215.9<span></span>
</td>
<td class="nump">217.0<span></span>
</td>
<td class="nump">219.4<span></span>
</td>
<td class="nump">219.4<span></span>
</td>
<td class="nump">219.3<span></span>
</td>
<td class="nump">213.0<span></span>
</td>
<td class="nump">218.8<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900101136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="9">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Mar. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 814.7<span></span>
</td>
<td class="nump">$ 385.6<span></span>
</td>
<td class="nump">$ 382.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,253.6<span></span>
</td>
<td class="nump">1,973.3<span></span>
</td>
<td class="nump">2,012.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.0<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,458.7<span></span>
</td>
<td class="nump">1,237.3<span></span>
</td>
<td class="nump">1,161.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember', window );">Bristol-Myers Squibb [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember', window );">iPerian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DevelopmentalMilestonePayment', window );">Developmental Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember', window );">Alkermes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263.4<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_CambridgeMAMember', window );">Cambridge, MA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.8<span></span>
</td>
<td class="nump">$ 30.4<span></span>
</td>
<td class="nump">29.4<span></span>
</td>
<td class="nump">$ 353.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Ionis Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.3<span></span>
</td>
<td class="nump">$ 42.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember', window );">Remedy Pharmaceutical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DevelopmentalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Developmental Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DevelopmentalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Development Milestone And Collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IPerianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AlkermesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_CambridgeMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_CambridgeMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805497968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events Subsequent events (Details) - Karyopharm - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</a></td>
<td class="nump">$ 207.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_KaryopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_KaryopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>189
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_C=A)TW]F#_L?%5L&W@UUVT7U!+ P04    " "5A$%,F5R<(Q &  "<)P
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M'@Z$AYNVNHR'W?[MQ'W[/U!+ P04    " "5A$%,@=<KTF$#  "V#0  &
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M;925&07V&QWM(>KZ4JB]:1^E?:[[DT3_8O1I."6%UZ/:\C]02P,$%     @
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MI->K>?2_NG=7>?G@Q/?QW%3=^+UZ?NOZIIY;\5;J\OOT>SR-OY?IGR*?P^0
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M; 8.9Y.%CHCUE.4^573HB.LHSVW4D<QGX( VX>,".'I!8<$="3HB'5TUF='
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M1G;T6Z^>RN+^\N50/K3]Q[C[7(^'QN.7MCI/!^+;RZG\[?]02P,$%     @
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MM34#^[WG<O9X_+ HG[:['T/]\_KPUR*'#]OJ)?XES.CXYSA7_P%02P,$%
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M/\-<SX&2N?BO< 6%X4$)YBB-<G$EY>"\T3,+2M'B>=IE%_=QNCD<9M@V@,\
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MO59#0>/#\1;/=AZRV?!F6/X/6S]Q^0=02P,$%     @ E81!3([/<<ZU 0
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M@LJ'XPV>[3AFH^%--_T@-G_C_ -02P,$%     @ E81!3&!J1&^U 0  T@,
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M;_!LYS&;#6^&Y0>Q]1N7OP!02P,$%     @ E81!3%"X#J^S 0  T@,  !D
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MC<>7C?VOC/& 4C97.$(-?K#9D%#Y<+S&LQW';#2\Z:8?Q.9OG/\%4$L#!!0
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M[']MC >4DMSA"+7XP19#0>W#\2V>[31FD^%-/_\@MGSCXC=02P,$%     @
ME81!3#G*A>.S 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M?5-A;]P@#/TKB!]0[DC65J<D4J_3M$F;=&JU[3.7. DJQ"F02_?O"R1-LRW;
M%\#&[_G9F&Q$\V1; $=>M.IL3EOG^@-CMFQ!"WN%/73^ID:CA?.F:9CM#8@J
M@K1B?+>[9EK(CA99])U,D>'@E.S@9(@=M!;FUQ$4CCG=TS?'@VQ:%QRLR'K1
MP".X[_W)>(LM+)74T%F)'3%0Y_1N?SBF(3X&_) PVM69A$K.B$_!^%+E=!<$
M@8+2!0;AMPO<@U*!R,MXGCGIDC( U^<W]D^Q=E_+65BX1_535J[-Z2TE%=1B
M4.X!Q\\PU_.!DKGXKW !Y<.#$I^C1&7C2LK!.M0SBY>BQ<NTRR[NXW1SD\ZP
M;0"? 7P!W,8\;$H4E7\43A29P9&8J?>]"$^\/W#?FS(X8ROBG1=OO?=2\&2?
ML4L@FF..4PQ?Q;Q',,^^I.!;*8[\+SC?AB>;"I,(3WY3^ ^"=),@C03I?TO<
MBDG^2,)6/=5@FCA-EI0X='&25]YE8.]X?)/W\&G:OPG3R,Z2,SK_LK'_-:(#
M+V5WY4>H]1]L,134+AQO_-E,8S89#OOY!['E&Q>O4$L#!!0    ( )6$04R]
M\RJ6M $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;'U386_<
M( S]*X@?4.Y(VE6G)%*OT[1)JW3JM/4SES@)*L09D$O[[P<DS=(NVA? QN_Y
MV9AL1/-L6P!'7K3J;$Y;Y_H#8[9L00M[A3UT_J9&HX7SIFF8[0V(*H*T8GRW
MNV%:R(X66?2=3)'AX)3LX&2(';06YO4("L><[NF;XU$VK0L.5F2]:. 'N)_]
MR7B++2R5U-!9B1TQ4.?T;G\XIB$^!OR2,-K5F81*SHC/P?A6Y707!(&"T@4&
MX;<+W(-2@<C+^#USTB5E *[/;^Q?8NV^EK.P<(_J25:NS>DM)1748E#N$<>O
M,-=S3<E<_'>X@/+A08G/4:*R<27E8!WJF<5+T>)EVF47]W&Z29(9M@W@,X O
M@-N8ATV)HO+/PHDB,S@2,_6^%^&)]P?N>U,&9VQ%O//BK?=>"IZD&;L$HCGF
M.,7P5<Q^B6">?4G!MU(<^3]PO@U/-A4F$9Z\4WB]39!N$J21(/UOB5LQ-Q^2
ML%5/-9@F3I,E)0Y=G.25=QG8.Q[?Y&_X-.T/PC2RL^2,SK]L['^-Z,!+V5WY
M$6K]!UL,!;4+QT_^;*8QFPR'_?R#V/*-BS]02P,$%     @ E81!3$M3-':R
M 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL?5/1;MLP#/P5
M01]0)4JZ=H%MH&DQ;, &!!VV/2LV;0N51$^2X^[O)\F.YW7&7BR2YAV/%)4-
M:%]<"^#)JU;&Y;3UOCLPYLH6M' WV($)?VJT6OC@VH:YSH*H$D@KQC>;=TP+
M:6B1I=C)%AGV7DD#)TM<K[6POXZ@<,CIEEX#S[)I?0RP(NM$ U_!?^M.-GAL
M9JFD!N,D&F*ASNG#]G#<Q_R4\%W"X!8VB9V<$5^B\ZG*Z28* @6ECPPB'!=X
M!*4B49#Q<^*D<\D(7-I7]@^I]]#+63AX1/5#5K[-Z3TE%=2B5_X9AX\P]7-+
MR=3\9[B "NE12:A1HG+I2\K>>=032Y"BQ>MX2I/.8>*_PM8!? +P-P V%DK*
MGX07169Q(':<?2?B%6\//,RFC,$TBO0OB'<A>BGX[BYCET@TY1S''+[(V<X9
M++#/)?A:B2/_!\[7X;M5A;L$W_VE\'Z=8+]*L$\$^_^VN);S_DT1MIBI!MND
M;7*DQ-ZD35Y$YX5]X.E._J2/V_Y%V$8:1\[HP\VF^=>('H*4S4U8H38\L-E1
M4/MHW@7;CFLV.AZ[Z06Q^1D7OP%02P,$%     @ E81!3$?7I::S 0  T@,
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M?S;3F$V&PW[^06SYQL5/4$L#!!0    ( )6$04SFRVQ]L $  -(#   9
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MCJ#,D-$M_70\R[KQP<'RM!,UO(#_WITL6FQF*:6&UDG3$@M51N^VAV,2XF/
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M\65C_VMC/*"4W0V.4(L?;#$4U#X</^#93F,V&=[T\P]BRS<N?@-02P,$%
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M/L%<SRTE<_%?X0H2PX,2S%$:Z>)*RL%YHV86E*+$Z[1W.N[C=),<9M@V@,\
MO@#N8AXV)8K*/PLOBLR:D=BI][T(3[P_<NQ-&9RQ%?$.Q3OT7@M^2#)V#41S
MS&F*X:N8_1+!D'U)P;=2G/A_<+X-3S85)A&>O%.8;A.DFP1I)$C?$=Q^*'$K
MYO A"5OU5(%MXC0Y4II!QTE>>9>!O>?Q3?Z%3]/^3=BFTXY<C,>7C?VOC?&
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M:5#*@^YOE^:^';J<8:!5,W9PR=1&;OX"4$L#!!0    ( )6$04R;2!P@N $
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M/]AB2&A<.#[XLYG&;#(<]O,/8LLW+O\ 4$L#!!0    ( )6$04QN!N65MP$
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MP19#0>W#\2.>[31FD^%-/_\@MGSCXB]02P,$%     @ E81!3/DF(0^W 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL;5/;;MP@$/T5Q >$
M7>QLTY5M*9NH:J566J5J^LS:8QL%/"[@=?KW!>RX;NH78(9SSEP8LA'-BVT!
M''G5JK,Y;9WKCXS9L@4M[ WVT/F;&HT6SINF8;8W(*I(THKQW>[ M) =+;+H
M.YLBP\$IV<'9$#MH+<SO$R@<<[JG;XXGV;0N.%B1]:*![^!^]&?C+;:H5%)#
M9R5VQ$"=T_O]\90&? 0\2QCMZDQ")1?$EV!\J7*Z"PF!@M(%!>&W*SR 4D'(
MI_%KUJ1+R$!<G]_4/\7:?2T78>$!U4]9N3:G=Y144(M!N2<</\-<SRTE<_%?
MX0K*PT,F/D:)RL:5E(-UJ&<5GXH6K],NN[B/T\TAF6G;!#X3^$*XBW'8%"AF
M_BB<*#*#(S%3[WL1GGA_Y+XW97#&5L0[G[SUWFN1<)ZQ:Q":,:<)PU>8_8)@
M7GT)P;="G/A_=+Y-3S8S3"(]64?_>-@62#<%TBB0_E-B\J[$+4SZ+@A;]52#
M:>(T65+BT,5)7GF7@;WG\4W^PJ=I_R9,(SM++NC\R\;^UX@.?"J[&S]"K?]@
MBZ&@=N'XP9_--&:3X;"??Q!;OG'Q!U!+ P04    " "5A$%,Q$,%T<0!   W
M!   &0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6QM5.]NVR 0?Q7$ Q2'
MQ&T6V9::3E,G;5+4:>UG8I]M5# NX+A[^P%V72_CBX'C]^<..&>CTJ^F!;#H
M78K.Y+BUMC\08LH6)#,WJH?.[=1*2V;=4C?$]!I8%4A2$)HDMT0RWN$B"[&3
M+C(U6,$[.&ED!BF9_G,$H<8<;_!'X(DWK?4!4F0]:^ 7V-_]2;L5650J+J$S
M7'5(0YWC^\WAF'I\ #QS&,UJCGPE9Z5>_>)[E>/$)P0"2NL5F!LN\ !">"&7
MQMNLB1=+3US//]2_A=I=+6=FX$&)%U[9-L=[C"JHV2#LDQH?8:XGQ6@N_@=<
M0#BXS\1YE$J8\$7E8*R2LXI+1;+W:>1=&,=I)]W/M#B!S@2Z$/;!ATQ&(?.O
MS+(BTVI$>CK[GODKWARH.YO2!\-1A#V7O''12[&E:48N7FC&'"<,76$V"X(X
M]<6"QBR.]#\ZC=.WT0RW@;Y=TY,D+K"+"NR"P.Z?$F^O2HQA[N(F:=0DC0CL
MKTQBF"]7)F1U<1)T$YZL0:4:NM NJ^C2%?<T7/PG?&JIGTPWO#/HK*Q[/N&2
M:Z4LN%22&Y=+Z[IX60BHK9_>N;F>WO*TL*J?VY0L_XKB+U!+ P04    " "5
MA$%,&IL[*+8!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6QM
M4]MNW" 0_17$!P0;;]IH95O*IHI:J956J=H^L_;XH@#C EZG?U_ CN.F?@%F
MF'/FS##D$YIGVP$X\J*DM@7MG!N.C-FJ R7L#0Z@_4V#1@GG3=,R.Q@0=00I
MR7B2?&!*])J6>?2=39GCZ&2OX6R('942YL\))$X%3>FKXZEO.Q<<K,P'T<)W
M<#^&L_$66UGJ7H&V/6IBH"GH?7H\'4)\#/C9PV0W9Q(JN2 ^!^-+7= D" ()
ME0L,PF]7>  I Y&7\7OAI&O* -R>7]D?8^V^EHNP\(#R5U^[KJ!WE-30B%&Z
M)YP^PU+/+25+\5_A"M*'!R4^1X72QI54HW6H%A8O18F7>>]UW*?Y)N,+;!_
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M,^I.4B.$!E-*<&,:[LQ3L04,&FVGMV8NEPNS!%J,ZUM M@>I? =02P,$%
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M9?UT[^9Z?,OCPJIN:E,R_ROR=U!+ P04    " "5A$%,'NIA&[4!  #2 P
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M&SS;:<PFPYM^_D%L^<;%?U!+ P04    " "5A$%,4O/I%,0!   W!   &0
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M]>Q\;R[^*UR!:KC)1&L4G$K[](I!*LYF%IT*(^_3V7;V'&?^6Y@[ ,\!>!.
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M8'Z,9V579%.I>P&#[N6 %#0%OH^/I\SA/>!G#[/>S9&KY"+EDUM\J0L<.4/
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M#RQE46X!&":.-5"E%#:::D:[KE*D5(^-C[ :PB4 HQA;:E^#8&ZH.O< P-S
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M'GWQG#<WSN:EY&=YF[;;*_W\/U!+ P04    " "5A$%,B $DBS,#  !-#0
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M[Z4'Q@25'&53^]Y)OFWZ24D/0@US.>;=!;^;"-:8QTO8OZ!6_P!02P,$%
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MG^S^.S,]C6E]WT9AL/;?NT0C9C=@:((1=X1OLM^[(-3%CJQPFG>PMQ&2<<@
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M^%)5K38D \_LEI/.C_>70K^TW6-LGNOA'G9X::OK>,?LWR^ZM_\"4$L#!!0
M   ( )6$04RJ_-,6$P(  "(&   9    >&PO=V]R:W-H965T<R]S:&5E=#8T
M+GAM;(U5[6Z;,!1]%<0#8+[LT(@@K6FG3=JDJ%.WWTYR$U -9K83NK>?;2@C
M8$WY@WVOSSF^QU_D'1=OL@10WGO-&KGQ2Z7:-4+R4$)-9<!;:/3(B8N:*AV*
M,Y*M 'JTI)JA. P)JFG5^$5N<SM1Y/RB6-7 3GCR4M=4_'D$QKN-'_D?B9?J
M7"J30$7>TC/\ /7:[H2.T*ARK&IH9,4;3\!IXW^*UL_$X"W@9P6=G/0]XV3/
M^9L)OAXW?F@* @8'912H;JZP!<:,D"[C]Z#ICU,:XK3_H?[9>M=>]E3"EK-?
MU5&5&S_SO2.<Z(6I%]Y]@<$/]KW!_#>X M-P4XF>X\"9M%_O<)&*UX.*+J6F
M[WU;-;;M^A&<##0W(1X(\4B(TO\2DH&0W$M(!T)Z+P$/!#PCH-Z[7<PGJFB1
M"]YYHC\.+36G+EICO5T'D[2[8\?T>DJ=O1881SFZ&J$!\]ACX@DFOD5LEX@D
MO(4\.2"S>9Z7$(S_S82TC]%,[#036X'T1B"9F>DQ*XMI+&9%HH#,#"U1),0!
MGGERH$@<K&:VEJ@T2X+,;2QQ&DL<QE*W0.H42.]8F1Z33>J,LH?%RCA0A 0/
M[F*PLQCL* :[!8A3@-SAIL>029UX-3^V9+DS239QW)>")G?)O)[?J3A7C?3V
M7.EK:2_/B7,%6C$,M+=2/]ACP."D3'>E^Z)_MOI \79XD='X6RC^ E!+ P04
M    " "5A$%,'+6/"3$"  "5!@  &0   'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6Q]E6^OFR 4QK^*\0,(XM_>6).UR[(E6]+<97>O:7M:S45Q0.O=MQ^@
MUUCE[HUP\#D/OP,$BIZ+5UD!*.^M8:W<^I52W1-"\E1!0V7 .VCUGPL7#54Z
M%%<D.P'T;),:A@C&*6IHW?IE8<<.HBSX3;&ZA8/PY*UIJ/B[ \;[K1_Z[P//
M];529@"514>O\!/4K^X@=(0FEW/=0"MKWGH"+EO_4_BTSXW>"EYJZ.6L[YE*
MCIR_FN#;>>MC P0,3LHX4-W<80^,&2.-\6?T]*<I3>*\_^[^Q=:N:SE2"7O.
M?M=G56W]W/?.<*$WIIYY_Q7&>A+?&XO_#G=@6FY(]!PGSJ3]>J>;5+P9731*
M0]^&MFYMVP]_XGA,<R>0,8%,">'_$Z(Q(5HDH(',EOJ9*EH6@O>>&#:KH^9,
MA$^17LR3&;1K9__I:J4>O9=)DA;H;HQ&S6[0D)F&/"KV:T6$)PG2 !,%<5(0
MFQ\]4&1N@\AI$%F#^,$@7Y0Q:#*K::TF3$D0+TIQJ#(\4SW Q$Z8V &S6< ,
MFGPV38J3(%O .%2;//A@91(G3+*&2?$")EE-$R;9:F4<*KTRD1LF=<*D#IAP
M 9.NIMF0)$@6,&M5B*/-1_N4.6DR!\WB9.^R-0TFJWU:JT*,PR!UT^1.FMQ!
M$RUH\M7A)"18G//]6A1E,]& @F87A+FP?U!QK5OI';G2=XV]$2Z<*]"&.- [
M7^DW8@H87)3I9KHOAIMR"!3OQD< 32]1^0]02P,$%     @ E81!3(7-X:]I
M @    @  !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULE57;CILP%/P5
MQ < YDY$D'+9JI5:*=JJ[;-#G(#68&H[R?;O:QLO2\#9IGD(]F%FSAD;^^17
M0E]8A1"W7AO<LJ5=<=XM7)>5%6H@<TB'6O'F2&@#N9C2D\LZBN!!D1KL^IX7
MNPVL6[O(56Q'BYR<.:Y;M*,6.S<-I'_6")/KT@;V6^"Y/E5<!MPB[^ )?4?\
M1[>C8N8.*H>Z02VK26M1=%S:*[!X H$D*,3/&EW9:&Q)*WM"7N3DRV%I>[(B
MA%')I004CPO:((REDJCCMQ:UAYR2.!Z_J7]2YH69/61H0_"O^L"KI9W:U@$=
MX1GS9W+]C+2AR+:T^Z_H@K" RTI$CI)@IOZM\LPX:;2***6!K_VS;M7SVK^)
M(TTS$WQ-\ <"B#\D!)H0O!/"#PFA)H2/$B)-B"8$M_>N%G,+.2QR2JX6[;^'
M#LK/#BPBL5VE#*K=4>_$>C(1O111'.;N10IIS+K'^",,&!"N4!]2^*84:W]&
M]V\3;.:(P+N%; T0< MYFD/"+# 7&AC7(E "P<U:1&:!T"@0*H'P1B">+&:/
M212F59@D=C)O])OXVLP98>I,EG!K  $G,Q<?&8N/9L6'V1WWL5$@?GSY$J-
M,JL@R29[G,QL A [=S['U)@E-6Q28A;(C +9XSZ!9SYTWK^=:DPZLIJ&SKT\
M=PXW,'A-[T@8#^\*^/_AUGRL0/" VV"VL0%PXDD>=W2K-8B>5(MA5DG.+9<G
M?Q0=VMC*E[?B)+X&BVW?C-YE^M[X#=)3W3)K3[BX<]7->"2$(U&DYX@C4HEV
M/$PP.G(Y3,28]CVIGW#2Z7[K#DV_^ M02P,$%     @ E81!3(XJ*FG:!@
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MZ/W_7\!%!C"5,?\R&C367X@"JTD1% DF] AP08+8HA,F4X7&)0EF'R@T+B.
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MCO*C$)H;SB@P)I_-[:Z?E/RH[3 W8]E><=J)%DUW?0O[.^3V'U!+ P04
M" "5A$%,D>P7*E,"   I!P  &0   'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6R-5=N.FS 4_!7$>S&8:R*"M$E4M5(KK;9J^^P0)Z UF-I.V/Y]?6$) 6_4
ME]@^GAG/.2;'>4_9*Z\P%LY;0UJ^<2LANC4 O*QP@[A'.]S*G1-E#1)RR<Z
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MH:8K.6>FHYF%H-W0K-'XQ<C_ 5!+ P04    " "5A$%,?U<"8.4!  #'!
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ME-EN]%ZXV7*&XN/\;.#E[2K_ 5!+ P04    " "5A$%,1].H(L,!   @!
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M^TYG*_7J;9MG>!W?C*-1LQLT>*9Q%'M?09))$FN B0*#%-C:DWD$5, .".B
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M_7#\#A,ENO%J$4_WF^T_4$L#!!0    ( )6$04S3+RU =P,  $@/   9
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MMPID]XJ$N/*!JQQE=U@"UR:RBQ.P)+<;$LEP8)VM((X&CO+ <+'C"# F<U#
MQ8[1?&.PXPC',XPQH''">4Z"20FM09CS9,%PR6.[Y!.2.RC@*L3D#EO@*L1T
MCBW4W@=IG-B^@#@2N!XV7-78KNJ$.LX7#-<B3N\P!JY%#!VYEC&9]<Z&4CP]
M8 PJO48AJ[^$HW?G_NOG.VOW1=UY+T*JUW#]LKP30G+%&07*ZH/ZX+H,2KZ3
M_6VJ[MOAJV,82-&8+ZKP\EFW^@]02P,$%     @ E81!3#AL'6W^ 0  OP4
M !D   !X;"]W;W)K<VAE971S+W-H965T.#4N>&UL=93;CILP$(9?!?$ L3'A
M%!&D9JM5*[52M%6WUTXR!+0&L[83MF]?V["(@G.#3__\WXRQG?=<O,D*0'D?
M#6OEWJ^4ZG8(R7,%#94;WD&K5THN&JKT4%R1[ 30BPUJ&"(8QZBA=>L7N9T[
MBB+G-\7J%H["D[>FH>+O 1CO]W[@?TZ\U-=*F0E4Y!V]PB]0O[NCT",TN5SJ
M!EI9\]834.[]+\'ND!F]%;S6T,M9WS.5G#A_,X/OE[V/34+ X*R, ]7-'9Z
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MN-:M]$Y<Z6ML+UO)N0)MB3<ZYTJ_IM. 0:E,-]%],;PIPT#Q;GPNT?1F%_\
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M]5O5? WK[T5W*MU=5/G!G+A[IV/_^?]02P,$%     @ E81!3%%DU)WC 0
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M3Y@-&S//&!..F0W&1""UWZ9F^WW ,8)H"N3BC>*V!NZH47S<P<,=O-;!&SF
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M!;;5J?_.+BR7<%6)Y-CRO&Z^K>VY%KSHLLA2BO2UO69E<[VV3T*_"\,#2!=
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MD>L,[K_#':A*UY4HC8)18?Z=XB8DJP<654I-7OMGU9AGUZ_$X0"S _P!X(^
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M\( $G#/1.1!#!S+##B1T(#L'<C0CDDSZ2:,ZS;[3: <D]X<;4K AY?=42^Q
M0P?:[ZE6I*<GC1[TE&F#&TEA(REH1)-&D";%C1C8B $.:* ;;\X#<9'!)C+0
M! GT1>8U0<+\\7\5RTN*43=9@G,^\3N:)C3I3Z)T.!D1"=)'(&()52U[U3!"
M1"! 6(!2#/28T1XSOS,L"J"*05;=,0X:XK0A) I$"L,(8<)S85(=<($APN3U
M&&(8#TR!@5 0]2*<%2?J DF ,@QCA@'.I)0S2,0U[<IET;@S&$<,L":E/(*B
ME'8&B4*1C['% +=2 I5[)&+>]/ETRV1P/6$8<0PPSGCH0"*Z4D,1QYWAF&,<
M<,R0V%QPP#'F@0RILHCX6G(?9"P)I!S').. 9(:F7"_*1L#D$:V:'I S^MP?
MD3-NHL0;G*^3F4-^ &P< Y3[;#0FL%!SS$;^B?J*8S9R4&%Y8.-^B14:*\8G
M1_BD:8=$(2!Q3$>.Z$B!!$6AB<?@XPA7E#5(9+Q!I][4&I%<*%\YIA\'8/-P
M T7>BP$2A7"#V<<1L;S'D/E%B(XTS4E?Y:"4T8ST56D6!=8/@1DI$",#82$P
ML@2[/A\%IH) %1/-QUYT13Z*P'N97U3Y^8A$H7P4F"X"T84& A2%)A[S12"^
MT'Q$(B\?!2C0DDOY*#")!(",EX]0%"C#!2:10)#Q9CA%]3Y=_GJ5&:(H(G18
M(E<\"M2P K-*(,(8VA!XQ>3AIX!!)'P0F4&<CS<@,!9D\HD]#(P%B=[):'0B
MD:'OQ+UH%)TZ7)I*S!@)&.-5@[UH7,'1-_!>-'ZKE13B2R#CKF@,Y+C$S)(
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M=3I=/OUHRD-_<AZ?C^_G_P%02P,$%     @ E81!3#L0SH=< P  1PT  !H
M  !X;"]W;W)K<VAE971S+W-H965T,3 S+GAM;(U776^;,!3]*XCW@C\Q5$FD
M)M&T29M4==KV3!,G006<@9-T_W[FHQ3L2]47P.;<XW.O[7OMQ4U5+_5)2NV]
M%GE9+_V3UN?[,*QW)UFD=:#.LC1_#JHJ4FV:U3&LSY5,]ZU1D8<$H2@LTJST
M5XNV[[%:+=1%YUDI'RNOOA1%6OU;RUS=EC[VWSJ>LN-)-QWA:G%.C_*GU+_.
MCY5IA0/+/BMD66>J]"IY6/H/^'Z+16/0(GYG\E:/OKW&E6>E7IK&M_W21XTB
MF<N=;BA2\[K*C<SSALGH^-N3^L.8C>'X^XW]2^N\<>8YK>5&Y7^RO3XM_=CW
M]O*07G+]I&Y?9>\0][W>^^_R*G,#;Y28,78JK]NGM[O46A4]BY%2I*_=.RO;
M]ZW[(Z+>##8@O0$9#/#'!K0WH.\&[$,#UALPRR#L7&ECLTUUNEI4ZN95W?2>
MTV85X7MFHK]K.MM@M_],>&K3>UTE2;((KPU1CUEW&#+"X $1&O9A" (-L2:.
M.9D.L'$1%$TA6P R(X*"?M+6GHY]0 C!# QD8"T#FS)@*U0=2+2@LI/)&0J8
MY3  BSBW85L 1N,H$+!L#LKFD&QK M8=*!X-A'D<.[(!&!$BB"S9 (S&: 2;
MR(Y V9$CFUM+8ATYPW!,XB"V1'<P/H*QA%)+LLO%1"0""DL6H&0!+;$9AAAD
MB*&YLB9A'3M2"4'8F2L7ABEB@>TX ".8!3-[*P%E)Y!L;LE.G&G@PI*<N!/*
M VN';5T0C>>6%D9PSD.?V1,]:A(:%-N+?0/ . FL%+J%4"S@,[)G4C5V97,[
M ?6@<9P)C>Q(]ZB);PP39W5 .(I$0&:$@P7@ 1-H9\S-&9R_,?W,WNA1$^\9
MMIVGCE-WF' GC<&X9':QP64#@W7#WAT]:CQ68B^B#0"ZHW:^VT(H/.*:BH:+
M!OY4U<!NHK_#/ GL\@[A&!!OB&XV%6&X;F"W< ";Q$WW"0Z<3>)6CCLLN*W:
MY3*J^>PJ@6L'%E# A:U;. <"PGCL*G=QF%#A;F\ AR/L: ]'I\E"5L?VI%Y[
M.W4I=7,H&_4.MX$'TIQ&K?YU<TMH3ZGO--T5XT=:';.R]IZ5-F?=]D1Z4$I+
M(Q,%9@I.YE8S-')YT,VG,-]5=[3O&EJ=^VM+.-R=5O\!4$L#!!0    ( )6$
M04REJ&+DJ0(  '@)   :    >&PO=V]R:W-H965T<R]S:&5E=#$P-"YX;6Q]
MEE&OFR 4Q[^*\7T*HJA-VV1U6;9D2V[NLNV9MK0U5\4I;>^^_0"ML7!<'RK@
M_QQ^AW- UG?1O?47SJ7W7E=-O_$O4K:K,.P/%UZS/A M;]2;D^AJ)E6W.X=]
MVW%V-$9U%48(T;!F9>-OUV;LI=NNQ5569<-?.J^_UC7K_NYX)>X;'_N/@=?R
M?)%Z(-RN6W;F/[C\V;YTJA=.7HYES9N^%(W7\=/&_XA7!2;:P"A^E?S>S]J>
M#F4OQ)ON?#UN?*2)>,4/4KM@ZG'C!:\J[4EQ_!F=^M.<VG#>?GC_;()7P>Q9
MSPM1_2Z/\K+Q,]\[\A.[5O)5W+_P,:#$]\;HO_$;KY1<DZ@Y#J+JS;]WN/92
MU*,7A5*S]^%9-N9Y']XD#S/8(!H-HLD Q_\U(*,!L0S"@<R$^HE)MEUWXNYU
M0[9:IHL"KXA:S(,>-&MGWJEH>S5ZVV*$LG5XTYY&T6X013-1]*PH7 5!DR14
M!!-&!&)$QI[,[&-$80<$=$",@_@YCMR*8Q!1(VJ,B"(KD$&2SB01P@&&46(0
M)090L#7/;A!ELWEPG ;6PA>N*DI0L+ P"4B30#38HDF<>4B:.32N*D[RF>J)
MAH(T%**QBFE'W:A1[M"X*IH$.9K]%K*6@F2I2X;M^DE=,!I8HL(541PD,$H&
MHF0."DDLD@PHC,#*:C&(DGF^<I@C!SER*%G$(LD=D@^8SDIT0(%5"PG""#ZJ
M$,03VV<5<J;*"':J!Y!AE.*E:L8+IR>&D.QDC:JGZ/4^3FTF0$=2NK3?,7R4
MX@ABHC93!&0$I4XU@SI,E@H:PZ<SAHYGG-I,[N%+DLRI)4 6Y\@IIG#V"=1W
MDN^L.Y=-[^V%5%]3\\T["2&Y<HD"M4DNZAHT=2I^DKJ9JG8WW 6&CA3M>,\)
MI\O6]A]02P,$%     @ E81!3';#H8+- @  V0L  !H   !X;"]W;W)K<VAE
M971S+W-H965T,3 U+GAM;(V6[VZ;,!3%7P7Q  4#^5<ED1JB:9,VJ>JT[;.;
M. DJ8(:=I'O[V8;0<#EI^R5@\[O'Q\ZU?>=G6;^H@Q#:>RWR4BW\@];5?1"H
MS4$47-W)2I3FRT[6!=>F6>\#5=6";UU0D0=1&(Z#@F>EOYR[OL=Z.9='G6>E
M>*P]=2P*7O];B5R>%S[S+QU/V?Z@;4>PG%=\+WX*_:MZK$TKZ%2V62%*E<G2
MJ\5NX3^P^S5+;( C?F?BK*[>/3N59RE?;./;=N&'UI'(Q49;"6X>)Y&*/+=*
MQL??5M3OQK2!U^\7]2]N\F8RSUR)5.9_LJT^+/RI[VW%CA]S_23/7T4[H9'O
MM;/_+DXB-[AU8L;8R%RY7V]S5%H6K8JQ4O#7YIF5[GEN]2]A."!J Z(N@(W?
M#8C;@/@M('DW(&D#$A(0-%-Q:[/FFB_GM3Q[=?/W5MQF$;M/S.IO;*=;;/?-
M+(\RO:<E"]ET'IRL4@NM&BBZACHB,/+=&!$:8Q4-PJ/^ .F0B,,^L@;(#1,Q
MG&CLXN.K^"2<8H$$"B1.(.FOU(RL%((B,I7T,]#Z ZAG> 0-CY "(X8A1/^>
M(32+2(ZLH5",_8ZAWS%22(A?"(V(7PB-B6$(3;#A"30\00IT[T"(I$V*H,$.
M@-"-/3"%AJ<HA<GBK1 4TXR 4$P,#Z%9?",C9M#O#(U",P)"-",^ ZTA-,:&
M68B/TQ!I3.AY"BF2.2F@9H,L_@#J>[YQ!3#DAIYL@!H< BF$!I;?A_J6X8WR
MP")@.0FI94@QZAE1$<WEC[3ZKO$5Q.*!!LW!%6 &*Y@"R)B)J&5(W=B #%]Z
M#%U#"=V"F*)[$%.#[( 4/9>#J_JF$/7>U8[*V\ACJ6V5<-7;U:</D:V/2/_*
MUJVN;GJ3:8K>'[S>9Z7RGJ4VU9>KD792:F%,AG?FMCN8.KMKY&*G[>O$O-=-
ML=DTM*S:0CKHJOGE?U!+ P04    " "5A$%,4<*NGI\"   G"0  &@   'AL
M+W=O<FMS:&5E=',O<VAE970Q,#8N>&ULC5;1CILP$/P5Q'L!@X$0)9&.H*J5
M6NET5=MG7^(DZ !3VTFN?U_;<!RQ-Z?F(=AF9G;6<7:]NC+^(DZ42N^U;3JQ
M]D]2]LLP%+L3;8D(6$\[]>; >$NDFO)C*'I.R=Z0VB:,HR@+6U)W_F9EUA[Y
M9L7.LJD[^L@]<6Y;PO^6M&'7M8_\MX6G^GB2>B'<K'IRI#^H_-D_<C4+)Y5]
MW=).U*SS.#VL_0>TK%"D"0;QJZ97,1M[.I5GQE[TY.M^[4?:$6WH3FH)HAX7
MNJ5-HY64CS^CJ#_%U,3Y^$W]LTE>)?-,!-VRYG>]EZ>UO_"]/3V0<R.?V/4+
M'1-*?6_,_AN]T$;!M1,58\<:8;Z]W5E(UHXJRDI+7H=GW9GG=7B3QR,-)L0C
M(9X(*/N0D(R$Y)V /R3@D8 M0CBD8O:F(I)L5IQ=/3[\O#W1IP@ML=K]G5XT
MFVW>J>T1:O6R01%>K,*+5AI!Y0"*YZ )$2KY*48,Q2ACAQ[?!MBZB"2ZA50
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M@]3#7(WYT+J'B63]>"T)I[O1YA]02P,$%     @ E81!3." :-,Q!   ,Q4
M !H   !X;"]W;W)K<VAE971S+W-H965T,3 W+GAM;)58[:ZC-A!]%<0# /X
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MR>6IZ1Y%^UP-UWC#2Z.NXQ6E_[@GW?P'4$L#!!0    ( )6$04QU=V_JY@,
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M*$8+,"W 3@(,/A3@6H /%?"U@#]4(- "P5 !H07$4(%0"X1#!2(M$ T5B+5
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M1-.2 GF6K@V6\0KF?/4C8=%AF64@S@BP97R .3_\"#6W*PWJ57/H6VO*,D/
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M+]H7$>U#E>_U2Q;W]*9G]A]02P,$%     @ E81!3-)KCG>N @  E@D  !H
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MXAK(=@,US.Y3=$?-^N[LH%M.]\TL@#*CEQ5".%U$%ZO4@=8M" ] ))O?8C8
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MN>/G((3FQF,\,U7B9"Y)?:?D!VV;F6G+]J;0=K1HNEM0U%_%5O\ 4$L#!!0
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MT=D''$[:;I=F+]L!T@9:U-UL)/V 3O\#4$L#!!0    ( )6$04QT;:GI#@X
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M IV^B9^>0I4&$1J,@ZX#HSUA<I6-\Q.HTB!"<7'0E6"T.S;7Z#A_'0$1ZKW
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M^+$0Y@S3:>+^,%1&"T=VV\FBOBRD<I' \4@X'NG%0TCD+)AU)Q*]D3CU)F=
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MU\4LS?E3O;P_?5C5#_OVU_;D:WM\%^[X8=^\7!]?])N?WC:\^3]02P,$%
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M[>NR]J+*C]VK0/O\/G+^/U!+ P04    " "5A$%,^TR'Z=P"   Z"P  &@
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M;VP3LA-"<:TR"O3^/.A&=AB4?*?,(]7/;=?-=0,EFKY3#8=V>?$/4$L#!!0
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M/&=9Z4.%610:\]6G3Z>;G7\NJTL;KO/F^*ZY*;-C>S09G\Y'K_\'4$L#!!0
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MP_UCIV8G>DIP7'C7>ID_\S'X$T]F"]I4/'28FE)/M,XWM'U+LK7$ 81445!
M&%Z*9XWQD<:=RX""G^)G9ZP1M2M) )T5^?9A04,(T5'TGL*B1?*(-+9\CN@
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M.>IPH,:E:;)SVO56E!120ST"R&_HQX.'T@,"+6&HQ]N 5J' ,I\*,E?]IYJ
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M>>\Y#\(BRIF;V68S+;$2W]A,3?.*JYH;?=5HY/SG7.67WE'11=\[;<UT+,%
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ML?]V[;Y-W+<,#.$6)0V)/17)%:=2'N\J0.40<W@5<)I1+S6I(?01B#"7C+[
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M_1Y\>*.W['C8[PZBD^CX H@"_ACUZ)^7E%[L,*OTMGBT%8Y_'X_IZ0$,?3R
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M#TMMR^FZ6P<-?;S5TV34M#*\NK/^X+($[KVH-6N-[ALLDC[ NULFCH$T*7[
MZ]\Y[+R7:7<^'/J6K?)JU**YITR@@&O!C_,:B,K:N.1*A(=VJX:4BZ]848%J
MT+R^N=M+$!HR,E'\H_A"M6[5KD=?#?M3.H<Z5'P#RO@E;AYK!35-J<'S0C$(
M==N\I(_A$XDMLV58DD$:+O.G?1-%5$9WI_Q6N</@5AOMNT12PX/\[O$XF7N]
ML5O0J3A+%?7DY3%) L$PS;_J3;O;L[/;D@R(Y1Y%H\&P.\9_7$2C7A_47*K<
M'YYCDA#\M1\-QAAZA[\.H@&%A5T*15/!A$"*4N)+3M@<S%R#%'3'>1R&M$15
M7I3^]J.#!)^ZM%3X+<5O,5H]F5Q0$!L3@S$9]4T8 '/O5O@%=_,: DY8$S&B
M^+K&\Z_%LL<?N:'ZG<$$D\O[G1XEF[/)VD?7SO& <X[]K*6$1^8[ZDR& TIR
MTYE_J@?M#(*X"RC$F47\F%I:5(381]$Q"::]04-N6G#<CAKZKQW$8RM!#@?H
MS.V9];NYJ  'F1SC/<($W*G-2D!/C#4K/1B_:5H@!?SSZ!@,U26L[Y$-1TSL
M/PNS'/IG0X->AYP%(>.E9^A)U<7&?D/N+R*Z!G>O"(&IT>#?KF)JP!%=_HB\
MU7RU8=PX\G5TA29=&H/>R"\-7;:Q%Q(T@HIO\Z>,Q,2><.&;]:SV49CKE^(.
MPS=I^1:[U*2:##KLYC+Y@E?Z_AEY8UY I=4TN+=X)W^A._F>(2SHN1V/^<RX
M705&+>-*"ZXIM;M!GV4D["38Z'B*K:E556T#I675!>%""P*#HK?,!9G -3NV
M(4_RDKA&Q=AC$8A=08LK-CS<JP)M/F<F>< $BG2F?]^2<U545"8C'ZTDC"X_
M7+-L_'^V.1[439%*CL4E>](8/Q]X_SN:8/\DNC-*'-^CCU/,-Y3>[:#6NJ<'
MX=,_9WG;DT.%W?V><7<1+@!F2^>$*<]<^F!+UNJ?O?>=K.?)%+1-A @2Q"N/
M_%;Y"B5C#RM*=)3JOW\D.'*ZJ^97_<Y%'^63/E7]]WM0;QZP)5 EI19DT^PW
M<OJXH28CK#+U*7+V7V9) G%LYX":"OU'']<_7R=%*JAI"F<*"P4N[!9I_HX]
MO*VNY9ICV$+?:("X/N[G]A^<9'<433J8#(:E&#0G^F XI%(-?=1@!G_?/$G\
M<9\T%G/2E4^NVGK!V(8"G(!9W1C^U,UXR/.MOXJ?^S_NG@RH-& 2+*G^V1??
M$](@S3T)_MU\3P:=_MG 4D[EWR^X)^-)WU!M^*^=]V2 ITS_.>B>3/HV8]7^
MX[";,AR9]07_4+H[ZXS'YU1P.& "A ^^Y*8,*T==^>"@>S*:G#7<$_Y4YXO9
MM8.F-\EC-8^S4'644F-W\<)*C0RG?\^JQ(OGOVHE3(X<!H@^VK!%\\ HM6IF
MH9I%@9+0I,/U1UE>;=4])Q4B@$&@^RV6G" .M+^J05<"'?".,MY):MOK+5CR
M^/L;T)!F=,9M2LK+]/[7N&W79M?#LW'I$[2]YG0LT)4>GE%ROE4!'&Y,:77Y
MMXC2 [M"E?E4I0FW8-(]/QO_/KI+,BP3Y-\@'AG[O5FW]GP'RYO/L%"^UVOX
MC4=/Y_PA,.O[G3%!?\&? [1T@)0'3:^K_71 I5=8=\^F[20:=7OC@]XZAI^<
MC_OTT[,++&0==P<'37@T1@Y^AO<,AJ"V:4;@GG.YP82RTD?H3/Z >$ *^<BQ
MMCG&-1BPZ+"MY585V(WD 91:% 9 [QDZFY8F8^=H'/2=X]M6LX()S62>B+NP
M?DL&':H?F )-LSW\4C.W'K/+6JF,@L0F;X_0\HCI1$;BIB1Q;>16*V$59(K+
MSG9:B(VSHP8R\!Z3R!0<!<=I:DR.I]BQ<V0@T*+(*3L !:6"9NY/<ZA?_F]\
M+$;P7 6"YZ,1/-=?E51(.837'PY*#62$']<#E8!$S0XYJ[GB-A)_AOJU':R9
M2^]A'VXS9LH>%V #2V[M<&BD=06#J!1>/52+D];Q(H[\UDVDV8/($AX48@)*
MN/*>2T/85'C=Q^P !U+BM;EC1A30,G[[OM#WQRJWOK'-H^)\5ITJDM#@[*(*
MWS,834S*0@-^3W/,G[/.#CD/\9SM:P/1W$5E?VVE3_'VT2Y]8M=;VRO%N_8(
MFU=_T+KC &E2P$(KN9W>.8_N6P97K.5R4OIF&:A>.^Z>":J&#5,K69SBL24U
MB[AQMXDTI4QG8LJ9SDQA*&YDT)/2W_P9?2KSC1G_C@_8;Y)IEA'TRPXR5XI$
MFT+8Z3>Z=S *(N4II>MS9H[/L !V)M7Z?+17D+E;515:SO_=$*TC"=1"*Y;.
M:8$NDA@;&G@^=4G9>EIH3*%I<(_^N%F\1-1ZWDT2ULKOFM==BEN-#&8OO;W$
M#]*UVVCQ$,]^XPF9ESM'7%I]7FZ9%YS-;L6O-2A>++ =E>^7RQ6QC&L,>G!7
M.O\>P% X3A#T!)9(JM\X9+6.B@P-P=O079W,?>>R?+NY9W]N_K=DYE2)6@ME
M0W1,7C$[]S&JV07EW.86AE%,K3\G54KV5%H[B#Y)Z8FH,HN* &OQC68]\V;F
M_DB=@W5X!^'85*9"[\ #T4YSC6UO,9);6G"^5L:K.3O"I!L5'=60]M^,:@_H
M>@2APVGPHN&]C$P/4 J:LM_2'<VY#0URGONXKD6,SP- @;#JI!I.#PG6*/-&
MNW2$VDREO2I$?0.M4W74+O(=>?+%:+RR21>#1DA[F'1:_E8K+:(\7Q4<CFCY
M\&F_J06FU$B:?;>YWLWZ!9U%9<OWJ1&!'.\T-K;>HW@<IEMX%:M-R^AB/E,
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M532L=& ?FJAQ\_7X@N9!M;[M&XH:EUH)YG<;-31B;(QNWJXG5U.XS!BLOM6
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MIYHFFZ<D:8.WE/=4CKI&"GH&.1"2.?),*WM\4C_M(-YN-*34@I*0^.FKNH%
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M]#1&O)P[N.Z-RR>OY3>ZE?OIDT5 ]6K][OATDY_VM83BVA?5C'?0,$HO5YI
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M4ML+0UA5P&T/L;1K2H$1TR#CW*0HZ.CP0.DM%8^RAP:PO1!)?R.F_X+WHC*
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M*Z\)13]K2.*W5"9!++=VX2[]O8:,ZDG?FU/L7W_"U)@Y%OCMO63> *4;0Z]
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M[BK-'^V_*2WT2NQB9SB24W"<>AV(@[5+R6:NU\@@-<I2%SLVZA@E56(\QS6
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M<3D]T/#^U2$NV;=Q BA-8X=)K>:$=)FU6@>;'O.$>E XDV&G8=!L$Z@1 "S
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M0&.5+:R' ()Q-N";?(T5OX6C&/Z<&P&P]J,5 8A1_:6.^MQ@]SQ80('BII"
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M^-,IAOB(,0I ;.;+[72>YAMD7S,,\IGC:@Z)-BIC= "NG5ZM[T6 K)-U1M2
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M'-EVI2?WS?\Y>JHVNH'U^P9>R+/4T.:]H/AE_44L[S3>JFXT;G>BWF!@0?B
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MYTY,F$:F)8Z']ZXN=:L.X_TAX/BUM"_]E=J7<IS_6WSC'585H^2\F<Y3N'9
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MZ?4%!9P.4$H$)HR3P?9GO.&NSAG<.*T6O.U8/7M-T#YDO$='CFI8:T;CONS
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MR!WQN%FV"V*!FF(BJP2[F'V! N^7L_QSG1:F01& ;0]M6^$FZW4BO<99)Y#
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M45=N"D;^A2"+#0GUM1&7OXEH ^M@Z-A^!39Q&U6G^3CM/+?&XJ@/J:=N,@G
MWKK875&HYD!7FV^PN=\0?]5_\XE*)Z\EMM8O6"^2",Z=@..4EM(]?\<[X.JR
MV^8+#/ZE%W 3]AJ^E*&4JRA#B0BWYK)Q(]3HPZZ4BX8GWLCE5;#.D2_W6Q5W
M%MT>I!+*I6K=&-W-0<_#]I 3E0?&$D-N+I1OYL7B-ZL0J)V%^JUW*'ANM>)/
M@W60G%8%^^4LQ?/C;Y=EA<ATN7^Q3TC)QHH'W,X! L(+&A%64D-AGST.5V.4
MU)IJGF)!6 ]RK-0K9@.#QIP"7&AUPT;DA[V8R:91<5N'_%EI0*#*24I9_T^^
M9(/:ORK<)7;SBG(K*XJ&4=+L'5KD"8F1B&>92ED3"&L13QPJ4LB(S%C6Z*_"
MZD5*6DJ.Z $SU4V!$S]F'%+)&'70B;SLJN2-#+!4(FWC/M36#AN$QXJ>*'=V
M8=UFZ++SZJ:A#C'9YZ@^9@%?E/JO'(3C'B<R</1Z7F$92BO,.EJME3E7?>^=
M+TZU@@A0?()E\T?2':"A^;JDF'1*%+%RM+4+8PR +72YUTJC!-ZUPBQGR!IB
M9 "DW^+G$18D[HRFS>:[B22?6H7V%"/$OMPT (*I FBK1!_58ZBL )DD;BV2
M\4+IPRW&)'(LJ@(%7!G*9Z <1!%X0\Q>5*P\NJ>ULH^*>7!EDXY+WS6*5J)(
M>/OL8RFQY:G)V[X#6]M4OG&08D ;U5'T&8++'$TB:GB$2@LJ>Z%K4DK#-%LP
ML+H858HZ0M.;60 \"ORXU'+[!Y3*?B8[O;V<]8)R!H3T@LVPU_+";U(&U!2A
M^":2X("<0A[694U'3VGBW ":JTA>*=<-\R#B*7.')2+-;@3&^Z^JH49=+\(2
MLQ*2+4MI46=YZTF/YR?(O,;5WI%VQ-'&A$'$_;3,L8XR&^7 -*.:#JKV\KEV
M2H [1T\->EX@;[L%(>"V8L0QWRS:N#J9+,G*1J&XI8\V:>T8;/%71>.1!BW'
MJ=;^=2G09%V<2=<6 ;&NP>"<_29U%DFO(7%#V()-GHC+415=,S=4S94O?B>,
M:2PU#]'F".-%Y>%J]# "MQ-9!TVCKFZ?NVK5@*Q%6@"V[2T#\0.D@*0R6B(H
M9:GY6B@7U$$@>P=AF3AI^$=,%,000@2$0,&*4H0(UT$0I=$!+[6N/'SC(P H
MH!03B3^&5R@Z^"^F?=.!;YQAAZVH8RW95WYI+=4\N8U,NS#R38B(V#WYU"JE
MC3IJ=EC-A0!1P;1;27E'7!7SJ\P6,P-7^8(HU>8\RYB 8"6SF2.?X4[:KVVW
MDFR:=@@;:(BG-+PM!J/8F&5OX?;N:5?SC6AG-^T=?:CEM5 6^"*DSH/#BU9'
MM(X3<J0X5H+11)[(R;4Z5>!CZKTK6R"$U"PIH F/F+.N6XX?4U!D"U6ZRJLJ
M;KRY/-#*ENUTEJ1(6O'/5WRW]182TS^4&,7IX"Q_(LTX0G&!8^XI@E:__0=+
MI'29[72(-_PZ_U. -:^95"S[_-56*N\XR1PK+!#U%/RX47#90/5?L50O&:JA
MV)JV.1B)@9P0E2N:["H*B X9+\2#BB)G7C;#ASBJ3A1 P<UO=;WRT8-163__
M@H*/68XMON:V4C==J)AXN!(^[O%?DA:;;WF].J>W'16J D8;PLN>Y0(\76Y]
MR9:;+Y\A**0A#$J*7],&[;A7Z@ML$(2G1+2[7(R%\W(]WSZ2=EE35"Y$Q9F;
M IW:[ZPQLK;62.6'=2)L0#B!S.BK#-:%;CX#RPI&+:)8J4M4^S$>;/_6XBPF
MQ"L/DV\4M[6.,1J"9&M2$'+?>2ME).WJG]IR!2<7G/XK02MGB@"I1N>S+N3M
M19'A]H")?TE)BD@*RI+CQT+94!.B>YM86"QC#AY6DQ3$+1T!/0 2=UWM%&[)
MG@41<=G!2C%W**-+G^"V .I8Y$L(<'.%Y*70D-MQEN#%9VG[TH722FV \VW3
MX4'ST;3HH/GOH*E+-$Y)1X%[C4?/%1;M",2VY;4"JT$UQ@T%;$GM7S%KL^7(
MY4V[<1BE)5*[,R1A^*$RAN1^7[J$""\@T2.&PDO9$+?A84P/1C]I#B1/D+[1
M"(-BN@#SR9(+E>]UH^ 5OD=RB8JDPNOL[/;VE[+@>'_ZXU@;M;R<M*\>-\>*
MEJ@>XJ*7F!^04Y"QKKG),6L2>.WEBY7U;W*D(!_?A=NX;LR=$8D$7T'C2W?;
M>:=8RO%H\["N5F=)-/7!WDA+M&6[K#2%BCJ!0U/(7REG0\55+S$2>=^ [\:L
M@ .^<F;KA:\9T-UX^#Q!VK6SG >T)Z2L:2_T!ENCTM[+\2)AC CV-9)8\JK\
MBE\+/Q/6,P%'HF&=/<X<<*6ET\WJQ +?,O(!"V=!_@DPL8$XI?"N=6T\E&8_
MU_,'#*-VYA9^4-T\=#O 80->HUIX-(NX7<MU)<98[MV5-+$OU$U;E%%=#*>A
MF[^BA&=DUT?;E4@6Q^3,P"T1@RH*&XB?-'<K5ZV]A1.A%-<()\3>$I0-(-OM
M+XT19_N,&"Z0ED'[HP+'("=NM6QM."\(MT>*X["VZA8$!HY\?]ING&W3)7*0
MD?NY+)80UD:F1PYV,WR3;[7Y<U(_5?PT61K\N0_LW*_XPJ0%R)64PPX%&8JM
MAX:Y$T'60=%"**1"KMS40F.LGSG$J]=-ZQFII,%;1^P;8ZT1N0+4YX:IF*&1
M;P4++5A($+((IKP'%)5:W()$8=;2A5[KZJEW& (<*>1]K(9-B#D@\^*:.%>U
M8]<B)ZTH$XH 7>P+J;Q1K##T#Z_2M:VN26)WJLA36P\D$-9*H!VT!BH+[4KP
M%C5>N.A*X0V.6I+':E$LO1 0I! % $1=LC-1<G3DEG'CX)$)O54JN@U71)R6
MK:_(MM,B450K!!^:P=V:0_$ 3]/1@0L//<WFG,"E $^LJ]^*]9\7!7H%\*C#
MIR5\A^)D[:)7W>%25YY=(Y1G)!^+0E51KS63P+M#+G)R/#E-$>N'=.WA+6IC
M9?&-5=MR;9^A- A.B<@W:S+D5K=PZ^#WM%#,Y,C8P;H^=Z**^Z&2^O^)B(MX
M&:#5*M,Z%BZG6+BSNTVQEFQ220'FJ;)Y9UXLH/H?2B(+HY>!,,.!L4"67\U!
M BLZPL?$;YM@G8*UV5F2UY7CL-SY@^+.GW4FAFB1S@J_N^"]IU1$XEI2]"[M
M9=OUW?:2#&+;E(AM#J!I<?M[A33TNK*3B^BG?C GA8I9FN>8X85IHL!#R>1I
M?KEPS#0B[T@HN)'*4-\'NYRK^5TK;\=#>?^ @+2F/70HY@NV9'^%Y'\.2I]+
MWYR_9!.\47!9%X &L-H\,%$O)$C.@KQ2%'[C$MBK5G?S):H7 I2^)H2X.^BZ
M>);#!86DZX9>93;K"?8"G<&8[B>X"89)R1AMDKEF)\U+".59MT<J/W76,]-^
M5L&%S44(]O-,2.G:DF<L/ZUY2<=2$<"W64130B@TQ+K5)61'SI8]#9(53*%;
MVBDG">2)(:*G<H/Q.)&079O,BES6;$FYL1#9-G=<&21= /<W0_P/E-XM^7?6
M8E]75J8$HP.A2;M\1M))P;._< 9FI?CQ]8+&[26A7HBWT/F,[W-@I!Q1[Q:5
M>(DSJ[#CRB;PZ6B=/(Q]@;PD*_L:9F&(7=;<";9T+K8K3EPB;/*UA$"B%_W;
M&MSOE*ANA_I@QX_^1R"UM!ED[B8(1B@P8$ ;K=DLOHE/299H$G,55VW"-K[@
M(MD7F+B"@3Y(]>*K1+\H"23%,^P3<W 7O"/ K@4"O2W\*!9>&6]?[@%1Q>;&
MK*C*NCMX$H8(E)S:D8H'O%@PEHMKSV%N.*.AL]1_96Q4E_Z!'=B &[%*<8:4
M#4FD\#TT@6YK,8/3.CY;*O&$,J,%K\DDBWYC&^8HX4V?O7@0-?Y&\M(F6(8$
MHZ17)_YM1M AYNXR!.F4&Q89*T%U4#VI-#9E/VLSY4LR/M^*QRFGZ.]I:XB@
M)$ 2B,O4/:?#?5W6O^U5R.B]JGL)%;8>G1]%9W.+PXHR>^>Z5QP>\Q1,_1-9
MUUZ/H9ZC;EVM]-3MD;>_(D)G\?B$!P \^H\@_>.A1TN< M9L[1@_U#<^!J0A
M^*,$"QE9.U]P2 3?AHC ;>9X%UVJO-9H;)(N@]9='#5Q!!4.=6]$BH(L;GK,
MO(!HUK+"LMRH0(=8:!F,D/E=<;\%1<=9W#S, QMM0N(+IML3GH],7 $[E;5]
MWD9K>N%05?--<^L]"\W3=&N.5R/K@-I9CL:!5 F:'B$B/"L[#IDB'C%CZ4&B
MF<GFRGG:('M3F7&*Q5W372H4H"FO$::OM&F]8U!+_J%B.'F0!%G:6S>,9_!.
MN=DR=D1-;*I86]2)\\Y3T,2.BW ,M F[S-<5BE2H7:\)5 IC\<W:@),2/8<V
M?AQ!*<'[49 ,I&J)6ZVV9A9+2@FY$E(-JTSB@+D#('V9\)O04/P(2^YRK1L5
M<.NXF>0@":SI?>?ZH? KGA>KR^M[D-F2CD0B,Y \Q*+WH >K)*+GO[GDQ8 4
M%-;I1EEK3-B$\1+8LU9:6+-"$#/8S"P(/7OI$%X-2S_BS+F'8&YS$1$X0UJ5
M0,S&IURZLC\[[?T@I2DGIYG]-(-/X^(5WGW-U,'F#??1&;]N?+L7*<V7CN%T
MO/H.5!;U_MG7O%S"-R=F4B>T DW3FHY!%9NW-E:P_= <B25>^2B'ZG"N'$V4
M7B#\]I'C?P3NT6ALQ8.1!(A):: >R/9D: N;ML[71?X[9^2:\[Q=+<7CRH,G
M7 %?"&7*@Y:5]*=D[J:-&F^<C<UH\IJOUJU-4*$BQ"59EK\5J&9#&!+ZB*@+
M% *IGUCCMP48C)-RHX*%81L$#Z!KL2UFB'7F1,6ME+Q%-E:4"R 8/DQ%ORF.
M55'/!8%;*/IQV*CX *-?*.IQ6J66-R#7J $\%KXJ4;":='0C3M%DH^]N"Q"Z
M[%;,0S2T$=1KF8,PDH1>&?0HMTX2O:8XC!/8XA.0S:JU))=;4XMMTSLY$A[#
M35%TUV+KQ%C]K8,OYJ%RD"YR#9>7AH$,!-GHD,J<Y?<N_UI1N"EZZTBV@_8H
M"'^ML-92!,N4&TOPY44\;533^.H922P !*%1L7/%SRJBO030C9^-]M%)9H)9
MJ\"0 W)!*!OI[!OJ6PTN!J>O278<A+'V=KRDM%$Q=^7"),6\[5&A9H\D:!3E
MYH&W''VV9/D52"D>N7QXI_QZH ,\L4+,5YE#"E.(8H[R(:BHDORP>GM_#\LC
M"ZP]0 !@N"TPW\27 QK3@7AQ0?6QAP/$(.]X.(^E1FXASH: "4:YC9\)'9B"
MZ""@E-K# '<B0D\P4CF)*$81L'8F/CXVB(0CC#AB4[8?%DABG_F-IACQO1G+
M!;M;S-:IJQA/Y2>W$I]E)9++1P!BM1%-,#PX9:3.FXF2&Z'V"M.@VT)V!YU-
M2B/AL#0,X5"W,5UU$84&4P:*?"45R2+;A6(5#9)4QHV-D)7\ >=NL',V4E<P
M LDD(H@<E?/=X+->2([FL,Z6BH.@,G[HVZMMQL47OT^.A@@E',46K,LTL+LI
MFD5NA_R@J:;2XFH68(44(YRD^PL['#RQ6QK#K=LV)YIZ:!0DSE,LCP0S@H\]
M@'DC==K*'YCW:;^D@QP586X+E\O6);Q0ZD-#>%%P/)$]M"$UC;'EZI+$,+#G
MYB@6 $.<=M^8&(:IV?P"+BS9\N@1D)2ZN^URJ>"\Z*;U:;QLN*,L1@SCKKK#
M!(^#$'=O=+NETK :TJ:>]#<;LJMC;%RP*D6I[:04C\&+R!@!;HKI@'II3\7"
MIF5\EA^+A3,$<^1QF'F(-JD[0+PQ]]8=@ ORS)E.6FE$(OQD''!P FD@Y<"]
M;D'/DL'_.?G-U\0=IK5@83E+SX;B:<5UYZ@%KS/G3GC G/"'4$[E(GN^I3J^
M]A25H4'OU,ELTYF6  >@=*;8N/*FY(9?196</^8H'WA&FZHTBZ8?K?#F"KGL
M968&;XF._FYX3!I145+J*B[).>^#BP/$0",%Q\RE9?#(B%05".*YOKZ1["6H
M9(>\RDF></.1X=@*(XS!RM5%@E.HRGC%YQ8>OE6ND,<A]!:CA^X:=EDBFJ^5
M70S):?]JRR7!K TIIBC6VB!7@<" U\EOF3-X(2ZPO;CA)2^&DE(01 [7\/VD
M^$K$M*\JV5@?"UZMPS$%Z7RGNN#B1EE$C8-T>T&EXL)9TZ45FR'BI7DO,9>'
M:NS%@DW4'G^(;848.>IM#5J-=0OAWK@[3&X0T,3@<6T*Q$M=;#O?I&X%9P ;
M,;'1%/CWS4>A]>R2TSY%%42GDO6&$>0,*A,4\,),GO.@Z>9Q:@L673V!<COT
M&Z"%T/Z0*5,2,V4]*-^4\LER +A9W5,\!]Y1GD=3'SSWJG*.KL!0NU0G?OX\
MYT 3B_[&9M-:,N!?J=E<^I@ '-\O5<65LJORH!&2@&T*E0?7[PKHU!(2PY"*
M+34[:"*X5$K  ,ZS1=T5SI9TU:QK -S\?F5DE1R#$U3A;S>I<VP?]DT>*B*[
MYDM(VI7 0%%X>]Z#H ^OH7G8' R20Y3:&\E?$,395%*SPIC_LK;,D!+<;VUX
M$<FF^)Z-:)-$XC( &A!I4&SNQ%]76],?Y(\(*#J9:PJGT@KC%IM&,S&2@2FY
M!(]U<CR(,<"M[8)O6B1 \F>Z7)G("B92>MI9:I#6(KV!LP0'+KS4HFTW&_,J
MGZZDDAUX%,FL6X!0!/ SZ.%=8SDZB^EEV'BQ)%!K\!7,G5&!;:V/3T8RMN84
MZ1OGZB$F0Y 9WCTH];20?]/L-J?4\9)<"$O:GDVE#Z"E"]"EY_9J8_>\0P^"
M(^P30E@;I%A]+=?5BH<B:X9WPQ;AW></I/Y[B/& ]5Q+U3DW7@61_F#.9K%V
M&^,Q"29[?VPH#3X42W,9E7<JRU6LDXU=5YHG"+HH,UK'S5?.I=-"!N5.6B6_
M<H$H)(6KZ)XG# #9$,[P,G]N&3J:+"W6M1QSN46^6K0@LF+Y#:0,FRHRB09W
M<*Y-C)M_(I@:24,R&A$4HEM&%!@_/9X0".[+YLSR<AEX;9O4I?/;FEQ'](%<
M60XJX3QT"KCNJ0H8T R"&(RRMD!2LMTWQYL1(SEG]V(B=1,<.R4_<0I:)-#L
MQB_BQ2);BBKAJI0$ 2>,TM:"Q"5=WT)M:. ?.4+.6%YU6RT(*_&V!C_BW *7
M?UDIOX&[<GXMK)V/';A@Z_/D!2GK!!)73;'AS<8I;&N!J"#XW<;)E=]*+-VL
M>E?(/JQPV> UL%C1]N"3K.]="@P1!F+%GO'M<I3Q9AO%R ^TU91W[ X+G&1N
M)U'LD:R@)0AR:PJQ+!&TXJ$EMWA1  10ZF<=2:-N?>JFO>@T.;-OP$'Q[O-&
M8CKQ>!NRP84WZ!"2&9WBMXCHQ4;#\#(").<S5;Z%4#G"(_35&G!M0;Y\@P'X
M(.:L2I+HY0"N*I0A(5/ 2&@NF(3]>+E+0\6U9 TA5]B)?BH9@"DZ6H+[\)64
M0[:H.97X<AQ:F@%IQB@/98< OD\W$C(I09 X>HX-:9F #I]L+D.@ZU]A5 -8
M=2"SA),@#?T\V3Q1-0MH*M5DPV<:4Y"<40&D08@N%GQL NF4Z C?-,"W-T<3
M>BJ7;X=$40I)W!IGT83B<GEDHJ0]0*@!V-]1A<3:K=;G  -5T5,%:<&JHHK'
ME7>MCY;O!<Y"#0CQ79< UK.@,)J63ILXR#(&+)#,,'=<0VBS=@J(1.4CN;G;
MI92\2BR$QR=$BHZT2-)26P>\:Z)8A3 &S0'0G+AO6*Y_%,)?](! F5\V7;>T
MIU2D8$&VNW*C N",[(;91PPR@S B8GM3PT1$ &M$Q:Q"<YG.N4ZXK3\NAB0M
M634'XT0:I2@)N^*Z/*R&4DH("G\Q[0FE'Y=^0O4IG2W_KA+("_1A>S>MT9U6
M8M$"!W1#6+74UP!I%8I0<M925 S8P_7VWI7BJ3W4;-&J>89HPY&P1 (Z4.Y$
M(@E$4@54)R$,?US-?:03H1;$;1TKUVX'HSLEY\%UPRAA<O9\=F]]<,*9Z:=+
M-&VF!I%K [!&PV+!$5I@R+TEZN=@4=I"/'9=W6V^D:>MH=M;4<,^0GGHT,[]
M&H/ UQMU_V&$'I]M;>MHNG0?\SGX+B3=RW$FWB^UJA@& UK*_</F!%4%=C7(
M<KN[R$SJ;KN$0M<.WL2"2? $)+!1A>BAB,I1Z) 18_CG'1@"(3J=@_,T>BX?
M4@K2X'&Z@ *VM74S8!=7[L],+(G[3LUFQ\N:NZ#-&HN;!P4,,'\K.:?R!L_)
M%VKV S;[ 0;Y<[51<UPD;[?E<H%6^/X(5F;8XW7Y #GAZ#BXU,53/QB2=*5Q
M[;#O"HFQ0.M:. -*,7^_78/YF(W)[\O?X?<ZP9XGW/%'CW8N[*+B0YD,[UR(
M^T8H%Y[^:[Y>X!\#>'C$S_[*MCX(,^4*>IW[Q\9=*&<JE[PP4:0!CA"WOF6/
ML=MT!W=5.DC,75ERVI8(PJ"+)K['*BUL.'YQK+ZY2<UIP+!-RO2+534LW4-L
MJM30RG.^*FBH)PPALQ 3/QK^"0K)EK4'F47JEZ/$OW&OV6=-6\+Q6@TRKG-,
MJY3BDAA9VINE%%@$TJ=4/X',H57^*&#ZX<RB$98<6NFG:U#HC99[A)FQ07N/
M[>7X!$T[S&%RVZ*36&%1[A0L&@I"C?$KF?#5.T-VM,CF-%DVLR\/W,9C8([_
M66D.EH7+90D;A,DI,QS+?S;!AXW=JE*4[8VQ<6*\M:S)/(XWK6[+RN>QYL[T
M+I0::*+V=TB?@)":]L?K.-M_LZ+PNRYWV7K'/;>X#6M'@10P7:OU<B& 3ZAW
MOJ_6 !J37"$6<'+VYYL_)4?^A\<H"&"BUY;$:&::3BGP7_A3'7]#T^GGB_/W
ME^\NKL]2)CC_5,$*HU[PR!/D%8$W_WYS]O;ZDECL!4 .\-@O-=)PRE6,X8%C
MK""<W]U!45A*^\3WSJOU$T.AP TP/TW>Q0Y$<^5KJ5UR]LNGGR_^)E*1W,O?
M<D4Y5-IS1:#>.NQK?4_WY]NRN@?_!(('P4J813GG&0DR<ZU'"DT:/C<@;4!+
M)B$EQM=;%A!ZXRGL=U2M"<B>*$:?@G/KJG:P%4>I+_HB#$:)T6H:\PTO6\42
M0*Y _NNR_NYVS =J=I$=" _7BA((6%-$1#]P 9),B JP=>2I)#HG#FZ?%L+<
M\3) [" &9K.P$R!EI.(DV=O&0$%>RNJY](I/OF0=*J','5>%NR=3?4D*,]IY
M#UNW6PPBBX)]W75Q6V"I>YC4LT0?8])6"6%0<%_\)7FHOL&RI?10PPH8-><P
M%J(RWC;GRYC#?E=-HY!02,H0"9_FFTJR50[=T ZCD8ZR[#09A;GH?$]<NFVY
MUMOR3FW+T>75]?_*'Y_^\NZXO1UY)%$P98T[!'SH]QR.V2Z+T2K[M7G6<!XT
M#T4_U)VY<TMRN%B%N]%-'H[/MUK?VOO:F7QJ 4+!4;')7*(2'1?G&GS*^O"5
M"NBZC+1&TT[L]F&'F<NQ+6GE\.[E11#P5'0=^4\P!<-AM+@VR:=(-@]LE%!
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M7H0U:-I$+PP6::Y,9 :PJJ/QB'7^P62*OPW3WAA6_]H?,VB6/?QW@/?(R#W
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M<[7PNP%\:IL$5/.3NW6!M:<*N%&IU!$D[<#C?6BI!_^<T$<]:A1;&_1 LR@
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M,#>9R7"O=P$SE [ @"/]*.:)SBL8^Y[*M0O-&7IG!>[_&[0&(-%2]<?DB /
MCR'Z<&RTZR&WG.FPET!E 31Y\EV[M0VR-SBN0WD>'?B1BQ9Y!Y7-VN&R;[9/
M3TLI\>PB*!38:.<;JKX9>,YC[]N8?D('*%K8(RN7'&D]2B!N^SL&$Z#"85C*
M0LKRR(A@>%@7GNQ71KR84DQ7QOAR&$]PJ:5IO)/'8Q94QT,R\9K?)L,P8<<7
MT*IH1 E*(YVH<*_5#'AVW/$;H_:A+C8F.W>6X13Y(2NK@^" YR$;TUT" 85
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MV'<.Q4T"7E/<<PTT9VQKHR\I<FQ.Z1/QUU99PCWR/4/7FHFC&,>!9LH:4P^
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MDS-D+O3OQ&)] (EY-%?6#3R8C4_3Z%R4DCWH]=06V/W+OI^BK*!)CD-<]Z!
M<6ZCGS8%S!;#FZ 0/3 E1(\FAL3>6C2KHMC"6?%);GU<''D"[LC!".P]XH],
MDS=85T[]/>BIOQ%1>P#ZN'O"4,,31: NGU-M[P=+-DK17%$&%^\;VKHH"@?2
ML"NPRF&%B2LSJ,?\3S4F9B[!(+[U(*B=LVV_-_10K/'L%(6WUVT K;SUBC>6
MN0[7V;2S;@-#$1\ [H7G"8?N\I4U[[,1%@?U\<;Y@R&646'#V@*$\""2:(T[
M(TN>O+V\?-N;9:<HP?[K%T*=C1,L5537[8L#BT*X%KL7Y=K,>O%,ZZ+69//
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M#2.,SJ4%2Z/M<6 EX,YH6R_^/OHN!/G>FHTA,"7+Q%Y,][UV>FU4R@ZBXMA
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MG!Q*<-</ZWR^K4RU&!2+@E$#NBTV8J.)Q,PYU>'ZKD;7H5$=2* \QBKBNWS
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M7N\$>B>]W@GT3GJ]$^B=#)YUT\-NO=X)]$YZO1/HG?1Z)] [Z?5.H'?2ZYU
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M<F]P<R]A<' N>&UL4$L! A0#%     @ E81!3$:=D?KN    *P(  !$
M         ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ E81!
M3)E<G",0!@  G"<  !,              ( !M@(  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " "5A$%,6MAY7J "  "D"0  &
M@ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ E81!
M3'0,I/+M!   ?1<  !@              ( !S0L  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( )6$04R!URO280,  +8-   8
M      "  ? 0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" "5A$%,B+.M;YL$  !V%@  &               @ &'%   >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ E81!3!'54$'B 0  \@0  !@
M             ( !6!D  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( )6$04P+O%8!$ 8  *$?   8              "  7 ;  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "5A$%,Q@Z"K6H(  ":
M,P  &               @ &V(0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ E81!3+ P':^U 0  T@,  !@              ( !5BH
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( )6$04Q7FT)F
MM@$  -(#   8              "  4$L  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " "5A$%,0+-TBK8!  #2 P  &0
M@ $M+@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( )6$
M04R(3RCPMP$  -(#   9              "  1HP  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ E81!3*8%1PFV 0  T@,  !D
M         ( !"#(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " "5A$%,^+<0Z+4!  #0 P  &0              @ 'U,P  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( )6$04R.SW'.M0$  -(#
M   9              "  >$U  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ E81!3&!J1&^U 0  T@,  !D              ( !S3<
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "5A$%,4+@.
MK[,!  #2 P  &0              @ &Y.0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( )6$04PK3+X'M0$  -(#   9
M  "  :,[  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
ME81!3/FBCRVU 0  T@,  !D              ( !CST  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " "5A$%,\=@T*;,!  #2 P  &0
M            @ %[/P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( )6$04P%F8S.M $  -(#   9              "  65!  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ E81!3*QKP5^U 0
MT@,  !D              ( !4$,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " "5A$%,^FQ[J+0!  #2 P  &0              @ $\
M10  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( )6$04PY
MRH7CLP$  -(#   9              "  2='  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ E81!3+WS*I:T 0  T@,  !D
M     ( !$4D  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )6$04S7,>&1M0$  -(#   9              "
M :)2  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ E81!
M3()<&#:S 0  T@,  !D              ( !CE0  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " "5A$%,*,1QZ;4!  #2 P  &0
M        @ %X5@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( )6$04PTPT$^M@$  -(#   9              "  618  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ E81!3"HR2-BS 0  T@,
M !D              ( !45H  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " "5A$%,_-:M!+<!  #2 P  &0              @ $[7
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( )6$04QX+S)%
M&@,  %(.   9              "  2E>  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ E81!3)M('""X 0  T@,  !D
M ( !>F$  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "5
MA$%,;@;EE;<!  #2 P  &0              @ %I8P  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( )6$04SY)B$/MP$  -(#   9
M          "  5=E  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#
M%     @ E81!3,1#!='$ 0  -P0  !D              ( !16<  'AL+W=O
M<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "5A$%,&IL[*+8!  #2
M P  &0              @ % :0  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;%!+ 0(4 Q0    ( )6$04Q_#"1$T@$  )P$   9              "  2UK
M  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ E81!3'8^
MK531 0  G 0  !D              ( !-FT  'AL+W=O<FMS:&5E=',O<VAE
M970T,BYX;6Q02P$"% ,4    " "5A$%,C)OJL]P!   !!0  &0
M    @ $^;P  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M )6$04Q]S6U\SP$  )P$   9              "  5%Q  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ E81!3+QG_T2X 0  TP,  !D
M             ( !5W,  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " "5A$%,U[#:%,0!   W!   &0              @ %&=0  >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( )6$04P>ZF$;M0$
M -(#   9              "  4%W  !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ E81!3%+SZ13$ 0  -P0  !D              ( !
M+7D  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "5A$%,
MB2?,@K<!  #2 P  &0              @ $H>P  >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( )6$04P.1RBV+0(  &P'   9
M      "  19]  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ E81!3+4E :?< 0   04  !D              ( !>G\  'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "5A$%,O,J-*M(!  ":!
M&0              @ &-@0  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( )6$04Q,9GQ;[0$  &4%   9              "  9:#  !X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ E81!3/U1]UNW
M 0  T@,  !D              ( !NH4  'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " "5A$%,_JLUML4!   W!   &0
M@ &HAP  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( )6$
M04SXMT1TN $  -(#   9              "  :2)  !X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ E81!3.>@T?FQ P  'A,  !D
M         ( !DXL  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M    " "5A$%,^!K Q@4#   )#   &0              @ %[CP  >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( )6$04RDHL/*? (  *H(
M   9              "  ;>2  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL
M4$L! A0#%     @ E81!3(5OH.:Z P  W@\  !D              ( !:I4
M 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " "5A$%,B $D
MBS,#  !-#0  &0              @ %;F0  >&PO=V]R:W-H965T<R]S:&5E
M=#8Q+GAM;%!+ 0(4 Q0    ( )6$04P %1]^H@,  +\0   9
M  "  <6<  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
ME81!3( 9S/"[!   ]!8  !D              ( !GJ   'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " "5A$%,JOS3%A,"   B!@  &0
M            @ &0I0  >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( )6$04P<M8\),0(  )4&   9              "  =JG  !X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ E81!3(7-X:]I @
M  @  !D              ( !0JH  'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    " "5A$%,CBHJ:=H&  #L*   &0              @ 'B
MK   >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( )6$04S[
MW>I:"@,  ( +   9              "  ?.S  !X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ E81!3-PQD VM!0  Z24  !D
M     ( !-+<  'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )6$04S&NJ=/B@0  ,08   9              "
M 2+*  !X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ E81!
M3*L?O-%A @  M <  !D              ( !X\X  'AL+W=O<FMS:&5E=',O
M<VAE970W-2YX;6Q02P$"% ,4    " "5A$%,77*X-3("   ]!@  &0
M        @ %[T0  >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0
M   ( )6$04Q_5P)@Y0$  ,<$   9              "  >33  !X;"]W;W)K
M<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ E81!3$?3J"+# 0  ( 0
M !D              ( ! -8  'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q0
M2P$"% ,4    " "5A$%,N&-PJTL#  "[#P  &0              @ 'ZUP
M>&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( )6$04R%!>2X
M@0(  +L(   9              "  7S;  !X;"]W;W)K<VAE971S+W-H965T
M.# N>&UL4$L! A0#%     @ E81!3!4F;./B P  01,  !D
M ( !--X  'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    " "5
MA$%,%X]5%Y8"  #K"   &0              @ %-X@  >&PO=V]R:W-H965T
M<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( )6$04S3+RU =P,  $@/   9
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M970X-RYX;6Q02P$"% ,4    " "5A$%,N,_SA#D#    #@  &0
M    @ $M]@  >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    (
M )6$04QIFK"KKP0  ",8   9              "  9WY  !X;"]W;W)K<VAE
M971S+W-H965T.#DN>&UL4$L! A0#%     @ E81!3&>M995)!   EQ,  !D
M             ( !@_X  'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q02P$"
M% ,4    " "5A$%,"6/#XNP#  ";$@  &0              @ $# P$ >&PO
M=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( )6$04S@$!=*(0,
M *8,   9              "  28' 0!X;"]W;W)K<VAE971S+W-H965T.3(N
M>&UL4$L! A0#%     @ E81!3 U[1(\C P  )@T  !D              ( !
M?@H! 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4    " "5A$%,
MG/]04G("  !("   &0              @ '8#0$ >&PO=V]R:W-H965T<R]S
M:&5E=#DT+GAM;%!+ 0(4 Q0    ( )6$04QJC98:#@(  (8%   9
M      "  8$0 0!X;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L! A0#%
M  @ E81!3(<$BK,< P  (@P  !D              ( !QA(! 'AL+W=O<FMS
M:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4    " "5A$%,S<MQQ?H"  #M"P
M&0              @ $9%@$ >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+
M 0(4 Q0    ( )6$04Q(REV12@(  "T'   9              "  4H9 0!X
M;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ E81!3,6 085'
M @  + <  !D              ( !RQL! 'AL+W=O<FMS:&5E=',O<VAE970Y
M.2YX;6Q02P$"% ,4    " "5A$%,61;<F!X#   G#   &@
M@ %)'@$ >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4    " "5
MA$%,H1/L]&X"  !?"   &@              @ &?(0$ >&PO=V]R:W-H965T
M<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " "5A$%,50/Y/[0%  #*'P  &@
M            @ %%) $ >&PO=V]R:W-H965T<R]S:&5E=#$P,BYX;6Q02P$"
M% ,4    " "5A$%,.Q#.AUP#  !'#0  &@              @ $Q*@$ >&PO
M=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    " "5A$%,I:ABY*D"
M  !X"0  &@              @ '%+0$ >&PO=V]R:W-H965T<R]S:&5E=#$P
M-"YX;6Q02P$"% ,4    " "5A$%,=L.A@LT"  #9"P  &@
M@ &F, $ >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q02P$"% ,4    " "5
MA$%,4<*NGI\"   G"0  &@              @ &K,P$ >&PO=V]R:W-H965T
M<R]S:&5E=#$P-BYX;6Q02P$"% ,4    " "5A$%,X(!HTS$$   S%0  &@
M            @ &"-@$ >&PO=V]R:W-H965T<R]S:&5E=#$P-RYX;6Q02P$"
M% ,4    " "5A$%,=7=OZN8#  #V$   &@              @ 'K.@$ >&PO
M=V]R:W-H965T<R]S:&5E=#$P."YX;6Q02P$"% ,4    " "5A$%,![4^72$%
M  #U&0  &@              @ $)/P$ >&PO=V]R:W-H965T<R]S:&5E=#$P
M.2YX;6Q02P$"% ,4    " "5A$%,TFN.=ZX"  "6"0  &@
M@ %B1 $ >&PO=V]R:W-H965T<R]S:&5E=#$Q,"YX;6Q02P$"% ,4    " "5
MA$%,L)5K% L$  !G$P  &@              @ %(1P$ >&PO=V]R:W-H965T
M<R]S:&5E=#$Q,2YX;6Q02P$"% ,4    " "5A$%,7H%AE"\#  "+#   &@
M            @ &+2P$ >&PO=V]R:W-H965T<R]S:&5E=#$Q,BYX;6Q02P$"
M% ,4    " "5A$%,<5X^W!0"  "L!0  &@              @ 'R3@$ >&PO
M=V]R:W-H965T<R]S:&5E=#$Q,RYX;6Q02P$"% ,4    " "5A$%,=&VIZ0X.
M  #97P  &@              @ $^40$ >&PO=V]R:W-H965T<R]S:&5E=#$Q
M-"YX;6Q02P$"% ,4    " "5A$%,%HD]IE,#  #J#0  &@
M@ &$7P$ >&PO=V]R:W-H965T<R]S:&5E=#$Q-2YX;6Q02P$"% ,4    " "5
MA$%,I'O=D(<%  #G'P  &@              @ $/8P$ >&PO=V]R:W-H965T
M<R]S:&5E=#$Q-BYX;6Q02P$"% ,4    " "5A$%,;,QF73("  ";!@  &@
M            @ '.: $ >&PO=V]R:W-H965T<R]S:&5E=#$Q-RYX;6Q02P$"
M% ,4    " "5A$%,:NWT:HX"  "_"   &@              @ $X:P$ >&PO
M=V]R:W-H965T<R]S:&5E=#$Q."YX;6Q02P$"% ,4    " "5A$%,0^EQQ;0(
M  !Y.   &@              @ '^;0$ >&PO=V]R:W-H965T<R]S:&5E=#$Q
M.2YX;6Q02P$"% ,4    " "5A$%,1:'0_'\%  ";'   &@
M@ 'J=@$ >&PO=V]R:W-H965T<R]S:&5E=#$R,"YX;6Q02P$"% ,4    " "5
MA$%,^TR'Z=P"   Z"P  &@              @ &A? $ >&PO=V]R:W-H965T
M<R]S:&5E=#$R,2YX;6Q02P$"% ,4    " "5A$%,>=-<S<(%   K'0  &@
M            @ &U?P$ >&PO=V]R:W-H965T<R]S:&5E=#$R,BYX;6Q02P$"
M% ,4    " "5A$%,?!F_\R$%  "+&@  &@              @ &OA0$ >&PO
M=V]R:W-H965T<R]S:&5E=#$R,RYX;6Q02P$"% ,4    " "5A$%,_(+,!ZX!
M  ## P  &@              @ $(BP$ >&PO=V]R:W-H965T<R]S:&5E=#$R
M-"YX;6Q02P$"% ,4    " "5A$%,GB<F_[%U 0!MP@4 %
M@ 'NC $ >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " "5A$%,,>LS
M3Y("  #"#P  #0              @ '1 @, >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( )6$04SN#34 >0<  $Q0   /              "  8X% P!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "5A$%,DLLR.W\#  !.20  &@
M        @ $T#0, >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "5A$%,9\48B*T"   [1@  $P              @ 'K$ , 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     A0"% *XD  #)$P,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>741</ContextCount>
  <ElementCount>614</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>204</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff</Role>
      <ShortName>Hemophilia Spin-Off Hemophilia Spin-Off</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Restructuring Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuring</Role>
      <ShortName>Restructuring Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Revenue Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenueReserves</Role>
      <ShortName>Revenue Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Guarantees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Guarantees</Role>
      <ShortName>Guarantees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2127100 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2129100 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2130100 - Disclosure - Subsequent Events Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents</Role>
      <ShortName>Subsequent Events Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables</Role>
      <ShortName>Hemophilia Spin-Off Hemophilia Spin-Off (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Restructuring Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringTables</Role>
      <ShortName>Restructuring Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuring</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Revenue Reserves (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenueReservesTables</Role>
      <ShortName>Revenue Reserves (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenueReserves</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Indebtedness (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessTables</Role>
      <ShortName>Indebtedness (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Equity</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2317301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2323301 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformation</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2329301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2401403 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Acquisitions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsDetailsTextual</Role>
      <ShortName>Acquisitions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Acquisitions</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails</Role>
      <ShortName>Hemophilia Spin-Off Hemophilia Spin-Off (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual</Role>
      <ShortName>Hemophilia Spin-Off Hemophilia Spin-Off (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Restructuring Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringDetails</Role>
      <ShortName>Restructuring Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuringTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Restructuring Restructuring (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual</Role>
      <ShortName>Restructuring Restructuring (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuringTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Revenue Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenueReservesDetails</Role>
      <ShortName>Revenue Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenueReservesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Revenue Reserves (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenueReservesDetails1</Role>
      <ShortName>Revenue Reserves (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenueReservesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Inventory (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetailsTextual</Role>
      <ShortName>Inventory (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Financial Instruments (Details Textual 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1</Role>
      <ShortName>Financial Instruments (Details Textual 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Derivative Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails1</Role>
      <ShortName>Derivative Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Derivative Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual</Role>
      <ShortName>Derivative Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Property, Plant and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual</Role>
      <ShortName>Property, Plant and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Indebtedness (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails1</Role>
      <ShortName>Indebtedness (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2415404 - Disclosure - Indebtedness (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetailsTextual</Role>
      <ShortName>Indebtedness (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2417403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Share-Based Payments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails2</Role>
      <ShortName>Share-Based Payments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2419405 - Disclosure - Share-Based Payments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails3</Role>
      <ShortName>Share-Based Payments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2419406 - Disclosure - Share-Based Payments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails4</Role>
      <ShortName>Share-Based Payments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2419407 - Disclosure - Share-Based Payments (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails5</Role>
      <ShortName>Share-Based Payments (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Share-Based Payments (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails6</Role>
      <ShortName>Share-Based Payments (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Share-based Payments Share-Based Payments (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7</Role>
      <ShortName>Share-based Payments Share-Based Payments (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Share-Based Payments (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails8</Role>
      <ShortName>Share-Based Payments (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Share-Based Payments (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails9</Role>
      <ShortName>Share-Based Payments (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - Share-Based Payments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual</Role>
      <ShortName>Share-Based Payments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>2420404 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>2420405 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>2420406 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Other Consolidated Financial Statement Detail (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>2422401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>110</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>2423402 - Disclosure - Collaborative and Other Relationships (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails</Role>
      <ShortName>Collaborative and Other Relationships (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>2423403 - Disclosure - Collaborative and Other Relationships (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1</Role>
      <ShortName>Collaborative and Other Relationships (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>2423404 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails2</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>2423405 - Disclosure - Collaborative and Other Relationships (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual</Role>
      <ShortName>Collaborative and Other Relationships (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>2425403 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>116</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>2427401 - Disclosure - Employee Benefit Plans Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>2427402 - Disclosure - Employee Benefit Plans (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1</Role>
      <ShortName>Employee Benefit Plans (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>118</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>119</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Segment Information (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetails1</Role>
      <ShortName>Segment Information (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>2428404 - Disclosure - Segment Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetailsTextual</Role>
      <ShortName>Segment Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>121</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>2429402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>122</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>2429403 - Disclosure - Quarterly Financial Data (Unaudited) (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>123</Position>
    </Report>
    <Report instance="biib-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>2430401 - Disclosure - Subsequent Events Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents</ParentRole>
      <Position>124</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>biib-20171231.xml</File>
    <File>biib-20171231.xsd</File>
    <File>biib-20171231_cal.xml</File>
    <File>biib-20171231_def.xml</File>
    <File>biib-20171231_lab.xml</File>
    <File>biib-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>195
<FILENAME>0000875045-18-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-18-000005-xbrl.zip
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M:?5OC-/XI_3UA?\$-[V'NW@<C);?V_^EXA=B_KB5$O(37,UO3()1-0EP01"
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MTO-OF>=_]"-OJ]/",HAOS39/&\Y%'P0*Z3ZVPWWL+H#DUI $BO0B+U=.=FE
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M&8>*@D.I$*1"D KA4@KAT@6J'0@/CJ(0\F=(%2!50*8"*@$QH+"@Y8O^\)S
MG3_IVF"-OJWOBX7^:[(?T%)N>80OE[)<REU8RFV(S7N[E&5$+M=XF^/P-BS^
MEB?FY.*7B[^?B[\-2;B66WZ9A.O;PA]Z$DY:?!FY]WE]#RAR;X/];OE2EO:[
M;^M[Z/;[THM^LQF]/%_6DD,N\GS9XGIOA@0T7FHM.E_6ZZ4FSY/)I28;&EQ^
M"<J&!NT[VMF2I=D.*SB\)2FMHER*LM%="Q:B;'37VV4XS[NBS_EL,<\?"=_G
MM; $Y_VUHTF4/L_B<&.UW,0BC9:^W@"44AJ.W;]GP8N@DKW>O[X4^[!_\,..
M!'!9HK"*&7G#[2(WC@3#&KQ<87+%S+:F"Q5\@II[_'EMCX#-DB#D24)'P*DD
M*"+6#1(_Z ;<E@JYFIX%Z-8(.E]MMM&H-ENQWF.E%2(_2$&Q60!,#9\&B)I3
MJ:DB2P>"V_G0"BSUU%F\H@WQ':\;6S.7J.W".Z)/<S31G:1[UWSL@UQ\9RL#
MN^SXBG,["=V)8CKA()P]CKFT<W!NO'[T1\_P]/AU_3X)X*,!> =_!X+H/)DK
M_:7.)0 W&P]7C-=;U6&D/+GQ7_V'"<_RPHN_=ZY*N3Q$;U6$L)/$;KK$FULM
M4L27%O%)5G'34;C/,>?9H,B[X/O]MQVC(N%B]\5?FHK;G/PSY3+.K^ /G9+<
M;/.U>G!]KS!UA$G+1]\^K69[)RT90%F1AJQ%ADPYR7[T1OIN$,JEC2NY34D^
MP(5B?D9W3A,[!I8]T\=N\/2<WHG#?%56/KO*>4>"TB;VZ!#ZSP,GQ13XJ VG
M^>W'GRJOMG$T='%CBYQ@8VNU+WGW[,?\EK_,XM&SG_";.'J*_>EJ,5$1K%3?
M] ?WX_M(B*%;"V<[R8L%U(#F,WE1)]K=7((@/Z)H3_PDN7Z\2Z/17RL,?%D[
MEW$3\T<>QWR<W=,QP6\C<R'W?71VTF5N*NP[>#I/_K//<MY!8G=%3*12[Y12
M)Y=3ZLL[LG5 >[K4E[=LI[*[JQU]1HU6.ZJ^J6/"KK/&=U)Z%H&C8MGSL4KT
M"ZU1I(9OJ89O57N-BA[U2X4IZA325SN:OD0A_#/9;+,QF\XFPA'^Q-,O8<S]
M2?!_^'AU#BAOM=(Q#.VBOM#]HA'YYRORN&B?],T]1HFE3F'IU'N,;X*&PQ^#
MD(\9#^$OJ:BZ2NCX7[,YA_H.C!K$=Q,6QS! ]S&P8][&:SB(V$'T0(S-,: C
ME<JEE$JKH'0,OR4WTEX<35=GP:_CSS,PYX^O0?@DF@IZD^B;.!W>M2J#@WR9
MPUC234,F(*1)_Z:+JF@-%EH;_1NI7+J@7/IET*1/W8?HZLU&2:J>+JB>4QJP
M8T!(IO3:D-)K'S2DD>F+B[NY^2B51)>41.NV)(\ )^FVM-YMZ1WLI#V[2/;X
MTM#9/#PM4W]=3/V=J&^JW)_J)C+ZI6&D9>J#1GDS#*1?W 6_N.T0DI%Z&])Y
MISI7+R.@3MB9C9/WEY^R_%;H2-O4!=O4.]C)"*L5$=:EH;3U;*3TBSKF%YWO
M>+Q4,6U7,6?H(B^W/3NK-'IG@*3_W'K_N=6&2D;O?3%,&R7GMWPDNE\ D^<=
MRJ]GZ?7C&@_FLU2!5S%_%AP5309'T;0X(^#0A\R9)A7;5LR^13HK2+]-/+N@
M/C0=W:I*_HI=9+F:Y6J6J_F@U7SIC?P>VN;^!+!#7[FMB<7;8'.-UJU2N8R.
MLXQZE#1J)U"E<]C9M3%HY[ -J[EGH9YT#ONR<EOC'+8AA.N9S96K5*[2'MK2
M]B5:Y#)J70C7AEQ#^YP^"=36 ;4-?L^&1J5 PCB8S,14NCL^FL5!&O#$_3Z:
MS,9\+&(\P;19.F?JH^O'(41XR0V/LR;L[+7Z :LF]?<@\=_ C/'Q+?P9!Z-T
M,9WA2QBD'7--3LBL17O[.MP:KE:58)5@;:]F-218)5B[$EB=6[-^].._>"KA
MN0V>U?R1VO-D@,Q8??TBOI[0<.Q.7R;1*^?9QS?Y8*&)W[%YP:<':C.^28TJ
M 2P!+#6P= DZYA*T0:.>.U4E =EB0+8A'75N0$H3WR,3?VD ;[:-HM_\>'S_
M^L)[FE%:)Z\5.: S-WZ2\AURCF_S(+%$P^56^SGZ5A3EFW\*-O,QBJ=^..*9
M[>RV5/./MU UH)6]W8Y+R7?&9N]6T5*0G5+'&]G?>7'1LO[S0S2O2BI*%NCN
M6F^.'72M"7>-L.'F3^M X(Y/)A#;_LI#'OL3"%7I>!J$ 7@KO@ANW>\O(("N
M+?E:&&E$^4 L^X%Z1(*H32#JJ";*0J39*)W%X@ ?F.3.G<NLA9CM9$H=LP<>
MW(]'S[#&'/Z53Z*7[%C+?('U$R?[Z!V0/M&E<WM)Y_;2.P<'0D":% D/Z;9V
MQ&UM X@.<%NEF9&NJ30STA&5D4O[(I>.FA0)F$L!I@T&:'\13<>K1"L*)09?
M:+QY=$,*?7B^A!3Z /T!403\R9_V1N;K]+1!Y&U0[OH^D?>I#K(" "TJBNV$
M!E@K3>H' *H)&I &(%+D W?NRB(7/8KO>)I.^+CC%985XM]/W( 4_EXH].18
M704.Y,&WVB9 @D :!>D']&[=[_7VY;KOO_^_=]W+I,_@UKU,^@Q) ^QU_R0<
MAN0([M4.,CL@-8.$PL"TPEXH2#>Q;R+?:PBH<%#=NYN;SLMZ@Y(!J?C]0D:6
MU1,A%RD9D)#W*F^YDKNOKO<+6:[DS@MY;[9.KN3NY^?V"UFNY,X+>7\M?7^"
MZZIJV]9$UY=VT&JTGI5(.!42+M?"3@KV7((]24N[G0<D9'O"0=GNLH/F!#$?
MI5&<]*)8HH*:@=CFXW4.7W[_/@!]>/UX%8Z#K\%XYD\*&B-G=;<P<XH&TPU^
MOI*E*WU5Y.F D(OE(;[SVB;<3.CX,L=U^U3.T;[6]JU+&=;:QC.NIV'P,$O<
MOV= 8"^\EEUD#<@([#_)+?7!H(*7_5Z!S$H,PEN8YZ=4:1G.8QD*&2F%O,?*
M<3-2^QT_N:X'X_3MM_H2#(.Q^#LU@\Q5#U@3[!'^\KIPGX/PJ=BB.)LWZB=\
M+":2@CSF[?.RY\?PI&=^'7:L)>#Q0-3@1]=XN]8%N3YS!Z3(#NT_N,O%35,_
M" 5SKA_7Y&S'00KO!Y>$Y]UI%!^8%GVCBUV?K0/)Q=2H!I#9^*/&6"<HY]A3
MIR,%>$0!7F@,]!X+<NN'3T7?Z:/_/9C.ID.4=8,?7/)MY>,4&#<0*_"6AKJ[
M,!B$$H,'87"=<3(JE'IP('JP#='<*?2@Q&!W,-A7/2AM<7=L<1OTX"EB$HG!
M[F#PTC')9F9J/ACGWO].9^ES% ,MQ1)EN)BDP<B.9F$:OVZ6-_O?[9B/@]3V
MX_CU,8J%4 O?7TSV8[,D"'G2L1Q)-6_6:HVKF',DN&YE[>KG*WG;S73;U@%5
M)6!F*O++CW<_BF^(JZ.T'Z#*-& 585(Q52DF+XIY\!1*O52AEZIX(]72&S"9
M*9T%5[D?AT'XE*0%I^TZ?>;QX@YW<<<&*/NFT#*%M84I"W6VG2M'@F.+E.DY
M<)A#B?F3>7T"Y\7)C?/>W3%_\8-QZG_O6EW/-KKR'MXEPOHASKYIAH&OS@,\
MEZY+]%#/HS="S2;+TG LM-;D/V9QD(R#D5!?C3W3? AMOX"QAS_G\TZ+[)78
ME%%3ZR ZR !JXV(00N@@"@FCQY&?//OA6/R'_ST+OOH3($H&5YM7:W),!EYO
M/5(=1^/9*+V.[WC\-1BM0?C/JT_L]H][V@V$+>MY*^A9R+%(T,#RD/-S4[/I
M; )AZ%=^!XLH^<"_\LE*X'?!]Y3S\"&83,K6-%??= 1+, F*(;HWF_HOSWX\
MI4\;7]L.KWL^>@3)QWXW\#4_F;6%?PN 53'P2 IJ"_MSW;G)_R/]ZH[%M"&^
M3NO#SZ /Y?J0ZZ.3ZV/#VB#ETB7"QF?T><W!R.(00=>O/'J*00S!:-$W;#1/
MJ_S7U7W;P5V(J:IH^>&7!3$_7]VWU;%0\-$="[S6@4'*^10F#Q^[VX(0&UI+
MMDBQG4)LZ!2>BO99E8KU](I5>Z]H#12K5ERA9XW8O."QY%!)O[2Q7[J=C=([
M;7GT1K+H[6P@/%2GD&9^^=&/"RR<M3;RZ83.CK.QL?2;'P?^PX1?P2TQ3U)7
MO%W $_9J3_PD@;>?UVA</V97UG+NG_@L#J;36=>:@AQ"\4)%;)+<V@A6.<'!
M&KSN:$G8M!\V^GO%:'061K&.ZK15[*Q(V+0?-FW9G=GO=M\&Z>Q[Y_I7;O=
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M C<&X,*U(9=7'ZOK+L\0U6=MGZ_#VK,-B*P=5-S=7'VZI7\VL^B]U9Y%;@Q
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MC]#E(1T1K93+XK".CN=.+U_[3%PXGVY4+%4UP !31]&0J6F.0Y93<G67E/N
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MM3M%ZXA9+ 8\["O,8LST%,-1+:I1Q$P+W+J\K8/GEAMV+U7< 5QLMPC4BXE
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M)]5UNOIG_'DMH;_+%OUZ;^]KIZ6; "P'86RJFDHTL46.L9@+H@$2K5+. F\
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MA!3E_VDP8OB"*M0&/2N>!6F A^FGT7AI .7O/[S_(=.1OWO3L6-T!:N9!=0
M)X+ T# &::(Q@FDK R;R.=;HGEPJHTN[R.A9!#I[1)G_1)S_Q-F$9HBU/! )
MW%"E.47I:10:F)AA%&+WN!<QA\CL[_=W8Y0(Q@O52,_/O=OFPVAA7N=+!H:>
M#IMQ+42VVWC_;DL#EFMYA@2B8@K<21(PU4I,<Y';WIP-/-4ST,LF\R#^3BT=
MC$C.)!V""4@"'XS5D1LNP&F#P0EZ9:^99E6[("57*!ZYFWAV&%\.F(,)FC*
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M]C?V<&KT>P"8C4C,QZ/TJLQ*:&&@AF^7SQ(3K'F,_TZ?J(0@S#N;K,L5+DH
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MI<8=]\II[7/&E +EDW4?N!8NJJ8MZJ5J\8\2F&/*6H2L(4<1440/J_.07K1
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MLY>./0@=0AM(6:G(1;E=445/67>=K5JT';6$/JU>'(O0(? *,@803.3@G*-
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M>:^(W:\[UG@I"B'W30$N$XE25U$Z>NK;;\[8T$:6KIF4>/C;MZ=J8UTWEW=
MY00JRD2R8";6AQ*D(+%Y<P4KH3$*6U!%(>_=(.'BS>?]KU=WTM[UF9#)K%AY
MR?<>)4LYU$X'"!#:.C1O=CIL1]4Q^-CX")^S3=988L'$R+B$%6!]8*P-Q,_
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M(^H.8N_3UUFWXSEF$V5.'(*A] <Y4K1>^?.4N[5K#0Z[IP_H/(S3WZ<[-M%
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MT)=2^XQP()]U/U_9.1''\^5ZAO(>^&G:3_Z_+P?.=L>N\A2S SF:LAXQ2RS
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MY,L'^OKT<N_K5M:K&J%"-F3/#63F>'TR4A;-(3/D^W-Q;AD-A9Y>J:P-9UC
MVKE"QG.M7TC58OAM/QCY>D0T<-=XI#PY4393UI$&'[RR=6>:<L;VO"EL/^IS
M+B']^_3JDC[B_I<\ 'HYXHU+2+D>.!4TI</"J *:74VW!V@?"K8&&#B4E><1
MU\#EHS3&281@)"7*@<RXK2@"I1NBW52WPP3MZY374.I'5ILR8A311RG* (,T
MM=5:4=BY_WC8T<7U #)R\^*J"B#J+O[GEC[^,3!:F$Y^ZV9?NLE%]^'K:'8]
MNNAN;\H&Z,&&,3),.:0L*('!C#8+MHH/*'9H9A=T[WO= R8V,;@7ZB6/(8$
M;E7,5F+*GE5\0"R>ND7-8_VGN04XYZ%PHAG)I!GA5.02D#2-V2I-$S/T(/RQ
M_C1Z-UKWA8B,RFD?C0F:*SIL!E#;[]$:EYL 6HM^F(Y>4O8E>)-\=>EM#,QI
M8[EP6FF[:M6UF$2;%Z'H+Z%N1W'YJ]'\Z_+F[[NG/#)FF8C2,5ZPHX&K.KL.
M+&G6T$QYK^V]9'W4[$GRX$!3B84SF(R:2QV2Y;4I3V7CVT#&V-[4ZH@4#QA\
M ]&&' ,72DL70O986S/ICO5L4B;-Z"WW;4ORD9;8YYQ%-H[,A@ODL#3E_;PN
M1'+<MZUZO#]BW&JO\'ZT_S#;7@Y!,*$$AYP/Q?.>JR!Y$BL?Y,"TSXMO^F&-
M3W)* W<Y&G)(P(@!9<HJ.:U4-3^A/#^MB[3/2/M?&D8:9BV QA@]^&RD64Q&
MUGW;4K=>8IV+./XA#9A>7^K@: I>$I0F$C B51-F<[OSDTS8.LM[*MK_4C!*
M(4GH2@H>;;:9@Z00M9HP12EE#Z2?[8WU=CJF64F)9O<;K7H/Z!^/#JB FE[<
M+#.GJ]&#%,>5[W[T]X$RG>'&&ZNCSBY9&1A#<K4LABQ2D*ABHHBAF>7C:["@
M>]AI6"[O"_.?R_[/VXZ.:X\189N<4DEG"=[1A<K.WA^2;OR,D,VF]CXZ]J7S
M7E<OOG:7M^7M9*FL/W4W7Z</=+#]:M>]&]W=FR5R]^AZ?COYXL?3^?AZ?#6:
MN2^SKMNFYSPS*US27DFF23(@:OBLHL#8I/+8;/X\C43J[?U;-_TR&WW[6I+M
MA]L^OSS]R[_-IK??YN\_+_>(4.*Q^,+BEP_EZ-&F6'!:9-G.3K%XCG=!HLH.
MVP'%Y^/]8KDCY?_\\G%]/%*>'3@FST+9!!J8MW7?DS/:M<L35'\L=3ZF5J9X
M/HCPG[1"%+*@<*?(F<ZL3MZH0'>[N;_/KJSU.]+MC*SZ4(S"=;"*/(A4.7HA
M@[2V7D7R%4TE1O+>5IV#N<-_\']L>ICG9"QMC$(DHT'EY.M>/A%$;$,ITU_3
M.@*98A.93$>R;$PHRK(#,LFEK-@',2O>+JWKS[&/0*;<1&9TH(6S(4HFLA#,
M1EY+6@#"-=*T_=WG1R!3;233>F,PT96ST0<.*>7:)PYEQ*-YGF*G.O3-P?("
M7D]ZK;3 [$DC*^J>AIQ:F'7)^T?SCD3GBW#P+"LPRC RAB)&M)B=E(G.,D0Z
MPT;!Z,J<12)G=/"%6[IB@1L7'1>)0:H8YA3BM(MCGX_W+1P\>7=9@)\9I;$R
M>0UV!7A(<4QN5%P(U5NB?0ZFMEG^XW[]]3_&0ZZ2DJO(>0 *:DHC'3 HN[@<
M"$VACS--VX7@IS1'QPURF-72FZB50.ZR]-RZNPA.:>=,^\CQW!=VIR#'F&P$
M&@X\QM*C'92O>;(ES]?<1=W?+W,P=WISD*-3*(C@D1O#$NF8T;INW<S.M<A)
MMC^I/0*9&X,<YY,'3^XN\DS*(:+/NAH#:5K\#]7?-7($,C<'.>B#"29I'LEB
M,9)?ONOEE([2E4:EE>FMPA^!S(U!#AHAO#?668O LP-?=UTHGT*[YYAK>RIQ
M;JXY1VL2*^^?=&-0N.SK"+Y6C+>S3G+-(K$CT?EDT>?*4/C1U6ART7W\VG4W
M;G+I+B\7K^JCJSB>7UQ-Y[>S;NZ_T[]\F\ZK>Z>/N+HM[_[E>^C7C>E77]XM
MW)Q.YO=N@@*AWQ9?_6UHS 900J9,J@2"@6(>J4GEG# J :7]3?R#ZF2Z]T(B
MPI@XW<2<P3FMA1&0>!WFXBZT^Q77@'T?72)GC AS4CS9R+@!YG@TP.NTH#*4
MX#1!U//QOD5$:,@%*(O)2R&9\A3C2UXS7<';"1^A^DO/S\'4T2+"D#C7]/\4
M I?Y)C*-M:5;BYA24SSA_8MFSR>#'2)"G61 3]ZIK*1/48,3=UDM2*U:C/-G
MO[ [180ZEU8R,CPF:">-5&E5@38BZW9 3>]JH.L6\#R=?9A-+[KN<C%UO/BQ
MI6TMH,$7Y$MZ^L2V>%:0Q6;8)#T4,+:4T&"-PE*0MLE&5 .QM".%1V5NJ#?2
MJRA,PLQ40A2*R\!K\AS!-P&[$$^/YSF9&QJ:R4Z2J3!@R6:JC.0(ZTK60"EC
M$S_?+9\_.G,_=]]N9Q=?1_.N>+/KZ^GDX\WTXE^[#WOF!-I$KB%IG6V(VE=+
MP2RT XQWFY/7<;2&K$.9&-INQ1$IE['1,1="63TG*RZ/8 $;A"G^+$P,:59Y
M1PM2@\^.<C$=5;4).MJ>&)U+A*>ER',Q<6_1OX[*,H'ZPZ309->O'[\1\_YO
M&MQX%ZS77J,-B@N1/5HM1=G43.9"B9Z4Y75( _N_Z9_=:/9I&LD_]LC%/+2N
M8,I>!!4MV4V;R%]@J)EQ OO_V'NWYCAO'6WTO\S]2A$$#^#-5!$\K/&N)/8X
M7FMFS<TNQ6K'O4>67"TI7_S]^@VV]+8E\54?I#ZH;:]D,BJK+1$@"#X @0<]
M"<!V;?W.:_\:U4-W:P,N+EM,)W\VF?UYOWYCF(CZ;C+[-#V?QVT/2C-65"'8
M)U0A)#$L*HD-ZU;@(WJDC&B4]8HTVGXX[U(EWOGU>U5=^?3Y[.++9/+;I,6V
M$COO7G%ME&!*&LE5[VWPS/%6<2"'M6_RZQ\=]Z>Y+9F*+3H*I"'4I8@7\M[C
M7&)72>+@'DUW^=7M2MS54+W@8V91;,*6JC/$UEMD,;I&\-:Z9E*J_>#WAT'6
MBU#= 8X98P6NJ!TW4A)6-028*\ZZ3+5_M>GZL?:GN.T(7'7*+GEJ38P6D4Q(
M/!>8E"[>="#./,RD;B*P7'8GGZ=7\\SB#2N+G(;-J\,4:D.*<N6Y)XQR'^M0
ME ;G!<EU*821Q8XNY!DK7H&4O0-;)-P2?5JG6*>055NQ4B7K8CNXOX<5KVXD
MD'6:D"UXAC9ME22:S#43F 8%N^M&=;F,)ZP\3WZ_*G^U2.QZ>OFQ_6'S#N/A
MXK(' K0F*VM+,8+@:S#@8AMGY*(&%(OI&WH>7_LC2QI??Q4'?_[^UJEMGI]H
M/)':>$(O*%/0=[9V>/^F0'U4:/QC^8F'2QE;[MO)#8/3Q;N3O_YK>O7QXTTC
M7Z.':%B9!9R>MFK<R?GER9/.:2LO3>QR09U=\R_DXL#S%+F?'N&[6I2G+G4W
MXJ[J,$@5E0200:)(D2\U"IDA'.:1!W]Z;/->AK2K6DM)<>%6/AQR<@@^+^)F
MP1W]<XU]V-^W36G?7<R[06>3^.?)]*PQ?=V2G'SM1=V<#*$6+IAL;5C 9+EE
MAM<7BP"Q:\UV)*IX1,8UUK<UL599J=6-9Q%"C;)E[95ML%)3(Z61<CO QW#U
M/L5:88XZ:ZMT#'($%63R$A4M. ?:_,;>'*W=E5A#A_+\G>OROBPBBGH0.BUM
M:*[7GTX^MT[F^,>JFML<$V&" "TH3-Y0&LI1.*G2UX_I1Q,4CTGR'*GEN,&.
M>[A)H_-6[D];+-BH( RL<#H9UY>/B0(>=@UL20/S+O=&BWK[G=/-B2'(%Q*L
M;70F%0P6Y&%V@?*:^VZ-T)5B;+*^[<FUROTTVGRCHFZ1AG@BR'XH_!0XW\^9
M/+@\J[A.Q.WX5GTD'XZYQ8PP,"R@A"9=OG07\KPZG[]H-!:BR\G)[/U'":>S
MA,QG%Y\_=:WEZ\#0(C&*2I9;A;NRRLVQ?XM?1,":.E^Z3*85:]NN7"MLKST<
MY6R*RK$:DR.Z*$%!\479-A%C67GI8>5:-;LU2LB@6P$BV4#L"S>D4MJP;6JS
M?#M?L8;G?YY\5R?G?TSEWHQBS$^(@ZP$]DHSL!40G5OYL[^%7I@E&.T?EAY]
M@WAT3<\48(6EQ0H^8<B:6"+.8*. Y>&Y,L41 :"K]]NU!*NZ6>><CI0=A@+D
M'5$H TQL57==GMYO>0]NZ$1G%Z?7[4WVJ99D:A'O98P'1A\+JCPP>PCZBSTD
M(+OZ:(RN;!NRK'K@MTDA!T;(6I"NQ6B&]C<?E>TAP7#,#R+,*KP^+_;QC4W;
M*8A>KLHA-V %%_3O:;L1YMD&AB$$0FXE[3766**)BZH+K_I9:'W3]\HU/5.
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MCACSEOKXOJ"/2O)TB>UZ$L>_OTLK0S'V42+3JD 10DR.'&*RE-C8^/!V%E=
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MBWJN",NF9_A4?"BQ^AQB"(TD>&!E=M[DV&?7+8'J\\6;B?#GY/SZ"94(.IJ
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MV^2/3PL:Q=MB[<NKUQ_^ZV)VMFJTI-/BC[3)V5!C906!@D/9(3&[D>&E#X.
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M:*=H4T*\]AKL.\Q[: VNV[X@0EGK+13EV3GFKV^RQA'D#N5AD#]^4:+MB#K
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M_VT$AW?UGVF>7G8:4A&+#IG2T.2,5K[W2*RRC8KUH]3_-F+%>_8?R%9?T>6
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MR.U61\6'E!0QDP*T(,"3U9!12,6-)4JZTKV#ZVA5&1F6DE-D5)X2E*R\@Z'
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M!3N3)VEF0V=BJ IBE_\4+ME2);F\;WVM+D"V0VV;)$:>I:2-4K*/3U!)(3,
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MK<1UY<,O6!D;%>USR<F11+H<6PS<"$$6'L+X/OS=MJL;:P->%0BCBQ*E:99
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M\\GGR\GK#_'SY[/I^]9OVMY\KJ_DCWZ>?IK*UT_R^+4-OF^M9!%1W+X X;K
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MZ]+-E7MV.'&=WD =JJHN]<'@]U3)ZII9=3IIH&W,![9V*"BWUI<DDIWI T8
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MJ#^H/_64#^I/#3VJ&CM-XGFUJE-?=V'EMN5^XAOGXGFZD=]AOZ;L=Z.50M)
MTGB--#0KO\KNR!K(&L@:Y\ :9GYI09$TD#20-,Z - Q#05<CYV60YN87K$L!
M\Z-IJ2[PTSM*?I'T38$?&FU$RMKSE):D:6T=L8)80:SLP(HJX4P0@8) V<.H
M&(:5WQGOIF %YS_UJKK=&+Q=R/FE/%S7G@:L3>66LQ3-V1G"2\;Y$>($<;*'
M&3+RJ]B#=@CQA?A:PU=NFTKGC2^<BM6ZC'1S(*LK2G[>XWEC%FTB FR#36SI
M9H[Y)!%B"#&$V,O51807P@OA51"\E);4Z:"3B!.[&DSL*JYAW!Q0ZVIY14G/
M&_%H5!&?;\%G844($* (4 3HT9/.3GY[B8A/Q"?B,U]\&E('#>A)S&D;.Z4]
MH0*Z=1=E>?5\BA-6>>1GEEFG!T,&S\;-0%Y"7CI&6IJ58]8!)"8D)B0F)*8\
MI*7+1>V&("\A+R$O(2^],4V3I.<7>'$VQ+17856L?9K5/NUTVI:D2X:E* 9T
MV=*Q$NJ+V[$>YLFV'CM_*IW'2JA8"76[U%^7-%9";=*L"?40*Z$B@A!!Y6HB
M5D)%+:Q>"[$2:H%K:IM%KDCR(6ML6$D.6;$45D3]0?U!_4']0?TI3SX8RHR5
M4.NSQ]V$+6S-Q$HG:*6JM^)(&B=$&JIE8OUD9 UD#62-0UR-#I(&D@:2!I+&
M06>2U/P2.32%-3!+&59"+0E^>@<+$:/1QCR<NZO\M$Q500<7L8)8V;U^A(O.
M"!0$RCZ54!6EDU]QQJ9@!><_6 FU$/E=R&TU;\(^SZ1S:,X07AO@92"^$%^(
MK\+PI6&%1\07XJLH?*D*VJ]:)"5N[A0.*ZCF"UE-TML=Q"S:1+2)!?F<+46W
M\MOX0H@AQ!!BSR&FY+==AO!">"&\7EHPPS 08CBQJ\'$#BNHYC7OT["^%!K5
M4S.JYX-/I6/D-VE$@") $: Y>\5R4;GM$9^(3\3GT7N1>F%E!!&@N<YI&SNE
MQ0JJ]3OT>Q:%=_3"Y@X-KKN#;@;R$O)2L;RD65A!%8D)B0F)J6;$9.87!(>\
MA+R$O(2\E(>T# -+SI=0037[^V\_WCG.W8>N1]VGT D_3[HS7AT-_O7&_2GU
M[MF5]R7PQ[$=7;,'YL7LFL'@/;#PEK_F%F32<WW[V]__^[_^ECPI#./9/.*9
MEKZ&;'SE_4;=F/+/GR>_TN ;BWH4OK^)X*:OGA.]> Z,@<<%?<TF/[\;#11)
M-O^I_7X[>$><,7Q![>AR)"N&.M3DGM51K;XQ[!M=6>F89D?3K'Y''[W[^XN!
M6QV$'056-XW[6H7959B)Z)27FK%:.U;E%Y0!G-LI(W0I?!*#E'G\B!\'Y"$;
M T(#1N":&0W@[C'<0":^"_8C_/"JJKTFCCU$^(S6:UY=5Y:D_.KIYE1.5SNR
ML*=5;5W2TWK]F^J:UFEYOX#:5SGLT^E84VS?FF(C/UC*.IJRY8??11C@XN,0
M&'2\_#A@-IO=L96;5;GU!A<"U?YHM3]*U>^H_>T^ #]LS"V0'WSXRUC\KUIQ
MEX&'M+N*;JIW= LZN$^($_8J)NPU*]=='4&#"N9^. !5L$H5+*)"9J7ZN7>D
M'H:R; EE^3YG=@1S9&B' S 9DR>'N>/<U+I8&U^*/A<B_.<NP JI6(JL_/0>
M:;<<VCUW-43%0\4[+<5#0[Y9EM=\%X/X$\(RBQ[RS0=^L-)FY,'G9RY=)WHZ
M$<M>:^7=8+Q5M2V])Y=$U=L&DNA)D6BM52U1+JNM<.72I+:)RH7*E:]RR2ES
MJ:!D:(5SLL*!$WZ[G 2,$8>/) LC$M"('9+< ,WO_N97:G>X#LMH?)$?<X:T
M!#H%JL4U['1%AZI53]52$M:2T/ >Z\5(!+K-O#$-R)@^$0J2H&"*5R?!OD?N
MX=$17!#E=VH3#?&J(?ZK8JAMV0*MAK_,MI5;#5/DS+K)IQK.!+4"BVQR!5,E
MK6WA#C4J6,X*9IIM5><*IBE&6]D["@=-\V:!_DOLV[/Q96:3YRP@X93':"_-
M,9E0)XG@1LM<D&56+:6MYYX2'NFR+O*IB"Y5Q6I+N5<'0;6JBWPJ4BNMH[:U
MO=7JZ)-AQYWG6IP+Z\6AX[$P_ RC]^"PQR^^Z]A/AYS[TM2^HDI=TS"[1L<<
M](>#CIF<^U*UH:)U*SKWE9WSXD>4RAC_GN/?,X\X(:'DWO7OJ$ON''\.7L.,
MVBP6R !ISD!OG\C$M\4Y,)C@CYW0YHB&'K3(F#TPUY_#WX1Z8_CH.LE/Y-$/
MW/&C,^;+\Y[_ "/]P$@$0*9SA_'38@%X*?[<901N$3<XT93PYOIQ2#P6!V!@
M[T4C^)/%%V,&+88GB&=!.QAH3-B"%]ANS"6:'5.S?>'Y^(_P1'"":,CW"V:Q
M&SG\?:'MLL /H>,7O][\L'RZ,YO%'G_I4XMTW3]AQ&;9$0A+D<V?PNR5Y*([
M^"'M+T^\[- 6F8%(^-_\&A$R$BX?/(M#.W;YLDGVVVJ;0Y >=')Q$8T"&(4G
M<G'S:S=Y"YT]^>)+&%D7/+D +E_I1/>7FQ_:Y%^,4#?TR=RE'L_[['@/?$L$
M) +M"N[YFYY))(SM*3^V-Z>.UR+P\&A*W5G:?='L>?AD3QUHSE/2"CL&)S(;
MF*<VN?((5V0.X19Y9.)(()O-7?\I&8KEJ#-[*@3+!QZ:EFD0F?N1$)]+(FA3
M6EV6:T; G\5?RL<;-'&SY#Q X2-]$J,K'L"_S-0"= T\T_NI>$2J>$]<'/ G
MF0?L@>N9^T3$ /H>/\/(Y;(4)* [G@!?Q&E3  H@2!M:"SCB4 D=P!X-Q.OI
M^($G*AOS[X7:ANU7B;7^]/ 9<#03O R]FB<G=\-4^(S<#ONCJ\'PN@M0^>WS
MI^'_M<B77X8?KZ\&O[?([>\WW=[U58O\^^I3[_KWVZZ0WZC[ZY??K[MB?/D8
M+(:<R^_7FQ:Y^7+UZ;K[[RU7 !J2QWS]M0LO_G7S52'P$8P7@."/&/X!I7$H
M@&0YJE.8(A$;##^H/;E+;8EX\ 1@Z/'A)<**APDA!2SDP3Y<;:^O;K_^7_?3
MYA=[OG?Y#W]\_\WQ_B<D[M-L/@7[T"(V:*''<2N^L9^X,KLL_L9F#B47_5]^
M22#N<P7EMBO!$ZCYQ^Z_?_]MBRS@MJ3)O@O&3[#&\HV?^]?#W[[>;+YS'C@P
MJ$]\0.^A:R&'YZ\WXF$\:?P\Y!!*OTC:M,0H3"2=RSZ8U!4:AZD?7$.).-=Z
MYP?IX6!X=L*&0H8? 8$>)X$6<(;=)A>++WYHP;V/4[CYZ=)_Y""<B8-G M'0
M]FO?AO]^!"#/V^3$ ?4O?F!Z/O>#2-BH<1#?+YCP*;4FPI@*P;$)C%^T9#$N
M#<Y SE+5P5]T)F @X2,,)3S3?DZOP./P/:,!)_H7CQ?C3V>)YB]@L'J%+YH:
M@R?F<!L[I]Q7YJH&G,E'==74\H=LM#)M,@(M])BX*WJ$MC&;CJ&98"X$$MWD
M;#GOW=:V<G0!TR^5#OHHE%JP!MS&#?O2^+N,"NO FP\ <?R$7U9,3)M\\A_%
MM8MW.N&JBY.9-5!Z9P:B2DQ[F+5TC;DR6\I_7&OY]XAD7HOOO?" ^,T"(N""
M^=P,^M D&#KP,;A_Y - [T!R 9OSM9LQG?'%'9N*=MX])>]+[%W"<$'*<G0^
M=X45YIT,;8<C&%1%1"[".,+C>64(WX41"/T9R^ V\\%CL,$/<)EWG_ETW 5T
MV?>-_E9WT'I&):#@@(Q8I)\ E7%#<&.^W'P1,!<V?<%P\#X80#J9,&Y6,N\)
M1#EG@B@>G% PB6C /==">/PD]NS$W?@"ELGQ0I^3;>:5\6O!%VJ"X5UQGA*>
M6%&JE[Y(2KD@F >!59+(F0\:OS[1%*X'2Y=E%4M\&$ M$@_/YBP JC%C8\?F
MG)!:!C#^+*4@T)"[&%PQ3RCPE%$WFMHB&\13&+%9N%!$EXG%R$P+E^X4_\:F
M<WK'HV6=]!W?//_Q<@JPY 26]+:UYH(E_L@SWROCQQL@LQ@>#+,:-G= 2?D[
M_^,[(+ 'D )_@@#:RG6_"#^-]/TV^24:@UE:^2WQX<"M_BH,7,)TF<R7]DWX
MO6FK> -#YKJD-_PT_-+]!?P?\,191 '[-INO-ALD.@$WQ>,Y)L@0?*3A+ZW$
MN?GEZO^ZO>1.QYNXSG<PUW?;[KP>_GK5!V<HXZ4A=]H9W KS9U")BV'[:_N'
MW.WFEOPDLE4\/M(U5UVU%%5/?^0/_>!$T"H[>=\_V(Q/E5SPKVY@:G7Y>3(I
MB!&4LAC!(R-V%\3<<9-;A*]I",5+0,X1SD>?SR,O_<F$DSG7U^E2#IF!;W'5
M?D@FT*DKMOR"DW28*-Z8S9GH([![? >2Y=8[ ,,]SA8$VN2S@(0G#D10WH;$
M$(O9$&AA8NY>>M9@T1+V3^<1F?'G[ T6)1(O6'GF\LXP@B\2*PP0<(5+#IU>
M<=I77K^Y]X*PP+;QW1'''R^YXW^!9KALU52X15F0LO2%^URK+HPWX9EPA-P3
M#V0_70'=XF85G)TQ.$PP]U=;ZUR24[OWQ_)Z'HH\12=\2Z&/._7P=2UYL?JY
M8]5RL;K9][\$_LSG8P5_3)SH9DJYP80AG8'S?7".JYYF#4U)'1GJ2-5E;2"/
MC'2M4U>[YD K=:W3V&%"RB/4.-L>Y4LW'J"?KW1>SC/1<Y\69"\<?O9=.$5P
M8:&*]U==:DL$;H<)BU>LBC^ 1G$W7BP"+C)X97,;D1/K#OROQQ:)YRE?)+F]
MN,_!<[=%F.2KD"1?:BY)OBSER#179JE9M@Z/Z:AGU$$9P1X;8@Z^PLS>S18+
M1TX T[-/OG?)5PA'@R[ISOGR!76/WAS-7?!U3B"Z0<Z:E$/1Q[V$V)1".!N$
MB#'8N8JS.XE8L!O[)!8<D5R07GT[A?G2U'?'9)!'I/9;1^#$2$#MY$0"B'5T
M '(E@5? G<+_AO&U]P+Q?\[>@6KF4-$2O0/T#G(GAL)A?P[HUM'L%PGB_>))
M<]NI*F,G5[QO#-A+]D$^B#@9WNQTA?Z9LYYY\*_-UW-= 9PQN$ L[,$[GT4X
M3D3#:#9S\"=9XQPOW1H"E4YV$D1T4#2%;Z$/.6Z9/".4VHS5?@1:T"CQ^!DG
MB8JZ<'YXEM([.=J3QF]L5:O%@#H3\K5]T^9!.F%(0NJR<&60LY"Q><!L)@(\
M^"X(LV,1B2 KES-HYS3=/R.//-*.1CS@!MY:[.JX7-[R.,C@PGDIY007_-AS
M*NK%4>@_8AIP0TN%N=U[1!:3<Q& \<J8I+%6/ C[M<$0T50!H_:4C1LS%GEO
MQ*X8A+JQS$%^6D$TLZ^2GY2VZE)IVDIXZ9S7!A($ZI$[($U[ZK '$3-Q3X.Q
MFVXP/DZ9,*KIO5,:PL7,2]D[V:.C(M*8D\G2%A<(DTJV9U]W(9]OK!^T8;[8
M9K_R(NK=._!;-PQ9% Z_IQ&-'WU__ BZ<G@Q*4TRNQUYT%>'2L?L6'VEUTDV
MV@U34WO6>6ZT+^7,2TJ!H/G1$A$72VT[Y@/$HROHS(>I4A+(V.(1M]0)1*BC
M#6-YGP8(TO%_XC ](H+%ITK=EU;RJ3ZE'%M_J=R-Z9QO/^G&'WE[Q76[<-RQ
M[ZCSC1UW+#A66L$QE-II2*UV&3>6S96/+-]8W#;SZ]I7EZIU7;%4D%5H7)Q9
M0%VMH:XV0"4/4<*]$P6^R6+7NH1@\;9I\T!<7'G9VF;X0UX<@)+>(.EA&#DS
ML5SUBS/)+8,>TNVSXP]U4\NZ\F_?#R-4053!*EV Y0+^JY*N7;M7-AL00@BA
M"E7Q$T,21PU$/P)5\(Q5$/T(A!!"J"P_ H_.;,L($EVZ#@PASZPWISSE96Z%
M!"N58"EG9L3S9/524<D3H\$)2ZYV?)B[?+;NGQ51Z;RB0TA_S6TE?-=FXVN"
M+D">59V TS6UG5L!BOIKX*LHAOON B)2G/[\SO,]]N['A1#*4#DD0R1#),,*
MR?!"5_5V;D7Q\CWQWR"]S6\[&QFU!HQZ6LI7"](\,5XTV[E%H=5"BZKT I&:
M\I=/C1DH7\XY<6K)?\:)K(&L@:QQ!JQQH2MJ?E.S-\W ZJXON4VKD&R0;,Z:
M;.1.?A.>IG@HN+^\65<&24DK7JHG*X;Z=+I$7 W<=-Q?+C#>1MD5;U/1N<O*
MDGZV)$DO8=.S*<R/J_ (PORWVI268>61=+^0S;8:.QVXGX9(KA625=E 8XH+
MO14@K0F *L(C1:P@5AJ+%>XXJEI^8&F:?XA; 0BQ8\V1*><W,6N*,<+U[VV)
MH'EU95%).6 A"->>BJS.XV1=G*=U/EJ5*I=F>=B[\L9LXGC.HKJ;[<]F+. 5
MRO%(*L[I2YK3&Y940AQ\4TP#+JLA!'.'X*)XEU*\'B(0$8@(1+2%N&97*Z0U
M 5 )A#0+%Q00*8B4W072\O?Z$"^(E\;B!2T++E7OK2RW 1VS&0V^)74'(_Z1
M>'3&3CCLN.)%ZM,5W.F2]]E-P+42PD2;POVX!(8(Q+5H!"("L8E 1%.("P:X
M8'#<@@&N%R!0$"BX$HUX0;R@8<&%Z H6HKOV'[$3L+%8AG:\97T*T85D=1I+
M5;Q%LMJE;&$FD<JFXS6M\%Y=II&.*;>UW&;L;Q5O4^P)KJGAFEKN(+V06R#*
M'%&*F4@0R8CD"K1/:5ERCB=7S]Z<(M;R<WV; +G4I]4L.<=Z$#ODAEA#K)TM
MUBY,TVC+94&M:?YIOAXI O0,%_65EBGE6!&N*<;LV'5]JZD+^[=^1%WB>!'U
M[IT[EQ$:ANR4%_%KQT$HG]P\ !4\@+$?<S4]QG.JQ32Y3G4!=PGYC H'6BW%
MT'(\/?]FT3;%\N*Z:2.HL4'%?$^#-QM5I5IKJ9:>XSKWT8+'0M9(VTC;)Z6Z
M2-OE!P-99J<.OG!MM!CW6\Z,6&M,D263XHE/]<7SS):I*3F6?MDE,Z0FI":D
M)J2F?3;.U59'S?.L]+Y"P[US9+2:,%IMW/R3I[N3G85F\T[)*M%-JXW>E10!
M\6-$H?L;K]_P]]]^O'.<NP]7BQ"!KH@0&'ZWW9CKW4??'S\ZKGO+'WH+$NBY
MOOWM[__]7W\3]WT!6O.#&?5L%GM.%%([<AZ<Z.GYY2!8CTOOFDU^?C<:*))L
M_E/[_7;PCCAC^ )NNASJ5E^5A@-#,<Q>MS_L6XJB=$RSHQF6/NAH[_[^8C16
M)7OKS%A(/K%'<NU#6[9*>.5V4%IV.66"S&5%>O\,=S)'V<OA%I\=#]@[^J#R
M"\H R^V4D8GO@N6 MA$QLB2,9S,:P'4A\>. ?/E*,JE_>%5=7NO]'A)[QOE2
M)J!4(/SSZD,]KA3N<Z'R:Q8/3KIB,]=-K_GYG?1.? 8$VMGGP\?ZT1E'TP^=
M3MN2=,D )3*@?Y;^/J,!@+A+YR'[D/VQ-L[+)JZ&$BVH0=T8&+9_,%+20$MY
MOYM[-K)@<K]L'GG_8;<?%F"%7M::UE010KQ#EJ];.!M0S8(525CY4AQ_G/CT
MF!#&G>^.D^??3&FP?P94/-*_V7!\]1Y8&/$C_1$9,)O-[EA 5+E%P/@67SVB
M+O.#JO969%EJ0;,+E_.Y^;9O@;C<6(S_@\W\^=1Q'4K"N>-=^I,)H>/_Q&&4
M2Y7#PD]MUA_':BDH1J V'*@?X1YNBR]H/2-T3@R56CG&%6'9<%C^)CQD1&0>
M(:#E6,JF;6L=$\.)L-X"ZY$?3)B#R,XI&U$'D7U:R&XLL%];TRHH <A;XH?/
M==&K(^?*%!A/O"='O&G#=[^-V^4^;\ B^OU+X$^<B"_0@QJ#F9W%+CUXIW=@
M]>6>8AG&0--[4G]D#8:=9*=7ZVJ]KE'J3J]1EXW>SW% 0K[S0?P)H9X74Y?,
MA;A# D]BWVT6AORW-07)LQ5_U:6V1.!VU_&]0M]$'D")6-@B-%QN://DPR2:
MLG2C^XZY_F.+Q',_^7:Y$<X>>"YBW.Y.M[ME2<(-[A(WN+G+5:,C<M6[ME^]
MR'')R G"B'SL_OOWW[KD=AJP<.J[8S*@.=1ES%WD)^9<J9T<HH?W$F*#9V#O
M<0:6ISB[DP@F8*^@GL2"%VX8>(7C HGA'/!OMO5<984P1ZN?"_X+1_=9F_T\
M\FJ@V2]K467/59+%LLHUG\C&+)P$?'(7.?V!(L%,-Z!S%L,(S@/_/J"S\. U
MEIZEC89]8Z"9BJIK9M?H:+UDC<54M,&HW&CZVJRQ9-(F7-R$R_N2"YRL2)QD
M(B=\*69E88*&Z?(#KCH4LNH@*[DL.^AJJ<L&:[=7_'KL_)ET_D0.9&RW_04<
M)\CAF(8LUSO5>W6G,L"/68H6#.;RP^^BNMWBXQ!LU7CY,=NG77ZCRJUBYF?5
M':6I$PHV#]_%E9=MZX2'Q*"N[@H<)?4R)\[58^CY)&3SD.09M(!'[?+3U$8J
MY%85S.TL&*H@JN#;5'#O=6W<E=F\KM%S_'OF_4^X#""9!^PRHM]7(TAX ,77
M]DV;3/R 7%_=?OV_[B=1V#E9N&W!-6G*!W%IP)S971R$C!\EXX\,&7@/\"._
M9<P>F.O/Q4_L^YS7BJZTID3]0\'JE" 5\Y^*I\LM539**+-:&QW$'(+US;A5
MXE;6Z>7,.O%MO91M%*V3PQ9^*A+D#>0-Y(WSX VCT[:0-W JN-<Q KZ7#9.W
M_3>ZW[*^<6PVJ[,K!*\I^4'XS<)M"O;19R@/J4T I'B>45B!*IS4(] 0:$N@
M=7)<4SL3H&']ZE?K5Q?DSAZ@>EB:^/1JM=5Y:K]Q.T+7.VVE>M$VA531>ZDA
M ]:8Z$JFMA-GL,46JI;?I@967$-J0FI":LJ)FM0RW:FF4-.Q1R#?=*)Q>1[2
M?Z)N]-3WP\B?W%"7A5]@PF\_'73VL3<<&:K5US1I8)B:KG0U*3G[J.I&3]7/
M\^SCOQB9T6\,M%1(F,SI$P_?"TGD$TJ\6.32\R<PIW:",?P*( !!P.P OH81
MX"%^Q _(/ [L*86_Z7W 6/($&H:^[5">F._1B::B*!&U_XB=T(D<W^-/=6#0
M7)?949K6:@X@>VJ3VRD+-S2)!S%&3W..0O>)P'_MV!6/I_ ;@7MYN"J]9^0B
MNS6 GW](FL](R/6&?^ -@9>-8SL)@:1)O_C3 O($ &DO3=/ME$9D]7$@+OB#
MS2C<"$H71J#-(D@R8#21Q9BE?_->\QQ=U)Z*QY([^'9,TJQ5D5C#H#.8:B6!
ME*)YXSC(0BVS;%\P=OZX38;\,7_$T%(60/>3KUODD1$61LZ,-XUW+'ELUF+_
M#O2+"G'S^$Z1+2MVW:0Y/&0S8+9_[X%.B-_X$/@!OWS9-!"N#;A;-G'1"YJ,
MV[)-R>\O1P-N7+XS:^LXN;A-1M L]AWD[3(08S)2+H\CY?=Y+$H?RH?)$X/.
MO'$Z3 NIATEHZNHHI;+GW_-+A9QXO3+18=!D+JKGW8)QII[(()8\@;L^*_<_
M&[ME+^YX>^#?U9>W7R?5%\2XB]H6)'AC3]DX=MGG29^&TQL612X;K^3K2PKD
M=-]:::T[U'15EH9#U=([([7;,;JC]&RX)'7D$59:VU9IK7^#M=;6CX%CK;5=
M]S?R:&_M9HR5;L6=Z.D;K+66A^DXO5IK=9Z^;]H;412L^/*V23R6AEA]'E9,
M*QJJ6#$-@9H#4+%B6JZHM!"6",L<8(D5TW*KJV1@7:43JZO47%ACQ;0\D:UJ
MB.S30G9C@8T5TVI-%;*D8\FTDPEM.69?=L/F[J\T^,:BFPA^_<HKL+UY0[=O
M: .KH_2[BJ2K76UD=;MFLJ&K]X>C80\W=+=MZ/YZ@_NY9>[GFKGLYQK'[L?J
M)YUH^LC;-=S,7L=G\S>S3SW_]&$[U:AA^VL8)BO=6PG_);[8L4Q2MT9W85CI
M_>NEF.K69K']LY)$?E<IJ;JU?T2=@/Q&W7CO"EBX@M&4V)HF+5 HJE3*6N99
MK#^4JH4-\U9R]^;JKXIURM. *:.3X"9=;QO(AAAC@3&*I[Q#6\[^;%. BF[+
M*;@M-6:UNGHF)\9:B0):BJP4#]VF<!<Z&1A?708V.^A2H$N!+@6Z%*=%6ZJE
MM/4.TA9Z$W@LI!Z(O)#E<HXZ8_0XNB/HCJ [4B?R4V6YG>.QA#HH$KHCC3C.
M5ED]J_J#]D(K\ S+&T2-#@TZ-.C0H$-3!VY43:6MYI<>OPZ*5&.'IK'^3 -/
M\9X8D&53KL=!W:9 '3T4]%#00ZF>V%13:ELJ>BB'>RA'IA#8[_3_AK0!7]+J
M"5]<ZD5=;SS\(W;F/#+T:\@FL?N+ [["P2D$-+4K:;*ER-W^L#OLR_JPIV8U
M,_3A4"X\A< >]^ 9^NQ < YGZ'7IN&/@A]Y_(N? MW-/&4<'Q=O'O&Z%J.3Q
M051?X5J='N0,0Q:1/HW8O1\\5>DP-%C("8L20:/%S5LK.%-=>_?M%^J5MF!?
MJ7SY40YG\E2!B#_Y$1FS><"2<DVHWV4*OQ<[+N] 026J:R;DZI1<UGE-,TU:
MSJUY82<D\W+)G)?KFH*])5>S>> _)*7B4/,+%CIXB$%6!B]./!G7F8AJ=:(4
M'0MFV<\!"^>,3SIY&388+,1'F4,UB@.8]<<!$\7Y1LYW_C?BHUBA"\-@HEVH
M4.]_I?84YEK!D]#[Q=H5*G[QBJ^@1U2EYO?]V3P& [P<A!M_$CW2@"V_X3/@
MQ8=_T& L?D9L%+H#PK&A'P^-(_<##E_67^X-B-2(5V$8L_%7OIHUG,U=_XDQ
ML;OP):W8S!]\>&IAT^AK(V4PE+K2<#CJ6CU32_8%E'['ZA2_+_!L 5^9GTYJ
MX>'-ER^86[C$?1$YIXT1M=KTO!6_'CM_)IW'#;GUO:*WA^0L.R%7D$WW)'+G
MCOP5US>:KGB]OPN/:_%Q")9KQ0W. AZ7WZARJYBIRRDXRA7LF";'/*X\ @]S
M'=\+6X1]M]D<WL4]3T)G?NQ%X2&G$Q;=/3;Y=)EQ@M4CZ_GT9?- Y1D3C,&6
MF";]#5R19VIF5$%4P;>IX-[G;O#8R>95CF1=B3AB88F(."FQ<\AE*]8WWJ+#
M.^N95).*_7615W;LQ# Q_7I91T[0TNR/TL:#,8%?)]_J!X@R1!FB[.7S3 M!
MA@>E"_58Y4[G1#S6NB%T@U.*>:C1*IZ:5:P;K(H"$N(%\=)8O'1R=12; A7T
M!3=K2Y^&4Q(PFSD/1Z]>YC]+JX/#@QDW*LFXT6E;Z#>C'Y"7'U"L[:\7!>5+
M.B?.+>)YFMS.+;\@D@:2!I+&&9"&W&GGEO*K*:2!TZC#IE%O65+':11.HW 7
M ATC=(QJP43H&.&.#'('<@=R1Q["4*4V[DUMGU2]+3W"&S,;+%,CB$/Y3Y\G
M67KE:^;RS(>W?I\?,[]+DX#^RXFF/#\']9Z&7&&>/^W@K FCH24;([W;DXQA
MMV=T-$L:I=F41Y;4T<XT:T(WS9'PQ%.09:D18&XI1H1GX>#SRJ$34H<\&QW2
MO0^82"!'G)#0,$V]$+X]J\).^3QCZTTY%?88E9W/J%%>!EF2ZI>)P:CV/+YR
MTMD$L/.GTGG,Q("9&,K.Q"!,K<B[0$2Z!8)9%FJ79:&)^13R.IV"R1:.E_"I
M+:_4[!C\*:GR5N6M69H&5%Y4WLH3/-30PRXPDZ4?49>,V0-S?9%NE+#O<^:%
MC#B>'0<!N(9W3\);M)\MR<!;5F_R)Z37_:1HDISD=58,J5,EM=0_TT%#H@:*
MD&=EV38THZT4+M3::"#N%C9KM[ VBE7WK<23Y2SQO([>EG,CJ;JH#')1L[@(
MZ>:$(A<L+3]&:0IIX)1QJ[KT'/^>>?\3IME_-TW]-DXH S9QF<VW^N%]O$2"
M[7O"XHCM_S""?T21./Y$F'SZ,R;R#+LQEP^)YY. =X*_ YK.P@C&E,SI4ZZ%
MY3 (O=KI9)VY<H/,3"V_@S2U4"/TP] /0S^L(C],E_ L+Y(&D@:2QB$) *2V
MAJ2Q=?+VMK#S_*/&CXA(OX&YU.&5^X;&R.H,!CU]: RZ'1Z*WA]DE?OZO8%4
MLQCTUV*J<]WOW%"YC]<G=\;08;H:H,[W/+^V;]HO-C[Y_)-/7A>3WV1O]!(>
M,O/%%:X?AKP(H$?^??6I=_W[;9=/>+/'O3UH'6/4<XQ1MW()43>U:@.5I9,.
MLS[R]G)??_(+@O6,TC8Q2%M\>C5(&V.T,48;:]YA&'8MEALPDK5H5=X[*!MS
M5FV>Y'T)_'%L1R3@,^>8A2WBL:A*?JC%W@YN$58A,UW-,5RK#FJ$J_W-6NVO
M30Q@C?BIR4&D&^1F8$0IY@K-P>_J^V$4BA7R-.;KD+BL17=VUMLJ<WI<MT(H
M&]#;4=JY'>-\LVR; FWT0,H#:D/QJ.>8"&Z7")L"NY/?72G2J*[O+:_L)Q>C
M:2IHVMB/^7;N,6BM_R'(&DTZ=HX GM--,VUV\HN3?+O0:Z/"Z [5=T&F&%:M
MB^:=$GF>&4=J:CNW!!R[.;(N"HDN:DU.!&X*B&R2T[KA534>I"9XK?E)O++T
M,D:9E%Q_)4:_]7S]5N3/@AS7TZ=)1:[&<VTP&Y9_'FK#F:7U$U!P[<SW1"F/
M@X\WJ2-#TM1!M]OOF*:E&Y(I]](2&WK?-,HML6'L.MVD5'BZ:<Q".W#NH,/<
M^_9B'D'.773AJX>$QM'4#^ QXQ9Q1*&5](A3%$;P!W\.7)RDZ^##!4WE(T1%
MFHXU!<RS,QO#W<G&4-\\7RNZ7^@;-H9XYOF"MY\QVP,)9WMD3,[GS)AR[)DQ
M/+6%!^[.4?;8>CRM6/%I1>M$0]/J<KBE*[S&S+$C6_TY7-6I7%4;H)&'Z&!!
M9Z[P'&V!YVBKB#^L_7'9+4J_F.4CU^;/M:B(>RMB4LL7E1"5L$(E_+Q<W$1-
M1$U$NXR*>.Z*B'89E;!R)7R#7<:CN-M.#2TW:_-"=:ZKETT*MI9;T.@<#_WA
MD9.RM+!A1J<\P9T80A55QTH=]=0DA."90%"6<SRV>>X01*3E+Y\Z ZH(/Q.Q
M@EAI+%84U<)J2H@41,INI,AZ?B=NFH*4W([,;#WDLGX>)DU;?)UD+;YF,&0/
M++SR> E4-K[R^BOU4GO4I9[-;J:,1>'!IV?ZLMX=*EUI8/1T3>U*DF9UD],S
MNJ*JIG+&Q8$B/Z)NECGZ,D@..L'G9# (O0/&:O'ZM&)0-I:RO4O&AH1B<%J$
MGXE/"@OQC3Y^="8YHQ/B.8WTG$:GT[8D73(L13&@?Y9>MT(_AEEM]'C%=8;.
MJ?,8.H^%?JJ-1WZ#CX*AR%C2YW1V__<Y*H+G0II<M:=F"KE5!;$4SY%3JFO&
MI[0\"Q@8.6K;0'%1"-,IFSD/8EI=(<3K'V=1ISPUF'PVV8.Q.CFFVZ^]!N)J
M=+-6HVNC6&\Q)EC?9^^=8B/_9(/5ZTQ]TKN>CP/'$WJ!,.&!B0,7\ Q167F?
M)%54!*/REJD(%OHYL+"(J917600CK-#[J/0,2]T *9ZGJ59YQ;::@K0C3:O<
M6-MZ^^I><S%J5G22]!K+_&33H-=YNK%!J*8A%T62APBV*?2)CDH-^:_&-%<R
ML9TX?XGG&9)>8DFQIA!3;C&2.04^+B(J><S9;RR$J^%94>#8\)>(P/SJ.5&8
M)3$_.&IRU)<45>T: W5D#.%_1D>WDJA)S3(52:I9U*128M3DRZ3CBW#'4(1'
M7M]\)305.P8]%A_T:-8CZ%$_Z;!#C%H\ \\Q]R6N4P]'O!%E(7!NDK^&8>35
MWDKX+_'%CGQ4=6MT%X:5WK\>T52W-G^$9T1+M1Z AWU2[1]1)R"_43?>.Y ,
M]WDW>_%?O0<Q8R(T>GMR;,Q_L7U5U+(L?GR_<%$V974!D]#4*6RL#MI6I^V>
M\]G-426UK>472U8'1<+-[@H<C'^PF3^?.JY#23AWO$M_,B%T_)\XC&;@/M;2
M*IP84F4%'0QT,-#!0 ?CI&@K44!+D97BH=L4[D(O8XN7(1:TV)A<T$/.<:-+
ML06;FJ&A3X$^!?H4Z%.<%&\I';6MR4A;Z$X<YTXD462U9/\30^2%JDNEN!+K
M2G;:X;P;9%E/UQ;=$71'T!W9LH=BM24-W1%T1XYS1T9^,&%.GAY)94?LZP_:
M"]G*=T/E6%FC1X,>#7HTZ-'4@1R5CM+6<TO060M%JK%'TUB'YK6HT_RTZ^BS
M^0WV<BRU0"<'C^NCAX(>"GHHU7@H<MO"@I-O\%#>=)C_+6?N^8'].+R\IW3^
MH0OZQO-$4W?D>-2S'>I>>1-^0IM_.W!"V_7#.#CHP+[9URVMKPX51=+Z6J?7
MUV4U.;!O:+(V4LL_L+_R$"5G&"A+&.BF)7>,Y,>U(U.?>;I&LII2@2PD3FXB
M^(+'XX(W%E''?55[<DM5(%O%IRIXSA#)C_RA'YP(6F5O$=9-/)^[0B @G#X-
MIV0$]I*L:&8N$C+JDLOA67_'"]#QW)\V[SWW%HBS[#V!OP@H%'D"V@D)\WA-
MK#61Y-G";):P]"^V3A?R?&VKV%YM/&27YPM$IM:BN[!N;?,= B?$XFFEYA&1
ME5P2B>AGE8JC9K>K)]WZDQKY$TG"<FJEXV2YWNF'*TQ_X*_X0>"&+3_\SOVQ
MY<<A=\Q6\CQL<J**6<NN+KE)G5"P>?BP[!R6G6OV@BXF/RJV[!RJ(*I@,2JX
M]\HY;FUO*9S#U\OF%!1H' <.SXR:+I/Q-;/7%R_>JL#56O/:(1^9,2?%0OU!
M_4'].4P^&,.^Q2Y><:>&A;EE_,&PD.-E>$YA(9;<QKA5M(+U]1)JS$'YLLZ)
MD\N"3I2\!(*L@:R!K'$&K*%VVKDE)VD*:>"$:>N$R?9GC$3T>[5U.6KA[.*D
MJ0J9R2W),-J8P  =('2 T '*01ARR] 4G#@A;R!O(&\<QANFUK:0-[;.G;8?
MWBNM88>?"RO_')BN6HJJIS_RAV;GP,3[/OG>I3CO]'G. AI!@UOD2J0JX($<
M_"A->F0./F5'&W,126T.@EUY(EYEXL=!-"5_Q#2(6,"/@?$ 2?+("+7M("[Z
ML-=?#4EJ2UF,;*&O(O'<]TC J#WEHUILMV0=>G5W8*]>PVGQQ[O^*AMO:/.;
M1@(NCWQ^ -&.9[$+\'M@)*0NKR4](:.OOW8'P^M?18]OA_W1%7SJDHO(OV?\
M9&M+Z.THGM'YE 8SDM86#W]H$UZHFLY@VAFUB,<B_K2(?B=WS&,3![Y[I"%7
M:WX!*#8_V<B_\* ]-NA%R*!5Y-[WQX\@!-Y(?FTPYM7(R:,#*.$O3N_G*A1&
MT$0:C F=SX%9Q!DP>,)=' (#A"&8F]D=L @_1AF2QRGS$EC]$3L!/Y.;]: E
M>NJ$A'V?,WZJ6CR$):%E3@I3)PBC%RBUVF3$N[ X5_WLW*;/;X2'1C! (2_-
M[7LM,G=%-Z&S8_+)CQA1E.+./6ZAWKX_FSFB)% H.M[WA309D"T+U\\HY*IX
M(%B0)DC 7CT=/5F<C@ZST]%A>UTLA9R,+I/OH=,>$YJP5&<NB"B(DV]!KW@Q
M=Y<&]^PR!&>* 1^ .;UW[)#,J!=/0)&26$?XRW'!*'(%O8%+HFD<@(+=P(/_
M9($+ ]M:-2+VE#\S!,US::KA\\"W 27\80P@,1>'TKE",.\>1,K$:Z _#XZ=
M$ .@+/"_.Z#?S'TJG+]+,TLE$'MY-A8NYQKT#%YWU!44&DX9B\0!7QC,0IM1
MT1'R4HY@%WN*O 4(#;D5 I/L/NUE8.!CQ*WRFFV1-YPX*]:T<%\ _/GHJ46^
M@,XE=#+,R 5M2X&V99';C:MH>=,'3=?:5CG4MF*ZN.$,610EB32$EH$.,@\&
MG]X'+/E6F%C SR/W$+]P1X_FX+"9I?MK5QZXN?<.=VZ[8<A2K^UCZB;7!U3-
MP]2(W07@\3]Q3.G)]!6F%* 2J\Z:F$^$3O85>-,/+.#>-!,.6,#X%(;G7Q3I
ME(2C'0EI.F.Q\L%ONX.^TNP)Q0)6,;6V7I)C%<(4*DAF@0#8>1R %PJJ- \
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M_(%L,F%V)!*#C]F$!8'(2B"R%(CJ%FN@#XDSV:H4CRQ@RZ>*K :,0E?O@%M
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MM\&D<#_&8TE3!1+%8(.SPYE(D.[S_@BMF]$Q?SN)Y]!"_F+ZE#UZ;7QSG6^
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M4@>K\F-O9W28: 1>W+X.1BT:_!OW.''))/]M' 3-WCKX,?##O3.NU*+%7[V
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M*)*<>VWS,Y[^YZ:J#=#(0W30>,-4;W]F+4+8)\2\FP?BXLHC\##7\;WPD!7
MO7,D5B#UNBK],)LM[CM/JT6K1S"S7;(@^8W/<=%6Y&\K$$C[6X]L=>6D@-3W
MP]P"R! X"!RT0 @D!!):H&(L$,:*;][V&<2,P!V^Q\@3HP'Q ^*R,+?T!V\1
MXM8%K12P8ONETHP=1VU/YAP_L&OU[S5!%R#/4H(*-@A4:<FRGN.AP-KK8)4!
MGKDN.3?,_2B/#I'Q#F:\$R0U(\?,,'70) Q,;Q8]U9B%\N6=$Z>7E%!TPVKO
MO2]U+LG2D3>0-Y W=O!&CMDWF\(;N*BT?5&)3B(6+->5HBDXGO=3,G$>DF_>
M5(%W9S+<BF*AJIL@F*J$$P1<V"AS7P5!B"!$;[L>6&L"I#(/4U=P9HI80:SL
MA95.?GE+FH(5G(WMFHT5//FJZ4&5JOQ"53&+2N)Q@'";@FZ<NI4Q=4,(KT&X
MH,(<"&%T9@M$:A, F3B[IH'U+Q%IB+02D&86E::IN4C#.NNO%MC;D ?H1&KL
MU<(;JU/8Y2XAGU%<IMZ23:7$E':UT$6<W-?3D4%J1&JL%S6J)18SK84NXE3N
MS!BPQD17,K6=.(.EG(4%F)&:D)J0FFI(35@:\!R3I]<A&S@%':+W;)FI^TUI
MOZE(C;@FGCP;F^5=7#+TUB2@>;Y69$8O] T;<TCFVH5'&)Y"WU#P&"R'? :_
M3L/BQT1>SS&1ZX@D_6B1@(5S9D?. W.?VCFS2^U+,WP)?)NQ<4@F@3\C*_5,
M!YQPFER"8?ZLY[-%+0JAV)Q0!9V^1L%P'>A.[$;0/_@+.L7+*MQ3QTM^=/TP
MY-=AV84*RRXHN91=T-5J\\]7_'KL_)ET'BL/%%)Y0);K'?I288I.?V4R$4W9
M\L/O(GI^\7$(EFN\_+B: ?X-4U5,_G[:R=__/WO?VMPV<B7Z>?=7H+R97;F*
MXI#4V\FD2M8C4>[8XY7D3&:_-8$FB3$(</"0S/SZ>\[I;J!!@A0E 2 (=6HW
ML22@T7WZO)]UAJFW3SJ;#.<PDSA,;]LM\_+G#.(P*&A0L!H4W#A9S%0Q%CM'
MOCSI&-DFD3>_7VR3\J5,SV(9W#LZ/NJ>50[6QN"@249H;C*"R378 #B[G$IP
MTCDX.2V/VQB^8?B&X1MO@&\<=GK')69TMX5O&#NM&%UN<Q'G1MID#09A4\VN
M)G.IHKX=IAVC48", F04H#* <5!>_K7A&89G&)[Q!GA&O[SN &WA&<9@>L)@
M$HFYQF(R%M,68#88= ^-R634'Z/^&/6G!)^Q,9D,SS \P_",9[E9C,FTVF0R
M5>RO-ZVL48"#Z.1$.HZE&^TL3)^%+M9U>G,KY!Z+N14'ECN=,3>< OPC^*T=
MC'V"3.!;-M 0@R_(\OZ"&OYUY::1]<@MUX\!G/B9B'L>PCCB"T\Q696*G\$[
MN&??K8LD%OF;_PB&D75NTQ\1/-8>/D+_PN?@+^\[6?4K&W/?GEO3((S'\.]]
MM#?@*-GW.D#SX2P(\>C#P'?$1\8H\'R$@/9HUVHLDE1<^E^$)"F(%^#7>1KF
M!&+X/ <, CC&RT\T&-3+DF?'05TR(V]\PX"[&"$XAN5O_ <>Q<3G2@%"8[H#
MG)M&*LUMI-(AT1FE6.BF6&@!<<>CP',#:K9B!U/@!A%*WI'V5 0L ?';'U<+
MB#^='G5/59'DCE_JG\[.NF>UG"7?C:5C/<*+$^J@X?JVEZ#<@@7UVUS@T!'^
M'3'$#GQ*OP<T<:PA\YAO@Z(TX?!(U_KE:122WXMR'X.U^1\)=FC29 1*%JG8
M#=T@YO;$!\XZGA,&,E^)D85U'N ?"9S+9C/DM]8H0>WI$0["25+#CSSTYHBG
MN>,2*(IWL>+KZT64^O=??DRB_3%CLP\7+)K@_U_!-QY =L)GSWTG:PV3-86Y
M!^[\T0OL;W_]S__XB_ZZ*B&Z!38'-^G ^Z!=?N0^'[GQ=1A,[R9PD(\,J/,+
MF^/)SA]9Z$3WN'ZZ*MXA"H!;/OKIW?4E<L?_/?SM_O*=Y3KP"V;'^U?]XZO>
MX/+J^.KL^./U4>]Z,.@-SDY.S@Z/SL]/SB_>_75! ND(^D1ODB(;=D?,,>QO
M(YK,(/X(>R)M01,1?K%ID/C"1@"]?RBN)NMB@PIC%.,E!+,8R[P)AVVX6[1I
MZ%)%?1BNQ;_ST 96BZOE7C(=;DR'FT;V.6G8Z^;PIL/-ILY2T^'F;76XR9F(
M+_!GFU8WIM7-[K1U,*UN7A5M,GU&3*L;@X)O!05-JYO7^DDV<GULD] ;D>%I
M$H6W4UII\H2-C"U-QIJ<O[><\W=H^DH8GF%XAN$9SRFM[)LF5L:2V@Q7+IX9
M&38VE;&IM@"S7K<TSW$CL,CH1T8_,OK1EO2C07=Y0MT;5X\,SS \P_",-< H
M<<1P6WC&1K673Z<LEY-SG,MDQHS,(58,P7KG(=SVF.-[EVYD>T&4A,]*5;X>
MG%\='@XN/EY?7EV?G_0N/UZ<BE3EP^.#P<E!_:G*VB*#DO%]D*G?1R>G_;/C
M%4','(@IQ?@7RN6_Q>HMM!,G[JQEU44W/B*+CS4.@6\]NO&$ZA6&203;CR)5
MEX#%#]R:,  +A9BI\B$.K <6ND&"Y2TIY& 9-@XYE^4M$Q;C<-,'U^$6/$A?
M( :'I2^6PQ^X%\PZ^(B3V +HHNQ4_@J>P[V,TZJ&;W[PN#\)'CN65EZ K\U@
MHP 8N?@4GL7GL=YB+FLP]-N=L3#V>1AUK7L>3B-5GOKD@:8,J_G^2-R0S@-G
MF+)O').R>!0#MX&%Y^+)9 9O4G*[/7'AG%32H95GR/-AC0GP*BPL@4-(@(AG
MA[^+VI-(G@^^',R9)RHL?&N44,T&511V+'<$3\$]46GA=(J>#N9E0,QFPZ;N
MD-P9RRX=W#9B7_(9]W%?EKR%_/6SC($2:HMKM8/0H=H7EV;H(NNF1/P@1.C3
M/V7Q3I31BL*D#OPM$J75^#V?T>U(O+*#"+8(/!]7G@+B,M^-IG2O#.\8ZV=P
M17=ILW UHD((X.F.0/ "C!:P,SN+*,EQ0"0D$>YE",CT6-/5]D^;6B7Z-Q"[
M/G(+:^\VL &\?PN#9+8^?_+9G%PA>*\F!/]5\N.TVDNQ;,2ID>L#EB(#D.Q0
M\%U1S89,Z_;F_NN_SC^GI=AQR%FL.!1H3?M_#YSQ-]?_G\CRYM/9!.1\Q[KX
M^6>MP@WDAN.26.Q8?SO_O]_^>5Z\FGH+2X!<._%8J"WYR\7MU3^_WA6_*>JG
MY\C$@ %'$1+NISMK[\N73W?OY<1KK%)!FL+?WZI?BPW. A0(" 2@&7?_ A0A
M_$;(9LA J:3-8JLXO8!8BCD=>/)Q H_.]X-'%"I3,?!3DK>&5B!0\K\0]79P
M!U$RW <(<#_B/!-0F#/&Z6H DN[0]9 5*'!HXJ #;_C)"+A%0DR$*J!21N_^
M6^P?]B/O0G*2K]V[[G(]YF[S]E_RTGSAVCR/]%_73T1QXFB$.)_ ;SSB]" U
M&=RC> =I ?29*=!+S)=9;\?BWVT^BX4> R+V4=9"C@-$G0GR7?P(?C ,O YV
MO'! Q?=%:6BP>J.=#+> CD45'-$J[FB&.@$<AN&%C@#-X'?#9)X]%.DTC)A
M!XMBB[NB^M2F7:>?$+Z!TT'_Y,^17!)E6@)J!\BL%<_)+TEY%K$I)U!16P_$
M9UJGJYV#8,^\"#:+J OG1!3U[20,X0D .6R:>);ZL$,0RDX$"HPJGTTI-M5@
M )ZZ=H17^UW> )(+D\J14 ;SZV8DD7M%7/<4%(5(W([#(SMTA^+RB!T)F4]2
MU%I&NSR/$(7>R,!@@7@"M#^>$(,!W$"R14:4B6K:IA_$VI._!\ 2TEI<V*"
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M,@3,HU8;\-D9FVO=R '-IU$VRJ!PZ$'7.K=M4+GA6KUY!Q=V7(<6#KD=C'V
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M M%H)&Q==1>Y2P :16URJ@+M(5[^"K(1#"-#H2Q=0UN2;!8X 5[K"CY:',!
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MEOFH-6=ODQ$RX^$H /3 ?"5LTC&7O6ERD2_@41'_(\&//.V(TEH'D7]%>?=
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M\<E!I#3FW-2F@0Y]'KE,CUE<3%R?T5_N@@0(YO\%0()='(6]KFQ6?%KUF9"
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ML$?9@IK6YO2AMN1[4FU%6U"\12--"G(]E]E39XG_2G<-F0Y4"X93U2G[712
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MQZIW<@GA\'7'PAFN&4>3W3RUDS+M<'-9BX0^)2UR?5)VX+GQDE*3D/#/"&A
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M#!LP;& GV<!!B2$LPP8,&S!L8"?90)D9CH8-&#9@V,".LH'RG'R&#1@V8-C
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M<27/9<,,1Q@L$@(2SW IP$";S=P8]BQ6 -C@:E,0@K'%_X#SX^%P9X!R[I2
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M(M:>6])7TVM$5!8:RS);1+L462J2MWP^$F;7\C7;S+,33]/UR!K-:>":PEW
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M[(%;\ 4XAAM-X$_CQ'4X(D=^SQ* 5#XL-CIEL1I?Y@)RTSQ6>#)B(SY.6.C
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MVF@ZW5@GYYXW*B_7[&6JY!?D._,Q9$-29UEEOV25/6"5W91P9H/E9D_$DK.
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M0-=^EQ2K,4,D5$I0+5Q(14:X$_X.9$9$<2]\"_@*])8F-(6L+ZT+ 9_%K41
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MW4")&F9INX'<!A*2\SF:6GCY7'4@0!/4P3'XTO1N78(SP8B5FL-J!:X?X80
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M?_FA;'R]$R 1@3)WY19&:YX+.@D;(:%R*T@E;82Y!WPA-O@HI2+><B=\VXN
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M=*I/NL/N:-+KC6!^D^'WB44'!G7$*I!ODC]V>"0;8OYX)K7PD\*CN,,/>-0
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MU'.M](4VS-%6C?<1-I4IC18+#*'IO,\7ZZB< K(50I\?D.E7G"*L"PIJP%)
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M5,$-?0GR".0@/3]D,=:TTE@0DN=;W)+[!8:@$)50$]GVN@4$/Q >P1.(JC&
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MC1(TMKENN*];*Y$JXR&L*["V2N)%A=6*U)-H&)',/@AX..79?,&D+D"3[F"
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MYJZJ/,.SSFZK/&7F!9H !NR+&55?Z';_TVARBEOA3KY\^NT=%@%XH#V&+M.
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MYDDZ7H@Z9N% FL'&"+M&?1M>4SPJ78"J(N0R-URUBU-5^'&OI/B&>%F.)%_
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M"'WQY>'S^Y;V^XTV];VY=F<'S-8^NF9;NQ _OY=GAK*/0[WVJ!J#*Z$LG&U
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M!.#DB1O'%B^ ++BS3\R)>+QMTTB8+7B2G4?SF,W9BVBX+40 /BLR/_/<K.5
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M$6X1;IT8;HT)MPBW"+<(MTX)M_1.:] C?SWYZP_UU__.0\UV36_."<D(R8Y
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M?6-$SKHMW6Z*9V;/CS+5\^^9467PDR!SH#W/N*LQQY'CK[,#F$S@,K@9$Y.
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MO4#L+Q\?_OA_5[^+K_QR]7__^-O53Z\G3Y=ZR"=IJZ6T9<5M:^YHEKSE\^5
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M@RFM">U= /4CC,5YJSM*K2MH+8=/-!7<5*@29UZXKI-)-7I9=:- B<7=VEZ
M,B>GKQ&JHZL"CV'W%FQ7]C[P;"3D/XEIKF9B:SE_S9/X!XI=)V=UA9K07&&O
MY@HK[>G08:%I\P#SB0X+"#WO832_+F;,C$GP6)(A>.N*G6F%AZ@M=]S61>5Y
M)9FXWLH(N\.ZRNA]2*Q*8JFKY0PUYR3=%GA4V#7JJ?4,H;NNV"F=)=0/BD2
M ?&F?#;1_R[2 I;CB/;9#R MH&Q:@&(+3-M&7@ <%.0%-)(7H.KBDL>1&%!E
M#+E/B0$K@>-JE!/9 <@.J-I'TDVGJMS)?23;%=:%D]1<% <I!K5(KZ4D.*<]
MPU6JRC5]0V1=8;>]?4H1 P%+#/K;-"LP">Z\++BC%U&:)7DQ"/I7+X@^Q6EZ
M$7W+O*P8#OUE<CZ?&>V%7QG_\;%PD5]JBJ"AGFIG[OGQB7%FGISII_:)>KR8
M(FB.3LY'M4X1+ )N4HP1O+JEB[%_[-[(?)S>XU# E&3LSW0RH7[&)PLRN;,'
MBLA\U+?_P']Q[R7C0OP)DW+*O/*4O8.M6C%0D"WS#;]N\+2X[.=B0B'[2+'9
M*]Z:+M>Y&& 81'X\I?M/(5P1[+_S- LF#[LLV#-+)/E@0E51Q(TBU&PALPC=
M5@_S4UI]]WCXOCZ\UNJ[;[?L\?!M>?A-!NR9#:P]PE\^ 5"*(7/G\<KP3^8@
M/KWX@WK)RMC0,^8[C5]/#B4"!H8^+3>F ^Z\<+RW)M];I3]^X-LKNF5PJ&RW
M?TG]T$O38!*P'<,DB:=D].7D@N=8QN3+8\O0BV+ST)8'F__Y55+\A[-BS\6V
MQ>0K3UF(HQ_(AV"_B:^(7[XM'U!)+ZDDOHG8>\9S^N"/TPWBN(BH(.K K&Y1
MVO8I]LMV_P1I[TC:&&..,>;]T-1.*N1&%12>& X5E$4%%]]2G)F\^HJVZ*>P
M'$CHIPPZ"8^R[TH(CQ(>9<\TM9,*"8^R?RK8+X]RK\"<3&Y2==ELE_2.1KFX
M&A! 7;Q\-OI'NZ-8+LV3M4=)%?)LKC9&$UAV*+3RI4-JBV-EF7FSI7HFEA"[
MS'O%]<RA+CATUKS&H DPJ A4U#HJ4FU]J(&,0$92DU'[HA3%2,5%E1OY0+_S
M\< 4OK?$.H:8!6(6Y:=]U#"G6AK]@U7M&./)HEAP\:N4E":\*6/S&@,J A6!
MBEI'10:HJ,(10_W:8#]6@RXVUT@(D)G?T1.SKW-)%(']+F70(KB>W:(FB1FH
M=N]29FJ9YPBIXE*$]LH$DEU;<,0 J@'5B!#&7&4<3=6$Z0S<%'!'CW;H. )O
MF8Y)L;_"+KV1Y'M%8!H8IDZ WV3D-XE5"?[WR^L)'!@!OQN< <[H 6=@S[[+
M4;*(J3!"1KJ4F!>SX:)Q&O >.>=>D/S3"_-2TV).3UWC;'1L&R<GYIEQIMLC
M4UU.BS%/'1O38C9-BYDP<9,[+N]BPO(LH2F[Q?G(Y76C7ZZ]D*\[26\IG8]_
MX6^)\RS-V.?YUXP?UYP/C_'#O/AM=ANG=/NXF?VGR.RP:L]LAN0C8UQW:*F*
MJEN&J6F&:FOB!LB80N;'& >.!#CT\X=.-'"DF&BP2UX4>JFMME[Y<%%!7W6I
M)=U<FYOC.=D_>>_?..L_O=RCKQWZME76MXU[3J1PG38YF*/"8*\.]B!EFKT=
M.N&Z@Z<C\Y?\,L_ZNO_?A6=SL:MG@\A F5W>[B32+$G();@#X:MV$;_OYK28
MTFQUW])>J#9W.#P?,IJQ?1T?+=ND!''TV=NC3V4HK'.M%%J$@A3);*A\\FF"
M\2\B9B2S^0!H'C6,"PL Y@?S-\C\U>>\])/Y>[01^!1XUT$89 _8#.R]E_+]
M)%\=(_M8TOGX&V8QGEX4I@,V S:C 9DY!K8+V"Y@NU!/@"B,^7/19$K"A9D-
M2AG7Q^?2Z@SZEC@':HK&-!UEV77YOEW$Z(8SK#EJGS*X<(*%$RR<8$F'7IQ@
MX01+!D%B3RI$9NK0@2\'<X X9M,6%7%,V(R6V Q]J,!FE+<9FVNG4#/R<IN*
MFA'4C*!FI#V2;KQFA!2E(J3)"I%.%H*L%_J^I1\[GQLT%3:7IC5X7^I"A E<
MKLAQ&5Y!9!VA%$36NQE9EUU>: &S<CU3&1JBY-'!^ 72L,#%7:C:D%UNX.25
MZUGB<LWZ2<D]\IUQ#"E)ZBPHN\^4;8"R90EG2HR;#1%+9 $C)(F0I"P@14@2
M(4GX4HWZ4L)2K>!+=9RGL?WM7Q:N[ (%F:]<SP69OT'F%8T6*-O]?\-@@2"=
MQ:D7_IK$^8Q=<]%FGOV:#PL((D8:BZGR<<3_'$_IX]<N,M2*!+51-!XQQ>5O
M\T+^Z3!.\X2F988/C)Q3_4P]UG7S?&2/G.,S5[.T,T<?&8YAG-M-#1^0<-C
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M<-(?G, -W* KO.G.QSN:\C.SA/U?$OC\Q[D+F$=!5DW'S-ZY?AB["),&DW:
M21,&(. $..DP3H2-WND*3N#Z;="5W[SD3YI5[NJA.7IE4<"^]T:'":P/IUV
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MWOH-+WBH&]I5*JI-KKSO9.1G<$L%]-C6:G!+N[)MA,V#S=L@)D=3-6%R EZ
M%^"E?WB!T[=>92ZF,R](II1=,9Z0_[GX?'SYQQ7OLQQZ?'8+[XR,<VEQ5=YP
M"&'@8.!@X( 7X 5X@4,HGT/X)6,RYZ/ZIE[$O<(@HU,X?T*</V']K>'\P9CU
MSYBA=0EP ISL@A-AAJ8K.(&S]X:S)\PKJ7/FB<PHW-B_6^A&;&]Q=P74,'[5
M*E#78+DPCN)*P[;(#S@#SGJ,,V$EU'W!V8%.JMI9+_7LU:#>:E1KW5#M'ONL
MABWPN/I@07<E5QG#?>2SR6OTL6OXGF<DFP)[SNXJP:X %U %5&N$JE'51A50
MW<4#_S'SF(36OG_-SS_]F*<?;SQO=O3-OZ7C/*1?)H]>ZT7DQU-ZY7V_9)[K
M)?7CR _"H&A)><6_Y(H)YSB,_3]_^>M??EISG>DLC!\H_4:3N\"GWVZ]A![S
MWD$G\71&H[2XT"AD%RA^^C+A7W$3,6&,OS+AQ.Q]:98^?@E;J8@OQR6=_/SN
M_)07_?QN_'%U^HX$8_8+S\\^JHIZ9AP?*^;)R>G)R-&/=4O57-MV#=,UCG7S
MW2\OEG=UJ:Z"*4W)9WI/+N.IMYE<5C[.%I9^O)V/0E4UY?TS[;.8JKU4G^)U
M$#'NRHYTKHMUZ-/5+263F,GYGMT:*=2#I/ETZB7L?2E)^;I\O"Z:.ODK*T/H
M=_XS)4'DA_FX:/E$XCSAZU#L8XL\VY2/4^)9N"E/PPT*C3EZ4VW?DM\.,G]&
MFLI2Q@N9\M>K%XWB9.J%SY9%Y>]YO/!<&CX-P\5[?GZGO"M>,U+PEZ_+:\M]
M,,YNCUQWZ"BF8CF:QA11<<SW2TICK!-ZLY0>+7]XI2I/M[BZI7YB*VWM6.#=
M=^7S.S39+6WEP[6,/?^\>N#'M6:_'@_?V,?U6K^^7(BJ,0=WL[M1P2#O_=W>
MIX=0&YB0WHIYZ.=Q\B3:[)8^O?B#>DGZ]/*,6:[QT\M3ZM/I-5WYL*X.J@G$
M5KA$+4+!^N7[<!$1=K&0^4%IF?87CP^F'P@,H?';+<O1/(:>QQ;7+PEW^!&Z
M$!:Z$*:IG53(C2HH?.@.5! J6$X%=TXF1O+@^H#()4V9#^;?%J-7QO2.AO&,
MAS":A+8426^'GPC^E[#0[S;_IZ4Q\C4RLPUQS5BE4"/D=,E[*%7CF5-M?"Z,
M=%K.+<7U' /51B -D 9(HPQI..*FR7:%-+![6J\KWVC(/G$S(#<THHD7%KLH
M;SP-HB#-^ 3+NS)9KH_/IVV+ 526T"H!"-?L"EP39?<P\!4$V[8!K0MX*JZG
M:BH*BH$4(&4'I-CBJIZZ@A3X?QNCYUF2+^<!^;=><D/+]%G:W>-KK"Q? ERB
M%!_FL&7FL.%<KW9.--E5:)VJ<,! (<"S0G@*#&8"GA6ZR-TM_/^67V=QYH72
M!T(7^ET4QKS=GT("=*_QB57+K2%,NKN4X K#UNZ; =8F*"YR$<77^@)CP!@P
MMHHQ@:'97F ,<=OUFG3BS0+FDO+R^LTUWSXON4<PMWK']8-;WR:USRVJ$&I"
MJ*G*2+"!6!-"P<"GM/A4!=;6 )^(!>\1"R[37ZF(&A=>>)%6NWA+-1XYXLBK
M<61%8(=)Q)%AJ!'CVCW]T'&%)U0 8\ 8,+:",=="'!EQ9 &:-.\*6TPTH$6G
M6(2+:P@7&UI].8>(%\,$(QY523S*%-GK!?$HX!/X%(M/$ZG]B!>W)UX<T6S1
M=)]X698$U_F\HWT6D^,@OJ$18>[ZL!J-%C311/YHJ4QM\0X>1R8DJB%9#YMU
M 7U5?-[<'E*71H<1C92WO58UM"J+YC7:G&MGT7:1%N=$J%?FTJXC0EFT#GP'
MO@/?]9'O#$5< U3PW8NMNH#I@F*G FX8/1AE0?;PKV!,+Z()GP''+W5)[VB4
MT_,DGIY]SV@2>>%)GK*%I4EZ_/ UB<>YGZ6C:+RXM5*C!T?G^KFNC(Z/-?W<
MM,_T<^78F(\>U$>Z>ZS6.GJP"(Y(,7MP(?.47#^0V5S"A"WXT_S!,?'2Q73"
M%',#%W,#5441-RE0MX1,"E2=1N?%6:T>=G?8Q^TVWSS6'>N.=<>SX]GQ[-(\
M.\;!5C(.5C?E3B1H=!PLR6XI*8:_DF+F*ZE_U"LTN/*!QDTEIF)*:R?CZ.(4
MLP/ZMU'C,)05&M>)&:P52K9%=GR]U!L?R5Z!U&75\']$04;';PI9MEO^EGE9
MJ4)Y& +@1K02\MD8))ZT"CC_BI/P;:@#-\!-M3IX5;)9-G00.@B?!SX/<-.\
M$L+G 6Z &_@\T,'VZ2!\'N &N('/ ]P -]+Y/$TU8*NAIJ>JY)??\C +9B$E
MW_R0)G$:I.3#;]]^>+NP8E^U%IGI<L@JM($LFI1D3UBV1B&V07#2" L:!XV#
MPUA&L: _T!_H#_0'^@/]D4@^T!_H#_0'^@/]D5 ^+6^G6U5 ].KLY/SB].QR
MU"0.-P8*I)5=I2UL#^A0*ZC[6#T2TP>:*[+=?[5:U'R;,00M)?(=P%F]Y"Q7
M4\!88"PP%ABK)8QE##057I8XS@(UB9>/M PDEG-:32V++9MJN4-#E$# &> ,
M<$;'.<-VG:&PEE=@## &&*/CC*$/7,L9JN ,< 8X YRQDRBT@:LX0PV< <X
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M5USWE:[@!$>O:W5E].GKY9=/%_]=!9SZ%7O65#3]$V:U</8#_)7$GPGX 7Z
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M ^Z SP'> &^ -^!SR-+YIKN!D7E>65'B,J;7[++4SY/J!F7V,2@'NP7]@?Y
M?Z _TLH'^E.=[Z0Y7?6=3N)D%B=>]LIUVD?SMG4&/7CW)LLN11M8ECYTL$,!
M2U?51;<S6,&.'G@!7F!;@!5@!;:E+='B[NYX?N6XC:9\UAAV.SM:)-76AB80
M!HL$BP2+!+P +[ MP JP MLB"UZPV]F4&Q,GV8UW0XD7C4G,F[$0C]=;$]ZQ
MEXZQ!=I-C*:E#FV #D8*1@I&"G@!7F!9@!0@!99%#KR@-&![:0#OG) ]8,.S
M8UQ.X#C6KJ ,5@E  5  %  %[AOP KP +]CNR+7=.65_N?/X8!!V<U&6>'ZI
M-G'] YFE#A6@"]8(U@C6"'@!7F!8 !0 !89%"KQ@F[-!9[Z&7C1/8TO))$[(
MF$YHDE .G^F,1BG; <51%:BK8FB2E*C4#7$YV=N$UA6XPKP!:#*8/^ -> />
M8-@ -  -AJV%>#MPWV<87=WW7<69%U:C33K3IG&<\T1!85"44(+">HWO++TV
M-R.W!Z;IB(OC;I595P@,#@.H"=34FK13\!)X";P$7A+D,NGZ4 4U@9I 3: F
MF:BI\HA4A^GIT/XZ'8Q(S5_RRQP%&?M:?_X-GP+O.@@Q?0K37VJ5#_0'^@/]
M@?Y ?R24#Q(YJZE7JS9#6D)Y853PRO54'?/%8:F:M^0@C1:1!LI-P!W@#G '
M' Z0!D@#I &'HSGN0%ADXU#N*&-WS$?4^7&4!F.:%"6M)+YF-U+\6$E;G]X4
M)QB6+<Z4]Z4L :8>2)/!_ %OP!OP!KP!;\!;XWB#)XD"5Q2XRB-!I$278B]'
M'6JU2:PK] 5' <0$8FKW-@;T!'H"/8&>FL\$ "^!E\!+X"7)HU$=)J:5<-2/
MQ:S0M>]?\_-//^;IQQO/FQU]\V_I. _IE\FY%R3_],*<CHK^U*-HO%(1^AOU
MTCRAXR_1)1]#FC#].O;2(+WBWWK%1'0<QOZ?O_SU+S^MN7">L8_^%D3!-)]>
MTBCSPJ_>PY3]D)['R9=9D2,0W7QB7T%?7+ HKF O+NGDYW?GIYJBVK\;?UR=
MOB/!F/W"\[./MCW2S_1CS=:<8^WD1#\WK1/-M6W7T,_M4_7\W2\O%G1U<:Z"
M*4W)9WI/+N.IMYE'5S[.%)M^O*4%;:N:\OX9_(K,CI<:4[P.(L;3V9'.WU '
MH$8IB2?DE2*)_(I3ZM/I-4V>#(:N#@A?HTJ_=D"F<U4B2:%+O'?Z-,@*?2(Y
M$W-"&)(^^E[DT[ 8H!L6FC4@$<VX4(*(?8*221)/2<IY8?Y7WH^=>OXM?TMV
M2]F[OV=DPBM\'A@\4^)%8Y+Q,"?_:T*]2<:^Z9[]1#S>S#UDYGA+X?1;6K2#
MYCVSDLI2T1:*Q5^O7C2*DZD7/E=._I['"\]G"S,1A8OW_/Q.>5>\9F3H+U^7
MQ\Q],,YNV8_LF18\S/@U]&8I/5K^\ HA3S>U&E1_.K-QUIZ@[!Z7G]^3KK[?
MSOQKS<SBF0[[N-WHM^/9\>QX=CP[GKU;SU[N1+K")(>JSJP=L1ZRLVR <S_W
MDZ[C<#R__H>+B'F68<ASE'\HL17=N8%  U)_6](^<QQITH2LV2;!0?1-?'83
M5+","@KK0PL5A KNI8*:L!;M4$&HX'XJ**SE+500*KB?"@K+Y(,*0@7W4,&K
MQX ^%!&*V*0BEDFC1VOC]0>$BY/F^;$?F2V.FE^?A=8([6O/__,FB?-HS$_#
MXN3H;^/BWU+WB^.Y1JMF2@IZ\12::>O7GNB$ETW"VD70%<BSEBR8-0*U-8$I
M,=(K8),)?%LUKL=F'%P(+I2""W5P(;@07 @N[#L76L[0 !>""\&%X,+><Z$E
M<)JL] H(+@072J**X$+YN- <OJZ\ 1>""\&%X,*><:%FJP)G>4NO@2##OI,A
M^*XTW[6,TBS5'@I+%Y9"CR3NU-G9Y)A/-$V/UI? DP_J7G5/A[;4%6I 9.NU
MNP;('S1#X&'FH<)]4MWJ*+,A*U-&F^'B[.GB@ 8.H %Q\1K0 &@ --!*&M %
M'F&!!D #H(%6TH#(#$?0 &@ --!2&A 7Y ,-@ 9  VVD 5N%-P :  WTG 94
MQQF:X &)>.#0<T6GJP>+GVGVV)C[>>5]-?HK:(R$% ?A,B54;!-RCS(N#*<J
M)ZR,7+N2D0$/JJ(\,O B>+%>7JQS5H\4B@A>!"^"%\&+6WC1J&JS#EX$+X(7
MP8NMY47XB^!%\")X$;RXRHMZ50G@X$7P(G@1O-A.7E1==RAL/!B($<0(8@0Q
M=H$8#:VR=* ^$N-*+L^/Q3CT=>^O[<9*#61?U6V5:_+JK;V<T$XVW>,;L]*5
M7=#Q7-NJ&EK+GK&,QC&$T8^W\\DJJJ:\7UDAESW\,TZV^%.*PZV[*EPA&OC3
MCWGZ\<;S9D??_%LZSD/Z97*>9WE"%U-.+FF4>>'71:K5>9Q\F='$R]@3?BJ:
M.ESQJUXQ$!Z'L?_G+W_]RT^O+_AK'(_O@S!\?!N3<,2!>TDG/[\[/]44U?[=
M^./J]!T)QNP7GI]]U$_.U1/#')FN>ZX=CT[M<^5$<VW;-2Q'L8ZU=[^\6):W
M%'23?KZUJJL(X,NX0C3_SM,LF#S,?Q5$S)'(CO1'D%2<!W=U2QG>0N;$L+LC
M<U#/DO@N&+-']I@>AR'[>W+O)6,23TC&WN[?>M$-^RO[HCA/R,UB.<BU%WJ1
M3X_>U*;=-'^C7)_!05G*<2$T_GKUHE&<3+WPF>A5915"I3BLA$;,28EO"Q13
ML1Q-L]CS.>;[I1%CC!!ZLY0>+7_X^TN[LY[S'IG$69L-O#MES6_0:GCNN='F
MN>GM>OB]YJ[7OZ&J=:ZZ@ H!NX%9<:V8##=*N;4XI3Z=7M.$Z.I@#Q]C=TUM
M8":?3)J\?@T^7$2$72P,XBC=JU/6H9,0*X[4[-[.LGF4/-\=KU\O[K>*VBW7
M+>&V!<J$Z7C_5'FC\NZ<-(%FA^OW8LN-[8!<TYL@BOB.C%G1!^HU.NA7_G["
M,L5_T=&ZN+H^L"P70_#J.1+#R5<%K">+8NUC283169=9:^ZW,)[2A1_?-Z\U
M\C2KEC"85)TZG87!-(B\C.VYN>OV&!OWPC#VO8R.21874?-;.HUGMT$8>.0Z
M3X.(IF4*SW=O4=&W%A2Z:M0P20,M)N"<5 '7+J!R14R.IFK"G+A^6L]7T0^U
ML[;S(O*3HA,+,Y%+PPF;*" _=:!9=@U;\:X % 8-!NW5]=2!H@D<WML5K,"8
M;="7+QD3>B76"TT'GULW18(.Q%V!,TQ??4#M A[G,1=-'1IU0;!KD9=RL1:<
MG&\[.:?16/29>;UU4]*<(,ATJ%YE455KSZ_655P-+%V3H>9*&BV&MR3OL7PU
MQ"J+YC5Z;K^S:+M(C)4D(&VE0EGTKO$2U'4_KRL,?%7'M[[<[R*ZHU$6)P\G
M>9*PGYZ7".Y0^^?HY[ICF_:9H1V?NO:QH[GZO/;/.%<,S6VR]J]8X<8*__QX
M.F,Z$&5%M4:P%#3Q$DK2?#KU$O:9,?'218E@BMH^U/;)6-XFV<=1VU?*KJ&V
M#[5]35?@2*O)Z]>@Z[5]D@&AG>5[K8X<2%:A)YE";E1!%.$=N"^Z].[)U&,+
M&'BAL%E@."% V5T]V1"6)O L5GH-1'1?WN@^@O<HNMN43&DKPC-&FM<9B?,L
M.^NM_2M._N2-Z&9)[*.$3H@+82FFP#[_R)CLO9?0OV(!RW7$0:@K2($)6Z\L
MYT$4I+=T7-2\P8*)V 2;=@V;X*[@$A8,%FSM#DU8[E17D()BMTVY1''FA4_Y
M0X)W]DB\1^*]5#&L-1)W-1-I]W!89'%8D':/M/O&^B3H;E7EH$B[ESK#\R4-
M+O._G3U2VAO,)VHVLTUJ(4+A*E"XONL5 L.O3.G\);_,4<"VUH$__X;C^80M
M\NV6THR<A%Z:!A,F&]YN].W2G&YP8>.8EIS_&I>/Y)P'GI.,YXKK78B.&PH-
M"THL/5D3:F7>I*Z+W2D:$EY@!27V$B3FH-HS7V4FEV4$3%&'.]?AX/ 4WD^:
M%>.PB<>;E_'&H83M[&B&9" !UEW3!$YW@7'OO7'O7RZ0;HM#4%> @E0@I +)
MMP)(!9+ X4 J$/P5B?P5I (A%0BI0)UA/*$=.-]NK;F^'>=O7I:SAPMH^F7R
M*8YNKF@R/:77Y=MRNK9MC%17,8[/SHXUVU1T9]F6<S2R[//^MN7,"A^:6?4T
M)3/OH8@-#0C][H<YO^%B?N@DB+R(M[$D7L*^YH;R=PW(.*>$^0(T*=XT9NNR
M^O>TZ.R)=IXK=[YHY^D,#=T6V,33$-+$TU&:[6/IR-_'$MT!T1WPK260I3O@
MZZ:9I$S#0)R>;!C?KJC"8I,((4F<4]+:K= :@>I#K7*12J-_$D?AN\R*92:5
MXNQX U KF&+>^2-D8'(3)K4R<TJ!R4W-70:F(G+D*_#86SRJP"-L)# I%2;+
M[(R R8TV4H&-!!Y%X%$ODI)Y3C+U)ADM,U1Y=WC6&4UN 7QUP2[NON(%O.>*
MY705WT6R9C5JAA1-I&A*2[ 6\X]$!N&1I+DC_1Z>LK1;^M'ZU*7/,6^4X86C
M*5N*C%W@2YZE&?-OF*J?LL>_\[+@CGZ-TX"_+RV=T332=<VR3D?'Y[HR<@SU
MU#:U>4:39:GVJ5IK1E-18B!-2E.T$#VY\\*<\J/P29RP.X^(7Z2>^0_\%_=>
M,B[DG#!QILSK]#)RSSQ/4ASBTS$)HBPF[']L16]H<0G?2S/VAX3>T2BGBQ*Z
M&4W84D8WA'Z?T2AEOPY2##3&0./VS/25[.,8:%S*YF*@\1Z[[>;&9B[] C)W
M#'8U"5+<^RA]4HIX\O3S,M/LZ3>8T]S \IPOO)R3A9=S1)";*5UN)B8W8W)S
MPS2.R<V'[S//\B1N$L92Q-%E"D?VIX6<.G!L4US/)RDT"77;\M9M'[P5DXN%
MQ/).R^FEN)YCJY@@"<=G-V4YY@<BZ2V9<8O!+DH3=H&;?3QV)%*]G"2I#,M4
M4L"JPZJ+05H7 %55?G!7\ )[MEYEOMT':4HF[),^6J *L&*.P&GD,&(P8C!B
M,&(P8EM4YL2+O''@163,TV:JR9OOFQW3!3;6A!V#'8,=@QT39,>ZWM%[>[JN
M,&9&'4G3![>H(]EQMLA =47NK5%' H^FND-C-/NN[,@9S;Z%'EBCU?<+C_3P
MNKF#:M_6E]-]X5T!/L?18[G51>3'4WHVK[DJ73UW:FFFJMFGQR-M=#)R3A7'
M.9Y7SYEGQY9ZW,]^X"?Q=,8TA_?NCB>+X7!!(6?R85'=]L. 1#0;%+V]4>36
M4)&;J@FI<C/U9@N]&OYZ/'Q/'AXE?I64^*DJ:OR*5^L*L9Y$RZSHTXL_F'NV
M4D1WQBS7&'5TDM71H6H.57/=#MV@:J[:JCFH(%2P&A7<.2<!J3+K8QP717>?
M-%L$-II$M/PG+#*=$^(8L+BZ[=20ER2- N*(3]XC/IS@55@TVEK**JYGZ<)'
M\3:O,N B<!&XJ'5<I&G#,K-7P$78.6[9.2Z.PO<)=J#*XOENYH-F*D-A0U6W
M2N])V<J*3RY]7"/),@<5<#4$P;4+J%S@T!(X!*1K< /  +!# >::XN)V_<87
M_-/U OS58^__$,9I^@.)(Q)$=\Q9G?)LSB)G$^ZJ '=5MX8ZO%5XJS"FC8:7
MQ;FJ70G: "? R6NG4Q<76^F:48+/*4* RY$3]+M_ZT4WE-PP)S2=>Z$T_0&.
MIZ@A@C6XG3"%,(7=-84N3"'"FX!799ZF)JXBO]_X@JNY7H!%!X#J',HZ2[)D
M@_"Z2*>J"T^;V5^X76$"1$+EL+L-5R;7:)=56URL=%>I=06MP"?P63D^!89H
M@<\*_>JN]UQ]H]M3-?J)9JMHMBH'$Z_-2U9-X25,!XB]%&5W2//A?8GSOAK@
MYI8J8LVDVV5N7;*I72.;]HHT09.@2=!D-VA2U?0:^UJ#)G>)%1S>#;M,Z^KU
MS:]_S[V$#UI^. \B+_(#+[R()KR[,6^?7;KWM6.?'CNCDQ/GY/34-LZ<4^5<
M7?2^=D]'ME5Y[^L=/O.,1OO;Z%E3A#1ZUJUFV_TJK6Y6C(?'P^/AY7YX-#^N
MHOGQ@.=UTUE&F.="TEL^\\&;C_1HI"UR!>OQ]AHTV$$\2-*WSUUDN^.%CXI
MA/C3<N!F9RW\1MG^9PS@ #@ 3BDMO+H-$N &N %NRHYZR9/L%L !< "<<@:'
M9YVU"C=\=M.N2M'ZD6-U)?B4'.RS,])ZA*0/'H[_&^!R,;+:_3Q58O4C'Z[9
M?S[[;PQ5A"J"":%^/54_\H&R_R;LOQOVWRW4L9_J*)?PT%%@?3K8UR0>YWY&
M$GI'HYR6;I,J7 NE:,TD4[G2 =5(,F=[KML'#W1'$=AQ009-:K+)5YTCE-MF
M2<%;X"UQO&7IKL"D=1DT";P%W@)O=9ZW-*V&2;K@+? 6> N\)8ZW;%436$LM
M@R:!M\!;X*UN\Y:J#'33P$810?L#@_:7BV ]F23QE'A1%GP\.=44PHNLO1G-
MF53(+(EO$F^:@NO =0W(3#>4H06B@X<&#PVLU1[6<FV</X*UP%I@K1:QEJ%8
MB.*#M<!:8*TVL99J"AS+(8,>@;7 6F"M;K.6.C!-=ZB!MQ#"/WR2WV/6/<@,
M9-: S%P%'A@\,'A@(*T6D9:AXF 1I 72 FFUB;0<@2,N95 CD!9("Z35;=)2
M;1>N%E@+K 76:A%KZ1:B6HC/'QJ?GP\$1WP>5-9HH:.C*J@7@@L&%PR\U2+>
MT@>*[:! &[P%W@)OM8RW; 3JP5O@+?!6JWA+5VP$O<!;X"WP5HMX2]4&FJT/
M71 7HO4'1>M_3>(TY2UO)D%&/JB-CIR00@G!9\W$ZPW-0@,)^&'PP\!;K>(M
MWE 518W@+? 6>*M5O*4@7@_> F^!MUK&6RYX"[P%W@)OM8FW5&5@&8C7(UY_
M:+S^,\U($/GQE(+)P&0-R,PV;+1,A?\%_PNLU2+6<BP-NT:P%E@+K-4BUE('
M&K(BP%O@+?!6JWCK@VI90[TVP3TAL#I1-J1]PO(Q07V@/E!?]3+3!I:MP&5#
MG%]8G)]X698$UWGF78>49#$Y#N(;&I&+R!^"Y$!R#9T!H+TA7#.X9F"M]K 6
MS@# 6F ML%:[6 MG . M\!9XJVV\]4%S[1H:&>(, -0'Z@/UR41]VL#47;AL
M. ,0=P8PHPE);[V$'I70JL<GTM_)8QA:;PQ@1:%QT#A9! >-@\9!XUHA.&F$
M!8WK@\8=N*M0.[NM./92]DZV5XO8?:=/6PLD&B&2(EDD11\:F.$%$XOP+TBK
M/:1E#!60%D@+I 72:@]IF4,'4W! 6B MD%9[2.N#.C2J/V9'BA&8#\P'YI.)
M^51UZ&)*-(X"#CP*. W"/*-C' : \^3G/'UHH.@8CAH<-9!6>T@+AP$@+9 6
M2*M5I&4.;4RJ &F!M$!:[2$M?AA0_1$F#@/ ?& ^,)],S,</ S""NJ;#@,Z>
M!?R+\ENEXX\>$X%W0^?G "G)4SHF[%),)GX>>AE[*A0A-VTA8%JA<= X600'
MC8/&0>-:(3AIA 6-ZX/&(?.HF2+DQP?6ZM36;;HI0:Q 4TVT[H?!J--@ ((O
M(:@.<;P*" *"C4(0Z?. ("#8* 1-0! 0! 2;@Z"&O2!".8>&<BHO(@. WPCF
M8"<)&PH;VJ@-1>X5( @(-KJ3Q%Q/0! 0;-0*HGT<( @(-@A!'1#<)YCS8Q&=
M6/O^E9]7GHLM$_UX6V3+'ZF:\G[C#:Y\YIG2*4RC"N$$$</4_/7J1:,XF7KA
M,[U4^7L>+SR/I_@T#!?O^?F=\JYXS9;#7[Y>(]*K8$I3\IG>D\MXZKV"\WTP
MSFZ/7'?H**9B.9IFL>=SS/=_OXZ3,4VX+H3>+*5'RQ_^_G*-GVXQ60M:92V2
M=H^RS>]0M]YOU\2UZC[_O'K@QY5FOQX/CX?'PW?ZX<L=-BRM]IRE%WZ+.OM.
MTC@,QN1O2O%/JCHV1ZQ7Q"]7O+J?F]#K.!PORL(O(L(N%@9QE X(_>[36;9Z
M0C%E7DZ6EJEYWCT3NO[U>'L-?.9MT*2)53@/DC1[4\:RW?'ON9>PKQ;E46/K
M!MSLH87?J!]'8P 'P %P2FGAU6V0 #? #7!3TE&+\R2[!7  ' "GG,&),R]L
M%6[^H-[.H-DK'B%3O*&28YCU<M44M4Q6[<Y@$R/.!62+0X57>&U7<;5\^B>=
M?-JD7%*0XH= 6/M#J!_4;P_U(Q_^#16$"C:K@G^R_T*H86O5L(2F57\PMZ?4
MT*AS?;W5UR0>YWY&$GI'HYRF Q+1M\_6*H:J[ (3UE.X.EG4DC4XWYT.=,45
MU_R@*PF!,&'@#?#&F[QA6):X#&/P!G@#O-$+WC!U5UR;"? &> .\T0_>4#1Q
MW2W &^ -\$8/>,,=.*H-WD P=3=UN5P$4<DDB:?$B[+@X\FIII",+84WHSF3
M"IDE\4WB35-P$#AH)V'HFBNNMV57& B>"U@#K/$6:QBNN%9B8 VP!EBC#ZS!
M=CN(KH(UP!I@C3*LX<#7 &N -< :)82A#G350&0#L=7=U.4+#Z(^IJF"9< R
M.PG#P?$-7!.X)B"-,L*P7>2F@C1 &B"-,KDB#D*G( V0!DBCA#!,!=L3D 9(
M Z11ZKS%0LTMXJ:[*4O12@YQ4W!,V8H96[/$3<+K"LO -P%O@#?>Y W'-9 -
M MX ;X W2O&&:YKP-\ ;X WP1CE_PQ8X+AB\ =X ;_2 -U1U8!@.' Z$47?3
MEU^3.$UY\?XDR,@'M=%NQK++"D3SS$$Q5!T\ P<%#@IXHUS+,DU'<@AX [P!
MWBC9(M4!;X WP!O@C7+[%%='.2YX [P!WBC5(M6UE:$*WD <=1=U^4PS$D1^
M/*5@&##,;@QCH94A_!+X)6"-<NV%%,-!F0QX [P!WBC'&[H"?P.\ =X ;Y00
MAF6@TQA8 ZP!UBA5RC^P7'-H@S<0/2T7/25>EB7!=9YYUR$E64R.@_B&1N0B
M\H=@'[#/;I%5&^V'X+/ 9P%KE(VLNLAH!V^ -\ ;)2.K&,(-W@!O@#?*15:1
M_P'6 &N -<I%5FU%PRX%D=72D=4934AZZR7TJ(3R/#Z1_JYV8NXE&7?,6$%_
MH#_0'^@/]$=.^4!_H#][R^= IUOMK-=][*7LG6PK$['[3I\\;V0W( )PL#",
MH8'R#UBRQBT]2*-5I&'CA!*D =( :90B#1Q0@C1 &B"-$@>40P5C"T :( V0
M1HD<2FOH8LH\PJN[:<MI$.89'2/ "C*J*,"J@XO@P<"# 6D@P K2 &F -"HC
M#708!FF -$ :)28:#%UX&B -D 9(HUR %4$-L0'6SL97_T7YK=+Q1X^)P+NA
M\]AJ2O*4C@F[%).)GX=>QIX*M602,W3'+!CT!_H#_8'^0'_DE _T!_J#6C+1
MSGC%M62/#ZQ5H)3;5+"9^)F*.<*@[P/HNT=(<3$!$T@!4F!3@!0@11!2K"$R
MO8$4(&47FX)&#P@32%(3T4< ND.<F<-4P53M@A28*B %2 %2@!0@10Q2["$:
M20 I0,HN@0(,A-@<*/BQV/FN??_*SRO/Q>1//]X62;!'JJ:\?Z89!E.#S0_N
MBEWDQ\M]4'\@OR9QRO;U23P),A*DCVFX;-?OI6QCGWDA2>@=C7*:DI"R]_IQ
MFI%X0E*/O1P0^MT/<_X@Q)O&;/'_U\N"..)O\/S_Y$%29/=F7G03\$B!EZ8T
M2]\.$<QC"CX-PX6(?GZGO"M>,[7QEZ\7(EB58A&(697)53!E=_V9WI/+>.I%
M?R>;E&)=V.<^&&>W1[JR"W<]Q\+N;RX=>2J#I%<:]^+IGW&5Q1^S"B+YX/UP
M,(WPD-M!3][T_.EH3**=QE$S#4U(=DO))$C2;$!2ZL?1>,!^%23CXCJ3.$^R
M6_*?W$LRFJ0<:)JBVOS:#(?LX@S,]&/F?2?^K9?<4/Z&5PM0YCG7/MQ_Z:8^
MM C[4,C0?M#UM\EQ4,7M:VS'U-Z[UY6:[K[0N&H>P*E)_ E-9]3/@CL:/O!7
M<]O&4,=P1/XQ_#8LGI&]JS!J]W$2CDD8^#1**;=_Y#Q.[CV&O:\,35/O_TNY
M-6.FB%TR9Z:1&<X9XRIVY3G^N!W<[1.KMW)U=G)^<7IV.=HY=K[1$X'Q[)3Q
MO(;QW,-XSJWFTD:^-)'I:QO)KL,8@.T*_-OB^\;,XPWCV92R)Z+?9YP,JK*C
MBC)4ZN%R+ATO(OELDO#+SKR'XOFX#'_[QG[-O'8N/#^,4TYC['DY17HW":7+
M-Q;.?EIPZ9(DR?'%Q;'B:J N4-<SZO)!7351U\I&^R-S+WR^2]](9]70&)-V
M\S1VR7AJ_#!GLA46XV(MX@YDEC.)>(RS,O;%J>?S2 5X"[SUC+?&X*UNNUQ6
MO52U^F1L_\>NQO::<<0D<.MEY)KZ'I^CZSTLI5M$?^)DNDRUNHW#\2+0$WP-
MV)<5Y,<H;OR,X8J $;M.%G )!G-?[FO!=AKY^NTK>ZB<D2._)7AL8+YUS$?!
M?&]0W> I-OLL!+ODNL';9!?%[!NB+(D9[S#4\IC0,NA4A3]FUDQR*V[89YHG
MP72:,XICEV);QELONJ&+]XE_5M5\7^T#,L\Z+UQ%_CA)_."%/'KG96RAE[3-
M_C:+,_;\ 6-XIDB,O'W^8W%&5IR%L4MX43[UKH<'E3&#?SO,OQ/P[SXG96O9
M^(F,GU-QVJ#CJ3EU<7)%QS8U&Y77FWS^7![A=C2(\GFBP>)/+P]ZV"J/PC\I
M<Z.W9!N 9WO'LS?@V0IX5J(=OF8V'XR\B*,@G6_4*??U%TY_S.04,?@S=0F]
MZSB9D]BS0Y9@S!W)R4/Q/H_]F')1?8R9LL11[H<TSMA;R#C);PAS*L?!N/!%
ME^N4)=3+EJ'>;[_A3!GT]YS^;D%_%=!?%9OX@6K7E66UFH["'W>6Q'=!RKXU
M7088B\>]8O0^\K/5=)<J]O3_Y3IN70^^-$5Y-*;SI;[BIT-!0<Q7C*;Y0X-$
M0:+/2#0 B>Y]2K0]G=5:<2O9<G(H%JES<_]R3-E/?C!WG9;P+5+5.1]5$DVM
M+5VQFKNW6QUV4(V:W/F7002/1WB3;)D*-69*QTTBUVZ?\I,U1K_YQ/.SO'#O
M^>/?>3XSH\7;TZD7AA]3!GA*KH,XC&\"/WWQ$?93$ ;9 P\MGWC3ZR08W] !
M^6W$O_N>&0?^_SR7@;Z\^GUQ-)BS/W#[483:OS$8)G=,3L45AJ^7 C:KUS;K
MW[!9>]BLN:UZ[O=;4H8]['K#'H\9H!/*$QB"\5/8HR O]K3\&(S/=^"$%<^R
M!7<N)%)(Y^FPC'T%^?;UXO/EZ'\0LP!U/:>N/T%=HF(6<G)7W?D*3VE8RYCM
M."^>_RQ(O>!E-"2(V![DJ;!UD5>E$[8$;%_"KWBF68H+V@)M/:.M$+15!VU5
M0TF&:=2T[7]9EOC_V![12Q[F(=>49EE('X^_ET[7TY'1?<"$];SH\' B6K[_
MIQ_S]..-Y\V.OOFW=)R'],OD]_G"A _G0>1%W'>[B'C&:D&05_PJ5TSGCL/8
M__.7O_[EI]<7N&34F^2+/3![P7:M]/CAZF'&_G82I]GCQXNC?O;BDDY^?G=^
MRN7QN_''U>D[$HS9+]@V^J-S<G*NFN>C\]'H[/SDV'+,\Q/-M6W7,,_.;%M]
M]\L+@+Q%DINPL6L?AX*%"\ %$3_%FU-H'8B[*G 3AO$]#RO,X97FTZF7L/>E
M\\*N10(,UZ*4V?(B>O]"\YB$S:(8]G%Y^$G 3>)-F7TL7O(U>'M VXYDY!?'
MHKN(_!E9*R\DS%^O?DW$%3%\OBK**L&7,K$EE(6)^B:(YC?IY5F\_,6\!4[Q
MF[E9==VAHYB*Y6B:Q83BF.__?ATG8YI\+ Z%9RD]6O[PBKS76^TGBZ"M;2:S
MN]6=WZ&IOR]K]Y]]7CWPXPU_/1Z^)P]?S@5=-#-:8'71P$F=?2=I' 9C\C>E
M^"?5.$]'K+GAERM>W<^Y]CH.QPM/]R):>DII&9]WY_%5#4C];4F_,E^UR?I?
M<?(G<[=\NJL5EN*N+Y=9] ?OB-"6#NC97P^_!C/*_<56@>?KW =/@1U@IT$U
MO.(Y%GN$%G9WKF1RGJK;K#^+?Q01]^2.]RC@@:Q3ZM/I-4V(K@Z*[7B3F%_H
M?K&)?J7X$DN9W4R<'/U-,VW]VEN$\T3+L6:QU=+Z=8W<='UHBQ*=-.J$=LJ-
MVE[P%'A*.$^)FP GC3:!ID!3H*ENT90M;OR7-.HDSW"^7FTCS^896?L$/?HP
MQV(-^@P,5(8?@.DO)5%C8KH84 /4E$2-JF#0*YRYG9VYK_,T]#)'?'U'V ==
M'6JB&?M)8\H*22ZE6B.OPY/18=V O07V7'&#- $]0 _0VQUZA@*S5P7VX)UN
M]$Y'XW_G:=%5KFB@.DOH71#G*:%I%DQY^[D!+_("B'<'L0D,PW["?C:@2QH.
M 8 :H*:LP=+$A3-AL.!T"DZ3%IW\)33=7YI$#8GR?G:5<T_R@C1QVX%MDI5&
M&YOT:.JIZA$F:NG<(7 H.%0^#A6VL0.'@D/!H>#0WG&H.53!H8UE//%F?_W8
MVU>9[G3M^7_>)'$>C3\N-'Q<_.ML:$X56**[37:(V0D0(N+H0/&: +NX[0M0
M#!0#Q8TD9PFL0P>*<7Y6T_F9Z!XO"\'I;&,WCG/><?>@P,4F)$BSAY0VHK%F
M!;;R2D]B'<I06'.M_64NC08W&DF&JP6V!=MVFFWGRN]HJE:?]LNOR6!=L"Y8
M%ZP+'[?M;+MUE-*FG]>-6-IY0M*F 4MW-,KI>1)/S[YG-(F\\"1/,SX?.!TM
M)G#1\55\'B>4"?.$K1G[)4V/'WZEO-/XC"G;**%>F4%,IFHKMCTZ.SLSS[53
M3=4MQ9P/8M*=DW/-J'40$Q_I]E)9GLUEXCBO(P:S9BY36@C38]?Q&<[X_T^6
M<[1(\#1(BUP_D)O'U2 >6X[]YR[M(,]G-DO:*4N+.2^*(FYHDJ8(&9ID-#LZ
MQVWUW!\\.YX=SR[OLU<R*4NB_6>M([2>N^G%WUZ-VGAU/D,P8JN^02?_&'[;
M>82J?&>-T@53H(+E5? L3^)9F=Z^4$(HH6@E'*6!!Q6$"C:H@E\RM@C00>A@
M-^?>]:CB(XGY!%B2S&/3*9DD\93017B:^,OX=)-8E_\$0Z8S.!RQ%5>W!VQ[
M+K!L3GH=1,Z"G*:]/CH$XY5FO):1FC9P#&/H5"XY\!9X"[P%WA(V=<52:G#%
MP%I@+; 66$O<D'6MAA8.8"VP%E@+K"5NPMU -PT0U\[XP]' ID+UU2,!+\J"
MCR>GFD+XT9\WHSF3"IDE/!5Z*N?Q@,0"!M>)X;J!89LUM/;H"M7!1X./!MYJ
MGK<4<!8X"YP%SFH19U71*4(&;0)W@;O 7=WF+D<7-Q=;"C4":8&T0%K=)BUU
M8)JNP %D,F@2XOCUQ_&+6IUV)OA++%J0G)B,5L,5V M+!CV":P;7#*S5;=:R
M;"3A@[1 6B"M%I&6@6Q6D!9("Z35)M+"J2.X"]P%[FHC=^F6@F-'A.\/#-]_
MBODC!G=T3+PTI:6&,X/-P&;BCB,US:IA&&Y7^ Q>&+PP\)8,O.4:#M(HP%O@
M+?!6BWC+!&>!L\!9X*P6<9:&+E_@+' 6.*M%G*4/5$<;&N"M2N+T!V!2+&<M
M1F1J?!YFX_SU>.O;QCU4(+>VR0IZ!;V"7D&OVB(KZ!7T"GH%O6J%K"J9("Q3
M7DYMT\A>C@:V,!H8HX';&E^#"F(T,)2PA4J(T<!0P895$*.!H8--ZR!& PLH
M/&C#:&#992CL0+;EYZ[%]>R!8BKB3EJ[<J *&PC> &^\(0QMH.FVN&Q8\ 9X
M [S1!]Y0[:$.U@!K@#7 &CL+0U<%-HL':X UP!H]8 UWX#!O0UAWA*[P!F*K
M[9ZM*KL<P4$KUU,'0KNI=X6#X+N -\ ;;_$&_!9P!C@#G%%"&!7TY05W@#O
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M)KS*"/A$HXO]&ETL6U,_@5L7U^IB:\_D?<0MA=<G4[N+@WN =Z<UKF4)S/)
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M."D2-V7*(.Y/@K"M"BQ/E$&-FLRS@_D$:8&TJI>9X6@89@/6 FN!M5K$6J;
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MJ?"RQ'$6J$F\?*1E(+&<TVIJ66S95,L=&J($ LX 9X S.LX9MNL,A;6\ F.
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M2&A Q5CGT9FG63Q;((U7X,L%7&=MKUDVD(J9=>A5F=,H$.*1E)[[X^ JQR2
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M#)'@&I5MKY-$MK=67HQQDZP C-*C(U#WXF[ SC!H+3F455$9\J@,0"XX\+!
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M,$!!:OT7MNV JA5&"AJ;)QAA7A4$O,^4(;?)59O\E07A>Q2$]]WB!X^W4L)
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M>JHTQLJO DK4G,?E4H/J_'QA+A:LUT<B]GGP50;,A[:#YB?%'B3:,G3",*P
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M&2BI#U34>0\-M?TT10%T;=^[)-RCPB]%>?6:A^"PGD^H05R'N<\4!JN-#"U
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M"1%8 WO:+Q*0;4NUX8-TKO60UII5:LOT[7=ZA\VC[C*H"-K4[9@1S</GBE4
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MM-LZ/>V?-/N]'C^[?732/GE7M9Y5]SQJ/>^:O?99[^R@<?SN\.ST[%VS)1V
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M^M[53AW;IF-'FU;CD;M-LWJLL/7-#_@P_70W1.GG7_'W]!]02P,$%     @
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MM$@/)ZXJ;$-Z$$M80KQ* 5PG^LP97\=]-R2BOCK7,!*@%_+)? Z:T7#%?!1
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M[)@-[]T+>JZDVV#J%N>ZM-Y<Y/">)B=?_6:4ID(_3X] H&>#-B^J^S7UKQP
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M0OTK]SJA?XX^7]S_.2UM':H\_=<)_MN)E%MX2[Q"O__M_P-02P,$%     @
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M7F??8>O@CQ$'_8FJ&AS:U3= %_=%?N-^/P:3\UIJB,C$*NK $1_ F)!!*6F
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M,0W<_J QE,RJ[6,?W&1:XC _SA<EN?]UPKVW99CC)&TC":/>.(WR1(-.4B=
MQ!2 ^B2)S,FI+I7EZEB__6%E"'G5CHF_2B$ARG$0J O;1\;WD34Q:JUEB)"%
M\R 5T6 ]IZA8DS49=V9#KSXKIT=T]"NJBR]0/ENG'W&8OY4SW\^71/[O?#);
M?;]>3F9I>;".X&G*1G)FHK$9G$?_7^$8P/)P>Q,U!9E5JXN38^;2=)_RX:15
MU1]NZST\_+BAP0O'C8"$/C\P3@BXB)YCH"DR8X/)VO620W/5..A50.-;#*V"
M(FW(&^*\%1*%::3T(+Q$:UL[!U8:SWS&G3 \$ANSFX<YC*SJW?V8OT^+U:>7
MT_+<W2P6 _E]N?-XW!$]1M90*\JZH"4$E" D'L!26C*/0H@T*&Z[W"&J:5%V
M0D;/,JH7BEBYV=L)(GHK ^3VA]]WJ6?E'9Z/D^FQVP%MR!N:$U'$," :%P61
M# 6<6,*=D[B<;%2>=<BZJ&E5=D+(0+*JA906:/@\"LN=$L$E]*ZI YF*+@R&
M@W0QVVP%I5W>2*EI5'::\0[R&,%L;'^"\O7WC?5,YW*(&(75H)C&;2]D#\I+
M(QDK"0+])&!?]WSW)9Q*=1<.5!QXZ0K;[])J$H8ONO"%A]<K_'-3?^%%+L&[
M'Z?SC^-5/]@?17R9%I-Y?#X+);D^/4O;_Y\=P-W?3!,C0PWO%5"2$2W:./ .
M'0Y/#5.(1.G,B*]NE=@'#@/MG \XB?'[3[\M$X[A<]&<)V$U^7 J*;M](XT0
MPM-R:38+[7#%) XDH!4MN<XZ">?-]1]X##?]\XIRK>B=Y,GJ[G/7^WV1W4>-
MBRYD(A/H1"7XJ B45Z# :,&9,3(&=O7WT(>:N(?>R>52JY?U\WZ1PF0C-OS[
M-&UF9!:?W)0[,/^S^?W1S)_3Y W7G@1>7B:-IMC76D/,T8)S4CEM.1?IZF\+
M5<+,0/*L5ANE/#?\/2K66"[2IMGR%'[V$S2)IQ2R*7?E+ $AE0;CI 7IB3.)
MZ6#DU<<W*B&F-PG6SC/<WJY^XW[_X??"=OH^S5(^>DOY!&63M8R$>EP-Z/*!
M)SI"$ [-?Y<48;@N"+_ZF$<U/=.W**LZS\730REMN=^Q?LJ!WD>#JI0Z$7DJ
MS^4Y[(KG4E12@>?!*6TUY>T2TTX&38:\Q5P),WU*L5ZH];[!_WSV\(#Y:*CU
M-#GZ$,)GA\8=M=I",,A(,LX"2H42$4@4N4,B8*6;\)4P-)! QX/39E%\EM*N
M^LRI%,.VC316L9"#I.7H,X(KA<TI4[X\(,=<UKBALPY%-_0?'%H]BG4\@-UF
M71Z/\1RE:WSFV6I&P#O%T0<-Z#HPER!I*9S*7'0Z+C1_<!AUD^2UJ*:3J?KM
M&FA<L"7!0X!*@@#E*8(IN1[4,<*)L$S%#L<.]@^.I9Y$.JKYM%BGV*X<2!OR
M1@N?I$?M*P-1$'1YH,%&!RQ:I8@W--HN]5#)'\EM&TB@H\/ILQOZ^4+\):AZ
MV$K#$J&$. ::H,2=EQPL%1Q4%E2YR+(F'0[%Z1\J7CVL7*]E'[Q4<QULI=&)
M>Z^90'<EVU(!2D/DY:R9H#W@*$U4=LCBI'^H^/:P<JV%L1_=9+&YTO++IM[;
MY@2]//WPVVSNEVFQ\6*?S]ZO-U[M?!9P1)LY>%4R%Q<XS._=<K*\'>NGG]QD
M5HZ)MO7'BMAO*PH>06@U'IK(M<<5[H&E;, (J4%;F\&+G!R5."6F@Q-*^1_*
MY+OF::FU/%ZE9<*^RBG\L_0A3>>;G,SG,Y1]V']QHB5EDU.PBEN*EC*7D&/F
M($NU;TJ4,,)H;W(75?N'"O'W+\M:^#D@H.*'+[MFO>QII-&$4TN-0B_>1]#4
MV')S@4'RCJGL+>>R0QF".OOWV%DO_<BU8M9+2"DNR]6C<J4 )?>+6Y5;!9]>
MY,/W#8ZGR%S28H.^FD=CA@-E,J "=Q*E11P*RFB&J][C3X\TGZ8S)![FTU02
M<348WKXX/W\2<-$NTF70:]]*8T/R'OU_8,HFD(Y:D,(;H(&SQ)0BL5VZXRA/
MO]7&VZ!R'0UC&X<+91?714SI9%RX70.-\5'[DK0M?2* <@^@%!H6:*]$JKS$
MF>YPIW5<)V%P9/4ETM% ]=FLW&]UG@.O$TTU:)M8JCV*(5KDS> J<^@*X:)3
MDBHMHZ =@";^V$#K7[BC0>[V?GC:OLZQ,8"W_Q+/@=N19AH;N0R6,ER +(*Q
M64-*GH.AS.&ZI-%W*?(R;G;0X%#K5["CP>S@'=-S0':P$?3"$V6>2E!>,%#H
M>P$:#!ER)IQX:SAG'2HCCIL\-#C$^A3KB%OG_2NJY^V5]VD;[M&QIPZ=F_(*
M08S1@:4AE7=,1$I*H:O?06.-FS!487/L+,W:*$)/Y*Y;O+$CSXN3G=E2(Y-S
MWB8'7%M<5$93M!4,FJ?,6Z58XCIUJ.P[;B[14 @;3K8CAV1_G,S<+'0,R>YI
MI(G)"^N5@8#Z&C0J<+1#;7F*B1,:G)/1YVN_ #)V2+8?N8Z@T5ZE]VMT35 L
M:#9^>>>SG1([0-P81X4E00 O;T%*RAG0G!@P]&H<BM?'+CLC'55O=9[IPWJK
M/W'6!M*KM'F)[\W\C?N]G,"6AYM01"5V=^XMM4N;;%14.BLA(%%+($FT':P0
M%E+)G=&NE+/K<'0^;KAU*-!5$')]6__VI;?-$'9/B+4R]/<1-AE=9.I3@B@S
M[AA&,K ZH&$2112F)/AU>5UAW%CK4+#J391CG%'^.E^UR8P\1-)0(DD,1$ V
M@0'AC@,7+H/0F:3@O).Y0P7:4=,F>L=+?S*LEV_S?@?R%_G$(RU??XK*TWH=
M465RZRT.*'*P21C@7@O'E:'$=C@0'#?$V3<T>A!>[9VGQ%TWUYZ>39;;QTS;
M63I[Z1JK/*<FELSR[$$'AIXJ.L! %%J!F@>*(GRLP<JA]IV^)#EF /SBH^('
M1YHYH HEG$(9)[JYA$/@Q /ET:H<G2+BT<8GA[-<^I/F&,;+'6]R$_DZ+VAT
M9DN-#2(Q)P,D(Y MZQCDD WNVB1D)W#'[O).O?FCFCK#B/8+W"H5U;M7T Z=
M1#3TT4_$%;.]PW*?NYJE[1[RLCD511_WDE?'CZR7GGMJ8E0V<:*!!W20F!$E
M^YA*,-EI%X02;,P">4=&>YF,&F$MH26&P*@BX%)D8"3:^L209(((*L0.D>=*
M)?#&Q,#73\/T*NN*YQU;7D]4QKOW7:,$]:AT/3CF.;!$$AAN+% A9<X\&]GI
MILS8V#EOOAX>4G225-7Z0GN$4-B^%<3>M;,MX7H$*QU;;C2+E&G)(94\YF+Z
M@3%>@44_PD3M=>YR@E'IFL) Z*HOVVO X^&$Y"?Q_ZV7JUTI_%/;85]=-%(8
M94K.((M<@% L@'26@7/:9AJ$"+3+]:PJ"*V*I#-0//!$C WGWV:+Y*:3_TGQ
M+]OSGMN;CR]F=T:ZF"SQGYZMRT7)[4%Z!WAW[;*1.AF7M(!8)C@H9L&6HP06
MB64V1&Z[/&0_/MR'@UQ+W(\P0V.O@S*Z5RE,W7(YR9.P!<5G:1=/_<F+I\]W
M$_(BWWD+IYN>[]1GXSPGQ 0.00:<<E.>T5"4 [>AW(JQ0K(.)? JG7-?]5(8
M8XZN82T\PP7]P968Y_(_UJ@+\J=-W:2_I/BV,^9;M=V$H(.T:(PRZ@)0Q1-:
MI+9<[:*9498R81WJ$]4QNZ_5J!EJ!L9&[I>-Z\N.=6>L0]DQYW;6J)Q25)8
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M/@5P>)ATD==HR"BOKGV<3*>;TY[6;P.=TTR3:"S5*PUD81UX7#;H[',+E)#
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MZ(A(FDG>)7&N3MRES\E_4!=]<'G6VLB/2.E)".N;,GNI;3+<^8TU@:=HG%2
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M0E B\L!Y%*G#;>4ZB9[#(&A8*=9"U,9 O,3X.D[8,$D"]RR#CEZ")L: ,B$
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ME VT$S6_2G$G[+)RQ^-@FRB8=P1B$MP (20.OB(RM 3,&C+N3;=V:MO/@<Y
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MR=7J_M=D/M\\NVFQ.+ACU^4[(A7,0*F4XIP$RQ]2;%'Q06H Z(@XUX^ZTW$
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ML'(*D:!Y(?3>TAXZUE=;2!HK[<)\=+]__G1<84\>BH!4A#N($71<(XV\Y$7
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MEOH6)^)?3?RU%Z0&RX8[=L65^SZ=K_.8B9INAY6'4=)IO%R:='G,M&C1:T0
M]-8I)QPT0AH;$"O2U3@QI,5!BM<06!T>P>:+U7*5W$Z>S(7%%/CY+B"_#8CD
M?[^X>C2&,"*3WMX&QREY-'D>]%"Z?4MDB=;: L2",E0PY:# IC3B2)NK[5Y-
MN/2LB/:]X?A+%H>A99<WD\6+#:]MY.WR6_II_:4R;-K7^R+F+)*4<LN XM *
M#%2A,Q%LR^9GJ7M+5SQ_PMM(E'%^\@Y!V!P7(!$W &B6'_5!RCNGB\H2@GL[
MHMR9-TC2TQ5P?F(^_K#"SX/.JN'G"#).*71 $Q>499S7Y=%A$7[3O+!R;\5C
MWA!AVRFCFVSTXE+59&&3Y=WZ<+;@\581Y-HKJ0TP5$F6GU+5NHST(-Y\YNNM
M>LWYB=0II&T#I^\6TW46?")]_T2LBG#I@5:10!@S;"0RDEE*/!>T#/I2I9K'
M-WJK?'-^.G0*:6,ZZ"2]#F+D>SA/]N9V6W)I-D^7R\-^9\WF$9(>*^B%Q1A9
MEI^NXZ6SK04;4?K-> C2#[9#A<Q4D&WU[O9NDF0Y+B8,XWHOCXXWB(0P GGA
MG5%,&^X<5JQTG)EI?FZMMTH^9V5.IV@.Q97/BRR>IM>+Y'_BV>7DNXX7<<[P
M;0YWF""#:;6,;;S][Q$*G=1/Y#!@P"KG.,,.$Q%\AR+!GT/!1I2:,RIF]0GR
M4(3;5%YYO'U]/ =@W^.1$LX82[STU!H?K'?/^,-.!6FQS==;*:-1\*<#,+OQ
MA;:.6YZ^$KRX6G[0DQ:1E!@AC8.];B'&$A+\X+]!)9H[T_V5-3J_4=,9GIT$
M<\I#H2J?OVIY0C6;1T@XRJ"5 B@G(*72EMM+@G/5/(#=7_&C\[.C'W"'6E5L
M$E;&51D8RG<9=P=)=[[>D26FLFU$J/-*"2:,E\(@J9@I5M)@U>$6.6=O,]K<
M%[)#L<GGFHK?)YML^57 )ODRCS=F_>F&\<E]1?FJ"ZW"-MANE#,8W(,RLI[7
MI1M1$M.HV-8WTHV7O??)-">[CP^&?!^>B#R@ECJ-("(<*4RL+8-/ 946Q6*Z
MSU<:A?;;X=<Z$?+AS6&P'^/K]3S7Q_V+G+NJK,>Z_430*\0)UTQBYH#65/,B
M2TM(V":?[8T'?'M$N3&+/M\%M#:9*R]$^'4RBR_3)]!]F&2KQ9'ZOTTZBPRS
M7 H7#'X(/$&84EC.@52:%J[4&XX/#P%U8U(=SOP]Q)S#+2(BM9;28$!=OB^&
M+"SO1Q+(MDEV?)M!X&[Q;'YL-\YN\YV+1Y[;I*JPR;$V$:/* 6#SO7+(E*:.
M@X<(@40MSF*\S9!MUX@.Y?I\R.*[23+;^6<!J4W,<&M%'_%RCC6+)%. .:$9
ML(PC[8"ALN2\1+@Q=]#;#M=V"&H'B\EM,97=[5:ZJS2[VY9LFTX6LV0V6<7K
M97#S)[/DZBK.PB.WZ6PR3U;WU>M.B\XCR(TE.K^;77B.',&(%U4X\@V/%O1Z
MP\'@<T#?0=PXO;K:'&N>/:1]3]/E:IG%\SQA?)5N+K&J#B#7ZR<B@#NCA? @
M# =S R4NH!7:JN;6#_I31))[0;DQBQX=%:AO&A]M%!DLE#.;6L56&$PU=N4D
MC*%LGEN#WF9@N'-(FT\IZ2J\+9G,MV427KAQ^4F29+49>7IYDV2SW(F[5W=A
M9OR^.9PR/[BJ==!UY)7'*OB*.H JN-<.PR+M7RI-FM?N0F\S!GPFX)O3;YW?
M.[/<9)?=WH:AK]+I/PX2:M_#D9- .82<\UIS)Y!QI-B(DY*U2() ;SA0W 64
M0[EBNV!EOFMVS/5Z_%A$%5)<.>H4D@(A%,A;))D%E[+%L1CT-J/#'8 X:.+4
MUOG+8<DSE_>:+4>?CYSAA$"*C6%>,BR=A[:<WQQJ7C4'O<UP;Y=H-B^4L%G/
M'E]7]MB@+A:U0\M'O=:1ALA3BIU%3!,EC+3(E),@<<VWG=$;CO3V@FUCGKQ;
M? T6SP8!??]@X;Q;_%L:$/X]_#X(N\GIJ:QRW:"K"-O\KA;@F"3:$RZ9(44T
M(#?A6\PM;SA&W#_0C>GT6(*+;XLX^W23W#UX]X_%/42C$[J(!-:$8LI9F%*5
M9M#",@P@:9MZC?AMAHE[!G@HN\;]L4Y6][_&JYL\0Z?\&(Y8-@=:1-RY8,,+
M:##R7D)CC,+E+,MM\Q4,O\U <+=XGI<O&^XOGW#_9 ;MZ2.LW-YC06D8[Z9B
MB8&^"$=)!E4+3KW-"'#?"#=/V*HKT.[>LH,)6R?V$SG!'6'&2I1?I$8LX:H<
MGY&R>2E:_(9CQ#VC/-1<M2W.^#Y=+GT ^?25KE;[B')E)(1 *,(T)QY#493K
MDU")%K50WF:PN$]T.YZ?ED7FXL-YG<-U56OW$ ',M2)":Z0]5=0XX6'I0$#0
MPM1^P['CWO!]X,R__OP,VB#R/S;_L.?WNSZ>H/SMV[>_?-D<7D]F\?0O@=\_
M;T!^BMXND^1CO@V; Q-FU.U]V<NG@L7?5_%B%L\*Z5H+401$EIM:;8O\4$B\
MF";G>Z^-5Y-D?N[7[ZKF'9"B_V5*Y_D=\7*YJ=:X+ :Y_5:.K$['FD58>"(I
M(,9AZPFV.*\H;SC7!BM%'T[2'9MB^AGMPS7S>P:PU/>/_K;Y*(X@<&I7$:*$
M:.VT91@J0"C3$.]0X1+X%FF4)\^[D_G\\&S;C6J?%RWO%ZW--)H/=[;ZE^D\
M7<:SO_ZXRM;QPR_#IQ>^*C??K Q__7$97V]#H(-9@I>3[VH=UH\L+"3YU>>5
MIM_S!I$.7KA@'"DF"%4>.0+%#A(!F1[R3MF;^_QRB?67^*?RTO?#A.I/]WN-
MNI:X#>L?/!;6;JRADWBQ;1)&*#0&BE@/H#"&*>54,4(*D(Z"VB?K^6I AI2\
M^.G9NU_RHZW:*EG0"J6WR(?S\.#)<,9+@XZ<NL]_^?27_+>Y!-/5KT]<G!?'
MM_8\&VU&JXBRC%N2%]SD3A9R<H:;YX'U%M%N#WG:+2@M=]U+>WU5YI-=AGZ7
M!Y;OFBTC88E#P6KRBBFCM17.%3:48+)%C8K3P\KC6L?[ ; G$AR<G6NWC91@
M0$I'B2%4.LAX^$**<4C%[3B7[<ZU5%_[K7![O3P8U7(]?O5WI/9'N>H/-PH<
M7\>/-(GRHA*$&P0T(H9IPQCWA=2.D!;%';I>SGO0Q($S "U!:JS:/<?_*S1[
MN$4D'<D+H"LJ/7"*$<<9*&0VRK1(?7IEBNT,H\9ZW7<'R'&]'FX1&2^9D01@
M8ZSU6L*\(/!.9BME\VH;_=Q UY]>.\.HN5[7MSFSDJ_QIH+A^WP&.6:$'WH^
M@A!SA(D60N8;>Q P4C@BTK?:D'\+IG='L'6JYN/FU>$6$<]/<W#K,710*&05
M$["0V5 )1VQ<M]=#E59;8?0Z]#L^HWDT:NW*+TK7V2J.%U^VUVT<7VCW/ASE
M-TH*Z"GW88:2FDJD2DDMD"TJ$/6RQG:!>=HQ*,VS3N9Y(>!:RMOS:(2D\<(X
M*SSW@BA'J4*%E)2UN%N@I[N8.U9=>T@:*^[R6SS_&M=2W)Y'(T\ ",89=@!+
MQCDPUK!"RESZD=FU72NN/23-%7>3U)\P]SX<$10&YC1!$GE"G ?8N4)2$'RJ
MQLKKZ9+CKI77 2C-U[ODZL6[*Q:]@RTB8+S!SE!.<%CV(6;!^RIDU@@TSP;I
MZ6KBKE>^KI!IK,U/R??:W^*^9R/A*(=$YN5N!+340T7R<3LJI<Y/VS368$]7
M 7>LP0XP::R[BT6LZ^CM^7.1\ Q1I2A!3D%)N-2F"$I+8EO<L-O3!;L=ZZPE
M'LU-S<GTYJ'JU(,4G^\NT[ >+U;WM=1Y8C<1RZ_<T=9S2B0&7H;A\7)9][KY
M1FOGIYK[,5%[A:N%%93%]3[?ET\&2\U198-L 0H*L=5AL2AD5-BHQBKM_)AQ
M3_9/2T2&RF;ZL*TB=Y%]BK.OR32NR'C<]WAD'-+,4,8)-_E: @$KS3KM;/,=
ML]-MW7$%:SM$;6 ^Y%GP.V$/;YQ7MHD"/%Q[$>8H[Z2BPBM1C%$!9,DX8[O=
MJ&T_!SH#Z6T28E3!X)'QH*ME/9Y>)0&S2<6:_O2Q*#AZA%J03X$>(!;^'Q8[
MB(I:.&BJ:KTLQPZ03CL#I'DP8S)-\CJN[W-$<^2.Y33N>3:"PM"\D W(DWD$
M<<J88M%2!(CFEMCI 8QQK<Y=0=:9:BLRU/8^'5E!M/,VF)/*$ PWE"YDY=Z/
M>?NT'?;'M-@*FW'K<U0KY#C4V%6@,9VGJYMU5A5C?/I8I(V34JD@(*%&0<C,
MHW6 H='E"[;$..T,BJ$LV#W+1X67>Z!%A$7@LA.(;:P^;H$5J!R?(,WC5*='
MDL>UE'8+W#F)D?^8Q7&EBU/9-B+!#[ >8JQ9^"Z,M[!,N5.*(#G.A;DS3=9@
M1A=X_3FX,JI%?[P4Z<I#OE].OF3)SG^L<)/W/!LIBQ! VM'@9R*'G%'(E(LI
M<BTN-^[+5^X0^[1;=%J<!KJ=W-U,LEMU7;'Y__S!2 K)(-,((:]A6 )1ON=6
MC)61YGO^O=63ZTE_;:'I["C7[GH GV9JL5A/YG]/L_GL6S*+?XM7FQV;?*\,
M@=V.RV%-M^DU8EH+GH.'O>"<0,E-L1.D!(;-+S$:\K-^W[A$R/ 0=DV??%=N
M>9/.9R<2I&P7"1:6,RL,,P@$/\?G5:D*^1UL4<9MR)FA'PHT!6FX.>+R9K)R
MWZ=Q/.M^IMC3=P0Q]<9B8R4(0P?!AW)%100%G&D>,N^MJ.0(YHOV0 [M$ICT
M]DNRV 13'L89?EIN=@NVJGLHA?<Q_^GBZF*=UYZ/E[]/YNOX;\GU30W_H9L7
M1811[)%%#&B)K9 P3^';HJF);U%8L+=*E+U4NCHKJH/MWNZN5;I,=^9@,>IX
M^4N6+H^F>E0TC9 #V' E$0G?)W328%K8\9IJUOQRH][J4_;"HXYQ&HH9OZ1I
MF'?G\YW0,[O. O4_Q%F2[C./ZC2+L / &$\L1%)3AB"&Q;ZJQJ;%5F-O%QOU
MPH@.,>KT"-\A8V??LQ$2QC,H):   8R)=ZH8O+9"-==E;W<0=6^\= !,8P6.
M_/)#"(1VE"@$E7%:0T7+()\&@(XH9;<_>@R/XU"+PZ;TL#EV:]6!)R,A.228
M2<TP] 0J9V1I!DGEF_L\O5TOU,L2T Z6H=1LXZLX"PM47KEM<VW:QF"I=7-=
M5=/(&^F=Y5A#2B1SV,'\Q(* ^6D39%GS]0/V=E-0+TSH&*@S4.-],OF2IPPD
M.X/6G$*. XTC8Y7 U 6OB0KAPW=A<1&.SLO/M(BEOHY@:F]0/1"DQT+U!XNE
M#U*A?K%,YYLK[V=Z,I\LIO&GFSA>G>FM84T/0-S$JV1ZL#I\]R)\6H4_-QJX
MN#*3Y8V?I]^& ^#)V]/;NRR^R?>,O\;;PJ)GD6-[\\.!5P]0L+X0I9P2CLR/
M+Q^.N,AK1FB"@" RO_K"($61 99:[K&H5?"HYY%5%MI_\F 4AD*D0@Q:XB T
MW&I.=B.B2K2X'KWC,OIME/&\>'X;!"9C+HV_N3+E8WRWNYK[0Y9>9Y/;BC2Z
MPXTB;8D&GC)A.3""<X"I+J"!:-"DR=,RZ1IJ^#E1ND)F*'-PO\"5F4_'FD7.
M*J DU((C* FUD%I1C!1)CL:=(->%"FNQHA5:;YD?HTR*&QLM.HI&JO KME^0
M_XPGV65JP[QX/,WJA"XBP8%5X7\(.DVY#PX5-+M1,>7'>-BL&R6E@^#5B@5P
MOTC5NC_:,"(<>R%E>!V1X4-A5!I9C(!ZV=Q:["VQIA^-=XG28)-_811M?;#<
M(TP7F^A A7UXK%UDF&6>28*MIHQ)JRPIQTI<B\W$OF]?Z,A$[!"<H8CP3-3*
MY7_O\Q'B+L_W"4Z7A9X:Q8TNO"^&^.CMPF[TMO>JYFZ0>EML&*<5."(2G"GQ
M*-L%MC^MTND_#EH'QQZ/$"8"(D6L9%Y+CXBBM!B95V"$%RNUU-"+4A&M01E*
MW?F60+JHI^L7ST;*LP ."(,@7B$N$>3EF#3VS:N"]&;\=:OHMH@,I>6'(F4?
M)LGLW<),[I+59%ZI\:/M(BN<H5)QK0WW*K_RV<-BK "UN%6GMS3I;K7?)3J#
M,6$ZW>9&Q;,BU>'Y+E U*^KV$4$4/![KK0.&"!T\'^U1Z?9PWKR"9V\9RQTS
MI">DAF++Q_P*[44\<Y-LD2RN#U_U<KQ!A"20GC+GM1<.&Q70+$='PJ+8F >]
M91QWRX-.8!E*Z9=9/%FNL_MZ1L&>IZ/-;IN6A&!"K/)6P8=H!^&F^24PO:43
M=ZON]I@,I>L\G2E=K )4H>OK=XM5G,7+PR>GZS2+%(#2V@ <0) Q9Y A]&$J
M@\W-@MX2D+O5?H?@#'?:),^%J7;V'CT6Y3LATA(,I E3F+0 >5#LM6OGFI^U
M[BV1N&,GKSD8P\5WP_R3G^R,L^5V\,'FF*]G^:&&--O OEIER9?U*H]X7J;[
MF7LT$-S%"R(8H+:"..PDM]1K0#4KT),(CZ@24R^Y)V? \'P,/(E-$6(,:0BQ
M1]I0+Q CME@UN1-DR+V$,3#C1#R&TO*OR6)S&7F-&>/YHY'5A K)A!2$2^6A
MDV58C,/@*(\OB-"AAENB,6B2R/+=<KF.CQTQ?/Q8Q!4@4#%L-$8.2T$]MB4D
M!C7/!.C-]>_RRVV.Q&"6?[S:!B#>'S]-_.2YX,48+C5PQBD%F(%..%B.1<#F
M7VMOCGR'6FT#Q5G4VM*Z.[FO2'$&,3=6:^,%S[,=4$EUH5M4*.C-\>^+'CW
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M_'03#-A5G-W.'@0YFE9ZL$%DD<,>4:B1XDPPBB3CA<1.\2&/KE3X(ATAG_8
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MS%/??8UC/V+"/=HVX(@,8P1P+8411".+X0XHA28;(%&<*+^DE,V+;+$49WO
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M"H1!%O=6XJ*J1*->C1EIYRF)&I"I<K1+I"*2' )2;_&IQ3^KYKK:OR*_\%0
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M6'V/2G]OFX M=%I+3[@G%%BDN-AMK\:2_LO :+%K^>6?"YUS7KB>>+,:@ ?
M80,X!]1R[1CE.U792#7!+*6C&B,S8'2VX\1))XBX1TH(F $08\J=\1HAZ=I9
M63<@%]]H7WPYR?=!J)3<6T<S7S<OWEF]E%YZ3Y-X4 88&<NIMMQ JX3E<@<6
MX_UW_=$"7D?E0":<SNQPT]S.%NKROV]7ZS09>.*.\&L'@5,DD?*<:8J((Y8
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M.D07!G4:.JF>+=)?]59*M^T#M"12WL;)8FJ0BK_QAVT4@0GEQBPGYI.4U'Y
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MM,U"P\3V,@>R@?0V"3%)>]!$>)#I OAK=?$]KH;-[+ ?][/'@G!$< JH59I
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M3@DOXP$;R <TI5#I)]'>#%T=\;CL&ZOA@FQNXSN__%(LBM7L-O9?7=]%.LK
MZ\W\>[$?PNG:TV>])R"M-09 6"HA9(258-0Z)_$9WDON1V[Z1&W 52:JW%>;
M^U4<B8D*W9<&XG+XH6 L!@( 2J!B,JIT'HM:K<.X11[^WJQ;O:TIW4 TE"!\
MFI7FMI/4/VX6(*14, 0]D@X:JR%$K!J)=RK=)=W;;95^R&X!RF [Q8FS6ER]
MS.ULO9[?S'<_>+?P\\5L<36?W=9P-;K>W.F' M<8>>" ==H*:;P!P-64.-TB
MF7UOUO)<+#QC$C%8[HW=<(KKET>[WX*/B&NS%P2-"<<::((D0U$'9)S7)#@O
M,TSM.A;]SQ-]](%O7M+UL=A<W%S._FPM9=6+ I&,2%#ZO(@A"'GH'=BC8;1L
M43*LOVC;*4E;(LY#25TW&XB9?9MO9K?E3]5=&<'<N[/KIR\&1Z-"Y2FEVI3:
ME!<"58?FJ!BI=/M3?Q?8\Y#C/ A)OR5R;/9%%?SV_KJX?K?8=C(B6AV4#X7B
M)+XNN-)&J'T<++'0>(VYKD=+:(MJSOU=IA]7_ 9$.ZO%-.X%NEA$IC=E.,MY
M"F0W'PB":6:I518KCC@WD9_**&" \.GGG-Z*[TYIJ>P:_R$"C X%WXR8A'ZR
MT3<<2$VE8T)YI0Q%5E"U9Y<Q:AK=AWJ+OCGLS)?.>(L%P%)9X3TWN)Z\+&X#
M0SH:!XV^:2Q7@T3?G,="UM$WGVYGBX^SN^)$N,WC9L%K 8WF%B L2'FO6NO*
M\,JTMD->D,H@OJ:Q,#RW9:=#.IBK8M_%D]$13QL&Z#A3"G/FM3%E6N@X:VM(
MK 1YA\RD$7. W5:(3)WG+,->QJ"WH^/^A]GJ7\7FU\WRZE^_1<P.^X^/M X<
M 2$A!@(Z;SSQ4G#WL)7*]*""_NI+)X*][!J,9.(NHW3^O5AOBNNMNWI^55I.
M&]+8Y-D@(+32 R\01)9#8:Q]V(0P3 ]Y[:\2=0>D]@!-,L5FMO[Z:['9W&Y5
MA.UEE<5>LSA!\.DG U%2(PL5=T(9Z 57"#^(:8[VW2[H[1R89'(??;[!C'VY
M=0#>&1PE3FJ@8W\UI*C& $F2OO#V9B7M@L1.P$B_IEHI^N6J\.E^=?4U:OGE
ML(XS>.*Q0( "1&LL*56">"&H\U7O(=+I:5]Z,R)V066WJ*0[/>[O[F:K'Q<W
M1PWH:KU>7LU+%^4_YINO=GYS4Y2Q0]4]Z2,!-MU_)%A,A &:8HN,(024^=+W
MR'!MW:"*\CC!-><:<$8G(:_0A_:!-4X 112("RX'<7:6_ZQ<\%Q0W:C<Z("I
M44:B/BVHYCQL\Y*L[H-JO/?.P3C3&8@[NX=6.U*C04!Z$IY^DKE,2=(2,<[*
M!SR)@!HN"8588T80]-)"QU1U:.26L_35LO,#5T8RG <94P^FB0.U+IYE-8U[
MAZ!2&0"KT;)(1S['Q Q$;T"DQPQ%>!85,53Z$3S.9\F!SXYV>6.UFBV^;)VS
M^L=/O59_S%;7[QO$6K1_>0#*2$PQ8^5]%V !X$@27I8'A+3,]YA#>,7)8:X/
MC;-Y2$7+;P3*R_M@1CO-J>86<<K)'D<,(4RWWW0<1C&DR!R,G!@6[*RC)7:C
MBOT\$2[QI%V(0V4"244-)YPRKXA@%0!E:L?\XR4&$X'GIZ(6.(Y\X:\!-@^C
M6UPW=L'W\;G D5-:<6>]L!@HS#SG>V2)<)3D';"1*"7-KO&- >R;Z':'<)8Q
M*!.6V)Q"6:RETBILM<6&$40MMZ;6;7B+:_%#7Q8=B+(& 3'G0=H9_>IJ,_\^
MW_PXY98[]5RPQ%$HRL0?VE ?NQZ5C:K_FH)!ZQ=U)!+=Z_A]0)G-GG4(+O?O
M^SBZ=XLR7<AVIFTKW5Y^G2TNOI6O6']<+KYO@XD^WI_*XC-4'P+ 3 AE/ 4"
M0(RH9-Y7'!"+,JI0W[%,G;O5C83X*Y+Z?Q3S+U_CG^I[L9I]*7Z)K][8V:;P
ML_GJ[[/;^Z.6F0RZ%^(!TTOE@/0<4(*MU=[5JZ 7Z3?[^BHB,=VYTC49TY]&
M.P?6N\5569&[L,7NSU&FS,M="98K* %2TA(IM%84(5LQ0AU+SW71CTMS@M.C
M$^"SF0H'3R+[T6Y'OVWQ?,3;<B41B6>KA/NS6%W-U\6GU?RJU<SHMV<A2E(\
M1QF@G(0:<>B0K+5IH'EZ"J)^'+#C392L>,AFWB0O']M==%U!,\K6\;0+P8JX
M8"'.* 5< R8]M+4N#!1)#UOM/,QYJEM&*\!?F\CG>0(YLX_!(,FAILAQR(D6
M4)6)6O8<(FG3KV*QMTDS!"/3GU6[*W&C;B1/NQ PCK+"//.2$NX94TZ)/0/,
M>Y >3LG?YD0'@+\VD<]S(SFSCX%B3[ P'$AON/4\GB!K#IWWZ=XM\39IAF!D
M^K/*+U<WQ7SLO>2G7@0"(&#0<6T]M01)H52E)C.H7?IU:/DV,[K!_-7(_OVJ
M6.>YG9S3P7BPY,822 B3-"Y>B'M>F>.91:;%[3_P-F5ZYV/,JP?/S--OP?@/
M]0+BBNBIL(QS"H%%7BD>3YH"6"40P(W">M^"\8O ,%).: Z\1\!!20&U%8[
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M)THG[$Q_ON07?(@DLEQ3'4_M3#FB.56H6K$4!.D;2<X6^OSF1RM6IC\OG@8
M91 G%ICQWD/HK75>&0,5E*QB #N9GADCY\LW^<V+5JQ,?U[XY>JFF(\]-7[J
M13""0D@]@%JS,AL9D;[F 2J,DV='SE>'\IL=;8D9Q1>\=1.LGW:D]OON>]/V
MH_>_KXM_W\>ON>];]_.S?X_Z\;WG>SS']]/^-')G'W@D,.W+&ML>*&*U8=XS
MSHGA0L7I0,"H3NJG73[I;WZA>2 &:2A,/)]XYPS$GB.Q'QWV" ]9&?VXZ[@U
M/<]7K/9H9.W;+>VD%S>/5N!3^=-?:A\,\9Q#2#1QUB%57A,R%2!:M;B?W;>O
MMQ6[S[,1=P#-8,EG']G1U>+ZXW(Q>_A)F?I_/;O:[JLG/0YGOBD8QR2+&W-4
M6#'#E(!XFJOP<)+EG@J]'<?/'?V#8/<F4UEZ0_,6I8ZN8_QMMOJQ_!85W[OC
MV=*>MPO *A@76QXW:R^@T0+#:K_&0),,*[+TQL"R.YP&,P,\VU=/QXX=>")8
M1TV<!M;&Z2"9-PY%G/9ZFW0\?6KW79ZM2\VB&W!&)/]TD,RA9X*6G MJL69Q
MIA@@'*6L&J,V*O-TXJV9.RT)K7!ZG3*1Y7Z?CRAD(0*GZ[>]U#YXA[D#<4S<
M "45AT32,GLH1)X3[S.LH=P!3\>93T(F6:/[[5L<8E16%]<?YK?%>K-<%)4Y
M\\/LNKA<FN5M9'.YFFWFW^-_K3:+PVI?TLM"'*+B@!#E%,"($P4DK'#C$)CL
M92#=+#48:ND7L->;^=VLO"MX?;W%=W9;=>ZW;Q'MJZ_SXOM6)[ZXL?%OM\MO
MV\//HG0)W$4%:SZ[K8=U^$9VIU\)"&G.C//&6"5<1!Z5<V>+#37>ITM4?Z$Q
MG4K4J' .X7JYO[N+)Z>+FU_G7Q;SF_G5+';^ZFIYORB+:'Y:WLZOYKT[8IIT
M86R/R*?5,AYR=@7>2WI+O]N6ZB:^D=,/!XXIM 8 Y QWR'GIF"7(4D>9+1-2
MCN@EJ:_]'!Q&\YMZQU\1.&,$QU776QZ/[11Q)_P>!0.)S\:;TB6A!R_:=8I5
MUKX6/;O=19 7Q>9]26I)WG&SR*%' @. (&I87.&)XD*4V0H)+N-!M"2.#)D,
M/O%V75>\+WM!;*A3T4O=/7DR/OQ0H!9!)Q4K#P.,6ND%!;M1&LRAY'F;2]J3
MUT :6B'U6N4B2Y-)3N(PCAC8XJ98K8KKR]F?:KTN-B=%X.4' C58(VXQM )[
M(;17CN]&YPCP9E"+6;,#3A=4/2\+VP4V0S'_N3P)+(IK-ULMX@'AM-/TY0<"
M1L(ZR*7E0%-I$-9$Q-$A%'=287VZ(ZVWHVT/S'>"3;))Y,/L?Y8K.R^+%/U^
M']$]H/,=;!NB1NVA5 XH8Z4V&I(RF<U.%P*,IL>8]NT$ZTO9ZPJJSB@]N"X?
M:1TDI) +%0<K,=(X'J$$J_JJK9%YZFH=8'^,Q5;8Y,UG5CI6'C1V1-^C#U\L
MBN.A)B^U#58RQ "54+.H0@(L">=5/[VG*A_]J!.TE]WBT05OEW\L&_-6MPU2
M*R2E!5[&_8-::CUS53\)Y>GNP,ZUFSYY2\5C,%VV#(,Z8>FJVP0#.4=EZ4?-
MA,96<.U@95*4R*1;1\^_AYF'MM,6HD%I/GU.>6@5 *2$Q$T&2NLT4E(+@:IQ
M>.U<GAI0"SY>8K05%M/E-BMM:!Q*QZ%R7\+K))E/V@5CA/:",,I5/"Q;+"RH
M- ++B1C29]70CI#$Q+([# ;C<U<#ZS2?C]L%9CB4<1>R#"+H8"G@-2*:XPQ#
M'CKALP4&0_%Y4'O0/QH$4C=X.D '."(F:AVJ+ 89^Z$J?=-:2H:\T9^7AM4]
M>*,+3:-0VP9/A[@+>H@ <A';<F,L5\)JW ;PS#V+G3+;5&I:H_?7D9XLM<'<
MA68DU_3]_/9ZOOAR4N%XVC!P(27U!"C,O9';.NJU]D2QS\C&U@M'SUW1;< 9
MBFI_OXIHWZ_*5)I^_F?YM]..R,,/!65%Q$0 C9QDV N.4#U*Z%!ZU%)O2F>?
M(M 94,.=-*Z^SA?%ZL=C(!J<.PX^%0QW3@-GI&2T!$TX4Y^RR^LO ]KZ,A"(
M[I :2B+*-#[WFV+57!H./!$P]M)C:3"!U&J"%?.F&E^K-*Z]91GK4Q*Z06DP
M*;B_VY9__5[L2@!>W'PL_G@4W+Z:+Z[FWVZ+*C?3Q8VZ7F[S-AT3E.27AKA@
M&F#C45Y( 21C0L RK@-"[1P =,C@V+:R]+YUI/5@."9[ ??UUV=?BL_%53'_
MOLV*=7'SCZ\1P/7LMGCLH-[UNTSS99:+]?)V?EU>6WGTW"'W8:<?"0SA^$L3
M!J&T5BOH24T&MC+=&CJ\(I,N8:/C.OKQ^+=U<7-_^WY^<^Q:2(.G@^-<,<05
MIAX[SA"4"-262-OB6NOP>E#[%:M[P+*Y8I;15;.3R0?W4)6_E358__/__1]0
M2P,$%     @ EH1!3%8UJ XQS0$ '@T8 !4   !B:6EB+3(P,3<Q,C,Q7VQA
M8BYX;6SDO6USW#B6)OI]?P5NS[V[51%R%?A.]L[L!D 0/;KALCVVJWMF*VYD
M4)F4Q*D4J28S96M^_07XEBE9F0) @*2KHSO*LBSE><YSR.< !P? /__OKW=;
M\)!5=5X6__(GZR?X)Y 5ZW*3%S?_\J=?/[U!G^++RS_][__UW_[Y_WKSYM_Q
MQ[> E.O]75;L0%QEZ2[;@"_Y[A;\;9/5OX/KJKP#?RNKW_.'],V;]I= \\4V
M+W[_,__/55IGX&N=_[E>WV9WZ=MRG>X:V[>[W?V??_[YRY<O/WV]JK8_E=7-
MSS:$SL_#;YW\"?ZW-_V/O>'?>F/9;QSKIZ_UYD^ >5C4C6T!(_V/?_WFY[\X
MS4];413]W/SK\*-U_M(/LH^U?O[W7]Y^:OQ\DQ?U+BW6V9_^UW\#H*6C*K?9
MQ^P:\#]__7AY$EWT,_^)GXOLAO/](:OR<O-IEU:[M^E5MF4PFD^[K;+KES]B
M6U5//H$S%'&&+)\S]$^O?/#N\3[[ES_5^=W]EM'S\PC\"H!WWX(UA:XAX9T*
MR'.L/O] S7@_LU<WTXOXVX_4C+E]T))B8^+Y??ZQFK'KA6STR2AWZ5;SD_'-
M1Y[$O.4_]99]U?T@__0S\ML8[T3UZ(.SK[NLV&2;1C2??#3(-__R)_;5:E^_
MN4G3^Q7)Z_6VK/=5]OXZ+N_NLZ)N$LO';,NAQV6]JS_=IE7&57[S(7WD.:Q&
M5_6N2M>[50"QY9(P=D+;B:+0CD)*[2@((0E\S_?AJK&ZRHHWOW[J,3;?FA3%
MGV38_#9.55:7^VK=)CD&G^?XUJ/_=0 .RFMP#!UTV$$#_@(T\-\T^$'O /BM
M=^'_^^>?#]P\B5JY?NDQ;(!?I_55@[ZCD7EA!3]GVUW=?^<-_\X;:'5)_9_T
M\/T\D.5ZZD"V<=GR05!9=2_0D^<<56M05INL8H.S_I?2:OW* ]#]Q,_KDHTX
M[G=OGCP+?) VC[/E+"]+RS&CY"5^U74$'X/ZS)0*,TI_7Z& 0-^UH.TA&&%"
M+1C;/2K+LNB*#;:ORB[!ZM,3130R@G(,7%A77E*+DQ(Q3T T*_L$D9A6VKD/
MH'%BJ>+^,N4ZU'UD,+\S>1_KK:J^:V%95.#9!'>7<4OOKVE>L"EYGFX_E'7.
MD0VYA?HV\@+D8=N%$7*@XT0.,QW;%HGLQ/$%14.++7/*,,#CPC  !#W"V49U
M(K2=>;NULKZ,5UBO2Z7!IU3N941UG1T-Z:R0NI:+/.C$$8E=&]MAU!N!+O;E
M!D^2'VY\+(0^?4H^?Y(;_<@2)*9+!IF14Z 6R&Q"\Y2',Y*B2-@RQ$,5?*GE
MH5$1A'A?54R/!EN1SXS!F,8Q(I1$),$N[&RAP/82%5V0M6%<'CI (&W@_5E%
M)Z1YDY$+DX2IJ,8%Z!F;5SZ>\?*JBJCRN"0Q4?;A14T9QXBHM,1I?8N*#?\C
M^?L^?TBW33EI%Z=5]9@7-W]-M_ML90?$"R+B\&E&%!/B!T'8VX[]P)&3&CTV
MS4L/PP?28@/6_(OL@%1.A#0Q+"9*TU,K)U(#I\T71Q O0+H#/4K0P)Q6MH28
M.R-C>IE?AJQI]JDT^:Q*CJ@>TIS]?9O1LOK$#'_*UON*S>VR7G97V/$3VPK\
M"'K,8L1L-X7TUFY(B.3H:K0]XW+W2UK]GNTX1E /Z"3'6^-9%1Q[34JGY#BL
MQ_;FNJS>U P=., ;AF<3C\E>X^O<^$P;U\L0-8W^/!^W:69*6,S6ZW+/I/-C
MMLZ8C#( [[)=;]*A'J&A$X:(A#CTK=#%@TF/34HE=6R,*?.UI X=J 9X%Z#(
M3K]L!N@4%+"I>)34KI[ CT<$,F1SR=89ELXIE@YR%R)66EQYKE/Z^'E-HJ[R
M_&I%]AEEGOU:,*?K<IMO^$+7_UOFQ0[OZ[S(ZGH51DF8A+YO!8'+1G@0^5[0
M6\6)+3C:TF7-N% QC&U;<%KL\C<QL2'8W695>I_M=_D:W%?E397>"8Z^M'%\
M7KKF(%=R3;]G=?\$'OA/C@]<=0 G)G73=88WB[R+(O<),F&2#Z(AP#5@0V#
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MJ0$4J#FJ"W"?5N"!8P/_-_P)0@O<9]T=5K*GNRKP*:92IHF4DZ<#@Y]:!AM
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MQUL]9-55J:8^HPS+O%W'&(5?LJ?[1\L"U.TDJ."Y88Q C>-;1;,F(WJ4C%V
M)WM0+T +%1RPSJEMYS@4ECLM@5BB NIQ[*PH:N1.J(AZ^/0/:?77=+O/WE\?
M3757,(Q#;,,X=-B0#]D$81)U)OV(VK:8,FHQ95P+/V:;[.Z>EXS _8"5S2TK
M\,#1\O,*Y=51#\L"==$IZ953P ,R-J.L0(,-O+]^4H2>DDR)6N:4I*H5+4>1
M*U:6?(6$4_5'7=PMH-"HS972P+,EH?:7Q;KB1VAOXK2J'O/B!MV5^V+WU"X)
MD.?$,'8<CUFB;%".^TY2WPIP(+Q IL6:X2GY@!&L.Y @;5!RM<\5#U?1R+6
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M5GR0>E=J4JO5L&%E[NJW^Z+.V+ EVX J>RBW#WSTMVX< ->=!^"N=0%<]3Z
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M?[O\_'^2CV_1.R*F'S),G!<*0R1(+D0)^']&!^IL_=--^?!SYTLK ]U?GBO
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MB?VF*G:$7IMA!]DS2,*OT(>JW.S7NPM^S*#D]C$E\L2DQAQA:GM0.1S0X;D
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M. -FK >EOL=$<D\,U_MF<A%#%]F6[5D.I=C'-HI#:_C\Q$<R(W;Q3S4\S&Z
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M<J$%?2L),*$><>TH1*BO6?L63ORE3/OED4\V\Q^@+64@H1#EN8<*AL*[\,'
MX/4?KPKP34!GR>3JC]4?/5>/8&:R;#PV>HO)MWNF-J\/)D@8Q,2U7->//#:>
ML ,:]+NR?&+'4UV=-ZU3BZD%+#6+:WIV%I+@IW]H%I[[]\T0\A^K!B#S+,PY
M;-#[L/Z#C"@TDS;U8,-$S.<?ASP_AB8,70N[K@.#&$40TC"D=H\_8/_2G=62
M%+//^V61RQ_'TCLIG"/8+ZB=F_:=R?023[X2#?\?76R5>9GMY"NYR"U(,@6R
M@6O[CI7$V+7L($0!BCTT5(%]&BU03<<[-8/0_F.-DO\XQPN)/DK_,**MD;(E
M'B\D%V]AJ5_?9IO]-GM_':?U+=V67S[M[^^WC5?IEN3U>EO6?/C^.;W:9I^S
MKSO,POK[RD9>#&/V7]=)H!W$%F9HPL1"$?&]"&&I8P8,83!]V,\12+!FR,$U
M@P[RXKJL[IHG1++H92H4@E6J!41!LJS4(>97C7/,@(-F\X7CN!SA!K\UR &'
M#AKLIT^P-Y/5U!@^EX@,QVPAN<.TE\_E?A)6Y16Z21XL8Y1LY,?TI;BY+-;E
M799\Y2DI>P8FP-3W F;:#@.41#;$L <31+;C2ZY[F %A?)VBK1'G#43P0]:"
M_/$"%)GL\2R&HB"KS;/1KR[-;0R.,8/++B =[!\7),TR! LILY&(+4V8S3AY
M4I<-<BHORVB]KO;9YFV>7N7;?)=_DQ<"% ;0)HF-',^SD&53FO0 D./*+D'K
M,VQ<?CN$H!/>&J3%!I0\>*KJ.YYL6<6=E&5UE>VI/L*Y(%5]C40A)=46B:6I
MIS['3BJF9N[D53*YN]^6CUGV*:L>\G5VHJ2R;8+"OGI__3%;ES=%_E_9IFU3
MBLMZ5Q_PAK8=0"^)/ :;PL1*+)S841#;,"8,>JPJJE/C-*[!QTT5Z^/FBTZ4
M^>AXN]^T[9+LT:W+;<XOO-V >L?^:'LMF,"T@VA5W9X\_+(RO^2XJV>%WBO0
MN?6DQ>;8LPMP\(W_XL&[_LSAQK\%I13- 1/*0',])$M+6+/Q<#*_S1L9A6K[
M$2QNFI;5MTL(1\<6'D-_V;G& ?SX@6G!L]0>.TY$'!):%"&+1A&FL=/[8@>N
MK9HJE^2#^32ZO[M+JT>NC?5K&36MZW*=-SGT2[Z[!5FZON6_R#[[Q"\7-^"^
M*F^J]$[V@L!%1D-^R6%!X"=:L#A^<#A8<%U6+W? 'OG]/$V?[*QML_75(^ $
M+"AK3QAHL763!3YX2\OVB^3H])K-$M$JCA)>QM/<0-PU$/1W$#\#!B,G<DGB
M))2ZE@W9M-[%/3 &-E%;GC<&Q_1*?7/-=ME E+P.?LJ8R";-181#,@.>G'ZV
M,1HV<ARNFU],ZE*E6R@/&8_ETI**>8=/9HB)N!:5>]YD\*$JUUFVJ=FL-,L?
ML@TJ-I_3KS@KLNM\1QF-+_>7/2_BA@B[-L(X@C%-;)Q$?D3M*+))Y%A)$DM=
M_C(A+,/RSR"#JQ9SLP#5]&I5G4N /Z2@/LX067>DO^14;,HXBJ6*A890+F4T
MG5V]%Z!WHPDD#VSG21O&DQL(YR]<ZHO%F7PR0\"7D5?F<+R<_643RS-7>7YU
ME/U^2:O?LUV3[7XM\MVI7(=L)[*@9_DDHHYK6WY(AEP7)Q")I!(SE@UGBQ9E
MEQ'V'*?DE,$0W^<E?WZJ%4MA[Z]!QW@[ VC@*@W_IPC"IEPWC?S-B''!P7B"
M4W=0?A+-G)R')A]:=I<-E9AY(>&997C>G&;8MW**9U0B,Z&ZWM^UTZY?:WXJ
M#=_NTM7C6E1-OCQ >P;)I3:*0S?R+2=&H>=XMH5Z2#CVA>8\DP QG+>.X(-]
MW;9S//0>\+6"N_:-;D?'1^E-0E"-QTH@R2TI3'(Y[SA"'#JX+,  _DAS&_Q/
ME'=4%C0>-(FDN*3@J>5(Y==L;-8<2=VI)#I51!:04R=SM9SAB5>:"_(YZZ=L
MM]LV73#-OL6B:YXY-0(@T+*PDT#LV#9U0TB0'?9X?!A1A7FA 12&<VU3DZI;
MR.#^@+GM[A@Y8301%*G)X\SQ4)](-F'ID(,CZ-T1,MIGE28BI33#G#EBXV>;
MHI'3-_64I^SU::C!,"P@?4[CY\O34^/,"B7.(]/-D"Y]V;(?."%%E$)L4\NU
MG#!Q@V&9,(C%4Z0F>X:3X?'KJEPOU46M0**;@56YE'::T'&)2Q?'$BEJ!J[5
MDI$>SL62D!@II]*-9DH7D%AT>U2:>P EDL7G_"YK;[[XR/Y;Y>O=\2SO1-(*
M_03:5N0@;#FN[3J)99,>AQ,05SAU&+%NND^#87[3'H<$J@'UV)4X,W$0R#.S
MAT NZW"X_45*!\ &5N7,!$0B*<T>&+44)1&@L=,D%89.Y2NC;"\@>YGUKYSJ
MN96I'S;3KLNZWF>;7PO&[;#YCH/YP![?V[3.7FB7]T)^CK,''=XW&1#B!;;;
M84GB"(7BM4-3"$PWHK?5C+P!SE(:0PZR?HMNF^?N._#@GOVF3%7*6%!$:H=+
MB(=DW; -18L9-*"/=DLWH>AQ2^^AFC(Z,O7")41)L58H^>*,KA,J4G6R1FB:
M^@4D0O,^EE,^S')-_,,YK4?' Z(KEJ79C&656!3[)(")ZU'?L^W #SW7)E[B
MQM1C_Q-LYQYEPYR2'@Z)?GK:9@]MXD;K<RR=:9W60NXRFJ'UN%(:>/@4WRE4
MUQD;X!;'QQ?]DJ4<P^9]\3%;[ZLJ+V[8#[PKBZK_*T[KO%U-7_F)2QW'P9[M
M(,=%;I+ J,=G^5!J7\QTJ P/1H_OZ6I]:395'!\@UKL#R@(,#C4_=>P2:'SJ
M!DB"HZ(98BPILHL*K[(B=XB[PP/.Q/"UZ)G5ZK%DBPC[9 %=6!:8SN]3*6-B
MYJ7S"WX<OOS7/*O8[]\^OLT>6*"^YO6*)B3!,/ ]*[*=D$*/!6,P#A.AG3":
M34Z8&09T;$#'H*G*^TB*);5[.G95A5F"6+/*>Y8J$5G5P_7"-%.34Z<$42=G
MTFIW/"3X%@8I[]*\6'D^H2&T;&3;7I($T'<\U&/PL2-4JC5C>4+M>SIX.AI5
M';V[+6I56=03"TEUG#P,RJ-7"9[-JJ0(92)BJ97ZA6FF7M].2:<!!J45]+*X
MW^_J1K"M7[+F(CZ*;,<*?8@AY!OA2.('06_1CDDD=\;B&$LR+Z;228C_MB_Y
MNO.'*E_SDGS1KCIGW>ZE&OS0P 76CXJ:J,*NI (:IE5]4-@"NP =A>"W%MU<
MLO<M3R(B-X+=A4G:&$]."=AH=L;(E=U9=&W+M>W8\7#LQ9:+'<L>AIC(\H+Q
M<B5JR;A<?<IOBOPZ7_-++=NK:-Y?U5GUT*SFMH![R;(U2)8PP^J298):79)E
M+TBR;"7)DF5WN9(E[8F 9*FQ,T:RG-XBM#V^:FN[2>SB(&)?#&M," ;)>,D2
MM32I9/U:E*?DRM$@5\+LJLN5"5IUR96S(+ERE.1*EMWERI6T)P)RI<:.P@+"
MT;245MG?]UFQ?FR*><2Q$\NGU/9AY,01]B$=EBY"QU4KI(VP-UGYC!\^?H02
M###'+B2H4RV]BC )RW):ID2IZ26$4SR)K1^,9GEAFJ;#H],K!YK8&K-L,-CM
MRFW8)2ZQ4>0C-FV-D4\#RVTM$QCZ*!Z[6"!K;YXE@N/74=NJ@#35ZFL!)EE6
M'Z\I$CS9<L SUB07 50Y7YCBZ?!(H. _CJU1"Z5#DTHWH$PBZ"#H1'X8)\AW
M0Y?&86\Z0I0JSD;'F#0^+3V]-#I U; ,*LWTB-5/DQ1KD;PG/7LS3U7/$">[
M]*G*^W)E3]TED87.<7PI3&>;CKUXF]9U,[1TDY!]M!-#UX)V%*(@"5!OCT D
MM"U]O)5)IZX--M" &SMAE253>IIJD$<Y%9,@S?24]"DG8A-111X7IDKJ?IR>
M=(YB1G&_QPL=PDU+\'%%O"GU\:L\BW6^S9L]A<=@NW%B&/O(#A)(:.R'EN6$
M*+9ZN/P.EQ';/Z8#.>&DMML-\O+NC\:]BQ?6)<!3%R^^4=%QD^+)'PI)&5[R
M\S!"Q>>=:&LF520-S!7'A661V6@XOXEDKK@(7^955O=EE>XRDEWM/G&(W6Z7
M9MR. L^G#G;BP+>2$">Q&^'>)G8PD:L:C+-EO%PPP ,;A@_4 T#):[7&,2JF
MXM-1*2?%!PXY,'! -E,QX"Q/9]15#[_+D$A-OCR_/DHC0Z)B]>NGSU6CIX^H
MV/RE9&]YP<L-G4T[<2P7.0ZQ[""T8HBQD_0V;8\Z<F(USI9QL3H@4A:JD6R*
M"=5T-,H)U:^?0 ^LV5M\Q.<\2G66J#-*I8?@92B5)E]*$X^@G%(UHS><KG_/
M-M]H(R4>]7#B0X*=P H1Q)$S:",.0SF=&F/)N$K]4E:[F_0F:UZQLFEF3IO)
MVE4#6%FZ1M$K)EQ3\:HPU7W3L3?[Z.H,1V<42P>SR] K+9Z4^I^[Z8^M>9L7
MV>4NNZM7#IN8P@@ZT \"!%W;MC#L,?H$>5,?72..;/J"Y;CC:[AGH'%MAC-L
M) *N5)=<4*S5%\8G"_-B#[L9(B)>R9PH\LO((#/Y;N#@&]4(F,I2#:CAP#<O
M:D[+CQB4 !,K=!MD7?$4QY)C;K-8C(_*/^WO[E(V[RVOV]%XJU#;(X5BH>6/
M_@:D.W#-!>V!>VLVRT@&S$Q6,1>IL5GDXDD*X0%K#@Z]+;=,HNK_ 9*_[_E)
M]V?60.<_X5(E"!H3AUIPO\]$H>CKR,0PAF&ITLKA*(W#\9Z#73MP*(P#$H61
M&P;41@$Y%)\)=14*+*/L&1?T%N*?%6HHXWB4J*1,1J!"/>7I64D'?+,)YJN,
MO59=T<+V,H1/HS\O55HT,B6\Y)[6MTQ)^1\\:;.AU9.S@0XX5C;E%1[,5=,A
M,+1CZD6'VC26'+7JLVM^*9Y?KYD=0$JNP.LC6' U?A9F)5?F.:5\V-A\<03S
MA/A-O$XORN"Y-7OM45B& AKPZ_E:OB'FA(=T#VF^Y9U0M*P^,>.'PO<J03$-
MB(T2.XKCR$$VLH>2-[3$[B;58,9P;;@]BJQI31W5>S2&2,'!W#0<2H[B>E!O
MKLOJ3<U@':V-33QT.\G/N3';>%*7(54Z''D^2M/%C:@871;\2L>[4PI(:!2X
M'F:?[_FQXR9L=GM0P 3;<F.RD<;,+^ ?A"EK"TRJTC265C%YFI!/.8DZ K:(
M ==YHLYHE2:&EZ%7NIPIC3R%D@LD997E-T6\KRJ^Y3PNBV82V\QR7T(16 $*
M*$YL.PPBEU"*#Y-;$CM(<DE$LW7CRD:RB@UTFX-@UQU824733KC@DL:,3$LN
M8K1(00\5]%B[-8U%"*$DG>>6(PP%9AE2:<R[YTL.1ED4NB^67\+7%0?+BF37
M&8.RB<N[^ZRHF]TY+^.('>@&R/9=)[9<XOE.W.&PJ.\)'O=HSKYQ06TN'>W6
MD]DTC$UD6^!,7@_():X@-1.%\QJ[#/KE5+;AO>LT8H!!CQ@<0Y94VJFB(7$9
M[.Q14;L(E@[=$S5[.7C+Q>XV U<I^Z%U!NK;+-N!#=\OQ9LQMMO^!6)_>_']
M:2Z+K<?>%JO"Y0N)SWQ<%G!+K%G_RJF><$UK[*N04(]:+F0/E><Z-&&SE\%>
M""'6M+;^JAWCZ>QSN4NWFE;47V=MY$JZ5KHTKJ O9-E<9;E<F-)E#,\U^"&Z
M/"[)C*CF''46G5N3IY%O4RNT'0\Z441=Z"=]T=>*[4CR6'5-1HVKT1%.R38?
M7;2**=0,?,K)U1' I77]B'%W1LLTD[\,8=/M5&GT@=52LJU[4(\OJ:]EDRB@
M-@TM!\61X_K8]0?U18[L29XF('R_Q=N1U(^JX$['N:8R[E%/^N,B!H JQ,H7
M=/7$:1GJ:M9%L=*N3CY%E1?OZ[S(ZII-KZ_RHIE=<SAY<9,5._95G3/BFV\/
MX%9Q' :^@Q-DT<2/0^I#-QF0>"&4$UX3",SW90X(N>X>((+R:IO?-%]*ZK"1
M0(C)\-P1D%/A'BTX@GL!C@+R!/&1,D\KP0JDGE%@DR%:A@ ;];"<[H'7.==?
M$4PH<JF+D.\D <4Q&;I,+9^&P6K'BW,Z9OBOFI)J_!Q0F:PRCN5.QT1>*VV2
MHU'VY!;K/-WV&^:OAV^\/K=?TH1>>2(O3/XR%$Z7,U(3=TF.A'6KY.K92>;Z
M\;*X+JN[1C'15;G?O65PVE'0+^F.MX$/]0.,?,( 8>B$H15;"?)M;$=!:$'7
M]P(B>DB&,?L&"VYE,V89,/,;#0?4(.6PP0$WZ(#/5X139/C<VVPZ: MYSXV[
M^5P!IN%56!NRFW3;FRHV!V1,H3YG7W>8D?7[*G)"WJOD>#Z)"2(V<;RXMPU1
M*'FBKAZ;$ZQ>]*&0'.KHH5106R?G4E)(.;Y!'YN=?,<0P6\<)&A03JV9(LR=
M$TBMS"]$#?7Z]%SZ## FJG-)6A7,V/]/WKMV-XYCV8)_A5]FW:JUG'7Y!,F9
M3W@QKV<B(]P1SNKI6Q^T:(FVV26++E&*3/>O'X OR0Y+Q@$!BM'3J[O3X8>P
MSS[ /@>O@_JFV'Y[S(_V2((((R]@W'.C*$.)C^1SCJ(YE\<H\SW5*QS:GV]O
MZ/60'('):4!=+#\YQ<Z9X36:T'F,J/%F5(8[VKAQ<QBG$<DHBOTD(A&-:$)]
M'O"^/3=EP,+5^NU8SP.&<?3<CR-8/C""0CWML</=>/&Y6*@_21! ?^"DSE.
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M*,SDK3(#$ZD#%)U9/)P=P"3>*DMZ<_@#I+'G1]\:=VK>KDW"#*;M^M@K$]T
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M2'N0T74,35VQ!,I?OC<PG>V TZDE4&<OD0(2%3,4*R1SDW,+4RX)SVGQ.0>
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MWLF=A%6E\V^DK+XW+7WOSMAEG!+J!AE/D,>CE"74BX>5DS11VJ[2^V3+"GG
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M7+X%=W2,LOV6G!W($_@+E],$^QE!<5L>/&)9,&28D0<JVF>N5<L9X?$QYW)
MYLC;2D7M;+OZ<D*)'SX:Y[;9AV61TQ*OEUT*>>U07KTZ;GX ZDBDE\D[/R10
M(1\UYX1Y:*@%NT[DKZ:9@ZKEUVJ]SJKM'_EVM> 9]K* Q2%.TX0%*6>QU[>4
M8(;4:@6,:0$R%+6J WS;/SWEVQ>9AVYE->;[%ECS4MEC(>M<;1Z$'):;D3((
MHA4F>+;XU)TX2SQ.!^A"4^<C2A3$2H? ><F2E@4G!$B?#:C4++#/41)0@H/
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M#:Y?H;P1P^$QKPL)4J!)LX0BZOE^Z*?RODI H@%-2A!H\]42!MM[KPT^IVR
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M#Z-HR$>B0' ]<S(X,R4 *O/)Z5QD+/R;\\VD*<"RO6<\%3#G18WIP(O@G^[
MFN%M7HMJBFQL_K&O=_?-#S=7JVY85TC7ZRKCC5\\J7MT 4H>U-_M[M+B'6OH
MH:SXZ=)\N+_,/Y^E!'?9YI8%]PN0L\\O'O__C.-DM]&;=:CUR)\V\U T=WSV
M,8;G\8O?*Q*&-':#)"!>$%J0.@$D?8,.2HC,4W<CFI&ZRR3_P%W[QGOZ<F'S
M6,V6MS&FM.8HS/72%Q#%#1%>#93D1G5\\?%^:/3)"&^6P5<(!FY$?>+ZR JM
M!,/ M@\P/*DG<+4WOH2QJ'-S:+PWU/9_)G7$Z"V>)D/_?-(%2]B_>8M0";G4
MYIMEBJ@^\]Z05LT\B@KN55:QCGO/$_K/=RQYKW_/[K]FU<I/^!).X"/?(@@G
ML>5 RXM\0OAE<8JE:JRIMB$EGPJE*PZPP+[(96L!*3,GIH%3D"8G=<=\M9#
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MHDQN]?.9W2RLRT>:5Z/@;VE>?"CK^GWQ>9?NFH6YRQN:%VFQSM/MT9L-1_7
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M/>A6"%(&]1W'"G8'L."A0POR CP,IDEDB$8<(Y!KS^T1)4FNP?L"'/ "#AC
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M]_;>%^N*UQI)LO;/%22.@XB;0!Q9)/$3BS]=QZ:S7A0Z=BCW*.\<^ R?=6U
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MUK#8O+]_J,IO[666WZJRKE?8I]1&@85=BX2>#ST/N7V;"7)<F6$\KB7#XWL
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MR@Z]=T5#%-JN$R>![<3(B2,?]3?8 ALC\04LPS@,KV]UZ,$ '[3XP6  8!:
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MQB2PYS8QJ6L5KY#92YO%Y0(YT-)]+9?W'#(;EL8T]C3'5FO^;7NBM3<*O"_
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M*)WPG,$3.HYZCO>([*%/,:+>/OVIF? %Q#ISMKU^'M0(@V(1K-RQQO)T2QL
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MP:8/F)0[EA"U)V^;];YB \IF8^TFD]V?E"-,;#_2&%=R(MJ?%6]P3+O9>,S
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MPMW2-$7)A[.JHLZ(C*Y@;NBN,;;)'E9N&CD8(Q([;D03AWFV'_7/Q]R<K);
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M/:]\O>%E1*C4.5R&)$W 7^EZFQ3.N9[]0+VB+O4\EP0!CITHY#&U$X2#T2@
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M3=S*B?>,I"II<]-_^ C@E=5#%.?(>I"-ZLZKN5+$C4BJ7N*7H9B:?:I,OJJ
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M4S,L ;TT\#!R(75ABH*(T#A(QT$"+U)KJ:;VHRTKWXA&L<Y8D1XY!;/(C)I
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M+KYUE3D?2E& ,';E^\_\]KXK8N1_U'6X28MFNZN:?9V+'GT)Y^R?FR3&/HP
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M98E9(THE2^I\BG5D2U6W-'A>L7KI6".C8=HLR2K9T#0TV3=%F3?C^LUC?AI
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M&)7Z,( J,C-U+,N"T\'K:I,Z@,XI0L4'6J:2*B=#<_*I)DB7J%Q(EMXAZX)
MF:)Y'5)ES)J7[ZX894E6OH;:A.=*R3P"8PA"WX]\$D6ABU,V#@6#1"EAHS6
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M<O(!V-SOY;U%RX5I-I''=<RIJ4:\>D?/ "?238[J/&OV]8_3G5:80A8D"(
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M\#R,0$3@6(^("$ABM1K<N5!9K]?E()VO>9G?%6U_MTAIU;.LQ^24=U6NTGS
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M6/BV]%H>@&6A'H&L=L(?F#(ST]6)_^FFN(:)^G-;ET\+D[I['WU0& 0 Q"B
M.$D\@/P@CB$<P= @\"Q-:Q4(EB=V!\7NJDN)<.,++EM<VUYK=;C7OLPZ(=>,
M[NIXZZ=37BTC];57GU/IOK3=#Q>5?]*@-LC%+O-!$D:$QJX?\GC@'N* IU:C
M86-\VP=I'63GIL[*YBZO\UL-#;9"NYP +\VX]7.Q!717@],+HFO30^M07*L6
MONS;:IU-.X4.-?_W7XOL:['KKDN3?5V+A&@,W !ZE+F)[\4@9,#G@6& QO?<
MJ;WZ!DU ]LL:!#"'?G_*RV8X!^]78 -"YP2TS8H'78?9*'28P5<SU#=TCCTQ
MXVITZ6I7U6>I-U;),-&SZ]#_>4V>5+=@A&];N9"/G.X>T G$#:#490!Z$0+8
M]=W8(^"P4XB1W=2('J(Y,B7.KU5Y_]>;O'Z<)2!,\8^=3(I]U\R36'D6$(Y&
MK38FG"??8.)EFG-_NJA@PN:):1D3C,O&A9,1U#8RF 8Q]5U*XC1(:)("EAZ3
M1J&?J(0":R LJ_\)[D/21B]K8\\-<HJ_"@_8%GF9X&Q%TG79O:#BUAVV#N&V
M;V8U\T10D^<OVX?\=K_+K^\^E-]X0*CJ'\,^X:;K;91_;Q/.US\W$*8IPS%S
M0T99&I$H!,,%&A8&( W5.LH9&U9E^FOUC1,O(U6E:.0DKL45(UHU]37'LIS:
M+D*OFKJ.$ 6K!Y"'+(GS1P?4$4B=#NK,731E&;R@H,:=L [%-&]69?GCU55$
MMF_W=?Y;41:/^\?/70^XH;];PZIZ4.;R_M<\:_+F!;8H!AZ,0\+%&01>$,3,
MBX!/H!MAF" :Z\JE34S6M72 [=1]CT=Q&[SH&C$USK[DGZU35N5?M]VUS6[V
M[SHK=*76JOM4=7@M?M,7Z=X"9_1A;\/8:K-Q[JK:.9CA]':L2,4G\"\E\7/X
M=VWZ/XO-9X/#?(P?(\?IU_LK_]7_^5_C[_!_B-ZS_^=__7]02P,$%     @
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MB LK+HC*$OTN(OS]*Z&Y);U^,WFSBOYKF06]7.4;"W]+]5X3NE;O1'L=/ $
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M4#V'PGJ$KLMN;A?/B>T*R$<_E2BJ1=AEL&>22D0=\=!44G*2QMSI'Z#O^JI
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M_5"BI6" (E%>5.<T^*^:5.>1&HJHJB0G'\9>!'3/JI_SH;T1<K=<*HP)UM3
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M*^UYX?/B[F#K&NHO^67]9G&@UJ9?TFF^JM'Z9A;$-M[]3D3-GHFG@5=-/'8
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M;!$.?<X5UR2?$;L$3K>\'2<8Z\G]7"I4<[U_!9W=GFZO4W>2@$RT0:)'KK5
MV KI)<05%Y34.6&"$WQ.[$LU]<3NH4!W+/5^6SQI>UX_U)[8F;KI)/]X<]HV
MRY@U519DP@!HF"'$.Z(<<@?;P#HSY!WM^&TTVP)S. D,A=0:1N:C1.JH\4_>
M\ISR@#O^IJ  ]0!2*K R6"L, 14/_ 2#VH"CU=?I.;-]7)F-6;AC>YVP?KJ>
M-UVP0T,(M"421+VE.-2>D5V]=^L!H?5N./OAU9>K;\7U_:+X>//4(%U_O/EX
MOUEO9LOK[5511?NG<CW?JN:MC%-I%AT7]L\3?.OH&P+6VF!JD1&8 BPM\@I7
M/&0.LB$?&*:NLFKC[7DYY5%D-=1Q_4#=R8I+[Y:'*IP?;_Q\.5M>S6>+:#9'
M$^4N7;,V0WU'WQ605MY:R[C3SB.%- 2^XJD7+@?_%W=DY^-_'*E-9"<<H6^_
MV0\N00?[H.DW!6,4-0 S;)PD!C"$/*CX:5U6B-[KZ?TQ[B[H669#&:[EU2Y/
M;GGMEIOYYN>[Y7;WIKE:6*['2ON<^)83-F?ML0&*U) 30^8HM5QP9O;UZ*VE
MGI):@<]U[INOBWE2+R3])=%)'FF5^*.P6^'GXG:>%K9+NWB!L&,?#98P$"FA
MPGO,HV:T1*@]'8PA>B$!W#W(M>R4L>T>(^J!PQ3I$7KQ+NZEO_]/\?,D.IY]
M-@!&#$\OTIPYCZGCRIB*"LK=A12P&0(>>9SM!Q^[BY&-CT?8;/'?Q6SEEM<V
M'C%'('+LX\%+QC1R4*L(<X85MDI6M&!*<NYI)_1 U2]*.F)NGXK$SQ?%RL0U
MW9:KTVKDR2>#I2P2+0CAD!#%4S+Q015&RRCGTG-"KTM#*)$<OO:#C(K@%.%T
M!!*//Q(0$%Q)H!G$0C+C-;6T6K,#*"?>9D)A]_UB(8.A_8(@>N+S\OKT(?+B
M9X.Q7A* H'+"4TB@@]!75!A*<^H732B6<!A8Y'"V7WP\'&X^_N2E=[<3GP[,
MV4@#P,H+G?J04V3M0=UQGY/SS-\:1O)X.P1*=BBNCY-'GP\64(:8QPA'FQI"
MQ;@\Z$1 LJJ'B[>)E/;<[0<K*B[M>KN\Q>SV"#Z>?"8@+Z!23$N(A#7084!$
MM6H5B<C A'PKF,CA:*\W'.7=7;G\LBFO_OGE6^3/^M&CV>GKCA,# TX5AZWW
M#'H7W2Y/-&<5?58"E',U!MX*9#KG<Y\X^J]BL?@_R_)?RR_%;%TNB^MWZ_7]
MBVE59\<D+>D Q-YJ8XDD7*7T^SU52*.<.Q'XQFY6NV%QG\#YSW)Q'^6TVCGH
MQPR6%S\;@%04:X25P]HB%$UU30[W.PQEJ9DW=L>:Q]I>3ZC=[=[GXGOJ'+6\
M32]Y1PW;4T."TUY[Y$@*!G4<* <]/_ASQF551'PSEZT=<KA/U'RZ_VLQO_*+
M<O;28^6+GPL6 V"59MX0X(C&V+C#I:#0/*N6SAN[;6W/UH'>TMULE3*@UM$[
MVYI5HT5^/E](C;#.8T,"IJF!GW404.J9B)ZFW"EMQYE'L-9Y. R5=>)PCHX)
M5'O#.!)44T.-,,CM<1GI!-(.6KAAB(B:?(&7_;!VI,VZ[[)X$7M6\^T3E$;
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MCGRI:)'&9 6+3 XG&:)\7JHY@XFMU8$MEN7=?%E'(;SPT2 EXD JHBV,1B7
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MO>@#8SUR>SR<[?_Z\:_%_/9<)%Z-T4$"H8SU3$'"E7 4,5J9CE"KK.-O4L5
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MEPQY*!"F $OI"6"N,D6A0<-6\;[<.XU>A#&R ;<^M)?NQ(H[.5V R,JXV[V
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M(HHA Y#RM^70%=];OTC^.5\4ZTVY+#[-?FX!_^?LNK#WR2SYM"VS<NPE\NS
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M7<[1-<G8Y9Z!TS7#.X5,7:539VS 1B.*<.1.I$0SSPU].-TESWD_F^0KR C
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M,1822!12GB.AX<%*)%!D/?7^?NMM!?V!9#FU'(Y](=4WF,KA!"8">08MD8P
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MN2>=N##/IG<IGDQ#;,;KR[$QWD\L#9$@CZWF %%L!26,4Z$J.7!K<U)OWV3
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MJ<05-PYQK)#D C@@I:>M#IO#S/#3S;?J=C.K=B]T6[A3+C =?]J_C\SS6+.
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M2Z6C\?]$P-I[TE*+<D@[*@T[=M)VD\>(N1I_?+='N:,]!DJ,,)K&XUPT?1B
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MP2LG&>-,1O9[!H#EEM6X0$&*9N IH7L*L^EYMIZ!Y3,VI73IW.6O0S=!;JW
MEC!(&=<R/0TY(IS'AL-HHEXR[* >[$F'PQ\^#$08@*7@E#C&+9!Q5?C]C!#
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M]IH\ 7H@4'\H%_,$F,QO3Y+G\:. ,0!$"4.\\XQY[(5KU@2%*L<-_C6]]/?
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M@=D.#PK&8B  H 0J5L?!/1:MG8%QTCVI!695C*;-AB%O+B;Z?4NLHVSS^+$
M(:6"(>B1=-!8#2%BS4J\4RD5%47VI!B'51)(FBW9>A OYI<N*=C#?BD8:BEW
MRG%15RUXR1U\T-@,9CUI>FM^Y[189K/^CBPKVA3F=K9>SV_FNQ]\6/CY8K:X
MFL]N6U72J2'BH!\*7&/D@0/6:2ND\08 UZHKIY.NTRU1>4_&C<\MSBEAS"44
M^^54UR^O=F]6O\+LW5X0-"8<:Z )D@Q%KY!QWH+@O,S3X$;NF'A1?:DG/*Z"
MGXAYGK?9'@.=LGCSMVKS\>;S[)]D'FU>%(AD1((Z@YH8@I"'WH$]-8R6).L]
MU%F27LZ)5WNB=%X&N)E]FV]FM_5/U5V="#2Z(?[3%X.CT4WRE%)M:A_)"X&:
M$%YT=U1*$+Y[<.&IQOX\OEU>ABB4@6G_JI#7!#CZYK?WU]7UA\5VDI&B3>SN
M8*U(O]<%5Q^9:!\72RPT7F.NV]42RK-&/3*XE-.R;D:DBM+E<2O2U:*ZF6_J
MS,[3;.=A/A $T\Q2JRQ6''%N(CZ-VV^ \"D.(GVWK=.4]-#H39TR-]W%KZ7F
MS $&B+0&*:V<YHIHSII ,!.6=K*3WG/F#@<UI3/>8@&P5%9X7R>$->+)XC9Q
M8<D@N9@Q2\[<:=!E.T"[G2U^F]U51Y+D'C\6O!;0:&X!PH+4?3JU;NFJ=;>;
MHL^'"2?FAN?';OV!R,U21_/>GCX8H.-,*<R9U\;4=V0JKUJ26)ER5T"!;-4/
MR /<T(N""7T-5_^I-G]LEE?_^7,QWQS.VGCEZ< 1$!)B(*#SQA,O!6\%@%&9
MD@A4Y$%.7ZB60Y.R-^R?YW?5?U?KN/%NTT3F5W5TLB,3=!D;!(16>N %@LAR
M*(RU#SH1PY1LZR)#S4.PQ B$[<T@9K;^^D>UV=QN][MM9?-BOTT>88_C(P-1
M4B,+%7="&>@%5P@_,'FF"&SVW2&%-08G:F_&>/3Y#KKBY:<#\,[@R*U2 QWG
MJR%%+0V0)"D;1H$!S"$88!!"]F_CUEC+M3;Z_7YU]36:RO6R7D?_R+! @ )$
M:RPI58)X(:CSS>PATBF=M+O']\YLDQB6ID5%G(M,W^- :BH=$Q$<92BR@JH'
MM6HNM]M[ 0[RM%CV/R6\O[N;K7Y\O'GUU$BMU\NK>1W[^O=\\]7.;R(C1(2:
M#IU'^\P-^9%@,1$&:(HM,H804-^*NJ<,U]9E]=?/,16O,V<M"X&PK%2G]#0\
M)X B"D1#B(.X[]7_;))FN* ZY3[XHAAX2L;IEX)W&C)E\>7P*7C>>^=@U!,,
M1'O=0ZL=::E!0$J[EZ+B(F?'IST1.B\#NH3T.RX)A5AC1A#TTD+'5&,,\KJ9
MSD6EWQ4D!F7@>>ZI=W&AUAGH-8V;EZ!2&0";U;((QV5$K@I@VXPH39UZ]"P3
MZCWU*"A&G;!("NF454 +" 'A$CMF-=2D5^K1(;U2Q]$^?MO*XM5F_GV^^7'4
M]3X\)&I#[J+:XP8)((U'1$6C83]S@V#6I)XS:.?7&>CE*/2?N$)SM9HMOFR3
M-O6/G[2#^GNVNMZM<OWQ?K/>S!;7\\677</RUY+5AOY6B'M[':?3&&/B$?9&
M2-70E*"DTYJ3>?K;UA3Y8S-;;4;<^89@L&Y%E]E@.4-6_W<U__(U*A$5%=GL
M2^7^J597\W7U^RJ:KWD$X+49!,,E4G4+(,JTHI"QNN9D3W^@>8HI>+(K_RX6
M@X)5OK!LOE:K[7]%*WA5Q?^VU>[/403CX->"<@AIAZTR CA++8@$)9$5B. (
M<NLN(Y6C0/8?"I)B6'U]3-(/KGA[[UU4?V/M%^/.+'!DH&2DOE9&,( %(S;N
MXXYYS0&F**5Y7W$AA2E$J"CXBA&W(T3Y5WQPLVX(,**U]?1#P6M%&)&*UJ@[
MS1Q1LC5J%<Z:$G2)PC F&L7P]C&)?[K*J;:-[K,(=;\^0RPVE'OF%?&ZWM)W
M.'CJ4]JKLY*B2N5N$J.!E4UH:JI^6*_OJVN[;0FY6\DNA?@1R=?-8EY5^B>_
M+#C!,3,<2J,5$UABS'1#%4%TBK?,2ZKE'H^%QZ;YV:CO9H&3:_"3)A(L54)(
M#XQ#!%#"%35MK!MKD"(!XEV)3XU7,=)SA 9^N;JIYIO[597#NG_A:R%24WK,
M&$5,U7_R^CQX1U<#O4GI0B;?QDXP.2C%,/LQB7]AJ5-M%B=.)<2=6CM#''$T
M[M9  N=:1#AA22?)X'V_F!ZR8H2HZ,-GA.IR1B%L7)RB1"A+&F_*(,V2[D?L
M>?KL%F]LPTA%Y0PYO?"SY^C101]-4X4P)-9;0@%NZ$\]2FJ=W?/P^2U+Q8!8
M39V,^*PE\GLR8J@KK"FS#&'AC'&JKF$D"#,''3/2=;K H6,RXD-3O;K5WVS]
M]5-U5<V_5]=UC[W',G D0_'4]P3+HN H*CRR478,$P")=HW,Y.EB?CYIBYU9
M8ID/E*(J49YVAVSTX<>;QW'*U-J3+M\(%G!*);#8*$FU5L1Q3A!%6F][46:]
MF'9T)VH\#DOO$#H(/MG:GJV65U5UO7Y&MTYG(T?'!N^TTI(Z1KDS7D'!+6BH
M'@V$K#<"70Y/#DWWJ0TQ\FZ(/=MU&1& "24HT)IX)AGVNX"\ T9JWBE1:B3'
MLVV;T3_FU+T);>(W N7UI7]&.\VIYA9QRG=A*@<QA# EQZ; YHRYF.Y@X]F\
M<&4KH-].,'[R2+?9)\^%VNL52"IJ.(D6M%=$L&8MV)JL%Q7G[*:3C0>>U[XG
M4+^8J-U!VCRL;G'=N5/M&)\+'#FE%7?1BK 8*,P\YWO*$N%HRME^@7S=DZL&
M.YX9#(AIV^9:2Z55V.KH_;#H]%ANS7ZN5/*DRVN+\DW+ +Q#\]W3 "E&/QZB
MVB\=VN6EOSP 922FF+'ZMF!@ >!(ME1#+(6-B^Z0-]6>GAVRP;1DUP+[8^."
M)8Y"(2%DVE ?9=2B1NBICI;ZF].< T+^FIY,!*)XC>G^YSZN[L,BKNY^*\';
MVJ#/7V>+?3#IM^7B^[9#]WB9$*?.(0#,A%#&4R  Q(A*YGV# ;$HI02SS/+\
MX;AR*,TZ,F87)#?/3LJW915VMJG\;+[Z[]GM_2C)%0-.+\0=VTOE@/0<4(*M
MU=ZU>M2+E,R+,JO^SUG:AH;S_ 5QE\68HVE SZD$RQ64 "EIB11:*XJ0;1"I
MSVX2!*RTC@)G*%J#@%:,&+W9G@.1DX3%!B@GH48<.B1;;P!HGI+O4UK/@>F$
MK"@,BY&YWJIG_)8$)TXA6!&5'>*,4L U8-)#VUKQ0)&4KOE%W5]RKIM5$ER7
M)C!E>EXGSC$8)#G4%#D..=$"JOIJ]3V&2-J4>^7*ZX1P]B(W-)[G+Y.[^_TF
MW<2>3B%@''F%>>8E)=PSIIP2>P28]R"E'WMYC1G.4**2X+HT@2ES$SMQCH%B
M3[ P'$AON/4\^LTMAL[[E!/3\CI!G+W(#8WG^<ODOBYZXGWLIUD$ B!@T'%M
M/;4$2:%48^ SJ%U*R7QYG27.4*Y2$;L8R:D["I2YE9TRP>A0<V,))(1)&E4?
MXIXWAR?,(I-TZ5IY+2K.5^#&0//\9;'$7 XA"-2$8,"-D@!X(3QJ,(A^<E(>
M<8G=+LY0IM(@NR"Q*7,#.^'L/QH<#$-G-(&("\65H:HUVUF2&U9D$XUS%K:A
MT9RZNO/9B?A[=6>(X#&$%(L.0;1 K)/0U\%A :R*AHGK)(WOU9U5I"-23F@.
MO$? 04D!M0T=X^Z4]0:R\JL[NS+=:-6=I\%5=G6GA48P2#TR  NCE-42-&LA
M.*TK57FL-P$/O%K=>1KUBS%$SZ"ZDXA(1Z\IDUX"%IUBA5A#V?C#K.4FN:L[
M.W-5CNK.TX"8MKH3>\0LI=PYCRWWQFG#6Z%FZ.)::DT+>(?JSM, R:4?/]7D
M.;++ML\$ XA"$%&(O==,(V4$;-?@6$KZRT776O;=8?M2/BOW'%1/+SP5/)?<
M4.$]L(!["YF5+24T1DG]=,OCH![XO<0!O6B7BP=^G2_F=_=W1[G@R7-U5U)J
MM)# >:*IAQC'W7R_%A47=VG;4R\<E\-1,!LWS/[IQ@V/GPN:"UXWJ07(Q>T1
M0J^BHMRO!2N>M8;_;+@A@8+%>%\3]XXP  )/A66<4P@L\DJU-AD".*4?5$'%
M7N78,]DAZ^V#U4'][>0^WFR#_=7UHX.+(_TCNHP-5&DL1=T[AF'";70L"-VO
M0TJ?=M1:HLK+"?UR7#"*UY[MJ91:K^_OFCZDWZJKN'H[_SZ_KA;7GV:;44Y(
MNWX[<!_IK36&6#(@#73(D(;FVJNLO?A&3]X9E@N'TJHC8776\O'?R]OXFMOY
MYL<4$O+TZT&*:,DAC(0%LKYD@M;_V--=470A\98SE9 DK,Y21C[-U__QJZKZ
M$.&)7+6IU[UW2G,)RBM3"-!0P)663!&-'(PV*6,M C*IE.AD:_Y]1QD!LLL1
MFIWO/JG0[*80!)#:":0,)@9(0007KD' 69$2>CFY%<.[T(P 66\7>)_KMJ70
MMN7#QT6;]_9A89>WM[/5^K#Z/_D=P3 %./( ,*D!$,X:)YIU(4U3K)WR^AF,
MPHICTWQD7CJH%4]^1T!::&XIA5QY%,E'&5?-NJS7*9><E%>H/S4O]:)Y\9OY
MFVQPH8S" D$2[3%N=71EJ&OR;23&-L4<Z%Z._Y8]SHD1G3HQ_5G"Z7MB>D .
M4,H)A181)*R+YIXG@CJGM>8<=;HNYSTQO0I(>$PH4UI'R\9Q;XAW>SH::]B%
M95'F8KK1$M-/@ZOLQ'2 /)58204C^;2'UGC9K,58FF*,%LAZ$_# JXGIIU&_
M&+/T#!+3J2=& HT4!8Q;YSR7NJ&LQR!K$E?NQ/3.7)4C,?TT('I[\?7]F7]4
MF\UMG%BUNEFN[F:+_?6K1Y+4CX\,T6ET&$23VD13%6$)!&G7@#1*ZN90'C--
MRP;+,:$I1H-.G%PFH;/1;*+8 @PE1UYKVE MFE?O%Q,-O.MGAVP4/7HLN:S+
MV&"A5MYKA)S$1 AB+</-.J"U[\EE"=!WU9T]P2A>>YYE8YNX*1J""30 6L4M
M)!&"5J<XD+7L),NU*<-RYG07%9V$V_G+SAG<CX(8]<8Q02$BBB,&!6@0$1ZF
MU)469-6<LPP- MSYBU)Y]S5(*7C=D)5SXKGS4@O+]PA8K&W*37GEY:>=J? D
M07;^0E->?WB/$>68QLW?8LB4$T"B!@$N:$J,L7M^6JZFNF<J-$F0G;_0E-J/
M6E$,H;*.$P X<2!ZMDV(VE*C4IR>[OET[Z(S*FKG+STEA@LPD1I[Z+5%T#,K
M(>=-"-)"8%)NUCHY>S!#9\XSE9TTU*;.='IV[OR>Z108T)YCA*C#5C(DA(4[
MS2<ML:Q;:.$]TZD*D#KB+!80.<"1JZ]%;>A(A;FT?G&YF&ZT3*?3X"H\TXD;
MA215TB%@B/:08;%?"\,(9BWJ/J<SS\X\\'JFTTG4+\9T/(-,)XV9$B82$VH2
M/5L(D04-9276EYWIU)6K<F0ZG09$[Q/ZS_.[:A?5^!1_7\VOGE0'O)[KU&5L
M< PBRJS03% /G4.6LW8=!F?=HXLXH1^5&9;CPE.,)ITXXPDHQ142T9)2PA-%
MO1 MU3C&*;W?"SH;+&?WSPY9;WWZDJ@]O__CD#[M,C9(K0RU0$IH&(NVO,:(
MM.MP-B5B<Y[Z=$#HE^."4;SV/,L0)M22 AQ--66L!D0Y*'&# 8JX7US&T["<
M.5D0\S3<+DAVRJR?/N$&*$R-LY0IA10&+BI7#7R#G$ DY;BMYW5>[Q*7%=+S
M%\;RTP^1A]Y8J)"INY4('YTQUR "4%(@IJ".O><L7H, 5XPH'?3<]JO=KG[[
MQ/,5'^C0X/ZI5E?S=;7MIC)*&'.0F051^W!68("@P=@*#N@#7D:DE)"<W!?L
MH@6M*!R+D;L+2ONUPC+-O-'&1"?;.B@<W"/ .82=&GB<35NS,]VTDB"[-*$I
MTQ,[M>\1M5)@2"R3Q%.-A2"MXN-:N\OJ '<18C<TIN<OE^6EXPO))(C^L.;2
M4$Z )/N"B(A 5(PI9F'W_G"Y<HK/5*J2(+LTH2ES,SMQCL%#B2'D6ECCM!01
M0ZY;@T3[E.8HXGTS.P=,SU\N2RV3 1(I;:V$P I%&<+>-$'>J#%52M:"?-_2
MRD#M8J3G/C):F5O:*1,,#!#)/9+UC2G.4&5KRV2/'K(P*9\2O&]HQ2-Z_O)8
M8LZ'4A1)32 F$@J!"<? M)8^ BD-!F#/I(]1Z];.5*[28+L@T2ES(SLA/R :
M\,QS1AP !FH-L=U7NM?Q*//\5O;3!*YGSL>[P&5$=.H:TF<-"=]K2 -Q7JK(
M;D [2*25W$"#D4= &@I!MYO$QZXA=7??;I<_JMVM*A__7E2K]=?YM[JVP?WQ
M\?<' JR[EXR>]LH $::P-LLDT!XBXCD2#948DBFM20LL9\K%4@<K1$=%)Y<]
MT-3>'*D'??Q8(( [)9URQB!MJ'28RV8E1.2M<LI9$#(6X,O!:)V;:XZ6;3XK
M[3*"(6PI\9("3C6AR+1"Q[V_L(++?D >X(9>%.Q=V:/BCZC[X_??7R^*?/98
MB X/19RQR/$"2(68L[I5J@IE[5"<#]]3H5D.1L'^^$(IN^#[]+'@B04T6M($
M:B8LT9JZEHFMYRD'5@66 @Z";Q(%<^GSSCO;+QU*3D]_66#0,F:$@18+PRUS
M7+2D!8ZEU/D5R%?9+8K1$<D6O:H7\&&]OJ^N[?UJOOBR.S;:];1ZLLK?[U=7
M7Z/A7R_RU?KH?F\,3'IAF($($13U@8\[.&WI(W7*\6*!.]V8#/3<O\H"R,0,
MNXU*'5S,Z>SZ^OL"$HQ;A>MN2)!)B(!&L*$-933%83M9O>8HHYZ>70<%9.IX
MY.?JG\W][/;II-ZCDD$R #6,[ $8-4Q&:Q#N6NC$+=H(WRD7>>RHY#ETMB.0
M*>NDHDK$7P 9;]">C@Y'&E_67IJ+Z4;K;'<:7"4',BU4!AK'F :."D>DH^U*
MH#19[X\YI\XVG3G@M<CF:<0O/;()(SD40592RB&&4C@%FM7$A5W89;#]@'P]
MLGD:!7M'ONQ\55U%VJ_KS[\>_7KAT>"I4H!Q0S @$L19TOTU=AQY2/3%=7CK
M"])R4#HFQ;'YQ[O%_*_[]2ZAX#CLKXT)@ +FH4;"2X<8-'$K-JWJ<TE;1H&1
MJB'0'Y"<_=E@$QV91;V+?;QYU O=K.:1AO/X7W$(/L(5W5\1@"5Q>]2UEP<(
MUYS2^J29610=2X62E$1![2P&99+1J)O+<*CK1*+[?\3\?/140% ;AXQEE'LE
MJ!;:D(90 K.4KLH%JI+IK<_^M,_,0T=MSR?/!2V)%G$_=80I+QQ2F,IF*U54
M)*4KEL='O5!\F1-ZT6_B1-VM&$1)B=+T<5$=W+)ZO"5PQITW7FL *>'2&6MI
M0P?$';U(/CJ5![IEMPY WUQ\]GF^J97RA\7U_/O\^GYV>V0'>_'Y@.,B.&>>
M.:>LE1I:R%KZ:9:2>EB@Q3/]7C8$"I-QV+_GFZ_;:&>=Q?UU_NWSTBTVT2\X
MNN^=^*; J;$$>N68)W5LE%G\('%QV[@LC9;($\<X;%!:Y^*])O1P=*-\^F"
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MISYD7"SB[]M+;+86SK&]^\5! 3FE@+;0;LM9"%< MX+L $]ANO-T@T;>LH=
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M0IWDIN,S_^F4?#/P-X- B /J)!4<>."@@]HU=/;>=4IJ.H>JSMQL>3 =9UH
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M__I__B]02P$"% ,4    " "5A$%,MWE,+093!  PVTL $0
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M+3(P,3<Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "6A$%,Z#J16\DO 0#@DP\
M%0              @ &81P< 8FEI8BTR,#$W,3(S,5]P<F4N>&UL4$L%!@
0   &  8 B@$  )1W"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
